{"PromptID":{"0":213,"1":150,"2":191,"3":113,"4":163,"5":140,"6":106,"7":169,"8":162,"9":142,"10":178,"11":149,"12":196,"13":148,"14":152,"15":154,"16":125,"17":121,"18":207,"19":124,"20":157,"21":107,"22":170,"23":173,"24":156,"25":171,"26":176,"27":105,"28":187,"29":133,"30":103,"31":158,"32":174,"33":179,"34":126,"35":118,"36":132,"37":194,"38":190,"39":122,"40":211,"41":198,"42":172,"43":167,"44":202,"45":201,"46":141,"47":181,"48":151,"49":112,"50":153,"51":102,"52":129,"53":195,"54":104,"55":206,"56":116,"57":168,"58":136,"59":208,"60":182,"61":165,"62":197,"63":161,"64":184,"65":200,"66":123,"67":180,"68":203,"69":135,"70":139,"71":183,"72":101,"73":212,"74":144,"75":189,"76":160,"77":145,"78":147,"79":155,"80":209,"81":117,"82":143,"83":166,"84":111,"85":137,"86":114,"87":210,"88":108,"89":128,"90":193,"91":159,"92":188,"93":134,"94":177,"95":185,"96":175,"97":115,"98":127,"99":131,"100":109,"101":146,"102":205,"103":192,"104":110,"105":100,"106":204,"107":138,"108":199,"109":119,"110":400,"111":472,"112":344,"113":474,"114":315,"115":279,"116":480,"117":324,"118":406,"119":481,"120":224,"121":374,"122":319,"123":440,"124":268,"125":286,"126":309,"127":241,"128":216,"129":307,"130":302,"131":326,"132":443,"133":341,"134":403,"135":347,"136":231,"137":389,"138":482,"139":367,"140":402,"141":283,"142":397,"143":233,"144":254,"145":282,"146":447,"147":385,"148":467,"149":305,"150":273,"151":456,"152":269,"153":463,"154":238,"155":265,"156":395,"157":264,"158":278,"159":370,"160":479,"161":261,"162":387,"163":276,"164":237,"165":298,"166":292,"167":423,"168":323,"169":295,"170":316,"171":217,"172":258,"173":441,"174":377,"175":218,"176":255,"177":393,"178":289,"179":473,"180":228,"181":275,"182":401,"183":310,"184":355,"185":287,"186":427,"187":290,"188":391,"189":384,"190":259,"191":407,"192":226,"193":368,"194":257,"195":220,"196":369,"197":250,"198":450,"199":232,"200":227,"201":477,"202":293,"203":296,"204":281,"205":266,"206":299,"207":380,"208":256,"209":285,"210":361,"211":300,"212":365,"213":461,"214":328,"215":294,"216":386,"217":363,"218":452,"219":455,"220":366,"221":338,"222":360,"223":420,"224":457,"225":415,"226":242,"227":459,"228":280,"229":236,"230":356,"231":451,"232":465,"233":337,"234":318,"235":475,"236":219,"237":340,"238":243,"239":270,"240":408,"241":327,"242":357,"243":230,"244":436,"245":396,"246":223,"247":308,"248":253,"249":351,"250":222,"251":329,"252":388,"253":297,"254":444,"255":462,"256":394,"257":311,"258":332,"259":221,"260":235,"261":352,"262":306,"263":418,"264":453,"265":321,"266":262,"267":378,"268":349,"269":312,"270":372,"271":291,"272":267,"273":249,"274":272,"275":404,"276":320,"277":469,"278":346,"279":611,"280":571,"281":578,"282":495,"283":619,"284":608,"285":595,"286":593,"287":551,"288":617,"289":556,"290":519,"291":620,"292":583,"293":599,"294":582,"295":560,"296":485,"297":500,"298":561,"299":534,"300":502,"301":589,"302":601,"303":510,"304":615,"305":602,"306":512,"307":610,"308":572,"309":522,"310":531,"311":491,"312":536,"313":501,"314":498,"315":487,"316":609,"317":591,"318":539,"319":543,"320":573,"321":533,"322":314,"323":333,"324":335,"325":390,"326":359,"327":425,"328":348,"329":330,"330":331,"331":234,"332":325,"333":383,"334":410,"335":244,"336":468,"337":214,"338":364,"339":215,"340":382,"341":317,"342":445,"343":248,"344":263,"345":304,"346":322,"347":478,"348":411,"349":476,"350":437,"351":483,"352":484,"353":421,"354":399,"355":239,"356":379,"357":247,"358":252,"359":458,"360":336,"361":417,"362":381,"363":454,"364":414,"365":362,"366":419,"367":439,"368":350,"369":274,"370":339,"371":405,"372":343,"373":449,"374":245,"375":301,"376":424,"377":225,"378":464,"379":354,"380":426,"381":398,"382":240,"383":288,"384":271,"385":303,"386":229,"387":251,"388":342,"389":260,"390":334,"391":438,"392":358,"393":371,"394":409,"395":413,"396":373,"397":471,"398":416,"399":313,"400":353,"401":466,"402":392,"403":412,"404":514,"405":515,"406":517,"407":526,"408":529,"409":535,"410":540,"411":541,"412":422,"413":552,"414":553,"415":557,"416":558,"417":566,"418":568,"419":569,"420":574,"421":576,"422":577,"423":584,"424":588,"425":594,"426":596,"427":597,"428":600,"429":606,"430":612,"431":613,"432":486,"433":488,"434":489,"435":618,"436":490,"437":496,"438":504,"439":506,"440":508,"441":513,"442":516,"443":518,"444":520,"445":521,"446":523,"447":524,"448":525,"449":527,"450":528,"451":530,"452":532,"453":537,"454":538,"455":542,"456":549,"457":550,"458":554,"459":555,"460":559,"461":562,"462":564,"463":565,"464":567,"465":570,"466":575,"467":579,"468":585,"469":590,"470":592,"471":598,"472":605,"473":614,"474":656,"475":693,"476":695,"477":246,"478":769,"479":284,"480":826,"481":832,"482":834,"483":839,"484":840,"485":863,"486":866,"487":870,"488":872,"489":874,"490":876,"491":878,"492":888,"493":889,"494":895,"495":898,"496":901,"497":903,"498":905,"499":908,"500":910,"501":920,"502":921,"503":926,"504":927,"505":931,"506":932,"507":946,"508":947,"509":949,"510":954,"511":964,"512":492,"513":493,"514":494,"515":497,"516":499,"517":505,"518":507,"519":509,"520":511,"521":897,"522":770,"523":650,"524":906,"525":907,"526":909,"527":911,"528":918,"529":919,"530":922,"531":928,"532":935,"533":938,"534":939,"535":941,"536":942,"537":943,"538":948,"539":696,"540":824,"541":825,"542":956,"543":829,"544":959,"545":833,"546":966,"547":841,"548":604,"549":864,"550":868,"551":869,"552":871,"553":873,"554":877,"555":881,"556":884,"557":885,"558":887,"559":890,"560":1026,"561":1029,"562":1160,"563":1161,"564":1034,"565":1035,"566":1163,"567":1164,"568":1040,"569":1167,"570":1043,"571":1044,"572":1045,"573":1171,"574":1047,"575":1048,"576":1172,"577":1050,"578":1175,"579":1052,"580":1176,"581":1182,"582":1055,"583":1183,"584":1184,"585":1058,"586":1059,"587":1185,"588":1187,"589":1188,"590":1190,"591":1066,"592":1194,"593":1196,"594":1070,"595":1071,"596":1197,"597":1076,"598":1204,"599":1078,"600":1083,"601":1087,"602":1088,"603":1091,"604":1097,"605":1098,"606":972,"607":973,"608":975,"609":1105,"610":978,"611":982,"612":983,"613":984,"614":988,"615":989,"616":1117,"617":1118,"618":1119,"619":994,"620":1123,"621":1124,"622":1002,"623":1006,"624":1133,"625":1008,"626":1134,"627":1010,"628":1140,"629":1014,"630":1143,"631":1019,"632":1023,"633":1024,"634":1025,"635":1028,"636":1038,"637":1041,"638":1042,"639":1046,"640":1054,"641":1057,"642":1061,"643":1062,"644":1064,"645":1074,"646":1075,"647":1080,"648":1084,"649":1086,"650":1089,"651":1099,"652":1100,"653":1101,"654":1104,"655":1106,"656":1107,"657":1111,"658":1113,"659":1114,"660":1115,"661":1122,"662":1126,"663":1128,"664":1129,"665":1130,"666":1132,"667":1136,"668":1141,"669":1142,"670":1144,"671":1145,"672":1156,"673":1158,"674":1165,"675":1168,"676":1173,"677":1174,"678":1177,"679":1180,"680":1189,"681":1191,"682":1192,"683":1193,"684":1195,"685":1198,"686":1199,"687":1201,"688":1203,"689":694,"690":1208,"691":1210,"692":865,"693":882,"694":883,"695":891,"696":892,"697":896,"698":900,"699":925,"700":934,"701":936,"702":961,"703":967,"704":968,"705":969,"706":971,"707":976,"708":979,"709":980,"710":981,"711":987,"712":993,"713":1001,"714":1009,"715":1013,"716":1015,"717":1017,"718":1020,"719":1022,"720":1027,"721":1030,"722":1031,"723":1033,"724":1036,"725":1063,"726":1069,"727":1077,"728":1085,"729":1092,"730":1093,"731":1094,"732":1096,"733":1103,"734":1108,"735":1109,"736":1110,"737":1112,"738":1125,"739":1127,"740":1135,"741":1139,"742":1147,"743":1153,"744":1154,"745":1155,"746":1170,"747":668,"748":1179,"749":1181,"750":1186,"751":678,"752":1205,"753":1207,"754":1209,"755":771,"756":807,"757":808,"758":815,"759":822,"760":830,"761":835,"762":836,"763":837,"764":838,"765":862,"766":867,"767":875,"768":879,"769":894,"770":899,"771":902,"772":904,"773":912,"774":913,"775":914,"776":915,"777":916,"778":917,"779":929,"780":930,"781":933,"782":940,"783":944,"784":945,"785":950,"786":951,"787":952,"788":953,"789":955,"790":958,"791":962,"792":963,"793":965,"794":970,"795":974,"796":977,"797":985,"798":990,"799":991,"800":992,"801":1003,"802":1011,"803":1012,"804":1018,"805":1021,"806":1284,"807":1286,"808":1288,"809":1290,"810":1295,"811":1305,"812":1307,"813":1308,"814":1313,"815":1318,"816":1323,"817":1324,"818":1327,"819":1328,"820":1332,"821":1336,"822":1212,"823":831,"824":1216,"825":1217,"826":1218,"827":1222,"828":1227,"829":1228,"830":1230,"831":1231,"832":1232,"833":1234,"834":1239,"835":1242,"836":1246,"837":1248,"838":1251,"839":1254,"840":616,"841":1256,"842":1257,"843":1258,"844":1259,"845":1262,"846":1268,"847":503,"848":1275,"849":1277,"850":1409,"851":1410,"852":1413,"853":1414,"854":1417,"855":1418,"856":1423,"857":1424,"858":1429,"859":1431,"860":1432,"861":1438,"862":1442,"863":1447,"864":1448,"865":1449,"866":1451,"867":1454,"868":1462,"869":1463,"870":1464,"871":1465,"872":1469,"873":1472,"874":1346,"875":1474,"876":1476,"877":1349,"878":1350,"879":1477,"880":1352,"881":1353,"882":1480,"883":1481,"884":1356,"885":1484,"886":1360,"887":1361,"888":1490,"889":1363,"890":1366,"891":1368,"892":1500,"893":1373,"894":1502,"895":1504,"896":1505,"897":1506,"898":1385,"899":1514,"900":1387,"901":1517,"902":1391,"903":1519,"904":1520,"905":1524,"906":1398,"907":1400,"908":1402,"909":1403,"910":1404,"911":586,"912":1213,"913":1219,"914":1223,"915":1225,"916":1226,"917":1233,"918":1237,"919":1238,"920":1240,"921":1243,"922":1245,"923":1250,"924":1252,"925":1253,"926":1255,"927":1261,"928":1264,"929":1265,"930":1267,"931":1269,"932":1271,"933":1278,"934":1280,"935":1281,"936":1287,"937":1291,"938":1292,"939":1293,"940":1298,"941":1303,"942":1304,"943":1306,"944":1310,"945":1312,"946":1319,"947":1320,"948":1321,"949":1322,"950":1325,"951":1331,"952":1333,"953":1335,"954":1340,"955":1343,"956":1355,"957":1359,"958":1364,"959":1369,"960":1370,"961":1372,"962":1374,"963":1375,"964":1377,"965":1378,"966":1380,"967":1383,"968":1393,"969":1394,"970":1401,"971":1416,"972":1419,"973":1420,"974":1428,"975":1430,"976":1434,"977":1435,"978":1440,"979":1441,"980":1444,"981":1452,"982":1453,"983":1456,"984":1459,"985":1460,"986":1461,"987":1466,"988":1467,"989":1470,"990":1471,"991":1473,"992":1478,"993":1482,"994":1485,"995":1492,"996":1493,"997":1494,"998":1495,"999":1496,"1000":1497,"1001":1498,"1002":1499,"1003":1501,"1004":1503,"1005":1510,"1006":1511,"1007":1512,"1008":1515,"1009":1522,"1010":1523,"1011":1525,"1012":1526,"1013":1032,"1014":1289,"1015":1037,"1016":1166,"1017":1169,"1018":1049,"1019":1051,"1020":1178,"1021":1053,"1022":1311,"1023":1315,"1024":1060,"1025":1317,"1026":1065,"1027":1068,"1028":1200,"1029":1330,"1030":563,"1031":1206,"1032":1334,"1033":1215,"1034":1345,"1035":1090,"1036":1221,"1037":1095,"1038":1102,"1039":1235,"1040":1236,"1041":345,"1042":986,"1043":1241,"1044":1116,"1045":1247,"1046":1120,"1047":1121,"1048":1249,"1049":1000,"1050":1131,"1051":1260,"1052":1007,"1053":1137,"1054":1138,"1055":1270,"1056":1016,"1057":1272,"1058":1273,"1059":1151,"1060":1536,"1061":1537,"1062":1665,"1063":1666,"1064":1667,"1065":1672,"1066":1674,"1067":1675,"1068":1676,"1069":1550,"1070":1551,"1071":1679,"1072":1554,"1073":1555,"1074":1561,"1075":1563,"1076":1564,"1077":1571,"1078":1573,"1079":1574,"1080":1575,"1081":1578,"1082":1580,"1083":1583,"1084":1584,"1085":1588,"1086":1591,"1087":1596,"1088":1598,"1089":1600,"1090":1601,"1091":1604,"1092":1607,"1093":1608,"1094":1609,"1095":1611,"1096":1616,"1097":1623,"1098":1630,"1099":1631,"1100":1636,"1101":1637,"1102":1647,"1103":1648,"1104":1655,"1105":1656,"1106":1658,"1107":1531,"1108":1663,"1109":1282,"1110":1283,"1111":1294,"1112":1296,"1113":1297,"1114":1300,"1115":1302,"1116":1316,"1117":1326,"1118":1329,"1119":1337,"1120":1338,"1121":1341,"1122":1220,"1123":1224,"1124":587,"1125":1229,"1126":1266,"1127":1274,"1128":1539,"1129":1540,"1130":1543,"1131":1545,"1132":1547,"1133":1548,"1134":1677,"1135":1678,"1136":1680,"1137":1553,"1138":1681,"1139":1556,"1140":1685,"1141":1559,"1142":1562,"1143":1565,"1144":1567,"1145":1660,"1146":1570,"1147":1662,"1148":1585,"1149":1587,"1150":1589,"1151":1594,"1152":1595,"1153":1599,"1154":1603,"1155":1605,"1156":1610,"1157":1612,"1158":1613,"1159":1614,"1160":1617,"1161":1618,"1162":1619,"1163":1624,"1164":1625,"1165":1628,"1166":1635,"1167":1638,"1168":1640,"1169":1642,"1170":1644,"1171":1645,"1172":1651,"1173":1652,"1174":1653,"1175":1654,"1176":1657,"1177":1532,"1178":1661,"1179":1534,"1180":1792,"1181":1797,"1182":1805,"1183":1808,"1184":1809,"1185":1813,"1186":1814,"1187":1688,"1188":1694,"1189":1822,"1190":1696,"1191":1697,"1192":1826,"1193":1831,"1194":1704,"1195":1705,"1196":1834,"1197":1707,"1198":1836,"1199":1709,"1200":1711,"1201":1759,"1202":1763,"1203":1765,"1204":1766,"1205":1767,"1206":1768,"1207":1778,"1208":1779,"1209":1780,"1210":1782,"1211":1786,"1212":1408,"1213":1527,"1214":1415,"1215":1421,"1216":1422,"1217":1426,"1218":1427,"1219":1433,"1220":1437,"1221":1439,"1222":1445,"1223":1450,"1224":1455,"1225":1457,"1226":1458,"1227":1468,"1228":1347,"1229":1351,"1230":1354,"1231":1483,"1232":1357,"1233":1486,"1234":1487,"1235":1489,"1236":1362,"1237":1367,"1238":1371,"1239":1244,"1240":1376,"1241":1379,"1242":1381,"1243":1382,"1244":1513,"1245":1386,"1246":1388,"1247":1518,"1248":1392,"1249":1521,"1250":1397,"1251":1399,"1252":1407,"1253":1538,"1254":1669,"1255":1542,"1256":1671,"1257":1544,"1258":1673,"1259":1546,"1260":1549,"1261":1684,"1262":1557,"1263":1686,"1264":1560,"1265":1436,"1266":1443,"1267":1572,"1268":1446,"1269":1579,"1270":1581,"1271":1582,"1272":1586,"1273":1590,"1274":1592,"1275":1593,"1276":1475,"1277":1348,"1278":1479,"1279":1358,"1280":1615,"1281":1621,"1282":1627,"1283":1629,"1284":1509,"1285":1384,"1286":1641,"1287":1389,"1288":1390,"1289":1646,"1290":1395,"1291":1396,"1292":1528,"1293":1659,"1294":1533,"1295":1406,"1296":1535,"1297":1795,"1298":1807,"1299":1811,"1300":1692,"1301":1824,"1302":1825,"1303":1698,"1304":1699,"1305":1828,"1306":1701,"1307":1703,"1308":1832,"1309":1833,"1310":1708,"1311":1710,"1312":1712,"1313":1758,"1314":1760,"1315":1764,"1316":1769,"1317":1773,"1318":1775,"1319":1776,"1320":1785,"1321":1788,"1322":1789,"1323":1790,"1324":1791,"1325":2054,"1326":2057,"1327":2060,"1328":2068,"1329":2071,"1330":2072,"1331":2073,"1332":2074,"1333":2076,"1334":2079,"1335":2081,"1336":2086,"1337":2089,"1338":2091,"1339":2093,"1340":2094,"1341":2095,"1342":2104,"1343":2105,"1344":1214,"1345":1309,"1346":1853,"1347":1855,"1348":1857,"1349":1870,"1350":1875,"1351":1876,"1352":1878,"1353":1880,"1354":1881,"1355":1886,"1356":1887,"1357":1889,"1358":1893,"1359":1894,"1360":1897,"1361":1898,"1362":1900,"1363":1901,"1364":1905,"1365":1913,"1366":1916,"1367":1918,"1368":1923,"1369":1924,"1370":1931,"1371":1932,"1372":1937,"1373":1938,"1374":1943,"1375":1944,"1376":1945,"1377":1960,"1378":1964,"1379":1965,"1380":1971,"1381":1973,"1382":1976,"1383":1977,"1384":1982,"1385":1988,"1386":1992,"1387":1999,"1388":2000,"1389":2001,"1390":2003,"1391":2019,"1392":2021,"1393":2024,"1394":2026,"1395":2031,"1396":2032,"1397":2033,"1398":2034,"1399":2035,"1400":2036,"1401":2037,"1402":2038,"1403":2044,"1404":2045,"1405":1541,"1406":2062,"1407":1558,"1408":1566,"1409":1568,"1410":1569,"1411":1576,"1412":1577,"1413":1602,"1414":1606,"1415":1620,"1416":1622,"1417":1626,"1418":1639,"1419":1643,"1420":1650,"1421":1664,"1422":1668,"1423":1682,"1424":1683,"1425":1687,"1426":1690,"1427":1691,"1428":1693,"1429":1695,"1430":1700,"1431":1702,"1432":1706,"1433":1761,"1434":1762,"1435":1770,"1436":1771,"1437":1772,"1438":1774,"1439":1777,"1440":1781,"1441":1783,"1442":1784,"1443":1787,"1444":1793,"1445":1794,"1446":1796,"1447":1798,"1448":1804,"1449":1806,"1450":1810,"1451":1812,"1452":1815,"1453":1816,"1454":1823,"1455":1827,"1456":1829,"1457":1830,"1458":1835,"1459":1849,"1460":1856,"1461":1885,"1462":1936,"1463":1956,"1464":1963,"1465":1986,"1466":1990,"1467":2025,"1468":1529,"1469":1530,"1470":2047,"1471":2048,"1472":2049,"1473":2052,"1474":2055,"1475":2065,"1476":2066,"1477":2067,"1478":2069,"1479":2077,"1480":2080,"1481":2082,"1482":2084,"1483":2088,"1484":2090,"1485":2100,"1486":2103,"1487":2111,"1488":2113,"1489":1848,"1490":1851,"1491":1852,"1492":1854,"1493":1859,"1494":1860,"1495":1862,"1496":1864,"1497":1865,"1498":1867,"1499":1872,"1500":1874,"1501":1877,"1502":1879,"1503":1884,"1504":1888,"1505":1890,"1506":1895,"1507":1899,"1508":1902,"1509":1906,"1510":1907,"1511":1909,"1512":1914,"1513":1915,"1514":1920,"1515":1926,"1516":1927,"1517":1928,"1518":1929,"1519":1930,"1520":1934,"1521":1941,"1522":1946,"1523":1948,"1524":1957,"1525":1962,"1526":1966,"1527":1972,"1528":1974,"1529":1980,"1530":1981,"1531":1985,"1532":1997,"1533":1998,"1534":2004,"1535":2006,"1536":2008,"1537":2010,"1538":2011,"1539":2012,"1540":2013,"1541":2014,"1542":2015,"1543":2022,"1544":2023,"1545":2029,"1546":2030,"1547":2042,"1548":2043,"1549":2114,"1550":2117,"1551":2123,"1552":2127,"1553":2129,"1554":2130,"1555":2133,"1556":2136,"1557":2141,"1558":2142,"1559":2143,"1560":2147,"1561":2153,"1562":2184,"1563":2187,"1564":2188,"1565":2194,"1566":2196,"1567":2197,"1568":2198,"1569":2199,"1570":2200,"1571":2203,"1572":2206,"1573":2207,"1574":2212,"1575":2214,"1576":2215,"1577":2217,"1578":2221,"1579":2222,"1580":2223,"1581":2226,"1582":2227,"1583":2228,"1584":2229,"1585":2230,"1586":2231,"1587":2238,"1588":2244,"1589":2245,"1590":2246,"1591":2252,"1592":2254,"1593":2255,"1594":2256,"1595":2259,"1596":2262,"1597":2266,"1598":2269,"1599":2271,"1600":2272,"1601":2273,"1602":2274,"1603":2277,"1604":2279,"1605":2280,"1606":2281,"1607":2282,"1608":2284,"1609":2285,"1610":2289,"1611":2291,"1612":2295,"1613":2296,"1614":2299,"1615":2300,"1616":2302,"1617":2305,"1618":2306,"1619":2307,"1620":2310,"1621":2050,"1622":2051,"1623":2056,"1624":2061,"1625":2063,"1626":2064,"1627":2070,"1628":2075,"1629":2078,"1630":2083,"1631":2085,"1632":2092,"1633":2096,"1634":2097,"1635":2099,"1636":2101,"1637":2102,"1638":2106,"1639":2107,"1640":2108,"1641":2110,"1642":2112,"1643":2324,"1644":2327,"1645":1850,"1646":2365,"1647":2369,"1648":1858,"1649":1861,"1650":1863,"1651":1866,"1652":1868,"1653":2381,"1654":1871,"1655":1873,"1656":1882,"1657":1883,"1658":2396,"1659":1892,"1660":1896,"1661":2410,"1662":1904,"1663":1908,"1664":1910,"1665":1911,"1666":1912,"1667":1917,"1668":1919,"1669":1921,"1670":1922,"1671":1933,"1672":1935,"1673":1942,"1674":2459,"1675":1949,"1676":1950,"1677":1952,"1678":1953,"1679":1954,"1680":1955,"1681":1958,"1682":1968,"1683":1970,"1684":2486,"1685":1975,"1686":1979,"1687":2495,"1688":1983,"1689":1987,"1690":1989,"1691":1991,"1692":1994,"1693":1995,"1694":2517,"1695":2005,"1696":2521,"1697":2009,"1698":2016,"1699":2017,"1700":2018,"1701":2027,"1702":2041,"1703":2115,"1704":2116,"1705":2122,"1706":2125,"1707":2126,"1708":2128,"1709":2131,"1710":2132,"1711":2134,"1712":2135,"1713":2137,"1714":2138,"1715":2139,"1716":2140,"1717":2144,"1718":2145,"1719":2146,"1720":2148,"1721":2149,"1722":2150,"1723":2151,"1724":2152,"1725":2185,"1726":2186,"1727":2189,"1728":2191,"1729":2193,"1730":2195,"1731":2201,"1732":2204,"1733":2205,"1734":2208,"1735":2209,"1736":2210,"1737":2211,"1738":2213,"1739":2216,"1740":2218,"1741":2219,"1742":2224,"1743":2225,"1744":2232,"1745":2233,"1746":2234,"1747":2235,"1748":2236,"1749":2237,"1750":2239,"1751":2240,"1752":2241,"1753":2242,"1754":2243,"1755":2247,"1756":2251,"1757":2253,"1758":2257,"1759":2260,"1760":2261,"1761":2263,"1762":2264,"1763":2265,"1764":2267,"1765":2268,"1766":2270,"1767":2275,"1768":2276,"1769":2278,"1770":2283,"1771":2287,"1772":2293,"1773":2294,"1774":2297,"1775":2298,"1776":2301,"1777":2303,"1778":2304,"1779":1847,"1780":2561,"1781":2563,"1782":2565,"1783":2566,"1784":2567,"1785":2569,"1786":2570,"1787":2572,"1788":2575,"1789":2576,"1790":2577,"1791":2578,"1792":2580,"1793":2581,"1794":2582,"1795":2583,"1796":2585,"1797":2586,"1798":2589,"1799":2590,"1800":2591,"1801":2592,"1802":2596,"1803":2597,"1804":2601,"1805":2602,"1806":2603,"1807":2608,"1808":2609,"1809":2610,"1810":2612,"1811":2615,"1812":2616,"1813":2619,"1814":2620,"1815":2621,"1816":2623,"1817":2624,"1818":2625,"1819":2626,"1820":2629,"1821":2631,"1822":2632,"1823":2634,"1824":2636,"1825":2639,"1826":2640,"1827":2642,"1828":2643,"1829":2647,"1830":2288,"1831":2314,"1832":2315,"1833":2318,"1834":2328,"1835":2329,"1836":2332,"1837":2338,"1838":2339,"1839":2340,"1840":2341,"1841":2348,"1842":2349,"1843":2351,"1844":2359,"1845":2363,"1846":2364,"1847":2367,"1848":2380,"1849":2385,"1850":2386,"1851":2394,"1852":2398,"1853":2406,"1854":2414,"1855":2415,"1856":2416,"1857":2417,"1858":2418,"1859":2424,"1860":2425,"1861":2428,"1862":2431,"1863":2434,"1864":2442,"1865":2443,"1866":2445,"1867":2451,"1868":2452,"1869":2453,"1870":2456,"1871":2458,"1872":2462,"1873":2465,"1874":2469,"1875":2472,"1876":2478,"1877":2482,"1878":2496,"1879":2497,"1880":2501,"1881":2502,"1882":2504,"1883":2505,"1884":2506,"1885":1993,"1886":2508,"1887":2510,"1888":2514,"1889":2523,"1890":2524,"1891":2540,"1892":2541,"1893":2544,"1894":2552,"1895":2554,"1896":2558,"1897":2559,"1898":2437,"1899":2438,"1900":2313,"1901":2319,"1902":2321,"1903":2449,"1904":2450,"1905":2325,"1906":2454,"1907":2457,"1908":2331,"1909":2464,"1910":2466,"1911":2343,"1912":2345,"1913":2352,"1914":2485,"1915":2358,"1916":2360,"1917":2362,"1918":2490,"1919":2492,"1920":2493,"1921":2366,"1922":2494,"1923":2370,"1924":2372,"1925":2373,"1926":2374,"1927":2500,"1928":2499,"1929":2378,"1930":2507,"1931":2387,"1932":2388,"1933":2389,"1934":2516,"1935":2519,"1936":2520,"1937":2522,"1938":2525,"1939":2400,"1940":2403,"1941":2404,"1942":2409,"1943":2411,"1944":2412,"1945":2422,"1946":2430,"1947":2560,"1948":2562,"1949":2564,"1950":2568,"1951":2573,"1952":2574,"1953":2579,"1954":2584,"1955":2587,"1956":2588,"1957":2594,"1958":2595,"1959":2598,"1960":2600,"1961":2604,"1962":2605,"1963":2606,"1964":2607,"1965":2611,"1966":2613,"1967":2614,"1968":2617,"1969":2618,"1970":2622,"1971":2628,"1972":2630,"1973":2633,"1974":2635,"1975":2637,"1976":2638,"1977":2641,"1978":2644,"1979":2645,"1980":2646,"1981":2648,"1982":2649,"1983":2650,"1984":2651,"1985":2652,"1986":2653,"1987":2654,"1988":2330,"1989":2333,"1990":2334,"1991":2336,"1992":2337,"1993":2342,"1994":2344,"1995":2346,"1996":2347,"1997":2350,"1998":2368,"1999":2375,"2000":2376,"2001":2377,"2002":2379,"2003":2395,"2004":2399,"2005":2401,"2006":2405,"2007":2407,"2008":2408,"2009":2413,"2010":2419,"2011":2421,"2012":2426,"2013":2427,"2014":2429,"2015":2432,"2016":2433,"2017":2435,"2018":2436,"2019":2441,"2020":2446,"2021":2447,"2022":2448,"2023":2455,"2024":2460,"2025":2461,"2026":2463,"2027":2468,"2028":2470,"2029":2471,"2030":2473,"2031":2477,"2032":2479,"2033":2480,"2034":2483,"2035":2484,"2036":2487,"2037":2488,"2038":2489,"2039":2491,"2040":2498,"2041":2503,"2042":2509,"2043":2511,"2044":2512,"2045":2513,"2046":2515,"2047":2526,"2048":2527,"2049":2528,"2050":2529,"2051":2530,"2052":2532,"2053":2533,"2054":2534,"2055":2536,"2056":2538,"2057":2539,"2058":2542,"2059":2543,"2060":2545,"2061":2546,"2062":2547,"2063":2548,"2064":2553,"2065":2555,"2066":2556,"2067":2557,"2068":2655,"2069":2657,"2070":2658,"2071":2660,"2072":2661,"2073":2665,"2074":2666,"2075":2673,"2076":2678,"2077":2680,"2078":2683,"2079":2693,"2080":2696,"2081":2698,"2082":2699,"2083":2700,"2084":2707,"2085":2712,"2086":2713,"2087":2720,"2088":2721,"2089":2722,"2090":2723,"2091":2732,"2092":2740,"2093":2742,"2094":2744,"2095":2745,"2096":2747,"2097":2748,"2098":2755,"2099":2756,"2100":2760,"2101":2762,"2102":2765,"2103":2766,"2104":2771,"2105":2777,"2106":2778,"2107":2780,"2108":2784,"2109":2787,"2110":2788,"2111":2797,"2112":2798,"2113":2799,"2114":2811,"2115":2813,"2116":2825,"2117":2828,"2118":2829,"2119":2830,"2120":2837,"2121":2840,"2122":2841,"2123":2842,"2124":2845,"2125":2852,"2126":2857,"2127":2859,"2128":2864,"2129":2866,"2130":2870,"2131":2877,"2132":2881,"2133":2895,"2134":2903,"2135":2913,"2136":2915,"2137":2918,"2138":2921,"2139":2922,"2140":2923,"2141":2789,"2142":2695,"2143":2717,"2144":2792,"2145":2795,"2146":2750,"2147":2733,"2148":2671,"2149":2737,"2150":2768,"2151":2739,"2152":2773,"2153":2715,"2154":2812,"2155":2685,"2156":2718,"2157":2692,"2158":2694,"2159":2706,"2160":2709,"2161":2710,"2162":2714,"2163":2716,"2164":2719,"2165":2725,"2166":2599,"2167":2728,"2168":2729,"2169":2730,"2170":2731,"2171":2734,"2172":2735,"2173":2736,"2174":2741,"2175":2809,"2176":2746,"2177":2753,"2178":2758,"2179":2759,"2180":2763,"2181":2767,"2182":2774,"2183":2776,"2184":2779,"2185":2783,"2186":2656,"2187":2786,"2188":2659,"2189":2663,"2190":2793,"2191":2670,"2192":2801,"2193":2674,"2194":2675,"2195":2804,"2196":2677,"2197":2802,"2198":2805,"2199":2808,"2200":2681,"2201":2810,"2202":2684,"2203":2818,"2204":2820,"2205":2821,"2206":2823,"2207":2848,"2208":2862,"2209":2863,"2210":2872,"2211":2873,"2212":2874,"2213":2885,"2214":2889,"2215":2897,"2216":2906,"2217":2908,"2218":2909,"2219":2910,"2220":2916,"2221":2920,"2222":2691,"2223":2705,"2224":2711,"2225":2726,"2226":2727,"2227":2807,"2228":2743,"2229":2749,"2230":2754,"2231":2757,"2232":2764,"2233":2770,"2234":2772,"2235":2775,"2236":2785,"2237":2790,"2238":2791,"2239":2667,"2240":2796,"2241":2669,"2242":2672,"2243":2800,"2244":2803,"2245":2676,"2246":2806,"2247":2682,"2248":2816,"2249":2817,"2250":2819,"2251":2824,"2252":2826,"2253":2827,"2254":2832,"2255":2833,"2256":2834,"2257":2835,"2258":2708,"2259":2838,"2260":2839,"2261":2846,"2262":2847,"2263":2849,"2264":2851,"2265":2853,"2266":2854,"2267":2855,"2268":2861,"2269":2865,"2270":2867,"2271":2868,"2272":2869,"2273":2871,"2274":2875,"2275":2876,"2276":2878,"2277":2879,"2278":2880,"2279":2882,"2280":2883,"2281":2884,"2282":2886,"2283":2887,"2284":2888,"2285":2893,"2286":2896,"2287":2898,"2288":2899,"2289":2900,"2290":2901,"2291":2902,"2292":2907,"2293":2911,"2294":2912,"2295":2914,"2296":2917,"2297":2814,"2298":2815,"2299":3072,"2300":2945,"2301":2946,"2302":3074,"2303":2948,"2304":2949,"2305":3076,"2306":3081,"2307":3084,"2308":2958,"2309":3087,"2310":2964,"2311":2967,"2312":2968,"2313":2974,"2314":2982,"2315":2983,"2316":2987,"2317":2860,"2318":2992,"2319":2995,"2320":3063,"2321":2998,"2322":2999,"2323":3001,"2324":3002,"2325":3005,"2326":3012,"2327":3013,"2328":3067,"2329":3016,"2330":3020,"2331":3027,"2332":3031,"2333":3032,"2334":3035,"2335":3036,"2336":3071,"2337":3044,"2338":3048,"2339":3050,"2340":3051,"2341":3052,"2342":2925,"2343":2926,"2344":2927,"2345":3054,"2346":3062,"2347":2935,"2348":3064,"2349":2939,"2350":2940,"2351":3070,"2352":2943,"2353":3041,"2354":2947,"2355":2980,"2356":3047,"2357":2984,"2358":3079,"2359":2668,"2360":2988,"2361":2960,"2362":2961,"2363":2738,"2364":3039,"2365":2971,"2366":2782,"2367":2975,"2368":2944,"2369":3075,"2370":3080,"2371":2953,"2372":2954,"2373":2955,"2374":3082,"2375":2957,"2376":3085,"2377":2959,"2378":3088,"2379":3089,"2380":2962,"2381":2963,"2382":3086,"2383":2965,"2384":2969,"2385":2972,"2386":2976,"2387":2977,"2388":2978,"2389":2979,"2390":2986,"2391":2991,"2392":2993,"2393":2994,"2394":2996,"2395":3000,"2396":3003,"2397":3006,"2398":3007,"2399":3008,"2400":3066,"2401":3011,"2402":3015,"2403":3018,"2404":3019,"2405":3021,"2406":3022,"2407":3025,"2408":3030,"2409":3034,"2410":3046,"2411":2924,"2412":2929,"2413":2930,"2414":3057,"2415":3059,"2416":3060,"2417":2934,"2418":3061,"2419":3065,"2420":2938,"2421":2942,"2422":3204,"2423":3208,"2424":3107,"2425":3113,"2426":3119,"2427":3123,"2428":3125,"2429":3126,"2430":3127,"2431":3132,"2432":3135,"2433":3141,"2434":3142,"2435":3146,"2436":3148,"2437":3153,"2438":3157,"2439":3158,"2440":3162,"2441":3165,"2442":3166,"2443":3169,"2444":3170,"2445":3171,"2446":3174,"2447":3175,"2448":3180,"2449":3181,"2450":3187,"2451":3190,"2452":3191,"2453":3073,"2454":3077,"2455":2950,"2456":2951,"2457":2952,"2458":3083,"2459":2956,"2460":3090,"2461":2966,"2462":2970,"2463":2973,"2464":2981,"2465":2985,"2466":2997,"2467":3009,"2468":3017,"2469":3026,"2470":3037,"2471":3038,"2472":3043,"2473":3045,"2474":3049,"2475":3053,"2476":3055,"2477":2928,"2478":3056,"2479":2931,"2480":2933,"2481":2936,"2482":2937,"2483":3069,"2484":3200,"2485":3202,"2486":3206,"2487":3209,"2488":3211,"2489":3212,"2490":3096,"2491":3101,"2492":3102,"2493":3104,"2494":3105,"2495":3106,"2496":3110,"2497":3112,"2498":3114,"2499":3121,"2500":3124,"2501":3128,"2502":3130,"2503":3134,"2504":3137,"2505":3143,"2506":3145,"2507":3151,"2508":3154,"2509":3159,"2510":3161,"2511":3163,"2512":3172,"2513":3178,"2514":3179,"2515":3182,"2516":3186,"2517":3189,"2518":3192,"2519":3213,"2520":3217,"2521":3218,"2522":3219,"2523":3220,"2524":3221,"2525":3227,"2526":3229,"2527":3234,"2528":3241,"2529":3246,"2530":3248,"2531":3250,"2532":3251,"2533":3252,"2534":3254,"2535":3264,"2536":3266,"2537":3267,"2538":3268,"2539":3273,"2540":3275,"2541":3276,"2542":3280,"2543":3283,"2544":3285,"2545":3287,"2546":3293,"2547":3294,"2548":3296,"2549":3302,"2550":3308,"2551":3309,"2552":3310,"2553":3317,"2554":3203,"2555":3078,"2556":3210,"2557":3100,"2558":3109,"2559":3111,"2560":2989,"2561":3117,"2562":3118,"2563":3129,"2564":3133,"2565":3014,"2566":3144,"2567":3147,"2568":3149,"2569":3197,"2570":3033,"2571":3167,"2572":3040,"2573":3168,"2574":3042,"2575":3176,"2576":3183,"2577":3188,"2578":3196,"2579":2941,"2580":3222,"2581":3223,"2582":3224,"2583":3226,"2584":3233,"2585":3235,"2586":3236,"2587":3237,"2588":3239,"2589":3242,"2590":3243,"2591":3245,"2592":3247,"2593":3253,"2594":3255,"2595":3257,"2596":3258,"2597":3259,"2598":3260,"2599":3262,"2600":3138,"2601":3274,"2602":3277,"2603":3281,"2604":3288,"2605":3289,"2606":3290,"2607":3297,"2608":3299,"2609":3300,"2610":3304,"2611":3306,"2612":3307,"2613":3311,"2614":3312,"2615":3331,"2616":3459,"2617":3460,"2618":3337,"2619":3338,"2620":3340,"2621":3341,"2622":3342,"2623":3343,"2624":3344,"2625":3345,"2626":3346,"2627":3348,"2628":3350,"2629":3352,"2630":3353,"2631":3354,"2632":3359,"2633":3360,"2634":3363,"2635":3370,"2636":3371,"2637":3372,"2638":3374,"2639":3376,"2640":3381,"2641":3383,"2642":3384,"2643":3385,"2644":3389,"2645":3393,"2646":3396,"2647":3397,"2648":3398,"2649":3399,"2650":3405,"2651":3450,"2652":3410,"2653":3411,"2654":3412,"2655":3451,"2656":3415,"2657":3417,"2658":3291,"2659":3420,"2660":3453,"2661":3425,"2662":3430,"2663":3431,"2664":3434,"2665":3439,"2666":3443,"2667":3444,"2668":3445,"2669":3448,"2670":3322,"2671":3323,"2672":3324,"2673":3325,"2674":3326,"2675":3327,"2676":3207,"2677":3215,"2678":3230,"2679":3231,"2680":3232,"2681":3238,"2682":3115,"2683":3120,"2684":3139,"2685":3150,"2686":3152,"2687":3156,"2688":3286,"2689":3164,"2690":3292,"2691":3295,"2692":3173,"2693":3184,"2694":3185,"2695":3313,"2696":3314,"2697":3315,"2698":3193,"2699":3198,"2700":3328,"2701":3329,"2702":3330,"2703":3456,"2704":3332,"2705":3334,"2706":3335,"2707":3336,"2708":3457,"2709":3339,"2710":3347,"2711":3349,"2712":3351,"2713":3356,"2714":3361,"2715":3362,"2716":3364,"2717":3365,"2718":3366,"2719":3367,"2720":3368,"2721":3373,"2722":3375,"2723":3377,"2724":3378,"2725":3379,"2726":3380,"2727":3382,"2728":3386,"2729":3387,"2730":3388,"2731":3390,"2732":3400,"2733":3401,"2734":3402,"2735":3403,"2736":3404,"2737":3406,"2738":3407,"2739":3408,"2740":3409,"2741":3413,"2742":3414,"2743":3416,"2744":3418,"2745":3419,"2746":3421,"2747":3422,"2748":3423,"2749":3424,"2750":3298,"2751":3426,"2752":3433,"2753":3435,"2754":3436,"2755":3437,"2756":3438,"2757":3440,"2758":3441,"2759":3442,"2760":3447,"2761":3449,"2762":3452,"2763":3454,"2764":3455,"2765":3587,"2766":3588,"2767":3589,"2768":3463,"2769":3464,"2770":3591,"2771":3592,"2772":3468,"2773":3470,"2774":3599,"2775":3479,"2776":3482,"2777":3486,"2778":3487,"2779":3488,"2780":3489,"2781":3493,"2782":3494,"2783":3502,"2784":3503,"2785":3511,"2786":3517,"2787":3522,"2788":3533,"2789":3534,"2790":3536,"2791":3540,"2792":3542,"2793":3554,"2794":3558,"2795":3559,"2796":3572,"2797":3573,"2798":3578,"2799":3579,"2800":3580,"2801":3214,"2802":3216,"2803":3228,"2804":3240,"2805":3244,"2806":3249,"2807":3256,"2808":3261,"2809":3263,"2810":3265,"2811":3270,"2812":3272,"2813":3278,"2814":3282,"2815":3284,"2816":3301,"2817":3303,"2818":3305,"2819":3316,"2820":3319,"2821":3320,"2822":3584,"2823":3586,"2824":3593,"2825":3601,"2826":3602,"2827":3608,"2828":3609,"2829":3610,"2830":3611,"2831":3612,"2832":3613,"2833":3614,"2834":3615,"2835":3616,"2836":3619,"2837":3620,"2838":3621,"2839":3623,"2840":3624,"2841":3625,"2842":3627,"2843":3630,"2844":3632,"2845":3633,"2846":3635,"2847":3641,"2848":3642,"2849":3643,"2850":3645,"2851":3647,"2852":3648,"2853":3658,"2854":3661,"2855":3662,"2856":3668,"2857":3669,"2858":3670,"2859":3671,"2860":3674,"2861":3675,"2862":3676,"2863":3678,"2864":3679,"2865":3683,"2866":3684,"2867":3686,"2868":3688,"2869":3690,"2870":3698,"2871":3699,"2872":3701,"2873":3704,"2874":3708,"2875":3709,"2876":3713,"2877":3715,"2878":3717,"2879":3719,"2880":3720,"2881":3721,"2882":3722,"2883":3723,"2884":3724,"2885":3736,"2886":3737,"2887":3738,"2888":3739,"2889":3741,"2890":3742,"2891":3743,"2892":3744,"2893":3746,"2894":3748,"2895":3749,"2896":3751,"2897":3753,"2898":3754,"2899":3755,"2900":3756,"2901":3759,"2902":3760,"2903":3761,"2904":3763,"2905":3765,"2906":3766,"2907":3767,"2908":3769,"2909":3770,"2910":3771,"2911":3772,"2912":3462,"2913":3467,"2914":3471,"2915":3472,"2916":3473,"2917":3476,"2918":3477,"2919":3484,"2920":3490,"2921":3496,"2922":3497,"2923":3498,"2924":3499,"2925":3504,"2926":3505,"2927":3507,"2928":3508,"2929":3509,"2930":3510,"2931":3514,"2932":3525,"2933":3526,"2934":3529,"2935":3530,"2936":3538,"2937":3539,"2938":3543,"2939":3548,"2940":3549,"2941":3562,"2942":3563,"2943":3567,"2944":3571,"2945":3577,"2946":3968,"2947":3969,"2948":3842,"2949":3845,"2950":3846,"2951":3973,"2952":3979,"2953":3980,"2954":3853,"2955":3981,"2956":3855,"2957":3856,"2958":3984,"2959":3986,"2960":3860,"2961":3862,"2962":3863,"2963":3990,"2964":3865,"2965":3991,"2966":3994,"2967":3995,"2968":3997,"2969":3999,"2970":4000,"2971":3878,"2972":3880,"2973":3884,"2974":3758,"2975":3887,"2976":3892,"2977":3902,"2978":3903,"2979":3905,"2980":3906,"2981":3911,"2982":3785,"2983":3786,"2984":3914,"2985":3916,"2986":3917,"2987":3919,"2988":3920,"2989":3921,"2990":3794,"2991":3925,"2992":3927,"2993":3928,"2994":3802,"2995":3930,"2996":3807,"2997":3935,"2998":3936,"2999":3937,"3000":3812,"3001":3940,"3002":3815,"3003":3816,"3004":3945,"3005":3821,"3006":3822,"3007":3965,"3008":3960,"3009":3837,"3010":3585,"3011":3590,"3012":3465,"3013":3466,"3014":3595,"3015":3596,"3016":3469,"3017":3474,"3018":3475,"3019":3483,"3020":3485,"3021":3491,"3022":3492,"3023":3495,"3024":3500,"3025":3501,"3026":3506,"3027":3512,"3028":3513,"3029":3518,"3030":3519,"3031":3520,"3032":3521,"3033":3523,"3034":3524,"3035":3527,"3036":3528,"3037":3531,"3038":3535,"3039":3537,"3040":3541,"3041":3555,"3042":3560,"3043":3564,"3044":3566,"3045":3569,"3046":3575,"3047":3576,"3048":3581,"3049":3582,"3050":3603,"3051":3605,"3052":3607,"3053":3617,"3054":3618,"3055":3622,"3056":3626,"3057":3628,"3058":3629,"3059":3631,"3060":3634,"3061":3636,"3062":3637,"3063":3638,"3064":3639,"3065":3640,"3066":3644,"3067":3646,"3068":3649,"3069":3650,"3070":3651,"3071":3652,"3072":3653,"3073":3654,"3074":3655,"3075":3656,"3076":3659,"3077":3663,"3078":3664,"3079":3665,"3080":3666,"3081":3667,"3082":3672,"3083":3673,"3084":3677,"3085":3680,"3086":3681,"3087":3682,"3088":3685,"3089":3687,"3090":3691,"3091":3692,"3092":3693,"3093":3694,"3094":3695,"3095":3696,"3096":3697,"3097":3700,"3098":3702,"3099":3705,"3100":3706,"3101":3707,"3102":3710,"3103":3711,"3104":3712,"3105":3714,"3106":3716,"3107":3725,"3108":3726,"3109":3727,"3110":3728,"3111":3729,"3112":3730,"3113":3731,"3114":3732,"3115":3735,"3116":3740,"3117":3745,"3118":3747,"3119":3750,"3120":3752,"3121":3757,"3122":3762,"3123":3764,"3124":3768,"3125":3773,"3126":3774,"3127":3775,"3128":3776,"3129":3781,"3130":3782,"3131":3783,"3132":3784,"3133":3788,"3134":3789,"3135":3798,"3136":3801,"3137":3805,"3138":3808,"3139":3809,"3140":3811,"3141":3817,"3142":3818,"3143":3819,"3144":3820,"3145":3823,"3146":3826,"3147":3829,"3148":3838,"3149":3839,"3150":3840,"3151":3841,"3152":3843,"3153":3844,"3154":3850,"3155":3852,"3156":3859,"3157":3866,"3158":3885,"3159":3888,"3160":3890,"3161":3891,"3162":3893,"3163":3896,"3164":3898,"3165":3899,"3166":3900,"3167":3907,"3168":3908,"3169":3909,"3170":3912,"3171":3913,"3172":3918,"3173":3926,"3174":3932,"3175":3933,"3176":3939,"3177":3941,"3178":3943,"3179":3946,"3180":3948,"3181":3949,"3182":3951,"3183":3953,"3184":3954,"3185":3955,"3186":3957,"3187":3958,"3188":3961,"3189":3963,"3190":3966,"3191":3971,"3192":3461,"3193":3975,"3194":3976,"3195":3978,"3196":3982,"3197":3983,"3198":3985,"3199":3992,"3200":3996,"3201":3851,"3202":3857,"3203":3858,"3204":3987,"3205":3998,"3206":3877,"3207":3904,"3208":3910,"3209":3787,"3210":3791,"3211":3793,"3212":3922,"3213":3800,"3214":3810,"3215":3938,"3216":3944,"3217":3947,"3218":3950,"3219":3825,"3220":3831,"3221":3834,"3222":3967,"3223":4098,"3224":4101,"3225":4107,"3226":4109,"3227":4112,"3228":4113,"3229":4114,"3230":4115,"3231":4117,"3232":4118,"3233":4119,"3234":4120,"3235":4121,"3236":4124,"3237":4126,"3238":4128,"3239":4002,"3240":4003,"3241":4004,"3242":4005,"3243":4006,"3244":4130,"3245":4014,"3246":4017,"3247":4019,"3248":4020,"3249":4021,"3250":4022,"3251":4025,"3252":4026,"3253":4027,"3254":4031,"3255":4032,"3256":4036,"3257":4037,"3258":4038,"3259":4040,"3260":4048,"3261":4049,"3262":4050,"3263":4051,"3264":4055,"3265":4056,"3266":4057,"3267":4062,"3268":4063,"3269":4064,"3270":4069,"3271":4070,"3272":4072,"3273":4079,"3274":4085,"3275":4087,"3276":4090,"3277":4091,"3278":4092,"3279":4096,"3280":4097,"3281":4099,"3282":4100,"3283":4102,"3284":4103,"3285":4105,"3286":4106,"3287":4108,"3288":4111,"3289":4116,"3290":4122,"3291":4123,"3292":4125,"3293":4127,"3294":4129,"3295":4131,"3296":4132,"3297":4133,"3298":4134,"3299":4135,"3300":4137,"3301":4138,"3302":4139,"3303":4140,"3304":4142,"3305":4143,"3306":4145,"3307":4150,"3308":4151,"3309":4153,"3310":4154,"3311":4155,"3312":4156,"3313":4158,"3314":4161,"3315":4164,"3316":4167,"3317":4170,"3318":4171,"3319":4172,"3320":4174,"3321":4175,"3322":4176,"3323":4177,"3324":4179,"3325":4181,"3326":4184,"3327":4185,"3328":4187,"3329":4188,"3330":4189,"3331":4192,"3332":4193,"3333":4197,"3334":4202,"3335":4205,"3336":4206,"3337":4208,"3338":4210,"3339":4212,"3340":4213,"3341":4215,"3342":4218,"3343":4222,"3344":4223,"3345":4224,"3346":4226,"3347":4228,"3348":4229,"3349":4230,"3350":4231,"3351":4232,"3352":4236,"3353":4237,"3354":4239,"3355":4244,"3356":4249,"3357":4253,"3358":4254,"3359":4255,"3360":4258,"3361":4263,"3362":4267,"3363":4269,"3364":4270,"3365":4272,"3366":4273,"3367":4275,"3368":4277,"3369":4278,"3370":4279,"3371":4280,"3372":4281,"3373":4282,"3374":4290,"3375":4293,"3376":4301,"3377":4302,"3378":4306,"3379":4308,"3380":4309,"3381":3836,"3382":4001,"3383":4007,"3384":4009,"3385":4010,"3386":4011,"3387":4012,"3388":4013,"3389":4015,"3390":4016,"3391":4018,"3392":4023,"3393":4024,"3394":4028,"3395":4029,"3396":4033,"3397":4034,"3398":4035,"3399":4039,"3400":4041,"3401":4042,"3402":4044,"3403":4045,"3404":4046,"3405":4047,"3406":4052,"3407":4053,"3408":4054,"3409":4058,"3410":4059,"3411":4061,"3412":4067,"3413":4068,"3414":4074,"3415":4075,"3416":4076,"3417":4077,"3418":4078,"3419":4080,"3420":4081,"3421":4083,"3422":4084,"3423":4088,"3424":4089,"3425":4093,"3426":4094,"3427":4095,"3428":3974,"3429":3848,"3430":3977,"3431":3854,"3432":3861,"3433":3989,"3434":3864,"3435":3993,"3436":3879,"3437":3886,"3438":3897,"3439":3915,"3440":3790,"3441":3795,"3442":3923,"3443":3797,"3444":3799,"3445":3931,"3446":3806,"3447":3813,"3448":3942,"3449":3952,"3450":3827,"3451":3828,"3452":3830,"3453":3833,"3454":3962,"3455":3835,"3456":3964,"3457":4609,"3458":4610,"3459":4611,"3460":4612,"3461":4614,"3462":4616,"3463":4617,"3464":4622,"3465":4623,"3466":4635,"3467":4638,"3468":4640,"3469":4649,"3470":4650,"3471":4651,"3472":4652,"3473":4654,"3474":4663,"3475":4665,"3476":4670,"3477":4672,"3478":4677,"3479":4678,"3480":4680,"3481":4682,"3482":4686,"3483":4688,"3484":4690,"3485":4699,"3486":4702,"3487":4704,"3488":4706,"3489":4707,"3490":4709,"3491":4713,"3492":4714,"3493":4726,"3494":4731,"3495":4733,"3496":4735,"3497":4749,"3498":4752,"3499":4756,"3500":4758,"3501":4762,"3502":4763,"3503":4311,"3504":4312,"3505":4313,"3506":4316,"3507":4319,"3508":4323,"3509":4326,"3510":4327,"3511":4328,"3512":4331,"3513":4332,"3514":4333,"3515":4334,"3516":4335,"3517":4339,"3518":4340,"3519":4341,"3520":4342,"3521":4347,"3522":4348,"3523":4349,"3524":4350,"3525":4351,"3526":4352,"3527":4353,"3528":4354,"3529":4359,"3530":4361,"3531":4362,"3532":4363,"3533":4367,"3534":4371,"3535":4373,"3536":4374,"3537":4376,"3538":4379,"3539":4380,"3540":4381,"3541":4382,"3542":4384,"3543":4385,"3544":4386,"3545":4387,"3546":4388,"3547":4390,"3548":4391,"3549":4392,"3550":4394,"3551":4396,"3552":4397,"3553":4399,"3554":4404,"3555":4406,"3556":4407,"3557":4410,"3558":4411,"3559":4412,"3560":4415,"3561":4416,"3562":4418,"3563":4419,"3564":4432,"3565":4435,"3566":4438,"3567":4439,"3568":4441,"3569":4442,"3570":4444,"3571":4446,"3572":4450,"3573":4452,"3574":4461,"3575":4466,"3576":4470,"3577":4473,"3578":4483,"3579":4488,"3580":4490,"3581":4491,"3582":4494,"3583":4496,"3584":4498,"3585":4501,"3586":4503,"3587":4506,"3588":4507,"3589":4513,"3590":4517,"3591":4522,"3592":4524,"3593":4532,"3594":4533,"3595":4539,"3596":4544,"3597":4545,"3598":4546,"3599":4548,"3600":4556,"3601":4557,"3602":4558,"3603":4559,"3604":4560,"3605":4562,"3606":4565,"3607":4567,"3608":4569,"3609":4576,"3610":4577,"3611":4581,"3612":4582,"3613":4583,"3614":4584,"3615":4588,"3616":4589,"3617":4595,"3618":4596,"3619":4602,"3620":4605,"3621":4608,"3622":3970,"3623":4489,"3624":4618,"3625":3849,"3626":4628,"3627":4515,"3628":3882,"3629":4657,"3630":4540,"3631":3901,"3632":4551,"3633":4552,"3634":3792,"3635":3796,"3636":3924,"3637":3929,"3638":3803,"3639":4580,"3640":4458,"3641":3824,"3642":4467,"3643":3956,"3644":3959,"3645":4606,"3646":4613,"3647":4615,"3648":4619,"3649":4620,"3650":4626,"3651":4627,"3652":4631,"3653":4632,"3654":4633,"3655":4634,"3656":4637,"3657":4639,"3658":4645,"3659":4136,"3660":4141,"3661":4655,"3662":4144,"3663":4656,"3664":4146,"3665":4147,"3666":4149,"3667":4660,"3668":4662,"3669":4152,"3670":4666,"3671":4157,"3672":4669,"3673":4159,"3674":4160,"3675":4673,"3676":4162,"3677":4163,"3678":4674,"3679":4165,"3680":4166,"3681":4676,"3682":4168,"3683":4169,"3684":4681,"3685":4683,"3686":4689,"3687":4178,"3688":4180,"3689":4692,"3690":4183,"3691":4694,"3692":4695,"3693":4186,"3694":4190,"3695":4191,"3696":4703,"3697":4705,"3698":4194,"3699":4195,"3700":4196,"3701":4708,"3702":4198,"3703":4199,"3704":4200,"3705":4201,"3706":4710,"3707":4203,"3708":4204,"3709":4711,"3710":4712,"3711":4207,"3712":4715,"3713":4209,"3714":4716,"3715":4211,"3716":4719,"3717":4720,"3718":4216,"3719":4217,"3720":4721,"3721":4219,"3722":4220,"3723":4221,"3724":4725,"3725":4728,"3726":4729,"3727":4225,"3728":4730,"3729":4227,"3730":4738,"3731":4740,"3732":4742,"3733":4743,"3734":4745,"3735":4746,"3736":4747,"3737":4238,"3738":4750,"3739":4240,"3740":4241,"3741":4242,"3742":4243,"3743":4245,"3744":4246,"3745":4247,"3746":4248,"3747":4753,"3748":4250,"3749":4251,"3750":4252,"3751":4759,"3752":4761,"3753":4764,"3754":4256,"3755":4257,"3756":4765,"3757":4259,"3758":4260,"3759":4261,"3760":4262,"3761":4766,"3762":4264,"3763":4265,"3764":4266,"3765":4268,"3766":4271,"3767":4274,"3768":4276,"3769":4283,"3770":4284,"3771":4286,"3772":4288,"3773":4291,"3774":4292,"3775":4294,"3776":4295,"3777":4296,"3778":4297,"3779":4298,"3780":4299,"3781":4300,"3782":4722,"3783":4303,"3784":4304,"3785":4305,"3786":4307,"3787":4723,"3788":4310,"3789":4724,"3790":4314,"3791":4315,"3792":4317,"3793":4318,"3794":4320,"3795":4321,"3796":4322,"3797":4324,"3798":4325,"3799":4329,"3800":4330,"3801":4336,"3802":4337,"3803":4338,"3804":4343,"3805":4344,"3806":4345,"3807":4346,"3808":4355,"3809":4356,"3810":4357,"3811":4358,"3812":4360,"3813":4364,"3814":4365,"3815":4366,"3816":4368,"3817":4369,"3818":4370,"3819":4372,"3820":4377,"3821":4378,"3822":4383,"3823":4389,"3824":4393,"3825":4395,"3826":4398,"3827":4401,"3828":4402,"3829":4403,"3830":4405,"3831":4408,"3832":4409,"3833":4413,"3834":4414,"3835":4417,"3836":4420,"3837":4421,"3838":4422,"3839":4423,"3840":4424,"3841":4425,"3842":4426,"3843":4427,"3844":4428,"3845":4429,"3846":4430,"3847":4431,"3848":4433,"3849":4434,"3850":4436,"3851":4437,"3852":4440,"3853":4443,"3854":4445,"3855":4448,"3856":4449,"3857":4451,"3858":4453,"3859":4454,"3860":4455,"3861":4457,"3862":4459,"3863":4460,"3864":4464,"3865":4465,"3866":4468,"3867":4469,"3868":4755,"3869":4471,"3870":4472,"3871":4476,"3872":4477,"3873":4479,"3874":4482,"3875":4484,"3876":4485,"3877":4487,"3878":4495,"3879":4497,"3880":4504,"3881":4505,"3882":4512,"3883":4516,"3884":4518,"3885":4519,"3886":4523,"3887":4525,"3888":4530,"3889":4531,"3890":4535,"3891":4536,"3892":4541,"3893":4543,"3894":4547,"3895":4549,"3896":4553,"3897":4561,"3898":4564,"3899":4572,"3900":4574,"3901":4575,"3902":4579,"3903":4586,"3904":4599,"3905":4603,"3906":4736,"3907":4739,"3908":4744,"3909":4748,"3910":4754,"3911":4757,"3912":4760,"3913":4667,"3914":4668,"3915":4671,"3916":4675,"3917":4679,"3918":4685,"3919":4693,"3920":4696,"3921":4697,"3922":4698,"3923":4700,"3924":4718,"3925":4732,"3926":4734,"3927":4481,"3928":4500,"3929":4493,"3930":4992,"3931":4997,"3932":5005,"3933":5011,"3934":4884,"3935":4888,"3936":4889,"3937":4892,"3938":5020,"3939":5021,"3940":5022,"3941":5024,"3942":5025,"3943":5030,"3944":4778,"3945":4907,"3946":4914,"3947":4921,"3948":4795,"3949":4926,"3950":5056,"3951":4929,"3952":4802,"3953":5058,"3954":5059,"3955":4941,"3956":4814,"3957":4822,"3958":4829,"3959":4831,"3960":4960,"3961":4833,"3962":4834,"3963":4964,"3964":4966,"3965":4842,"3966":4843,"3967":4970,"3968":4845,"3969":4847,"3970":4975,"3971":4977,"3972":4850,"3973":4978,"3974":4989,"3975":4480,"3976":4486,"3977":4873,"3978":4875,"3979":4492,"3980":4621,"3981":4879,"3982":4625,"3983":4499,"3984":5012,"3985":4502,"3986":5016,"3987":4508,"3988":4509,"3989":4510,"3990":4511,"3991":4636,"3992":4641,"3993":4514,"3994":4643,"3995":4896,"3996":4646,"3997":4647,"3998":4527,"3999":4528,"4000":4529,"4001":4658,"4002":4659,"4003":4911,"4004":4661,"4005":4534,"4006":4664,"4007":4537,"4008":4538,"4009":4542,"4010":5060,"4011":4933,"4012":4550,"4013":4944,"4014":4563,"4015":4566,"4016":4568,"4017":4570,"4018":4571,"4019":4573,"4020":4447,"4021":4578,"4022":4456,"4023":4585,"4024":4969,"4025":4587,"4026":4462,"4027":4463,"4028":4591,"4029":4594,"4030":4851,"4031":4597,"4032":4727,"4033":4600,"4034":4601,"4035":4475,"4036":4604,"4037":4478,"4038":4607,"4039":4779,"4040":4780,"4041":4782,"4042":4783,"4043":4787,"4044":4790,"4045":4791,"4046":4793,"4047":4796,"4048":4797,"4049":4808,"4050":4816,"4051":4824,"4052":4825,"4053":4826,"4054":4830,"4055":4832,"4056":4835,"4057":4839,"4058":4840,"4059":4848,"4060":4849,"4061":4855,"4062":4856,"4063":4857,"4064":4858,"4065":4859,"4066":4863,"4067":4866,"4068":4874,"4069":4880,"4070":4881,"4071":4882,"4072":4886,"4073":4887,"4074":4893,"4075":4895,"4076":4898,"4077":4901,"4078":4902,"4079":4903,"4080":4905,"4081":4906,"4082":4908,"4083":4917,"4084":4920,"4085":4930,"4086":4935,"4087":4936,"4088":4940,"4089":4950,"4090":4953,"4091":4955,"4092":4958,"4093":4961,"4094":4962,"4095":4963,"4096":4967,"4097":4971,"4098":4972,"4099":4973,"4100":4976,"4101":4979,"4102":4981,"4103":4982,"4104":4983,"4105":4984,"4106":4985,"4107":4987,"4108":4990,"4109":4991,"4110":4994,"4111":4996,"4112":4999,"4113":5000,"4114":5001,"4115":5003,"4116":5006,"4117":5007,"4118":5018,"4119":5019,"4120":5028,"4121":5032,"4122":5038,"4123":5040,"4124":5051,"4125":5054,"4126":5055,"4127":5057,"4128":3321,"4129":186,"4130":1491,"4131":2537,"4132":3895,"4133":3446,"4134":3199,"4135":2535,"4136":3689,"4137":5120,"4138":5123,"4139":5125,"4140":5128,"4141":5129,"4142":5137,"4143":5139,"4144":5140,"4145":5141,"4146":5142,"4147":5144,"4148":5146,"4149":5150,"4150":5151,"4151":5156,"4152":5157,"4153":5158,"4154":5159,"4155":5160,"4156":5161,"4157":5163,"4158":5168,"4159":5169,"4160":5170,"4161":5172,"4162":5173,"4163":5176,"4164":5177,"4165":5181,"4166":5187,"4167":5189,"4168":5192,"4169":5194,"4170":5195,"4171":5196,"4172":5198,"4173":5200,"4174":5202,"4175":5204,"4176":5205,"4177":5206,"4178":5208,"4179":5210,"4180":5216,"4181":5218,"4182":5219,"4183":5220,"4184":5225,"4185":5226,"4186":5227,"4187":5229,"4188":5230,"4189":5232,"4190":5233,"4191":5234,"4192":5238,"4193":5241,"4194":5245,"4195":5247,"4196":5248,"4197":5252,"4198":5256,"4199":5258,"4200":5263,"4201":5267,"4202":5274,"4203":4769,"4204":5280,"4205":4771,"4206":5281,"4207":5283,"4208":5284,"4209":4775,"4210":5290,"4211":5293,"4212":4786,"4213":4789,"4214":5303,"4215":4792,"4216":4794,"4217":5308,"4218":4798,"4219":4799,"4220":4800,"4221":5312,"4222":5313,"4223":5314,"4224":4805,"4225":4806,"4226":5319,"4227":4809,"4228":5324,"4229":4817,"4230":5329,"4231":5331,"4232":5340,"4233":5341,"4234":5347,"4235":5348,"4236":4846,"4237":5359,"4238":4854,"4239":5367,"4240":5368,"4241":4860,"4242":5378,"4243":5379,"4244":4869,"4245":4871,"4246":4872,"4247":5381,"4248":5386,"4249":4876,"4250":5388,"4251":5393,"4252":5394,"4253":4883,"4254":5398,"4255":4891,"4256":5404,"4257":4897,"4258":5415,"4259":5423,"4260":4912,"4261":5428,"4262":4918,"4263":5431,"4264":5434,"4265":4923,"4266":4924,"4267":5435,"4268":4927,"4269":5442,"4270":5443,"4271":4937,"4272":4938,"4273":4939,"4274":5449,"4275":5450,"4276":5454,"4277":4943,"4278":5460,"4279":4949,"4280":4951,"4281":5465,"4282":4954,"4283":5466,"4284":5467,"4285":4957,"4286":4959,"4287":5470,"4288":5477,"4289":5478,"4290":5480,"4291":5481,"4292":5488,"4293":4980,"4294":5492,"4295":5494,"4296":5498,"4297":5013,"4298":5027,"4299":5034,"4300":5036,"4301":5037,"4302":5046,"4303":5047,"4304":5050,"4305":5052,"4306":5061,"4307":5063,"4308":5065,"4309":5067,"4310":5069,"4311":5070,"4312":5072,"4313":5074,"4314":5080,"4315":5082,"4316":5083,"4317":5085,"4318":5087,"4319":5088,"4320":5090,"4321":5096,"4322":5100,"4323":5101,"4324":5102,"4325":5103,"4326":5105,"4327":5106,"4328":5107,"4329":5108,"4330":5109,"4331":5115,"4332":5116,"4333":5117,"4334":5118,"4335":4993,"4336":5002,"4337":5004,"4338":4877,"4339":4878,"4340":5014,"4341":4894,"4342":4899,"4343":4773,"4344":4774,"4345":5029,"4346":4776,"4347":4777,"4348":4781,"4349":4784,"4350":4913,"4351":4915,"4352":4916,"4353":5041,"4354":5045,"4355":4919,"4356":5048,"4357":4928,"4358":4803,"4359":4942,"4360":4818,"4361":4947,"4362":4820,"4363":4821,"4364":4948,"4365":4819,"4366":4952,"4367":4827,"4368":4836,"4369":4965,"4370":4841,"4371":4852,"4372":4988,"4373":5121,"4374":5122,"4375":5124,"4376":5126,"4377":5130,"4378":5131,"4379":5132,"4380":5133,"4381":5134,"4382":5135,"4383":5136,"4384":5138,"4385":5143,"4386":5145,"4387":5147,"4388":5148,"4389":5149,"4390":5152,"4391":5153,"4392":5155,"4393":5162,"4394":5164,"4395":5166,"4396":5167,"4397":5171,"4398":5174,"4399":5175,"4400":3131,"4401":5179,"4402":5180,"4403":5182,"4404":5183,"4405":5184,"4406":5185,"4407":5186,"4408":5190,"4409":5191,"4410":5193,"4411":5197,"4412":5199,"4413":5201,"4414":5203,"4415":5207,"4416":5209,"4417":5211,"4418":5212,"4419":5213,"4420":5214,"4421":5215,"4422":5217,"4423":5222,"4424":5224,"4425":5228,"4426":5231,"4427":5235,"4428":5236,"4429":5237,"4430":5239,"4431":5240,"4432":5242,"4433":5243,"4434":5244,"4435":5246,"4436":5249,"4437":5250,"4438":5251,"4439":4741,"4440":5253,"4441":5254,"4442":5255,"4443":5257,"4444":5259,"4445":5260,"4446":5262,"4447":5264,"4448":5268,"4449":5269,"4450":5270,"4451":5271,"4452":5272,"4453":5273,"4454":5275,"4455":5276,"4456":5277,"4457":5278,"4458":5282,"4459":5286,"4460":5287,"4461":5288,"4462":5289,"4463":5291,"4464":5292,"4465":5296,"4466":5298,"4467":5299,"4468":5300,"4469":5304,"4470":5305,"4471":5306,"4472":5307,"4473":5310,"4474":5311,"4475":5316,"4476":3271,"4477":5320,"4478":5325,"4479":5326,"4480":5327,"4481":5328,"4482":5330,"4483":5333,"4484":5335,"4485":5336,"4486":5342,"4487":5349,"4488":5350,"4489":5351,"4490":5353,"4491":5355,"4492":5356,"4493":5360,"4494":5362,"4495":5363,"4496":5364,"4497":5365,"4498":5366,"4499":5370,"4500":5375,"4501":5376,"4502":5382,"4503":5384,"4504":5385,"4505":5387,"4506":5390,"4507":5391,"4508":5395,"4509":5396,"4510":5397,"4511":5400,"4512":5401,"4513":5405,"4514":5406,"4515":5407,"4516":5408,"4517":5411,"4518":5412,"4519":5413,"4520":5414,"4521":5416,"4522":5417,"4523":5418,"4524":5421,"4525":5422,"4526":5425,"4527":5429,"4528":5430,"4529":5432,"4530":5433,"4531":5436,"4532":5437,"4533":5438,"4534":5439,"4535":5441,"4536":5444,"4537":5445,"4538":5448,"4539":5451,"4540":5452,"4541":5456,"4542":5457,"4543":5458,"4544":5459,"4545":5461,"4546":5463,"4547":5469,"4548":5471,"4549":5474,"4550":5482,"4551":5483,"4552":5484,"4553":5489,"4554":5490,"4555":5491,"4556":5496,"4557":5497,"4558":5500,"4559":5062,"4560":5064,"4561":5066,"4562":5068,"4563":5073,"4564":5075,"4565":5076,"4566":5077,"4567":5078,"4568":5079,"4569":5081,"4570":5084,"4571":5086,"4572":5089,"4573":5091,"4574":5092,"4575":5093,"4576":5095,"4577":5097,"4578":5098,"4579":5099,"4580":5104,"4581":5110,"4582":5111,"4583":5112,"4584":5113,"4585":5114,"4586":5635,"4587":5636,"4588":5639,"4589":5640,"4590":5642,"4591":5644,"4592":5652,"4593":5653,"4594":5654,"4595":5656,"4596":5657,"4597":5658,"4598":5661,"4599":5662,"4600":5664,"4601":5666,"4602":5673,"4603":5674,"4604":5679,"4605":5681,"4606":5682,"4607":5687,"4608":5690,"4609":5694,"4610":5696,"4611":5698,"4612":5699,"4613":5700,"4614":5706,"4615":5707,"4616":5708,"4617":5709,"4618":5710,"4619":5711,"4620":5715,"4621":5716,"4622":5719,"4623":5726,"4624":5727,"4625":5728,"4626":5732,"4627":5733,"4628":5739,"4629":5742,"4630":5744,"4631":5745,"4632":5746,"4633":5747,"4634":5748,"4635":5749,"4636":5751,"4637":5752,"4638":5757,"4639":5758,"4640":5760,"4641":5765,"4642":5766,"4643":5768,"4644":5769,"4645":5771,"4646":5261,"4647":5773,"4648":5775,"4649":5782,"4650":5783,"4651":5784,"4652":5788,"4653":5279,"4654":5792,"4655":5793,"4656":5794,"4657":5795,"4658":5796,"4659":5285,"4660":5799,"4661":5800,"4662":5801,"4663":5802,"4664":5805,"4665":5294,"4666":5295,"4667":5297,"4668":5809,"4669":5301,"4670":5302,"4671":5815,"4672":5816,"4673":5820,"4674":5309,"4675":5823,"4676":5315,"4677":5827,"4678":5317,"4679":5318,"4680":5830,"4681":5831,"4682":5322,"4683":5323,"4684":5837,"4685":5841,"4686":5843,"4687":5332,"4688":5845,"4689":5334,"4690":5847,"4691":5337,"4692":5338,"4693":5339,"4694":5850,"4695":5851,"4696":5852,"4697":5343,"4698":5344,"4699":5345,"4700":5855,"4701":5857,"4702":5859,"4703":5861,"4704":5862,"4705":5863,"4706":5352,"4707":5865,"4708":5354,"4709":5357,"4710":5869,"4711":5870,"4712":5872,"4713":5361,"4714":5873,"4715":5876,"4716":5879,"4717":5880,"4718":5369,"4719":5881,"4720":5371,"4721":5372,"4722":5373,"4723":5374,"4724":5882,"4725":5884,"4726":5377,"4727":5885,"4728":5891,"4729":5380,"4730":5892,"4731":5894,"4732":5383,"4733":5897,"4734":5898,"4735":5899,"4736":5389,"4737":5903,"4738":5392,"4739":5904,"4740":5905,"4741":5906,"4742":5911,"4743":5912,"4744":5402,"4745":5403,"4746":5916,"4747":5917,"4748":5918,"4749":5409,"4750":5410,"4751":5921,"4752":5922,"4753":5923,"4754":5925,"4755":5926,"4756":5927,"4757":5928,"4758":5929,"4759":5931,"4760":5932,"4761":5933,"4762":5934,"4763":5426,"4764":5427,"4765":5938,"4766":5941,"4767":5943,"4768":5944,"4769":5945,"4770":5946,"4771":5950,"4772":5440,"4773":5952,"4774":5954,"4775":5956,"4776":5446,"4777":5447,"4778":5959,"4779":5960,"4780":5961,"4781":5962,"4782":5963,"4783":5964,"4784":5965,"4785":5966,"4786":5968,"4787":5971,"4788":5973,"4789":5462,"4790":5975,"4791":5464,"4792":5472,"4793":5473,"4794":5475,"4795":5479,"4796":5485,"4797":5486,"4798":5487,"4799":5493,"4800":5499,"4801":5501,"4802":5502,"4803":5504,"4804":5505,"4805":5506,"4806":5508,"4807":5511,"4808":5512,"4809":5513,"4810":5514,"4811":5515,"4812":5517,"4813":5520,"4814":5522,"4815":5523,"4816":5525,"4817":5526,"4818":5527,"4819":5528,"4820":5529,"4821":5530,"4822":5532,"4823":5534,"4824":5535,"4825":5536,"4826":5537,"4827":5538,"4828":5540,"4829":5543,"4830":5544,"4831":5545,"4832":5546,"4833":4526,"4834":5555,"4835":5557,"4836":5563,"4837":5567,"4838":5570,"4839":5573,"4840":5576,"4841":5577,"4842":5580,"4843":5583,"4844":5588,"4845":5590,"4846":5591,"4847":5593,"4848":5596,"4849":5597,"4850":5600,"4851":5602,"4852":5604,"4853":5606,"4854":5607,"4855":5610,"4856":5611,"4857":5615,"4858":5616,"4859":5618,"4860":5619,"4861":5622,"4862":5624,"4863":5625,"4864":5627,"4865":5630,"4866":5631,"4867":4864,"4868":4995,"4869":4868,"4870":4998,"4871":6150,"4872":6283,"4873":4885,"4874":5015,"4875":5017,"4876":4890,"4877":5023,"4878":6175,"4879":4770,"4880":4772,"4881":4900,"4882":5031,"4883":4904,"4884":5033,"4885":4909,"4886":4910,"4887":5039,"4888":5043,"4889":4788,"4890":6197,"4891":5049,"4892":4925,"4893":5053,"4894":4801,"4895":4804,"4896":4807,"4897":4810,"4898":4813,"4899":4815,"4900":6231,"4901":4828,"4902":4837,"4903":4862,"4904":6144,"4905":6146,"4906":6147,"4907":6151,"4908":6154,"4909":6155,"4910":6157,"4911":6158,"4912":6160,"4913":6161,"4914":6162,"4915":6166,"4916":6167,"4917":6170,"4918":6171,"4919":6174,"4920":6177,"4921":6179,"4922":6180,"4923":6183,"4924":6186,"4925":6189,"4926":6191,"4927":6192,"4928":6193,"4929":6195,"4930":6199,"4931":6201,"4932":6202,"4933":6204,"4934":6208,"4935":6210,"4936":6216,"4937":6218,"4938":6219,"4939":6220,"4940":6221,"4941":6222,"4942":6223,"4943":6225,"4944":6226,"4945":6227,"4946":6228,"4947":6230,"4948":6234,"4949":6235,"4950":6236,"4951":6238,"4952":6239,"4953":6240,"4954":6241,"4955":6251,"4956":6253,"4957":6254,"4958":6255,"4959":6257,"4960":6265,"4961":6269,"4962":6271,"4963":6275,"4964":6276,"4965":6279,"4966":6286,"4967":5453,"4968":5503,"4969":5507,"4970":5509,"4971":5510,"4972":5516,"4973":5518,"4974":5519,"4975":5521,"4976":5524,"4977":5531,"4978":5533,"4979":5539,"4980":5542,"4981":5547,"4982":5548,"4983":5549,"4984":5550,"4985":5551,"4986":5552,"4987":5553,"4988":5554,"4989":5558,"4990":5559,"4991":5560,"4992":5561,"4993":5562,"4994":5564,"4995":5565,"4996":5566,"4997":5569,"4998":5571,"4999":5572,"5000":5574,"5001":5575,"5002":5578,"5003":5579,"5004":5582,"5005":5584,"5006":5585,"5007":5587,"5008":5594,"5009":5595,"5010":5598,"5011":5599,"5012":5601,"5013":5605,"5014":5608,"5015":5609,"5016":5617,"5017":5620,"5018":5621,"5019":5623,"5020":5626,"5021":5629,"5022":5632,"5023":5633,"5024":5634,"5025":5637,"5026":5638,"5027":5643,"5028":5645,"5029":5646,"5030":5647,"5031":5648,"5032":5650,"5033":5651,"5034":5655,"5035":5659,"5036":5663,"5037":5665,"5038":5668,"5039":5670,"5040":5671,"5041":5672,"5042":5675,"5043":5676,"5044":5677,"5045":5678,"5046":5683,"5047":5684,"5048":5685,"5049":5686,"5050":5688,"5051":5693,"5052":5695,"5053":5697,"5054":5701,"5055":5702,"5056":5704,"5057":5705,"5058":5712,"5059":5713,"5060":5714,"5061":5720,"5062":5721,"5063":5722,"5064":5724,"5065":5725,"5066":5729,"5067":5730,"5068":5731,"5069":5734,"5070":5735,"5071":5736,"5072":5737,"5073":5738,"5074":5740,"5075":5741,"5076":5743,"5077":5750,"5078":5753,"5079":5754,"5080":5755,"5081":5756,"5082":5759,"5083":5761,"5084":5762,"5085":5763,"5086":5764,"5087":5767,"5088":5770,"5089":5772,"5090":5774,"5091":5776,"5092":5777,"5093":5778,"5094":5779,"5095":5780,"5096":5781,"5097":5785,"5098":5786,"5099":5787,"5100":5789,"5101":5790,"5102":5791,"5103":5797,"5104":5798,"5105":5803,"5106":5804,"5107":5806,"5108":5807,"5109":5808,"5110":5810,"5111":5811,"5112":5812,"5113":5813,"5114":5814,"5115":5817,"5116":5818,"5117":5819,"5118":5821,"5119":5822,"5120":5824,"5121":5825,"5122":5826,"5123":5828,"5124":5829,"5125":5832,"5126":5833,"5127":5834,"5128":5836,"5129":5838,"5130":5839,"5131":5840,"5132":5842,"5133":5844,"5134":5846,"5135":5848,"5136":5849,"5137":5853,"5138":5858,"5139":5864,"5140":5866,"5141":5867,"5142":5868,"5143":5871,"5144":5874,"5145":5875,"5146":5878,"5147":5883,"5148":5886,"5149":5887,"5150":5888,"5151":5889,"5152":5890,"5153":5893,"5154":5895,"5155":5896,"5156":5900,"5157":5901,"5158":5902,"5159":5907,"5160":5908,"5161":5910,"5162":5913,"5163":5914,"5164":5915,"5165":5919,"5166":5920,"5167":5930,"5168":5935,"5169":5937,"5170":5939,"5171":5940,"5172":5942,"5173":5947,"5174":5948,"5175":5949,"5176":5951,"5177":5953,"5178":5955,"5179":5957,"5180":5958,"5181":5970,"5182":5972,"5183":5974,"5184":5976,"5185":5977,"5186":5978,"5187":5979,"5188":5980,"5189":5981,"5190":5982,"5191":5983,"5192":5984,"5193":5985,"5194":5986,"5195":5987,"5196":5988,"5197":5990,"5198":5991,"5199":5992,"5200":5993,"5201":5994,"5202":5995,"5203":5996,"5204":5997,"5205":5998,"5206":5999,"5207":6000,"5208":6001,"5209":6002,"5210":6003,"5211":6004,"5212":6005,"5213":6007,"5214":6009,"5215":6010,"5216":6011,"5217":6012,"5218":6013,"5219":6014,"5220":6015,"5221":6016,"5222":6017,"5223":6018,"5224":6019,"5225":6020,"5226":6021,"5227":6022,"5228":6023,"5229":6024,"5230":6025,"5231":6026,"5232":6027,"5233":6028,"5234":6029,"5235":6030,"5236":6031,"5237":6032,"5238":6033,"5239":6034,"5240":6035,"5241":6036,"5242":6037,"5243":6038,"5244":6039,"5245":6040,"5246":6041,"5247":6042,"5248":6044,"5249":6045,"5250":6046,"5251":6047,"5252":6048,"5253":6049,"5254":6050,"5255":6051,"5256":6052,"5257":6053,"5258":6054,"5259":6055,"5260":6057,"5261":6058,"5262":6059,"5263":6060,"5264":6061,"5265":6062,"5266":6063,"5267":6064,"5268":6065,"5269":6066,"5270":6067,"5271":6068,"5272":6069,"5273":6070,"5274":6071,"5275":6073,"5276":6074,"5277":6075,"5278":6076,"5279":6077,"5280":6078,"5281":6079,"5282":6081,"5283":6082,"5284":6083,"5285":6084,"5286":6085,"5287":6086,"5288":6087,"5289":6088,"5290":6089,"5291":6090,"5292":6091,"5293":6092,"5294":6093,"5295":6094,"5296":6095,"5297":6096,"5298":6097,"5299":6098,"5300":6099,"5301":6100,"5302":6102,"5303":6103,"5304":6104,"5305":6105,"5306":6106,"5307":6107,"5308":6108,"5309":6110,"5310":6111,"5311":6115,"5312":6116,"5313":6117,"5314":6118,"5315":6120,"5316":6121,"5317":6122,"5318":6124,"5319":6125,"5320":6127,"5321":6128,"5322":6129,"5323":6130,"5324":6131,"5325":6132,"5326":6133,"5327":6134,"5328":6135,"5329":6136,"5330":6137,"5331":6138,"5332":6139,"5333":6140,"5334":6141,"5335":6142,"5336":6149,"5337":6287,"5338":6288,"5339":6290,"5340":6294,"5341":6298,"5342":6299,"5343":6301,"5344":6302,"5345":6303,"5346":6304,"5347":6305,"5348":6307,"5349":6309,"5350":6310,"5351":6311,"5352":6313,"5353":6314,"5354":6315,"5355":6317,"5356":6318,"5357":6324,"5358":6328,"5359":6329,"5360":6335,"5361":6337,"5362":6338,"5363":6343,"5364":6344,"5365":6345,"5366":6346,"5367":6348,"5368":6349,"5369":6351,"5370":6352,"5371":6353,"5372":6356,"5373":6358,"5374":6362,"5375":6365,"5376":6366,"5377":6367,"5378":6372,"5379":6374,"5380":6376,"5381":6379,"5382":6381,"5383":6382,"5384":6388,"5385":6392,"5386":6393,"5387":6394,"5388":6395,"5389":6396,"5390":6397,"5391":6401,"5392":6402,"5393":6405,"5394":6409,"5395":6411,"5396":6414,"5397":6415,"5398":6416,"5399":6417,"5400":6419,"5401":6422,"5402":6423,"5403":6424,"5404":6427,"5405":6429,"5406":6432,"5407":6433,"5408":6434,"5409":6436,"5410":6438,"5411":6439,"5412":6442,"5413":6446,"5414":6449,"5415":6450,"5416":6453,"5417":6454,"5418":6455,"5419":6458,"5420":6459,"5421":6461,"5422":6462,"5423":6465,"5424":6467,"5425":6468,"5426":6469,"5427":6470,"5428":6472,"5429":6474,"5430":6475,"5431":6478,"5432":6479,"5433":6484,"5434":6488,"5435":6489,"5436":6490,"5437":6491,"5438":6493,"5439":6496,"5440":6498,"5441":6499,"5442":6500,"5443":6501,"5444":6503,"5445":6504,"5446":6506,"5447":6508,"5448":6509,"5449":6514,"5450":6516,"5451":6517,"5452":6521,"5453":6524,"5454":6525,"5455":6526,"5456":6527,"5457":6529,"5458":6530,"5459":6531,"5460":6532,"5461":6534,"5462":6535,"5463":6536,"5464":6539,"5465":6540,"5466":6545,"5467":6546,"5468":6550,"5469":6553,"5470":6556,"5471":6558,"5472":6564,"5473":6566,"5474":6567,"5475":6569,"5476":6570,"5477":6571,"5478":6574,"5479":6578,"5480":6579,"5481":6580,"5482":6586,"5483":6590,"5484":6593,"5485":6595,"5486":6598,"5487":6599,"5488":6601,"5489":6605,"5490":6606,"5491":6607,"5492":6611,"5493":6613,"5494":6614,"5495":6615,"5496":6620,"5497":6621,"5498":6622,"5499":6623,"5500":6624,"5501":6625,"5502":6626,"5503":6629,"5504":6630,"5505":6631,"5506":6634,"5507":6636,"5508":6638,"5509":6639,"5510":6640,"5511":6642,"5512":6643,"5513":6646,"5514":6647,"5515":6649,"5516":6650,"5517":6652,"5518":6655,"5519":6656,"5520":6658,"5521":6659,"5522":6662,"5523":6663,"5524":6664,"5525":6665,"5526":6666,"5527":6667,"5528":6668,"5529":6669,"5530":6671,"5531":6676,"5532":6679,"5533":6684,"5534":6685,"5535":6686,"5536":6689,"5537":6690,"5538":6691,"5539":6693,"5540":6694,"5541":6695,"5542":6699,"5543":6700,"5544":6701,"5545":6703,"5546":6704,"5547":6706,"5548":6707,"5549":6708,"5550":6709,"5551":6710,"5552":6711,"5553":6713,"5554":6714,"5555":6719,"5556":6721,"5557":6723,"5558":6726,"5559":6727,"5560":6728,"5561":6730,"5562":6733,"5563":6735,"5564":6737,"5565":6740,"5566":6741,"5567":6745,"5568":6748,"5569":6749,"5570":6751,"5571":6752,"5572":6755,"5573":6756,"5574":6757,"5575":6760,"5576":6761,"5577":6763,"5578":6764,"5579":6766,"5580":6768,"5581":6772,"5582":6773,"5583":6775,"5584":6777,"5585":6780,"5586":6782,"5587":6785,"5588":6786,"5589":6791,"5590":6792,"5591":6795,"5592":6798,"5593":6799,"5594":6800,"5595":6801,"5596":6802,"5597":6804,"5598":6805,"5599":6806,"5600":6811,"5601":6814,"5602":6817,"5603":6820,"5604":6821,"5605":6823,"5606":6829,"5607":6833,"5608":6836,"5609":6843,"5610":6844,"5611":6847,"5612":6848,"5613":6849,"5614":6850,"5615":6851,"5616":6853,"5617":6854,"5618":6856,"5619":6857,"5620":6860,"5621":6865,"5622":6867,"5623":6870,"5624":6875,"5625":6877,"5626":6890,"5627":6891,"5628":6894,"5629":6895,"5630":6896,"5631":6898,"5632":6899,"5633":6900,"5634":6902,"5635":6903,"5636":6904,"5637":6905,"5638":6906,"5639":6908,"5640":6909,"5641":6912,"5642":6913,"5643":6916,"5644":6918,"5645":6919,"5646":6920,"5647":6921,"5648":6923,"5649":6924,"5650":6926,"5651":6929,"5652":6930,"5653":6932,"5654":6934,"5655":6935,"5656":6939,"5657":6940,"5658":6942,"5659":6943,"5660":6944,"5661":6945,"5662":6948,"5663":6952,"5664":6954,"5665":6957,"5666":6959,"5667":6960,"5668":6961,"5669":6968,"5670":6969,"5671":6970,"5672":6971,"5673":6972,"5674":6973,"5675":6974,"5676":6975,"5677":6976,"5678":6979,"5679":6983,"5680":6984,"5681":6988,"5682":6993,"5683":7000,"5684":7001,"5685":7003,"5686":7007,"5687":7009,"5688":7010,"5689":7012,"5690":7015,"5691":7016,"5692":7018,"5693":7019,"5694":7023,"5695":7027,"5696":7029,"5697":7032,"5698":7033,"5699":7035,"5700":7038,"5701":7041,"5702":7043,"5703":7045,"5704":7046,"5705":7050,"5706":7053,"5707":7055,"5708":7056,"5709":7058,"5710":7061,"5711":7062,"5712":7065,"5713":7066,"5714":7067,"5715":7068,"5716":7070,"5717":7071,"5718":7074,"5719":7077,"5720":7078,"5721":7087,"5722":7088,"5723":7089,"5724":7091,"5725":7092,"5726":7095,"5727":7098,"5728":7100,"5729":7101,"5730":7104,"5731":7105,"5732":7110,"5733":7114,"5734":7123,"5735":7128,"5736":7129,"5737":7132,"5738":7137,"5739":7138,"5740":7139,"5741":7143,"5742":7144,"5743":7146,"5744":7147,"5745":7148,"5746":7152,"5747":7154,"5748":7158,"5749":7164,"5750":7165,"5751":7170,"5752":7172,"5753":7174,"5754":7176,"5755":7184,"5756":7187,"5757":7188,"5758":7192,"5759":7197,"5760":7198,"5761":7202,"5762":7204,"5763":7205,"5764":7207,"5765":7208,"5766":7210,"5767":7213,"5768":7217,"5769":7220,"5770":7222,"5771":7225,"5772":7230,"5773":7240,"5774":7242,"5775":7255,"5776":7259,"5777":7261,"5778":7262,"5779":7270,"5780":7272,"5781":7274,"5782":7276,"5783":7282,"5784":7286,"5785":7291,"5786":7292,"5787":7293,"5788":7296,"5789":7300,"5790":7301,"5791":7305,"5792":7308,"5793":7310,"5794":7323,"5795":7328,"5796":7329,"5797":7330,"5798":7332,"5799":7335,"5800":7338,"5801":7340,"5802":7347,"5803":7358,"5804":7360,"5805":7362,"5806":7367,"5807":7372,"5808":7373,"5809":7375,"5810":7377,"5811":7388,"5812":7390,"5813":7394,"5814":7406,"5815":7410,"5816":7415,"5817":7421,"5818":7426,"5819":7433,"5820":7439,"5821":7444,"5822":7448,"5823":7450,"5824":7455,"5825":7456,"5826":7466,"5827":7470,"5828":7480,"5829":7482,"5830":7493,"5831":7495,"5832":7496,"5833":7499,"5834":7500,"5835":7506,"5836":7514,"5837":7517,"5838":7524,"5839":7527,"5840":7529,"5841":7530,"5842":7533,"5843":7541,"5844":7542,"5845":7543,"5846":7544,"5847":7546,"5848":7551,"5849":7556,"5850":7560,"5851":7563,"5852":7565,"5853":7569,"5854":7571,"5855":7578,"5856":7579,"5857":7582,"5858":7585,"5859":7591,"5860":7602,"5861":7604,"5862":6272,"5863":6273,"5864":6274,"5865":6278,"5866":6153,"5867":6280,"5868":6281,"5869":6156,"5870":6285,"5871":6159,"5872":6163,"5873":6164,"5874":6165,"5875":6169,"5876":6172,"5877":6176,"5878":6181,"5879":6182,"5880":6185,"5881":6187,"5882":6188,"5883":6190,"5884":6196,"5885":6198,"5886":6200,"5887":6203,"5888":6205,"5889":6207,"5890":6209,"5891":6213,"5892":6214,"5893":6215,"5894":6217,"5895":6224,"5896":6229,"5897":6232,"5898":6233,"5899":6511,"5900":6512,"5901":6513,"5902":6515,"5903":6518,"5904":6519,"5905":6520,"5906":6522,"5907":6523,"5908":6528,"5909":6533,"5910":6537,"5911":6538,"5912":6541,"5913":6543,"5914":6544,"5915":6547,"5916":6548,"5917":6549,"5918":6551,"5919":6552,"5920":6554,"5921":6555,"5922":6557,"5923":6559,"5924":6560,"5925":6561,"5926":6562,"5927":6563,"5928":6565,"5929":6568,"5930":6572,"5931":6573,"5932":6575,"5933":6576,"5934":6577,"5935":6581,"5936":6584,"5937":6585,"5938":6587,"5939":6588,"5940":6589,"5941":6591,"5942":6592,"5943":6594,"5944":6596,"5945":6597,"5946":6600,"5947":6602,"5948":6603,"5949":6604,"5950":6608,"5951":6609,"5952":6610,"5953":6612,"5954":6616,"5955":6617,"5956":6618,"5957":6619,"5958":6627,"5959":6628,"5960":6633,"5961":6635,"5962":6637,"5963":6641,"5964":6644,"5965":6645,"5966":6651,"5967":6653,"5968":6654,"5969":6657,"5970":6660,"5971":6661,"5972":6670,"5973":6672,"5974":6673,"5975":6674,"5976":6677,"5977":6678,"5978":6680,"5979":6681,"5980":6682,"5981":6683,"5982":6687,"5983":6688,"5984":6692,"5985":6696,"5986":6697,"5987":6698,"5988":6702,"5989":6705,"5990":6712,"5991":6715,"5992":6716,"5993":6717,"5994":6718,"5995":6720,"5996":6722,"5997":6724,"5998":6725,"5999":6729,"6000":6731,"6001":6732,"6002":6734,"6003":6736,"6004":6738,"6005":6739,"6006":6742,"6007":6743,"6008":6744,"6009":6746,"6010":6747,"6011":6750,"6012":6753,"6013":6754,"6014":6758,"6015":6759,"6016":6762,"6017":6765,"6018":6767,"6019":6769,"6020":6770,"6021":6771,"6022":6774,"6023":6776,"6024":6778,"6025":6779,"6026":6781,"6027":6783,"6028":6784,"6029":6787,"6030":6788,"6031":6789,"6032":6790,"6033":6793,"6034":6794,"6035":6796,"6036":6797,"6037":6803,"6038":6807,"6039":6808,"6040":6809,"6041":6810,"6042":6812,"6043":6813,"6044":6819,"6045":6822,"6046":6824,"6047":6825,"6048":6826,"6049":6827,"6050":6830,"6051":6831,"6052":6832,"6053":6834,"6054":6835,"6055":6837,"6056":6838,"6057":6839,"6058":6840,"6059":6841,"6060":6842,"6061":6845,"6062":6846,"6063":6852,"6064":6855,"6065":6858,"6066":6859,"6067":6861,"6068":6862,"6069":6863,"6070":6864,"6071":6866,"6072":6868,"6073":6869,"6074":6871,"6075":6872,"6076":6873,"6077":6874,"6078":6876,"6079":6878,"6080":6879,"6081":6880,"6082":6881,"6083":6882,"6084":6883,"6085":6897,"6086":6901,"6087":6907,"6088":6910,"6089":6911,"6090":6914,"6091":6915,"6092":6917,"6093":6922,"6094":6925,"6095":6927,"6096":6928,"6097":6931,"6098":6936,"6099":6937,"6100":6938,"6101":6941,"6102":6946,"6103":6947,"6104":6949,"6105":6950,"6106":6951,"6107":6953,"6108":6955,"6109":6956,"6110":6958,"6111":6962,"6112":6963,"6113":6964,"6114":6965,"6115":6967,"6116":6977,"6117":6978,"6118":6980,"6119":6981,"6120":6982,"6121":6985,"6122":6986,"6123":6989,"6124":6990,"6125":6991,"6126":6992,"6127":6994,"6128":6995,"6129":6996,"6130":6997,"6131":6998,"6132":6999,"6133":7002,"6134":7004,"6135":7005,"6136":7006,"6137":7008,"6138":7011,"6139":7013,"6140":7014,"6141":7017,"6142":7020,"6143":7021,"6144":7022,"6145":7025,"6146":7026,"6147":7028,"6148":7030,"6149":7031,"6150":7034,"6151":7036,"6152":7037,"6153":7040,"6154":7042,"6155":7044,"6156":7047,"6157":7049,"6158":7057,"6159":7059,"6160":7063,"6161":7064,"6162":7069,"6163":7072,"6164":7073,"6165":7075,"6166":7076,"6167":7079,"6168":7080,"6169":7081,"6170":7082,"6171":7083,"6172":7084,"6173":7085,"6174":7086,"6175":7090,"6176":7096,"6177":7097,"6178":7099,"6179":7102,"6180":7103,"6181":7106,"6182":7107,"6183":7109,"6184":7111,"6185":7113,"6186":7115,"6187":7116,"6188":7117,"6189":7118,"6190":7120,"6191":7122,"6192":7124,"6193":7126,"6194":7127,"6195":7130,"6196":7133,"6197":7135,"6198":7136,"6199":7140,"6200":7141,"6201":7145,"6202":7150,"6203":7151,"6204":7153,"6205":7155,"6206":7156,"6207":7157,"6208":7159,"6209":7160,"6210":7161,"6211":7163,"6212":7167,"6213":7168,"6214":7171,"6215":7173,"6216":7175,"6217":7178,"6218":7180,"6219":7182,"6220":7183,"6221":7186,"6222":7189,"6223":7191,"6224":7195,"6225":7200,"6226":7206,"6227":7209,"6228":7211,"6229":7212,"6230":7214,"6231":7216,"6232":7218,"6233":7219,"6234":7223,"6235":7229,"6236":7231,"6237":7232,"6238":7233,"6239":7234,"6240":7235,"6241":7236,"6242":7241,"6243":7243,"6244":7244,"6245":7245,"6246":7246,"6247":7247,"6248":7248,"6249":7250,"6250":7251,"6251":7252,"6252":7253,"6253":7254,"6254":7256,"6255":7257,"6256":7258,"6257":7260,"6258":7263,"6259":7266,"6260":7267,"6261":7269,"6262":7273,"6263":7275,"6264":7277,"6265":7279,"6266":7281,"6267":7283,"6268":7284,"6269":7287,"6270":7288,"6271":7294,"6272":7295,"6273":7298,"6274":7303,"6275":7304,"6276":7307,"6277":7309,"6278":7313,"6279":7314,"6280":7315,"6281":7317,"6282":7318,"6283":7319,"6284":7320,"6285":7321,"6286":7324,"6287":7325,"6288":7327,"6289":7331,"6290":7333,"6291":7337,"6292":7341,"6293":7342,"6294":7343,"6295":7346,"6296":7349,"6297":7352,"6298":7353,"6299":7354,"6300":7355,"6301":7361,"6302":7363,"6303":7366,"6304":7368,"6305":7370,"6306":7374,"6307":7376,"6308":7379,"6309":7380,"6310":7383,"6311":7385,"6312":7386,"6313":7387,"6314":7391,"6315":7392,"6316":7393,"6317":7395,"6318":7396,"6319":7397,"6320":7398,"6321":7399,"6322":7400,"6323":7402,"6324":7405,"6325":7407,"6326":7408,"6327":7409,"6328":7412,"6329":7413,"6330":7416,"6331":7417,"6332":7418,"6333":7419,"6334":7423,"6335":7425,"6336":7430,"6337":7431,"6338":7436,"6339":7437,"6340":7438,"6341":7440,"6342":7442,"6343":7443,"6344":7447,"6345":7451,"6346":7452,"6347":7453,"6348":7459,"6349":7462,"6350":7471,"6351":7472,"6352":7473,"6353":7476,"6354":7483,"6355":7484,"6356":7486,"6357":7487,"6358":7488,"6359":7489,"6360":7490,"6361":7491,"6362":7492,"6363":7494,"6364":7502,"6365":7503,"6366":7693,"6367":7694,"6368":7695,"6369":7698,"6370":7699,"6371":7703,"6372":7710,"6373":7711,"6374":7712,"6375":7714,"6376":7716,"6377":7718,"6378":7722,"6379":7724,"6380":7730,"6381":7731,"6382":7734,"6383":7742,"6384":7746,"6385":7747,"6386":7752,"6387":7758,"6388":7761,"6389":7763,"6390":7766,"6391":7767,"6392":7769,"6393":7773,"6394":7774,"6395":7780,"6396":7781,"6397":7783,"6398":7787,"6399":7788,"6400":7789,"6401":7790,"6402":7794,"6403":7804,"6404":7805,"6405":7808,"6406":7809,"6407":7811,"6408":7812,"6409":7815,"6410":7820,"6411":7821,"6412":7827,"6413":7828,"6414":7830,"6415":7831,"6416":7832,"6417":7833,"6418":7834,"6419":7837,"6420":7839,"6421":7842,"6422":7843,"6423":7847,"6424":7849,"6425":7854,"6426":7855,"6427":7857,"6428":7858,"6429":7861,"6430":7863,"6431":7865,"6432":7867,"6433":7868,"6434":7871,"6435":7872,"6436":7876,"6437":7877,"6438":7878,"6439":7879,"6440":7883,"6441":7884,"6442":7886,"6443":7892,"6444":7895,"6445":7896,"6446":7897,"6447":7898,"6448":7899,"6449":7905,"6450":7907,"6451":7908,"6452":7911,"6453":7913,"6454":7917,"6455":7921,"6456":7922,"6457":7924,"6458":7925,"6459":7926,"6460":7930,"6461":8191,"6462":7932,"6463":7933,"6464":7934,"6465":7938,"6466":7939,"6467":7944,"6468":7947,"6469":7949,"6470":7441,"6471":7953,"6472":7954,"6473":7446,"6474":7958,"6475":7964,"6476":7965,"6477":7454,"6478":7966,"6479":7967,"6480":7457,"6481":7969,"6482":7460,"6483":7972,"6484":7464,"6485":7977,"6486":7468,"6487":7469,"6488":7979,"6489":7980,"6490":7984,"6491":7985,"6492":7986,"6493":7987,"6494":7988,"6495":7477,"6496":7478,"6497":7479,"6498":7991,"6499":7994,"6500":7995,"6501":7485,"6502":7998,"6503":7999,"6504":8001,"6505":8002,"6506":8006,"6507":8007,"6508":8008,"6509":8011,"6510":8012,"6511":7504,"6512":8016,"6513":8019,"6514":7508,"6515":7509,"6516":7510,"6517":8020,"6518":7512,"6519":8021,"6520":8025,"6521":8026,"6522":8028,"6523":8029,"6524":7518,"6525":8031,"6526":7521,"6527":8033,"6528":8034,"6529":7525,"6530":7526,"6531":8038,"6532":8044,"6533":8047,"6534":8048,"6535":8049,"6536":7539,"6537":8054,"6538":8055,"6539":7547,"6540":8060,"6541":7549,"6542":7550,"6543":7555,"6544":8066,"6545":8068,"6546":7561,"6547":8073,"6548":8075,"6549":7566,"6550":8078,"6551":8081,"6552":8082,"6553":8085,"6554":8087,"6555":8089,"6556":8090,"6557":8091,"6558":8092,"6559":8093,"6560":8099,"6561":8102,"6562":8103,"6563":8104,"6564":8106,"6565":8107,"6566":8108,"6567":8109,"6568":8110,"6569":8113,"6570":8114,"6571":8115,"6572":8116,"6573":8117,"6574":7607,"6575":8119,"6576":8121,"6577":8122,"6578":8124,"6579":8125,"6580":7614,"6581":8126,"6582":8127,"6583":8129,"6584":7620,"6585":8130,"6586":8131,"6587":8133,"6588":8134,"6589":7625,"6590":8138,"6591":8142,"6592":7633,"6593":8145,"6594":7635,"6595":8146,"6596":8147,"6597":7638,"6598":8149,"6599":8151,"6600":7641,"6601":8155,"6602":7644,"6603":8156,"6604":7647,"6605":7648,"6606":8159,"6607":7651,"6608":7652,"6609":8163,"6610":7654,"6611":8166,"6612":8167,"6613":7657,"6614":8169,"6615":8170,"6616":8171,"6617":8175,"6618":8176,"6619":7666,"6620":8183,"6621":8184,"6622":8186,"6623":8187,"6624":8188,"6625":7677,"6626":7679,"6627":7690,"6628":7697,"6629":7700,"6630":7701,"6631":7702,"6632":7715,"6633":7717,"6634":7723,"6635":7725,"6636":7726,"6637":7727,"6638":7728,"6639":7732,"6640":7735,"6641":7740,"6642":7743,"6643":7744,"6644":7749,"6645":7623,"6646":7624,"6647":7799,"6648":7755,"6649":7760,"6650":7801,"6651":7634,"6652":7762,"6653":7764,"6654":7637,"6655":7765,"6656":7639,"6657":7642,"6658":7643,"6659":7772,"6660":7645,"6661":7777,"6662":7650,"6663":7779,"6664":7653,"6665":7782,"6666":7656,"6667":7785,"6668":7786,"6669":7659,"6670":7806,"6671":7661,"6672":7664,"6673":7665,"6674":7793,"6675":7667,"6676":7668,"6677":7669,"6678":7795,"6679":7671,"6680":7800,"6681":7673,"6682":7675,"6683":7678,"6684":8198,"6685":8199,"6686":8201,"6687":8202,"6688":8203,"6689":8204,"6690":8205,"6691":8206,"6692":8208,"6693":8209,"6694":8211,"6695":8216,"6696":8222,"6697":8229,"6698":8231,"6699":8232,"6700":8233,"6701":8234,"6702":8236,"6703":8237,"6704":8238,"6705":8240,"6706":8241,"6707":8243,"6708":8244,"6709":8246,"6710":8248,"6711":8249,"6712":8250,"6713":8253,"6714":8256,"6715":8259,"6716":8260,"6717":8261,"6718":8262,"6719":8268,"6720":8269,"6721":8271,"6722":8273,"6723":8275,"6724":8278,"6725":8280,"6726":8282,"6727":8286,"6728":8287,"6729":8291,"6730":8292,"6731":8294,"6732":8295,"6733":8296,"6734":8302,"6735":8303,"6736":8304,"6737":8305,"6738":8306,"6739":8313,"6740":8315,"6741":8316,"6742":8319,"6743":8322,"6744":8324,"6745":8325,"6746":8326,"6747":8327,"6748":8329,"6749":8330,"6750":8331,"6751":8335,"6752":8338,"6753":8340,"6754":8343,"6755":8346,"6756":8348,"6757":8349,"6758":8350,"6759":8355,"6760":8358,"6761":8359,"6762":8360,"6763":8361,"6764":8363,"6765":8364,"6766":8365,"6767":8367,"6768":8369,"6769":8373,"6770":8374,"6771":8378,"6772":8382,"6773":8383,"6774":8384,"6775":8385,"6776":8386,"6777":8387,"6778":8394,"6779":8398,"6780":8400,"6781":8402,"6782":8404,"6783":8410,"6784":8411,"6785":8414,"6786":8415,"6787":8417,"6788":8421,"6789":8422,"6790":8423,"6791":8424,"6792":8425,"6793":8426,"6794":8427,"6795":8429,"6796":8430,"6797":8434,"6798":8437,"6799":8438,"6800":8440,"6801":8441,"6802":8443,"6803":8444,"6804":8448,"6805":8452,"6806":8455,"6807":8457,"6808":8460,"6809":8461,"6810":8463,"6811":8468,"6812":8469,"6813":9106,"6814":9107,"6815":9108,"6816":9109,"6817":9111,"6818":9113,"6819":9115,"6820":9116,"6821":9124,"6822":9132,"6823":9134,"6824":9135,"6825":9136,"6826":9138,"6827":9142,"6828":9143,"6829":9146,"6830":9148,"6831":9153,"6832":9154,"6833":9158,"6834":9162,"6835":9164,"6836":9165,"6837":9168,"6838":9174,"6839":9178,"6840":9180,"6841":9181,"6842":9184,"6843":9187,"6844":9189,"6845":9190,"6846":9191,"6847":9192,"6848":9193,"6849":9194,"6850":9195,"6851":9196,"6852":9201,"6853":9205,"6854":9206,"6855":9207,"6856":9212,"6857":9214,"6858":9215,"6859":9218,"6860":9221,"6861":9223,"6862":9225,"6863":9229,"6864":9231,"6865":9232,"6866":9234,"6867":9235,"6868":9236,"6869":9237,"6870":9238,"6871":9239,"6872":9243,"6873":9244,"6874":9245,"6875":9253,"6876":9255,"6877":9256,"6878":9262,"6879":9263,"6880":9264,"6881":9267,"6882":9268,"6883":9270,"6884":9271,"6885":9272,"6886":9275,"6887":9277,"6888":9280,"6889":9285,"6890":9286,"6891":9287,"6892":9289,"6893":9290,"6894":9294,"6895":9296,"6896":9298,"6897":9299,"6898":9301,"6899":9302,"6900":9303,"6901":9307,"6902":9309,"6903":9312,"6904":9313,"6905":9315,"6906":9316,"6907":9317,"6908":9318,"6909":9321,"6910":9326,"6911":9327,"6912":9329,"6913":9330,"6914":9331,"6915":9333,"6916":9334,"6917":9338,"6918":9340,"6919":9341,"6920":9342,"6921":7962,"6922":9345,"6923":9347,"6924":9354,"6925":9355,"6926":9358,"6927":9359,"6928":9362,"6929":9363,"6930":9364,"6931":9366,"6932":9369,"6933":9371,"6934":9372,"6935":9373,"6936":9374,"6937":9375,"6938":9376,"6939":9377,"6940":9378,"6941":9379,"6942":9381,"6943":9383,"6944":9385,"6945":9394,"6946":9395,"6947":9396,"6948":9397,"6949":9398,"6950":9399,"6951":9400,"6952":9401,"6953":9403,"6954":9404,"6955":9411,"6956":9412,"6957":9415,"6958":9416,"6959":9417,"6960":9418,"6961":9419,"6962":9421,"6963":9423,"6964":9424,"6965":9427,"6966":9429,"6967":9434,"6968":9437,"6969":9438,"6970":9439,"6971":7983,"6972":9449,"6973":9453,"6974":9455,"6975":9456,"6976":9457,"6977":9458,"6978":9459,"6979":9461,"6980":9462,"6981":9464,"6982":9465,"6983":9467,"6984":9473,"6985":9475,"6986":7989,"6987":9477,"6988":9481,"6989":9483,"6990":9484,"6991":9489,"6992":9496,"6993":9500,"6994":9501,"6995":9503,"6996":9508,"6997":9510,"6998":9512,"6999":9514,"7000":9515,"7001":9517,"7002":9518,"7003":9521,"7004":9527,"7005":9529,"7006":9532,"7007":9536,"7008":9537,"7009":9539,"7010":9540,"7011":9543,"7012":9544,"7013":9548,"7014":9550,"7015":9552,"7016":9558,"7017":9559,"7018":9560,"7019":9562,"7020":9563,"7021":9564,"7022":9566,"7023":9567,"7024":9568,"7025":9569,"7026":9571,"7027":9572,"7028":9574,"7029":9576,"7030":9577,"7031":9579,"7032":9581,"7033":9582,"7034":9583,"7035":9584,"7036":9585,"7037":9587,"7038":9589,"7039":9590,"7040":9598,"7041":9600,"7042":9604,"7043":9605,"7044":9606,"7045":9609,"7046":9613,"7047":9614,"7048":9616,"7049":9617,"7050":9621,"7051":9622,"7052":9623,"7053":9625,"7054":9629,"7055":9630,"7056":9631,"7057":9632,"7058":9637,"7059":9639,"7060":9644,"7061":9646,"7062":9647,"7063":9650,"7064":9651,"7065":9657,"7066":9662,"7067":9663,"7068":9664,"7069":9665,"7070":9671,"7071":9676,"7072":9683,"7073":9684,"7074":9687,"7075":9690,"7076":9692,"7077":9694,"7078":9696,"7079":9702,"7080":9705,"7081":9709,"7082":9710,"7083":9711,"7084":9717,"7085":9718,"7086":9719,"7087":9724,"7088":9725,"7089":9726,"7090":9728,"7091":9729,"7092":9731,"7093":9733,"7094":9735,"7095":9737,"7096":9747,"7097":9749,"7098":9752,"7099":9754,"7100":9755,"7101":9756,"7102":9758,"7103":9759,"7104":9763,"7105":9765,"7106":9766,"7107":9771,"7108":9772,"7109":9773,"7110":9774,"7111":9775,"7112":9777,"7113":9780,"7114":9781,"7115":9782,"7116":9786,"7117":9787,"7118":9789,"7119":9792,"7120":9794,"7121":9795,"7122":9796,"7123":9801,"7124":9803,"7125":9804,"7126":9805,"7127":9806,"7128":9807,"7129":9809,"7130":9810,"7131":9811,"7132":9813,"7133":9815,"7134":9817,"7135":9821,"7136":9822,"7137":9823,"7138":9830,"7139":9831,"7140":9833,"7141":9834,"7142":9836,"7143":9838,"7144":9842,"7145":9843,"7146":9844,"7147":9846,"7148":9847,"7149":9851,"7150":9854,"7151":9855,"7152":9856,"7153":9857,"7154":9858,"7155":9860,"7156":9861,"7157":9863,"7158":9864,"7159":9867,"7160":9868,"7161":9869,"7162":9870,"7163":9877,"7164":9878,"7165":9879,"7166":9883,"7167":9884,"7168":9889,"7169":9890,"7170":9893,"7171":9895,"7172":9896,"7173":9897,"7174":9899,"7175":9902,"7176":9903,"7177":9905,"7178":9907,"7179":9909,"7180":9913,"7181":9914,"7182":9916,"7183":9917,"7184":9919,"7185":9920,"7186":9922,"7187":9923,"7188":9925,"7189":9931,"7190":9938,"7191":7890,"7192":9940,"7193":7891,"7194":9942,"7195":7893,"7196":7894,"7197":9945,"7198":9946,"7199":9948,"7200":7900,"7201":9950,"7202":9951,"7203":9952,"7204":9953,"7205":9954,"7206":7901,"7207":7902,"7208":9957,"7209":7903,"7210":7904,"7211":7906,"7212":7909,"7213":7910,"7214":7912,"7215":9966,"7216":7915,"7217":9969,"7218":7916,"7219":9971,"7220":9972,"7221":9973,"7222":7918,"7223":7919,"7224":9976,"7225":7920,"7226":9978,"7227":7923,"7228":9980,"7229":7928,"7230":7931,"7231":7935,"7232":7936,"7233":7937,"7234":9989,"7235":9990,"7236":7941,"7237":7942,"7238":7943,"7239":9995,"7240":9998,"7241":7950,"7242":7951,"7243":10001,"7244":10003,"7245":7955,"7246":10005,"7247":7956,"7248":10007,"7249":10008,"7250":7959,"7251":10010,"7252":10012,"7253":10013,"7254":7960,"7255":10015,"7256":10016,"7257":10017,"7258":7961,"7259":7963,"7260":7968,"7261":10022,"7262":6237,"7263":6242,"7264":6243,"7265":6244,"7266":6246,"7267":6247,"7268":6248,"7269":6249,"7270":6250,"7271":6252,"7272":6256,"7273":6258,"7274":6259,"7275":6260,"7276":6262,"7277":6264,"7278":6266,"7279":6268,"7280":6270,"7281":6143,"7282":6289,"7283":6291,"7284":6292,"7285":6293,"7286":6295,"7287":6296,"7288":6300,"7289":6306,"7290":6308,"7291":6312,"7292":6316,"7293":6319,"7294":6320,"7295":6321,"7296":6322,"7297":6323,"7298":6326,"7299":6327,"7300":6330,"7301":6332,"7302":6333,"7303":6334,"7304":6336,"7305":6339,"7306":6340,"7307":6341,"7308":6342,"7309":6347,"7310":6350,"7311":6354,"7312":6355,"7313":6357,"7314":6360,"7315":6361,"7316":6363,"7317":6364,"7318":6368,"7319":6369,"7320":6370,"7321":6373,"7322":6375,"7323":6377,"7324":6378,"7325":6380,"7326":6383,"7327":6384,"7328":6385,"7329":6386,"7330":6387,"7331":6389,"7332":6390,"7333":6391,"7334":6398,"7335":6399,"7336":6400,"7337":6403,"7338":6404,"7339":6406,"7340":6407,"7341":6408,"7342":6410,"7343":6412,"7344":6413,"7345":6420,"7346":6421,"7347":6425,"7348":6426,"7349":6428,"7350":6430,"7351":6431,"7352":6435,"7353":6437,"7354":6440,"7355":6441,"7356":6443,"7357":6444,"7358":6445,"7359":6447,"7360":6448,"7361":6452,"7362":6456,"7363":6457,"7364":6460,"7365":6463,"7366":6464,"7367":6466,"7368":6471,"7369":6473,"7370":6476,"7371":6477,"7372":6480,"7373":6481,"7374":6482,"7375":6483,"7376":6485,"7377":6486,"7378":6495,"7379":6497,"7380":6502,"7381":6505,"7382":6507,"7383":6510,"7384":8192,"7385":8193,"7386":8194,"7387":8195,"7388":8196,"7389":8197,"7390":8200,"7391":8207,"7392":8210,"7393":8212,"7394":8213,"7395":8214,"7396":8215,"7397":8217,"7398":8218,"7399":8220,"7400":8221,"7401":8224,"7402":8225,"7403":8226,"7404":8228,"7405":8230,"7406":8235,"7407":8239,"7408":8242,"7409":8245,"7410":8247,"7411":8251,"7412":8252,"7413":8255,"7414":8257,"7415":8258,"7416":8263,"7417":8264,"7418":8265,"7419":8266,"7420":8267,"7421":8274,"7422":8276,"7423":8277,"7424":8279,"7425":8281,"7426":8283,"7427":8284,"7428":8285,"7429":8288,"7430":8289,"7431":8290,"7432":8293,"7433":8297,"7434":8298,"7435":8299,"7436":8300,"7437":8301,"7438":8307,"7439":8308,"7440":8309,"7441":8311,"7442":8312,"7443":8314,"7444":8317,"7445":8318,"7446":8320,"7447":8321,"7448":8323,"7449":8332,"7450":8339,"7451":8341,"7452":8347,"7453":8351,"7454":8352,"7455":8366,"7456":8372,"7457":8379,"7458":8413,"7459":8418,"7460":8420,"7461":8428,"7462":8432,"7463":8435,"7464":8445,"7465":8446,"7466":8451,"7467":8454,"7468":8459,"7469":8467,"7470":8471,"7471":8491,"7472":8500,"7473":8503,"7474":8507,"7475":8518,"7476":8529,"7477":8539,"7478":8549,"7479":8551,"7480":8565,"7481":8571,"7482":8576,"7483":8581,"7484":8583,"7485":8587,"7486":8588,"7487":8594,"7488":8599,"7489":8609,"7490":8613,"7491":8616,"7492":8617,"7493":8624,"7494":8641,"7495":8649,"7496":8674,"7497":8676,"7498":8690,"7499":8710,"7500":8712,"7501":8714,"7502":8721,"7503":8726,"7504":8728,"7505":8735,"7506":8753,"7507":8754,"7508":7108,"7509":7112,"7510":7119,"7511":7121,"7512":7125,"7513":7131,"7514":7134,"7515":7142,"7516":7149,"7517":7162,"7518":7166,"7519":7169,"7520":7177,"7521":7179,"7522":7181,"7523":7190,"7524":7193,"7525":7194,"7526":7196,"7527":7201,"7528":7203,"7529":7215,"7530":7221,"7531":7227,"7532":7228,"7533":7249,"7534":7264,"7535":7265,"7536":7268,"7537":7271,"7538":7278,"7539":7280,"7540":7285,"7541":7289,"7542":7290,"7543":7297,"7544":7299,"7545":7302,"7546":7306,"7547":7311,"7548":7312,"7549":7316,"7550":7322,"7551":7326,"7552":7334,"7553":7336,"7554":7339,"7555":7344,"7556":7345,"7557":7348,"7558":7350,"7559":7351,"7560":7356,"7561":7357,"7562":7359,"7563":7365,"7564":7369,"7565":7371,"7566":7381,"7567":7382,"7568":7384,"7569":7389,"7570":7401,"7571":7403,"7572":7411,"7573":7414,"7574":7422,"7575":7424,"7576":7427,"7577":7434,"7578":8470,"7579":8474,"7580":8476,"7581":8478,"7582":8479,"7583":8480,"7584":8483,"7585":8486,"7586":8487,"7587":8488,"7588":8490,"7589":8493,"7590":8494,"7591":8497,"7592":8498,"7593":8501,"7594":8502,"7595":8508,"7596":8509,"7597":8510,"7598":8512,"7599":8513,"7600":8516,"7601":8517,"7602":8521,"7603":8522,"7604":8523,"7605":8524,"7606":8527,"7607":8531,"7608":8532,"7609":8533,"7610":8535,"7611":8537,"7612":8538,"7613":8542,"7614":8544,"7615":8546,"7616":8548,"7617":8550,"7618":8553,"7619":8554,"7620":8556,"7621":8560,"7622":8562,"7623":8563,"7624":8567,"7625":8570,"7626":8573,"7627":8578,"7628":8579,"7629":8585,"7630":8590,"7631":8595,"7632":8596,"7633":8597,"7634":8598,"7635":8600,"7636":8601,"7637":8602,"7638":8605,"7639":8606,"7640":8608,"7641":8610,"7642":8611,"7643":8612,"7644":8620,"7645":8621,"7646":8622,"7647":8626,"7648":8628,"7649":8629,"7650":8632,"7651":8633,"7652":8634,"7653":8636,"7654":8637,"7655":8638,"7656":8639,"7657":8640,"7658":8643,"7659":8644,"7660":8645,"7661":8647,"7662":8648,"7663":8652,"7664":8653,"7665":8654,"7666":8657,"7667":8659,"7668":8660,"7669":8661,"7670":8662,"7671":8664,"7672":8665,"7673":8667,"7674":8668,"7675":8670,"7676":8671,"7677":8673,"7678":8679,"7679":8680,"7680":8681,"7681":8682,"7682":8683,"7683":8684,"7684":8686,"7685":8694,"7686":8698,"7687":8700,"7688":8701,"7689":8702,"7690":8704,"7691":8705,"7692":8706,"7693":8709,"7694":8711,"7695":8713,"7696":8715,"7697":8717,"7698":8719,"7699":8723,"7700":8724,"7701":8725,"7702":8727,"7703":8729,"7704":8731,"7705":8732,"7706":8733,"7707":8736,"7708":8737,"7709":8738,"7710":8740,"7711":8743,"7712":8745,"7713":8746,"7714":8747,"7715":8749,"7716":8752,"7717":7507,"7718":7515,"7719":7516,"7720":7519,"7721":7520,"7722":7522,"7723":7523,"7724":7528,"7725":7532,"7726":7535,"7727":7536,"7728":7537,"7729":7538,"7730":7540,"7731":7545,"7732":7548,"7733":7557,"7734":7559,"7735":7562,"7736":7564,"7737":7567,"7738":7568,"7739":7570,"7740":7574,"7741":7576,"7742":7580,"7743":7581,"7744":7583,"7745":7584,"7746":7586,"7747":7587,"7748":7588,"7749":7589,"7750":7590,"7751":7592,"7752":7593,"7753":7595,"7754":7598,"7755":7599,"7756":7605,"7757":7606,"7758":7608,"7759":7610,"7760":7611,"7761":7612,"7762":7613,"7763":7615,"7764":7621,"7765":7622,"7766":7626,"7767":7627,"7768":7628,"7769":7629,"7770":7630,"7771":7632,"7772":7636,"7773":7640,"7774":7649,"7775":7658,"7776":7660,"7777":7663,"7778":7670,"7779":7672,"7780":7674,"7781":7676,"7782":7680,"7783":7681,"7784":7682,"7785":7683,"7786":7684,"7787":7691,"7788":7692,"7789":7696,"7790":7705,"7791":7706,"7792":7707,"7793":7709,"7794":7713,"7795":7719,"7796":7720,"7797":7721,"7798":7729,"7799":7733,"7800":7736,"7801":7737,"7802":7738,"7803":7739,"7804":7741,"7805":7745,"7806":7748,"7807":7750,"7808":7751,"7809":7754,"7810":7756,"7811":7757,"7812":7759,"7813":7768,"7814":7770,"7815":7771,"7816":7775,"7817":7776,"7818":7778,"7819":7784,"7820":7791,"7821":7792,"7822":7796,"7823":7797,"7824":7798,"7825":7802,"7826":7807,"7827":7810,"7828":7813,"7829":7814,"7830":7818,"7831":7819,"7832":7822,"7833":7823,"7834":7825,"7835":7826,"7836":7829,"7837":7835,"7838":7838,"7839":7841,"7840":7844,"7841":7846,"7842":7848,"7843":7850,"7844":7851,"7845":7852,"7846":7853,"7847":7859,"7848":7862,"7849":7864,"7850":7866,"7851":7869,"7852":7870,"7853":7873,"7854":7875,"7855":7880,"7856":7881,"7857":7882,"7858":7885,"7859":8707,"7860":8708,"7861":9219,"7862":9220,"7863":9222,"7864":9224,"7865":9227,"7866":8716,"7867":9228,"7868":8718,"7869":9230,"7870":8720,"7871":9233,"7872":9240,"7873":9241,"7874":8730,"7875":9242,"7876":8734,"7877":9248,"7878":8739,"7879":9251,"7880":8741,"7881":8742,"7882":9254,"7883":8744,"7884":9257,"7885":9258,"7886":9259,"7887":8748,"7888":9261,"7889":8750,"7890":8751,"7891":9266,"7892":8757,"7893":9269,"7894":8759,"7895":9274,"7896":8763,"7897":9276,"7898":9278,"7899":8767,"7900":9279,"7901":9281,"7902":8770,"7903":9283,"7904":8776,"7905":9288,"7906":8778,"7907":9292,"7908":9293,"7909":9295,"7910":8785,"7911":9297,"7912":9300,"7913":8793,"7914":9305,"7915":8795,"7916":8796,"7917":9308,"7918":8798,"7919":9310,"7920":9311,"7921":9314,"7922":8803,"7923":8804,"7924":8805,"7925":8806,"7926":9319,"7927":9320,"7928":8809,"7929":8810,"7930":9324,"7931":8814,"7932":9328,"7933":8819,"7934":9332,"7935":9335,"7936":8695,"7937":9337,"7938":8826,"7939":9343,"7940":8832,"7941":9344,"7942":9346,"7943":8837,"7944":9349,"7945":8839,"7946":8328,"7947":8841,"7948":9352,"7949":9356,"7950":8845,"7951":8333,"7952":8334,"7953":8848,"7954":8336,"7955":8337,"7956":9357,"7957":9360,"7958":8853,"7959":8342,"7960":8855,"7961":8344,"7962":8345,"7963":8858,"7964":9365,"7965":8860,"7966":9367,"7967":8862,"7968":9370,"7969":8353,"7970":8354,"7971":8356,"7972":8357,"7973":8870,"7974":9380,"7975":9382,"7976":9388,"7977":8877,"7978":8878,"7979":8880,"7980":8368,"7981":8370,"7982":8371,"7983":9393,"7984":9391,"7985":8375,"7986":8888,"7987":8376,"7988":8377,"7989":8891,"7990":8381,"7991":8894,"7992":9407,"7993":8896,"7994":8897,"7995":8898,"7996":9408,"7997":9405,"7998":9413,"7999":8902,"8000":8903,"8001":9414,"8002":8388,"8003":8389,"8004":8391,"8005":8392,"8006":8393,"8007":8910,"8008":9422,"8009":8912,"8010":9200,"8011":9426,"8012":8915,"8013":8916,"8014":8405,"8015":9428,"8016":8407,"8017":8408,"8018":8409,"8019":8920,"8020":8923,"8021":8924,"8022":8922,"8023":9431,"8024":8927,"8025":8416,"8026":8929,"8027":9433,"8028":8419,"8029":8932,"8030":8933,"8031":9443,"8032":8935,"8033":9446,"8034":9447,"8035":8938,"8036":9448,"8037":9444,"8038":9445,"8039":8943,"8040":8944,"8041":8433,"8042":8945,"8043":8946,"8044":8439,"8045":9392,"8046":8442,"8047":9209,"8048":8395,"8049":8447,"8050":8449,"8051":8450,"8052":8396,"8053":8453,"8054":9211,"8055":8456,"8056":8397,"8057":8458,"8058":8462,"8059":8464,"8060":8465,"8061":8466,"8062":8472,"8063":8473,"8064":8475,"8065":8401,"8066":8477,"8067":8481,"8068":8482,"8069":8484,"8070":8485,"8071":8489,"8072":8492,"8073":8495,"8074":8496,"8075":8499,"8076":8406,"8077":8504,"8078":8505,"8079":8506,"8080":8514,"8081":8515,"8082":8519,"8083":8525,"8084":8526,"8085":8528,"8086":8412,"8087":9430,"8088":8534,"8089":8536,"8090":8540,"8091":8541,"8092":8545,"8093":8547,"8094":8552,"8095":8555,"8096":8557,"8097":8558,"8098":8559,"8099":9435,"8100":8561,"8101":9436,"8102":8564,"8103":8566,"8104":8569,"8105":8572,"8106":8574,"8107":8575,"8108":8577,"8109":8580,"8110":8582,"8111":8584,"8112":8586,"8113":8589,"8114":8591,"8115":8592,"8116":8593,"8117":9104,"8118":9110,"8119":9114,"8120":8603,"8121":8604,"8122":9119,"8123":9120,"8124":9121,"8125":9125,"8126":8614,"8127":9127,"8128":8615,"8129":9129,"8130":8618,"8131":8619,"8132":9130,"8133":9126,"8134":8623,"8135":8625,"8136":8627,"8137":9139,"8138":9141,"8139":8630,"8140":8631,"8141":9144,"8142":8635,"8143":9147,"8144":9149,"8145":9150,"8146":9151,"8147":9152,"8148":8642,"8149":9159,"8150":9160,"8151":9161,"8152":8650,"8153":8651,"8154":9163,"8155":8688,"8156":9166,"8157":8655,"8158":8656,"8159":8658,"8160":9171,"8161":9172,"8162":9173,"8163":9175,"8164":8666,"8165":8669,"8166":9182,"8167":9183,"8168":8672,"8169":9186,"8170":8675,"8171":9188,"8172":8677,"8173":8678,"8174":8685,"8175":9198,"8176":8687,"8177":9199,"8178":8689,"8179":9202,"8180":8691,"8181":8692,"8182":8693,"8183":9203,"8184":9204,"8185":8696,"8186":8697,"8187":9361,"8188":8699,"8189":8703,"8190":8834,"8191":8840,"8192":8843,"8193":8846,"8194":8847,"8195":8849,"8196":8851,"8197":8857,"8198":8863,"8199":8864,"8200":8866,"8201":8873,"8202":8874,"8203":8756,"8204":8884,"8205":8886,"8206":8892,"8207":8766,"8208":8895,"8209":8772,"8210":8777,"8211":8905,"8212":8779,"8213":8780,"8214":8781,"8215":8906,"8216":8913,"8217":8786,"8218":8789,"8219":8918,"8220":8919,"8221":8792,"8222":8925,"8223":8928,"8224":8801,"8225":8802,"8226":8934,"8227":8807,"8228":8937,"8229":8811,"8230":8812,"8231":8813,"8232":8942,"8233":8940,"8234":8823,"8235":8825,"8236":8830,"8237":8755,"8238":8758,"8239":8760,"8240":8761,"8241":8762,"8242":8764,"8243":8765,"8244":8768,"8245":8773,"8246":8774,"8247":8787,"8248":9216,"8249":9217,"8250":9732,"8251":9734,"8252":9736,"8253":9226,"8254":9741,"8255":9744,"8256":9745,"8257":9746,"8258":9748,"8259":9750,"8260":9751,"8261":9753,"8262":9246,"8263":9247,"8264":9760,"8265":9249,"8266":9761,"8267":9471,"8268":9764,"8269":9252,"8270":9768,"8271":9260,"8272":9776,"8273":9778,"8274":9779,"8275":9783,"8276":9273,"8277":9785,"8278":9788,"8279":9791,"8280":9284,"8281":9797,"8282":9798,"8283":9800,"8284":9802,"8285":9291,"8286":9808,"8287":9812,"8288":9816,"8289":9306,"8290":9818,"8291":9819,"8292":9820,"8293":9827,"8294":9828,"8295":9835,"8296":9325,"8297":9837,"8298":9839,"8299":9840,"8300":9841,"8301":9845,"8302":9336,"8303":9849,"8304":9850,"8305":9852,"8306":9853,"8307":9348,"8308":9862,"8309":9353,"8310":9865,"8311":9872,"8312":9873,"8313":9875,"8314":9876,"8315":9880,"8316":9882,"8317":9886,"8318":9887,"8319":9891,"8320":9892,"8321":9894,"8322":9384,"8323":9898,"8324":9386,"8325":9900,"8326":9901,"8327":9389,"8328":9904,"8329":9906,"8330":9908,"8331":9910,"8332":9911,"8333":9912,"8334":9402,"8335":9915,"8336":9918,"8337":9406,"8338":9409,"8339":9410,"8340":9921,"8341":9926,"8342":9930,"8343":9935,"8344":9937,"8345":9941,"8346":9943,"8347":9432,"8348":9944,"8349":9947,"8350":9949,"8351":9440,"8352":9955,"8353":9960,"8354":9961,"8355":9450,"8356":9451,"8357":9965,"8358":9452,"8359":9967,"8360":9968,"8361":9970,"8362":9460,"8363":9974,"8364":9463,"8365":9975,"8366":9208,"8367":9979,"8368":9470,"8369":9982,"8370":9983,"8371":9985,"8372":9986,"8373":9987,"8374":9476,"8375":9988,"8376":9478,"8377":9991,"8378":9480,"8379":9992,"8380":9993,"8381":9994,"8382":9996,"8383":9485,"8384":9486,"8385":9487,"8386":9999,"8387":10000,"8388":9490,"8389":9492,"8390":9493,"8391":9494,"8392":9495,"8393":10006,"8394":9498,"8395":10009,"8396":9502,"8397":9504,"8398":10018,"8399":9507,"8400":10020,"8401":9509,"8402":10021,"8403":9511,"8404":10024,"8405":9513,"8406":10023,"8407":10026,"8408":10028,"8409":10029,"8410":9520,"8411":10032,"8412":9522,"8413":10035,"8414":9525,"8415":9526,"8416":9528,"8417":9531,"8418":9534,"8419":10047,"8420":10049,"8421":9538,"8422":10053,"8423":9542,"8424":9545,"8425":9546,"8426":9549,"8427":9551,"8428":9555,"8429":9556,"8430":9557,"8431":9561,"8432":9565,"8433":9570,"8434":9573,"8435":9575,"8436":9580,"8437":9586,"8438":9588,"8439":9591,"8440":9597,"8441":9599,"8442":9602,"8443":9603,"8444":9611,"8445":9612,"8446":9615,"8447":9618,"8448":9619,"8449":9620,"8450":9624,"8451":9627,"8452":9628,"8453":9117,"8454":9118,"8455":9633,"8456":9122,"8457":9123,"8458":9635,"8459":9640,"8460":9128,"8461":9642,"8462":9643,"8463":9131,"8464":9137,"8465":9649,"8466":9140,"8467":9653,"8468":9652,"8469":9656,"8470":9145,"8471":9658,"8472":9659,"8473":9661,"8474":9155,"8475":9667,"8476":9157,"8477":9668,"8478":9669,"8479":9670,"8480":9672,"8481":9673,"8482":9675,"8483":9674,"8484":9677,"8485":9167,"8486":9680,"8487":9169,"8488":9682,"8489":9170,"8490":9686,"8491":9176,"8492":9177,"8493":9689,"8494":9179,"8495":9691,"8496":9693,"8497":9695,"8498":9185,"8499":9697,"8500":9698,"8501":9700,"8502":9703,"8503":9706,"8504":9197,"8505":9712,"8506":9713,"8507":9714,"8508":9715,"8509":9716,"8510":9156,"8511":9720,"8512":9210,"8513":9213,"8514":9727,"8515":8769,"8516":8936,"8517":8907,"8518":8876,"8519":8939,"8520":8782,"8521":8783,"8522":8784,"8523":8816,"8524":8850,"8525":8947,"8526":8788,"8527":8824,"8528":8799,"8529":8790,"8530":8791,"8531":8794,"8532":8797,"8533":8800,"8534":8808,"8535":8815,"8536":8817,"8537":8818,"8538":8820,"8539":8821,"8540":8822,"8541":8827,"8542":8828,"8543":8829,"8544":8833,"8545":8835,"8546":8836,"8547":8842,"8548":8844,"8549":8852,"8550":8854,"8551":8856,"8552":8859,"8553":8861,"8554":8867,"8555":8868,"8556":8869,"8557":8871,"8558":8872,"8559":8875,"8560":8879,"8561":8882,"8562":8883,"8563":8885,"8564":8889,"8565":8890,"8566":8893,"8567":8899,"8568":8900,"8569":8901,"8570":8904,"8571":8908,"8572":8909,"8573":8911,"8574":8914,"8575":8917,"8576":8921,"8577":8926,"8578":8930,"8579":8931,"8580":8941,"8581":8948,"8582":8949,"8583":8951,"8584":8952,"8585":8953,"8586":8954,"8587":8955,"8588":8956,"8589":8957,"8590":8959,"8591":8960,"8592":8961,"8593":8962,"8594":8963,"8595":8964,"8596":8965,"8597":8966,"8598":8967,"8599":8968,"8600":8969,"8601":8970,"8602":8971,"8603":8972,"8604":8973,"8605":8974,"8606":8975,"8607":8976,"8608":8977,"8609":8978,"8610":8979,"8611":8980,"8612":8981,"8613":8982,"8614":8983,"8615":8984,"8616":8985,"8617":8986,"8618":8987,"8619":8988,"8620":8989,"8621":8990,"8622":8991,"8623":8992,"8624":8993,"8625":8994,"8626":8995,"8627":8996,"8628":8997,"8629":8998,"8630":8999,"8631":9000,"8632":9001,"8633":9002,"8634":9004,"8635":9005,"8636":9006,"8637":9007,"8638":9008,"8639":9009,"8640":9010,"8641":9011,"8642":9012,"8643":9013,"8644":9014,"8645":9015,"8646":9016,"8647":9017,"8648":9018,"8649":9019,"8650":9020,"8651":9021,"8652":9022,"8653":9023,"8654":9024,"8655":9025,"8656":9026,"8657":9027,"8658":9028,"8659":9029,"8660":9030,"8661":9031,"8662":9032,"8663":9033,"8664":9034,"8665":9035,"8666":9036,"8667":9037,"8668":9038,"8669":9039,"8670":9040,"8671":9041,"8672":9042,"8673":9043,"8674":9044,"8675":9045,"8676":9046,"8677":9047,"8678":9048,"8679":9049,"8680":9050,"8681":9051,"8682":9052,"8683":9053,"8684":9054,"8685":9055,"8686":9056,"8687":9057,"8688":9058,"8689":9059,"8690":9060,"8691":9061,"8692":9062,"8693":9063,"8694":9064,"8695":9065,"8696":9066,"8697":9067,"8698":9068,"8699":9069,"8700":9070,"8701":9071,"8702":9072,"8703":9073,"8704":9074,"8705":9075,"8706":9077,"8707":9078,"8708":9079,"8709":9080,"8710":9081,"8711":9082,"8712":9083,"8713":9084,"8714":9085,"8715":9086,"8716":9087,"8717":9088,"8718":9089,"8719":9090,"8720":9091,"8721":9092,"8722":9093,"8723":9094,"8724":9095,"8725":9096,"8726":9097,"8727":9098,"8728":9099,"8729":9100,"8730":9101,"8731":9102,"8732":9103,"8733":9105,"8734":10240,"8735":10241,"8736":9730,"8737":10246,"8738":10247,"8739":10248,"8740":9743,"8741":10257,"8742":10258,"8743":9757,"8744":9762,"8745":9767,"8746":9770,"8747":10288,"8748":10290,"8749":10291,"8750":10292,"8751":9784,"8752":10297,"8753":9790,"8754":9793,"8755":10306,"8756":10307,"8757":9799,"8758":10321,"8759":10325,"8760":9814,"8761":10335,"8762":9824,"8763":9825,"8764":9826,"8765":10338,"8766":10343,"8767":10344,"8768":10356,"8769":9848,"8770":9859,"8771":10377,"8772":9866,"8773":10382,"8774":9871,"8775":10383,"8776":9874,"8777":10388,"8778":10389,"8779":9885,"8780":9888,"8781":10401,"8782":10403,"8783":10405,"8784":10408,"8785":10410,"8786":10413,"8787":10414,"8788":10415,"8789":10427,"8790":10433,"8791":10434,"8792":10435,"8793":9924,"8794":10436,"8795":10443,"8796":9939,"8797":10459,"8798":9956,"8799":9962,"8800":9963,"8801":9454,"8802":10481,"8803":9977,"8804":9466,"8805":10491,"8806":9981,"8807":9469,"8808":10493,"8809":9984,"8810":9472,"8811":9474,"8812":10502,"8813":10505,"8814":9482,"8815":9997,"8816":9488,"8817":10002,"8818":9491,"8819":10004,"8820":10518,"8821":10523,"8822":9499,"8823":10014,"8824":10527,"8825":9505,"8826":9506,"8827":10529,"8828":10532,"8829":10535,"8830":10538,"8831":9516,"8832":10540,"8833":9519,"8834":9523,"8835":9524,"8836":10551,"8837":9530,"8838":10555,"8839":9533,"8840":10558,"8841":9535,"8842":10048,"8843":10557,"8844":10563,"8845":10057,"8846":9547,"8847":9553,"8848":9554,"8849":10067,"8850":10577,"8851":10069,"8852":10076,"8853":10080,"8854":10592,"8855":10593,"8856":10086,"8857":10598,"8858":9578,"8859":10092,"8860":10090,"8861":10094,"8862":10095,"8863":10102,"8864":9593,"8865":10621,"8866":9601,"8867":10629,"8868":9607,"8869":9608,"8870":9610,"8871":10128,"8872":10130,"8873":10642,"8874":10649,"8875":10143,"8876":10144,"8877":10145,"8878":9634,"8879":9636,"8880":9638,"8881":10150,"8882":10663,"8883":9641,"8884":10155,"8885":9645,"8886":9648,"8887":10673,"8888":10164,"8889":10676,"8890":10677,"8891":10169,"8892":10170,"8893":9660,"8894":10174,"8895":9666,"8896":10192,"8897":9681,"8898":10194,"8899":10196,"8900":10207,"8901":9699,"8902":9704,"8903":10217,"8904":9707,"8905":10219,"8906":10223,"8907":10225,"8908":10232,"8909":9721,"8910":10237,"8911":10242,"8912":10243,"8913":10245,"8914":10251,"8915":10252,"8916":10253,"8917":10254,"8918":10256,"8919":10259,"8920":10260,"8921":10261,"8922":10263,"8923":10271,"8924":10274,"8925":10276,"8926":10278,"8927":10280,"8928":10281,"8929":10284,"8930":10285,"8931":10289,"8932":10293,"8933":10295,"8934":10299,"8935":10302,"8936":10303,"8937":10304,"8938":10305,"8939":10308,"8940":10309,"8941":10310,"8942":10311,"8943":10312,"8944":10313,"8945":10315,"8946":10316,"8947":10317,"8948":10318,"8949":10319,"8950":10322,"8951":10323,"8952":10324,"8953":10329,"8954":10330,"8955":10331,"8956":10332,"8957":10333,"8958":10334,"8959":10336,"8960":10339,"8961":10341,"8962":10342,"8963":10345,"8964":10346,"8965":10348,"8966":10349,"8967":10350,"8968":10351,"8969":10352,"8970":10353,"8971":10354,"8972":10361,"8973":10363,"8974":10364,"8975":10366,"8976":10367,"8977":10368,"8978":10370,"8979":10373,"8980":10374,"8981":10375,"8982":10376,"8983":10380,"8984":10381,"8985":10384,"8986":10386,"8987":10387,"8988":10391,"8989":10392,"8990":10395,"8991":10397,"8992":10398,"8993":10399,"8994":10400,"8995":10404,"8996":10406,"8997":10417,"8998":10418,"8999":10419,"9000":10420,"9001":10422,"9002":10423,"9003":10424,"9004":10425,"9005":10429,"9006":10432,"9007":10437,"9008":10439,"9009":10440,"9010":10441,"9011":10445,"9012":10446,"9013":10451,"9014":10455,"9015":10456,"9016":10457,"9017":10458,"9018":10461,"9019":10462,"9020":10463,"9021":10466,"9022":10467,"9023":10468,"9024":10244,"9025":10249,"9026":10250,"9027":10255,"9028":10262,"9029":10264,"9030":10265,"9031":10266,"9032":10267,"9033":10268,"9034":10269,"9035":10270,"9036":10272,"9037":10273,"9038":10275,"9039":10277,"9040":10279,"9041":10282,"9042":10283,"9043":10286,"9044":10287,"9045":10294,"9046":10296,"9047":10298,"9048":10300,"9049":10301,"9050":10314,"9051":10320,"9052":10326,"9053":10327,"9054":10328,"9055":10337,"9056":10340,"9057":10347,"9058":10355,"9059":10357,"9060":10358,"9061":10359,"9062":10360,"9063":10362,"9064":10365,"9065":10369,"9066":10371,"9067":10372,"9068":10378,"9069":10379,"9070":10385,"9071":10394,"9072":10396,"9073":10402,"9074":10409,"9075":10411,"9076":10412,"9077":10416,"9078":10421,"9079":10426,"9080":10428,"9081":10430,"9082":10431,"9083":10438,"9084":10442,"9085":10444,"9086":10447,"9087":10448,"9088":10449,"9089":10450,"9090":10452,"9091":10453,"9092":10454,"9093":10460,"9094":10464,"9095":10465,"9096":10469,"9097":10470,"9098":10471,"9099":10476,"9100":10478,"9101":10480,"9102":10483,"9103":10485,"9104":10487,"9105":10489,"9106":10492,"9107":10494,"9108":10499,"9109":10501,"9110":10509,"9111":10510,"9112":10512,"9113":10516,"9114":10517,"9115":10520,"9116":10524,"9117":10530,"9118":10531,"9119":10534,"9120":10537,"9121":10539,"9122":10541,"9123":10542,"9124":10544,"9125":10547,"9126":10549,"9127":10550,"9128":10559,"9129":10561,"9130":10565,"9131":10058,"9132":10572,"9133":10573,"9134":10062,"9135":10576,"9136":10065,"9137":10066,"9138":10579,"9139":10581,"9140":10071,"9141":10072,"9142":10073,"9143":10074,"9144":10075,"9145":10583,"9146":10079,"9147":10081,"9148":10084,"9149":10596,"9150":10599,"9151":10600,"9152":10089,"9153":10601,"9154":10602,"9155":10603,"9156":10604,"9157":10087,"9158":10608,"9159":10098,"9160":10099,"9161":10610,"9162":10611,"9163":10617,"9164":10618,"9165":10108,"9166":10620,"9167":10110,"9168":10112,"9169":10114,"9170":10117,"9171":10120,"9172":10634,"9173":10635,"9174":10636,"9175":10125,"9176":10637,"9177":10127,"9178":10640,"9179":10641,"9180":10643,"9181":10133,"9182":10134,"9183":10135,"9184":10136,"9185":10648,"9186":10138,"9187":10651,"9188":10652,"9189":10650,"9190":10142,"9191":10146,"9192":10149,"9193":10661,"9194":10152,"9195":10665,"9196":10667,"9197":10668,"9198":10670,"9199":10159,"9200":10672,"9201":10166,"9202":10167,"9203":10678,"9204":10173,"9205":10178,"9206":10182,"9207":10183,"9208":10184,"9209":10187,"9210":10188,"9211":10197,"9212":10203,"9213":10204,"9214":10205,"9215":10210,"9216":10218,"9217":10222,"9218":10224,"9219":10227,"9220":10228,"9221":10229,"9222":10230,"9223":10233,"9224":10235,"9225":10236,"9226":8141,"9227":8100,"9228":8040,"9229":8041,"9230":8143,"9231":8042,"9232":8144,"9233":8101,"9234":8045,"9235":8046,"9236":8150,"9237":8000,"9238":8050,"9239":8152,"9240":8051,"9241":8015,"9242":8052,"9243":8123,"9244":8053,"9245":8056,"9246":8022,"9247":8158,"9248":8057,"9249":8013,"9250":8058,"9251":8160,"9252":8059,"9253":8161,"9254":8061,"9255":8023,"9256":8062,"9257":10669,"9258":8063,"9259":8165,"9260":8003,"9261":8064,"9262":8105,"9263":8065,"9264":8067,"9265":8004,"9266":8069,"9267":10614,"9268":8070,"9269":8071,"9270":8072,"9271":8005,"9272":8074,"9273":8076,"9274":8077,"9275":8128,"9276":8079,"9277":8182,"9278":10625,"9279":10626,"9280":7981,"9281":10627,"9282":8083,"9283":8084,"9284":10472,"9285":10473,"9286":10474,"9287":10475,"9288":10630,"9289":10477,"9290":8086,"9291":10479,"9292":10482,"9293":10484,"9294":10632,"9295":10486,"9296":8088,"9297":10488,"9298":8190,"9299":10490,"9300":10495,"9301":10496,"9302":10497,"9303":10498,"9304":10500,"9305":10503,"9306":10504,"9307":7990,"9308":10506,"9309":10507,"9310":10508,"9311":10511,"9312":10513,"9313":10514,"9314":10515,"9315":7992,"9316":8094,"9317":8111,"9318":10519,"9319":10521,"9320":10522,"9321":10525,"9322":10526,"9323":7970,"9324":7971,"9325":8097,"9326":7973,"9327":7974,"9328":10536,"9329":10025,"9330":7975,"9331":10027,"9332":7976,"9333":7978,"9334":10030,"9335":10031,"9336":10543,"9337":10033,"9338":10034,"9339":10545,"9340":10036,"9341":10546,"9342":10038,"9343":10040,"9344":10041,"9345":10042,"9346":10043,"9347":10044,"9348":10045,"9349":10046,"9350":10552,"9351":10553,"9352":10554,"9353":10050,"9354":10051,"9355":10052,"9356":9541,"9357":10054,"9358":10055,"9359":10056,"9360":10560,"9361":10562,"9362":10059,"9363":10060,"9364":10061,"9365":10548,"9366":10063,"9367":10064,"9368":10571,"9369":10574,"9370":10575,"9371":10578,"9372":10070,"9373":10580,"9374":10582,"9375":10584,"9376":10586,"9377":10587,"9378":10588,"9379":10077,"9380":10078,"9381":10590,"9382":10591,"9383":10589,"9384":10082,"9385":10594,"9386":10085,"9387":10597,"9388":10653,"9389":10088,"9390":10658,"9391":8009,"9392":8035,"9393":8036,"9394":10093,"9395":10606,"9396":10605,"9397":10096,"9398":10097,"9399":10607,"9400":10609,"9401":10100,"9402":10101,"9403":10556,"9404":10103,"9405":10104,"9406":10105,"9407":10106,"9408":10107,"9409":10612,"9410":10109,"9411":10613,"9412":10616,"9413":10113,"9414":10622,"9415":10115,"9416":10116,"9417":10623,"9418":10118,"9419":10119,"9420":10624,"9421":10121,"9422":10122,"9423":10123,"9424":10124,"9425":10628,"9426":10126,"9427":10633,"9428":10631,"9429":10129,"9430":10638,"9431":10131,"9432":10132,"9433":10639,"9434":10644,"9435":10645,"9436":10646,"9437":10137,"9438":10647,"9439":10139,"9440":10140,"9441":10141,"9442":10654,"9443":10564,"9444":10656,"9445":10657,"9446":10655,"9447":10147,"9448":10148,"9449":10659,"9450":10660,"9451":10151,"9452":10666,"9453":10153,"9454":10154,"9455":10566,"9456":10156,"9457":10157,"9458":10158,"9459":10567,"9460":10160,"9461":10161,"9462":10162,"9463":10163,"9464":10671,"9465":10165,"9466":10674,"9467":10675,"9468":10168,"9469":10679,"9470":8024,"9471":10171,"9472":10172,"9473":8118,"9474":8120,"9475":10175,"9476":10176,"9477":10177,"9478":8014,"9479":10179,"9480":10180,"9481":10181,"9482":7996,"9483":10662,"9484":8027,"9485":10185,"9486":10186,"9487":8132,"9488":8135,"9489":10189,"9490":8010,"9491":10191,"9492":8098,"9493":10193,"9494":8030,"9495":10195,"9496":8139,"9497":8140,"9498":10198,"9499":10199,"9500":10200,"9501":10201,"9502":10202,"9503":8017,"9504":8032,"9505":8148,"9506":10206,"9507":7997,"9508":10208,"9509":10209,"9510":8154,"9511":10211,"9512":10212,"9513":10213,"9514":10214,"9515":10215,"9516":10216,"9517":8112,"9518":8136,"9519":8162,"9520":10220,"9521":10221,"9522":8137,"9523":8168,"9524":8172,"9525":8018,"9526":10226,"9527":8173,"9528":8174,"9529":8037,"9530":8177,"9531":10231,"9532":8178,"9533":10664,"9534":10234,"9535":8179,"9536":8180,"9537":8181,"9538":10238,"9539":10239,"9540":10752,"9541":10753,"9542":10754,"9543":10755,"9544":10756,"9545":10757,"9546":10758,"9547":10759,"9548":10760,"9549":10761,"9550":10762,"9551":10763,"9552":10764,"9553":10765,"9554":10766,"9555":10767,"9556":10768,"9557":10769,"9558":10770,"9559":10771,"9560":10772,"9561":10773,"9562":10774,"9563":10775,"9564":10776,"9565":10777,"9566":10778,"9567":10779,"9568":10780,"9569":10781,"9570":10782,"9571":10783,"9572":10784,"9573":10785,"9574":10786,"9575":10787,"9576":10788,"9577":10789,"9578":10790,"9579":10791,"9580":10792,"9581":10793,"9582":10794,"9583":10795,"9584":10796,"9585":10797,"9586":10798,"9587":10799,"9588":10800,"9589":10801,"9590":10802,"9591":10803,"9592":10804,"9593":10805,"9594":10806,"9595":10807,"9596":10808,"9597":10809,"9598":10810,"9599":10811,"9600":10812,"9601":10813,"9602":10814,"9603":10815,"9604":10816,"9605":10817,"9606":10818,"9607":10819,"9608":10820,"9609":10821,"9610":10822,"9611":10823,"9612":10824,"9613":10825,"9614":10826,"9615":10827,"9616":10828,"9617":10829,"9618":10830,"9619":10831,"9620":10832,"9621":10833,"9622":10834,"9623":10835,"9624":10836,"9625":10837,"9626":10838,"9627":10839,"9628":10840,"9629":10841,"9630":10842,"9631":10843,"9632":10844,"9633":10845,"9634":10846,"9635":10847,"9636":10848,"9637":10849,"9638":10850,"9639":10851,"9640":10852,"9641":10853,"9642":10854,"9643":10858,"9644":10859,"9645":10860,"9646":10861,"9647":10862,"9648":10863,"9649":10864,"9650":10865,"9651":10866,"9652":10867,"9653":10868,"9654":10869,"9655":10870,"9656":10871,"9657":10872,"9658":10873,"9659":10874,"9660":10875,"9661":10876,"9662":10877,"9663":10878,"9664":10879,"9665":10880,"9666":10881,"9667":10882,"9668":10883,"9669":10884,"9670":10885,"9671":10886,"9672":10887,"9673":10888,"9674":10889,"9675":10890,"9676":10891,"9677":10892,"9678":10893,"9679":10894,"9680":10895,"9681":10896,"9682":10897,"9683":10898,"9684":10899,"9685":10900,"9686":10901,"9687":10902,"9688":10903,"9689":10904,"9690":10905,"9691":10906,"9692":10907,"9693":10908,"9694":10909,"9695":10910,"9696":10911,"9697":10912,"9698":10913,"9699":10914,"9700":10915,"9701":10916,"9702":10680,"9703":10681,"9704":10682,"9705":10683,"9706":10684,"9707":10685,"9708":10686,"9709":10687,"9710":10688,"9711":10689,"9712":10690,"9713":10691,"9714":10692,"9715":10693,"9716":10694,"9717":10695,"9718":10696,"9719":10697,"9720":10698,"9721":10700,"9722":10701,"9723":10702,"9724":10703,"9725":10704,"9726":10705,"9727":10706,"9728":10707,"9729":10708,"9730":10709,"9731":10710,"9732":10711,"9733":10712,"9734":10713,"9735":10714,"9736":10715,"9737":10716,"9738":10717,"9739":10718,"9740":10719,"9741":10720,"9742":10721,"9743":10722,"9744":10723,"9745":10724,"9746":10725,"9747":10726,"9748":10727,"9749":10728,"9750":10729,"9751":10730,"9752":10731,"9753":10732,"9754":10733,"9755":10734,"9756":10735,"9757":10736,"9758":10737,"9759":10738,"9760":10739,"9761":10740,"9762":10741,"9763":10742,"9764":10743,"9765":10744,"9766":10745,"9767":10746,"9768":10747,"9769":10748,"9770":10749,"9771":10750,"9772":10751,"9773":10919,"9774":10921,"9775":10922,"9776":10924,"9777":10925,"9778":10926,"9779":10927,"9780":10928,"9781":10929,"9782":10930,"9783":10938,"9784":10939,"9785":10940,"9786":10941,"9787":10943,"9788":10944,"9789":10945,"9790":10947,"9791":10951,"9792":10955,"9793":10957,"9794":10959,"9795":10960,"9796":10962,"9797":10963,"9798":10964,"9799":10965,"9800":10966,"9801":10967,"9802":10968,"9803":10970,"9804":10973,"9805":10975,"9806":10977,"9807":10979,"9808":10980,"9809":10982,"9810":10984,"9811":10987,"9812":10989,"9813":10992,"9814":10996,"9815":10998,"9816":11003,"9817":11008,"9818":11014,"9819":11017,"9820":11018,"9821":11022,"9822":11026,"9823":11027,"9824":11029,"9825":11030,"9826":11031,"9827":11036,"9828":11038,"9829":11040,"9830":11041,"9831":11044,"9832":11045,"9833":11046,"9834":11049,"9835":11052,"9836":11053,"9837":11059,"9838":11061,"9839":11062,"9840":11064,"9841":11065,"9842":11068,"9843":11072,"9844":11073,"9845":11075,"9846":11076,"9847":11077,"9848":11078,"9849":11081,"9850":11082,"9851":11083,"9852":11084,"9853":11086,"9854":11087,"9855":11089,"9856":11090,"9857":11093,"9858":11095,"9859":11096,"9860":11097,"9861":11098,"9862":11100,"9863":11101,"9864":11102,"9865":11103,"9866":11104,"9867":11106,"9868":11109,"9869":11111,"9870":11112,"9871":11114,"9872":11116,"9873":11117,"9874":11122,"9875":11124,"9876":11125,"9877":11127,"9878":11130,"9879":11131,"9880":11132,"9881":11133,"9882":11134,"9883":11135,"9884":11138,"9885":11142,"9886":11143,"9887":11146,"9888":11148,"9889":11149,"9890":11150,"9891":11151,"9892":11152,"9893":11154,"9894":11157,"9895":11158,"9896":10917,"9897":10918,"9898":10920,"9899":10923,"9900":10931,"9901":10932,"9902":10933,"9903":10934,"9904":10935,"9905":10936,"9906":10942,"9907":10946,"9908":10948,"9909":10949,"9910":10950,"9911":10952,"9912":10953,"9913":10954,"9914":10956,"9915":10958,"9916":10961,"9917":10969,"9918":10971,"9919":10972,"9920":10974,"9921":10976,"9922":10978,"9923":10981,"9924":10983,"9925":10985,"9926":10986,"9927":10988,"9928":10990,"9929":10991,"9930":10993,"9931":10994,"9932":10995,"9933":10997,"9934":10999,"9935":11000,"9936":11001,"9937":11002,"9938":11004,"9939":11005,"9940":11006,"9941":11007,"9942":11009,"9943":11010,"9944":11011,"9945":11012,"9946":11013,"9947":11015,"9948":11016,"9949":11019,"9950":11020,"9951":11021,"9952":11023,"9953":11024,"9954":11025,"9955":11028,"9956":11032,"9957":11033,"9958":11034,"9959":11035,"9960":11037,"9961":11039,"9962":11042,"9963":11043,"9964":11047,"9965":11048,"9966":11050,"9967":11051,"9968":11054,"9969":11055,"9970":11056,"9971":11057,"9972":11058,"9973":11060,"9974":11063,"9975":11066,"9976":11067,"9977":11069,"9978":11070,"9979":11071,"9980":11074,"9981":11079,"9982":11080,"9983":11085,"9984":11088,"9985":11091,"9986":11092,"9987":11094,"9988":11099,"9989":11105,"9990":11107,"9991":11108,"9992":11110,"9993":11113,"9994":11115,"9995":11118,"9996":11119,"9997":11120,"9998":11121,"9999":11123,"10000":11126,"10001":11128,"10002":11129,"10003":11136,"10004":11137,"10005":11139,"10006":11140,"10007":11141,"10008":11144,"10009":11145,"10010":11147,"10011":11153,"10012":11155,"10013":11156,"10014":11159,"10015":11160,"10016":11161,"10017":11162,"10018":11163,"10019":130,"10020":375,"10021":937,"10022":1339,"10023":1365,"10024":1516,"10025":1689,"10026":1903,"10027":2053,"10028":2481,"10029":2761,"10030":3478,"10031":4590,"10032":4642,"10033":5223,"10034":5691,"10035":5909,"10036":6126,"10037":7511,"10038":8164,"10039":8254,"10040":8543,"10041":8771,"10042":10011},"PMCID":{"0":2206488,"1":2871176,"2":2517154,"3":2871176,"4":2708184,"5":2871176,"6":2871176,"7":2864284,"8":2708184,"9":2871176,"10":2864284,"11":2871176,"12":3187863,"13":2871176,"14":2871176,"15":2871176,"16":2871176,"17":2871176,"18":4106715,"19":2871176,"20":2708184,"21":2871176,"22":2864284,"23":2864284,"24":2708184,"25":2864284,"26":2864284,"27":2871176,"28":2517154,"29":2871176,"30":2871176,"31":2708184,"32":2864284,"33":2864284,"34":2871176,"35":2871176,"36":2871176,"37":3187863,"38":2517154,"39":2871176,"40":2206488,"41":3187863,"42":2864284,"43":3001156,"44":4106715,"45":2688140,"46":2871176,"47":2517154,"48":2871176,"49":2871176,"50":2871176,"51":2871176,"52":2871176,"53":3187863,"54":2871176,"55":4106715,"56":2871176,"57":2864284,"58":2871176,"59":2206488,"60":2517154,"61":3001156,"62":3187863,"63":2708184,"64":2517154,"65":2688140,"66":2871176,"67":2864284,"68":4106715,"69":2871176,"70":2871176,"71":2517154,"72":2871176,"73":2206488,"74":2871176,"75":2517154,"76":2708184,"77":2871176,"78":2871176,"79":2708184,"80":2206488,"81":2871176,"82":2871176,"83":3001156,"84":2871176,"85":2871176,"86":2871176,"87":2206488,"88":2871176,"89":2871176,"90":3187863,"91":2708184,"92":2517154,"93":2871176,"94":2864284,"95":2517154,"96":2864284,"97":2871176,"98":2871176,"99":2871176,"100":2871176,"101":2871176,"102":4106715,"103":1852268,"104":2871176,"105":2871176,"106":4106715,"107":2871176,"108":3187863,"109":2871176,"110":2690844,"111":2847809,"112":3580134,"113":2847809,"114":3580134,"115":2375236,"116":2447617,"117":3580134,"118":2690844,"119":2899760,"120":1475568,"121":3580134,"122":3580134,"123":2600646,"124":2691927,"125":1871574,"126":2817867,"127":3090298,"128":1475568,"129":2817867,"130":2817867,"131":3580134,"132":1468428,"133":3580134,"134":2690844,"135":3580134,"136":3090298,"137":2690844,"138":2899760,"139":3580134,"140":2690844,"141":2361806,"142":2690844,"143":3090298,"144":1831737,"145":2361806,"146":2607225,"147":2721929,"148":3387601,"149":2817867,"150":2691927,"151":3446002,"152":2691927,"153":1876597,"154":3090298,"155":2691927,"156":2690844,"157":2691927,"158":2375236,"159":3580134,"160":2447617,"161":1831737,"162":2721929,"163":2375236,"164":3090298,"165":1871574,"166":1871574,"167":1187893,"168":3580134,"169":1871574,"170":3580134,"171":1475568,"172":1831737,"173":2600646,"174":3580134,"175":1475568,"176":1831737,"177":2690844,"178":1871574,"179":2847809,"180":1475568,"181":2375236,"182":2690844,"183":3580134,"184":3580134,"185":1871574,"186":1187893,"187":1871574,"188":2690844,"189":2721929,"190":1831737,"191":2690844,"192":1475568,"193":3580134,"194":1831737,"195":1475568,"196":3580134,"197":2922723,"198":2720945,"199":3090298,"200":1475568,"201":2447617,"202":1871574,"203":1871574,"204":2361806,"205":2691927,"206":1871574,"207":3580134,"208":1831737,"209":2361806,"210":3580134,"211":1871574,"212":3580134,"213":1876597,"214":3580134,"215":1871574,"216":2721929,"217":3580134,"218":2720945,"219":3446002,"220":3580134,"221":3580134,"222":3580134,"223":1784771,"224":3446002,"225":2575601,"226":3090298,"227":1913177,"228":2361806,"229":3090298,"230":3580134,"231":2720945,"232":3387601,"233":3580134,"234":3580134,"235":2447617,"236":1475568,"237":3580134,"238":2922723,"239":2691927,"240":2575601,"241":3580134,"242":3580134,"243":3090298,"244":1201146,"245":2690844,"246":1475568,"247":2817867,"248":1831737,"249":3580134,"250":1475568,"251":3580134,"252":2690844,"253":1871574,"254":1468428,"255":1876597,"256":2690844,"257":3580134,"258":3580134,"259":1475568,"260":3090298,"261":3580134,"262":2817867,"263":1784771,"264":2720945,"265":3580134,"266":1831737,"267":3580134,"268":3580134,"269":3580134,"270":3580134,"271":1871574,"272":2691927,"273":2922723,"274":2691927,"275":2690844,"276":3580134,"277":2430614,"278":3580134,"279":5577662,"280":5602855,"281":4577567,"282":2253708,"283":4139977,"284":5577662,"285":4819709,"286":4819709,"287":125315,"288":5062234,"289":4785315,"290":1261533,"291":4139977,"292":4819709,"293":4819709,"294":3800940,"295":2888205,"296":2806484,"297":2956883,"298":2888205,"299":3198285,"300":2956883,"301":4819709,"302":2891743,"303":1964758,"304":5062234,"305":2891743,"306":2829413,"307":5577662,"308":5602855,"309":1261533,"310":2364680,"311":2363351,"312":3198285,"313":2956883,"314":2364533,"315":2806484,"316":5577662,"317":4819709,"318":2722000,"319":2650992,"320":5602855,"321":3221331,"322":3580134,"323":3580134,"324":3580134,"325":2690844,"326":3580134,"327":1187893,"328":3580134,"329":3580134,"330":3580134,"331":3090298,"332":3580134,"333":2721929,"334":2575601,"335":2922723,"336":3387601,"337":1475568,"338":3580134,"339":1475568,"340":3580134,"341":3580134,"342":1468428,"343":2922723,"344":2691927,"345":2817867,"346":3580134,"347":2447617,"348":2575601,"349":2447617,"350":1201146,"351":2899760,"352":3108665,"353":1187893,"354":2690844,"355":3090298,"356":3580134,"357":2922723,"358":1831737,"359":1913177,"360":3580134,"361":1784771,"362":3580134,"363":2720945,"364":2575601,"365":3580134,"366":1784771,"367":1201146,"368":3580134,"369":2691927,"370":3580134,"371":2690844,"372":3580134,"373":2720945,"374":2922723,"375":2817867,"376":1187893,"377":1475568,"378":3387601,"379":3580134,"380":1187893,"381":2690844,"382":3090298,"383":1871574,"384":2691927,"385":2817867,"386":3090298,"387":2922723,"388":3580134,"389":1831737,"390":3580134,"391":1201146,"392":3580134,"393":3580134,"394":2575601,"395":2575601,"396":3580134,"397":2430614,"398":2575601,"399":3580134,"400":3580134,"401":3387601,"402":2690844,"403":2575601,"404":2829413,"405":2829413,"406":1261533,"407":3349250,"408":2361948,"409":3198285,"410":2722000,"411":2650992,"412":1187893,"413":2830179,"414":2830179,"415":4785315,"416":4785315,"417":3490871,"418":5256321,"419":5256321,"420":4419460,"421":4577567,"422":4577567,"423":4819709,"424":4819709,"425":4819709,"426":4819709,"427":4819709,"428":4819709,"429":5062194,"430":5577662,"431":4794897,"432":2806484,"433":2806484,"434":2806484,"435":4139977,"436":2363351,"437":2253708,"438":2376383,"439":2376383,"440":1964758,"441":2829413,"442":2829413,"443":1261533,"444":1261533,"445":1261533,"446":3349250,"447":3349250,"448":3349250,"449":3349250,"450":2361948,"451":2361948,"452":3221331,"453":2722000,"454":2722000,"455":2650992,"456":125315,"457":125315,"458":2830179,"459":2830179,"460":2888205,"461":2888205,"462":2888205,"463":2888205,"464":3490871,"465":5256321,"466":4577567,"467":5294349,"468":4819709,"469":4819709,"470":4819709,"471":4819709,"472":5062194,"473":4794897,"474":2607225,"475":2944158,"476":2858204,"477":2922723,"478":2361948,"479":2361806,"480":4819709,"481":4819709,"482":4819709,"483":4819709,"484":4819709,"485":4078386,"486":5680306,"487":5332972,"488":5209819,"489":5729252,"490":2974815,"491":4088715,"492":5801479,"493":5801479,"494":4140547,"495":1198254,"496":4677000,"497":4320624,"498":4320624,"499":5816054,"500":2774638,"501":3015551,"502":3015551,"503":3220090,"504":4192987,"505":4183415,"506":5462761,"507":4693888,"508":4693888,"509":3278655,"510":3330821,"511":4889691,"512":2363351,"513":2363351,"514":2253708,"515":2364533,"516":2956883,"517":2376383,"518":2376383,"519":1964758,"520":2829413,"521":1198254,"522":2361948,"523":2600646,"524":4320624,"525":5816054,"526":2774638,"527":2774638,"528":3616124,"529":3616124,"530":3015551,"531":4192987,"532":4264479,"533":4918678,"534":4918678,"535":3039191,"536":5551012,"537":5551012,"538":4693888,"539":2858204,"540":4819709,"541":4819709,"542":3330821,"543":4819709,"544":2656477,"545":4819709,"546":5372931,"547":4819709,"548":5062194,"549":4078386,"550":5332972,"551":5332972,"552":5209819,"553":5729252,"554":2974815,"555":5539984,"556":5514258,"557":5514258,"558":5801479,"559":5519461,"560":4486943,"561":4221638,"562":3296686,"563":3296686,"564":4138383,"565":4138383,"566":3296686,"567":4223523,"568":4588874,"569":4223523,"570":5746685,"571":4748685,"572":4748685,"573":3224529,"574":4748685,"575":4748685,"576":3224529,"577":5089605,"578":4821313,"579":4075638,"580":3752932,"581":5064056,"582":2223531,"583":5064056,"584":4653470,"585":3787573,"586":3787573,"587":3971783,"588":3971783,"589":5122238,"590":3743641,"591":520750,"592":3743641,"593":3743641,"594":4821226,"595":4821226,"596":3743641,"597":1562433,"598":4280954,"599":4667210,"600":5610854,"601":4395717,"602":4082484,"603":2644667,"604":4109867,"605":4109867,"606":3491047,"607":3491047,"608":3798949,"609":5064802,"610":5619630,"611":5490116,"612":5490116,"613":5490116,"614":2920262,"615":2920262,"616":5215617,"617":3577738,"618":3577738,"619":3074545,"620":5489138,"621":3611646,"622":3878029,"623":3442969,"624":5225252,"625":5003313,"626":4627811,"627":5018157,"628":3895597,"629":5101425,"630":3742017,"631":3159986,"632":4895766,"633":4895766,"634":4486943,"635":4486943,"636":4588874,"637":5746685,"638":5746685,"639":4748685,"640":2223531,"641":3787573,"642":3787573,"643":5100099,"644":5100099,"645":1562433,"646":1562433,"647":4565804,"648":5610854,"649":4395717,"650":4082484,"651":4109867,"652":4109867,"653":4109867,"654":4109867,"655":5064802,"656":5064802,"657":4940009,"658":3423952,"659":3423952,"660":3423952,"661":5489138,"662":3611646,"663":5936036,"664":5936036,"665":5225252,"666":5225252,"667":4627811,"668":3895597,"669":3895597,"670":4893237,"671":5851630,"672":3296686,"673":3296686,"674":4223523,"675":5354011,"676":4821313,"677":4821313,"678":3752932,"679":5002324,"680":5122238,"681":3743641,"682":3743641,"683":3743641,"684":3743641,"685":3743641,"686":3743641,"687":3743641,"688":4280954,"689":2858204,"690":4526336,"691":4306068,"692":5680306,"693":5539984,"694":5539984,"695":5519461,"696":5618071,"697":4140547,"698":1198254,"699":5295802,"700":4264479,"701":4918678,"702":2656477,"703":5372931,"704":5372931,"705":3491047,"706":3491047,"707":3798949,"708":5619630,"709":5619630,"710":5490116,"711":2920262,"712":3074545,"713":3878029,"714":5003313,"715":5018157,"716":5101425,"717":5101425,"718":3159986,"719":4895766,"720":4486943,"721":4221638,"722":4221638,"723":4138383,"724":4588874,"725":5100099,"726":4821226,"727":4667210,"728":5610854,"729":2644667,"730":2644667,"731":2644667,"732":4109867,"733":4109867,"734":4940009,"735":4940009,"736":4940009,"737":3423952,"738":3611646,"739":3611646,"740":4627811,"741":3895597,"742":5626376,"743":5626376,"744":5626376,"745":5626376,"746":3224529,"747":1913177,"748":3752932,"749":5002324,"750":3971783,"751":2430614,"752":4280954,"753":4280954,"754":4306068,"755":2361948,"756":3490871,"757":3490871,"758":4419460,"759":3329632,"760":4819709,"761":4819709,"762":4819709,"763":4819709,"764":4819709,"765":4078386,"766":5680306,"767":2974815,"768":4088715,"769":4140547,"770":1198254,"771":4677000,"772":4320624,"773":2774638,"774":4713214,"775":4713214,"776":4713214,"777":5332489,"778":3616124,"779":4183415,"780":4183415,"781":5462761,"782":4918678,"783":5504551,"784":5504551,"785":3278655,"786":3278655,"787":3597472,"788":3597472,"789":3330821,"790":4803984,"791":4889691,"792":4889691,"793":4889691,"794":3491047,"795":3798949,"796":5619630,"797":5062220,"798":2920262,"799":2920262,"800":3074545,"801":3878029,"802":5018157,"803":5018157,"804":3159986,"805":4895766,"806":4132637,"807":4132637,"808":4132637,"809":4132637,"810":3636800,"811":3596913,"812":5789132,"813":5789132,"814":5873424,"815":4124480,"816":5236513,"817":5236513,"818":3478519,"819":4716419,"820":3917204,"821":5673730,"822":5397544,"823":4819709,"824":3743198,"825":3743198,"826":3743198,"827":3917123,"828":3452313,"829":5966469,"830":2694465,"831":2694465,"832":2694465,"833":5506592,"834":5228611,"835":3051215,"836":3466198,"837":3056193,"838":5225191,"839":3172326,"840":5062234,"841":4864053,"842":4488484,"843":4488484,"844":4488484,"845":5414544,"846":3655855,"847":2376383,"848":4880652,"849":3585965,"850":5578640,"851":5578640,"852":4092608,"853":4092608,"854":5456350,"855":5456350,"856":5330006,"857":5330006,"858":5553001,"859":5566825,"860":5566825,"861":5336430,"862":5336430,"863":4859395,"864":4859395,"865":4859395,"866":4859395,"867":3406743,"868":4600230,"869":2837815,"870":2837815,"871":2837815,"872":4367028,"873":4222592,"874":5628593,"875":4222592,"876":4222592,"877":5628593,"878":5820389,"879":4222592,"880":5820389,"881":3179725,"882":4673066,"883":4673066,"884":3179725,"885":4881089,"886":3842830,"887":3842830,"888":5379843,"889":4365564,"890":5311860,"891":5311860,"892":3846239,"893":5285426,"894":2627861,"895":5850185,"896":5850185,"897":5850185,"898":3464379,"899":2361520,"900":3464379,"901":5593173,"902":4599543,"903":5593173,"904":4107254,"905":4518214,"906":5766333,"907":5766333,"908":5766333,"909":5766333,"910":5766333,"911":4819709,"912":5397544,"913":5741263,"914":3917123,"915":3917123,"916":4996255,"917":5506592,"918":5228611,"919":5228611,"920":5228611,"921":3466198,"922":3466198,"923":5225191,"924":3172326,"925":3172326,"926":4864053,"927":5414544,"928":3933059,"929":3933059,"930":4709985,"931":3655855,"932":4401879,"933":3585965,"934":5928476,"935":4132637,"936":4132637,"937":5551214,"938":5551214,"939":3636800,"940":5951568,"941":5451423,"942":5451423,"943":5789132,"944":3258678,"945":3258678,"946":5494586,"947":5494586,"948":5494586,"949":5494586,"950":5236513,"951":4716419,"952":3917204,"953":5673730,"954":4012222,"955":5320660,"956":3179725,"957":3842830,"958":4365564,"959":5311860,"960":5285426,"961":5285426,"962":3628658,"963":3628658,"964":3628658,"965":3628658,"966":4659198,"967":4659198,"968":4599543,"969":5724392,"970":5766333,"971":5456350,"972":5456350,"973":2361654,"974":5553001,"975":5566825,"976":5566825,"977":5336430,"978":5336430,"979":5336430,"980":5610684,"981":3406743,"982":3406743,"983":3406743,"984":4600230,"985":4600230,"986":4600230,"987":2837815,"988":4367028,"989":4367028,"990":4367028,"991":4222592,"992":4673066,"993":4881089,"994":4881089,"995":5021748,"996":5021748,"997":4274342,"998":4274342,"999":4274342,"1000":4274342,"1001":3846239,"1002":3846239,"1003":2627861,"1004":5854362,"1005":4134501,"1006":4134501,"1007":2361520,"1008":2361520,"1009":4107254,"1010":4107254,"1011":4092926,"1012":4092926,"1013":4221638,"1014":4132637,"1015":4588874,"1016":4223523,"1017":3697211,"1018":5089605,"1019":4075638,"1020":3752932,"1021":4075638,"1022":3258678,"1023":4124480,"1024":3787573,"1025":4124480,"1026":5100099,"1027":520750,"1028":3743641,"1029":4716419,"1030":2888205,"1031":4280954,"1032":5673730,"1033":3743198,"1034":5320660,"1035":4082484,"1036":5741263,"1037":2644667,"1038":4109867,"1039":5228611,"1040":5228611,"1041":3580134,"1042":5062220,"1043":3051215,"1044":5215617,"1045":3466198,"1046":3577738,"1047":5489138,"1048":5225191,"1049":3878029,"1050":5225252,"1051":4488484,"1052":3442969,"1053":4627811,"1054":4627811,"1055":4401879,"1056":5101425,"1057":4880652,"1058":4880652,"1059":5626376,"1060":5941723,"1061":5941723,"1062":5017045,"1063":5017045,"1064":5017045,"1065":2941605,"1066":4737200,"1067":4737200,"1068":4737200,"1069":4396724,"1070":4396724,"1071":4737200,"1072":1488892,"1073":1488892,"1074":5916905,"1075":3094237,"1076":3094237,"1077":4924222,"1078":5791393,"1079":5791393,"1080":5791393,"1081":5074260,"1082":5074260,"1083":5642191,"1084":5642191,"1085":3810136,"1086":2714198,"1087":2911596,"1088":5434251,"1089":5434251,"1090":5434251,"1091":4335741,"1092":4335741,"1093":4086013,"1094":4086013,"1095":4086013,"1096":3430047,"1097":3719224,"1098":3640164,"1099":3640164,"1100":5420386,"1101":5420386,"1102":5498096,"1103":5498096,"1104":2291328,"1105":2291328,"1106":2291328,"1107":5343624,"1108":3489577,"1109":4132637,"1110":4132637,"1111":3636800,"1112":3901329,"1113":5951568,"1114":5951568,"1115":3924124,"1116":4124480,"1117":3478519,"1118":4716419,"1119":5673730,"1120":5673730,"1121":5320660,"1122":5741263,"1123":3917123,"1124":4819709,"1125":2694465,"1126":3933059,"1127":4880652,"1128":3269796,"1129":3269796,"1130":5396972,"1131":5396972,"1132":5396972,"1133":4396724,"1134":4737200,"1135":4737200,"1136":4737200,"1137":1488892,"1138":4737200,"1139":1488892,"1140":4737200,"1141":5916905,"1142":3094237,"1143":3094237,"1144":5379203,"1145":3489577,"1146":4924222,"1147":3489577,"1148":5642191,"1149":3810136,"1150":3810136,"1151":2911596,"1152":2911596,"1153":5434251,"1154":4335741,"1155":4335741,"1156":4086013,"1157":4086013,"1158":5934937,"1159":5934937,"1160":3430047,"1161":3430047,"1162":3430047,"1163":3719224,"1164":3719224,"1165":3640164,"1166":5420386,"1167":270000,"1168":270000,"1169":3309311,"1170":3309311,"1171":5498096,"1172":2856148,"1173":2856148,"1174":2856148,"1175":2291328,"1176":2291328,"1177":5343624,"1178":3489577,"1179":5941723,"1180":3798206,"1181":4900317,"1182":111193,"1183":111193,"1184":3154934,"1185":5003869,"1186":5003869,"1187":5362210,"1188":3600348,"1189":3388481,"1190":4045368,"1191":4045368,"1192":4733710,"1193":2967098,"1194":5556332,"1195":5556332,"1196":5599918,"1197":5556332,"1198":5599918,"1199":5742644,"1200":5742644,"1201":4199180,"1202":4526979,"1203":4526979,"1204":4526979,"1205":4780150,"1206":4780150,"1207":4137650,"1208":4137650,"1209":4137650,"1210":5697397,"1211":4878364,"1212":5578640,"1213":4092926,"1214":4092608,"1215":2361654,"1216":3814588,"1217":5330006,"1218":5553001,"1219":5566825,"1220":5336430,"1221":5336430,"1222":5610684,"1223":4859395,"1224":3406743,"1225":3406743,"1226":4600230,"1227":4367028,"1228":5628593,"1229":5820389,"1230":3179725,"1231":4881089,"1232":3403961,"1233":5932317,"1234":5932317,"1235":5379843,"1236":3842830,"1237":5311860,"1238":5285426,"1239":3466198,"1240":3628658,"1241":4659198,"1242":4659198,"1243":4659198,"1244":2361520,"1245":3464379,"1246":3464379,"1247":5593173,"1248":4599543,"1249":4107254,"1250":3456942,"1251":5766333,"1252":3106384,"1253":3269796,"1254":5017045,"1255":3269796,"1256":2941605,"1257":5396972,"1258":2941605,"1259":5396972,"1260":4396724,"1261":4737200,"1262":5916905,"1263":4737200,"1264":5916905,"1265":5336430,"1266":5610684,"1267":4924222,"1268":4859395,"1269":5074260,"1270":5074260,"1271":5074260,"1272":3810136,"1273":3810136,"1274":2714198,"1275":2911596,"1276":4222592,"1277":5628593,"1278":4673066,"1279":3403961,"1280":3430047,"1281":4409094,"1282":3640164,"1283":3640164,"1284":4134501,"1285":3464379,"1286":270000,"1287":4599543,"1288":4599543,"1289":5498096,"1290":5724392,"1291":5228669,"1292":5343624,"1293":3489577,"1294":5941723,"1295":3106384,"1296":5941723,"1297":4900317,"1298":111193,"1299":3154934,"1300":3600348,"1301":3388481,"1302":3388481,"1303":4045368,"1304":4045368,"1305":4733710,"1306":3403627,"1307":3403627,"1308":5599918,"1309":5599918,"1310":5742644,"1311":5742644,"1312":5742644,"1313":4199180,"1314":4199180,"1315":4526979,"1316":4780150,"1317":4472776,"1318":4472776,"1319":4137650,"1320":5697397,"1321":4878364,"1322":4878364,"1323":3798206,"1324":3798206,"1325":3793419,"1326":4045752,"1327":5404215,"1328":5659064,"1329":3835146,"1330":3921228,"1331":3921228,"1332":3921228,"1333":4628236,"1334":4628236,"1335":4628236,"1336":4342682,"1337":4471244,"1338":5452066,"1339":5452066,"1340":5360580,"1341":5360580,"1342":4760045,"1343":4760045,"1344":3743198,"1345":3258678,"1346":5145296,"1347":5145296,"1348":4223282,"1349":3657931,"1350":3259296,"1351":3259296,"1352":3259296,"1353":5291156,"1354":5291156,"1355":4188762,"1356":2742700,"1357":3687261,"1358":3687261,"1359":5389230,"1360":5389230,"1361":5389230,"1362":5045666,"1363":5045666,"1364":3000449,"1365":5630555,"1366":3276929,"1367":3276929,"1368":4374260,"1369":4374260,"1370":4175246,"1371":4175246,"1372":4094699,"1373":5340016,"1374":5340016,"1375":4481831,"1376":4481831,"1377":4048120,"1378":3293139,"1379":4723180,"1380":4404560,"1381":5376493,"1382":5376493,"1383":5376493,"1384":4227976,"1385":5193306,"1386":3232004,"1387":5012042,"1388":5012042,"1389":5012042,"1390":4845428,"1391":4235088,"1392":5614293,"1393":3178704,"1394":3178704,"1395":4747995,"1396":4747995,"1397":3101755,"1398":3101755,"1399":3101755,"1400":5609057,"1401":4477402,"1402":4477402,"1403":4121500,"1404":4121500,"1405":3269796,"1406":5404215,"1407":5916905,"1408":5379203,"1409":4924222,"1410":4924222,"1411":5791393,"1412":5791393,"1413":5434251,"1414":4335741,"1415":4409094,"1416":3719224,"1417":3640164,"1418":270000,"1419":3309311,"1420":2856148,"1421":3489577,"1422":5017045,"1423":4737200,"1424":4737200,"1425":4737200,"1426":5362210,"1427":3600348,"1428":3600348,"1429":3600348,"1430":4045368,"1431":3403627,"1432":5556332,"1433":4199180,"1434":4526979,"1435":4780150,"1436":4780150,"1437":4472776,"1438":4472776,"1439":4137650,"1440":5697397,"1441":5697397,"1442":5697397,"1443":4878364,"1444":3798206,"1445":4900317,"1446":4900317,"1447":4900317,"1448":111193,"1449":111193,"1450":3154934,"1451":5003869,"1452":5003869,"1453":5003869,"1454":3388481,"1455":4733710,"1456":4733710,"1457":4733710,"1458":5599918,"1459":2375877,"1460":5145296,"1461":4188762,"1462":4094699,"1463":4048120,"1464":3293139,"1465":4202748,"1466":5193306,"1467":3178704,"1468":5343624,"1469":5343624,"1470":4584261,"1471":5049622,"1472":5049622,"1473":5049622,"1474":5723168,"1475":5659064,"1476":5659064,"1477":5659064,"1478":3835146,"1479":4628236,"1480":4628236,"1481":4628236,"1482":4628236,"1483":4471244,"1484":4471244,"1485":3190091,"1486":4760045,"1487":5534500,"1488":2772252,"1489":2375877,"1490":2375877,"1491":5145296,"1492":5145296,"1493":4223282,"1494":4223282,"1495":5332296,"1496":5332296,"1497":5332296,"1498":3657931,"1499":5019463,"1500":3259296,"1501":3259296,"1502":5291156,"1503":4188762,"1504":2742700,"1505":3687261,"1506":5389230,"1507":5045666,"1508":3000449,"1509":3000449,"1510":3480782,"1511":3480782,"1512":3276929,"1513":3276929,"1514":5863418,"1515":4374260,"1516":3278262,"1517":3278262,"1518":4322313,"1519":4322313,"1520":4175246,"1521":5340016,"1522":4481831,"1523":3085176,"1524":4048120,"1525":3293139,"1526":4723180,"1527":4404560,"1528":5376493,"1529":4227976,"1530":4227976,"1531":4202748,"1532":5012042,"1533":5012042,"1534":4845428,"1535":2671648,"1536":2671648,"1537":2671648,"1538":5976967,"1539":4338635,"1540":4338635,"1541":4338635,"1542":4338635,"1543":5614293,"1544":5614293,"1545":5426756,"1546":4747995,"1547":4121500,"1548":4121500,"1549":5437665,"1550":5437665,"1551":2815285,"1552":5787910,"1553":5787910,"1554":5787910,"1555":4860224,"1556":5444773,"1557":5387905,"1558":5867479,"1559":5867479,"1560":5029935,"1561":5174811,"1562":3118076,"1563":4509558,"1564":4509558,"1565":3735552,"1566":5320759,"1567":5320759,"1568":5320759,"1569":5320759,"1570":5320759,"1571":5372065,"1572":4064763,"1573":4064763,"1574":5308129,"1575":5308129,"1576":4313493,"1577":3556334,"1578":3804449,"1579":3804449,"1580":3804449,"1581":4477338,"1582":4477338,"1583":3329148,"1584":3329148,"1585":3329148,"1586":4056626,"1587":3210325,"1588":5372977,"1589":5372977,"1590":5372977,"1591":3467590,"1592":3467590,"1593":3467590,"1594":3467590,"1595":5223669,"1596":4379665,"1597":5589093,"1598":5589093,"1599":5589093,"1600":5589093,"1601":5589093,"1602":5589093,"1603":5589093,"1604":5589093,"1605":5589093,"1606":5589093,"1607":5589093,"1608":5337766,"1609":5337766,"1610":5695666,"1611":1971065,"1612":5337626,"1613":5337626,"1614":5509597,"1615":5509597,"1616":4025600,"1617":3747462,"1618":3747462,"1619":3747462,"1620":3065646,"1621":5049622,"1622":5049622,"1623":4045752,"1624":5404215,"1625":4019890,"1626":5659064,"1627":3835146,"1628":4628236,"1629":4628236,"1630":4628236,"1631":4342682,"1632":5452066,"1633":5360580,"1634":5360580,"1635":3190091,"1636":4760045,"1637":4760045,"1638":5534500,"1639":5534500,"1640":5534500,"1641":5534500,"1642":5534500,"1643":4348728,"1644":4538249,"1645":2375877,"1646":4763632,"1647":5127177,"1648":4223282,"1649":4223282,"1650":5332296,"1651":5332296,"1652":3657931,"1653":4652407,"1654":5019463,"1655":5019463,"1656":5291156,"1657":5291156,"1658":5040779,"1659":3687261,"1660":5389230,"1661":4842481,"1662":3000449,"1663":3480782,"1664":3480782,"1665":5630555,"1666":5630555,"1667":3276929,"1668":3276929,"1669":5863418,"1670":4374260,"1671":4175246,"1672":4094699,"1673":5340016,"1674":5482825,"1675":3085176,"1676":3085176,"1677":3085176,"1678":3085176,"1679":4048120,"1680":4048120,"1681":4048120,"1682":2920889,"1683":4404560,"1684":5391070,"1685":5376493,"1686":4227976,"1687":3661884,"1688":4202748,"1689":4415132,"1690":5193306,"1691":5193306,"1692":5808396,"1693":5808396,"1694":3539990,"1695":4845428,"1696":4519544,"1697":2671648,"1698":4338635,"1699":4338635,"1700":4235088,"1701":3178704,"1702":4121500,"1703":5437665,"1704":5437665,"1705":2815285,"1706":2815285,"1707":2815285,"1708":5787910,"1709":4860224,"1710":4860224,"1711":5444773,"1712":5444773,"1713":5444773,"1714":5444773,"1715":5387905,"1716":5387905,"1717":5867479,"1718":5867479,"1719":5867479,"1720":5029935,"1721":5174811,"1722":5174811,"1723":5174811,"1724":5174811,"1725":3118076,"1726":3118076,"1727":3627033,"1728":3794450,"1729":3735552,"1730":3735552,"1731":5615441,"1732":5372065,"1733":5372065,"1734":4064763,"1735":4064763,"1736":3561645,"1737":3561645,"1738":5308129,"1739":3556334,"1740":3556334,"1741":3556334,"1742":3804449,"1743":4477338,"1744":4056626,"1745":4056626,"1746":4056626,"1747":3525032,"1748":3525032,"1749":3525032,"1750":3210325,"1751":4678179,"1752":4678179,"1753":4678179,"1754":4678179,"1755":5372977,"1756":3373832,"1757":3467590,"1758":5223669,"1759":4796902,"1760":4796902,"1761":4379665,"1762":4379665,"1763":4379665,"1764":5589093,"1765":5589093,"1766":5589093,"1767":5589093,"1768":5589093,"1769":5589093,"1770":5337766,"1771":4392900,"1772":1971065,"1773":5337626,"1774":5509597,"1775":5509597,"1776":4025600,"1777":4025600,"1778":3747462,"1779":2375877,"1780":4814821,"1781":4814821,"1782":3961219,"1783":3961219,"1784":3961219,"1785":4280425,"1786":4280425,"1787":4884360,"1788":3400348,"1789":3400348,"1790":3400348,"1791":5615289,"1792":5615289,"1793":5615289,"1794":5615289,"1795":4191553,"1796":4191553,"1797":4191553,"1798":3850342,"1799":3850342,"1800":4590407,"1801":4590407,"1802":3263888,"1803":3620559,"1804":3620559,"1805":5446455,"1806":5446455,"1807":5446455,"1808":5446455,"1809":3549413,"1810":3549413,"1811":2887326,"1812":2887326,"1813":2409647,"1814":2409647,"1815":2409647,"1816":2409647,"1817":5446666,"1818":5446666,"1819":5446666,"1820":5556716,"1821":5767990,"1822":5767990,"1823":4802087,"1824":3580611,"1825":5021260,"1826":5101645,"1827":5101645,"1828":5831281,"1829":4639339,"1830":4392900,"1831":4051747,"1832":5031764,"1833":3668955,"1834":4538249,"1835":4538249,"1836":4602159,"1837":4749757,"1838":4749757,"1839":4749757,"1840":4749757,"1841":5331772,"1842":5331772,"1843":5331772,"1844":4794540,"1845":4763632,"1846":4763632,"1847":4763632,"1848":4652407,"1849":2662857,"1850":2662857,"1851":5040779,"1852":3210361,"1853":2806387,"1854":4842481,"1855":4662683,"1856":4662683,"1857":4662683,"1858":3771300,"1859":3614647,"1860":3614647,"1861":3614647,"1862":5054611,"1863":5054611,"1864":2001223,"1865":2001223,"1866":2639700,"1867":4574984,"1868":4574984,"1869":4574984,"1870":5482825,"1871":5482825,"1872":5482825,"1873":5482825,"1874":5622764,"1875":4365008,"1876":5742427,"1877":5742427,"1878":3661884,"1879":3661884,"1880":4266420,"1881":5738810,"1882":5738810,"1883":5738810,"1884":5738810,"1885":5808396,"1886":5738810,"1887":4516063,"1888":5038569,"1889":4759876,"1890":4759876,"1891":5057302,"1892":3376507,"1893":3376507,"1894":4714728,"1895":4714728,"1896":4204994,"1897":4204994,"1898":5808689,"1899":5808689,"1900":4051747,"1901":3536989,"1902":5300822,"1903":4574984,"1904":4574984,"1905":4348728,"1906":5482825,"1907":5482825,"1908":4602159,"1909":5482825,"1910":5482825,"1911":4199615,"1912":4199615,"1913":5331772,"1914":5391070,"1915":4794540,"1916":4794540,"1917":4794540,"1918":3956949,"1919":3956949,"1920":4296406,"1921":4763632,"1922":4296406,"1923":5127177,"1924":4760038,"1925":4760038,"1926":4760038,"1927":4266420,"1928":4266420,"1929":4652407,"1930":5738810,"1931":2662857,"1932":2662857,"1933":2662857,"1934":3539990,"1935":4519544,"1936":4519544,"1937":4519544,"1938":4759876,"1939":3210361,"1940":3210361,"1941":3663169,"1942":4842481,"1943":4842481,"1944":4842481,"1945":3445058,"1946":5054611,"1947":4814821,"1948":4814821,"1949":4814821,"1950":4280425,"1951":4884360,"1952":4884360,"1953":5615289,"1954":4191553,"1955":4191553,"1956":4191553,"1957":3263888,"1958":3263888,"1959":3620559,"1960":3620559,"1961":5446455,"1962":5446455,"1963":5446455,"1964":5446455,"1965":3549413,"1966":3549413,"1967":2887326,"1968":2409647,"1969":2409647,"1970":2409647,"1971":5556716,"1972":5556716,"1973":5767990,"1974":4802087,"1975":3580611,"1976":3580611,"1977":5101645,"1978":5831281,"1979":4639339,"1980":4639339,"1981":4341495,"1982":4341495,"1983":4341495,"1984":4341495,"1985":4131263,"1986":4131263,"1987":4131263,"1988":4538249,"1989":1716162,"1990":1716162,"1991":5604419,"1992":5604419,"1993":4749757,"1994":4199615,"1995":4199615,"1996":4199615,"1997":5331772,"1998":5127177,"1999":4760038,"2000":4760038,"2001":4652407,"2002":4652407,"2003":5040779,"2004":3210361,"2005":3210361,"2006":3663169,"2007":4842481,"2008":4842481,"2009":4842481,"2010":3771300,"2011":3445058,"2012":3614647,"2013":3614647,"2014":5054611,"2015":5054611,"2016":5054611,"2017":5054611,"2018":5808689,"2019":2001223,"2020":2639700,"2021":2752772,"2022":4574984,"2023":5482825,"2024":5482825,"2025":5482825,"2026":5482825,"2027":5622764,"2028":4365008,"2029":4365008,"2030":4365008,"2031":4520847,"2032":5742427,"2033":5742427,"2034":5742427,"2035":5391070,"2036":3956949,"2037":3956949,"2038":3956949,"2039":3956949,"2040":3661884,"2041":5738810,"2042":5738810,"2043":3878739,"2044":3878739,"2045":3878739,"2046":5038569,"2047":4759876,"2048":4874073,"2049":4874073,"2050":4874073,"2051":3881871,"2052":4593658,"2053":4593658,"2054":4593658,"2055":5057302,"2056":5057302,"2057":5057302,"2058":3376507,"2059":3376507,"2060":3376507,"2061":2801838,"2062":2801838,"2063":2801838,"2064":4714728,"2065":4714728,"2066":4714728,"2067":4204994,"2068":3137994,"2069":3219777,"2070":3219777,"2071":3219777,"2072":5777197,"2073":2806530,"2074":2806530,"2075":5385703,"2076":4517027,"2077":4517027,"2078":5529957,"2079":1796543,"2080":3019750,"2081":3919744,"2082":3919744,"2083":3919744,"2084":3599990,"2085":3452084,"2086":3843300,"2087":5856914,"2088":4362117,"2089":4362117,"2090":5268424,"2091":3348688,"2092":2212351,"2093":2212351,"2094":2212351,"2095":3604854,"2096":3604854,"2097":3604854,"2098":4053826,"2099":4053826,"2100":3688436,"2101":3688436,"2102":4715405,"2103":4715405,"2104":5735486,"2105":4972969,"2106":4972969,"2107":5579675,"2108":5579675,"2109":2430617,"2110":4884260,"2111":5079604,"2112":3329100,"2113":4918317,"2114":5491994,"2115":4247720,"2116":3831918,"2117":5297995,"2118":5297995,"2119":5297995,"2120":4888158,"2121":5722109,"2122":5422432,"2123":5422432,"2124":5422432,"2125":5586978,"2126":4631853,"2127":5870330,"2128":5126155,"2129":4112748,"2130":4112748,"2131":5106877,"2132":5129820,"2133":3267052,"2134":4155124,"2135":5459456,"2136":5459456,"2137":4021263,"2138":5771895,"2139":5771895,"2140":5771895,"2141":4884260,"2142":3019750,"2143":5740257,"2144":5079604,"2145":5079604,"2146":3893543,"2147":3348688,"2148":4776564,"2149":2797436,"2150":5735486,"2151":2212351,"2152":4972969,"2153":3843300,"2154":4247720,"2155":5529957,"2156":5740257,"2157":1796543,"2158":1796543,"2159":3599990,"2160":3452084,"2161":3452084,"2162":3843300,"2163":3843300,"2164":5740257,"2165":5923799,"2166":3620559,"2167":5923799,"2168":5923799,"2169":5923799,"2170":5307758,"2171":3348688,"2172":3348688,"2173":3348688,"2174":2212351,"2175":5491994,"2176":3604854,"2177":5460737,"2178":4053826,"2179":4053826,"2180":4715405,"2181":4715405,"2182":4972969,"2183":4972969,"2184":4972969,"2185":5579675,"2186":3137994,"2187":2430617,"2188":3219777,"2189":5777197,"2190":5079604,"2191":4776564,"2192":4918317,"2193":5385703,"2194":5385703,"2195":5781260,"2196":4517027,"2197":5781260,"2198":5781260,"2199":5491994,"2200":5529957,"2201":5491994,"2202":5529957,"2203":4450208,"2204":4450208,"2205":4450208,"2206":3831918,"2207":5422432,"2208":5126155,"2209":5126155,"2210":4776123,"2211":4776123,"2212":4776123,"2213":4249579,"2214":4249579,"2215":4729786,"2216":4069273,"2217":4069273,"2218":4069273,"2219":4069273,"2220":4021263,"2221":5771895,"2222":1796543,"2223":3599990,"2224":3452084,"2225":5923799,"2226":5923799,"2227":5781260,"2228":2212351,"2229":3893543,"2230":5460737,"2231":4053826,"2232":4715405,"2233":5735486,"2234":4972969,"2235":4972969,"2236":5579675,"2237":5079604,"2238":5079604,"2239":4387644,"2240":5079604,"2241":4387644,"2242":4776564,"2243":4918317,"2244":5781260,"2245":4517027,"2246":5781260,"2247":5529957,"2248":3757993,"2249":4450208,"2250":4450208,"2251":3831918,"2252":3166670,"2253":3166670,"2254":5483302,"2255":3626705,"2256":3626705,"2257":3626705,"2258":3599990,"2259":4888158,"2260":4888158,"2261":5422432,"2262":5422432,"2263":5586978,"2264":5586978,"2265":5586978,"2266":4631853,"2267":4631853,"2268":5870330,"2269":5126155,"2270":4112748,"2271":4112748,"2272":4112748,"2273":4112748,"2274":4776123,"2275":4776123,"2276":5106877,"2277":5106877,"2278":5129820,"2279":5129820,"2280":4249579,"2281":4249579,"2282":4249579,"2283":4249579,"2284":4249579,"2285":3267052,"2286":4729786,"2287":4729786,"2288":4729786,"2289":4729786,"2290":4729786,"2291":4155124,"2292":4069273,"2293":4069273,"2294":5459456,"2295":5459456,"2296":4021263,"2297":3757993,"2298":3757993,"2299":5870915,"2300":4993942,"2301":4993942,"2302":3650212,"2303":5600923,"2304":5600923,"2305":3650212,"2306":5148913,"2307":5148913,"2308":3597059,"2309":4530661,"2310":4770250,"2311":4152682,"2312":4152682,"2313":5452353,"2314":4323894,"2315":4323894,"2316":2836298,"2317":5870330,"2318":3671204,"2319":5980459,"2320":5377263,"2321":4586379,"2322":3220859,"2323":4730432,"2324":4730432,"2325":4347450,"2326":5043523,"2327":3636767,"2328":5377263,"2329":4630743,"2330":3152513,"2331":5156617,"2332":4483405,"2333":5864139,"2334":3506580,"2335":3506580,"2336":5870915,"2337":3321528,"2338":5735476,"2339":5735476,"2340":3177395,"2341":3177395,"2342":4286912,"2343":4286912,"2344":4286912,"2345":3177395,"2346":4726501,"2347":5601935,"2348":5377263,"2349":2744923,"2350":2744923,"2351":5870915,"2352":4993942,"2353":3321528,"2354":5600923,"2355":2762969,"2356":5735476,"2357":4323894,"2358":3967502,"2359":4387644,"2360":5423967,"2361":3597059,"2362":3597059,"2363":2212351,"2364":3671234,"2365":4152682,"2366":5579675,"2367":5452353,"2368":4993942,"2369":3650212,"2370":3967502,"2371":2928344,"2372":2928344,"2373":2928344,"2374":5148913,"2375":3597059,"2376":5148913,"2377":3597059,"2378":4950806,"2379":4950806,"2380":4770250,"2381":4770250,"2382":4530661,"2383":4770250,"2384":4152682,"2385":5452353,"2386":5452353,"2387":2762969,"2388":2762969,"2389":2762969,"2390":2836298,"2391":3214395,"2392":3671204,"2393":3671204,"2394":5980459,"2395":3220859,"2396":4347450,"2397":4347450,"2398":3263747,"2399":3263747,"2400":5377263,"2401":5900060,"2402":4630743,"2403":3152513,"2404":3152513,"2405":3152513,"2406":3152513,"2407":4240932,"2408":5156617,"2409":5864139,"2410":5735476,"2411":4286912,"2412":3476139,"2413":3476139,"2414":1968469,"2415":5140822,"2416":5140822,"2417":5601935,"2418":4726501,"2419":5377263,"2420":2744923,"2421":2744923,"2422":4787139,"2423":2784386,"2424":3994428,"2425":5516192,"2426":4188585,"2427":3775615,"2428":4815378,"2429":5200917,"2430":5200917,"2431":4078065,"2432":5156970,"2433":3845560,"2434":5014878,"2435":4435250,"2436":4083640,"2437":5094682,"2438":5094682,"2439":5842771,"2440":3652505,"2441":3652505,"2442":3536709,"2443":3536709,"2444":3536709,"2445":3536709,"2446":3503942,"2447":3503942,"2448":4563303,"2449":4563303,"2450":4836241,"2451":4836241,"2452":4836241,"2453":3650212,"2454":3650212,"2455":5600923,"2456":5600923,"2457":2928344,"2458":5148913,"2459":2928344,"2460":4950806,"2461":4770250,"2462":4152682,"2463":5452353,"2464":4323894,"2465":2836298,"2466":4586379,"2467":3263747,"2468":4630743,"2469":5156617,"2470":3506580,"2471":3506580,"2472":3321528,"2473":5735476,"2474":5735476,"2475":3177395,"2476":1968469,"2477":3476139,"2478":1968469,"2479":3476139,"2480":5601935,"2481":5601935,"2482":5601935,"2483":5870915,"2484":4568196,"2485":4787139,"2486":5295074,"2487":2784386,"2488":3977448,"2489":3977448,"2490":5091897,"2491":4830045,"2492":4450164,"2493":3994428,"2494":3994428,"2495":3994428,"2496":3132864,"2497":5516192,"2498":5516192,"2499":4188585,"2500":4815378,"2501":4078065,"2502":4078065,"2503":5156970,"2504":3845560,"2505":5790265,"2506":4435250,"2507":4083640,"2508":5094682,"2509":5842771,"2510":3652505,"2511":3652505,"2512":3536709,"2513":4563303,"2514":4563303,"2515":4563303,"2516":4836241,"2517":4836241,"2518":4836241,"2519":4495314,"2520":4495314,"2521":3994324,"2522":3994324,"2523":3994324,"2524":3994324,"2525":3089991,"2526":3346674,"2527":5720557,"2528":3958613,"2529":2972614,"2530":5851532,"2531":5457851,"2532":5457851,"2533":5457851,"2534":5457851,"2535":4464926,"2536":3712888,"2537":3712888,"2538":3712888,"2539":5682159,"2540":5682159,"2541":4276527,"2542":4276527,"2543":4610927,"2544":4610927,"2545":4610927,"2546":3504074,"2547":3504074,"2548":3504074,"2549":4450462,"2550":3662597,"2551":3662597,"2552":3662597,"2553":5219826,"2554":4787139,"2555":3650212,"2556":2784386,"2557":4830045,"2558":3132864,"2559":3132864,"2560":5423967,"2561":5516192,"2562":5516192,"2563":4078065,"2564":5156970,"2565":4630743,"2566":5790265,"2567":4435250,"2568":4083640,"2569":4568196,"2570":5864139,"2571":3536709,"2572":3671234,"2573":3536709,"2574":3321528,"2575":3503942,"2576":5633216,"2577":4836241,"2578":4568196,"2579":2744923,"2580":5847600,"2581":5847600,"2582":5847600,"2583":3089991,"2584":5720557,"2585":5720557,"2586":5720557,"2587":5720557,"2588":3958613,"2589":3958613,"2590":2972614,"2591":2972614,"2592":2972614,"2593":5457851,"2594":4285787,"2595":4285787,"2596":4285787,"2597":4285787,"2598":3475525,"2599":3475525,"2600":3845560,"2601":5682159,"2602":4276527,"2603":4519214,"2604":3427491,"2605":3427491,"2606":3427491,"2607":4594140,"2608":4594140,"2609":4594140,"2610":4450462,"2611":4450462,"2612":3662597,"2613":3662597,"2614":3321403,"2615":5410668,"2616":4842387,"2617":4842387,"2618":4069535,"2619":4893393,"2620":4297469,"2621":4297469,"2622":4297469,"2623":4297469,"2624":4297469,"2625":4297469,"2626":4297469,"2627":4389977,"2628":4389977,"2629":4389977,"2630":4389977,"2631":5919699,"2632":3215167,"2633":2788265,"2634":5167461,"2635":5374834,"2636":5374834,"2637":4768887,"2638":4768887,"2639":4768887,"2640":3564767,"2641":4310883,"2642":4310883,"2643":4310883,"2644":3206382,"2645":3206382,"2646":5623480,"2647":4320136,"2648":4320136,"2649":4320136,"2650":4544133,"2651":4685630,"2652":4302388,"2653":4302388,"2654":4067355,"2655":3702153,"2656":4067355,"2657":4067355,"2658":3427491,"2659":5768344,"2660":3702153,"2661":4183082,"2662":4183082,"2663":4183082,"2664":4234827,"2665":3704267,"2666":3517846,"2667":3517846,"2668":3517846,"2669":4685630,"2670":5295657,"2671":5295657,"2672":5295657,"2673":5149084,"2674":5149084,"2675":4832354,"2676":5295074,"2677":4495314,"2678":3346674,"2679":3346674,"2680":3346674,"2681":3958613,"2682":5516192,"2683":4188585,"2684":3845560,"2685":4083640,"2686":5094682,"2687":5094682,"2688":4610927,"2689":3652505,"2690":3427491,"2691":3504074,"2692":3503942,"2693":5633216,"2694":5633216,"2695":3321403,"2696":3321403,"2697":3321403,"2698":3446145,"2699":4568196,"2700":4832354,"2701":5410668,"2702":5410668,"2703":4449043,"2704":5410668,"2705":4069535,"2706":4069535,"2707":4069535,"2708":4842387,"2709":4297469,"2710":4502126,"2711":4389977,"2712":4389977,"2713":5919699,"2714":2788265,"2715":2527839,"2716":5167461,"2717":5167461,"2718":5167461,"2719":3150240,"2720":3150240,"2721":4768887,"2722":4768887,"2723":3564767,"2724":3564767,"2725":3564767,"2726":3564767,"2727":4310883,"2728":4310883,"2729":4310883,"2730":3206382,"2731":3206382,"2732":4320136,"2733":3877023,"2734":3877023,"2735":3877023,"2736":3877023,"2737":4544133,"2738":4544133,"2739":4544133,"2740":4544133,"2741":4067355,"2742":4067355,"2743":4067355,"2744":5768344,"2745":5768344,"2746":5768344,"2747":5768344,"2748":5768344,"2749":5768344,"2750":4594140,"2751":4183082,"2752":4234827,"2753":4234827,"2754":4234827,"2755":4234827,"2756":3704267,"2757":3704267,"2758":3517846,"2759":3517846,"2760":3517846,"2761":4685630,"2762":3702153,"2763":3702153,"2764":3702153,"2765":2570683,"2766":2570683,"2767":2570683,"2768":5158040,"2769":5158040,"2770":4560512,"2771":4757976,"2772":3914427,"2773":3914427,"2774":4489004,"2775":4223943,"2776":4223943,"2777":5498715,"2778":5498715,"2779":3936610,"2780":3936610,"2781":3422059,"2782":3422059,"2783":5684963,"2784":5684963,"2785":3441250,"2786":5061809,"2787":4050230,"2788":5957406,"2789":5957406,"2790":5957406,"2791":3434899,"2792":3963555,"2793":4298817,"2794":2755038,"2795":2755038,"2796":5176312,"2797":4263705,"2798":3782468,"2799":3782468,"2800":3782468,"2801":4495314,"2802":4495314,"2803":3089991,"2804":3958613,"2805":2972614,"2806":5851532,"2807":4285787,"2808":3475525,"2809":4464926,"2810":4464926,"2811":3712888,"2812":4619975,"2813":4276527,"2814":4519214,"2815":4610927,"2816":4594140,"2817":4450462,"2818":4450462,"2819":5219826,"2820":5219826,"2821":5219826,"2822":4731690,"2823":3712961,"2824":4757976,"2825":4489004,"2826":4489004,"2827":4831612,"2828":4831612,"2829":4831612,"2830":4831612,"2831":4128673,"2832":4128673,"2833":4128673,"2834":4128673,"2835":4128673,"2836":2211287,"2837":2211287,"2838":2211287,"2839":3290117,"2840":3290117,"2841":3290117,"2842":2194675,"2843":2194675,"2844":2194675,"2845":2194675,"2846":4558976,"2847":3664086,"2848":3664086,"2849":4467206,"2850":4467206,"2851":3716527,"2852":3716527,"2853":3532974,"2854":2956327,"2855":2956327,"2856":5753687,"2857":4185107,"2858":4185107,"2859":4185107,"2860":4251531,"2861":4251531,"2862":4251531,"2863":4251531,"2864":4251531,"2865":3780629,"2866":3780629,"2867":4871571,"2868":4871571,"2869":3511949,"2870":4839526,"2871":4839526,"2872":4839526,"2873":5972262,"2874":3781545,"2875":3781545,"2876":3781545,"2877":3781545,"2878":4772687,"2879":4776542,"2880":4776542,"2881":4776542,"2882":4776542,"2883":4776542,"2884":4776542,"2885":4115605,"2886":4115605,"2887":4115605,"2888":4115605,"2889":3546023,"2890":3546023,"2891":3546023,"2892":3546023,"2893":3546023,"2894":3529678,"2895":3529678,"2896":3529678,"2897":3529678,"2898":3529678,"2899":3529678,"2900":3529678,"2901":3395326,"2902":3395326,"2903":3395326,"2904":3395326,"2905":5117579,"2906":5117579,"2907":5117579,"2908":5732563,"2909":5732563,"2910":5732563,"2911":5732563,"2912":3441250,"2913":3914427,"2914":3914427,"2915":4569275,"2916":4569275,"2917":4569275,"2918":5593355,"2919":5498715,"2920":3936610,"2921":3410988,"2922":3410988,"2923":3410988,"2924":3410988,"2925":5684963,"2926":2710065,"2927":3441250,"2928":3441250,"2929":3441250,"2930":3441250,"2931":3661239,"2932":2464595,"2933":2464595,"2934":4425923,"2935":5976501,"2936":3434899,"2937":3434899,"2938":3963555,"2939":4255428,"2940":522822,"2941":4284021,"2942":4284021,"2943":4284021,"2944":5176312,"2945":3782468,"2946":4412792,"2947":4412792,"2948":3160381,"2949":3160381,"2950":4402460,"2951":5307611,"2952":4260664,"2953":3376478,"2954":4141382,"2955":3376478,"2956":4141382,"2957":4141382,"2958":3738485,"2959":3738485,"2960":3383212,"2961":3383212,"2962":4280721,"2963":5486467,"2964":4280721,"2965":5486467,"2966":3972946,"2967":3972946,"2968":5504600,"2969":5504600,"2970":5504600,"2971":4357072,"2972":4357072,"2973":5564101,"2974":3395326,"2975":5564101,"2976":3984270,"2977":4709811,"2978":4709811,"2979":3694465,"2980":4231047,"2981":5103331,"2982":3432828,"2983":3432828,"2984":5103331,"2985":3914313,"2986":3914313,"2987":3914313,"2988":4697245,"2989":4697245,"2990":5550381,"2991":5220753,"2992":5220753,"2993":5220753,"2994":3890270,"2995":4793655,"2996":3734718,"2997":4960789,"2998":4960789,"2999":4960789,"3000":3864139,"3001":5560591,"3002":5153686,"3003":5153686,"3004":5593668,"3005":3952602,"3006":3952602,"3007":4412792,"3008":4440033,"3009":5832511,"3010":4731690,"3011":4560512,"3012":5158040,"3013":5158040,"3014":4757976,"3015":4757976,"3016":3914427,"3017":4569275,"3018":4569275,"3019":5498715,"3020":5498715,"3021":3936610,"3022":3936610,"3023":3410988,"3024":5684963,"3025":5684963,"3026":2710065,"3027":4616107,"3028":4616107,"3029":5061809,"3030":5061809,"3031":5061809,"3032":4050230,"3033":3026127,"3034":3026127,"3035":4598931,"3036":4425923,"3037":5976501,"3038":5957406,"3039":5957406,"3040":3434899,"3041":4298817,"3042":2755038,"3043":4284021,"3044":4284021,"3045":5176312,"3046":3782468,"3047":3782468,"3048":4731690,"3049":4731690,"3050":5370326,"3051":4831612,"3052":4831612,"3053":4128673,"3054":2211287,"3055":3290117,"3056":2194675,"3057":2194675,"3058":2194675,"3059":2194675,"3060":4558976,"3061":4558976,"3062":4744284,"3063":4744284,"3064":3664086,"3065":3664086,"3066":4467206,"3067":3716527,"3068":4398439,"3069":4398439,"3070":4398439,"3071":4398439,"3072":4398439,"3073":4283612,"3074":4283612,"3075":4283612,"3076":2956327,"3077":2956327,"3078":5687903,"3079":5687903,"3080":5687903,"3081":5753687,"3082":4251531,"3083":4251531,"3084":4251531,"3085":4251531,"3086":3780629,"3087":3780629,"3088":4871571,"3089":4871571,"3090":3511949,"3091":3511949,"3092":3511949,"3093":3511949,"3094":3511949,"3095":4839526,"3096":4839526,"3097":4839526,"3098":4839526,"3099":5972262,"3100":5972262,"3101":3781545,"3102":3781545,"3103":3781545,"3104":3781545,"3105":3781545,"3106":4772687,"3107":4776542,"3108":4776542,"3109":3034877,"3110":3034877,"3111":3034877,"3112":3577896,"3113":3382694,"3114":3382694,"3115":4115605,"3116":3546023,"3117":3546023,"3118":3529678,"3119":3529678,"3120":3529678,"3121":3179931,"3122":3395326,"3123":3395326,"3124":5117579,"3125":5732563,"3126":5958330,"3127":5958330,"3128":5958330,"3129":5789513,"3130":5789513,"3131":5789513,"3132":5789513,"3133":3432828,"3134":3432828,"3135":3890270,"3136":3890270,"3137":3734718,"3138":3864139,"3139":3864139,"3140":3864139,"3141":5153686,"3142":5153686,"3143":3952602,"3144":3952602,"3145":3952602,"3146":5461594,"3147":5461594,"3148":5832511,"3149":5832511,"3150":5832511,"3151":3160381,"3152":3160381,"3153":3160381,"3154":4402460,"3155":4141382,"3156":3383212,"3157":4280721,"3158":5564101,"3159":5797014,"3160":3984270,"3161":3984270,"3162":3984270,"3163":3846267,"3164":3846267,"3165":3846267,"3166":4709811,"3167":4231047,"3168":4231047,"3169":4231047,"3170":5103331,"3171":5103331,"3172":3914313,"3173":5220753,"3174":4793655,"3175":4793655,"3176":5560591,"3177":5560591,"3178":5593668,"3179":5593668,"3180":4824463,"3181":4824463,"3182":4824463,"3183":4844154,"3184":4844154,"3185":4844154,"3186":4440033,"3187":4440033,"3188":4808543,"3189":4808543,"3190":4412792,"3191":2748711,"3192":5898527,"3193":5307611,"3194":4260664,"3195":4260664,"3196":3738485,"3197":3738485,"3198":3738485,"3199":3972946,"3200":3972946,"3201":4402460,"3202":3383212,"3203":3383212,"3204":4222660,"3205":5504600,"3206":4226329,"3207":4709811,"3208":5103331,"3209":3432828,"3210":5550381,"3211":5550381,"3212":4697245,"3213":3890270,"3214":3864139,"3215":5560591,"3216":5593668,"3217":4824463,"3218":4824463,"3219":5461594,"3220":3144183,"3221":3144183,"3222":4412792,"3223":4140238,"3224":5440738,"3225":4161265,"3226":3382640,"3227":5399146,"3228":5399146,"3229":5399146,"3230":5399146,"3231":5529983,"3232":4274545,"3233":4274545,"3234":4274545,"3235":4274545,"3236":5846302,"3237":4093188,"3238":4093188,"3239":4879328,"3240":4879328,"3241":4879328,"3242":4879328,"3243":4879328,"3244":4093188,"3245":5153622,"3246":3420321,"3247":3420321,"3248":4414618,"3249":4414618,"3250":4414618,"3251":4414618,"3252":4414618,"3253":2887151,"3254":5429471,"3255":5429471,"3256":5747102,"3257":5747102,"3258":5409664,"3259":5409664,"3260":2741450,"3261":2741450,"3262":2741450,"3263":5458653,"3264":4755968,"3265":4755968,"3266":4755968,"3267":4717319,"3268":4717319,"3269":2429977,"3270":2429977,"3271":2429977,"3272":3346068,"3273":3346068,"3274":4301837,"3275":4301837,"3276":5137281,"3277":5137281,"3278":5137281,"3279":5137281,"3280":5137281,"3281":5440738,"3282":5440738,"3283":5440738,"3284":5440738,"3285":4161265,"3286":4161265,"3287":3382640,"3288":5399146,"3289":5529983,"3290":4274545,"3291":5846302,"3292":5846302,"3293":4093188,"3294":4093188,"3295":4093188,"3296":4093188,"3297":5704449,"3298":5704449,"3299":5704449,"3300":5704449,"3301":5704449,"3302":3713866,"3303":3713866,"3304":3713866,"3305":3713866,"3306":4636858,"3307":4164149,"3308":4164149,"3309":4164149,"3310":4164149,"3311":3984795,"3312":3984795,"3313":3984795,"3314":4758401,"3315":4758401,"3316":4632405,"3317":4632405,"3318":3314673,"3319":3314673,"3320":3314673,"3321":4292865,"3322":4292865,"3323":4292865,"3324":4292865,"3325":3926947,"3326":2723123,"3327":2723123,"3328":2723123,"3329":5022334,"3330":5022334,"3331":5022334,"3332":5022334,"3333":5728078,"3334":5124283,"3335":4253794,"3336":4253794,"3337":4253794,"3338":4610679,"3339":4610679,"3340":4610679,"3341":4950066,"3342":4950066,"3343":3633335,"3344":3633335,"3345":3633335,"3346":3633335,"3347":2361515,"3348":2361515,"3349":2361515,"3350":2361515,"3351":5846971,"3352":5846971,"3353":5947263,"3354":5947263,"3355":5350209,"3356":5015408,"3357":3897026,"3358":3897026,"3359":3897026,"3360":4648234,"3361":5471755,"3362":2360030,"3363":2360030,"3364":2360030,"3365":4984795,"3366":1913602,"3367":1913602,"3368":1913602,"3369":3678237,"3370":3678237,"3371":3678237,"3372":3678237,"3373":3678237,"3374":4558453,"3375":4704894,"3376":165418,"3377":165418,"3378":3937058,"3379":3937058,"3380":3937058,"3381":5832511,"3382":4879328,"3383":5515187,"3384":5515187,"3385":5515187,"3386":5153622,"3387":5153622,"3388":5153622,"3389":5153622,"3390":5153622,"3391":3420321,"3392":4414618,"3393":4414618,"3394":2887151,"3395":3813772,"3396":5429471,"3397":5429471,"3398":5747102,"3399":5409664,"3400":3733287,"3401":4319305,"3402":2741450,"3403":2741450,"3404":2741450,"3405":2741450,"3406":5458653,"3407":5458653,"3408":5458653,"3409":4755968,"3410":4755968,"3411":4717319,"3412":2429977,"3413":2429977,"3414":3346068,"3415":3346068,"3416":3346068,"3417":3346068,"3418":3346068,"3419":4369830,"3420":4369830,"3421":4301837,"3422":4301837,"3423":4301837,"3424":4301837,"3425":5137281,"3426":5137281,"3427":5137281,"3428":5307611,"3429":4402460,"3430":4260664,"3431":4141382,"3432":3383212,"3433":5486467,"3434":4280721,"3435":3972946,"3436":4357072,"3437":5564101,"3438":3846267,"3439":3914313,"3440":5550381,"3441":4554233,"3442":4697245,"3443":4554233,"3444":3890270,"3445":4793655,"3446":3734718,"3447":3864139,"3448":5560591,"3449":4844154,"3450":5461594,"3451":5461594,"3452":5461594,"3453":3144183,"3454":4808543,"3455":3144183,"3456":4808543,"3457":2630316,"3458":2630316,"3459":2630316,"3460":2630316,"3461":2427034,"3462":2427034,"3463":2427034,"3464":3576519,"3465":3576519,"3466":4823346,"3467":5656562,"3468":5656562,"3469":3095445,"3470":3095445,"3471":3095445,"3472":3095445,"3473":5457252,"3474":3056480,"3475":5129854,"3476":5472412,"3477":5472412,"3478":1774569,"3479":1774569,"3480":5721317,"3481":5721317,"3482":4329963,"3483":5509647,"3484":5509647,"3485":5312688,"3486":3154486,"3487":3154486,"3488":5384532,"3489":3982948,"3490":3982948,"3491":3573831,"3492":3573831,"3493":5539943,"3494":3798588,"3495":3293068,"3496":3293068,"3497":5331968,"3498":4941182,"3499":3214443,"3500":2848004,"3501":4079189,"3502":3896966,"3503":4139980,"3504":4139980,"3505":4139980,"3506":5920342,"3507":4283272,"3508":4283272,"3509":3043099,"3510":3557743,"3511":3557743,"3512":3557743,"3513":3511947,"3514":3511947,"3515":3511947,"3516":3511947,"3517":5122613,"3518":5122613,"3519":5122613,"3520":5551190,"3521":5103733,"3522":5103733,"3523":5103733,"3524":5103733,"3525":5103733,"3526":5292014,"3527":5292014,"3528":4030712,"3529":4395675,"3530":5588713,"3531":5588713,"3532":5588713,"3533":4396730,"3534":4198846,"3535":5054596,"3536":5054596,"3537":5054596,"3538":3199060,"3539":3199060,"3540":3199060,"3541":5986454,"3542":5986454,"3543":5986454,"3544":5986454,"3545":5018700,"3546":5018700,"3547":5018700,"3548":5018700,"3549":4892327,"3550":4892327,"3551":5590362,"3552":5590362,"3553":5590362,"3554":4540107,"3555":4540107,"3556":4540107,"3557":5564145,"3558":5564145,"3559":5564145,"3560":3829814,"3561":3829814,"3562":4317856,"3563":4317856,"3564":5726464,"3565":4128609,"3566":4128609,"3567":2686715,"3568":5047020,"3569":5047020,"3570":3941910,"3571":3961596,"3572":3961596,"3573":5697645,"3574":5360998,"3575":4411465,"3576":3612585,"3577":3612585,"3578":3289190,"3579":5448649,"3580":5880177,"3581":5880177,"3582":5874317,"3583":5874317,"3584":5874317,"3585":4701182,"3586":4701182,"3587":4786378,"3588":4450858,"3589":4030092,"3590":4030092,"3591":2689169,"3592":5010179,"3593":1831486,"3594":1831486,"3595":5107204,"3596":3459547,"3597":3459547,"3598":3459547,"3599":2892494,"3600":4855961,"3601":4855961,"3602":4855961,"3603":4359119,"3604":4359119,"3605":4359119,"3606":4639584,"3607":4639584,"3608":4639584,"3609":4973627,"3610":4973627,"3611":4941128,"3612":4941128,"3613":4941128,"3614":4941128,"3615":4149239,"3616":4149239,"3617":1839864,"3618":1839864,"3619":4232010,"3620":3724560,"3621":2630316,"3622":2748711,"3623":5448649,"3624":2427034,"3625":4402460,"3626":5866927,"3627":4030092,"3628":4357072,"3629":5457252,"3630":5107204,"3631":4709811,"3632":2892494,"3633":2892494,"3634":5550381,"3635":4554233,"3636":4697245,"3637":5220753,"3638":3734718,"3639":4973627,"3640":5705350,"3641":5461594,"3642":4411465,"3643":4440033,"3644":4440033,"3645":3724560,"3646":2427034,"3647":2427034,"3648":3576519,"3649":3576519,"3650":5866927,"3651":5866927,"3652":4823346,"3653":4823346,"3654":4823346,"3655":4823346,"3656":5656562,"3657":5656562,"3658":4273016,"3659":5704449,"3660":3713866,"3661":5457252,"3662":4636858,"3663":5457252,"3664":4636858,"3665":4636858,"3666":4164149,"3667":3056480,"3668":3056480,"3669":4164149,"3670":5129854,"3671":3984795,"3672":5472412,"3673":3984795,"3674":3984795,"3675":5472412,"3676":4758401,"3677":4758401,"3678":5472412,"3679":4758401,"3680":4632405,"3681":2944304,"3682":4632405,"3683":4632405,"3684":5721317,"3685":5721317,"3686":5509647,"3687":4292865,"3688":3926947,"3689":5986478,"3690":2723123,"3691":5986478,"3692":5986478,"3693":2723123,"3694":5022334,"3695":5022334,"3696":3154486,"3697":5384532,"3698":5728078,"3699":5728078,"3700":5728078,"3701":3982948,"3702":5728078,"3703":5728078,"3704":5124283,"3705":5124283,"3706":5884950,"3707":5124283,"3708":5124283,"3709":5884950,"3710":3573831,"3711":4253794,"3712":3571647,"3713":4253794,"3714":3571647,"3715":4610679,"3716":5292678,"3717":5292678,"3718":4950066,"3719":4950066,"3720":5292678,"3721":4950066,"3722":4950066,"3723":3633335,"3724":5539943,"3725":3798588,"3726":3798588,"3727":3633335,"3728":3798588,"3729":2361515,"3730":3293068,"3731":3816909,"3732":3816909,"3733":3816909,"3734":5653840,"3735":5331968,"3736":5331968,"3737":5947263,"3738":4941182,"3739":5947263,"3740":5947263,"3741":5350209,"3742":5350209,"3743":5350209,"3744":5350209,"3745":5350209,"3746":5015408,"3747":3214443,"3748":5015408,"3749":5015408,"3750":5015408,"3751":2848004,"3752":4079189,"3753":3896966,"3754":3897026,"3755":3897026,"3756":3896966,"3757":4648234,"3758":4648234,"3759":5471755,"3760":5471755,"3761":3896966,"3762":5471755,"3763":5471755,"3764":2360030,"3765":2360030,"3766":4984795,"3767":1913602,"3768":1913602,"3769":3678237,"3770":3557008,"3771":3557008,"3772":3557008,"3773":4558453,"3774":4558453,"3775":4704894,"3776":4704894,"3777":4704894,"3778":4823408,"3779":4823408,"3780":4823408,"3781":4823408,"3782":5292678,"3783":165418,"3784":165418,"3785":165418,"3786":3937058,"3787":5539943,"3788":4139980,"3789":5539943,"3790":5920342,"3791":5920342,"3792":5920342,"3793":5920342,"3794":4283272,"3795":4283272,"3796":4283272,"3797":3043099,"3798":3043099,"3799":3557743,"3800":3557743,"3801":3511947,"3802":5122613,"3803":5122613,"3804":5551190,"3805":5551190,"3806":5551190,"3807":5551190,"3808":4030712,"3809":4030712,"3810":4395675,"3811":4395675,"3812":5588713,"3813":4396730,"3814":4396730,"3815":4396730,"3816":4396730,"3817":4198846,"3818":4198846,"3819":5054596,"3820":1781578,"3821":1781578,"3822":5986454,"3823":5018700,"3824":4892327,"3825":4892327,"3826":5590362,"3827":5876016,"3828":5876016,"3829":4540107,"3830":4540107,"3831":5564145,"3832":5564145,"3833":3829814,"3834":3829814,"3835":3829814,"3836":4317856,"3837":4317856,"3838":4483334,"3839":4483334,"3840":4483334,"3841":4483334,"3842":5288524,"3843":5288524,"3844":5288524,"3845":5288524,"3846":5726464,"3847":5726464,"3848":5726464,"3849":5726464,"3850":4128609,"3851":4128609,"3852":2686715,"3853":5047020,"3854":3941910,"3855":3961596,"3856":3961596,"3857":5697645,"3858":5697645,"3859":5697645,"3860":5697645,"3861":5705350,"3862":5705350,"3863":5360998,"3864":5360998,"3865":4411465,"3866":4411465,"3867":4411465,"3868":3214443,"3869":3612585,"3870":3612585,"3871":3953472,"3872":3953472,"3873":3953472,"3874":3289190,"3875":3289190,"3876":5448649,"3877":5448649,"3878":5874317,"3879":5874317,"3880":4701182,"3881":4786378,"3882":4030092,"3883":4030092,"3884":2689169,"3885":2689169,"3886":2689169,"3887":5010179,"3888":3990364,"3889":1831486,"3890":1831486,"3891":1831486,"3892":5107204,"3893":3459547,"3894":3459547,"3895":2892494,"3896":2892494,"3897":4359119,"3898":4359119,"3899":4173342,"3900":4327560,"3901":4973627,"3902":4973627,"3903":4149239,"3904":4232010,"3905":4232010,"3906":3293068,"3907":3293068,"3908":5653840,"3909":5331968,"3910":3214443,"3911":2848004,"3912":2848004,"3913":5129854,"3914":5472412,"3915":5472412,"3916":2944304,"3917":5721317,"3918":3929824,"3919":5986478,"3920":5986478,"3921":5312688,"3922":5312688,"3923":3154486,"3924":5292678,"3925":3293068,"3926":3293068,"3927":3289190,"3928":4701182,"3929":5874317,"3930":2360567,"3931":3407981,"3932":3682293,"3933":4764962,"3934":3546025,"3935":3546025,"3936":3546025,"3937":1175929,"3938":3925077,"3939":4129110,"3940":4129110,"3941":4129110,"3942":4129110,"3943":4215680,"3944":3466131,"3945":3339723,"3946":400417,"3947":4260384,"3948":2613135,"3949":4493951,"3950":4080584,"3951":4331939,"3952":5515881,"3953":4080584,"3954":4080584,"3955":4907437,"3956":5124485,"3957":3904487,"3958":2748072,"3959":2748072,"3960":5555437,"3961":4984426,"3962":4984426,"3963":5462678,"3964":5462678,"3965":4138551,"3966":4138551,"3967":3608893,"3968":4535555,"3969":4535555,"3970":5958473,"3971":5958473,"3972":5425769,"3973":5694844,"3974":2885597,"3975":3953472,"3976":5448649,"3977":4958948,"3978":4958948,"3979":5880177,"3980":3576519,"3981":3778569,"3982":5866927,"3983":4701182,"3984":5009836,"3985":4701182,"3986":5009836,"3987":4450858,"3988":4450858,"3989":4450858,"3990":4450858,"3991":4823346,"3992":5656562,"3993":4030092,"3994":4273016,"3995":1175929,"3996":4273016,"3997":4273016,"3998":3990364,"3999":3990364,"4000":3990364,"4001":5457252,"4002":3056480,"4003":3215945,"4004":3056480,"4005":1831486,"4006":3056480,"4007":5107204,"4008":5107204,"4009":3459547,"4010":4080584,"4011":4877983,"4012":2892494,"4013":4907437,"4014":4359119,"4015":4639584,"4016":4639584,"4017":4173342,"4018":4173342,"4019":4327560,"4020":3961596,"4021":4973627,"4022":5697645,"4023":4941128,"4024":3608893,"4025":4149239,"4026":5360998,"4027":5360998,"4028":4149239,"4029":1839864,"4030":5425769,"4031":1839864,"4032":5539943,"4033":4232010,"4034":4232010,"4035":3953472,"4036":3724560,"4037":3953472,"4038":2630316,"4039":3466131,"4040":3466131,"4041":4468068,"4042":3457720,"4043":3457720,"4044":3693661,"4045":3693661,"4046":1713239,"4047":2613135,"4048":3108651,"4049":3591547,"4050":5124485,"4051":3904487,"4052":5080766,"4053":5080766,"4054":2748072,"4055":4984426,"4056":4138551,"4057":4138551,"4058":4138551,"4059":5425769,"4060":5425769,"4061":3692346,"4062":3692346,"4063":3692346,"4064":3692346,"4065":3692346,"4066":2974661,"4067":4958948,"4068":4958948,"4069":3778569,"4070":3774725,"4071":3774725,"4072":3546025,"4073":3546025,"4074":1175929,"4075":1175929,"4076":1175929,"4077":1175929,"4078":3315657,"4079":3315657,"4080":3339723,"4081":3339723,"4082":3215945,"4083":3537701,"4084":4260384,"4085":4331939,"4086":3262135,"4087":3262135,"4088":4907437,"4089":4616122,"4090":4269914,"4091":4269914,"4092":5555437,"4093":4221863,"4094":4221863,"4095":4221863,"4096":5462678,"4097":3608893,"4098":3608893,"4099":5958473,"4100":5958473,"4101":5694844,"4102":5694844,"4103":4759860,"4104":4759860,"4105":4759860,"4106":4759860,"4107":2885597,"4108":2885597,"4109":2885597,"4110":2360567,"4111":3407981,"4112":3407981,"4113":4227298,"4114":4227298,"4115":4227298,"4116":3682293,"4117":3682293,"4118":3925077,"4119":3925077,"4120":4215680,"4121":5106769,"4122":5741844,"4123":5309308,"4124":4461930,"4125":4461930,"4126":4080584,"4127":4080584,"4128":5295657,"4129":2517154,"4130":5021748,"4131":5057302,"4132":3846267,"4133":3517846,"4134":4568196,"4135":4593658,"4136":3511949,"4137":3980039,"4138":5865731,"4139":5865731,"4140":5301372,"4141":5301372,"4142":5986443,"4143":4148632,"4144":4148632,"4145":4148632,"4146":4148632,"4147":4148632,"4148":4545550,"4149":4545550,"4150":1852293,"4151":2713840,"4152":2713840,"4153":2713840,"4154":2713840,"4155":2713840,"4156":3785902,"4157":3785902,"4158":5091022,"4159":5091022,"4160":5091022,"4161":5091022,"4162":4831776,"4163":4831776,"4164":4831776,"4165":4009088,"4166":3669111,"4167":3669111,"4168":3781502,"4169":3781502,"4170":3781502,"4171":3570228,"4172":3570228,"4173":3570228,"4174":4311411,"4175":4311411,"4176":4311411,"4177":4311411,"4178":3112403,"4179":3112403,"4180":2882922,"4181":5856907,"4182":5856907,"4183":5856907,"4184":4815882,"4185":4815882,"4186":4815882,"4187":4815882,"4188":5215525,"4189":5215525,"4190":5215525,"4191":5215525,"4192":4609664,"4193":4609664,"4194":4804082,"4195":4804082,"4196":5339463,"4197":5339463,"4198":3898240,"4199":3898240,"4200":4731528,"4201":5868223,"4202":4713813,"4203":5395991,"4204":5718865,"4205":5395991,"4206":5718865,"4207":5911298,"4208":5911298,"4209":5119624,"4210":4281164,"4211":4281164,"4212":3457720,"4213":3693661,"4214":2703617,"4215":3693661,"4216":1713239,"4217":3195393,"4218":3108651,"4219":5515881,"4220":5515881,"4221":3944580,"4222":3944580,"4223":5511285,"4224":4968829,"4225":4968829,"4226":4674480,"4227":3591547,"4228":4153077,"4229":5331731,"4230":4183888,"4231":4183888,"4232":5509595,"4233":5509595,"4234":4667406,"4235":4667406,"4236":4535555,"4237":3432818,"4238":5425769,"4239":3117815,"4240":3117815,"4241":4141579,"4242":4967427,"4243":4967427,"4244":4958948,"4245":4958948,"4246":4958948,"4247":4967427,"4248":3894078,"4249":4958948,"4250":4415997,"4251":4472939,"4252":4472939,"4253":3774725,"4254":2800022,"4255":1175929,"4256":2689497,"4257":1175929,"4258":4899895,"4259":3920467,"4260":3215945,"4261":4399299,"4262":4260384,"4263":4399299,"4264":4399299,"4265":4260384,"4266":4493951,"4267":3222191,"4268":4493951,"4269":3685524,"4270":3685524,"4271":3262135,"4272":3262135,"4273":3262135,"4274":4478821,"4275":4478821,"4276":5863632,"4277":4907437,"4278":5501521,"4279":4616122,"4280":4616122,"4281":4156403,"4282":4269914,"4283":4156403,"4284":4156403,"4285":5555437,"4286":5555437,"4287":5434591,"4288":3263438,"4289":3263438,"4290":5244020,"4291":5244020,"4292":3417877,"4293":5694844,"4294":4733270,"4295":4733270,"4296":5380326,"4297":5009836,"4298":4215680,"4299":5106769,"4300":5741844,"4301":5741844,"4302":2363617,"4303":2363617,"4304":4461930,"4305":4461930,"4306":5610548,"4307":5610548,"4308":5610548,"4309":2949642,"4310":2949642,"4311":2949642,"4312":3219771,"4313":3219771,"4314":5617873,"4315":5617873,"4316":5617873,"4317":3689826,"4318":4423288,"4319":4423288,"4320":4423288,"4321":5103135,"4322":5103135,"4323":5103135,"4324":3682900,"4325":3682900,"4326":3682900,"4327":3682900,"4328":3682900,"4329":4524824,"4330":4524824,"4331":3980039,"4332":3980039,"4333":3980039,"4334":3980039,"4335":2360567,"4336":4227298,"4337":3682293,"4338":3778569,"4339":3778569,"4340":5009836,"4341":1175929,"4342":1175929,"4343":4334043,"4344":5119624,"4345":4215680,"4346":5119624,"4347":3466131,"4348":4468068,"4349":3457720,"4350":400417,"4351":3537701,"4352":3537701,"4353":5309308,"4354":2363617,"4355":4260384,"4356":4461930,"4357":4331939,"4358":5515881,"4359":4907437,"4360":5331731,"4361":4616122,"4362":5331731,"4363":5331731,"4364":4616122,"4365":5331731,"4366":4269914,"4367":5080766,"4368":4138551,"4369":5462678,"4370":4138551,"4371":5425769,"4372":2885597,"4373":5865731,"4374":5865731,"4375":5865731,"4376":5865731,"4377":5301372,"4378":5301372,"4379":5986443,"4380":5986443,"4381":5986443,"4382":5986443,"4383":5986443,"4384":5986443,"4385":4148632,"4386":4545550,"4387":4545550,"4388":4545550,"4389":4545550,"4390":1852293,"4391":1852293,"4392":2713840,"4393":3785902,"4394":3785902,"4395":3785902,"4396":5091022,"4397":5091022,"4398":4831776,"4399":4831776,"4400":4078065,"4401":4009088,"4402":4009088,"4403":4009088,"4404":4009088,"4405":3669111,"4406":3669111,"4407":3669111,"4408":3781502,"4409":3781502,"4410":3781502,"4411":3570228,"4412":3570228,"4413":3570228,"4414":4311411,"4415":4311411,"4416":3112403,"4417":3112403,"4418":3112403,"4419":3112403,"4420":2882922,"4421":2882922,"4422":2882922,"4423":5856907,"4424":4815882,"4425":4815882,"4426":5215525,"4427":5215525,"4428":4609664,"4429":4609664,"4430":4609664,"4431":4609664,"4432":4804082,"4433":4804082,"4434":4804082,"4435":4804082,"4436":5339463,"4437":5339463,"4438":5339463,"4439":3816909,"4440":5339463,"4441":3898240,"4442":3898240,"4443":3898240,"4444":3898240,"4445":3898240,"4446":4731528,"4447":4731528,"4448":5868223,"4449":5868223,"4450":5868223,"4451":4713813,"4452":4713813,"4453":4713813,"4454":4713813,"4455":4713813,"4456":5718865,"4457":5718865,"4458":5718865,"4459":5911298,"4460":5911298,"4461":5911298,"4462":4281164,"4463":4281164,"4464":4281164,"4465":5530360,"4466":5530360,"4467":5530360,"4468":5530360,"4469":2703617,"4470":2703617,"4471":3195393,"4472":3195393,"4473":3944580,"4474":3944580,"4475":5511285,"4476":4619975,"4477":4674480,"4478":4153077,"4479":4153077,"4480":4183888,"4481":4183888,"4482":4183888,"4483":4175229,"4484":4175229,"4485":3996328,"4486":5509595,"4487":4667406,"4488":4676931,"4489":4676931,"4490":4676931,"4491":4676931,"4492":3432818,"4493":3883373,"4494":3883373,"4495":3883373,"4496":3883373,"4497":3883373,"4498":3117815,"4499":3117815,"4500":5559992,"4501":5559992,"4502":4967427,"4503":3894078,"4504":3894078,"4505":3875215,"4506":4415997,"4507":4415997,"4508":2967052,"4509":2967052,"4510":2967052,"4511":2800022,"4512":2800022,"4513":2689497,"4514":2689497,"4515":2689497,"4516":2689497,"4517":4899895,"4518":4899895,"4519":4899895,"4520":4899895,"4521":4899895,"4522":5316445,"4523":5316445,"4524":5316445,"4525":5316445,"4526":3920467,"4527":4399299,"4528":4399299,"4529":4399299,"4530":4399299,"4531":3222191,"4532":3222191,"4533":3222191,"4534":3222191,"4535":3685524,"4536":3685524,"4537":3685524,"4538":4478821,"4539":4478821,"4540":4478821,"4541":5863632,"4542":5863632,"4543":5863632,"4544":5501521,"4545":5501521,"4546":5501521,"4547":5434591,"4548":5434591,"4549":3263438,"4550":5244020,"4551":5244020,"4552":5244020,"4553":3417877,"4554":5446410,"4555":5446410,"4556":5380326,"4557":5380326,"4558":5380326,"4559":5610548,"4560":5610548,"4561":5610548,"4562":2949642,"4563":3219771,"4564":3219771,"4565":3219771,"4566":3219771,"4567":5617873,"4568":5617873,"4569":5617873,"4570":3689826,"4571":3689826,"4572":4423288,"4573":4423288,"4574":4423288,"4575":3279644,"4576":3279644,"4577":5103135,"4578":5103135,"4579":5103135,"4580":3682900,"4581":3329225,"4582":3329225,"4583":3329225,"4584":3329225,"4585":3329225,"4586":5712123,"4587":5712123,"4588":5712123,"4589":4307639,"4590":4307639,"4591":4307639,"4592":3176493,"4593":3176493,"4594":3176493,"4595":3176493,"4596":3176493,"4597":2759629,"4598":2759629,"4599":2759629,"4600":2759629,"4601":3200258,"4602":4392433,"4603":4392433,"4604":3721088,"4605":3721088,"4606":3721088,"4607":4883261,"4608":4329409,"4609":5019971,"4610":5019971,"4611":5019971,"4612":5019971,"4613":5019971,"4614":5887937,"4615":5887937,"4616":5887937,"4617":5887937,"4618":3343759,"4619":3343759,"4620":3750766,"4621":3750766,"4622":3750766,"4623":5858425,"4624":3956097,"4625":3956097,"4626":3956097,"4627":4319300,"4628":4119719,"4629":4119719,"4630":4060171,"4631":4060171,"4632":4060171,"4633":4060171,"4634":2364538,"4635":2364538,"4636":2364538,"4637":2364538,"4638":4488565,"4639":5524701,"4640":5524701,"4641":5548257,"4642":5548257,"4643":5548257,"4644":5548257,"4645":3281341,"4646":4731528,"4647":3281341,"4648":5415292,"4649":5532580,"4650":4237982,"4651":4237982,"4652":5852865,"4653":5718865,"4654":4825255,"4655":4825255,"4656":4825255,"4657":4825255,"4658":4007144,"4659":5911298,"4660":4007144,"4661":4007144,"4662":4007144,"4663":4562579,"4664":4562579,"4665":4281164,"4666":5530360,"4667":5530360,"4668":3506492,"4669":2703617,"4670":2703617,"4671":3283075,"4672":3283075,"4673":4723179,"4674":3195393,"4675":4723179,"4676":5511285,"4677":4398332,"4678":5511285,"4679":4674480,"4680":3951509,"4681":5228186,"4682":4674480,"4683":4674480,"4684":5584005,"4685":3376511,"4686":3376511,"4687":4183888,"4688":3376511,"4689":4175229,"4690":4608185,"4691":3996328,"4692":5509595,"4693":5509595,"4694":4608185,"4695":4608185,"4696":4608185,"4697":5509595,"4698":4667406,"4699":4667406,"4700":5013640,"4701":270049,"4702":270049,"4703":3040733,"4704":3040733,"4705":3040733,"4706":4676931,"4707":4175232,"4708":4676931,"4709":3432818,"4710":3348575,"4711":3348575,"4712":3348575,"4713":3883373,"4714":3348575,"4715":4916104,"4716":4916104,"4717":4916104,"4718":3117815,"4719":4065280,"4720":3117815,"4721":5559992,"4722":5559992,"4723":5559992,"4724":4065280,"4725":4065280,"4726":5559992,"4727":4065280,"4728":5011602,"4729":4967427,"4730":4339173,"4731":4339173,"4732":3459660,"4733":4339173,"4734":2650591,"4735":2650591,"4736":4415997,"4737":3821116,"4738":4415997,"4739":3821116,"4740":3821116,"4741":3821116,"4742":3327628,"4743":3327628,"4744":2800022,"4745":2800022,"4746":1859980,"4747":1859980,"4748":1859980,"4749":2689497,"4750":5427603,"4751":3411720,"4752":3411720,"4753":3411720,"4754":5454908,"4755":5454908,"4756":5454908,"4757":3539107,"4758":3539107,"4759":3539107,"4760":3539107,"4761":3539107,"4762":3539107,"4763":3920467,"4764":3920467,"4765":3916855,"4766":3932017,"4767":3932017,"4768":3932017,"4769":3932017,"4770":3751685,"4771":3751685,"4772":3222191,"4773":5937795,"4774":5937795,"4775":3786468,"4776":3685524,"4777":4478821,"4778":3786468,"4779":5844554,"4780":5844554,"4781":5844554,"4782":5844554,"4783":5571924,"4784":5571924,"4785":5571924,"4786":5549592,"4787":4429825,"4788":4429825,"4789":5501521,"4790":4682219,"4791":5501521,"4792":5434591,"4793":5434591,"4794":3263438,"4795":5244020,"4796":3417877,"4797":3417877,"4798":3417877,"4799":4733270,"4800":5380326,"4801":5380326,"4802":5707653,"4803":5707653,"4804":5707653,"4805":5707653,"4806":4731919,"4807":4994668,"4808":4994668,"4809":4994668,"4810":4994668,"4811":4994668,"4812":4895420,"4813":4895420,"4814":4144850,"4815":4144850,"4816":4144850,"4817":4144850,"4818":4608626,"4819":4608626,"4820":4608626,"4821":4608626,"4822":2876942,"4823":2876942,"4824":2876942,"4825":2876942,"4826":2876942,"4827":3912320,"4828":3912320,"4829":3952721,"4830":3952721,"4831":4913581,"4832":4913581,"4833":5010179,"4834":2994546,"4835":5133227,"4836":5104394,"4837":5440538,"4838":3337377,"4839":3337377,"4840":3003523,"4841":3003523,"4842":3003523,"4843":4805129,"4844":3985324,"4845":4737269,"4846":4737269,"4847":4737269,"4848":4355974,"4849":4355974,"4850":4355974,"4851":5506697,"4852":5506697,"4853":5506697,"4854":4030328,"4855":4030328,"4856":4030328,"4857":3487501,"4858":3487501,"4859":4356062,"4860":4356062,"4861":4356062,"4862":4476212,"4863":4476212,"4864":4476212,"4865":2841147,"4866":2841147,"4867":5450983,"4868":3407981,"4869":4958948,"4870":3407981,"4871":5343026,"4872":420060,"4873":3546025,"4874":5009836,"4875":3925077,"4876":1175929,"4877":4129110,"4878":4598910,"4879":5395991,"4880":4334043,"4881":1175929,"4882":5106769,"4883":3339723,"4884":5106769,"4885":3215945,"4886":3215945,"4887":5741844,"4888":5309308,"4889":3457720,"4890":3515338,"4891":4461930,"4892":4493951,"4893":4461930,"4894":5515881,"4895":4968829,"4896":4968829,"4897":3591547,"4898":3635629,"4899":5124485,"4900":2678276,"4901":5080766,"4902":4138551,"4903":4141579,"4904":2800200,"4905":2800200,"4906":5343026,"4907":5343026,"4908":3425748,"4909":3425748,"4910":3511948,"4911":3511948,"4912":3511948,"4913":3511948,"4914":5346637,"4915":5346637,"4916":5346637,"4917":5520118,"4918":5520118,"4919":4598910,"4920":4598910,"4921":3620378,"4922":3620378,"4923":3620378,"4924":5573300,"4925":5122106,"4926":5122106,"4927":5122106,"4928":3515338,"4929":3515338,"4930":4554239,"4931":4554239,"4932":4554239,"4933":5598124,"4934":5598124,"4935":5289138,"4936":3482439,"4937":3482439,"4938":3143315,"4939":3143315,"4940":3143315,"4941":3143315,"4942":4517637,"4943":4517637,"4944":4517637,"4945":2678276,"4946":2678276,"4947":2678276,"4948":3759706,"4949":3759706,"4950":3759706,"4951":4282128,"4952":4282128,"4953":4282128,"4954":4282128,"4955":3776379,"4956":3776379,"4957":4222010,"4958":4222010,"4959":4222010,"4960":4223972,"4961":5168897,"4962":5168897,"4963":5747224,"4964":5747224,"4965":2671107,"4966":420060,"4967":5863632,"4968":5707653,"4969":5707653,"4970":4731919,"4971":4994668,"4972":4994668,"4973":4895420,"4974":4895420,"4975":4144850,"4976":4144850,"4977":4608626,"4978":2876942,"4979":3912320,"4980":3952721,"4981":4913581,"4982":4913581,"4983":4913581,"4984":4913581,"4985":2994546,"4986":2994546,"4987":2994546,"4988":2994546,"4989":5133227,"4990":5133227,"4991":5133227,"4992":5104394,"4993":5104394,"4994":5440538,"4995":5440538,"4996":5440538,"4997":5440538,"4998":3337377,"4999":3337377,"5000":3337377,"5001":3003523,"5002":3003523,"5003":3003523,"5004":4805129,"5005":4805129,"5006":4805129,"5007":3985324,"5008":4737269,"5009":4355974,"5010":4355974,"5011":4355974,"5012":5506697,"5013":5506697,"5014":4030328,"5015":4030328,"5016":3487501,"5017":4356062,"5018":4356062,"5019":4476212,"5020":4476212,"5021":2147023,"5022":2841147,"5023":2841147,"5024":2841147,"5025":5712123,"5026":5712123,"5027":4307639,"5028":3903148,"5029":3903148,"5030":3903148,"5031":3903148,"5032":4457092,"5033":4457092,"5034":3176493,"5035":2759629,"5036":2759629,"5037":3200258,"5038":3200258,"5039":3585302,"5040":3585302,"5041":3585302,"5042":4392433,"5043":4392433,"5044":4392433,"5045":4392433,"5046":3721088,"5047":4883261,"5048":4883261,"5049":4883261,"5050":4883261,"5051":4329409,"5052":5019971,"5053":5019971,"5054":3892103,"5055":3892103,"5056":5887937,"5057":5887937,"5058":3343759,"5059":3343759,"5060":3343759,"5061":3750766,"5062":5858425,"5063":5858425,"5064":5858425,"5065":5858425,"5066":3956097,"5067":3956097,"5068":3956097,"5069":4319300,"5070":4319300,"5071":4319300,"5072":4319300,"5073":4119719,"5074":4119719,"5075":4119719,"5076":4060171,"5077":2364538,"5078":4488565,"5079":4488565,"5080":4488565,"5081":4488565,"5082":5524701,"5083":5524701,"5084":5524701,"5085":5524701,"5086":5548257,"5087":5548257,"5088":5548257,"5089":3281341,"5090":3281341,"5091":5415292,"5092":5415292,"5093":5532580,"5094":5532580,"5095":5532580,"5096":5532580,"5097":4237982,"5098":4237982,"5099":4237982,"5100":5852865,"5101":4825255,"5102":4825255,"5103":4007144,"5104":4007144,"5105":4562579,"5106":4562579,"5107":4562579,"5108":4562579,"5109":3506492,"5110":3506492,"5111":3506492,"5112":3506492,"5113":3506492,"5114":3283075,"5115":3283075,"5116":3283075,"5117":3283075,"5118":4723179,"5119":4723179,"5120":4398332,"5121":4398332,"5122":4398332,"5123":4398332,"5124":4398332,"5125":5228186,"5126":5228186,"5127":5228186,"5128":5584005,"5129":5584005,"5130":5584005,"5131":5584005,"5132":3376511,"5133":3376511,"5134":3376511,"5135":4608185,"5136":4608185,"5137":5013640,"5138":270049,"5139":4175232,"5140":4424841,"5141":4424841,"5142":4424841,"5143":3348575,"5144":3348575,"5145":4916104,"5146":4916104,"5147":4065280,"5148":4065280,"5149":5011602,"5150":5011602,"5151":5011602,"5152":5011602,"5153":4339173,"5154":4339173,"5155":4339173,"5156":2650591,"5157":3821116,"5158":3821116,"5159":3327628,"5160":3327628,"5161":3327628,"5162":1859980,"5163":1859980,"5164":1859980,"5165":3411720,"5166":3411720,"5167":3539107,"5168":3539107,"5169":3916855,"5170":3916855,"5171":3916855,"5172":3932017,"5173":3751685,"5174":3751685,"5175":3751685,"5176":5937795,"5177":5937795,"5178":5937795,"5179":3786468,"5180":3786468,"5181":4429825,"5182":4429825,"5183":4682219,"5184":4682219,"5185":4682219,"5186":4682219,"5187":1618957,"5188":1618957,"5189":1618957,"5190":1618957,"5191":3321723,"5192":3321723,"5193":3321723,"5194":3321723,"5195":3321723,"5196":3321723,"5197":3321723,"5198":3321723,"5199":1332199,"5200":1332199,"5201":1332199,"5202":1332199,"5203":1332199,"5204":1332199,"5205":4477769,"5206":4477769,"5207":4477769,"5208":4090726,"5209":4090726,"5210":4090726,"5211":4090726,"5212":4090726,"5213":3954418,"5214":3954418,"5215":3604641,"5216":3604641,"5217":3604641,"5218":3604641,"5219":4453270,"5220":4453270,"5221":4453270,"5222":4453270,"5223":3932201,"5224":3932201,"5225":4883760,"5226":4883760,"5227":4883760,"5228":2409349,"5229":2409349,"5230":2409349,"5231":2409349,"5232":4220866,"5233":4220866,"5234":5459273,"5235":5459273,"5236":5459273,"5237":5459273,"5238":5459273,"5239":3044150,"5240":4488551,"5241":4488551,"5242":4488551,"5243":4488551,"5244":4488551,"5245":4488551,"5246":4488551,"5247":4488551,"5248":4488551,"5249":4488551,"5250":4488551,"5251":4488551,"5252":4488551,"5253":4488551,"5254":4360779,"5255":4360779,"5256":3267522,"5257":3267522,"5258":3267522,"5259":3267522,"5260":3267522,"5261":3267522,"5262":3267522,"5263":3267522,"5264":3267522,"5265":3267522,"5266":3267522,"5267":1489930,"5268":1489930,"5269":1489930,"5270":3961877,"5271":3961877,"5272":3961877,"5273":3961877,"5274":3961877,"5275":5450266,"5276":5450266,"5277":5450266,"5278":5450266,"5279":5450266,"5280":5450266,"5281":5568359,"5282":5568359,"5283":5568359,"5284":5568359,"5285":5568359,"5286":5874977,"5287":4513485,"5288":4513485,"5289":4513485,"5290":4513485,"5291":4513485,"5292":4513485,"5293":5433398,"5294":5433398,"5295":5433398,"5296":3161280,"5297":3161280,"5298":3161280,"5299":3161280,"5300":3161280,"5301":4215531,"5302":4215531,"5303":4215531,"5304":4215531,"5305":2644279,"5306":2644279,"5307":2644279,"5308":2644279,"5309":5643992,"5310":5643992,"5311":3144604,"5312":3144604,"5313":3144604,"5314":3144604,"5315":3144604,"5316":5282794,"5317":5282794,"5318":5282794,"5319":5927490,"5320":5927490,"5321":5927490,"5322":5927490,"5323":4574282,"5324":4574282,"5325":4283690,"5326":4283690,"5327":4298088,"5328":4298088,"5329":4298088,"5330":5331547,"5331":5331547,"5332":5331547,"5333":5331547,"5334":5331547,"5335":2800200,"5336":5343026,"5337":5703870,"5338":5703870,"5339":5703870,"5340":5466093,"5341":5168495,"5342":5168495,"5343":3929816,"5344":3929816,"5345":3929816,"5346":5367746,"5347":3208342,"5348":4300351,"5349":4300351,"5350":4300351,"5351":4300351,"5352":3162205,"5353":3162205,"5354":3162205,"5355":3391000,"5356":3391000,"5357":4344344,"5358":2074536,"5359":2074536,"5360":4687242,"5361":3726585,"5362":3726585,"5363":3381083,"5364":3381083,"5365":3381083,"5366":5662620,"5367":5662620,"5368":5662620,"5369":4069731,"5370":4069731,"5371":4069731,"5372":3304380,"5373":3304380,"5374":3232074,"5375":2758835,"5376":3790036,"5377":3790036,"5378":4048141,"5379":4048141,"5380":4221328,"5381":5404432,"5382":5404432,"5383":3786549,"5384":4763824,"5385":5265791,"5386":5265791,"5387":3137438,"5388":3137438,"5389":4183584,"5390":4183584,"5391":5133722,"5392":3170595,"5393":3170595,"5394":3103853,"5395":3103853,"5396":4544795,"5397":4544795,"5398":4544795,"5399":5610004,"5400":3654355,"5401":3654355,"5402":3654355,"5403":1868022,"5404":1868022,"5405":3813126,"5406":3813126,"5407":3697207,"5408":3697207,"5409":4092903,"5410":4092903,"5411":4092903,"5412":4672844,"5413":2909923,"5414":2909923,"5415":4140394,"5416":4140394,"5417":4140394,"5418":4140394,"5419":5301061,"5420":5301061,"5421":5301061,"5422":4371718,"5423":4371718,"5424":5380277,"5425":5380277,"5426":5380277,"5427":5380277,"5428":5380277,"5429":5643995,"5430":5643995,"5431":5471569,"5432":4270681,"5433":5419060,"5434":5419060,"5435":5419060,"5436":4620004,"5437":4620004,"5438":4620004,"5439":4293505,"5440":4293505,"5441":4293505,"5442":4293505,"5443":4293505,"5444":3333807,"5445":3333807,"5446":3333807,"5447":3637243,"5448":3637243,"5449":5493377,"5450":5493377,"5451":5493377,"5452":4061622,"5453":3788226,"5454":3788226,"5455":3788226,"5456":3302141,"5457":3302141,"5458":3302141,"5459":3302141,"5460":3302141,"5461":5406030,"5462":5406030,"5463":5406030,"5464":3892495,"5465":3892495,"5466":5033379,"5467":5033379,"5468":4033571,"5469":4033571,"5470":4099602,"5471":4099602,"5472":3551224,"5473":3551224,"5474":2769033,"5475":2769033,"5476":2769033,"5477":2769033,"5478":5966460,"5479":4355443,"5480":4355443,"5481":4355443,"5482":5762965,"5483":5762965,"5484":4734818,"5485":4734818,"5486":5384512,"5487":5384512,"5488":5384512,"5489":4658539,"5490":4658539,"5491":4658539,"5492":3326921,"5493":5129050,"5494":5129050,"5495":5129050,"5496":4751474,"5497":4751474,"5498":4751474,"5499":4751474,"5500":4751474,"5501":4751474,"5502":4282314,"5503":4282314,"5504":4282314,"5505":4282314,"5506":5754420,"5507":5754420,"5508":5754420,"5509":4510702,"5510":4510702,"5511":4510702,"5512":4510702,"5513":4114185,"5514":4114185,"5515":4114185,"5516":4114185,"5517":3698473,"5518":5719521,"5519":5719521,"5520":5719521,"5521":4876157,"5522":5599448,"5523":5599448,"5524":5599448,"5525":5655938,"5526":5655938,"5527":5655938,"5528":5655938,"5529":5655938,"5530":3882495,"5531":3882495,"5532":5126873,"5533":5351968,"5534":5351968,"5535":5351968,"5536":3816860,"5537":3816860,"5538":3816860,"5539":5815696,"5540":5815696,"5541":5154016,"5542":5154016,"5543":5154016,"5544":4266769,"5545":4266769,"5546":4266769,"5547":4266769,"5548":4511304,"5549":4511304,"5550":4511304,"5551":4511304,"5552":4511304,"5553":2447849,"5554":2447849,"5555":4427989,"5556":4030121,"5557":3556767,"5558":3556767,"5559":3556767,"5560":3556767,"5561":4869362,"5562":4869362,"5563":3941354,"5564":3941354,"5565":3941354,"5566":5325897,"5567":5244277,"5568":3821103,"5569":3821103,"5570":3821103,"5571":3821103,"5572":5273788,"5573":5273788,"5574":5273788,"5575":3424202,"5576":3424202,"5577":3424202,"5578":3424202,"5579":5003992,"5580":5003992,"5581":3931696,"5582":3931696,"5583":3931696,"5584":3931696,"5585":4525010,"5586":4525010,"5587":3918522,"5588":3918522,"5589":5426394,"5590":5426394,"5591":5426394,"5592":5200867,"5593":5200867,"5594":5200867,"5595":5200867,"5596":5200867,"5597":5141553,"5598":5141553,"5599":5141553,"5600":3432554,"5601":3432554,"5602":5122147,"5603":5122147,"5604":3230393,"5605":3230393,"5606":4724125,"5607":4724125,"5608":4084282,"5609":3830844,"5610":3830844,"5611":4663612,"5612":4663612,"5613":4663612,"5614":4663612,"5615":4663612,"5616":3421236,"5617":3421236,"5618":2981076,"5619":2981076,"5620":2981076,"5621":5683978,"5622":3271295,"5623":3271295,"5624":2571050,"5625":2571050,"5626":4482193,"5627":4482193,"5628":4482193,"5629":4173360,"5630":4173360,"5631":4173360,"5632":4173360,"5633":3827502,"5634":3827502,"5635":3827502,"5636":3827502,"5637":4867039,"5638":4867039,"5639":4867039,"5640":4867039,"5641":4942591,"5642":4942591,"5643":4411165,"5644":4411165,"5645":4411165,"5646":5636096,"5647":5636096,"5648":5636096,"5649":5636096,"5650":2936735,"5651":2936735,"5652":5760819,"5653":5963741,"5654":5963741,"5655":5963741,"5656":4968528,"5657":4968528,"5658":5099199,"5659":5099199,"5660":5099199,"5661":5099199,"5662":4258972,"5663":4241940,"5664":4241940,"5665":3407716,"5666":3407716,"5667":3407716,"5668":3407716,"5669":5925011,"5670":5925011,"5671":5925011,"5672":3806324,"5673":3806324,"5674":3806324,"5675":3806324,"5676":4894062,"5677":4894062,"5678":4894062,"5679":5412886,"5680":5412886,"5681":3169777,"5682":4059969,"5683":4235563,"5684":4377530,"5685":4377530,"5686":2853089,"5687":4845107,"5688":4845107,"5689":4845107,"5690":4845107,"5691":3806618,"5692":3806618,"5693":3806618,"5694":4862081,"5695":5349672,"5696":5349672,"5697":5560514,"5698":5560514,"5699":4385682,"5700":4882797,"5701":4882797,"5702":3050701,"5703":3050701,"5704":3050701,"5705":3135864,"5706":3135864,"5707":4631431,"5708":4631431,"5709":4566202,"5710":4566202,"5711":4566202,"5712":2995234,"5713":2995234,"5714":2995234,"5715":2995234,"5716":5065057,"5717":5065057,"5718":3649350,"5719":3649350,"5720":3649350,"5721":4803206,"5722":3208043,"5723":3208043,"5724":3208043,"5725":5776520,"5726":5776520,"5727":5593818,"5728":5593818,"5729":5593818,"5730":3517358,"5731":3517358,"5732":5358282,"5733":5358282,"5734":4210064,"5735":4210064,"5736":4662763,"5737":4662763,"5738":2500197,"5739":2500197,"5740":2984512,"5741":5976903,"5742":5976903,"5743":5976903,"5744":5976903,"5745":5976903,"5746":4296330,"5747":4296330,"5748":2966708,"5749":4858101,"5750":4858101,"5751":4826692,"5752":4826692,"5753":4826692,"5754":4893238,"5755":5136709,"5756":5136709,"5757":5136709,"5758":4969326,"5759":4279802,"5760":3140921,"5761":4744955,"5762":4744955,"5763":4744955,"5764":4336131,"5765":4336131,"5766":4336131,"5767":3227609,"5768":3227609,"5769":3898378,"5770":3898378,"5771":5358738,"5772":5881763,"5773":2765950,"5774":4867750,"5775":4889193,"5776":3132856,"5777":3132856,"5778":3132856,"5779":5381869,"5780":5381869,"5781":5381869,"5782":4126186,"5783":2291568,"5784":2291568,"5785":3479017,"5786":3479017,"5787":3479017,"5788":2759981,"5789":2759981,"5790":2759981,"5791":4112798,"5792":3253463,"5793":3253463,"5794":4269544,"5795":3349215,"5796":3349215,"5797":3349215,"5798":3017961,"5799":4914255,"5800":4914255,"5801":4914255,"5802":3822756,"5803":4265247,"5804":4834398,"5805":4834398,"5806":3533739,"5807":3785381,"5808":3785381,"5809":3307993,"5810":3307993,"5811":5467351,"5812":5467351,"5813":4168417,"5814":4946773,"5815":5214464,"5816":4331314,"5817":4119301,"5818":5395810,"5819":4212559,"5820":3515466,"5821":4744782,"5822":4335628,"5823":1550608,"5824":5904467,"5825":5904467,"5826":3438419,"5827":3087256,"5828":2948428,"5829":2948428,"5830":4840766,"5831":4840766,"5832":4840766,"5833":3730064,"5834":3730064,"5835":2837810,"5836":4701161,"5837":5985784,"5838":4621723,"5839":5465806,"5840":2898847,"5841":3425422,"5842":3425422,"5843":5928132,"5844":5928132,"5845":5928132,"5846":4532714,"5847":4532714,"5848":5067642,"5849":2699080,"5850":4181789,"5851":4181789,"5852":5534217,"5853":5499864,"5854":5499864,"5855":3987287,"5856":3987287,"5857":3987287,"5858":3987287,"5859":4386768,"5860":4386768,"5861":4386768,"5862":5168897,"5863":5747224,"5864":5747224,"5865":2671107,"5866":3425748,"5867":2671107,"5868":2671107,"5869":3425748,"5870":420060,"5871":3511948,"5872":5346637,"5873":5346637,"5874":5346637,"5875":5520118,"5876":5520118,"5877":4598910,"5878":3620378,"5879":3620378,"5880":5573300,"5881":5573300,"5882":5573300,"5883":5122106,"5884":3515338,"5885":4554239,"5886":4554239,"5887":4554239,"5888":5598124,"5889":5598124,"5890":5289138,"5891":5289138,"5892":3482439,"5893":3482439,"5894":3482439,"5895":4517637,"5896":2678276,"5897":3759706,"5898":3759706,"5899":3637243,"5900":3637243,"5901":3637243,"5902":5493377,"5903":5493377,"5904":4061622,"5905":4061622,"5906":3788226,"5907":3788226,"5908":3302141,"5909":5406030,"5910":5406030,"5911":3892495,"5912":3892495,"5913":5033379,"5914":5033379,"5915":5033379,"5916":5033379,"5917":4033571,"5918":4033571,"5919":4033571,"5920":4033571,"5921":4099602,"5922":4099602,"5923":4099602,"5924":4099602,"5925":3551224,"5926":3551224,"5927":3551224,"5928":3551224,"5929":2769033,"5930":2769033,"5931":5966460,"5932":3253336,"5933":3253336,"5934":4355443,"5935":5661713,"5936":5762965,"5937":5762965,"5938":5762965,"5939":5762965,"5940":5762965,"5941":4734818,"5942":4734818,"5943":4734818,"5944":4734818,"5945":5384512,"5946":5384512,"5947":5384512,"5948":4658539,"5949":4658539,"5950":4658539,"5951":3326921,"5952":3326921,"5953":3326921,"5954":5129050,"5955":5129050,"5956":5129050,"5957":4751474,"5958":4282314,"5959":4282314,"5960":5754420,"5961":5754420,"5962":5754420,"5963":4510702,"5964":4510702,"5965":4114185,"5966":3698473,"5967":3698473,"5968":5719521,"5969":5719521,"5970":4876157,"5971":5599448,"5972":5655938,"5973":3882495,"5974":3882495,"5975":3882495,"5976":5126873,"5977":5126873,"5978":5126873,"5979":5351968,"5980":5351968,"5981":5351968,"5982":3816860,"5983":3816860,"5984":5815696,"5985":5154016,"5986":5154016,"5987":5154016,"5988":4266769,"5989":4266769,"5990":4511304,"5991":2447849,"5992":2447849,"5993":2447849,"5994":2447849,"5995":4030121,"5996":3556767,"5997":3556767,"5998":3556767,"5999":4869362,"6000":4869362,"6001":4869362,"6002":4869362,"6003":3941354,"6004":3941354,"6005":3941354,"6006":5325897,"6007":5244277,"6008":5244277,"6009":5244277,"6010":5244277,"6011":3821103,"6012":3821103,"6013":5273788,"6014":5273788,"6015":5273788,"6016":3424202,"6017":3424202,"6018":5003992,"6019":5003992,"6020":5003992,"6021":5003992,"6022":3931696,"6023":3931696,"6024":4525010,"6025":4525010,"6026":4525010,"6027":4525010,"6028":3918522,"6029":3918522,"6030":3918522,"6031":5426394,"6032":5426394,"6033":5426394,"6034":5426394,"6035":5426394,"6036":5200867,"6037":5141553,"6038":5141553,"6039":5141553,"6040":3432554,"6041":3432554,"6042":3432554,"6043":3432554,"6044":5122147,"6045":3230393,"6046":3230393,"6047":3230393,"6048":3230393,"6049":3313169,"6050":4724125,"6051":4724125,"6052":4724125,"6053":4084282,"6054":4084282,"6055":4084282,"6056":4084282,"6057":4084282,"6058":3830844,"6059":3830844,"6060":3830844,"6061":3830844,"6062":4663612,"6063":3421236,"6064":3421236,"6065":2981076,"6066":2981076,"6067":5683978,"6068":5683978,"6069":5683978,"6070":5683978,"6071":5683978,"6072":3271295,"6073":3271295,"6074":3271295,"6075":2571050,"6076":2571050,"6077":2571050,"6078":2571050,"6079":4766670,"6080":4766670,"6081":4766670,"6082":4766670,"6083":4766670,"6084":4766670,"6085":4173360,"6086":3827502,"6087":4867039,"6088":4942591,"6089":4942591,"6090":4942591,"6091":4411165,"6092":4411165,"6093":5636096,"6094":2936735,"6095":2936735,"6096":2936735,"6097":5760819,"6098":5963741,"6099":4968528,"6100":4968528,"6101":4968528,"6102":5099199,"6103":4258972,"6104":4258972,"6105":4258972,"6106":4258972,"6107":4241940,"6108":4241940,"6109":4241940,"6110":3407716,"6111":5756602,"6112":5756602,"6113":5756602,"6114":5756602,"6115":5925011,"6116":4894062,"6117":4894062,"6118":5412886,"6119":5412886,"6120":5412886,"6121":3169777,"6122":3169777,"6123":3169777,"6124":4059969,"6125":4059969,"6126":4059969,"6127":4059969,"6128":4059969,"6129":4235563,"6130":4235563,"6131":4235563,"6132":4235563,"6133":4377530,"6134":2853089,"6135":2853089,"6136":2853089,"6137":2853089,"6138":4845107,"6139":4845107,"6140":4845107,"6141":3806618,"6142":3806618,"6143":4862081,"6144":4862081,"6145":4862081,"6146":5349672,"6147":5349672,"6148":5560514,"6149":5560514,"6150":4385682,"6151":4385682,"6152":4385682,"6153":4882797,"6154":4882797,"6155":3050701,"6156":3050701,"6157":3135864,"6158":4631431,"6159":4566202,"6160":2995234,"6161":2995234,"6162":5065057,"6163":5065057,"6164":5065057,"6165":3649350,"6166":3649350,"6167":5354681,"6168":5354681,"6169":5354681,"6170":5354681,"6171":5354681,"6172":4803206,"6173":4803206,"6174":4803206,"6175":3208043,"6176":5776520,"6177":5593818,"6178":5593818,"6179":3517358,"6180":3517358,"6181":3517358,"6182":2474851,"6183":5358282,"6184":5358282,"6185":5358282,"6186":5358282,"6187":3233513,"6188":3233513,"6189":3233513,"6190":3233513,"6191":3233513,"6192":4210064,"6193":4210064,"6194":4210064,"6195":4662763,"6196":4662763,"6197":2500197,"6198":2500197,"6199":2984512,"6200":2984512,"6201":5976903,"6202":4296330,"6203":4296330,"6204":4296330,"6205":2966708,"6206":2966708,"6207":2966708,"6208":5762262,"6209":5762262,"6210":5762262,"6211":5762262,"6212":4858101,"6213":4858101,"6214":4826692,"6215":4826692,"6216":4893238,"6217":3880665,"6218":3880665,"6219":3880665,"6220":3880665,"6221":5136709,"6222":5136709,"6223":4969326,"6224":4969326,"6225":3140921,"6226":4336131,"6227":4336131,"6228":4336131,"6229":5889380,"6230":3227609,"6231":3227609,"6232":3227609,"6233":3898378,"6234":3898378,"6235":5358738,"6236":5881763,"6237":5881763,"6238":5881763,"6239":5881763,"6240":5881763,"6241":4359791,"6242":4867750,"6243":4867750,"6244":4867750,"6245":4867750,"6246":4867750,"6247":4877819,"6248":4877819,"6249":4877819,"6250":4889193,"6251":4889193,"6252":4889193,"6253":4889193,"6254":4889193,"6255":3653258,"6256":3653258,"6257":3132856,"6258":3132856,"6259":4354356,"6260":4354356,"6261":5381869,"6262":5381869,"6263":4126186,"6264":4126186,"6265":4126186,"6266":2291568,"6267":2291568,"6268":2291568,"6269":3635879,"6270":3635879,"6271":3479017,"6272":3479017,"6273":2759981,"6274":4112798,"6275":4112798,"6276":3253463,"6277":3253463,"6278":3134103,"6279":3134103,"6280":3134103,"6281":3134103,"6282":554986,"6283":554986,"6284":4269544,"6285":4269544,"6286":4269544,"6287":4269544,"6288":2785868,"6289":3349215,"6290":3017961,"6291":4914255,"6292":3822756,"6293":3822756,"6294":3822756,"6295":3822756,"6296":2752780,"6297":4265247,"6298":4265247,"6299":4265247,"6300":4265247,"6301":4834398,"6302":4834398,"6303":3533739,"6304":3785381,"6305":3785381,"6306":3785381,"6307":3307993,"6308":3379583,"6309":3379583,"6310":4166083,"6311":4166083,"6312":4166083,"6313":5467351,"6314":4168417,"6315":4168417,"6316":4168417,"6317":4168417,"6318":3021887,"6319":3021887,"6320":3021887,"6321":3021887,"6322":3021887,"6323":5968838,"6324":4946773,"6325":5416724,"6326":5416724,"6327":5416724,"6328":5214464,"6329":4710971,"6330":4331314,"6331":4331314,"6332":4917725,"6333":5346199,"6334":4119301,"6335":4119301,"6336":4339160,"6337":4339160,"6338":4212559,"6339":4212559,"6340":3515466,"6341":3515466,"6342":4744782,"6343":4744782,"6344":4335628,"6345":1550608,"6346":1550608,"6347":1550608,"6348":5594766,"6349":2845036,"6350":3087256,"6351":3087256,"6352":3087256,"6353":4804276,"6354":5241452,"6355":5241452,"6356":5521936,"6357":5521936,"6358":5521936,"6359":5521936,"6360":3961020,"6361":3268925,"6362":4840766,"6363":4840766,"6364":3730064,"6365":5820800,"6366":3775167,"6367":3775167,"6368":3775167,"6369":5518918,"6370":5518918,"6371":5413468,"6372":5056957,"6373":5056957,"6374":5056957,"6375":4085197,"6376":4085197,"6377":4261896,"6378":4332717,"6379":4332717,"6380":5946268,"6381":5946268,"6382":5380284,"6383":5897859,"6384":2818614,"6385":2818614,"6386":4990278,"6387":3292461,"6388":3292461,"6389":2900076,"6390":2900076,"6391":4552663,"6392":4552663,"6393":3599938,"6394":3599938,"6395":4018592,"6396":4018592,"6397":4018592,"6398":4101294,"6399":4101294,"6400":4101294,"6401":4101294,"6402":3508963,"6403":5960495,"6404":3368260,"6405":5623327,"6406":5623327,"6407":2602945,"6408":2602945,"6409":2602945,"6410":5341634,"6411":5341634,"6412":5754508,"6413":5754508,"6414":4230312,"6415":4541185,"6416":4541185,"6417":4541185,"6418":4541185,"6419":4738984,"6420":4546316,"6421":1896161,"6422":1896161,"6423":3224655,"6424":3224655,"6425":5379244,"6426":4517417,"6427":4955417,"6428":5324269,"6429":4368876,"6430":4368876,"6431":2778511,"6432":5513842,"6433":5513842,"6434":5234109,"6435":5234109,"6436":5234109,"6437":5234109,"6438":3691930,"6439":3691930,"6440":5471294,"6441":5471294,"6442":3814649,"6443":4124476,"6444":3438438,"6445":3438438,"6446":3556012,"6447":3556012,"6448":3556012,"6449":60007,"6450":4389469,"6451":4389469,"6452":2877680,"6453":2796659,"6454":4258079,"6455":4856346,"6456":1475428,"6457":1475428,"6458":3526879,"6459":3526879,"6460":3526879,"6461":4963027,"6462":3526879,"6463":1868720,"6464":1868720,"6465":4486927,"6466":4491277,"6467":4274965,"6468":4061773,"6469":4061773,"6470":4744782,"6471":3603112,"6472":3603112,"6473":4335628,"6474":3816862,"6475":3940644,"6476":3940644,"6477":1550608,"6478":2784472,"6479":2784472,"6480":3611073,"6481":2784472,"6482":5594766,"6483":4494428,"6484":2845036,"6485":3996149,"6486":3087256,"6487":3087256,"6488":3996149,"6489":3996149,"6490":3651817,"6491":3651817,"6492":3651817,"6493":4314171,"6494":4314171,"6495":4804276,"6496":2948428,"6497":2948428,"6498":5154305,"6499":5154305,"6500":4898395,"6501":5241452,"6502":4898395,"6503":4898395,"6504":4207147,"6505":4207147,"6506":5125808,"6507":5125808,"6508":5125808,"6509":5118645,"6510":5118645,"6511":5820800,"6512":3441280,"6513":5772830,"6514":2837810,"6515":4701161,"6516":4701161,"6517":5772830,"6518":4701161,"6519":5772830,"6520":3881751,"6521":3881751,"6522":5771357,"6523":5771357,"6524":5985784,"6525":5771357,"6526":5985784,"6527":4251615,"6528":4251615,"6529":4621723,"6530":5465806,"6531":5008205,"6532":5694526,"6533":5694526,"6534":5453890,"6535":5453890,"6536":3620516,"6537":5534041,"6538":5534041,"6539":5940475,"6540":5908397,"6541":5940475,"6542":5067642,"6543":2699080,"6544":4206772,"6545":4179329,"6546":4181789,"6547":2694359,"6548":4483416,"6549":5534217,"6550":4483416,"6551":4141807,"6552":4141807,"6553":5761719,"6554":5761719,"6555":3339727,"6556":3339727,"6557":3339727,"6558":3339727,"6559":3339727,"6560":4890862,"6561":4890862,"6562":5405916,"6563":5405916,"6564":5405916,"6565":5405916,"6566":5835896,"6567":5835896,"6568":5835896,"6569":4932043,"6570":4932043,"6571":4932043,"6572":4932043,"6573":4932043,"6574":4705007,"6575":2822946,"6576":2822946,"6577":2822946,"6578":4711101,"6579":4711101,"6580":5245138,"6581":4711101,"6582":4711101,"6583":4804512,"6584":4284010,"6585":4804512,"6586":4804512,"6587":4804512,"6588":4804512,"6589":5689110,"6590":5133075,"6591":3635645,"6592":3066231,"6593":3635645,"6594":3916852,"6595":3635645,"6596":5573922,"6597":3916852,"6598":5573922,"6599":3580622,"6600":3916852,"6601":3580622,"6602":4673714,"6603":3580622,"6604":4673714,"6605":4976892,"6606":4808857,"6607":4686557,"6608":4686557,"6609":4808857,"6610":4686557,"6611":5800236,"6612":3628802,"6613":5893461,"6614":3628802,"6615":3628802,"6616":3628802,"6617":2762857,"6618":2762857,"6619":5125721,"6620":4069047,"6621":4069047,"6622":4069047,"6623":4069047,"6624":4069047,"6625":5432698,"6626":4056784,"6627":3775167,"6628":5518918,"6629":5518918,"6630":5518918,"6631":5413468,"6632":4085197,"6633":3590739,"6634":4332717,"6635":4332717,"6636":4332717,"6637":3332247,"6638":3332247,"6639":5946268,"6640":5380284,"6641":5897859,"6642":5897859,"6643":2818614,"6644":2442760,"6645":5689110,"6646":5689110,"6647":5477737,"6648":4616075,"6649":3292461,"6650":5960495,"6651":3066231,"6652":3292461,"6653":2900076,"6654":3916852,"6655":2900076,"6656":3916852,"6657":4673714,"6658":4673714,"6659":3599938,"6660":4673714,"6661":4118506,"6662":4976892,"6663":4118506,"6664":4686557,"6665":4018592,"6666":5893461,"6667":3584097,"6668":3584097,"6669":3835502,"6670":3368260,"6671":3835502,"6672":5125721,"6673":5125721,"6674":3508963,"6675":4881125,"6676":4881125,"6677":4881125,"6678":3508963,"6679":5432698,"6680":5960495,"6681":5432698,"6682":5432698,"6683":4056784,"6684":4756047,"6685":4756047,"6686":4756047,"6687":3943081,"6688":1414018,"6689":1414018,"6690":1414018,"6691":1414018,"6692":1414018,"6693":5301992,"6694":5301992,"6695":5739798,"6696":5530334,"6697":5409660,"6698":3617313,"6699":3617313,"6700":3617313,"6701":3617313,"6702":3617313,"6703":2681019,"6704":2681019,"6705":4297089,"6706":3139306,"6707":3139306,"6708":3139306,"6709":3139306,"6710":4461907,"6711":3511173,"6712":3511173,"6713":3511173,"6714":3301259,"6715":3301259,"6716":3301259,"6717":4228518,"6718":4228518,"6719":4947329,"6720":4947329,"6721":4947329,"6722":4558893,"6723":4558893,"6724":4558893,"6725":4431324,"6726":4431324,"6727":4682450,"6728":4682450,"6729":4577526,"6730":4577526,"6731":5852701,"6732":5852701,"6733":5852701,"6734":3984416,"6735":2129145,"6736":2129145,"6737":2129145,"6738":2129145,"6739":3793422,"6740":3793422,"6741":3793422,"6742":2887201,"6743":2887201,"6744":5662512,"6745":5662512,"6746":5662512,"6747":5662512,"6748":3572221,"6749":3009979,"6750":3009979,"6751":5525241,"6752":5524909,"6753":5524909,"6754":5524909,"6755":4064756,"6756":4064756,"6757":4064756,"6758":2639329,"6759":3848942,"6760":3848942,"6761":3848942,"6762":5634356,"6763":5634356,"6764":5634356,"6765":5634356,"6766":5634356,"6767":5431359,"6768":5431359,"6769":5648980,"6770":5648980,"6771":4754570,"6772":3586143,"6773":3586143,"6774":3586143,"6775":3586143,"6776":3586143,"6777":3586143,"6778":3767244,"6779":3767244,"6780":4694650,"6781":2717426,"6782":2717426,"6783":3215316,"6784":3215316,"6785":5629940,"6786":5629940,"6787":5629940,"6788":4570722,"6789":4570722,"6790":5655345,"6791":5655345,"6792":5655345,"6793":5655345,"6794":5655345,"6795":4442156,"6796":3295238,"6797":3295238,"6798":5568719,"6799":5568719,"6800":3192699,"6801":3192699,"6802":5320771,"6803":5320771,"6804":5260131,"6805":5260131,"6806":4893099,"6807":4893099,"6808":3263860,"6809":3263860,"6810":3263860,"6811":5611398,"6812":5426232,"6813":5793008,"6814":5793008,"6815":5793008,"6816":5125190,"6817":5125190,"6818":5746709,"6819":4869417,"6820":4869417,"6821":5721363,"6822":1924504,"6823":4555141,"6824":4555141,"6825":4555141,"6826":4555141,"6827":4868208,"6828":4868208,"6829":3364603,"6830":3364603,"6831":4435702,"6832":4435702,"6833":4608292,"6834":4608292,"6835":2500257,"6836":2500257,"6837":2500257,"6838":4895399,"6839":2645358,"6840":2645358,"6841":4278388,"6842":4278388,"6843":5667629,"6844":5667629,"6845":3696265,"6846":3696265,"6847":3696265,"6848":3696265,"6849":3696265,"6850":3696265,"6851":3221066,"6852":3221066,"6853":5338176,"6854":4761605,"6855":4761605,"6856":3564932,"6857":3564932,"6858":3564932,"6859":3564932,"6860":1185549,"6861":4094569,"6862":4094569,"6863":3806550,"6864":4015738,"6865":4015738,"6866":4015738,"6867":4015738,"6868":4015738,"6869":3204557,"6870":3204557,"6871":3204557,"6872":4969982,"6873":4969982,"6874":4969982,"6875":3698010,"6876":3217852,"6877":3217852,"6878":4789479,"6879":3657667,"6880":3657667,"6881":3657667,"6882":3657667,"6883":4868921,"6884":4868921,"6885":4868921,"6886":5029174,"6887":5029174,"6888":5029174,"6889":4341337,"6890":4341337,"6891":4341337,"6892":4305224,"6893":4305224,"6894":4288428,"6895":4288428,"6896":4288428,"6897":4288428,"6898":4910973,"6899":4910973,"6900":4910973,"6901":2249589,"6902":2277487,"6903":3917884,"6904":3917884,"6905":3917884,"6906":3917884,"6907":5784025,"6908":5784025,"6909":5784025,"6910":3053227,"6911":3053227,"6912":5525580,"6913":5525580,"6914":5525580,"6915":5525580,"6916":5525580,"6917":5442667,"6918":5442667,"6919":4829247,"6920":4829247,"6921":3642659,"6922":4829247,"6923":4676364,"6924":4190894,"6925":4190894,"6926":4190894,"6927":4145491,"6928":4684352,"6929":4684352,"6930":4684352,"6931":4684352,"6932":4153084,"6933":4153084,"6934":4153084,"6935":4153084,"6936":4540789,"6937":4540789,"6938":4540789,"6939":4540789,"6940":4540789,"6941":4784207,"6942":4784207,"6943":4234788,"6944":4234788,"6945":5491162,"6946":5491162,"6947":5491162,"6948":5986505,"6949":5986505,"6950":5986505,"6951":5986505,"6952":5986505,"6953":4499954,"6954":5045904,"6955":3650238,"6956":3650238,"6957":4859374,"6958":4859374,"6959":4816246,"6960":4816246,"6961":4816246,"6962":4183968,"6963":4183968,"6964":2992187,"6965":2992187,"6966":3653044,"6967":4213554,"6968":4213554,"6969":4213554,"6970":4213554,"6971":3651817,"6972":5073301,"6973":2778406,"6974":5446739,"6975":5446739,"6976":5446739,"6977":5446739,"6978":5156604,"6979":5156604,"6980":5156604,"6981":4344586,"6982":4344586,"6983":4344586,"6984":3542441,"6985":3542441,"6986":4314171,"6987":2652457,"6988":2652457,"6989":2652457,"6990":4530210,"6991":4610775,"6992":2724496,"6993":2660282,"6994":2660282,"6995":2660282,"6996":5886394,"6997":5886394,"6998":3854508,"6999":3854508,"7000":3854508,"7001":3854508,"7002":3154347,"7003":4319071,"7004":3640161,"7005":3640161,"7006":3640161,"7007":2584124,"7008":2584124,"7009":2584124,"7010":5518919,"7011":5518919,"7012":5518919,"7013":3180783,"7014":3180783,"7015":3180783,"7016":4472927,"7017":4483448,"7018":4483448,"7019":5462369,"7020":5462369,"7021":5462369,"7022":3733184,"7023":3733184,"7024":3150311,"7025":3150311,"7026":3150311,"7027":3150311,"7028":4763545,"7029":4763545,"7030":4763545,"7031":4763545,"7032":4990534,"7033":4990534,"7034":4289223,"7035":4289223,"7036":4289223,"7037":4632359,"7038":4632359,"7039":4632359,"7040":5315239,"7041":5315239,"7042":3953439,"7043":3953439,"7044":3953439,"7045":5372064,"7046":4006506,"7047":4006506,"7048":4006506,"7049":5668634,"7050":4026558,"7051":4026558,"7052":4026558,"7053":5835461,"7054":5835461,"7055":5835461,"7056":5789491,"7057":5789491,"7058":2047288,"7059":2047288,"7060":5404992,"7061":4004388,"7062":4252671,"7063":4252671,"7064":4252671,"7065":5715878,"7066":5018291,"7067":5018291,"7068":5018291,"7069":5018291,"7070":4269816,"7071":3868309,"7072":2363753,"7073":2363753,"7074":4096666,"7075":4096666,"7076":5809709,"7077":5809709,"7078":5809709,"7079":4893758,"7080":4893758,"7081":3491019,"7082":3491019,"7083":3491019,"7084":3329820,"7085":3329820,"7086":3648394,"7087":3648394,"7088":3648394,"7089":3938677,"7090":3938677,"7091":3938677,"7092":3938677,"7093":4975837,"7094":4975837,"7095":4975837,"7096":5264483,"7097":5264483,"7098":5536130,"7099":5536130,"7100":5536130,"7101":5944439,"7102":5944439,"7103":5944439,"7104":4096387,"7105":4096387,"7106":4096387,"7107":4334515,"7108":5040733,"7109":5040733,"7110":5040733,"7111":5040733,"7112":4145879,"7113":5714973,"7114":5714973,"7115":5714973,"7116":4121491,"7117":4305536,"7118":4305536,"7119":4305536,"7120":4052655,"7121":4052655,"7122":4052655,"7123":2228375,"7124":2228375,"7125":2228375,"7126":2228375,"7127":2228375,"7128":3272014,"7129":4501118,"7130":4501118,"7131":4501118,"7132":4501118,"7133":5520264,"7134":5520264,"7135":5627563,"7136":5627563,"7137":5627563,"7138":3136370,"7139":3136370,"7140":3136370,"7141":3496170,"7142":3496170,"7143":3496170,"7144":4928400,"7145":4928400,"7146":4928400,"7147":4237335,"7148":4237335,"7149":5672307,"7150":4837927,"7151":4837927,"7152":4837927,"7153":2442830,"7154":3141615,"7155":3141615,"7156":3141615,"7157":3141615,"7158":4171887,"7159":5592353,"7160":5592353,"7161":5592353,"7162":5592353,"7163":3712263,"7164":3712263,"7165":3712263,"7166":5215647,"7167":5215647,"7168":3748549,"7169":3748549,"7170":3678501,"7171":3678501,"7172":3678501,"7173":4808872,"7174":4808872,"7175":3702085,"7176":3702085,"7177":3702085,"7178":3271555,"7179":4296455,"7180":3399388,"7181":3399388,"7182":3399388,"7183":3399388,"7184":4487203,"7185":4487203,"7186":4487203,"7187":4487203,"7188":4487203,"7189":3897023,"7190":3840393,"7191":4124476,"7192":3840393,"7193":4124476,"7194":3840393,"7195":4124476,"7196":4124476,"7197":4414381,"7198":4414381,"7199":4414381,"7200":3556012,"7201":4414381,"7202":4414381,"7203":4414381,"7204":4414381,"7205":4414381,"7206":3556012,"7207":60007,"7208":5088157,"7209":60007,"7210":60007,"7211":4389469,"7212":3877985,"7213":2877680,"7214":2796659,"7215":3492023,"7216":2796659,"7217":3492023,"7218":4258079,"7219":3897937,"7220":3897937,"7221":3897937,"7222":4856346,"7223":4856346,"7224":4436815,"7225":4856346,"7226":4436815,"7227":1475428,"7228":4436815,"7229":3526879,"7230":3526879,"7231":1868720,"7232":4486927,"7233":4486927,"7234":4785405,"7235":4785405,"7236":4491277,"7237":4274965,"7238":4274965,"7239":3917191,"7240":4155290,"7241":4061773,"7242":2715417,"7243":4155290,"7244":4608345,"7245":3603112,"7246":4126761,"7247":3603112,"7248":4126761,"7249":4126761,"7250":3816862,"7251":5954168,"7252":1905915,"7253":1905915,"7254":3642659,"7255":1905915,"7256":4113835,"7257":4113835,"7258":3642659,"7259":3642659,"7260":2784472,"7261":4113835,"7262":3759706,"7263":4282128,"7264":4282128,"7265":5116460,"7266":5116460,"7267":5116460,"7268":5116460,"7269":3776379,"7270":3776379,"7271":3776379,"7272":4222010,"7273":4222010,"7274":4488801,"7275":4488801,"7276":4488801,"7277":4223972,"7278":4223972,"7279":5168897,"7280":5168897,"7281":2800200,"7282":5703870,"7283":5466093,"7284":5466093,"7285":5466093,"7286":3309323,"7287":3309323,"7288":5168495,"7289":3208342,"7290":4300351,"7291":3162205,"7292":3162205,"7293":3391000,"7294":3391000,"7295":3391000,"7296":4540839,"7297":4344344,"7298":4344344,"7299":4344344,"7300":2074536,"7301":4687242,"7302":4687242,"7303":4687242,"7304":3726585,"7305":3726585,"7306":3726585,"7307":3381083,"7308":3381083,"7309":5662620,"7310":5662620,"7311":4069731,"7312":4069731,"7313":3304380,"7314":3232074,"7315":3232074,"7316":2758835,"7317":2758835,"7318":3790036,"7319":3790036,"7320":3790036,"7321":4048141,"7322":4048141,"7323":4221328,"7324":4221328,"7325":5404432,"7326":3786549,"7327":4763824,"7328":4763824,"7329":4763824,"7330":4763824,"7331":5265791,"7332":5265791,"7333":5265791,"7334":4183584,"7335":4183584,"7336":5133722,"7337":3170595,"7338":3170595,"7339":3170595,"7340":3103853,"7341":3103853,"7342":3103853,"7343":4544795,"7344":4544795,"7345":3654355,"7346":3654355,"7347":1868022,"7348":1868022,"7349":1868022,"7350":3813126,"7351":3813126,"7352":4092903,"7353":4092903,"7354":4092903,"7355":4672844,"7356":4672844,"7357":2909923,"7358":2909923,"7359":2909923,"7360":2909923,"7361":4140394,"7362":5301061,"7363":5301061,"7364":5301061,"7365":4371718,"7366":4371718,"7367":4371718,"7368":5380277,"7369":5380277,"7370":5643995,"7371":5471569,"7372":4270681,"7373":4270681,"7374":4270681,"7375":4270681,"7376":5419060,"7377":5419060,"7378":4620004,"7379":4293505,"7380":3333807,"7381":3333807,"7382":3333807,"7383":3637243,"7384":3575357,"7385":3575357,"7386":3575357,"7387":5103151,"7388":5103151,"7389":4756047,"7390":4756047,"7391":1414018,"7392":5301992,"7393":5301992,"7394":5301992,"7395":5739798,"7396":5739798,"7397":5739798,"7398":5530334,"7399":5530334,"7400":5530334,"7401":5956569,"7402":5956569,"7403":5409660,"7404":5409660,"7405":5409660,"7406":3617313,"7407":2681019,"7408":3139306,"7409":3139306,"7410":3139306,"7411":3511173,"7412":3511173,"7413":3301259,"7414":3301259,"7415":3301259,"7416":4228518,"7417":4228518,"7418":4228518,"7419":4228518,"7420":4947329,"7421":4558893,"7422":4558893,"7423":4558893,"7424":4431324,"7425":4431324,"7426":4431324,"7427":4682450,"7428":4682450,"7429":4682450,"7430":4682450,"7431":4577526,"7432":5852701,"7433":3984416,"7434":3984416,"7435":3984416,"7436":3984416,"7437":3984416,"7438":2129145,"7439":2129145,"7440":2129145,"7441":3793422,"7442":3793422,"7443":3793422,"7444":2887201,"7445":2887201,"7446":2887201,"7447":2887201,"7448":5662512,"7449":3009979,"7450":5524909,"7451":5524909,"7452":4064756,"7453":2639329,"7454":2639329,"7455":5431359,"7456":5648980,"7457":4754570,"7458":3191350,"7459":5629940,"7460":4570722,"7461":5655345,"7462":3295238,"7463":3295238,"7464":5320771,"7465":5320771,"7466":5260131,"7467":4893099,"7468":4893099,"7469":5611398,"7470":5426232,"7471":5807031,"7472":5435062,"7473":4595235,"7474":4595235,"7475":5722122,"7476":4061186,"7477":4065461,"7478":3215881,"7479":2503659,"7480":2952311,"7481":4076897,"7482":4526789,"7483":2808793,"7484":2808793,"7485":4433997,"7486":4433997,"7487":5045523,"7488":3248601,"7489":5077078,"7490":4162719,"7491":4599047,"7492":4599047,"7493":4508540,"7494":4636656,"7495":3944283,"7496":4644305,"7497":4774750,"7498":3148260,"7499":5971365,"7500":5971365,"7501":5971365,"7502":4374075,"7503":2770415,"7504":5812048,"7505":4304200,"7506":5119439,"7507":5119439,"7508":2474851,"7509":5358282,"7510":3233513,"7511":3233513,"7512":4210064,"7513":4662763,"7514":4662763,"7515":2984512,"7516":4296330,"7517":5762262,"7518":4858101,"7519":4858101,"7520":4893238,"7521":3880665,"7522":3880665,"7523":4969326,"7524":4969326,"7525":4969326,"7526":4279802,"7527":4744955,"7528":4744955,"7529":3227609,"7530":3898378,"7531":5358738,"7532":5358738,"7533":4877819,"7534":3132856,"7535":4354356,"7536":4354356,"7537":5381869,"7538":4126186,"7539":4126186,"7540":2291568,"7541":3635879,"7542":3479017,"7543":2759981,"7544":2759981,"7545":4112798,"7546":3253463,"7547":3253463,"7548":3134103,"7549":3134103,"7550":4269544,"7551":2785868,"7552":3017961,"7553":4914255,"7554":4914255,"7555":3822756,"7556":3822756,"7557":2752780,"7558":2752780,"7559":2752780,"7560":4265247,"7561":4265247,"7562":4834398,"7563":4834398,"7564":3785381,"7565":3785381,"7566":5494175,"7567":5494175,"7568":4166083,"7569":5467351,"7570":5968838,"7571":5968838,"7572":5214464,"7573":4710971,"7574":4119301,"7575":4119301,"7576":5395810,"7577":4212559,"7578":5426232,"7579":5139733,"7580":5139733,"7581":5139733,"7582":4960805,"7583":4960805,"7584":5910333,"7585":5910333,"7586":5910333,"7587":5910333,"7588":5807031,"7589":2876855,"7590":2876855,"7591":5435062,"7592":5435062,"7593":5435062,"7594":5435062,"7595":4595235,"7596":4704299,"7597":4704299,"7598":4704299,"7599":4704299,"7600":5722122,"7601":5722122,"7602":5395856,"7603":5395856,"7604":5395856,"7605":5395856,"7606":4061186,"7607":4432080,"7608":4432080,"7609":4861095,"7610":3979125,"7611":5094122,"7612":5094122,"7613":4065461,"7614":4065461,"7615":3215881,"7616":3215881,"7617":2503659,"7618":2503659,"7619":2503659,"7620":5541727,"7621":5541727,"7622":2952311,"7623":2952311,"7624":2952311,"7625":4076897,"7626":4076897,"7627":4526789,"7628":2808793,"7629":4433997,"7630":5045523,"7631":3248601,"7632":3248601,"7633":3248601,"7634":3248601,"7635":5738975,"7636":5738975,"7637":5738975,"7638":3439673,"7639":3439673,"7640":5077078,"7641":5077078,"7642":5077078,"7643":4162719,"7644":4508540,"7645":4508540,"7646":4508540,"7647":4696773,"7648":4696773,"7649":4696773,"7650":5404516,"7651":5404516,"7652":5404516,"7653":2865639,"7654":2865639,"7655":2865639,"7656":2865639,"7657":2865639,"7658":4636656,"7659":4636656,"7660":4636656,"7661":3944283,"7662":3944283,"7663":5294576,"7664":5294576,"7665":5294576,"7666":4630885,"7667":4630885,"7668":4361464,"7669":4361464,"7670":4361464,"7671":4361464,"7672":4361464,"7673":4418140,"7674":4418140,"7675":4418140,"7676":4418140,"7677":4644305,"7678":4774750,"7679":4774750,"7680":3513028,"7681":3513028,"7682":3513028,"7683":3513028,"7684":3148260,"7685":5079608,"7686":4081799,"7687":4081799,"7688":3576910,"7689":3576910,"7690":3576910,"7691":5187654,"7692":5187654,"7693":5187654,"7694":5971365,"7695":5971365,"7696":3747414,"7697":3747414,"7698":4374075,"7699":2770415,"7700":2770415,"7701":2770415,"7702":2770415,"7703":5812048,"7704":5812048,"7705":5812048,"7706":5812048,"7707":4304200,"7708":4304200,"7709":4304200,"7710":3840008,"7711":3840008,"7712":4555162,"7713":4555162,"7714":4555162,"7715":4555162,"7716":5119439,"7717":2837810,"7718":5369693,"7719":5985784,"7720":5985784,"7721":5985784,"7722":5985784,"7723":5985784,"7724":2898847,"7725":3425422,"7726":3199893,"7727":3199893,"7728":3199893,"7729":3620516,"7730":3620516,"7731":4532714,"7732":5940475,"7733":2699080,"7734":4181789,"7735":4181789,"7736":4181789,"7737":5534217,"7738":5534217,"7739":5499864,"7740":5499864,"7741":5752784,"7742":3987287,"7743":3987287,"7744":3987287,"7745":3987287,"7746":3987287,"7747":3987287,"7748":3987287,"7749":3987287,"7750":4386768,"7751":4386768,"7752":4386768,"7753":4386768,"7754":4386768,"7755":4386768,"7756":4386768,"7757":4705007,"7758":4705007,"7759":4273020,"7760":5245138,"7761":5245138,"7762":5245138,"7763":5245138,"7764":4284010,"7765":4284010,"7766":5689110,"7767":5689110,"7768":5689110,"7769":3066231,"7770":3066231,"7771":3066231,"7772":3916852,"7773":3916852,"7774":4976892,"7775":3835502,"7776":3835502,"7777":3835502,"7778":4881125,"7779":5432698,"7780":5432698,"7781":5432698,"7782":4056784,"7783":4056784,"7784":4056784,"7785":4056784,"7786":4198969,"7787":3775167,"7788":3775167,"7789":5518918,"7790":3335250,"7791":3335250,"7792":3335250,"7793":3335250,"7794":5056957,"7795":3790836,"7796":3790836,"7797":3790836,"7798":5946268,"7799":5946268,"7800":5380284,"7801":5380284,"7802":5380284,"7803":5897859,"7804":5897859,"7805":2818614,"7806":2442760,"7807":4990278,"7808":4990278,"7809":4616075,"7810":4616075,"7811":4616075,"7812":3292461,"7813":4552663,"7814":4552663,"7815":4552663,"7816":4118506,"7817":4118506,"7818":4118506,"7819":4018592,"7820":4101294,"7821":3508963,"7822":5477737,"7823":5477737,"7824":5477737,"7825":5960495,"7826":5623327,"7827":5623327,"7828":2602945,"7829":2602945,"7830":4324646,"7831":5341634,"7832":5341634,"7833":5341634,"7834":4314848,"7835":4314848,"7836":4230312,"7837":4541185,"7838":4738984,"7839":4207773,"7840":4483323,"7841":4483323,"7842":3224655,"7843":3224655,"7844":5597285,"7845":5597285,"7846":5597285,"7847":5324269,"7848":4368876,"7849":2778511,"7850":5513842,"7851":5513842,"7852":5513842,"7853":5234109,"7854":5234109,"7855":3691930,"7856":5471294,"7857":5471294,"7858":3814649,"7859":5187654,"7860":5187654,"7861":1185549,"7862":1185549,"7863":1185549,"7864":4094569,"7865":4094569,"7866":3747414,"7867":4094569,"7868":4374075,"7869":3806550,"7870":4374075,"7871":4015738,"7872":3204557,"7873":3204557,"7874":5812048,"7875":4969982,"7876":4304200,"7877":4045244,"7878":3840008,"7879":3698010,"7880":3840008,"7881":3840008,"7882":3698010,"7883":3840008,"7884":3217852,"7885":3217852,"7886":3217852,"7887":4555162,"7888":4789479,"7889":5119439,"7890":5119439,"7891":3657667,"7892":2994863,"7893":4868921,"7894":2994863,"7895":4868921,"7896":5217809,"7897":5029174,"7898":5029174,"7899":4545275,"7900":5029174,"7901":4341337,"7902":4280732,"7903":4341337,"7904":3316967,"7905":4305224,"7906":3316967,"7907":4305224,"7908":4305224,"7909":4288428,"7910":5609346,"7911":4288428,"7912":4910973,"7913":3800406,"7914":4910973,"7915":3800406,"7916":2581757,"7917":2249589,"7918":2581757,"7919":2277487,"7920":3917884,"7921":3917884,"7922":4467620,"7923":4467620,"7924":4467620,"7925":4330076,"7926":5784025,"7927":5784025,"7928":4330076,"7929":4330076,"7930":3053227,"7931":4445854,"7932":3053227,"7933":3856598,"7934":5525580,"7935":5442667,"7936":5079608,"7937":5442667,"7938":4696975,"7939":4829247,"7940":5668004,"7941":4829247,"7942":4829247,"7943":5620095,"7944":4676364,"7945":5730627,"7946":3572221,"7947":5730627,"7948":4676364,"7949":4190894,"7950":4262215,"7951":5525241,"7952":5525241,"7953":4262215,"7954":5525241,"7955":5525241,"7956":4190894,"7957":4145491,"7958":5702366,"7959":5524909,"7960":4533227,"7961":4064756,"7962":4064756,"7963":4533227,"7964":4684352,"7965":5763662,"7966":4684352,"7967":5763662,"7968":4153084,"7969":2639329,"7970":3848942,"7971":3848942,"7972":3848942,"7973":5633234,"7974":4784207,"7975":4784207,"7976":4397550,"7977":4546110,"7978":4546110,"7979":4461648,"7980":5431359,"7981":5431359,"7982":5431359,"7983":5491162,"7984":4397550,"7985":5648980,"7986":5636088,"7987":5648980,"7988":5648980,"7989":5636088,"7990":4754570,"7991":4059551,"7992":5045904,"7993":4059551,"7994":4059551,"7995":5588958,"7996":5045904,"7997":5045904,"7998":3650238,"7999":5588958,"8000":2687939,"8001":3650238,"8002":3477095,"8003":3477095,"8004":3477095,"8005":3477095,"8006":3767244,"8007":4402481,"8008":4183968,"8009":4402481,"8010":3221066,"8011":2992187,"8012":4727651,"8013":4727651,"8014":2717426,"8015":2992187,"8016":3215316,"8017":3215316,"8018":3215316,"8019":5447816,"8020":4676914,"8021":4676914,"8022":4676914,"8023":3653044,"8024":5508614,"8025":5629940,"8026":5508614,"8027":3653044,"8028":5629940,"8029":4143738,"8030":4143738,"8031":3868679,"8032":4143738,"8033":5073301,"8034":5073301,"8035":4624894,"8036":5073301,"8037":3868679,"8038":5073301,"8039":2755037,"8040":2755037,"8041":3295238,"8042":2755037,"8043":2755037,"8044":5568719,"8045":5491162,"8046":5320771,"8047":4761605,"8048":3767244,"8049":5320771,"8050":5260131,"8051":5260131,"8052":3767244,"8053":5260131,"8054":4761605,"8055":4893099,"8056":3767244,"8057":4893099,"8058":3263860,"8059":3263860,"8060":5611398,"8061":5611398,"8062":5426232,"8063":5426232,"8064":5139733,"8065":2717426,"8066":5139733,"8067":4960805,"8068":4960805,"8069":5910333,"8070":5910333,"8071":5807031,"8072":5807031,"8073":2876855,"8074":5435062,"8075":5435062,"8076":3215316,"8077":4595235,"8078":4595235,"8079":4595235,"8080":5722122,"8081":5722122,"8082":5395856,"8083":4061186,"8084":4061186,"8085":4061186,"8086":3191350,"8087":3653044,"8088":3979125,"8089":5094122,"8090":4065461,"8091":4065461,"8092":3215881,"8093":3215881,"8094":2503659,"8095":5541727,"8096":5541727,"8097":5541727,"8098":5541727,"8099":4213554,"8100":5541727,"8101":4213554,"8102":2952311,"8103":2952311,"8104":5506593,"8105":4076897,"8106":4076897,"8107":4526789,"8108":4526789,"8109":2808793,"8110":2808793,"8111":4433997,"8112":4433997,"8113":4433997,"8114":5045523,"8115":5045523,"8116":5045523,"8117":5793008,"8118":5125190,"8119":5746709,"8120":3439673,"8121":3439673,"8122":4058264,"8123":4058264,"8124":4058264,"8125":5721363,"8126":4162719,"8127":5536158,"8128":4162719,"8129":1924504,"8130":4599047,"8131":4508540,"8132":1924504,"8133":5536158,"8134":4508540,"8135":4696773,"8136":4696773,"8137":4868208,"8138":4868208,"8139":4696773,"8140":5404516,"8141":4868208,"8142":2865639,"8143":3364603,"8144":4435702,"8145":4435702,"8146":4435702,"8147":4435702,"8148":4636656,"8149":4608292,"8150":4608292,"8151":4608292,"8152":5294576,"8153":5294576,"8154":2500257,"8155":3148260,"8156":2500257,"8157":4630885,"8158":4630885,"8159":4630885,"8160":4895399,"8161":4895399,"8162":4895399,"8163":2645358,"8164":4418140,"8165":4418140,"8166":4278388,"8167":4278388,"8168":4644305,"8169":4278388,"8170":4644305,"8171":5667629,"8172":4774750,"8173":4774750,"8174":3513028,"8175":3221066,"8176":3148260,"8177":3221066,"8178":3148260,"8179":5450344,"8180":5079608,"8181":5079608,"8182":5079608,"8183":5338176,"8184":5338176,"8185":4081799,"8186":4081799,"8187":4145491,"8188":4081799,"8189":3576910,"8190":5620095,"8191":5730627,"8192":4262215,"8193":4262215,"8194":4262215,"8195":5702366,"8196":5702366,"8197":4533227,"8198":5763662,"8199":3373522,"8200":5716426,"8201":5633234,"8202":4546110,"8203":2994863,"8204":3883318,"8205":3883318,"8206":5636088,"8207":4545275,"8208":4059551,"8209":4280732,"8210":3316967,"8211":2687939,"8212":3316967,"8213":3316967,"8214":5609346,"8215":2687939,"8216":4727651,"8217":5861900,"8218":5861900,"8219":5447816,"8220":5447816,"8221":3800406,"8222":4676914,"8223":5508614,"8224":4467620,"8225":4467620,"8226":4143738,"8227":4330076,"8228":4143738,"8229":4330076,"8230":4445854,"8231":4445854,"8232":4624894,"8233":4624894,"8234":4696975,"8235":4696975,"8236":5668004,"8237":2994863,"8238":2994863,"8239":2994863,"8240":2994863,"8241":5217809,"8242":4545275,"8243":4545275,"8244":4545275,"8245":4280732,"8246":4280732,"8247":5861900,"8248":3564932,"8249":3564932,"8250":4975837,"8251":4975837,"8252":4975837,"8253":4094569,"8254":2931380,"8255":5264483,"8256":5264483,"8257":5264483,"8258":5264483,"8259":5536130,"8260":5536130,"8261":5536130,"8262":4969982,"8263":4045244,"8264":5944439,"8265":3698010,"8266":4096387,"8267":3386590,"8268":4096387,"8269":3698010,"8270":3804653,"8271":3217852,"8272":4145879,"8273":4145879,"8274":4145879,"8275":5714973,"8276":4868921,"8277":4121491,"8278":4305536,"8279":4305536,"8280":4341337,"8281":4052655,"8282":4052655,"8283":2228375,"8284":2228375,"8285":4305224,"8286":3272014,"8287":4501118,"8288":5520264,"8289":2249589,"8290":5520264,"8291":5520264,"8292":5520264,"8293":5627563,"8294":3136370,"8295":3496170,"8296":3053227,"8297":3496170,"8298":3496170,"8299":4928400,"8300":4928400,"8301":4928400,"8302":5442667,"8303":4237335,"8304":5672307,"8305":5672307,"8306":5672307,"8307":4676364,"8308":3141615,"8309":4190894,"8310":5592353,"8311":5587697,"8312":5587697,"8313":5587697,"8314":5587697,"8315":3712263,"8316":5215647,"8317":5215647,"8318":5215647,"8319":3748549,"8320":3678501,"8321":3678501,"8322":4234788,"8323":4808872,"8324":4234788,"8325":3702085,"8326":3702085,"8327":4397550,"8328":3702085,"8329":3271555,"8330":3271555,"8331":4296455,"8332":3399388,"8333":3399388,"8334":4499954,"8335":3399388,"8336":4487203,"8337":5045904,"8338":3705347,"8339":3705347,"8340":4487203,"8341":4487203,"8342":3897023,"8343":4674443,"8344":3840393,"8345":3840393,"8346":4414381,"8347":3653044,"8348":4414381,"8349":4414381,"8350":4414381,"8351":3868679,"8352":4414381,"8353":5654157,"8354":5654157,"8355":2778406,"8356":2778406,"8357":5811944,"8358":2778406,"8359":3492023,"8360":3492023,"8361":3897937,"8362":5156604,"8363":3897937,"8364":5156604,"8365":3897937,"8366":4761605,"8367":4436815,"8368":3386590,"8369":4436815,"8370":4436815,"8371":5300803,"8372":5300803,"8373":4785405,"8374":3542441,"8375":4785405,"8376":2652457,"8377":4785405,"8378":2652457,"8379":4785405,"8380":3046916,"8381":3046916,"8382":3917191,"8383":4530210,"8384":4530210,"8385":4610775,"8386":4155290,"8387":4155290,"8388":4171519,"8389":4171519,"8390":4171519,"8391":4171519,"8392":4171519,"8393":4126761,"8394":2660282,"8395":4126761,"8396":2660282,"8397":2660282,"8398":4113835,"8399":5886394,"8400":4113835,"8401":5886394,"8402":4113835,"8403":3484141,"8404":5502308,"8405":3854508,"8406":4113835,"8407":5502308,"8408":3849694,"8409":3849694,"8410":3154347,"8411":3567118,"8412":4319071,"8413":3567118,"8414":4319071,"8415":4319071,"8416":3640161,"8417":3640161,"8418":2584124,"8419":4077042,"8420":4077042,"8421":2584124,"8422":2972641,"8423":5518919,"8424":5518919,"8425":5518919,"8426":3180783,"8427":3180783,"8428":4472927,"8429":4472927,"8430":4472927,"8431":4483448,"8432":3733184,"8433":3150311,"8434":3150311,"8435":4763545,"8436":4990534,"8437":4632359,"8438":4632359,"8439":4632359,"8440":5034497,"8441":5315239,"8442":5315239,"8443":5315239,"8444":4006506,"8445":4006506,"8446":4006506,"8447":5668634,"8448":5668634,"8449":3966825,"8450":4026558,"8451":5835461,"8452":5835461,"8453":4058264,"8454":4058264,"8455":5789491,"8456":5721363,"8457":5721363,"8458":5789491,"8459":2047288,"8460":5536158,"8461":5404992,"8462":5404992,"8463":1924504,"8464":4555141,"8465":4252671,"8466":4868208,"8467":4252671,"8468":4252671,"8469":4799034,"8470":3364603,"8471":5715878,"8472":5715878,"8473":5715878,"8474":5890227,"8475":5018291,"8476":4608292,"8477":5018291,"8478":4269816,"8479":4269816,"8480":4269816,"8481":4269816,"8482":3868309,"8483":4269816,"8484":3868309,"8485":2500257,"8486":3868309,"8487":4895399,"8488":2363753,"8489":4895399,"8490":4096666,"8491":2645358,"8492":2645358,"8493":4096666,"8494":2645358,"8495":5809709,"8496":5809709,"8497":5809709,"8498":4278388,"8499":5809709,"8500":3599792,"8501":3599792,"8502":4893758,"8503":4893758,"8504":3221066,"8505":3329820,"8506":3329820,"8507":3329820,"8508":3329820,"8509":3329820,"8510":5890227,"8511":3648394,"8512":4761605,"8513":3564932,"8514":3938677,"8515":4545275,"8516":4143738,"8517":2687939,"8518":4546110,"8519":4624894,"8520":5609346,"8521":5609346,"8522":5609346,"8523":4445854,"8524":5702366,"8525":2755037,"8526":5861900,"8527":4696975,"8528":2581757,"8529":5861900,"8530":3800406,"8531":3800406,"8532":2581757,"8533":2581757,"8534":4330076,"8535":4445854,"8536":3856598,"8537":3856598,"8538":3856598,"8539":3856598,"8540":4696975,"8541":4696975,"8542":5668004,"8543":5668004,"8544":5620095,"8545":5620095,"8546":5620095,"8547":5730627,"8548":4262215,"8549":5702366,"8550":4533227,"8551":4533227,"8552":5763662,"8553":5763662,"8554":5716426,"8555":5716426,"8556":5716426,"8557":5633234,"8558":5633234,"8559":4546110,"8560":4461648,"8561":4461648,"8562":4461648,"8563":3883318,"8564":5636088,"8565":5636088,"8566":4059551,"8567":5588958,"8568":5588958,"8569":5588958,"8570":2687939,"8571":4402481,"8572":4402481,"8573":4402481,"8574":4727651,"8575":5447816,"8576":5447816,"8577":4676914,"8578":5508614,"8579":5508614,"8580":4624894,"8581":2912679,"8582":2912679,"8583":3577773,"8584":3577773,"8585":4339981,"8586":4339981,"8587":4339981,"8588":4339981,"8589":4339981,"8590":5362536,"8591":5362536,"8592":4440276,"8593":4440276,"8594":4440276,"8595":4440276,"8596":4440276,"8597":2680972,"8598":2680972,"8599":2680972,"8600":2867787,"8601":2867787,"8602":3842969,"8603":3842969,"8604":3842969,"8605":3842969,"8606":3842969,"8607":3842969,"8608":5051624,"8609":5051624,"8610":5051624,"8611":5051624,"8612":5051624,"8613":4497728,"8614":4497728,"8615":4497728,"8616":4497728,"8617":4497728,"8618":4497728,"8619":4497728,"8620":4497728,"8621":4497728,"8622":5641458,"8623":5641458,"8624":5641458,"8625":5641458,"8626":5641458,"8627":5641458,"8628":3120180,"8629":3120180,"8630":3120180,"8631":3685599,"8632":3685599,"8633":3685599,"8634":3685599,"8635":3685599,"8636":3685599,"8637":3685599,"8638":3685599,"8639":3685599,"8640":3685599,"8641":3685599,"8642":5789697,"8643":3266205,"8644":3266205,"8645":3266205,"8646":3266205,"8647":4538741,"8648":4538741,"8649":4538741,"8650":4538741,"8651":4538741,"8652":4538741,"8653":4538741,"8654":3263163,"8655":3263163,"8656":3263163,"8657":3263163,"8658":3263163,"8659":3263163,"8660":3263163,"8661":3263163,"8662":5634755,"8663":5634755,"8664":3191394,"8665":3191394,"8666":3191394,"8667":5695311,"8668":5695311,"8669":5695311,"8670":5674649,"8671":5674649,"8672":5674649,"8673":5674649,"8674":5674649,"8675":4506382,"8676":4506382,"8677":4506382,"8678":4721471,"8679":4721471,"8680":5101386,"8681":5101386,"8682":5101386,"8683":5101386,"8684":5393542,"8685":5393542,"8686":5393542,"8687":5393542,"8688":5565373,"8689":5565373,"8690":5565373,"8691":5565373,"8692":5565373,"8693":5565373,"8694":4085217,"8695":4085217,"8696":4085217,"8697":4085217,"8698":5439319,"8699":5439319,"8700":5439319,"8701":5439319,"8702":5439319,"8703":5341660,"8704":5341660,"8705":5341660,"8706":3681374,"8707":3681374,"8708":3681374,"8709":3681374,"8710":4596416,"8711":4596416,"8712":4596416,"8713":4596416,"8714":5370803,"8715":5370803,"8716":5370803,"8717":5370803,"8718":5370803,"8719":5370803,"8720":5370803,"8721":5370803,"8722":5370803,"8723":5370803,"8724":5370803,"8725":5370803,"8726":5370803,"8727":5370803,"8728":5648411,"8729":5648411,"8730":5880517,"8731":5880517,"8732":5880517,"8733":5793008,"8734":3559346,"8735":3559346,"8736":3938677,"8737":5706318,"8738":5706318,"8739":5706318,"8740":2931380,"8741":4881703,"8742":4286921,"8743":5944439,"8744":4096387,"8745":3804653,"8746":4334515,"8747":5116111,"8748":5712637,"8749":5712637,"8750":5712637,"8751":4121491,"8752":5812876,"8753":4305536,"8754":4305536,"8755":5571493,"8756":5571493,"8757":4052655,"8758":3907426,"8759":4837818,"8760":4501118,"8761":5635946,"8762":5627563,"8763":5627563,"8764":5627563,"8765":3790030,"8766":3752632,"8767":3752632,"8768":4395706,"8769":4237335,"8770":3141615,"8771":3608590,"8772":5592353,"8773":4610922,"8774":5587697,"8775":4610922,"8776":5587697,"8777":3571894,"8778":3571894,"8779":5215647,"8780":3748549,"8781":4274041,"8782":4274041,"8783":4274041,"8784":4782022,"8785":5859768,"8786":5859768,"8787":4598102,"8788":4598102,"8789":5306110,"8790":3315554,"8791":3315554,"8792":4311106,"8793":4487203,"8794":4311106,"8795":3503752,"8796":3840393,"8797":4173506,"8798":5088157,"8799":5811944,"8800":5811944,"8801":2778406,"8802":3581780,"8803":4436815,"8804":4344586,"8805":3017527,"8806":4436815,"8807":3414768,"8808":3017527,"8809":4436815,"8810":3542441,"8811":3542441,"8812":5424452,"8813":5424452,"8814":2652457,"8815":3917191,"8816":4610775,"8817":4608345,"8818":4171519,"8819":4608345,"8820":4610088,"8821":2409966,"8822":2660282,"8823":1905915,"8824":4194359,"8825":5886394,"8826":5886394,"8827":4194359,"8828":4809001,"8829":5331589,"8830":5331589,"8831":3854508,"8832":4170550,"8833":3154347,"8834":4319071,"8835":4319071,"8836":4839625,"8837":3640161,"8838":4839625,"8839":2584124,"8840":3658388,"8841":2584124,"8842":4077042,"8843":3658388,"8844":5909776,"8845":3893439,"8846":3180783,"8847":4472927,"8848":4472927,"8849":5299497,"8850":2569033,"8851":5299497,"8852":5135478,"8853":4604314,"8854":4009639,"8855":4009639,"8856":5630558,"8857":4114003,"8858":4763545,"8859":5346512,"8860":5630558,"8861":5346512,"8862":5346512,"8863":4241936,"8864":5034497,"8865":5264222,"8866":5315239,"8867":4674925,"8868":5372064,"8869":5372064,"8870":5372064,"8871":4590893,"8872":4590893,"8873":5052963,"8874":3010035,"8875":4810948,"8876":4810948,"8877":4810948,"8878":5789491,"8879":2047288,"8880":2047288,"8881":3552315,"8882":3311713,"8883":5404992,"8884":2635353,"8885":5404992,"8886":4252671,"8887":3276927,"8888":4173437,"8889":3276927,"8890":5773205,"8891":3376522,"8892":5595267,"8893":5715878,"8894":5595267,"8895":5018291,"8896":3642008,"8897":2363753,"8898":3642008,"8899":4166382,"8900":4280366,"8901":3599792,"8902":4893758,"8903":3504298,"8904":4893758,"8905":3504298,"8906":4779585,"8907":4779585,"8908":5686687,"8909":3648394,"8910":3559346,"8911":3559346,"8912":3841356,"8913":3841356,"8914":5706318,"8915":4881703,"8916":4881703,"8917":4881703,"8918":4881703,"8919":4286921,"8920":4286921,"8921":4286921,"8922":4286921,"8923":5654031,"8924":5654031,"8925":3972107,"8926":3972107,"8927":3972107,"8928":3972107,"8929":5116111,"8930":5116111,"8931":5116111,"8932":5712637,"8933":5712637,"8934":4006208,"8935":3349167,"8936":3349167,"8937":3349167,"8938":5571493,"8939":5571493,"8940":5571493,"8941":5571493,"8942":4416300,"8943":4416300,"8944":4416300,"8945":4416300,"8946":4416300,"8947":4165641,"8948":4165641,"8949":3907426,"8950":3907426,"8951":3907426,"8952":3907426,"8953":4837818,"8954":4837818,"8955":4830153,"8956":4830153,"8957":4830153,"8958":4830153,"8959":3790030,"8960":3790030,"8961":3790030,"8962":3752632,"8963":3752632,"8964":3752632,"8965":3696875,"8966":3696875,"8967":3696875,"8968":3696875,"8969":3696875,"8970":5838916,"8971":5838916,"8972":5207750,"8973":4822094,"8974":4822094,"8975":4822094,"8976":4822094,"8977":4681902,"8978":4681902,"8979":3608590,"8980":3608590,"8981":3608590,"8982":3608590,"8983":4610922,"8984":4610922,"8985":3571894,"8986":3571894,"8987":3571894,"8988":5514953,"8989":5514953,"8990":4663570,"8991":4663570,"8992":4663570,"8993":4663570,"8994":4274041,"8995":4274041,"8996":5731010,"8997":4598102,"8998":4598102,"8999":2546382,"9000":2546382,"9001":3474173,"9002":5289293,"9003":5289293,"9004":5289293,"9005":5306110,"9006":3315554,"9007":4311106,"9008":4311106,"9009":5294435,"9010":5294435,"9011":3503752,"9012":3503752,"9013":4296355,"9014":5296807,"9015":5296807,"9016":4173506,"9017":4173506,"9018":4173506,"9019":4957966,"9020":4957966,"9021":4957966,"9022":4052786,"9023":4052786,"9024":3841356,"9025":5706318,"9026":5706318,"9027":4881703,"9028":4286921,"9029":4018698,"9030":4018698,"9031":4018698,"9032":4018698,"9033":4018698,"9034":4018698,"9035":5654031,"9036":5654031,"9037":5654031,"9038":5654031,"9039":3972107,"9040":3972107,"9041":4355923,"9042":4355923,"9043":5116111,"9044":5116111,"9045":5712637,"9046":5812876,"9047":4006208,"9048":4006208,"9049":3349167,"9050":4416300,"9051":3907426,"9052":4837818,"9053":4837818,"9054":4837818,"9055":3790030,"9056":3790030,"9057":3696875,"9058":4395706,"9059":4395706,"9060":4395706,"9061":4395706,"9062":4395706,"9063":4822094,"9064":4822094,"9065":4681902,"9066":4681902,"9067":3608590,"9068":4610922,"9069":4610922,"9070":3571894,"9071":5514953,"9072":4663570,"9073":4274041,"9074":4782022,"9075":5859768,"9076":5859768,"9077":4598102,"9078":3474173,"9079":5306110,"9080":5306110,"9081":5306110,"9082":3315554,"9083":4311106,"9084":3503752,"9085":3503752,"9086":4296355,"9087":4296355,"9088":4296355,"9089":4296355,"9090":5296807,"9091":5296807,"9092":5296807,"9093":4173506,"9094":4957966,"9095":4957966,"9096":4052786,"9097":4052786,"9098":4026398,"9099":4871204,"9100":4871204,"9101":3581780,"9102":3581780,"9103":5773988,"9104":4951371,"9105":4951371,"9106":3017527,"9107":3017527,"9108":4459874,"9109":5424452,"9110":4738038,"9111":4738038,"9112":5803937,"9113":5803937,"9114":4610088,"9115":4610088,"9116":2409966,"9117":4809001,"9118":4809001,"9119":4809001,"9120":5331589,"9121":4170550,"9122":4170550,"9123":4170550,"9124":4170550,"9125":3284878,"9126":3284878,"9127":4839625,"9128":3658388,"9129":5909776,"9130":5909776,"9131":3893439,"9132":5711682,"9133":5711682,"9134":4076224,"9135":2569033,"9136":4076224,"9137":5299497,"9138":2569033,"9139":3460347,"9140":5299497,"9141":5299497,"9142":5135478,"9143":5135478,"9144":5135478,"9145":3460347,"9146":5135478,"9147":4604314,"9148":4604314,"9149":4114003,"9150":2782153,"9151":2782153,"9152":5630558,"9153":2782153,"9154":2782153,"9155":2782153,"9156":2782153,"9157":5630558,"9158":4023937,"9159":4241936,"9160":4241936,"9161":4907713,"9162":4907713,"9163":3613423,"9164":3613423,"9165":5682702,"9166":5264222,"9167":3228981,"9168":3228981,"9169":3228981,"9170":5863413,"9171":5863413,"9172":5047648,"9173":5852772,"9174":5852772,"9175":5702778,"9176":5852772,"9177":5702778,"9178":5052963,"9179":5052963,"9180":5052963,"9181":4590893,"9182":4776972,"9183":4776972,"9184":4776972,"9185":3010035,"9186":4776972,"9187":3010035,"9188":3010035,"9189":3010035,"9190":4810948,"9191":3406192,"9192":3552315,"9193":3311713,"9194":2635353,"9195":4870813,"9196":5508798,"9197":5508798,"9198":5508798,"9199":5808274,"9200":3276927,"9201":4173437,"9202":4173437,"9203":5773205,"9204":5595267,"9205":4872285,"9206":5002172,"9207":5002172,"9208":5002172,"9209":4793173,"9210":4793173,"9211":4166382,"9212":2908852,"9213":2908852,"9214":2908852,"9215":3716952,"9216":3504298,"9217":4779585,"9218":4779585,"9219":5892275,"9220":5892275,"9221":5892275,"9222":5892275,"9223":5686687,"9224":5686687,"9225":5686687,"9226":3635645,"9227":4890862,"9228":5008205,"9229":5008205,"9230":3635645,"9231":5008205,"9232":3635645,"9233":4890862,"9234":5694526,"9235":5694526,"9236":5573922,"9237":4207147,"9238":5453890,"9239":3580622,"9240":5453890,"9241":3441280,"9242":5453890,"9243":4711101,"9244":5534041,"9245":5534041,"9246":5772830,"9247":4808857,"9248":5534041,"9249":5118645,"9250":5908397,"9251":4808857,"9252":5908397,"9253":4808857,"9254":5908397,"9255":3881751,"9256":5908397,"9257":5508798,"9258":4206772,"9259":2954378,"9260":5125808,"9261":4206772,"9262":5405916,"9263":4206772,"9264":4179329,"9265":5125808,"9266":4179329,"9267":4907713,"9268":4179329,"9269":2694359,"9270":2694359,"9271":5125808,"9272":2694359,"9273":4483416,"9274":4483416,"9275":4711101,"9276":4483416,"9277":4928948,"9278":4674925,"9279":4674925,"9280":3996149,"9281":4674925,"9282":4141807,"9283":4141807,"9284":4026398,"9285":4026398,"9286":4871204,"9287":4871204,"9288":5047648,"9289":4871204,"9290":5761719,"9291":3581780,"9292":3581780,"9293":5773988,"9294":5047648,"9295":5773988,"9296":5761719,"9297":4951371,"9298":4963027,"9299":3017527,"9300":5367005,"9301":5367005,"9302":4459874,"9303":4459874,"9304":4459874,"9305":5424452,"9306":5424452,"9307":5154305,"9308":5424452,"9309":4738038,"9310":4738038,"9311":5803937,"9312":5803937,"9313":5803937,"9314":5803937,"9315":5154305,"9316":4625433,"9317":5835896,"9318":4610088,"9319":2409966,"9320":2409966,"9321":2409966,"9322":4194359,"9323":2784472,"9324":4494428,"9325":4625433,"9326":4494428,"9327":4494428,"9328":5331589,"9329":5502308,"9330":4494428,"9331":3849694,"9332":3996149,"9333":3996149,"9334":4709816,"9335":4709816,"9336":4170550,"9337":3567118,"9338":3567118,"9339":3284878,"9340":3567118,"9341":3284878,"9342":3567118,"9343":3104134,"9344":4318496,"9345":3094245,"9346":3544341,"9347":3544341,"9348":3601258,"9349":4077042,"9350":4839625,"9351":4839625,"9352":4839625,"9353":5129592,"9354":4984916,"9355":2972641,"9356":5518919,"9357":2972641,"9358":3893439,"9359":3893439,"9360":3658388,"9361":5909776,"9362":3893439,"9363":3893439,"9364":4076224,"9365":3284878,"9366":4076224,"9367":4076224,"9368":5711682,"9369":5711682,"9370":5711682,"9371":2569033,"9372":5299497,"9373":2569033,"9374":3460347,"9375":3460347,"9376":5407976,"9377":5407976,"9378":5407976,"9379":5135478,"9380":5135478,"9381":5407976,"9382":4009639,"9383":5407976,"9384":4604314,"9385":4009639,"9386":4604314,"9387":4114003,"9388":3010035,"9389":5630558,"9390":5656289,"9391":5118645,"9392":4251615,"9393":4251615,"9394":5346512,"9395":4023937,"9396":4023937,"9397":5346512,"9398":5346512,"9399":4023937,"9400":4023937,"9401":4241936,"9402":4241936,"9403":3658388,"9404":4241936,"9405":4882374,"9406":4882374,"9407":4882374,"9408":5682702,"9409":4907713,"9410":5682702,"9411":4907713,"9412":3613423,"9413":3228981,"9414":5264222,"9415":3228981,"9416":5863413,"9417":5264222,"9418":5863413,"9419":5863413,"9420":5264222,"9421":5863413,"9422":5702778,"9423":5702778,"9424":5702778,"9425":4674925,"9426":5702778,"9427":5047648,"9428":5047648,"9429":4590893,"9430":5852772,"9431":4590893,"9432":4590893,"9433":5052963,"9434":2396624,"9435":2396624,"9436":2396624,"9437":4776972,"9438":2396624,"9439":4776972,"9440":4810948,"9441":4810948,"9442":5656289,"9443":5909776,"9444":5656289,"9445":5656289,"9446":5656289,"9447":3406192,"9448":3552315,"9449":3311713,"9450":3311713,"9451":2635353,"9452":5508798,"9453":2635353,"9454":2635353,"9455":4691672,"9456":2635353,"9457":5808274,"9458":5808274,"9459":4691672,"9460":5808274,"9461":5808274,"9462":5808274,"9463":4173437,"9464":3276927,"9465":4173437,"9466":3276927,"9467":3276927,"9468":4173437,"9469":5773205,"9470":3881751,"9471":5595267,"9472":5595267,"9473":2822946,"9474":2822946,"9475":4872285,"9476":4872285,"9477":4872285,"9478":3441280,"9479":4872285,"9480":4872285,"9481":5002172,"9482":4898395,"9483":3311713,"9484":3881751,"9485":5002172,"9486":5002172,"9487":4804512,"9488":5133075,"9489":4793173,"9490":5118645,"9491":4793173,"9492":4625433,"9493":3642008,"9494":5771357,"9495":3642008,"9496":5133075,"9497":5133075,"9498":4166382,"9499":4166382,"9500":4166382,"9501":4166382,"9502":2908852,"9503":3441280,"9504":5771357,"9505":5573922,"9506":2908852,"9507":4898395,"9508":4280366,"9509":3716952,"9510":3580622,"9511":3716952,"9512":3716952,"9513":3716952,"9514":3716952,"9515":3504298,"9516":3504298,"9517":5835896,"9518":5133075,"9519":4808857,"9520":4779585,"9521":4779585,"9522":5133075,"9523":3628802,"9524":3628802,"9525":5772830,"9526":5892275,"9527":2762857,"9528":2762857,"9529":4251615,"9530":2762857,"9531":5892275,"9532":2762857,"9533":4870813,"9534":5686687,"9535":2762857,"9536":4928948,"9537":4928948,"9538":3559346,"9539":3559346,"9540":5086025,"9541":5086025,"9542":5086025,"9543":5086025,"9544":5086025,"9545":5086025,"9546":3965881,"9547":3965881,"9548":3965881,"9549":3965881,"9550":3965881,"9551":3965881,"9552":3338089,"9553":3338089,"9554":4334844,"9555":4334844,"9556":3528484,"9557":3528484,"9558":3528484,"9559":3528484,"9560":3528484,"9561":3528484,"9562":3778304,"9563":3778304,"9564":5971505,"9565":5971505,"9566":5971505,"9567":5971505,"9568":5971505,"9569":5971505,"9570":2039813,"9571":2039813,"9572":2039813,"9573":5131536,"9574":5131536,"9575":5131536,"9576":5131536,"9577":5131536,"9578":5131536,"9579":3412848,"9580":5354029,"9581":5354029,"9582":5354029,"9583":5354029,"9584":5614960,"9585":5614960,"9586":5614960,"9587":5614960,"9588":5511020,"9589":5511020,"9590":5511020,"9591":5511020,"9592":5511020,"9593":5511020,"9594":5073953,"9595":5073953,"9596":5742508,"9597":5742508,"9598":5742508,"9599":5742508,"9600":5120636,"9601":5120636,"9602":3750435,"9603":3750435,"9604":3750435,"9605":3750435,"9606":3750435,"9607":3750435,"9608":4946267,"9609":4946267,"9610":4946267,"9611":3590543,"9612":3590543,"9613":3590543,"9614":3590543,"9615":3590543,"9616":3590543,"9617":4689520,"9618":4689520,"9619":4689520,"9620":4689520,"9621":4689520,"9622":2265739,"9623":2265739,"9624":2265739,"9625":2265739,"9626":2265739,"9627":2265739,"9628":4604289,"9629":4604289,"9630":4604289,"9631":4604289,"9632":4604289,"9633":4604289,"9634":5536558,"9635":5536558,"9636":5536558,"9637":5536558,"9638":5536558,"9639":5536558,"9640":2935390,"9641":2935390,"9642":2935390,"9643":4224669,"9644":4224669,"9645":4224669,"9646":4224669,"9647":4224669,"9648":4224669,"9649":4923578,"9650":4923578,"9651":4923578,"9652":4923578,"9653":4233044,"9654":4233044,"9655":4233044,"9656":4233044,"9657":4233044,"9658":4233044,"9659":4796524,"9660":4796524,"9661":4796524,"9662":4796524,"9663":4796524,"9664":5030464,"9665":5030464,"9666":5030464,"9667":5030464,"9668":5030464,"9669":5030464,"9670":3087029,"9671":3087029,"9672":3087029,"9673":3087029,"9674":3087029,"9675":3087029,"9676":4668172,"9677":4668172,"9678":4668172,"9679":4668172,"9680":4668172,"9681":3785973,"9682":3785973,"9683":3785973,"9684":3785973,"9685":3898429,"9686":3898429,"9687":3898429,"9688":3898429,"9689":3898429,"9690":3713669,"9691":3018908,"9692":3018908,"9693":3018908,"9694":3018908,"9695":3018908,"9696":3018908,"9697":5937443,"9698":5937443,"9699":5937443,"9700":5937443,"9701":5937443,"9702":4600913,"9703":4600913,"9704":4600913,"9705":4600913,"9706":4600913,"9707":4600913,"9708":5442201,"9709":3714520,"9710":3714520,"9711":3714520,"9712":3714520,"9713":3714520,"9714":5053082,"9715":5053082,"9716":5053082,"9717":5053082,"9718":5053082,"9719":5729670,"9720":5729670,"9721":5729670,"9722":5729670,"9723":5729670,"9724":3266479,"9725":3266479,"9726":3266479,"9727":3266479,"9728":3781572,"9729":3781572,"9730":1693558,"9731":1693558,"9732":1693558,"9733":1693558,"9734":1693558,"9735":5585595,"9736":5585595,"9737":4689777,"9738":4689777,"9739":4689777,"9740":4689777,"9741":4689777,"9742":4163237,"9743":4163237,"9744":4163237,"9745":4994121,"9746":4994121,"9747":4994121,"9748":4994121,"9749":4994121,"9750":3611071,"9751":3611071,"9752":3611071,"9753":3611071,"9754":3611071,"9755":3611071,"9756":3611071,"9757":4812817,"9758":4812817,"9759":4812817,"9760":4812817,"9761":4812817,"9762":4812817,"9763":4324478,"9764":4324478,"9765":4324478,"9766":4324478,"9767":5643294,"9768":5643294,"9769":5643294,"9770":5643294,"9771":5643294,"9772":5643294,"9773":3726903,"9774":3726903,"9775":4206289,"9776":4206289,"9777":4206289,"9778":4537543,"9779":4537543,"9780":4537543,"9781":4537543,"9782":4537543,"9783":4015540,"9784":4015540,"9785":4015540,"9786":4015540,"9787":4046846,"9788":4046846,"9789":4046846,"9790":3644688,"9791":3644688,"9792":4173331,"9793":4173331,"9794":4888027,"9795":4888027,"9796":4888027,"9797":4888027,"9798":4323432,"9799":4323432,"9800":4323432,"9801":4323432,"9802":4323432,"9803":4937273,"9804":4937273,"9805":5530572,"9806":5530572,"9807":5530572,"9808":3266642,"9809":3266642,"9810":3266642,"9811":5562134,"9812":4127855,"9813":4127855,"9814":2781775,"9815":4904283,"9816":3133979,"9817":4480825,"9818":4324609,"9819":4324609,"9820":4324609,"9821":3269087,"9822":4796446,"9823":4796446,"9824":4796446,"9825":5771358,"9826":5771358,"9827":4239746,"9828":4239746,"9829":4239746,"9830":3838646,"9831":3838646,"9832":4160145,"9833":4160145,"9834":4640056,"9835":4640056,"9836":4640056,"9837":3856388,"9838":3856388,"9839":4064768,"9840":4064768,"9841":4064768,"9842":5120251,"9843":3750227,"9844":3750227,"9845":3488813,"9846":3488813,"9847":3488813,"9848":5655920,"9849":5655920,"9850":5655920,"9851":5075282,"9852":5075282,"9853":5075282,"9854":5075282,"9855":3480944,"9856":3480944,"9857":3889827,"9858":3889827,"9859":3889827,"9860":4713759,"9861":4713759,"9862":4054662,"9863":4054662,"9864":4054662,"9865":4054662,"9866":4054662,"9867":3602032,"9868":3602032,"9869":5774613,"9870":5774613,"9871":5774613,"9872":5685077,"9873":5685077,"9874":4382580,"9875":4382580,"9876":4382580,"9877":3747459,"9878":3357231,"9879":3357231,"9880":3357231,"9881":3357231,"9882":3357231,"9883":3357231,"9884":4639684,"9885":3821124,"9886":3821124,"9887":4996097,"9888":4776406,"9889":4776406,"9890":4776406,"9891":4776406,"9892":3590825,"9893":3590825,"9894":5414231,"9895":5414231,"9896":3726903,"9897":3726903,"9898":3726903,"9899":4206289,"9900":4537543,"9901":3499334,"9902":3499334,"9903":3499334,"9904":3499334,"9905":4015540,"9906":4046846,"9907":4046846,"9908":3644688,"9909":3644688,"9910":3644688,"9911":4173331,"9912":4173331,"9913":4173331,"9914":4173331,"9915":4888027,"9916":4888027,"9917":4323432,"9918":4937273,"9919":4937273,"9920":4937273,"9921":5530572,"9922":5530572,"9923":3266642,"9924":3266642,"9925":3266642,"9926":5562134,"9927":5562134,"9928":4127855,"9929":4127855,"9930":4127855,"9931":2781775,"9932":2781775,"9933":4904283,"9934":4904283,"9935":4904283,"9936":3133979,"9937":3133979,"9938":3133979,"9939":3133979,"9940":3133979,"9941":4480825,"9942":5839221,"9943":5839221,"9944":5839221,"9945":5839221,"9946":5839221,"9947":4324609,"9948":4324609,"9949":4324609,"9950":3269087,"9951":3269087,"9952":3269087,"9953":3269087,"9954":3269087,"9955":4796446,"9956":5771358,"9957":5771358,"9958":5771358,"9959":4239746,"9960":4239746,"9961":4239746,"9962":3838646,"9963":3838646,"9964":4160145,"9965":4160145,"9966":4640056,"9967":4640056,"9968":4748830,"9969":4748830,"9970":4748830,"9971":4748830,"9972":4748830,"9973":3856388,"9974":4064768,"9975":4064768,"9976":5120251,"9977":5120251,"9978":5120251,"9979":3750227,"9980":3750227,"9981":5655920,"9982":5655920,"9983":5075282,"9984":5075282,"9985":5390629,"9986":5390629,"9987":3889827,"9988":4713759,"9989":3602032,"9990":3602032,"9991":3602032,"9992":3602032,"9993":5774613,"9994":5774613,"9995":5685077,"9996":5685077,"9997":4382580,"9998":4382580,"9999":4382580,"10000":3747459,"10001":3747459,"10002":3747459,"10003":4639684,"10004":4639684,"10005":4639684,"10006":4639684,"10007":4639684,"10008":3821124,"10009":4996097,"10010":4996097,"10011":3590825,"10012":3590825,"10013":5414231,"10014":5414231,"10015":5414231,"10016":5414231,"10017":4202567,"10018":4202567,"10019":2871176,"10020":3580134,"10021":4918678,"10022":5673730,"10023":4365564,"10024":5593173,"10025":5362210,"10026":3000449,"10027":3793419,"10028":5742427,"10029":3688436,"10030":5593355,"10031":4149239,"10032":4273016,"10033":5856907,"10034":4329409,"10035":3327628,"10036":5927490,"10037":4701161,"10038":2954378,"10039":3511173,"10040":4065461,"10041":4280732,"10042":5954168},"Outcome":{"0":"IL-6r (ng\/ml)","1":"Incidence of minor hypoglycaemia","2":"Dysmenorrhea scores","3":"Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%","4":"Berg Balance Scale score","5":"HOMA-IR","6":"HbA1c level at 26 weeks","7":"Parasite clearance at day 2","8":"Physical performance battery scores","9":"Reductions in systolic blood pressure","10":"Parasitaemias associated with gametocytaemia","11":"Pulse variations","12":"Pain relief: Epidural anesthesia","13":"Pulse variations","14":"Incidence of minor hypoglycaemia","15":"Changes in calcitonin at week 26","16":"Postprandial plasma glucose","17":"ADA fasting plasma glucose goals between 5.0 mmol\/l and less than 7.2 mmol\/l","18":"attain 8 weeks continuous abstinence from weeks 19 through 26","19":"Postprandial plasma glucose","20":"Locomotor-training effects","21":"HbA1c level at 26 weeks","22":"Recurrent infections at day 56","23":"Baseline white blood cell count","24":"Paretic step length ratio","25":"Superiority of treatment given by survival curves","26":"Headache","27":"HbA1c level at 26 weeks","28":"Bleeding during surgery","29":"Proinsulin : insulin ratio","30":"Postprandial plasma glucose","31":"Self-selected overground walk velocity","32":"Fever resolution by day 1","33":"Pruritus","34":"ADA postprandial plasma glucose goals less than 10.0 mmol\/l","35":"ADA fasting plasma glucose goals between 5.0 mmol\/l and less than 7.2 mmol\/l","36":"Proinsulin : insulin ratio","37":"Labour dystocia","38":"Pain killers intake","39":"ADA fasting plasma glucose goals between 5.0 mmol\/l and less than 7.2 mmol\/l","40":"C-reactive protein (mg\/l)","41":"Postpartum haemorrhage","42":"Serious adverse events","43":"Care-seeking from unqualified providers (such as village doctors) for ill newborns ","44":"Prolonged abstinence from smoking rates to 6 months","45":"The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents of patients with ARDS","46":"Reductions in systolic blood pressure","47":"Severity of pain","48":"Incidence of minor hypoglycaemia","49":"Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%","50":"Changes in calcitonin at week 26","51":"Fasting plasma glucose at week 26","52":"ADA postprandial plasma glucose goals less than 10.0 mmol\/l","53":"Oxytocin infusion for augmentation of labour","54":"Postprandial plasma glucose","55":"Reduction of daily cigarette consumption and cotinine","56":"Fasting plasma glucose at week 26","57":"Parasite clearance at day 1","58":"HOMA-B","59":"Procalcitonin, IL 8, IL 10, endothelial leukocyte adhesion molecule-1, intercellular adhesion molecule-1, troponin-I","60":"Nodules diameters","61":"Care-seeking from qualified providers for ill newborns ","62":"Pain relief: Acupuncture","63":"Improvement in lower extremity Fugl-Meyer score ","64":"Extend of the disease as visualized during surgery","65":"The survival rate \/ overall mortality of patients with ARDS","66":"Postprandial plasma glucose","67":"Haemoglobin concentration","68":"Prolonged abstinence from smoking rates to 6 months","69":"HOMA-B","70":"HOMA-IR","71":"Endometrial thickness","72":"Fasting plasma glucose at week 26","73":"IL-6 (pg\/ml)","74":"Reductions in systolic blood pressure","75":"Pain estimates after surgery","76":"Late Life Function and Disability Instrument","77":"Decreases in diastolic blood pressure","78":"Pulse variations","79":"Self-selected overground walk velocity","80":"Cardiac index ","81":"Fasting plasma glucose at week 26","82":"Reductions in systolic blood pressure","83":"Care-seeking from the Kumudini Hospital for ill newborns ","84":"Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%","85":"HOMA-B","86":"Patients reaching HbA1c goals less than 7.0% ","87":"systemic vascular resistance","88":"HbA1c level at 26 weeks","89":"ADA postprandial plasma glucose goals less than 10.0 mmol\/l","90":"Perineal outcome: the number of episiotomies or the incidence of sphincter injuries","91":"6-minute walk test","92":"Tissue examination by routine pathology","93":"Proinsulin : insulin ratio","94":"Cure rate at day 28","95":"Macroscopic aspect of the tissue","96":"Fever resolution by day 2","97":"Fasting plasma glucose at week 26","98":"ADA postprandial plasma glucose goals less than 10.0 mmol\/l","99":"Proinsulin : insulin ratio","100":"HbA1c level at 26 weeks","101":"Decreases in diastolic blood pressure","102":"Prolonged abstinence from smoking rates to 12 months","103":"obstetric\/postpartum infection or gynecologic\/postoperative infection","104":"Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%","105":"HbA1c level at 26 weeks","106":"Prolonged abstinence from smoking rates to 12 months","107":"HOMA-B","108":"Neonatal outcomes were evaluated by Apgar score <7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth","109":"ADA fasting plasma glucose goals between 5.0 mmol\/l and less than 7.2 mmol\/l","110":"Complications after surgery","111":"Complications and mortality","112":"Time to first COPD exacerbation","113":"The primary arteriovenous fistula failures at two months","114":"1-hour post-dose FEV1 improvements","115":"Information recall","116":"The analysis using the dichotomization of GOS scores at 6 months post injury","117":"Mean FEV1 at 12 hours at end of treatment","118":"Scar width","119":"Fusion rate","120":"Minnesota living with heart failure (MLHF) questionnaire baseline scores","121":"Sleep score improvement","122":"Peak expiratory flow in the morning and evening ","123":"mean Hb","124":"Need for opiates","125":"Quit attempt of 1 week or longer reported at 3 months","126":"Local recurrence rate through the study","127":"Higher-order aberrations during the study","128":"Heart failure-related quality of life at the end of treatment","129":"Overall survival rate at 5 years","130":"Blood loss during surgery","131":"Baseline-adjusted average 12-hour FEV1 at end of treatment","132":"Puerperal and neonatal infection rates ","133":"1-hour post-dose inspiratory capacity mean improvements from baseline to the average over the randomized treatment period","134":"Infection of the surgical site","135":"Amount of exacerbations per patient-treatment year","136":"Uncorrected distance visual acuity at 1 month","137":"Smaller incision ","138":"clinical outcomes","139":"Overall use of daily rescue medication improvement","140":"Urinary retention","141":"Overall survival","142":"Procedure performed directly by the staff surgeon","143":"Corrected distance visual acuity at 6 months","144":"Patients infected with T. vaginalis","145":"Time to treatment failure","146":"cognitive functioning","147":"Urgency score improvement","148":"negative correlation between CSF protein and duration of mechanical ventilation","149":"Hospital stay","150":"Time to nasogastric decompression","151":"side effects","152":"Hospital permanence","153":"Adverse Events","154":"Contrast sensitivity at 3 months seen at 3 cpd","155":"Visual analog scale pain score at day 3","156":"Average patient's weight","157":"Visual analog scale pain score at day 1","158":"Anxiety","159":"Cough score improvement","160":"The analysis using the dichotomization of GOS scores at 3 months post injury","161":"Programme meeting attendance","162":"Urgency score improvement","163":"Prognosis information given","164":"Contrast sensitivity at 1 month seen at 3 cpd","165":"Smoking cessation at 6 months","166":"Baseline cotinine level","167":"Knee injury and Osteoarthritis Outcome Score quality of life subscale at 6 months","168":"Mean FEV1 at 12 hours on the day of randomization","169":"Smoking reduction at 3 months","170":"1-hour post-dose FEV1 improvements","171":"Baseline hypertension","172":"Intake of STI treatment","173":"Adverse events","174":"24-hour urinary cortisol at 6 months","175":"Baseline diabetes","176":"Secondary school education","177":"Pain on day three after surgery","178":"Baseline smoking habits","179":"First hemodialysis success","180":"Baseline life-quality score","181":"Prognosis enquiry","182":"Cardiac complications","183":"Time to discontinuation","184":"Breathlessness Cough and Sputum Scale improvement","185":"Gender","186":"Functional performance improvement","187":"Baseline nicotine dependence variables","188":"Pain on day one after surgery","189":"Urgency score improvement","190":"Self-reported STI symptoms","191":"Better cosmetic appearance of the incision as subjectively assessed by patients","192":"Knowledge about heart failure","193":"Dyspnoea score improvement","194":"Genital discharge history","195":"Baseline beta-blockers intake","196":"Breathlessness Cough and Sputum Scale improvement","197":"Visual analogue scale scores for efficacy","198":"Side effects","199":"Corrected distance visual acuity at 1 month","200":"Self-efficacy","201":"The mean intracranial pressure values 72 hours and 7 days after injury","202":"Baseline CO level","203":"Inhaling less smoke, measured at 3 months","204":"Overall response rates","205":"Visual analog scale pain score at day 7","206":"Quit attempt of 1 week or longer reported at 6 months","207":"Incidence of pneumonia","208":"Spatial mobility","209":"Grade 3\/4 digestive system toxic events","210":"Dyspnoea score improvement","211":"Smoking habits at 6 months","212":"Sleep score improvement","213":"unadjusted risk of recurrent falciparum parasitemia","214":"Baseline-adjusted average 12-hour FEV1 on the day of randomization","215":"Smoking cessation at 3 months","216":"Micturition frequency","217":"Cough score improvement","218":"Mean of sum of number, duration and severity of exacerbations during 6 months of treatment","219":"The duration of phototherapy","220":"Awakening-free nights percentage improvement","221":"Pre-dose inspiratory capacity","222":"Overall use of daily rescue medication improvement","223":"Infection","224":"Total serum bilirubin level","225":"Sepsis related Organ-Failure Assessment (SOFA) baseline scores","226":"Higher-order aberrations at 6 months","227":"Wound complications","228":"Clinical response rates at 14 weeks","229":"Contrast sensitivity","230":"Cough score improvement","231":"Quality of life","232":"Pediatric Intensive Care Unit (PICU) stay","233":"Pre-dose inspiratory capacity","234":"Peak expiratory flow in the morning and evening ","235":"The modified Functional Independence Measure scores","236":"Baseline systolic dysfunction","237":"1-hour post-dose inspiratory capacity mean improvements from baseline to the average over the randomized treatment period ","238":"Sputum expectoration during a single session","239":"Ulcer mean diameter","240":"Refractory intracranial pressure","241":"Baseline-adjusted average 12-hour FEV1 at end of treatment","242":"Sputum score improvement","243":"Uncorrected distance visual acuity at 3 months","244":"Pain on walking","245":"Average patient's lenght","246":"Baseline angiotensin II receptor blockers (ARBs) intake","247":"Disease-free survival rate at 5 years","248":"HIV-1 prevalence","249":"Improvements in St. George's Respiratory Questionnaire overall score","250":"Baseline digoxin intake","251":"Baseline-adjusted average 12-hour FEV1 on the day of randomization","252":"Incisional hernia apparition at follow-up","253":"Smoking less of a cigarette, measured at 3 months","254":"Median labour time","255":"the risk of recurrent parasitemia due to possible recrudescence","256":"Analgesics use","257":"Time to discontinuation","258":"Baseline-adjusted average 12-hour FEV1 on the day of randomization","259":"Baseline angiotensin-converting enzyme (ACE) inhibitors intake","260":"Contrast sensitivity","261":"Improvements in St. George's Respiratory Questionnaire overall score","262":"Rate of complications","263":"Baseline demographic differences","264":"Trouble in breathing, dyspnea in the morning and dyspnea at rest","265":"Peak expiratory flow in the morning and evening ","266":"High-risk sexual behaviour","267":"24-hour urinary cortisol at end of treatment","268":"Amount of exacerbations per patient-treatment year","269":"Pre-dose FEV1 improvement","270":"Overall use of daily rescue medication improvement","271":"Baseline quit motivation","272":"Postoperative complications","273":"Visual analogue scale scores for urinary leakage","274":"Median loss of blood","275":"Hospital stay","276":"Peak expiratory flow in the morning and evening ","277":"the parasitological and clinical failure rate at day 28 post treatment","278":"Time to first COPD exacerbation","279":"percentage changes in area","280":"Quality of life","281":"internal work","282":"7-day point prevalence abstinence","283":"Improvement in bowel habit","284":"percentage changes in area","285":"Full return to normal work\/employment","286":"Wearing clothes that show the legs","287":"The median stay in hospital","288":"The visual analog scale scores at rest and on coughing","289":"Postnatal depression (Edinburgh Postnatal Depression Scale17 EPDS)","290":"Decrease in haematocrit level at day 7","291":"quality-of-life ","292":"Bending the legs without discomfort","293":"walking short distances without discomfort, walking long distances, looking after children, full return to normal work\/employment","294":"Indralupta is a unique, idiopathic, non-cictricial, non-inflammatory alopecia, presents as discoid areas of hair loss.","295":"pain","296":"Virological failure","297":"Gel efficacy in consistent gel users","298":"six-minute walk test","299":"low\u2013glycemic index","300":"Adverse events","301":"Having a bath or shower","302":"transurethral resection (TUR) syndrome","303":"8-year survivorship in patients with osteoarthritis","304":"The 24 h morphine requirement","305":"transurethral resection (TUR) syndrome","306":"Levels of LDL cholesterol after 6 weeks of treatment","307":"global assessment of improvement","308":"Health care burden","309":"P. vivax parasitaemia diagnosed during follow up","310":"wound problem","311":"Overall survival at 3 years","312":"Birth weight (kg), Birth weight centile, Small for gestational age, Macrosomia, Infant head circumference, Infant length (cm), Ponderal index (kg\/m3), Maternal weight gain (kg), Insulin treatment, Emergency caesarean","313":"Gel efficacy in inconsistent gel users","314":"Preterm delivery","315":"Costs for the health service","316":"Mean change in nodular consistency and hardness","317":"Doing housework","318":"rebleeding","319":"The mean drainage duration","320":"Self-detected pulse irregularity and outcome events","321":"did not attempt to quit smoking at all","322":"Pre-dose FEV1 improvement","323":"Baseline-adjusted average 12-hour FEV1 on the day of randomization","324":"Mean FEV1 at 12 hours at end of treatment","325":"Better cosmetic appearance of the incision as subjectively assessed by surgeons","326":"Awakening-free nights percentage improvement","327":"SF-36 Mental Component Summary scale at 6 weeks","328":"Amount of exacerbations per patient-treatment year","329":"Mean FEV1 at 12 hours on the day of randomization","330":"Mean FEV1 at 12 hours on the day of randomization","331":"1 line or more of CDVA at 6 months","332":"Mean FEV1 at 12 hours at end of treatment","333":"Micturition frequency","334":"Infection","335":"FEV1%","336":"side effects","337":"Hospitalization or death","338":"Sputum score improvement","339":"Daily weight monitoring at the end of treatment","340":"Incidence of pneumonia","341":"1-hour post-dose FEV1 improvements","342":"Episiorraphy dehiscence rates","343":"Visual analogue scale scores for comfort","344":"Surgery duration","345":"Need for ICU ","346":"Mean FEV1 at 12 hours on the day of randomization","347":"Instances of complications and adverse events","348":"Hypotension","349":"The mortality rate","350":"50% reduction in pain","351":"Radiological fusion","352":"Postoperative complications","353":"Knee injury and Osteoarthritis Outcome Score","354":"Skin-to-skin time","355":"Contrast sensitivity at 1 month seen at 12 cpd","356":"Incidence of pneumonia","357":"Sputum expectoration between treatments in a 24-hour period","358":"HIV-1 incidence","359":"Postoperative Mortality","360":"Pre-dose inspiratory capacity","361":"Changes in Bishop score after 6 hours","362":"Incidence of pneumonia","363":"Dyspnea during exercise","364":"Intracranial pressure recurrence after treatment withdrawal","365":"Breathlessness Cough and Sputum Scale improvement","366":"Induction time","367":"Dry skin at the application site","368":"Amount of exacerbations per patient-treatment year","369":"Better scar appearance score as measured by visual analog scale","370":"Pre-dose inspiratory capacity","371":"Scar length","372":"1-hour post-dose inspiratory capacity mean improvements from baseline to the average over the randomized treatment period ","373":"change of FVC and VC","374":"O2 saturation","375":"Duration of surgery","376":"Baseline characteristics","377":"Cardiac-related hospitalization","378":"Period of mechanical ventilation ","379":"Dyspnoea score improvement","380":"SF-36 Mental Component Summary scale at 6 months","381":"Surgery duration","382":"Contrast sensitivity at 6 months seen at 3 cpd","383":"Socio-economic position","384":"Ulcer location ","385":"Transfusion requirements","386":"Uncorrected distance visual acuity at 6 months","387":"Adverse events","388":"1-hour post-dose inspiratory capacity mean improvements from baseline to the average over the randomized treatment period ","389":"HIV\/AIDS meeting attendance","390":"Baseline-adjusted average 12-hour FEV1 at end of treatment","391":"good or very good PGA response and OMERACT-OARSI responder","392":"Sleep score improvement","393":"Sleep score improvement","394":"Intracranial pressure control","395":"Mean barbiturate coma length","396":"Cough score improvement","397":"parasitological or clinical failure rates by day 14 or day 28 in G6PD deficient children","398":"Sepsis related Organ-Failure Assessment (SOFA) maximum score during treatment","399":"Pre-dose FEV1 improvement","400":"Improvements in St. George's Respiratory Questionnaire overall score","401":"could walk unaided within four weeks after PICU discharge","402":"Pain on day two after surgery","403":"Administration of hyperosmolar treatments","404":"Apolipoprotein-B levels after 6 weeks of treatment","405":"Patients attaining the NCEP ATP III goal","406":"Adverse events","407":"Quality-adjusted survival times","408":"6- and 12-month survival probabilities","409":"birth weight, birth weight centile, prevalence of macrosomia, insulin treatment, adverse pregnancy outcomes","410":"Total mortality and 30-day mortality","411":"drainage duration","412":"Knee injury and Osteoarthritis Outcome Score quality of life subscale at 6 weeks","413":"pain during movement","414":"Pain on rest (0-10)","415":"Antenatal attendances","416":"Mother-to-infant bonding","417":"weight change","418":"The 10mWT (10-m walking test )","419":"trunk strength (BPR score)","420":"HbA1c at 12 or 24 months.","421":"contact time","422":"stride frequency","423":"Lifting heavy objects without discomfort","424":"Walking long distances (> 20 min)","425":"Partial return to normal work\/employment","426":"Going out socially","427":"Sporting activity or exercise","428":"Bending the legs without discomfort, Lifting heavy objects without discomfort, Moving from standing to sitting without discomfort, Standing still for a long time (> 15 min) without discomfort, Walking short distances (< 20 min) without discomfort, Walking long distances (> 20 min), Driving a car, Doing housework, Looking after children, Partial return to normal work\/employment, Full return to normal work\/employment, Going out socially, Sporting activity or exercise, ","429":"preoperative anxiety","430":"global assessment of improvement","431":"pyridinoline","432":"Mortality rates","433":"Admission diagnoses","434":"Increase in CD4-cell counts","435":"decrease in abdominal pain and distension severity","436":"Progression-free survival after 3 years","437":"6-month prolonged abstinence","438":"Need of feeding tube","439":"Candida sp. colonisation during the study","440":"8-year survivorship","441":"Levels of non-high-density lipoprotein cholesterol after 6 weeks of treatment","442":"Changes in glucose and insulin levels","443":"Fever clearance times","444":"New P. falciparum infections during the 42-day follow-up","445":"PCR-adjusted cure rates after 42 days","446":"Adverse events","447":"Overall survival","448":"Quality-of-life scores","449":"Duration of median PFS","450":"Overall survival time","451":"degree of relief of all analysed symptoms","452":"Continuous abstinence at 6 months","453":"The incidence of bacterial infection","454":"Enteric bacteria","455":"overall drain output","456":"Sequential Organ Failure Assessment (SOFA) score ","457":"The 28-day mortality","458":"Qualeffo Total (0-100)","459":"Timed loaded standing test (s)","460":"perceived functional deficits","461":"Fatigue severity scale","462":"Body mass index (BMI)","463":"Center for Epidemiologic Studies Depression Scale (CES-D)","464":"Smoking cessation","465":"he Berg Balance Scale (BBS), Timed Up and Go Test (TUG), Functional Reach Test (FRT), the Korean version of the Fall Efficacy Scale-International (KFES-I) ","466":"stride length","467":"datasets of 3D coordinates","468":"Moving from standing to sitting without discomfort","469":"Driving a car","470":"Looking after children","471":"Bending the legs without discomfort, lifting heavy objects without discomfort, Moving from standing to sitting without discomfort, Standing still for a long time (> 15 min) without discomfort, Driving a car, Doing housework, Partial return to normal work\/employment, Going out socially, Sporting activity or exercise","472":"postoperative satisfaction","473":"beta-isomer of carboxy-terminal telopeptide of type I collagen","474":"Appetite loss","475":"hospital costs per patient for the course of IV therapy","476":"In the intention-to-treat analysis, complete healing of the index ulcer","477":"Sputum expectoration over a 24-hour period","478":"Overall survival time","479":"Progression-free survival","480":"Moving from standing to sitting without discomfort","481":"Doing housework","482":"Wearing clothes that show the legs","483":"Bending the legs without discomfort, lifting heavy objects without discomfort, Moving from standing to sitting without discomfort, Standing still for a long time (>?15 min) without discomfort, Driving a car, Doing housework, Partial return to normal work\/employment, Going out socially, Sporting activity or exercise","484":"walking short distances without discomfort, walking long distances, looking after children, full return to normal work\/employment","485":"mean of HCV-RNA numbers at the end of treatment ","486":"hsCRP, TNF, MCP-1, IFN-?, any of the interleukins","487":"comfortable gait speed and fast gait speed ","488":"The proportion of patients present at the ADDO who received a diagnostic test ","489":"overall survival of patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF)","490":"discontinued treatment","491":"rate of intubations","492":"gene expression of transforming growth factor beta (TGF-?), protein kinase C (PKC), mitogen-activated protein kinases 1 (MAPK1) ","493":"nuclear factor kappa B (NF-kB), interleukin (IL)-4, IL-6, and vascular endothelial growth factor (VEGF) ","494":"By month 12, the proportion surviving with a functioning graft","495":"glutathione red-ox ratio","496":"On average (median) pain in the paediatric population","497":"peak FEV1","498":"Dose-dependent changes from baseline in trough FEV1","499":"breathlessness, leg discomfort, chest tightness to exercise cessation were not significantly different across treatments.","500":"Estimation of underreported calcium as daily calcium intake increased","501":"The mean time to remove both tubal segments","502":"Postoperative pain at 6 hours","503":"thickness of the keratinized tissue (TKT)","504":"17-hydroxy progesterone and testosterone levels","505":"completion of each dose at the correct time","506":"cold perception thresholds","507":"Cardiac index, catecholamines ICU-stay and mortality (1 death in the control group)","508":"peak CKMB","509":"maximum total point motion (MTPM)","510":"Beck Depression Inventory-II (BDI-II) after 4 months","511":"The hospital discharge rate of the patients with OHCA","512":"Full clinical responses","513":"Toxicity","514":"24-hour point prevalence abstinence","515":"Low birth weight ","516":"HIV-1 incidence","517":"Weight loss","518":"Aerobic Gram-negative bacilli colonisation at 3-5 weeks","519":"4-year survivorship","520":"Total cholesterol after 6 weeks of treatment","521":"total fecal counts of lactobacilli","522":"6- and 12-month survival probabilities","523":"Gametocyte dynamics","524":"Change from baseline in normalized FEV1 AUC0\u20136, FEV1 AUC0\u201312, and FEV1 AUC0\u20132","525":"The duration of nebulization","526":"Estimation of total daily calcium intake","527":"obtained calcium from dairy ","528":"preeclampsia risk in Hispanic Hp 2-2 women.","529":"preeclampsia risk","530":"Outpatient recovery","531":"Median 17-hydroxy progesterone and testosterone levels","532":"blood-stage infection","533":"Arithmetic","534":"Silent reading","535":"the result of frequency doubling technique (FDT) perimetry.","536":"birthweight, incidence of congenital birth defect and mean Apgar scores","537":"mean Apgar","538":"CKMB AUC and Troponin-T AUC","539":"In the per-protocol analysis, complete healing of the index ulcer","540":"Bending the legs without discomfort","541":"Lifting heavy objects without discomfort","542":"The overall satisfaction score","543":"Walking long distances (>?20 min)","544":"self-efficacy related to social pressure and restraint in overweight and obese endometrial cancer survivors.","545":"Looking after children","546":"14 (poly)phenol metabolites","547":"Bending the legs without discomfort, Lifting heavy objects without discomfort, Moving from standing to sitting without discomfort, Standing still for a long time (>?15 min) without discomfort, Walking short distances (<?20 min) without discomfort, Walking long distances (>?20 min), Driving a car, Doing housework, Looking after children, Partial return to normal work\/employment, Full return to normal work\/employment, Going out socially, Sporting activity or exercise, ","548":"neonatal outcome","549":"mean of HCV-RNA numbers 6 months after treatment ","550":"FMA-LE: the Fugl-Meyer Assessment of the lower extremity; SIAS: Stroke Impairment Assessment Set;","551":"TUG: Timed \"Up & Go\" test;","552":"Pre-treatment testing performed within the ADDO","553":"hospital-free survival of patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF)","554":"The percentage of patients with controlled blood pressure (<140\/90 mmHg)","555":"Primary outcome effect","556":"survival","557":"survival","558":"gene expression of interleukin (IL), tumor necrosis factor alpha (TNF-?), interferon gamma (IFN-?) ","559":"H. pylori eradication","560":"Number of positive screens","561":"Intracranial haemorrhage","562":"serum IL-8 levels at day-14","563":"day-14 in serum IL-28B, TNF-?, IL-1?, IL-1?, IL-6, IL-8, IL-10, IFN-?, MCP-1 and HGF","564":"Self-confidence in applying methods to deal with mental illness","565":"Patients striving for recovery","566":"serum ALT, AST, IL-8 or other inflammatory mediators","567":"sleep efficiency ","568":"Nicotine concentration after ad lib use","569":"Spatial Working Memory (SWM), Spatial Span (SSP), and Reaction Time (RTI) tasks","570":"Attrition after 12 months","571":"Systolic blood pressure","572":"LDL values","573":"fragmentation index","574":"Self-reported consumption of fruits and vegetables","575":"Self-reported consumption of sweets","576":"episodes of central apnea and ineffective efforts","577":"ACR20\/50\/70 response","578":"eGFR ","579":"Decrease in symptoms among patients with high immature defense style after 3 years","580":"the mean number of incontinence episodes\/24 h and the mean number of micturitions\/24 h","581":"Mean pain intensity","582":"Toxicity","583":"Mean disability","584":"Absolute increase in performance of insulin therapy for DM.","585":"Timed Up and Go test","586":"Western Ontario and McMaster Universities Osteoarthritis Index for pain","587":"O2sat, PaO2","588":"PaCO2 and Respiratory rates ","589":"incidence and intensity of shivering","590":"mean daily number of moderate to severe hot flushes at week 4","591":"HAMD17 total score,","592":"increase from baseline in the mean proportion of intermediate cells","593":"improvement in the women's most bothersome vulvovaginal atrophy symptoms","594":"femoral head necrosis (FHN)","595":"the head survival rate","596":"reduction in the incidence of dyspareunia","597":"vastus lateralis obliquus (VLO) EMG activity","598":"serum TC and non-HDL-C levels ","599":"the appearance time of the MSG symptom complex","600":"intraocular pressure (IOP)-lowering medications","601":"reduction in pain","602":"flow-mediated vasodilation (FMD)","603":"Mean \u00b1 SD patient global assessment scores at the end of the SR phase","604":"average daily feed intake (ADFI)","605":"gain:feed","606":"Long-term adherence to the program","607":"Total adherence to the program","608":"Savings in drugs and dispensing costs","609":"Hemodynamic data","610":"Improvement in the Hamilton Rating Scale for Depression at 24 weeks","611":"Mean visual analog scale","612":"Mean visual analog scale","613":"Glucometric random blood sugar at 24 hours","614":"Improvement in SF-36 physical component score","615":"Breath hold time","616":"The median duration of exclusive breastfeeding","617":"website use and terms of the number of pages visited and terms of time on the website","618":"focused on the social presence elements in terms of frequency and duration","619":"Use of health care services","620":"confirmed disability progression","621":"names forgotten, numbers forgotten, memory impairment in recalling special events in life, forgetfulness, losing of valuables, difficulty in remembering multiple items to be purchased, inability to concentrate, impaired recognition, memory impairment of recall of previous histories, difficulty in recalling information quickly, depression, and inability to relax ","622":"Smoking abstinence after 2 weeks","623":"Overall survival","624":"the Gag response rate","625":"Symptom severity after 8 weeks ","626":"VO2peak tended","627":"Risk of hypotension","628":"Abdominal pain and discomfort assessed using VAS scores, diaries, and IBS-QoL","629":"Thrombocytopenia rate","630":"performed on KABC-II Composite Index Simultaneous Processing and on subtest Rover","631":"Improvement in respiratory endurance","632":"Control of foul smell","633":"Control of infection","634":"Programme engagement","635":"Tobacco abstinence","636":"Serious adverse events","637":"Weight rebound after 12 months","638":"Change in body mass index","639":"Triglyceride levels","640":"Median AUC(inf)","641":"Numerical Rating Scale","642":"Western Ontario and McMaster Universities Osteoarthritis Index for stiffness","643":"Blood pH levels","644":"Systolic arterial pressure","645":"vastus medialis obliquus (VMO) EMG activity ","646":"vastus lateralis longus (VLL) EMG activity","647":"morphine doses","648":"The absolute risk for ?2 lost lines of vision","649":"repositioning error in flexion and right and left side-bending and reduction in pain","650":"postprandial FMD","651":"IgG concentrations","652":"IgM concentrations","653":"Meat cholesterol concentration","654":"saturated fatty acids (SFA), unsaturated fatty acids, poly unsaturated fatty acid (PUFA) or mono unsaturated fatty acid content in muscles","655":"Postoperative troponin T","656":"activation of p38 MAPK, ERK 1\/2 or levels of HSP27 and PKC-? in the human heart","657":"grade 2 of POM","658":"erythrocyte SOD, total glutathione, glutathione peroxidase, gene transcripts for interferon-gamma, interleukin-10, and interleukin-1? in blood","659":"plasma nitric oxide","660":"chondroitin sulfate-846 (CS) in synovial fluid (SF) and adjusted-PGE2, ","661":"confirmed disability progression","662":"high density lipoprotein (HDL)","663":"drop-out rates","664":"quality of treatment, the duration and the number of session, or whether their expectations for treatment had been met.","665":"Gag-specific IFN-? enzyme-linked immunospot\u2013determined response rates and geometric mean responses","666":"The GMTs","667":"Quality of life","668":"The incidence of adverse events","669":"the degree of symptom reduction in abdominal pain using symptom diaries from week 1 ","670":"mortality in old people with femoral neck fracture.","671":"absolute beta power (ABP) after exercise","672":"HCV RNA at day-14","673":"day-14 fasting serum glucose and the 2-hr glucose (Glucose-120 min) after an OGTT ","674":"awake time","675":"willingness?to?pay.","676":"the pH of urine","677":"serum creatinine","678":"mean volume voided\/micturition, mean level of urgency, mean number of urgency episodesand mean number of urgency incontinence episodes\/24 h","679":"the limits of stability (LOS) performance and one-leg stance (OLS) tests","680":"Mean central temperature, Mean peripheral temperature, Mean blood pressure, Mean heart rate","681":"mean daily number of moderate to severe hot flushes at week 12","682":"mean proportion of superficial cells","683":"reduction from baseline in the mean proportion of parabasal cells","684":"vaginal pH","685":"sexual function and total scores","686":"lumbar spine bone mineral density (BMD)","687":"risk for serious adverse events, such as venous thromboembolism, cardiovascular events, endometrial cancer, or breast cancer,","688":"serum glucose","689":"complete healing of the index ulcer at 1-year of follow-up","690":"proportion of words out of the total number of words","691":"The mean timing to analgesic administration","692":"Serum 25(OH)D concentrations","693":"prevalence of psychiatric inpatient admission","694":"reduction of total needs and the increase of met needs","695":"Eradication of H. pylori with homo EM genotype and those with hetero IM or PM genotype.","696":"ADI-R (algorithm for current condition), the Autism Behavioral Checklist (ABC), and the Autism Treatment Evaluation Checklist (ATEC) after 1 month","697":"Mean calculated GFR at 1 year.","698":"Total Antioxidative Activity","699":"all ten cytokines\/growth factors - IL-1, IL-1?, IL-6, IL-8, IL-1Ra, interferon-? (IFN-?), tumor necrosis factor-? (TNF-?), EGF, TGF-?, and vascular endothelial growth factor (VEGF)","700":"blood-stage infection","701":"Writing","702":"depression","703":"flavonols, valerolactones, benzoic acids, cinnamic acids, phenylacetic acids, benzaldehydes ","704":"12 (poly)phenol metabolites","705":"Short-term adherence to the program at 3 months","706":"Total adherence to the program","707":"Extra clinic visits and CT scans assessments","708":"Improvement in Presumptive Stressful Life Events Scale","709":"Relapse rates","710":"Glucometric random blood sugar at 24 hours","711":"Improvement in HAD anxiety score","712":"Depression mean scores","713":"Cigarettes smoked per day","714":"Symptom severity after 4 weeks ","715":"Five-minute Apgar score","716":"Bleeding rate after surgery","717":"Hb levels","718":"Lung function parameters","719":"Healing of diabetic wounds","720":"Time to relapse","721":"Risk of death","722":"Risk of thromboembolic events","723":"Negative feelings","724":"Baseline nicotine concentrations","725":"Peak inspiratory pressures","726":"clinical outcome","727":"The intensity of the MSG symptom complex (characterized by unpleasant reactions such as numbness, tingling, headaches, muscle tightness, general weakness, and flushing )","728":"Cataract progression","729":"mean \u00b1 SD investigator global assessment scores","730":"mean scores for the secondary efficacy variables and MMSE and ECOG scores","731":"'pain now PM'","732":"average daily gain (ADG) of Hanwoo steers","733":"concentration of stearic acid (C18:0) and linolenic acid (C18:3n-3)","734":"Postoperative myalgia (POM)","735":"Changes in heart rate after induction and intubation","736":"the incidence of POM","737":"erythrocyte SOD, total glutathione, glutathione peroxidase, gene transcripts for interferon-gamma, interleukin-10, and interleukin-1? in blood, and decreased plasma nitric oxide.","738":"serum cholesterol, serum triglyceride, low density lipoprotein (LDL), and very low density lipoprotein (VLDL) levels","739":"overall effect","740":"brachial and superficial femoral artery diameter, peak blood flow, and FMD","741":"The VAS scores of abdominal pain at week 4","742":"At early follow-up (3 months), total WOMAC scores Western Ontario and McMaster Universities Arthritis Index (WOMAC)","743":"At 18 months, the higher improvement in total WOMAC","744":"At 18 months, the higher improvement in total WOMAC","745":"The percentage of patients achieving the MCII for both pain and function at 18 months","746":"Proportions of REM sleep duration","747":"Reherniation","748":"the Treatment Satisfaction-Visual Analogue Scale (TS-VAS)","749":"directional control in the LOS test","750":"The nocturnal enuresis","751":"the parasitological and clinical failure rate at day 28 post treatment","752":"HDL-C levels","753":"the aortic cholesterol content","754":"The proportion of patients who received analgesics","755":"degree of relief of all analysed symptoms","756":"weight change","757":"Smoking cessation","758":"HbA1c at 12 or 24?months.","759":"ICER (incremental cost-effectiveness ratio)","760":"Having a bath or shower","761":"Partial return to normal work\/employment","762":"Full return to normal work\/employment","763":"Going out socially","764":"Sporting activity or exercise","765":"mean of HCV-RNA numbers in 12 weeks of therapy","766":"NF?B activity","767":"percentage of patients with controlled blood pressure","768":"hospital and ICU length of stay","769":"The proportion of patients who met the primary end point (composite of acute rejection, graft loss, death by month 6)","770":"glutathione red-ox ratio","771":"pain in the paediatric population","772":"peak FEV1","773":"difference in mean (SD) dairy calcium","774":"catheter related bladder discomfort During the first three days of post-operative period","775":"required tolterodine","776":"catheter related bladder discomfort On the fifth day after surgery","777":"International Prostate Symptom Score (IPSS), BPH Impact Index (BII), question 8 of the IPSS (IPSS-Q8)]","778":"risk of the primary outcome or preeclampsia","779":"patient adherence","780":"Completed treatment","781":"cold perception threshold, warm perception threshold, cold pain threshold and heat pain threshold","782":"Oral reading","783":"physical activity ","784":"The duration of wearing the accelerometer","785":"subsidence","786":"The proportion of \"at risk\" components at 5 years","787":"the rate of S. japonicum infection in humans, bovines, snails, cow dung and mice","788":"infection risk in humans","789":"absolute and relative presenteeism","790":"The mean length of the first and second stages of labor","791":"return of spontaneous circulation (ROSC)","792":"The 24-h survival rate of OHCA","793":"The proportion of patients with OHCA and a cerebral performance category score of 1 or 2 points at hospital discharge ","794":"Long-term adherence to the program","795":"Treatment cost","796":"Improvement in the Hamilton Rating Scale for Depression at 12 weeks","797":"Time to tracheal extubation","798":"Single breath counting and functional exercise capacity","799":"Recovery time after incremental shuttle walk test","800":"Changes in total Composite Abuse Scale score","801":"Adverse reactions","802":"IV ephedrine total dosage","803":"One-minute Apgar score","804":"Improvement in myasthenia score","805":"Adverse reactions","806":"stroke incidence","807":"major bleeding","808":"the rate of life-threatening or fatal bleeding or the rate of intracranial bleeding","809":"major or minor bleeding (by TIMI criteria)","810":"proportion of data points","811":"progression-free survival and overall survival","812":"The mean SEM score","813":"The mean pain score and mean SEM scores in female patients","814":"total sleep time","815":"Mean SGRQ scores","816":"lower abdominal pain\/discomfort scores at week 8","817":"Bristol Stool Scale (BSS) score","818":"total fat, FM%, and percentage of trunk fat","819":"Death and serious infections","820":"Probing depth (PD), Gingival recession (GR), Clinical attachment level (CAL)","821":"HbA1C","822":"Alpha-angle values","823":"Driving a car","824":"Rate of certain diagnosis","825":"Postural blood pressure measurement","826":"Cardiac enzymes and electroencephalography testing","827":"Total score of fatigue","828":"headache relief for attacks occurring inside and outside the menstrual period (migraine attacks)","829":"increase of fluency in the double loops tasks","830":"pain intensity","831":"Cumulative morphine consumption","832":"The plasma morphine concentration","833":"The mean expenditure on the products,","834":"rate of any adverse events","835":"hsCRP, and adiponectin","836":"detectable L. crispatus or L. jensenii","837":"Hamilton Rating Scale for Depression (HAM-D) and the Montgomery-Asberg Rating Scale (MADRS)","838":"GASE-generic (generic side effects)","839":"The total number of pethidine injections in first 24 hours postoperatively","840":"intraoperative supplemental fentanyl","841":"The BP of the GABA ligand","842":"support for training first responders to use naloxone","843":"providing naloxone to friends and family members of people using opioids","844":"passing laws to protect people who administer naloxone","845":"HBsAg positivity","846":"Red cell and plasma phospholipid eicosapentaenoic acid and docosahexaenoic acid concentrations","847":"Mucositis throughout the study period","848":"SpO2 at 5 minutes","849":"the rate and extent of absorption of GLPG0259","850":"ESAS QoL-score after three months","851":"infections after 3 months","852":"patients reached the target INR in the first hour after ending cardiopulmonary bypass (CPB)","853":"received an additional dose of PPSB","854":"scores of the DEKA Usability subscales","855":"The Overall subscale","856":"Values of total antioxidant capacity (TAC)","857":"interleukin 6 levels during exercise tests","858":"the Beck Depression Inventory-II (BDI-II) difference ","859":"episodes of infection\/allergy related to immunity","860":"absent due to infection\/allergy\/immunity related illnesses","861":"The proportional reduction from baseline in the total number of AK lesions per patient ","862":"Treatment-emergent adverse events","863":"plaque components and number of TCFAs per vessel","864":"plaque area","865":"constrictive remodeling","866":"Among lowa\u0302\u20ac? wall shear stress (WSS) segments I\u0302\"EEM area ","867":"engaging in vigorous physical activity","868":"completed scans during the 2 months of clinical training","869":"rotations or translations","870":"The mean distal translation","871":"The mean rotation around the longitudinal axis","872":"Bispectral index values","873":"self-reported subjective feelings of satisfaction for the AUC(0-5h)","874":"Maximal voluntary isometric contraction","875":"self-reported subjective feelings of satisfaction","876":"the AUC(0-3h) for blood insulin","877":"Attendance rates","878":"Number of absence days due to sickness at 6 months","879":"desire to eat for the AUC(0-3h)","880":"Number of absence days due to sickness at 12 months","881":"Patient adherence","882":"extraneous or germane load","883":"evaluation of the lecturers","884":"Secondary outcomes including spontaneously expectorated sputum volume, and forced expired volume in 1 second","885":"mean scores in work pace, influence at work, meaning of work, predictability, rewards, role conflicts and social support from supervisor ","886":"Secondary efficacy variables","887":"Daily OFF time","888":"calculus formation","889":"Major neurological complications","890":"Effective use of syndromic alerts after 1 year","891":"Alert response during the first year","892":"At 24 h post surgery, VAS pain scores","893":"Sexual function scores in females","894":"maternal blood lead concentrations in the second\/third trimester","895":"pDF strength at A1 and A2","896":"pDF strength at A1 and A2","897":"TUG completion time at A2","898":"Adverse events","899":"overall QoL","900":"Plasma PAI-1","901":"Fluency and flexibility","902":"levels of fibrinogen","903":"Torrance test (TTCT)","904":"New oral anticoagulants administration","905":"overall survival (OS) in patients with locoregionally advanced nasopharyngeal carcinoma (NPC)","906":"The percentage of patients who showed restlessness ","907":"incidence of hypoxemia","908":"the incidence of bradycardia","909":"The maintenance dose of PF","910":"the number of times a rescue PF injection","911":"Standing still for a long time (> 15 min ) without discomfort","912":"Maximum amplitude values","913":"Stroke duration","914":"Fatigue score in the sensory dimension","915":"Fatigue score in the sensory dimension","916":"the number of steps to use, time taken to use and ease of use","917":"the proportion of households who purchased anti-mosquito products in the last month","918":"eGFR","919":"quantitative proteinuria (urine protein-to-creatinine ratio) and tubular proteinuria (retinol binding protein-to-creatinine ratio and beta 2 microglobulin-to-creatinine ratio)","920":"HIV-1 RNA <50 copies per mililiter at week 24;","921":"The median vaginal and cervical pH","922":"CVL concentrations of lactoferrin and interleukin-1 receptor antagonist (IL-1ra), an anti-inflammatory protein,","923":"GASE-AD (antidepressant-specific side effects)","924":"visual analogue scale (VAS).","925":"The interval time for the first analgesic request","926":"mean decrease in [11C]Ro15?4513 BP","927":"The rate of HBsAg positivity","928":"Systolic blood pressure (SBP), diastolic blood pressure (DBP)","929":"flow-mediated dilation (FMD)","930":"would have liked more information on acupuncture","931":"central pulse wave velocity, augmentation index, aortic systolic blood pressure, BMI, waist, total cholesterol, serum glucose, IL-8, and IL-10,CRP ","932":"fasting blood sugar, insulin and homeostatic model assessment of insulin resistance","933":"the rate of absorption of methotrexate","934":"bulk-fill composite resin values and calcium silicate cement values","935":"The incidence of the primary composite endpoint","936":"non-CABG-related major bleeding","937":"the Aberrant Behaviour Checklist-Community Edition (ABC-C)","938":"Childhood Autism Rating Scale, Second Edition (CARS2)","939":"the total quantitative feedback score","940":"Overall pain scores","941":"Cmax, Tmax, t1\/2, elimination rate constant, AUC0-t and AUC0-inf","942":"Cmax, Tmax, t1\/2, elimination rate constant, AUC0-t and AUC0-inf","943":"The mean pain score using FRS scale","944":"hippocampus volume (HV) change","945":"Alzheimer Disease Assessment Scale \u2013 cognitive subscale (ADAS-cog)","946":"glucose incremental peaks","947":"insulin excursions ","948":"the 2-hour plasma ghrelin","949":"P300 latency incremental values","950":"stool consistency","951":"Composites of unfavourable outcomes (death, doubling of serum creatinine, non-remission and intolerance to treatment)","952":"Clinical improvement in multi-rooted teeth ","953":"numbers of babies were delivered after 38 weeks of pregnancy","954":"Global performance status and STS","955":"Mean overall satiety score","956":"Dyspnea improvement","957":"Daily OFF time","958":"Complications related to approach method","959":"All responses, excluding 'watchful waiting'","960":"Urological function scores in females","961":"Male sexual function scores","962":"Hospital stay","963":"Loss of blood during surgery","964":"Surgery time","965":"Harris hip values and union time of fractures","966":"Bilirubin levels after 3 days","967":"Baseline medical characteristics","968":"postoperative bleeding","969":"transcranial Doppler (TCD) flow velocities","970":"the minimum pulse rate","971":"wanted to receive a DEKA Arm","972":"rated the DEKA function and the external battery life","973":"colposcopy referrals (sensitivity?)","974":"PTSD-Checklist-Civilian version (PCL-C) difference ","975":"total duration of illnesses","976":"CGI-I scale improvement","977":"The percentage of patients with complete clinical clearance (CCC) 8 weeks after the end of treatment (primary endpoint)","978":"the TSQM convenience and side effect domain scores","979":"DLQI total score 8 weeks after the end of treatment","980":"tension, anxiety, well-being","981":"engaging in moderate physical activity","982":"engaging in moderate physical activity","983":"readiness to engage in vigorous physical activity","984":"a pre-established pass\/fail level of 50.0% in OSAUS score","985":"image optimization, systematic examination, interpretation of images, documentation of examination, and medical decision-making","986":"knowledge of equipment ","987":"The Merle d'Aubigne Postel score","988":"SBP and DBP","989":"Nitroglycerine and fentanyl use","990":"PACU stay","991":"desire to eat for the AUC(0-5h)","992":"performance on the diagnostic performance test","993":"prevalence rates of reported musculoskeletal symptoms","994":"any of the scales of the Thai version of the COPSOQ questionnaire","995":"protamine usage for haemostasis","996":"heparin dosages required to produce an ACT 15 min after the initial bolus that was identical to the control (110U\/kg)","997":"The mean (SD) increase in endometrial thickness based on TVUS","998":"vaginal bleeding","999":"endometrial cancer","1000":"pelvic organ prolapse","1001":"The analgesic requirement","1002":"At 1, 2, 4, 6, and 12 h post surgery, VAS pain scores","1003":"maternal blood lead concentrations","1004":"anxiety and depressive symptoms ","1005":"The safety profiles","1006":"Partial responses","1007":"Median survival","1008":"time to disease progression or survival","1009":"Dextrans administration","1010":"willing to join a randomized trial evaluating any of the methods used in VTE prophylaxis in stroke patients","1011":"goats body weight at slaughter","1012":"Weights, carcass yields, rib eye area of goats","1013":"Risk of unfavorable outcome on the Glasgow Outcome Score","1014":"The composite of major or minor bleeding (by PLATO criteria)","1015":"Urge to smoke","1016":"Montgomery-Asberg Depression Rating Scale and Hamilton Depression Rating Scale-17 item (HDRS-17)","1017":"serum level of IgM","1018":"Improvement in patient?reported outcomes at the end of treatment","1019":"Decrease in symptoms among patients with low immature defense style after 1 year","1020":"mean number of nocturia episodes\/24 h","1021":"Overall symptom reduction after 3 years","1022":"adverse effects","1023":"total weight lifted","1024":"Western Ontario and McMaster Universities Osteoarthritis Index for physical function","1025":"Mean treadmill endurance times","1026":"Cardiac index improvement","1027":"Standard errors","1028":"breast tenderness","1029":"complete and partial remission rates and times to remission","1030":"Number of tender points","1031":"TC, non-HDL-C and TG levels","1032":"newborns weight","1033":"Medical costs","1034":"body composition","1035":"systemic and forearm hemodynamics, or any biochemical parameters including oxidative stress markers","1036":"Normalized jerk","1037":"the time to withdrawal, irrespective of phase","1038":"myristic acid (C14:0) and palmitoleic acid (C16:ln-7) concentration","1039":"mean HIV treatment satisfaction total scores at weeks 24 and 48","1040":"days with missed doses","1041":"Time to first COPD exacerbation","1042":"Perioperative complications","1043":"mean changes in body weight, BMI, and waist circumference","1044":"received colostrum as the first food","1045":"G. vaginalis","1046":"efficiency, effectiveness, enjoyment, active trust, and interest","1047":"confirmed disability progression","1048":"medication-attributed, antidepressant-specific side effect score","1049":"Smoking status","1050":"Functional CD8+ T-cell responses with greater breadth, magnitude, and frequency in a viral inhibition assay","1051":"support all policies: providing naloxone to friends and family members, training first responders to use naloxone, passing laws to protect people if they administer naloxone, and passing laws to protect people if they call for medical help for an overdose ","1052":"Progression-free survival in patients with codon 13 mutations","1053":"maximal oxygen uptake","1054":"maximal workload, peak oxygen uptake (VO2peak) related to the predicted VO2peak, oxygen uptake at the anaerobic threshold, and maximal oxygen pulse","1055":"energy, protein, and fat and zinc intake","1056":"Complications","1057":"the modified Aldrete scores at 60 minutes, systolic pressures at 0 minutes, oxygen saturation at 10, 15, 20 minutes, diastolic blood pressure at 10, 15, 20 minutes, heart rates, and visual analogue scores","1058":"systolic blood pressures at 5, 10, 15, and 20 minutes","1059":"At 18 months, the higher improvement in total WOMAC","1060":"Needle pain intensity","1061":"Severe adverse events","1062":"The mean consultation duration","1063":"The mean consultation duration in the subgroup patients who required casting","1064":"number of operated patients","1065":"Skin reaction","1066":"early stance peak EKAM","1067":"second peak in EKAM during late stance","1068":"mobility","1069":"Changes in fitness measures","1070":"Maximal heart rate at the end of the test","1071":"knee adduction angular impulse (KAAI)","1072":"Increase in CD4 T lymphocyte count ","1073":"Increase in CD4 T lymphocyte count ","1074":"Insulin sensitivity after meals","1075":"Adverse side effects","1076":"Symptom severity by PANSS measure","1077":"Augmentation index (AIx)","1078":"Pain intensity","1079":"Hospital stay after surgery","1080":"Fever","1081":"Change in levels of glycated haemoglobin after 26 weeks","1082":"Overall confirmed hypoglycaemia","1083":"Baseline characteristics","1084":"SDQ change scores","1085":"Free IGF-1 concentrations at day 4 and day 6","1086":"Survival time","1087":"HR, MAC and SE values after fentanyl boluses","1088":"Number of practiced exercises ","1089":"PTQ (perseverative thinking) scores","1090":"SCS-D (self-compassion) scores","1091":"Vocal cords patency","1092":"Scores for ease of laryngoscopy","1093":"Fertilization","1094":"Pregnancy","1095":"Live birth rate","1096":"PHS criteria and bupivacaine consumption","1097":"the variables, knowledge","1098":"The duration of the procedure, time from anesthesia induction until start of surgery, and surgery time","1099":"he anesthesia-related side effects","1100":"all of the scales","1101":"ratings of blissful state, insightfulness, and changed meaning of percepts","1102":"pain intensity and disability index","1103":"pain intensity and functional disability","1104":"heart rate reduction and blood pressure reduction in CIBIS-II study ","1105":"heart rate, hospital admission, sudden cardiac death, hospital admission for worsening heart failure in CIBIS-II study ","1106":"hospitalization hospitalization for worsening CHF in CIBIS-III","1107":"Formation of new bone","1108":"total cholesterol and LDL-C ","1109":"Cardiovascular death","1110":"myocardial infarction","1111":"numbers of entries","1112":"The prostate volumes","1113":"Overall scores for anxiety","1114":"levels of pain","1115":"Rates of intervention attendance for the high and low attendance groups","1116":"TDI focal score","1117":"total fat, FM%, and percentage of trunk fat","1118":"The early discontinuation rates","1119":"fasting blood sugar (FBS) at term ","1120":"number of cesarean sections due to feto-maternal disproportion","1121":"peptide YY [PYY]","1122":"Writing velocity","1123":"Total score of fatigue","1124":"Walking short distances (< 20 min ) without discomfort","1125":"forced vital capacity (FVC), FEV1\/FVC and PaO2\/FiO2 ratio","1126":"C-reactive protein (CRP), intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), E-selectin and interleukin-6 (IL-6)","1127":"Diastolic blood pressures at 5 minutes","1128":"Mean procedure time","1129":"Pain scores recorded by physicians","1130":"Overall adverse cardiac events","1131":"Mean arterial pressure and heart rate during surgery","1132":"Troponin I levels","1133":"Duration of vigorous physical activity weekly","1134":"knee adduction angular impulse (KAAI)","1135":"knee adduction angular impulse (KAAI)","1136":"early stance peak EKAM","1137":"Change in CD4 T lymphocyte count at 24 weeks","1138":"early stance peak EKAM","1139":"Change in plasma HIV RNA","1140":"walking speed","1141":"Basal insulin sensitivity","1142":"L-lysine blood concentration","1143":"Capacity to solve problems","1144":"Waiting time","1145":"dietary fiber","1146":"Central blood pressure (cBP)","1147":"plasma glucose levels","1148":"Symptom scores for emotional problems in high SDQ scorers","1149":"Gastrocnemius masses on day 4 and 6","1150":"Levels of insulin","1151":"Surgical Stress Index values during surgery","1152":"MAC and SE values before fentanyl boluses","1153":"PHQ-9 (depressive symptoms) scores","1154":"Baseline demographic characteristics","1155":"Jaw relaxation scores","1156":"Implantation rates","1157":"Embryos with minimal fragmentation rate","1158":"improvement in the Dysphagia Symptom Questionnaire (DSQ) score","1159":"mean DSQ scores","1160":"the incidence of adverse effects, such as pneumonia, atelectasis, bronchoscopic interventions, reintubations, hypersensitivity and postoperative ICU and hospital stay","1161":"VAS scores for 24 hr","1162":"VAS mean score at 16 h","1163":"perceived susceptibility","1164":"perceived benefits","1165":"Incisional pain","1166":"overall ASC scale","1167":"chemical, clinical and continuing pregnancies, rate of live birth","1168":"adverse events","1169":"differences in the disc herniation, HDD, annulus tear, and HIZ","1170":"The proportion of HIZ incidence","1171":"pain intensity and disability index","1172":"days spend in the ICU","1173":"Mortality at discharge from ICU","1174":"duration of weaning","1175":"mortality in CIBIS trial","1176":"mortality in CIBIS-III ","1177":"Density changes","1178":"Waist circumference","1179":"MASS index","1180":"Rates of myocardial infarction ","1181":"Wound infection incidence","1182":"Surgery duration","1183":"Hospital stay","1184":"Baseline characteristics","1185":"Adherence in patients starting with RAS-inhibitors, statins and bisphosphonates.","1186":"Adherence in patients starting with antidepressants","1187":"Risk of severe brain injury or death","1188":"Causes of reintubation","1189":"Success of external cephalic version (ECV) procedure","1190":"Follow-up duration","1191":"Severity of the tibial plateau fractures","1192":"Hemoglobin at day 1 after surgery","1193":"Improvement rate","1194":"UPAT scores","1195":"Consumption of morphine after the surgery","1196":"Need for additional analgesic rescues, number of bolus attempts, and bolus deliveries","1197":"Satisfaction with pain control as reported by surgeons","1198":"Total dose of ephedrine","1199":"Stimulation outcomes","1200":"Brain regions with adaptive coding ","1201":"Rate of morbidity and complications","1202":"Self-management as measured on the OAQI, after 12 months","1203":"Domains examined for the heiQ","1204":"Treatment categories change scores","1205":"Total body stores of vitamin A","1206":"Vitamin A concentrations in the liver","1207":"Mean systolic arterial pressure after intubation","1208":"Mean diastolic arterial pressure after intubation","1209":"Mean rate pressure product up to 15 min after intubation","1210":"Phosphorylation of p70S6K 3 hours after exercise","1211":"Gait speed","1212":"fentanyl dose after 1 month and 3 months","1213":"The commercial cuts and yields and goats","1214":"factor II and factor X","1215":"Specificity","1216":"cognitive, habitual behavioral, affective","1217":"serum iron","1218":"had seen a social worker at preassessment","1219":"energy, physical fitness, strength and stamina","1220":"the proportion of patients who achieved PC of AK lesions eight weeks after the end of treatment,","1221":"overall treatment satisfaction and effectiveness domain mean scores at 8 weeks after the end of treatment,","1222":"Subjective stress markers","1223":"excessive expansive remodeling","1224":"engaging in vigorous physical activity","1225":"readiness to engage in vigorous physical activity","1226":"OSAUS scores of the clinical performance test ","1227":"pulse rate","1228":"Concentric peak torque of knee extensors","1229":"Sustainable return to work","1230":"Patient satisfaction","1231":"prevalence rates of reported musculoskeletal symptoms","1232":"ECBI Intensity scale after treatment","1233":"week \u00d7 diameter \u00d7 application types in terms of LII ","1234":"The length of the arch perimeter between the canines and the length of the arch perimeter between the first molars","1235":"calculus formation","1236":"Daily ON time with problematic dyskinesia","1237":"Generated alerts","1238":"Baseline rectal cancer diagnosis","1239":"at least one local adverse event","1240":"Incision lenght","1241":"Defecation frequency after 3 days","1242":"Total food intake","1243":"Body weight","1244":"progression-free survival","1245":"Microparticles count","1246":"Intraplatelet tGSH","1247":"the extent to which players found categories of shapes that were non-standard, naming it \"out-of-the-boxnessa\u0302\u20ac?, OB","1248":"free from any allogeneic blood product transfusions","1249":"interested in joining randomized trials evaluating any of the methods used in VTE prophylaxis","1250":"response rate (RR), disease control rate (DCR), progression-free survival (PFS)","1251":"The satisfaction scores","1252":"The PAP till 6 minutes after pneumoperitoneum was attained","1253":"Mean length of the specimens","1254":"number of 'discharged patients' (i.e. in those who were not referred for operation, a standard consultation or any follow-up appointment for chronic disorders with the orthopaedic department within six months).","1255":"Patient willingness to repeat the produce","1256":"myelosuppression","1257":"Dynamic VAS pain score","1258":"Nausea","1259":"Postoperative complications","1260":"Adherence to training after 1 month","1261":"knee adduction angular impulse (KAAI)","1262":"Secretion of insulin","1263":"walking speed ","1264":"Triglycerides levels","1265":"differences between 5-FU 0.5%\/salicylic acid 10% and vehicle during treatment","1266":"cortisol concentration from 20 to 45 min post-stressor onset","1267":"Carotid femoral pulse wave velocity (cfPWV)","1268":"external elastic membrane (EEM) area and lumen area","1269":"Mean fasting plasma glucose at 26 weeks","1270":"Nocturnal confirmed hypoglycaemia","1271":"Adverse events","1272":"Gastrocnemius masses after 2 days","1273":"S6K1 phosphorylation","1274":"Leeches activity level","1275":"Decrease in Surgical Stress Index after fentanyl boluses","1276":"self-reported subjective feelings of satisfaction for the AUC(0-3h)","1277":"Eccentric peak torque of knee extensors","1278":"intrinsic cognitive load","1279":"ECBI Problem Scale after treatment","1280":"mean pain scores at 8 and 24h","1281":"Thrombotic\/thromboembolic events (TEE) or DVT ","1282":"unpleasant feelings during surgery and anxiety","1283":"satisfied with the anesthesia procedure","1284":"Mean pertuzumab Cmin at day 43","1285":"Platelet\u2013monocyte conjugation","1286":"pain score","1287":"clotting time","1288":"clot firmness","1289":"pain intensity and disability index","1290":"Iron burden","1291":"intraoperative estimated blood loss, postoperative drainage, total blood loss","1292":"Volume reduction","1293":"blood pressure, other anthropometric or laboratory measures","1294":"Number of sensations elicited","1295":"oxygen saturation (SpO2) or end-tidal carbon dioxide (EtCO2)","1296":"Spreading range","1297":"Pain scores","1298":"Mean artery blood pressure during surgery","1299":"Mortality rates in children who did not receive FU-VAS","1300":"Baseline characteristics","1301":"Baseline characteristics","1302":"Success of external cephalic version (ECV) procedure","1303":"Mean knee scores at follow-up","1304":"Mean functional score at follow-up","1305":"Rates of utilization of allogeneic RBC, total allogeneic RBC and total RBC","1306":"Pain scores","1307":"Passive knee motion at 3 days after surgery","1308":"Pain intensity after surgery","1309":"Pain intensity after surgery","1310":"Subjective well-being","1311":"Habituation from phase I to phase III","1312":"Discrimination between stimulation intensities","1313":"Chance of survival ","1314":"MDF scores and MELD scores at 4 weeks","1315":"Weight reduction as measured on the OAQI, after 12 months","1316":"Anthropometric indices","1317":"Number of days in the ICU","1318":"Catheter-related bloodstream infection","1319":"Mean arterial pressure after laryngoscopy and intubation","1320":"Recovery of muscle function","1321":"Handgrip strength","1322":"Baseline characteristics","1323":"Rates of myocardial infarction ","1324":"Risk of vascular death","1325":"burning sensation","1326":"The anti-HBs level ","1327":"flow-mediated dilation (FMD) score at 240 min postconsumption","1328":"Inspiratory muscle strength","1329":"C3 levels","1330":"happiness ","1331":"POMS depression","1332":"state anxiety","1333":"expression of PDE-5","1334":"Expression of MMP-9 and MMP-2","1335":"the slope of EDPVR","1336":"choosing the best treatment","1337":"Mortality","1338":"median PFS (Progression-free survival)","1339":"Median OS","1340":"Plasma PlsPE","1341":"occurrence of adverse events","1342":"suffered from bradycardia","1343":"VAS score","1344":"Admission rate","1345":"Clinical Dementia Rating \u2013 Sum of Boxes (CDR-SB)","1346":"chronic cough","1347":"foreign body sensation","1348":"men discussing and using condoms within stable relationships","1349":"mean dose of propofol required for induction","1350":"glucose concentration at 120 minutes in study 1","1351":"AUCg and AUCi values for 0-15 min, 0-30 min, 0-45 min, 0-60 min, and 0-90 min in study 2","1352":"AUCg and AUCi values for 0-15 min, 0-30 min, 0-45 min, 0-60 min, 0-90 min, and 0-120 min in study 1","1353":"percentage of images of suitable quality at the right pyriform sinus","1354":"pain evaluated by VAS in the presence of sedation","1355":"heart rate","1356":"mean systolic and diastolic blood pressure","1357":"peak blood glucose","1358":"amplitude of glycemic excursion","1359":"Emergence agitation ","1360":"Extubation times","1361":"Discharge times","1362":"Mean serum levels of vitamin D","1363":"Baseline levels of high-density lipoprotein cholesterol (HDL-C) and vitamin D","1364":"Patient being held responsible for the weight-related symptoms","1365":"The titers of GADAb","1366":"Morning stiffness in participants with OA knees","1367":"Diastolic blood pressure","1368":"premature ejaculation (PE).","1369":"Weak scanty ejaculation","1370":"anterior, non-paretic and paretic reach","1371":"anterior reach","1372":"the results of sit-and-reach test","1373":"The clinical response rates","1374":"the post-chemotherapy pathologic T and N stages","1375":"durations of the gait phases","1376":"peak value immediately after contact of the foot with the ground (PVF1)","1377":"Modified gingival index","1378":"negative psychosocial consequences","1379":"passive drag","1380":"the falls rate in the women only","1381":"Non-technical skills concerning situation awareness and teamwork","1382":"'command roles and responsibilities', 'speaking up', 'debriefing', 'feedback and critique', 'realistic appraisal of stress', and 'denial of stress'","1383":"'Teamwork' over time","1384":"mean score of sexual satisfaction","1385":"irritable bowel syndrome (IBS) symptoms (pain, bloating, constipation and diarrhoea)","1386":"The response rate","1387":"Circumferential and radial strains","1388":"longitudinal strain","1389":"navigator efficiency and signal-to-noise ratio (SNR)","1390":"levels of decompression ","1391":"psychometric hepatic encephalopathy score (PHES) after 8 weeks","1392":"The mean score of final visual acuity","1393":"weight, BMI, body fat, waist circumference, and visceral fat area (VFA)","1394":"body weight, BMI, body fat, muscle mass and VFA","1395":"AUCinf","1396":"Cmax","1397":"the mean and maximum duration of analgesia","1398":"Total epidural dose of fentanyl and bupivacaine","1399":"pruritus, nausea, vomiting during first 24 h","1400":"Mean score of general symptoms","1401":"Length of ICU","1402":"The length of survival","1403":"bradycardia, hypoxemia, hypotension and hypertension","1404":"oral dryness, tachycardia, excessive bradycardia and use of atropine and ephedrine","1405":"Pain scores recorded by patients","1406":"flow-mediated dilation (FMD) score at 240 min postconsumption in participants (n = 6) with a higher baseline LDL-cholesterol concentration (>100 mg\/dL)","1407":"Daylong glycemia","1408":"Mean costs per patient","1409":"Improvement in peripheral diastolic blood pressure ","1410":"Central pulse pressure ","1411":"Bacteriuria","1412":"Acute urinary retention and post-void residual urine volume ","1413":"Freiburg Mindfulness Inventory (Freiburger Fragebogen zur Achtsamkeit, FFA) scores","1414":"Limb movement score","1415":"plasma D-dimer values","1416":"the variables of knowledge, perceived susceptibility, and perceived benefit","1417":"The use of midazolam","1418":"total dose of FSH administered, the duration of treatment or peak estradiol levels","1419":"The proportion of HIZ incidence","1420":"time spent on mechanical ventilation","1421":"HDL-C","1422":"numbers of consultations ","1423":"second peak in EKAM","1424":"mobility","1425":"maximum external knee flexion moment (KFM) (etable 3) during early stance","1426":"Burden of hyperoxia within the 4th quartile versus quartile 1\u20133","1427":"Positive predictive value for extubation failure","1428":"Extubation failure","1429":"Breathing trial failure","1430":"Mean VAS pain score","1431":"Use of analgesic drugs","1432":"Rate of complications","1433":"Child-Pugh, GAHS, MDF, and MELD scores at 3 months, 6 months, and 1 year","1434":"Baseline demographics","1435":"Anaemia","1436":"Baseline MRDR values","1437":"Mean cost per patient","1438":"Number of days admitted in the hospital","1439":"Mean heart rate after intubation","1440":"Leucine concentrations in blood","1441":"Rates of muscle protein synthesis","1442":"Phosphorylation of p70S6K and rates of muscle protein synthesis ","1443":"Sit to stand performance","1444":"Cardiovascular and all-cause mortality rates","1445":"Need of morphine during 48 hours after surgery","1446":"Extubation time","1447":"Time of hospital or ICU admission ","1448":"Blood loss, excluding intraoperative blood loss","1449":"Amount of transfused blood","1450":"Mortality rates after FU-VAS","1451":"Mean adherence rates","1452":"Therapy discontinuation in patients starting with antidepressants","1453":"Therapy discontinuation in patients starting with RAS-inhibitors, statins and bisphosphonates.","1454":"Success of external cephalic version (ECV) procedure","1455":"Rates of utilization of autologous blood","1456":"Baseline characteristics","1457":"Blood transfusion-related complications and mortality rates","1458":"Total dose of remifentanil","1459":"increased ability to identify patients who have a high risk of severe asthma attacks","1460":"heart burn","1461":"mean blood pressure","1462":"the body weight and body mass index (BMI)","1463":"plaque levels","1464":"negative psychosocial consequences","1465":"lasma levels of TBARS (thiobarbituric acid-reactive substances)","1466":"the level of pain","1467":"glucose AUC","1468":"Ratio of remaining material","1469":"Vascularization and ratio of connective tissue","1470":"levels of depression, anxiety, pain, fatigue and sleep disturbance","1471":"number of nocturnal or severe hypoglycaemic events","1472":"percentage of participants experiencing \u22651 nocturnal confirmed or severe hypoglycaemic event during the 12\ufffdmonth","1473":"adverse events","1474":"oral health status at the end of 4th of 8th week","1475":"plasma vitamin D, EPA, DHA, and n\ufffd3 FA","1476":"body mass, skeletal muscle mass (SMM,) and FM","1477":"body mass and FM","1478":"mature and total B-cells","1479":"PKG activity","1480":"the profibrotic mediator TGF-\u03b21 and fibrosis marker fibronectin","1481":"The values of load-independent, P\u2013V-loop derived contractility indexes (Ees, PRSW)","1482":"Tau (Weiss; ms)","1483":"lactate levels at 24 hours","1484":"24-hour SOFA score","1485":"numbers of non-wife partners and episodes of unprotected sex with non-wife partners ","1486":"required amount of diclofenac sodium injection as rescue analgesics in first 20 h of postoperative period","1487":"The mean postoperative hospital stay, the mean time of removal of NGTs, the mean time of successful enteral feeding, the mean time for removal of intra-abdominal drains ","1488":"Catheter-associated urinary tract infection (CAUTI)","1489":"improved ability to assess the severity of an asthma attack","1490":"higher confidence levels regarding the ongoing management of infrequent episodic asthma","1491":"Throat cleansing","1492":"postnasal drip","1493":"male's reported sexual concurrency","1494":"women's ability to refuse sex","1495":"insulin levels among women in the middle IA ancestry tertile","1496":"HOMAIR among women in the middle IA ancestry tertile","1497":"circulating concentrations of IGFBP-3 among women in the middle IA ancestry tertile","1498":"dosage of propofol required by males","1499":"Appointment adherence, exemplified by the attendance of one or more follow-up visits","1500":"concentrations of serum glucose at 15 min, 30 min, and 45 min in study 1","1501":"concentrations of serum glucose at 15 min and 30 min in study 2","1502":"number of times that a gag reflex was triggered in absence of sedation","1503":"withdrawal response of rocuronium","1504":"RN and MD visits","1505":"plasma GLP-1 before consuming the meal","1506":"Need of nalbuphine for pain and agitation episodes after surgery","1507":"Mean serum levels of high-density lipoprotein cholesterol (HDL-C)","1508":"Negative stereotyping","1509":"Patient being held responsible for symptoms unrelated to weight","1510":"Immediate efficacy","1511":"Sensory attributes","1512":"Resting pain in participants with OA knees","1513":"State anxiety in participants with OA knees","1514":"The mean TNF-\u03b1 value at 24 h ","1515":"adverse events","1516":"the mean MOCUS score","1517":"performing successfully two of the seven MOCUS items","1518":"low-density lipoprotein cholesterol","1519":"hsCRP","1520":"total length of COP","1521":"pCR (pCR in both the breast and lymph nodes) rates","1522":"peak value before lifting the foot from the ground (PVF2)","1523":"Resting metabolic rates (RMR)","1524":"Bone loss","1525":"the scales and single items: 'sleep', 'stigmatisation', 'harm of smoking', 'busy to take mind off things', 'less interest in sex' and 'self-rated health'.","1526":"passive drag","1527":"rate of injury when men only fell ","1528":"Decision making","1529":"mean score of sexual satisfaction","1530":"average score of sexual function","1531":"HDL-C, VO2max, DBP. SBP","1532":"navigator efficiency","1533":"signal-to-noise ratio (SNR)","1534":"surgical time, blood loss, and surgical transfusion","1535":"percentage of pregnant women who quitted smoking","1536":"Attempts to quit smoking","1537":"reduce smoking rate","1538":"the amount of canal transportation","1539":"blood carboxyhaemoglobin concentrations","1540":"augmentation index","1541":"pulse wave velocity","1542":"forearm blood flow","1543":"The average of final visual acuity","1544":"The average of final macular thickness","1545":"adverse events","1546":"adverse events","1547":"heart rate","1548":"Systolic blood pressure","1549":"Fatigue score at week 4","1550":"Concentrations of ALT, AST, Cr, or CPK","1551":"Blood volume in the retroperitoneal hematoma","1552":"Mean acne severity","1553":"Patients' satisfaction score","1554":"Frequency of side effects","1555":"Nonurgent ED visit","1556":"Surfactant protein B expression","1557":"Mean pain scores 2 hours after the procedure","1558":"Levels of S100B","1559":"Levels of NGF","1560":"Mortality rates","1561":"Frequency of sputum production at night-time","1562":"Rate of success","1563":"Glycated hemoglobin A1c (HbA1c)","1564":"HbA1c, FBG and C peptid","1565":"The mean duration of antibiotic exposure in the subgroup of community-acquired pneumonia (CAP) patients","1566":"intubation time","1567":"success rate of intubation","1568":"the frequencies of dry throat, sore throat and hoarseness","1569":"The intubation success rates at the first, second, and third attempt","1570":"The intubation time at the second attempt","1571":"Systolic BP, mm Hg","1572":"induction duration, duration of the 1st and the 2nd stages of labor, delivery method; and labor outcomes such as: hyper-stimulation of uterine, postpartum bleeding, 5-minute Apgar score, and infant's birth weight; and neonatal outcomes (admission to NICU, oxygen and intubation)","1573":"Mean drug dose","1574":"Hepatic Encephalopathy Scoring Algorithm (HESA) score","1575":"blood level of ammonia","1576":"IOP (intraocular pressure)","1577":"number of zones involved","1578":"home environmental safety","1579":"caregiver strain ","1580":"caregiver self-efficacy","1581":"Total cholesterol, HDL and LDL","1582":"percent suppression of Endogenous Glucose Production (EGP)","1583":"H. pylori eradication rate","1584":"H. pylori eradication rate","1585":"total score descending of symptoms","1586":"cough reflex","1587":"Depression ratings","1588":"plasma and salivary nitrate and nitrite concentrations","1589":"Mean HR","1590":"High-intensity intermittent running performance as assessed by the Yo-Yo IR1","1591":"medication intensification","1592":"intensification of medications to control BP","1593":"intensification of medications to control LDL","1594":"haemogloblin A1c (%) among patients with worse glucose control - >9%","1595":"LDL measured by LDA ","1596":"debris extrusion","1597":"intraoperative fluid balance","1598":"intraoperative metaraminol","1599":"intraoperative ephedrine","1600":"dopamine and\/or dobutamine","1601":"intraoperative beta-blockers","1602":"volumes of crystalloid or colloid fluids on both postoperative Day 1 and Day 2","1603":"most severe complications","1604":"delayed gastric emptying","1605":"blood transfusion","1606":"electrolyte derangements","1607":"cardiorespiratory complications","1608":"The duration of stimulation","1609":"The serum estradiol level","1610":"weight after 1 year","1611":"amount of remission of Seasonal Affective Disorder (SAD)","1612":"patients achieving pathological tumour responses","1613":"the proportions of R0 resections","1614":"improvement in proprioception","1615":"muscle activity and proprioception","1616":"HbA1c, Total cholesterol, LDL cholesterol, HDL cholesterol, Triglycerides ","1617":"RBCs count, PCV %, and Hb concentration","1618":"Serum Creatinine and Uric Acid","1619":"activities of AST and ALT","1620":"case fatality 1 year after stroke","1621":"at least one hypoglycaemic event during 12 months of treatment","1622":"weight","1623":"the anti-HBs level ","1624":"flow-mediated dilation (FMD) score at 240 min postconsumption in participants with higher baseline total cholesterol (TC)","1625":"median and mean peak IFN-\u03b3 T cell response","1626":"plasma levels of vitamin D, EPA, DHA, and total n\ufffd3 FA","1627":"Ig levels","1628":"nitro-oxidative stress","1629":"profibrotic TGF-\u03b21","1630":"ANF and the \u03b2-MHC\/\u03b1-MHC ratio","1631":"choosing the best treatment","1632":"median PFS (Progression-free survival) for patients with platinum-resistant disease","1633":"WMS-R (30 min) In the patients aged 77 years or younger,","1634":"WMS-R (0 min)","1635":"five episodes of unprotected sex with non-wife partners","1636":"Onset of both sensory and motor block","1637":"The mean time from block placement to first request for pain medication","1638":"compliant to enforced mobilization within 24 hours after surgery","1639":"tolerated earlier oral feeding (fluids) without severe PONV","1640":"The times of removal of urinary catheters","1641":"wound infection, respiratory tract infections, and anastomotic leak","1642":"Complications","1643":"Urinary Retention relief","1644":"reduce of glycaemic control.","1645":"likelihood of providing a written asthma action plan to children","1646":"Frequency of nevi enlargement","1647":"Sedentary habits","1648":"male reports of undergoing HIV testing","1649":"women making decisions jointly with their partner","1650":"glucose levels among women in the middle IA ancestry tertile","1651":"IGF-1 levels among women in the middle IA ancestry tertile","1652":"dosage of propofol required by females","1653":"Liver enzymes","1654":"number of follow-up appointments during the one year study period","1655":"adherence rates for patients who attended two or more follow-up appointments","1656":"number of times that a gag reflex was triggered in the presence of sedation","1657":"occurrence of adverse events","1658":"The difficulty score of using the device","1659":"overall blood glucose","1660":"Median scores of FLACC pain","1661":"(PWV) pulse wave velocity","1662":"Perception of good health status","1663":"Preferred intranasal corticosteroid","1664":"Urge to sneeze, aftertaste, run down to throat, and run off from nose following the use of intranasal corticosteroids ","1665":"BMI (or body weight), blood pressure and HbA1c","1666":"the \u2211C-peptide values during the oral glucose tolerance test","1667":"Systolic blood pressure","1668":"Pulse rate","1669":"TNF-\u03b1 levels after 168 h","1670":"Mean intra-vaginal ejaculatory latency time (IELT)","1671":"average velocity and total path length of COP","1672":"skinfold thicknesses at lower corner of scapula, triceps brachii, and abdomen,","1673":"The frequency of neutropenia","1674":"low-density lipoprotein","1675":"Resting metabolic rates (RMR)","1676":"Resting metabolic rates (RMR)","1677":"heart rate and blood pressure ","1678":"self-report ratings for the 10 symptoms","1679":"mean peri-implant crevicular fluid volume (CFV)","1680":"maxillary CFV at time points 2 and 3","1681":"Gingival retraction and probing depth","1682":"Depression or Anxiety or Adjustment Disorder with Depressed Mood, Anxiety, or Mixed Anxiety and Depressed Mood","1683":"the rate of injury","1684":"The incidence of adverse events","1685":"The attitude 'handling errors'","1686":"frequency of sexual dysfunction","1687":"strength in the exercises for leg extension (LE) and Low Row (LR)","1688":"Waist circumference, HDL-C, VO2max, and TBARS","1689":"The average readings for the SBP and DBP","1690":"irritable bowel syndrome (IBS) symptoms (pain, bloating, constipation and diarrhoea)","1691":"physical functioning, general health","1692":"felt stigma after 6 months of treatment","1693":"felt stigma after treatment","1694":"triglyceride (TG) levels at week 24 and 36 between the 2 study arms","1695":"the visual analog scale back and leg pain (VAS-BP, VAS-LP) scores and Oswestry Disability Index (ODI) scores at 2 weeks, 3 months, 6 months, and 12 months after operation","1696":"level of first theta power peak","1697":"The effectiveness of smoking cessation attempts (success rate)","1698":"vasodilatation to bradykinin","1699":"effect on bradykinin-induced tissue-plasminogen activator release, thrombus area or markers of platelet activation","1700":"psychometric hepatic encephalopathy score (PHES)","1701":"glucose area under the curve (AUC) ","1702":"Bispectral index (BIS) after 10 minutes interval","1703":"Level of physical activity","1704":"Effects in reduction of lipids levels","1705":"Improvement in hemodynamic variables","1706":"Circulating red cell volume","1707":"Transcapillary refill","1708":"Baseline characteristics, except gender","1709":"Change on knowledge scores","1710":"Baseline characteristics","1711":"Mean airway pressure","1712":"mRNA expression of IL-6 and type III procollagen","1713":"Alveolar collapse, interstitial edema, septal thickening, or DAD score in nIAP animals","1714":"Alveolar collapse, interstitial edema, or DAD score in animals with IAH","1715":"Mean pain VAS scores at 4 and 6 hours after the procedure","1716":"Mean pain scores at 4 and 6 hours after the procedure","1717":"Levels of BDNF","1718":"Scores of visual space, executive function, attention, and delayed memory","1719":"Targeted network efficiency and control network efficiency","1720":"Survival benefit in hypoxemic COPD","1721":"E-RS cough\/sputum domain scores","1722":"E-RS cough\/sputum domain scores","1723":"Morning cough severity and phlegm","1724":"Night-time cough frequency and severity","1725":"Soft tissue parameters","1726":"Papillary index score","1727":"Disease Activity Score 28 joints C-reactive protein (DAS28-CRP) and simplified disease activity index (SDAI) score","1728":"rate of early improvement at 24 h","1729":"Antibiotic prescribing rates","1730":"the mean duration of antibiotic treatment in subgroup of non-community-acquired pneumonia (CAP)","1731":"learning achievement","1732":"HbA1c, %","1733":"Total cholesterol, mg\/dL","1734":"duration of contractions","1735":"Number of postpartum hemorrhage","1736":"risk of episodes of high reliever use","1737":"The risk of hospitalisation\/ER visits","1738":"length of hospital stay","1739":"mean weight gain","1740":"cavity size","1741":"MTBs-induced IFN-g secretion","1742":"risky behaviors and accidents","1743":"serum triglyceride levels","1744":"Mean arterial pressure (MAP), ICP, SjO2 and mVMCA","1745":"Mean arterial pressure (MAP), cerebral perfusion pressure (CPP), SjO2 and mVMCA","1746":"ICP ","1747":"serum cortisol levels after CO2 insufflation","1748":"adrenalin, noradrenalin and dopamine values","1749":"cortisol levels 20 minutes after CO2 insufflation","1750":"the anxiety ratings","1751":"progression-free-survival (PFS)","1752":"Median overall survival (OS)","1753":"Response rates","1754":"rate of adverse events","1755":"Ratings of perceived exertion as determined with the Borg scale","1756":"Grip strength","1757":"incremental benefit","1758":"LDL value measured by ANCOVA and cLDA","1759":"Habituation","1760":"time and trials to attain the habituation criterion","1761":"debris extrusion","1762":"debris extrusion","1763":"debris extrusion","1764":"Crystalloid","1765":"intraoperative colloid or blood products","1766":"intraoperative noradrenaline","1767":"Postoperative complications","1768":"Total number of complications","1769":"Postoperative pancreatic fistula","1770":"The number of ampoules of Follicle Stimulating Hormone (FSG)","1771":"mean percent weight loss of subjects with prediabetes and\/or MetS","1772":"time of sleep end","1773":"evidence of a treatment effect","1774":"muscle activity","1775":"improvement in proprioception","1776":"reduction in absolute weight","1777":"IL-1Ra and IL-6 levels","1778":"Serum glucose at the 3rd week.","1779":"increased knowledge about asthma","1780":"time to first COPD-related emergency room (ER) visit","1781":"ER visits for all causes","1782":"The mean normalized area under the curve (AUC) values for the second phase","1783":"The mean normalized AUC values for the first phase","1784":"The mean normalized AUC values for the first and second clinical trials","1785":"duration of hospitalization","1786":"Total morbidity","1787":"carbon monoxide-confirmed continuous abstinence rates (CAR)","1788":"mean reduction in BP for both systolic blood pressure (SBP) and diastolic blood pressure (DBP) ","1789":"reduction in BP for systolic blood pressure (SBP) and diastolic blood pressure (DBP) ","1790":"DBP change among non-Black patients","1791":"The onset of tolerable and intolerable mucositis ","1792":"the incidence of grade 2 mucositis at week 2","1793":"The incidence of intolerable mucositis (only grade 3) at the end of week 7 ","1794":"weight loss","1795":"the reduction in risk of 24-month incidence of new or worsening vertebral fracture","1796":"Bone mineral density after 3 months at the lumbar spine, total hip, and femoral neck, and 6 months at the distal one third radius","1797":"Bone mineral density after 3 months at the lumbar spine, total hip, and femoral neck, at 12 and 24 months at the femoral neck, and from 18 months at the distal one third radius","1798":"percentage of excellent embryos","1799":"the length, weight babies born ","1800":"The body mass index-for-age","1801":"The EG had increased in the soft tissue (primarily FFM)","1802":"AIGR0\u201330 during the 4-year follow-up","1803":"The number of oocytes per the number of aspirated follicles","1804":"oocyte yield among women with normal ovarian reserve","1805":"Visual Analog Scale (VAS), Pain Disability Index (PDI) and Headache Impact Tests (HIT)","1806":"Visual Analog Scale (VAS), Pain Disability Index (PDI) and Headache Impact Tests (HIT)","1807":"VT: Vitality","1808":"VT: Vitality","1809":"bone mineral density (BMD) At the 6-month time point","1810":"Endometrial Thickness","1811":"The prominent efficacy rate","1812":"the aggravated rate, defined as ratio of patients whose TEA had increased more than 50% at 24 weeks from the beginning of the study","1813":"bone events requiring surgery","1814":"the number of skeletal fractures","1815":"the mean number of measurement periods with events per patient","1816":"the bone marker urinary CTx over the 96-week study period","1817":"well-being at 4 weeks","1818":"Subscales of Mental Health Continuum-Short Form (MHC-SF)","1819":"mood, energy, rest, and sleep","1820":"level of patients dissatisfaction","1821":"probing depth (PD)","1822":"The mean GI after 3 months","1823":"Forced Expiratory Volume in the first second (FEV1)","1824":"The 30-day rate of stroke or death","1825":"The median coverage","1826":"The sedation scores","1827":"the mean pain scores","1828":"the mean intensity of pruritus","1829":"reduction in intussusception","1830":"incidence rate of type 2 diabetes","1831":"prenatal knowledge, attitudes,behaviors and beliefs related to text4baby","1832":"decrease in the levels of impulsivity and aggressiveness in experimental group","1833":"Relief of plantar pain","1834":"Increase of glycaemic control.","1835":"reduced cardiovascular risk.","1836":"apnea, laryngospasm, bronchospasm, vomiting","1837":"Improvement in the 12-item MS Walking Scale (MSWS-12) Score during 24 weeks","1838":"Improvement in Timed Up and Go (TUG) speed during 24 weeks","1839":"Improvement in Berg Balance Scale (BBS) Score during 24 weeks","1840":"Adverse Events","1841":"Density of type 1 monocytes chemo tactic protein (MCP-1)","1842":"Intercellular adhesion molecule-1 (ICAM-1)","1843":"Baseline characteristics","1844":"General health","1845":"Demoscopic changes","1846":"Demoscopic changes","1847":"Formation of new dot-globule ","1848":"Atherogenic index","1849":"mean physician Clinical Global Impression (CGI) scale - eye contact","1850":"Mean parental CGI scores - overall functioning ","1851":"success rate of intubation on the first, second, and third attempts","1852":"accuracy in the timing task","1853":"The intensity of an unpleasant sensation","1854":"compliance coefficient (CC)","1855":"recovery","1856":"number of patients experienced pneumonia","1857":"recovery","1858":"index lesion cure rate after 6 months follow-up","1859":"Follicle Stimulating Hormone (FSH) level in group APMM","1860":"estradiol (E2) level in group APMM","1861":"severity of individual menopausal symptoms (hot flushes and night sweating in particular)","1862":"successfull insertion","1863":"The mean peak inspiratory pressure and plateau pressure","1864":"numbers of breast-conserving surgery","1865":"reducing tumor proliferation","1866":"mean weekly steps during the first month","1867":"numbers overall complications","1868":"level of postoperative pain","1869":"overall mortality","1870":"mean arterial pressure","1871":"total cholesterol","1872":"interleukin-6","1873":"C-reactive protein","1874":"average daily risk range","1875":"glutathione peroxidase (GPx) and superoxide dismutase (SOD) levels","1876":"perceived stress","1877":"heart rate","1878":"strength in the exercises for leg extension (LE) and Low Row (LR)","1879":"flexibility of joints","1880":"The subjective fatigue on day 3.","1881":"change in dogs' body weight","1882":"PVF change with time","1883":"Pain at manipulation","1884":"lameness, pain at palpation and joint mobility at T0 and T3","1885":"felt stigma after treatment","1886":"Coll2\u20131 and Coll2\u20131 NO2 serum concentrations","1887":"bond strength values","1888":"central macular thickness (CMT) at 1 month and at 4 months","1889":"The total blood loss after Total knee arthroplasty (TKA)","1890":"The mean visible blood drainage during the first 24 h and between 24 and 48 h after TKA","1891":"Safety laboratory parameters, ECG, and physical exam.","1892":"Body mass index","1893":"Improvement in waist-to-height ratio","1894":"mean scores of Constant\u2013Murley score","1895":"activities","1896":"percentages of migrated isoforms (PMI) on days 4 and 11","1897":"percentages of migrated isoforms (PMI) on day 25","1898":"numbers of positively response to the following question about the hospitalization: \"Are you satisfied with the information you received on your diseases and medication?\ufffd","1899":"numbers of positively response to the following question about the hospitalization: \"Are you satisfied with the planning before discharge from the hospital?\ufffd ","1900":"attitudes and behaviors related to Text4baby","1901":"effectiveness in posterior restoration.","1902":"reduce muscle damage.","1903":"Health-Related Quality of Life at 12 month - females","1904":"Health-Related Quality of Life at 12 month - males","1905":"Urinary Retention relief","1906":"systolic blood pressure","1907":"pulse pressure","1908":"Cough","1909":"tumour necrosis factor \u03b1","1910":"nuclear factor kappa beta","1911":"Blood glucose concentrations over 7.5 hours","1912":"%carbohydrate contribution","1913":"VO2max","1914":"abdominal pain, acid reflux, belching, heartburn, bloating, nausea, and vomiting","1915":"Mean scores of anxiety and depression","1916":"Positive well-being and vitality scores","1917":"Self-control domain","1918":"the mean analgesic requirement","1919":"Abnormal ejaculation","1920":"the mean of the gastric pH alteration","1921":"Nevi hyperpigmentation","1922":"Incidence of pneumonia","1923":"Self-reported leisure-time physical activity ","1924":"Score of needle visibility","1925":"Block performance time","1926":"Number of needle passes","1927":"The length of time spent wearing the assigned shoes","1928":"The subjective fatigue on day 3.","1929":"Fasting blood glucose","1930":"Pain interference change","1931":"Mean parental CGI scores - receptive language","1932":"Mean parental CGI scores - eye contact","1933":"sensory\/cognitive awareness","1934":"Low-density lipoprotein cholesterol (LDL-C0 ","1935":"Externalizing symptoms","1936":"internalizing symptomatology","1937":"level of second theta power peak","1938":"The hidden blood loss after TKA","1939":"colour task","1940":"incidence of overestimates","1941":"pigmentation, vascularity, pliability, and height","1942":"diastolic diameter","1943":"carotid to radial pulse transit time standard deviation","1944":"Arterial stiffness","1945":"electromyographic (EMG) activity of infraspinatus ","1946":"oropharyngeal seal pressure in right position","1947":"the time to first re-admission for COPD exacerbation","1948":"the number of all-cause re-admissions over a period of six months","1949":"episodes of COPD-related re-admissions or ER visits per capita","1950":"duration of operation","1951":"Adverse events","1952":"The frequency of serious adverse events","1953":"signs of grade 1 mucositis at the end of the first week","1954":"risk of new or worsening vertebral fracture at 24 months among females","1955":"C-telopeptide of type 1 collagen (CTX-1), bone-specific alkaline phosphatase (BSAP) at 1 month","1956":"C-telopeptide of type 1 collagen (CTX-1) - at 1 month, bone-specific alkaline phosphatase (BSAP) at 3 month","1957":"body weight and BMI","1958":"Matsuda index of insulin sensitivity (Matsuda ISI) during the 4-year follow-up","1959":"Operating time","1960":"oocyte yields among women with diminished ovarian reserve","1961":"the average number of days of pain in individuals who had mild and severe pain","1962":"the average number of days of pain in individuals who had moderate degree pain","1963":"PF: Physical function, BP: Body perception,VT: Vitality, MH: Mental health","1964":"RP: Role-physical","1965":"bone mineral density (BMD)","1966":"estradiol (E2)","1967":"total equivalent amount (TEA)","1968":"The mean skeletal morbidity period rate (SMPR) for all new bone events","1969":"bone events requiring radiotherapy","1970":"risk reduction for a skeletal event","1971":"surgeons graded outcomes for ultrasound-guided reduction","1972":"amount of dissatisfaction for breathing difficulty during exercise","1973":"The mean CALs after 3 months ","1974":"COPD exacerbation","1975":"The probability of the occurrence of a primary end-point event","1976":"risk of death and stroke","1977":"The sedation scores","1978":"the mean intensity of pruritus","1979":"The mean duration of a successful reduction","1980":"the possibility of manipulation","1981":"Adjective Rating Scale for Withdrawal (ARSW) score","1982":"Clinical Opiate Withdrawal Scale (COWS) score","1983":"VAS score","1984":"Mean (SD) age","1985":"Using of Intention-to-treat (ITT) analysis for Beck Depression Inventory (BDI) scores","1986":"Using structural mean modelling (SMM) approach for Beck Depression Inventory (BDI) scores","1987":"physical health (SF-12 physical subscale score)","1988":"reduced cardiovascular risk.","1989":"Change in haemoglobin, iron status indicators, and worm infection","1990":"Change in haemoglobin, iron status indicators, and worm infection","1991":"neurodevelopment disorder in young children","1992":"Growth retardation in young children","1993":"Improvement on PGIC","1994":"Serum insuline concentrations over 7.5 hours","1995":"Serum FFA over 7.5 hours","1996":"Fasting blood lactate levels","1997":"Serum interleukin-10 (IL-10)","1998":"Pedometer counts per week","1999":"Complications","2000":"Satisfaction of the patients and physicians","2001":"HbA1c levels","2002":"Insulin and cholesterol levels","2003":"The number of attempts","2004":"speeding of RTs at the long interval","2005":"CADSS time perception subscale","2006":"pigmentation, vascularity, pliability, and height of the scar","2007":"augmentation index","2008":"systolic diameter","2009":"distensibility coefficient (DC)","2010":"final cure rate ","2011":"electromyographic (EMG) activity of anterior deltoid muscle","2012":"Progesterone (PRG) and Luteinizing Hormone (LH) levels in group APMM","2013":"High Density Lipoprotein (HDL) level ","2014":"oropharyngeal seal pressure in extension","2015":"minor airway interventions","2016":"The oropharyngeal seal pressure during neck extension","2017":"incidence of post-operative sore throat","2018":"numbers of positively response to the following question about the hospitalization: \"Did you get the nursing from the ward staff that you needed?\ufffd","2019":"overall response rate","2020":"percent change in fitness","2021":"incidence of the withdrawal movements","2022":"postoperative in-hospital stay","2023":"Diastolic BP","2024":"high-density lipoprotein","2025":"triglycerides","2026":"monocyte chemoattractant protein-1","2027":"maximal glucose value","2028":"total cholesterol, LDL-c, and non-HDL-c levels","2029":"Triglycerides concentrations","2030":"concentrations of zinc and selenium of studied groups.","2031":"increase in IL-6 levels","2032":"objective stress index","2033":"systolic blood pressure","2034":"sleep quality","2035":"The rate of H. pylori eradication","2036":"stone expulsion rate","2037":"mean expulsion time","2038":"The average number of hospital visits for colicky pain","2039":"side effects such as headache, dizziness, orthostatic hypotension, and backache","2040":"cortisol secretion or growth hormone concentration","2041":"PVF values for the most severely affected limb","2042":"PI change (\u2206 T3-T0) on the ability to rise to standing","2043":"proliferation index of \u03b3\u03b4-T cells","2044":"ability of PBMC to secrete interferon-\u03b3 (IFN-\u03b3)","2045":"total number of symptoms of influenza","2046":"The mean best-corrected visual acuity (BCVA) at 1 month, and at 4 months","2047":"Allogeneic transfusion requirements","2048":"The mean heart rate","2049":"mean arterial pressure (MAP)","2050":"The Ramsay Sedation Scores","2051":"Chromatic alterations","2052":"Contrast-induced nephropathy","2053":"Age and sex of the patients at baseline","2054":"Serum creatinine","2055":"Improvement in symptom score","2056":"Improvement in peak nasal inspiratory flow","2057":"Birch\ufffdpollen\ufffd and Bet v 1\ufffdspecific immunoglobulin levels","2058":"Weight loss","2059":"Changes in waist circumference","2060":"Improvement in eating habits","2061":"Mean lutein concentration at baseline","2062":"Mean lutein concentration at week 12","2063":"All adverse events","2064":"level of pain","2065":"range of motion","2066":"strength","2067":"percentages of migrated isoforms (PMI) on days 4 and 11","2068":"Mortality rate","2069":"Verbal numerical rating scales after incision","2070":"Observer's Assessment of Alertness\/Sedation scores after incision","2071":"Satisfaction scale of physicians and patients","2072":"Risk of death in the first four months","2073":"Transcallosal inhibition in women","2074":"Transcallosal inhibition in men","2075":"Vitiligo Area Scoring Index score","2076":"Alertness after exercise","2077":"Appetite control","2078":"Improvement of cardiac index in persistent\/recurrent patients","2079":"Changes in TLR5 and TLR10","2080":"Enamel wear","2081":"COP path length in the AP plane","2082":"Vibration frequency","2083":"Amplitude parameters","2084":"Differences between self-reported and measured body mass index","2085":"Time course of total pain relief (TOTPAR)","2086":"serum level of blood urea nitrogen (BUN) and creatinine (Cr)","2087":"The CANDEN spine inflammation score","2088":"decline in the percentage of sites harboring Tannerella forsythia (Tf)","2089":"percentage of Prevotella intermedia (Pi) and Porphyromonas gingivalis (Pg)","2090":"score on the general dimension scale of negative affects (referred to as NA from here onward)","2091":"The bending stiffness anterior-posterior, medial-lateral and the torsional stiffness ","2092":"fasting blood glucose (FBG)","2093":"fasting blood glucose (FBG) levels","2094":"serum lipids","2095":"The mean preoperative refraction and cylinder","2096":"Mean postoperative cylinder 3 and 6 month after PRK","2097":"haze formation rate","2098":"pain scores at rest at 8 hours and at 16 hours ","2099":"pain score on movement","2100":"Young Mania Rating Scale (YMRS) on the first day","2101":"YMRS and the BPRS scale over the course of 4 weeks","2102":"Mean\u00b1SD level of blood glucose before sleeping at 28 weeks of pregnancy","2103":"Mean\u00b1SD of differences in levels of fasting blood glucose between 28 and 32 weeks and between 28 and 36 weeks of pregnancy","2104":"MAP and HR","2105":"proportion of patients with a negative malaria test result prescribed an antimalarial in integrated management of infectious diseases (IMID)- mid-level practitioners (MLP) group","2106":"Within the No-IMID subgroup - the proportion of emergency and priority patients admitted, detained or referred","2107":"fatty acid oxidation (FAO)","2108":"Hunger, Prospective eating, desire to eat (Pre, immediately before, after, and 30 min post exercise).","2109":"adverse events","2110":"analgesic requirement","2111":"Disposition index (DI) and incremental area under the curve for insulin (AUCi) ","2112":"volume of O2 maximum (VO2max), systolic blood pressure (SBP) , white blood cell (WBC) and diastolic blood pressure (DBP)","2113":"The survival times","2114":"rating the quality of the physician's explanation","2115":"rate of retention","2116":"pulse wave velocit (PWV), elastic modulus (Ep), forward expansion wave that decelerates flow and reduces pressure (W2), negative area (NA), and (RC) reflection coefficient ","2117":"coronal growth of approximal gingival margin on the neighboring teeth","2118":"embarrassment and problems with taste, speech, gum color, tooth color and the visibility of the implant","2119":"bone apposition","2120":"residual antimicrobial activity of CHX at one week and at three and six weeks","2121":"success rate of inferior alveolar nerve block (IANB) in posterior mandible teeth with symptomatic irreversible pulpitis.","2122":"Story recall improved at post-intervention","2123":"thematic recall","2124":"category fluency at follow-up","2125":"the VAS scores after surgery","2126":"pain level","2127":"fracture resistance","2128":"The stability of pacing during follow-up","2129":"the time to maximum concentration","2130":"The frequency of rescue medication","2131":"serums Vit D level","2132":"The Functional Assessment of Cancer Therapy\/National Comprehensive Cancer Network Ovarian Symptom Index (FOSI)","2133":"cumulative plaque scores","2134":"insulin sensitivity","2135":"inflexion-extension and lateral bending for the C2-C6, C2-C4, C4-C5, and C5-C6 segments","2136":"new bone formation around the screws and bone-implant contact (BIC) in both sections","2137":"M. tuberculosis or nontuberculous mycobacteria detection","2138":"sleep disturbances","2139":"average severity scores of hot flashes and night sweats","2140":"average severity scores of hot flashes and night sweats","2141":"first analgesic administration","2142":"Enamel hardness","2143":"Global intellectual ability (IQ)","2144":"hyperglycemia relapse-free survival","2145":"Cox proportional hazards of failure-free survival","2146":"epileptiform discharges after 1, 2, and 6 month","2147":"Connectivity and the compression strength and the maximum axial torque","2148":"Quality of life score regarding satisfaction","2149":"AUCinf (ng h\/mL), Cmax, t1\/2 in Caucasian and Japanese","2150":"number of patients and dosage of esmolol","2151":"HbA1c levels within 12 months","2152":"estimated proportion of emergency patients who received at least one appropriate treatment","2153":"creatinine (Cr)","2154":"the rate of memory retention","2155":"Improvement in 6 min walk distance at week 16","2156":"adverse events (AE): respiratory AE (cough)","2157":"Changes in TLR3, TLR7, TLR8, and IRF7","2158":"CD8\u03b2 expression","2159":"Differences between self-reported and measured height","2160":"assessment of tolerability","2161":"pain intensity difference (PID)","2162":"serum level of blood urea nitrogen (BUN) ","2163":"the lung injury score","2164":"adverse events (AE): gastrointestinal complaints, primarily stomatitis\/aphthous ulcers","2165":"Stork test of balance","2166":"Oocyte yield","2167":"scores for anger, fatigue, or confusion","2168":"sociability score","2169":"cognitive function for the word , color, or color-word tests","2170":"proliferation levels of RNA","2171":"The trabecular number","2172":"the trabecular spacing (Th.Sp.),","2173":"the trabecular thickness","2174":"fasting blood glucose (FBG) levels","2175":"self-rated understanding of disease stat","2176":"Mean postoperative sphere in 3 and 6 months after PRK.","2177":"Collagen III and IV","2178":"Time to bowel recovery, incidence of nausea\/vomiting, mean length of hospitalization","2179":"patient satisfaction","2180":"mean level of blood glucose, 2 hours after lunch at 28 weeks of pregnancy","2181":"Rate of postpartum glucose screening test","2182":"proportion of patients with a negative malaria test result prescribed an antimalarial","2183":"estimated proportion of patients with acid-fast bacilli (AFB) smear negative results who received empiric treatment for acute respiratory infection in integrated management of infectious diseases (IMID)- mid-level practitioners (MLP) group","2184":"Within the No-IMID subgroup - estimated proportion of emergency patients who received at least one appropriate treatment","2185":"HR","2186":"Rate of rebleeding","2187":"HBeAg sero-conversion rate","2188":"Apnea","2189":"Risk of death after 4 months","2190":"The restricted mean time to hyperglycemia relapse","2191":"Baseline characteristics","2192":"Positive and Negative Syndrome (PANS) Scale","2193":"Baseline characteristics such as age, sex, and distribution of vitiligo patches ","2194":"Rate of side effects or laboratory abnormalities","2195":"Exercise-induced Creatine kinase (CK)","2196":"Thirst after exercise","2197":"exercise-related loss of muscle strength","2198":"Glutathione peroxidase (GPxP)","2199":"physician's explanation of their treatment","2200":"Pulmonary vascular resistance","2201":"effectiveness of the visualization","2202":"Mean pulmonary artery pressure","2203":"the effects of the program 1 year after completing the intervention","2204":"the use of aggressive strategies as an interpersonal conflict-resolution technique","2205":"assertive social interaction strategies, attention, and emotional clarity","2206":"retrograde shear","2207":"story recall at post-intervention","2208":"The effective pacing rate immediately after the procedure","2209":"The effective sensitivity rate","2210":"improving of level laterality cofactor (LCF) in cerebellum network included bilateral cerebellum hemispheres (CereN)","2211":"improving of level laterality cofactor (LCF) ","2212":"global LCF of CereN","2213":"maximum observed plasma concentration after oral administration (Cmax) and predicted area under the plasma concentration time curve after the last dose from zero time to infinity (AUC0\u2013last)values","2214":"t1\/2","2215":"mood scales, stress scales","2216":"the plaque index score and gingival index score","2217":"pocket depth, clinical attachment level (CAL), and percentage of bleeding on probing (BOP)","2218":"Exercise","2219":"The percentage of participants who modified diet","2220":"APTB adequate specimens collection ","2221":"domain scores pertaining to sleep efficiency, sleep duration, or daytime dysfunction","2222":"Changes in gene expression","2223":"Differences between self-reported and measured weight","2224":"assessment of tolerability","2225":"vigor","2226":"tension, depression","2227":"adverse events","2228":"BMI","2229":"The seizure recurrence rate over 24 months","2230":"intensity of staining","2231":"The mean total sufentanil consumption at 48 hours ","2232":"Mean\u00b1SD level of blood glucose 2 hours after breakfast at 28 weeks of pregnancy","2233":"Side effects ","2234":"number of patients per provider per month from Time 0 to Time 1","2235":"estimated proportion of malaria cases who received an appropriate antimalarial in integrated management of infectious diseases (IMID)- mid-level practitioners (MLP) group","2236":"prospective eating score","2237":"Hyperglycemia relapse-free survival","2238":"The 2-year failure rate","2239":"Demographic characteristics","2240":"The probability of relapse","2241":"Systolic and diastolic blood pressure","2242":"Quality of life score regarding importance","2243":"functioning at longer-term follow-up","2244":"Movement induced pain (VAS)","2245":"Mental fatigue after exercise","2246":"Interleukin 6","2247":"Improvement of cardiac index in inoperable patients","2248":"changes in diet, physical activity, and weight loss","2249":"pretest\u2013posttest change","2250":"attention, clarity, emotional repair, assertive cognitive social interaction strategies, internal control of anger and the cognitive ability to analyze negative feelings","2251":"diastolic antegrade and mean shear","2252":"numbers of positive proton pump inhibitor (PPI) test","2253":"numbers of positive proton pump inhibitor (PPI) test","2254":"Small dense low-density lipoprotein cholesterol (sd-LDL-C) level at 52wks","2255":"The median progression-free survival (PFS)","2256":"At 6 months, the rate of overall survival","2257":"Median overall survival (OS)","2258":"Patients who consented to be measured","2259":"Residual antimicrobial activity","2260":"Residual antimicrobial activity","2261":"gains in episodic memory","2262":"story recall at post-intervention","2263":"Anal exsufflation time","2264":"The visual analog scale (VAS) scores","2265":"Postoperative nerve compression symptoms ","2266":"systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP) and saturation levels","2267":"changes in Ramsey scores","2268":"fracture resistance","2269":"The rate of adverse event","2270":"The proportion of patients who were pain-free at 4 hours without rescue medication","2271":"cumulative hazard of migraine recurrence","2272":"nausea, photophobia , and phonophobia","2273":"adverse events","2274":"LCF ","2275":"LCF of lFPN ","2276":"mean level of proteinuria","2277":"fasting blood sugar (FBS), glycosylated hemoglobin (HbA1C), erythrocyte sedimentation rate (ESR) and C-Reactive Protein (CRP) levels","2278":"Trial Outcome Index (TOI)","2279":"Functional Assessment of Cancer Therapy Ovarian (FACT-O) questionnaire","2280":"magnitude of QTc interval prolongation","2281":"oral clearance (CL\/F) and V\/F values","2282":"primaquine terminal elimination half-life; (t1\/2)","2283":"carboxyprimaquine exposures","2284":"V\/F","2285":"clinical attachment level (CAL)","2286":"the three-way interaction of probe location, picture type, and group","2287":"compatibility effect","2288":"compatibility effect","2289":"main effect of training on the stress ratings","2290":"tension","2291":"plasma cathepsin S levels","2292":"The average score of overall attitude, oral health attitude, and diabetes attitude","2293":"The percentage of participants who received foot examination, always wore covered shoes, and participated in screening of feet","2294":"surgery time, blood loss, recovery time, and time before eating","2295":"The stiffness","2296":"Bacteriological confirmation","2297":"The mean number of login attempts","2298":"INTERHEART risk score (IHRS)","2299":"The daily body weight gain from SD 1 to SD 29","2300":"Peripapillary nerve fiber layer thickness","2301":"Complications","2302":"The tipping","2303":"Tumor volume after 2 years of therapy","2304":"Rate of local recurrence","2305":"Treatment time","2306":"adjusted mean change of PEF","2307":"abnormalities in haematology or blood chemistry parameters","2308":"Baseline characteristics","2309":"systolic and diastolic BP","2310":"Systemic adverse events","2311":"Pulse rate during surgery","2312":"Pulse rate and blood pressure after surgery","2313":"Levels of NO3 \u2212 in plasma","2314":"Improvement in Glasgow outcome score at 6 months post-trauma","2315":"Improvement in Glasgow outcome score at 6 months post-trauma","2316":"Continued abstinence at 1 year","2317":"fracture resistance","2318":"pain scores after six weeks","2319":"pH of abomasal outflow fluid for 4 hours","2320":"Th1 and Th1\/Th2","2321":"The elasticity of the major vessels, i.e., the movement of vessel wall between the systole and diastole, as well as blood velocity within these vessels","2322":"glucose infusion rate (GIR)","2323":"intention to seek information about clinical trials","2324":"intention to seek information about clinical trials","2325":"Judge 2's performance quality ratings between time 2 and 3","2326":"folate intakes","2327":"patients, who achieve the BP target of systolic\/diastolic BP < 140\/90 mmHg","2328":"implant infection","2329":"Pain on cervical dilatation","2330":"MADRS remission rates in patients with baseline MADRS total scores \u226520","2331":"The mean astigmatic refractive error","2332":"pain or range of motion (ROM) improvement","2333":"Cases of pancreatic cancer","2334":"mean pain intensity","2335":"heat pain thresholds (HPT)","2336":"the number of days with diarrhoea and the number of piglets that had diarrhoea","2337":"handgrip strength","2338":"Time for rescue analgesia","2339":"mean arterial pressure (MAP) falls","2340":"dental plaque on smooth and approximal tooth surfaces after 14 days","2341":"mean values of plaque indices after 14 days","2342":"Antigens of co-administered vaccines","2343":"Serious adverse events","2344":"Reactogenicity and safety profiles","2345":"Mean values of the SBI after 42 days","2346":"the incidence of positive urine dipstick albumin","2347":"Quality of fetuses","2348":"IL-2 and TNF-\u03b1","2349":"Effectiveness at day 28","2350":"Effectiveness at day 42","2351":"the number of piglets that excreted countable oocyst numbers","2352":"Subfoveal choroidal thickness","2353":"wrist flexion, hip flexion, knee extension, and ankle dorsiflexion","2354":"Tumor size before or after surgery","2355":"Use of statins and anti-platelet therapy at 18 months","2356":"The time taken for complete sensory recovery","2357":"Rate of complications","2358":"healthy eating behaviour","2359":"Improvement of systolic and diastolic blood pressure","2360":"weight loss","2361":"Cardiac output during spinal anesthesia","2362":"Heart rate","2363":"HbA1c levels after 12 months","2364":"VAS score","2365":"Analgesia duration ","2366":"total AUC for Total Energy Expenditure (TEE)","2367":"Performance","2368":"Central retinal thickness","2369":"Mesial movement of the second premolars","2370":"the proportion of healthy items in total items chosen,","2371":"Insulin requirements at 6, 12, and 24 months","2372":"C-peptide response","2373":"Levels of calcium and phosphate","2374":"pre-dose morning FEV1","2375":"Hypotension","2376":"The ACQ scores","2377":"Cardiac output during spinal anesthesia","2378":"The percentage changes in lumbar BMD","2379":"BAP (U\/l),NTX (nmol BCE\/l)","2380":"CFU\/g reduction in bacterial density of Pseudomona aeruginosa ","2381":"Time to first pulmonary exacerbation","2382":"BMI and waist to hip ratio","2383":"Requirement of antibiotics for pulmonary exacerbation","2384":"Requirement of fentanyl during surgery","2385":"Level of VO2 max after 5 minutes into cycling time trial to exhaustion at 100%VO2max","2386":"Systolic blood pressure","2387":"Overall outcomes","2388":"Use of the interdisciplinary diabetes care teams in primary care physicians and patients","2389":"Improvements in levels of HbA1c and LDL-cholesterol at 18 months","2390":"Continued abstinence at 1 year","2391":"laryngoscopy duration, laryngospasm, bronchospasm, laryngoscopy failure, extremity movement, awakening","2392":"pain scores after 12 weeks","2393":"total time spent on PA ","2394":"Least square means and standard deviation pH of abomasal outflow fluid","2395":"endogenous glucose production (EGP)","2396":"self-reported Music performance anxiety (MPA)","2397":"Judge 2's performance quality ratings between time 1 and 3","2398":"mean number of attacks per day","2399":"levels of vascular cell adhesion molecule-1 (sVCAM-1), Soluble intercellular adhesion molecule-1 (sICAM-1), The monocyte chemoattractant protein-1 (MCP-1)","2400":"TLR-4 and ALP levels","2401":"Survival from NIV months","2402":"Meantime needed for further cervical dilatation","2403":"Montgomery-Asberg Depression Rating Scale (MADRS) total score changes in patients with baseline MADRS total scores \u226520 on day on day 7 and 21","2404":"LS mean \u00b1 SE changes in MADRS total score in patients with a mixed episode at baseline","2405":"In patients with baseline CGI-BP-D severity score \u22654, MADRS remission rates","2406":"In patients with a mixed episode at baseline, MADRS remission rates","2407":"California verbal learning test (CVLT), and symbol digit modality test (SDMT)","2408":"The Efron grading scale scores","2409":"Cases of pancreatic cancer","2410":"The time taken for two-segment sensory regression","2411":"Immune response","2412":"Cephalea relief at 24 hours","2413":"Side effects","2414":"change in anthropometric measurements, weight, performance status, energy, mood or pain","2415":"static and dynamic balance and cadence","2416":"static balance, dynamic balance, velocity, and cadence","2417":"Number of oocytes or M2 oocytes","2418":"The annual change in eGFR","2419":"IL-10 level","2420":"Adequate clinical and parasitological response rates at days 28 and 42","2421":"Hemoglobin levels at days 14 and 28","2422":"bradycardia, hypotension and level 4 sedation","2423":"treatment success in non-ICU subjects","2424":"Mortality","2425":"The incision length","2426":"The maximum difference in summed pain intensity differences (SPID)","2427":"HBeAg levels","2428":"Mean weight changes of neonates 7 weeks","2429":"reaction time in simple speeded response task ","2430":"blood pressure","2431":"ApoA-I and HDL-mediated cholesterol effluxes","2432":"relief of overall symptoms","2433":"Distant metastasis","2434":"Mean antibody reactivity against the associated HPV","2435":"relationship equity","2436":"postoperative pain on day 5","2437":"glomerular filtration rate (eGFR)","2438":"body weight","2439":"The Mini Mental State Examination (MMSE)","2440":"better compliance","2441":"number size framing effect","2442":"Energy intake","2443":"the amount of fat","2444":"difference in the weight","2445":"strong ion difference (SID)","2446":"The changes in visual analog scale","2447":"The changes in McGill pain questionnaire","2448":"Right (cm)\u2021","2449":"Timed Up and Go (TUG) (sec)\u2021","2450":"KMI and hot flash\/sweating score","2451":"estradiol (E2) leve","2452":"follicle-stimulating hormone (FSH), luteinizing hormone (LH)","2453":"The maxillary molars movement","2454":"The speed of maxillary molar distalization","2455":"Lipid profile improvement after 8 months","2456":"Lipid profile improvement after 16 months and 24 months","2457":"A1C levels at 6, 12, and 24 months","2458":"The mean average use of rescue medication","2459":"Adverse events","2460":"FSSG score","2461":"FEV1, SGRQ total score, and 6MWT distance","2462":"Visual analog scale scores","2463":"Level of VO2 max after 5 minutes into cycling time trial to exhaustion at 100%VO2max","2464":"Improvement in Glasgow outcome score at 6 months post-trauma","2465":"Continued abstinence at 1 year","2466":"aorta wall thicknesses","2467":"E-selectin, metalloproteinase-9 (MMP-9), Granulocyte colony-stimulating factor (G-CSF) , and Vascular endothelial growth factor (VEGF)","2468":"Perioperative side effects of which preoperative abdominal cramp and nausea vomiting","2469":"the myopic refractive error","2470":"Individual patient responses","2471":"PREPOST, STIM and BLOCK ","2472":"handgrip strength","2473":"The onset time of sensory block","2474":"Heart rate falls","2475":"reduction in gingival inflammation after 42 days","2476":"appetite between weeks 0 (pre-study) and 3 and 0 and 6","2477":"Cephalea relief at 2 hours","2478":"serum thyroid binding pre-albumin and retinol binding protein","2479":"Overall cephalea relief and improvement of associated symptoms","2480":"Number of follicles","2481":"Total number of fetuses","2482":"Fertility outcomes","2483":"The number of days with AF detectable excretion and the number of piglets that excreted AF detectable oocysts","2484":"high-sensitive-C-reactive protein (hs-CRP) after 6 weeks","2485":"systolic blood pressure (SBP)","2486":"serum 25(OH)D from baseline to study","2487":"treatment success in ICU subjects","2488":"Relative and absolute flow-mediated dilation (FMD) ","2489":"IL-6, ET-1 levels","2490":"Household smoking bans ","2491":"Birth status","2492":"ureteropelvic junction obstruction","2493":"Hematoma enlargement","2494":"Secondary brain herniation.","2495":"neurological status","2496":"discriminative formula","2497":"The time taken to complete the approach","2498":"blood lost","2499":"intraepidermal nerve fiber density (IENFD) to 1 month","2500":"Mean hospitalization time","2501":"mRNA stability","2502":"arginine and ornithine","2503":"daily bloating and gas in all 12 weeks","2504":"neutropenia , leucopenia , thrombocytopenia , and anemia","2505":"positive rate of HUTT (Head-up tilt testing (HUTT) after 30 days","2506":"relationship control, gender norms supporting female autonomy in relationships","2507":"postoperative complications","2508":"rates of minor to moderate hypoglycemia","2509":"Activities of Daily Living (ADL) score","2510":"positive evaluation","2511":"risk seeking","2512":"VO2 at 40, 60 and 80% of VO2max","2513":"Posterior (cm)\u2021","2514":"Left (cm)\u2021","2515":"BBS: Berg Balance Scale","2516":"KMI and hot flash\/sweating score","2517":"follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) level and endometrial thickness","2518":"incidence of vaginal bleeding, breast distending pain","2519":"Baseline age and level of education of the mothers","2520":"Proportion of emotionally distressed parents at 6 months","2521":"Adherence","2522":"Decrease in intraocular pressure","2523":"Satisfaction with information given about travoprost","2524":"Baseline intraocular pressure","2525":"Face and scalp sensations","2526":"Improvement of rash sites","2527":"Use of non\ufffdcoplanar beams","2528":"P2Y12 reaction unit (PRU) values higher than 235","2529":"Adverse effects","2530":"Sensitivity and specificity","2531":"Self-reported pain intensity","2532":"Time of onset of anesthesia","2533":"Time of anesthesia action","2534":"Overall satisfaction score of the participants and operators","2535":"Trismus","2536":"Recurrence of bacterial vaginosis after 6 months","2537":"Baseline characteristics ","2538":"Signs and symptoms of bacterial vaginosis","2539":"Overall satisfaction of the patients","2540":"Improvement according to the patients at the M12 and M18 visits","2541":"Postprandial triglycerides","2542":"Serum leptin","2543":"Demographic and anesthetic parameters","2544":"Cumulative fentanyl dose","2545":"Value of the Touch-Test sensory evaluation after surgery","2546":"Improvement in Psoriasis Area and Severity Index \u226575% after 24 weeks","2547":"Improvement in Psoriasis Area and Severity Index \u226550% and \u226590% after 24 weeks","2548":"Physician's Global Assessment of clear\/almost clear","2549":"Reduction in body weight after 20 weeks","2550":"Lipid parameters","2551":"Levels of nitrate\/nitrite (NOx), cortisol, and high sensitivity C-reactive protein (hs-CRP)","2552":"Body fat","2553":"Intermediate and near clarity-of-vision","2554":"rate pressure product (RPP)","2555":"the ratio of the maxillary molar distalization movement relative to the overall opening space between the molars and second premolars","2556":"renal function in ICU and non-ICU subjects","2557":"Embryo quality","2558":"diagnose restriction","2559":"discriminative formula","2560":"light touch sensation in the feet","2561":"The pain score, swelling, incision redness, and discharge at 48 hours postoperative","2562":"incision redness, swelling, or discharge at 10 days postoperative","2563":"apoA-I- and HDL-mediated cholesterol efflux","2564":"weekly consistency relief","2565":"Baseline cervical dilatation","2566":"Incidence of recurrent syncope after 12 months","2567":"partner victimization","2568":"The mean consumption of tramadol hydrochloride","2569":"low-density lipoprotein-cholesterol (LDL-C)","2570":"risk for acute pancreatitis","2571":"intake of protein","2572":"The duration of analgesia","2573":"The intake of carbohydrates","2574":"the total MRC score of the legs","2575":"neck range of motion","2576":"plaque index and gingival index","2577":"KMI and hot flash\/sweating score","2578":"total cholesterol (TC)","2579":"Hemoglobin levels at days 7, 14, and 28","2580":"Change in rates of alcohol consumption per week","2581":"Score of Alcohol Use Disorders Identification Test ","2582":"Usage and positive rates of Normative Feedback, Cognitive Bias Re-training, Identity Change or Action Planning","2583":"Inhibition of food cravings","2584":"Plan preference, planner, or planning institution","2585":"Number of iterations","2586":"Hot spot located inside or outside the target","2587":"Dose delivered to normal tissues","2588":"P2Y12 reaction unit (PRU) values at 30 days","2589":"Life threatening bleeding events","2590":"Severity of pain","2591":"Shoulder Pain and Disability Index score","2592":"Laboratory parameters","2593":"Bleeding tendency","2594":"Glycosuria","2595":"Adverse events","2596":"Genital mycotic infections in women","2597":"Triglycerides and HDL-C levels","2598":"Correct selection of the healthier product","2599":"Taste perception and intent of purchase","2600":"grade 3 stomatitis","2601":"GAIS Scores","2602":"Insulin","2603":"Visual search performance","2604":"Hepatic disorders and asthenia","2605":"Progression-free survival","2606":"Survival rate","2607":"Anaerobic power after 12 weeks","2608":"Changes in epinephrine at 30-minute recovery","2609":"Decrease in IgA levels","2610":"Improvement in pain score","2611":"Blood pressure","2612":"Cardiovascular health parameters ","2613":"Total body mass and fat-free mass ","2614":"Voiding symptoms","2615":"carbon, calcium, nitrogen, phosphorus and strontium","2616":"audio\/visual memory, abstract thinking, memory retrieval, and combined total function test scores","2617":"combined total scores of the memory function","2618":"Pulse pressure variation (PPV) and stroke volume variation (SVV)","2619":"intensity of pain","2620":"clinically relevant finding\/action ('actionable visits')","2621":"unscheduled visits","2622":"non-office-based contacts","2623":"Internet sessions","2624":"in-clinic discussions","2625":"hospitalizations, shorter length-of-stay","2626":"total FU cost for providers","2627":"mean number of terminal hairs","2628":"hair shedding counts following hair washing","2629":"Self-Assessment Questionnaire score at Visit 2","2630":"total scores on the Quality of Life Questionnaire","2631":"moderate physical activity","2632":"incidence and severity of GI discomfort","2633":"Progression-free survival","2634":"forced expiratory volume in one second (FEV1)","2635":"rise in heart rate (HR)","2636":"the level of sedation","2637":"use of right-sided approach ","2638":"overall sensitivity and an accuracy in the detection of the metastasis","2639":"Disease-free survival (DFS)","2640":"Smoking status","2641":"Costs","2642":"disposition of patients from the OR to the intensive care unit","2643":"use of robotic technique","2644":"improvement in Hb by month 1","2645":"serum ferritin level by month 4","2646":"Primary outcome: the proportion of patients who did not have 70% resolution of ST-segment elevation and did not meet the criteria for Thrombolysis In Myocardial Infarction (TIMI) flow 3 at initial angiography. Secondary outcome: the composite of death, MI, stent thrombosis, stroke or urgent revascularisation and major or minor bleeding at 30 days.","2647":"Ferritin concentration","2648":"Percent iron absorption","2649":"Total amount of absorbed iron ","2650":"CRP levels","2651":"Service costs","2652":"whole-blood Se concentration","2653":"developing pre-eclampsia and pregnancy-induced hypertension (PE\/PIH)","2654":"the risk of stroke, all-cause mortality","2655":"precise Fischer tests 48 hours after treatment - reduction of redness","2656":"the risk of stroke\/systemic embolism , stroke, hemorrhagic stroke and systemic embolism","2657":"risk of stroke","2658":"Response duration","2659":"Dose reductions","2660":"Chi-square test - frequency distribution of the redness","2661":"sore throat 2 hours post\u2013operation","2662":"developed fasciculation","2663":"Muscle ache and fasciculation","2664":"The duration of sedation","2665":"The rates of continuous abstinence at the 48 month follow-up","2666":"The proportion of women who started using insulin during the intervention","2667":"gaining weight","2668":"glycemic index (GI) ","2669":"Clinically meaningful symptom","2670":"The mean LDL\/HDL ratio","2671":"fasting blood sugar (FBS)","2672":"The mean LDL\/HDL ratio","2673":"mean pain scores","2674":"mean ulcer size","2675":"informed about the treatment choice, aware of options, knowledgeable about treatment benefits, and knowledgeable about treatment risks\/side effects ","2676":"serum 25(OH)D at 4 weeks","2677":"Edinburgh postnatal depression scale (EPDS) scores","2678":"Adverse effect","2679":"Baseline characteristics","2680":"History of diseases or disorders that might influence the development of diaper dermatitis ","2681":"P2Y12 reaction unit (PRU) values at baseline","2682":"The pain score or swelling 24 hours postoperative","2683":"skin reactions","2684":"vomiting, diarrhea, anorexia, weight loss, and skin (irradiation field) toxicity","2685":"The mean consumption of dipyrone","2686":"urinary albumin-to-creatinine ratio (UACR)","2687":"edema","2688":"Pain scores as measured by the NRS at 6 hours and 24 hours after surgery","2689":"preferred the risky option","2690":"Neutropenia and leukopenia","2691":"Improvement in Psoriasis Area and Severity Index \u226550%, \u2265 75%, and \u226590% after 12 weeks","2692":"pain threshold (lb\/cm2)","2693":"plaque index and gingival index","2694":"terms of bleeding index","2695":"Uroflowmetry","2696":"Improvement in pain scores","2697":"Severity of IC symptoms at baseline","2698":"The state anxiety score","2699":"high-sensitive-C-reactive protein (hs-CRP) after 3 weeks","2700":"decision satisfaction, decision regret, cancer\ufffdrelated worry (Assessment of Survivor Concerns), mood, and trust in the treating physician, subscale measures of cancer worry or health worry of the Assessment of Survivor Concerns questionnairerespective anxiety, worry , interest, or depression measures of the Patient Health Questionnaire for Depression and Anxiety 4 mood screening questionnaire.","2701":"colloidal stability","2702":"carbon, calcium, nitrogen, phosphorus and magnesium","2703":"Vibriocidal responses to O1 Ogawa in the percentage seroconversion","2704":"oxygen; carbon; calcium; nitrogen; phosphorus; silicon and sodium","2705":"Pulse pressure variation (PPV) ","2706":"Pulse pressure variation (PPV) and stroke volume variation (SVV)","2707":"Pulse pressure variation (PPV) and stroke volume variation (SVV)","2708":"Subjective hypomnesis\/memory loss (SML)","2709":"follow-up (FU) visits","2710":"dentinal defects","2711":"the number of vellus hairs","2712":"terminal hair diameter","2713":"6-minute walk test, change in chair-to-standing repetitions","2714":"Overall survival","2715":"The median relative dose intensity per patient","2716":"standardized area under the curve for FEV1 from 0 to 12 hours (FEV1 AUC0\u201312 hours)","2717":"rate of moderate or severe exacerbations","2718":"The incidence of pneumonia","2719":"Total Points (TP) score","2720":"Total Points (TP) score","2721":"removal of more involved lymph nodes, their stations","2722":"Overall survival (OS)","2723":"Attitudes Towards Nicotine Replacement Therapy Scale (ANRT-12)","2724":"Attitudes Towards Smoking Scale (ATS-18)","2725":"Smoking Self-Efficacy Questionnaire (SEQ-12)","2726":"Number of cigarettes smoked per day","2727":"length of stay (LOS)","2728":"Utilization of total parenteral nutrition","2729":"Time to regular diet","2730":"percentage of reticulocytes at day 7","2731":"improvement in Hb by month 4","2732":"Iron content","2733":"quantitative contour sharpness","2734":"contrast-to-noise ratios (CNR) ","2735":"Scanning times","2736":"The mean signal-to-noise (SNR) values","2737":"CRP levels","2738":"Erythrocyte sedimentation rate (ESR)","2739":"lipid profile","2740":"Adverse effect","2741":"The risk of major bleedings","2742":"major bleedings, intracranial bleedings, and death from any cause","2743":"gastrointestinal bleeding, myocardial infarction","2744":"anemia (AN)","2745":"peripheral neuropathy (PNP)","2746":"hand-foot syndrome, cough and phlebitis","2747":"Peripheral neuropathy","2748":"diarrhea, edema of the limbs","2749":"Serious adverse events (SAEs), Admission to the hospital due to a SAE","2750":"Decrease in body weight, VO2max, and % fat","2751":"At 12 and 24 hours post operation","2752":"Mortality at day 90","2753":"procedure-related complications","2754":"dead without tracheotomy","2755":"The crude 90-day mortality","2756":"The rates of continuous abstinence from month 24 to the end of month 30","2757":"The mean exhaled CO","2758":"Fasting plasma glucose","2759":"Fasting plasma glucose","2760":"risk of preeclampsia, intrauterine, and neonatal death","2761":"Service costs","2762":"Chi-square test - reduction of redness 2 days after treatment","2763":"recovery of the bed wound","2764":"recovery time","2765":"the proportions of malaria cases among all health facility attendance (all causes diseases)","2766":"incidence of disease episodes","2767":"Non-malaria diseases treated at the health facility level","2768":"Presence of diastolic dysfunction during hospitalization","2769":"Presence of diastolic dysfunction after 4 months ","2770":"incidence of eye pain and influenza","2771":"eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma, Red Blood Cell Count (RBC), and PBMC (\tPurified Blood Mononuclear Cells)","2772":"Improvement in Sexual Intercourse Attempt diary scores","2773":"Improvement in Sexual Health Inventory of Men","2774":"(Disease Activity Score in 28 joints, Health Assessment Questionnaire Disability Index and 36-item Short Form Health Survey scores","2775":"Means scores of expectations and childbirth self-efficacy","2776":"Baseline characteristics","2777":"Scores of external regulation and amotivation","2778":"Body mass index","2779":"Baseline ranges of HR, MAP, and QTc intervals","2780":"Tp-e interval","2781":"Shear bond strength","2782":"ARI degrees","2783":"Glycemic response after dinner","2784":"Area under the curve (AUC)","2785":"Reduction in FVC, FEV-1, and PEFR after surgery","2786":"fluency","2787":"periodontal disease","2788":"gastrointestinal (GI) side effects","2789":"The overall Fight Gone Bad (FGB)","2790":"maximum carbon dioxide production","2791":"Patient satisfaction","2792":"recurrent episodes of bronchiolitis in the first year","2793":"International Index of Erectile Function (IIEF) questionnaire","2794":"\u226550% restenosis","2795":"the risks of 50% or more restenosis","2796":"scores for the Mobility subscale","2797":"scores of WSC total scale, horizontal and vertical dimensions","2798":"nervousness, muscle twitching, and sweating","2799":"headache, or nausea","2800":"total side effect intensity","2801":"Use of midwife contacts","2802":"Mean age and work experience of the midwives","2803":"Hours elapsed since the participant's last meal","2804":"P2Y12 reaction unit (PRU) values at 30 days","2805":"Motion range","2806":"Positive Predictive Value or Negative Predictive Value","2807":"Body weight reduction","2808":"Scores on the saturated fat, sugar, and sodium quizzes","2809":"Rates of pain","2810":"Swelling","2811":"Probability of being free of BV relapse (survival analysis of Kaplan Meyer)","2812":"Expression of substance P (SP) and calcitonin gene-related peptide (CGRP)","2813":"Storage of dietary fatty acids (FA)","2814":"Visual detection time","2815":"Consumption of additional analgesics","2816":"Changes in % fat, VO2max, and HRmax","2817":"Changes in electrochemical skin conductance in the foot","2818":"Lipid profile","2819":"High contrast visual acuity at 40 cms","2820":"Overall vision satisfaction and ocular comfort","2821":"Purchase preferance","2822":"HAS shrinkage and alteplase effect","2823":"HIV RNA <50 copies\/mL","2824":"DHA","2825":"cost","2826":"cost","2827":"cleaning efficacy in the coronal third","2828":"shaping ability","2829":"shaping ability","2830":"preparation time","2831":"biopsy-proven acute rejection (BPAR)","2832":"Patient survival at 1 year","2833":"Delayed graft function","2834":"the serum creatinine at 12 months post-transplant","2835":"leukopenia","2836":"change in energy expenditure","2837":"Changes in metabolic rate (MR) (kcal\/min and kcal\/min\/kg ffm)","2838":"Changes in metabolic rate (MR) (kcal\/min and kcal\/min\/kg ffm)","2839":"Final tumor size","2840":"Mean Ki-67","2841":"C-peptide (ng\/mL)","2842":"total cholesterol, LDL-cholesterol, or high-density lipoprotein (HDL)-cholesterol levels","2843":"plasma \u03b2-carotene concentrations","2844":"plasminogen activator inhibitor 1 (PAI-1) concentrations","2845":"plasminogen activator inhibitor 1 (PAI-1) concentrations","2846":"AAA extinction learning","2847":"achieving pathologic complete response","2848":"quality of life score and side effects","2849":"SF-36 mental component summary (MCS), sense of coherence (SOC)","2850":"SF-36 mental component summary (MCS), sense of coherence (SOC)","2851":"helping to diagnosed and communication, specific medical and mental health problems","2852":"post-test in the GP Confidence scale","2853":"changes in medication usage ","2854":"initial body mass index (BMI)","2855":"initial weight loss regained","2856":"CD endoscopic index of severity (CDEIS) after Colonoscopy ","2857":"overall rate of early postoperative complications","2858":"The reoperation rate","2859":"The total rate of SSI and organ space surgical site infections (SSI)","2860":"The sum CTC-NCI toxicity score","2861":"The sum CTC-NCI toxicity score","2862":"The sum CTC-NCI toxicity score","2863":"\"Breast cancer-related pain and discomfort\ufffd and \"Breast cancer treatment problem last week\ufffd","2864":"\"Breast cancer-related pain and discomfort\ufffd and \"Breast cancer treatment problem last week\ufffd","2865":"disability, anxiety, and repetitive negative thinking","2866":"The Beck Depression Inventory\u20132nd edition (BDI-II), nine-item Depression Scale of the Patient Health Questionnaire (PHQ-9), and The 10-item Kessler Psychological Distress Scale (K10)","2867":"The concentration of CN54rgp140 antibodies","2868":"adverse events","2869":"visual analog scale (VAS) scores at the end of 12th week","2870":"CGI-I score","2871":"The patient-reported perceived deficits questionnaire (PDQ)","2872":"Trail Making Test B Total Time","2873":"bispectral index (BIS) at sputum suction (T5), extubation (T6) and 1 min (T7), 5 min (T8),","2874":"steady-state plasma glucose (SSPG) concentration","2875":"steady-state plasma glucose (SSPG) concentration","2876":"gastrointestinal side effect","2877":"systolic blood pressure, fasting glucose , and triglyceride","2878":"mean modified psoriasis area and severity index (mPASI) score","2879":"postanesthesia care unit (PACU) time","2880":"postoperative nausea and vomiting (PONV)","2881":"postoperative nausea and vomiting (PONV)","2882":"postoperative nausea and vomiting (PONV)","2883":"The overall patient satisfaction","2884":"visual analog scale (VAS) of nausea","2885":"Improvement in symptom-impact subscore","2886":"Mean standing systolic blood pressure (BP), mean supine systolic BP","2887":"systolic BP while supine","2888":"adverse events","2889":"Urine cotinine levels ","2890":"serum \u03b11-antitrypsin","2891":"The percentage of B cells","2892":"The percentage of B cells","2893":"The percentage of NK cells","2894":"Processed meat, serves\/week","2895":"Vegetables, serves\/day","2896":"Waist circumference, cm","2897":"Bodily Pain","2898":"General Health","2899":"Vitality","2900":"Physical HRQoL","2901":"average total blood loss","2902":"mean hemoglobin level at admission","2903":"mean hemoglobin level at admission at the discharge","2904":"patients required blood transfusion","2905":"The incidence of hypotension","2906":"The incidence of bradycardia and desaturation","2907":"The mean HR and mean blood pressure (MBP)","2908":"rate of pain relief (VRS\/minute)","2909":"analgesic spread (spinal level\/minute)","2910":"The time to VRS \u22643 and level of sensory block 20 minutes after dosing","2911":"maternal mean arterial blood pressure or maternal heart rate","2912":"Frequency of nausea","2913":"Satisfaction with sexual relationship","2914":"Improvement in Aging Male Symptom scale","2915":"Estimated infection hazard ratios for men","2916":"Estimated infection hazard ratios for women","2917":"Reported use of condom or increase in number of sexual partners","2918":"Risk of cardiovascular death","2919":"Sedentary behavior and agility test","2920":"Change of MAP","2921":"Baseline characteristics regarding the patient's age, gender, or educational level of the parents","2922":"Overall adverse events","2923":"CVLT-II Free Recall Total Score","2924":"DAS-II Recall of Digits score","2925":"Mean amplitude of glycemic excursion","2926":"Microbiological and clinical parameters","2927":"Nausea at 2 hours","2928":"Incidence of vomiting","2929":"Sore throat, dizziness, cephalea, and general well being","2930":"Use of anti-emetic drugs","2931":"Post-test scores","2932":"overall complications","2933":"the time to drain removal","2934":"receiving the treatment for cancer among oncologists and pulmonologists ","2935":"self-perception of effort spent ","2936":"duration of the disease","2937":"effectiveness according to chi-square test","2938":"wheezing and coughing frequency, triggers and severity","2939":"alcohol use in pregnancy","2940":"serum total cholesterol, LDL, HDL and triglycerides","2941":"high-density lipoprotein-cholesterol (HDL-C)","2942":"low-density lipoprotein cholesterol (LDL-C)","2943":"Apolipoprotein B-100 (apo B)","2944":"the Advanced-level subtotal Wheelchair Skills Test (WST) - baseline, post-training","2945":"blurred vision severity","2946":"Decrease in blood pressure ","2947":"Amount of PAX2+\/p-ERK+-positive cells","2948":"Vital capacity (after 12 months)","2949":"Vital capacity (after 3 months)","2950":"IL-8.","2951":"Mean scores of the constructs of the Protection Motivation Theory at baseline","2952":"Baseline characteristics","2953":"Open communication","2954":"Anesthetics during surgery","2955":"Association of parental beliefs with change in parental monitoring","2956":"Time needed for rescue analgesics ","2957":"Dipyrone needed","2958":"Increase in serum albumin levels","2959":"Decrease in HIV viral load","2960":"Adverse reactions","2961":"T max","2962":"severity of pain in primary dysmenorrhea","2963":"Cumulative achievement rates of target serum phosphorus levels","2964":"severity of pain in primary dysmenorrhea","2965":"Time course of mean serum phosphorus levels","2966":"Patient's demand and pump's delivery count for bolus dose","2967":"Total analgesic requirements on postoperative 1st and 24th hours","2968":"Incidence of constipation","2969":"Incidence of Vomiting on day 1","2970":"Pain intensity during exercise in the first 24h of post operatory","2971":"improvement in symptom scores","2972":"reduction in erythematous area","2973":"the duration of anesthesia","2974":"hidden blood loss","2975":"The number of cases requiring additional anesthetic","2976":"short-term graft function","2977":"Improvement in the composite score of vaginal symptoms","2978":"Vaginal pH","2979":"Placement of hands in the abdominal region","2980":"Minimal mean hepatic threshold dose 6 weeks after radiotherapy","2981":"Improvement of Rhinoconjunctivitis Quality of Life Questionnaire score after 8 weeks","2982":"Equol concentrations","2983":"Calcium absorption","2984":"Improvement in visual analogue scale scores after 8 weeks","2985":"Fastest heart rate ","2986":"Lowest heart rate ","2987":"Severe adverse effects","2988":"Changes in diastolic blood pressure 1 minute after induction of anaesthesia","2989":"Changes in diastolic blood pressure 1 minute after endotracheal extubation","2990":"Loss of Brain volume","2991":"Mortality rate","2992":"Target lesion revascularization and target vessel revascularization","2993":"Emergency CABG","2994":"Reported calorie intake","2995":"Sway in the A\/P direction","2996":"Viral load","2997":"Peripheral intravenous catheter failure rates per 1000 hours","2998":"Peripheral intravenous catheter failure rates per 1000 hours","2999":"Peripheral intravenous catheter failure rates per 1000 hours","3000":"Epistaxis intensity(outside OR)","3001":"Total need of morphine ","3002":"Opioid usage","3003":"Opioid usage","3004":"Peritoneal recurrence related to PECAM1 expression","3005":"Resuppression ","3006":"Viral load <200 copies\/mL","3007":"Glomerulosclerosis at day 14","3008":"Serum 25-OHD after 12 weeks","3009":"Iron levels (at 2 weeks)","3010":"HAS shrinkage and alteplase effect","3011":"IOP-lowering effect","3012":"Improvement of diastolic function echocardiographic markers ","3013":"Measurements of cardiac structure and function during hospitalization","3014":"RBC, and PBMC of EPA","3015":"insulin concentration in serum","3016":"Improvement in erectile hardness","3017":"Infections detected","3018":"Annualized HIV-1 incidence rate","3019":"Physical activity and physical fitness ","3020":"Scores of intrinsic motivation, perception of competence and autonomy, enjoyment, and health care climate","3021":"Rate of complications","3022":"QTc interval values","3023":"Test scores on measures of episodic and spatial memory","3024":"Glycemic response after breakfast","3025":"Glycemic response after lunch","3026":"Baseline characteristics","3027":"Maximum voluntary isometric contraction or endurance","3028":"Median frequency (MDF), and muscle fatigue index","3029":"flexibility","3030":"originality","3031":"fluency, flexibility, originality in patients over 65 years old","3032":"The plaque index (PI) and the gingival index (GI)","3033":"the cured rate","3034":"treatment success rate","3035":"apnea-hypopnea index (AHI)","3036":"treat the patients with cancer among oncologists and general practitioners","3037":"coping ability","3038":"time to ventilatory threshold (VT), workload at VT and heart rate at VT in incremental cycling (ICT)","3039":"Pyruvate concentration and creatine kinase activity before incremental cycling (ICT)","3040":"side effects","3041":"maximum urinary flow rate or mean residual urine volume","3042":"The incidence of ipsilateral non-perioperative stroke or transient ischaemic attack","3043":"systolic blood pressure (SBP) and diastolic blood pressure (DBP)","3044":"Apolipoprotein AI (apo AI)","3045":"The median interquartile range (IQR) latencies - post-training and 1 year follow-up","3046":"eye strain, and blurred vision","3047":"eye strain severity","3048":"6-month outcome (Oxford Handicap Scale [OHS])","3049":"6-month outcome (Oxford Handicap Scale [OHS])","3050":"mean blood pressure","3051":"cleanliness","3052":"cleaning efficacy in the middle third","3053":"The incidence of severe infection requiring hospital admission","3054":"overall effect of BMI","3055":"mean BMI","3056":"fasting and postprandial triglyceride concentrations","3057":"retinol concentrations","3058":"retinol concentrations","3059":"plasma \u03b2-carotene concentrations","3060":"extinction learning in a novel context (ABA condition)","3061":"activation during ABA and AAA extinction in bilateral dlPFC (BA 9) and OFC (BA 10), fusiform gyrus and temporal pole, right hippocampus and left lingual gyrus","3062":"shoulder abduction, external rotation, internal rotation range of movements & Shoulder Pain and Disability Index (SPDI) after 5 weeks","3063":"shoulder abduction, external rotation, internal rotation range of movements & Shoulder Pain and Disability Index (SPDI)","3064":"The objective response rate","3065":"effectiveness in premenopausal patients and patients with ECOG score of zero","3066":"SF-36 mental component summary (MCS), sense of coherence (SOC)","3067":"deciding about medication and referrals","3068":"body weight","3069":"body weight","3070":"% Fat according to DXA","3071":"%Fat according to skinfolds","3072":"%Fat according to skinfolds (chest, waist, hip, subscapular, and tricep)","3073":"terms of the duration of therapy","3074":"Revised-Western Aphasia Battery (R-WAB)","3075":"Cognitive Linguistic Quick Test (CLQT), executive function subtest, visuospatial skill subtest, Composite Severity score","3076":"Age, education.","3077":"patients that maintained a clinically important weight loss","3078":"Vertigo after intervention","3079":"nausea and vomiting","3080":"drowsiness","3081":"corticosteroid dosage, Crohn's disease activity index (CDAI), Harvey-Bradshaw index (HBI)","3082":"The sum of target lesions","3083":"Response Evaluation Criteria In Solid Tumors (RECIST) classification","3084":"\"Breast cancer-related pain and discomfort\ufffd and \"Breast cancer treatment problem last week\ufffd","3085":"\"Breast cancer related pain and discomfort\ufffd, \"Breast cancer treatment problem last week,\ufffd and \"Physical activity problem\ufffd","3086":"primary measures of depressive symptoms and distress","3087":"primary measures of depressive symptoms and distress","3088":"The median titers in vaccinees who had received three HIV-DNA and two HIV-MVA immunizations followed by two CN54rgp140\/GLA-AF immunizations","3089":"ADCC-mediating antibody response","3090":"Patients who needed NSAID supplementation","3091":"WOMAC pain, stiffness and, function scores","3092":"WOMAC pain, stiffness and, function scores","3093":"Patients who needed NSAID supplementation","3094":"side effect","3095":"8 in the digit symbol substitution test (DSST)","3096":"8 in the digit symbol substitution test (DSST)","3097":"Trail Making Test B Total Time","3098":"8 in the digit symbol substitution test (DSST)","3099":"The Steward recovery scores at T7 and T8","3100":"The time of waking, extubation, recovery of consciousness and time in the PACU","3101":"weight loss","3102":"systolic blood pressure, fasting glucose , and triglyceride","3103":"Inflammatory markers","3104":"pulse","3105":"nausea","3106":"treatment success","3107":"VAS of pain","3108":"dizziness and headache","3109":"mean serum 25(OH)D","3110":"parathyroid hormone (PTH) concentrations","3111":"demographic and prognostic variables, and baseline values of outcome measurements","3112":"osteoclacin (OC) and \u03b2-CrossLaps levels","3113":"The mean stone size","3114":"The mean stone size","3115":"Improvement Orthostatic Hypotension Questionnaire (OHQ)","3116":"tocopherol and tocotrienol levels","3117":"CD4+\/CD8+ ratio","3118":"minutes moderate-vigorous physical activity (MVPA)","3119":"Body mass index, kg\/m2","3120":"Physical Functioning","3121":"returned fecal occult blood test (FOBT) cards","3122":"mean duration of surgery","3123":"hospital stay","3124":"The need for treatment of hypotension","3125":"adverse events","3126":"C-peptide levels","3127":"(HOMA-B) homeostasis model assessment of \u03b2-cell function ","3128":"homeostasis model assessment of insulin resistance index (HOMA-IR)","3129":"incidence of clinical cure","3130":"ventilator days","3131":"ventilator days","3132":"ICU days","3133":"Bone strength of femur","3134":"Calcium absorption","3135":"VO2max","3136":"Body mass","3137":"Viral load","3138":"Epistaxis (Overall)","3139":"Epistaxis (inside OR)","3140":"Epistaxis episodes (outside OR)","3141":"Pain score","3142":"Pain scores","3143":"Viral load suppression after 96 weeks","3144":"Viral load suppression maintenance (from week 48 to week 96)","3145":"Thymidine analogue mutations \u22653 ","3146":"Low density lipoprotein (LDL)","3147":"Time between menstrual cycles ","3148":"Copper levels (at 2 weeks)","3149":"Copper levels (at 6 weeks)","3150":"Zinc levels (at 2 weeks)","3151":"Vital capacity (after 3 months)","3152":"Vital capacity (after 3 months)","3153":"Vital capacity (after 12 months)","3154":"Mature vessels ","3155":"Isoflurane consumption","3156":"AUC 0\u2013t","3157":"severity of pain in primary dysmenorrhea","3158":"The onset speed of anesthesia","3159":"the prognostic value of CEA, CA19-9, CA72-4 combined on gastric cancer","3160":"primary dysfunction after kidney transplant","3161":"inflammation after kidney transplant","3162":"Urine flow","3163":"Dry cavity after 1 month of treatment","3164":"Dry cavity after 3 months of treatment","3165":"Patients with 25% involvement with granulation tissue in the mastoid cavity after three months","3166":"Improvement in urinary incontinence","3167":"Focal radiation-induced liver injury at 12 weeks","3168":"EQ5D and distribution of ECOG performance status","3169":"Median overall survival after radiotherapy","3170":"Intake of relief medication","3171":"Rate of adverse events","3172":"Improvement of symptom scores","3173":"Stent thrombosis or Myocardial Infarction","3174":"Time spent in the no feedback zone","3175":"Peak A\/P tilts for the MCT and ADT perturbations","3176":"Mean patient-controlled analgesia morphine demand","3177":"Incidence of nausea 30 min after surgery","3178":"Metastasis and relapse rates","3179":"Hematogenous recurrence related to TOP2A expression","3180":"Incidence of moderate or severe anaemia after the first episode of fever","3181":"Incidence of the overall episodes of malaria","3182":"Rates of mortality","3183":"Depression","3184":"Tinnitus related outcomes","3185":"Quality-of-life scores","3186":"Serum interleukin-10","3187":"Serum interleukin-6 in non-diabetic patients","3188":"Improvement of Total Nasal Symptom Score","3189":"Improvement of fatigue level by Chalder Fatigue Scale","3190":"Urinary albumin-to-creatinine ratio at day 14","3191":"Baseline TIMP-2","3192":"CRC screening frequency","3193":"Perceived susceptibility","3194":"Beck Depression Inventory-II score","3195":"Beck Anxiety Inventory","3196":"Increase in fat free body mass","3197":"Increment of the haemoglobin level","3198":"Increase in CD4 T lymphocyte count","3199":"the score of the Visual Analog Scale at rest (VASr)","3200":"Side effects","3201":"Hypoxia","3202":"Plasma concentration","3203":"C max","3204":"Decrease in average Sugar Sweetened Beverages Consumption","3205":"Total score of side effect events","3206":"reduction of the risk for relapse to substance use in criminal offenders","3207":"Baseline characteristics","3208":"Improvement of Rhinoconjunctivitis Quality of Life Questionnaire score after 4 weeks","3209":"Bone strength of femur","3210":"Loss of Brain volume","3211":"Loss of Brain volume","3212":"Baseline characteristics","3213":"VO2max","3214":"Epistaxis insidence (outside OR)","3215":"Postoperative numerical rating scale at 30 min and 2 hours","3216":"Expression of GGH, PECAM1, or TOP2A ","3217":"Proportion of patients with fever receiving ACT","3218":"Incidence of severe febrile illness per child and year","3219":"High density lipoprotein (HDL)","3220":"Meet all criteria for \"being cured\"","3221":"Side effects (grade 1 to 2)","3222":"Podocyte proliferation","3223":"ocular itching","3224":"depressive symptom severity","3225":"activity of the hypothalamic area or the trigeminal nuclei","3226":"the standard deviation of speed, mental effort, and subjective sleepiness ","3227":"The absolute plasma concentration of activated FVII","3228":"circadian variation of F1+2","3229":"circadian pattern for D-dimer","3230":"the plasma concentrations of PAI-1, a fibrinolytic inhibitor","3231":"Treatment satisfaction","3232":"incidence of suspected Necrotizing enterocolitis (NEC)","3233":"Hospitalization time","3234":"sepsis","3235":"time of reaching full volume of milk","3236":"Serious adverse events within 30 days post-surgery","3237":"half carcasses","3238":"fat content","3239":"waist circumference","3240":"effects for walking and vigorous activity","3241":"FFBQ Total Index Score","3242":"weekly moderate physical activity sessions","3243":"accelerometer-assessed moderate to vigorous physical activity (MVPA)\t","3244":"internal fat depot - intermuscular and on subcutaneous fat","3245":"voided volume","3246":"IKET hold-time","3247":"maximal voluntary isometric contraction (MVIC)","3248":"weakness","3249":"force of pressure on the piston","3250":"force of pressure on the piston","3251":"CSP duration","3252":"motor evoked potentials (MEP)","3253":"Median peak (4 hours after administration), aFXa levels","3254":"bond strength","3255":"bond strength","3256":"Clinician's Interview-Based Impression of Change-Plus (CIBIC-Plus) values at 12-week treatment phase (T1) and 12-week follow-up period (T2)","3257":"Activities of Daily Living Scales (ADAS-ADL23) and Neuropsychiatric Index (NPI)","3258":"The Disease Activity Score 28 (DAS 28 score)","3259":"eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), n-3 polyunsaturated fatty acids (PUFA) and total PUFA","3260":"Systolic blood pressure","3261":"diastolic blood pressure","3262":"moderate or vigorous physical activity","3263":"mean plasma glucose level, HbA1c","3264":"measure of mean overall balance (OLB)","3265":"dynamic limit-of-stability balance test (DLOS)","3266":"The sense of balance improvement","3267":"risk of relapse","3268":"adverse event and extrapyramidal symptoms (EPS)-related adverse events","3269":"Bleeding complications","3270":"TIMI-flow <3 after PCI","3271":"Bleeding complications","3272":"The median time to first postsurgical use of rescue opioid medication","3273":"cumulative pain","3274":"plasma aldosterone concentration at 12 h","3275":"ACTH-stimulated aldosterone levels","3276":"level of perfusion left middle and right superior prefrontal cortex and left caudate nucleus and at the border of left posterior part of the putamen and insular cortex","3277":"cerebral blood flow (CBF) bilateral visual cortex, but also in the bilateral cerebellum","3278":"cerebral blood flow (CBF) of the right cerebellum, thalamus, and fusiform cortex","3279":"CBF in the bilateral caudate nuclei, left brainstem (including substantia nigra), and the left SMA and middle frontal gyrus","3280":"CBF in the left cerebellum and brainstem (including substantia nigra) and right hypothalamus","3281":"attending of sessions","3282":"time staying in therapy","3283":"depressive symptom severity","3284":"the degree of symptom reduction","3285":"activity of the secondary somatosensory cortex (SII)","3286":"Mean Pain intensity rating","3287":"standard deviation of lateral position (SDLP) in the first and second hour after the break","3288":"circadian variation of F1+2, a marker of thrombin generation, and D-dimer, a marker of activated coagulation and fibrinolysis","3289":"improvements in physical limitation , angina frequency and quality of life","3290":"Mortality","3291":"Median time to hemostasis","3292":"difference in any surgical procedure or target bleeding site (TBS) characteristic","3293":"the weight of half carcasses","3294":"internal fat depot - kidney with pelvic fat","3295":"The fat of pelvic limb ","3296":"The concentrations of Se and Zn in the blood plasma of ram-lambs","3297":"Low density lipoprotein","3298":"Triglycerides ","3299":"Weight gained","3300":"Baby's weight at birth","3301":"Need for C-section","3302":"Salivary secretion","3303":"Salivary secretion","3304":"Xerostomia ","3305":"Difficulties with chewing","3306":"Multiple sclerosis plaques ","3307":"Positive \u03b2-hCG at start","3308":"Pregnancy with fetal cardiac activity (in uterus)","3309":"Babies born alive","3310":"Babies taken home","3311":"Fasting blood glucose","3312":"Fasting blood glucose","3313":"Lipid profile improvement","3314":"Elevation of glucose and glucagon after 1 hour","3315":"Glucagon AUC 0\u20133 h","3316":"SF-36 questionnaire","3317":"Pre-diabetes reversion","3318":"Perceived stress scale","3319":"Global Severity Index of the SCL 90-r","3320":"Anxiety Index of the SCL-90-r","3321":"Pancreatitis","3322":"Evident bleeding","3323":"Hemorrhage ","3324":"Perforation","3325":"Need for reminders","3326":"Dentin mineral loss","3327":"Dentin mineral loss","3328":"Depth of the lesion","3329":"Surgery time","3330":"Visual analogue scale","3331":"Amount of lymph nodes removed","3332":"Complications","3333":"Low-density lipoprotein cholesterol","3334":"Macrophage migration inhibitory factor ","3335":"Time needed to intubate","3336":"Increase in Rate pressure product (First 3 minutes)","3337":"Mean arterial blood pressure (after 5 minutes)","3338":"Physical activity","3339":"Mortality rate (after 8 years)","3340":"Glucose measurement frequency","3341":"Glycated hemoglobin","3342":"Blood pressure ","3343":"Vomiting","3344":"Vomiting","3345":"Nausea","3346":"Nausea","3347":"Duration of response","3348":"Time to tumor progression","3349":"Diarrhoea of some grade","3350":"Asthenia ","3351":"Quality of life after 3 months","3352":"Sense of coherence","3353":"AUC (FEV1)\/h","3354":"Period effects for AUC (FEV1)\/h","3355":"Speed of alcohol consumption","3356":"HASBLED score of \u22653","3357":"Recovery time","3358":"Post-Surgical Pain","3359":"Anesthetic usage","3360":"Agreement between Experts and Sponsors","3361":"Abdominal discomfort","3362":"Response duration","3363":"Hand-foot syndrome","3364":"Grade 3\u20134 toxicity","3365":"Liver metastasis","3366":"Systolic blood pressure ","3367":"Systolic blood pressure ","3368":"Personal PM 2.5","3369":"Consciousness Commands improvement","3370":"Facial palsy score improvement","3371":"Motor arm Score improvement","3372":"Best language score improvement","3373":"Sensory score improvement","3374":"Heart Rate in virtual immersive environment","3375":"Intervention engagement for all groups over time","3376":"improvement in GHbA1c","3377":"glycemic control","3378":"documentation for the previously given, 'historical' vaccine doses","3379":"cost of intervention ","3380":"confidence to use reminder\/recall systems","3381":"CD4 count","3382":"weight loss","3383":"self-efficacy","3384":"average of physical activity","3385":"systolic and diastolic BP","3386":"International Prostate Symptom Score (IPSS-T (total)","3387":"detrusor pressure","3388":"maximum flow rate","3389":"post-void residual volume","3390":"Patient perception of Bladder Condition","3391":"Impulse values","3392":"force of pressure on the piston","3393":"CSP duration","3394":"prothrombin time (PT), Activated Partial Thromboplastin Time (APTT), activity, antithrombin (AT), platelet count, fibrinogen, thrombin-antithrombin complexes (TAT) complexes, or D-dimer levels","3395":"Mu rhythm desynchronization of hand area of cortex in child","3396":"bond strength","3397":"bond strength","3398":"The Assessment Scale-Cognitive (ADAS-cog) scores at 12-week follow-up period (T2)","3399":"phospholipids the n-6\/n-3 fatty acids ratio","3400":"Quality of life (QOL)","3401":"amount of debris","3402":"steps\/day","3403":"steps\/day","3404":"waist, BMI, waist\/hip ratio, HR or % body fat","3405":"Systolic blood pressure","3406":"mean plasma glucose level, HbA1c","3407":"mean plasma glucose level, HbA1c","3408":"HbA1c","3409":"fatigue after the training session","3410":"enjoyment attribute","3411":"time to relapse","3412":"Periprocedural troponin elevation","3413":"death\/periprocedural MI\/stroke or transient ischaemic attack\/re-intervention within 7 days","3414":"patient satisfaction scores","3415":"\"satisfied\ufffd or \"extremely satisfied\ufffd with their postoperative analgesia at 24 hours after surgery","3416":"\"satisfied\ufffd or \"extremely satisfied\ufffd with their postoperative analgesia at 72 hours after surgery","3417":"mean satisfaction ratings, based on an 11-point NRS (0 = completely unsatisfied; 10 = completely satisfied)","3418":"mean satisfaction ratings, based on an 11-point NRS (0 = completely unsatisfied; 10 = completely satisfied) at 96 hours","3419":"overall survival (OS) in patients with metastatic colorectal cancer (mCRC)","3420":"progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC)","3421":"24-h urinary cortisol","3422":"Levels of the cortisol precursor 11-deoxycortisol","3423":"ACTH-stimulated aldosterone levels","3424":"Levels of the cortisol precursor 11-deoxycortisol","3425":"global CBF","3426":"perfusion of the left middle and right superior prefrontal cortex and left caudate nucleus and at the border of left posterior part of the putamen and insular cortex","3427":"CBF","3428":"SCPBs","3429":"IL-8","3430":"Montgomery A\u030asberg Depression Rating Scale score","3431":"VAS sedation","3432":"Biological half-life","3433":"Decrease in serum phosphorus levels","3434":"severity of pain in primary dysmenorrhea","3435":"the score of the Visual Analog Scale while coughing (VASc)","3436":"reduction in burning sensation","3437":"the intensity of intra-operative pain during the administration of the drug","3438":"Involvement with granulation tissue in the mastoid cavity at the third phase of treatment","3439":"Mean heart rate ","3440":"Loss of Brain volume","3441":"Self-adhesive resin cement strength","3442":"Neonatal Apgar scores at 1 and 5 min","3443":"Self-adhesive resin cement strength","3444":"VO2max","3445":"Rate of improvement","3446":"CD4 count","3447":"Epistaxis first episode (outside OR)","3448":"Mean pain score at 30 mins and 2 hours after surgery","3449":"Tinnitus suppression","3450":"Triglycerides ","3451":"Cholesterol","3452":"Body mass index","3453":"Negative culture after having had positve culture","3454":"Improvement of Rhinoconjunctivitis Quality of Life Questionnaire scores","3455":"Side effects (grade 2)","3456":"Baseline characteristics","3457":"Health related quality of life (physical)","3458":"Health related quality of life (mental)","3459":"Waiting time","3460":"Patient satisfaction","3461":"23S rRNA","3462":"A2143G mutation","3463":"AAGGG \u2192 CTTCA sequence alterations","3464":"Nasal congestion","3465":"Interferon \u03b3 response ","3466":"Return to work","3467":"Sildenafil levels","3468":"Sildenafil levels","3469":"Voiding score improvement","3470":"Postmicturition score improvement","3471":"Storage score improvement","3472":"Postmicturition score improvement","3473":"Shear bond strength","3474":"SEAR Sexual Relationship Satisfaction domain","3475":"diurnal intraocular pressure (IOP)","3476":"24-hour duration of action in relieving ocular itch","3477":"total redness at onset of action and 24 hours post-dosing","3478":"Risk of non-completion of detoxification","3479":"clean urine sample","3480":"Preoperative mechanical alignment - varus","3481":"With survival for aseptic reasons","3482":"mean post-test scores of health-promoting lifestyle scale, health-related QoL scale, and all constructs of Pender's health promotion model (self-efficacy, perceived affect, perceived social support, and perceived barriers)","3483":"mean and maximum potentiation","3484":"theta- gamma coupling following PAS","3485":"The Community Programs for Clinical Research on AIDS (CPCRA) Adherence Self-Report Questionnaire","3486":"differences in the changes of the anthropometric measurements, RMR, and physical activity level","3487":"Plasma total cholesterol","3488":"The total number of days on which MRSA-positive admitted patients were not isolated","3489":"birth characteristics, complications during the prenatal period, the need for mechanical ventilation during the first 5 days of life, use of surfactant","3490":"The occurrence of apnea","3491":"right breast exposure dose in lumbar spine imaging in both projections (anteroposterior (AP) and lateral)","3492":"left breast exposure dose in lumbar spine imaging in both projections (anteroposterior (AP) and lateral)","3493":"Motivational Interviewing (MI) knowledge","3494":"consumption of at least 800 mg\/day of dietary calcium","3495":"bloatedness at 3 hours post dehydrating exercise","3496":"Plasma osmolality","3497":"Heart rate, beats\/mind - ratio between low frequency power (LF) and HF (LF:HF) of the autonomous nervous system, log m\/s2c","3498":"Rates of safety events","3499":"The mean difference in the reduction of both SBP and DBP","3500":"FEV1 after one dose","3501":"The consequently number of pads","3502":"intestinal cholesterol absorption, blood non-HDL cholesterol, and hepatic cholesterol","3503":"Serum lipids at 8 weeks","3504":"Serum hemoglobin and ferritin levels at 8 weeks","3505":"Need of erythropoietin","3506":"Time of hospitalization after the surgery","3507":"C-peptide AUC","3508":"Hypoglyacemic events","3509":"Glucose area under the curve","3510":"Days of post-surgical hospitalization ","3511":"Rate of minor and major complications ","3512":"Comorbidities","3513":"24-h visual analog score","3514":"Complete analgesia and effective analgesia duration","3515":"Complete analgesia and effective analgesia duration","3516":"Need of rescue analgesia","3517":"Left SCTT","3518":"Adverse events","3519":"Baseline characteristics and diet","3520":"Distance ran","3521":"Central venous pressure","3522":"Heart rate","3523":"Mean arterial pressure after the surgery","3524":"Cardiac troponin I during the preoperative period","3525":"Serum levels of CK","3526":"Improvement in mean scores of lifestyle-related vaginal health scale","3527":"Demographic characteristics and vaginitis relapse","3528":"Rate of bone mineral density loss","3529":"Overall balance ability","3530":"Adverse events","3531":"Leukocytes in blood","3532":"Coagulation parameters","3533":"LDL-C and blood pressure","3534":"Improvement in the Insight and Treatment Attitude Questionnaire","3535":"Movement times","3536":"IoF-scores improvement","3537":"Force required to pick-up an object","3538":"Energy expenditure","3539":"Baseline characteristics","3540":"Enjoyment by playing Resident evil","3541":"Improvement in Uchida\u2013Kraepelin test score ","3542":"Subjective feelings and body temperature","3543":"Net incremental area under the curve","3544":"RMSSD and HF","3545":"Mean blood pressure","3546":"Heart rate","3547":"Bispectral index","3548":"Rate of complications","3549":"Active caspase-3-positive neurons in CA1 area","3550":"Bax\/Bcl-2 ratio","3551":"Mean pain score","3552":"Mean pain score","3553":"Weight at randomization","3554":"Morphine levels in plasma","3555":"Plasma TNF-\u03b1","3556":"Methadone requirement","3557":"Success rate","3558":"Onset of local anesthesia","3559":"Duration of surgery","3560":"Production of IFN-\u03b3","3561":"Lung function and asthma symptoms","3562":"Median progression-free survival","3563":"Median overall survival","3564":"Glucose and insulin","3565":"UPDRS total score","3566":"Mean 'off'-time percentage during waking hours","3567":"Motor performance improvement","3568":"Level of base excess after therapy","3569":"Incidence of adverse events","3570":"Number of proliferated shoots","3571":"Serious adverse effects ","3572":"Fasting glucose","3573":"Reaching Glycated hemoglobin <6.5%","3574":"Good TMT-A results","3575":"Improvement of nausea ","3576":"Complete response (no emesis + no rescue medication)","3577":"Complete response (no emesis + no rescue medication)","3578":"Flexibility","3579":"IFN\ufffd\u03b3 spot numbers","3580":"Risk of death","3581":"Risk of death","3582":"Knee flexion (1-rep Max)","3583":"Squat jump","3584":"Horizontal triple jump (non-dominant leg) ","3585":"Viral load improvement","3586":"Mortality","3587":"Score on knowledge test","3588":"Need of oxytocin","3589":"Primary outcomes (CVD deaths, nonfatal MI, nonfatal stroke)","3590":"Lipid levels","3591":"Severity of dental compression","3592":"Recurrence-free survival","3593":"Nicotine replacement therapy","3594":"Nicotine replacement therapy","3595":"Psychomotor activities","3596":"Itch control time","3597":"Remission period","3598":"Remission period","3599":"Hospitalization","3600":"25-hydroxyvitamin D","3601":"25-hydroxyvitamin D","3602":"Pregnancy outcomes","3603":"Functional ability","3604":"Fear-avoidance responses improvement","3605":"Mental health score","3606":"Weight after 8 weeks","3607":"Fasting glucose","3608":"LDL","3609":"General mortality\t","3610":"General mortality\t","3611":"Overall UPDRS improvement","3612":"Limb bradykinesia improvement","3613":"Axial symptoms improvement","3614":"Tremor improvement","3615":"Gastric inhibitory polypeptide","3616":"Glucagon-like peptide-1","3617":"Correct identification of cause of death","3618":"Incorrect identification of cardiac causes of death","3619":"MOBID-2 score improvement after 8 weeks","3620":"Risk of falling","3621":"Pain","3622":"Matrix metalloproteinases in cerebrospinal fluid in early treatment","3623":"Peptide\ufffdspecific IgG","3624":"AAGGG \u2192 CTTCA sequence alterations","3625":"Microvessel density","3626":"Vineland Socialization","3627":"Any Myocardial infarction","3628":"reappearance of erythematous areas after 2 months posttreatment","3629":"Mode of Failure","3630":"Psychomotor activities","3631":"Improvement in vaginal dryness","3632":"Hospitalization","3633":"Discharge","3634":"Loss of Brain volume","3635":"Self-adhesive resin cement strength","3636":"Heart rate at 1 minute after induction of anesthesia and intubation","3637":"Cerebral vascular accident","3638":"CD4 reduction","3639":"Cardiovascular mortality\t","3640":"Changes in lesion-free area","3641":"Waist circumference","3642":"Improvement of epigastric fullness ","3643":"Overall reduction in serum interleukin-6 after 12 weeks","3644":"Serum hs-CRP","3645":"Hospital admissions ","3646":"23S rRNA","3647":"A2143G mutation","3648":"Headache ","3649":"Abdominal pain","3650":"Receptive One Word Picture Vocabulary","3651":"Stanford Binet\ufffdKnowledge","3652":"Symptoms ","3653":"Symptoms ","3654":"Pain","3655":"Sport","3656":"Sildenafil levels","3657":"Sildenafil levels","3658":"Work performance","3659":"Preterm birth","3660":"Xerostomia ","3661":"Shear bond strength","3662":"Multiple sclerosis plaques","3663":"Shear bond strength","3664":"Multiple sclerosis plaques after 6 months","3665":"Expanded disability status scale","3666":"Pregnancy rate","3667":"IIEF Overall Satisfaction domain score","3668":"EDITS Index","3669":"Implantation","3670":"Mean diurnal IOP change","3671":"Lipid profile improvement","3672":"conjunctival redness at onset and 24 hours","3673":"Atherogenic Index","3674":"Atherogenic Index","3675":"total redness at onset of action and 24 hours post-dosing","3676":"Elevation of glucose and glucagon after 1 hour","3677":"Glucose AUC 0\u20133 h","3678":"safety concerns","3679":"Hypoglycemia after 24 hours","3680":"Incidence of Diabetes","3681":"Adverse events","3682":"Patient compliance","3683":"Baseline values","3684":"3\u00b0 deviation from neutral alignment","3685":"With survival for any reason","3686":"peak Paired associative stimulation (PAS)-induced neuroplasticity in the dorsolateral prefrontal cortex (DLPFC)","3687":"Amylase levels","3688":"Responsiveness","3689":"the serum level of lactate","3690":"Dentin mineral loss","3691":"the serum level of the lipid species","3692":"serum level of TAG 48:1","3693":"Depth of the lesion","3694":"Numerical scoring system","3695":"Amount of blood lost","3696":"waist circumference","3697":"turnaround time from admission to reporting","3698":"25-hydroxyvitamin D levels","3699":"Triglycerides level","3700":"High-density lipoprotein cholesterol","3701":"number of doses of surfactant","3702":"Fasting glucose levels","3703":"Systolic blood pressure","3704":"CXCL7","3705":"CXCL12 ","3706":"objective-SCORAD score","3707":"Plasminogen activator inhibitor 1","3708":"High-sensitivity C-reactive protein","3709":"chemokines CXCL9","3710":"breast exposure dose in lumbar spine imaging","3711":"Mean arterial blood pressure (first 3 minutes)","3712":"Bowel motions per fortnight M (SD)","3713":"Drop in pulse rate (first 3 minutes)","3714":"Resolution of Constipation n (%)","3715":"Influenza vaccinations","3716":"The overall response rate","3717":"cumulative incidence of relapse survival from relapse; relapse-free or overall survival ","3718":"Glycated hemoglobin","3719":"Liver function markers","3720":"The median day of recovery of neutrophils and platelets","3721":"Arterial Stiffness (Pulse Wave Velocity)","3722":"Arterial Stiffness (Pulse Wave Velocity)","3723":"Vomiting","3724":"Frequency of client \"change talk\ufffd (CT)","3725":"The overall score for the evidence-based status of health education","3726":"brisk walking and low-impact training, such as stretching in elderly persons","3727":"Nausea","3728":"overall improvement the evidence-based status of health education","3729":"Overall response rate","3730":"stomach upset","3731":"reversion rates of the metabolic syndrome (MetS)","3732":"reversion rates of the MetS at 6 months, at 2 years","3733":"reversion rates of the MetS at 6 months, at 2 years","3734":"improving of Southampton Hand Assessment Procedure (SHAP)","3735":"salivary cortisol","3736":"Total Mood Disturbance(TMD)","3737":"FEV1 Max","3738":"improvements in efficacy parameters at month 3","3739":"Period effects for FEV1 Max","3740":"Mortality or significant adverse events","3741":"Speed of alcohol consumption","3742":"Speed of alcohol consumption","3743":"Acceptance of alcohol","3744":"Acceptance of alcohol","3745":"Acceptance of alcohol","3746":"OAC candidates rates","3747":"The mean difference in the reduction of both SBP and DBP","3748":"HASBLED score of \u22655","3749":"Probability for adequate OAC prescription","3750":"Dual antiplatelet therapy prescribed","3751":"Standardised AUC measurements for FEV1 at Week 12","3752":"The number of bleeding days ","3753":"Blood triglycerides (TG) concentrations","3754":"Usage of analgesics","3755":"Time for extubation ","3756":"plasma concentrations of CE-16:0, CE-18:1, and CE-18:2","3757":"Kappa values","3758":"Agreement between Experts and Sponsors","3759":"Mini-Mental State Examination improvement","3760":"ADAS-cog score improvement","3761":"campesterol and sitosterol","3762":"Changes in blood count","3763":"Renal function","3764":"Response rate","3765":"Diarrhoea","3766":"Overall survival","3767":"Diastolic blood pressure ","3768":"Diastolic blood pressure ","3769":"Motor leg Score improvement","3770":"Heart rate","3771":"Systolic blood preasure","3772":"Diastolic blood pressure","3773":"Sense of presence in virtual immersive environment","3774":"Assessment of Mental State - PEPS and PSYCH","3775":"Engagement in Precontemplation and Contemplation groups","3776":"Engagement in Contemplation group","3777":"Engagement in Preparation group","3778":"Laryngeal, pharyngeal and oral axes alignment","3779":"View of Larynx","3780":"Tracheal intubation success rate","3781":"Discomfort score for tracheal intubation","3782":"red cell and platelet transfusions, days on antibiotic and days in hospital","3783":"Quality of life","3784":"investigator-rated aspects of mental health","3785":"Insulin sensitivity","3786":"participants' confidence for giving reminder\/recalls","3787":"reflections of sustain talk","3788":"Baseline characteristics","3789":"\"sustain talk\ufffd (ST)","3790":"Operation time","3791":"Loss of blood during surgery","3792":"Soleus muscle latency and amplitude of H-reflex latency","3793":"Height of intervertebral space after 1 year","3794":"Blood glucose AUC","3795":"Insulin use","3796":"IDA-A1C","3797":"Insulin area under the curve","3798":"Improvement in Low density lipoprotein-cholesterol and small dense LDL particles concentrations","3799":"Early reoperations","3800":"Weight loss at 6 and 12 months","3801":"Need of rescue analgesia","3802":"Improvement in faeces consistency ","3803":"Colonic transit time","3804":"Heart rate","3805":"Happiness","3806":"Anxiety levels","3807":"Feeling of anger","3808":"Baseline characteristics (except age and intact PTH level)","3809":"Serum 25(OH)D levels","3810":"Dynamic balance improvement","3811":"Baseline characteristics (except age)","3812":"Neutrophils in blood","3813":"Urine albumin","3814":"Routine hematologic and chemistry indices in blood","3815":"Body weight and glycemic parameters","3816":"Change in urine TGF-beta1","3817":"Improvement in the Wisconsin Card Sorting Test","3818":"Improvement in the Scale of Social Skills of chronic schizophrenia Inpatients","3819":"Reach times","3820":"C-reactive protein levels","3821":"Interleukin-6 serum concentration","3822":"Vagally-mediated heart rate variability indices","3823":"Peripheral oxygen saturation","3824":"Ischemia\/reperfusion-induced caspase-3 activation","3825":"Bcl-2 protein levels","3826":"Gender at randomization","3827":"Daytime mean glucose","3828":"Serious adverse events","3829":"Treatment retention","3830":"Changes in plasma cytokine levels and BDNF levels","3831":"Duration of soft tissue anesthesia","3832":"Pain during the surgery","3833":"Production of sCD23","3834":"Production of TGF-\u03b2","3835":"Total nasal symptom scores and peak nasal inspiratory flow","3836":"Grade 3 or 4 adverse events","3837":"Overall response rate","3838":"Amount of calcium and phosphate on enamel surface","3839":"Amount of calcium and phosphate on enamel surface","3840":"Amount of calcium and phosphate on enamel surface","3841":"Total weight percentage of phosphate","3842":"Improvement in swallowing solid and liquid consistencies","3843":"Improvement of frequency of symptoms domain in SWALQOL questionnaire","3844":"Improvement of mental health domain in SWALQOL questionnaire","3845":"Fiberoptic endoscopic evaluation of swallowing","3846":"25(OH)D levels","3847":"Lipid profile","3848":"Changes in body mass index","3849":"Metabolic syndrome","3850":"Incidence of adverse events","3851":"Baseline characteristics","3852":"Thumb movement","3853":"Baseline level of base excess, age and sex of the patients","3854":"Shoot proliferation","3855":"Creatinine ","3856":"BUN","3857":"Glycated hemoglobin reduction","3858":"Improvement in HOMA\ufffd\u03b2 index","3859":"Insulin levels","3860":"Glucagon-like peptide-1","3861":"Onychomycosis cured","3862":"Patient satisfaction","3863":"Good TMT-A results","3864":"MOCA-K ability","3865":"Improvement of functional dyspepsia ","3866":"Improvement of epigastric pain","3867":"Improvement of bloating","3868":"The mean difference in the reduction of both SBP and DBP","3869":"Complete response (no emesis + no rescue medication)","3870":"Complete response (no emesis + no rescue medication)","3871":"Rate of force development ","3872":"Rate of force relaxation ","3873":"Muscle fiber cross-sectional area (type II fibers)","3874":"Lumbo-pelvic stability","3875":"Flexibility","3876":"Progression\ufffdfree survival ","3877":"IL\ufffd6","3878":"Change of direction improvement","3879":"Horizontal countermovement jump","3880":"Mortality","3881":"Assessment checklist score","3882":"Primary outcomes (CVD deaths, nonfatal MI, nonfatal stroke)","3883":"Stroke","3884":"Intubation success ","3885":"Intubation success ","3886":"Severity of dental compression","3887":"Overall survival","3888":"Lumbar spine range of motion","3889":"Nicotine replacement therapy","3890":"Withdrawal symptom","3891":"Withdrawal symptoms","3892":"Adverse effects","3893":"Itch control time","3894":"Adverse effects","3895":"Hospitalization","3896":"Discharge","3897":"Sport activity score improvement","3898":"Total activity","3899":"Effective duration of analgesia","3900":"Progression-free survival in Chemo-naive Patients","3901":"General mortality\t","3902":"Cardiovascular mortality\t","3903":"Flow mediated dilatation","3904":"MOBID-2 score improvement after 8 weeks","3905":"Daily activities ","3906":"body mass","3907":"heart rate, systolic blood pressure, or diastolic blood pressure","3908":"improving of Clothespin Relocation Task","3909":"Heart rate, beats\/mind - high frequency power (HF) of the autonomous nervous system, log m\/s2c","3910":"The mean difference in the reduction of both SBP and DBP","3911":"forced expiratory volume in 1 s (FEV1) at Week 12","3912":"The overall rate of adverse events (ASs)","3913":"The percent diurnal IOP change","3914":"24-hour duration of action in relieving ocular itch","3915":"conjunctival redness at onset and 24 hours","3916":"Geometric mean time to recovery of the train-of-four ratio to 0.9","3917":"Knee Society Knee Score (KS) 10 years postoperatively using the two one-sided test (TOST)","3918":"Rhodes index scores","3919":"The serum level of the circulating BCAAs isoleucine, valine and leucine","3920":"level of ceramide 18:1\/14:0, LPC 20:4 and 22:5, LPE 18:0, PA 34:2, 36:1 , 36:2, 36:1 , PE 34:0 , 34:1, 34:2, 36:3 , 40:4 , 40:5 , PE 40:4, PE 40:5, PC 34:3 , PC 36:4 , PC 36:5 , PC 38:5 , PC 40:5 and PC 40:8 .","3921":"HIV-related and ART medication knowledge","3922":"VAS mean score","3923":"total energy derived from saturated fatty acids (SAFAs) and carbohydrate","3924":"overall survival","3925":"measures of fluid retention","3926":"fluid retention (based on body mass)","3927":"Lumbo-pelvic stability","3928":"CD4+","3929":"Knee extension (1-rep Max)","3930":"Tumour-specific survival after 5 years","3931":"Glucose levels obtained 30 min post-feeding","3932":"mean oxygenation index after adjusting for age, blood products, and ECC time","3933":"Wexner score","3934":"absolute amount of weight loss","3935":"muscle phenyalanine enrichments","3936":"Skeletal muscle protein FSR","3937":"C-reactive protein","3938":"probability of antibiotic prophylaxis being cost-effective from a societal perspective","3939":"intend to continue","3940":"exercise initiation","3941":"BMI","3942":"Time spent completing daily workouts","3943":"bacteriological methods","3944":"overall survival (OS)","3945":"adverse effects","3946":"the proportion of patients achieving an American College of Rheumatology (ACR) 20 response at 24 weeks","3947":"probing depth changes","3948":"Cmax","3949":"The sedation score recorded in the postanesthesia care unit (PACU) over the 2-h observation period","3950":"total score","3951":"pain rating scale [PRS]","3952":"memory score","3953":"physical functioning","3954":"psychosocial functioning","3955":"pain-related disability at 12 mo","3956":"median progression-free survival (PFS)","3957":"The duration of sedation","3958":"Operation theatre costs","3959":"outpatient clinic and admittance related costs, indirect costs, and total costs","3960":"Median progression-free survival","3961":"median maximum COWS scores","3962":"pain ratings","3963":"effect of balance taping for prevention of menstrual pain in female middle school students after 24 hours","3964":"effect of balance taping for prevention of menstrual pain in female middle school students after 4 hours","3965":"molar extrusion","3966":"The overbite","3967":"Loss in initial weight","3968":"Late gadolinium enhancement ","3969":"mean circumferential extent obtained by a combination of LGE&T2 signal overlay","3970":"high abstinence rates of smoking in smokers hospitalized due to community-acquired pneumonia (CAP)","3971":"improved quality of Life (QoL)","3972":"Holden Communication Scale (HCS) ","3973":"Microleakage of Two Bulk Fill and One Conventional Composite in Class II Restorations of Primary Posterior Teeth","3974":"alkaline phosphatase","3975":"Capillarization per fiber (type II fibers)","3976":"Overall survival ","3977":"Bile acids (BAs), glycine and taurine conjugated , CDCA, CA and UDCA","3978":"total GLP-1","3979":"Risk of death","3980":"Diarrhoea","3981":"self-confidence due to timely action and inner calmness due to timely action","3982":"Expressive One Word Picture Vocabulary","3983":"CD4+","3984":"Use of phenylephrine","3985":"Viral load improvement","3986":"overall incidence of APGAR score","3987":"Need of C-section","3988":"Failed induction","3989":"Infections","3990":"Uterine hyperstimulation","3991":"Return to work","3992":"Sildenafil levels","3993":"Primary outcomes (CVD deaths, nonfatal MI, nonfatal stroke)","3994":"Job satisfaction","3995":"Heart rate","3996":"Problem-solving","3997":"Seeking social suppor","3998":"Spinal inclination","3999":"Sacral\/hip range of motion","4000":"Thoracic range of motion","4001":"Mode of Failure","4002":"IIEF Overall Satisfaction domain score","4003":"left femoral neck T-score","4004":"IIEF Overall Satisfaction domain score","4005":"Withdrawal symptom","4006":"Overall Relationship Satisfaction","4007":"Wheal and flare responses","4008":"Wheal and flare responses","4009":"Itch control time","4010":"PedsQL","4011":"overall neonatal mortality","4012":"Hospitalization","4013":"Social integration","4014":"Pain intensity","4015":"Insulin resistance","4016":"Fasting insuline","4017":"Systolic blood pressure","4018":"Diastolic blood pressure","4019":"Progression-free survival in prior Chemo-Patients","4020":"Hypoglycemia","4021":"Cardiovascular mortality\t","4022":"Hypoglycaemia","4023":"Freezing improvement","4024":"body weight over 6 months in obese patients with type 2 diabetes","4025":"Glycated hemoglobin","4026":"Good TMT-B results","4027":"Good TMT-B results","4028":"CD34","4029":"Death certificate completion score","4030":"Holden Communication Scale (HCS) score ","4031":"Postintervention score improvement","4032":"Motivational Interviewing (MI) knowledge","4033":"MOBID-2 score improvement after 8 weeks","4034":"MOBID-2 score improvement after 8 weeks","4035":"Peak force","4036":"Drugs per patient","4037":"Electromyography parameters","4038":"Healing after 3 months","4039":"neutropenia and diarrhea","4040":"Vomiting","4041":"Alzheimer's Disease Assessment Scale-cognitive subscale (Chinese version) (ADAS-cog) at the follow-up at week 48","4042":"Hmax (H-reflex )\/Mmax(maximum M-wave) ratio","4043":"diastolic blood pressure at week six or week seven","4044":"The mean of weight, body mass index (BMI), waist-to-hip ratio (WHR), body fat, protein, mineral and total water","4045":"Potassium, creatinine, urea and uric acid","4046":"Borg score","4047":"The time to maximum plasma concentration (tmax)","4048":"anemia and fatigue","4049":"The average returning time of respiration after discontinuing of the drugs","4050":"time from initial surgery\/histology to treatment","4051":"The duration of sedation piperine pretreatment group","4052":"TC and LDL-C levels","4053":"TC and LDL-C levels","4054":"Operative time","4055":"Clinical Opiate Withdrawal Scale(COWS) - 24-hour period","4056":"proclination in maxillary incisors ","4057":"Maxillary incisors retroclinding ","4058":"Maxillary incisors - overjet","4059":"level of change in communication ability","4060":"level of change in communication ability","4061":"forced expiratory volume in one second (FEV1)","4062":"Numbers of patients with completely or well controlled asthma","4063":"the mean number of asthma-free days during the study","4064":"dysphonia, headache , tremor, and hoarseness","4065":"Daily inhaled corticosteroid (ICS) consumption","4066":"mean breathlessness change scores","4067":"Reduction of body weight, trunk fat mass","4068":"FGF-19 levels","4069":"Frequency distribution of fear of suffering from complication of febrile seizure in the child","4070":"resolution rate","4071":"effect on resolution time in the first three months","4072":"preservation of lean tissue","4073":"Basal plasma phenyalanine enrichments","4074":"temperature, TNF-\u03b1 plasma levels, IL-1\u03b2, C-reactive protein","4075":"mean arterial blood pressure","4076":"Forearm blood flow","4077":"microvascular permeability parameters","4078":"moderate to severe nausea","4079":"The overall incidence of vomiting","4080":"headache intensity after 24 h","4081":"headache intensity after 48 h","4082":"vertebral bone density","4083":"Improvement in function and lumbar ROM as well as endurance time","4084":"depth reduction","4085":"Oswestry low-back pain disability index [ODI].","4086":"analgesic effects of low doses after knee surgery","4087":"analgesic effects of low doses after knee surgery","4088":"analgesics","4089":"affective subscale of the Short-Form McGill Pain Questionnaire","4090":"swimming velocity","4091":"Corticosterone concentration","4092":"overall survival 2 years","4093":"mucositis induced by chemoradiotherapy in head and neck cancer patients","4094":"average time to progress to Grade 2 mucositis from the beginning of radiation in both groups","4095":"average time to progress to grade 3 mucositis from the beginning of radiation in both groups","4096":"effect of balance taping for prevention of menstrual pain in female middle school students after 24 hours","4097":"improvements in HbA1c after 6 months of treatment","4098":"larger weight losses were associated with greater reductions in HbA1c","4099":"Smoking cessation improved QoL","4100":"high abstinence rates of smoking in smokers hospitalized due to bronchial asthma attack","4101":"Microleakage of Two Bulk Fill and One Conventional Composite in Class II Restorations of Primary Posterior Teeth","4102":"Microleakage (dye penetration depth)","4103":"ease of pedaling","4104":"subjective feelings of muscle fatigue immediately after exercise","4105":"increased plasma L-arginine levels","4106":"subjective feelings of concentration immediately after exercise","4107":"alanine aminotranferase","4108":"gamma-glutamyl transpeptidase","4109":"total cholesterol","4110":"IL-2-related toxicity","4111":"serum insulin during recovery from cycling exercise","4112":"Glucose levels obtained 30 min post-feeding","4113":"Sample size requirements to estimate SDp from external pilot randomised controlled trials","4114":"Binary primary outcome","4115":"event rate estimation","4116":"postoperative pulmonary complications after adjusting for age, blood products, and ECC time","4117":"postoperative sedation have any beneficial effects on myocardial injury in cardiac surgery patients after on-pump valve replacement.","4118":"Cost of Prophylactic Antibiotics to Prevent Cellulitis of the Leg","4119":"probability of antibiotic prophylaxis being cost-effective from an NHS perspective","4120":"progression of chronic prostatitis plus IBS toward chronic microbial prostate-vesiculitis (PV) or prostate-vesiculo-epididymitis (PVE) in infertile males","4121":"Optical density of MP (MPOD)","4122":"amount of the smear layer remaining in the coronal third","4123":"currently experienced pain level","4124":"cerebrospinal fluid phosphorylated tau (p-tau)","4125":"cerebrospinal fluid phosphorylated tau (p-tau)","4126":"proportion who reported meeting PA guidelines in the past seven days","4127":"PedsQL","4128":"HDL-C rate","4129":"Surgery duration","4130":"activated clotting time (ACT)","4131":"Improvement in symptom score","4132":"Baseline characteristics","4133":"clinical outcomes","4134":"total antioxidant capacity (TAC)","4135":"Glomerular filtration rate","4136":"visual analog scale (VAS) scores at every visit over 12 weeks","4137":"Total insulin secretion","4138":"Happiness ","4139":"Anxiety","4140":"On-treatment deaths","4141":"Des-continuation due to adverse effects","4142":"Chest press","4143":"Membrane exposure","4144":"Probing pocket depth","4145":"Probing pocket depth","4146":"Clinical improvement","4147":"Bone level change","4148":"HDL","4149":"hs-CRP","4150":"Cured patients using 5 criteria","4151":"Patency period ","4152":"Patency period ","4153":"Success rate","4154":"Success rate","4155":"Success rate","4156":"Systolic blood pressure after extubation","4157":"Systolic blood pressure during injection","4158":"Hematocrit after 72 hrs","4159":"Total blood suctioned after 48 hrs","4160":"Total blood suctioned after 24 hrs","4161":"Blood products used","4162":"Lactate concentrations ","4163":"Insulin AUC","4164":"Time to exhaustion","4165":"Median frecuency on Rectus femoris","4166":"Calcium-phosphorus product","4167":"Phosphorus","4168":"Goal HbA1c <7.0%","4169":"Weight","4170":"Gastrointestinal events","4171":"Mean BP","4172":"Heart rate","4173":"Eye opening time","4174":"Overall Neuropathy Limitations Scale improvement","4175":"Sensitive Conduction Velocity ","4176":"Charcot Marie Tooth Neuropathy Score","4177":"Charcot Marie Tooth Neuropathy Score","4178":"Body weight","4179":"Waist circumference","4180":"Negative events","4181":"Test scores","4182":"Subjective understanding ","4183":"Subjective learning skills ","4184":"Overall survival","4185":"Time to progression ","4186":"Response rate","4187":"Toxicity ","4188":"Body weight","4189":"Pre-diabetes ","4190":"Systolic blood pressure","4191":"Diastolic blood pressure","4192":"Cracks","4193":"Cracks","4194":"Glutathione ","4195":"Superoxide dismutase levels","4196":"Child-Turcotte-Pugh score","4197":"Mortality","4198":"Serum Lutein","4199":"HDL 3 Lecithin\u2013cholesterol acyltransferase","4200":"Cytotoxicity ","4201":"Visiting the ophthalmologist ","4202":"Constipation assessment scale improvement ","4203":"The primary macular hole closure rates","4204":"Pain after 3 days","4205":"The primary reattachment rate","4206":"Pain after 10 days","4207":"Remaining filling material","4208":"Dentin removed","4209":"overall response rate (ORR)","4210":"Mortality","4211":"Infectious complications","4212":"systolic blood pressure at week seven","4213":"weight, BMI, WHR","4214":"Waiting time of urgent patients","4215":"FBS, sodium, phosphorus and osmolarity levels","4216":"Forced expiratory volume (FEV1)","4217":"Continuous restraint ","4218":"grade 3\u20134 neutropenia","4219":"dynamic balance performance on the stability platform","4220":"center of pressure (CoP) sway velocity","4221":"Obestatin","4222":"Des-acyl ghrelin","4223":"Positional differences improvement (mediolateral)","4224":"peak HR in younger subjects","4225":"VO2max in older and younger subjects","4226":"Systolic blood pressure","4227":"stopping the anesthesia drugs up to opening eyes, return to verbal response, and discharge from the recovery","4228":"Monocytes and granulocytes engaged in phagocytosis","4229":"job satisfaction","4230":"Plaque control record improvement ","4231":"MucusTM improvement ","4232":"VO2max","4233":"VO2max","4234":"Progressive pain relief ","4235":"Important adverse effects ","4236":"mean LGE encirclement at 6 months follow-up","4237":"Delayed recall improvement","4238":"Mini-Mental State Examination (MMSE) scores","4239":"Physical aspect of Functional Assessment of Cancer Therapy-Breast","4240":"Emotional aspect of Functional Assessment of Cancer Therapy-Breast","4241":"Mean high-density lipoprotein (HDL) levels","4242":"Average work incapacity ","4243":"Disability pensions","4244":"HDL cholesterol","4245":"Bile acids (BAs), glycine and taurine conjugated BAs","4246":"CDCA, CA and UDCA","4247":"Integrity indemnity","4248":"Collony-forming units","4249":"total GLP-1, FGF-19 levels","4250":"Usage of sexually-transmitted infections services","4251":"C-reactive protein","4252":"LDL-cholesterol","4253":"effect on resolution time beyond first three months","4254":"Vitamin D concentration","4255":"TNF-\u03b1 plasma levels, IL-1\u03b2","4256":"Oxygen saturation","4257":"Heart rate","4258":"Respiratory exchange ratio during rest","4259":"Pruritus ","4260":"The levels of urine N-telopeptide, serum osteocalcin, and serum bone-specific alkaline phosphatase (BSAP)","4261":"Fasting liver triglycerides","4262":"the extent of root coverage at 6 months","4263":"Insulin sensitivity","4264":"Glycated hemoglobin","4265":"keratinized tissue","4266":"the incidence of postoperative nausea and vomiting (PONV)","4267":"Computer knowledge","4268":"The sedation score recorded in the postanesthesia care unit (PACU) over the 2-h observation period","4269":"Augmentation pressure","4270":"Pulse wave velocity","4271":"used NSAID's","4272":"One h postoperative, NSAID consumption","4273":"One h postoperative, NSAID consumption","4274":"Laryngeal mask airway insertion score improvement","4275":"Laryngeal mask airway insertion score improvement","4276":"Suicidal ideas","4277":"census global health question at 6- or 12-mo follow-up","4278":"Mean arterial blood pressure","4279":"Pain Disability Assessment Scale","4280":"number of nonorganic pain drawings","4281":"NLST thyroid cancer risk","4282":"serum testosterone levels","4283":"PLCO thyroid cancer risk in men","4284":"PLCO thyroid cancer risk in women","4285":"overall survival 5 years","4286":"median survival","4287":"Migration by RSA maximal total point motion after 2 years","4288":"Potassium","4289":"Vital signs ","4290":"Pain","4291":"Blood pressure","4292":"Skin texture","4293":"Microleakage of Two Bulk Fill and One Conventional Composite in Class II Restorations of Primary Posterior Teeth","4294":"Probability of having an injury","4295":"Probability of having an injury","4296":"Interferon gamma-induced protein 10 ","4297":"incidence of maternal nausea and vomiting","4298":"positive sperm culture (with CFU > 105 ml\u22121)","4299":"disability glare (DG) performance","4300":"amount of the smear layer at coronal, middle and apical thirds of the root canals","4301":"Root canal walls without any smear layer","4302":"N1 and N2 groups","4303":"better prognosticator","4304":"ventricular volume","4305":"plasma amyloid-\u03b2 (A\u03b2) peptides","4306":"Total Human milk oligosaccharides","4307":"Sialylated HMOs","4308":"Lactoferrin","4309":"Distant recurrence-free survival","4310":"Distant recurrence-free survival","4311":"Distant recurrence-free survival","4312":"pH","4313":"Strong ion difference","4314":"Serious adverse effects","4315":"Social withdrawal ","4316":"Compulsion scale","4317":"Kessler Psychological Distress Scale","4318":"Air-leak pressure","4319":"Air-leak pressure","4320":"Gastrotomy creation times","4321":"IVEF","4322":"Limitation of motion","4323":"Disease impacts","4324":"Cystatin C","4325":"Creatitine after 2 days","4326":"Creatitine after 10 days","4327":"Cystatin C after 4 days","4328":"Cystatin C after 10 days","4329":"Illness","4330":"Excessive adhesion formation","4331":"Beta cell glucose sensitivity","4332":"Beta cell glucose sensitivity","4333":"Insulin clearance","4334":"Insulin clearance","4335":"Tumour-specific survival after 1 year","4336":"Efficiency","4337":"Concentration of troponin T","4338":"mean score of knowledge , attitude and practice","4339":"mean score of knowledge , attitude and practice","4340":"elective cesarean delivery (CD) reduction in spinal-induced hypotension (SIH)","4341":"mean arterial blood pressure","4342":"Forearm blood flow","4343":"the total blood loss","4344":"durable response rate (DRR)","4345":"increased number of leukocytes (>10 HPF)","4346":"The incidence of any grade adverse events","4347":"progression-free survival (PFS)","4348":"Alzheimer's Disease Assessment Scale-cognitive subscale (Chinese version) (ADAS-cog) at the follow-up at week 48","4349":"balance measure at week seven in the eyes-closed, single-leg condition","4350":"deaths, malignancies, hospitalizations, infections requiring intravenous antibiotics occurred, autoimmune events","4351":"functional disability, measured by Functional Rating Index","4352":"Lumbar range of motion (ROM) as well as holding time during the Sorensen test and median frequency slope of all measured paravertebral muscles ","4353":"anxiety level","4354":"requirement for the examination of nodes for N0","4355":"the extent of root coverage at 6 months","4356":"amyloid peptides","4357":"visual analog scale [VAS]","4358":"spatial score","4359":"Depression","4360":"compensation","4361":"Duration of pain","4362":"administrators on average who left health centers","4363":"nurses on average who left health centers","4364":"Visual Analogue Scale","4365":"compensation","4366":"serum lactic acid concentration","4367":"the mean HDL-C level","4368":"overjet in in maxillary incisors","4369":"effect of balance taping for prevention of menstrual pain in female middle school students after 4 hours","4370":"vertical facial dimension","4371":"Holden Communication Scale (HCS) score ","4372":"triglycerides","4373":"Positive emotions","4374":"Self-confidence","4375":"Insecurity","4376":"Sadness ","4377":"Des-continuation due to diarrhea ","4378":"Des-continuation due to rash","4379":"Skeletal muscle mass","4380":"Total energy intake","4381":"Total energy intake","4382":"Lower limb lean soft tissue","4383":"Lower limb lean soft tissue","4384":"Chest press","4385":"Radiographic bone fill ","4386":"Total cholesterol","4387":"IL-6","4388":"Glycated hemoglobin","4389":"Waist circumference","4390":"Cured patients using 3 criteria","4391":"Cured patients using 2 criteria","4392":"Patency period ","4393":"Diastolic blood pressure after extubation","4394":"Heart rate during injection","4395":"Complications ","4396":"Hematocrit after 24 hrs","4397":"Estimated blood loss","4398":"Blood sugar concentrations after 60 minutes","4399":"Insulin concentration ","4400":"ABCA1 and ABCG1 protein levels in MDM cultured","4401":"Median frecuency on Vastus medialis first 24 hrs","4402":"Mean power frequency on Vastus medialis","4403":"Mean power frequency on Rectus femoris","4404":"Creatin kinase","4405":"Intact parathyroid hormone","4406":"Patients reaching primary endpoint","4407":"iPTH target (150 to 300)","4408":"Mean HbA1c","4409":"HbA1c at 24 weeks","4410":"Fasting plasma glucose.","4411":"Mean BP","4412":"Eye opening time","4413":"Extubation time","4414":"Distal Motor Latency improvement","4415":"Distal Motor Latency improvement","4416":"BMI","4417":"Fasting plasma glucose","4418":"Insulin concentration","4419":"IL-6","4420":"Hot flashes","4421":"Other side effects ","4422":"Event-free survival curves","4423":"Anxiety due to program ","4424":"Progression-free survival","4425":"Disease control rate","4426":"\u22655% body weight loss","4427":"Heart rate","4428":"Cracks","4429":"Cracks","4430":"Cracks","4431":"Cracks","4432":"Plasma homocysteine","4433":"Trolox equivalent antioxidant capacity","4434":"Malondialdehyde ","4435":"Oxidized glutathione","4436":"Child-Turcotte-Pugh score","4437":"Model for end-stage liver disease score","4438":"Model for end-stage liver disease score","4439":"reversion rates of the MetS at 6 months, at 2 years","4440":"Significant adverse effects","4441":"Serum \u03b1-carotene ","4442":"Serum \u03b2-cryptoxanthin","4443":"HDL 3 Lycopene","4444":"HDL 3 Paraoxonase 1","4445":"Apolipoprotein A1","4446":"Cytotoxicity ","4447":"Cytotoxicity ","4448":"Wearing sunglasses on sunny days","4449":"Knowledge on visual problems' symptoms ","4450":"Buying glasses from optical stores ","4451":"Bowel frequency","4452":"Bowel frequency","4453":"Constipation assessment scale improvement ","4454":"Bowel function improvement ","4455":"Bowel function improvement ","4456":"Episiotomy","4457":"Apgar scores","4458":"Pain after 3 months","4459":"Obstructions","4460":"Perforations","4461":"Fractures ","4462":"Acute tubular necrosis-Delayed graft function","4463":"Rejection-free graft survival","4464":"Non-infectious complications","4465":"Functional Assessment of Chronic Illness Therapy-Fatigue improvement","4466":"Health Assessment Questionnaire-Disability Index improvement","4467":"Activity impairment","4468":"Activity impairment","4469":"Patient that left without being seen","4470":"Mortality","4471":"Restraint frecuency","4472":"Intermittent restraint ","4473":"Leptin","4474":"Acyl ghrelin","4475":"Positional differences improvement (superoinferior)","4476":"Endogenous opioids","4477":"Systolic blood pressure","4478":"Monocytes engaged in phagocytosis","4479":"Monocytes engaged in phagocytosis","4480":"Oral Assessment Guide improvement","4481":"Oral mucositis grade","4482":"Saxon test improvement ","4483":"VAS pain score improvement ","4484":"Range of motion ","4485":"Lean tissue loss","4486":"Pulse wave velocity","4487":"Pain tolerance ","4488":"Beck Depression Inventory score improvement (4 weeks)","4489":"Beck Depression Inventory score (12 weeks)","4490":"Parkinson's disease quality of life questionnaire - cognition score improvement","4491":"Unified Parkinson's Disease Rating Scale Part II score improvement","4492":"Choice reaction improvement ","4493":"Recurrent urinary tract infections","4494":"Febrile urianry tract infections","4495":"New renal scars","4496":"Side effects ","4497":"Nitrofurantoine-sensitive E. coli after 3 years ","4498":"TOI of Functional Assessment of Cancer Therapy-Breast","4499":"Anxiety aspect of the Hospital anxiety and depression scale","4500":"Anxiety","4501":"Anxiety","4502":"Treatment costs ","4503":"Collony-forming units","4504":"Collony-forming units","4505":"Physical activity","4506":"Usage of peri\/postnatal services ","4507":"HIV counselling and testing","4508":"Tumor reduction","4509":"Tumor reduction","4510":"Tumor reduction","4511":"Bone mineral density","4512":"Bone mineral density","4513":"Venous oxygen saturation","4514":"Haemoglobin","4515":"Blood temperature","4516":"pH","4517":"Pre-exercise fat oxidation","4518":"Post-exercise fat oxidation","4519":"Epinephrine levels during exercise in untrained people","4520":"Epinephrine levels after exercise in untrained people","4521":"VO2","4522":"Berg Balance Scale score improvement 4 weeks","4523":"Berg Balance Scale score improvement 8 weeks","4524":"Activities-Specific Balance Confidence score improvement","4525":"Adverse events","4526":"CADESI score improvement ","4527":"Fasting plasma glucose","4528":"Alanine aminotransferase","4529":"Body weight","4530":"Suppression of hepatic glucose production","4531":"Procedural skills","4532":"eHealth literacy","4533":"Web knowledge","4534":"Attitude and practices ","4535":"Augmentation index","4536":"Heart rate","4537":"Blood pressure ","4538":"Surgeon satisfaction ","4539":"Laryngeal mask airway insertion attempts ","4540":"Laryngeal mask airway insertion attempts ","4541":"Recovery rates","4542":"Recovery rates","4543":"Recovery rates","4544":"Sevoflurane concentration","4545":"Systolic blood pressure","4546":"Fluid requirements","4547":"Migration by RSA maximal total point motion after 1 year","4548":"Migration by secondary MTPM variables after 2 years","4549":"FEV1","4550":"Blood pressure","4551":"Blood pressure","4552":"Heart rate","4553":"Keratin desquamation","4554":"Prepatent period","4555":"Parasite load ","4556":"Vitamin D levels","4557":"Th1\/Th2 cytokines","4558":"Interleukin 2","4559":"Total Human milk oligosaccharides","4560":"Sialylated HMOs","4561":"Lysozymes","4562":"Distant recurrence-free survival","4563":"PaCO2","4564":"Strong ion gap","4565":"Bicarbonate ","4566":"Lactate","4567":"Parent-rated Aberrant Behavior Checklis improvement","4568":"Clinician-rated Clinical Global Impression-Improvement scores","4569":"Inappropriate speech","4570":"Patient Health Questionnaire depression scale improvement","4571":"Work and Social Adjustment Scale","4572":"Gastrotomy creation times","4573":"Closure times","4574":"Closure times","4575":"MEP amplitudes","4576":"MEP amplitudes","4577":"peak E","4578":"E\/A","4579":"Respiratory symptoms","4580":"Creatitine after 4 days","4581":"Change of TGSS","4582":"Difference in radiographic progression","4583":"Change of TGSS","4584":"Joint damage progession","4585":"Joint damage progession","4586":"time to first rescue analgesic","4587":"postoperative pain","4588":"morphine requirements","4589":"loneliness score","4590":"younger age","4591":"physically active","4592":"IgG4","4593":"maternal immune responses","4594":"immune responsiveness of uninfected offspring","4595":"IgG1","4596":"SWA-specific IgE","4597":"radial-ulnar deviation","4598":"dorsiflexion","4599":"palmar flexion","4600":"pronation","4601":"therapeutic targets","4602":"urgent coronary revascularization","4603":"long\ufffdterm secondary prevention of thrombotic CV events","4604":"total time taken to complete the test for Line bisection test (LB)","4605":"feasibility of procedure in sub-acute stroke patients admitted to a rehabilitation center","4606":"total time taken to complete the test for Object Cancelation test (OC)","4607":"AUC0\u201360d","4608":"maintaining clinical response to week 4 following a 16-week","4609":"vWF","4610":"flow-mediated dilatation (FMD)","4611":"CCR5 expression in CD8+ T cells","4612":"hsCRP","4613":"D-dimer","4614":"biosimilarity","4615":"injection site reactions (ISRs)","4616":"efficacy","4617":"safety","4618":"improvment in ANELT by day 21","4619":"aphasia types","4620":"safety of multi-coil rTMS affect on the dorsal anterior cingulate cortex","4621":"reduction in acute induced pain","4622":"pain perception in dorsal anterior cingulate cortex ","4623":"descriptive improvements post measurement","4624":"physical pain after rehabilitation","4625":"improvement in the quality life of heart failure patients","4626":"social functioning","4627":"periodontal disease (PD) ","4628":"effectiveness after early ischemic stroke","4629":"Modified Barthel Index (MBI) after 3 months","4630":"improvement of medical compliance in patients with schizophrenia","4631":"completed follow-up","4632":"Remission","4633":"average bed day consumption throughout the 12 months","4634":"better define the labial microflora","4635":"fatty acid analyses of vaginal secretions","4636":"fatty acid analyses of vaginal secretions","4637":"increased carriage of medically important species after wearing panty liner","4638":"efficacy of treating patients with chronic functional constipation","4639":"realism score","4640":"post-test scores acute bacterial meningitis scenario","4641":"Pulmonary function","4642":"exercise capacity","4643":"saturation of oxygen during 6MWT","4644":"mean forced expiratory volume in one second (FEV1)","4645":"relationships between the \u03b2-endorphin plasma level and the course of the treadmill stress test","4646":"Cytotoxicity ","4647":"plasma level of \u03b2-endorphin after 2-week omeprazole administration","4648":"scores on pre-tests","4649":"Depression improvement ","4650":"Total adipose tissue in women","4651":"Subcutaneous adipose tissue in women","4652":"Macular pigment optical density","4653":"Second degree lacerations ","4654":"VAS pain during 3-4 cm dilatation ","4655":"VAS pain during second stage of labor","4656":"McGill scale's pain ","4657":"McGill scale's anxiety ","4658":"Partner physical violence ","4659":"Creation of ledges","4660":"Participation in household tasks","4661":"Men's intentions to use violence ","4662":"Believing a woman can refuse sex in all circumstances","4663":"Fat-free leg mass","4664":"Leg blood flow","4665":"Multiple infections","4666":"Functional Assessment of Chronic Illness Therapy-Fatigue improvement","4667":"Health Assessment Questionnaire-Disability Index improvement","4668":"Acute kidney injury","4669":"Waiting time of CTAS 4","4670":"Waiting time of CTAS 5","4671":"Mature oocytes amount ","4672":"Fertilized oocytes","4673":"Near dissociated phoria improvement of left eye","4674":"Restraint knowledge","4675":"Fusional divergence improvement","4676":"Positional differences improvement (anteroposterior)","4677":"Stoned feeling","4678":"Orientational differences improvement (Pitch)","4679":"Body weight ","4680":"Influenza risk","4681":"Vitamin D level","4682":"Hypoglycemia ","4683":"Hypoglycemia ","4684":"Communication about mistakes","4685":"Perception of efficiency","4686":"Time spent on the site","4687":"Gustatory measurement improvement ","4688":"Enjoyment","4689":"Pressure pain threshold improvement ","4690":"Systolic blood pressure ","4691":"Body mass index","4692":"Body fat","4693":"Body fat","4694":"Diastolic blood pressure ","4695":"Body mass index","4696":"Injury incidence ","4697":"Pulse wave velocity","4698":"Pain VAS (1 week)","4699":"Pain VAS (4 weeks)","4700":"Progression-free survival","4701":"Participation ","4702":"Session duration ","4703":"Hemorrhages area","4704":"Distance from optic disc to hemorrhage","4705":"Hemorrhages within the fovea.","4706":"Parkinson's disease quality of life questionnaire - mobility score improvement","4707":"Reaction time","4708":"Unified Parkinson's Disease Rating Scale Part I score improvement","4709":"Divided attention improvement","4710":"Systolic blood pressure ","4711":"Diastolic blood pressure ","4712":"Response at week 16","4713":"Afebrile urianry tract infections","4714":"Controlled patients at week 8","4715":"Balancing capacity","4716":"Borg's scale scores","4717":"Adverse events ","4718":"Functional aspect of Functional Assessment of Cancer Therapy-Breast","4719":"Total lesion count","4720":"Depression aspect of the Hospital anxiety and depression scale","4721":"Anxiety","4722":"Anxiety","4723":"Anxiety","4724":"Inflammatory lesions","4725":"Non-inflammatory lesions","4726":"Anxiety","4727":"Investigators Global Assessment-measured overall efficacy","4728":"10-minute walking test improvement ","4729":"Degree of disability","4730":"VO2 Max","4731":"Push-ups","4732":"Morning prebronchodilator FEV1","4733":"Sit and reach","4734":"Lung deposition in untrained patients ","4735":"Lung deposition in trained patients ","4736":"Usage of antenatal services ","4737":"Nausea ","4738":"Patient service satisfaction","4739":"Vomiting","4740":"Dizziness","4741":"Sedation","4742":"Medical survey response rate on the south","4743":"Overall survey response rate ","4744":"Calcium and phosphorus intake","4745":"Calcium and phosphorus intake","4746":"Dihydrotestosterone concentrations","4747":"Dihydrotestosterone concentrations","4748":"Dihydrotestosterone concentrations","4749":"PaCO2 level","4750":"Responders identification accuracy ","4751":"magnitude of the effect of zinc on rates of respiratory illness","4752":"magnitude of the effect of zinc on rates of fever without localizing signs","4753":"rate of diarrhea","4754":"Reduction of plasma levels of TGF-\u03b21","4755":"treatment differences","4756":"treatment differences","4757":"WBC counts","4758":"mean age of patients","4759":"perforation of appendix","4760":"Mean operating time","4761":"accompanying gastrointestinal symptoms","4762":"fever","4763":"+25% improvement ","4764":"+25% improvement ","4765":"haemoglobin","4766":"time of rotation peak displacement","4767":"Pulse wave velocity (PWV)","4768":"stiffness index (\u03b2)","4769":"compliance coefficient (CC)","4770":"Short Physical Performance Battery at 12 months","4771":"Between-group differences in frailty at 3 months","4772":"Learning Preferences","4773":"oocysts shedding","4774":"supportive care","4775":"waist-hip ratio of women","4776":"Successive NN interval differences >50 ms","4777":"Need of atricurium","4778":"antioxidant potential","4779":"WM capacity of individuals who rated higher levels of attachment avoidance","4780":"attachment anxiety positively predicted performance in n-back tasks in attachment related words","4781":"attachment anxiety positively predicted performance in n-back tasks in non-attachment related words","4782":"WM capacity of individuals who rated higher levels of attachment anxiety","4783":"advanced colorectal neoplasia (CRN)","4784":"discrimination performance using AUC (Area under the receiver operating curve) for high risk patients","4785":"discrimination performance using AUC (Area under the receiver operating curve) for high risk patients","4786":"saliva contamination effect on immediate bond strength","4787":"level of uncertainty for the intervention arm men","4788":"difference in the proportions of correct and incorrect trial arm allocations after vignettes standardization for intervention group","4789":"Heart rate","4790":"additional CIN lesions","4791":"Need of ephedrine ","4792":"Knee osteoarthritis outcome score after 1 year","4793":"Knee osteoarthritis outcome score after 2 years","4794":"Heart rate","4795":"Pain","4796":"Facial moisture","4797":"Sebum level","4798":"Elasticity","4799":"Probability of having an injury","4800":"Dipeptidyl peptidase-4 ","4801":"Tumor necrosis factor alpha","4802":"Gastric emptying rate","4803":"Body weight","4804":"Head circumference","4805":"Formula intakes","4806":"Dental flossing","4807":"Crohn's and Ulcerative Colitis Questionnaire scores","4808":"Short-Form Six-Dimension scores","4809":"EuroQol-5D scores","4810":"Colectomy rates","4811":"Adverse reactions ","4812":"Mortality","4813":"Resolving lesions >27 mm","4814":"Independent household latrines number","4815":"Open defecation","4816":"Helminth infections ","4817":"Anemia","4818":"Raven's Colored Progressive Matrice completion time","4819":"Neuropsychiatric Inventory score","4820":"Sleep time","4821":"Disability Assessment for Dementia score","4822":"Vomiting","4823":"Eye opening time ","4824":"Postoperative agitation","4825":"Fentanyl consumption","4826":"Time for discharge","4827":"Correct response rate for 500 Hz frequency","4828":"Correct response rate for 4,000 Hz frequency","4829":"Adverse effects ","4830":"Adverse effects ","4831":"Oxidative stress index","4832":"Glucose maximum concentration","4833":"Resection rates","4834":"Task analyses usage\t","4835":"Success rate of NGT insertion","4836":"Binge number","4837":"Calcium levels","4838":"Successful epidural space identification","4839":"Physician satisfaction ","4840":"Short-Form 36-Items improvement","4841":"Short-Form 36-Items improvement","4842":"Pain","4843":"Iron concentration","4844":"HCV infection","4845":"Ascent vertical toe clearance variability ","4846":"Ascent duration ","4847":"Ascent vertical toe clearance","4848":"ER visits","4849":"Days limited activity from asthma\t","4850":"Days patient had to slow down\t","4851":"Parent rated emotional well being","4852":"Parent rated self-esteem ","4853":"CDRS' depressed feelings improvement","4854":"Saccadic amplitude gain","4855":"Smooth pursuit saccadic frequency","4856":"Clinician Administered Dissociative States Scale scores","4857":"Leakage","4858":"Leakage","4859":"Viable follicles","4860":"Viable follicles","4861":"Viable follicles","4862":"overcome the exercise-induced adverse responses","4863":"exercise-induced increase in response of the plasma CRP","4864":"inflammatory markers","4865":"Methacholine reactivity at 24 hrs post allergen challenge","4866":"responses to allergen challenge in mild asthmatics","4867":"Psychological Readiness for Job Interviewing","4868":"serum insulin during recovery from cycling exercise","4869":"systolic and diastolic blood pressure, serum triglyceride levels , total cholesterol , LDL cholesterol , HbA1c , fasting blood glucose, fasting insulin and HOMA-I","4870":"Glucose levels obtained 30 min post-feeding","4871":"Measures of gesture","4872":"Remifentanil tolerance - ICU patients with various degrees of renal impairment","4873":"reduction in adipose tissue","4874":"incidence of bradycardia","4875":"reduction in the number of recurrences while on prophylaxis","4876":"Body temperature","4877":"Workouts","4878":"6-min walking test (6MWT) distance","4879":"The final reattachment rate","4880":"the average duration of surgery","4881":"microvascular permeability parameters","4882":"repeated-exposure photostress recovery (PSR)","4883":"headache intensity after 6 h","4884":"optical density of MP (MPOD)","4885":"femoral neck bone density","4886":"The change in vertebral T-score","4887":"amount of residual smear layer","4888":"sexual satisfaction (SS)","4889":"heart rate at week seven","4890":"mean number of QALYs after 9 months","4891":"plasma amyloid-\u03b2 (A\u03b2) peptides","4892":"the incidence of postoperative nausea and vomiting (PONV)","4893":"ventricular volume","4894":"VO2peak","4895":"peak HR in older subjects","4896":"improved VO2max (l\/min) from cycling to rowing","4897":"nausea and vomiting","4898":"Packed red blood cells (PRBC) transfusion","4899":"progression-free survival (PFS) in patients with IDHmt\/non-codel tumors","4900":"progression-free survival (PFS) in metastatic colorectal cancer (MCRC)","4901":"the mean HDL-C level","4902":"The mesial movement in maxillary first molars and extrusion","4903":"body mass index (BMI) standard deviation score (SDS), total daily insulin doses and serum meanlow-density lipoprotein (LDL) levels","4904":"numbers needed to treat (NNTs)","4905":"numbers needed to treat (NNTs)","4906":"rituals associated with smoking gestures","4907":"cognitive measures","4908":"positive attitudes towards mental health issues in post-test period","4909":"attitudes towards mental health issues in pre-intervention period","4910":"Duration of analgesia","4911":"faster onset of pain relief","4912":"Onset of action","4913":"faster onset of pain relief","4914":"post-treatment vascular endothelial growth factor (VEGF) levels","4915":"treatment-free survival (TFS)","4916":"CCL-3 levels with achievement of complete remission (CR)","4917":"hours spent working but without a decline in job performance","4918":"workaholism symptomatology","4919":"exercise capacity","4920":"difference in dyspnea between the two groups before training","4921":"pain duration at follow up","4922":"headache frequency","4923":"visits to general practitioners","4924":"pregnancy-specific stress during third trimester","4925":"weight loss","4926":"abdominal fat thickness","4927":"severe drug reaction","4928":"Total mental health care costs","4929":"clinical outcomes at 9 months","4930":"ProTaper Next system maintained root canal curvature","4931":"apical transportation values","4932":"performance of path-finding files","4933":"mean use of nitroglycerin (TNG)","4934":"mean HR during follow-up period","4935":"1,5-anhydroglucitol","4936":"mean duration of surgery","4937":"transfusion requirements","4938":"similarity to other behavioural support interventions","4939":"road traffic accidents","4940":"Biochemically verified continuous abstinence at 6 months","4941":"thumb pain","4942":"fractional albumin synthesis rate (FSRalb)","4943":"valine oxidation","4944":"BUN concentrations","4945":"overall survival (OS) in metastatic colorectal cancer (MCRC) ","4946":"rate of radical (R0) surgical resection in metastatic colorectal cancer (MCRC)","4947":"At the end of treatment, patients without evidence of the disease in metastatic colorectal cancer (MCRC)","4948":"Cold contact urticaria (CCU) change in critical temperature thresholds (CTT)","4949":"Cold contact urticaria (CCU) change in critical temperature thresholds (CTT)","4950":"histamine assessed 1\u20133 h after cold challenge ","4951":"smoking cessation - history of depression","4952":"smoking cessation","4953":"smoking cessation","4954":"smoking cessation - differential treatment effect (heterogeneity) across sites","4955":"sleep latency effects among patients with schizophrenia","4956":"mean activity level among patients with schizophrenia","4957":"headache severity","4958":"primary headaches in healthcare providers","4959":"headache frequency","4960":"HbA1c variation - effect of cognitive-behavioral group therapy on depressive symptoms in people with type 2 diabetes","4961":"mean intubation time - awake nasal intubation of oropharyngeal cancer patients with anticipated difficult intubation","4962":"post-intubation bleeding - awake nasal intubation of oropharyngeal cancer patients with anticipated difficult intubation","4963":"physical outcomes awareness -training effects on physical and psychological outcomes awareness of smoking in teenagers","4964":"training effects on physical and psychological outcomes awareness of smoking in teenagers","4965":"Fibrinolysis in Metabolic Syndrome","4966":"Remifentanil incidence of adverse events - ICU patients with various degrees of renal impairment","4967":"Suicidal ideas","4968":"Regurgitations ","4969":"Adverse reactions","4970":"Flossing intentions","4971":"Quality-adjusted survival","4972":"Costs","4973":"Resolving disease ","4974":"Resolving lesions <27 mm","4975":"Sanitation facility improvement","4976":"E. coli contaminated water ","4977":"Barthel Index score","4978":"Palatability","4979":"Correct response rate for 2,000 Hz frequency","4980":"QTc (individual correction) time","4981":"Insulin minimum concentration","4982":"Non-esterified fatty acids AUC","4983":"Insulin secretion ","4984":"Insulin half life","4985":"\"Education on thePrevention of RSI for Employees\" usage","4986":"RSI and Stress usage","4987":"Eyesight check usage","4988":"Individual Workstation Check usage\t","4989":"Tube insertion time","4990":"Pharyngeal bleeding","4991":"Kinking or knotting","4992":"Planned food intake","4993":"Consecutive binge refractory period","4994":"iPTH reductions of \u226530%","4995":"Adverse effects ","4996":"iPTH reduction from baseline","4997":"Achieved iPTH levels within KDOQI range","4998":"Failing on first 2 attempts","4999":"Time needed ","5000":"Ease of procedure","5001":"Health-related quality of life improvement","5002":"Mental Component Summary improvement","5003":"Fatigue Assessment Scale improvement","5004":"Haemoglobin increase from baseline","5005":"Iron concentration","5006":"Serum-ferritin","5007":"HB surface antigen ","5008":"Ascent duration ","5009":"Days of wheeze","5010":"Knowledge","5011":"School days missed for asthma\t","5012":"Patient rated self esteem","5013":"Children's depression rating scale-revised total score improvement","5014":"Saccadic amplitude gain","5015":"Smooth pursuit eye movements velocity gain","5016":"Leakage","5017":"Viable follicles","5018":"Viable follicles","5019":"levels of serum CK","5020":"variables changes ranges after exercise protocol","5021":"postal questionnaire sent","5022":"EAR (early response)","5023":"fall in minimum and weighted mean FEV1","5024":"LAR (late response)","5025":"time to first rescue analgesic","5026":"time to first rescue analgesic","5027":"PC users","5028":"respiratory disturbance index","5029":"Deep Sleep after 1 week","5030":"REM Sleep after 1 week","5031":"stage N2 sleep after 1 week","5032":"progression-free survival (PFS)","5033":"response rates","5034":"SEA-specific antibodies IgE levels","5035":"radiological outcome","5036":"supination","5037":"WBC","5038":"platelet count","5039":"global composition of the microbiota in colicky infants","5040":"Bacteroidetes","5041":"Bacteroidaceae","5042":"moderate or severe bleeding","5043":"CV death","5044":"Myocardial Infarction","5045":"stroke","5046":"total time taken to complete the test for Letter Cancelation test (LC)","5047":"bioequivalence in terms of the rate and extent of absorption","5048":"Cmax","5049":"Tmax","5050":"AUC0\u2013\ufffd","5051":"prior anti-TNF exposure at baseline, disease duration","5052":"endothelial function","5053":"CCR5 expression in CD4+ T cells","5054":"keen to learn the results themselves","5055":"preference for glycaemic control","5056":"immunogenicity","5057":"serious treatment related adverse events (AEs)","5058":"Amsterdam-Nijmegen everyday language test (ANELT)","5059":"history of myocardial infarction","5060":"communication ability","5061":"reliably of multi-coil rTMS affect on the dorsal anterior cingulate cortex","5062":"sitting time","5063":"standing time","5064":"mean changes for the digit span task","5065":"effect sizes for the digit span task","5066":"limitation of physical health","5067":"physical performance or functioning","5068":"energy","5069":"clinical healing","5070":"Total MMP-1 levels at 3 months","5071":"Total MMP-1 levels at 6 months","5072":"TIMP-1\/MMP-1 balance","5073":"activities of daily living","5074":"average FMA (Fugl-Meyer Assessment) lower extremity scores after 3 weeks treatment","5075":"Berg Balance Scale (BBS) after 3 months","5076":"effect on compliance","5077":"better define the labial microflora","5078":"tolerability of treating patients with chronic functional constipation","5079":"mean of weekly defecation frequency increase","5080":"side effects observed","5081":"Improvement in other measured outcomes concerning defecation difficulty","5082":"pre-test scores","5083":"post-test scores severe asthma exacerbation","5084":"post-test scores calcium channel blocker overdose","5085":"post-test scores severe sepsis","5086":"vital capacity (VC)","5087":"mean distance that participants walked during 6MWT","5088":"forced vital capacity (FVC)","5089":"average \u03b2-endorphin plasma concentration during the whole study period","5090":"\u03b2-endorphin plasma concentration in patients with CAD","5091":"accessing the program","5092":"referral approaches","5093":"Global functioning","5094":"Global functioning","5095":"Alcohol dependence improvement","5096":"Depression improvement ","5097":"Intermuscular adipose tissue in women","5098":"Visceral adipose tissue in women","5099":"Body weight in women","5100":"Macular pigment increase when baseline is high","5101":"Stress","5102":"VAS pain during 8-10 cm dilatation ","5103":"Partner sexual violence ","5104":"Hostility when managing conflicts ","5105":"Myofibrillar fractional synthetis rate","5106":"Femoral artery diameter","5107":"Mean arterial pressure","5108":"Intracellular free phenylalanine","5109":"Urinary neutrophil gelatinase-associated lipocalin","5110":"Cytokines","5111":"Mortality ","5112":"Total hospital stay","5113":"ICU stay","5114":"Mature oocytes amount ","5115":"Fertilized oocytes","5116":"Clinical pregnancy rate","5117":"Live birth rate","5118":"Near dissociated phoria improvement of right eye","5119":"Fusional convergence improvement","5120":"Facial affect recognition","5121":"Facial affect recognition ","5122":"Facial affect recognition","5123":"Stoned feeling","5124":"Stoned feeling","5125":"Vitamin D level","5126":"Calcium level","5127":"Calcium level","5128":"Patient counseling","5129":"Response to mistakes","5130":"Organizational learning and continuous improvement ","5131":"Patient safety perceptions ","5132":"Pages visited","5133":"Knowledge gained on the site","5134":"Effectiveness ","5135":"Systolic blood pressure ","5136":"Diastolic blood pressure ","5137":"Progression-free survival","5138":"Adherence ","5139":"Error rate","5140":"Task performance","5141":"3-Back Task","5142":"EEG amplitudes","5143":"Response at week 8","5144":"Controlled patients at week 16","5145":"Lower-limb muscle strength","5146":"10-m walking test ","5147":"Dermatology Life Quality Index scores","5148":"Hepatic function","5149":"Forced vital capacity improvement","5150":"Forced expiratory volume 1 improvement","5151":"6-minute walking test improvement ","5152":"Oxygen saturation ","5153":"40 yards technical test","5154":"Sit-ups ","5155":"50-meter speed ","5156":"Penetration index","5157":"Postoperative pain ","5158":"Need for opioids","5159":"Medical survey response rate on family physicians ","5160":"Medical survey response rate on internists","5161":"Medical survey response rate on the northeast ","5162":"Testosterone undecanoate concentrations","5163":"Testosterone undecanoate concentrations ","5164":"Testosterone undecanoate concentrations","5165":"number of clinic visits","5166":"magnitude of the effect of zinc on rates of diarrhea","5167":"Mean duration of preoperative symptoms","5168":"location of pain","5169":"serum ferritin level","5170":"serum iron","5171":"transferrin saturation","5172":"carotid IMT","5173":"number of deaths","5174":"prevalence of frailty at 12 months","5175":"differences in frailty at 12 months","5176":"physically and metabolically decompensated","5177":"plasma cortisol","5178":"serum total protein","5179":"ALT level in women","5180":"fasting plasma glucose","5181":"difference in the proportions of correct and incorrect trial arm allocations after vignettes standardization for control group","5182":"level of uncertainty for the control arm men","5183":"CIN3+ association","5184":"CIN3+ association","5185":"positive for round 1 CIN3+","5186":"positive for round 1 CIN2","5187":"growth hormone","5188":"symptom control","5189":"hyperhidrosis and headache","5190":"Plasma concentrations of IGF-1","5191":"Forced Expiratory Volume in the first second (FEV1)","5192":"FEV1","5193":"forced vital capacity (FVC)","5194":"transition dyspnea index (TDI) focal score","5195":"transition dyspnea index (TDI) focal score after 8 weeks of therapy","5196":"transition dyspnea index (TDI) focal score after 8 weeks of therapy","5197":"St. George's Respiratory Questionnaire (SGRQ)","5198":"exacerbation frequency and number of exacerbation days","5199":"Post operative pain scores","5200":"length of stay in postoperative care unit (PACU)","5201":"The necessity and total amount of morphine titration in the PACU","5202":"Extubation delays","5203":"maximum pain scores and the incidence and the amount of morphine requirements","5204":"The incidence of nausea and vomiting","5205":"the mean score of satisfaction among the parents of the children","5206":"the mean score of parent's educational satisfaction","5207":"psychological support","5208":"Ki-67 mitotic index","5209":"Ki-67 mitotic index","5210":"Ki-67 mitotic index","5211":"COX-2 expression","5212":"COX-2 expression","5213":"odds of cessation at 1 month","5214":"odds of cessation at delivery","5215":"plasma glucose levels","5216":"high-molecular-weight (HMW) adiponectin","5217":"The decreases in glycated hemoglobin (HbA1c)","5218":"hematocrit, red blood cells, and total hemoglobin","5219":"Vividness (Experiment 1)","5220":"Valence (Experiment 1)","5221":"Anxiety increase (Experiment 1)","5222":"Valence (Experiment 2)","5223":"the duration of anesthesia","5224":"the mean time to first analgesic request","5225":"post-intervention test scores","5226":"post-intervention test scores","5227":"post-intervention test scores","5228":"the prevalence of pathologic 24-hour esophageal reflux","5229":"the prevalence of pathologic nocturnal esophageal reflux","5230":"the prevalence of both pathologic 24-hour and nocturnal esophageal reflux in the 3rd study","5231":"the prevalence of pathologic postprandial esophageal reflux in the 3rd study","5232":"virologic failure (VF)","5233":"VF rate","5234":"Frequency distribution of catheter tip culture","5235":"Mean of body temperature at the second and fourth days","5236":"Mean of body temperature on other days","5237":"the positivity of the culture result","5238":"death","5239":"Mean post-surgical pain ratings","5240":"sIgA absolute concentration and secretion rate after 90 days","5241":"Prooxidant-antioxidant balance (PAB)","5242":"Prooxidant-antioxidant balance (PAB)","5243":"leukocyte count","5244":"neutrophil count","5245":"neutrophil count","5246":"creatine kinase (CK)","5247":"creatine kinase (CK)","5248":"aspartate aminotransferase (AST), lactate dehydrogenase (LDH),","5249":"uric acid (UA), creatinine (Cre)","5250":"uric acid (UA), creatinine (Cre)","5251":"leukocyte count","5252":"high sensitivity C-reactive protein (hs-CRP)","5253":"high sensitivity C-reactive protein (hs-CRP)","5254":"The neurotrophin brain-derived neurotrophic factor (BDNF)","5255":"The neurotrophin brain-derived neurotrophic factor (BDNF)","5256":"body weight","5257":"body weight","5258":"body weight","5259":"body mass index (BMI)","5260":"BMI","5261":"percent body fat","5262":"percent body fat","5263":"percent body fat","5264":"heart rate","5265":"diastolic blood pressure","5266":"systolic blood pressure","5267":"scores for Knowledge; Attitudes toward seriousness , complications , Practice","5268":"attitudes towards seriousness of diabetes","5269":"scores for Knowledge; Attitudes toward seriousness , complications , Practice","5270":"number of patients who developed grade 3 mucositis and grade 4 mucositis","5271":"number of patients who developed grade 1 and grade 2 mucositis","5272":"The mean duration of grade 3 mucositis or worse (grade 3 and grade 4)","5273":"the mean time to onset of mucositis","5274":"Grade 3 or worse mucositis","5275":"the risk of a first Clinically important deterioration' (CID) event","5276":"the risk of a first CID event","5277":"the risk of a first CID event","5278":"the risk of a sustained CID event","5279":"forced expiratory volume in 1 second (FEV1) and Transition Dyspnea Index (TDI), first and sustained CID; St George's Respiratory Questionnaire (SGRQ)","5280":"the risk of a sustained CID event","5281":"concerning body mass index (BMI)","5282":"waist hip ratio (WHR)","5283":"serum cholesterol, fasting plasma glucose, glycated haemoglobin (HbA1c), systolic\/diastolic blood pressure","5284":"weight, BMI, WC, WHR, HbA1c, and diet","5285":"alcohol consumption in males","5286":"intraocular pressure (IOP)","5287":"taking part in screening","5288":"taking part in screening","5289":"taking part in screening","5290":"taking part in screening","5291":"taking part in screening","5292":"taking part in screening","5293":"Median Multiple Sclerosis Impact Scale (MSIS) 29 score","5294":"Median Multiple Sclerosis Impact Scale (MSIS) 29 score","5295":"Median Multiple Sclerosis Impact Scale (MSIS) 29 score","5296":"Fasting glycemia","5297":"HbA1c levels","5298":"C-peptide levels","5299":"insulin and C-peptide responses to intravenous glucose administration","5300":"first- and second-phase insulin secretion","5301":"alpha power","5302":"alpha power","5303":"MCCB performance : Processing Speed , Attentional Vigilance , and Visual Learning","5304":"MCCB performance : Working Memory, Verbal Learning, Reasoning, or Social Cognition","5305":"State-Trait Anxiety Inventory (STAI) test","5306":"Hospital Anxiety and Depression Scale (HADS) test - anxiety level","5307":"Hospital Anxiety and Depression Scale (HADS) test - depression scores","5308":"aggression-hostility","5309":"the mean and the standard deviation of the \u03bcTBS to dentin","5310":"the mean and the standard deviation of the \u03bcTBS to dentin","5311":"Anxiety and insomnia (AI)","5312":"Social dysfunction (SF)","5313":"Severe depression (SP):","5314":"effect size in Sattva (gentle and controlled) subgroup","5315":"effect size in Tamas (dull and uncontrolled)subgroup","5316":"pain response","5317":"substantial scalp traumas (cephalhaematoma and skin abrasions\/lacerations)","5318":"The proportion of EDIN \u2265 5","5319":"Matrix metalloproteinase-9 (MMP9) level","5320":"Barthel Index (BI) score","5321":"modified Rankin Scale (mRS) score","5322":"Barthel Index (BI) score","5323":"C-reactive protein","5324":"sP-selectin","5325":"absenteeism and presenteeism","5326":"household work days","5327":"Insertion was successful with one attempt","5328":"The number of successful ventilations in the first trial","5329":"sealing pressure","5330":"Plasma TNF\u03b1","5331":"Weight, BMI and waist circumference","5332":"Systolic blood pressure","5333":"Diastolic blood pressure, pulse and quality of life","5334":"(serum C-reactive protein (CRP)","5335":"lessening of effectiveness with time","5336":"craving","5337":"Reduction of thickness and CG of the PL-biofilm","5338":"Overall effectiveness after 4 days","5339":"Bacterial viability","5340":"Markers of systemic inflammation","5341":"Adherence at 3 months","5342":"Adherence at 6 months","5343":"Baseline characteristics and general anesthesia procedure","5344":"Pathologic changes in the liver","5345":"Pathologic changes in the kidneys","5346":"Overexposure","5347":"TQ-score improvement","5348":"Treatment failure","5349":"Bleeding recurrence","5350":"Need of surgery","5351":"Number of blood units transfused","5352":"Mean fusion mass volume","5353":"Lenke scores at 12 months","5354":"Lenke scores at 3 months and 6 months","5355":"Baseline characteristics","5356":"Colon cleanliness","5357":"Overall safety at 96 weeks","5358":"Survival rate after 2 years in non-small cell lung cancer patients","5359":"Long-term morbidity","5360":"Vital parameters","5361":"Mean pre-prandial to post-prandial systolic and diastolic blood pressures ","5362":"Pre-meal reactive hyperemia index in individuals with endothelial dysfunction","5363":"Uncorrected visual acuity \u2265 20\/20 and \u2265 20\/40","5364":"Final refractive error within 1D of emmetropia","5365":"Time needed for debridement","5366":"Subjective well-being","5367":"Negative emotions or total mental health difficulties","5368":"Positive emotions","5369":"Duration of diarrhea","5370":"Improvement in faeces consistency","5371":"Baseline characteristics and duration of symptoms before enrollment","5372":"Inflammatory indices","5373":"Changes in gingival index, alteration in plaque index, bleeding index, and probing pocket depth.","5374":"Adverse events","5375":"Baseline headache characteristics","5376":"Improvement in PaO2 levels ","5377":"Improvement in PaO2 levels ","5378":"Severity category shift from \u2265 2 to < 2 on the reduced appetite MADRS item","5379":"Overall severity category shift from \u2265 4 to \u2264 2 ","5380":"Acute kidney injury","5381":"Recurrence rates","5382":"Rate of minor complications","5383":"Improvement in Vaginal Maturation Index","5384":"Patient-Specific Functional Scale score 24 hours after injection","5385":"Rates of good postoperative sleep quality","5386":"Lenght of hospital stay after surgery","5387":"Microleakage after three months","5388":"Microleakage after one week","5389":"Nonverbal behaviors","5390":"Baseline characteristics","5391":"Baseline demographic characteristics","5392":"Mean prednisone requirement (except for months 10 and 12)","5393":"Myasthenia gravis relapses","5394":"Clinical scores at week 12","5395":"Changes in serum biochemistry values","5396":"ABILHAND-Kids logit units' score at 12 and 18 weeks","5397":"ABILHAND-Kids logit units' score at 24 weeks","5398":"Grasp finger score","5399":"C-index in the NSCLC group","5400":"Body weight","5401":"Baseline characteristics, except age","5402":"Baseline eating behavior ","5403":"Cervicovaginal lavages levels of IL-8, IL-1\u03b2 and IL-6","5404":"Baseline characteristics","5405":"Mild to borderline airway responsiveness","5406":"Peak expiratory flow rate","5407":"Plantar fascia thickness","5408":"Pain ","5409":"Ruminal pH","5410":"Total viable rumen bacteria","5411":"Cellulolytic bacteria","5412":"Fracture resistance","5413":"Respiratory exchange ratio ","5414":"Muscle glycogen","5415":"Multiple-choice questionnaire right after procedure","5416":"OSCE total score 1 month after procedure","5417":"OSCE theoretical part score ","5418":"Student satisfaction ","5419":"Religious dimension improvement right after test ","5420":"Religious dimension improvement 1 month after test ","5421":"Spiritual existential aspect 1 month after test ","5422":"Osteocalcin","5423":"Alkaline phosphatase","5424":"Blood loss","5425":"Surgery time ","5426":"Spontaneous breath time ","5427":"Eye opening time ","5428":"Extubation time ","5429":"Depth of sealer penetration at coronal third","5430":"Depth of sealer penetration at middle third","5431":"Amount of correct answers ","5432":"Patient awareness ","5433":"Sample rejection rate ","5434":"Request-form errors","5435":"Preanalytical errors","5436":"Total cholesterol","5437":"Low density lipoprotein ","5438":"High density lipoprotein ","5439":"Nausea","5440":"Pain","5441":"Nausea","5442":"Ketorolac consumption","5443":"Adverse effects","5444":"Plasma renin activity","5445":"Angiotensin I","5446":"Brain natriuretic peptide","5447":"Infarct size","5448":"Left ventricular total area ","5449":"Pain","5450":"Pressure pain thresholds improvement","5451":"Conditioned pain modulation","5452":"Stress ","5453":"Atlantooccipital distance","5454":"Appropriate laryngoscopic view","5455":"Laryngoscopy time","5456":"BMI standard deviation score","5457":"Physical fitness","5458":"Insulin resistance","5459":"Lipid profile","5460":"High-sensitive C-reactive protein","5461":"Quality-adjusted life-years ","5462":"Drug-related rehospitalisation","5463":"Lost productivity costs","5464":"Fat oxidation rate ","5465":"Free fatty acid","5466":"Readiness for managing maternal sepsis","5467":"Readiness for managing obstructed labour ","5468":"Overall seizure median percent improvement ","5469":"Adverse effects ","5470":"Clinical complications ","5471":"Subjective dyspnoea","5472":"DAS28 improvement ","5473":"Achieving normal functional status ","5474":"Weekly physical activity","5475":"SF-36 mental health improvement ","5476":"Lipids levels ","5477":"Falls","5478":"Protein expression","5479":"Time to progression","5480":"Time-to-locally-non-treatable-progression","5481":"Overall survival","5482":"Serum iPTH \u226530% reduction ","5483":"Hypercalcemia ","5484":"Intraocular pressure after 1 hour","5485":"Uncorrected visual acuity after 15 days","5486":"Satisfying sexual events\/month","5487":"Sexual function index total score","5488":"Sexual distress improvement ","5489":"TH-like immunoreactive cells","5490":"TH-like immunoreactive cells","5491":"TH-like immunoreactive cells","5492":"Cure rate","5493":"Peer support","5494":"Well-being","5495":"Sociability","5496":"Medication persistence","5497":"Intermediate outcomes of care","5498":"Medication possession ratio","5499":"Systolic blood pressure improvement","5500":"LDL cholesterol improvement","5501":"Clinical improvement","5502":">5% weight loss","5503":"Weight loss at 12 weeks","5504":"Impact of Weight on Quality of Life","5505":"Health state (EQ-5D) ","5506":"HAD maximal activity","5507":"GLUT-4 expression","5508":"Na+\u2013K+ ATPase expresion","5509":"Time at target range","5510":"Mean overnight sensor glucose","5511":"Sensor hypoglycaemia ","5512":"Overnight insulin delivered ","5513":"Fugl-Meyer motor assessment scores","5514":"Fugl-Meyer motor assessment scores","5515":"Serious adverse events","5516":"Mortality","5517":"Creatinine ","5518":"Cessation of injected drugs","5519":"Cessation of injected drugs","5520":"Cessation of injected drugs","5521":"Onset of action speed","5522":"AUC 0\u2013\u221e ","5523":"t max","5524":"C Max","5525":"Asian-stereotypical words response speed","5526":"Knowledge score provided ","5527":"Communication score provided ","5528":"Overall score provided ","5529":"Feedback provided ","5530":"Resistance through the 22G cannula ","5531":"Static resistance for 18G cannula ","5532":"Fruit and vegetables intake","5533":"Glycogen synthase kinase 3 phosphorylation ","5534":"eIF2B\u03b5 phosphorylation ","5535":"Insulin level immediately after exercise ","5536":"Glycated hemoglobin","5537":"Fasting plasma glucose ","5538":"Adverse events","5539":"Schirmer test values in women","5540":"Chronic fatigue syndrome values","5541":"24 h drainage volume","5542":"Second 24 h drainage volume","5543":"Second 24 h drainage volume","5544":"Pain at movement","5545":"Pain at rest","5546":"Pain at rest","5547":"Compliance ","5548":"Glycated hemoglobin","5549":"Glycated hemoglobin","5550":"Glycated hemoglobin","5551":"Glycated hemoglobin","5552":"Glycated hemoglobin","5553":"Total adherence","5554":"Doses alteration ","5555":"Perceived stress ","5556":"Root mean square of the successive differences","5557":"Frequency of nausea","5558":"Mepridine consumption","5559":"Mepridine consumption","5560":"Hemodynamic parameters","5561":"Hydration ","5562":"Elasticity ","5563":"Retrieved oocytes","5564":"Implantation rate","5565":"Total number of embryos","5566":"First 2 tests results","5567":"Preference for less running out of the nose","5568":"VRS 1-hour post-operative scores","5569":"VRS 3-hours post-operative scores","5570":"VRS 12-hours post-operative scores","5571":"VRS 24-hours post-operative scores","5572":"Plasmodial reverse transcription PCR","5573":"Serum ferritin ","5574":"Hemoglobin ","5575":"Incidence of new infections","5576":"Fever prevalence at day 1","5577":"Overall fever prevalence ","5578":"Asthenia","5579":"Insulin concentration ","5580":"Serum progesterone","5581":"Diastolic blood pressure","5582":"Mean blood pressure","5583":"Kidney Injury Molecule-1","5584":"Aldosterone","5585":"Severity of illness","5586":"Probability of staying Reverse-trasncriptase-PCR positive","5587":"Degree of nausea ","5588":"Complete control","5589":"Pain","5590":"Nasal decongestion","5591":"Pain","5592":"Preservation of horizontal width","5593":"Mucogingival junction pushing to buccal side","5594":"Vertical reduction","5595":"Keratinized tissue width reduction","5596":"Change in ridge height at the buccal crest","5597":"Tube misplacement by physicians ","5598":"Mucosal damage by physicians ","5599":"Insertion time by students ","5600":"Exercise performance ","5601":"Cycle sprint total work","5602":"Monocyte chemoattractant protein-1","5603":"Blood glucose ","5604":"Urinary 1-Hydroxypyrene","5605":"Urinary 2-Hydroxyfluorene","5606":"Systolic blood pressure","5607":"C-Reactive Protein","5608":"ICU length of stay","5609":"Hannover Functional Ability Questionnaire score","5610":"Quality of life","5611":"Lethargic condition","5612":"Jittery condition","5613":"Depressed condition","5614":"Attentive condition","5615":"Focused condition","5616":"Montgomery\u2013Asberg Depression Rating Scale","5617":"Beck depression inventory-II","5618":"Preference","5619":"Compliance","5620":"Serious adverse events","5621":"Infectious emergent adverse effects in Japanese patients ","5622":"Appel ALS rating scale slope speed","5623":"Forced vital capacity","5624":"Time for reaching pH predetermined value ","5625":"Complications ","5626":"sustained improvement in quality of life","5627":"mean serum albumin","5628":"sustained improvement in liver functions","5629":"mean oxygen saturation","5630":"attenuation of hemodynamic responses","5631":"success rate of intubation","5632":"upper airway morbidity","5633":"retesting was recommended after chlamydia treatment","5634":"Aboriginal or Torres Strait Islander male with a sore throat - testing opportunities to asymptomatic patients aged \u226425 years","5635":"antenatal checkup - testing opportunities to asymptomatic patients aged \u226425 years","5636":"women having a pap smear - testing opportunities to asymptomatic patients aged \u226425 years","5637":"testosterone concentration","5638":"Sperm mobility status","5639":"Average sperm count","5640":"Sperm nucleus immaturity","5641":"Systolic Blood Pressure (SBP)","5642":"Diastolic Blood Pressure (DBP)","5643":"tympanic temperature from Pre to P20 (-0.28 \u00b10.11\u00b0C)","5644":"systolic BP","5645":"diastolic BP","5646":"Post hoc analysis of psychometric effects according to entry PSE","5647":"patients with an abnormal CRT index","5648":"mean portosystemic hepatic encephalopathy score (PHES)","5649":"mean CRT index change","5650":"decrease in infection - effect of multimodality chest physiotherapy in ICUs for prevention of VAP (ventilator-associated pneumonia) in intubated and mechanically ventilated patients","5651":"number of days' stay in the ICU - effect of multimodality chest physiotherapy in ICUs for prevention of VAP (ventilator-associated pneumonia) in intubated and mechanically ventilated patients","5652":"interferences at the retention time","5653":"testosterone levels","5654":"living conditions in perimenopausal women","5655":"emotional status in premenopausal women","5656":"25(OH) vitamin D concentration","5657":"25(OH) vitamin D concentration","5658":"nausea","5659":"eradication rates by intention-to-treat (ITT)","5660":"eradication rates by per-protocol (PP)","5661":"compliance to treatment","5662":"complain of mild pain","5663":"FOXOs expression in the injured carotid arteries of rats","5664":"effect of endurance exercise on neointimal formation in balloon-injured rat","5665":"no-drain group fluid accumulation","5666":"mean fluid accumulation on day 2","5667":"infections","5668":"no-drain group fluid accumulation","5669":"mean RF measured immediately after surgery","5670":"FD mesial values after six months of follow-up ","5671":"effect size after six months compared to immediate postoperative measurements","5672":"failure managed by optical internal urethrotomy (OIU)","5673":"operative time","5674":"suitability in cases where anterior urethra was found to be densely adhered to corpus cavernosum due to extensive spongiofibrosis","5675":"complication rate","5676":"Ruminococcus","5677":"PCoA of the weighted UniFrac distances","5678":"Lactobacillus","5679":"more effective for treating seasonal allergic conjunctivitis (SAC) on day 15","5680":"more effective for treating seasonal allergic conjunctivitis (SAC) on day 15","5681":"adverse event profile","5682":"flexion at 3 months - conventional total knee arthroplasty (TKA)","5683":"depression in MI (Myocardial Infarction) patients - at discharge","5684":"staphylococcal UTI","5685":"frequency of entrococcal infection","5686":"knowing whether the trial yielded useful results - Breast cancer patients participating in a trial on the efficacy of Trastuzumab","5687":"Lp\u2010PLA2","5688":"low\u2010density lipoprotein\u2010particle number","5689":"Net changes","5690":"PLAC","5691":"detectable levels of C-peptide - new-onset type 1 diabetes (T1D) - month 24 visit","5692":"use of exogenous insulin - new-onset type 1 diabetes (T1D)","5693":"decline in C-peptide at 2 years - new-onset type 1 diabetes (T1D)","5694":"intestinal villous height of fetus","5695":"median nausea ratings at rest","5696":"nausea ratings at movement at T30","5697":"pain reduction up to 3 weeks in patients with knee osteoarthritis - anteromedial subgroup","5698":"pain reduction up to 3 weeks in patients with knee osteoarthritis - anteromedial subgroup","5699":"efficacy in the reduction of dental biofilm after first use (t=1)","5700":"Antenatal corticosteroids (ACS)","5701":"Hypertensive disorders","5702":"improvements in swallowing","5703":"AUC results in severity of throat soreness","5704":"AUC results in severity of throat soreness","5705":"Pittsburgh sleep quality index at the 6-month follow-up","5706":"trait anxiety at 35 weeks","5707":"overall incidence of AEs","5708":"Mild AEs","5709":"Patients without Modic changes Type 1 - better","5710":"Patients with large Modic changes - worse","5711":"Patients without large Modic changes - better","5712":"change in bowel frequency in patients with respiratory tract infection receiving antibiotics","5713":"antibiotic use in patients with respiratory tract","5714":"normal bowel movement in patients with respiratory tract infection receiving antibiotics","5715":"change in bowel consistency in patients with respiratory tract infection receiving antibiotics","5716":"From baseline to week 12 (primary endpoint), mean (SD) NRS (numerical rating scale) pain scores","5717":"Patient-reported impression of treatment benefit","5718":"mean pain score","5719":"systolic blood pressures before the procedures","5720":"diastolic blood pressures before the procedures","5721":"weight loss of overweight persons","5722":"Pain relief at 24h - menstrually related migraine","5723":"cumulative hazard of recurrence during the follow-up - menstrually related migraine","5724":"Recurrence at 24h - menstrually related migraine","5725":"mitochondrial membrane potentials","5726":"decrease in activities of mitochondrial respiratory chain complex I\u2013IV","5727":"risk of converting from pre-diabetes to diabetes","5728":"mean age","5729":"increase in the proportion of patients developing diabetes","5730":"pre-test scores","5731":"time spent on the tutorials","5732":"Anxiety","5733":"Non-catheter-induced spasms","5734":"Glycated hemoglobin reduction ","5735":"Body weight changes ","5736":"Shear bond strength","5737":"Shear bond strength","5738":"Ability to communicate about sex ","5739":"Openness in communication about sex","5740":"Diametral tensile strength after 5 minutes","5741":"Opioid requirement","5742":"Rescue analgesics frequency ","5743":"Mean NRS value","5744":"Axilary numeric rating scale","5745":"Complications","5746":"Gastric reflux","5747":"Side effects","5748":"Cortisol levels ","5749":"Complete response ","5750":"Progression\u2010free interval","5751":"Secondary brain insults","5752":"TNF-\u03b1 levels","5753":"Hematoma volume","5754":"Mean tissue PGE2","5755":"Systolic blood pressure ","5756":"Body fat percentage","5757":"20 m sprint time","5758":"EQ-5D Self-Care improvement ","5759":"Diastolic blood pressure ","5760":"End-extinction gaze velocity","5761":"Whole\u2010mouth mean Modified Gingival Index score","5762":"Whole\u2010mouth mean Bleeding Index score","5763":"Adverse events related to oral soft tissue","5764":"Successful enteral feeding ","5765":"Gastric discharge volume ","5766":"Active ghrelin levels ","5767":"Gastrointestinal symptom","5768":"Overall adverse events ","5769":"Antenatal care visits timing ","5770":"Tetanus vaccination","5771":"Skin-to-Skin Contact % points ","5772":"Inflammatory Bowel Disease Questionnaire improvement (Induction 1)","5773":"Lipid hydroperoxide levels","5774":"Use of corporal punishment","5775":"Achieving the predefined target","5776":"Meteorism in IBS-Diarrhea ","5777":"Pain duration on IBS-Undifferentiated ","5778":"Pain duration on IBS-Diarrhea ","5779":"Countermovement power","5780":"Peak to peak power ","5781":"Take-off velocity","5782":"Low-density lipoprotein","5783":"Weight gain in not underweight children ","5784":"Weight gain in non-wasted children ","5785":"Average vegetable intake\/day","5786":"Fruit intake\/day","5787":"Weight ","5788":"Experience of childbirth","5789":"Elective Caesarean","5790":"Spontaneous vaginal delivery","5791":"Quality of life","5792":"P300 amplitude","5793":"Accuracy of choice reaction time ","5794":"Systolic blood pressure 7 min after intubation ","5795":"VAS pain score after therapy ","5796":"VAS pain score after 6 months","5797":"Thermal injuries ","5798":"Sattva improvement ","5799":"Mood","5800":"Visual attention test","5801":"Groton Maze Learning Test ilegal errors","5802":"Interleukin-10","5803":"Skin firmness and elasticity","5804":"Somatic anxiety","5805":"Skin conductance","5806":"number of clinic visits for cryotherapy","5807":"State\u2013Trait Anxiety Inventory Y1 (STAI Y1) scores at T2","5808":"State\u2013Trait Anxiety Inventory Y1 (STAI Y1) scores at T2","5809":"responder rate","5810":"responder rate in the subgroup of patients with gastroenteritis or antibiotics prior to irritable bowel syndrome onset","5811":"fasting insulin and homeostasis model assessment estimate of insulin resistance (Homa-IR)","5812":"insulin sensitivity index (ISI) and oral disposition index (DIo)","5813":"Perceived Usefulness and Perceived Satisfaction of System","5814":"Expanded Disability Status Scale (EDSS) score","5815":"forced inspiratory vital capacity (FIVC)","5816":"injury severity score, revised trauma score, and trauma injury severity score","5817":"preference rates","5818":"weight","5819":"cumulative incidence of type 2 diabetes mellitus (T2DM) among participants with baseline HbA1c levels \u22655.7%","5820":"mental component score of the Short Form 36 (SF-36) questionnaire","5821":"Caregiving status","5822":"peak oxygen consumption and workload at VT-1","5823":"the subjects who were married","5824":"The median primary patency period","5825":"The median primary patency durations of the right and left central veins","5826":"10-meter Walking Test (10mWT)","5827":"sensory blockade","5828":"Fasting plasma glucose","5829":"nausea and vomiting","5830":"fasting blood glucose (FBG) levels","5831":"area under blood glucose curve (AUCglu)","5832":"level of T3","5833":"uncorrected visual acuity (UCVA) and best-corrected visual acuity (BCVA)","5834":"the preoperative corneal neovascularization (NV) area","5835":"abduction","5836":"megalin mRNA in adults","5837":"serum alarmin levels","5838":"overactive bladder (OAB) symptom scores (OABSS)","5839":"The z-scores for endothelial dysfunction and low-grade inflammation","5840":"total symptom score, total number of symptoms reported , symptom severity and number of symptoms","5841":"90 min after the meal (PP), plasma insulin","5842":"U46619-induced fibrinogen binding","5843":"PAS-induced LTP","5844":"PAS-induced LTP","5845":"PAS-induced LTP","5846":"weekly volumes of physical activity","5847":"The number of audio-plays","5848":"BMI, waist circumference and percent body fat,","5849":"The duration of analgesic requirement","5850":"\"very easy\" or \"easy\" to ingest than patients","5851":"\"vomiting,\" \"abdominal pain,\" and \"abdominal distension\"","5852":"fever-alleviation time","5853":"differences in treatment choices","5854":"adherent patient who had recently been experiencing paranoid delusions","5855":"glucose uptake across the forearm muscle","5856":"fasting plasma triglyceride (TG) concentrations","5857":"fasting TNF\u03b1 concentrations","5858":"plasma acetate concentrations ","5859":"symptom scores","5860":"I-PSS scores","5861":"erectile function","5862":"incidence of sore throat - awake nasal intubation of oropharyngeal cancer patients with anticipated difficult intubation","5863":"mental outcomes -training effects on physical and psychological outcomes awareness of smoking in teenagers","5864":"training effects on physical and psychological outcomes awareness of smoking in teenagers","5865":"baseline fasting glucose in Metabolic Syndrome","5866":"changes in the attitude of Primary Health Care (PHC) physicians towards mental illnesses after a short-term training course","5867":"Heart Rate in Metabolic Syndrome","5868":"insulin sensitivity in Metabolic Syndrome","5869":"scores of positive attitudes towards mental health issues","5870":"Propofol consumption - ICU patients with various degrees of renal impairment","5871":"Duration of analgesia","5872":"PFS and TFS by IGHV mutational status","5873":"complete remission (CR) rate","5874":"progression-free survival (PFS)","5875":"Therapeutic gains over time","5876":"job performance","5877":"measure of pulmonary function","5878":"headache intensity","5879":"medication","5880":"Edinburgh Postnatal Depression Scale score","5881":"Depression subscale during second trimester","5882":"Anxiety subscale during second trimester","5883":"Abdominal circumference","5884":"improvement in HADS score","5885":"performance of path-finding files","5886":"ProTaper Next system safety","5887":"performance of path-finding files","5888":"systolic blood pressure (SBP)","5889":"mean arterial pressure (MAP)","5890":"blood glucose levels 2 h after dinner at the end of the 6-month study","5891":"HbA1c","5892":"average tip-apex distance","5893":"intraoperative femoral shaft fractures","5894":"intra-operative fluoroscopy time","5895":"effect on protein kinetics","5896":"Median duration of neoadjuvant treatment in metastatic colorectal cancer (MCRC)","5897":"IL-8 assessed 1\u20133 h after cold challenge ","5898":"critical temperature thresholds (CTT) value","5899":"Infarct area to area at risk ratio","5900":"Left-ventricular wall thickness","5901":"Septal wall thickness","5902":"Function ","5903":"Nociceptive flexor withdrawal reflex","5904":"Anxiety","5905":"Depression","5906":"Cervical spine movement at C0-C1","5907":"Cervical spine movement at C1-C2","5908":"Waist circumference","5909":"Unplanned rehospitalisations","5910":"Total costs","5911":"Human growth hormone ","5912":"Plasma glucose","5913":"Readiness for managing gestational hypertension ","5914":"Readiness for managing postpartum hemorrhage","5915":"Readiness for managing neonatal complications","5916":"Knowledge on active management of third stage of labor","5917":"Overall seizure median percent reduction","5918":"Seizure median percent improvement in North America","5919":"Seizure median percent improvement in North America","5920":"Adverse effects ","5921":"Blood gas analysis","5922":"Atelectasis ","5923":"ICU length of stay","5924":"Hospital length of stay","5925":"Stable low disease activity","5926":"ACR20 improvements ","5927":"Clinical remissions","5928":"Stop of radiographic progression","5929":"SF-36 physical functioning improvement ","5930":"Injuries ","5931":"Protein levels","5932":"Risk of symptomatic hypoglycaemia","5933":"Risk of asymptomatic hypoglycaemia","5934":"Progression-free survival","5935":"Serum glutamate levels","5936":"Achieving serum iPTH >110 pg\/ml ","5937":"Serum iPTH levels ","5938":"Osteocalcin","5939":"Bone alkaline phosphatase","5940":"Acute rejection","5941":"Ocular viscosurgical devices removal time","5942":"Total surgical time","5943":"Intraocular pressure after 48 hours","5944":"Endothelial cell density after 15 days","5945":"Satisfying sexual events\/month","5946":"Sexual function index total score","5947":"Sexual distress improvement ","5948":"TH-like immunoreactive cells","5949":"TH-like immunoreactive cells","5950":"Fos-like immunoreactive cells ","5951":"Cure rate","5952":"Cure rate","5953":"Cure rate","5954":"Shyness","5955":"Friendships","5956":"Barriers to physical activity ","5957":"Primary adherence","5958":"Attrition ","5959":"Weight loss at 4 weeks","5960":"Citrate synthase maximal activity","5961":"Phosphofructokinase activity","5962":"Resting muscle glycogen","5963":"Sensor hyperglycaemia ","5964":"24 hours insulin delivered ","5965":"Fugl-Meyer motor assessment scores","5966":"Blood pressure","5967":"Alkaline phosphatase","5968":"Cessation of injected drugs","5969":"Cessation of injected drugs","5970":"Duration of action","5971":"AUC 0\u2013t","5972":"Recalling the student","5973":"Resistance through the 20G cannula ","5974":"Resistance through the 18G cannula ","5975":"Static resistance for 22G cannula ","5976":"Processed food intake ","5977":"Snacks intake","5978":"African\/Caribbean food intake","5979":"Muscle protein synthesis after exercise ","5980":"Muscle protein synthesis after exercise ","5981":"Protein kinase B phosphorylation ","5982":"Urinary albumin-to-creatinine ratio at 24 weeks","5983":"Urinary albumin-to-creatinine ratio at 12 weeks","5984":"Schirmer test values in men","5985":"24 h drainage volume","5986":"Total drainage volume","5987":"Total drainage volume","5988":"Pain at movement","5989":"Mayor adverse effects","5990":"Glycated hemoglobin","5991":"SIMS score","5992":"MISS-21","5993":"Involvement in treatment discussion ","5994":"Difficulties with medication usage","5995":"Average R-R intervals SD","5996":"Frequency of nausea","5997":"Frequency of vomiting","5998":"Frequency of vomiting","5999":"Hydration ","6000":"Hydration ","6001":"Elasticity ","6002":"Skin texture improvement","6003":"Fertilization rate","6004":"Pregnancy rate","6005":"Number of transferred embryos","6006":"Final test results","6007":"Overall preference ","6008":"Preference for less dripping","6009":"Preference for more soothing ","6010":"Preference for less irritating","6011":"VRS 6-hours post-operative scores","6012":"VRS right-after-surgery scores","6013":"Microscopically detectable parasitaemia","6014":"Mean cell volume ","6015":"Children remaining iron deficient ","6016":"Fever prevalence at day 7","6017":"Red blood cell count decrease","6018":"Serum progesterone","6019":"Follicle-stimulating hormone at puberty","6020":"Luteinizing hormone at puberty","6021":"Estradiol at puberty","6022":"Potassium excretion","6023":"Aldosterone","6024":"Symptom resolution","6025":"Duration of virus detection","6026":"Probability of resolution","6027":"Maximum severity score","6028":"Complete response","6029":"Total adverse events","6030":"Serious adverse events","6031":"Discomfort","6032":"Discomfort","6033":"Blood pressure ","6034":"Heart rate","6035":"Endoscopy duration ","6036":"Keratinized tissue amount","6037":"Insertion time by physicians ","6038":"Tube misplacement by students ","6039":"Mucosal damage by students","6040":"Total blood CoQ10","6041":"Reduced blood CoQ10 (ubiquinol)","6042":"Oxidative stress","6043":"Maximal graded exercise test improvement","6044":"IL-10","6045":"Urinary 2-Hydroxynaphthalene","6046":"Urinary 3-Hydroxyfluorene","6047":"CO average exposure ","6048":"CO passive exposure ","6049":"Adverse effects ","6050":"Low density lipoprotein","6051":"High density lipoprotein","6052":"Triglycerides","6053":"ICU length of stay","6054":"ICU length of stay","6055":"Duration of mechanical ventilation","6056":"Readmission rate","6057":"90-day mortality","6058":"Area under the curve for the pain severity","6059":"Average pain severity","6060":"Accompanying therapies","6061":"Sick leave days","6062":"Groggy feeling","6063":"Hamilton Rating Scale for Depression","6064":"Serious adverse events","6065":"Efficacy","6066":"Patients with at least one adverse effect","6067":"Fecal calprotectin reduction","6068":"Fecal calprotectin reduction","6069":"Corticosteroid-free remission","6070":"Corticosteroid-free remission","6071":"Infectious emergent adverse effects in Japanese patients ","6072":"Gastrointestinal adverse events","6073":"ALS functional rating scale","6074":"Time to a 20-points progression in the AALSRS","6075":"Time for reaching glucose predetermined values ","6076":"Time for reaching glucose predetermined values ","6077":"Time for reaching bicarbonate predetermined values ","6078":"Hospitalization time","6079":"Symptom severity improvement","6080":"Insight into illness\/treatment","6081":"Functioning improvement ","6082":"Duration of re-hospitalisations","6083":"Medication adherence","6084":"Number of re-hospitalisations","6085":"age group of the patients","6086":"testing opportunities to asymptomatic patients aged \u226425 years","6087":"Viability power of sperm","6088":"Body mass","6089":"resting heart rate (RHR)","6090":"Yo-Yo Intermittent Endurance test level 1 (Yo-Yo IE1) performance","6091":"effects of cryostimulation on the ANS","6092":"Tskin of the head","6093":"portosystemic encephalopathy (PSE) test","6094":"Weaning of ventilation - effect of multimodality chest physiotherapy in ICUs for prevention of VAP (ventilator-associated pneumonia) in intubated and mechanically ventilated patients","6095":"mortality rates - effect of multimodality chest physiotherapy in ICUs for prevention of VAP (ventilator-associated pneumonia) in intubated and mechanically ventilated patients","6096":"number of days of ventilation - effect of multimodality chest physiotherapy in ICUs for prevention of VAP (ventilator-associated pneumonia) in intubated and mechanically ventilated patients","6097":"recoveries of MDL and IS","6098":"E2 (estradiol) levels","6099":"25(OH) vitamin D concentration","6100":"IL-17 levels","6101":"IL-13 levels","6102":"frequencies of adverse effects except nausea","6103":"complain of mild pain","6104":"consumption of propofol","6105":"consumption of propofol","6106":"consumption of propofol","6107":"Body weight of rats","6108":"effect of endurance exercise on endothelial dependent relaxation in balloon-injured rat","6109":"effect of endurance exercise on neointimal formation in balloon-injured rat","6110":"mean fluid accumulation on day 1","6111":"nursing satisfaction scores","6112":"total effective rate","6113":"mortality","6114":"28 d neonatal behavioral neurological assessment (NBNA)","6115":"FD analysis","6116":"GM Shannon diversity index","6117":"load of several potentially pro-inflammatory GM components","6118":"more effective for treating seasonal allergic conjunctivitis (SAC) on day 15","6119":"more effective for treating seasonal allergic conjunctivitis (SAC) on day 8","6120":"more effective for treating seasonal allergic conjunctivitis (SAC) on day 15","6121":"unexpected adverse events","6122":"Plasma endothelin-1 concentrations","6123":"adverse event profile","6124":"Function Score - conventional total knee arthroplasty (TKA)","6125":"risk of malalignment - conventional total knee arthroplasty (TKA)","6126":"operative time - conventional total knee arthroplasty (TKA)","6127":"flexion at 1 year - conventional total knee arthroplasty (TKA)","6128":"Knee Score - conventional total knee arthroplasty (TKA)","6129":"before intervention in MI (Myocardial Infarction) patients","6130":"anxiety in MI (Myocardial Infarction) patients - 3 months after discharge","6131":"depression in MI (Myocardial Infarction) patients - 3 months after discharge","6132":"anxiety in MI (Myocardial Infarction) patients - at discharge","6133":"rates of urinary tract infection (UTI) in rabbits","6134":"understanding clinical trials - Breast cancer patients participating in a trial on the efficacy of Trastuzumab","6135":"declared uptake of the trial results - Breast cancer patients participating in a trial on the efficacy of Trastuzumab","6136":"accurately understanding the results - Breast cancer patients participating in a trial on the efficacy of Trastuzumab","6137":"understanding the treatment received - Breast cancer patients participating in a trial on the efficacy of Trastuzumab","6138":"low\u2010density lipoprotein\u2010particle number","6139":"apoA\u2010I levels","6140":"apoA\u2010I levels","6141":"insulin production - new-onset type 1 diabetes (T1D)","6142":"drop in C-peptide AUC - new-onset type 1 diabetes (T1D)","6143":"maltase activity of fetus","6144":"fetal weight at d 90 of gestation","6145":"lactase activity of fetus","6146":"nausea ratings at movement at T60","6147":"nausea ratings at movement at T0","6148":"pain reduction up to 3 weeks in patients with knee osteoarthritis - anteromedial subgroup","6149":"improvement in function at 1 week in patients with knee osteoarthritis - anteromedial subgroup","6150":"similar reduction in plaque","6151":"efficacy in the reduction of dental biofilm after one week","6152":"preliminary time plaque index (PI)","6153":"fever","6154":"chorioamnionitis","6155":"improvements in swallowing","6156":"changes from baseline in throat soreness between 1 and 20 minutes","6157":"Depression scores","6158":"Moderate AEs","6159":"distributions of the MRI variables of interest","6160":"Mild abdominal discomfort in patients with respiratory tract infection receiving antibiotics","6161":"Antibiotic-associated diarrhea (AAD) in patients with respiratory tract infection","6162":"responders achieving \u226550% pain reduction","6163":"responders achieving \u226530% pain reduction","6164":"Pain control sensitivity analyses","6165":"severe and moderate pain","6166":"pulse rate before the procedures","6167":"expression of genes involved in wound healing and inflammation","6168":"Baseline levels of toenail selenium ","6169":"serum selenium levels after intervention","6170":"Baseline levels of serum selenium ","6171":"effect of selenium on the epithelial-to-mesenchymal transition (EMT)","6172":"JDA membership associatIon with changes in participants' body weight","6173":"Changes in body weight","6174":"relationship between RD expertise indicators and the magnitude of weight loss of the study participants","6175":"Pain relief at 2h - menstrually related migraine","6176":"NIHSS and AVLT scores recovery","6177":"incidence of adverse events","6178":"probability of achieving normalized blood glucose","6179":"Fever Without Source (FWS) topic","6180":"post-test scores","6181":"Oral Rehydration Solutions (ORS) topic","6182":"AUC for predicting prostate cancer at biopsy","6183":"Periprocedural pain perception","6184":"Local pain","6185":"Catheter-induced spasms","6186":"Significant adverse reactions ","6187":"FEV1 60-min increase","6188":"FEV1 60-min increase","6189":"St George's Respiratory Questionnaire score improvement ","6190":"Use of salbutamol as reliever ","6191":"Adverse events ","6192":"Achieving target HbA1c","6193":"Fasting glucose","6194":"AUC 0\u2013180 min glucose","6195":"Shear bond strength","6196":"Shear bond strength","6197":"Mean number of new sexual topics discussed","6198":"Condom usage review ","6199":"Diametral tensile strength after 5 minutes","6200":"Diametral tensile strength after 5 minutes","6201":"Analgesics side effects","6202":"Frequency of attempts ","6203":"Displacement for adequate ventilation","6204":"Airway leak","6205":"IL-6 levels ","6206":"C-reactive protein ","6207":"Hospital stay","6208":"Hemoglobin after 12 months","6209":"Hemoglobin after 18 months","6210":"Hemoglobin after 18 months","6211":"Hemoglobin after 18 months","6212":"Change in signs","6213":"Median survival time ","6214":"Favorable prognosis","6215":"IL-6 levels","6216":"Cryer score","6217":"Body mass ","6218":"Body fat percentage","6219":"Fasting glucose","6220":"Insulin resistance","6221":"Body mass index ","6222":"Yo-Yo intermittent recovery level 1 results","6223":"EQ-5D mobility improvement ","6224":"EQ-5D Anxiety\/depression improvement ","6225":"End-extinction head velocity","6226":"50% of the target enteral nutrition speed","6227":"Portion of enteral nutrition","6228":"Desacyl ghrelin levels ","6229":"Test performance ","6230":"Daily stool frequency","6231":"Stool consistency","6232":"Serious adverse events ","6233":"Receiving \u2265 4 antenatal care visits","6234":"Preventive malaria treatment ","6235":"Episiotomy","6236":"Inflammatory Bowel Disease Questionnaire improvement (Induction 2)","6237":"IBDQ least squares mean changes from baseline ","6238":"IBDQ least squares mean changes from baseline ","6239":"Remission ","6240":"Response ","6241":"Performance","6242":"Parenting warmth improvement ","6243":"Parenting stress","6244":"Intensity of child behavior problems","6245":"Follow through on discipline ","6246":"Parenting self-efficacy ","6247":"Fatigue Severity Scores","6248":"Relapse rate","6249":"Inflammatory parameters","6250":"Hypotension","6251":"Symptomatic hypotension","6252":"Renal function","6253":"Captopril doses","6254":"Achieving optimal ACE inhibitors doses","6255":"Systolic blood","6256":"Diastolic blood","6257":"Meteorism in IBS-Mixed","6258":"Pain duration on IBS-Constipation ","6259":"Subjective feelings of sedation","6260":"Subjective feelings of intoxication ","6261":"Countermovement velocity","6262":"Total work","6263":"5-hydroxy-vitamin D levels","6264":"Total cholesterol ","6265":"High-density lipoprotein","6266":"Weight gain in underweight children ","6267":"Weight gain in stunted children ","6268":"Weight gain in non-stunted children ","6269":"Probability of identifying 3 out of 5 ECG diagnoses","6270":"Probability of self-studying 2 h\/week extra ","6271":"Systolic blood pressure ","6272":"Diastolic blood pressure ","6273":"Epidural analgesia","6274":"Overall survival","6275":"Grade 3\/4 adverse event ","6276":"P300 amplitude","6277":"P300 latency ","6278":"Blood loss after 2 days","6279":"Blood loss after 3 days","6280":"First postopertive PT time","6281":"Lowest hematocrit ","6282":"Time for removal of dressing","6283":"Time for application of fresh dressing","6284":"Heart rate during induction ","6285":"Heart rate at intubation ","6286":"Systolic blood pressure 10 min after intubation ","6287":"Diastolic blood pressure","6288":"Hip fracture frequency","6289":"Overall complications ","6290":"Decrease in Tamas","6291":"Set-Shifting cognitive flexibility task","6292":"Bradykinin","6293":"Tissue-type plasminogen activator","6294":"Need of plasma transfusion","6295":"Interleukin-6","6296":"Hamilton Rating Scales for Anxiety","6297":"Urinary isoflavone levels","6298":"Urinary isoflavone levels","6299":"Daidzein excretion","6300":"Genistein excretion","6301":"Self-confidence","6302":"Skin conductance","6303":"number of times salicylic acid was applied","6304":"vitality (VT), physical functioning (PF), role limitation due to physical problems (RP), role limitation due to emotional problems (RE), and mental health (MH) ","6305":"PF","6306":"pain levels","6307":"responder rate in the subgroup of patients with gastroenteritis or antibiotics prior to irritable bowel syndrome onset","6308":"mean fasting plasma glucose (FPG)","6309":"Self-measured plasma glucose levels","6310":"Agitation score","6311":"Agitation incidence","6312":"laryngospasm","6313":"improvement in height","6314":"effect on BBS score","6315":"effect on BBS score","6316":"mobility","6317":"System Environment Satisfaction and Perceived Satisfaction of System","6318":"weight","6319":"HDL-cholesterol","6320":"triglyceride levels","6321":"The mean waist circumference","6322":"treatment-emergent adverse events (TEAEs)","6323":"suturing time","6324":"number of relapses","6325":"Intubation difficulty scale (IDS) score","6326":"Cormack-Lehane glottic view","6327":"heart rate and mean arterial blood pressures","6328":"Maximal oxygen uptake (VO2max)","6329":"General Movement Optimality Score","6330":"Ventilator time and overall hospital stay","6331":"ICU stay","6332":"subscales on emotional and mental health and health change","6333":"systolic blood pressure","6334":"oral health related quality of life","6335":"taste","6336":"muscle thickness","6337":"Maximal voluntary isometric contraction (MVIC)","6338":"2 h plasma glucose and the glucose the area under the curve (AUC) - among participants with baseline HbA1c\u22655.7%","6339":"fasting plasma glucose (FPG) and HbA1c","6340":"mental component score of the Short Form 36 (SF-36) questionnaire","6341":"measures of breathing control, functional exercise capacity or daily physical activity","6342":"negative mood and anxiety","6343":"caregiving self\u2010efficacy","6344":"homocysteine (Hcy) levels","6345":"incidence of asthma","6346":"shortness of breath","6347":"higher levels of asthma","6348":"The mean heart rate","6349":"The geometric mean C-peptide AUC at 2 years","6350":"Pain","6351":"sedation score after 3hrs","6352":"sedation score after 3hrs","6353":"The total and LDL cholesterol","6354":"H. pylori-positive rate","6355":"The detection rates of H. pylori infection with each single biopsy taken from site 1, site 2 , and site 3","6356":"wound surface area (WSA)","6357":"pressure ulcer scale for healing (PUSH) tool","6358":"healing status of pressure ulcers","6359":"adverse effects","6360":"heart rate (HR) , Systolic BP (SBP), saturation of peripheral oxygen(SpO2) , end-tidal carbon dioxide (ETCO2) and Diastolic BP","6361":"Locoregional disease-free survival","6362":"height, weight and bone age","6363":"insulin-like growth factor-1 (IGF-1)","6364":"The corneal neovascularization (NV) area","6365":"telomere length","6366":"LDL cholesterol","6367":"Serum urea","6368":"High sensitivity C-reactive protein ","6369":"Healthcare costs","6370":"PeakVO2 ","6371":"Proportion of prevented signals on second series ","6372":"Weight and BMI reduction at 12 months","6373":"BMI z-score at 12months","6374":"Weight and BMI reduction at 24 months","6375":"Baseline characteristics, except for scaphoid bone","6376":"Pressure pain thresholds at the thumb CMC joint, scaphoid bone and hamate bone","6377":"Eye examination rates","6378":"Incidence of grade II-IV acute GVHD at 180 days","6379":"Incidence of relapse\/progression at four years","6380":"Reduction in radiation-induced diarrhea","6381":"10-year overall survival rate and 10-year disease free survival rate","6382":"Pain scores 48 hours after the surgery","6383":"Baseline characteristics","6384":"Changes in receptor activator of nuclear factor-kappaB ligand (RANKL) after 1 year","6385":"Rate of adverse events","6386":"Thickening of subfoveal choroid during the recovery period","6387":"Improvement in physical activity and energy expenditure","6388":"Improvement in waist circumference and hip circumference","6389":"Baseline characteristics","6390":"Deep vein thrombosis","6391":"Baseline characteristics","6392":"Vasopressor use during the surgery","6393":"Enrollment into the randomized controlled trial","6394":"Age of the participants","6395":"Weight until week 28 of pregnancy","6396":"BMI at week 28 of pregnancy","6397":"Newborns' height and Apgar score","6398":"Overall response rate","6399":"Disease control rate","6400":"Progression-free survival","6401":"Median survival","6402":"Pain relief","6403":"Baseline characteristics","6404":"Tryptophan levels","6405":"Percentage of patients achieving comprehensive disease control based on DAS28(CRP)\u22643.2, DAS28(CRP)<2.6 or SDAI\u22643.3 at week 52","6406":"patients with early RA (PREMIER), CDC based on DAS28(CRP)<2.6","6407":"Utilization of Physician time","6408":"exam room utilization time","6409":"exam room utilization time","6410":"time before rescue analgesic","6411":"Postoperative lower VAS scale","6412":"macrophage activation","6413":"concentration of sCD163","6414":"improvement of disorder","6415":"duration of sensory and motor block","6416":"duration of analgesia","6417":"onset of block","6418":"drop in heart rate","6419":"performance prediction","6420":"vision impairment","6421":"computerized quantification of wheezing and crackles in infants","6422":"respiratory rate and heart rate","6423":"lung function","6424":"paco2","6425":"glucose control","6426":"implantation rate, chemical pregnancy rate, clinical pregnancy rate, ongoing pregnancy rate, ectopic pregnancy rate, and miscarriage rate","6427":"The mean Paracetamol\u00ae dose\/patient","6428":"25(OH)D level","6429":"treatment condition","6430":"Montgomery-A\u030asberg Depression Rating Scale (MADRS; Montgomery and Asberg)","6431":"Patients preferense","6432":"Numerical Rating Scale (NRS) pain scores","6433":"nurse-administered morphine","6434":"HR, systolic blood pressure (SBP), and diastolic blood pressure (DBP)","6435":"oxygen uptake (VO2)","6436":"plasma creatine levels after 1h and 2h","6437":"HDL-C, LDL-C or triglyceride levels","6438":"The total effective rate","6439":"National Institutes of Health Stroke Scale (NIHSS) score, Fugl-Meyer Assessment Scale (FMA) score, and triple-stimulation technique (TST) ratio","6440":"Ongoing pregnancy (OP) rate","6441":"live birth (LB) rate","6442":"cleavage and blastocyst rates","6443":"the incidence of PONV or need for rescue antiemetics 0\u20132 h postoperatively","6444":"HbA1c and blood sugar","6445":"instructions for jogging","6446":"The frequency of defecation","6447":"The severity of pain during defecation and consistency of stool","6448":"fecal incontinence and retentive posturing","6449":"systolic blood pressure (SBP) and diastolic blood pressure (DBP)","6450":"evaluation of coronary flow","6451":"assessment of functional class - NYHA class","6452":"Similarly, lipid ratios, including total-cholesterol:HDL-cholesterol, LDL-cholesterol:HDL-cholesterol, TAG:HDL-cholesterol, non-HDL-cholesterol:HDL-cholesterol and apolipoprotein B:apolipoprotein AI","6453":"Hamilton Anxiety Rating Scale (HAM-A)","6454":"time sedation score curve (AUCsed)","6455":"viewing times","6456":"hSGLT3 transcript levels in skeletal muscle","6457":"whole-body muscle strength","6458":"body weight (BW), body fat (BF), fat mass (FM), lean mass (LM), and BMI","6459":"lean mass (LM)","6460":"BMI","6461":"Body mass index z-scores in obese kids ","6462":"change in BMI","6463":"Sickness absence","6464":"For duration of sick leave (days) and frequency of sickness absence (spells)","6465":"The SVR rates if the patients had IL-28B rs8099917 TT genotype, and GT\/GG genotype","6466":"pregnancy rates (PR), clinical pregnancy rates (cPR), miscarriage rates (MR), and live birth rates (LBR)","6467":"stress levels","6468":"Post-ingestion bicarbonate and base excess","6469":"blood lactate concentrations","6470":"Upset following behavior problems","6471":"HbA1c","6472":"HbA1c","6473":"cognitive function","6474":"body weight and BMI regain at follow-up","6475":"The relative risk of having had any fall at 24 months","6476":"time to first and second fall","6477":"Emergency Room Visits and health distress","6478":"Improvement in GSRS (Gastrointestinal Symptom Rating Scale) VAS-Gas score - in adults with post prandial intestinal gas-related symptoms and no GI diagnoses","6479":"Improvement in GSRS (Gastrointestinal Symptom Rating Scale) abdominal pain subscore - in adults with post prandial intestinal gas-related symptoms and no GI diagnoses","6480":"Sensory block levels","6481":"Improvement in GSRS (Gastrointestinal Symptom Rating Scale) total score - in adults with post prandial intestinal gas-related symptoms and no GI diagnoses","6482":"the mean blood pressure","6483":"Transport duration - effect on serum cortisol concentration","6484":"A1C","6485":"blood cholesterol - type 2 diabetes patients","6486":"duration of analgesia","6487":"The number of intramuscular diclofenac injections","6488":"LDL-C - type 2 diabetes patients","6489":"IL-6 - type 2 diabetes patients","6490":"mean values of Cmax","6491":"blood pressure","6492":"Cmax","6493":"average systolic BP level in patients who had stage I hypertension","6494":"after 10 days therapy - arterial BP level in patients who had stage I hypertension","6495":"high sensitivity C-reactive protein (hsCRP) and endothelial microparticle (EMPs) levels","6496":"HbA1c","6497":"HbA1c","6498":"treatment of RA (Rheumatoid arthritis) patients with a high disease activity at baseline","6499":"Juvenile Idiopathic Arthritis (JIA) - time to relapse","6500":"onset of a sufficient degree of sedation for safe handling","6501":"The positive rate of H. pylori infection with each single biopsy taken from site 2 , and site 3","6502":"respiratory rate","6503":"Recovery rate","6504":"HRV high frequency (HF) oscillations - Five minutes after nasotracheal suction","6505":"HRV low frequency (LF) oscillations - Five minutes after nasotracheal suction","6506":"BP-lowering effects at Week 8","6507":"BP-lowering effects at Week 4","6508":"BP-lowering effects at Week 8","6509":"median Emax scores","6510":"mean Emax scores","6511":"time to decresenig neutrophil fraction ","6512":"increase in plasma lithium","6513":"effect of homonymous hemianopia (HH) duration","6514":"pain ","6515":"Stra6 expression","6516":"Lrat expression","6517":"blind-side detection","6518":"Raldh-1 > Raldh-3 > Raldh-2. Raldh-1 expression","6519":"decreased blind-side detection with increasing age","6520":"relative horizontal attachment level (RHAL) gain","6521":"probing pocket depth (PPD) reduction","6522":"gender - patients undergoing CABG \/ CE","6523":"wall motion score - patients undergoing CABG \/ CE","6524":"IL-6 on day 2 and day 3","6525":"mean hospital stay - patients undergoing CABG \/ CE","6526":"Number of complications, in-hospital mortality, and 30-day mortality","6527":"improvements in quality of life (overall St. George's Hospital Respiratory Questionnaire and Clinical COPD Questionnaire)","6528":"first respiratory serious adverse event risk","6529":"discontinuation of drugs due to side effects","6530":"individual biomarkers of endothelial dysfunction and low-grade inflammation","6531":"decrease from baseline in mean fasting plasma glucose concentration","6532":"crude incidence of treatment-emergent nausea","6533":"irritable bowel syndrome with constipation (IBS-C) - incidence of treatment-emergent nausea, moderate","6534":"amnesia","6535":"sedation scores","6536":"acute medication intake","6537":"composite z-scores in autism spectrum disorder (ASD) ","6538":"overall working memory (WM) performance in autism spectrum disorder (ASD) ","6539":"six-minute walk test, Tinetti Gait Index, and TIS Total score","6540":"Percentage of treatment failure on day 10 - severe pneumonia in children","6541":"Tinetti Gait Index and the TIS Total Score","6542":"standard behavioral weight loss,","6543":"Mean total operative time with stent placement","6544":"walking distance improvement at week 12 - patients with Morquio A syndrome (mucopolysaccharidosis IVA)","6545":"alertness","6546":"easiness of bowel preparation experience","6547":"IL-6","6548":"Mean VO2max","6549":"The numbers of days required for the disappearance of influenza symptoms","6550":"cortisol levels - prior to exercise","6551":"reduction of HbA1c levels","6552":"In overweight group, fasting blood glucose (FBG)","6553":"pre-test probability of obstructive CAD","6554":"Goodness-of-fit","6555":"bradycardia","6556":"stable hemodynamic profile","6557":"Incidence of sore throat","6558":"decrease in systolic blood pressure","6559":"heart rate","6560":"Externalizing problems","6561":"Internalizing problems","6562":"likelihood a person voted","6563":"voter turnout","6564":"effective in spreading behavior to friends","6565":"\"multiplier\" effect","6566":"overall survival (OS) in metastatic colorectal cancer (CRC) - stage IIIb","6567":"relapse-free survival (RFS) in metastatic colorectal cancer (CRC)","6568":"Number of patients - stage IIIb in metastatic colorectal cancer (CRC)","6569":"elbow extension","6570":"gain in the range of motion","6571":"gain in the range of motion","6572":"gain in the range of motion","6573":"elbow extension","6574":"Energy intake","6575":"increased risk for PC in third round","6576":"proportion of false positive (FP) results","6577":"increased risk for PC in first round","6578":"Range of motion","6579":"Surgery time","6580":"including tidal volume (VT), ratio of time to peak [t-PTEF\/t-E (%)], ratio of momentary flow rate in case of exhalation of 75% of tidal volume to peak tidal expiratory flow [TEF75\/PTEF (%)] and ratio of medium term inspiration flow to medium term expiration flow (MTIF\/MTEF)","6581":"Blood loss ","6582":"Flexion\/extension of the femur","6583":"Pain during 30\u00b0 flexion ","6584":"Snapshot response","6585":"Pain at rest","6586":"Oxycodone consumption","6587":"Ability to mobilise","6588":"Length of stay","6589":"Yale Global Tics Severity Scale- total motor tic score ","6590":"Insulin incremental AUC","6591":"Systolic blood pressure ","6592":"Health Related Quality of Life - Physical Component","6593":"Heart rate","6594":"Perioperative fever","6595":"Heart rate","6596":"Sustained viral response 12 weeks","6597":"IgA levels","6598":"Discontinuation due to adverse events","6599":"Pleural opacity","6600":"IL-6 levels","6601":"Surgical referral at 3 months","6602":"Total cholesterol ","6603":"Hospital stay","6604":"LDL-C ","6605":"HIV-specific antibody response","6606":"Snacks intake","6607":"Pain at 1 min","6608":"Pain at 2 mins","6609":"Nutrition knowledge ","6610":"Pain at 4 mins","6611":"Months of sick leave ","6612":"Systolic blood pressure ","6613":"Mental health improvements","6614":"Systolic blood pressure","6615":"Purdue pegboard task score improvement (right hand)","6616":"Purdue pegboard task score improvement (right hand)","6617":"Cognition","6618":"Affect","6619":"Blood glucose ","6620":"IADL cognitive performance ","6621":"MMSE cognitive performance ","6622":"Pittsburgh Sleep Quality Index sleep efficiency","6623":"Neuropsychiatric Inventory score at week 24","6624":"Adverse events ","6625":"Hospital stay","6626":"Mean arterial pressure ","6627":"Blood pressure","6628":"Physical fitness","6629":"Peak workload","6630":"Health-related quality of life","6631":"Proportion of prevented signals on first series ","6632":"Tip and tripod pinch strength","6633":"Whole blood total antioxidant capacity ","6634":"Incidence of moderate\/severe chronic GVHD at 2 years","6635":"Incidence of nonrelapse mortality","6636":"4-year overall survival and progression-free survival","6637":"All-cause mortality rate","6638":"Digoxin dose","6639":"Dysphagia in patients suffering from head and neck tumors","6640":"Surgery duration","6641":"Erosive esophagitis recurrence rate after 24 weeks","6642":"Changes in vital signs, ECG, or laboratory test values","6643":"Serum osteoprotegrin after 1 year","6644":"Pain reduction","6645":"Yale Global Tics Severity Scale-TTS score","6646":"Yale Global Tics Severity Scale-TTS score","6647":"Transport-related PA at 18 months","6648":"Changes in 180\u00b0\/sec peak torque\/body weight (%) at the flexor of both knees","6649":"Improvement in body mass index","6650":"Quality of life","6651":"Health Related Quality of Life - Mental Component","6652":"Improvement in waist-hip ratio","6653":"Units of PRBC needed","6654":"In-hospital mortality","6655":"Mean volume of drainage fluid","6656":"IgG levels","6657":"Albuminuria ","6658":"eGFR decline","6659":"Attendance for eligibility screening","6660":"HDL-C","6661":"Baseline characteristics","6662":"Signal intensities against EnvA at week 56","6663":"Decrease in SpO2","6664":"Pain at 3 mins","6665":"BMI at delivery","6666":"Weight loss","6667":"LDL peak diameter and plasma levels of HDL-cholesterol","6668":"Levels of LDL-cholesterol, triglycerides, and all LDL subclasses except LDL-IIIb","6669":"Major adverse cardiac events rates","6670":"Tryptophan and other large neutral amino acids ratio (TRP:\u03a3LNAA) ","6671":"Mortality ","6672":"Urinary albumin to creatinine ratio","6673":"Urea nitrogen ","6674":"Response to treatment","6675":"Follow-up positive ETI scores","6676":"Follow-up negative ETI scores","6677":"Anxiety ","6678":"Baseline characteristics","6679":"Inotropic support requirements","6680":"Postoperative pain","6681":"Ventilation time","6682":"Pulmonarycomplications ","6683":"Mean arterial pressure ","6684":"Fasting plasma glucose","6685":"Insulin dose","6686":"Hypoglycemia","6687":"Atelectasis","6688":"Intravenous colloid usage","6689":"Dopexamine usage","6690":"Patients with complications ","6691":"Complications per patient ","6692":"60-day mortality ","6693":"Systolic blood pressure ","6694":"Pulse Rate","6695":"Overall survival ","6696":"Non-contact injuries","6697":"Vascular cell adhesion protein 1","6698":"Geometric mean titer against diphtheria","6699":"Geometric mean titer against diphtheria","6700":"Immunogenicity ","6701":"Geometric mean titer against tetanus ","6702":"Adverse reaction severity ","6703":"Adiponectin in women","6704":"Adiponectin in men","6705":"Total knee replacement surgery ","6706":"Respiratory obstruction","6707":"Nausea\/vomiting","6708":"Morphine usage at 12 hours","6709":"Rescue analgesia","6710":"Statins prescribing rate ","6711":"Stools per week","6712":"Days with stools","6713":"Taking >80% of the prescribed dose","6714":"IL-6","6715":"Pressure-adjusted heart rate improvement ","6716":"Adverse effects","6717":"Rhodes Index scores reduction for vomiting","6718":"Rhodes Index scores reduction for vomiting","6719":"Procollagen type 1 N-propeptide","6720":"Urinary N-terminal cross-linked telopeptide of type 1 collagen","6721":"Insulin concentration ","6722":"Body weight","6723":"Systolic blood pressure","6724":"High sensitivity C-reactive protein","6725":"Productivity losses","6726":"Accumulated quality-adjusted life-years","6727":"Wake time after sleep onset improvement ","6728":"Wake time after sleep onset improvement ","6729":"Home blood pressure ","6730":"Controlled office blood pressure","6731":"Appetite area under the curve at day 2","6732":"Food consumed ","6733":"Appetite score","6734":"Fat intake","6735":"Caloric intake","6736":"Body mass gains","6737":"Scanned mass","6738":"Fat mass","6739":"Bond strength","6740":"Bond strength","6741":"Bond strength","6742":"Vomiting","6743":"Pneumonia ","6744":"Microhardness ","6745":"Microhardness ","6746":"Microhardness ","6747":"Microhardness ","6748":"Cadmium concentration after 3 weeks","6749":"Postoperative infection","6750":"Post-cesarean endometritis","6751":"Transverse plane correction","6752":"Calbindin-28k","6753":"Parvalbumin ","6754":"Calretinin","6755":"Induction to abortion","6756":"Fever","6757":"Vomiting","6758":"Hospitalization duration","6759":"Likeliness to have temperature \u226537.5\u00b0C on day 4","6760":"Overall treatment failure","6761":"Receiving additional antibiotics","6762":"Burning sensation","6763":"Pain ","6764":"Inflammation ","6765":"Healing process","6766":"Bleeding on probing ","6767":"Stress","6768":"Depression ","6769":"Time for recovering from chest X-ray scan ","6770":"Hospitalization time","6771":"Microleakage at gingival vs incisal margin","6772":"Vandetaninb area under the plasma concentration-time curve from time 0 to 504 hours","6773":"Vandetaninb maximum plasma concentration","6774":"Vandetaninb area under the plasma concentration-time curve from time 0 to 504 hours","6775":"Vandetaninb maximum plasma concentration","6776":"Corrected QT interval","6777":"Hematology laboratory results ","6778":"Salivary cortisol 1 hour after waking","6779":"Total fat if +20% body fat","6780":"Risk of neonatal death with non-poor mothers","6781":"Peak blood glucose","6782":"Absolute insulin concentrations","6783":"Depression ","6784":"Irritable bowel syndrome","6785":"ACR20 results","6786":"Adverse events","6787":"Disease Activity Score 28-joint count-C reactive protein","6788":"Erythropoietin at week 48","6789":"Adverse events","6790":"Artemether AUC","6791":"Dihydroartemisinin AUC","6792":"Artemether peak concentration ","6793":"Dihydroartemisinin peak concentration ","6794":"Lumefantrine AUC","6795":"Adequate mental health","6796":"Blood pressure","6797":"Vasoconstriction to acetylcholine","6798":"Improvement in Epworth Sleepiness Scale","6799":"Improvement in Pittsburgh Insomnia Rating Scale","6800":"Attending the antenatal clinic with their partner","6801":"Getting tested for HIV","6802":"Hemorrhage","6803":"Need for blood transplants","6804":"Core temperature after reperfusion","6805":"Need for inotropic support","6806":"ACR20 response rate","6807":"Treatment-emergent adverse events","6808":"HbA1c reduction ","6809":"Severe hypoglycemia","6810":"Serious skin reactions","6811":"Snack food consumption in women ","6812":"Minimal luminal diameter","6813":"mindfulness","6814":"negative emotion control","6815":"agression","6816":"pain","6817":"pain","6818":"pain","6819":"NOF","6820":"NOF","6821":"function accounting baseline for mild dysfunction","6822":"Asthma Quality of Life Questionnaire score improvement at 52 weeks","6823":"Day-Night Stroop test results","6824":"9-boxes test results","6825":"False Belief Task results","6826":"Verbal IQ scores","6827":"Balance ability after 8 weeks","6828":"Walking speed after 4 weeks","6829":"Serum nonesterified fatty acid","6830":"Soluble vascular cell adhesion molecule 1","6831":"Hematology abnormalities ","6832":"Quality of life improvement ","6833":"Need for transfusions ","6834":"Need for ephedrin ","6835":"Hospital stay","6836":"Hospital charges","6837":"Echocardiography utilization ","6838":"Time for \u22653 and \u22654 intragastric pH ","6839":"Weight-Related Quality of Life","6840":"Depression","6841":"Pursuing exercising at least 3 times a week","6842":"Metabolic syndrome prevalence ","6843":"FEV1 improvement","6844":"Oswestry Disability Index improvement ","6845":"Grade 1 view","6846":"Grade 1 view","6847":"Grade 1 view","6848":"Intubation ease","6849":"Intubation ease","6850":"Intubation ease","6851":"Ethmoid sinuses opacity","6852":"Tenderness on maxillary sinus","6853":"Shear bond strength","6854":"Prothrombin time","6855":"Activated partial thromboplastin time","6856":"Hospital stay ","6857":"Vaginal birth rate","6858":"Induction to delivery time","6859":"Oxytocin requirements","6860":"Percent days of abstinence ","6861":"FEV1 AUC from 0\u20133 hours","6862":"FEV1 ","6863":"Perceived involvement in medical decision making","6864":"IL-6","6865":"IL-8","6866":"MMP-9\/TIMP-1 ratio","6867":"Bicarbonate ","6868":"Neutrophil gelatinase-associated lipocalin","6869":"Overall survival for metastases < 3cm","6870":"Disease-free survival for metastases < 3cm","6871":"Disease-free survival for metastases \u2265 3 cm","6872":"Exogenous lactate clearance ","6873":"Muscle lactate production","6874":"Portal lactate","6875":"Vaccine-related serious adverse events","6876":"FEV1 improvement ","6877":"FEV1 improvement ","6878":"Pain delay","6879":"Overall costs","6880":"Surgery consultations costs","6881":"Medications costs","6882":"Accident and emergency visits costs ","6883":"Performance in reverse Stroop","6884":"Logical Memory","6885":"Focus attention ","6886":"Sickness absence","6887":"Professional ambition","6888":"Satisfaction with life","6889":"Itching","6890":"Nasal congestion","6891":"Sneezing ","6892":"Risk of preterm delivery","6893":"Mean birthweight","6894":"Feeling less worthy and likeable to others","6895":"Feeling frustrated","6896":"Feeling enjoyment","6897":"Cortisol ","6898":"Global health status time until definitive deterioration ","6899":"Time until definitive deterioration of fatigue","6900":"Time until definitive deterioration of Nausea\/vomiting","6901":"Costs ","6902":"Reversible postoperative complication","6903":"Total cholesterol","6904":"LDL cholesterol","6905":"Fasting insulin","6906":"LDL cholesterol","6907":"Central systolic blood pressure","6908":"Central systolic blood pressure","6909":"N-terminal pro b-type natriuretic peptide ","6910":"Carbon dioxide tension","6911":"pH","6912":"Mortality","6913":"Acute Physiology and Chronic Health Evaluation II scores","6914":"Marshall scores","6915":"CD4 to CD8 lymphocytes ratio","6916":"High sensitivity reactive C protein","6917":"Vitality","6918":" Social functioning\t","6919":"P-wave duration","6920":"P-wave duration","6921":"The occurrence of cardiovascular complications","6922":"P-wave duration ","6923":"Overall willingness to eat vegetables","6924":"Brain-derived neurotrophic factor 10 minutes after extubation","6925":"Brain-derived neurotrophic factor after 24 hours","6926":"Bleeding ","6927":"Physical quality of life","6928":"Body weight","6929":"Resting energy expenditure","6930":"Adenosine monophosphate-activated protein kinase phosphorylation","6931":"Ratio of fat to lean body mass","6932":"Pons glucose metabolism","6933":"Cognitive test battery global cognitive score","6934":"Executive Function battery score","6935":"Liver enzyme changes","6936":"CCL2 gene expression level","6937":"HMOX1 gene expression level","6938":"IL8","6939":"TNF ","6940":"OGG1 gene expression level","6941":"Adequacy of consent index score","6942":"Satisfaction with information about common side effects","6943":"Sedation score","6944":"Oxygen saturation","6945":"Clinical remission rate","6946":"Changes in estimated glomerular filtration rate","6947":"Change in daily dose of prednisolone","6948":"Baseline characteristics","6949":"Average daily energy","6950":"HDLc levels","6951":"Fasting plasma triacylglycerol levels","6952":"LDLc levels","6953":"Modified Borg scale scores","6954":"Serum neuron-specific enolase level after 7 days","6955":"Physical symptoms improvement","6956":"Depression improvement","6957":"Interstage mortality rate","6958":"Interstage complications rate","6959":"pH shift","6960":"Serious adverse events","6961":"Changes in vital signs or EKG","6962":"Loss of weight","6963":"Hyperactivation of the reward system for high-calorie food cues","6964":"diabetes risk - metformin arm","6965":"diabetes risk - placebo arm","6966":"increase in force compensation - same cursor color","6967":"energy intake","6968":"Apgar score <7","6969":"preeclampsia","6970":"HbA1c","6971":"mean values of AUC0-t(last)","6972":"composite appetite score","6973":"weight loss, first 6 months","6974":"Weight bearing pain","6975":"aderse effects","6976":"local reaction","6977":"vital sign change","6978":"higher banana intake","6979":"higher mandarine intake","6980":"higher apple intake","6981":"perceived appetite ratings","6982":"energy intake","6983":"plasma ghrelin","6984":"body weight gain and food efficiency ratio","6985":"Visceral fat and liver weight gain","6986":"First 5 days - average systolic BP level in patients who had stage I hypertension","6987":"Level of enjoyment","6988":"Etiology retention performance percentage scores","6989":"Treatment retention performance percentage scores","6990":"Cutaneous tissue oxygen saturation","6991":"Amyloid betas 1-42 ","6992":"Mycophenolic acid exposure","6993":"Fat free mass","6994":"Fat free mass","6995":"Waist-to-hip ratio ","6996":"Attention improvement ","6997":"Sense of Value","6998":"Pain","6999":"Pain","7000":"Pain","7001":"Pain","7002":"Mineral density","7003":"High-energy snack intake","7004":"Time to first postoperative analgesic requirement","7005":"Analgesic consumption","7006":"Hypotension\/bradycardia","7007":"Venous glycerol concentration","7008":"Free fatty acid concentration","7009":"Postprandial energy expenditure","7010":"Montgomery\u2013A\u030asberg Depression Rating Scale ","7011":"Depression","7012":"Anxiety","7013":"Calcium","7014":"Phosphorus ","7015":"Zinc","7016":"TNF-\u03b1 ","7017":"Berg Balance Scale score","7018":"Timed Up and Go score","7019":"Rate of gametocyte carriage","7020":"Time to clearance","7021":"Hemoglobin ","7022":"Rate of error","7023":"Rate of error","7024":"Triglycerides","7025":"Triglycerides","7026":"LDL cholesterol ","7027":"LDL cholesterol ","7028":"SaO2","7029":"Perception of exertion ","7030":"Thermal discomfort ","7031":"Muscle activity","7032":"Blood pressure ","7033":"Accuracy scores","7034":"Salivary production","7035":"Salivary production","7036":"Salivary production","7037":"Pain","7038":"Component Summary scores and all domain scores improvement ","7039":"Functional Assessment of Chronic Illness Therapy-Fatigue improvement ","7040":"Quality-of-life improvement after 3 months","7041":"General health perception improvement after 6 months","7042":"Pain visual analogue scale","7043":"Oswestry disability index ","7044":"Roland-Morris questionnaire score","7045":"Rehospitalisation ","7046":"\u22642 yr oral rehydration therapy failure","7047":"2-3 yr oral rehydration therapy failure","7048":"Hospitalization during 48 hours follow up","7049":"Fatigue severity","7050":"Blood pressure","7051":"Heart rate","7052":"Brachial\u2013ankle pulse wave velocity (right side)","7053":"Onset of appearance speed","7054":"Time to 50% of maximum glucose infusion rate in the early part of the glucose infusion rate profile","7055":"Safety ","7056":"Pain","7057":"Pain","7058":"Response rate after reminder","7059":"Short Form-36 completeness of questionnaire ","7060":"Overall time in movement restricted devices","7061":"Overall clinical response","7062":"Erythema clinical severity scores","7063":"Dandruff clinical severity scores","7064":"Lesion extent clinical severity scores","7065":"Ovulation induction (mid\u2010luteal progesterone level \u22655 ng\/mL)","7066":"Pain VAS score","7067":"Pain VAS score","7068":"Total analgesic consumption (first day)","7069":"Total analgesic consumption (first day)","7070":"Serious adverse events","7071":"Total medication costs after 2 years","7072":"Days with fever","7073":"Hospital stay","7074":"Systolic blood pressure recovery","7075":"Septal mitral annular velocity during systole after 5 minutes","7076":"Time to first flatus","7077":"Postoperative pain","7078":"Mortality ","7079":"Duration of procedure","7080":"Satisfaction ","7081":"Psychological quality of life","7082":"Social Relationships-related quality of life","7083":"Spiritual quality of life","7084":"Hyperglycemia ","7085":"Hypoglycemia ","7086":"LF:HF component of HRV","7087":"Push-up test","7088":"Quality of life","7089":"Lactadherin+ CD41+ CD62P+","7090":"Lactadherin+ CD144+","7091":"SYTO 13+ CD41+\t","7092":"SYTO 13+ CD144+\t","7093":"Transcutaneous oxygen","7094":"Tidal volume","7095":"Heart rate","7096":"Energy intake","7097":"Adverse events","7098":"Tissue coring","7099":"Tissue coring with needle straight insertion ","7100":"Tissue coring with needle straight insertion ","7101":"Estradiol levels","7102":"Retrieved oocytes","7103":"Fertilization rate","7104":"Recurrence rate at 12 months ","7105":"Recurrence rate at 6 months ","7106":"Mean anal resting pressure","7107":"Symptoms of anxiety ","7108":"\u22651 adjudicated symptomatic recurrent venous thromboembolism","7109":"Any bleeding","7110":"Major bleeding","7111":"Mortality","7112":"Change times","7113":"Physical quality of life","7114":"Psychological quality of life","7115":"Social quality of life","7116":"Vasoconstriction threshold ","7117":"Area of the 95% confidence ellipse with the eyes open","7118":"Area of the 95% confidence ellipse with the eyes closed","7119":"Medial lateral displacement with the eyes closed","7120":"Fracture resistance","7121":"Fracture resistance","7122":"Fracture resistance","7123":"Morning peak expiratory flow","7124":"Reliever medication use","7125":"Reliever medication-free days","7126":"Total asthma symptom score","7127":"Symptom-free days","7128":"Heart rate","7129":"Number of diarrhea days","7130":"Consecutive diarrhea days","7131":"Abdominal pain\t","7132":"Miglustat AUC","7133":"Danger of smoking occasionally perception","7134":"Danger of smoking occasionally perception","7135":"Jaw relaxation","7136":"Laryngeal mask airway ease ","7137":"Time to laryngeal mask airway placement ","7138":"Fibromyalgia Impact Questionnaire scores","7139":"Center for Epidemiologic Studies Depression Scale score","7140":"Center for Epidemiologic Studies Depression Scale score","7141":"Learned irrelevance index","7142":"P3a latency ","7143":"N1 latency ","7144":"Complication ","7145":"Postoperative pain","7146":"Hospital stay","7147":"Past week drinking","7148":"Alcohol Use Disorders Identification Test","7149":"AUC0\u201324 h for EPA","7150":"Pain intensity at rest","7151":"Pain intensity during movement","7152":"Roland-Morris Disability Questionnaire improvement ","7153":"Interview times","7154":"Time spent on TV\/DVD during the week (girls)","7155":"Computer\/game-use during the week (girls)","7156":"Computer\/game-use during the weekend (girls)","7157":"Sugar-sweetened beverages intake during the weekend (boys)","7158":"Success rate","7159":"Waist circumference ","7160":"Hip circumference ","7161":"Glucose","7162":"Total cholesterol ","7163":"Apical dye penetration","7164":"Apical dye penetration","7165":"Apical dye penetration","7166":"ACR50","7167":"ACR70","7168":"Symptoms after exercise","7169":"Physical symptoms ","7170":"Quit smoking","7171":"Body mass improvement ","7172":"Anxiety","7173":"1 repetition maximum ","7174":"Jump performance","7175":"Systolic blood pressure ","7176":"Creatinine ","7177":"Quality of dialysis","7178":"ventilator-associated pneumonia (VAP) rate","7179":"Number of times oxygen saturation fell","7180":"Epithelial healing by day 3","7181":"Epithelial healing at week 1","7182":"Uncorrected vision and refraction","7183":"spherical higher order aberration","7184":"Structured Meal Timing","7185":"Family Meal Setting","7186":"Overt Restriction","7187":"Distrust In Appetite","7188":"Reward For Eating","7189":"verbal rating scale (VRS)","7190":"Plasma levels of anti-tetanus toxoid IgG","7191":"The incidences of PONV","7192":"TT-specific CD4+ T cells","7193":"incidence of complete response","7194":"cytokine responses to TT","7195":"the incidence of PONV 2\u201348h postoperatively","7196":"the incidence complete response 2\u201348h postoperatively","7197":"plasma concentrations of pro-inflammatory cytokines TNF-\u03b1 and IL-1\u03b2","7198":"the plasma concentration of IL-6","7199":"Acute phase proteins (APPs)","7200":"Drug's compliances","7201":"aspartate aminotransferase (AST), total proteins (T-PRO), albumin (ALB)","7202":"TLR4","7203":"TLR2","7204":"Expression of IL-10, an anti-inflammatory cytokine","7205":"mRNAs encoding APPs SAA3 , Hp and LBP , chemokines IL-8 , CCL5 and CCL20","7206":"improvement rate","7207":"maximal T block","7208":"\u03b4 wave, the \u03b8 wave, the \u03b1 wave, the \u03b2 wave, and the sensory motor rhythm (SMR)","7209":"Spontaneous recovery time","7210":"heart rate (HR)","7211":"the pulsatility index (PI)","7212":"oxytocin levels","7213":"Fasted serum lipids, including total-cholesterol, HDL-cholesterol, LDL-cholesterol, TAG, apolipoprotein B and apolipoprotein AI","7214":"Hamilton Depression Rating Scale 21-item (HAM-D)","7215":"The severity of sensual pain at 8, 12, and 24 hours after menstruation","7216":"Positive and Negative Affect Scale (PANAS)","7217":"Total pain","7218":"The maximum sedation scores for each animal and the overall levels of sedation (AUCsed)","7219":"mean villous area In HIV negative patients","7220":"median villous perimeter In HIV negative patients","7221":"crypt depth, villous width","7222":"ratings","7223":"self-assessment manikin (SAM) arousal ratings","7224":"Cough","7225":"Integrated skin conductance responses (iSCRs)","7226":"Shortness of breath","7227":"muscle glycogen","7228":"Sneezing or runny nose","7229":"changes in body weight (BW), body fat (BF), fat mass (FM), lean mass (LM), and BMI","7230":"change in BMI","7231":"The percentage of participating employees reporting sickness absence","7232":"The early virologic response (EVR) and the end-of-treatment virologic response","7233":"The SVR rates when the patients had BMI >30 kg\/m2","7234":"The mean frequency of loose or liquid stools per day of AAD","7235":"The mean time to onset of AAD","7236":"live birth rates (LBR)","7237":"stress levels","7238":"stress levels","7239":"mean score of anxiety","7240":"Sensory regression to L1 dermatome","7241":"blood lactate concentrations","7242":"immunohistochemistry (IHC)","7243":"Time required to reach highest sensory level, complete motor block","7244":"The incidence of fatigue , headache and dystonia","7245":"weight loss","7246":"difference in the mean BP","7247":"weight loss","7248":"pulse wave velocity (PWV)","7249":"endothelial function","7250":"intrahepatic lipids at follow-up","7251":"long-term biochemical progression free survival (bPFS)","7252":"Companion allowed","7253":"Other beneficial policies - Moving around in 1st stage","7254":"30-day mortality rate","7255":"Painful obstetric policies - Episiotomy","7256":"Relaxed","7257":"Calm","7258":"all-cause mortality, cardiovascular complications, acute respiratory distress syndrome, acute kidney injury requiring renal replacement therapy, septic shock or reoperation at 30 days","7259":"60 day mortality rate","7260":"Improvement in GSRS (Gastrointestinal Symptom Rating Scale) abdominal distension subscore - in adults with post prandial intestinal gas-related symptoms and no GI diagnoses","7261":"Overall Wellness","7262":"IL-6 assessed 1\u20133 h after cold challenge ","7263":"smoking cessation","7264":"smoking cessation","7265":"hippocampal choline at baseline","7266":"Gray volume changes in bilateral hippocampus in healthy seniors with mild cognitive impairment (MCI)","7267":"Gray matter volume dorsal anterior cingulate cortex (dACC) in healthy seniors with mild cognitive impairment (MCI)","7268":"choline","7269":"total wake minutes during sleep among patients with schizophrenia","7270":"beneficial effects on emotional measures among patients with schizophrenia","7271":"sleep percentage effects among patients with schizophrenia","7272":"primary headaches in healthcare providers","7273":"headache severity","7274":"bloating - effect of a gluten-free diet on gastrointestinal symptoms in patients with IBS","7275":"overall symptoms - effect of a gluten-free diet on gastrointestinal symptoms in patients with IBS","7276":"tiredness - effect of a gluten-free diet on gastrointestinal symptoms in patients with IBS","7277":"changes in the depression level - effect of cognitive-behavioral group therapy on depressive symptoms in people with type 2 diabetes","7278":"mean depression scores after 4 weeks - effect of cognitive-behavioral group therapy on depressive symptoms in people with type 2 diabetes","7279":"Cormack and Lehane glottic visualisation grades - awake nasal intubation of oropharyngeal cancer patients with anticipated difficult intubation","7280":"success rate of the first attempt - awake nasal intubation of oropharyngeal cancer patients with anticipated difficult intubation","7281":"numbers needed to treat (NNTs)","7282":"Reduction of thickness of the PL-biofilm after a single mouthwash","7283":"Decrease in serum creatinine","7284":"Minimal creatinine rise","7285":"AKI development","7286":"Movement time of the elbow","7287":"Mean angular velocity of the wrist","7288":"Baseline demographics and mean MAQ score","7289":"Response rate","7290":"Failure to obtain haemostasis","7291":"Fusion rates","7292":"Definite postoperative complications","7293":"Boston Bowel Preparation Scale score","7294":"Gastrointestinal problems and discomfort","7295":"Levels of blood electrolytes and BUN","7296":"Foot plantar pressure during the gait stance phase","7297":"VL <200 copies\/mL at 96 weeks","7298":"Laboratory parameters and metabolic syndrome rate","7299":"Rates of adverse events, AIDS, or mortality","7300":"Disease-free interval in patients with head and neck cancer","7301":"Increase from baseline in the mean VO2 max after 8 weeks","7302":"Quality of Life scores at 12 weeks","7303":"Quality of Life scores at 8 weeks","7304":"Mean resting post-prandial systolic and diastolic blood pressures ","7305":"Fasting lipoprotein lipid values","7306":"Adverse events","7307":"Mean spherical equivalent","7308":"Postoperative pain","7309":"Positive learning behaviors","7310":"Prosocial behavior","7311":"Number of stools per day","7312":"Adverse events","7313":"Changes in gingival index, alteration in plaque index, bleeding index, and probing pocket depth.","7314":"Michigan diabetic neuropathy score","7315":"Baseline characteristics (except cholesterol levels)","7316":"Global perceived effect and Headache Impact Test score (primary outcomes)","7317":"Reduction in headache frequency, pain intensity, medication intake, absenteeism, and use of additional professional help (secondary outcomes)","7318":"Improvement in alveolar-arterial difference in oxygen tension","7319":"Heart rate, mean arterial pressure, and minute ventilation","7320":"PaCO2 levels after 3 h of CO2-insufflation","7321":"Abscense of anxious depression","7322":"Severity category shift from \u2265 4 to \u2264 2 on the MADRS items of reduced appetite, concentration difficulties, inability to feel, and pessimistic thoughts","7323":"Levels of neutrophil gelatinase-associated lipocalin","7324":"Baseline characteristics","7325":"Baseline characteristics","7326":"Baseline characteristics","7327":"Mean visual analogue scale score for pain intensity after the injection","7328":"Baseline characteristics","7329":"Mean pain intensity score at baseline","7330":"Patient-Specific Functional Scale score at baseline","7331":"Time to the first flatus after surgery","7332":"Time to the first feces after surgery","7333":"Time to regular diet","7334":"Nonverbal behaviors","7335":"Motor-Affective subscale of the MASS dimensions","7336":"Visual Analogue Scale score during the first post-fracture period","7337":"Myasthenia gravis score improvement","7338":"Mean prednisone requirement at months 10 and 12","7339":"Rate of adverse events","7340":"Schirmer tear test I","7341":"Clinical scores at baseline, week 4, and week 8","7342":"Irritation signs ","7343":"Baseline characteristics","7344":"AHA unit score","7345":"Fat mass","7346":"Visceral fat","7347":"Levels of IL-12 p70 and TNF-\u03b1","7348":"Levels of IL-10","7349":"Total protein concentrations in cervicovaginal lavages","7350":"Moderate to severe airway responsiveness","7351":"Methacholine solution number which caused FEV1 decrease >20%","7352":"Ruminal temperature","7353":"Ruminal ammoniacal nitrogen ","7354":"Amylolytic bacteria","7355":"Fracture resistance","7356":"Fracture resistance","7357":"Plasma glucose","7358":"Blood lactate","7359":"VO2 peak","7360":"Muscle creatine phosphate","7361":"OSCE total score right after procedure","7362":"Spiritual well-being right after test ","7363":"Spiritual well-being 1 month after test ","7364":"Spiritual existential aspect right after test ","7365":"Alkaline phosphatase","7366":"Calcium ","7367":"Osteocalcin","7368":"Consciousness recovery time ","7369":"Hospital stay time ","7370":"Depth of sealer penetration at apical third","7371":"Reaction times","7372":"Systolic blood pressure","7373":"Diastolic blood pressure","7374":"Arterial O2","7375":"Heart rate ","7376":"Phlebotomy questionnaire score ","7377":"Techinque related rejections ","7378":"Waist circumference","7379":"Rescue antiemetics","7380":"Systolic blood pressure","7381":"Angiotensin II","7382":"Diacron-reactive oxygen metabolites","7383":"Left ventricular risk area ","7384":"EQ-5D quality of life in men","7385":"EQ-5D quality of life in women","7386":"FEV1\/FVC","7387":"Postoperative recovery agitation","7388":"Surgeon Satisfaction ","7389":"Glycated hemoglobin ","7390":"Body weight","7391":"Hospital stay duration ","7392":"Diastolic blood pressure ","7393":"Respiratory Rate","7394":"Anxiety","7395":"Metastasis","7396":"Progression free survival ","7397":"Fever (>38\u00b0C)","7398":"Head\/neck injury","7399":"Trunk injury","7400":"Contact injuries","7401":"Cumulative uptake at 3 months","7402":"Cumulative uptake at 6 months","7403":"P-selectin ","7404":"Monocyte Chemoattractant Protein-1","7405":"Toll-like receptor 4","7406":"Number of averse reactions","7407":"Adiponectin in men","7408":"Time to first analgesic request ","7409":"Morphine usage at 24 hours","7410":"Patient satisfaction","7411":"Difficulties associated with treatment","7412":"Good taste ","7413":"Tumor necrosis factor levels ","7414":"Multiple organ failure scores","7415":"PaO2\/FioO2 improvement ","7416":"Rhodes Index scores reduction for nausea","7417":"Rhodes Index scores reduction for nausea","7418":"Rhodes Index scores reduction for retching","7419":"Rhodes Index scores reduction for retching","7420":"Osteocalcin","7421":"Waist circumference","7422":"Diastolic blood pressure","7423":"HDL-cholesterol","7424":"Drug cost","7425":"Societal cost ","7426":"Healthcare costs","7427":"Wake time after sleep onset improvement ","7428":"Sleep latency improvement ","7429":"Wake time after sleep onset improvement ","7430":"Sleep latency improvement ","7431":"Office blood pressure","7432":"Appetite area under the curve at day 1","7433":"Total work of trained athletes ","7434":"Total work of non-trained athletes ","7435":"Energy intake","7436":"Carbohydrate intake","7437":"Protein intake","7438":"Body fat","7439":"Fatigue ","7440":"Hunger ","7441":"Bond strength","7442":"Bond strength","7443":"Bond strength","7444":"Energy requirements intake","7445":"Protein requirements intake","7446":"Regurgitation","7447":"Aspiration","7448":"Microhardness ","7449":"Duration of hospitalization","7450":"Calretinin","7451":"Glutamic acid decarboxylase positive neurons","7452":"Dose needed for expulsion ","7453":"Having at least 1 treatment-related adverse event","7454":"Treatment-related MAE","7455":"Somatic anxiety","7456":"Mechanical ventilation time","7457":"Microleakage at gingival vs incisal margin","7458":"Error rate","7459":"ACR50 results","7460":"Erythropoietin at week 24","7461":"Lumefantrine peak concentration ","7462":"LDL cholesterol ","7463":"Change in plaque volume","7464":"Pain","7465":"Diarrhea","7466":"Ventilation time","7467":"ACR20 response rate","7468":"Treatment-emergent adverse events","7469":"Snack food consumption in men","7470":"Diameter stenosis","7471":"Shoulder stiffness","7472":"Intragastric pH \u22654 mean percent time","7473":"Blood chemistry count","7474":"Systolic blood pressure ","7475":"Microcrack formation in the coronal section","7476":"Hemodiastase levels","7477":"Admission rates","7478":"Subcapital location","7479":"Methicillin-resistant Staphylococcus aureus eradication rate","7480":"Verbal rating scale pain intensity ","7481":"Post treatment pain in temporomandibular joint (TMJ) disorders","7482":"intrinsic motivation","7483":"patients reaching remission","7484":"Montgomery-Asberg Depression Rating Scale (MADRS) scores","7485":"balance confidence (ABC) scale at week 4","7486":"balance confidence (ABC) scale at week 8","7487":"response rate by degree","7488":"RPP (rate pressure product) values","7489":"correlation between target energy and visual analogue scale (VAS) values","7490":"time to complete the difficult model","7491":"leg pain - moderate degenerative lumbar spinal stenosis.","7492":"subjects achieving the primary composite endpoint - moderate degenerative lumbar spinal stenosis.","7493":"EI (Effectiveness Index) for Quality of life 6 months later","7494":"Psychosocial work characteristics at baseline","7495":"initial training of lower limb muscle activities - inpatients receiving physical therapy for chronic stroke","7496":"baseline detected temperature - Painful diabetic peripheral neuropathy (DPN)","7497":"mean values of EPG","7498":"hypoglycemia","7499":"clinically meaningful improvement at week 144 (\u2a7e3-point increase on the SDMT)","7500":"Symbol Digit Modalities Test (SDMT) score at week 144 in limited patients","7501":"clinically meaningful improvement at week 96 (\u2a7e3-point increase on the SDMT)","7502":"patients who achieved an HbA1c of <7.0% at week 14","7503":"Helping Alliance Questionnaire (HAQ)","7504":"Heart rate (HR) at 30 min","7505":"fiber intake at 12r months","7506":"other significant differences in translations at 5 years","7507":"other significant differences in rotations at 5 years","7508":"AUC for predicting prostate cancer at biopsy","7509":"Comfort during the procedure","7510":"Use of salbutamol as reliever ","7511":"Use of salbutamol as reliever ","7512":"Postprandial glucose","7513":"Shear bond strength","7514":"Shear bond strength","7515":"Diametral tensile strength after 1 hour","7516":"Insertion time","7517":"Hemoglobin after 18 months","7518":"Improvement in signs","7519":"Gastrointestinal toxicosis","7520":"Median histopathological scores","7521":"Waist to hip ratio","7522":"Maximal oxygen consumption","7523":"EQ-5D utility index scores improvement at 4 weeks","7524":"EQ-5D Usual activities improvement ","7525":"EQ-5D Pain improvement ","7526":"Systolic blood pressure ","7527":"Whole\u2010mouth mean Plaque index score","7528":"Proportion of bleeding sites","7529":"Vomiting","7530":"Antenatal care visits quality","7531":"Delayed Cord Clamping % points ","7532":"Uterine Sweeping % points ","7533":"Expanded Disability Status Scale","7534":"Adverse events ","7535":"Subjective feelings of rush ","7536":"Regions showing increased functional resting-state connectivity","7537":"Countermovement displacement","7538":"Triglycerides ","7539":"High Sensitivity C-Reactive Protein","7540":"Weight gain in wasted children ","7541":"Probability of using additional learning material","7542":"Physical activity levels","7543":"Parental stress","7544":"Emergency Caesarean","7545":"Neurological progression-free survival","7546":"N100 amplitude","7547":"Working memory","7548":"Blood loss during day 1","7549":"Lowest hemoglobin ","7550":"Heart 7 min after intubation ","7551":"Hip fracture frequency","7552":"Global self esteem ","7553":"N-back working memory test","7554":"Groton Maze Learning Test legal errors","7555":"Need of plasma transfusion","7556":"Plasminogen activator inhibitor-1 ","7557":"Treatment response rate","7558":"Hamilton Rating Scales for Depression ","7559":"Spielberger State Anxiety Inventory ","7560":"R3z value","7561":"R3z value","7562":"Cognitive anxiety","7563":"Heart Rate","7564":"vitality (VT), physical functioning (PF), role limitation due to physical problems (RP), role limitation due to emotional problems (RE), and mental health (MH) ","7565":"Hamilton Rating Scale for Depression (HAM-D) scores at T2","7566":"'Atlantis' and 'Number recall', and spatial ability tests-'Triangle', problem solving CCT-1 test","7567":"'Conceptual Thinking', 'Face recognition', 'Story completion', and reasoning tests-'Rover', 'Block counting', and 'Pattern Reasoning'","7568":"Agitation score","7569":"fasting glucose","7570":"operation time","7571":"intraoperative blood loss, drop in hemoglobin","7572":"forced vital capacity (FVC)","7573":"General Movement Assessment (GMA)","7574":"comfort, stability, chewing efficiency","7575":"Likert scores","7576":"waist circumference","7577":"cumulative incidence of type 2 diabetes mellitus (T2DM) among participants with baseline HbA1c levels <5.7%","7578":"Acute gain","7579":"Bloating improvement ","7580":"Frequency of bowel movements","7581":"Gas volume","7582":"Treatment-related adverse events","7583":"Increases in hemoglobin when GFR \u226590 mL\/min","7584":"50-ft Speed Walk improvement ","7585":"6-Minute Walk improvement ","7586":"SF-12 Physical Component Summary improvement ","7587":"SF-12 Physical Component Summary improvement ","7588":"Physician assessed symptoms","7589":"Heart rate","7590":"Systolic blood pressure ","7591":"Esomeprazole Max concentration","7592":"Esomeprazole AUC","7593":"Intragastric pH \u22654 mean percent time","7594":"Intragastric pH \u22654 mean percent time","7595":"Diastolic blood pressure ","7596":"Interquartile range number of CPT sessions","7597":"Duration of sessions","7598":"Strapping number of sessions","7599":"Participants using ankle-foot orthosis at least 1 session","7600":"Percentage of cracks","7601":"Microcrack formation","7602":"Total K7-positive cells","7603":"Macrophage content","7604":"CXCL14 ","7605":"SLC1A2","7606":"White blood cell count","7607":"Left inferior parietal lobe contrast in ASD","7608":"Left inferior parietal lobe contrast in ASD","7609":"Choosing single embryo transfer ","7610":"Adverse events","7611":"Experiencing a downward shift in monthly per capita consumption expenditure in Kanpur Dehat ","7612":"Experiencing a downward shift in monthly per capita consumption expenditure in Vaishali ","7613":"Admission rates","7614":"Heart rate","7615":"Subsequent subtrochanteric fractures ","7616":"Intertrochanteric location","7617":"Cure rate","7618":"Staphylococcus aureus eradication rate ","7619":"Methicillin-resistant Staphylococcus aureus eradication rate","7620":"Knee Injury and Osteoarthritis Outcome Score improvement ","7621":"Tibial bone expansion","7622":"Verbal rating scale pain intensity ","7623":"State-Trait Anxiety Inventory-I","7624":"Salivary alpha-amylase","7625":"Gastrointestinal adverse events","7626":"mandibular opening in temporomandibular joint (TMJ) disorders 60 days after starting treatment","7627":"competence in participants' ability to undertake CBAT","7628":"patients reaching remission","7629":"treatment of balance in patients with chronic stroke","7630":"response rate by gender","7631":"SpO2 values","7632":"intubation time in hypertensive patients","7633":"Systolic BP (SPB) measurements in hypertensive patients","7634":"Diastolic BP (DPB) measurements in hypertensive patients","7635":"trend in MELD over time in patients with compensated liver cirrhosis","7636":"change in MELD scores in patients with compensated liver cirrhosis","7637":"change in MELD scores in patients with compensated liver cirrhosis","7638":"high demanding\/low responsive feeding style","7639":"low demanding\/high responsive style","7640":"correlation between target energy and skin conductance response (SCR) magnitudes","7641":"deactivation of the posterior regions of the default mode network","7642":"Temperatures of warmth perception and thermal heat pain threshold (WPT) and (HPT)","7643":"residents preference","7644":"EI (Effectiveness Index) for the MAL immediately after treatment","7645":"EI (Effectiveness Index) for the MAL 6 months later","7646":"EI (Effectiveness Index) for Fugl-Meyer Assessment of Sensorimotor Recovery after Stroke (FMA) immediately after treatment","7647":"Vasorelaxation to sodium nitro-prusside (SNP) in LAD","7648":"bradykinin (BK) induced relaxation","7649":"Vasorelaxation to adenosine diphosphate (ADP) in LAD","7650":"Adverse events, mild","7651":"Adverse events, moderate","7652":"heart rate effect","7653":"washing","7654":"wiping","7655":"vaginal practices: washing, wiping, and insertion (of dry or absorbent materials) at baseline","7656":"vaginal practices: washing, at baseline","7657":"vaginal practices: wiping, at baseline","7658":"demographic characteristics","7659":"smokers","7660":"Health at baseline","7661":"stability index resulting from balance training - inpatients receiving physical therapy for chronic stroke","7662":"Muscle activity of the tibialis anterior muscle - inpatients receiving physical therapy for chronic stroke","7663":"After 12-week interventions, the mental control subscores","7664":"After 12-week interventions, the mental control subscores","7665":"average attendance rate","7666":"post-test Megacode","7667":"baseline Megacode assessment score","7668":"mean number of new or enlarging T2-hyperintense lesions - patients newly diagnosed with relapsing\u2013remitting multiple sclerosis (RRMS)","7669":"annualized relapse rate - patients newly diagnosed with relapsing\u2013remitting multiple sclerosis (RRMS)","7670":"annualized relapse rate - patients newly diagnosed with relapsing\u2013remitting multiple sclerosis (RRMS)","7671":"risk of relapse - patients newly diagnosed with relapsing\u2013remitting multiple sclerosis (RRMS)","7672":"mean number of new or enlarging T2-hyperintense lesions - patients newly diagnosed with relapsing\u2013remitting multiple sclerosis (RRMS)","7673":"heart rate","7674":"percentage of patients with SBP changes <20% of basal value to percentage of patients with SBP changes >20% of basal value","7675":"mean arterial pressures at 1, 3, and 5 minutes after intubation","7676":"(SBP) systolic blood pressures at 1, 3, and 5 minutes after intubation","7677":"Decrease in 10-point numerical rating scale (NRS) at the first follow-up evaluation - Painful diabetic peripheral neuropathy (DPN)","7678":"mean values of EPG","7679":"hematological profiles","7680":"effectiveness - combined type","7681":"pollinosis symptoms","7682":"quality of life (QOL)","7683":"effectiveness - sneezing\/rhinorrhea type","7684":"frequency of seizures","7685":"insulin sensitivity - 10\u201317 years old with recent-onset type 2 diabetes and \u226580% adherence to metformin therapy for \u22658 weeks","7686":"higher weight at end of intervention","7687":"higher weight at follow-up","7688":"QALYs (Quality Adjusted Life Year) excluding impact of AEs","7689":"drug cost","7690":"QALYs (Quality Adjusted Life Year) including impact of AEs","7691":"amplitude","7692":"wave I","7693":"latency","7694":"Symbol Digit Modalities Test (SDMT) score at week 96","7695":"clinically meaningful worsening at week 96 (\u2a7e3-point decrease on the SDMT)","7696":"Deqi sensation","7697":"visual analogue scale (VAS) ratings","7698":"patients who achieved an HbA1c drop of \u22650.5% at week 14","7699":"clinicians' baseline characteristics","7700":"Helping Alliance Questionnaire (HAQ) - total score","7701":"Patients' perceptions of the therapeutic alliance","7702":"Helping Alliance Questionnaire (HAQ) - Helpfulness","7703":"BF%Bioelectrical impedance analysis (BIA) derived BF(Body Fat)% at PRE and 15-min","7704":"Heart rate at PRE","7705":"Bioelectrical impedance analysis (BIA) derived BF(Body Fat)% at PRE and 15-min","7706":"Bioelectrical impedance analysis (BIA) derived BF(Body Fat)% at 30-90 min","7707":"fiber intake at four months","7708":"fat consumption at four months","7709":"weight loss","7710":"Trefoil factor 3 (TFF3) in each common clinical disease group","7711":"aberrant expression of TF localization","7712":"total energy intake at baseline","7713":"macro-nutrient contributions ","7714":"dietary intakes before intervention","7715":"macro-nutrient contributions after intervention","7716":"other significant differences in translations at 2 years","7717":"activity and motion ","7718":"attending the intervention SDCs","7719":"surgery time , blood loss , and amounts of intraoperatively administered fluids","7720":"surgery time, blood loss, amounts of intraoperatively administered fluids, and amounts of fresh frozen plasma administered ) in the cancer subgroup","7721":"ICU-LOS and H-LOS cancer subgroup","7722":"S100A8 protein on day 1 and day 2, and S100A12 protein on day 2 in thecancer subgroup","7723":"levels of IL-6 for all 3 days in th ecancer subgroup","7724":"anxiety, tension, arousal, discomfort, and fatigue and relaxation","7725":"enhanced U46619-induced platelet P-selectin expression","7726":"AD Cooperative Study-Activities of Daily Living (ADCS-ADL) scale","7727":"AD Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) score","7728":"incidence of adverse events","7729":"migraine attack frequency, migraine days, attack duration ","7730":"adverse events","7731":"utilizing audio-playlist devices","7732":"dynamic sitting balance and coordination","7733":"The postoperative hospital stay","7734":"Adequate bowel preparation rates","7735":"\"nausea\"","7736":"Patient Preference","7737":"total symptom scores (TSSs)","7738":"virus titer","7739":"preference for using long-acting injectable [LAI] medication","7740":"increase the dose and switch medications","7741":"incidences of Post-operative nausea and vomiting (PONV) ","7742":"fasting non-esterified fatty acid (FA) (NEFA) concentrations","7743":"differential suppression of NEFA by insulin during the two-step clamp","7744":"IL6 concentratio","7745":"Fasting plasma propionate and butyrate concentrations","7746":"Fasting GLP1 concentrations","7747":"meal GLP1 excursion","7748":"soleus intramyocellular lipid (S-IMCL) content","7749":"the tibialis IMCL (T-IMCL)","7750":"Symptom scores","7751":"American Urological Association [AUA] symptoms","7752":"Prostate volumes","7753":"International Prostate Symptom Score [I-PSS]) ","7754":"erectile function","7755":"Prostate volumes","7756":"erectile function","7757":"mean weight, physical activity","7758":"physical activity","7759":"Sleep efficiency","7760":"serum CD3+ and CD8+","7761":"IL-2 and IFN-\u03b3","7762":"IL-4 and IL-6 ","7763":"The effective rate and the degree of treatment","7764":"High viral loads","7765":"Efficacy-related discontinuation or failure","7766":"Yale Global Tics Severity Scale- impairment score ","7767":"Discontinuation rate ","7768":"Discontinuation rate ","7769":"Physical activity dose","7770":"Moderate and vigorous activity, min\/wk","7771":"Estimated maximal oxygen uptake","7772":"Total hospital stay >14 days","7773":"Lymphocyte count ","7774":"Signal intensities against EnvA at week 36","7775":"Ischemic-driven TVR at 2 years ","7776":"Myocardial infarction ","7777":"Target lesion revascularization","7778":"Self-efficacy","7779":"Inotropic support duration ","7780":"Neurologic complications ","7781":"ICU stay","7782":"Mean arterial pressure ","7783":"Central venous oxygen saturation ","7784":"Central venous oxygen saturation ","7785":"Central venous oxygen saturation ","7786":"Quercetin concentrations in healthy adults","7787":"Postprandial blood sugar","7788":"Total cholesterol ","7789":"Satisfaction ","7790":"Days of binge drinking after 10 weeks","7791":"Days of cigarette smoking after 10 weeks ","7792":"Cigarette per day after 10 weeks","7793":"Readiness to quit by the end of trial","7794":"BMI z-score at 24 months","7795":"Improvement in swelling\/edema\/inflammation scores","7796":"Improvement in ecchymosis\/hematoma scores","7797":"Patients' satisfaction","7798":"Se concentrations in whole blood","7799":"Ageusia rate","7800":"Rates of POI","7801":"Consumption of fentanyl ","7802":"Pain scores 24 hours and 72 hours after the surgery","7803":"Erosive esophagitis recurrence rate after 24 weeks","7804":"Safety profiles","7805":"Changes in BMD at the lumbar spine and hip after 1 year","7806":"Response rates","7807":"Baseline characteristics","7808":"Changes in SFChT at 1 hour","7809":"Changes in 60\u00b0\/sec peak torque\/body weight (%) at the right knee flexor","7810":"Isokinetic knee muscular function","7811":"Thighs circumferences ","7812":"Weight reduction","7813":"Quality of recovery after surgery","7814":"QoR-40 scores","7815":"PONV incidence","7816":"Pain score","7817":"Discomfort score, except after 10 minutes","7818":"Sedation score after 10 minutes","7819":"Newborn's weight and head circumference at birth","7820":"Baseline characteristics","7821":"Pain score after 5 minutes","7822":"Physical exercises scores after 12 months","7823":"Time of leisure or transport-related PA at 12 months","7824":"Moderate and vigorous PA","7825":"Impact on sex life","7826":"disease control in MTX-IR patients with established RA (DE019)","7827":"in patients with early aggressive RA who had inadequate response to MTX during the first 6 months of therapy with placebo+MTX (OPTIMA)","7828":"patient wait time for physician arrival once in the exam room","7829":"time spent with the physician","7830":"Difference in care for family planning based on ethnic group","7831":"sensory and motor block duration","7832":"onset of both sensory and motor blocks","7833":"block duration","7834":"decrease in plaque","7835":"decrease in plaque","7836":"improvement of disorder","7837":"drop in mean arterial pressure","7838":"symptom endorsement prediction","7839":"total cholesterol, LDL, non HDL cholesterol concentration","7840":"post-operative pain","7841":"trismus","7842":"FEV1","7843":"6 minute walking distance","7844":"bradykinin","7845":"glucose level","7846":"insulin","7847":"25(OH)D2 AUC140","7848":"presence of melancholic features and higher treatment resistance scores","7849":"giving preference among young and females younger, female, more highly educated and considered themselves owner of their tissue or the DNA in their tissue","7850":"postoperative mean arterial blood pressure, heart rate, respiratory rate, and oxygen saturation","7851":"The total tramadol consumption","7852":"first analgesic request time","7853":"carbon dioxide production (VCO2)","7854":"leg press, cycling sprint peak power, mean power, total work","7855":"adverse events, ECG, liver function, and kidney function","7856":"follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and progesterone (P)","7857":"implantation rate (IR)","7858":"Cleavage and blastocyst rates","7859":"wave V latency","7860":"wave V amplitude","7861":"Percent days of abstinence ","7862":"Drinks per drinking day","7863":"Drinks per drinking day","7864":"FEV1 AUC from 0\u20133 hours","7865":"Transition dyspnea index focal score","7866":"needle penetration","7867":"Need for rescue medication ","7868":"incidences of AEs","7869":"Satisfaction with care","7870":"change in HbA1c at week 14","7871":"IL-10","7872":"5-year disease-free survival ","7873":"5-year overall survival ","7874":"Bioelectrical impedance analysis (BIA) derived BF(Body Fat)% at 30-90 min","7875":"Exogenous lactate clearance ","7876":"weight loss - when adjusted for co-interventions (i.e., medical treatment) and incident morbidities that might affect weight","7877":"Proprioceptive drift effect during asynchronous stroking","7878":"Trefoil factor 3 (TFF3) in each common clinical disease group","7879":"Fever \u226539\u00b0C","7880":"Trefoil factor 3 (TFF3) in each common clinical disease group","7881":"aberrant expression of TF localization","7882":"Activity","7883":"aberrant expression of TF localization","7884":"FEV1 improvement ","7885":"Urinary cortisol excretion ","7886":"Urinary cortisol excretion ","7887":"dietary intakes after intervention","7888":"Substance P expression ","7889":"other significant differences in rotations at 2 years","7890":"Femoral stems degree of medio-lateral migration at 5 years","7891":"Home consultations costs","7892":"Demographic similarity","7893":"Performance in Stroop","7894":"Median age","7895":"Symbol Search speed","7896":"weight of infants","7897":"Subjective importance of work","7898":"Striving for perfection","7899":"mean anxiety score","7900":"Proactive problem-solving","7901":"Physician-assessed overall nasal signs and symptoms improvement ","7902":"mean scores of attitudes - before educational intervention","7903":"Reflective total ocular symptom scores","7904":"Score: improvement in visual analogue scale (VAS) for dyspnea - COPD patients due to exposure to sulfur mustard (SM) and refractory to conventional therapies","7905":"Risk of low birthweight","7906":"Score: cough improvement - COPD patients due to exposure to sulfur mustard (SM) and refractory to conventional therapies","7907":"Risk of active placental malaria ","7908":"Risk of adverse events","7909":"Feeling inadequate ","7910":"exploitative tendency with each additional task","7911":"Feeling angry","7912":"Time until definitive deterioration of pain","7913":"stain intensity after 21 days","7914":"Time until definitive deterioration of insomnia","7915":"amount of plaque formed at end of week 3","7916":"NO\/MDA ratios","7917":"Sick leave days","7918":"Elevated Plasma lipid peroxides (MDA) levels","7919":"Progression-free survival","7920":"Waist circumference","7921":"Fasting insulin","7922":"decrease in exercise intensity as time elapsed","7923":"weight reduction","7924":"accuracy of the cognitive tasks","7925":"reduced kidney glomerular filtration rate","7926":"Transcranial Doppler pulsatility index ","7927":"Transcranial Doppler pulsatility index ","7928":"slightly elevated body mass index","7929":"moderate hypertension","7930":"Shivering ","7931":"significant effect on bond strength","7932":"Arterial-oxygen saturation","7933":"survival","7934":"T helper to inducer lymphocytes ratio","7935":"Medication appropriateness index improvement ","7936":"oral disposition index (oDI) - 10\u201317 years old with recent-onset type 2 diabetes and \u226580% adherence to metformin therapy for \u22658 weeks","7937":" Physical functioning\t","7938":"prevalence of previous stroke\/transient ischemic attack","7939":"P-wave dispersion ","7940":"risk of death","7941":"P-wave dispersion ","7942":"P-wave dispersion ","7943":"reflux of bile in the remnant stomach","7944":"Willingness to eat swede","7945":"change from baseline on the ADHD-RS-IV hyperactivity\/impulsivity and inattentiveness subscales","7946":"Cadmium concentration after 3 weeks","7947":"Improvement on the dichotomized CGI-I at EOS","7948":"Willingness to eat lingonberry","7949":"Heart rate during injection","7950":"quality of life of patients - (individuals diagnosed with a malignant tumor)","7951":"Sagittal plane kyphosis","7952":"Sagittal plane lordosis ","7953":"scores of sleep factor before reatment (individuals diagnosed with malignant tumor)","7954":"Transverse plane maximum curvature reduction","7955":"Coronal plane apical axial rotation correction","7956":"Bispectral index during intubation ","7957":"Psychosocial quality of life","7958":"use of rescue medication (patients with COPD)","7959":"Calbindin-28k","7960":"maximal voluntary contraction (MVC)","7961":"Success rate at 24 hours","7962":"Success rate at 48 hours","7963":"maximal voluntary contraction (MVC)","7964":"Post-prandial respiratory quotient","7965":"operative success rate","7966":"Physical activity during light time periods","7967":"postoperative complications","7968":"ADAS-Cog total score","7969":"Proportions of NMAE relative to all AE","7970":"Likeliness to receive prompt and appropriate antibiotics for pneumonia","7971":"Fast breathing","7972":"Hospitalization","7973":"trend of temptation to smoke scores","7974":"Patients' understanding anesthesia procedure","7975":"Satisfaction with information rare complications","7976":"Analgesia duration","7977":"levels of anxiety","7978":"periodic leg movement index, PLMI","7979":"percentage of time with Pcuff 20\u201330 cmH2O versus Pcuff <20 cmH2O","7980":"Vital exhaustion ","7981":"Physical activity","7982":"Social support","7983":"Disappearance of hematuria","7984":"Demographic characteristics","7985":"Oxygen index","7986":"2D healing at 8 weeks","7987":"Head circumference","7988":"Height ","7989":"callus volumes at 4 weeks","7990":"Microleakage at gingival vs incisal margin","7991":"good adherence","7992":"Mortality rate","7993":"negatively associated with good adherence","7994":"negatively associated with good adherence","7995":"bradykinin-induced vasodilatation in people with type 2 diabetes mellitus (T2DM)","7996":"Glasgow outcome scale score at discharge and 3 months after discharge","7997":"Glasgow coma scale scores after 7 days","7998":"Improvement in mental health scores ","7999":"body weight in people with type 2 diabetes mellitus (T2DM)","8000":"acute grade 3 or 4 toxicity (early breast cancer)","8001":"Social functions or anxiety level","8002":"Pain intensity","8003":"Functional impairment","8004":"Severe adverse event ","8005":"Vital signs","8006":"Salivary cortisol at wake","8007":"increased thiobarbituric acid reactive substances (TBARS) concentration - immediately after exercise","8008":"Hyperactivation of the reward system for low-calorie food cues","8009":"increased uric acid concentration - immediately after exercise","8010":"Tenderness on frontal sinus","8011":"diabetes risk - lifestyle arm","8012":"improvement of mean ASIA motor score over 12 months - cases with complete TSCI (traumatic spinal cord injury)","8013":"mean motor score improvement - cases with incomplete TSCI (traumatic spinal cord injury)","8014":"Glucagon concentrations during infusion","8015":"diabetes risk - placebo arm","8016":"Fatigue","8017":"Abdominal pain","8018":"Joint pain","8019":"suturing test completion time","8020":"Weight gain","8021":"mean decrease in HbA1c level","8022":"annualized rate (events per participant-year) of confirmed [\u22643.9 mmol\/l (\u226470 mg\/dl)] or severe hypoglycaemia at any time of day (24 h) over the 6-month","8023":"increase in force compensation - cursor color (red or blue)","8024":"improvement in cognitive dysfunction (schizophrenia patients)","8025":"Laboratory tests","8026":"overall effect of onset age on PANSS (Positive and Negative Syndrome Scale) subscales (schizophrenia patients)","8027":"over the course of the exposure period maximum perpendicular error (MPE) decrease - same cursor color","8028":"ACR70 results","8029":"colonoscopic findings","8030":"colon preperation","8031":"cosmetic satisfaction","8032":"flush need","8033":"fullness","8034":"lower energy intake","8035":"dose reduction - patients with chronic hepatitis C with HCV genotype 6","8036":"palatability","8037":"Average blood loss","8038":"satiety","8039":"combined outcome of non-perioperative stroke or TIA - patients with carotid artery stenosis","8040":"rates of any stroke that lasted for more than 7 days - patients with carotid artery stenosis","8041":"HDL cholesterol ","8042":"death within 30 days of treatment - patients with carotid artery stenosis","8043":"minor strokes that lasted fewer than 7 days within 30 days of treatment - patients with carotid artery stenosis","8044":"Improvement in Patient Health Questionnaire","8045":"Reduction in proteinuria","8046":"Wexner scores","8047":"Blood loss","8048":"Lean tissue mass","8049":"Area occupied by muscles","8050":"End-tidal CO2","8051":"Partial pressure of CO2","8052":"Fat mass if +20% body fat","8053":"Hospital stay","8054":"Platelet function","8055":"ACR20 response rate","8056":"Trunk fat if +20% body fat","8057":"Treatment-emergent adverse events","8058":"Diabetic ketoacidosis","8059":"PAID questionnaire fear of fypoglycemia ","8060":"Food intake (lunch) in women","8061":"Food intake (lunch) in men","8062":"Late luminal loss","8063":"Binary restenosis","8064":"Abdominal pain improvement ","8065":"Glycaemic response","8066":"Sennoside needed","8067":"Increases in hemoglobin when GFR 60 to <90 mL\/min","8068":"Increases in hemoglobin when GFR <15 mL\/min","8069":"Symbol\u2013Digit Modalities Test improvement ","8070":"6-Minute Walk improvement ","8071":"Patient assessed symptoms","8072":"Physician-assessed moderate\/marked arm oedema","8073":"T-wave amplitude","8074":"Esomeprazole Max concentration","8075":"Esomeprazole half\u2010life","8076":"Blood transfusion interval","8077":"Complete blood count measures","8078":"Metabolic panel","8079":"Heart rate","8080":"Percentage of cracks","8081":"Percentage of cracks","8082":"Proliferative hepatocyte number","8083":"White blood cell count","8084":"White blood cell count","8085":"Hemodiastase levels","8086":"Performance","8087":"over the course of the exposure period maximum perpendicular error (MPE) decrease - movement in different workspace locations","8088":"IL-6 mRNA response","8089":"Need for borrowing ","8090":"Admission rates","8091":"Admission rates","8092":"New hip fractures","8093":"Adverse effects on the healing of fractures","8094":"Cure rate","8095":"Treatment-related serious adverse events ","8096":"Activities of daily living","8097":"Symptom improvement ","8098":"SF-36 bodily pain score improvement ","8099":"gestational weeks at delivery","8100":"Tibial cartilage volume loss","8101":"birth weight","8102":"Muscle hardness","8103":"State-Trait Anxiety Inventory-I","8104":"protective temephos effect","8105":"mandibular opening in temporomandibular joint (TMJ) disorders 90 days after starting treatment","8106":"pre-treatment pain intensity","8107":"additional benefit in hearing rehabilitation","8108":"actively engaged","8109":"Hamilton Rating Scales for Depression (HRSD) scores","8110":"Montgomery-Asberg Depression Rating Scale (MADRS) scores","8111":"activities of daily living measured with the FAI, week 8","8112":"functional balance performance scores of the patients at week 4","8113":"activities of daily living measured with the FAI, week 4","8114":"response rate","8115":"response rate","8116":"response rate by age","8117":"mindfulness","8118":"pain","8119":"disability","8120":"child weight","8121":"perceived stress score","8122":"further revascularization","8123":"rehospitalization","8124":"intensity of pain","8125":"function accounting baseline for moderate dysfunction","8126":"superior control","8127":"Systolic blood pressure reduction","8128":"time to complete the simple model","8129":"Symptom-free days","8130":"degradation in clinical success - moderate degenerative lumbar spinal stenosis.","8131":"EI (Effectiveness Index) for Quality of life immediately after treatment","8132":"Annual exacerbation rate","8133":"Reaching blood pressure target","8134":"EI (Effectiveness Index) for Fugl-Meyer Assessment of Sensorimotor Recovery after Stroke (FMA) 6 months later","8135":"bradykinin (BK) induced relaxation","8136":"Vasorelaxation to adenosine diphosphate (ADP) in LAD","8137":"Balance ability after 4 weeks","8138":"Balance ability after 8 weeks","8139":"Vasorelaxation to sodium nitro-prusside (SNP) in LAD","8140":"QT effect (mean \u0394\u0394QTcF)","8141":"Walking speed after 8 weeks","8142":"vaginal practices: insertion of dry or absorbent materials, at baseline","8143":"Malondialdehyde","8144":"\u226550% reduction in mean pain","8145":"\u226550% reduction in mean pain","8146":"Significant adverse events","8147":"Urinalysis abnormalities ","8148":"Warwick Edinburgh Mental Wellbeing Scale (WEMWBS) scores intervention effect","8149":"Length of the procedure","8150":"Mean arterial blood pressure after procedure","8151":"Blood loss","8152":"After 12-week interventions, the mental control subscores","8153":"efficiency in cognitive control","8154":"Further antibiotic use","8155":"Severe jaundice","8156":"Overall mortality","8157":"baseline sex distribution","8158":"post-test - written exam","8159":"baseline written exam score","8160":"Time for \u22653 and \u22654 intragastric pH ","8161":"Time for \u22653 and \u22654 intragastric pH ","8162":"Time for \u22653 and \u22654 intragastric pH ","8163":"Weight loss","8164":"(DBP) diastolic blood pressures at 1, 3, and 5 minutes after intubation","8165":"extubation time","8166":"Pursuing exercising at least 3 times a week","8167":"Pursuing exercising at least 3 times a week","8168":"superior efficacy","8169":"Cardiovascular outcomes","8170":"promising pain relief treatments for painful DNP","8171":"Pain VAS improvement ","8172":"fecal egg counts","8173":"nematodosis infection","8174":"effectiveness - nasal blockage type","8175":"Tenderness on maxillary sinus","8176":"mortality","8177":"Tenderness on ethmoid sinus","8178":"severe anemia","8179":"Adverse events","8180":"loss of glycemic control - 10\u201317 years old with recent-onset type 2 diabetes and \u226580% adherence to metformin therapy for \u22658 weeks","8181":"significant depressive symptoms at baseline - 10\u201317 years old with recent-onset type 2 diabetes and \u226580% adherence to metformin therapy for \u22658 weeks","8182":"Adherence to medication - 10\u201317 years old with recent-onset type 2 diabetes and \u226580% adherence to metformin therapy for \u22658 weeks","8183":"Shear bond strength","8184":"Shear bond strength","8185":"higher weight at follow-up","8186":"long-term predictors for favorable course","8187":"Quality of life total score","8188":"higher weight at end of intervention","8189":"medical cost","8190":"clinicopathological findings","8191":"efficacy in adolescents with ADHD","8192":"scores of optimistic factor - before the treatment (individuals diagnosed with a malignant tumor)","8193":"Karnofsky Performance Status (KPS) of patients - (individuals diagnosed with a malignant tumor)","8194":"degree of suicidal ideation of patients - (individuals diagnosed with a malignant tumor)","8195":"AE profile (patients with COPD)","8196":"trough FEV1 at week 8 in intent-to-treat (patients with COPD)","8197":"invested effort for the lowest Stake","8198":"intraoperative complications","8199":"treatment acceptability in women with primary dysmenorrhea","8200":"tapping task","8201":"maintenance stage of smoking cessation","8202":"levels of anxiety","8203":"baseline characteristics of the National Lung Screening Trial (NLST) population","8204":"Duration of parotid salivary flow following the use of TENS","8205":"Duration of parotid salivary flow following the use of TENS","8206":"2D healing at 4 weeks","8207":"mean anxiety score in control group","8208":"good adherence","8209":"Most preferred method; normal vaginal delivery","8210":"Score: quality of life - COPD patients due to exposure to sulfur mustard (SM) and refractory to conventional therapies","8211":"5-year overall survival rates (early breast cancer)","8212":"Score: night time awaking due to dyspnea improvement - COPD patients due to exposure to sulfur mustard (SM) and refractory to conventional therapies","8213":"Score: night time awaking due to cough improvement - COPD patients due to exposure to sulfur mustard (SM) and refractory to conventional therapies","8214":"low exploitation condition: receiving the first instruction","8215":"metastasis-free survival (early breast cancer)","8216":"Mean length of hospital","8217":"incidence of treatment-emergent serious adverse events (TE-SAEs) at 1-month postinfusion","8218":"short physical performance battery (SPPB) total score at 6 months","8219":"Nagoya University Micro Suturing Assessment System (NUMSAS) scores","8220":"length score - Nagoya University Micro Suturing Assessment System (NUMSAS) scores","8221":"stain intensity after 14 days","8222":"participants who reached target HbA1c after 6 months of treatment","8223":"duration of illness (schizophrenia patients)","8224":"accuracy of the cognitive tasks","8225":"differences in the accuracy","8226":"cecum and terminal ileum was intubated","8227":"SNPs on chromosome 11 (rs2514036, rs948445, and rs2514037) provided evidence for association reaching genome\u2010wide significance for ASBP (systolic blood pressure) response","8228":"Quality of sleep the night before colonoscopy","8229":"drug\u2010treated diabetes","8230":"mixed and cohesive failures were the most common fracture modes","8231":"storage time had significant effect on bond strength","8232":"subcutaneous injections of erythropoietin - patients with chronic hepatitis C with HCV genotype 6","8233":"relapse rates - patients with chronic hepatitis C with HCV genotype 6","8234":"required additional ablation","8235":"CHADS2 score","8236":"Basal HB levels","8237":"family history of lung cancer","8238":"Mean age of the entire cohort","8239":"Smoking patterns","8240":"history of selected diseases, including respiratory, cardiovascular and malignant diseases, as well as family history of cancer","8241":"favorite delivery method; before performing the act of consultation ","8242":"mean depression score","8243":"control group's cortisol levels","8244":"mean anxiety score in intervention group","8245":"age","8246":"mean score of attitude in women in all 3 groups","8247":"6-minute walk test (6MWT) at 6 months","8248":"Total inpatient time","8249":"Pain ","8250":"Transcutaneous carbon dioxide","8251":"Respiratory rate","8252":"End-expiratory lung volume","8253":"FEV1 ","8254":"Triglycerides","8255":"Body fat mass","8256":"Body fat mass","8257":"Body fat mass","8258":"Energy intake","8259":"Epidermis contamination","8260":"Dermis contamination","8261":"Tissue coring with needle straight insertion ","8262":"Portal lactate","8263":"Proprioceptive drift effect during synchronous stroking","8264":"Embryos obtained","8265":"Fever \u226538\u00b0C","8266":"Median visual analogue scale","8267":"pursued follow up","8268":"Success rate at 6 months ","8269":"Vaccine-related serious adverse events","8270":"M1 slope gap","8271":"Adverse events","8272":"Stop-signal processing times","8273":"Go processing-times","8274":"No-signal reaction time","8275":"Total quality of life","8276":"Digit symbol coding speed","8277":"Core temperature gradient","8278":"Area of the 95% confidence ellipse with the eyes open","8279":"Anterior posterior displacement with the eyes closed","8280":"Rhinorrhea ","8281":"Fracture resistance","8282":"Fracture resistance","8283":"Morning peak expiratory flow","8284":"Evening peak expiratory flow","8285":"Risk of maternal parasitaemia","8286":"Blood pressure","8287":"Miglustat Concentration Max","8288":"Danger of smoking occasionally perception","8289":"Kujala score on patellofemoral pain","8290":"Estimation of e-cigarette usage","8291":"Estimation of e-cigarette usage","8292":"Estimation of e-cigarette usage","8293":"Cough","8294":"Fibromyalgia Impact Questionnaire scores","8295":"P3a amplitude","8296":"Blood pressure","8297":"Self-report questionnaire","8298":"N1 amplitude ","8299":"Stone- free rate","8300":"Operative time","8301":"Time for return to daily activities ","8302":"Anticholinergic drug scale improvement ","8303":"Intervention costs ","8304":"AUC0\u201324 h for EPA","8305":"AUC0\u201324 h for DHA ","8306":"AUC0\u201324 h for DHA ","8307":"Willingness to eat carrot","8308":"Sugar-sweetened beverages intake during the weekend (girls)","8309":"Brain-derived neurotrophic factor at skin closure ","8310":"Weight","8311":"Negative Urgency\t","8312":"Lack of Perseverance\t","8313":"Stress ","8314":"Displeasure ","8315":"Coronal dye penetration","8316":"ACR20","8317":"Hemoglobin ","8318":"Bilirubin ","8319":"Psychological symptoms ","8320":"Systolic blood pressure ","8321":"Cholesterol ","8322":"Satisfaction score of the patients","8323":"Time to Optimal postactivation potentiation ","8324":"Intubation scores or grimace scores","8325":"Uric acid","8326":"Diastolic blood pressure ","8327":"Visual Analog Score for post-operative pain","8328":"Blood urea nitrogen ","8329":"Tracheobronchial colonization","8330":"survival rate","8331":"mean number of pulse oximetry alarms","8332":"baseline","8333":"photophobia scores","8334":"Pulmonary muscle strength","8335":"Corneal haze","8336":"Structured Meal Setting","8337":"Lenght of stay in the ICU","8338":"Tissue hydration","8339":"Anthropometric measurements","8340":"Covert Restriction","8341":"Persuasive Feeding","8342":"verbal rating scale (VRS)","8343":"percentage energy from fat","8344":"PCV7 serotypes 4, 9V, 18C, and 23F","8345":"total Treg numbers","8346":"The mean blood flows in the hepatic vein , portal vein and artery","8347":"over the course of the exposure period maximum perpendicular error (MPE) decrease - cursor color (red or blue)","8348":"Plasma lipopolysaccharide (LPS) concentrations in the hepatic vein, portal vein and artery","8349":"serum amyloid A (SAA), haptoglobin (Hp) and LPS-binding protein (LBP) in peripheral blood","8350":"alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (T-BIL)","8351":"Wound satisfaction score","8352":"TLR4 protein expression","8353":"loco-regional or distant failure rates","8354":"The median overall survival (OS)","8355":"weight loss, first 6 months","8356":"weight loss, first 6 months","8357":"hypoglycemia event","8358":"weight loss, first 6 months","8359":"Severity emotional pain","8360":"Severity Current pain","8361":"mean villous height In HIV negative patients","8362":"overall fruit intake","8363":"serious adverse events","8364":"higher grape intake","8365":"mean villous height , mean villous area, and median villous perimeter In HIV positive patients","8366":"Platelet number","8367":"Wheezing or whistling in chest","8368":"follow up advised","8369":"Burning or watery eyes","8370":"Back pain","8371":"torticollis overall assessment (TOA), congenital muscular torticollis (CMT)","8372":"average head tilt angle","8373":"hazard ratio (HR) of Antibiotic-associated diarrhea (AAD)","8374":"Visceral fat and liver weight gain","8375":"AAD cases per year","8376":"Level of confidence to identify a child with autism","8377":"changed initial antibiotics","8378":"Diagnosis retention performance percentage scores","8379":"Antibiotic treatment had to be stopped","8380":"Overall total per patient costs (including intervention costs)","8381":"Reductions in The Beck Depression Inventory II (BDI-II) scores","8382":"mean score of anxiety","8383":"Cutaneous capillary blood flow","8384":"Postcapillary Venous Filling Pressure","8385":"Cognitive status improvement ","8386":"The motor recovery to Bromage scale 1","8387":"Time for rescue analgesia","8388":"Blood glucose","8389":"Cumulative blood glucose","8390":"Bone resorption","8391":"Dual-energy x-ray absorptiometry","8392":"Femoral midshaft peripheral quantitative computed tomography changes","8393":"The augmentation index and augmentation pressure","8394":"Strength","8395":"flow-mediated dilation (FMD)","8396":"Body fat","8397":"Total serum cholesterol","8398":"Energetic","8399":"Verbal fluency improvement ","8400":"Not Hungry","8401":"Interest\/enjoyment","8402":"Not Sluggish","8403":"Risk of prostate cancer","8404":"effects on renal function","8405":"Pain","8406":"Standing (proportion)","8407":"left ventricular mass index (LVMi)","8408":"The effectiveness of the intervention ","8409":"The effectiveness of the intervention ","8410":"Osteocalcin ","8411":"Maximal bilateral isometric strength (MVC)","8412":"High-energy snack intake","8413":"serum concentrations of testosterone","8414":"Vegetable intake","8415":"Vegetable intake","8416":"Time to first postoperative analgesic requirement","8417":"Hypotension\/bradycardia","8418":"Local lipolysis ","8419":"improvement of QOLRAD-J (Japanese translation of Quality of Life in Reflux and Dyspepsia)","8420":"improvement of Epworth Sleepiness Scale (ESS)","8421":"Lipid oxidation rates","8422":"time to bloody stools","8423":"Improved Clinical Global Impressions-I","8424":"Stress","8425":"Occurrence of two adverse events","8426":"Phosphorus ","8427":"Iron","8428":"E-selectin","8429":"E-selectin","8430":"E-selectin","8431":"Postural Assessment Scale for Stroke Patients score","8432":"Speed of work","8433":"Total cholesterol concentrations","8434":"HDL cholesterol ","8435":"Total hemoglobin","8436":"Heart rate","8437":"Patient Global Assessment of Disease Activity improvement ","8438":"Health Assessment Questionnaire-Disability Index improvement ","8439":"Medical Outcomes Survey sleep scale improvement ","8440":"Running time","8441":"Quality-of-life improvement after 6 months","8442":"Use of painkillers","8443":"Patient satisfaction","8444":"Vomiting episodes during stay","8445":"Overall oral rehydration therapy failure","8446":"5-10 yr oral rehydration therapy failure","8447":"Fatigue severity","8448":"Fatigue severity ","8449":"Recruitment for RCT","8450":"Brachial\u2013ankle pulse wave velocity (left side)","8451":"Onset of action speed","8452":"Time to maximum glucose infusion rate","8453":"mortality","8454":"miocardial infarction","8455":"Injection of local anesthetic time","8456":"function without baseline","8457":"function accounting baseline for severe dysfunction","8458":"+5 days bleeding","8459":"Hospital Anxiety and Depression Scale completeness of questionnaire ","8460":"Diastolic blood pressure reduction","8461":"Ever practicing floor tummy time ","8462":"Practicing tummy time mostly on the floor","8463":"Asthma Quality of Life Questionnaire score improvement at 28 weeks","8464":"Executive IQ scores","8465":"Dandruff clinical severity scores","8466":"Balance ability 4 weeks","8467":"Sebum secretion","8468":"Lesion extent clinical severity scores","8469":"Lactic acid stinging test scores","8470":"Logarithmic-scaled reactive hyperemia index","8471":"Ovulation induction (mid\u2010luteal progesterone \u22659.4 ng\/mL)","8472":"Adverse events ","8473":"Deaths","8474":"Self-efficacy","8475":"Time to first rescue analgesics","8476":"Postoperative infection","8477":"Time to first rescue analgesics","8478":"Bronchodilation after 1 hour","8479":"Bronchodilation after 4 hours","8480":"Deaths ","8481":"Bronchodilation after 1 hour","8482":"Total medication costs after 1 year","8483":"Bronchodilation after 4 hours","8484":"Total medication costs after 3 years","8485":"ICU mortality","8486":"Non-Allergic medication costs after 3 years","8487":"Time for \u22653 and \u22654 intragastric pH ","8488":"Grade III\/IV stomatitis ","8489":"Time for \u22653 and \u22654 intragastric pH ","8490":"Bispectral index","8491":"Body size dissatisfaction","8492":"Body shape concerns","8493":"Septal mitral annular velocity during systole after 3 minutes","8494":"Self-esteem","8495":"Time to first bowel movement","8496":"Hospital stay","8497":"Cumulative opioid consumption","8498":"Cardiovascular outcomes","8499":"Adverse effects","8500":"AUC for the increment in plasma calcium","8501":"Plasma calcium concentration after 240 minutes ","8502":"Pain","8503":"Respiratory adverse events","8504":"Tenderness on frontal sinus","8505":"Postbreakfast plasma glucose","8506":"Postbreakfast plasma insulin ","8507":"Postbreakfast plasma glucose","8508":"Postbreakfast plasma insulin ","8509":"48-h glucose concentration","8510":"Daily activity","8511":"pNN50 ","8512":"Operation duration","8513":"Achieving vaginal birth within 12 hours","8514":"Lactadherin+ CD14+ HMGB1+","8515":"intervention group's cortisol levels","8516":"suction fluid during the procedure","8517":"5-year metastasis-free survival rates (early breast cancer)","8518":"levels of anxiety","8519":"sustained virological response (SVR) Rates - patients with chronic hepatitis C with HCV genotype 6","8520":"exploitation to exploration","8521":"exploitation to exploration","8522":"exploitation to exploration","8523":"degree of conversion (DC %)","8524":"range of compliance (patients with COPD)","8525":"cranial nerve palsies - patients with carotid artery stenosis","8526":"incidence of treatment-emergent serious adverse events (TE-SAEs) at 1-month postinfusion","8527":"longer procedure time","8528":"Elevated Plasma lipid peroxides (MDA) levels","8529":"6-minute walk test (6MWT) at 6 months","8530":"amount of plaque formed at end of week 1 and 2","8531":"amount of plaque formed at end of week 1, 2 and 3","8532":"nitric oxide contents","8533":"Elevated Plasma lipid peroxides (MDA) levels","8534":"all males","8535":"adhesive failure was the most common fracture mode","8536":"interleukin-1\u03b2","8537":"survival rate","8538":"alveolar collapse","8539":"collagen fiber content","8540":"left atrial volume index","8541":"sinus node dysfunction","8542":"GLUT-1 expression","8543":"vascular endothelial growth factor (VEGF) expression","8544":"Gastritis in the remnant stomach","8545":"time taken to perform the reconstruction","8546":"total surgery time","8547":"efficacy in adolescents with ADHD","8548":"scores of despair factor - before the treatment (individuals diagnosed with a malignant tumor)","8549":"odds of experiencing a clinically meaningful increase (100 mL or more) from baseline in trough FEV1 at week 8 (patients with COPD)","8550":"invested effort for the higher Stake","8551":"invest more effort","8552":"total effective rate","8553":"time of cyst treatment","8554":"manual dexterity ability prior to the intervention","8555":"manual dexterity scores after intervention","8556":"threading task","8557":"highly nicotine dependent","8558":"participating female","8559":"number of apnea-hypopnea episodes","8560":"percentage of patients receiving neuromuscular-blocking agents","8561":"number of underinflation episodes","8562":"percentage of patients receiving sedation","8563":"Duration of parotid salivary flow following the use of TENS","8564":"drug-related dehydration","8565":"hypercalcemia","8566":"good adherence","8567":"Lipid Profile in people with type 2 diabetes mellitus (T2DM)","8568":"platelet-monocyte activation in people with type 2 diabetes mellitus (T2DM)","8569":"HbA1c in people with type 2 diabetes mellitus (T2DM)","8570":"disease-free survival (early breast cancer)","8571":"increased serum bilirubin concentration - immediately after exercise","8572":"increased protein carbonyls (PC) concentration","8573":"increased total antioxidant capacity (TAC) - immediately after exercise","8574":"no motor improvement - cases with complete TSCI (traumatic spinal cord injury)","8575":"suturing test completion time","8576":"suturing test completion time","8577":"Average pre-injection self-monitored plasma glucose (SMPG) decrease","8578":"overall effect of onset age on negative symptoms (schizophrenia patients)","8579":"improvement in positive or negative symptoms (schizophrenia patients)","8580":"anemia rates - patients with chronic hepatitis C with HCV genotype 6","8581":"Positive And Negative Symptoms Scale (PANSS)","8582":"Extrapyramidal symptoms (EPS), prolactin levels and weight","8583":"VEGF-D level at 12 months","8584":"change in the kidney tumor size (sum LD)","8585":"disability (Neck Disability Index)","8586":"Physical Health State","8587":"Mental Health State","8588":"Quality of Life (5 dim) EuroQoL","8589":"Quality of Life VAS EuroQoL","8590":"progression-free survival (PFS)","8591":"progression-free survival (PFS) and B. overall survival (OS)","8592":"waist circumference","8593":"systolic blood pressure","8594":"resting heart rate","8595":"depression level and quality of life index","8596":"dietary pattern on carbohydrate, protein, dietary fiber, soluble fiber, sugar, fat, and cholesterol","8597":"AIDS progression\/death","8598":"progression or death but viral load \u226550 copies\/ml; progression or death and viral load of <50 copies\/ml at week 48","8599":"The time to a CD4+ count >50 cells\/mm3","8600":"the mean drain removal time","8601":"ineffective drainage","8602":"choice of drinks","8603":"Explicit liking","8604":"Expected satiety","8605":"consuming","8606":"consuming","8607":"The explicit wanting ratings","8608":"success rate","8609":"general characteristics","8610":"dissecting skin and muscles, pleural opening, and overall performance","8611":"Estimated median procedure time","8612":"The difficulty grading","8613":"lower limb proprioception function","8614":"the rate of average trace error on left lower limb","8615":"cardiorespiratory endurance","8616":"flexibility","8617":"explosive force of lower limb","8618":"attention","8619":"Lumbar muscle strength","8620":"vital capacity, blood pressure, heart rate, hand grip force, self-symptom intensity, stress, self-efficacy, quality of life, and quality of sleep","8621":"adverse event","8622":"The follicular fluid (FF) level of c-kit protein","8623":"GDF-9 expression","8624":"c-kit expression in unfertilized mature oocytes","8625":"GDF-9 expression","8626":"c-kit expression in unfertilized mature oocytes","8627":"BMP-15 protein in the mature unfertilized oocytes and GV oocytes","8628":"overall benefit of oral insulin","8629":"hazard rate after cessation of therapy","8630":"rate of type 1 diabetes development","8631":"plasminogen, sVCAM, d-dimer, and fibrinogen levels","8632":"sVCAM and d-dimer ","8633":"The inflammatory biomarker hs-CRP during the first 4 weeks","8634":"hs-CRP levels at Weeks 4 and 24","8635":"inflammatory biomarker interleukin-6 at week 48","8636":"Levels of sVCAM-1, a biomarker of endothelial activation, and d-dimer , a thrombotic biomarker","8637":"Fibrinogen","8638":"Fibrinogen","8639":"plasminogen at 12 weeks","8640":"plasminogen at 24 week","8641":"plasminogen at 96 week","8642":"CDAI (Clinical Disease Activity Index)scores at 6 months","8643":"total sulfate, S-adenosylmethionine","8644":"glutathione, ratio of oxidized glutathione","8645":"nitrotyrosine, ATP , NADH , and NADPH","8646":"Parental Global Impressions-Revised, and on the subscores for Hyperactivity, Tantrumming , Overall , and Receptive Language","8647":"Physician Global Assessment (PGA)","8648":"The RAND SF-36 Energy\/fatigue and Emotional well-being scores","8649":"Fatigue Severity Scale (FSS), SLE Disease Activity Index (SLEDAI)","8650":"Erythrocyte sedimentation rate ","8651":"serum IL-12","8652":"serum IL-13","8653":"Emotional well-being","8654":"uncorrected visual acuity (UCVA)","8655":"best corrected visual acuity (BCVA)","8656":"uncorrected visual acuity (UCVA)","8657":"best corrected visual acuity (BCVA)","8658":"UCVA or BCVA","8659":"intraocular pressure (IOP)","8660":"mean endothelial cell count and coefficient of variation (CV)","8661":"The hexagonal endothelial cell","8662":"The mean blood glucose concentration","8663":"The mean blood glucose concentration","8664":"area under the curve (AUC) for pain","8665":"opioid consumption or rate of healing","8666":"heart rate and blood pressure","8667":"The Tinnitus Handicap Inventory (THI) score","8668":"The Tinnitus Handicap Inventory (THI)","8669":"The Tinnitus Handicap Inventory (THI)","8670":"Mean of postoperative pain score","8671":"Mean of additive analgesic use during 12 h after recovery","8672":"Mean of additive analgesic use during 12-24 h after recovery","8673":"Mean of vomiting frequency and metoclopramide use","8674":"Excellent and good satisfaction score","8675":"circulating endothelial cells (CECs) after 4 and 6 weeks","8676":"circulating endothelial cells (CECs) after 4 and 6 weeks","8677":"circulating endothelial cells (CECs) after 4 and 6 weeks","8678":"Daily pedometer determined steps","8679":"total costs","8680":"two quality of life domains (role-physical and general health perceptions)","8681":"SF-36 physical functioning, SF-36 role-physical, SF-36 energy\/fatigue, SF-36 general health, and SF-36 mental health","8682":"health competence","8683":"perceived stress, mood disturbance, and improvements in other quality of life domains (SF-36 mental health, physical functioning, role-emotional, social functioning, and SF-36 energy\/fatigue","8684":"Salivary TF","8685":"Salivary TF","8686":"bleeding time","8687":"Swelling","8688":"serum FGF23 levels","8689":"serum FGF23 levels","8690":"serum calcium level","8691":"serum phosphorus level","8692":"concentrations of 25(OH)D","8693":"serum parathyroid hormone (PTH) levels","8694":"anteroposterior, mediolateral and total postural sway","8695":"anteroposterior, mediolateral and total postural sway","8696":"dynamic balance","8697":"dynamic balance","8698":"The wound healing rate","8699":"wound healing time","8700":"S. aureus with density more than 1 \u00d7 105 CFU\/ml on day 3, 7, 14","8701":"the number of microvessels","8702":"vascular endothelial growth factor (VEGF)","8703":"Intraoperative rescue sedation by propofol and postoperative rescue analgesia by acetaminophen","8704":"the time of the postanesthesia care unit (PACU) stay","8705":"bradycardia","8706":"the reintubation rates related to noninvasive ventilation (NIV) failure","8707":"duration of invasive mechanical ventilation ","8708":"the reintubation rate","8709":"total ICU length of stay","8710":"transepidermal water loss (TEWL)","8711":"transepidermal water loss (TEWL)","8712":"transepidermal water loss (TEWL)","8713":"The percentage of subjects experiencing at least one AE","8714":"mean HbA1c and fasting plasma glucose (FPG)","8715":"mean 2-hour postprandial plasma glucose (2hPG) changes","8716":"mean BMI","8717":"mean declines in waist circumference (WC)","8718":"proportion of patients with glycosylated hemoglobinA1c (HbA1c) \u22647.0%","8719":"total cholesterol [TC]","8720":"high-density lipoprotein cholesterol [HDL-C]","8721":"low-density lipoprotein cholesterol [LDL-C] and triglycerides [TG]","8722":"BP (systolic blood pressure [SBP], diastolic blood pressure (DBP))","8723":"mean reactive oxygen species (ROS) and MDA","8724":"SOD and GSH-Px","8725":"vital capacity [VC]%, forced vital capacity [FVC]%, forced expiratory volume in 1 second [FEV1]%, peak expiratory force [PEF]%, maximal voluntary ventilation [MVV]%, total lung capacity [TLC]%, forced expiratory volume in 1 second\/forced vital capacity [FEV1\/FVC%], and diffusing capacity for carbon monoxide of lung [DLCO]%, and diffusing capacity for carbon monoxide of lung\/unit volume [DLCO\/VA]%)","8726":"vital capacity [VC]%, forced expiratory volume in 1 second [FEV1]%, maximal voluntary ventilation [MVV]%, total lung capacity [TLC]% in the group having HbA1c levels \u22658.0","8727":"Serious Adverse events","8728":"Vascular Endothelial Growth Factor (VEGF)","8729":"interleukin-8 (IL-8)","8730":"IL-6 responses","8731":"IL-6 responses","8732":"IL-6 responses","8733":"agression","8734":"Nausea","8735":"Nausea","8736":"SYTO 13+ CD45+\t","8737":"Streptococcus mutans count","8738":"Streptococcus mutans count","8739":"Streptococcus mutans count","8740":"Triglyceride ","8741":"Coughing ","8742":"Agitation","8743":"Progesterone profile","8744":"Success rate at 12 months ","8745":"M1 angle","8746":"Symptoms of depression","8747":"Aesthetic appearance improvement by day 14","8748":"Nor-adrenaline plasma level","8749":"Nor-adrenaline plasma level","8750":"Systolic blood pressure ","8751":"Core temperature","8752":"Blood glucose ","8753":"Anterior posterior displacement with the eyes closed","8754":"Medial lateral displacement with the eyes closed","8755":"Glycemic level ","8756":"Glycemic level ","8757":"Fracture resistance","8758":"Gd-enhancing lesions on T1-weighted images","8759":"Cure time","8760":"Miglustat Time to maximum concentration ","8761":"Potency ","8762":"Hemodynamic response to laryngeal mask airway insertion ","8763":"Sore throat at recovery","8764":"Sore throat 24 hrs after surgery ","8765":"Heart rate","8766":"Intensity of morning pain","8767":"Hours of pain per day","8768":"Pressure value in the anterior foot region","8769":"EQ-5D index","8770":"Time spent on TV\/DVD during the weekend (girls)","8771":"Walking time per day.","8772":"BMI","8773":"Respiratory rate depression ","8774":"Lack of Premeditation","8775":"Intraoperative sedation scale","8776":"Pain ","8777":"Epstein Barr viremia","8778":"Citomegalovirus viremia","8779":"Disease Activity Score of 28 joints \u2013 C\u2010reactive protein","8780":"Symptoms during exercise","8781":"Rifaximin peak plasma concentration","8782":"Area under curve 0-t","8783":"Cumulative urinary excretion","8784":"Bone alkaline phosphatase after 36 months","8785":"Cervicobrachial pain intensity","8786":"Improvement in physical function","8787":"PANSS-total scores at week 4 and 8","8788":"PANSS-negative scores at week 4 and 8","8789":"Risk of death by cardiovascular causes","8790":"Renal function parameters","8791":"Hip bone mass density at weeks 24 and 48","8792":"Baseline characteristics","8793":"Reward For Behaviour","8794":"Medication compliance at 30 months","8795":"Hospitalization","8796":"anti-Hib IgG levels","8797":"Gastric pH level after tramadol","8798":"\u03b4 wave, the \u03b8 wave, the \u03b1 wave, the \u03b2 wave, and the sensory motor rhythm (SMR)","8799":"mean HbA1c","8800":"mean HbA1c","8801":"weight loss, first 6 months","8802":"Antiemetics use ","8803":"Mucus","8804":"Results for VAS scores of Hunger, Fullness, Desire to Eat, and Prospective Consumption","8805":"LDL cholesterol levels","8806":"Headache","8807":"expression profile of miRNA in plasma","8808":"Arterial elasticity","8809":"Burns","8810":"body weight gain and food efficiency ratio","8811":"body weight gain and food efficiency ratio","8812":"total work during knee joint extension","8813":"training had the most beneficial effect","8814":"Co-morbidities retention performance percentage scores","8815":"mean score of anxiety","8816":"Amyloid betas 1-40 ","8817":"severity of nausea","8818":"Femoral toughness","8819":"drowsiness and anxiety","8820":"rescue analgesia (morphine) postoperatively","8821":"more likely to be unemployed","8822":"Strength","8823":"Other beneficial policies - Moving around allowed in 2nd stage","8824":"cumulative recurrence rate reduction due to adjuvant chemotherapy (CMF)","8825":"Verbal memory improvement ","8826":"Working memory improvement ","8827":"frequency of tumours with diameter of 2cm or less (T1) and larger tumours (T2\/T3)","8828":"decline in galvanic skin response (GSR) - physiological reactions to the threat of layoffs","8829":"differences at baseline between groups for IQ","8830":"reduction in negative affect (NA)","8831":"Pain","8832":"mean load","8833":"Undercarboxylated osteocalcin","8834":"Fruit intake","8835":"Fruit intake","8836":"Pre-intervention characteristics","8837":"Analgesic consumption","8838":"Health facility delivery","8839":"Mean arterial blood pressure","8840":"Transient-Evoked Otoacoustic Emissions (TEOAE) pure-tone average (PTA)","8841":"Systemic lipolysis ","8842":"improvement of Pittsburg Sleep Quality Index (PSQI)","8843":"pure-tone average (PTA)","8844":"The frequency of knowledge of elder abuse after the intervention","8845":"pAMPK\/AMPK ratio in the hippocampus ","8846":"Calcium","8847":"IL-10","8848":"IL-10","8849":"Percentage of patients achieving an SLE Responder Index 4","8850":"LDL- C","8851":"British Isles Composite Lupus Assessment improvement","8852":"Pain interference with function after 3 days","8853":"Muscle tissue oxygenation","8854":"patient immobility","8855":"hemodynamic stability","8856":"HbA1c","8857":"frequency of conjunctivitis","8858":"Core temperature","8859":"Sheehan Disability Scale overall improvement ","8860":"Insulin dose","8861":"Sheehan Disability Scale overall improvement ","8862":"Sheehan Disability Scale overall improvement ","8863":"Insulin like-growth factor 1","8864":"Forced Vital Capacity","8865":"therapeutic equivalence - Patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate (MTX) treatment","8866":"Adverse effects","8867":"time to new metastases in patients whose disease progressed due to new metastases in vital organs (CNS, lungs, or liver) - women with advanced\/metastatic breast cancer (MBC)","8868":"Mortality ","8869":"Length of stay","8870":"Quality of life","8871":"Isometric maximum force in the tibialis anterior muscle","8872":"Electromyographic amplitude of gastrocnemius medialis","8873":"stabilized on SSRIs (selective serotinin reuptake inhibitors) - in social anxiety disorder (SAD)","8874":"Progression-free survival (children with acute lymphoblastic leukaemia who relapsed on present therapeutic regimens)","8875":"Total antioxidant status","8876":"Postoperative complication","8877":"Intraoperative complication","8878":"Persistent hematuria after 1 week","8879":"Response rate before reminder","8880":"Overall completeness of questionnaire ","8881":"Parenting practices","8882":"changes in C-terminal telopeptide of type I collagen (CTX)","8883":"Tummy time practice","8884":"Pain reduction","8885":"Use of an infant car seat when not traveling","8886":"Erythema clinical severity scores","8887":"relieving factors in reversible inguinal hernia","8888":"Postoperatively hematocrit ","8889":"effective in the treatment of reversible inguinal hernia","8890":"average flow estimation accuracy","8891":"Revisiting the program","8892":"Schirmer test score","8893":"Ovarian cyst","8894":"Corneal score\t","8895":"Total analgesic consumption (first day)","8896":"Gastrointestinal acute toxicity incidence","8897":"Glomerular filtration rate fall","8898":"Genitourinary acute toxicity incidence","8899":"Nausea ","8900":"Ambulatory motor index","8901":"Plasma calcium concentration after 240 minutes ","8902":"Failure rate ","8903":"Anxious symptoms ","8904":"Non- respiratory adverse events","8905":"Attentional Function","8906":"Muscle damage","8907":"Creatine kinase","8908":"Pain","8909":"Flexibility","8910":"Tenofovir serum concentrations","8911":"Headache","8912":"Weight","8913":"Weight Behavior Inventory score","8914":"Streptococcus mutans count","8915":"Analgesia improvement after 3 hours","8916":"Blood creatinine","8917":"Temperature","8918":"Respiratory rate","8919":"Agitation","8920":"Equilibrium ","8921":"Equilibrium ","8922":"Floppy eyelids","8923":"Analgesic consumption","8924":"Time to first analgesic requirement","8925":"VO2peak","8926":"Plasma apelin","8927":"Triglycerides","8928":"Total cholesterol","8929":"Postoperative swelling","8930":"Pain","8931":"Tolerance ","8932":"Systolic blood pressure ","8933":"Diastolic blood pressure ","8934":"Plaque levels","8935":"Waist circumference","8936":"Exercise capacity","8937":"HbA1c","8938":"Glycemic level ","8939":"QT interval ","8940":"QT interval ","8941":"Hypoglycemia ","8942":"Waist circumference","8943":"Triglycerides ","8944":"HDL cholesterol","8945":"Systolic blood pressure ","8946":"Side effects","8947":"Systolic blood pressure ","8948":"Distolic blood pressure ","8949":"New lesions on T2-weighted images ","8950":"Grey and white matter volumes","8951":"Number of relapse-free patients","8952":"Discontinuation of treatment ","8953":"Recurrence rate","8954":"Recurrence rate","8955":"Physical quality of life ","8956":"Physical pain","8957":"Energy ","8958":"Fatigue","8959":"Systolic blood pressure","8960":"Ramsay Sedation Scale score","8961":"Atropine requirements ","8962":"Episodes of pain per week","8963":"Gait pain","8964":"Pain while standing upright","8965":"Suicide ideation after 12 months ","8966":"Suicide ideation after 12 months ","8967":"Suicide ideation after 6 months ","8968":"Suicide ideation after 6 months ","8969":"Suicide ideation after 6 months ","8970":"Knowledge improvement ","8971":"Practice improvement ","8972":"HbA1c","8973":"Aronchick Scale score","8974":"Aronchick Scale score","8975":"Abdominal pain","8976":"Bloating","8977":"Sternocleidomastoid thickness ","8978":"Sternocleidomastoid thickness ","8979":"Adherence ","8980":"Anxiety ","8981":"Engagement in beneficial physical activity","8982":"Disability","8983":"Peripheral vitrectomy pain","8984":"Heart rate ","8985":"Total regimen-related toxicity","8986":"Regimen-related deaths","8987":"Epstein Barr virus associated diseases","8988":"Overall survival","8989":"Anemia ","8990":"C-Reactive Protein","8991":"C-Reactive Protein","8992":"Serum ferritin","8993":"IgA in Saliva","8994":"Rifaximin peak plasma concentration","8995":"Cumulative urinary excretion","8996":"Postoperative infection","8997":"Changes in levels of lipids (except low density lipoproteins) or fasting glucose","8998":"Adverse reactions","8999":"Cost-effectiveness","9000":"Severe hypoglycaemic events","9001":"Improvement in quality of life","9002":"Risk of death from PCa","9003":"Mortality rates","9004":"Rates of radical treatment","9005":"Risk of hospitalization due to heart failure or renal adverse events.","9006":"Lumbar spine bone mass density at weeks 24 and 48","9007":"Rate of re-hospitalizations","9008":"Medication adherence score (MAQ) and overall insight score (SAUMD) at the end of the study","9009":"Pain relief","9010":"Baseline characteristics","9011":"Staff training costs","9012":"Overall costs","9013":"Pain score 8 hours after the surgery","9014":"Brain relaxation scores","9015":"Recovery characteristics","9016":"Baseline characteristics","9017":"Baseline gastric pH level","9018":"Need of analgesic ","9019":"Oxygen delivery","9020":"Pressure-based haemodynamic variables","9021":"Biochemistry, O2 saturation, venous blood gas, and N-terminal pro B-type natriuretic peptide","9022":"Duration of clinical symptoms","9023":"Duration of hospitalization","9024":"BMI","9025":"Streptococcus mutans count","9026":"Streptococcus mutans count","9027":"Oxygen saturation","9028":"Equilibrium ","9029":"Mean arterial pressure ","9030":"Procedure time","9031":"Postoperative complications frequency ","9032":"Catheter-related problems","9033":"Pain","9034":"Heart Rate","9035":"Analgesic consumption","9036":"Pain score after 1 hour","9037":"Pain score after 1 hour","9038":"Adverse events","9039":"Carotid \u03b2-stiffness","9040":"Nitrite\/nitrate (NOx) concentrations","9041":"Vascular endothelial growth factor after 3 hours","9042":"Angiotensin-II after 3 hours","9043":"Infections","9044":"Aesthetic appearance improvement by day 7","9045":"Diastolic blood pressure ","9046":"Step counts ","9047":"Plaque levels","9048":"Plaque levels","9049":"Systolic blood pressure","9050":"Fasting glucose","9051":"Total lesion volume","9052":"Cure time","9053":"Cure time","9054":"Recurrence rate","9055":"Systolic blood pressure","9056":"Ramsay Sedation Scale score","9057":"Suicide ideation after 12 months ","9058":"Pressure value in the anterior foot region","9059":"Pressure value in the posterior foot region","9060":"Pressure value in the posterior foot region","9061":"Anterior-to-posterior ratio","9062":"Anterior-to-posterior ratio","9063":"Ottawa Bowel Preparation Scale score","9064":"Nausea","9065":"Sternocleidomastoid thickness ","9066":"Longus colli thickness ","9067":"Patient Health Questionnaire 9 scores","9068":"Patient satisfaction","9069":"Surgeon satisfaction","9070":"III-IV regimen-related toxicity","9071":"Grade 3 diarrhea","9072":"Serum ferritin","9073":"Area under curve 0-t","9074":"N-terminal telopeptide after 6 months","9075":"Baseline characteristics","9076":"Improvement in motion range","9077":"Prolactin levels in serum","9078":"Baseline characteristics","9079":"Risk of major adverse cardiovascular events","9080":"Risk of death by any cause","9081":"Reduction in glycated hemoglobin (HbA1c)","9082":"Bone turnover biomarkers (except osteoprotegerin)","9083":"Medication adherence score (MAQ) and overall insight score (SAUMD) at baseline","9084":"Unscheduled health care usage","9085":"General practitioner consultations","9086":"Duration of motor and sensory block","9087":"Onset time of anesthesia","9088":"Side effects","9089":"Pain score inmediately and 1 hour after the surgery","9090":"Arterial pressure","9091":"Heart rate during surgery","9092":"Heart rate 30 minutes after extubation","9093":"Incidence of pain","9094":"Cardiac index and systemic vascular resistance index ","9095":"Pulse rate","9096":"Baseline characteristics","9097":"Signs of pleural effusion and bronchopneumonia in chest X-rays","9098":"Reduction in levels and expression of matrix metalloproteinases ","9099":"Incidence of digestive symptoms","9100":"Baseline characteristics","9101":"Incidence of vomiting ","9102":"Rate of side-effects","9103":"Clinical attachment level","9104":"Visual analogue scale score improvement","9105":"Constant-Murley score","9106":"Oxidized LDL cholesterol","9107":"Levels of glucose, HbA1C, HDL cholesterol, or triglycerides","9108":"Total concentration of IgG1 and IgG3","9109":"total work for knee flexors at high angular velocity","9110":"laboratory investigations","9111":"fever","9112":"knowledge score","9113":"mean disability score related to work","9114":"dropouts","9115":"psychotomimetic symptoms","9116":"more likely to be diagnosed with a sexually transmitted infection","9117":"significant increase in heart rate (HR) in individuals exposed to the layoff notice","9118":"decline in galvanic skin response (GSR) during the post-task survey completion phase - physiological reactions to the threat of layoffs","9119":"participant began with similar GSR levels - physiological reactions to the threat of layoffs","9120":"reduction in negative affect (NA) 2 h after consuming","9121":"Among the prefabricated posts lowest bond strength","9122":"mean load","9123":"mean load","9124":"Among the prefabricated posts highest bond strength","9125":"abscess size - females with breast abscess","9126":"Hazard rate - females with breast abscess","9127":"timely care-seeking for newborn illness","9128":"high-frequency average (HFA)","9129":"The frequency of health promoting lifestyle after the intervention","9130":"The frequency of social support after the intervention","9131":"pAMPK\/AMPK ratio in the hippocampus ","9132":"In-stent late lumen loss at 9 months","9133":"no myocardial infarction (MI)","9134":"Referral uptake","9135":"triglycerides","9136":"Risk of being identified with any sleep disorder\t","9137":"Percentage of patients achieving an SLE Responder Index 4","9138":"non-HDL-cholesterol","9139":"main effects for drug, gum, group, or time block","9140":"Percentage of patients achieving an SLE Responder Index 6","9141":"Adverse events ","9142":"Pain after 2 days","9143":"Pain after 3 days","9144":"Pain interference with function after 2 days","9145":"hit rate in high - hallucinations\/delusions (H-HD)","9146":"Risk of experiencing \u22652 opioid-related symptoms","9147":"Time to completing trial cycling","9148":"Right ventricle to right atrium pressure gradient","9149":"beneficial preventive effects against neonatal conjunctivitis","9150":"Total duration of intubation - In infants by birth weight >1,500 g - treatment of respiratory distress syndrome (RDS)","9151":"clinical efficacy (infants birth weight <1,500 g) - treatment of respiratory distress syndrome (RDS)","9152":"Severe hypoglycemia","9153":"clinical efficacy (infants birth weight >1,500 g) - treatment of respiratory distress syndrome (RDS)","9154":"response type to surfactant - treatment of respiratory distress syndrome (RDS)","9155":"In \u22651,500 g group, the total doses of surfactant instilled - treatment of respiratory distress syndrome (RDS)","9156":"Total duration of intubation - In infants by birth weight <1,500 g - treatment of respiratory distress syndrome (RDS)","9157":"Glucose concentration","9158":"diarrhea incidence","9159":"Cognitive function level","9160":"Cognitive function level","9161":"3\/4 grade nausea\/vomiting\/diarrhea - in axillary lymph node (LN)-positive early-stage breast cancer","9162":"rate of pathological complete response in primary tumor - in axillary lymph node (LN)-positive early-stage breast cancer","9163":"body fat percentage (%BF) underestimation at the endpoint in males in obese or overweight Chinese adults","9164":"body fat percentage (%BF) underestimation in changes in males in obese or overweight Chinese adults","9165":"Score on knowledge-based questions 3 months after intervention","9166":"incidence of antidrug antibody development up to week 24 - Patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate (MTX) treatment","9167":"Abdominal pain\/discomfort frequency score","9168":"Abdominal pain\/discomfort frequency score","9169":"Abdominal bloating","9170":"Pain","9171":"Erythema","9172":"mean pain intensity after the 15-week exercise intervention","9173":"Serum (25-hydroxy-vitamin D) 25(OH)D3 levels at 16 weeks - severe secondary hyperparathyroidism (SHPT) hemodialysis (HD) patients","9174":"Serum Intact Parathyroid Hormone (iPTH) average target level (\u2264300 pg\/mL) at 24 weeks - severe secondary hyperparathyroidism (SHPT) hemodialysis (HD) patients","9175":"Microhardness changes","9176":"Serum (25-hydroxy-vitamin D) 25(OH)D3 levels at end of study - severe secondary hyperparathyroidism (SHPT) hemodialysis (HD) patients","9177":"Microhardness changes","9178":"social avoidance - in social anxiety disorder (SAD)","9179":"Mean duration of illness - in social anxiety disorder (SAD)","9180":"Changes on clinical global impression scale-severity (CGI-S) - in social anxiety disorder (SAD)","9181":"Third peak of coefficient of friction","9182":"Rate of mycologic cure by the end of the treatment ","9183":"Rate of effective treatment by the end of the treatment ","9184":"Rate of mycologic cure 2 weeks after the treatment ","9185":"risk of disease-related events (children with acute lymphoblastic leukaemia who relapsed on present therapeutic regimens)","9186":"Serious adverse effects","9187":"adjusted hazard ratio (HR) for overall survival (children with acute lymphoblastic leukaemia who relapsed on present therapeutic regimens)","9188":"toxic effects at grade 3 or higher (children with acute lymphoblastic leukaemia who relapsed on present therapeutic regimens)","9189":"overall survival (children with acute lymphoblastic leukaemia who relapsed on present therapeutic regimens)","9190":"Oxidative stress index","9191":"PSA ","9192":"Improvement in psychopathology ","9193":"Decrease in lumbar spine mineral density (BMD)","9194":"Improvement on median period of disability","9195":"number of parishes offering small media interventions - evidence-based strategies (EBS) for cancer control","9196":"maximal voluntary isometric contraction (MVC) torque - after the exercise","9197":"M-wave latency","9198":"maximal voluntary isometric contraction (MVC) torque - 1 day after the exercise","9199":"Hospital stay","9200":"frequency of occurrence in reversible inguinal hernia","9201":"Complications ","9202":"Adverse effects","9203":"a and b model coefficients (power law models)","9204":"Conjunctival score","9205":"Cardiovascular death","9206":"Need for blood transfusion\t","9207":"Postoperative blood loss\t","9208":"Post-operative hemoglobin ","9209":"Spermatozoa viability ","9210":"Spermatozoa viability ","9211":"Vomiting","9212":"Visual acuity after 1 month","9213":"Visual acuity after 3 months","9214":"Central macular thickness after 1 month","9215":"Days of abstinence","9216":"Difference of cortisol on waking and the highest level of following samples","9217":"Peak power in the sprint","9218":"Stress","9219":"Fasting plasma C-Peptide","9220":"2 h postprandial C-Peptide","9221":"Fructosamine ","9222":"Mean amplitude of glycemic excursions","9223":"Need for dipyrone","9224":"Prolactin levels","9225":"CA-125 levels","9226":"Systolic blood pressure ","9227":"Total problems","9228":"Gastrointestinal adverse events","9229":"mean HbA1c changes","9230":"Diastolic blood pressure ","9231":"At 104 weeks, the percentage of participants attaining the HbA1c target goal of <7%","9232":"Diastolic blood pressure ","9233":"rate of attrition","9234":"chronic idiopathic constipation (CIC) - incidence of treatment-emergent nausea","9235":"opioid-induced constipation (OIC) - incidence of treatment-emergent nausea, mild or moderate","9236":"Discontinuation due to adverse events","9237":"higher LF\/HF ratio in HRV","9238":"anxiety scores","9239":"Pleural opacity","9240":"systolic blood pressure","9241":"concentrations of the final catabolic product of ATP, uric acid","9242":"heart rate","9243":"Pain","9244":"overall working memory (WM) performance in autism spectrum disorder (ASD) ","9245":"overall working memory (WM) performance in autism spectrum disorder (ASD) ","9246":"effect of homonymous hemianopia (HH) side","9247":"Fruit intake","9248":"composite z-scores in autism spectrum disorder (ASD) ","9249":"mean Emax scores","9250":"time to resolution for all respiratory symptoms of severity - severe pneumonia in children","9251":"Vegetable intake","9252":"Percentage of treatment failure on day 5 - severe pneumonia in children","9253":"Energy intake","9254":"time to recovery from lower chest wall indrawing (LCWI) - severe pneumonia in children","9255":"percentage of furcation sites that needed retreatment at 6 months","9256":"sternal retraction - severe pneumonia in children","9257":"decrease in range of motion (ROM)","9258":"walking distance improvement at week 24 - patients with Morquio A syndrome (mucopolysaccharidosis IVA)","9259":"Home-based spirometry parameters ","9260":"BP-lowering effects at Week 4","9261":"6-min walk test (6MWT) distance at week 24 - patients with Morquio A syndrome (mucopolysaccharidosis IVA)","9262":"solely responsible for the significant joint treatment effect","9263":"6-min walk test (6MWT) distance at week 24 - patients with Morquio A syndrome (mucopolysaccharidosis IVA)","9264":"phasic alertness","9265":"target BP at Week 8","9266":"tingling sensations","9267":"hand-foot syndrome - in axillary lymph node (LN)-positive early-stage breast cancer","9268":"RTs","9269":"difference in risk of any of the endpoints","9270":"IL-6","9271":"target BP at Week 8","9272":"IL-6","9273":"Mean VO2max","9274":"cortisol levels - after a 30-min rest","9275":"Rotational alignment of the femur","9276":"cortisol levels - immediately after exercise","9277":"Long-acting reversible contraceptive insertion ","9278":"time to new metastases in patients whose disease progressed due to new metastases in vital organs (CNS, lungs, or liver) - women with advanced\/metastatic breast cancer (MBC)","9279":"median survival (OS) in patients with no reported disease progression - women with advanced\/metastatic breast cancer (MBC)","9280":"hs-CRP - type 2 diabetes patients","9281":"Median overall survival (OS) for patients whose disease progressed due to new metastases - women with advanced\/metastatic breast cancer (MBC)","9282":"After 48 weeks decrease in waist circumference, hip circumference, weight and BMI in the three groups ","9283":"After 24 weeks decrease in waist circumference, hip circumference, weight and BMI in the three groups ","9284":"Reduction in levels and expression of neutrophil gelatinase-associated lipocalin","9285":"Quality of life","9286":"Acute rejection","9287":"Improvement in renal function after 1 year","9288":"mean pain intensity before exercise intervention","9289":"Incidence of infection by cytomegalovirus ","9290":"symptoms of typical angina","9291":"Postoperative nausea and vomiting ","9292":"Anesthesia time","9293":"Probing pocket depth reduction","9294":"interstitial concentrations of pyruvate","9295":"Buccolingual measurements","9296":"discrimination","9297":"Baseline chaacteristics","9298":"Body mass index z-scores in Overweight kids ","9299":"Total cholesterol levels","9300":"Change in North Star Ambulatory Assessment score","9301":"Rate of serious adverse events","9302":"Haemagglutination inhibition titers","9303":"Total IgA levels at day 28","9304":"Levels of vaccine-specific IgA","9305":"average peak torque","9306":"mean values of peak torque","9307":"Juvenile Idiopathic Arthritis (JIA) - proportion of patients relapsed after stopping the treatment","9308":"mean values of total work during knee flexion","9309":"mixed diet","9310":"reduction of all signs and symptoms of chronic tonsillitis","9311":"Modified psoriasis life stress inventory (PLSI)","9312":"psoriasis disability index (PDI)","9313":"mean disability score related to daily activities","9314":"mean disability score related to treatment","9315":"treatment of RA (Rheumatoid arthritis) patients with a high disease activity at baseline","9316":"L\/P ratio","9317":"The 3-year elapse-free survival (RFS) in metastatic colorectal cancer (CRC)","9318":"mean morphine consumption","9319":"random effects variance","9320":"increased HIV risk behavior","9321":"risk scores","9322":"tumour-size-related mortality reduction","9323":"Improvement in GSRS (Gastrointestinal Symptom Rating Scale) SF-36v2 MCS score - in adults with post prandial intestinal gas-related symptoms and no GI diagnoses","9324":"Transport duration in summer season - effect on serum cortisol concentration","9325":"Concentration of lactate","9326":"Transport duration - effect on serum cortisol concentration","9327":"Transport duration - effect on serum cortisol concentration","9328":"positive affect (PA)","9329":"phenotype categories","9330":"Transport duration in fall season - effect on serum cortisol concentration","9331":"The effectiveness of the intervention ","9332":"TNF-\u03b1 - type 2 diabetes patients","9333":"triglyceride - type 2 diabetes patients","9334":"susceptibility, severity, barriers and benefits","9335":"the mean scores of all HBM components","9336":"bond strength","9337":"rate of force development (RFD)","9338":"serum concentrations of testosterone","9339":"cost of procedure - females with breast abscess","9340":"Serum cortisol","9341":"demographic characteristic - females with breast abscess","9342":"growth hormone (GH)","9343":"H. pylori resistance rates","9344":"gain anticipation in the right VS","9345":"DPT-3\/Hepatitis B completion rates","9346":"mean VAS pain score","9347":"erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)","9348":"Rates of HBsAg clearance","9349":"improvement of GERD-related quality of life (QOL) and sleep disturbance","9350":"birth preparation","9351":"cord care","9352":"thermal care","9353":"satisfaction, exhaustion and sleep disturbances","9354":"complications","9355":"time to bloody stools","9356":"Improved Clinical Global Impressions-S","9357":"safety profiles","9358":"pAMPK\/AMPK ratio in prefrontal cortex","9359":"pAMPK\/AMPK ratio in prefrontal cortex","9360":"Transient-Evoked Otoacoustic Emissions (TEOAE) high-frequency average (HFA)","9361":"The frequency of knowledge of elder abuse, self-efficacy, social support, health promoting behavior, and risk of elder abuse before the intervention","9362":"Ubiquitous mitochondrial creatine kinase","9363":"Ubiquitous mitochondrial creatine kinase","9364":"Risk of obstructive sleep apnea","9365":"abscess healing rate - females with breast abscess","9366":"Obstructive sleep apnea diagnosis rate","9367":"Completing the follow-up","9368":"no target lesion revascularization (TLR)","9369":"no stent thrombosis","9370":"rates of death","9371":"Total cholesterol","9372":"Percentage of patients achieving an SLE Responder Index 6","9373":"HDL-C","9374":"auditory event-related brain potential \u2013 mismatch negativity (MMN) in high - hallucinations\/delusions (H-HD)","9375":"d\u2032 (weight hits and false alarms into a single measure) in high - hallucinations\/delusions (H-HD)","9376":"peak aerobic capacity","9377":"mean daily intake of ketogenic low carbohydrate (CHO)","9378":"peak aerobic capacity","9379":"Morphine consumption after 1 day","9380":"Morphine consumption after 2 days","9381":"BM decreased over the 3 weeks of intensified training and mild energy deficit","9382":"mean arterial pressure (MAP)","9383":"BM decreased over the 3 weeks of intensified training and mild energy deficit","9384":"Time to completing trial cycling","9385":"preinduction HR (heart rate)","9386":"Right ventricle to right atrium pressure gradient","9387":"frequency of conjunctivitis","9388":"adjusted hazard ratio (HR) for progression-free survival (children with acute lymphoblastic leukaemia who relapsed on present therapeutic regimens)","9389":"Amplitude of glycemic excursion","9390":"decrease in BMI - older, lonely, chronically ill adults","9391":"median Emax scores","9392":"incidence of AEs","9393":"Improvements in trough FEV1","9394":"Sheehan Disability Scale overall improvement ","9395":"children with fever or cough without diarrhea, zinc use","9396":"median number of ORS sachets","9397":"Sheehan Disability Scale social life improvement ","9398":"Sheehan Disability Scale improvement ","9399":"median zinc concentrations","9400":"children still had diarrhea at follow-up","9401":"Insulin like-growth factor 1","9402":"Insulin like-growth factor 1","9403":"Connected Speech Test (CST) rau score","9404":"Brain-derived neuropathic factor changes","9405":"Glycated hemoglobin","9406":"Weight ","9407":"Severe hypoglycemia ","9408":"Score on knowledge-based questions right after intervention","9409":"objective remission rate - in axillary lymph node (LN)-positive early-stage breast cancer","9410":"Believing oral cavity exam during pregnancy isoutside the routine practice","9411":"clinical complete response (cCR) - in axillary lymph node (LN)-positive early-stage breast cancer","9412":"mean difference between body fat percentage (%BF) in females at baseline in obese or overweight Chinese adults","9413":"Flatulence","9414":"ACR70 (American College of Rheumatology 70% response rate at week 24 in the PPS and FAS - Patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate (MTX) treatment","9415":"Satisfied stool frequency","9416":"Pain","9417":"ACR50 (American College of Rheumatology 50% response rate at week 24 in the PPS and FAS - Patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate (MTX) treatment","9418":"Pain","9419":"Erythema","9420":"incidence of treatment-emergent adverse events - Patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate (MTX) treatment","9421":"Erythema","9422":"Microhardness changes","9423":"Microhardness changes","9424":"Microhardness changes","9425":"new metastases was associated with an increased risk of death - women with advanced\/metastatic breast cancer (MBC)","9426":"Microhardness changes","9427":"interstitial concentrations of lactate","9428":"interstitial concentrations of glutamate","9429":"Isometric maximum force in the gastrocnemius medialis muscle","9430":"Serum Intact Parathyroid Hormone (iPTH) level at 20 weeks - severe secondary hyperparathyroidism (SHPT) hemodialysis (HD) patients","9431":"Electromyographic amplitude of tibialis anterior","9432":"Gait Ground Reaction Forces","9433":"brief FNE (BFNE) improvement - in social anxiety disorder (SAD)","9434":"mean age - in new AFB positive tuberculosis (TB) patients","9435":"internalized social stigma score after 2 months - in new AFB positive tuberculosis (TB) patients","9436":"internalized social stigma score on day 15 - in new AFB positive tuberculosis (TB) patients","9437":"Rate of effective treatment 2 weeks after the treatment ","9438":"socioeconomic variables - in new AFB positive tuberculosis (TB) patients","9439":"Laboratory exams abnormality","9440":"C-reactive protein","9441":"Total oxidant status","9442":"change in IL6 expression at 17 weeks - older, lonely, chronically ill adults","9443":"The frequency of self-efficacy after the intervention","9444":"decrease in UCLA loneliness scores across 17 weeks - older, lonely, chronically ill adults","9445":"decrease in Geriatric Depression Scale Score - older, lonely, chronically ill adults","9446":"systolic blood pressure - older, lonely, chronically ill adults","9447":"PSA change ratio","9448":"Behaviour problems","9449":"nutrient intake","9450":"Decrease in Hip bone mineral density (BMD)","9451":"Improvement on median period of disability","9452":"nutritional status before the intake of supplements","9453":"Improvement in range of motion","9454":"Improvement in range of motion","9455":"association between flavonoid subclasses and site of colorectal cancer","9456":"Pain reduction","9457":"Mean operative time","9458":"Blood loss","9459":"Intakes of flavonoid subclasses associated with risk of colorectal cancer (CRC)","9460":"Pain","9461":"Postoperative complications ","9462":"Return of bowel function time","9463":"Total blood loss","9464":"symptoms of hernia such as heaviness, fullness and pain","9465":"Coagulation profile","9466":"pain in reversible inguinal hernia","9467":"aggravating factors in reversible inguinal hernia","9468":"Crystalloid solution needed","9469":"a and b model coefficients (power law models)","9470":"relative attachment level (RAL)","9471":"Tear break up time","9472":"Ocular surface disease index","9473":"proportion of men with false positive (FP) results","9474":"increased risk for PC in second round","9475":"Heart failure hospitalization","9476":"Heart failure hospitalization","9477":"Cardiovascular death","9478":"concentrations of the final catabolic product of ATP, uric acid","9479":"All-cause hospitalization","9480":"Volume depletion adverse events","9481":"Need for hysterectomy","9482":"Heart rate","9483":"changes in Osteocalcin (OC)","9484":"percentage of furcation sites that needed retreatment at 3 months","9485":"Wound infection\t","9486":"Fever","9487":"Time to mobilisation","9488":"Fasting glucose","9489":"Spermatozoa viability ","9490":"median Emax scores","9491":"Acrosome integrity","9492":"Concentration of glycerol","9493":"Gastrointestinal acute toxicity severity ","9494":"mean ICU stay - patients undergoing CABG \/ CE","9495":"Genitourinary acute toxicity severity","9496":"C-peptide AUC","9497":"C-peptide incremental AUC","9498":"Use of rescue antiemetic","9499":"Adverse effects","9500":"Patient satisfaction","9501":"Severity of nausea","9502":"Intraocular pressure after 3 months","9503":"concentrations of the final catabolic product of ATP, uric acid","9504":"mean age - patients undergoing CABG \/ CE","9505":"Virologic failure rate","9506":"Central macular thickness after 3 months","9507":"systolic blood pressure","9508":"Ambulation ability gain","9509":"Dropout rates","9510":"Surgical referral at 3 months","9511":"Substance use","9512":"Intimate partner violence","9513":"Marital satisfaction","9514":"Treatment satisfaction","9515":"Depressive symptoms ","9516":"Depressive symptoms ","9517":"The 3-year elapse-free survival (RFS) in metastatic colorectal cancer (CRC) - stage IIIb","9518":"Glucose AUC","9519":"BMI","9520":"5-min all-out performance after the first training","9521":"5-min all-out performance at day 6 ","9522":"Glucose incremental AUC","9523":"Diastolic blood pressure ","9524":"Purdue pegboard task score improvement (right hand)","9525":"blind-side detection","9526":"Dosages of insulin","9527":"Time looking at logo","9528":"Site content recalling","9529":"Improvements in FVC","9530":"Vulnerability","9531":"Blood glucose","9532":"Intentions","9533":"With the exception of reduction of structural barriers, a proportion of parishes that offered three of the other - evidence-based strategies types (EBS) for cancer control ","9534":"Need for Ibuprofen","9535":"Alcohol reduction ","9536":"Need for second opinion","9537":"Overall complication rate","9538":"Tenofovir Vaginal tissue concentrations","9539":"Tenofovir rectal fluid concentrations","9540":"Intuitive eating total score ","9541":"Psychological flexibility","9542":"General mental health ","9543":"Binge eating","9544":"BMI","9545":"General physical health","9546":"Platelet count","9547":"Quality of life","9548":"Prothrombin time","9549":"Partial thromboplastin time","9550":"Blood urea nitrogen levels","9551":"Creatinine levels ","9552":"Overall long-lasting insecticide-treated bed nets utilization ","9553":"Long-lasting insecticide-treated bed nets utilization by children under 5","9554":"Effectiveness problems","9555":"Compliance problems","9556":"FEV1","9557":"FEV1","9558":"FEV1","9559":"FEV1","9560":"FEV1","9561":"FEV1","9562":"5-year overall survival rate","9563":"5-year disease-specific survival rate","9564":"Mortality","9565":"Primary closure rates ","9566":"Surfactant therapy","9567":"Pulmonary hemorrhage","9568":"Sepsis","9569":"Necrotizing enterocolitis","9570":"Flow-mediated vasodilatation after 36 months","9571":"Flow-mediated vasodilatation after 6 months","9572":"Nitroglycerine response","9573":"Pathological complete response","9574":"Downstaging (stage 0 and I)","9575":"3-years overall survival","9576":"Disease-free survival","9577":"Positive lymph-nodes","9578":"Cancer progression","9579":"Proven\/probable cases of invasive candidiasis","9580":"Mean percentage of scored days","9581":"Occurrence of diarrhea within the first 14 days","9582":"Occurrence of \u22652 consecutive days of diarrhea","9583":"Adverse events","9584":"Task commitment","9585":"Time to failure","9586":"Perceived pain","9587":"Perceived exertion","9588":"FEV1","9589":"FEV1","9590":"FEV1","9591":"FEV1","9592":"FEV1","9593":"FEV1","9594":"Gestational age at the ultrasound visit ","9595":"Gestational age at birth ","9596":"Silness and Lo\u0308e index","9597":"Bleeding","9598":"Dental plaque","9599":"Gingival Brightness","9600":"Mean amount of drug used per week","9601":"Mean amount of aerosol foam used per week","9602":"People still on sick leave after three months","9603":"Total number of net sick leave days in the first three months","9604":"Number of individuals who were on partial sick leave 0\u20133 months","9605":"People still on sick leave after 12 months","9606":"Total number of gross sick leave days 3\u201312 months","9607":"Total number of net sick leave days 3\u201312 months","9608":"Perceived benefits ","9609":"Perceived self-efficacy ","9610":"Performance","9611":"Insertion time","9612":"Mean airway sealing pressure","9613":"Ease of gastric tube insertion ","9614":"Macroscopic blood staining of the device ","9615":"Dysphagia frequency ","9616":"Sore throat frequency ","9617":"Median endurance time","9618":"Isotime oxygen consumption","9619":"Mean areterial blood pressure","9620":"Systolic blood pressure","9621":"Resting diastolic blood pressure","9622":"WOMAC Osteoarthritis Index Pain score improvement ","9623":"WOMAC Osteoarthritis Index Pain score improvement ","9624":"WOMAC Osteoarthritis Index activity score improvement ","9625":"WOMAC Osteoarthritis Index activity score improvement ","9626":"Total WOMAC score improvement ","9627":"Total WOMAC score improvement ","9628":"Heart rate ","9629":"Heart rate ","9630":"Mean arterial pressure ","9631":"Mean arterial pressure ","9632":"Double burst time","9633":"Double burst time","9634":"Inhibition of the maximal resting pressure","9635":"Inhibition of the maximal resting pressure","9636":"Inhibition of the maximal resting pressure","9637":"Inhibition of the maximal squeezing pressure","9638":"Inhibition of the maximal squeezing pressure","9639":"Inhibition of the maximal squeezing pressure","9640":"Blood oxygenation level-dependent fMRI activation ","9641":"Blood oxygenation level-dependent fMRI activation ","9642":"Blood oxygenation level-dependent fMRI activation ","9643":"Young Mania Rating Scale score reduction","9644":"Response rate improvement ","9645":"Remission rate improvement ","9646":"Clinical Global Impressions for Bipolar Disorder-Severity of Illness","9647":"Clinical Global Impressions for Bipolar Disorder-Change of Illness","9648":"Proportions of patient improvement ","9649":"High-sensitivity C-reactive protein","9650":"Interleukin-6","9651":"Tumor necrosis factor-\u03b1","9652":"Matrix metalloproteinase-9","9653":"Overall adverse events frequency ","9654":"Serious adverse events frequency ","9655":"Overall surgical site infections","9656":"Serious surgical site infections","9657":"Anastomotic fistula frequency ","9658":"Peritonitis frequency ","9659":"Urinary leakage","9660":"Stent crustation","9661":"UTI after 2 weeks","9662":"UTI after 4 weeks","9663":"UTI during discharge","9664":"Overall hippocampal volume after 28 days","9665":"Overall hippocampal volume after 84 days","9666":"Amygdalar volume after 28 days","9667":"Amygdalar volume after 84 days","9668":"Left hippocampal volume after 28 days","9669":"Right hippocampal volume after 28 days","9670":"Risk of coronary artery disease","9671":"Risk of atrial fibrillation during transoesophageal echocardiography","9672":"Risk of mitral incompetence","9673":"CHADS2 score","9674":"Left ventricular ejection fraction","9675":"Systolic blood pressure","9676":"Forced vital capacity ","9677":"FEV1 ","9678":"Peak expiratory flow ","9679":"FEV1\/Forced vital capacity ","9680":"Maximum Voluntary Ventilation","9681":"Asthma-related quality of life","9682":"Asthma control","9683":"Inhaled corticosteroid dosage","9684":"FEV 1","9685":"Gall bladder volume change","9686":"Gall bladder volume change","9687":"Gall bladder volume change","9688":"Gall bladder volume change","9689":"Gall bladder volume change","9690":"Nausea complete response","9691":"Tumor control rates","9692":"Tumor control rates","9693":"Tumor control rates","9694":"Median survival","9695":"Median survival","9696":"Median survival","9697":"Morphine Cmax","9698":"Exposure to Morphine in the first 30 min ","9699":"Morphine Tmax ","9700":"Morphine-6-glucuronide Cmax","9701":"Morphine-6-glucuronide AUC 0\u20130.5h","9702":"Internal rotation","9703":"Postoperative anterior knee pain","9704":"Anterior range of motion ","9705":"Knee society score","9706":"Oxford Score","9707":"Overall satisfaction ","9708":"Pain","9709":"Postprandial plasma glucose","9710":"Insulin fluctuations ","9711":"Urinary glucose excretion","9712":"Appearance of oral glucose in plasma 0-1 h","9713":"Appearance of oral glucose in plasma 0-2 h","9714":"Physical restraint use per week during training ","9715":"Physical restraint use per week after training ","9716":"Use of STAT medications per week during training","9717":"Use of STAT medications per week after training","9718":"Perceived Stress","9719":"Mean blood glucose","9720":"Premeal blood glucose","9721":"Mean amplitude of glycemic excursion","9722":"Severe hypoglycemia ","9723":"Mortality","9724":"Overall mortality ","9725":"Duration of infusion","9726":"Mortality before ICU discharge ","9727":"Mortality before hospital discharge ","9728":"Probabilities of A1C <6.5%","9729":"Need for oral therapies","9730":"Bone Mineral Density at the lumbar spine","9731":"BMI","9732":"Balance improvement ","9733":"Bone Mineral Density at the femoral neck","9734":"Bone Mineral Density at other hip sites","9735":"Parenting stress","9736":"Glycated hemoglobin levels ","9737":"Nausea score","9738":"Complete response rate in acute phase ","9739":"Complete response rate during the first stage of the late phase","9740":"Complete response rate during the second stage of the late phase ","9741":"Complete control rate","9742":"Postoperative nausea and vomiting","9743":"Shoulder pain when leaving the recovery room","9744":"Shoulder pain 4 hours after the surgery","9745":"Stroke volume index ","9746":"Cardiac index","9747":"Postoperative inotrophyc requirement ","9748":"Postoperative cardiac enzyme levels","9749":"Need for intra-aortic balloon pump ","9750":"Early recovery times","9751":"Eye opening time","9752":"Extubation time","9753":"Time for obeying commands","9754":"Time for hand squeezing","9755":"Vomiting ","9756":"Recovery time after anesthesia","9757":"Total Gastrointestinal Symptoms Rating Scale score","9758":"Indigestion and constipation scores","9759":"Acid reflex scores ","9760":"Diarrhea scores ","9761":"Abdominal pain scores ","9762":"Abdominal bloating","9763":"Postoperative days until discharge","9764":"Postoperative apnea-hypopnea index","9765":"Number of analgesic administrations","9766":"Time to restart normal diet","9767":"Pain VAS scores at rest after 24 hours","9768":"Pain VAS scores on movement after 24 hours","9769":"Time to bowel recovery","9770":"Length of hospitalization","9771":"Sufentanil consumption","9772":"Nausea and vomiting ","9773":"Pain ","9774":"Postoperative complications","9775":"Systolic blood pressure ","9776":"Adequate blood pressure control","9777":"Estimated average daily sodium chloride intake","9778":"Self-efficacy","9779":"Valuation of Life","9780":"Mastery ","9781":"Depression ","9782":"Self esteem","9783":"50% pain reduction ","9784":"Global impression of pain improvement ","9785":"Overall adverse events ","9786":"Somnolence ","9787":"Self-efficacy","9788":"SF-36 quality of life","9789":"Multiple Sclerosis Impact Scale improvement ","9790":"Regression rate at 3 months","9791":"Hysterectomy rate ","9792":"Hemodynamic parameters","9793":"Nausea\/vomiting","9794":"Branden score","9795":"Area of pressure sore","9796":"Average cost of hospitalization","9797":"Dressing change time","9798":"Gastric peristalsis events","9799":"Duodenal peristalsis events","9800":"Procedure time","9801":"Tolerance of endoscopy","9802":"Dry mouth","9803":"LDL\u2010C reduction","9804":"Electrocardiographic results","9805":"Attending at least one session","9806":"Completing at least 8 sessions","9807":"Group cohesion ","9808":"Haemoglobin","9809":"Haemoglobin","9810":"Reports of illness","9811":"Skin temperature ","9812":"Mean operative time","9813":"Lower urinary tract symptoms","9814":"Pain","9815":"Negative affect","9816":"Pain","9817":"Probability for erectile function recovery","9818":"Low cardiac output episode","9819":"Troponin-T levels","9820":"Electrocardiographic signs of injury","9821":"Emotional symptoms","9822":"Wound healing mean score improvement after 24 hours","9823":"Wound healing mean score improvement after 8 days","9824":"Getting a score of 0 after 8 days","9825":"Onset of turniquet pain","9826":"Time for pain after opening the tourniquet ","9827":"Plaque Index improvement ","9828":"Gingival Index improvement ","9829":"Gingival Index improvement ","9830":"Scar length","9831":"Pain ","9832":"Dose-sparing for GH deficiency","9833":"Dose-sparing for idiopathic short stature","9834":"Total adaptation","9835":"Self-concept score","9836":"Interdependence score","9837":"20% reduction in HAM-D score","9838":"Adverse effects","9839":"Urinary urgency","9840":"Urinary urgency","9841":"Nocturnal urinary urgency","9842":"Decrease of platelets","9843":"Glomerular filtration rate increase ","9844":"Microalbuminuria decrease","9845":"Clinical depression","9846":"Response to happy faces ","9847":"Response to fear","9848":"Nausea and vomiting","9849":"Hypoglycaemia","9850":"Hypoglycaemia","9851":"Surgery time","9852":"Recurrence ","9853":"Pain between surgery and stitches removal","9854":"Patient satisfaction","9855":"Pain","9856":"Pain","9857":"Pre\/postoperative alignment","9858":"Lateral laxity","9859":"Postoperative flexion angle","9860":"Anterior region of the tongue improvement ","9861":"Posterior region of the tongue improvement ","9862":"Soluble vascular endothelial growth factor receptor-1 (Overall)","9863":"Placental growth factor","9864":"sFlt-1:PlGF","9865":"Soluble endoglin","9866":"Vascular cell adhesion molecule 1","9867":"Undertreatment rate","9868":"Mean duration of episodes","9869":"12-month primary patency","9870":"Clinically-driven target lesion revascularization rate","9871":"Procedure success","9872":"Total energy expenditure","9873":"Total energy expenditure","9874":"Range of motion of trunk extension","9875":"Hip extension","9876":"Hip abduction ","9877":"Pain AUC","9878":"Glycated hemoglobin","9879":"Triglycerides ","9880":"Insulin ","9881":"Fasting glucose","9882":"Fructosamine","9883":"C-peptide","9884":"Serum transferrin","9885":"Shivering ","9886":"Recovery time on opium addicted patients ","9887":"\"a\" vowel improvement ","9888":"Probabilities of experiencing a good physical component summary","9889":"Probabilities of experiencing a good physical component summary","9890":"Probabilities of experiencing a good mental component summary","9891":"Probabilities of experiencing a good mental component summary","9892":"Torque values (concentric contractions)","9893":"Torque values (eccentric contractions)","9894":"EPC1 expression","9895":"Alanine aminotransferase","9896":"Ingrown toenails recurrence ","9897":"Time to return to normal daily activities","9898":"Soft tissue infections frequency ","9899":"Diastolic blood pressure ","9900":"Life satisfaction","9901":"Mean burden scores of caregivers","9902":"Overall burden","9903":"Burden score for schizophrenic patients' caregivers","9904":"Family caregivers' burden of mood disorders","9905":"24\u2010h average pain","9906":"Fatigue severity","9907":"Adverse events","9908":"Regression rate at 6 months","9909":"Regression rate at 12 months","9910":"Median time to regression ","9911":"Analgesic properties","9912":"Analgesic properties","9913":"Hemodynamic parameters","9914":"Nausea\/vomiting","9915":"Improvement rate","9916":"Dressing change frequency ","9917":"Nausea","9918":"LDL\u2010C reduction","9919":"Vital signs","9920":"Hematologic parameters ","9921":"Completing at least 4 sessions","9922":"Group preference","9923":"Anaemia prevalence","9924":"Anaemia prevalence","9925":"Reports of illness","9926":"Decrease in core temperature ","9927":"Room temperature ","9928":"Mean duration of urethral catheter","9929":"Mean duration of drain removal","9930":"Hematuria ","9931":"Veterinary-assessed mobility index","9932":"Peak vertical force","9933":"Situational self-esteem","9934":"Perceived stress","9935":"Self-reported physiological arousal","9936":"Hospital stay","9937":"Operative duration","9938":"Hematoma frequency ","9939":"Paralytic ileus","9940":"Wound infection","9941":"Probability for erectile function recovery","9942":"Safety","9943":"Safety","9944":"Safety","9945":"Safety","9946":"Safety","9947":"Cardiac index at 6 h","9948":"Need for inotropic support in the first 12 h","9949":"Length of stay","9950":"Abdominal symptoms","9951":"Worry","9952":"Fatigue","9953":"Activity","9954":"Systemic symptoms","9955":"Getting a score of 0 after 24 hours","9956":"Postoperative pain","9957":"Analgesia prescription","9958":"Turniquet pain score","9959":"Plaque Index","9960":"Plaque Index improvement ","9961":"Gingival Index improvement ","9962":"Operation duration","9963":"Time to return to daily activities","9964":"Dose-sparing for GH deficiency","9965":"Dose-sparing for idiopathic short stature","9966":"Physiologic score","9967":"Role function score","9968":"Cumulative pain score","9969":"Nausea on post-operative day ","9970":"Pruritus","9971":"Wound complication","9972":"Transient peroneal nerve palsy","9973":"50% reduction in HAM-D score","9974":"Nocturnal urinary urgency","9975":"Discontinuation due to adverse events","9976":"Blood loss","9977":"Hemoglobin decrease ","9978":"Hematocrit decrease ","9979":"Hyperkalemia higher than 5 mmol\/L","9980":"Urinary potassium","9981":"Nausea and vomiting","9982":"Nausea and vomiting","9983":"Pain during surgery ","9984":"Cosmetic appearance","9985":"Patient satisfaction","9986":"Cumulated dissipated energy","9987":"Surgical time","9988":"Videofluoroscopic dysphagia scale","9989":"Recognition rates","9990":"Severity of depression","9991":"Functional impairment","9992":"Mean days on sick leave","9993":"Device success","9994":"Walking distance improvement ","9995":"Total energy expenditure","9996":"Total energy expenditure","9997":"Lequesne index improvement ","9998":"Oswestry Disability Index improvement ","9999":"Trunk flexion ","10000":"Pain AUC","10001":"Inducible pressure pain","10002":"Inducible pressure pain","10003":"Serum albumin","10004":"Serum prealbumin ","10005":"C3 levels","10006":"C4 levels","10007":"C- reactive protein ","10008":"Recovery time on opium non-addicted patients ","10009":"Total nasal resistance","10010":"\"n\" consonant improvement ","10011":"Torque values (concentric contractions)","10012":"Torque values (eccentric contractions)","10013":"EPC1 expression","10014":"Alanine aminotransferase","10015":"Aspartate aminotransferase","10016":"Aspartate aminotransferase","10017":"Working memory speed","10018":"Working memory Accuracy","10019":"Weight gain","10020":"Overall use of daily rescue medication improvement","10021":"Reading","10022":"glycemic control before and after the treatment","10023":"Rate of superficial wound infection","10024":"the creative foraging game (CFG) and the alternate uses test (AUT) scores","10025":"Burden of hypoxia within the 4th quartile versus quartile 1\u20133","10026":"Perception of patient adherence to given recommendations","10027":"histological parameters of Oral Submucous Fibrosis (OSF)","10028":"diastolic blood pressure","10029":"speech item and the sexual interest item","10030":"Dose-dependency for the effect of ASV on cardiovascular risk","10031":"Epidermal growth factor receptor","10032":"Psychological distress","10033":"Not wanting to participate again in the future","10034":"maintaining clinical response to week 4 following a 16-week","10035":"Medical survey response rate on cardiologists ","10036":"Matrix metalloproteinase-9 (MMP9) level","10037":"Raldh-1 > Raldh-3 > Raldh-2. Raldh-1 expression","10038":"Laboratory FEV1","10039":"Nausea","10040":"Heart rate","10041":"Most preferred method; normal vaginal delivery","10042":"The death rate"},"Intervention":{"0":"dextran-70 infusion was administered at a dose of 7.5 ml\/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml\/kg after the cessation of cardiopulmonary bypass","1":"Liraglutide (1.2 mg) plus glimepiride","2":"Infliximab","3":"Liraglutide (1.8 mg) plus glimepiride","4":"Body-weight supported treadmill training combined with Lokomat (Post-test)","5":"Liraglutide (all doses) plus glimepiride","6":"Liraglutide (0.6 mg) plus glimepiride","7":"Dihydroartemisinin-piperaquine","8":"Body-weight supported treadmill training combined with Lokomat (Post-test)","9":"Liraglutide (1.8 mg) plus glimepiride ","10":"Dihydroartemisinin-piperaquine","11":"Liraglutide (1.8 mg) plus glimepiride","12":"Midwife-led unit","13":"Liraglutide (1.2 mg) plus glimepiride","14":"Liraglutide (1.2 mg) plus glimepiride","15":"Liraglutide (all doses) plus glimepiride","16":"Liraglutide (1.8 mg) plus glimepiride","17":"Liraglutide (1.2 mg) plus glimepiride","18":"recipients with the highest serum anti-nicotine antibody response (top 30% by AUC)","19":"Liraglutide (0.6 mg) plus glimepiride","20":"Fast treadmill speed","21":"Liraglutide (1.8 mg) plus glimepiride","22":"Dihydroartemisinin-piperaquine","23":"Dihydroartemisinin-piperaquine","24":"Body-weight supported treadmill training combined with Lokomat","25":"Dihydroartemisinin-piperaquine","26":"Dihydroartemisinin-piperaquine","27":"Liraglutide (1.8 mg) plus glimepiride","28":"Infliximab","29":"Liraglutide (1.8 mg) plus glimepiride ","30":"Liraglutide (1.2 mg) plus glimepiride","31":"Body-weight supported treadmill training combined with Lokomat (Post-test)","32":"Dihydroartemisinin-piperaquine","33":"Dihydroartemisinin-piperaquine","34":"Liraglutide (0.6 mg) plus glimepiride","35":"Liraglutide (0.6 mg) plus glimepiride","36":"Liraglutide (1.2 mg) plus glimepiride ","37":"Midwife-led unit","38":"Infliximab","39":"Liraglutide (1.8 mg) plus glimepiride","40":"dextran-70 infusion was administered at a dose of 7.5 ml\/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml\/kg after the cessation of cardiopulmonary bypass","41":"Midwife-led unit","42":"Dihydroartemisinin-piperaquine","43":"Promotion by CHWs of maternal and newborn-care interventions ","44":"high Ab group","45":"Decremental PEEP titration group","46":"Liraglutide (1.2 mg) plus glimepiride ","47":"Infliximab","48":"Liraglutide (1.8 mg) plus glimepiride","49":"Liraglutide (1.2 mg) plus glimepiride","50":"Liraglutide (all doses) plus glimepiride","51":"Liraglutide (1.2 mg) plus glimepiride","52":"Liraglutide (all doses) plus glimepiride","53":"Midwife-led unit","54":"Liraglutide (1.2 mg) plus glimepiride","55":"non-abstainers (weeks 19\u201352) with high Ab levels","56":"Liraglutide (0.6 mg) plus glimepiride","57":"Dihydroartemisinin-piperaquine","58":"Liraglutide (1.8 mg) plus glimepiride ","59":"dextran-70 infusion was administered at a dose of 7.5 ml\/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml\/kg after the cessation of cardiopulmonary bypass","60":"Infliximab","61":"Promotion by CHWs of maternal and newborn-care interventions ","62":"Midwife-led unit","63":"Body-weight supported treadmill training combined with Lokomat (Post-test)","64":"Infliximab","65":"Decremental PEEP titration group","66":"Liraglutide (1.8 mg) plus glimepiride","67":"Dihydroartemisinin-piperaquine","68":"low Ab group","69":"Liraglutide (1.2 mg) plus glimepiride ","70":"Liraglutide (all doses) plus glimepiride","71":"Infliximab","72":"Liraglutide (1.2 mg) plus glimepiride","73":"dextran-70 infusion was administered at a dose of 7.5 ml\/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml\/kg after the cessation of cardiopulmonary bypass","74":"Liraglutide (1.8 mg) plus glimepiride ","75":"Infliximab","76":"Body-weight supported treadmill training combined with Lokomat (Post-test)","77":"Liraglutide (all doses) plus glimepiride","78":"Liraglutide (all doses) plus glimepiride","79":"Body-weight supported treadmill training combined with Lokomat","80":"dextran-70 infusion was administered at a dose of 7.5 ml\/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml\/kg after the cessation of cardiopulmonary bypass","81":"Liraglutide (1.8 mg) plus glimepiride","82":"Liraglutide (1.2 mg) plus glimepiride ","83":"Promotion by CHWs of maternal and newborn-care interventions ","84":"Liraglutide (1.8 mg) plus glimepiride","85":"Liraglutide (1.2 mg) plus glimepiride ","86":"Liraglutide (1.8 mg) plus glimepiride","87":"dextran-70 infusion was administered at a dose of 7.5 ml\/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml\/kg after the cessation of cardiopulmonary bypass","88":"Liraglutide (0.6 mg) plus glimepiride","89":"Liraglutide (1.8 mg) plus glimepiride","90":"Special unit","91":"Body-weight supported treadmill training combined with Lokomat (Post-test)","92":"Infliximab","93":"Liraglutide (1.8 mg) plus glimepiride ","94":"Dihydroartemisinin-piperaquine","95":"Infliximab","96":"Dihydroartemisinin-piperaquine","97":"Liraglutide (1.8 mg) plus glimepiride","98":"Liraglutide (1.2 mg) plus glimepiride","99":"Liraglutide (1.2 mg) plus glimepiride ","100":"Rosiglitazone plus glimepiride","101":"Liraglutide (all doses) plus glimepiride","102":"low Ab group","103":"Inravenous ertapenem, 1 g once a day","104":"Liraglutide (1.2 mg) plus glimepiride","105":"Liraglutide (1.2 mg) plus glimepiride","106":"high Ab group","107":"Liraglutide (1.8 mg) plus glimepiride ","108":"Midwife-led unit","109":"Liraglutide (1.2 mg) plus glimepiride","110":"Transverse incision","111":"Clopidogrel","112":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","113":"Clopidogrel","114":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","115":"Patients who received a question prompt sheet","116":"progesterone","117":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","118":"Transverse incision","119":"raditional Smith\u2013Robinson (SR) procedure with autograft ","120":"Follow-up and thorough education on self-care","121":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","122":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","123":"arthemeter-lumefantrine (AL) ","124":"Laparoscopic surgery","125":"Smoking cessation advice and NRT offered","126":"Radiofrequency ablation","127":"Photo-refractive keratectomy (PRK)","128":"Follow-up and thorough education on self-care","129":"Radiofrequency ablation","130":"Radiofrequency ablation","131":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","132":"1 litre saline enema","133":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","134":"Transverse incision","135":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","136":"Photo-refractive keratectomy (PRK)","137":"Transverse incision","138":"raditional Smith\u2013Robinson (SR) procedure with autograft ","139":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","140":"Transverse incision","141":"Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF)","142":"Transverse incision","143":"Photo-refractive keratectomy (PRK)","144":"Baseline communities that received additional education and preventive measures","145":"Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF)","146":"individual support, group rehabilitation and a combination of the two (Group rehabilitation)","147":"Bladder training plus tolterodine (Co)","148":"plasma exchange (PE)","149":"Radiofrequency ablation","150":"Laparoscopic surgery","151":"single dose of 50 mg\/kg clofibrate","152":"Laparoscopic surgery","153":"dihydroartemisinin-piperaquine ","154":"Photo-refractive keratectomy (PRK)","155":"Laparoscopic surgery","156":"Transverse incision","157":"Laparoscopic surgery","158":"Patients who received a question prompt sheet","159":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","160":"progesterone","161":"Baseline communities that received additional education and preventive measures","162":"Bladder training plus tolterodine (Co)","163":"Patients who received a question prompt sheet","164":"Photo-refractive keratectomy (PRK)","165":"Smoking cessation advice and NRT offered","166":"Smoking cessation advice and NRT offered","167":"Exercise","168":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","169":"Smoking cessation advice and NRT offered","170":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","171":"Follow-up and thorough education on self-care","172":"Baseline communities that received additional education and preventive measures","173":"arthemeter-lumefantrine (AL) ","174":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","175":"Follow-up and thorough education on self-care","176":"Baseline communities that received additional education and preventive measures","177":"Transverse incision","178":"Smoking cessation advice and NRT offered","179":"Clopidogrel","180":"Follow-up and thorough education on self-care","181":"Patients who received a question prompt sheet","182":"Transverse incision","183":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","184":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","185":"Smoking cessation advice and NRT offered","186":"Exercise","187":"Smoking cessation advice and NRT offered","188":"Transverse incision","189":"Tolterodine only (To)","190":"Baseline communities that received additional education and preventive measures","191":"Transverse incision","192":"Follow-up and thorough education on self-care","193":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","194":"Baseline communities that received additional education and preventive measures","195":"Follow-up and thorough education on self-care","196":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","197":"High frequency chest wall oscillation","198":"cineole","199":"Photo-refractive keratectomy (PRK)","200":"Follow-up and thorough education on self-care","201":"progesterone","202":"Smoking cessation advice and NRT offered","203":"Smoking cessation advice and NRT offered","204":"Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF)","205":"Laparoscopic surgery","206":"Smoking cessation advice and NRT offered","207":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","208":"Baseline communities that received additional education and preventive measures","209":"Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF)","210":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","211":"Smoking cessation advice and NRT offered","212":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","213":"dihydroartemisinin-piperaquine ","214":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","215":"Smoking cessation advice and NRT offered","216":"Bladder training plus tolterodine (Co)","217":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","218":"cineole","219":"single dose of 50 mg\/kg clofibrate","220":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","221":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","222":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","223":"Prostaglandin gel plus hygroscopic cervical dilators ","224":"single dose of 50 mg\/kg clofibrate","225":"Thiopental","226":"Photo-refractive keratectomy (PRK)","227":"components separation technique (CST)","228":"Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF)","229":"Thin-flap laser in situ keratomileusis (LASIK) ","230":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","231":"cineole","232":"plasma exchange (PE) ","233":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","234":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","235":"progesterone","236":"Follow-up and thorough education on self-care","237":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","238":"High frequency chest wall oscillation","239":"Laparoscopic surgery","240":"Thiopental","241":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","242":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","243":"Photo-refractive keratectomy (PRK)","244":"topical diclofenac solution (Pennsaid\u00ae)","245":"Transverse incision","246":"Follow-up and thorough education on self-care","247":"Radiofrequency ablation","248":"Communities that received additional education and preventive measures","249":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","250":"Follow-up and thorough education on self-care","251":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","252":"Transverse incision","253":"Smoking cessation advice and NRT offered","254":"1 litre saline enema","255":"dihydroartemisinin-piperaquine ","256":"Transverse incision","257":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","258":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","259":"Follow-up and thorough education on self-care","260":"Photo-refractive keratectomy (PRK)","261":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","262":"Radiofrequency ablation","263":"Prostaglandin gel plus hygroscopic cervical dilators ","264":"cineole","265":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","266":"Baseline communities that received additional education and preventive measures","267":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","268":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","269":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","270":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","271":"Smoking cessation advice and NRT offered","272":"Laparoscopic surgery","273":"High frequency chest wall oscillation","274":"Laparoscopic surgery","275":"Transverse incision","276":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","277":"Artesunate+amodiaquine (AS+AQ)","278":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","279":"receive a dose of 0.25 mg (1:1:1 ratio) and then allocated to active treatment (CCH)","280":"good motivation\/capability","281":"stride frequency manipulation","282":"Tailored letters","283":"receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles","284":"receive a dose of 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH)","285":"Ultrasound\u2010guided foam sclerotherapy","286":"Ultrasound\u2010guided foam sclerotherapy","287":"received standard therapy for sepsis and physiological-dose steroid therapy for 10 days;","288":"Transversus abdominis plane block with 0.375% ropivacaine ","289":"additional lay support (in this instance Pregnancy Outreach Workers, POWs)","290":"Artemether-lumefantrine","291":"receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles","292":"Ultrasound\u2010guided foam sclerotherapy","293":"Endovenous laser ablation","294":"Gomutra sodhit Langali moola with honey for external application","295":"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week","296":"Home-based HIV-care strategy","297":"0\u00b75% PRO2000 gel","298":"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week","299":"low\u2013glycemic index diet (target glycemic index [GI] ~50)","300":"PRO2000 gels","301":"Ultrasound\u2010guided foam sclerotherapy","302":"glycine 1.5% solution as irrigating fluid","303":"Initial Nottingham TSR design prosthesis","304":"Transversus abdominis plane block with 0.375% ropivacaine ","305":"glycine 1.5% solution as irrigating fluid","306":"Rosuvastatin","307":"receive a dose of 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH)","308":"good motivation\/capability","309":"Artemether-lumefantrine","310":"opening subcutaneous tissues with electrocautery","311":"Cisplatin and Cyclophosphamide, plus subcutaneous IFN-\u03b3 ","312":"low\u2013glycemic index diet (target glycemic index [GI] ~50)","313":"0\u00b75% PRO2000 gel","314":"Erythromycin","315":"Home-based HIV-care strategy","316":"receive a dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH)","317":"Ultrasound\u2010guided foam sclerotherapy","318":"received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days","319":"fibrin glue group (glue sprayed onto the axillary dissection site)","320":"good motivation\/capability","321":"an automated package of video and text messages over 6 months that was tailored to self-selected quit date, role model, and timing of messages. Extra messages were available on demand to beat cravings and address lapses.","322":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","323":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","324":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","325":"Transverse incision","326":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","327":"Exercise","328":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","329":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","330":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","331":"Photo-refractive keratectomy (PRK)","332":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","333":"Bladder training plus tolterodine (Co)","334":"Thiopental","335":"High frequency chest wall oscillation","336":"plasma exchange (PE) ","337":"Follow-up and thorough education on self-care","338":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","339":"Follow-up and thorough education on self-care","340":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","341":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","342":"1 litre saline enema","343":"High frequency chest wall oscillation","344":"Laparoscopic surgery","345":"Radiofrequency ablation","346":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","347":"progesterone","348":"Thiopental","349":"progesterone","350":"topical diclofenac solution (Pennsaid\u00ae)","351":"raditional Smith\u2013Robinson (SR) procedure with autograft ","352":"somatostatin","353":"Exercise","354":"Transverse incision","355":"Photo-refractive keratectomy (PRK)","356":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","357":"High frequency chest wall oscillation","358":"Communities that received additional education and preventive measures","359":"components separation technique (CST)","360":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","361":"Prostaglandin gel plus hygroscopic cervical dilators ","362":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","363":"cineole","364":"Thiopental","365":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","366":"Prostaglandin gel plus hygroscopic cervical dilators ","367":"topical diclofenac solution (Pennsaid\u00ae)","368":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","369":"Laparoscopic surgery","370":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","371":"Transverse incision","372":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","373":"cineole","374":"High frequency chest wall oscillation","375":"Radiofrequency ablation","376":"Exercise","377":"Follow-up and thorough education on self-care","378":"plasma exchange (PE) ","379":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","380":"Exercise","381":"Transverse incision","382":"Photo-refractive keratectomy (PRK)","383":"Smoking cessation advice and NRT offered","384":"Laparoscopic surgery","385":"Radiofrequency ablation","386":"Photo-refractive keratectomy (PRK)","387":"High frequency chest wall oscillation","388":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","389":"Baseline communities that received additional education and preventive measures","390":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","391":"topical diclofenac solution (Pennsaid\u00ae)","392":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","393":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","394":"Thiopental","395":"Thiopental","396":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","397":"Artesunate+amodiaquine (AS+AQ)","398":"Thiopental","399":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","400":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","401":"plasma exchange (PE) ","402":"Transverse incision","403":"Thiopental","404":"Rosuvastatin","405":"Rosuvastatin","406":"Artemether-lumefantrine","407":"Sunitinib","408":"palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20 Gy\/5 fractions (fr)\/5 days (arm A)","409":"low\u2013glycemic index diet (target glycemic index [GI] ~50)","410":"received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days","411":"fibrin glue group (glue sprayed onto the axillary dissection site)","412":"Exercise","413":"attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary","414":"attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary","415":"additional lay support (in this instance Pregnancy Outreach Workers, POWs)","416":"additional lay support (in this instance Pregnancy Outreach Workers, POWs)","417":"24-week intervention focussed on improving food choice and minimising weight gain","418":"Spine Balance 3D (CyberMedic)","419":"Spine Balance 3D (CyberMedic)","420":"The Child and Adolescent Structured Competencies Approach to Diabetes Education (CASCADE) is a structured educational group program, using psychological techniques, delivered primarily by diabetes nurses.","421":"stride frequency manipulation","422":"stride frequency manipulation","423":"Ultrasound\u2010guided foam sclerotherapy","424":"Ultrasound\u2010guided foam sclerotherapy","425":"Ultrasound\u2010guided foam sclerotherapy","426":"Ultrasound\u2010guided foam sclerotherapy","427":"Ultrasound\u2010guided foam sclerotherapy","428":"Endovenous laser ablation","429":"intravenous dose of 0.035 mg\/kg of midazolam","430":"receive a dose of 0.25 mg (1:1:1 ratio) and then allocated to active treatment (CCH)","431":"resistance training dyrung radiation therapy","432":"Home-based HIV-care strategy","433":"Home-based HIV-care strategy","434":"Home-based HIV-care strategy","435":"receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles","436":"Cisplatin and Cyclophosphamide, plus subcutaneous IFN-\u03b3 ","437":"Tailored letters","438":"PTA lozenge","439":"PTA lozenge","440":"Initial Nottingham TSR design prosthesis","441":"Rosuvastatin","442":"Rosuvastatin","443":"Artemether-lumefantrine","444":"Artemether-lumefantrine","445":"Artemether-lumefantrine","446":"Sunitinib","447":"Sunitinib","448":"Sunitinib","449":"Sunitinib","450":"palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20 Gy\/5 fractions (fr)\/5 days (arm A)","451":"palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20 Gy\/5 fractions (fr)\/5 days (arm A)","452":"an automated package of video and text messages over 6 months that was tailored to self-selected quit date, role model, and timing of messages. Extra messages were available on demand to beat cravings and address lapses.","453":"received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days","454":"received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days","455":"fibrin glue group (glue sprayed onto the axillary dissection site)","456":"received standard therapy for sepsis and physiological-dose steroid therapy for 10 days;","457":"received standard therapy for sepsis and physiological-dose steroid therapy for 10 days;","458":"attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary","459":"attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary","460":"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week","461":"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week","462":"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week","463":"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week","464":"24-week intervention focussed on improving food choice and minimising weight gain","465":"Spine Balance 3D (CyberMedic)","466":"stride frequency manipulation","467":"CT scan","468":"Ultrasound\u2010guided foam sclerotherapy","469":"Ultrasound\u2010guided foam sclerotherapy","470":"Ultrasound\u2010guided foam sclerotherapy","471":"Endovenous laser ablation","472":"intravenous dose of 0.035 mg\/kg of midazolam","473":"resistance training dyrung radiation therapy","474":"individual support, group rehabilitation and a combination of the two (Group rehabilitation)","475":"clinically indicated","476":"hyperbaric oxygen therapy","477":"High frequency chest wall oscillation","478":"palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20?Gy\/5 fractions (fr)\/5 days (arm A)","479":"Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF)","480":"Ultrasound?guided foam sclerotherapy","481":"Ultrasound?guided foam sclerotherapy","482":"Ultrasound?guided foam sclerotherapy","483":"Endovenous laser ablation","484":"Endovenous laser ablation","485":"20 mg atorvastatin nightly for 3 months","486":"vitamin D group receiving an initial bolus dose of 100,000 IU (in 2 capsules) followed by 4,000 IU (in 4 capsules) of cholecalciferol daily","487":"after 4 weeks of repetitive facilitative exercises and orthotic treatment.","488":"After trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results.","489":"bosentan","490":"phone calls\" group","491":"CPAP + standard of care (nCPAP group)","492":"vitamin D supplements at a dosage of 50,000 IU (n = 30) every 2 weeks for 12 weeks","493":"vitamin D supplements at a dosage of 50,000 IU (n = 30) every 2 weeks for 12 weeks","494":"belatacept groups","495":"Capsule trial, ME-3","496":"lidocaine gel (2%)","497":"Abediterol","498":"Abediterol","499":"furosemide","500":"calcium-focused food frequency questionnaire (CFFFQ)","501":"undergo a tubal resection after Pomeroy ligation","502":"undergo a tubal resection after Pomeroy ligation","503":"coronally positioned flap (CPF) with acellular dermal matrix allograft (ADMA).","504":"10-15 mg\/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was administered at 06.00-07.00 pm","505":"receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL).","506":"2?mA anodal tDCS, when applied for 15?min over the motor cortex","507":"Custodiol-N","508":"Custodiol-N","509":"The trabecular metal tibial monoblock component (TM)","510":"trained psychotherapists in addition to the pre-existing Employee Assistance Program (EAP)","511":"AutoPulse automated chest compression device","512":"Cisplatin and Cyclophosphamide, plus subcutaneous IFN-\u03b3 ","513":"Cisplatin and Cyclophosphamide, plus subcutaneous IFN-\u03b3 ","514":"Tailored letters","515":"Erythromycin","516":"0\u00b75% PRO2000 gel","517":"PTA lozenge","518":"PTA lozenge","519":"Redesigned Nottingham TSR prosthesis","520":"Rosuvastatin","521":"L. fermentum ME-3 fermented goat milk","522":"palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20?Gy\/5 fractions (fr)\/5 days (arm A)","523":"arthemeter-lumefantrine (AL) ","524":"Abediterol","525":"furosemide","526":"calcium-focused food frequency questionnaire (CFFFQ)","527":"white women","528":"daily doses of 400 IU of vitamin E and 1000 mg of vitamin C from 9-16 weeks gestation until delivery.","529":"Haptoglobin's (Hp) 1-1, 2-1, ","530":"undergo a tubal resection after Pomeroy ligation","531":"10-15 mg\/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was administered at 06.00-07.00 pm","532":"definitely exposed volunteers for both antigens ","533":"soundfield amplification devices in the classroom","534":"soundfield amplification devices in the classroom","535":"IOLs were selected randomly among two types of yellow IOLs (Acrysof SN60WF IOL, Hoya YA60BBR IOL)","536":"antibiotics","537":"antibiotics in less than 24 h to parturition","538":"Custodiol-N","539":"hyperbaric oxygen therapy","540":"Ultrasound?guided foam sclerotherapy","541":"Ultrasound?guided foam sclerotherapy","542":"trained psychotherapists in addition to the pre-existing Employee Assistance Program (EAP)","543":"Ultrasound?guided foam sclerotherapy","544":"lifestyle intervention (LI) consisting of exercise and nutritional counseling with cognitive-behavior modification","545":"Ultrasound?guided foam sclerotherapy","546":"cranberry juices","547":"Endovenous laser ablation","548":"intravenous dose of 0.035 mg\/kg of midazolam","549":"20 mg atorvastatin nightly for 3 months","550":"after 4 weeks of repetitive facilitative exercises and orthotic treatment.","551":"after 4 weeks of repetitive facilitative exercises and orthotic treatment.","552":"After trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results.","553":"bosentan","554":"phone calls\" group","555":"The Network for Mental Health (NWpG-IC)","556":"major salivary gland cancer in high risk group plus adjuvant radiation therapy","557":"major salivary gland cancer in low\/intermediate risk group plus adjuvant radiation therapy","558":"vitamin D supplements at a dosage of 50,000 IU (n = 30) every 2 weeks for 12 weeks","559":"amoxicillin (750 mg), clarithromycin (200 mg), and either esomeprazole (20 mg) (EAC group), twice a day for one week.","560":"Technology Enhanced Quitline-10 ","561":"Tranexamic acid","562":"Pioglitazone (30 mg\/day for 14 days)","563":"Pioglitazone (30 mg\/day for 14 days)","564":"Self-referral treatment","565":"Self-referral treatment","566":"Prednisone (40 mg\/day for 4 days)","567":"olanzapine","568":"E-cigarettes ","569":"olanzapine","570":"Enhanced weight loss maintenance program","571":"CAPSYS system","572":"CAPSYS system","573":"neurally adjusted ventilatory assist (NAVA)","574":"CAPSYS system","575":"CAPSYS system","576":"neurally adjusted ventilatory assist (NAVA)","577":"Golimumab plus?MTX","578":"sodium bicarbonate solution using the short regimen (intravenous bolus 3 mL\/kg\/h of 166 mEq\/L sodium bicarbonate for 1 hour immediately before radiocontrast)","579":"Short-term psychotherapy","580":"mirabegron (50 and 100 mg)","581":"tailored exercise therapy, including ultrasound-guided activation of deep muscles, strengthening and stretching exercises and advice","582":"Oral etoposide phosphate","583":"tailored exercise therapy, including ultrasound-guided activation of deep muscles, strengthening and stretching exercises and advice","584":"serious game called InsuOnLine\u00a9","585":"NMES plus exercise","586":"NMES plus exercise","587":"breathing exercises were performed for 45 minutes, and were pursued for four weeks in the morning following and prior to sleeping","588":"breathing exercises were performed for 45 minutes, and were pursued for four weeks in the morning following and prior to sleeping","589":"received 1 mg\/kg and 2 mg\/kg hydrocortisone","590":"BZA\/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),","591":"A mixed-effects model repeated measures approach (MMRM)","592":"BZA\/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),","593":"BZA\/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),","594":"core decompression with the application of bone marrow aspirate concentrate","595":"core decompression with the application of bone marrow aspirate concentrate","596":"BZA\/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),","597":"knee extension at 90\u00b0 of flexion","598":"high-fat diet enriched with ground flaxseed 15 g\/100 g of food, rich in ALA; ","599":"Capsules (300 mg) containing Lactobacillus brevis G101 (1\u00d71010 CFU\/individual)","600":"laser peripheral iridotomy (LPI) group 1","601":"upper thoracic manipulation (UTM)","602":"single serving of curry meal","603":"hydromorphone","604":"2% seamustard","605":"2% seamustard","606":"Walking and Behavioural intervention (WB)","607":"Walking and Behavioural intervention (WB)","608":"Academic, non-commercial sponsored trials","609":"Helium preconditioning (3 \u00d7 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp.","610":"Medication plus exercise","611":"Ropivacaine 0.2%, and intravenous injection dexamethasone 8 mg (Group B)","612":"Ropivacaine 0.2% with injection dexamethasone 8 mg (Group C)","613":"Ropivacaine 0.2%, and intravenous injection dexamethasone 8 mg (Group B)","614":"Singing classes","615":"Singing classes","616":"receive exclusive breastfeeding counselling from the counsellors","617":"website with social presence elements.","618":"website with social presence elements.","619":"Non-professional mentor support","620":"EDSS\/T25FW\/9HPT","621":"administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cow's ghee and sugar.","622":"Hypnotherapy","623":"FUFOX","624":"SLA and SHA groups","625":"Stretching exercises","626":"high-intensity interval training (HIT) for 12-weeks in patients NYHA II-III","627":"Low-dose bupivacaine spinal anesthesia in pre-eclamptic parturients","628":"tiropramide 100","629":"Desmopressin","630":"E-group - The Newborn Individualized Developmental Care and Assessment Program (NIDCAP) provides a system of NICU care and environmental structure that supports preterm infants' early brain development.","631":"Respiratory muscle endurance training","632":"Katupila Kalka with Tila Taila","633":"Katupila Kalka with Tila Taila","634":"Technology Enhanced Quitline-10 and Technology Enhanced Quitline-20","635":"Technology Enhanced Quitline-10 and Technology Enhanced Quitline-20","636":"E-cigarettes ","637":"Enhanced weight loss maintenance program","638":"Enhanced weight loss maintenance program","639":"CAPSYS system","640":"Oral etoposide phosphate","641":"NMES plus exercise","642":"NMES plus exercise","643":"Neurally Adjusted Ventilatory Assist","644":"Neurally Adjusted Ventilatory Assist","645":"knee extension at 90\u00b0 of flexion","646":"knee extension at 90\u00b0 of flexion","647":"gabapentin (10 mg\/kg)","648":"laser peripheral iridotomy (LPI) group 1","649":"upper thoracic manipulation (UTM)","650":"single serving of curry meal","651":"2% seamustard","652":"2% seamustard","653":"2% seamustard","654":"2% seamustard","655":"Helium preconditioning (3 \u00d7 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp.","656":"Helium preconditioning (3 \u00d7 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp.","657":"Group K, 0.5 mg\/kg of ketamine was injected intravenously,","658":"exercise","659":"exercise","660":"exercise","661":"timed 25-foot walk [T25FW],","662":"administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cow's ghee and sugar.","663":"simplified cognitive behavioral therapy (SCBT) on generalized anxiety disorder (GAD)","664":"simplified cognitive behavioral therapy (SCBT) on generalized anxiety disorder (GAD)","665":"groups primed with SeV-Gag and boosted with Ad35-GRIN (SLA and SHA)","666":"ASH group","667":"high-intensity interval training (HIT) for 12-weeks in patients NYHA II-III","668":"tiropramide 100","669":"tiropramide 100","670":"pulmonary emboli or cancer or cardiac failure or cardiovascular disease or dementia or dependence in P-ADL","671":"Taurine combined with Ethanol (TA+ET)","672":"Pioglitazone (30 mg\/day for 14 days)","673":"Pioglitazone (30 mg\/day for 14 days)","674":"olanzapine","675":"after treatment ","676":"sodium bicarbonate solution using the short regimen (intravenous bolus 3 mL\/kg\/h of 166 mEq\/L sodium bicarbonate for 1 hour immediately before radiocontrast)","677":"sodium bicarbonate solution using the short regimen (intravenous bolus 3 mL\/kg\/h of 166 mEq\/L sodium bicarbonate for 1 hour immediately before radiocontrast)","678":"mirabegron (50 and 100 mg)","679":"a balance-based exergaming group for an 8-week balance training period.","680":"received 1 mg\/kg and 2 mg\/kg hydrocortisone","681":"BZA\/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),","682":"BZA\/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),","683":"BZA\/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),","684":"BZA\/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),","685":"BZA\/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),","686":"BZA\/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),","687":"BZA\/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),","688":"high-fat diet enriched with ground flaxseed 15 g\/100 g of food, rich in ALA; or enriched with vitamin E, 40 mg ?-tocopherol\/100 g of food","689":"hyperbaric oxygen therapy","690":"mild cognitive impairment (MCI)","691":"pain score display group","692":"vitamin D group receiving an initial bolus dose of 100,000 IU (in 2 capsules) followed by 4,000 IU (in 4 capsules) of cholecalciferol daily","693":"The Network for Mental Health (NWpG-IC)","694":"The Network for Mental Health (NWpG-IC)","695":"amoxicillin (750 mg), clarithromycin (200 mg), and either esomeprazole (20 mg) (EAC group), twice a day for one week.","696":"after Non-Invasive Brain Stimulation (NIBS)","697":"belatacept groups","698":"L. fermentum ME-3 fermented goat milk","699":"after intervention","700":"aseptic, cryopreserved P. falciparum sporozoites (PfSPZ Challenge)","701":"soundfield amplification devices in the classroom","702":"lost weight","703":"cranberry juices","704":"cranberry juices","705":"Walking and Behavioural intervention (WB)","706":"Walking and Behavioural intervention (WB)","707":"Academic, non-commercial sponsored trials","708":"Medication plus exercise","709":"Medication plus exercise","710":"Ropivacaine 0.2%, and intravenous injection dexamethasone 8 mg (Group B)","711":"Singing classes","712":"Non-professional mentor support","713":"Hypnotherapy","714":"Stretching exercises","715":"Low-dose bupivacaine spinal anesthesia in pre-eclamptic parturients","716":"Desmopressin","717":"Desmopressin","718":"Respiratory muscle endurance training","719":"Katupila Kalka with Tila Taila","720":"Technology Enhanced Quitline-10 and Technology Enhanced Quitline-20","721":"Tranexamic acid","722":"Tranexamic acid","723":"Self-referral treatment","724":"E-cigarettes ","725":"Neurally Adjusted Ventilatory Assist","726":"core decompression with the application of bone marrow aspirate concentrate","727":"Capsules (300 mg) containing Lactobacillus brevis G101 (1\u00d71010 CFU\/individual)","728":"laser peripheral iridotomy (LPI) group 1","729":"hydromorphone","730":"hydromorphone","731":"hydromorphone","732":"2% seamustard","733":"2% seamustard","734":"Group K, 0.5 mg\/kg of ketamine was injected intravenously,","735":"Group K, 0.5 mg\/kg of ketamine was injected intravenously,","736":"Group K, 0.5 mg\/kg of ketamine was injected intravenously,","737":"3000 IU d?1 oral superoxide dismutase (SOD) powder for 6?wks - treatment group (TRT)","738":"administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cow's ghee and sugar.","739":"administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cow's ghee and sugar.","740":"high-intensity interval training (HIT) for 12-weeks in patients NYHA II-III","741":"tiropramide 100","742":"five injections of HA1 (Suprahyal\u00ae\/Adant\u00ae)","743":"three injections of HA3 (Synvisc\u00ae)","744":"four injections of HA2 (Orthovisc\u00ae)","745":"1) five injections of HA1 (Suprahyal\u00ae\/Adant\u00ae); 2) four injections of HA2 (Orthovisc\u00ae); 3) three injections of HA3 (Synvisc\u00ae); 4) a single injection of PRP (GPSTM II);","746":"neurally adjusted ventilatory assist (NAVA)","747":"components separation technique (CST)","748":"mirabegron (50 and 100 mg)","749":"a balance-based exergaming group for an 8-week balance training period.","750":"breathing exercises were performed for 45 minutes, and were pursued for four weeks in the morning following and prior to sleeping","751":"Artesunate+amodiaquine (AS+AQ)","752":"high-fat diet enriched with ground flaxseed 15 g\/100 g of food, rich in ALA; ","753":"high-fat diet enriched with ground flaxseed 15 g\/100 g of food, rich in ALA; or enriched with vitamin E, 40 mg ?-tocopherol\/100 g of food","754":"pain score display group","755":"palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20?Gy\/5 fractions (fr)\/5 days (arm A)","756":"24-week intervention focussed on improving food choice and minimising weight gain","757":"24-week intervention focussed on improving food choice and minimising weight gain","758":"The Child and Adolescent Structured Competencies Approach to Diabetes Education (CASCADE) is a structured educational group program, using psychological techniques, delivered primarily by diabetes nurses.","759":"ranibizumab ","760":"Ultrasound?guided foam sclerotherapy","761":"Ultrasound?guided foam sclerotherapy","762":"Ultrasound?guided foam sclerotherapy","763":"Ultrasound?guided foam sclerotherapy","764":"Ultrasound?guided foam sclerotherapy","765":"20 mg atorvastatin nightly for 3 months","766":"vitamin D group receiving an initial bolus dose of 100,000 IU (in 2 capsules) followed by 4,000 IU (in 4 capsules) of cholecalciferol daily","767":"phone calls\" group","768":"CPAP + standard of care (nCPAP group)","769":"belatacept groups","770":"L. fermentum ME-3 fermented goat milk","771":"lidocaine gel (2%)","772":"Abediterol","773":"white women","774":"received, intravesically, 40 mL of 20 nM Resiniferatoxin 20 hours before operation.","775":"received, intravesically, 40 mL of 20 nM Resiniferatoxin 20 hours before operation.","776":"received, intravesically, 40 mL of 20 nM Resiniferatoxin 20 hours before operation.","777":"fixed-dose combination (FDC) of dutasteride and tamsulosin","778":"daily doses of 400 IU of vitamin E and 1000 mg of vitamin C from 9-16 weeks gestation until delivery.","779":"receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL).","780":"receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL).","781":"2?mA anodal tDCS when applied over the Pcor for 15?minutes","782":"soundfield amplification devices in the classroom","783":"awareness of wearing an accelerometer (nonblinded group)","784":"awareness of wearing an accelerometer (nonblinded group)","785":"The trabecular metal tibial monoblock component (TM)","786":"The trabecular metal tibial monoblock component (TM)","787":"The routine interventions included praziquantel chemotherapy and controlling snails plus new interventions, mainly consisting of building fences to limit the grazing area for bovines, building safe pastures for grazing, improving the residents' health conditions and facilities,","788":"The routine interventions included praziquantel chemotherapy and controlling snails plus new interventions, mainly consisting of building fences to limit the grazing area for bovines, building safe pastures for grazing, improving the residents' health conditions and facilities,","789":"trained psychotherapists in addition to the pre-existing Employee Assistance Program (EAP)","790":"supportive care or acupuncture group","791":"AutoPulse automated chest compression device","792":"AutoPulse automated chest compression device","793":"AutoPulse automated chest compression device","794":"Walking and Behavioural intervention (WB)","795":"Academic, non-commercial sponsored trials","796":"Medication plus exercise","797":"Bispectral index (BIS) guided anesthesia","798":"Singing classes","799":"Singing classes","800":"Non-professional mentor support","801":"Hypnotherapy","802":"Low-dose bupivacaine spinal anesthesia in pre-eclamptic parturients","803":"Low-dose bupivacaine spinal anesthesia in pre-eclamptic parturients","804":"Respiratory muscle endurance training","805":"Katupila Kalka with Tila Taila","806":"ticagrelor","807":"ticagrelor","808":"ticagrelor","809":"ticagrelor","810":"completing 6 days of assessment (four sets of questions per day) with a native smartphone application","811":"receive FU 500 mg\/m2 IV bolus weekly \u00d76 weeks plus leucovorin 500?mg\/m2 IV weekly for 6 weeks during each 8-week cycle plus oxaliplatin 85?mg\/m2 IV on weeks 1, 3, and 5 of each 8-week (FLOX) ","812":"receive the injection with diabetic needle","813":"receive the injection with diabetic needle","814":"paracetamol\/buprenorphine","815":"12-weeks of progressive endurance and strength training at a local health club","816":"Saccharomyces cerevisiae (S. cerevisiae) CNCM I-3856","817":"Saccharomyces cerevisiae (S. cerevisiae) CNCM I-3856","818":"assigned to the dietary fat components who carried the AA genotype of FTO rs1558902","819":"enteric-coated mycophenolate sodium (EC-MPS) 1440?mg\/day for first 6?months","820":"received treatment with rotary instruments","821":"oral metformin 500 mg TDS (Group-A)","822":"Low-molecular-weight heparin before and after the surgery","823":"Ultrasound?guided foam sclerotherapy","824":"Educational program and ED protocol for syncope evaluation","825":"Educational program and ED protocol for syncope evaluation","826":"Educational program and ED protocol for syncope evaluation","827":"Routine unit care ","828":"sumatriptan for 2 months","829":"the combined and in the pure handwriting group","830":"400 ?g of intrathecal morphine followed by general anesthesia","831":"400 ?g of intrathecal morphine followed by general anesthesia","832":"400 ?g of intrathecal morphine followed by general anesthesia","833":"education and mobilisation activities","834":"elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide (E\/C\/F\/TAF) 150\/150\/200\/10 mg plus DRV 800 mg (Janssen) once daily","835":"anti-inflammatory agent (Diacerein treatment group)","836":"Acidform twice daily for 14 consecutive days","837":"placeboxetine (PB) hydrochloride extended release capsules","838":"amitriptyline","839":"received 0.5 mg\/kg of ketamine IV 10 minutes before the surgical incision","840":"Transversus abdominis plane block with 0.375% ropivacaine ","841":"MSD, 100 mg l?dopa plus 25 mg carbidopa","842":"Several message exposures","843":"Several message exposures","844":"Several message exposures","845":"male","846":"1.7 g of Long chain omega-3 fatty acids from fish oils (O3) per day for 4 weeks","847":"PTA lozenge","848":"fentanyl (1 \u03bcg\/kg) and propofol ","849":"GLPG0259 and methotrexate","850":"vitamin D 4000 IE\/day","851":"vitamin D 4000 IE\/day","852":"prothrombin complex concentrates (PCC)","853":"prothrombin complex concentrates (PCC)","854":"completers of in-laboratory (Part A) and home trial (Part B)","855":"completers of in-laboratory (Part A) and home trial (Part B)","856":"receiving 1200 mg of cranberry extract for 6 weeks","857":"receiving 1200 mg of cranberry extract for 6 weeks","858":"Internet-based guided self-help program, including weekly support from a therapist via encrypted email","859":"receive orally daily either CyavanaprA\u0308?A\u030a\u203aa (CP) (approx. 6 g) followed by a cup of milk (100 \u2013 200 ml)","860":"receive orally daily either CyavanaprA\u0308?A\u030a\u203aa (CP) (approx. 6 g) followed by a cup of milk (100 \u2013 200 ml)","861":"5-fluorouracil (5-FU) 0.5%\/salicylic acid 10%","862":"5-fluorouracil (5-FU) 0.5%\/salicylic acid 10%","863":"nebivolol","864":"nebivolol","865":"nebivolol","866":"nebivolol","867":"enhanced intervention (EIG)","868":"simulation-based training followed by clinical training","869":"SmartSet HV acrylic bone cements (without antibiotics)","870":"SmartSet HV acrylic bone cements (without antibiotics)","871":"SmartSet HV acrylic bone cements (without antibiotics)","872":"Trendelenburg (TBG) tilt >30\u00b0","873":"consumed a standardized breakfast with Avocado Added (AA)","874":"30-Hz whole-body vibration training","875":"consumed a standardized breakfast with Avocado Included (AI)","876":"consumed a standardized breakfast with Avocado Included (AI)","877":"30-Hz whole-body vibration training","878":"Inpatient program","879":"consumed a standardized breakfast with Avocado Added (AA)","880":"Inpatient program","881":"Active chest wall oscillation treatment","882":"schema-based lecture","883":"schema-based lecture","884":"Active chest wall oscillation treatment","885":"ergonomic intervention","886":"Istradefylline 20 mg or 40 mg","887":"Istradefylline 20 mg","888":"use the Total toothpastes","889":"Charite\u0301 artificial disc","890":"Standardized aberrant event detection algorithm and response protocol","891":"Standardized aberrant event detection algorithm and response protocol","892":"bupivacaine plus dexamethasone ","893":"Robotic surgery","894":"ingest 1,200 mg dietary calcium","895":"bilareal Transcutaneous electrical nerve stimulation (TENS) and taska\u0302\u20ac?oriented training (TOT)","896":"bilareal Transcutaneous electrical nerve stimulation (TENS) and taska\u0302\u20ac?oriented training (TOT)","897":"bilareal Transcutaneous electrical nerve stimulation (TENS) and taska\u0302\u20ac?oriented training (TOT)","898":"N-acetylcysteine","899":"receive immediate treatment","900":"N-acetylcysteine","901":"smelled and rated an odorant and were told that the odorant increases creativity and reduces inhibitions ","902":"received fibrinogen concentrate","903":"smelled and rated an odorant and were told that the odorant increases creativity and reduces inhibitions ","904":"centers admitting \u2265 200 patients\/year","905":"chemoradiotherapy ","906":"combination of propofol (PF) and dexmedetomidine (DEX) (Combination group)","907":"combination of propofol (PF) and dexmedetomidine (DEX) (Combination group)","908":"combination of propofol (PF) and dexmedetomidine (DEX) (Combination group)","909":"combination of propofol (PF) and dexmedetomidine (DEX) (Combination group)","910":"combination of propofol (PF) and dexmedetomidine (DEX) (Combination group)","911":"Ultrasound\u2010guided foam sclerotherapy","912":"Low-molecular-weight heparin before and after the surgery","913":"Amplitude training","914":"Acupressure","915":"Routine unit care","916":"ElliptaTM DPI","917":"education and mobilisation activities","918":"elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide (E\/C\/F\/TAF) 150\/150\/200\/10 mg plus DRV 800 mg (Janssen) once daily","919":"elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide (E\/C\/F\/TAF) 150\/150\/200\/10 mg plus DRV 800 mg (Janssen) once daily","920":"elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide (E\/C\/F\/TAF) 150\/150\/200\/10 mg plus DRV 800 mg (Janssen) once daily","921":"Acidform twice daily for 14 consecutive days","922":"Acidform twice daily for 14 consecutive days","923":"amitriptyline","924":"received 0.5 mg\/kg of ketamine IV 10 minutes before the surgical incision","925":"received 0.5 mg\/kg of ketamine IV 10 minutes before the surgical incision","926":"MSD, 100 mg l?dopa plus 25 mg carbidopa","927":"Zimbabwe","928":"Pomegranate juice (PJ)","929":"Pomegranate juice (PJ)","930":"tertiary education","931":"1.7 g of Long chain omega-3 fatty acids from fish oils (O3) per day for 4 weeks","932":"30mg\/day zinc gluconate for eight consecutive weeks","933":"GLPG0259 and methotrexate","934":"SureFil SDR or EverX Posterior bulk-fill composite resins' bond","935":"ticagrelor","936":"ticagrelor","937":"horse riding intervention","938":"horse riding intervention","939":"completing 6 days of assessment (four sets of questions per day) with a native smartphone application","940":"provided with written information about the electrodiagnostic testing","941":"empagliflozin after administration to German subjects","942":"empagliflozin after administration to Japanese and Chinese subjects","943":"receive the injection with diabetic needle","944":"78-week treatment with tramiprosate 150 mg BID","945":"78-week treatment with tramiprosate 100 mg or tramiprosate 150 mg BID","946":"3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream)","947":"3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream)","948":"3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream)","949":"B3: milk, apple, bread, and hazelnut chocolate cream","950":"Saccharomyces cerevisiae (S. cerevisiae) CNCM I-3856","951":"enteric-coated mycophenolate sodium (EC-MPS) 1440?mg\/day for first 6?months","952":"received treatment with rotary instruments","953":"oral metformin 500 mg TDS (Group-A)","954":"lower limb neuromuscular electrical stimulation (NMES) applied daily to both quadriceps muscles for six weeks.","955":"muffins enriched with 30 g HAM-RS2","956":"Active chest wall oscillation treatment","957":"Istradefylline 20 mg or 40 mg","958":"Charite\u0301 artificial disc","959":"Standardized aberrant event detection algorithm and response protocol","960":"Robotic surgery","961":"Robotic surgery","962":"Lateral decubitus position","963":"Lateral decubitus position","964":"Lateral decubitus position","965":"Lateral decubitus position","966":"Phototherapy plus massage","967":"Phototherapy plus massage","968":"received fibrinogen concentrate","969":"hydroxyurea","970":"combination of propofol (PF) and dexmedetomidine (DEX) (Combination group)","971":"completers of in-laboratory (Part A) and home trial (Part B)","972":"completers of in-laboratory (Part A) and home trial (Part B)","973":"primary hrHPV screening","974":"Internet-based guided self-help program, including weekly support from a therapist via encrypted email","975":"receive orally daily either CyavanaprA\u0308?A\u030a\u203aa (CP) (approx. 6 g) followed by a cup of milk (100 \u2013 200 ml)","976":"receive orally daily either CyavanaprA\u0308?A\u030a\u203aa (CP) (approx. 6 g) followed by a cup of milk (100 \u2013 200 ml)","977":"5-fluorouracil (5-FU) 0.5%\/salicylic acid 10%","978":"5-fluorouracil (5-FU) 0.5%\/salicylic acid 10%","979":"5-fluorouracil (5-FU) 0.5%\/salicylic acid 10%","980":"use their own Facebook profile","981":"enhanced intervention (EIG) - The enhanced intervention was delivered by CHWs as 3 individually tailored, one-on-one counseling sessions. The sessions occurred approximately 1 month, 2 months, and 6 months after screening. Each session averaged 50 minutes. Participants received transportation tokens and grocery store vouchers as incentives for attendance.","982":"usual care (UCG)","983":"enhanced intervention (EIG)","984":"simulation-based training followed by clinical training","985":"simulation-based training followed by clinical training","986":"simulation-based training followed by clinical training","987":"SmartSet HV acrylic bone cements (without antibiotics)","988":"Trendelenburg (TBG) tilt >30\u00b0 ","989":"Trendelenburg (TBG) tilt >30\u00b0","990":"Trendelenburg (TBG) tilt >30\u00b0","991":"consumed a standardized breakfast with Avocado Added (AA)","992":"schema-based lecture","993":"ergonomic intervention","994":"control","995":"rivaroxaban or apixaban or dabigatran ","996":"rivaroxaban or apixaban or dabigatran ","997":"ospemifene 60 mg\/day","998":"ospemifene 60 mg\/day","999":"ospemifene 60 mg\/day","1000":"ospemifene 60 mg\/day","1001":"bupivacaine plus dexamethasone ","1002":"bupivacaine plus dexamethasone ","1003":"ingest 1,200 mg dietary calcium","1004":"Cognitive Bias Modification for Interpretations (CBM-I) training","1005":"pertuzumab 840 mg for cycle 1 and 420 mg q3w for cycles 2\u20136 (Arm A)","1006":"pertuzumab 840 mg for cycle 1 and 420 mg q3w for cycles 2\u20136 (Arm A)","1007":"receive immediate treatment","1008":"receive immediate treatment","1009":"centers with stroke unit","1010":"centers with stroke unit","1011":"sunflower cake","1012":"sunflower cake","1013":"Tranexamic acid","1014":"ticagrelor","1015":"E-cigarettes ","1016":"olanzapine","1017":"type 1 DM","1018":"Golimumab plus?MTX","1019":"Short-term psychotherapy","1020":"mirabegron (50 and 100 mg)","1021":"Short-term psychotherapy","1022":"78-week treatment with tramiprosate 100 mg ","1023":"12-weeks of progressive endurance and strength training at a local health club","1024":"NMES plus exercise","1025":"12-weeks of progressive endurance and strength training at a local health club","1026":"Neurally Adjusted Ventilatory Assist","1027":"A mixed-effects model repeated measures approach (MMRM)","1028":"BZA\/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),","1029":"enteric-coated mycophenolate sodium (EC-MPS) 1440?mg\/day for first 6?months","1030":"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week","1031":"high-fat diet enriched with vitamin E, 40 mg ?-tocopherol\/100 g of food","1032":"oral metformin 500 mg TDS (Group-A)","1033":"Educational program and ED protocol for syncope evaluation","1034":"muffins enriched with 30 g HAM-RS2","1035":"single serving of curry meal","1036":"Amplitude training","1037":"hydromorphone","1038":"2% seamustard","1039":"elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide (E\/C\/F\/TAF) 150\/150\/200\/10 mg plus DRV 800 mg (Janssen) once daily","1040":"elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide (E\/C\/F\/TAF) 150\/150\/200\/10 mg plus DRV 800 mg (Janssen) once daily","1041":"Budesonide\/formoterol pMDI 320\/9 \u03bcg","1042":"Bispectral index (BIS) guided anesthesia","1043":"anti-inflammatory agent (Diacerein treatment group)","1044":"receive exclusive breastfeeding counselling from the counsellors","1045":"Acidform twice daily for 14 consecutive days","1046":"website with social presence elements.","1047":"timed 25-foot walk [T25FW],","1048":"amitriptyline","1049":"Hypnotherapy","1050":"groups primed with SeV-Gag and boosted with Ad35-GRIN (SLA and SHA)","1051":"receiving the combination of the sympathetic narrative and factual information","1052":"FUFOX","1053":"high-intensity interval training (HIT) for 12-weeks in patients NYHA II-III","1054":"training for 12-weeks in patients NYHA II-III","1055":"30mg\/day zinc gluconate for eight consecutive weeks","1056":"Desmopressin","1057":"fentanyl (1 \u03bcg\/kg) and propofol ","1058":"fentanyl (1 \u03bcg\/kg) and propofol ","1059":"five injections of HA1 (Suprahyal\u00ae\/Adant\u00ae)","1060":"Acupuncture","1061":"Acupuncture","1062":"video-assisted remote consultations","1063":"video-assisted remote consultations ","1064":"video-assisted remote consultations","1065":"Cisplatin 40mg\/m2","1066":"barefoot walking","1067":"lateral wedge insoles","1068":"barefoot conditions","1069":"High-intensity interval training","1070":"High-intensity interval training","1071":"supported wedge","1072":"IL-2 injection at 4.5 MIU dose","1073":"IL-2 injection at 7.5 MIU dose","1074":"Orange juice intake in-between meals (BM)","1075":"L-lysine","1076":"L-lysine","1077":"Increased intake of fruits, vegetables and dairy","1078":"With catheter (group II)","1079":"With catheter (group II)","1080":"With catheter (group II)","1081":"Liraglutide and metformin plus insulin degludec (IDeg)","1082":"Liraglutide and metformin plus insulin degludec (IDeg)","1083":"Lunch meals with fatty fish (fish group)","1084":"Lunch meals with fatty fish (fish group)","1085":"T-HS\/Ctr","1086":"Suture groups","1087":"Sevoflurane-fentanyl anesthesia","1088":"Patients receiving text message\u2013based feedback","1089":"Patients receiving text message\u2013based feedback","1090":"Patients receiving text message\u2013based feedback","1091":"Alfentanil","1092":"Alfentanil","1093":"New universal medium (GM501)","1094":"New universal medium (GM501)","1095":"New universal medium (GM501)","1096":"subpleural patient-controlled analgesia (SPCA) (0.02 cc\/kg\/h of 0.5% bupivacaine)","1097":"received educational intervention plus routine education","1098":"popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator","1099":"popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator","1100":"oral administration of 100 and 200 I\u03021\u20444g LSD","1101":"oral administration of 200 I\u03021\u20444g LSD","1102":"stabilization in prone and supine group (SIPS)","1103":"stabilization in prone (SIP)","1104":"Bisoprolol","1105":"Bisoprolol","1106":"10 mg\/day for bisoprolol","1107":"Xenogeneic bone substitute material (Bio-Oss\u00ae, BO) ","1108":"100 grams of instant oat cereal","1109":"ticagrelor","1110":"ticagrelor","1111":"completing 6 days of assessment (four sets of questions per day) with a native smartphone application","1112":"an experimental arm with an extreme hypo-fractionated regimen (7?\u00d7?6.1 Gy?=?42.7 Gy given every other weekday, and always including two weekends without RT)","1113":"provided with written information about the electrodiagnostic testing","1114":"provided with written information about the electrodiagnostic testing","1115":"2-hour program comprising comprehensive health education and hot spa bathing, offered once every 2 weeks, in addition to individualized programs once a week, for 24 weeks","1116":"12-weeks of progressive endurance and strength training at a local health club","1117":"assigned to the high-protein diet who carried the AA genotype of FTO rs1558902","1118":"enteric-coated mycophenolate sodium (EC-MPS) 1440?mg\/day for first 6?months","1119":"oral metformin 500 mg TDS (Group-A)","1120":"oral metformin 500 mg TDS (Group-A)","1121":"muffins enriched with 30 g HAM-RS2","1122":"Amplitude training","1123":"Accupressure","1124":"Ultrasound\u2010guided foam sclerotherapy","1125":"400 ?g of intrathecal morphine followed by general anesthesia","1126":"Pomegranate juice (PJ)","1127":"fentanyl (1 \u03bcg\/kg) and propofol ","1128":"OnControl Bone Marrow Biopsy System","1129":"OnControl Bone Marrow Biopsy System","1130":"General anesthesia plus epidural infusion (PCEA)","1131":"General anesthesia plus epidural infusion (PCEA)","1132":"General anesthesia plus epidural infusion (PCEA)","1133":"High-intensity interval training","1134":"barefoot condition","1135":"typical wedge","1136":"each of the two lateral wedge conditions","1137":"IL-2 injections","1138":"barefoot condition","1139":"IL-2 injections","1140":"mobility shoe","1141":"Orange juice intake in-between meals (BM)","1142":"L-lysine","1143":"L-lysine","1144":"Home-based approach","1145":"100 grams of instant oat cereal","1146":"Increased intake of fruits, vegetables and dairy","1147":"100 grams of instant oat cereal","1148":"Lunch meals with fatty fish (fish group)","1149":"T-HS\/EAA","1150":"T-HS\/Ctr","1151":"Sevoflurane-fentanyl anesthesia","1152":"Sevoflurane-fentanyl anesthesia","1153":"Patients receiving text message\u2013based feedback","1154":"Alfentanil","1155":"Alfentanil","1156":"New universal medium (GM501)","1157":"New universal medium (GM501)","1158":"histologic response (\u22646 eos\/hpf) after treatment","1159":"patients with heartburn, chest pain, regurgitation, nausea or vomiting","1160":"subpleural patient-controlled analgesia (SPCA) (0.02 cc\/kg\/h of 0.5% bupivacaine)","1161":"subpleural patient-controlled analgesia (SPCA) (0.02 cc\/kg\/h of 0.5% bupivacaine)","1162":"subpleural patient-controlled analgesia (SPCA) (0.02 cc\/kg\/h of 0.5% bupivacaine)","1163":"received educational intervention plus routine education","1164":"received educational intervention plus routine education","1165":"popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator","1166":"oral administration of 100 and 200 I\u03021\u20444g LSD","1167":"Bravelle(R) ","1168":"Bravelle(R) ","1169":"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","1170":"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","1171":"stabilization exercise in prone position group (SIP)","1172":"Noninvasive ventilation (NIV)","1173":"Noninvasive ventilation (NIV)","1174":"Noninvasive ventilation (NIV)","1175":"bisoprolol","1176":"10 mg\/day for bisoprolol","1177":"Xenogeneic bone substitute material (Bio-Oss\u00ae, BO) ","1178":"100 grams of instant oat cereal","1179":"Acupuncture","1180":"Dabigatran","1181":"Presternal catheter with continuous infusion of 5 mL\/h bupivacaine 0.25% (Group B)","1182":"Preoperative acute normovolaemic hemodilution (ANH)","1183":"Preoperative acute normovolaemic hemodilution (ANH)","1184":"Vitamin A supplementation (VAS)","1185":"Pharmacist telephone counseling","1186":"Pharmacist telephone counseling","1187":"Cerebral NIRS monitoring in combination with an evidence based intervention guideline","1188":"Automatic tube compensation","1189":"Hypnosis and Neurolinguistic Programming (NLP)","1190":"Locking plate fixation","1191":"Locking plate fixation","1192":"Peri-operative Transfusion Trigger Score of Emergency [POTTS-E] group","1193":"High dose (20 mg\/day) haloperidol","1194":"Combination of pregabalin, acetaminophen, and naproxen (PAN) before the surgery","1195":"Combination of pregabalin, acetaminophen, and naproxen (PAN) before the surgery","1196":"Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and Conventional thoracic epidural patient-controlled analgesia (E-PCA group)","1197":"Combination of pregabalin, acetaminophen, and naproxen (PAN) before the surgery","1198":"Fentanyl-based IV-PCA only (IV-PCA group)","1199":"Haloperidol","1200":"Haloperidol","1201":"Pentoxifylline plus prednisolone (Group 2)","1202":"Website users","1203":"Website users","1204":"Website users","1205":"Sachets of \"Sprinkles\ufffd with vitamin A","1206":"Sachets of \"Sprinkles\ufffd with vitamin A","1207":"Placebo (Group C) and esmolol (Group E)","1208":"Placebo (Group C) and esmolol (Group E)","1209":"Placebo (Group C) and esmolol (Group E)","1210":"Native whey protein","1211":"Exercise program","1212":"vitamin D 4000 IE\/day","1213":"sunflower cake","1214":"prothrombin complex concentrates (PCC)","1215":"primary hrHPV screening","1216":"problem based learning intervention or critical reading intervention","1217":"receiving 1200 mg of cranberry extract for 6 weeks","1218":"Internet-based guided self-help program, including weekly support from a therapist via encrypted email","1219":"receive orally daily either CyavanaprA\u0308?A\u030a\u203aa (CP) (approx. 6 g) followed by a cup of milk (100 \u2013 200 ml)","1220":"5-fluorouracil (5-FU) 0.5%\/salicylic acid 10%","1221":"5-fluorouracil (5-FU) 0.5%\/salicylic acid 10%","1222":"use their own Facebook profile","1223":"nebivolol","1224":"usual care (UCG)","1225":"usual care (UCG)","1226":"simulation-based training followed by clinical training","1227":"Trendelenburg (TBG) tilt >30\u00b0 ","1228":"30-Hz whole-body vibration training","1229":"Inpatient program","1230":"Active chest wall oscillation treatment","1231":"control (did not receive ergonomic training)","1232":"Parent\u2013Child Interaction Therapy","1233":"copper-nickel-titanium (CuNiTi) round archwires with increasing diameters applied sequentially to the mandibular arch ","1234":"copper-nickel-titanium (CuNiTi) round archwires with increasing diameters applied sequentially to the mandibular arch ","1235":"use the Abhaibhubejhr or Total toothpastes","1236":"Istradefylline 20 mg","1237":"Standardized aberrant event detection algorithm and response protocol","1238":"Robotic surgery","1239":"Acidform twice daily for 14 consecutive days","1240":"Lateral decubitus position","1241":"Phototherapy plus massage","1242":"Phototherapy plus massage","1243":"Phototherapy plus massage","1244":"receive immediate treatment","1245":"N-acetylcysteine","1246":"N-acetylcysteine","1247":"smelled and rated an odorant and were told that the odorant increases creativity and reduces inhibitions ","1248":"received fibrinogen concentrate","1249":"centers admitting \u2265 200 patients\/year","1250":"oxaliplatin (FOLFOX) plus bevacizumab ","1251":"combination of propofol (PF) and dexmedetomidine (DEX) (Combination group)","1252":"Proseal laryngeal mask airway (PLMA)","1253":"OnControl Bone Marrow Biopsy System","1254":"video-assisted remote consultations","1255":"OnControl Bone Marrow Biopsy System","1256":"Cisplatin 40mg\/m2","1257":"General anesthesia plus epidural infusion (PCEA)","1258":"Cisplatin 40mg\/m2","1259":"General anesthesia plus epidural infusion (PCEA)","1260":"High-intensity interval training","1261":"typical wedge","1262":"Orange juice intake in-between meals (BM)","1263":"barefoot walking","1264":"Orange juice intake in-between meals (BM)","1265":"5-fluorouracil (5-FU) 0.5%\/salicylic acid 10%","1266":"use their own Facebook profile","1267":"Increased intake of fruits, vegetables and dairy","1268":"nebivolol","1269":"Liraglutide and metformin plus insulin degludec (IDeg)","1270":"Liraglutide and metformin plus insulin degludec (IDeg)","1271":"Liraglutide and metformin plus insulin degludec (IDeg)","1272":"T-HS\/SE and T-HS\/EAA","1273":"T-HS\/EAA","1274":"Suture groups","1275":"Sevoflurane-fentanyl anesthesia","1276":"consumed a standardized breakfast with Avocado Added (AA)","1277":"30-Hz whole-body vibration training","1278":"schema-based lecture","1279":"Parent\u2013Child Interaction Therapy","1280":"subpleural patient-controlled analgesia (SPCA) (0.02 cc\/kg\/h of 0.5% bupivacaine)","1281":"intravenous injection of rhC1INH (50 IU\/kg for patients <84 kg, or 4200 IU for patients \u226584 kg)","1282":"popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator","1283":"popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator","1284":"pertuzumab 840 mg for cycle 1 and 420 mg q3w for cycles 2\u20136 (Arm A)","1285":"N-acetylcysteine","1286":"Bravelle(R) ","1287":"received fibrinogen concentrate","1288":"received fibrinogen concentrate","1289":"stabilization in supine position group (SIS)","1290":"phlebotomy (Alternative Arm) ","1291":"receiving a loading dose of 30 mg\/kg Tranexamic acid over 15 minutes before skin incision followed by a maintenance infusion of TA (2 mg\/kg\/h) were continued until skin closure in the TA group.","1292":"Xenogeneic bone substitute material (Bio-Oss\u00ae, BO) ","1293":"100grams of instant oat cereal","1294":"Acupuncture","1295":"Proseal laryngeal mask airway (PLMA)","1296":"Acupuncture","1297":"Presternal catheter with continuous infusion of 5 mL\/h bupivacaine 0.25% (Group B)","1298":"Preoperative acute normovolaemic hemodilution (ANH)","1299":"Vitamin A supplementation (VAS)","1300":"Automatic tube compensation","1301":"Neurolinguistic Programming (NLP) and Hypnosis","1302":"Hypnosis","1303":"Locking plate fixation","1304":"Locking plate fixation","1305":"Peri-operative Transfusion Trigger Score of Emergency [POTTS-E] group","1306":"Auricular acupressure therapy","1307":"Auricular acupressure therapy","1308":"Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and conventional thoracic epidural patient-controlled analgesia (E-PCA group)","1309":"Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group)","1310":"Haloperidol","1311":"Haloperidol","1312":"Haloperidol","1313":"Pentoxifylline plus prednisolone (Group 2)","1314":"Pentoxifylline plus prednisolone (Group 2)","1315":"Website users","1316":"Sachets of \"Sprinkles\ufffd with vitamin A","1317":"Chlorhexidine gluconate dressing","1318":"Chlorhexidine gluconate dressing","1319":"Placebo (Group C) and esmolol (Group E)","1320":"Native whey protein","1321":"Exercise program","1322":"Exercise program","1323":"Dabigatran","1324":"Dabigatran 150 mg BID","1325":"tablet colchicine orally, 0.5 mg twice daily and 0.5 ml intralesional injection Hyaluronidase 1,500 IU into each buccal mucosa once a week","1326":"paracetamol for 6 hours after (therapeutic use) vaccination","1327":"3 ounces (85 g) ground peanuts","1328":"oral nutritional supplementation, enriched with leucine, vitamin D, and omega\ufffd3 fatty acids (NUTRITION)","1329":"atacicept (single dose: 3, 9 or 18 mg\/kg; or multiple dose: 2 \u00d7 9 mg\/kg)","1330":"rtfMRI-nf from left amygdala (LA)","1331":"rtfMRI-nf from left amygdala (LA)","1332":"rtfMRI-nf from left amygdala (LA)","1333":"the sGC activator cinaciguat (10 mg\/kg\/day) orally for 8 weeks","1334":"the sGC activator cinaciguat (10 mg\/kg\/day) orally for 8 weeks","1335":"the sGC activator cinaciguat (10 mg\/kg\/day) orally for 8 weeks","1336":"unconscious-thought condition","1337":"thiamine","1338":"PM01183","1339":"PM01183","1340":"1 mg\/day of Pls purified from scallop","1341":"1 mg\/day of Pls purified from scallop","1342":"30 ml 0.5% ropivacaine + 100 I\u03021\u20444g of dexmedetomidine (RD)","1343":"30 ml 0.5% ropivacaine + 100 I\u03021\u20444g of dexmedetomidine (RD)","1344":"Educational program and ED protocol for syncope evaluation","1345":"78-week treatment with tramiprosate 100 mg or tramiprosate 150 mg BID","1346":"PPIs, lifestyle changes, and daily zinc capsules","1347":"PPIs, lifestyle changes, and daily zinc capsules","1348":"SASA! community mobilization intervention program","1349":"propofol induction guided by BIS","1350":"xylose-containing solution","1351":"xylose-containing test meal","1352":"5 g xylose-containing solution","1353":"lidocaine spray","1354":"lidocaine spray","1355":"remifentanil","1356":"nurse educator-conducted class and home blood pressure monitorization","1357":"sitagliptin and d-xylose","1358":"sitagliptin and d-xylose","1359":"Intranasal dexmedetomidine (Group D)","1360":"Intranasal dexmedetomidine (Group D)","1361":"Intranasal dexmedetomidine (Group D)","1362":"Vitamin D supplement","1363":"Vitamin D supplement","1364":"Interaction with an obese patient in a digital environment","1365":"sitagliptin","1366":"yoga","1367":"yoga","1368":"50 mg of tramadol and 100 mg of tramadol","1369":"50 mg of tramadol and 100 mg of tramadol","1370":"task-oriented training program with WBV, which was performed for 15 minutes, five times per week, for four weeks","1371":"control group","1372":"Baduanjin exercise","1373":"receive 4\u20136 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracil\u2013epirubicin\u2013cyclophosphamide (FEC) regimen","1374":"receive 4\u20136 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracil\u2013epirubicin\u2013cyclophosphamide (FEC) regimen","1375":"after Ice application","1376":"after Ice application","1377":"received implants immediately after extraction","1378":"screen group","1379":"Head-middle (HM): the swimmer looked downward at 90 degrees to the swimming direction, in a neutral position. The swimmer's ears were covered by the forearms, which were fully extended over the head or Head-down (HD): the swimmer looked backwards, and his ears were below the forearms, which were fully extended over the head.","1380":"exercise ","1381":"non-technical skills seminar","1382":"non-technical skills seminar","1383":"non-technical skills seminar","1384":"Sildenafil citrate and Elaeagnus angustifolia flower extract","1385":"'individualised' (holistic) hypnotherapy","1386":"sertraline","1387":"underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with the feedback game (FG)","1388":"underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with the feedback game (FG)","1389":"xtensive off-scanner training with the FG using a MRI simulator","1390":"MRI + (PM or DTI)","1391":"receive lactulose (30\u201360 mL\/day) + probiotic (200 million colony forming units of seven bacteria species\/day) (Gp-LPr) or probiotic alone (Gp-Pr)","1392":"combination of IVT and IVB","1393":"the diet only (DO)","1394":"diet with resistance training (RT)","1395":"ch14.18-UTC","1396":"ch14.18-UTC","1397":"magnesium sulfate injection 30 mg\/kg i.v. bolus was followed by infusion of magnesium sulfate at 10 mg\/kg\/hr and continued up to 24 hours","1398":"magnesium sulfate injection 30 mg\/kg i.v. bolus was followed by infusion of magnesium sulfate at 10 mg\/kg\/hr and continued up to 24 hours","1399":"magnesium sulfate injection 30 mg\/kg i.v. bolus was followed by infusion of magnesium sulfate at 10 mg\/kg\/hr and continued up to 24 hours","1400":"extract of three Cretan herbs","1401":"Ultra fast-track extubation (UFE)","1402":"Ultra fast-track extubation (UFE)","1403":"Group L - loading dose of 0.5 \u03bcg\/kg for 10 minutes","1404":"Group L - loading dose of 0.5 \u03bcg\/kg for 10 minutes","1405":"OnControl Bone Marrow Biopsy System","1406":"control meal","1407":"Orange juice intake in-between meals (BM)","1408":"Home-based approach","1409":"Increased intake of fruits, vegetables and dairy","1410":"Increased intake of fruits, vegetables and dairy","1411":"With catheter (group II)","1412":"With catheter (group II)","1413":"Patients receiving text message\u2013based feedback","1414":"Alfentanil","1415":"intravenous injection of rhC1INH (50 IU\/kg for patients <84 kg, or 4200 IU for patients \u226584 kg)","1416":"received educational intervention plus routine education","1417":"popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator","1418":"Bravelle(R) ","1419":"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","1420":"Noninvasive ventilation (NIV)","1421":"100 grams of instant oat cereal","1422":"video-assisted remote consultations","1423":"both of the lateral wedge insoles","1424":"both of the lateral wedge insoles","1425":"barefoot condition","1426":"Cerebral NIRS monitoring in combination with an evidence based intervention guideline","1427":"Automatic tube compensation","1428":"Automatic tube compensation","1429":"Automatic tube compensation","1430":"Locking plate fixation","1431":"Auricular acupressure therapy","1432":"Combination of pregabalin, acetaminophen, and naproxen (PAN) before the surgery","1433":"Pentoxifylline plus prednisolone (Group 2)","1434":"Website users","1435":"Sachets of \"Sprinkles\ufffd with vitamin A","1436":"Sachets of \"Sprinkles\ufffd with vitamin A","1437":"Chlorhexidine gluconate dressing","1438":"Chlorhexidine gluconate dressing","1439":"Placebo (Group C) and esmolol (Group E)","1440":"Native whey protein","1441":"Native whey protein","1442":"Native whey protein","1443":"Exercise program","1444":"Dabigatran 150 mg or 110 mg","1445":"Presternal catheter with continuous infusion of 5 mL\/h bupivacaine 0.25% (Group B)","1446":"Presternal catheter with continuous infusion of 5 mL\/h bupivacaine 0.25% (Group B)","1447":"Presternal catheter with continuous infusion of 5 mL\/h bupivacaine 0.25% (Group B)","1448":"Preoperative acute normovolaemic hemodilution (ANH)","1449":"Preoperative acute normovolaemic hemodilution (ANH)","1450":"Vitamin A supplementation (VAS)","1451":"Pharmacist telephone counseling","1452":"Pharmacist telephone counseling","1453":"Pharmacist telephone counseling","1454":"Neurolinguistic Programming (NLP)","1455":"Peri-operative Transfusion Trigger Score of Emergency [POTTS-E] group","1456":"Peri-operative Transfusion Trigger Score of Emergency [POTTS-E] group","1457":"Peri-operative Transfusion Trigger Score of Emergency [POTTS-E] group","1458":"Fentanyl-based IV-PCA only (IV-PCA group)","1459":"small group asthma education workshops and received locally adapted asthma management guidelines","1460":"PPIs, lifestyle changes, and daily zinc capsules","1461":"remifentanil","1462":"Baduanjin exercise","1463":"received implants immediately after extraction","1464":"screen group and control group","1465":"performed a single period of continuous exercise (Long-bout group: 30 min \u00d7 1) 3 d per week,","1466":"'individualised' (holistic) hypnotherapy or standard 'gut-directed' hypnotherapy or relaxation therapy","1467":"diet with aerobic exercise (AE)","1468":"Xenogeneic bone substitute material (Bio-Oss\u00ae, BO) ","1469":"Xenogeneic bone substitute material (Bio-Oss\u00ae, BO)","1470":"Cranial electrical stimulation (CES)","1471":"insulin glargine 300 U\/ml (Gla\ufffd300)","1472":"insulin glargine 300 U\/ml (Gla\ufffd300)","1473":"insulin glargine 300 U\/ml (Gla\ufffd300)","1474":"oral health care program (OHCP)","1475":"oral nutritional supplementation, enriched with leucine, vitamin D, and omega\ufffd3 fatty acids (NUTRITION)","1476":"oral nutritional supplementation, enriched with leucine, vitamin D, and omega\ufffd3 fatty acids (NUTRITION)","1477":"oral nutritional supplementation, enriched with leucine, vitamin D, and omega\ufffd3 fatty acids (NUTRITION)","1478":"atacicept (single dose: 3, 9 or 18 mg\/kg; or multiple dose: 2 \u00d7 9 mg\/kg)","1479":"the sGC activator cinaciguat (10 mg\/kg\/day) orally for 8 weeks","1480":"the sGC activator cinaciguat (10 mg\/kg\/day) orally for 8 weeks","1481":"the sGC activator cinaciguat (10 mg\/kg\/day) orally for 8 weeks","1482":"the sGC activator cinaciguat (10 mg\/kg\/day) orally for 8 weeks","1483":"thiamine","1484":"thiamine","1485":"study-specific prevention activities","1486":"30 ml 0.5% ropivacaine + 100 I\u03021\u20444g of dexmedetomidine (RD)","1487":"enhanced recovery","1488":"amikacin bladder wash","1489":"small group asthma education workshops and locally adapted asthma management guidelines","1490":"small group asthma education workshops and locally adapted asthma management guidelines","1491":"PPIs, lifestyle changes, and daily zinc capsules","1492":"PPIs, lifestyle changes, and daily zinc capsules","1493":"SASA! community mobilization intervention program","1494":"SASA! community mobilization intervention program","1495":"traditional Mexican diet","1496":"traditional Mexican diet","1497":"traditional Mexican diet","1498":"propofol induction guided by BIS","1499":"assistance from a patient navigator","1500":"xylose-containing solutions","1501":"xylose-containing test meal","1502":"lidocaine spray","1503":"lidocaine, ketamine, or remifentanil","1504":"nurse educator-conducted class and home blood pressure monitorization","1505":"d-xylose","1506":"Intranasal dexmedetomidine (Group D)","1507":"Vitamin D supplement","1508":"Interaction with an obese patient in a digital environment","1509":"Interaction with an obese patient in a digital environment","1510":"Ciclesonide (CIC)","1511":"Ciclesonide (CIC)","1512":"yoga","1513":"yoga","1514":"preadjusted edgewise appliance (PEA) and self-ligating (SL) systems","1515":"50 mg of tramadol and 100 mg of tramadol","1516":"Packaging Instructions","1517":"Packaging Instructions","1518":"simvastatin\/ezetimibe","1519":"simvastatin\/ezetimibe","1520":"task-oriented training program with WBV, which was performed for 15 minutes, five times per week, for four weeks ","1521":"receive 4\u20136 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracil\u2013epirubicin\u2013cyclophosphamide (FEC) regimen","1522":"after Ice application","1523":"p-synephrine (50 mg) alone","1524":"received implants immediately after extraction","1525":"screen group","1526":"Head-middle (HM): the swimmer looked downward at 90 degrees to the swimming direction, in a neutral position. The swimmer's ears were covered by the forearms, which were fully extended over the head ","1527":"exercise ","1528":"non-technical skills seminar","1529":"Elaeagnus angustifolia flower extract","1530":"Sildenafil citrate","1531":"performed 3 short bouts of exercise (Short-bouts group: 10 min \u00d7 3) 3 d per week","1532":"underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with the feedback game (FG)","1533":"underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with the feedback game (FG)","1534":"experimental group","1535":"four visits of a midwife trained in smoking cessation techniques to the home of a smoking pregnant woman","1536":"four visits of a midwife trained in smoking cessation techniques to the home of a smoking pregnant woman","1537":"four visits of a midwife trained in smoking cessation techniques to the home of a smoking pregnant woman","1538":"preparation of the mesiobuccal canal with One Shape or Reciproc rotary systems","1539":"exposed to wood smoke (~1 mg\/m3 particulate matter concentration) for one hour during intermittent exercise","1540":"exposed to wood smoke (~1 mg\/m3 particulate matter concentration) for one hour during intermittent exercise","1541":"exposed to wood smoke (~1 mg\/m3 particulate matter concentration) for one hour during intermittent exercise","1542":"intra-brachial infusion of acetylcholine or sodium nitroprusside","1543":"combination of IVT and IVB","1544":"combination of IVT and IVB","1545":"ulinastatin","1546":"ch14.18-UTC","1547":"Group L - loading dose of 0.5 \u03bcg\/kg for 10 minutes","1548":"Group L - loading dose of 0.5 \u03bcg\/kg for 10 minutes","1549":"Simvastatin","1550":"Simvastatin","1551":"Lactated Ringer (group II) ","1552":"Conventional isotretinoin dose","1553":"Conventional isotretinoin dose","1554":"Conventional isotretinoin dose","1555":"Intensified anticipatory guidance program","1556":"Pressure support ventilation (PSV)","1557":"Diclofenac potassium group and paracetamol group","1558":"Dexmedetomidine","1559":"Dexmedetomidine","1560":"Long-term oxygen therapy 15 h\/day","1561":"Aclidinium (ACCORD)","1562":"Immediate loading implants (group I)","1563":"laparoscopic sleeve gastrectomy (SG)","1564":"laparoscopic sleeve gastrectomy (SG)","1565":"PCT guidance algorithm established for adult LRTI in the subgroup of community-acquired pneumonia (CAP) patients","1566":"transillumination-assisted technique group (T group) ","1567":"transillumination-assisted technique group (T group) ","1568":"transillumination-assisted technique group (T group) ","1569":"transillumination-assisted technique group (T group) ","1570":"transillumination-assisted technique group (T group) ","1571":"Phase I (months 1\u20136), an individually tailored intervention promoting a Mediterranean-style dietary and Phase II (months 7\u201312), option of a 16-week weight loss intervention, Phase III (months 13\u201324), weight loss maintenance intervention ","1572":"10 units of Syntocinon (Novartis Pharma Canada) in 500 cc Ringer lactate","1573":"10 units of Syntocinon (Novartis Pharma Canada) in 500 cc Ringer lactate","1574":"PEG\u2013lactulose group received the 20-30 grams of lactulose of oral or rectal lactulose, plus 280 grams of PEG in 4 liters of water orally as a single dose in 30-120 minutes ","1575":"PEG\u2013lactulose group received the 20-30 grams of lactulose of oral or rectal lactulose, plus 280 grams of PEG in 4 liters of water orally as a single dose in 30-120 minutes","1576":"group A bimatoprost 0.03% eye drops once daily for a period of 4 weeks","1577":"600,000 IU of Intramuscular vitamin D3","1578":"Home Safety Toolkit (HST), including a new booklet based on health literacy principles, and sample safety items","1579":"Home Safety Toolkit (HST), including a new booklet based on health literacy principles, and sample safety items","1580":"Home Safety Toolkit (HST), including a new booklet based on health literacy principles, and sample safety items","1581":"3.9 g\/day EPA+DHA","1582":"3.9 g\/day EPA+DHA","1583":"group A received 20 mg of Esomeprazole, 500 mg of Clarithromycin for the first 5 days, followed by 20 mg of Esomeprazole, 500 mg of Clarithromycin, and 1000 mg of Amoxicillin for the remaining 5 days.","1584":"group A received 20 mg of Esomeprazole, 500 mg of Clarithromycin for the first 5 days, followed by 20 mg of Esomeprazole, 500 mg of Clarithromycin, and 1000 mg of Amoxicillin for the remaining 5 days and Group B received 20 mg of Esomeprazole, 1000 mg of Amoxicillin for the first 5 days, followed by 20 mg of Esomeprazole, 500 mg of Clarithromycin, and 1000 mg of Amoxicillin for the remaining 5 days.","1585":"group A received 20 mg of Esomeprazole, 500 mg of Clarithromycin for the first 5 days, followed by 20 mg of Esomeprazole, 500 mg of Clarithromycin, and 1000 mg of Amoxicillin for the remaining 5 days and Group B received 20 mg of Esomeprazole, 1000 mg of Amoxicillin for the first 5 days, followed by 20 mg of Esomeprazole, 500 mg of Clarithromycin, and 1000 mg of Amoxicillin for the remaining 5 days.","1586":"100 \u03b3\/kg\/min of racemic ketamine for 10 minutes ","1587":"received an Attention bias modification procedure designed to induce a bias in attention toward positive pictures","1588":"ingested nitrate-rich (140 mL; ~800 mg nitrate\/day; BR) for six subsequent days","1589":"ingested nitrate-rich (140 mL; ~800 mg nitrate\/day; BR) for six subsequent days","1590":"ingested nitrate-rich (140 mL; ~800 mg nitrate\/day; BR) for six subsequent days","1591":"web-based continuing medical education (CME), performance feedback and quality improvement tools in experimental group and control group","1592":"web-based continuing medical education (CME), performance feedback and quality improvement tools in experimental group and control group","1593":"web-based continuing medical education (CME), performance feedback and quality improvement tools in experimental group and control group","1594":"web-based continuing medical education (CME), performance feedback and quality improvement tools in experimental group and control group","1595":"Group Medical Clinics (GMC)","1596":"Group 1: WaveOne (primary) single reciprocating file (WO; Dentsply Maillefer, Ballaigues, Switzerland) (25\/08), ","1597":"pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT)","1598":"pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT)","1599":"pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT)","1600":"pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT)","1601":"pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT)","1602":"pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT)","1603":"pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT)","1604":"pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT)","1605":"pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT)","1606":"pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT)","1607":"pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT)","1608":"group C Human Follicle Stimulating Hormone (hFSH)","1609":"group D Human Follicle Stimulating Hormone\/ Recombinant human follicle stimulating hormone (hFSH\/rFSH)","1610":"moderate-to-vigorous intensity physical activity (MVPA)","1611":"efficient light-emitting diodes (LEDs)","1612":"7\u00b75 mg\/kg intravenous bevacizumab on day 1 of every cycle of chemotherapy and for six further doses once every 21 days following chemotherapy and three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg\/m2 epirubicin and 60 mg\/m2 cisplatin on day 1 and 1250 mg\/m2 oral capecitabine on days 1\u201321.","1613":"7\u00b75 mg\/kg intravenous bevacizumab on day 1 of every cycle of chemotherapy and for six further doses once every 21 days following chemotherapy and three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg\/m2 epirubicin and 60 mg\/m2 cisplatin on day 1 and 1250 mg\/m2 oral capecitabine on days 1\u201321.","1614":"control group","1615":"motor imagery training ","1616":"traditional low-fat diet (LFD)","1617":"Vaccinated group","1618":"Vaccinated group","1619":"Vaccinated group","1620":"minimally invasive stereotactic puncture and thrombolysis therapy (MISPTT)","1621":"insulin glargine 300 U\/ml (Gla\ufffd300)","1622":"insulin glargine 300 U\/ml (Gla\ufffd300)","1623":"paracetamol for 24 hours starting at the time of (prophylactic use) before vaccination","1624":"control meal","1625":"1000 I\u03021\u20444g (arm C) of CEA peptide emulsified in Montanide and GM-CSF, given every 2 weeks until disease progression.","1626":"oral nutritional supplementation, enriched with leucine, vitamin D, and omega\ufffd3 fatty acids (NUTRITION)","1627":"atacicept (single dose: 3, 9 or 18 mg\/kg; or multiple dose: 2 \u00d7 9 mg\/kg)","1628":"the sGC activator cinaciguat (10 mg\/kg\/day) orally for 8 weeks","1629":"the sGC activator cinaciguat (10 mg\/kg\/day) orally for 8 weeks","1630":"the sGC activator cinaciguat (10 mg\/kg\/day) orally for 8 weeks","1631":"unconscious-thought condition","1632":"PM01183","1633":"1 mg\/day of Pls purified from scallop","1634":"1 mg\/day of Pls purified from scallop","1635":"study-specific prevention activities","1636":"30 ml 0.5% ropivacaine + 100 I\u03021\u20444g of dexmedetomidine (RD)","1637":"30 ml 0.5% ropivacaine + 100 I\u03021\u20444g of dexmedetomidine (RD)","1638":"enhanced recovery","1639":"enhanced recovery","1640":"enhanced recovery","1641":"enhanced recovery","1642":"enhanced recovery","1643":"hot pack","1644":"RxING study first six month","1645":"small group asthma education workshops and locally adapted asthma management guidelines","1646":"Psoralen-ultraviolet A (PUVA)","1647":"Structured Booster Break program","1648":"SASA! community mobilization intervention program","1649":"SASA! community mobilization intervention program","1650":"traditional Mexican diet","1651":"traditional Mexican diet","1652":"propofol induction guided by BIS","1653":"Commercially produced Scoparia dulcis porridge (SDC)","1654":"assistance from a patient navigator","1655":"assistance from a patient navigator","1656":"lidocaine spray","1657":"lidocaine spray","1658":"Macintosh blade","1659":"sitagliptin and d-xylose","1660":"Intranasal dexmedetomidine (Group D)","1661":"WBV training","1662":"Interaction with an obese patient in a digital environment","1663":"Ciclesonide (CIC)","1664":"Ciclesonide (CIC)","1665":"sitagliptin","1666":"sitagliptin","1667":"yoga","1668":"yoga","1669":"preadjusted edgewise appliance (PEA)","1670":"50 mg of tramadol and 100 mg of tramadol","1671":"task-oriented training program with WBV, which was performed for 15 minutes, five times per week, for four weeks and control","1672":"Baduanjin exercise","1673":"receive 4\u20136 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracil\u2013epirubicin\u2013cyclophosphamide (FEC) regimen","1674":"Low advanced glycation end products (AGEs) diet","1675":"600 mg naringin with 50 mg p-synephrine","1676":"100 mg hesperidin in addition to the 50 mg p-synephrine plus 600 mg naringin","1677":"1000 mg hesperidin with 50 mg p-synephrine plus 600 mg naringin and other groups","1678":"1000 mg hesperidin with 50 mg p-synephrine plus 600 mg naringin and other groups","1679":"received implants immediately after extraction","1680":"received implants immediately after extraction","1681":"received implants immediately after extraction","1682":"invited to attend a half-day program with up to five couples and one month old infants, facilitated by trained, supervised nurses","1683":"exercise ","1684":"Arm B triple therapy plus polaprezinc 150 mg twice daily, ","1685":"non-technical skills seminar","1686":"Sildenafil citrate","1687":"the static stretching (SSG) or passive interval (PIG)","1688":"performed a single period of continuous exercise (Long-bout group: 30 min \u00d7 1) 3 d per week,","1689":"Measuring BPs in the forearm (FA) ","1690":"'individualised' (holistic) hypnotherapy","1691":"'individualised' (holistic) hypnotherapy or standard 'gut-directed' hypnotherapy or relaxation therapy","1692":"Cognitive Processing Therapy","1693":"Cognitive Processing Therapy or individual support","1694":"primary care physicians (PCP) alone","1695":"experimental","1696":"long-term improvers (IMPs)","1697":"four visits of a midwife trained in smoking cessation techniques to the home of a smoking pregnant woman","1698":"exposed to wood smoke (~1 mg\/m3 particulate matter concentration) for one hour during intermittent exercise","1699":"exposed to wood smoke (~1 mg\/m3 particulate matter concentration) for one hour during intermittent exercise","1700":"receive lactulose (30\u201360 mL\/day) + probiotic (200 million colony forming units of seven bacteria species\/day) (Gp-LPr) or probiotic alone (Gp-Pr) or lactulose + placebo (Gp-L)","1701":"the diet only (DO)","1702":"L received a loading dose of 0.5 \u03bcg\/kg ","1703":"Simvastatin","1704":"Simvastatin","1705":"Lactated Ringer (group II) and hypertonic saline plus dextran (group III)","1706":"Lactated Ringer (group II) ","1707":"Lactated Ringer (group II) ","1708":"Conventional isotretinoin dose","1709":"Intensified anticipatory guidance program","1710":"Intensified anticipatory guidance program","1711":"Pressure support ventilation (PSV)","1712":"Pressure support ventilation (PSV)","1713":"Pressure support ventilation (PSV)","1714":"Pressure support ventilation (PSV)","1715":"Diclofenac potassium group","1716":"Paracetamol group","1717":"Dexmedetomidine","1718":"Dexmedetomidine","1719":"Dexmedetomidine","1720":"Long-term oxygen therapy 15 h\/day","1721":"Aclidinium 400 \u03bcg (ATTAIN)","1722":"Aclidinium (active-comparator study)","1723":"Aclidinium (active-comparator study)","1724":"Aclidinium (ACCORD)","1725":"Immediate loading implants (group I)","1726":"Immediate loading implants (group I)","1727":"golimumab (100 mg) every 4 weeks, with or without methotrexate (MTX) and 50 mg golimumab plus MTX","1728":"intravenous rtPA","1729":"PCT guidance algorithm established for adult LRTI","1730":"PCT guidance algorithm established for adult lower respiratory tract infection (LRTI) and non-community-acquired pneumonia (CAP)","1731":"a mandatory course \"Evidence-based Medicine\ufffd","1732":"Phase I (months 1\u20136), an individually tailored intervention promoting a Mediterranean-style dietary and Phase II (months 7\u201312), option of a 16-week weight loss intervention, Phase III (months 13\u201324), weight loss maintenance intervention ","1733":"Phase I (months 1\u20136), an individually tailored intervention promoting a Mediterranean-style dietary and Phase II (months 7\u201312), option of a 16-week weight loss intervention, Phase III (months 13\u201324), weight loss maintenance intervention ","1734":"10 units of Syntocinon (Novartis Pharma Canada) in 500 cc Ringer lactate","1735":"10 units of Syntocinon (Novartis Pharma Canada) in 500 cc Ringer lactate","1736":"(Symbicort SMARTTM, Turbuhaler\u00ae) 160\/4.5 \u03bcg twice daily plus as needed with similar or higher maintenance doses of ICS\/LABA plus SABA or formoterol.","1737":"budesonide\/formoterol regimens","1738":"PEG\u2013lactulose group received the 20-30 grams of lactulose of oral or rectal lactulose, plus 280 grams of PEG in 4 liters of water orally as a single dose in 30-120 minutes","1739":"600,000 IU of Intramuscular vitamin D3","1740":"600,000 IU of Intramuscular vitamin D3","1741":"600,000 IU of Intramuscular vitamin D3","1742":"Home Safety Toolkit (HST), including a new booklet based on health literacy principles, and sample safety items","1743":"3.9 g\/day EPA+DHA","1744":"propofol and remifentanil","1745":"100 \u03b3\/kg\/min of racemic ketamine for 10 minutes","1746":"100 \u03b3\/kg\/min of racemic ketamine for 10 minutes","1747":"laryngeal Mask (PLMA)","1748":"laryngeal Mask (PLMA)","1749":"laryngeal Mask (PLMA) or endotracheal intubation (ETT)","1750":"received an Attention bias modification procedure designed to induce a bias in attention toward positive pictures","1751":"vismodegib plus gemcitabine (GV)","1752":"vismodegib plus gemcitabine (GV)","1753":"vismodegib plus gemcitabine (GV)","1754":"vismodegib plus gemcitabine (GV)","1755":"ingested nitrate-rich (140 mL; ~800 mg nitrate\/day; BR) for six subsequent days","1756":"dextrose prolotherapy","1757":"web-based continuing medical education (CME), performance feedback and quality improvement tools","1758":"Group Medical Clinics (GMC)","1759":"Silence condition","1760":"Silence condition","1761":"Group 2: Self-adjusting file (SAF; ReDent-Nova, Ra'anana, Israel) (1.5 mm) ","1762":"Group 3: ProTaper NEXT X1 and X2 (PTN; Dentsply Tulsa Dental, Tulsa, OK) (25\/06)","1763":"Group 1: WaveOne (primary) single reciprocating file (WO; Dentsply Maillefer, Ballaigues, Switzerland) (25\/08),","1764":"pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT)","1765":"pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT)","1766":"pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT)","1767":"pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT)","1768":"pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT)","1769":"pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT)","1770":"group D Human Follicle Stimulating Hormone\/ Recombinant human follicle stimulating hormone (hFSH\/rFSH)","1771":"intent-to-treat population using multiple imputation (ITT-MI) ","1772":"efficient light-emitting diodes (LEDs) and control treatment","1773":"7\u00b75 mg\/kg intravenous bevacizumab on day 1 of every cycle of chemotherapy and for six further doses once every 21 days following chemotherapy and three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg\/m2 epirubicin and 60 mg\/m2 cisplatin on day 1 and 1250 mg\/m2 oral capecitabine on days 1\u201321.","1774":"motor imagery training and neurodevelopmental treatment","1775":"motor imagery training ","1776":"traditional low-fat diet (LFD)","1777":"low-carbohydrate diet (LCD)","1778":"glycyrrhizin-treated and vaccinated","1779":"small group asthma education workshops and locally adapted asthma management guidelines","1780":"telemonitoring group","1781":"telemonitoring group","1782":"Bowman-Birk inhibitor concentrate (BBIC)","1783":"Bowman-Birk inhibitor concentrate (BBIC)","1784":"Bowman-Birk inhibitor concentrate (BBIC)","1785":"laparoscopy within the group with ASA 1\u20133","1786":"laparoscopy within the group with ASA 4\u20135","1787":"standard nicotine patch (NRT), extended use of combined formulations of nicotine replacement therapy (NRT+)","1788":"telmisartan 80 mg combined with hydrochlorothiazide (HCTZ) 25 mg","1789":"telmisartan 80 mg combined with hydrochlorothiazide (HCTZ) 25 mg","1790":"telmisartan 80 mg combined with hydrochlorothiazide (HCTZ) 25 mg","1791":"honey mitigates","1792":"honey mitigates","1793":"honey mitigates","1794":"honey mitigates","1795":"denosumab 60 mg sc every 6 months ","1796":"denosumab 60 mg sc every 6 months","1797":"denosumab 60 mg sc every 6 months","1798":"culture in ISM1 (MediCult)","1799":"culture in ISM1 (MediCult)","1800":"10 mg Zn\/day","1801":"10 mg Zn\/day","1802":"lifestyle intervention ","1803":"20 G\/ 35 mm (thin) needle","1804":"20 G\/ 35 mm (thin) needle","1805":"Body Awareness Therapy (BAT) and aerobic exercise ","1806":"control","1807":"aerobic exercise ","1808":"aerobic exercise ","1809":"placebo","1810":"calcium only or the geniVidaTM bone blend (GBB)","1811":"Hochu-ekki-to","1812":"Hochu-ekki-to","1813":"oral ibandronate 50 mg","1814":"oral ibandronate 50 mg","1815":"oral ibandronate 50 mg","1816":"oral ibandronate 50 mg","1817":"Web-based self-guided app recommendation service (\"The Toolbox\ufffd)","1818":"Web-based self-guided app recommendation service (\"The Toolbox\ufffd)","1819":"Web-based self-guided app recommendation service (\"The Toolbox\ufffd)","1820":"ultrasound-guided reduction Plane II fracture","1821":"Group A: scaling and root planing (SRP) with A. aspera gel","1822":"Group A: scaling and root planing (SRP) with A. aspera gel","1823":"100,000 IU of oral vitamin D per month, for 6 months","1824":"percutaneous transluminal angioplasty and stenting (PTAS)","1825":"high coverage rings","1826":"the bupivacaine-dexmedetomidine group (Group BD) received 0.25% bupivacaine (1 mL\/kg) plus 2 \u03bcg\/kg dexmedetomidine","1827":"the bupivacaine-dexmedetomidine group (Group BD) received 0.25% bupivacaine (1 mL\/kg) plus 2 \u03bcg\/kg dexmedetomidine","1828":"1 week with clemastine and levocetirizine","1829":"Midazolam at the concentration of 1.0 mg\/kg (up to 3 mg) was infused, and then barium reduction was performed under fluoroscopy guideline","1830":"intent-to-treat population using multiple imputation (ITT-MI) of subjects with prediabetes and\/or MetS","1831":"Text4baby mHealth program","1832":"mindfulness training psycho-educative program","1833":"real trigger point dry needling","1834":"RxING study first six month","1835":"RxING study first six month","1836":"topical lidocaine","1837":"Prolonged-release fampridine","1838":"Prolonged-release fampridine","1839":"Prolonged-release fampridine","1840":"Prolonged-release fampridine","1841":"High-intensity interval training (HIIT) plus either ginger or placebo","1842":"High-intensity interval training (HIIT) plus either ginger or placebo","1843":"High-intensity interval training (HIIT) plus either ginger or placebo","1844":"Yogic intervention and medication","1845":"All uncovered nevi","1846":"Psoralen-ultraviolet A (PUVA)","1847":"Psoralen-ultraviolet A (PUVA)","1848":"Commercially produced Scoparia dulcis porridge (SDC)","1849":"40 hourly treatments of either hyperbaric treatment","1850":"40 hourly treatments of either hyperbaric treatment","1851":"McGRATH MAC and C-MAC","1852":"ketamine (100 ng\/ml blood plasma level)","1853":"saline 9 mg\/ml syringes","1854":"WBV training","1855":"early initiation group (3 days after stroke) with swallowing therapy ","1856":"early initiation group (3 days after stroke) with swallowing therapy ","1857":"(2) medium group (2 weeks after stroke) with swallowing therapy ","1858":"Paromomycin Alone (15% paromomycin) for 20 days","1859":"Pre-Gelatinized Organic Maca (Maca-GO) treatment","1860":"Pre-Gelatinized Organic Maca (Maca-GO) treatment","1861":"Pre-Gelatinized Organic Maca (Maca-GO) treatment","1862":"The Laryngeal Tube Suction Disposable (LTS-D)","1863":"the Supreme Laryngeal Mask Airway (SLMA)","1864":"aromatase inhibitors (AIs) - letrozole","1865":"aromatase inhibitors (AIs) - letrozole","1866":"non-exercise control group","1867":"intervention group, i.e. patient empowerment through information booklet and diary keeping ","1868":"intervention group, i.e. patient empowerment through information booklet and diary keeping ","1869":"intervention group, i.e. patient empowerment through information booklet and diary keeping ","1870":"Low advanced glycation end products (AGEs) diet","1871":"Low advanced glycation end products (AGEs) diet","1872":"Low advanced glycation end products (AGEs) diet","1873":"Low advanced glycation end products (AGEs) diet","1874":"Stomacol\u00ae tablets (1.53 g of \u03b2-glucan)","1875":"10 mg rosuvastatin over 4 months with zinc (30 mg\/d) and selenium (150 I\u03021\u20444g\/d) supplementation.","1876":"deep breathing with essential oils","1877":"deep breathing with essential oils","1878":"the static stretching (SSG) ","1879":"the static stretching (SSG) or passive interval (PIG)","1880":"trail running shoes ","1881":"an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT)","1882":"an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT)","1883":"an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT)","1884":"an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT)","1885":"Cognitive Processing Therapy","1886":"an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT)","1887":"All Bond 2 (Group III)","1888":"intravitreal injections of ziv-aflibercept (1.25 mg\/0.05 mL)","1889":"subcutaneous indwelling closed suction drainage method ","1890":"subcutaneous indwelling closed suction drainage method ","1891":"Sublingual immunotherapy (SLIT) ","1892":"Standard version or enhanced version of commercial Web-based weight-loss program","1893":"Standard version or enhanced version of commercial Web-based weight-loss program","1894":"Group B with autogenous semitendinosus graft and endobutton technique","1895":"Group B with autogenous semitendinosus graft and endobutton technique","1896":"low-dose Epoetin beta (5000 IU on days 1, 3, 5, 7, 9, 11 and 13)","1897":"high-dose Epoetin beta (30.000 IU on days 1, 2 and 3 and placebo on days 5, 7, 9, 11 and 13) and low-dose Epoetin beta (5000 IU on days 1, 3, 5, 7, 9, 11 and 13), ","1898":"comprehensive geriatric assessment (CGA) group","1899":"comprehensive geriatric assessment (CGA) group","1900":"Text4baby","1901":"Biodentine","1902":"pre-exercise vibration stimulation","1903":"intervention group, i.e. patient empowerment through information booklet and diary keeping - females","1904":"intervention group, i.e. patient empowerment through information booklet and diary keeping - males","1905":"hot pack and water soaked gauze","1906":"Low advanced glycation end products (AGEs) diet","1907":"Low advanced glycation end products (AGEs) diet","1908":"topical lidocaine","1909":"Low advanced glycation end products (AGEs) diet","1910":"Low advanced glycation end products (AGEs) diet","1911":"Hypoxic trials","1912":"Exercise trial in hypoxia (HYP-Ex)","1913":"High-intensity interval training (HIIT) plus either ginger or placebo","1914":"Arm A triple therapy (omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily) plus polaprezinc 75 mg twice daily; Arm B triple therapy plus polaprezinc 150 mg twice daily, Arm C triple therapy alone","1915":"Yogic intervention and medication","1916":"Yogic intervention and medication","1917":"Yogic intervention and medication","1918":"tamsulosin with tadalafil (group B) + 5-mg prednisolone once daily (maximum 1 week)","1919":"tamsulosin with tadalafil (group B) + 5-mg prednisolone once daily (maximum 1 week)","1920":"treatment with omeprazole suspension 2 mg\/ml (40 mg every day), pantoprazole suspension 2 mg\/ml (40 mg every day) ","1921":"Psoralen-ultraviolet A (PUVA)","1922":"treatment with omeprazole suspension 2 mg\/ml (40 mg every day), pantoprazole suspension 2 mg\/ml (40 mg every day) ","1923":"Structured Booster Break program","1924":"Ultrasound-guided paravertebral block (Group I)","1925":"Ultrasound-guided paravertebral block (Group I)","1926":"Ultrasound-guided paravertebral block (Group I)","1927":"unstable shoes (Masai Barefoot Technology [MBT])","1928":"unstable shoes (Masai Barefoot Technology [MBT])","1929":"Commercially produced Scoparia dulcis porridge (SDC)","1930":"an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT)","1931":"40 hourly treatments of either hyperbaric treatment","1932":"40 hourly treatments of either hyperbaric treatment","1933":"40 hourly treatments of either hyperbaric treatment","1934":"Counselling and Advisory Care for Health (COACH) programme","1935":"An evidence-based treatment program called SNAP (Stop Now and Plan)","1936":"An evidence-based treatment program called SNAP (Stop Now and Plan)","1937":"long-term improvers (IMPs)","1938":"subcutaneous indwelling closed suction drainage method ","1939":"ketamine (100ng\/ml blood plasma level)","1940":"ketamine (100ng\/ml blood plasma level)","1941":"silicone gel","1942":"WBV training","1943":"WBV training","1944":"WBV training","1945":"upright active forward elevation ","1946":"The Laryngeal Tube Suction Disposable (LTS-D)","1947":"telemonitoring group","1948":"telemonitoring group","1949":"telemonitoring group","1950":"laparoscopy within the group with American Society of Anesthesiologists (ASA) 1\u20133 physical status","1951":"standard nicotine patch (NRT), extended use of combined formulations of nicotine replacement therapy (NRT+)","1952":"standard nicotine patch (NRT), extended use of combined formulations of nicotine replacement therapy (NRT+)","1953":"honey mitigates","1954":"denosumab 60 mg sc every 6 months ","1955":"denosumab 60 mg sc every 6 months","1956":"oral alendronate 35 mg weekly","1957":"lifestyle intervention ","1958":"lifestyle intervention ","1959":"20 G\/ 35 mm (thin) needle","1960":"20 G\/ 35 mm (thin) needle","1961":"Body Awareness Therapy (BAT) and aerobic exercise ","1962":"Body Awareness Therapy (BAT) and aerobic exercise ","1963":"aerobic exercise ","1964":"Body Awareness Therapy (BAT) and aerobic exercise ","1965":"calcium only or the geniVidaTM bone blend (GBB)","1966":"calcium only or the geniVidaTM bone blend (GBB)","1967":"Hochu-ekki-to","1968":"oral ibandronate 50 mg","1969":"oral ibandronate 50 mg","1970":"oral ibandronate 50 mg","1971":"ultrasound-guided reduction Plane II fracture","1972":"ultrasound-guided reduction Plane II fracture","1973":"Group A: scaling and root planing (SRP) with A. aspera gel","1974":"100,000 IU of oral vitamin D per month, for 6 months","1975":"percutaneous transluminal angioplasty and stenting (PTAS)","1976":"percutaneous transluminal angioplasty and stenting (PTAS)","1977":"the bupivacaine group (Group B) received 0.25% bupivacaine (1 ml\/kg)","1978":"1 week with clemastine ","1979":"Midazolam at the concentration of 1.0 mg\/kg (up to 3 mg) was infused, and then barium reduction was performed under fluoroscopy guideline","1980":"Midazolam at the concentration of 1.0 mg\/kg (up to 3 mg) was infused, and then barium reduction was performed under fluoroscopy guideline","1981":"tramadol plus gabapentin ","1982":"tramadol plus gabapentin ","1983":"tramadol plus gabapentin ","1984":"tramadol plus gabapentin","1985":"reboxetine","1986":"reboxetine","1987":"reboxetine","1988":"RxING study first six month","1989":"iron fortification + mebenzadole","1990":"iron fortification + mebendazole","1991":"vitamin-D deficiency","1992":"vitamin-D deficiency","1993":"Prolonged-release fampridine","1994":"Hypoxic trials","1995":"Exercise trial in hypoxia (HYP-Ex)","1996":"Hypoxic trials","1997":"High-intensity interval training (HIIT) plus either ginger or placebo","1998":"Structured Booster Break program","1999":"Ultrasound-guided paravertebral block (Group I)","2000":"Ultrasound-guided paravertebral block (Group I)","2001":"Commercially produced Scoparia dulcis porridge (SDC)","2002":"Commercially produced Scoparia dulcis porridge (SDC)","2003":"McGRATH MAC and C-MAC","2004":"ketamine (100ng\/ml blood plasma level)","2005":"ketamine (100ng\/ml blood plasma level)","2006":"silicone gel","2007":"WBV training","2008":"WBV training","2009":"WBV training","2010":"WR 279,396 (15% paromomycin + 0.5% gentamicin) for 20 days","2011":"The upright-assisted exercises","2012":"Pre-Gelatinized Organic Maca (Maca-GO) treatment","2013":"Pre-Gelatinized Organic Maca (Maca-GO) treatment","2014":"The Laryngeal Tube Suction Disposable (LTS-D)","2015":"the Supreme Laryngeal Mask Airway (SLMA)","2016":"The Laryngeal Tube Suction Disposable (LTS-D) ","2017":"The Laryngeal Tube Suction Disposable (LTS-D) ","2018":"comprehensive geriatric assessment (CGA) group","2019":"aromatase inhibitors (AIs) - letrozole","2020":"groups with exercise energy expenditure of 4 , 8 , or 12 kcal\/kg\/week (KKW)","2021":"antihistamine group (Group A) were pre-medicated with 2 mL (45.5 mg) pheniramine maleate","2022":"intervention group, i.e. patient empowerment through information booklet and diary keeping","2023":"Low advanced glycation end products (AGEs) diet","2024":"Low advanced glycation end products (AGEs) diet","2025":"Low advanced glycation end products (AGEs) diet","2026":"Low advanced glycation end products (AGEs) diet","2027":"Stomacol\u00ae tablets (1.53 g of \u03b2-glucan)","2028":"10 mg rosuvastatin over 4 months with zinc (30 mg\/d) and selenium (150 I\u03021\u20444g\/d) supplementation.","2029":"10 mg rosuvastatin over 4 months with zinc (30 mg\/d) and selenium (150 I\u03021\u20444g\/d) supplementation.","2030":"10 mg rosuvastatin over 4 months with zinc (30 mg\/d) supplementation.","2031":"CO2 pneumoperitoneum -10 mm Hg, 12 mm Hg and 15 mm Hg).","2032":"deep breathing with essential oils","2033":"deep breathing with essential oils","2034":"deep breathing with essential oils","2035":"Arm A triple therapy (omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily) plus polaprezinc 75 mg twice daily; Arm B triple therapy plus polaprezinc 150 mg twice daily,","2036":"treatment with tamsulosin (group A) + 5-mg prednisolone once daily (maximum 1 week)","2037":"treatment with tamsulosin (group A) + 5-mg prednisolone once daily (maximum 1 week)","2038":"tamsulosin with tadalafil (group B) + 5-mg prednisolone once daily (maximum 1 week)","2039":"tamsulosin with tadalafil (group B) + 5-mg prednisolone once daily (maximum 1 week)","2040":"the static stretching (SSG) ","2041":"an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT)","2042":"an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT)","2043":"low calorie cranberry beverage (450 ml)","2044":"low calorie cranberry beverage (450 ml)","2045":"low calorie cranberry beverage (450 ml)","2046":"intravitreal injections of ziv-aflibercept (1.25 mg\/0.05 mL)","2047":"subcutaneous indwelling closed suction drainage method ","2048":"Group D received a loading dose of dexmedetomidine 1 I\u03021\u20444g\/kg over 10 min followed by an infusion 0.5-1.0 I\u03021\u20444g\/kg\/h","2049":"Group D received a loading dose of dexmedetomidine 1 I\u03021\u20444g\/kg over 10 min followed by an infusion 0.5-1.0 I\u03021\u20444g\/kg\/h","2050":"Group D received a loading dose of dexmedetomidine 1 I\u03021\u20444g\/kg over 10 min followed by an infusion 0.5-1.0 I\u03021\u20444g\/kg\/h","2051":"MTA Fillapex sealer","2052":"N-acetylcysteine plus normal saline (Group A) and Ascorbic acid plus normal saline (Group B)","2053":"N-acetylcysteine plus normal saline (Group A) and Ascorbic acid plus normal saline (Group B)","2054":"N-acetylcysteine plus normal saline (Group A) and Ascorbic acid plus normal saline (Group B)","2055":"Sublingual immunotherapy (SLIT) 20 000 AUN\/ml and 40 000 AUN\/ml","2056":"Sublingual immunotherapy (SLIT) 40 000 AUN\/ml","2057":"Sublingual immunotherapy (SLIT) 40 000 AUN\/ml","2058":"Standard version or enhanced version of commercial Web-based weight-loss program","2059":"Standard version or enhanced version of commercial Web-based weight-loss program","2060":"Standard version or enhanced version of commercial Web-based weight-loss program","2061":"Breastfed infants","2062":"Breastfed infants","2063":"Breastfed infants","2064":"Group B with autogenous semitendinosus graft and endobutton technique","2065":"Group B with autogenous semitendinosus graft and endobutton technique","2066":"Group B with autogenous semitendinosus graft and endobutton technique","2067":"high-dose Epoetin beta (30.000 IU on days 1, 2 and 3 and placebo on days 5, 7, 9, 11 and 13)","2068":"Surgical treatment","2069":"Midazolam plus remifentanil plus ketamine","2070":"Midazolam plus remifentanil plus ketamine","2071":"Midazolam plus remifentanil plus ketamine","2072":"High-dose continuous lenalidomide group","2073":"Alcohol","2074":"Alcohol","2075":"Betamethasone valerate cream plus oral simvastatin (Group B)","2076":"Pre-exercise breakfast","2077":"Pre-exercise breakfast","2078":"Riociguat group","2079":"Imiquimod 5% cream","2080":"Saliva with fluoride (G2)","2081":"Exercises with whole-body vibration (Group I)","2082":"Exercises with whole-body vibration (Group I)","2083":"Exercises with whole-body vibration (Group I)","2084":"Informed group","2085":"paracetamol 1,000mg\u2013caffeine 130mg (PCF) and naproxen sodium 550 mg (NAP)","2086":"sham-operated group","2087":"adalimumab","2088":"One month after administeration systemic doxycycline after the completion of scaling and root planing (SRP)","2089":"One month after systemic doxycycline during the reevaluation visit 45 days after the completion of scaling and root planing (SRP)","2090":"view a video featuring individuals that live in extreme poverty","2091":"triple injection of 1 mL rhBMP-2\/NaCl (4 mg rhBMP-2\/ml) (A) ","2092":"diabetic meal delivery for 12 months (group M)","2093":"individual dietary counseling for 12 months (group D)","2094":"individual dietary counseling for 12 months (group D) or diabetic meal delivery for 12 months (group M)","2095":"low dose intraoperative MMC (LDMMC)","2096":"low dose intraoperative MMC (LDMMC)","2097":"low dose intraoperative MMC (LDMMC)","2098":"the ropivacaine continuous infusion (the Ropi group)","2099":"the ropivacaine continuous infusion (the Ropi group)","2100":"donepezil in addition to lithium","2101":"donepezil in addition to lithium","2102":"telephone intervention was performed for 10 weeks","2103":"telephone intervention was performed for 10 weeks","2104":"Group F receiving preoperative flupirtine","2105":"on-site support (OSS)","2106":"on-site support (OSS)","2107":"2 g of YM","2108":"2 g of YM","2109":"30 \u03bcg YIC, 60 \u03bcg of YIC","2110":"Caudal Group received 1 ml\/kg of 0.25% bupivacaine","2111":"subjects who remained in remission","2112":"8-week interval training (60-79% HR max reserve) program of between 45 minutes to 60 minutes","2113":"Long-chain omega-3 polyunsaturated fatty acids (PUFAs)","2114":"explanation of patients anatomy, disease state, and treatment options using the education model as an aid","2115":"cognitive intervention through a training program for picture book reading for In the participants with mild cognitive impairment (MCI)","2116":"pneumatic cuff was applied to the calf and inflated to 70 mmHg","2117":"zirconia implant abutments","2118":"follow\ufffdup appointments were planned at two weeks (T 1) and 12 months (T 12) after delivery of the restoration","2119":"zirconia implant abutments","2120":"gutta-percha\/AH26 ","2121":"3.2 mL 4% articaine with epinephrine 1:200000 and 0.4 mL 50 mg\/mL ketamine hydrochloride (A-ketamine group)","2122":"Active experiencing (AE)","2123":"Active experiencing (AE)","2124":"Active experiencing (AE)","2125":"The mini-open anterior approach focal cleaning combined with posterior internal fixation in period I - group A","2126":"propofol (1.5 mg\/kg) in Group \u0399, remifentanil (0.05 \u03bcg\/kg), fentanyl (1 \u03bcg\/kg) + propofol (1.5 mg\/kg) combination in Group III","2127":"G4 was prepared with the occlusal extension of 1mm in depth and width. G5: The occlusal extension was 1mm in depth and 2 mm in width","2128":"pacemaker Qinming8631 DR (Qinming Medical, Baoji, China)","2129":"frovatriptan","2130":"frovatriptan and rizatriptan","2131":"Vit D as 50 000 IU\/week","2132":"olaparib 400 mg b.i.d. (capsules)","2133":"fruit\/vegetable (FV)","2134":"healthy Nordic diet (ND)","2135":"ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC","2136":"ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating","2137":"sputum induction with 7% saline nebulization in clinic (SI) ","2138":"transdermal 17\u03b2-estradiol (t-E2; 50 \u03bcg\/d) plus cyclic progesterone (Prometrium, 200 mg) ","2139":"transdermal 17\u03b2-estradiol (t-E2; 50 \u03bcg\/d) plus cyclic progesterone (Prometrium, 200 mg) or oral conjugated equine estrogens (o-CEE; 0.45 mg\/d) ","2140":"transdermal 17\u03b2-estradiol (t-E2; 50 \u03bcg\/d) plus cyclic progesterone (Prometrium, 200 mg) ","2141":"Caudal Group received 1 ml\/kg of 0.25% bupivacaine","2142":"Saliva with fluoride (G2)","2143":"4.5 mg\/m2 per day of oral everolimus once daily for 6 months","2144":"metformin 1,000 mg daily","2145":"metformin 1,000 mg daily","2146":"listened to Mozart K.448 daily before bedtime for at least six months","2147":"triple injection of 1 mL rhBMP-2\/NaCl (4 mg rhBMP-2\/ml) (A) ","2148":"Hope-promoting interventions based on religious beliefs","2149":"5 mg axitinib with 600 mg rifampin","2150":"Group F receiving preoperative flupirtine","2151":"individual dietary counseling for 12 months (group D)","2152":"on-site support (OSS)","2153":"N-acetylcysteine (NAC) (150 mg\/kg)","2154":"cognitive intervention through a training program for picture book reading for community-dwelling older adults.","2155":"Riociguat group","2156":"4.5mg\/m2 per day of oral everolimus once daily for 6 months","2157":"Imiquimod 5% cream","2158":"Imiquimod 5% cream","2159":"Informed group","2160":"naproxen sodium 550 mg (NAP)","2161":"paracetamol 1,000mg\u2013caffeine 130mg (PCF) ","2162":"N-acetylcysteine (NAC) (150 mg\/kg)","2163":"N-acetylcysteine (NAC) (150 mg\/kg)","2164":"4.5mg\/m2 per day of oral everolimus once daily for 6 months","2165":"Taekwondo (TKD) ","2166":"20 G\/ 35 mm (thin) needle","2167":"Taekwondo (TKD) ","2168":"Taekwondo (TKD) ","2169":"Taekwondo (TKD) ","2170":"RT-qPCR","2171":"triple injection of 1 mL rhBMP-2\/NaCl (4 mg rhBMP-2\/ml) (A) ","2172":"triple injection of 1 mL rhBMP-2\/NaCl (4 mg rhBMP-2\/ml) (A) ","2173":"triple injection of 1 mL rhBMP-2\/NaCl (4 mg rhBMP-2\/ml) (A) ","2174":"conventional dietary education (group C)","2175":"explanation of patients anatomy, disease state, and treatment options using the education model as an aid","2176":"low dose intraoperative MMC (LDMMC)","2177":"mesh repair for the various hernias","2178":"the ropivacaine continuous infusion (the Ropi group)","2179":"the ropivacaine continuous infusion (the Ropi group)","2180":"telephone intervention was performed for 10 weeks","2181":"telephone intervention was performed for 10 weeks","2182":"on-site support (OSS)","2183":"on-site support (OSS)","2184":"on-site support (OSS)","2185":"2 g of YM","2186":"Surgical treatment","2187":"60 \u03bcg of immune complexes (YIC)","2188":"Midazolam plus remifentanil plus ketamine","2189":"High-dose continuous lenalidomide group","2190":"metformin 1,000 mg daily, sitagliptin 100 mg daily","2191":"Hope-promoting interventions based on religious beliefs","2192":"Long-chain omega-3 polyunsaturated fatty acids (PUFAs)","2193":"Betamethasone valerate cream plus oral simvastatin (Group B)","2194":"Betamethasone valerate cream plus oral simvastatin (Group B)","2195":"lemon verbena extract","2196":"Pre-exercise breakfast","2197":"lemon verbena extract","2198":"lemon verbena extract","2199":"explanation of patients anatomy, disease state, and treatment options using the education model as an aid","2200":"Riociguat group","2201":"explanation of patients anatomy, disease state, and treatment options using the education model as an aid","2202":"Riociguat group","2203":"a program of emotional intelligence (EI) 20 one-hour sessions","2204":"a program of emotional intelligence (EI) 20 one-hour sessions","2205":"a program of emotional intelligence (EI) 20 one-hour sessions - boys","2206":"pneumatic cuff was applied to the calf and inflated to 70 mmHg","2207":"Active Control","2208":"pacemaker Qinming8631 DR (Qinming Medical, Baoji, China)","2209":"pacemaker Qinming8631 DR (Qinming Medical, Baoji, China)","2210":"right- and left- frontoparietal networks (FPNs) and control","2211":"right lateral frontoparietal networks (rFPN) left lateral frontoparietal networks (lFPN)","2212":"conrtol after scanning","2213":"primaquine phosphate and dihydroartemisinin-piperaquine","2214":"primaquine phosphate and dihydroartemisinin-piperaquine","2215":"negative training (pull negative, push positive pictures)","2216":"attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction","2217":"attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction","2218":"attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction","2219":"attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction","2220":"sputum induction with 7% saline nebulization in clinic (SI) ","2221":"transdermal 17\u03b2-estradiol (t-E2; 50 \u03bcg\/d) plus cyclic progesterone (Prometrium, 200 mg) ","2222":"Imiquimod 5% cream","2223":"Informed group","2224":"paracetamol 1,000mg\u2013caffeine 130mg (PCF) ","2225":"Taekwondo (TKD) ","2226":"Taekwondo (TKD) ","2227":"lemon verbena extract","2228":"individual dietary counseling for 12 months (group D) or diabetic meal delivery for 12 months (group M)","2229":"listened to Mozart K.448 daily before bedtime for at least six months","2230":"mesh repair for the various hernias","2231":"the ropivacaine continuous infusion (the Ropi group)","2232":"telephone intervention was performed for 10 weeks","2233":"Group F receiving preoperative flupirtine","2234":"on-site support (OSS)","2235":"on-site support (OSS)","2236":"2 g of YM","2237":"metformin 1,000 mg daily, sitagliptin 100 mg daily","2238":"metformin 1,000 mg daily, sitagliptin 100 mg daily","2239":"Stretching exercises group and walking group","2240":"metformin 1,000 mg daily, sitagliptin 100 mg daily","2241":"Walking group","2242":"Hope-promoting interventions based on religious beliefs","2243":"Long-chain omega-3 polyunsaturated fatty acids (PUFAs)","2244":"lemon verbena extract","2245":"Pre-exercise breakfast","2246":"lemon verbena extract","2247":"Riociguat group","2248":"multimedia intervention","2249":"a program of emotional intelligence (EI) 20 one-hour sessions","2250":"a program of emotional intelligence (EI) 20 one-hour sessions","2251":"pneumatic cuff was applied to the calf and inflated to 70 mmHg","2252":"lansoprazole at a dose of 15 mg, 30 mg or 60 mg once daily - erosive reflux disease (ERD)","2253":"lansoprazole at a dose of 15 mg, 30 mg once daily ","2254":"ezetimibe (10 mg) add-on statin (EAT)","2255":"oral trametinib (2 mg once daily)","2256":"oral trametinib (2 mg once daily)","2257":"docetaxel plus selumetinib (75mg twice daily q21 days)","2258":"Informed group","2259":"gutta-percha\/AH26 negative control - one week\t","2260":"Resilon\/RealSeal SE negative control - one week","2261":"Active experiencing (AE)","2262":"Active experiencing (AE)","2263":"The mini-open anterior approach focal cleaning combined with posterior internal fixation in period I - group A","2264":"conventional anterior extraperitoneal approach focal cleaning combined with posterior internal fixation in period I - group B","2265":"The mini-open anterior approach focal cleaning combined with posterior internal fixation in period I - group A","2266":"propofol (1.5 mg\/kg) in Group \u0399, remifentanil (0.05 \u03bcg\/kg) + propofol (1.5 mg\/kg) combination in Group II","2267":"propofol (1.5 mg\/kg) in Group \u0399, remifentanil (0.05 \u03bcg\/kg) + propofol (1.5 mg\/kg) combination in Group II","2268":"G3 was prepared with an occlusal extension that extended one-third of buccolingual width and 2 mm in depth","2269":"pacemaker Qinming8631 DR (Qinming Medical, Baoji, China)","2270":"frovatriptan","2271":"frovatriptan","2272":"frovatriptan and rizatriptan","2273":"frovatriptan and rizatriptan","2274":"lFPN in the training group","2275":"control after scanning","2276":"Vit D as 50 000 IU\/week","2277":"Vit D as 50 000 IU\/week","2278":"olaparib 400 mg b.i.d. (capsules)","2279":"olaparib 400 mg b.i.d. (capsules)","2280":"primaquine phosphate ","2281":"primaquine phosphate and dihydroartemisinin-piperaquine","2282":"primaquine phosphate and dihydroartemisinin-piperaquine","2283":"primaquine phosphate and dihydroartemisinin-piperaquine","2284":"primaquine phosphate and dihydroartemisinin-piperaquine","2285":"fruit\/vegetable (FV) and FVB","2286":"negative training (NT) (pull negative, push positive pictures)","2287":"dysphoric","2288":"PT groups (dysphoric, non-dysphoric)","2289":"PT groups (dysphoric, non-dysphoric)","2290":"PT groups (dysphoric, non-dysphoric)","2291":"healthy Nordic diet (ND)","2292":"attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction","2293":"attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction","2294":"ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC","2295":"ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC","2296":"sputum induction with 7% saline nebulization in clinic (SI) ","2297":"multimedia intervention","2298":"multimedia intervention","2299":"45 mg toltrazuril + 200 mg gleptoferron (Forceris\u00ae) or with 20 mg toltrazuril\/kg body weight as an oral suspension (Baycox\u00ae 5%)","2300":"Panretinal photocoagulation (PRP) with green laser","2301":"Panretinal photocoagulation (PRP) with green laser","2302":"using the FA alone","2303":"Alginate oligosaccharide (AOS; AG group)","2304":"Alginate oligosaccharide (AOS; AG group)","2305":"using the FA alone","2306":"BDP\/FF 200\/6 I\u03021\u20444g pMDI extrafine (two puffs twice a day)","2307":"BDP\/FF 200\/6 I\u03021\u20444g pMDI extrafine (two puffs twice a day)","2308":"Crystalloid (RS group) and colloid (HES group)","2309":"consumed 200 ml\/day of probiotic soy milk containing Lactobacillus planetarium A7 for 8 weeks","2310":"Dual release ciprofloxacin for inhalation (DRCFI)","2311":"Transversus abdominis plane block with 0.25% bupivacaine (Group B)","2312":"Transversus abdominis plane block with 0.25% bupivacaine (Group B)","2313":"Pomegranate extract (POMx)","2314":"Deep-cooling","2315":"Deep-cooling","2316":"Intensive group intervention (IGI)","2317":"G4 was prepared with the occlusal extension of 1mm in depth and width. G5: The occlusal extension was 1mm in depth and 2 mm in width","2318":"physical activity (PA) program for patients with knee and\/or hip osteoarthritis (OA)","2319":"famotidine administered at 0.4 mg\/kg","2320":"HBD-3 (standard, 10 \u03bcg:50 \u03bcg:1 mg, Art no., CSB-P12186-3; Beijing Biodee Biotechnology Co., Ltd., Beijing, China) of 10 ml once a day, for 7 days.","2321":"Hydroxychloroquine (HCQ)","2322":"detemir","2323":"church-based educational intervention","2324":"control","2325":"cognitive behavioral (CB) group-delivered intervention","2326":"knowledge of MTHFR 677C \u2192 T genotype","2327":"telmisartan 80 mg + hydrochlorothiazide 25 mg (T80\/H25)","2328":"HBD-3 (standard, 10 \u03bcg:50 \u03bcg:1 mg, Art no., CSB-P12186-3; Beijing Biodee Biotechnology Co., Ltd., Beijing, China) of 10 ml once a day, for 7 days.","2329":"400 I\u03021\u20444g of misoprostol","2330":"flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter)","2331":"astigmatism of 1.25 to 4.0 D","2332":"Maitland mobilization","2333":"sitagliptin, 23 (0.3%)","2334":"Transcranial direct current stimulation (tDCS)","2335":"Transcranial direct current stimulation (tDCS)","2336":"45 mg toltrazuril + 200 mg gleptoferron (Forceris\u00ae) or with 20 mg toltrazuril\/kg body weight as an oral suspension (Baycox\u00ae 5%)","2337":"dominant hand","2338":"Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 I\u03021\u20444g (0.5 ml)","2339":"Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 I\u03021\u20444g (0.5 ml), Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 I\u03021\u20444g (0.5ml) , Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 I\u03021\u20444g (0.5 ml)","2340":"received herbal extract dentifrices or used a conventional dentifrice","2341":"received herbal extract dentifrices ","2342":"PHiD-CV Phase III Clinical (Clin group)","2343":"PHiD-CV Phase III Clinical (Clin group)","2344":"PHiD-CV Phase III Clinical (Clin group)","2345":"received herbal extract dentifrices ","2346":"receive aspirin (81 mg or 100 mg daily,","2347":"Recombinant- follicle stimulating hormone (r-FSH) plus recombinant-luteinizing hormone (rLH)","2348":"HBD-3 (standard, 10 \u03bcg:50 \u03bcg:1 mg, Art no., CSB-P12186-3; Beijing Biodee Biotechnology Co., Ltd., Beijing, China) of 10 ml once a day, for 7 days.","2349":"Chlorproguanil-dapsone (CPD)","2350":"Chlorproguanil-dapsone (CPD)","2351":"45 mg toltrazuril + 200 mg gleptoferron (Forceris\u00ae) or with 20 mg toltrazuril\/kg body weight as an oral suspension (Baycox\u00ae 5%)","2352":"Panretinal photocoagulation (PRP) with green laser","2353":"electrical muscle stimulation (EMS)","2354":"Alginate oligosaccharide (AOS; AG group)","2355":"Use of the interdisciplinary diabetes care teams (IDCT)","2356":"Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 I\u03021\u20444g (0.5 ml)","2357":"Mild-cooling or deep-cooling","2358":"completed internet intention questions","2359":"Stretching exercises group ","2360":"intensive lifestyle intervention (ILI)","2361":"Crystalloid (RS group)","2362":"Crystalloid (RS group) and colloid (HES group)","2363":"diabetic meal delivery for 12 months (group M)","2364":"bupivacaine in 0 (immediately in the postoperative recovery room), 1st, 2nd, 3rd, and 4th hours in the postoperative period","2365":"Transversus abdominis plane block with 0.25% bupivacaine (Group B)","2366":"2 g of YM","2367":"Cycling time trial to exhaustion at 100%VO2max at sea-level (SEA)","2368":"Panretinal photocoagulation (PRP) with green laser","2369":"using the FA alone","2370":"completed questions","2371":"Calcitriol","2372":"Calcitriol","2373":"Calcitriol","2374":"BDP\/FF 200\/6 I\u03021\u20444g pMDI extrafine (two puffs twice a day)","2375":"Crystalloid (RS group) and colloid (HES group)","2376":"BDP\/FF 200\/6 I\u03021\u20444g pMDI extrafine (two puffs twice a day)","2377":"Colloid (HES group)","2378":"alendronate (AD) ","2379":"alendronate (AD) ","2380":"Dual release ciprofloxacin for inhalation (DRCFI)","2381":"Dual release ciprofloxacin for inhalation (DRCFI)","2382":"consumed 200 ml\/day of probiotic soy milk containing Lactobacillus planetarium A7 for 8 weeks","2383":"Dual release ciprofloxacin for inhalation (DRCFI)","2384":"Transversus abdominis plane block with 0.25% bupivacaine (Group B)","2385":"Exercise at 1657 m of altitude plus Pomegranate extract (ALTPOMx)","2386":"Pomegranate extract (POMx)","2387":"Advanced Quality Improvement Program (AQIP)","2388":"Advanced Quality Improvement Program (AQIP)","2389":"Use of the interdisciplinary diabetes care teams (IDCT)","2390":"Intensive group intervention (IGI)","2391":"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 50","2392":"PA program for patients with knee and\/or hip OA","2393":"PA program for patients with knee and\/or hip OA","2394":"famotidine administered at 0.4 mg\/kg","2395":"detemir","2396":"cognitive behavioral (CB) group-delivered intervention","2397":"cognitive behavioral (CB) group-delivered intervention","2398":"plant extract St. John's Wort (SJW)","2399":"plant extract St. John's Wort (SJW)","2400":"HBD-3 (standard, 10 \u03bcg:50 \u03bcg:1 mg, Art no., CSB-P12186-3; Beijing Biodee Biotechnology Co., Ltd., Beijing, China) of 10 ml once a day, for 7 days.","2401":"noninvasive ventilation (NIV)","2402":"400 I\u03021\u20444g of misoprostol","2403":"flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter)","2404":"flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter)","2405":"flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter)","2406":"flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter)","2407":"B. papyrifera (capsule 300 mg, twice a day)","2408":"myopia of -0.75 to -6.0 diopters (D) and astigmatism of 1.25 to 4.0 D","2409":"DPP-4i therapy","2410":"Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 I\u03021\u20444g (0.5 ml)","2411":"PHiD-CV Phase III Clinical (Clin group)","2412":"Rizatriptan","2413":"Rizatriptan","2414":"MPA (100 mg tds orally) ","2415":"climbed onto a horse riding simulator, and performed the horse riding simulation exercise","2416":"climbed onto a horse riding simulator, and performed the horse riding simulation exercise or took part in the horse riding exercises without a blindfold","2417":"Recombinant- follicle stimulating hormone (r-FSH) plus recombinant-luteinizing hormone (rLH)","2418":"receive aspirin (81 mg or 100 mg daily,","2419":"HBD-3 (standard, 10 \u03bcg:50 \u03bcg:1 mg, Art no., CSB-P12186-3; Beijing Biodee Biotechnology Co., Ltd., Beijing, China) of 10 ml once a day, for 7 days.","2420":"Artemether-lumefantrine (AL)","2421":"Artemether-lumefantrine (AL)","2422":"DEX full","2423":"micafungin (100 mg\/day for subjects > 40 kg; 2 mg\/kg\/day for subjects \u2264 40 kg)","2424":"ICP monitoring","2425":"electrosurgical device","2426":"capsaicin","2427":"lamivudine (LAM) (100 mg\/day","2428":"palady","2429":"tolcapone","2430":"tolcapone","2431":"3.2 g\/day citrulline","2432":"azithromycin","2433":"2 cycles of sinusoidal chronomodulated infusion (Arm A)","2434":"quadrivalent HPV vaccine (Gardasil\u00ae)","2435":"females in group Men's Health CoOp\/Women's Health CoOp [MHC\/WHC]","2436":"neurovascular bundle preservation (NBP)","2437":"acarbose","2438":"pioglitazone","2439":"\u03b2-asarone 10 mg\/d, tenuigenin 10 mg\/d, and memantine 5\u201320 mg\/d","2440":"question: Doctor tells you that although you particularly like to eat bacon, if you stop eating, your body cholesterol content would be significantly reduced, and thus the possibility of suffering from cardiovascular disease would be greatly reduced. Would you continue to eat bacon?","2441":"Eye surgery may lead to two potential sequelas: one is a minor decline of visual acuity and the other is keratitis. Imagine you will take this kind of surgery and two doctors' medical records revealed that: Doctor A: Of 200 patients, 191 were not found postoperative visual acuity declined but 3 suffered from keratitis; Doctor B: Of 200 patients, 198 were not found postoperative visual acuity declined but 10 suffered from keratitis. Which doctor you will choose?","2442":"low-protein vegetarian diet (LPVD)","2443":"low-protein vegetarian diet (LPVD)","2444":"low-protein vegetarian diet (LPVD)","2445":"low-protein vegetarian diet (LPVD)","2446":"extracorporeal shock wave therapy (ESWT)","2447":"extracorporeal shock wave therapy (ESWT)","2448":"visual feedback group (VFG)","2449":"visual feedback group (VFG)","2450":"Control","2451":"Tibolone, ","2452":"Tibolone, ","2453":"using the FA alone","2454":"using the FA alone","2455":"Alginate oligosaccharide (AOS; AG group)","2456":"Alginate oligosaccharide (AOS; AG group)","2457":"Calcitriol","2458":"BDP\/FF 200\/6 \u03bcg pMDI extrafine (two puffs twice a day)","2459":"Calcitriol","2460":"alendronate (AD) ","2461":"Dual release ciprofloxacin for inhalation (DRCFI)","2462":"Transversus abdominis plane block with 0.25% bupivacaine (Group B)","2463":"Exercise at sea-level plus Pomegranate extract (SEAPOMx)","2464":"Mild-cooling","2465":"Intensive individual intervention (III)","2466":"Hydroxychloroquine (HCQ)","2467":"plant extract St. John's Wort (SJW)","2468":"400 \u03bcg of misoprostol","2469":"myopia of -0.75 to -6.0 diopters (D)","2470":"Transcranial direct current stimulation (tDCS)","2471":"Transcranial direct current stimulation (tDCS)","2472":"Intensive Care Unit acquired weakness (ICU-AW)","2473":"Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 \u03bcg (0.5 ml)","2474":"Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 \u03bcg (0.5 ml), Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 \u03bcg (0.5ml) , Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 \u03bcg (0.5 ml)","2475":"received herbal extract dentifrices ","2476":"MPA (100 mg tds orally) ","2477":"Rizatriptan","2478":"MPA (100 mg tds orally) ","2479":"Rizatriptan","2480":"Recombinant- follicle stimulating hormone (r-FSH) plus recombinant-luteinizing hormone (rLH)","2481":"Recombinant- follicle stimulating hormone (r-FSH) plus recombinant-luteinizing hormone (rLH)","2482":"Recombinant- follicle stimulating hormone (r-FSH) plus recombinant-luteinizing hormone (rLH)","2483":"45 mg toltrazuril + 200 mg gleptoferron (Forceris\u00ae) or with 20 mg toltrazuril\/kg body weight as an oral suspension (Baycox\u00ae 5%)","2484":"hypocaloric diet without legumes (HDWL), hypocaloric diet enriched with legumes (HDEL)","2485":"'DEX full' at 10 min, 90, 120, 150, 180 and 210 min","2486":"800 IU vitamin D3","2487":"micafungin (100 mg\/day for subjects > 40 kg; 2 mg\/kg\/day for subjects \u2264 40 kg)","2488":"16 weeks of aerobic (5 d\/wk) and resistance training (2 d\/wk) (combined: \u2265250 kcal\/d) and caloric restriction (\u2212500 kcal\/d versus requirement)","2489":"16 weeks of aerobic (5 d\/wk) and resistance training (2 d\/wk) (combined: \u2265250 kcal\/d) and caloric restriction (\u2212500 kcal\/d versus requirement)","2490":"Intervention group","2491":"Patients in the 3h group","2492":"internal drainage group","2493":"ICP monitoring","2494":"ICP monitoring","2495":"ICP monitoring","2496":"derivation group","2497":"electrosurgical device","2498":"electrosurgical device","2499":"capsaicin","2500":"palady","2501":"3.2 g\/day citrulline","2502":"3.2 g\/day citrulline","2503":"azithromycin","2504":"2 cycles of sinusoidal chronomodulated infusion (Arm A)","2505":"Valsalva maneuver (MVM)","2506":"Couples Health CoOp [CHC]","2507":"neurovascular bundle preservation (NBP)","2508":"acarbose","2509":"\u03b2-asarone 10 mg\/d, tenuigenin 10 mg\/d, and memantine 5\u201320 mg\/d","2510":"question: 100 patients taking one kind of medicine, 70 patients became better. How would you evaluate the drug effect?","2511":"There are 600 critically ill patients in one hospital. Two rescue programs are under consideration. If program A is adopted, 200 patients will be saved; If program B is adopted, there is a 1\\3 chance that all patients will be saved and there is 2\/3 chance that none will be saved. Which program will you choose?","2512":"low-protein vegetarian diet (LPVD)","2513":"visual feedback group (VFG)","2514":"visual feedback group (VFG)","2515":"visual feedback group (VFG)","2516":"Kuntai, Tibolone, Control","2517":"Kuntai, Tibolone, Control","2518":"Tibolone, ","2519":"Extended postpartum care (Intervention group, IG)","2520":"Extended postpartum care (Intervention group, IG)","2521":"Novel glaucoma education and motivational support package using behaviour change counselling","2522":"Novel glaucoma education and motivational support package using behaviour change counselling","2523":"Novel glaucoma education and motivational support package using behaviour change counselling","2524":"Novel glaucoma education and motivational support package using behaviour change counselling","2525":"Prefrontal rTMS","2526":"Aloe cream","2527":"Pinnacle plan","2528":"Prasugrel 5 mg ","2529":"Laser therapy (Group I)","2530":"Self-collected vaginal specimens","2531":"2% lidocaine with 1:80,000 epinephrine ","2532":"2% lidocaine with 1:80,000 epinephrine ","2533":"2% lidocaine with 1:80,000 epinephrine ","2534":"2% lidocaine with 1:80,000 epinephrine ","2535":"Hermetical closure of the wound","2536":"Vaginal vitamin C","2537":"Vaginal vitamin C","2538":"Vaginal vitamin C","2539":"Cohesive Polydensified Matrix 26 mg\/ml HA (CPM-26)","2540":"Cohesive Polydensified Matrix 26 mg\/ml HA (CPM-26)","2541":"Short-term estradiol (E2)","2542":"Short-term estradiol (E2)","2543":"Remifentanil 0.05 (Group RL) or remifentanil 0.3 (group RH)","2544":"Remifentanil 0.3 (group RH)","2545":"Remifentanil 0.3 (group RH)","2546":"Etanercept plus methotrexate","2547":"Etanercept plus methotrexate","2548":"Etanercept plus methotrexate","2549":"Prescribed diet plus vitamin B12 supplement","2550":"Multi-ingredient performance supplement (MIPS) group","2551":"Multi-ingredient performance supplement (MIPS) group","2552":"Multi-ingredient performance supplement (MIPS) group","2553":"Extended depth-of-focus (EDOF)","2554":"DEX full","2555":"using the FA alone","2556":"micafungin (100 mg\/day for subjects 40 kg; 2 mg\/kg\/day for subjects \u2264 40 kg)","2557":"Patients in the 3h group","2558":"formula","2559":"VALIDATION GROUP the sensitivity, specificity, PPV, NPV were 95%, 44%, 22%, and 98%","2560":"intensive lifestyle intervention (ILI)","2561":"electrosurgical device","2562":"electrosurgical device","2563":"3.2 g\/day citrulline","2564":"azithromycin","2565":"400 \u03bcg of misoprostol","2566":"Valsalva maneuver (MVM)","2567":"females in group Men's Health CoOp\/Women's Health CoOp [MHC\/WHC]","2568":"neurovascular bundle preservation (NBP)","2569":"hypocaloric diet without legumes (HDWL)","2570":"DPP-4i therapy","2571":"low-protein vegetarian diet (LPVD)","2572":"12.5 mg hyperbaric bupivacaine along with preservative free midazolam 0.4 mL (2 mg)","2573":"low-protein vegetarian diet (LPVD)","2574":"electrical muscle stimulation (EMS)","2575":"extracorporeal shock wave therapy (ESWT)","2576":"Group I (CHX\/thymol mouthwash-Vi-one), Group II (CHX mouthwash-Behsa)","2577":"Kuntai","2578":"hypocaloric diet without legumes (HDWL)","2579":"Chlorproguanil-dapsone (CPD)","2580":"Enhanced version of the app","2581":"Enhanced version of the app","2582":"Enhanced version of the app","2583":"Prefrontal rTMS","2584":"Pinnacle plan","2585":"Pinnacle plan","2586":"Pinnacle plan","2587":"Pinnacle plan","2588":"Prasugrel 5 mg ","2589":"Clopidogrel 75 mg or prasugrel 5 mg ","2590":"Laser therapy (Group I)","2591":"Laser therapy (Group I)","2592":"Laser therapy (Group I)","2593":"2% lidocaine with 1:80,000 epinephrine ","2594":"Canagliflozin","2595":"Canagliflozin","2596":"Canagliflozin","2597":"Canagliflozin","2598":"MTL+caloric intake group and choices group","2599":"MTL group and MTL+caloric intake group","2600":"2 cycles of sinusoidal chronomodulated infusion (Arm A)","2601":"Cohesive Polydensified Matrix 26 mg\/ml HA (CPM-26)","2602":"Short-term estradiol (E2)","2603":"Training with visual functions","2604":"TOMOX","2605":"TOMOX","2606":"TOMOX","2607":"Interval training combined with Judo training (IJ) or Resistance training combined with Judo training (RJ)","2608":"Resistance training combined with Judo training (RJ)","2609":"Interval training combined with Judo training (IJ) or Resistance training combined with Judo training (RJ)","2610":"Prescribed diet plus vitamin B12 supplement","2611":"Prescribed diet plus vitamin B12 supplement","2612":"Multi-ingredient performance supplement (MIPS) group","2613":"Multi-ingredient performance supplement (MIPS) group","2614":"Hydrodistension plus intravesical resiniferatoxin (RTX)","2615":"G2- brushing with Sensodyne\u00aeRapid Relief;","2616":"BrainPower Advanced capsules ","2617":"BrainPower Advanced capsules","2618":"Dexmedetomidine","2619":"lidocaine (5 mgs\/kg)","2620":"Home Monitoring facilitated FU (HM ON)","2621":"Home Monitoring facilitated FU (HM ON)","2622":"Home Monitoring facilitated FU (HM ON)","2623":"Home Monitoring facilitated FU (HM ON)","2624":"Home Monitoring facilitated FU (HM ON)","2625":"Home Monitoring facilitated FU (HM ON)","2626":"Home Monitoring facilitated FU (HM ON)","2627":"oral marine protein supplement (MPS)","2628":"oral marine protein supplement (MPS)","2629":"oral marine protein supplement (MPS)","2630":"oral marine protein supplement (MPS)","2631":"6-week home-based exercise program","2632":"750 mL of water with either 9 g of EG (manufacturer recommendations), 0.1 g\u00b7kg-1 of NaHCO3","2633":"5-fluorouracil (350 mg m\u22122 per day on each day of radiotherapy, RT-5-FU arm)","2634":"IND\/GLY 110 \u03bcg\/50 \u03bcg","2635":"hyoscine group","2636":"ketamine group","2637":"Fluorodeoxyglucose-positron emission tomography (PET)\/computed tomography (CT)","2638":"Fluorodeoxyglucose-positron emission tomography (PET)\/computed tomography (CT)","2639":"Fluorodeoxyglucose-positron emission tomography (PET)\/computed tomography (CT)","2640":"two sessions of 1.5 hours each of the Pick-Klop game or two sessions of 1.5 hours each of psychoeducation","2641":"alvimopan","2642":"alvimopan","2643":"alvimopan","2644":"Iron polymaltose complex (IPC), ferrous sulfate twice daily, (both 5 mg iron\/kg\/day)","2645":"Iron polymaltose complex (IPC), ferrous sulfate twice daily, (both 5 mg iron\/kg\/day)","2646":"in-hospital administration of ticagrelor","2647":"500 g\/day of cooked banana for 4 days","2648":"480 g\/day of raw banana for 6 days","2649":"480 g\/day of raw banana for 6 days","2650":"atorvastatin 40 mg daily, rosuvastatin 20 mg daily for 4 weeks","2651":"Pre-School Autism Communication Trial (PACT)+ treatment as usual (TAU)","2652":"Brazil nuts, consuming more than two seafood portions per week","2653":"Brazil nuts, consuming more than two seafood portions per week","2654":"non vitamin K antagonist oral anticoagulant (NOAC)","2655":"position was changed every 2-3 hours and the bed sore was washed with water and cotton-wool and fish oil with thickness of 2-3 mm was applied on the place of sore","2656":"non vitamin K antagonist oral anticoagulant (NOAC)","2657":"edoxaban ","2658":"TOMOX","2659":"docetaxel-doxorubicin-cyclophosphamide (TAC)","2660":"position was changed every 2-3 hours and the bed sore was washed with water and cotton-wool and fish oil with thickness of 2-3 mm was applied on the place of sore","2661":"Succinylcholine group","2662":"Succinylcholine group","2663":"Succinylcholine group","2664":"early tracheotomy ","2665":"behavioral intervention","2666":"Group 1: all types of CHO","2667":"type 2 DM","2668":"Group 2","2669":"Pre-School Autism Communication Trial (PACT)+ treatment as usual (TAU)","2670":"40 mg\/day of Lovastatin plus 2 g\/day powder of Kelussia odoratissima, 40 mg\/day of lovastatin","2671":"40 mg\/day of Lovastatin plus 2 g\/day powder of Kelussia odoratissima","2672":"40 mg\/day of Lovastatin plus 2 g\/day powder of Kelussia odoratissima","2673":"Group II - 2 mg Amlexanox paste respectively, group III received diode laser","2674":"Group I - herbal combination of Acacia nilotica and Licorice (A and L)","2675":"Patient decision aids (P\ufffdDAs)","2676":"800 IU vitamin D3","2677":"Extended postpartum care (Intervention group, IG)","2678":"Aloe cream","2679":"Aloe cream","2680":"Aloe cream","2681":"Clopidogrel 75 mg or prasugrel 5 mg ","2682":"electrosurgical device","2683":"capsaicin","2684":"2 cycles of sinusoidal chronomodulated infusion (Arm A)","2685":"neurovascular bundle preservation (NBP)","2686":"acarbose","2687":"pioglitazone","2688":"Remifentanil 0.3 (group RH)","2689":"Imagine one of your relatives was diagnosed with a cancer that must be treated. His choices are as follows: Surgery: Of 100 people having surgery, 50 live through the operation, and 40 are alive at the end of five years. Radiation therapy: Of 100 people having radiation therapy, all live through the treatment, and 20 are alive at the end of five years. Which treatment would you advise him to choose?","2690":"TOMOX","2691":"Etanercept plus methotrexate","2692":"trigger point injections (TPI)+transcutaneous electrical nerve stimulation (TENS)","2693":"Group I (CHX\/thymol mouthwash-Vi-one)","2694":"Group I (CHX\/thymol mouthwash-Vi-one)","2695":"Hydrodistension plus intravesical resiniferatoxin (RTX)","2696":"Hydrodistension plus intravesical resiniferatoxin (RTX)","2697":"Hydrodistension plus intravesical resiniferatoxin (RTX)","2698":"preoperative preparation program on children's anxiety","2699":"hypocaloric diet without legumes (HDWL), hypocaloric diet enriched with legumes (HDEL)","2700":"Patient decision aids (P\ufffdDAs)","2701":"D1 (Colgate Sensitive Pro-Relief\u00ae), dentifrice D3 (Sensodyne Repair & Protect\u00ae)","2702":"D1 (Colgate Sensitive Pro-Relief\u00ae)","2703":"re-immunization with 2 booster doses in previously immunized","2704":"G3- brushing with Sensodyne\u00aeRepair & Protect;","2705":"propofol SD2","2706":"propofol SD1 and SD2","2707":"propofol SD1 and SD2","2708":"BrainPower Advanced capsules","2709":"Home Monitoring facilitated FU (HM ON)","2710":"ProTaper, K3 SybronEndo, and Easy RaCe rotary","2711":"oral marine protein supplement (MPS)","2712":"oral marine protein supplement (MPS)","2713":"6-week home-based exercise program","2714":"5-fluorouracil (350 mg m\u22122 per day on each day of radiotherapy, RT-5-FU arm)","2715":"S-1 40\u201360 mg two times daily according to body surface area on days 1\u201328 every 6 weeks","2716":"IND\/GLY 110 \u03bcg\/50 \u03bcg","2717":"IND\/GLY 110 \u03bcg\/50 \u03bcg","2718":"IND\/GLY 110 \u03bcg\/50 \u03bcg","2719":"Group A subjects receiving active treatmen","2720":"Group B subjects receiving placebo","2721":"Fluorodeoxyglucose-positron emission tomography (PET)\/computed tomography (CT)","2722":"Fluorodeoxyglucose-positron emission tomography (PET)\/computed tomography (CT)","2723":"two sessions of 1.5 hours each of the Pick-Klop game or two sessions of 1.5 hours each of psychoeducation","2724":"two sessions of 1.5 hours each of the Pick-Klop game or two sessions of 1.5 hours each of psychoeducation","2725":"two sessions of 1.5 hours each of the Pick-Klop game","2726":"two sessions of 1.5 hours each of the Pick-Klop game","2727":"alvimopan","2728":"alvimopan","2729":"alvimopan","2730":"Iron polymaltose complex (IPC)","2731":"Iron polymaltose complex (IPC), ferrous sulfate twice daily, (both 5 mg iron\/kg\/day)","2732":"480 g\/day of raw banana for 6 days","2733":"short-bore MR scanner","2734":"short-bore MR scanner","2735":"high-field horizontal open MR scanner","2736":"short-bore MR scanner","2737":"rosuvastatin 20 mg daily for 4 weeks","2738":"rosuvastatin 20 mg daily for 4 weeks","2739":"rosuvastatin 20 mg daily for 4 weeks","2740":"rosuvastatin 20 mg daily for 4 weeks","2741":"edoxaban 30","2742":"non vitamin K antagonist oral anticoagulant (NOAC)","2743":"non vitamin K antagonist oral anticoagulant (NOAC)","2744":"adjuvant dose-dense doxorubicin-cyclophosphamide (ddAC)","2745":"docetaxel-doxorubicin-cyclophosphamide (TAC)","2746":"adjuvant dose-dense doxorubicin-cyclophosphamide (ddAC)","2747":"docetaxel-doxorubicin-cyclophosphamide (TAC)","2748":"docetaxel-doxorubicin-cyclophosphamide (TAC)","2749":"adjuvant dose-dense doxorubicin-cyclophosphamide (ddAC)","2750":"Interval training combined with Judo training (IJ)","2751":"Succinylcholine group","2752":"late tracheotomy","2753":"early tracheotomy ","2754":"early tracheotomy ","2755":"early tracheotomy ","2756":"behavioral intervention","2757":"sustained quitters","2758":"Group 1: all types of carbohydrates (CHO), Group 2: low GI foods","2759":"Group 1: all types of CHO","2760":"Group 1: all types of CHO\t","2761":"Pre-School Autism Communication Trial (PACT)+ treatment as usual (TAU)","2762":"position was changed every 2-3 hours and the bed sore was washed with water and cotton-wool and fish oil with thickness of 2-3 mm was applied on the place of sore","2763":"position was changed every 2-3 hours and the bed sore was washed with water and cotton-wool and fish oil with thickness of 2-3 mm was applied on the place of sore","2764":"position was changed every 2-3 hours and the bed sore was washed with water and cotton-wool and fish oil with thickness of 2-3 mm was applied on the place of sore","2765":"Home Management of Malaria (HMM)","2766":"Home Management of Malaria (HMM)","2767":"Home Management of Malaria (HMM)","2768":"Metformin","2769":"Metformin","2770":"fixed-combination bimatoprost 0.03%\/timolol 0.5% (FCBT PF) in treatment-nai\u0308ve patients","2771":"echium oil (EO) ","2772":"Physta plus Polygonum minus","2773":"Physta plus Polygonum minus","2774":"abatacept, rituximab","2775":"Training-based strategies (experimental group)","2776":"Training-based strategies (experimental group)","2777":"Motivational interviewing through self-determination theory sessions","2778":"Motivational interviewing through self-determination theory sessions","2779":"Group D (dexmedetomidine)","2780":"Group D (dexmedetomidine)","2781":"Conventional etching with 37% phosphoric acid (group 1)","2782":"Conventional etching with 37% phosphoric acid (group 1)","2783":"High glycemic index intervention","2784":"High glycemic index intervention","2785":"Intravenous colloid","2786":"Free-walking","2787":"rinse their mouths with 0.2% chlorhexidine for 1 minute twice daily for two weeks","2788":"150 mg\u2219kg-1 of Sodium bicarbonate (SB) for 10 days","2789":"150 mg\u2219kg-1 of SB for 10 days","2790":"150 mg\u2219kg-1 of SB for 10 days","2791":"NBUVB - 9 J\/cm2 for 6 weeks","2792":"fraction of exhaled nitric oxide (FeNO group)","2793":"levofloxacin (500 mg\/d) and mirodenafil (50 mg\/d) (group ML) for six weeks","2794":"endovascular arm","2795":"endovascular arm","2796":"Wheelchair Skills Training Program (WSTP)","2797":"workplace social capital intervention among those lost to follow-up","2798":"bright white light (10,000 lux), dim red light (< 500 lux) post-treatment","2799":"bright white light (10,000 lux), dim red light (< 500 lux) post-treatment","2800":"bright white light (10,000 lux), dim red light (< 500 lux) post-treatment","2801":"Extended postpartum care (Intervention group, IG)","2802":"Extended postpartum care (Intervention group, IG)","2803":"Prefrontal rTMS","2804":"Prasugrel 5 mg ","2805":"Laser therapy (Group I)","2806":"Self-collected vaginal specimens","2807":"Canagliflozin","2808":"MTL group and MTL+caloric intake group","2809":"Hermetical closure of the wound","2810":"Hermetical closure of the wound","2811":"Vaginal vitamin C","2812":"Asymptomatic inflammation group (EXPg)","2813":"Short-term estradiol (E2)","2814":"Training with visual functions","2815":"Remifentanil 0.3 (group RH)","2816":"Resistance training combined with Judo training (RJ)","2817":"Prescribed diet plus vitamin B12 supplement","2818":"Prescribed diet plus vitamin B12 supplement","2819":"Extended depth-of-focus (EDOF)","2820":"Extended depth-of-focus (EDOF)","2821":"Extended depth-of-focus (EDOF)","2822":"proximal extensive HAS","2823":"directly administered antiretroviral therapy (DAART)","2824":"echium oil (EO) ","2825":"TNFi","2826":"TNFi","2827":"Reciproc","2828":"Reciproc","2829":"Reciproc, Mtwo","2830":"Reciproc","2831":"standard dose ATG (total dose 3.75 mg\/kg)(sATG)","2832":"standard dose ATG (total dose 3.75 mg\/kg)(sATG)","2833":"standard dose ATG (total dose 3.75 mg\/kg)(sATG)","2834":"standard dose ATG (total dose 3.75 mg\/kg)(sATG)","2835":"standard dose ATG (total dose 3.75 mg\/kg)(sATG)","2836":"normal weight group following consumption of the high protein, high fat meal","2837":"underweight","2838":"normal weight group - high protein, high fat meal","2839":"NC with supervised bootcamp (NC + BC)","2840":"NC with supervised bootcamp (NC + BC)","2841":"NC with supervised bootcamp (NC + BC)","2842":"plant sterol (PS) from fish oil (FO)","2843":"plant sterol (PS) from fish oil (FO)","2844":"plant sterol (PS) from fish oil (FO)","2845":"plant sterol (PS) from fish oil (FO)","2846":"tiapride","2847":"neoadjuvant DE (docetaxel: 75 mg\/m2, d1, epirubicin: 75 mg\/m2, d1, every 3 weeks)","2848":"neoadjuvant DE (docetaxel: 75 mg\/m2, d1, epirubicin: 75 mg\/m2, d1, every 3 weeks)","2849":"therapeutic acupuncture (TA) , salutogenic dialogue (IT)","2850":"therapeutic acupuncture (TA)","2851":"intervention group (where mood, stress and daily activities were monitored with program mobiletype)","2852":"intervention group (where mood, stress and daily activities were monitored with program mobiletype)","2853":"'Florence'- interactive mobile phone texting service","2854":"weight loss program - minimal user group","2855":"weight loss program -in the consistent user group","2856":"umbilical cord mesenchymal stem cells (UC-MSCs) 1\u00d7106 UC-MSCs\/kg, with one infusion per week","2857":"gentamicin collagen implant (GCI)","2858":"gentamicin collagen implant (GCI)","2859":"gentamicin collagen implant (GCI)","2860":"intramuscular injections of 0.035 mg\/kg of body weight BP-C1","2861":"placebo","2862":"intramuscular injections of 0.035 mg\/kg of body weight BP-C1","2863":"placebo","2864":"intramuscular injections of 0.035 mg\/kg of body weight BP-C1","2865":"CBM-I (cognitive-bias modification (CBM) + Internet-based cognitive behavioral therapy (iCBT)","2866":"CBM-I ","2867":"two CN54rgp140\/GLA-AF immunizations","2868":"two CN54rgp140\/GLA-AF immunizations","2869":"Group M - morphine plus bupivacaine intra-articularly, Group T - triamcinolone plus bupivacaine intra-articularly ","2870":"vortioxetine (10\u201320 mg)","2871":"duloxetine 60 mg","2872":"duloxetine 60 mg","2873":"creatine phosphate sodium (1.0 g\/100 ml 0.9% saline; group P)","2874":"liraglutide 1.8 mg","2875":"liraglutide 1.8 mg","2876":"liraglutide 1.8 mg","2877":"liraglutide 1.8 mg","2878":"Cal\/BD aerosol foam at week 1 and week 4","2879":"saline 0.90% in group S","2880":"midazolam 0.75 mg\/kg and ondansetron 4 mg in group MO","2881":"ondansetron 4 mg in group O","2882":"midazolam 0.75 mg\/kg in group M, ondansetron 4 mg in group O","2883":"midazolam 0.75 mg\/kg and ondansetron 4 mg in group MO","2884":"midazolam 0.75 mg\/kg and ondansetron 4 mg in group MO","2885":"droxidopa dose optimization (100\u2013600 mg 3 times daily)","2886":"droxidopa dose optimization (100\u2013600 mg 3 times daily)","2887":"droxidopa dose optimization (100\u2013600 mg 3 times daily)","2888":"droxidopa dose optimization (100\u2013600 mg 3 times daily)","2889":"200 mg\/day palmvitee smokers ","2890":"200 mg\/day palmvitee smokers ","2891":"200 mg\/day palmvitee nonsmokers ","2892":"200 mg\/day palmvitee smokers ","2893":"200 mg\/day palmvitee smokers ","2894":"telephone-delivered multiple health behaviour change intervention","2895":"telephone-delivered multiple health behaviour change intervention","2896":"telephone-delivered multiple health behaviour change intervention","2897":"telephone-delivered multiple health behaviour change intervention","2898":"telephone-delivered multiple health behaviour change intervention","2899":"telephone-delivered multiple health behaviour change intervention","2900":"telephone-delivered multiple health behaviour change intervention","2901":"epoetin-\u03b1","2902":"epoetin-\u03b1","2903":"epoetin-\u03b1","2904":"epoetin-\u03b1","2905":"Group A, 1 \u03bcg\/kg of dexmedetomidine was intravenously 10 min, followed by the maintenance infusion of dexmedetomidine 0.2 \u03bcg\/kg\/hr after 5 min of intrathecal bupivacaine injection","2906":"Group A, 1\u03bcg\/kg of dexmedetomidine was intravenously 10min, followed by the maintenance infusion of dexmedetomidine 0.2\u03bcg\/kg\/hr after 5min of intrathecal bupivacaine injection","2907":"Group A, 1\u03bcg\/kg of dexmedetomidine was intravenously 10min, followed by the maintenance infusion of dexmedetomidine 0.2\u03bcg\/kg\/hr after 5min of intrathecal bupivacaine injection","2908":"10 mL loading dose (0.125% bupivacaine with fentanyl 2 \u03bcg\/mL) through either the epidural needle","2909":"10 mL loading dose (0.125% bupivacaine with fentanyl 2 \u03bcg\/mL) through either the epidural needle","2910":"10 mL loading dose (0.125% bupivacaine with fentanyl 2 \u03bcg\/mL) through either the epidural needle","2911":"10 mL loading dose (0.125% bupivacaine with fentanyl 2 \u03bcg\/mL) through either the epidural needle","2912":"crystalloid","2913":"Physta plus Polygonum minus","2914":"Physta plus Polygonum minus","2915":"Vaccine group","2916":"Vaccine group","2917":"Vaccine group","2918":"ASV group","2919":"Motivational interviewing through self-determination theory sessions","2920":"Group D (dexmedetomidine)","2921":"Memantine","2922":"Memantine","2923":"Memantine","2924":"Memantine","2925":"High glycemic index intervention","2926":"Single-dose intravenous antibiotic prophylaxis","2927":"Intravenous colloid","2928":"Intravenous colloid","2929":"Intravenous colloid","2930":"Intravenous colloid","2931":"group A","2932":"received intraoperative application of a fibrin sealant following inguino-femoral lymph node dissection","2933":"received intraoperative application of a fibrin sealant following inguino-femoral lymph node dissection","2934":"smoking","2935":"5-aminolevulinic acid (5-ALA)","2936":"NBUVB - 9 J\/cm2 for 6 weeks","2937":"NBUVB - 9 J\/cm2 for 6 weeks","2938":"fraction of exhaled nitric oxide (FeNO group)","2939":"screening method with Screening and Brief Intervention (SBI) program","2940":"12.7 g of psyllium hydrophilic mucilloid","2941":"evacetrapib (10\u2013600 mg)","2942":"evacetrapib (10\u2013600 mg)","2943":"evacetrapib (10\u2013600 mg)","2944":"Wheelchair Skills Training Program (WSTP)","2945":"bright white light (10,000 lux), dim red light (< 500 lux) post-treatment","2946":"Enalapril","2947":"Enalapril","2948":"Pirfenidone (high-dose) ","2949":"Pirfenidone (low-dose) ","2950":"Bevacizumab (1 dose)","2951":"Theory-based educational intervention","2952":"Internet-based cognitive behavior therapy","2953":"Parental monitoring","2954":"Caudal Sufentanil + neostigmine","2955":"Parental monitoring","2956":"Caudal Sufentanil + neostigmine + Adrenaline","2957":"Caudal Sufentanil + neostigmine ","2958":"Spirulina Platensis","2959":"Spirulina Platensis","2960":"Brand-name desogestrel ","2961":"Brand-name desogestrel ","2962":"extracts of fennelin","2963":"PA21","2964":"extracts of vitagnus or fennelin","2965":"PA21","2966":"Preemptive Thoracic Epidural Analgesia (Group P)","2967":"Preemptive Thoracic Epidural Analgesia (Group P)","2968":"perioperative oral extended-release tapentadol","2969":"perioperative oral extended-release tapentadol","2970":"perioperative oral extended-release tapentadol","2971":"topical pimecrolimus cream 1%","2972":"topical pimecrolimus cream 1%","2973":"4% lidocaine along with 1:100,000 epinephrine","2974":"epoetin-\u03b1","2975":"2% lidocaine along with 1:100,000 epinephrine","2976":"\u03b1-melanocyte stimulating hormone (\u03b1-MSH)","2977":"Hyaluronic acid","2978":"Hyaluronic acid","2979":"Specific instructions","2980":"Pentoxifylline, ursodeoxycholic acid, and low-dose low molecular weight heparin.","2981":"Active catgut implantation group","2982":"Isoflavone + Fructooligosaccharides diet (GIF)","2983":"Fructooligosaccharides diet (GF) and Isoflavone + Fructooligosaccharides diet (GIF)","2984":"Active catgut implantation group","2985":"Shensong Yangxin","2986":"Shensong Yangxin","2987":"Shensong Yangxin","2988":"Alfentanil","2989":"Alfentanil","2990":"Teriflunomide 14 mg (1 year) + presence of on-study disability worsening","2991":"Eptifibatide","2992":"Eptifibatide","2993":"Eptifibatide","2994":"Aerobic interval training ","2995":"Attractive cuing","2996":"Highly active antiretroviral treatment","2997":"0.9 % sodium chloride 10 mL flush","2998":"Flush frequency every 24 hours","2999":"Flush frequency","3000":"Laryngeal mask ","3001":"2 Hertz EA stimulation","3002":"Ropivacaine (0.33%) 30ml","3003":"Ropivacaine (0.25%) 40ml","3004":"Adjuvant S-1 therapy after sugery","3005":"Nevirapine","3006":"Nevirapine","3007":"Enalapril","3008":"Vitamin D + Calcium","3009":"ARV","3010":"more extensive hyperdense artery sign (HAS)","3011":"fixed-combination bimatoprost 0.03%\/timolol 0.5% (FCBT PF) in treatment-nai\u0308ve patients","3012":"Metformin","3013":"Metformin","3014":"fish oil (FO)","3015":"echium oil (EO) ","3016":"Physta plus Polygonum minus","3017":"Vaccine group","3018":"Vaccine group","3019":"Motivational interviewing through self-determination theory sessions","3020":"Motivational interviewing through self-determination theory sessions","3021":"Group D (dexmedetomidine)","3022":"Group D (dexmedetomidine)","3023":"Memantine","3024":"High glycemic index intervention","3025":"High glycemic index intervention","3026":"Single-dose intravenous antibiotic prophylaxis","3027":"Active myofascial trigger point group, or Latent myofascial trigger point group","3028":"Active myofascial trigger point group","3029":"Free-walking","3030":"Free-walking","3031":"Free-walking","3032":"rinse their mouths with 0.2% chlorhexidine or triphala mouthwash for 1 minute twice daily for two weeks","3033":"supervision by tuberculosis health visitors (TBHVs)","3034":"supervision by tuberculosis health visitors (TBHVs)","3035":"mandibular advancement device (MAD)","3036":"smoking","3037":"5-aminolevulinic acid (5-ALA)","3038":"150 mg\u2219kg-1 of SB for 10 days","3039":"150 mg\u2219kg-1 of SB for 10 days","3040":"NBUVB - 9 J\/cm2 for 6 weeks","3041":"levofloxacin (500 mg\/d) and mirodenafil (50 mg\/d) (group ML) for six weeks","3042":"patients with 70% or more restenosis in the first year","3043":"evacetrapib (10\u2013600 mg)","3044":"evacetrapib (10\u2013600 mg)","3045":"Wheelchair Skills Training Program (WSTP)","3046":"bright white light (10,000 lux)","3047":"bright white light (10,000 lux), dim red light (< 500 lux) post-treatment","3048":"more extensive hyperdense artery sign (HAS)","3049":"proximal extensive HAS","3050":"peribulbuar block with 5ml lignocaine 2% +3 ml bupivacaine 0.5% +1 ml hyaluronidase (250 IU) + 1 ml normal saline - Group S, ","3051":"Reciproc","3052":"Reciproc","3053":"standard dose ATG (total dose 3.75 mg\/kg)(sATG)","3054":"overweight group","3055":"NC with supervised bootcamp (NC + BC)","3056":"plant sterol (PS) from fish oil (FO)","3057":"plant sterol (PS) from fish oil (FO)","3058":"plant sterol (PS) from fish oil (FO)","3059":"plant sterol (PS) from fish oil (FO)","3060":"tiapride","3061":"tiapride (TIA)","3062":"exercise and manual therapy group","3063":"exercise and manual therapy group","3064":"neoadjuvant DE (docetaxel: 75 mg\/m2, d1, epirubicin: 75 mg\/m2, d1, every 3 weeks)","3065":"neoadjuvant DE (docetaxel: 75 mg\/m2, d1, epirubicin: 75 mg\/m2, d1, every 3 weeks)","3066":"conventional treatment (CT)","3067":"intervention group (where mood, stress and daily activities were monitored with program mobiletype)","3068":"a protein gel, and a multi-vitamin (SUP), the high-protein diet with isocaloric placebo supplements (PLA)","3069":"a protein gel, and a multi-vitamin (SUP)","3070":"a protein gel, and a multi-vitamin (SUP)","3071":"a protein gel, and a multi-vitamin (SUP)","3072":"a protein gel, and a multi-vitamin (SUP)","3073":"iPad-based software platform","3074":"iPad-based software platform","3075":"iPad-based software platform","3076":"weight loss program -in the consistent user group","3077":"weight loss program -in the consistent user group","3078":"promethazine intramuscularly at a dose of 25 mg (group A)","3079":"8 mg betahistine tablets (group B)","3080":"promethazine intramuscularly at a dose of 25 mg (group A)","3081":"umbilical cord mesenchymal stem cells (UC-MSCs) 1\u00d7106 UC-MSCs\/kg, with one infusion per week","3082":"intramuscular injections of 0.035 mg\/kg of body weight BP-C1","3083":"intramuscular injections of 0.035 mg\/kg of body weight BP-C1","3084":"intramuscular injections of 0.035 mg\/kg of body weight BP-C1","3085":"intramuscular injections of 0.035 mg\/kg of body weight during the 64 days of BP-C1 treatment","3086":"cognitive behavioral therapy (iCBT)","3087":"CBM-I (cognitive-bias modification (CBM) + Internet-based cognitive behavioral therapy (iCBT)","3088":"two CN54rgp140\/GLA-AF immunizations","3089":"two CN54rgp140\/GLA-AF immunizations","3090":"Group M - morphine plus bupivacaine intra-articularly, Group T - triamcinolone plus bupivacaine intra-articularly ","3091":"Group M - morphine plus bupivacaine intra-articularly","3092":"Group M - morphine plus bupivacaine intra-articularly, Group T - triamcinolone plus bupivacaine intra-articularly ","3093":"Group M - morphine plus bupivacaine intra-articularly","3094":"Group M - morphine plus bupivacaine intra-articularly, Group T - triamcinolone plus bupivacaine intra-articularly ","3095":"duloxetine 60 mg","3096":"vortioxetine (10\u201320 mg)","3097":"vortioxetine (10\u201320 mg)","3098":"vortioxetine (10\u201320 mg)","3099":"creatine phosphate sodium (1.0 g\/100 ml 0.9% saline; group P)","3100":"creatine phosphate sodium (1.0 g\/100 ml 0.9% saline; group P)","3101":"liraglutide 1.8 mg","3102":"liraglutide 1.8 mg","3103":"liraglutide 1.8 mg","3104":"liraglutide 1.8 mg","3105":"liraglutide 1.8 mg","3106":"Cal\/BD aerosol foam","3107":"midazolam 0.75 mg\/kg and ondansetron 4 mg in group MO","3108":"midazolam 0.75 mg\/kg and ondansetron 4 mg in group MO","3109":"D3 supplementation (daily 800 IU or 100,000 IU\/3 months)","3110":"vitamin D 800 IU\/day or 100,000 IU\/3 months","3111":"vitamin D 800IU\/day or 100,000IU\/3months","3112":"0.25 \u03bcg calcitriol per day for one year","3113":"Extracorporeal Shock Wave Lithotripsy (ESWL) in group A, stone size \u226410 mm; - success group","3114":"Extracorporeal Shock Wave Lithotripsy (ESWL) group B, stone size10 mm - success group","3115":"droxidopa dose optimization (100\u2013600 mg 3 times daily)","3116":"200 mg\/day palmvitee smokers , 200 mg\/day palmvitee nonsmokers","3117":"200 mg\/day palmvitee smokers ","3118":"telephone-delivered multiple health behaviour change intervention","3119":"telephone-delivered multiple health behaviour change intervention","3120":"telephone-delivered multiple health behaviour change intervention","3121":"FOBT plus a mailed reminder","3122":"epoetin-\u03b1","3123":"epoetin-\u03b1","3124":"Group A, 1 \u03bcg\/kg of dexmedetomidine was intravenously 10min, followed by the maintenance infusion of dexmedetomidine 0.2\u03bcg\/kg\/hr after 5min of intrathecal bupivacaine injection","3125":"10 mL loading dose (0.125% bupivacaine with fentanyl 2 \u03bcg\/mL) through either the epidural needle","3126":"BV juice (480 mL\/day","3127":"BV juice (480 mL\/day)","3128":"BV juice (480 mL\/day)","3129":"Group II -IV amikacin 20 mg\/kg\/24 h and meropenem 2 g over 30 min\/8 h in addition to nebulized amikacin 25 mg\/kg\/day every 8 h. Group III received IV amikacin 20 mg\/kg\/24 h, nebulized amikacin 25 mg\/kg\/day every 8 h, and meropenem 2 g diluted in 240 ml normal saline over 3 h\/8 h ","3130":"Group II -IV amikacin 20 mg\/kg\/24 h and meropenem 2 g over 30 min\/8 h in addition to nebulized amikacin 25 mg\/kg\/day every 8 h. ","3131":"Group III received IV amikacin 20 mg\/kg\/24 h, nebulized amikacin 25 mg\/kg\/day every 8 h, and meropenem 2 g diluted in 240 ml normal saline over 3 h\/8 h","3132":"Group III received IV amikacin 20 mg\/kg\/24 h, nebulized amikacin 25 mg\/kg\/day every 8 h, and meropenem 2 g diluted in 240 ml normal saline over 3 h\/8 h","3133":"Fructooligosaccharides diet (GF) and Isoflavone + Fructooligosaccharides diet (GIF)","3134":"Isoflavone diet (GI)","3135":"Aerobic interval training (ITT)","3136":"Aerobic interval training ","3137":"Polyherbal formulation","3138":"Laryngeal mask ","3139":"Laryngeal mask ","3140":"Laryngeal mask ","3141":"Ropivacaine (0.33%) 30ml","3142":"Ropivacaine (0.25%) 40ml","3143":"Nevirapine","3144":"Nevirapine","3145":"Nevirapine","3146":"Omega-3","3147":"Omega-3","3148":"ARV","3149":"ARV","3150":"ARV","3151":"Pirfenidone (high-dose) ","3152":"Pirfenidone (high and low dose) ","3153":"Pirfenidone (high and low dose) ","3154":"Bevacizumab (1 dose)","3155":"IV Sufentanil ","3156":"Brand-name desogestrel ","3157":"mefenamic acid","3158":"4% lidocaine along with 1:100,000 epinephrine","3159":"three-tumor marker classifier","3160":"\u03b1-melanocyte stimulating hormone (\u03b1-MSH)","3161":"\u03b1-melanocyte stimulating hormone (\u03b1-MSH)","3162":"\u03b1-MSH","3163":"Mitomycine C","3164":"Mitomycine C","3165":"Mitomycine C","3166":"Hyaluronic acid","3167":"Pentoxifylline, ursodeoxycholic acid, and low-dose low molecular weight heparin.","3168":"Pentoxifylline, ursodeoxycholic acid, and low-dose low molecular weight heparin.","3169":"Pentoxifylline, ursodeoxycholic acid, and low-dose low molecular weight heparin.","3170":"Active catgut implantation group","3171":"Active catgut implantation group","3172":"Shensong Yangxin","3173":"Eptifibatide","3174":"Attractive cuing","3175":"Attractive cuing","3176":"2 Hertz EA stimulation","3177":"2 Hertz EA stimulation","3178":"Adjuvant S-1 therapy after sugery","3179":"Adjuvant S-1 therapy after sugery","3180":"Rapid diagnostic tests","3181":"Rapid diagnostic tests","3182":"Rapid diagnostic tests","3183":"Tinnitus Implant ","3184":"Tinnitus Implant ","3185":"Tinnitus Implant ","3186":"Vitamin D + Calcium","3187":"Vitamin D + Calcium","3188":"Aromatherapy oil inhalation","3189":"Aromatherapy oil inhalation","3190":"Enalapril","3191":"Dexamethasone","3192":"network A","3193":"Theory-based educational intervention","3194":"Internet-based cognitive behavior therapy","3195":"Internet-based cognitive behavior therapy","3196":"Spirulina Platensis","3197":"Spirulina Platensis","3198":"Spirulina Platensis","3199":"Preemptive Thoracic Epidural Analgesia (Group P)","3200":"Preemptive Thoracic Epidural Analgesia (Group P)","3201":"Bevacizumab (1 dose)","3202":"Brand-name desogestrel ","3203":"Brand-name desogestrel ","3204":"The water campaign","3205":"perioperative oral extended-release tapentadol","3206":"Methylphenidate treatment","3207":"Hyaluronic acid","3208":"Active catgut implantation group","3209":"Fructooligosaccharides diet (GF) and Isoflavone + Fructooligosaccharides diet (GIF)","3210":"Teriflunomide 14 mg (2 years)","3211":"Teriflunomide 7 mg (2 years)","3212":"Alfentanil","3213":"Maximal volitional interval training","3214":"Laryngeal mask ","3215":"2 Hertz EA stimulation","3216":"Adjuvant S-1 therapy after sugery","3217":"Rapid diagnostic tests","3218":"Rapid diagnostic tests","3219":"Omega-3","3220":"Ivermectin","3221":"Ivermectin","3222":"Enalapril","3223":"bepotastine besilate ophthalmic solution (BBOS) 1.5%","3224":"CBT for depression with the addition of a text messaging adjunct","3225":"Acetylsalicylic acid","3226":"a single cup of coffee (80 mg caffeine)","3227":"able-bodied men without any intervention","3228":"2 mg of melatonin given 4 days for tetraplegic patients and placebo for tetraplegic patients","3229":"2 mg of melatonin given 4 days for tetraplegic patients and placebo for tetraplegic patients","3230":"2 mg of melatonin given 4 days for tetraplegic patients and placebo for tetraplegic patients","3231":"standard care plus CT coronary angiography (CTCA), standard care","3232":"prebiotic mixture (SCGOS\/LCFOS; 9:1)","3233":"prebiotic mixture (SCGOS\/LCFOS; 9:1)","3234":"prebiotic mixture (SCGOS\/LCFOS; 9:1)","3235":"prebiotic mixture (SCGOS\/LCFOS; 9:1)","3236":"VerisetTM hemostatic patch","3237":"group C, indoor with no supplement; S, indoor with supplement,","3238":"group C, indoor with no supplement; S, indoor with supplement,","3239":"Get Healthy, Stay Healthy' (GHSH)","3240":"Get Healthy, Stay Healthy' (GHSH)","3241":"Get Healthy, Stay Healthy' (GHSH)","3242":"Get Healthy, Stay Healthy' (GHSH)","3243":"Get Healthy, Stay Healthy' (GHSH)","3244":"G, outdoor with no supplement","3245":"onabotulinumtoxinA (100 U) ","3246":"\u03b2-alanine (n = 7; 6.4 g\u00b7d-1 over 4 weeks)","3247":"\u03b2-alanine (n = 7; 6.4 g\u00b7d-1 over 4 weeks)","3248":"low frequency transcutaneous electrical nerve stimulation (TENS)","3249":"low frequency transcutaneous electrical nerve stimulation (TENS)","3250":"non- low frequency transcutaneous electrical nerve stimulation (TENS)","3251":"non- low frequency transcutaneous electrical nerve stimulation (TENS)","3252":"non- low frequency transcutaneous electrical nerve stimulation (TENS)","3253":"60 mg SC enoxaparin for a period of 24 hours","3254":"No irrigant","3255":"saline","3256":"acupuncture three times per week","3257":"acupuncture three times per week","3258":"12 week supplementation with fish oil (group I), fish oil with primrose evening oil (group II)","3259":"12 week supplementation with fish oil (group I)","3260":"record the number of steps on a daily basis for 12 weeks","3261":"record the number of steps on a daily basis for 12 weeks, was not able to record their steps daily","3262":"record the number of steps on a daily basis for 12 weeks","3263":"vildagliptin (50 mg twice daily) for 12weeks","3264":"Biodex Balance System (BBS) balance training, virtual-reality (VR) balance training","3265":"Biodex Balance System (BBS) balance training, ","3266":"Biodex Balance System (BBS) balance training, ","3267":"(40\u201380 mg\/d, flexibly dosed) for an additional 28-week treatment period","3268":"(40\u201380 mg\/d, flexibly dosed) for an additional 28-week treatment period","3269":"group A ('non-selective'\u2014clopidogrel 600 mg >6 h before CAG;","3270":"group A ('non-selective'\u2014clopidogrel 600 mg 6 h before CAG; in subgroup of patients who underwent PCI","3271":"group A ('non-selective'\u2014clopidogrel 600 mg 6 h before CAG; in subgroup of patients who underwent PCI","3272":"liposome bupivacaine","3273":"liposome bupivacaine","3274":"LCI699","3275":"LCI699","3276":"quetiapine (dopamine receptor antagonist)","3277":"quetiapine (QT)","3278":"pramipexole (PX) (dopamine agonist of the nonergoline class) ","3279":"pramipexole (PX)","3280":"pramipexole (PX)","3281":"CBT for depression with the addition of a text messaging adjunct","3282":"CBT for depression with the addition of a text messaging adjunct","3283":"standard group CBT for depression standard group","3284":"standard group CBT for depression standard group","3285":"Acetylsalicylic acid","3286":"Acetylsalicylic acid","3287":"a single cup of coffee (80 mg caffeine)","3288":"2 mg of melatonin given 4 days for tetraplegic patients","3289":"standard care plus CT coronary angiography (CTCA)","3290":"prebiotic mixture (SCGOS\/LCFOS; 9:1)","3291":"VerisetTM hemostatic patch","3292":"VerisetTM hemostatic patch","3293":"group C, indoor with no supplement; S, indoor with supplement,","3294":"G, outdoor with no supplement","3295":"group C, indoor with no supplement; S, indoor with supplement,","3296":"S, indoor with supplement,","3297":"Aerobic and resistance exercice + prenatal care","3298":"Aerobic and resistance exercice + prenatal care","3299":"Aerobic and resistance exercice + prenatal care","3300":"Aerobic and resistance exercice + prenatal care","3301":"Aerobic and resistance exercice + prenatal care","3302":"Pilocarpine","3303":"Bromhexine","3304":"Bromhexine","3305":"Policarpine","3306":"Mitoxantrone + methylprednisolone","3307":"Subcutaneous progesterone","3308":"Subcutaneous progesterone","3309":"Subcutaneous progesterone","3310":"Subcutaneous progesterone","3311":"Probiotic (VSL#3)","3312":"Omega-3","3313":"Omega-3","3314":"Insulin + Pramlintide (all doses)","3315":"Insulin + Pramlintide (all doses)","3316":"JQJT tablets","3317":"JQJT tablets","3318":"Second Life program","3319":"Second Life program","3320":"Second Life program","3321":"E-mode Endoscopic sphincterotomy","3322":"E-mode Endoscopic sphincterotomy","3323":"E-mode Endoscopic sphincterotomy","3324":"E-mode Endoscopic sphincterotomy","3325":"Interactive Voice Response","3326":"Fluoride toothpaste (5000 ppm) ","3327":"Fluoride mouth rinse (250 ppm) ","3328":"Fluoride toothpaste (5000 ppm) ","3329":"Thyroidectomy via BABA","3330":"Thyroidectomy via BABA","3331":"Thyroidectomy via BABA","3332":"Thyroidectomy via BABA","3333":"Vitamin D supplementation","3334":"Purified anthocyanins","3335":"GlideScope video-laryngoscope","3336":"GlideScope video-laryngoscope","3337":"GlideScope video-laryngoscope","3338":"Health risk assessment (HRA)","3339":"Health risk assessment (HRA)","3340":"Health risk assessment (HRA)","3341":"Vitamin D3 (cholecalciferol) supplementation","3342":"Vitamin D3 (cholecalciferol) supplementation","3343":"Propofol + Ondansetron","3344":"Propofol alone","3345":"Sevoflurane + Ondansetron","3346":"Propofol alone","3347":"Oxaliplatin + Raltitrexed","3348":"Oxaliplatin + Raltitrexed","3349":"Oxaliplatin + Raltitrexed","3350":"Oxaliplatin + Raltitrexed","3351":"Resistance training (Once a week)","3352":"Resistance training (Twice a week)","3353":"Procaterol hydrochloride inhaler","3354":"Procaterol hydrochloride inhaler","3355":"Visual warning (image)","3356":"Electronic alert system","3357":"Ketamine","3358":"Ketamine","3359":"Ketamine","3360":"New law criteria (Concept)","3361":"MLC601","3362":"Irinotecan","3363":"Irinotecan","3364":"Irinotecan","3365":"Low Ang-2 ","3366":"Improved cookstove","3367":"Improved cookstove + smoking","3368":"Improved cookstove","3369":"Erythropoietin","3370":"Erythropoietin","3371":"Erythropoietin","3372":"Erythropoietin","3373":"Erythropoietin","3374":"Exercise of moderate intensity","3375":"TTM based posts (beginning)","3376":"paroxetine","3377":"paroxetine","3378":"webinar consultations","3379":"$99.95 for the webinar","3380":"webinar consultations","3381":"ARV","3382":"Get Healthy, Stay Healthy' (GHSH)","3383":"6 weekly sessions including exercises, weight control, medication adherence, and home self-monitoring","3384":"6 weekly sessions including exercises, weight control, medication adherence, and home self-monitoring","3385":"6 weekly sessions including exercises, weight control, medication adherence, and home self-monitoring","3386":"onabotulinumtoxinA (100 U)","3387":"onabotulinumtoxinA (100 U)","3388":"onabotulinumtoxinA (100 U) ","3389":"placebo","3390":"onabotulinumtoxinA (100 U)","3391":"\u03b2-alanine (n = 7; 6.4 g\u00b7d-1 over 4 weeks)","3392":"low frequency transcutaneous electrical nerve stimulation (TENS)","3393":"low frequency transcutaneous electrical nerve stimulation (TENS)","3394":"70 mg SC enoxaparin for a period of 24 hours","3395":"adult reach towards and touch an object using her hand ","3396":"saline","3397":"saline","3398":"acupuncture three times per week","3399":"12 week supplementation with fish oil (group I), fish oil with primrose evening oil (group II)","3400":"psycho-educational intervention","3401":"The WaveOne group","3402":"record the number of steps on a daily basis for 12 weeks","3403":"was not able to record their steps daily","3404":"record the number of steps on a daily basis for 12 weeks","3405":"record the number of steps on a daily basis for 12 weeks","3406":"alogliptin (25 mg once daily)","3407":"switching from vildagliptin to high-dose sitagliptin (100 mg daily)","3408":"vildagliptin (50 mg twice daily) for 12weeks","3409":"Biodex Balance System (BBS) balance training, ","3410":"Biodex Balance System (BBS) balance training, ","3411":"(40\u201380 mg\/d, flexibly dosed) for an additional 28-week treatment period","3412":"group A ('non-selective'\u2014clopidogrel 600 mg >6 h before CAG;","3413":"group A ('non-selective'\u2014clopidogrel 600 mg 6 h before CAG; in subgroup of patients who underwent PCI","3414":"liposome bupivacaine 266 mg","3415":"liposome bupivacaine 266 mg ","3416":"liposome bupivacaine 266 mg ","3417":"liposome bupivacaine 532 mg at day 8","3418":"liposome bupivacaine 266 mg ","3419":"Regorafenib (RE)","3420":"Regorafenib (RE)","3421":"LCI699","3422":"LCI699","3423":"eplerenon","3424":"eplerenon","3425":"pramipexole (PX)","3426":"quetiapine (QT)","3427":"pramipexole (PX)","3428":"Theory-based educational intervention","3429":"Bevacizumab (2 doses)","3430":"Internet-based cognitive behavior therapy","3431":"Caudal Sufentanil + neostigmine","3432":"Brand-name desogestrel ","3433":"PA21","3434":"extracts of vitagnus","3435":"Preemptive Thoracic Epidural Analgesia (Group P)","3436":"topical pimecrolimus cream 1%","3437":"4% lidocaine along with 1:100,000 epinephrine","3438":"Mitomycine C","3439":"Shensong Yangxin","3440":"Teriflunomide 14 mg (1 year)","3441":"Tannic acid","3442":"Alfentanil","3443":"Ferric sulphate","3444":"Aerobic interval training (PP)","3445":"Attractive cuing","3446":"Highly active antiretroviral treatment","3447":"Endotracheal tube","3448":"2 Hertz EA stimulation","3449":"Tinnitus Implant","3450":"Omega-3","3451":"Omega-3","3452":"Omega-3","3453":"Ivermectin","3454":"Aromatherapy oil inhalation","3455":"Ivermectin","3456":"Aromatherapy oil inhalation","3457":"Care at home","3458":"Care at home","3459":"Care at home","3460":"Care at home","3461":"Amoxicillin + Omeprazole + Clarithromycin","3462":"Amoxicillin + Omeprazole + Clarithromycin","3463":"Amoxicillin + Omeprazole + Clarithromycin","3464":"Oral vaccine","3465":"Oral vaccine","3466":"Tape","3467":"CYP2C9 Intermediate metabolizers ","3468":"CYP2C9 Intermediate metabolizers ","3469":"Naftopidil 75 mg","3470":"Naftopidil 75 mg","3471":"Naftopidil 50 mg","3472":"Naftopidil 50 mg","3473":"1.0 M EDC treatment ","3474":"Sildenafil 100 mg","3475":"fixed-combination brinzolamide\/brimonidine (BBFC) adjunctive to a prostaglandin analog (PGA)","3476":"Olopatadine HCl 0.77%","3477":"Olopatadine HCl 0.77%","3478":"buprenorphine","3479":"buprenorphine","3480":"gap balancing (GB) technique","3481":"gap balancing (GB) technique","3482":"a group for training of methamphetamine users who were in recovery phase (intervention group 1) and control","3483":"consumption of an alcohol (1.5 g\/l of body water)","3484":"consumption of an alcohol (1.5 g\/l of body water)","3485":"interactive short message service (SMS)","3486":"~1100 kJ\/d of hazelnuts,","3487":"~1100 kJ\/d of hazelnuts","3488":"rapid point-of-care screening (POCS)","3489":"CPAP","3490":"CPAP","3491":"breast shielding","3492":"breast shielding","3493":"Language Enhanced Attention and Focus MI training condition (MI-LEAF), MI training (MI-AU)","3494":"Current health education programs for osteoporosis prevention","3495":"pure coconut water (VitaCoco\u00ae: CW), coconut water from concentrate (CWC)","3496":"coconut water from concentrate (CWC)","3497":"blue (Castelldefels beach)","3498":"tofacitinib 5 or 10 mg twice daily bDMARD-naive","3499":"Salt Intake Reduction (NG III) to at least half of their previous intake,","3500":"indacaterol 150 \u03bcg o.d","3501":"15 ml oral myrtle syrup daily (5 ml three times a day) for 7 days","3502":"phytosterols (PS), ezetimibe (EZ)","3503":"Omega-3 therapy","3504":"Omega-3 therapy","3505":"Omega-3 therapy","3506":"Soleus muscle H-reflex monitoring","3507":"Sitagliptin and lansoprazole","3508":"Sitagliptin and lansoprazole","3509":"Mexican Americans","3510":"Laparoscopic sleeve gastrectomy","3511":"Laparoscopic sleeve gastrectomy","3512":"Laparoscopic sleeve gastrectomy","3513":"Fentanyl and neostigmine (group III)","3514":"Fentanyl and neostigmine (group III)","3515":"Fentanyl and neostigmine (group III)","3516":"Fentanyl and neostigmine (group III)","3517":"Digestion-resistant maltodextrin","3518":"Digestion-resistant maltodextrin","3519":"Digestion-resistant maltodextrin","3520":"Self-selected entertainment","3521":"Esmolol group","3522":"Esmolol group","3523":"Esmolol group","3524":"Esmolol group","3525":"Esmolol group","3526":"Educational intervention","3527":"Educational intervention","3528":"Calcium and vitamin D3 supplementation","3529":"Gait training with constrained induced movement therapy","3530":"Nanoparticles","3531":"Nanoparticles","3532":"Nanoparticles","3533":"Sulodexide composed of 80% fast-moving heparin and 20% dermatan sulfate","3534":"Cognitive remediation therapy","3535":"Indirect grasping","3536":"Direct grasping","3537":"Indirect grasping","3538":"Motion-based controllers","3539":"Motion-based controllers","3540":"Motion-based controllers","3541":"Acidified milk protein drink","3542":"Acidified milk protein drink","3543":"Acidified milk protein drink","3544":"Acidified milk protein drink","3545":"Oxycodone (Group O\/70 and Group O\/100)","3546":"Oxycodone (Group O\/70 and Group O\/100)","3547":"Oxycodone (Group O\/70 and Group O\/100)","3548":"Oxycodone (Group O\/70 and Group O\/100)","3549":"Ischemia group","3550":"Ischemia group","3551":"Breastfeeding (group 1)","3552":"Breastfeeding (group 1)","3553":"Breastfeeding (group 1) or Massage (group 2)","3554":"Dextromethorphan (DM60)","3555":"Dextromethorphan (DM60)","3556":"Dextromethorphan (DM60 and DM120)","3557":"Double cartridges of 4% articaine","3558":"Double cartridges of 4% articaine","3559":"Double cartridges of 4% articaine","3560":"Lactobacillus casei Shirota","3561":"Lactobacillus casei Shirota","3562":"Docetaxel with zoledronic acid (group DZ)","3563":"Docetaxel with zoledronic acid (group DZ)","3564":"Vitamin D plus calcium supplementation","3565":"Pramipexole extended-release","3566":"Pramipexole extended-release","3567":"Methylphenidate","3568":"Hydroxyethyl starch (Voluven)","3569":"Hydroxyethyl starch (Voluven)","3570":"MS medium containing 1.5 mg\/L kinetin + 0.15 mg\/L NAA","3571":"Luseogliflozin","3572":"Luseogliflozin","3573":"Evogliptin","3574":"Being in the Safe gruop","3575":"Ginger and artichoke supplementation","3576":"Oral Palonosetron 0.5 mg","3577":"IV Palonosetron 0.5 mg","3578":"Pilates 4 weeks","3579":"Cyclophosphamide","3580":"Being on Class 1","3581":"Being on Class 1","3582":"Bilateral training","3583":"Bilateral training","3584":"Bilateral training","3585":"Tipranavir\/Ritonavir (500\/100)","3586":"Lopinavir\/Ritonavir (400\/100)","3587":"Virtual reality training","3588":"Balloon catheter ripening (at home)","3589":"Intensive treatment of BP","3590":"Intensive treatment of glycemia and lipids","3591":"Glydescope laryngoscope","3592":"Uracil-tegafur and leucovorin","3593":"1 auricular acupressure bead","3594":"1 auricular acupressure bead","3595":"Bilastine 20 mg","3596":"Olopatadine 10 mg","3597":"Olopatadine 10 mg","3598":"Olopatadine 5 mg","3599":"High PSP Score","3600":"30.000 IU monthly","3601":"60.000 IU monthly","3602":"60.000 IU monthly","3603":"PASTOR approach","3604":"PASTOR approach","3605":"PASTOR approach","3606":"Fiber enriched flour","3607":"Fiber enriched flour","3608":"Fiber enriched flour","3609":"Physical activity alone","3610":"Healthy eating alone","3611":"Adaptive deep brain stimulation","3612":"Adaptive deep brain stimulation","3613":"Adaptive deep brain stimulation","3614":"Adaptive deep brain stimulation","3615":"Sitagliptin","3616":"Sitagliptin","3617":"Interactive workshop","3618":"Interactive workshop","3619":"Pregabalin ","3620":"Integrative medicine","3621":"Care at home","3622":"Dexamethasone","3623":"Cyclophosphamide","3624":"Amoxicillin + Omeprazole + Clarithromycin","3625":"Bevacizumab (1 dose)","3626":"AUCB","3627":"Intensive treatment of glycemia","3628":"pimecrolimus","3629":"1.0 M EDC treatment ","3630":"Bilastine 50 mg","3631":"Hyaluronic acid","3632":"\u2265 75 to < 95","3633":"\u2265 95 PANSS ","3634":"Teriflunomide 7 mg (1 year)","3635":"Aluminium chloride","3636":"Alfentanil","3637":"Eptifibatide","3638":"Polyherbal formulation","3639":"Healthy eating alone","3640":"Nd:YAG","3641":"Omega-3","3642":"Ginger and artichoke supplementation","3643":"Vitamin D + Calcium","3644":"Vitamin D + Calcium","3645":"Integrative medicine","3646":"Amoxicillin + Omeprazole","3647":"Amoxicillin + Omeprazole + Clarithromycin","3648":"Oral vaccine","3649":"Oral vaccine","3650":"AUCB","3651":"AUCB","3652":"Tape","3653":"Tape","3654":"Lace-up ankle suppor","3655":"Lace-up ankle suppor","3656":"CYP3A4 Intermediate metabolizers ","3657":"CYP2C9 Poor metabolizers ","3658":"Stress managin training","3659":"Aerobic and resistance exercice + prenatal care","3660":"Pilocarpine","3661":"1.0 M EDC treatment ","3662":"Mitoxantrone + methylprednisolone","3663":"0.01 M EDC treatment ","3664":"Mitoxantrone + methylprednisolone","3665":"Mitoxantrone + methylprednisolone","3666":"Subcutaneous progesterone","3667":"Sildenafil 100 mg","3668":"Sildenafil 100 mg","3669":"Subcutaneous progesterone","3670":"fixed-combination brinzolamide\/brimonidine (BBFC) adjunctive to a prostaglandin analog (PGA)","3671":"Probiotic (VSL#3)","3672":"Olopatadine HCl 0.77%","3673":"Probiotic (VSL#3)","3674":"Omega-3","3675":"Olopatadine HCl 0.77%","3676":"Insulin + Pramlintide (6 mcg\/U)","3677":"Insulin + Pramlintide (all doses)","3678":"Olopatadine HCl 0.77%","3679":"Insulin + Pramlintide (all doses)","3680":"JQJT tablets","3681":"sugammadex 4 mg\/kg","3682":"JQJT tablets","3683":"JQJT tablets","3684":"gap balancing (GB) technique","3685":"gap balancing (GB) technique","3686":"consumption of an alcohol (1.5 g\/l of body water)","3687":"E-mode Endoscopic sphincterotomy","3688":"Interactive Voice Response","3689":"the lean-seafood diet period","3690":"Fluoride toothpaste (5000 ppm) ","3691":"non-seafood diet period at time 120 min and 360 min in postprandial state","3692":"non-seafood diet period at time 360 min in postprandial state","3693":"Fluoride toothpaste (5000 ppm) ","3694":"Thyroidectomy via BABA","3695":"Thyroidectomy via BABA","3696":"~1100 kJ\/d of hazelnuts, potato crisps","3697":"rapid point-of-care screening (POCS)","3698":"Vitamin D supplementation","3699":"Vitamin D supplementation","3700":"Vitamin D supplementation","3701":"CPAP","3702":"Vitamin D supplementation","3703":"Vitamin D supplementation","3704":"Purified anthocyanins","3705":"Purified anthocyanins","3706":"extensively hydrolyzed whey-based formula with short-chain galacto-oligosaccharides\/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).","3707":"Purified anthocyanins","3708":"Purified anthocyanins","3709":"extensively hydrolyzed whey-based formula with short-chain galacto-oligosaccharides\/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).","3710":"breast shielding","3711":"GlideScope video-laryngoscope","3712":"effects of cow's milk","3713":"GlideScope video-laryngoscope","3714":"effects of cow's milk","3715":"Health risk assessment (HRA)","3716":"daunorubicin\/clofarabine (DClo)","3717":"daunorubicin\/clofarabine (DClo)","3718":"Vitamin D2 (ergocalciferol) supplementation ","3719":"Vitamin D3 (cholecalciferol) supplementation","3720":"daunorubicin\/clofarabine (DClo)","3721":"Vitamin D2 (ergocalciferol) supplementation ","3722":"Vitamin D3 (cholecalciferol) supplementation","3723":"Sevoflurane + Ondansetron","3724":"Language Enhanced Attention and Focus MI training condition (MI-LEAF)","3725":"Current health education programs for osteoporosis prevention","3726":"Current health education programs for osteoporosis prevention","3727":"Propofol + Ondansetron","3728":"Current health education programs for osteoporosis prevention","3729":"Oxaliplatin + Raltitrexed","3730":"pure coconut water (VitaCoco\u00ae: CW), coconut water from concentrate (CWC)","3731":"high-fat diet group among rs1522813 A-allele carriers","3732":"high-fat diet group amond CC genotype or among participants with CT\/TT genotype","3733":"high-fat diet group among participants with GG genotype","3734":"recognition control","3735":"green (Collserola Natural Park)","3736":"green (Collserola Natural Park), blue (Castelldefels beach)","3737":"Procaterol hydrochloride inhaler","3738":"tofacitinib 5 or 10 mg twice daily","3739":"Procaterol hydrochloride inhaler","3740":"Procaterol hydrochloride inhaler","3741":"Visual warning (image)","3742":"Visual warning (text)","3743":"Visual warning (image)","3744":"Visual warning (text)","3745":"Visual warning (image)","3746":"Electronic alert system","3747":"Physical Exercise (NG II)-brisk walking for 50 to 60 minutes, three to four days\/week, Salt Intake Reduction (NG III) to at least half of their previous intake, Yoga (NG IV) for 30 to 45 minutes\/day, five days\/week","3748":"Electronic alert system","3749":"Electronic alert system","3750":"Electronic alert system","3751":"indacaterol 150 \u03bcg o.d","3752":"15 ml oral myrtle syrup daily (5 ml three times a day) for 7 days","3753":"phytosterols (PS), ezetimibe (EZ)","3754":"Ketamine","3755":"Ketamine","3756":"phytosterols (PS), ezetimibe (EZ)","3757":"New law criteria (Concept)","3758":"Commercial sponsor","3759":"MLC601","3760":"MLC601","3761":"phytosterols (PS),","3762":"MLC601","3763":"MLC601","3764":"Irinotecan","3765":"Irinotecan","3766":"Low Ang-2 + bevacizumab","3767":"Improved cookstove","3768":"Improved cookstove + smoking","3769":"Erythropoietin","3770":"Ephedrine","3771":"Ephedrine","3772":"Ephedrine","3773":"Exercise of moderate intensity","3774":"Exercise of moderate intensity","3775":"TTM Decisional Balance posts","3776":"TTM posts Dramatic Relief and Self-Liberation","3777":"TTM posts based on Consciousness Raising","3778":"8 cm pillow during tracheal intubation","3779":"8 cm pillow during tracheal intubation","3780":"8 cm pillow during tracheal intubation","3781":"8 cm pillow during tracheal intubation","3782":"daunorubicin\/ara-C (DA)","3783":"paroxetine","3784":"paroxetine","3785":"paroxetine","3786":"post-consultation","3787":"Language Enhanced Attention and Focus MI training condition (MI-LEAF)","3788":"Omega-3 therapy","3789":"Language Enhanced Attention and Focus MI training condition (MI-LEAF)","3790":"Soleus muscle H-reflex monitoring","3791":"Soleus muscle H-reflex monitoring","3792":"Soleus muscle H-reflex monitoring","3793":"Soleus muscle H-reflex monitoring","3794":"Sitagliptin and lansoprazole","3795":"Sitagliptin and lansoprazole","3796":"Sitagliptin and lansoprazole","3797":"Mexican Americans","3798":"Mexican Americans","3799":"Laparoscopic sleeve gastrectomy","3800":"Laparoscopic sleeve gastrectomy","3801":"Fentanyl and normal saline (group II)","3802":"Digestion-resistant maltodextrin","3803":"Digestion-resistant maltodextrin","3804":"Self-selected entertainment","3805":"Self-selected entertainment","3806":"Self-selected entertainment","3807":"Self-selected entertainment","3808":"Calcium and vitamin D3 supplementation","3809":"Calcium and vitamin D3 supplementation","3810":"Gait training with constrained induced movement therapy","3811":"Gait training with constrained induced movement therapy","3812":"Nanoparticles","3813":"Sulodexide composed of 80% fast-moving heparin and 20% dermatan sulfate","3814":"Sulodexide composed of 80% fast-moving heparin and 20% dermatan sulfate","3815":"Sulodexide composed of 80% fast-moving heparin and 20% dermatan sulfate","3816":"Sulodexide composed of 80% fast-moving heparin and 20% dermatan sulfate","3817":"Cognitive remediation therapy","3818":"Cognitive remediation therapy","3819":"Indirect grasping","3820":"Ozonated autohemotherapy","3821":"Ozonated autohemotherapy","3822":"Acidified milk protein drink","3823":"Oxycodone (Group O\/70 and Group O\/100)","3824":"Ischemia group","3825":"Ischemia group","3826":"Breastfeeding (group 1) or Massage (group 2)","3827":"Glucose control in overnight-only closed-loop control (CLC) mode","3828":"Glucose control in overnight-only closed-loop control (CLC) mode","3829":"Dextromethorphan (DM60)","3830":"Dextromethorphan (DM60 and DM120)","3831":"Double cartridges of 4% articaine","3832":"Double cartridges of 4% articaine","3833":"Lactobacillus casei Shirota","3834":"Lactobacillus casei Shirota","3835":"Lactobacillus casei Shirota","3836":"Docetaxel with zoledronic acid (group DZ)","3837":"Docetaxel with zoledronic acid (group DZ)","3838":"CPP-ACP plus laser (group D)","3839":"CPP-ACP plus laser (group D)","3840":"CPP-ACP plus laser (group D)","3841":"CPP-ACP plus laser (group D)","3842":"Experimental group","3843":"Experimental group","3844":"Experimental group","3845":"Experimental group","3846":"Vitamin D plus calcium supplementation","3847":"Vitamin D plus calcium supplementation","3848":"Vitamin D plus calcium supplementation","3849":"Vitamin D plus calcium supplementation","3850":"Pramipexole extended-release","3851":"Pramipexole extended-release","3852":"Methylphenidate","3853":"Hydroxyethyl starch (Voluven)","3854":"BAP + kinetin + NAA","3855":"Luseogliflozin","3856":"Luseogliflozin","3857":"Evogliptin","3858":"Evogliptin","3859":"Evogliptin","3860":"Evogliptin","3861":"Nd:YAG","3862":"Nd:YAG","3863":"Being in the Safe gruop","3864":"Being in the Caution gruop","3865":"Ginger and artichoke supplementation","3866":"Ginger and artichoke supplementation","3867":"Ginger and artichoke supplementation","3868":"Physical Exercise (NG II)-brisk walking for 50 to 60 minutes, three to four days\/week;","3869":"Oral Palonosetron 0.5 mg","3870":"Oral Palonosetron 0.75 mg","3871":"Strength training","3872":"Strength training","3873":"Strength training","3874":"Pilates 8 weeks","3875":"Pilates 8 weeks","3876":"Cyclophosphamide","3877":"Cyclophosphamide","3878":"Bilateral training","3879":"Bilateral training","3880":"Lopinavir\/Ritonavir (400\/100)","3881":"Virtual reality training","3882":"Intensive treatment of glycemia","3883":"Intensive treatment of BP","3884":"Glydescope laryngoscope","3885":"AWS laryngoscope","3886":"AWS laryngoscope","3887":"Uracil-tegafur and leucovorin","3888":"Flexibility training","3889":"2 auricular acupressure beads","3890":"1 auricular acupressure bead","3891":"1 auricular acupressure bead","3892":"Bilastine 10 mg","3893":"Olopatadine 5 mg","3894":"Olopatadine 5 mg","3895":"High PSP Score","3896":"\u2265 75 to < 95 PANSS","3897":"PASTOR approach","3898":"PASTOR approach","3899":"Epidural block","3900":"Everolimus","3901":"Physical activity + Healthy eating","3902":"Physical activity alone","3903":"Sitagliptin","3904":"Stepwise Pain Protocol","3905":"Acetaminophen","3906":"coconut water from concentrate (CWC)","3907":"pure coconut water (VitaCoco\u00ae: CW), coconut water from concentrate (CWC)","3908":"recognition control","3909":"green (Collserola Natural Park)","3910":"Physical Exercise (NG II)-brisk walking for 50 to 60 minutes, three to four days\/week;","3911":"indacaterol 150 \u03bcg o.d","3912":"indacaterol 150 \u03bcg o.d","3913":"fixed-combination brinzolamide\/brimonidine (BBFC) adjunctive to a prostaglandin analog (PGA)","3914":"Olopatadine HCl 0.77%","3915":"Olopatadine HCl 0.77%","3916":"sugammadex 4 mg\/kg","3917":"gap balancing (GB) technique","3918":"ginger","3919":"the lean-seafood diet period (postprandial state)","3920":"120 min postprandial the non-seafood diet","3921":"interactive short message service (SMS)","3922":"interactive short message service (SMS)","3923":"~1100 kJ\/d of hazelnuts,","3924":"daunorubicin\/clofarabine (DClo)","3925":"pure coconut water (VitaCoco\u00ae: CW), coconut water from concentrate (CWC","3926":"pure coconut water (VitaCoco\u00ae: CW), coconut water from concentrate (CWC)","3927":"Pilates 4 weeks","3928":"Lopinavir\/Ritonavir (400\/100)","3929":"Bilateral training","3930":"preoperative administration of interleukin-2 (IL-2)","3931":"HCLP","3932":"sevoflurane","3933":"Group II, biofeedback therapy was applied only 6 months after the surgery","3934":"essential amino acid meal replacement (EAAMR)","3935":"essential amino acid meal replacement (EAAMR)","3936":"essential amino acid meal replacement (EAAMR)","3937":"endotoxin intravenously (2 ng\/kg Escherichia coli O113)","3938":"low dose penicillin V","3939":"high-intensity functional training (HIFT)","3940":"high-intensity functional training (HIFT)","3941":"high-intensity functional training (HIFT)","3942":"high-intensity functional training (HIFT)","3943":"rifaximin followed by the probiotic VSL#3","3944":"group A (irinotecan, capecitabine, bevacizumab, every 3 weeks; XELIRI-bevacizumab)","3945":"recumbent positioning, IV or oral hydration, analgesics with caffeine, stool softeners, and soft diet) plus 2 ml ","3946":"30 \u03bcg IFN-\u03b2-1a by weekly self-injection for 24 weeks","3947":"Group B were treated with envelope type of CAF along with the Type I collagen membrane (NEOMEM)","3948":"400 mg Eudorlin\u00ae extra* (Ibuprofen)","3949":"and H2 (haloperidol 2 mg)","3950":"intervention group","3951":"Chukyu (spinehealing)- pharmacopuncture-treated group ","3952":"demanding balance training program","3953":"intervention group","3954":"intervention group","3955":"COPERS intervention","3956":"temozolomide (TMZ) (75 mg\/m2 daily \u00d7 21 days, q28 days, max. 12 cycles)","3957":"piperine (15 mg) and midazolam (10 mg)","3958":"laparoscopic","3959":"laparoscopic","3960":"66 Gy in 33 once-daily fractions of 2 Gy over 45 days","3961":"Buccal buprenorphine (BBUP)","3962":"Buccal buprenorphine (BBUP)","3963":"balance taping","3964":"balance taping","3965":"group 1 treated with the Segmented Pendulum (SP) and fixed appliances;","3966":"group 1 treated with the Segmented Pendulum (SP) and fixed appliances;","3967":"portion-controlled diet (PCD)","3968":"robotic-assisted navigation (Hansen Sensei\u00ae X)","3969":"robotic-assisted navigation (Hansen Sensei\u00ae X)","3970":"Varenicline in combination with behavioral support","3971":"Varenicline in combination with behavioral support","3972":"Sonas programme","3973":"SonicFill bulk fill","3974":"fenofibrate plus UDCA","3975":"Strength training","3976":"Cyclophosphamide","3977":"Control","3978":"Active Body Control","3979":"Being on Class 2","3980":"Oral vaccine","3981":"educational program on mothers for prevention of febrile seizure in children","3982":"AUCB","3983":"Lopinavir\/Ritonavir (400\/100)","3984":"colloid preload - hydroxyethyl starch (6% in normal saline, 500 ml)","3985":"Lopinavir\/Ritonavir (400\/100)","3986":"colloid preload - hydroxyethyl starch (6% in normal saline, 500 ml)","3987":"Balloon catheter ripening (at home)","3988":"Balloon catheter ripening (at home)","3989":"Balloon catheter ripening (at home)","3990":"Balloon catheter ripening (at home)","3991":"Tape","3992":"CYP3A5 Poor metabolizers ","3993":"Intensive treatment of glycemia and BP","3994":"Stress managin training","3995":"placebo","3996":"Stress managin training","3997":"Stress managin training","3998":"Flexibility training","3999":"Flexibility training","4000":"Flexibility training","4001":"1.0 M EDC treatment ","4002":"Sildenafil 50 mg","4003":"zoledronic acid (4 mg) IV infusion","4004":"Sildenafil 100 mg","4005":"2 auricular acupressure beads","4006":"Sildenafil 100 mg","4007":"Bilastine 20 mg","4008":"Bilastine 50 mg","4009":"Olopatadine 10 mg","4010":"intervention non-completers","4011":"ACT intervention","4012":"\u2265 95 PANSS ","4013":"COPERS intervention","4014":"PASTOR approach","4015":"Fiber enriched flour","4016":"Fiber enriched flour","4017":"Epidural block","4018":"Epidural block","4019":"Everolimus","4020":"Luseogliflozin","4021":"Physical activity + Healthy eating","4022":"Evogliptin","4023":"Adaptive deep brain stimulation","4024":"portion-controlled diet (PCD)","4025":"Sitagliptin","4026":"Being in the Safe gruop","4027":"Being in the Safe gruop","4028":"Sitagliptin","4029":"Interactive workshop","4030":"control group","4031":"Interactive workshop","4032":"Language Enhanced Attention and Focus MI training condition (MI-LEAF)","4033":"Morphine ","4034":"Buprenorphine transdermal patch","4035":"Strength training","4036":"Integrative medicine","4037":"Strength training","4038":"Care at home","4039":"group A (irinotecan, capecitabine, bevacizumab, every 3 weeks; XELIRI-bevacizumab)","4040":"group A (irinotecan, capecitabine, bevacizumab, every 3 weeks; XELIRI-bevacizumab)","4041":"donepezil hydrochloride (DH) group) group at 48 week","4042":"therapeutic massage (TM)","4043":"therapeutic massage (TM)","4044":"fasting + exercise (FE), ","4045":"fasting + exercise (FE), fasting + non exercise (FNE)","4046":"budesonide\/formoterol and salbutamol","4047":"400 mg Eudorlin\u00ae extra* (Ibuprofen)","4048":"800 mg\/day imatinib","4049":"10 \u03bcg\/kg of Alfentanil, infusion of Alfentanil 1 \u03bcg\/kg\/min","4050":"IDHmt\/non-codel (9.0 months)","4051":"females","4052":"GH doses of 0.033 (low) for 260 weeks","4053":"0.067 (high) mg\/kg\/day for 260 weeks","4054":"laparoscopic","4055":"Buccal buprenorphine (BBUP)","4056":"group 1 treated with the Segmented Pendulum (SP) and fixed appliances;","4057":"group 1 treated with the Segmented Pendulum (SP) and fixed appliances;","4058":"group 1 treated with the Segmented Pendulum (SP) and fixed appliances;","4059":"Sonas programme","4060":"Sonas programme","4061":"higher-dose (HD) ICS in combination with a long-acting beta-agonist (LABA)","4062":"higher-dose (HD) ICS in combination with a long-acting beta-agonist (LABA)","4063":"higher-dose (HD) ICS in combination with a long-acting beta-agonist (LABA)","4064":"higher-dose (HD) ICS in combination with a long-acting beta-agonist (LABA)","4065":"higher-dose (HD) ICS in combination with a long-acting beta-agonist (LABA)","4066":"hand-held fan (HHF)","4067":"Active Body Control","4068":"Active Body Control","4069":"educational program on mothers for prevention of febrile seizure in children","4070":"patient navigation (PN) program","4071":"patient navigation (PN) program","4072":"essential amino acid meal replacement (EAAMR)","4073":"essential amino acid meal replacement (EAAMR)","4074":"placebo","4075":"endotoxin intravenously (2 ng\/kg Escherichia coli O113)","4076":"endotoxin intravenously (2 ng\/kg Escherichia coli O113)","4077":"endotoxin intravenously (2 ng\/kg Escherichia coli O113)","4078":"ramosetron group (group R","4079":"ramosetron group (group R","4080":"recumbent positioning, IV or oral hydration, analgesics with caffeine, stool softeners, and soft diet) plus 2 ml","4081":"recumbent positioning, IV or oral hydration, analgesics with caffeine, stool softeners, and soft diet) plus 2 ml","4082":"zoledronic acid (4 mg) IV infusion","4083":"continuous US (1 MHz &1.5 W\/cm2) plus exercise","4084":"Group B were treated with envelope type of CAF along with the Type I collagen membrane (NEOMEM)","4085":"Chukyu (spinehealing)- pharmacopuncture-treated group ","4086":"Ropivacaine","4087":"Bupivacaine","4088":"COPERS intervention","4089":"good outcome group","4090":"experimental group was supplemented with 500 mg of SAA per kg of body mass, dissolved in 250 ml of a Carborade Drink\u00ae;","4091":"Intervention","4092":"66 Gy in 33 once-daily fractions of 2 Gy over 45 days","4093":"prophylactic use of RJ (Royal Jelly)","4094":"average time was 25.9 \u00b1 9.6 days in the RJ group","4095":"average time was 37.4 \u00b1 11.8 days in the RJ group","4096":"balance taping","4097":"portion-controlled diet (PCD)","4098":"portion-controlled diet (PCD)","4099":"Varenicline in combination with behavioral support","4100":"Varenicline in combination with behavioral support","4101":"3M bulk fill","4102":"gingival margin of all groups","4103":"L-citrulline","4104":"L-citrulline","4105":"L-citrulline","4106":"L-citrulline","4107":"fenofibrate plus UDCA","4108":"fenofibrate plus UDCA","4109":"fenofibrate plus UDCA","4110":"IL-2","4111":"carbohydrate-only (CHO)","4112":"CHO","4113":"at least 70 measured subjects (35 per group)","4114":"a total of at least 120 subjects (60 in each group)","4115":"60 to 100 subjects in a single group","4116":"sevoflurane","4117":"sevoflurane","4118":"low dose penicillin V","4119":"low dose penicillin V","4120":"rifaximin followed by the probiotic VSL#3","4121":"macular carotenoids (MC): 10 mg L + 2 mg total Z (1 mg Z + 1 mg MZ; n = 24)","4122":"group 2: XPF with 1 mL of 17% EDTA for one minute","4123":"Flexible cystoscopy (CS)","4124":"semagacestat 100 mg","4125":"semagacestat 140 mg","4126":"intervention non-completers","4127":"intervention group","4128":"40 mg\/day of Lovastatin plus 2 g\/day powder of Kelussia odoratissima","4129":"Infliximab","4130":"the warfarin or dabigatran ","4131":"Sublingual immunotherapy (SLIT) 10 000 AUN\/ml","4132":"Mitomycine C","4133":"GDM","4134":"hypocaloric diet enriched with legumes (HDEL)","4135":"N-acetylcysteine plus normal saline (Group A) and Ascorbic acid plus normal saline (Group B)","4136":"Group M - morphine plus bupivacaine intra-articularly, ","4137":"Canagliflozin 300 mg","4138":"Expansive posture","4139":"Expansive posture","4140":"Dovitinib ","4141":"Dovitinib","4142":"Protein then Placebo","4143":"Nonchemical membrane","4144":"Nonchemical membrane","4145":"Nonchemical membrane","4146":"Bilayer membrane","4147":"Nonchemical membrane","4148":"Yoga","4149":"Yoga","4150":"Clindamycin cream","4151":"Uncovered nitinol stent","4152":"Flare type covered stent","4153":"Uncovered nitinol stent","4154":"Uncovered nitinol stent","4155":"Flare type covered stent","4156":"Propofol","4157":"Propofol","4158":"3.2 mm drain","4159":"3.2 mm drain","4160":"3.2 mm drain","4161":"3.2 mm drain","4162":"Carbohydrates + protein","4163":"Carbohydrates + protein","4164":"Carbohydrates + protein","4165":"Glutamine ","4166":"Cinacalcet","4167":"Cinacalcet","4168":"Lixisenatide","4169":"Lixisenatide","4170":"Lixisenatide","4171":"Remifentanil 5 ng\/ml (induction) and 4 ng\/ml (maintenance)","4172":"Remifentanil 5 ng\/ml (induction) and 4 ng\/ml (maintenance)","4173":"Remifentanil 5 ng\/ml (induction) and 4 ng\/ml (maintenance)","4174":"High dose (baclofen, naltrexone, sorbitol)","4175":"High dose (baclofen, naltrexone, sorbitol)","4176":"Low dose (baclofen, naltrexone, sorbitol)","4177":"Intermediate dose (baclofen, naltrexone, sorbitol)","4178":"Flaxseed ","4179":"Flaxseed ","4180":"Late tamoxifen","4181":"\"Question writing\" method","4182":"\"Question writing\" method","4183":"\"Question writing\" method","4184":"Simvastatine","4185":"Simvastatine","4186":"Simvastatine","4187":"Simvastatine","4188":"Dapagliflozin + exenatide","4189":"Dapagliflozin + exenatide","4190":"Dapagliflozin + exenatide","4191":"Dapagliflozin + exenatide","4192":"Reciproc system","4193":"Mtwo","4194":"Vitamin B6","4195":"Vitamin B6","4196":"Granulocyte-colony stimulating factor","4197":"Granulocyte-colony stimulating factor + peripheral blood monocyte cell","4198":"Fruits and vegetables +6 portions","4199":"Fruits and vegetables +6 portions","4200":"Biodentine","4201":"Eye health promotion program","4202":"Acupuncture ","4203":"internal limiting membrane (ILM) flap technique","4204":"Perioneal massage","4205":"internal limiting membrane (ILM) flap technique","4206":"Perioneal massage","4207":"Pro Taper universal retreatment ","4208":"Pro Taper universal retreatment ","4209":"Talimogene laherparepvec","4210":"Thymoglobulin single infusion ","4211":"Thymoglobulin single infusion ","4212":"therapeutic massage (TM)","4213":"fasting + exercise (FE), fasting + non exercise (FNE)","4214":"Fast track area","4215":"fasting + exercise (FE), fasting + non exercise (FNE)","4216":"budesonide\/formoterol and salbutamol","4217":"After restraint reduction program","4218":"800 mg\/day imatinib","4219":"demanding balance training program","4220":"demanding balance training program","4221":"Motor-driven treadmill exercise ","4222":"Motor-driven treadmill exercise ","4223":"Genioplasty template system","4224":"rowing","4225":"rowing","4226":"Insulin degludec and liraglutide","4227":"10 \u03bcg\/kg of Alfentanil, infusion of Alfentanil 1 \u03bcg\/kg\/min","4228":"Galacto-oligosaccharides","4229":"Performance-based financing (PBF)","4230":"Prophylactic professional oral health care","4231":"Prophylactic professional oral health care","4232":"Endurance exercise ","4233":"Half bath","4234":"Anesthetic injections ","4235":"Anesthetic injections ","4236":"robotic-assisted navigation (Hansen Sensei\u00ae X)","4237":"Astaxanthin-rich Haematococcus pluvialis","4238":"Sonas programme","4239":"Weekly docetaxel ","4240":"Weekly docetaxel ","4241":"carb counting","4242":"Intensive case management ","4243":"Intensive case management ","4244":"Active Body Control","4245":"Active Body Control","4246":"Active Body Control","4247":"Intensive case management ","4248":"Microwave sanitization ","4249":"Control","4250":"Sexual and Reproductive Health Intervention","4251":"Atorvastatin","4252":"Atorvastatin","4253":"patient navigation (PN) program","4254":"Breast milk + Vit. D","4255":"endotoxin intravenously (2 ng\/kg Escherichia coli O113)","4256":"Inhaled human activated protein C + IV ovine lipopolysaccharide","4257":"endotoxin intravenously (2 ng\/kg Escherichia coli O113)","4258":"Green tea","4259":"Dimetinden","4260":"zoledronic acid (4 mg) IV infusion","4261":"Vildagliptin","4262":"Group A, which were treated with the envelope type of CAF","4263":"Vildagliptin","4264":"Vildagliptin","4265":"Group B were treated with envelope type of CAF along with the Type I collagen membrane (NEOMEM)","4266":"H1(haloperidol 1 mg), and H2 (haloperidol 2 mg)","4267":"Collaborative eHealth literacy intervention","4268":"H0 (saline)","4269":"Wood smoke","4270":"Wood smoke","4271":"Bupivacaine group","4272":"Bupivacaine group","4273":"Ropivacaine","4274":"Atracurium 100% dose ","4275":"Atracurium 50% dose ","4276":"Training only","4277":"COPERS intervention","4278":"Lignocaine","4279":"good outcome group","4280":"good outcome group","4281":"Randomized CT scan","4282":"experimental group was supplemented with 500 mg of SAA per kg of body mass, dissolved in 250 ml of a Carborade Drink\u00ae;","4283":"Randomized CT scan","4284":"Randomized CT scan","4285":"66 Gy in 33 once-daily fractions of 2 Gy over 45 days","4286":"66 Gy in 33 once-daily fractions of 2 Gy over 45 days","4287":"Denosumab","4288":"Fluticasone furoate + vilanterol","4289":"Fluticasone furoate + vilanterol","4290":"Lavender ","4291":"Linalyl acetate","4292":"Cellulose mask","4293":"3M bulk fill","4294":"Being schizoid ","4295":"Hyperactivity","4296":"Vitamin D supplementation ","4297":"colloid preload - hydroxyethyl starch (6% in normal saline, 500 ml)","4298":"rifaximin followed by the probiotic VSL#3","4299":"macular carotenoids (MC): 20 mg L + 4 mg total Z (2 mg Z + 2 mg MZ; n = 25)","4300":"Group 2: XPF with 1 mL of 17% EDTA for one minute","4301":"Group 1, 2, 3, 4","4302":"5th edition (1997) of the TNM classification for gastric cancer","4303":"5th edition (1997) of the TNM classification for gastric cancer","4304":"semagacestat 100 mg","4305":"semagacestat 140 mg","4306":"Lipi\u0301d based nutrient suplement","4307":"Lipi\u0301d based nutrient suplement","4308":"Lipi\u0301d based nutrient suplement","4309":"Tamoxifen + low levels of HOXB13","4310":"Tamoxifen + No HOXB13","4311":"Tamoxifen + intermediate levels of HOXB13","4312":"Heated CO2","4313":"Heated CO2","4314":"Aripiprazole","4315":"Aripiprazole","4316":"Aripiprazole","4317":"E-mail based Self-Help for Depression ","4318":"Tunnel + OTSC","4319":"Tunnel + OTSC","4320":"Tunnel + endoclips","4321":"Bisoprolol + trimetazidine","4322":"Bisoprolol + trimetazidine","4323":"Bisoprolol + trimetazidine","4324":"N-acetylcysteine","4325":"N-acetylcysteine","4326":"N-acetylcysteine","4327":"N-acetylcysteine","4328":"N-acetylcysteine","4329":"Colorectal anastomosis without leakage","4330":"Colorectal anastomosis without leakage","4331":"Canagliflozin 100 mg","4332":"Canagliflozin 300 mg","4333":"Canagliflozin 100 mg","4334":"Canagliflozin 300 mg","4335":"preoperative administration of interleukin-2 (IL-2)","4336":"use a larger pilot study","4337":"sevoflurane","4338":"educational program on mothers for prevention of febrile seizure in children","4339":"control","4340":"colloid preload - hydroxyethyl starch (6% in normal saline, 500 ml)","4341":"placebo","4342":"placebo","4343":"group A, uterine arteries were ligated after the cornual pedicles","4344":"Talimogene laherparepvec","4345":"rifaximin followed by the probiotic VSL#3","4346":"Talimogene laherparepvec","4347":"group A (irinotecan, capecitabine, bevacizumab, every 3 weeks; XELIRI-bevacizumab)","4348":"Yishen Huazhuo decoction (YHD) group","4349":"therapeutic massage (TM)","4350":"30 \u03bcg IFN-\u03b2-1a by weekly self-injection for 24 weeks","4351":"continuous US (1 MHz &1.5 W\/cm2) plus exercise , placebo US plus exercise","4352":"continuous US (1 MHz &1.5 W\/cm2) plus exercise","4353":"Flexible cystoscopy (CS)","4354":"5th edition (1997) of the TNM classification for gastric cancer","4355":"Group B were treated with envelope type of CAF along with the Type I collagen membrane (NEOMEM)","4356":"Semagacestat 100 mg","4357":"Chukyu (spinehealing)- pharmacopuncture-treated group ","4358":"demanding balance training program","4359":"COPERS intervention","4360":"Performance-based financing (PBF)","4361":"good outcome group","4362":"Performance-based financing (PBF)","4363":"Performance-based financing (PBF)","4364":"good outcome group","4365":"control 1 (C1; enhanced financing) group","4366":"experimental group was supplemented with 500 mg of SAA per kg of body mass, dissolved in 250 ml of a Carborade Drink\u00ae;","4367":"GH doses of 0.033 (low) for 260 weeks","4368":"group 1 treated with the Segmented Pendulum (SP) and fixed appliances;","4369":"balance taping","4370":"group 1 treated with the Segmented Pendulum (SP) and fixed appliances;","4371":"reading group","4372":"fenofibrate plus UDCA","4373":"Expansive posture","4374":"Expansive posture","4375":"Expansive posture","4376":"Expansive posture","4377":"Dovitinib ","4378":"Dovitinib ","4379":"Protein then Placebo","4380":"Protein then Placebo","4381":"Protein then Placebo","4382":"Protein then Placebo","4383":"Placebo then protein ","4384":"Placebo then protein ","4385":"Bilayer membrane","4386":"Yoga","4387":"Yoga","4388":"Yoga","4389":"Yoga","4390":"Clindamycin cream","4391":"Clindamycin cream","4392":"Uncovered nitinol stent","4393":"Propofol","4394":"Propofol","4395":"Propofol","4396":"3.2 mm drain","4397":"3.2 mm drain","4398":"Carbohydrates + protein","4399":"Carbohydrates + protein","4400":"3.2 g\/day citrulline","4401":"Glutamine ","4402":"Glutamine ","4403":"Glutamine ","4404":"Glutamine ","4405":"Cinacalcet","4406":"Cinacalcet","4407":"Cinacalcet","4408":"Lixisenatide","4409":"Lixisenatide","4410":"Lixisenatide","4411":"Remifentanil 5 ng\/ml (induction) and 4 ng\/ml (maintenance)","4412":"Remifentanil 5 ng\/ml (induction) and 4 ng\/ml (maintenance)","4413":"Remifentanil 5 ng\/ml (induction) and 4 ng\/ml (maintenance)","4414":"High dose (baclofen, naltrexone, sorbitol)","4415":"Low dose (baclofen, naltrexone, sorbitol)","4416":"Flaxseed ","4417":"Flaxseed ","4418":"Flaxseed ","4419":"Flaxseed ","4420":"Late tamoxifen","4421":"Late tamoxifen","4422":"Late tamoxifen","4423":"\"Question writing\" method","4424":"Simvastatine","4425":"Simvastatine","4426":"Dapagliflozin + exenatide","4427":"Dapagliflozin + exenatide","4428":"Reciproc system","4429":"Reciproc system","4430":"ProTaper system","4431":"Mtwo","4432":"Vitamin B6","4433":"Vitamin B6","4434":"Vitamin B6","4435":"Vitamin B6","4436":"Granulocyte-colony stimulating factor","4437":"Granulocyte-colony stimulating factor","4438":"Granulocyte-colony stimulating factor","4439":"high-fat diet group among participants with GA\/AA genotype","4440":"Granulocyte-colony stimulating factor + peripheral blood monocyte cell","4441":"Fruits and vegetables +6 portions","4442":"Fruits and vegetables +6 portions","4443":"Fruits and vegetables +6 portions","4444":"Fruits and vegetables +6 portions","4445":"Fruits and vegetables +6 portions","4446":"Calcium-enriched mixture","4447":"Octacalcium phophate ","4448":"Eye health promotion program","4449":"Eye health promotion program","4450":"Eye health promotion program","4451":"Silver spike point","4452":"Acupuncture","4453":"Silver spike point","4454":"Silver spike point","4455":"Acupuncture ","4456":"Perioneal massage","4457":"Perioneal massage","4458":"Perioneal massage","4459":"Pro Taper universal retreatment ","4460":"Pro Taper universal retreatment ","4461":"Pro Taper universal retreatment ","4462":"Thymoglobulin single infusion ","4463":"Thymoglobulin single infusion ","4464":"Thymoglobulin single infusion ","4465":"Baricitinib 4 mg","4466":"Baricitinib 4 mg","4467":"Baricitinib 2 mg","4468":"Baricitinib 4 mg","4469":"Fast track area","4470":"Fast track area","4471":"After restraint reduction program","4472":"After restraint reduction program","4473":"Motor-driven treadmill exercise ","4474":"Motor-driven treadmill exercise ","4475":"Genioplasty template system","4476":"Asymptomatic inflammation group (EXPg)","4477":"Insulin degludec and liraglutide ","4478":"Bifidobacterium lactis","4479":"Bifidobacterium lactis","4480":"Prophylactic professional oral health care","4481":"Prophylactic professional oral health care","4482":"Prophylactic professional oral health care","4483":"Kinesio taping ","4484":"Kinesio taping ","4485":"Eccentric exercise ","4486":"Endurance exercise ","4487":"Anesthetic injections ","4488":"Rasagiline","4489":"Rasagiline","4490":"Rasagiline","4491":"Rasagiline","4492":"Astaxanthin-rich Haematococcus pluvialis","4493":"Probiotics + antibiotics ","4494":"Probiotics + antibiotics ","4495":"Probiotics + antibiotics ","4496":"Probiotics + antibiotics ","4497":"Probiotics + antibiotics ","4498":"Weekly docetaxel ","4499":"Weekly docetaxel ","4500":"Buprenophine 32 mg","4501":"Buprenophine 32 mg","4502":"Intensive case management ","4503":"Ultraviolet sanitization ","4504":"Microwave sanitization ","4505":"SystemCHANGETM -HIV","4506":"Sexual and Reproductive Health Intervention","4507":"Sexual and Reproductive Health Intervention","4508":"Siltuximab 3mg\/kg","4509":"Siltuximab 3mg\/kg","4510":"Siltuximab 6mg\/kg (\u2264 4 infusions)","4511":"Formula","4512":"Formula","4513":"Inhaled human activated protein C + IV ovine lipopolysaccharide","4514":"Inhaled human activated protein C + IV ovine lipopolysaccharide","4515":"Inhaled human activated protein C + IV ovine lipopolysaccharide","4516":"Inhaled human activated protein C + IV ovine lipopolysaccharide","4517":"Green tea","4518":"Green tea","4519":"Green tea","4520":"Green tea","4521":"Green tea","4522":"Wi-Fit exercise program","4523":"Wi-Fit exercise program","4524":"Wi-Fit exercise program","4525":"Wi-Fit exercise program","4526":"Hydroxyzine + chlorpheniramine","4527":"Vildagliptin","4528":"Vildagliptin","4529":"Vildagliptin","4530":"Vildagliptin","4531":"Collaborative eHealth literacy intervention","4532":"Collaborative eHealth literacy intervention","4533":"Collaborative eHealth literacy intervention","4534":"Collaborative eHealth literacy intervention","4535":"Wood smoke","4536":"Wood smoke","4537":"Wood smoke","4538":"Atracurium 100% dose ","4539":"Atracurium 100% dose ","4540":"Atracurium 100% dose ","4541":"Training + coaching","4542":"Training only","4543":"Training + coaching","4544":"Lignocaine","4545":"Lignocaine","4546":"Lignocaine","4547":"Denosumab","4548":"Denosumab ","4549":"Fluticasone furoate + vilanterol","4550":"Lavander","4551":"Linalyl acetate","4552":"Linalyl acetate","4553":"Cellulose mask","4554":"DSM265","4555":"DSM265","4556":"Vitamin D supplementation ","4557":"Vitamin D supplementation ","4558":"Vitamin D supplementation ","4559":"Lipi\u0301d based nutrient suplement","4560":"Lipi\u0301d based nutrient suplement","4561":"Lipi\u0301d based nutrient suplement","4562":"Tamoxifen + high levels of HOXB13","4563":"Heated CO2","4564":"Heated CO2","4565":"Heated CO2","4566":"Heated CO2","4567":"Aripiprazole","4568":"Aripiprazole","4569":"Aripiprazole","4570":"E-mail based Self-Help for Depression ","4571":"E-mail based Self-Help for Depression ","4572":"Tunnel + OTSC","4573":"Tunnel + endoclips","4574":"Tunnel + endoclips","4575":"cathodal-tDCS + iTBS","4576":"sham-tDCS + iTBS","4577":"Bisoprolol + trimetazidine","4578":"Bisoprolol + trimetazidine","4579":"Bisoprolol + trimetazidine","4580":"N-acetylcysteine","4581":"Tocilizumab","4582":"Tocilizumab","4583":"Tocilizumab 4 mg\/kg","4584":"Tocilizumab 4 mg\/kg","4585":"Tocilizumab 8 mg\/kg","4586":"duloxetine 60 and etoricoxib 120mg (group D\/E)","4587":"duloxetine 60 and etoricoxib 120mg (group D\/E)","4588":"E, D and D\/E groups","4589":"committed with interest group","4590":"committed with interest group","4591":"committed with interest group","4592":"praziquantel","4593":"praziquantel","4594":"praziquantel","4595":"praziquantel","4596":"praziquantel","4597":"dorsiflexed-immobilized method (DF)","4598":"dorsiflexed-immobilized method (DF)","4599":"dorsiflexed-immobilized method (DF)","4600":"dorsiflexed-immobilized method (DF)","4601":"HCT < 45%","4602":"Vorapaxar","4603":"Vorapaxar","4604":"computer-based prism adaptation (PA)","4605":"computer-based prism adaptation (PA)","4606":"computer-based prism adaptation (PA)","4607":"single dose of 0.2g hydroxychloroquine sulfate tablets (0.1g\/piece) with 250ml water in the test formulation","4608":"certolizumab pegol (CZP) 200 mg every 2 weeks + methotrexate","4609":"maraviroc intensification","4610":"maraviroc intensification","4611":"maraviroc intensification","4612":"maraviroc intensification","4613":"maraviroc intensification","4614":"GP2015","4615":"continued treatment arms (pooled continued)","4616":"continued treatment arms (pooled continued)","4617":"continued treatment arms (pooled continued)","4618":"higher level of education (>12 years)","4619":"very early speech and language therapy (SLT)","4620":"multi-coil rTMS","4621":"multi-coil rTMS","4622":"multi-coil rTMS","4623":"Intervention group (IG) with standing desks and balance pads for 11 weeks","4624":"after rehabilitation program","4625":"after rehabilitation program","4626":"after rehabilitation program","4627":"scaling and root planning (SRP) in combination with amoxicillin plus metronidazole","4628":"4 Channel Functional Electrical Stimulation (FES)","4629":"4 Channel Functional Electrical Stimulation (FES)","4630":"system-oriented therapy","4631":"system-oriented therapy","4632":"system-oriented therapy","4633":"system-oriented therapy","4634":"panty liner B (Always\u00ae non-deodorant)","4635":"panty liner B (Always\u00ae non-deodorant)","4636":"panty liner wear groups A (Always\u00ae deodorant)","4637":"labia","4638":"Lax-Asab powder","4639":"SP-based scenarios","4640":"SP-based scenarios ","4641":"after vitamin D supplementation in COPD patients","4642":"after vitamin D supplementation in COPD patients","4643":"after vitamin D supplementation in COPD patients","4644":"after vitamin D supplementation in COPD patients","4645":"double omeprazole dose","4646":"Mineral trioxide aggregate ","4647":"class III anginal symptoms","4648":"completers","4649":"Sexual Assault history","4650":"Intensive lifestyle intervention","4651":"Intensive lifestyle intervention","4652":"Diacetate esters of macular carotenoids","4653":"Perioneal massage","4654":"Prenatal education","4655":"Prenatal education","4656":"Prenatal education","4657":"Prenatal education","4658":"Intimate partner prevention intervention","4659":"Pro Taper universal retreatment ","4660":"Intimate partner prevention intervention","4661":"Intimate partner prevention intervention","4662":"Intimate partner prevention intervention","4663":"Resistance exercise","4664":"Resistance exercise","4665":"Thymoglobulin single infusion ","4666":"Baricitinib 2 mg","4667":"Baricitinib 2 mg","4668":"Erythropoietin","4669":"Fast track area","4670":"Fast track area","4671":"GnRH antagonist ","4672":"GnRH antagonist ","4673":"Sports Vision Training","4674":"After restraint reduction program","4675":"Sports Vision Training","4676":"Genioplasty template system","4677":"Tetrahydrocannabinol","4678":"Genioplasty template system","4679":"Insulin degludec and liraglutide","4680":"Home Environment Interventions","4681":"Vitamin D + Calcium","4682":"Insulin degludec and liraglutide ","4683":"Insulin degludec and liraglutide ","4684":"Continuous quality improvement program","4685":"High user control","4686":"High user control","4687":"Prophylactic professional oral health care","4688":"High user control","4689":"Kinesio taping ","4690":"Chi running program","4691":"Eccentric exercise ","4692":"Endurance exercise ","4693":"Endurance exercise ","4694":"Chi running program","4695":"Chi running program","4696":"Chi running program","4697":"Half bath","4698":"Anesthetic injections ","4699":"Anesthetic injections ","4700":"High hepatocyte growth factor levels","4701":"Resistance exercise program","4702":"Resistance exercise program","4703":"Climbing profile 1 ","4704":"Climbing profile 1 ","4705":"Climbing profile 1 ","4706":"Rasagiline","4707":"Galvanic vestibular stimulation","4708":"Rasagiline","4709":"Astaxanthin-rich Haematococcus pluvialis","4710":"Azilsartan ","4711":"Azilsartan ","4712":"Azilsartan ","4713":"Probiotics + antibiotics ","4714":"Azilsartan ","4715":"Exercise gaming","4716":"Exercise gaming","4717":"Exercise gaming","4718":"Weekly docetaxel ","4719":"Pantothenic acid","4720":"Weekly docetaxel ","4721":"Buprenophine 32 mg","4722":"Buprenophine 64 mg","4723":"Buprenophine 96 mg","4724":"Pantothenic acid","4725":"Pantothenic acid","4726":"Buprenophine 64 mg","4727":"Pantothenic acid","4728":"Intensive aerobic exercise","4729":"Intensive case management ","4730":"Thai massage ","4731":"Thai massage ","4732":"Tiotropium","4733":"Thai massage ","4734":"Respimat\u00ae Soft MistTM","4735":"Respimat\u00ae Soft MistTM","4736":"Sexual and Reproductive Health Intervention","4737":"Pregabalin","4738":"Sexual and Reproductive Health Intervention","4739":"Pregabalin","4740":"Pregabalin","4741":"Pregabalin","4742":"Offering free continuing medical education","4743":"Offering free continuing medical education","4744":"Formula","4745":"Formula","4746":"19 grams of lipids ","4747":"19 grams of lipids ","4748":"19 grams of lipids ","4749":"Inhaled human activated protein C + IV ovine lipopolysaccharide","4750":"Rocker-sole footwear","4751":"zinc","4752":"zinc","4753":"zinc","4754":"galunisertib ","4755":"galunisertib ","4756":"galunisertib ","4757":"diverticulitis group","4758":"diverticulitis group","4759":"diverticulitis group","4760":"diverticulitis group","4761":"diverticulitis group","4762":"diverticulitis group","4763":"Hydroxyzine + chlorpheniramine","4764":"Dimetinden","4765":"vitamin A group","4766":"diabetes group","4767":"diabetes group","4768":"diabetes group","4769":"diabetes group","4770":"usual health care and support services ","4771":"interdisciplinary multifaceted treatment","4772":"Collaborative eHealth literacy intervention","4773":"confinement housing","4774":"confinement housing","4775":"Mauritian green tea","4776":"Wood smoke","4777":"Atracurium 25% dose ","4778":"Mauritian green tea","4779":"secure conditions","4780":"secure conditions","4781":"secure conditions","4782":"secure conditions","4783":"high-risk group","4784":"final model","4785":"final model","4786":"simplified conventional system Transbond XTTM Light cure adhesive","4787":"phase 2","4788":"phase 2","4789":"Lignocaine","4790":"both HC2 and COBAS at baseline","4791":"Lignocaine","4792":"Denosumab ","4793":"Denosumab ","4794":"Fluticasone furoate + vilanterol","4795":"Linalyl acetate","4796":"Cellulose mask","4797":"Cellulose mask","4798":"Cellulose mask","4799":"Anxiety\/Depression","4800":"Vitamin D supplementation ","4801":"Vitamin D supplementation ","4802":"Partially Hydrolysed Whey Formula","4803":"Partially Hydrolysed Whey Formula","4804":"Partially Hydrolysed Whey Formula","4805":"Partially Hydrolysed Whey Formula","4806":"Oral health promotion program + free dental treatment","4807":"Infliximab","4808":"Infliximab","4809":"Infliximab","4810":"Infliximab","4811":"Infliximab","4812":"Gallium maltolate","4813":"Gallium maltolate","4814":"Total Sanitation Campaign","4815":"Total Sanitation Campaign","4816":"Total Sanitation Campaign","4817":"Total Sanitation Campaign","4818":"Singing Training","4819":"Singing Training","4820":"Singing Training","4821":"Singing Training","4822":"Ketamine","4823":"Ketamine","4824":"Ketamine","4825":"Ketamine","4826":"Ketamine","4827":"Occupational noise","4828":"Occupational noise","4829":"Fluticasone furoate + vilanterol","4830":"Fluticasone furoate + vilanterol","4831":"Antioxidant supplementation","4832":"Antioxidant supplementation","4833":"Uracil-tegafur and leucovorin","4834":"RSI QuickScan intervention","4835":"Tube-exchanger","4836":"Sequential binge intervention","4837":"Paricalcitol","4838":"Epidrum\u00ae","4839":"Epidrum\u00ae","4840":"Certolizumab 200 mg","4841":"Certolizumab 400 mg","4842":"Certolizumab 400 mg","4843":"IV iron isomaltoside 1000 (500 mg)","4844":"Long-term buprenorphine-naloxone","4845":"Intermediate addition multifocals","4846":"Intermediate addition multifocals","4847":"Intermediate progressive addition lenses ","4848":"BostonBreathes system","4849":"BostonBreathes system","4850":"BostonBreathes system","4851":"Olanzapine + fluoxetine","4852":"Olanzapine + fluoxetine","4853":"Olanzapine + fluoxetine","4854":"Risperidone + saline","4855":"Ketamine ","4856":"Ketamine ","4857":"Lateral compaction","4858":"Lateral compaction","4859":"EG plus DMSO in ascending concentrations","4860":"EG plus DMSO in ascending concentrations","4861":"EG plus DMSO in ascending concentrations","4862":"14-day coenzyme Q10 supplementation (5mg.kg-1.day-1)","4863":"acute coenzyme Q10 supplementation ","4864":"coenzyme Q10 supplementation ","4865":"selective phosphodiesterase 4 inhibitor (GSK256066)","4866":"selective phosphodiesterase 4 inhibitor (GSK256066)","4867":"Job Interview Simulation Training (JIST)","4868":"carbohydrate-only (CHO)","4869":"Active Body Control","4870":"CHO","4871":"electronic-cigarettes (e-cigarette)","4872":"moderate\/severe renal impairment ","4873":"essential amino acid meal replacement (EAAMR)","4874":"colloid preload - hydroxyethyl starch (6% in normal saline, 500 ml)","4875":"low dose penicillin V","4876":"endotoxin intravenously (2 ng\/kg Escherichia coli O113)","4877":"high-intensity functional training (HIFT)","4878":"training group (group T)","4879":"internal limiting membrane (ILM) flap technique","4880":"group A, uterine arteries were ligated after the cornual pedicles","4881":"placebo","4882":"macular carotenoids (MC): 20 mg L + 4 mg total Z (2 mg Z + 2 mg MZ; n = 25)","4883":"recumbent positioning, IV or oral hydration, analgesics with caffeine, stool softeners, and soft diet) plus 2 ml","4884":"macular carotenoids (MC): 20 mg L + 4 mg total Z (2 mg Z + 2 mg MZ; n = 25)","4885":"zoledronic acid (4 mg) IV infusion","4886":"zoledronic acid (4 mg) IV infusion","4887":"group 4: XP-endo Finisher file for 30 seconds in association with 2.5% NaOCl and 17% EDTA for 30 seconds","4888":"Flexible cystoscopy (CS)","4889":"therapeutic massage (TM)","4890":"Problem-Solving Treatment (PST)","4891":"semagacestat 100 mg","4892":"H1(haloperidol 1 mg)","4893":"semagacestat 140 mg","4894":"demanding balance training program","4895":"cycling ","4896":"younger subjects","4897":"10 \u03bcg\/kg of Alfentanil, infusion of Alfentanil 1 \u03bcg\/kg\/min","4898":"20% albumin (50-100 mL) or fresh frozen plasma (FFP) (1-2 units)","4899":"temozolomide (TMZ) (75 mg\/m2 daily \u00d7 21 days, q28 days, max. 12 cycles)","4900":"XELIRI (irinotecan 250 mg\/m2 given on day one and capecitabine 1000 mg\/m2 twice daily from day 2\u201315, every 21 days)","4901":"0.067 (high) mg\/kg\/day for 260 weeks","4902":"group 1 treated with the Segmented Pendulum (SP) and fixed appliances;","4903":"carb counting","4904":"etoricoxib","4905":"celecoxib","4906":"electronic-cigarettes (e-cigarette)","4907":"e-cigarette","4908":"study group","4909":"study group","4910":"combination of sufentanil 25 mcg and morphine 2 mg (SM)","4911":"sufentanil-morphine group (SM)","4912":"sufentanil 50 mcg (S)","4913":"sufentanil 50 mcg (S)","4914":"chemoimmunotherapy with bevacizumab (PCR-B)","4915":"chemoimmunotherapy with bevacizumab (PCR-B)","4916":"chemoimmunotherapy with bevacizumab (PCR-B)","4917":"meditation awareness training (MAT)","4918":"meditation awareness training (MAT)","4919":"training group (group T)","4920":"training group (group T)","4921":"homeopathy group","4922":"homeopathy group","4923":"homeopathy group","4924":"group with postpartum depression symptoms","4925":"AE ointment","4926":"AE ointment","4927":"AE ointment","4928":"Problem-Solving Treatment (PST)","4929":"Problem-Solving Treatment (PST)","4930":"previously prepared with path-finding files","4931":"previously prepared with path-finding files","4932":"group 1 with #10, #15 and #20 K-type (Dentsply Maillefer, Ballaigues, Switzerland) stainless steel manual files","4933":"1.5 mg\/kg of lidocaine for 90 s before cannulation","4934":"1.5 mg\/kg of lidocaine for 90 s before cannulation","4935":"vildagliptin group (received vildagliptin 100 mg\/day for 6 months)","4936":"group A, hip fractures managed with sliding hip screws (SHS)","4937":"group A, hip fractures managed with sliding hip screws (SHS)","4938":"mobile phone text messaging smoking cessation programme (txt2stop)","4939":"mobile phone text messaging smoking cessation programme (txt2stop)","4940":"mobile phone text messaging smoking cessation programme (txt2stop)","4941":"mobile phone text messaging smoking cessation programme (txt2stop)","4942":"short-term high-protein (HP) diet in infants following cardiac surgery","4943":"short-term high-protein (HP) diet in infants following cardiac surgery","4944":"short-term high-protein (HP) diet in infants following cardiac surgery","4945":"XELIRI (irinotecan 250 mg\/m2 given on day one and capecitabine 1000 mg\/m2 twice daily from day 2\u201315, every 21 days)","4946":"XELIRI (irinotecan 250 mg\/m2 given on day one and capecitabine 1000 mg\/m2 twice daily from day 2\u201315, every 21 days)","4947":"XELIRI (irinotecan 250 mg\/m2 given on day one and capecitabine 1000 mg\/m2 twice daily from day 2\u201315, every 21 days)","4948":"Bilastine 20 mg","4949":"Bilastine updosing to 80 mg","4950":"Bilastine updosing to 80 mg","4951":"bupropion plus nicotine replacement therapy (NRT)","4952":"bupropion ","4953":"bupropion plus nicotine replacement therapy (NRT)","4954":"bupropion plus nicotine replacement therapy (NRT)","4955":"experimental period - acupuncture","4956":"experimental period - acupuncture","4957":"transcutaneous electrical nerve stimulation (TENS)","4958":"transcutaneous electrical nerve stimulation (TENS)","4959":"neurofeedback behavioural therapy (NFB)","4960":"cognitive-behavioral group therapy","4961":"GlideScope\u00ae video laryngoscope (G)","4962":"GlideScope\u00ae video laryngoscope (G)","4963":"intervention groups","4964":"intervention groups","4965":"ramipril (10 mg\/day), tadalafil (10 mg o.d.), and ramipril plus tadalafil","4966":"moderate\/severe renal impairment ","4967":"Training + coaching ","4968":"Partially Hydrolysed Whey Formula","4969":"Partially Hydrolysed Whey Formula","4970":"Oral health promotion program + free dental treatment","4971":"Infliximab","4972":"Infliximab","4973":"Gallium maltolate","4974":"Gallium maltolate","4975":"Total Sanitation Campaign","4976":"Total Sanitation Campaign","4977":"Singing Training","4978":"Ketamine","4979":"Occupational noise","4980":"Moxifloxacin","4981":"Antioxidant supplementation","4982":"Antioxidant supplementation","4983":"Antioxidant supplementation","4984":"Antioxidant supplementation","4985":"RSI QuickScan intervention","4986":"RSI QuickScan intervention","4987":"RSI QuickScan intervention","4988":"RSI QuickScan intervention","4989":"Tube-exchanger","4990":"Tube-exchanger","4991":"Tube-exchanger","4992":"Sequential binge intervention","4993":"Sequential binge intervention","4994":"Paricalcitol","4995":"Paricalcitol","4996":"Paricalcitol","4997":"Paricalcitol","4998":"Epidrum\u00ae","4999":"Epidrum\u00ae","5000":"Epidrum\u00ae","5001":"Certolizumab 200 mg","5002":"Certolizumab 400 mg","5003":"Certolizumab 200 mg","5004":"IV iron isomaltoside 1000 (1000 mg)","5005":"IV iron isomaltoside 1000 (1000 mg)","5006":"IV iron isomaltoside 1000 (500 mg)","5007":"Long-term buprenorphine-naloxone","5008":"Intermediate progressive addition lenses ","5009":"BostonBreathes system","5010":"BostonBreathes system","5011":"BostonBreathes system","5012":"Olanzapine + fluoxetine","5013":"Olanzapine + fluoxetine","5014":"Risperidone + saline","5015":"Ketamine + Risperidone","5016":"Warm vertical compaction","5017":"EG plus DMSO in ascending concentrations","5018":"EG plus DMSO in ascending concentrations","5019":"coenzyme Q10 supplementation ","5020":"1acute coenzyme Q10 supplementation ","5021":"directly by the GP","5022":"selective phosphodiesterase 4 inhibitor (GSK256066)","5023":"selective phosphodiesterase 4 inhibitor (GSK256066)","5024":"selective phosphodiesterase 4 inhibitor (GSK256066)","5025":"duloxetine 60 and etoricoxib 120mg (group D\/E)","5026":"duloxetine 60 and etoricoxib 120mg (group D\/E)","5027":"committed with interest group","5028":"high altitude","5029":"high altitude","5030":"high altitude","5031":"high altitude","5032":"sorafenib plus platinum-based chemotherapy","5033":"sorafenib plus platinum-based chemotherapy","5034":"praziquantel","5035":"dorsiflexed-immobilized method (DF)","5036":"dorsiflexed-immobilized method (DF)","5037":"HCT < 45%","5038":"HCT < 45%","5039":"L. reuteri DSM 17938","5040":"responders","5041":"feeding intolerance","5042":"Vorapaxar","5043":"Vorapaxar","5044":"Vorapaxar","5045":"Vorapaxar","5046":"computer-based prism adaptation (PA)","5047":"single dose of 0.2 g hydroxychloroquine sulfate tablets (0.1 g\/piece) with 250 ml water in the test formulation","5048":"single dose of 0.2g hydroxychloroquine sulfate tablets (0.1g\/piece) with 250ml water in the test formulation","5049":"single dose of 0.2g hydroxychloroquine sulfate tablets (0.1g\/piece) with 250ml water in the test formulation","5050":"single dose of 0.2g hydroxychloroquine sulfate tablets (0.1g\/piece) with 250ml water in the test formulation","5051":"certolizumab pegol (CZP) 400 mg every 4 weeks + methotrexate","5052":"maraviroc intensification","5053":"maraviroc intensification","5054":"self-monitoring of blood glucose (SMBG) ","5055":"self-monitoring of blood glucose (SMBG) ","5056":"continued treatment arms (pooled continued)","5057":"continued treatment arms (pooled continued)","5058":"very early speech and language therapy (SLT)","5059":"very early speech and language therapy (SLT)","5060":"very early speech and language therapy (SLT)","5061":"multi-coil rTMS","5062":"Intervention group (IG) with standing desks and balance pads for 11 weeks","5063":"Intervention group (IG) with standing desks and balance pads for 11 weeks","5064":"Intervention group (IG) with standing desks and balance pads for 11 weeks","5065":"Intervention group (IG) with standing desks and balance pads for 11 weeks","5066":"after rehabilitation program","5067":"after rehabilitation program","5068":"after rehabilitation program","5069":"scaling and root planning (SRP) in combination with amoxicillin plus metronidazole","5070":"scaling and root planning (SRP) in combination with amoxicillin plus metronidazole","5071":"scaling and root planning (SRP) in combination with amoxicillin plus metronidazole","5072":"scaling and root planning (SRP) in combination with amoxicillin plus metronidazole","5073":"4 Channel Functional Electrical Stimulation (FES)","5074":"4 Channel Functional Electrical Stimulation (FES)","5075":"4 Channel Functional Electrical Stimulation (FES)","5076":"system-oriented therapy","5077":"panty liner wear groups A (Always\u00ae deodorant)","5078":"Lax-Asab powder","5079":"Lax-Asab powder","5080":"Lax-Asab powder","5081":"Lax-Asab powder","5082":"SP-based scenarios ","5083":"SP-based scenarios ","5084":"SP-based scenarios ","5085":"SP-based scenarios ","5086":"after vitamin D supplementation in COPD patients","5087":"after vitamin D supplementation in COPD patients","5088":"after vitamin D supplementation in COPD patients","5089":"Responders\ufffd were defined as subjects who reported decrease in chest pain frequency after omeprazole administration by more than 50%","5090":"double omeprazole dose","5091":"Non-Hispanics","5092":"program link via e-mail","5093":"Sexual assault history","5094":"Physical assault history","5095":"Physical assault history","5096":"Physical assault history","5097":"Intensive lifestyle intervention","5098":"Intensive lifestyle intervention","5099":"Intensive lifestyle intervention","5100":"Diacetate esters of macular carotenoids","5101":"Prenatal education","5102":"Prenatal education","5103":"Intimate partner prevention intervention","5104":"Intimate partner prevention intervention","5105":"Resistance exercise","5106":"Resistance exercise","5107":"Resistance exercise","5108":"Resistance exercise","5109":"Erythropoietin","5110":"Erythropoietin","5111":"Erythropoietin","5112":"Erythropoietin","5113":"Erythropoietin","5114":"GnRH antagonist ","5115":"GnRH antagonist ","5116":"GnRH antagonist ","5117":"GnRH antagonist ","5118":"Sports Vision Training","5119":"Sports Vision Training","5120":"Tetrahydrocannabinol","5121":"Cannabidiol","5122":"Tetrahydrocannabinol","5123":"Tetrahydrocannabinol + Cannabidiol","5124":"Cannabidiol","5125":"Vitamin D + Calcium","5126":"Vitamin D + Calcium","5127":"Calcium","5128":"Continuous quality improvement program","5129":"Continuous quality improvement program","5130":"Continuous quality improvement program","5131":"Continuous quality improvement program","5132":"High user control","5133":"High user control","5134":"High user control","5135":"Chi running program","5136":"Chi running program","5137":"High insulin levels","5138":"Resistance exercise program","5139":"Galvanic vestibular stimulation","5140":"Transcranial alternating current stimulation","5141":"Transcranial alternating current stimulation","5142":"Transcranial alternating current stimulation","5143":"Azilsartan ","5144":"Azilsartan ","5145":"Exercise gaming","5146":"Exercise gaming","5147":"Pantothenic acid","5148":"Pantothenic acid","5149":"Intensive aerobic exercise","5150":"Intensive aerobic exercise","5151":"Intensive aerobic exercise","5152":"Intensive aerobic exercise","5153":"Thai massage ","5154":"Thai massage ","5155":"Thai massage ","5156":"Respimat\u00ae Soft MistTM","5157":"Pregabalin","5158":"Pregabalin","5159":"Offering free continuing medical education","5160":"Offering free continuing medical education","5161":"Offering free continuing medical education","5162":"19 grams of lipids ","5163":"19 grams of lipids ","5164":"19 grams of lipids ","5165":"zinc","5166":"zinc","5167":"diverticulitis group","5168":"diverticulitis group","5169":"vitamin A group","5170":"vitamin A group","5171":"vitamin A group","5172":"diabetes group","5173":"interdisciplinary multifaceted treatment","5174":"interdisciplinary multifaceted treatment","5175":"interdisciplinary multifaceted treatment","5176":"confinement housing","5177":"confinement housing","5178":"confinement housing","5179":"Mauritian green tea","5180":"Mauritian green tea","5181":"phase 2","5182":"phase 2","5183":"HPV 16","5184":"HPV 16","5185":"HC2","5186":"HC2","5187":"lanreotide Autogel\u00ae 120 mg","5188":"lanreotide Autogel\u00ae 120 mg","5189":"lanreotide Autogel\u00ae 120 mg","5190":"lanreotide Autogel\u00ae 120 mg","5191":"tiotropium 18 \u03bcg once daily, salmeterol, 50 \u03bcg","5192":"tiotropium 18 \u03bcg once daily ","5193":"tiotropium 18 \u03bcg once daily ","5194":"tiotropium 18 \u03bcg once daily ","5195":"salmeterol, 50 \u03bcg","5196":"salmeterol, 50 \u03bcg","5197":"salmeterol, 50 \u03bcg","5198":"salmeterol, 50 \u03bcg, salmeterol, 50 \u03bcg","5199":"fentanyl, sufentanil","5200":"remifentanil","5201":"fentanyl, sufentanil","5202":"remifentanil","5203":"remifentanil","5204":"remifentanil","5205":"Family-centered care (FCC) ","5206":"Family-centered care (FCC) ","5207":"Family-centered care (FCC) ","5208":"exemestane 25 mg day\u22121\u00b1celecoxib 800 mg day\u22121","5209":"exemestane 25 mg","5210":"exemestane 25 mg day\u22121\u00b1celecoxib 800 mg day\u22121","5211":"exemestane 25 mg day\u22121\u00b1celecoxib 800 mg day\u22121","5212":"exemestane 25 mg","5213":"women with higher baseline cotinine levels","5214":"women with a higher baseline cotinine level ","5215":"100, 150 mg of MSDC-0160 (an mTOT modulator), 45 mg pioglitazone HCl (a PPAR-\u03b3 agonist)","5216":"MSDC-0160 (an mTOT modulator)","5217":"100, 150 mg MSDC-0160 (an mTOT modulator)","5218":"50, 100, 150 mg MSDC-0160 (an mTOT modulator)","5219":"Positive unrelated,","5220":"Positive unrelated","5221":"Positive unrelated","5222":"Positive related","5223":"10 mg combined with 75 \u03bcg clonidine (group C)","5224":"10 mg combined with 75 \u03bcg clonidine (group C)","5225":"12 hours of game play (game group) for teaching optometry students elements of the core optometric curriculum","5226":"12 hours of interactive didactic instruction (lecture group) for teaching optometry students elements of the core optometric curriculum","5227":"12 hours of interactive didactic instruction (lecture group) for teaching optometry students elements of the core optometric curriculum","5228":"integrated acidity","5229":"integrated acidity","5230":" integrated acidity","5231":"integrated acidity","5232":"lopinavir\/ritonavir (LPV\/r) - based regimens","5233":"lopinavir\/ritonavir (LPV\/r) - based regimens","5234":"400 mg garlic tablet daily for 6 days","5235":"400 mg garlic tablet daily for 6 days","5236":"400 mg garlic tablet daily for 6 days","5237":"400 mg garlic tablet daily for 6 days","5238":"400 mg garlic tablet daily for 6 days","5239":"post-surgical visit","5240":"4 mg of astaxanthin (Asx)","5241":"4 mg of astaxanthin (Asx)","5242":"Placebo (P group)","5243":"placebo (P group)","5244":"placebo (P group)","5245":"4 mg of astaxanthin (Asx) ","5246":"4 mg of astaxanthin (Asx) ","5247":"placebo (P group)","5248":"placebo (P group)","5249":"4 mg of astaxanthin (Asx) ","5250":"placebo (P group)","5251":"4 mg of astaxanthin (Asx) ","5252":"placebo (P group)","5253":"4 mg of astaxanthin (Asx)","5254":"cognitive rehabilitation protocol","5255":"placebo","5256":"green coffee extract product GCATM high-dose (1050 mg)","5257":"green coffee extract product GCATM (GCA) - low-dose (700 mg)","5258":"placebo","5259":"green coffee extract product GCATM high-dose (1050 mg)","5260":"placebo","5261":"green coffee extract product GCATM high-dose (1050 mg)","5262":"green coffee extract product GCATM high-dose (700 mg)","5263":"placebo","5264":"green coffee extract product GCATM high-dose (1050 mg), green coffee extract product GCATM high-dose (700 mg), ","5265":"green coffee extract product GCATM high-dose (1050 mg), green coffee extract product GCATM high-dose (700 mg), ","5266":"green coffee extract product GCATM high-dose (1050 mg), green coffee extract product GCATM high-dose (700 mg), placebo","5267":"culturally appropriate educational intervention programme for South Asians with Type 2 diabetes","5268":"ethnic control groups","5269":"white control group","5270":"oral glutamine suspension daily 2h before radiation in the study arm (10 g in 1000 ml of water)","5271":"oral glutamine suspension daily 2h before radiation in the study arm (10 g in 1000 ml of water)","5272":"oral glutamine suspension daily 2h before radiation in the study arm (10 g in 1000 ml of water)","5273":"oral glutamine suspension daily 2h before radiation in the study arm (10 g in 1000 ml of water)","5274":"oral glutamine suspension daily 2h before radiation in the study arm (10 g in 1000 ml of water)","5275":"aclidinium bromide (AB) 400 \u03bcg\/formoterol fumarate (FF) 12 \u03bcg","5276":"aclidinium bromide (AB) 400 \u03bcg\/formoterol fumarate (FF) 12 \u03bcg","5277":"aclidinium bromide (AB) 400 \u03bcg\/formoterol fumarate (FF) 12 \u03bcg","5278":"aclidinium bromide (AB) 400 \u03bcg\/formoterol fumarate (FF) 12 \u03bcg","5279":"aclidinium bromide (AB) 400 \u03bcg\/formoterol fumarate (FF) 12 \u03bcg","5280":"aclidinium bromide (AB) 400 \u03bcg\/formoterol fumarate (FF) 12 \u03bcg","5281":"health dialogue, supported by a visualised health profile, with a possibility for further activities","5282":"health dialogue, supported by a visualised health profile, with a possibility for further activities","5283":"health dialogue, supported by a visualised health profile, with a possibility for further activities","5284":"health dialogue, supported by a visualised health profile, with a possibility for further activities","5285":"health dialogue, supported by a visualised health profile, with a possibility for further activities","5286":"liberal fluid management protocol","5287":"UK Lung Cancer Screening (UKLS) among women","5288":"UK Lung Cancer Screening (UKLS) among current smokers","5289":"UK Lung Cancer Screening (UKLS) among older individuals","5290":"UK Lung Cancer Screening (UKLS) among younger individuals","5291":"UK Lung Cancer Screening (UKLS) among lowest socioeconomic group","5292":"UK Lung Cancer Screening (UKLS) among higher affective risk perception","5293":"integrated multidisciplinary (IMD group) approach in disabled multiple sclerosis (MS) patients","5294":"integrated multidisciplinary (IMD group) approach in disabled multiple sclerosis (MS) patients","5295":"usual care in MS patients","5296":"insulin glargine over 8 weeks","5297":"insulin glargine over 8 weeks","5298":"insulin glargine over 8 weeks","5299":"insulin glargine over 8 weeks","5300":"insulin glargine over 8 weeks","5301":"facial affect training (FAT) in 20 daily 1-hour sessions ","5302":"facial affect training (FAT) in 20 daily 1-hour sessions ","5303":"facial affect training (FAT) in 20 daily 1-hour sessions ","5304":"facial affect training (FAT) in 20 daily 1-hour sessions ","5305":"30 min aromatherapy massage twice a week for 4 weeks (eight times in total)","5306":"30 min aromatherapy massage twice a week for 4 weeks (eight times in total)","5307":"30 min aromatherapy massage twice a week for 4 weeks (eight times in total)","5308":"30 min aromatherapy massage twice a week for 4 weeks (eight times in total)","5309":"VertiseTM Flow (Kerr) (self-adhering flowable composite); - (VF)","5310":"G-aenial Universal Flo\u00ae (GC Europe) (used with one-step self-etch system) - (GUF); ","5311":"Yoga(Y) group practised an integrated yoga module that included asanas, pranayama, meditation, notional correction and devotional sessions; practised mild to moderate physical exercises (PE)","5312":"Yoga(Y) group practised an integrated yoga module that included asanas, pranayama, meditation, notional correction and devotional sessions; practised mild to moderate physical exercises (PE)","5313":"Yoga(Y) group practised an integrated yoga module that included asanas, pranayama, meditation, notional correction and devotional sessions; practised mild to moderate physical exercises (PE)","5314":"Yoga(Y) group practised an integrated yoga module that included asanas, pranayama, meditation, notional correction and devotional sessions;","5315":"Yoga(Y) group practised an integrated yoga module that included asanas, pranayama, meditation, notional correction and devotional sessions;","5316":"plastic cap","5317":"plastic cap","5318":"metal\/placebo","5319":"Bromelin 500 mg","5320":"500 mg Bromelin","5321":"Standard therapy","5322":"Standard therapy","5323":"supplementation with selenium and coenzyme Q10","5324":"supplementation with selenium and coenzyme Q10","5325":"CZP 200 mg every 2 weeks (Q2W) or CZP 400 mg every 4 weeks (Q4W)","5326":"CZP 200 mg every 2 weeks (Q2W) or CZP 400 mg every 4 weeks (Q4W)","5327":"i-gel prewarmed to 42\u00b0C; W group","5328":"i-gel prewarmed to 42\u00b0C; W group","5329":"i-gel prewarmed to 42\u00b0C; W group","5330":"encapsulated fruit and vegetable (F&V) juice concentrate","5331":"encapsulated fruit and vegetable (F&V) juice concentrate","5332":"encapsulated fruit and vegetable (F&V) juice concentrate","5333":"encapsulated fruit and vegetable (F&V) juice concentrate","5334":"encapsulated fruit and vegetable (F&V) juice concentrate","5335":"etoricoxib","5336":"classic cigarette","5337":"T-EO formulation","5338":"T-EO formulation and Af-EO formulation","5339":"T-EO formulation ","5340":"Preoperative oxygen delivery","5341":"Tailored intervention","5342":"Tailored intervention","5343":"Intraabdominal pressure 20 mm Hg","5344":"Intraabdominal pressure 20 mm Hg","5345":"Intraabdominal pressure 20 mm Hg","5346":"Tac starting dose based on bodyweight","5347":"Low-frequency right prefrontal followed by low-frequency left temporal rTMS","5348":"Injection of adrenaline solution and bipolar electrocoagulation (A + BE)","5349":"Injection of adrenaline solution and bipolar electrocoagulation (A + BE)","5350":"Injection of adrenaline solution and bipolar electrocoagulation (A + BE)","5351":"Injection of adrenaline solution and bipolar electrocoagulation (A + BE)","5352":"Porous \u03b2-calcium pyrophosphate (\u03b2-CPP) plus autograft","5353":"Porous \u03b2-calcium pyrophosphate (\u03b2-CPP) plus autograft","5354":"Porous \u03b2-calcium pyrophosphate (\u03b2-CPP) plus autograft","5355":"Gatorade and polyethylene glycol (PEG) with bisacodyl","5356":"Gatorade and polyethylene glycol (PEG) with bisacodyl","5357":"Lopinavir\/ritonavir (LPV\/r) and raltegravir (RAL)","5358":"Continuous hyperfractionated accelerated radiation therapy ","5359":"Continuous hyperfractionated accelerated radiation therapy ","5360":"Ashwagandha (Withania somnifera [L.] Dunal)","5361":"Dairy treatment","5362":"Dairy treatment","5363":"Alcohol-assisted epithelial removal","5364":"Alcohol-assisted epithelial removal","5365":"Alcohol-assisted epithelial removal","5366":"Positive psychology-based intervention","5367":"Positive psychology-based intervention","5368":"Positive psychology-based intervention","5369":"Lactobacillus GG","5370":"Lactobacillus GG","5371":"Lactobacillus GG","5372":"Group 4 (extract and SRP) and group 5 (powder and SRP) ","5373":" Treatment alone","5374":"Semelil (ANGIPARSTM)","5375":"Usual care","5376":"Use of positive end-expiratory pressure","5377":"10 cmH2O of positive end-expiratory pressure","5378":"Vilazodone","5379":"Vilazodone","5380":"Propofol","5381":"Cone of pressure flap","5382":"Cone of pressure flap","5383":"Vaginal estriol plus viable Lactobacillus acidophilus KS400 ","5384":"Intracutaneous sterile water injection","5385":"Dexmedetomidine group","5386":"Dexmedetomidine group","5387":"Calcium hydroxide","5388":"Calcium hydroxide","5389":"Pro-social priming group ","5390":"Pro-social priming group ","5391":"Intranasal salmon calcitonin","5392":"Methotrexate","5393":"Methotrexate","5394":"Tacrolimus","5395":"Tacrolimus","5396":"BITT","5397":"BITT","5398":"BoNT-A and BoNT-A + BITT","5399":"Training cohort","5400":"Intensive lifestyle intervention (ILI) group","5401":"Intensive lifestyle intervention (ILI) group","5402":"Intensive lifestyle intervention (ILI) group","5403":"Pap smear at enrollment","5404":"Pap smear at enrollment","5405":"Atorvastatin","5406":"Atorvastatin","5407":"Extracorporeal shock wave therapy","5408":"Extracorporeal shock wave therapy","5409":"Mulberry leaf pellet at 600 g\/hd\/d","5410":"Mulberry leaf pellet at 600 g\/hd\/d","5411":"Mulberry leaf pellet at 600 g\/hd\/d","5412":"Gutta-percha","5413":"Creatine supplementation ","5414":"Creatine supplementation ","5415":"Video e-learning ","5416":"Video e-learning ","5417":"Video e-learning ","5418":"Video e-learning ","5419":"Religious programs","5420":"Religious programs","5421":"Religious programs","5422":"Calcitriol + Hind-limb suspension","5423":"Calcitriol + Hind-limb suspension","5424":"Heated infusions ","5425":"Heated infusions ","5426":"Heated infusions ","5427":"Heated infusions ","5428":"Heated infusions ","5429":"Chitosan","5430":"Chitosan","5431":"Digital stereopsis","5432":"Bispectral monitoring ","5433":"Phlebotomy training programme","5434":"Phlebotomy training programme","5435":"Phlebotomy training programme","5436":"Motivational interviewing ","5437":"Motivational interviewing ","5438":"Motivational interviewing ","5439":"Dexamethasone + ramosetron","5440":"Dexamethasone + ramosetron","5441":"Dexamethasone + ramosetron","5442":"Dexamethasone + ramosetron","5443":"Dexamethasone + ramosetron","5444":"Aliskiren","5445":"Aliskiren","5446":"Aliskiren","5447":"Lixisenatide","5448":"Lixisenatide","5449":"Transcranial direct current stimulation","5450":"Transcranial direct current stimulation","5451":"Transcranial direct current stimulation","5452":"Religious prayers","5453":"Truview laryngoscope","5454":"Truview laryngoscope","5455":"Truview laryngoscope","5456":"Behavioral lifestyle intervention","5457":"Behavioral lifestyle intervention","5458":"Behavioral lifestyle intervention","5459":"Behavioral lifestyle intervention","5460":"Behavioral lifestyle intervention","5461":"COACH program","5462":"COACH program","5463":"COACH program","5464":"Pre-exercise meal","5465":"Pre-exercise meal","5466":"Onsite Nurse Mentoring","5467":"Onsite Nurse Mentoring","5468":"Extended-release oxcarbazepine 2400 mg","5469":"Extended-release oxcarbazepine 1200 mg","5470":"Intrapulmonary percussive ventilation","5471":"Intrapulmonary percussive ventilation","5472":"Adalimumab +MTX","5473":"Adalimumab +MTX","5474":"Primary care based exercise programme ","5475":"Primary care based exercise programme ","5476":"Primary care based exercise programme ","5477":"Primary care based exercise programme ","5478":"Carbopol gel","5479":"Selective internal radiotherapy","5480":"Selective internal radiotherapy","5481":"Selective internal radiotherapy","5482":"Paricalcitol","5483":"Paricalcitol","5484":"Hydroxypropylmethylcellulose","5485":"Hydroxypropylmethylcellulose","5486":"Bremelanotide 1.75","5487":"Bremelanotide 1.25","5488":"Bremelanotide 1.25","5489":"Placebo analgesic + Haloperidol","5490":"Placebo analgesic + Haloperidol","5491":"Placebo analgesic + Haloperidol","5492":"Secnidazole ","5493":"GoActive intervention","5494":"GoActive intervention","5495":"GoActive intervention","5496":"Telephone Outreach","5497":"Telephone Outreach","5498":"Telephone Outreach","5499":"Telephone Outreach","5500":"Telephone Outreach","5501":"Telephone Outreach","5502":"Meal provision","5503":"Meal provision","5504":"Meal provision","5505":"Meal provision","5506":"Speed endurance training","5507":"Speed endurance training","5508":"Speed endurance training","5509":"Closed\u2010loop insulin","5510":"Closed\u2010loop insulin","5511":"Closed\u2010loop insulin","5512":"Closed\u2010loop insulin","5513":"Brain-Computer Interface + Haptic Knob","5514":"Haptic Knob","5515":"Brain-Computer Interface + Haptic Knob","5516":"Brain-Computer Interface + Haptic Knob","5517":"Dimethylamylamine suplement ","5518":"Engaging in prohibited street-based income generation","5519":"Engaging in illegal income generating activities ","5520":"Incarceration in the last 6 months ","5521":"0.2% lidocaine in a one-per-mil solution","5522":"Pirfenidone tablet","5523":"Pirfenidone tablet","5524":"Pirfenidone tablet","5525":"Viewing stereotype-consistent performances","5526":"Asian students","5527":"Asian students","5528":"Asian students","5529":"Asian students","5530":"Cannula P","5531":"Cannula P","5532":"Diet and physical activity","5533":"Protein + carbohydrate","5534":"Protein + carbohydrate","5535":"Protein + carbohydrate","5536":"Linagliptin ","5537":"Linagliptin ","5538":"Linagliptin ","5539":"Hydroxypropyl methylcellulose ","5540":"Hydroxypropyl methylcellulose ","5541":"Stypro hemostatic sponge","5542":"Stypro hemostatic sponge","5543":"Collagen hemostatic sponge","5544":"Paracetamol + naproxen","5545":"Paracetamol + naproxen","5546":"Paracetamol + naproxen","5547":"Paracetamol + naproxen","5548":"Luseogliflozin + sulfonylureas","5549":"Luseogliflozin + biguanides","5550":"Luseogliflozin + DPP-4 inhibitors","5551":"Luseogliflozin + thiazolidinediones","5552":"Luseogliflozin + glinides ","5553":"Questionnaires made by the GP ","5554":"Questionnaires made by the GP ","5555":"Phone-Based Education and Counseling","5556":"Vasovagal syncope","5557":"Fentanyl","5558":"Fentanyl","5559":"Fentanyl + morphine","5560":"Fentanyl + morphine","5561":"Podiatry","5562":"Podiatry","5563":"Triptorelin","5564":"Triptorelin","5565":"Triptorelin","5566":"Evaluation with feedback","5567":"fluticasone furoate nasal spray","5568":"Tramadol ","5569":"Tramadol ","5570":"Tramadol ","5571":"Tramadol ","5572":"Elemental iron (IPM)","5573":"Elemental iron (IPM)","5574":"Elemental iron (IPM)","5575":"Dihydroartemisinin-piperaquine","5576":"Dihydroartemisinin-piperaquine","5577":"Dihydroartemisinin-piperaquine","5578":"Dihydroartemisinin-piperaquine","5579":"Glucose high dose","5580":"Glucose high dose","5581":"Misoprostol + celecoxib","5582":"Misoprostol + celecoxib","5583":"Misoprostol + celecoxib","5584":"Misoprostol + celecoxib","5585":"Oseltamivir","5586":"Oseltamivir","5587":"Ondansetron","5588":"Ondansetron","5589":"Lidocaine + Oxymetazoline","5590":"Lidocaine + Oxymetazoline","5591":"Lidocaine","5592":"Hidden X suture ","5593":"Hidden X suture ","5594":"Hidden X suture ","5595":"Hidden X suture ","5596":"Hidden X suture ","5597":"Visual nasogastric tube insertion ","5598":"Visual nasogastric tube insertion ","5599":"Visual nasogastric tube insertion ","5600":"Coenzyme Q10","5601":"Coenzyme Q10","5602":"Metformin","5603":"Metformin 1000 mg","5604":"Patsari Biomass Stove","5605":"Patsari Biomass Stove","5606":"Exercise training","5607":"Exercise training","5608":"Bispectral index monitoring","5609":"Individualized acupuncture","5610":"Individualized acupuncture","5611":"Theacrine","5612":"Theacrine","5613":"Theacrine","5614":"Theacrine","5615":"Theacrine","5616":"Transcranial direct current stimulation","5617":"Transcranial direct current stimulation","5618":"Olanzapine orodispersible tablet","5619":"Olanzapine orodispersible tablet","5620":"Olanzapine orodispersible tablet","5621":"Ustekinumab 130 mg ","5622":"Ursodeoxycholic acid","5623":"Ursodeoxycholic acid","5624":"Insulin 0.07 IU\/kg infusion","5625":"Insulin 0.07 IU\/kg infusion","5626":"stem cell infusion - two session treatment (G-II) ","5627":"stem cell infusion - one session treatment (G-I)","5628":"stem cell infusion - two session treatment (G-II) ","5629":"group ILMA, Intubating Laryngeal Mask Airway","5630":"group ILMA, Intubating Laryngeal Mask Airway","5631":"group ILMA, Intubating Laryngeal Mask Airway","5632":"group ILMA, Intubating Laryngeal Mask Airway","5633":"practice nurses (PNs)","5634":"practice nurses (PNs)","5635":"practice nurses (PNs)","5636":" practice nurses (PNs)","5637":"phenylhydrazine plus Ethyl pyruvate (PHZ+EP)","5638":"phenylhydrazine (PHZ)","5639":"phenylhydrazine (PHZ)","5640":"phenylhydrazine (PHZ)","5641":"exercise intervention with Football Fitness","5642":"exercise intervention with Football Fitness","5643":"whole-body to cold (whole-body cryostimulation, WBC)","5644":"whole-body to cold (whole-body cryostimulation, WBC)","5645":"whole-body to cold (whole-body cryostimulation, WBC)","5646":"anti-HE intervention (lactulose+branched-chain amino acids+rifaximin)","5647":"anti-HE intervention (lactulose+branched-chain amino acids+rifaximin)","5648":"anti-HE intervention (lactulose+branched-chain amino acids+rifaximin)","5649":"anti-HE intervention (lactulose+branched-chain amino acids+rifaximin)","5650":"positioning and chest wall vibrations in addition to MH plus suctioning (multimodality chest physiotherapy)","5651":"positioning and chest wall vibrations in addition to MH plus suctioning (multimodality chest physiotherapy)","5652":"MDL (a main metabolite of nicergoline)","5653":"Mild moxibustion","5654":"Mild moxibustion","5655":"Mild moxibustion","5656":"diabetic peripheral neuropathy patients (GII)","5657":"diabetic peripheral neuropathy patients (GII)","5658":"S10 (lansoprazole and amoxicillin for the first 5 days, followed by lansoprazole, clarithromycin and metronidazole for another 5 days)","5659":"S10 (lansoprazole and amoxicillin for the first 5 days, followed by lansoprazole, clarithromycin and metronidazole for another 5 days)","5660":"S10 (lansoprazole and amoxicillin for the first 5 days, followed by lansoprazole, clarithromycin and metronidazole for another 5 days)","5661":"S10 (lansoprazole and amoxicillin for the first 5 days, followed by lansoprazole, clarithromycin and metronidazole for another 5 days)","5662":"clonidine (Group 2)","5663":"Balloon-induced exercise (BIE)","5664":"Balloon-induced control (BIC)","5665":"resected glands above 36.5 cm","5666":"drain group","5667":"drain group","5668":"total thyroidectomy","5669":"intervention group with added low-intensity power ultrasound treatment (LIPUS)","5670":"intervention group with added low-intensity power ultrasound treatment (LIPUS)","5671":"intervention group with added low-intensity power ultrasound treatment (LIPUS)","5672":"dorsal BMG urethroplasty by ventral urethrotomy (Group B) (Asopa)","5673":"dorsal BMG urethroplasty by ventral urethrotomy (Group B) (Asopa)","5674":"dorsal BMG urethroplasty by ventral urethrotomy (Group B) (Asopa)","5675":"dorsal BMG urethroplasty by ventral urethrotomy (Group B) (Asopa)","5676":"T2D (type 2 diabetes) patients","5677":"T2D (type 2 diabetes) patients","5678":"T2D (type 2 diabetes) patients","5679":"olopatadine hydrochloride 0.1% twice a day","5680":"olopatadine hydrochloride 0.1% twice a day","5681":"macitentan dose of 600 mg","5682":"Patients operated with fluoroscopy assistance (F)","5683":"educated through face to face training and an educational booklet","5684":"Nelatone catheter","5685":"Nelatone catheter","5686":"Internet group (who received the letter of invitation)","5687":"combination ezetimibe\/simvastatin 10\/20mg (ES10\/20) OR rosuvastatin 10 mg (R10)","5688":"combination ezetimibe\/simvastatin 10\/20mg (ES10\/20)","5689":"combination ezetimibe\/simvastatin 10\/20mg (ES10\/20)","5690":"combination ezetimibe\/simvastatin 10\/20mg (ES10\/20) OR rosuvastatin 10 mg (R10)","5691":"teplizumab","5692":"teplizumab","5693":"teplizumab","5694":"high fat diets (HF diet)","5695":"blindfolded","5696":"blindfolded","5697":" Cingal","5698":" Cingal","5699":"B. dracunculifolia","5700":"hospital settings","5701":"Pakistan","5702":"AMC\/DCBA Cool lozenge","5703":"AMC\/DCBA Warm lozenge","5704":"AMC\/DCBA Cool lozenge","5705":"intervention group (craniosacral therapy)","5706":"intervention group (craniosacral therapy)","5707":"IV ibuprofen","5708":"IV ibuprofen","5709":"rest group","5710":"rest group","5711":"rest group","5712":" Lactobacillus (Lacidofil\u00ae cap)","5713":"Lactobacillus (Lacidofil\u00ae cap)","5714":" Lactobacillus (Lacidofil\u00ae cap)","5715":" Lactobacillus (Lacidofil\u00ae cap)","5716":"buprenorphine HCl buccal film - BBUP group","5717":"buprenorphine HCl buccal film - BBUP group","5718":"group A, who were allowed to observe DJ stent insertion","5719":"group A, who were allowed to observe DJ stent insertion","5720":"group A, who were allowed to observe DJ stent insertion","5721":"routine counseling group","5722":"frovatriptan","5723":"frovatriptan","5724":"frovatriptan","5725":"propofol + remifentanil","5726":"propofol + remifentanil","5727":"JinqiJiangtang tablets (JQJT tablets, a traditional Chinese patent medicine)","5728":"JinqiJiangtang tablets (JQJT tablets, a traditional Chinese patent medicine)","5729":"JinqiJiangtang tablets (JQJT tablets, a traditional Chinese patent medicine)","5730":"relevant computer tutorial = \"in sequence\"","5731":"relevant computer tutorial = \"in sequence\"","5732":"Diazepam + chlorpheniramine","5733":"Diazepam + chlorpheniramine","5734":"Combining nateglinide + vildagliptin","5735":"Combining nateglinide + vildagliptin","5736":"pH 3.8 saliva ","5737":"pH 6.8 saliva","5738":"Parent-adolescent communication program ","5739":"Parent-adolescent communication program ","5740":"Protemp 3 Garan","5741":"Pectoral nerve block type II ","5742":"Pectoral nerve block type II ","5743":"Pectoral nerve block type II ","5744":"Pectoral nerve block type II ","5745":"Pectoral nerve block type II ","5746":"i\u2013gelTM","5747":"i\u2013gelTM","5748":"Laparoscopic hysterectomy","5749":"Mitoxantrone","5750":"Mitoxantrone","5751":"Nao-Xue-Shu oral liquid","5752":"Nao-Xue-Shu oral liquid","5753":"Nao-Xue-Shu oral liquid","5754":"Rebamipide","5755":"FIFA 11 for Health' programme","5756":"FIFA 11 for Health' programme","5757":"FIFA 11 for Health' programme","5758":"Naloxegol ","5759":"Dexmedetomidine in hypertensive patients ","5760":"Mid-ramp extinction ","5761":"Lauroyl arginate\u2010containing mouthrinse ","5762":"Lauroyl arginate\u2010containing mouthrinse ","5763":"Lauroyl arginate\u2010containing mouthrinse ","5764":"Rikkunshito ","5765":"Rikkunshito ","5766":"Rikkunshito ","5767":"Oligosaccharides Prebiotic Formula","5768":"Oligosaccharides Prebiotic Formula","5769":"Mobile phone intervention","5770":"Mobile phone intervention","5771":"Simulation and team-training program","5772":"Tofacitinib 10 mg","5773":"Noni juice 118 mL","5774":"Parent Training Intervention","5775":"Rapid uptitration","5776":"Mesalazine ","5777":"Mesalazine ","5778":"Mesalazine ","5779":"Active anodal tsDCS","5780":"Active anodal tsDCS","5781":"Active anodal tsDCS","5782":"Atorvastatin","5783":"Albendazole","5784":"Albendazole","5785":"Comprehensive lifestyle intervention","5786":"Comprehensive lifestyle intervention","5787":"Comprehensive lifestyle intervention","5788":"Natural childbirth preparation","5789":"Natural childbirth preparation","5790":"Natural childbirth preparation","5791":"Erlotinib ","5792":"Zingiber officinale 400 mg","5793":"Zingiber officinale 800 mg","5794":"Fentanyl + nitroglycerin","5795":"Linear-polarized near-infrared light irradiation","5796":"Linear-polarized near-infrared light irradiation","5797":"Linear-polarized near-infrared light irradiation","5798":"Yoga","5799":"D-serine","5800":"D-serine","5801":"D-serine","5802":"Candesartan","5803":"Oral supplement 1","5804":"Acupuncture ","5805":"Acupuncture ","5806":"salicylic acid","5807":"(group C), had to receive patient-centered counseling throughout the hospitalization","5808":"group NC), receiving the analgesic treatment without receiving counseling","5809":"Escherichia coli Nissle 1917 (EcN)","5810":"Escherichia coli Nissle 1917 (EcN)","5811":" three injections per week (TIW) (GHT), daily (GHT)","5812":"receive daily GH treatment (GHT)","5813":"telerehabilitation (Tele)","5814":"smoking cigarettes","5815":"Elevation Training Masks\u00a9 (ETM)","5816":"specially designed molding titanium clips","5817":"alginate impressions","5818":"self-image at recruitment (early image) ","5819":"intensive lifestyle intervention group (ILG)","5820":"singing classes","5821":"a 14\u2010week behavioral intervention using video instructional materials, workbook and telephone coaching in behavioral management, pleasant events scheduling, and relaxation","5822":"(2) an experimental group trained at a heart rate intensity corresponding to ventilatory threshold 1 (VT-1) for 60 min\/day 3 times weekly on alternate days for 6 months using a cycle ergometer","5823":"questionnaires online","5824":"double paclitaxel-coated balloons (diameter 6\u20137 mm) plus a high pressure balloon (diameter 12\u201314 mm)","5825":"double paclitaxel-coated balloons (diameter 6\u20137 mm) plus a high pressure balloon (diameter 12\u201314 mm)","5826":"conventional therapy","5827":"Group I received lignocaine 1% (9ml) with normal saline (1ml)","5828":"taspoglutide 20 mg, titration to 30 mg (20\/30), 40 mg (20\/40)","5829":"taspoglutide 20 mg, titration to 30 mg (20\/30), 40 mg (20\/40)","5830":"recombinant human growth hormone (rhGH) 0.1","5831":"recombinant human growth hormone (rhGH) 0.1, recombinant human growth hormone (rhGH) 0.05 U\/kg ","5832":"recombinant human growth hormone (rhGH) 0.05 U\/kg ","5833":"2.5 mg of bevacizumab (group 1)","5834":"2.5 mg of bevacizumab (group 1)","5835":"arthroscopic partial repair","5836":"VARA","5837":"mixed laparoscopy group (LPS)","5838":"Group 1 received 5 mg solifenacin per day","5839":"Plant sterols (PS)","5840":"Terrestrial Trunked Radio Telecommunications System (TETRA)","5841":"insulin aspart 0.1 units\/kg","5842":"insulin aspart 0.1 units\/kg or 0.2 units\/kg","5843":"L-DOPA and rivastigmine","5844":"Dextromethorphan","5845":"baclofen","5846":"tempo-pace synchronized audio-devices with personalized music playlists + usual-care (rhythmic auditory stimulation (RAS))","5847":"tempo-pace synchronized audio-devices with personalized music playlists + usual-care (rhythmic auditory stimulation (RAS)","5848":"standard behavioral weight loss, a technology\u2010based system combined with a monthly intervention telephone call (TECH) ; an enhanced technology\u2010based system combined with a monthly intervention telephone call (EN\u2010TECH)","5849":"laparoscopic (LP)","5850":"Sodium phosphates (L-NaP) preparation","5851":"Sodium phosphates (L-NaP) preparation","5852":"peramivir (Rapiacta)","5853":"patient drug adherence information (PDAI)","5854":"patient drug adherence information (PDAI)","5855":"40 g of type 2 RS (HAM-RS2)","5856":"40 g of type 2 RS (HAM-RS2)","5857":"40 g of type 2 RS (HAM-RS2)","5858":"40 g of type 2 RS (HAM-RS2)","5859":"Tamsulosin","5860":"tadalafil and finasteride","5861":"tadalafil","5862":"GlideScope\u00ae video laryngoscope (G)","5863":"intervention groups","5864":" intervention groups - pretest","5865":"tadalafil (10 mg o.d.)","5866":"Study groups","5867":"tadalafil (10 mg o.d.)","5868":"ramipril (10 mg\/day), tadalafil (10 mg o.d.), and ramipril plus tadalafil","5869":"more than four weeks clinical rotation in psychiatry","5870":"Remifentanil","5871":"morphine 4 mg (M)","5872":"chemoimmunotherapy with bevacizumab (PCR-B)","5873":"chemoimmunotherapy with bevacizumab (PCR-B)","5874":"chemoimmunotherapy with bevacizumab (PCR-B)","5875":"meditation awareness training (MAT)","5876":"meditation awareness training (MAT)","5877":"training group (group T)","5878":"homeopathy group","5879":"homeopathy group","5880":"group with postpartum depression symptoms","5881":"group with postpartum depression symptoms","5882":"group with postpartum depression symptoms","5883":"AE ointment","5884":"Problem-Solving Treatment (PST)","5885":"group 2 with Path-File (Dentsply Maillefer) #1, #2, and #3","5886":"previously prepared with path-finding files","5887":"group 1 with #10, #15 and #20 K-type (Dentsply Maillefer, Ballaigues, Switzerland) stainless steel manual files","5888":"1.5 mg\/kg of lidocaine for 90 s before cannulation","5889":"1.5 mg\/kg of lidocaine for 90 s before cannulation","5890":"vildagliptin group (received vildagliptin 100 mg\/day for 6 months)","5891":"vildagliptin group (received vildagliptin 100 mg\/day for 6 months)","5892":"group A, hip fractures managed with sliding hip screws (SHS)","5893":"group A, hip fractures managed with sliding hip screws (SHS)","5894":"group A, hip fractures managed with sliding hip screws (SHS)","5895":"short-term high-protein (HP) diet in infants following cardiac surgery","5896":"XELIRI (irinotecan 250 mg\/m2 given on day one and capecitabine 1000 mg\/m2 twice daily from day 2\u201315, every 21 days)","5897":"Bilastine updosing to 80 mg","5898":"Bilastine 20 mg","5899":"Lixisenatide","5900":"Lixisenatide","5901":"Lixisenatide","5902":"Transcranial direct current stimulation","5903":"Transcranial direct current stimulation","5904":"Religious prayers","5905":"Religious prayers","5906":"Truview laryngoscope","5907":"Truview laryngoscope","5908":"Behavioral lifestyle intervention","5909":"COACH program","5910":"COACH program","5911":"Pre-exercise meal","5912":"Pre-exercise meal","5913":"Onsite Nurse Mentoring","5914":"Onsite Nurse Mentoring","5915":"Onsite Nurse Mentoring","5916":"Onsite Nurse Mentoring","5917":"Extended-release oxcarbazepine 1200 mg","5918":"Extended-release oxcarbazepine 1200 mg","5919":"Extended-release oxcarbazepine 2400 mg","5920":"Extended-release oxcarbazepine 2400 mg","5921":"Intrapulmonary percussive ventilation","5922":"Intrapulmonary percussive ventilation","5923":"Intrapulmonary percussive ventilation","5924":"Intrapulmonary percussive ventilation","5925":"Adalimumab +MTX","5926":"Adalimumab +MTX","5927":"Adalimumab +MTX","5928":"Adalimumab +MTX","5929":"Primary care based exercise programme ","5930":"Primary care based exercise programme ","5931":"Griffithsin gel","5932":"Sitagliptin","5933":"Sitagliptin","5934":"Selective internal radiotherapy","5935":"Flunarizine 5 mg","5936":"Paricalcitol","5937":"Paricalcitol","5938":"Paricalcitol","5939":"Paricalcitol","5940":"Paricalcitol","5941":"Hydroxypropylmethylcellulose","5942":"Hydroxypropylmethylcellulose","5943":"Hydroxypropylmethylcellulose","5944":"Hydroxypropylmethylcellulose","5945":"Bremelanotide 1.25","5946":"Bremelanotide 1.75","5947":"Bremelanotide 1.75","5948":"Placebo analgesic + Naloxone","5949":"Placebo analgesic alone","5950":"Placebo analgesic alone","5951":"Tinidazole","5952":"Ornidazole ","5953":"Tinidazole","5954":"GoActive intervention","5955":"GoActive intervention","5956":"GoActive intervention","5957":"Telephone Outreach","5958":"Meal provision","5959":"Meal provision","5960":"Speed endurance training","5961":"Speed endurance training","5962":"Speed endurance training","5963":"Closed\u2010loop insulin","5964":"Closed\u2010loop insulin","5965":"Brain-Computer Interface + Haptic Knob","5966":"Dimethylamylamine suplement ","5967":"Dimethylamylamine suplement ","5968":"Recent drug dealing","5969":"Engaging in sexual work ","5970":"0.2% lidocaine in a one-per-mil solution","5971":"Pirfenidone tablet","5972":"Asian students","5973":"Cannula P","5974":"Cannula P","5975":"Cannula P","5976":"Diet and physical activity","5977":"Diet and physical activity","5978":"Diet and physical activity","5979":"Protein + carbohydrate","5980":"Protein + carbohydrate","5981":"Protein + carbohydrate","5982":"Linagliptin ","5983":"Linagliptin ","5984":"Hydroxypropyl methylcellulose ","5985":"Collagen hemostatic sponge","5986":"Stypro hemostatic sponge","5987":"Collagen hemostatic sponge","5988":"Paracetamol + naproxen","5989":"Paracetamol + naproxen","5990":"Luseogliflozin + \u03b1-glucosidase inhibitor","5991":"Questionnaires made by the GP ","5992":"Questionnaires made by the GP ","5993":"Questionnaires made by the GP ","5994":"Questionnaires made by the GP ","5995":"Vasovagal syncope","5996":"Fentanyl","5997":"Fentanyl","5998":"Fentanyl","5999":"Podiatry","6000":"Trichloroacetic acid ","6001":"Podiatry","6002":"Trichloroacetic acid ","6003":"Triptorelin","6004":"Triptorelin","6005":"Triptorelin","6006":"Evaluation with feedback","6007":"fluticasone furoate nasal spray","6008":"fluticasone furoate nasal spray","6009":"fluticasone furoate nasal spray","6010":"fluticasone furoate nasal spray","6011":"Tramadol ","6012":"Tramadol ","6013":"Elemental iron (IPM)","6014":"Elemental iron (IPM)","6015":"Elemental iron (IPM)","6016":"Dihydroartemisinin-piperaquine","6017":"Dihydroartemisinin-piperaquine","6018":"Glucose high dose","6019":"Glucose high dose","6020":"Glucose high dose","6021":"Glucose high dose","6022":"Misoprostol + celecoxib","6023":"Misoprostol + celecoxib","6024":"Oseltamivir","6025":"Oseltamivir","6026":"Oseltamivir","6027":"Oseltamivir","6028":"Ondansetron","6029":"Ondansetron","6030":"Ondansetron","6031":"Lidocaine","6032":"Lidocaine","6033":"Lidocaine + Oxymetazoline","6034":"Lidocaine + Oxymetazoline","6035":"Lidocaine + Oxymetazoline","6036":"Hidden X suture ","6037":"Visual nasogastric tube insertion ","6038":"Visual nasogastric tube insertion ","6039":"Visual nasogastric tube insertion ","6040":"Coenzyme Q10","6041":"Coenzyme Q10","6042":"Coenzyme Q10","6043":"Coenzyme Q10","6044":"Metformin 1000 mg","6045":"Patsari Biomass Stove","6046":"Patsari Biomass Stove","6047":"Patsari Biomass Stove","6048":"Patsari Biomass Stove","6049":"Hyperimmune egg","6050":"Exercise training","6051":"Exercise training","6052":"Exercise training","6053":"Interruption of continuous infusions of sedatives","6054":"Interruption of continuous infusions of sedatives","6055":"Interruption of continuous infusions of sedatives","6056":"Interruption of continuous infusions of sedatives","6057":"Interruption of continuous infusions of sedatives","6058":"Individualized acupuncture","6059":"Individualized acupuncture","6060":"Individualized acupuncture","6061":"Individualized acupuncture","6062":"Theacrine","6063":"Transcranial direct current stimulation","6064":"Transcranial direct current stimulation","6065":"Olanzapine orodispersible tablet","6066":"Olanzapine orodispersible tablet","6067":"Ustekinumab 130 mg","6068":"Ustekinumab 6 mg\/kg","6069":"Ustekinumab 130 mg every 8 weeks","6070":"Ustekinumab 130 mg every 12 weeks","6071":"Ustekinumab 6 mg\/kg","6072":"Ursodeoxycholic acid","6073":"Ursodeoxycholic acid","6074":"Ursodeoxycholic acid","6075":"Insulin 0.07 IU\/kg infusion","6076":"Insulin 0.07 IU\/kg infusion","6077":"Insulin 0.07 IU\/kg infusion","6078":"Insulin 0.07 IU\/kg infusion","6079":"Adherence therapy","6080":"Adherence therapy","6081":"Adherence therapy","6082":"Adherence therapy","6083":"Adherence therapy","6084":"Adherence therapy","6085":"group ILMA, Intubating Laryngeal Mask Airway","6086":"practice nurses (PNs)","6087":"PHZ group","6088":"exercise intervention with Football Fitness","6089":"exercise intervention with Football Fitness","6090":"exercise intervention with Football Fitness","6091":"whole-body to cold (whole-body cryostimulation, WBC)","6092":"whole-body to cold (whole-body cryostimulation, WBC)","6093":"anti-HE intervention (lactulose+branched-chain amino acids+rifaximin)","6094":"positioning and chest wall vibrations in addition to MH plus suctioning (multimodality chest physiotherapy)","6095":"positioning and chest wall vibrations in addition to MH plus suctioning (multimodality chest physiotherapy)","6096":"positioning and chest wall vibrations in addition to MH plus suctioning (multimodality chest physiotherapy)","6097":"MDL (a main metabolite of nicergoline)","6098":"Mild moxibustion","6099":"diabetes mellitus patients without neuropathy (GI)","6100":"diabetic peripheral neuropathy patients (GII)","6101":"diabetic peripheral neuropathy patients (GII)","6102":"S10 (lansoprazole and amoxicillin for the first 5 days, followed by lansoprazole, clarithromycin and metronidazole for another 5 days)","6103":"midazolam (Group 1)","6104":"midazolam (Group 1)","6105":"midazolam (Group 1)","6106":"clonidine (Group 2)","6107":"Balloon-induced exercise (BIE)","6108":"Balloon-induced exercise (BIE)","6109":"Balloon-induced exercise (BIE)","6110":"drain group","6111":"observation group (same treatment combined with mild hypothermia treatment and nursing)","6112":"observation group (same treatment combined with mild hypothermia treatment and nursing)","6113":"observation group (same treatment combined with mild hypothermia treatment and nursing)","6114":"observation group (same treatment combined with mild hypothermia treatment and nursing)","6115":"intervention group with added low-intensity power ultrasound treatment (LIPUS)","6116":"T2D (type 2 diabetes) patients","6117":"T2D (type 2 diabetes) patients","6118":"emedastine difumarate 0.05% twice a day","6119":"olopatadine hydrochloride 0.1% twice a day, emedastine difumarate 0.05% twice a day, or loteprednol etabonate (LE) 0.5% 4 times a day","6120":"olopatadine hydrochloride 0.1% twice a day, emedastine difumarate 0.05% twice a day, or LE 0.5% 4 times a day, respectively","6121":"macitentan doses of 0.2, 1, 5, 25, 100, 300 and 600 mg","6122":"macitentan dose of 600 mg","6123":"macitentan doses of 0.2, 1, 5, 25, 100, 300 mg","6124":"Patients operated with fluoroscopy assistance (F)","6125":"Patients operated with fluoroscopy assistance (F)","6126":"Patients operated with fluoroscopy assistance (F)","6127":"Patients operated with fluoroscopy assistance (F)","6128":"Patients operated with fluoroscopy assistance (F)","6129":"educated through face to face training and an educational booklet","6130":"educated through face to face training and an educational booklet","6131":"educated through face to face training and an educational booklet","6132":"educated through face to face training and an educational booklet","6133":"Nelatone catheter","6134":"Internet group (who received the letter of invitation)","6135":"Internet group (who received the letter of invitation)","6136":"Internet group (who received the letter of invitation)","6137":"Internet group (who received the letter of invitation)","6138":"combination ezetimibe\/simvastatin 10\/20mg (ES10\/20)","6139":"combination ezetimibe\/simvastatin 10\/20mg (ES10\/20)","6140":"combination ezetimibe\/simvastatin 10\/20mg (ES10\/20) OR rosuvastatin 10 mg (R10)","6141":"teplizumab","6142":"teplizumab","6143":"high fat diets (HF diet)","6144":"high fat diets (HF diet)","6145":"high fat diets (HF diet)","6146":"blindfolded","6147":"blindfolded","6148":" Monovisc","6149":" Cingal","6150":"B. dracunculifolia","6151":"B. dracunculifolia","6152":"B. dracunculifolia","6153":"Pakistan","6154":"Pakistan","6155":"AMC\/DCBA Warm lozenge","6156":"AMC\/DCBA Cool lozenge","6157":"intervention group (craniosacral therapy)","6158":"IV ibuprofen","6159":"rest group","6160":" Lactobacillus (Lacidofil\u00ae cap)","6161":"Lactobacillus (Lacidofil\u00ae cap)","6162":"buprenorphine HCl buccal film - BBUP group","6163":"buprenorphine HCl buccal film - BBUP group","6164":"buprenorphine HCl buccal film - BBUP group","6165":"group A, who were allowed to observe DJ stent insertion","6166":"group A, who were allowed to observe DJ stent insertion","6167":"300 \u03bcg selenium per day","6168":"300 \u03bcg selenium per day","6169":"300 \u03bcg selenium per day","6170":"300 \u03bcg selenium per day","6171":"300 \u03bcg selenium per day","6172":"JDA membership","6173":"routine counseling group","6174":"routine counseling group","6175":"frovatriptan","6176":"propofol + remifentanil","6177":"JinqiJiangtang tablets (JQJT tablets, a traditional Chinese patent medicine)","6178":"JinqiJiangtang tablets (JQJT tablets, a traditional Chinese patent medicine)","6179":"relevant computer tutorial = \"in sequence\"","6180":"relevant computer tutorial = \"in sequence\"","6181":"relevant computer tutorial = \"in sequence\"","6182":"Clinical full model","6183":"Diazepam + chlorpheniramine","6184":"Diazepam + chlorpheniramine","6185":"Diazepam + chlorpheniramine","6186":"Diazepam + chlorpheniramine","6187":"Formoterol 4.5 \u03bcg","6188":"Formoterol 9 \u03bcg","6189":"Formoterol 9 \u03bcg","6190":"Formoterol 9 \u03bcg","6191":"Formoterol 9 \u03bcg","6192":"Combining nateglinide + vildagliptin","6193":"Combining nateglinide + vildagliptin","6194":"Combining nateglinide + vildagliptin","6195":"pH 3.8 saliva ","6196":"pH 6.8 saliva","6197":"Parent-adolescent communication program ","6198":"Parent-adolescent communication program ","6199":"Fast set Temphase","6200":"Protemp 3 Garan","6201":"Pectoral nerve block type II ","6202":"i\u2013gelTM","6203":"i\u2013gelTM","6204":"i\u2013gelTM","6205":"Laparoscopic hysterectomy","6206":"Laparoscopic hysterectomy","6207":"Laparoscopic hysterectomy","6208":"Multivitamins","6209":"Multivitamins","6210":"Multivitamins","6211":"Zinc","6212":"Mitoxantrone","6213":"Mitoxantrone","6214":"Nao-Xue-Shu oral liquid","6215":"Nao-Xue-Shu oral liquid","6216":"Rebamipide","6217":"Moderate intensity aerobic exercise","6218":"Moderate intensity aerobic exercise","6219":"Moderate intensity aerobic exercise","6220":"Moderate intensity aerobic exercise","6221":"FIFA 11 for Health' programme","6222":"FIFA 11 for Health' programme","6223":"Naloxegol ","6224":"Naloxegol ","6225":"Mid-ramp extinction ","6226":"Rikkunshito ","6227":"Rikkunshito ","6228":"Rikkunshito ","6229":"Hypothetico-deduction condition","6230":"Oligosaccharides Prebiotic Formula","6231":"Oligosaccharides Prebiotic Formula","6232":"Oligosaccharides Prebiotic Formula","6233":"Mobile phone intervention","6234":"Mobile phone intervention","6235":"Simulation and team-training program","6236":"Tofacitinib 10 mg","6237":"Tofacitinib 10 mg","6238":"Tofacitinib 5 mg","6239":"Tofacitinib 10 mg","6240":"Tofacitinib 10 mg","6241":"Sniffin' Sticks test","6242":"Parent Training Intervention","6243":"Parent Training Intervention","6244":"Parent Training Intervention","6245":"Parent Training Intervention","6246":"Parent Training Intervention","6247":"Andrographis paniculata","6248":"Andrographis paniculata","6249":"Andrographis paniculata","6250":"Rapid uptitration","6251":"Rapid uptitration","6252":"Rapid uptitration","6253":"Rapid uptitration","6254":"Rapid uptitration","6255":"Commercial citrus sinensis juice","6256":"Commercial citrus sinensis juice","6257":"Mesalazine ","6258":"Mesalazine ","6259":"Heroin","6260":"Heroin","6261":"Active anodal tsDCS","6262":"Active anodal tsDCS","6263":"Atorvastatin","6264":"Atorvastatin","6265":"Atorvastatin","6266":"Albendazole","6267":"Albendazole","6268":"Albendazole","6269":"Summative assessments","6270":"Summative assessments","6271":"Comprehensive lifestyle intervention","6272":"Comprehensive lifestyle intervention","6273":"Natural childbirth preparation","6274":"Erlotinib ","6275":"Erlotinib ","6276":"Zingiber officinale 800 mg","6277":"Zingiber officinale 800 mg","6278":"N-acetylcysteine","6279":"N-acetylcysteine","6280":"N-acetylcysteine","6281":"N-acetylcysteine","6282":"Virtual reality game","6283":"Virtual reality game","6284":"Fentanyl + nitroglycerin","6285":"Fentanyl + nitroglycerin","6286":"Fentanyl + nitroglycerin","6287":"Fentanyl + nitroglycerin","6288":"Risedronate 5 mg","6289":"Linear-polarized near-infrared light irradiation","6290":"Yoga","6291":"D-serine","6292":"Ramipril ","6293":"Ramipril ","6294":"Ramipril ","6295":"Candesartan","6296":"Biofeedback ","6297":"Oral supplement 1","6298":"Oral supplement 2","6299":"Oral supplement 1","6300":"Oral supplement 1","6301":"Acupuncture ","6302":"Acupuncture ","6303":"salicylic acid","6304":"(group C), had to receive patient-centered counseling throughout the hospitalization","6305":"group NC), receiving the analgesic treatment without receiving counseling","6306":"(group C), had to receive patient-centered counseling throughout the hospitalization","6307":"Escherichia coli Nissle 1917 (EcN)","6308":"insulin (detemir)","6309":"insulin (detemir)","6310":"propofol-lidocaine [PL]","6311":"thiopental sodium-saline [TS]","6312":"thiopental sodium-saline [TS]","6313":"three injections per week (TIW) growth hormone treatment (GHT)","6314":"telerehabilitation (Tele), conventional therapy (Conv)","6315":"telerehabilitation (Tele)","6316":"telerehabilitation (Tele)","6317":"telerehabilitation (Tele)","6318":"rimonabant 20 mg","6319":"rimonabant 20 mg","6320":"rimonabant 20 mg","6321":"rimonabant 20 mg","6322":"rimonabant 20 mg","6323":"'baseball' suture technique","6324":"smoking cigarettes","6325":"AirtraqTM","6326":"AirtraqTM","6327":"Macintosh","6328":"Elevation Training Masks\u00a9 (ETM) , without the mask","6329":"craniosacral therapy (IG)","6330":"specially designed molding titanium clips","6331":"specially designed molding titanium clips","6332":"Internet program\u2014DirectLife (Philips)","6333":"Group 1 had the integrated care model including a multidisciplinary team and continuous care coordination, Group 2 had both the integrated care model and provider-level financial incentives,","6334":"alginate impressions","6335":"alginate impressions","6336":"Group I - control","6337":"Group I - control","6338":"intensive lifestyle intervention group (ILG)","6339":"intensive lifestyle intervention group (ILG)","6340":"singing classes, film club","6341":"singing classes","6342":"a 14\u2010week behavioral intervention using video instructional materials, workbook and telephone coaching in behavioral management, pleasant events scheduling, and relaxation","6343":"a 14\u2010week behavioral intervention using video instructional materials, workbook and telephone coaching in behavioral management, pleasant events scheduling, and relaxation","6344":"(2) an experimental group trained at a heart rate intensity corresponding to ventilatory threshold 1 (VT-1) for 60 min\/day 3 times weekly on alternate days for 6 months using a cycle ergometer","6345":"questionnaires online","6346":"questionnaires online","6347":"questionnaires online","6348":"pregabalin 150, gabapentin 900mg","6349":"mofetil (MMF) alone or with daclizumab (DZB)","6350":"Group I received lignocaine 1% (9ml) with normal saline (1ml), group II lignocaine1% (9ml) with neostigmine 100\u03bcg in saline (1ml) and group III received lignocaine 1% (9ml) with neostigmine 200\u03bcg in NS (1ml)","6351":"group II lignocaine1% (9ml) with neostigmine 100\u03bcg in saline (1ml) and group III received lignocaine 1% (9ml) with neostigmine 200\u03bcg in NS (1ml)","6352":"group II lignocaine1% (9ml) with neostigmine 100\u03bcg in saline (1ml) ","6353":"nutraceutical combination (NC)","6354":"group A (Rapid urease test (RUT) plus noninvasive tests)","6355":"group A (Rapid urease test (RUT) plus noninvasive tests)","6356":"Moist Exposed Burn Ointment (MEBO)","6357":"Moist Exposed Burn Ointment (MEBO)","6358":"Moist Exposed Burn Ointment (MEBO)","6359":"Moist Exposed Burn Ointment (MEBO)","6360":"Group I - alfentanil, Group II - fentanyl ","6361":"breast conserving surgery (BCS)","6362":"recombinant human growth hormone (rhGH) 0.1","6363":"recombinant human growth hormone (rhGH) 0.1","6364":"2.5 mg of bevacizumab (group 1)","6365":"parenteral nutrition (PN) (early PN)","6366":"Clopidogrel ","6367":"Clopidogrel ","6368":"Clopidogrel ","6369":"Home-based training with telemonitoring","6370":"Home-based training with telemonitoring","6371":"Unsolvable task","6372":"Multi-component physical activity ","6373":"Multi-component physical activity ","6374":"Multi-component physical activity ","6375":"Kaltenborn mobilization therapy","6376":"Kaltenborn mobilization therapy","6377":"Printed educational materials","6378":"Fludarabine plus 2 Gy total body irradiation (Flu-TBI arm)","6379":"Fludarabine plus 2 Gy total body irradiation (Flu-TBI arm)","6380":"Supplemental Se","6381":"Supplemental Se","6382":"Gum-chewing group","6383":"Vonoprazan 10 and 20 mg","6384":"Vitamin D3 40.000 IU (DD group) or Vitamin D3 20.000 IU (DP group)","6385":"Vitamin D3 40.000 IU (DD group) or Vitamin D3 20.000 IU (DP group)","6386":"Hyperopic defocus group ","6387":"12 week physical activity tailored program","6388":"12 week physical activity tailored program","6389":"Tranexamic acid","6390":"Tranexamic acid","6391":"Oral carbohydrate group or oral rehydration solution group","6392":"Oral carbohydrate group or oral rehydration solution group","6393":"Follow-up invitation by telephone","6394":"Follow-up invitation by telephone","6395":"Multivitamin-mineral supplement","6396":"Multivitamin-mineral supplement","6397":"Multivitamin-mineral supplement","6398":"CT-PFNECII plus second-line chemotherapy (combination group)","6399":"CT-PFNECII plus second-line chemotherapy (combination group)","6400":"CT-PFNECII plus second-line chemotherapy (combination group)","6401":"CT-PFNECII plus second-line chemotherapy (combination group)","6402":"Intravenous lidocaine","6403":"Heavyweight mesh","6404":"ATD","6405":"therapy with adalimumab in addition to MTX","6406":"therapy with adalimumab in addition to MTX","6407":"patients who came on time","6408":"on-time patients","6409":"new patient","6410":"nalbuphine hydrochloride in addition to levobupivacaine","6411":"nalbuphine hydrochloride","6412":"LPS exposure","6413":"LPS exposure","6414":"quetiapine 600 mg\/day","6415":"ropivacaine + diluted clonidine with saline","6416":"ropivacaine + diluted clonidine with saline","6417":"ropivacaine + diluted clonidine with saline","6418":"ropivacaine + diluted clonidine with saline","6419":"positive input","6420":"topical steroid","6421":"albuterol","6422":"albuterol","6423":"routine pharmacological treatment","6424":"routine","6425":"day-and-night closed-loop insulin","6426":"DFE 2 cm","6427":"RO (had external ring opened, hernial sac twisted and doubly ligated), ST (had hernial sac twisted and doubly ligated without opening the ring), DL (had double ligation of hernial sac without ring opening nor twisted) while SL (had single ligation of hernial sac with neither ring opening nor sac twisting)","6428":"D2, D3, D2\/D3","6429":"ultrabrief (at 8 times seizure threshold) RUL ECT","6430":" ultrabrief (at 8 times seizure threshold) RUL ECT","6431":"'one-time general consent' (asked written informed consent), 'opt-out plus' (had the opportunity to opt out by a form)","6432":"paravertebral block (PVB)","6433":"paravertebral block (PVB)","6434":"pre-workout dietary supplement (PWS) with p-synephrine (S); pre-workout dietary supplement (PWS) without p-synephrine","6435":"pre-workout dietary supplement (PWS) with p-synephrine (S); ","6436":"pre-workout dietary supplement (PWS) with p-synephrine (S); pre-workout dietary supplement (PWS) without p-synephrine (S);","6437":"pre-workout dietary supplement (PWS) with p-synephrine (S); pre-workout dietary supplement (PWS) without p-synephrine (S);","6438":"electroacupuncture plus western conventional medication (WCM)","6439":"electroacupuncture plus western conventional medication (WCM)","6440":"GnRH agonist","6441":"GnRH agonist","6442":"Vitrified group: COCs were exposed to VS1 and VS2, loaded on cryotops, vitrified in liquid nitrogen and then warmed in TCM-199 + 17.1% sucrose + 20% CS at 37 C for 1 min.","6443":" ramosetron (0.3mg; group C)","6444":"program and jogging based on health belief model (HBM) on sugar control in type 2 diabetic patients","6445":"program and jogging based on health belief model (HBM) on sugar control in type 2 diabetic patients","6446":"cassia fistula emulsion (CFE) ","6447":"cassia fistula emulsion (CFE) ","6448":"cassia fistula emulsion (CFE) ","6449":"mivacurium 250 \u03bcg\/kg","6450":"(A group) graft of right internal mammary artery to the anterior interventricular branch","6451":"(A group) graft of right internal mammary artery to the anterior interventricular branch","6452":"whole grain wheat sourdough bread","6453":"NIR to left forehead at F3 to right forehead at F4","6454":"Detomidine at 80kg\u22121 was administered to ten calves sublingually (GEL)","6455":"positive Twitter messages","6456":"resistance training (3x\/wk)","6457":"resistance training (3x\/wk)","6458":"appropriate weight (AW) trained (AWT) group","6459":"obesity (O) trained (OT) group","6460":"appropriate weight (AW) control (AWC) groups, overweight (OW) control (OWC) group","6461":"Information sessions plus digital resources","6462":"obesity (OT) group","6463":"at risk' group","6464":"at risk' group","6465":"peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks","6466":"cohort A, hCG application was performed two days before blastocyst transfer, ","6467":"younger adults","6468":"(ACU) sodium citrate dihydrate (Na-CIT) supplementation (0.5kg-1; chronic sodium citrate dihydrate (Na-CIT) (CHR) supplementation (0.1kg-1 for three days and 0.3kg-1 on the forth day 120;min pre-trial","6469":"(ACU) sodium citrate dihydrate (Na-CIT) supplementation (0.5kg-1; acute placebo (PLC-A),), and chronic placebo (PLC-C); chronic sodium citrate dihydrate (Na-CIT) (CHR) supplementation (0.1kg-1 for three days and 0.3kg-1 on the forth day 120;min pre-trial","6470":"a 14\u2010week behavioral intervention using video instructional materials, workbook and telephone coaching in behavioral management, pleasant events scheduling, and relaxation","6471":"walk for 5 minutes per hour for most waking hours for 24 weeks","6472":"control","6473":"(2) an experimental group trained at a heart rate intensity corresponding to ventilatory threshold 1 (VT-1) for 60 min\/day 3 times weekly on alternate days for 6 months using a cycle ergometer","6474":"6-month hypocaloric diet","6475":"multifactorial intervention to reduce falls among the oldest-old people","6476":"multifactorial intervention to reduce falls among the oldest-old people","6477":"questionnaires online","6478":"Digestive AdvantageTM Gas Defense Formula (GD) group","6479":"Digestive AdvantageTM Gas Defense Formula (GD) group","6480":"supine position immediately after 6.5 mg hyperbaric bupivacaine were injected (L group)","6481":"Digestive AdvantageTM Gas Defense Formula (GD) group","6482":"pregabalin 150","6483":"hogs being transported for 6 h","6484":"mofetil (MMF) with daclizumab (DZB)","6485":"10 grams cocoa powder and 10 grams milk powder","6486":"Group I received lignocaine 1% (9ml) with normal saline (1ml)","6487":"Group I received lignocaine 1% (9ml) with normal saline (1ml)","6488":"10 grams cocoa powder and 10 grams milk powder","6489":"10 grams cocoa powder and 10 grams milk powder","6490":"inhalative epinephrine","6491":"inhalative epinephrine","6492":"inhalative epinephrine","6493":"Before therapy- Sulphate-sulphide mineral water \"Mljec\u030canica\" plus kinesitherapy and electrotherapy","6494":"Sulphate-sulphide mineral water \"Mljec\u030canica\" plus kinesitherapy and electrotherapy","6495":" nutraceutical combination (NC)","6496":"taspoglutide 20 mg, titration to 30 mg (20\/30), 40 mg (20\/40)","6497":"taspoglutide 20 mg, titration to 30 mg (20\/30), 40 mg (20\/40)","6498":" abatacept","6499":"abatacept","6500":"fentanyl-midazolam-medetomidine (FMM)","6501":" group A (Rapid urease test (RUT) plus noninvasive tests)","6502":"fentanyl-midazolam-medetomidine (FMM)","6503":"fentanyl-midazolam-medetomidine (FMM)","6504":"acute bronchiolitis group (BG); conventional physical therapy (CPT) for airway clearance and nasotracheal suction","6505":"acute bronchiolitis group (BG); conventional physical therapy (CPT) for airway clearance and nasotracheal suction","6506":"CKD-828 2.5\/40 mg (who failed to respond after 4-week S-amlodipine 2.5 mg monotherapy)","6507":"CKD-828 2.5\/40 mg (who failed to respond after 4-week S-amlodipine 2.5 mg monotherapy)","6508":"CKD-828 2.5\/80 mg (who failed to respond after 4-week S-amlodipine 2.5 mg monotherapy)","6509":"oxycodone (OXY) 60mg oral","6510":"oxycodone (OXY) 60mg oral","6511":"parenteral nutrition (PN) (early PN)","6512":"administration via proximal-release pellets","6513":"p-prisms after training ","6514":"arthroscopic partial repair","6515":"VARA","6516":"VARA","6517":"p-prisms after training ","6518":"VARA","6519":"p-prisms after training ","6520":"subgingival instrumentation with an ultrasonic device using PVP-I (10%) as the cooling liquid (test group)","6521":"subgingival instrumentation with an ultrasonic device using PVP-I (10%) as the cooling liquid (test group)","6522":"group 1, the patients were given warfarin (INR) between 2-3) together with 80 mg aspirin daily for 3 months","6523":"group 1, the patients were given warfarin (INR) between 2-3) together with 80 mg aspirin daily for 3 months","6524":"mixed laparoscopy group (LPS)","6525":"group 1, the patients were given warfarin (INR) between 2-3) together with 80 mg aspirin daily for 3 months","6526":"mixed laparoscopy group (LPS)","6527":"arformoterol","6528":"arformoterol","6529":"Group 1 received 5 mg solifenacin per day","6530":"Plant sterols (PS)","6531":"dulaglutide (1.5 or 0.75 mg)","6532":"lubiprostone (24 mcg BID for CIC and OIC; 8 mcg BID for IBS-C)","6533":"lubiprostone (8 mcg BID for IBS-C)","6534":"triazolam 0.25 mg or 0.375 mg","6535":"triazolam 0.25 mg or 0.375 mg","6536":"Transcranial direct current stimulation (tDCS)","6537":"right dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS)","6538":"right dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS)","6539":"7 in the chest expansion exercise with transcutaneous electrical nerve stimulation (TENS) group (experimental group); 7 in the chest expansion exercise with placebo transcutaneous electrical nerve stimulation (TENS) (control group)","6540":"zinc as an adjunct treatment","6541":"7 in the chest expansion exercise with transcutaneous electrical nerve stimulation (TENS) group (experimental group)","6542":"standard behavioral weight loss; a technology\u2010based system combined with a monthly intervention telephone call (TECH) ; an enhanced technology\u2010based system combined with a monthly intervention telephone call (EN\u2010TECH)","6543":"laparoscopic (LP)","6544":"elosulfase alfa 2.0mg\/kg\/week (weekly)","6545":"single real session biparietal tDCS","6546":"Sodium phosphates (L-NaP) preparation","6547":"fatal other CV events","6548":"control group before intervention","6549":"peramivir (Rapiacta)","6550":"exercise group","6551":"acarbose","6552":"acarbose","6553":"patients with minimal-risk","6554":"PROMISE minimal-risk tool","6555":"F1 (fentanyl 1 mcg\/kg)","6556":"F1 (fentanyl 1 mcg\/kg)","6557":"F1 (fentanyl 1 mcg\/kg)","6558":"F1 (fentanyl 1 mcg\/kg)","6559":"F1 (fentanyl 1 mcg\/kg)","6560":"intervention group, involving home visits","6561":"intervention group, involving home visits","6562":"banner","6563":"banner plus news feed (Facebook)","6564":"banner","6565":"banner","6566":"patients with HLA-A*2402 ","6567":"patients with HLA-A*2402","6568":"patients with HLA-A*2402","6569":"G4: infrared plus neural mobilization","6570":"Neural Mob","6571":"Infrared","6572":"Infrared and Neural Mob.","6573":"G4: infrared plus neural mobilization","6574":"telephone-delivered weight loss intervention","6575":"men with BPH medication","6576":"repeat screening","6577":"men with BPH medication","6578":"Mini-midvastus","6579":"Mini-midvastus","6580":"intravenous infusion of salbutamol aerosol combined with magnesium sulfate, ","6581":"Mini-midvastus","6582":"Mini-midvastus","6583":"Ropivacaine","6584":"Abacavir\/lamivudine","6585":"Ropivacaine","6586":"Ropivacaine","6587":"Ropivacaine","6588":"Ropivacaine","6589":"Aripiprazole low-dose","6590":"Red meat\/refined grain diet ","6591":"Remifentanil 6 ng\/mL","6592":"Physical activity promotion programme","6593":"Remifentanil 6 ng\/mL","6594":"Olive oil-based lipid emulsion","6595":"Remifentanil 4 ng\/mL","6596":"Glecaprevir 300mg + pibrentasvir 120 mg + ribavirin ","6597":"Olive oil-based lipid emulsion","6598":"Glecaprevir 200mg + pibrentasvir 80 mg ","6599":"Tissue plasminogen activator + deoxyribonuclease ","6600":"Olive oil-based lipid emulsion","6601":"Deoxyribonuclease ","6602":"Pitavastatin","6603":"Tissue plasminogen activator + deoxyribonuclease ","6604":"Pitavastatin","6605":"DNA prime-rAd5 boost vaccine","6606":"Dietitian-Based Nutrition Education Strategy","6607":"Technetium-99m Tilmanocept","6608":"Technetium-99m Tilmanocept","6609":"Dietitian-Based Nutrition Education Strategy","6610":"Technetium-99m Tilmanocept","6611":"Nacadia\u00ae nature-based therapy","6612":"Nostril yoga breathing","6613":"Intensive lifestyle intervention","6614":"Breath awareness control session","6615":"Nostril yoga breathing","6616":"Breath awareness control session","6617":"Negative Cues","6618":"Negative Cues","6619":"Tartary buckwheat","6620":"Prolonged-release melatonin","6621":"Prolonged-release melatonin","6622":"Prolonged-release melatonin","6623":"Prolonged-release melatonin","6624":"Prolonged-release melatonin","6625":"Glucose-insulin-potassium","6626":"30\u00b0 head of bed elevation","6627":"Clopidogrel ","6628":"Home-based training with telemonitoring","6629":"Home-based training with telemonitoring","6630":"Home-based training with telemonitoring","6631":"Unsolvable task","6632":"Kaltenborn mobilization therapy","6633":"Healthy group","6634":"Fludarabine plus 2 Gy total body irradiation (Flu-TBI arm)","6635":"Fludarabine plus 2 Gy total body irradiation (Flu-TBI arm)","6636":"Fludarabine plus 2 Gy total body irradiation (Flu-TBI arm)","6637":"Women diagnosed with HF","6638":"Women diagnosed with HF","6639":"Supplemental Se","6640":"Gum-chewing group","6641":"Vonoprazan 10 mg","6642":"Vonoprazan 10 and 20 mg","6643":"Vitamin D3 40.000 IU (DD group) or Vitamin D3 20.000 IU (DP group)","6644":"8 Gy in a single fraction","6645":"Aripiprazole low-dose","6646":"Aripiprazole high-dose","6647":"Health education group ","6648":"Bodyweight-based exercise with blood flow restriction","6649":"12 week physical activity tailored program","6650":"Heavyweight mesh","6651":"Physical activity promotion programme","6652":"12 week physical activity tailored program","6653":"Tranexamic acid","6654":"Olive oil-based lipid emulsion","6655":"Tranexamic acid","6656":"Olive oil-based lipid emulsion","6657":"Pitavastatin","6658":"Pitavastatin","6659":"Follow-up invitation by telephone","6660":"Pitavastatin","6661":"Fentanyl","6662":"DNA prime-rAd5 boost vaccine","6663":"Fentanyl","6664":"Technetium-99m Tilmanocept","6665":"Multivitamin-mineral supplement","6666":"Intensive lifestyle intervention","6667":"Simvastatin-niacin treatment","6668":" Simvastatin-niacin treatment","6669":"Everolimus-eluting stent ","6670":"ATD","6671":"Everolimus-eluting stent ","6672":"Tartary buckwheat","6673":"Tartary buckwheat","6674":"Intravenous lidocaine","6675":"Work-related self-affirming implementation intention","6676":"Work-related self-affirming implementation intention","6677":"Work-related self-affirming implementation intention","6678":"Intravenous lidocaine","6679":"Glucose-insulin-potassium","6680":"Heavyweight mesh","6681":"Glucose-insulin-potassium","6682":"Glucose-insulin-potassium","6683":"45\u00b0 head of bed elevation","6684":"<65 years","6685":"<65 years","6686":"<65 years","6687":"Chest physiotherapy","6688":"Goal-directed therapy","6689":"Goal-directed therapy","6690":"Goal-directed therapy","6691":"Goal-directed therapy","6692":"Goal-directed therapy","6693":"Slow-stroke back massage","6694":"Slow-stroke back massage","6695":"Radical surgery + surgical wound surface injection ","6696":"Pre-activity movement control exercise programme","6697":"Dry-cured ham","6698":"GC1107-T5.0 diphtheria vaccine","6699":"GC1107-T7.5 diphtheria vaccine","6700":"GC1107-T5.0 diphtheria vaccine","6701":"GC1107-T5.0 diphtheria vaccine","6702":"GC1107-T5.0 diphtheria vaccine","6703":"Red wine","6704":"Ethanol solution","6705":"Chondroitin sulfate","6706":"Dexmedetomidine ","6707":"Dexmedetomidine ","6708":"Dexmedetomidine ","6709":"Dexmedetomidine ","6710":"Diabetes quality improvement intervention","6711":"PEG-based laxatives","6712":"PEG-based laxatives","6713":"PEG-based laxatives","6714":"Pentoxifylline ","6715":"Pentoxifylline ","6716":"Pentoxifylline ","6717":"Ginger","6718":"Ginger","6719":"Daily prednisone ","6720":"Daily prednisone ","6721":"Daily prednisone ","6722":"Exenatide ","6723":"Exenatide ","6724":"Exenatide ","6725":"Infliximab ","6726":"Infliximab ","6727":"Naproxen sodium + diphenhydramine (440mg\/25mg)","6728":"Naproxen sodium + diphenhydramine (440mg\/25mg)","6729":"Original-xLosartan","6730":"Original-xLosartan","6731":"Regular activity breaks","6732":"Regular activity breaks","6733":"Regular activity breaks","6734":"\u03b2-alanine ","6735":"ForsLeanTM","6736":"ForsLeanTM","6737":"ForsLeanTM","6738":"ForsLeanTM","6739":"Ethylene di-amine tetra-acetic acid","6740":"Ethylene di-amine tetra-acetic acid + Ethanol","6741":"Ethanol","6742":"Enhanced protein-energy provision","6743":"Enhanced protein-energy provision","6744":"Proanthocyanidin","6745":"Fluoride varnish","6746":"Fluoride varnish + proanthocyanidin ","6747":"Fluoride varnish + proanthocyanidin + casein phosphopeptide amorphous calcium phosphate","6748":"Cadium + 40 mg\/L taurine ","6749":"Ampicillin\/sulbactam","6750":"Ampicillin\/sulbactam","6751":"Computer-Aided Design\/Computer-Aided Manufacturing + numerical simulation","6752":"Ischaemia + vehicle","6753":"Ischaemia + vehicle","6754":"Long infusion of peptide ","6755":"Sublingual misoprostol and vaginal placebo ","6756":"Sublingual misoprostol and vaginal placebo ","6757":"Sublingual misoprostol and vaginal placebo ","6758":"Discharged 24 h after PM implant\/4\u20136 h after replacement","6759":"Integrated community case management of malaria and pneumonia","6760":"Integrated community case management of malaria and pneumonia","6761":"Integrated community case management of malaria and pneumonia","6762":"Coe-PakTM dressing","6763":"Coe-PakTM dressing","6764":"Coe-PakTM dressing","6765":"Coe-PakTM dressing","6766":"Coe-PakTM dressing","6767":"Cognitive behavioral therapy","6768":"Cognitive behavioral therapy","6769":"Budesonide ","6770":"Budesonide ","6771":"Acid etching + Transbond XT primer + transillumination","6772":" Rifampicin 600mg\/day+ vandetanib 300mg on day 10","6773":"Rifampicin 600mg\/day+ vandetanib 300mg on day 10","6774":" Itraconazole 200mg\/day on days 1\u201324 + vandetanib 300mg on day 4","6775":"Itraconazole 200mg\/day on days 1\u201324 + vandetanib 300mg on day 4","6776":"Rifampicin 600mg\/day+ vandetanib 300mg on day 10","6777":"Rifampicin 600mg\/day+ vandetanib 300mg on day 10","6778":"Moderate-intensity exercise training","6779":"Moderate-intensity exercise training","6780":"Facilitation of Local Stakeholder Groups on Equity in Neonatal Survival","6781":"Exogenous glucagon-like peptide-1 infusion","6782":"Exogenous glucagon-like peptide-1 infusion","6783":"Dhatri Avaleha","6784":"Dhatri Avaleha","6785":"ABP 501","6786":"ABP 501","6787":"ABP 501","6788":"Ruxolitinib","6789":"Ruxolitinib + erythropoiesis-stimulating agents","6790":"Nevirapine + Artemether-lumefantrine ","6791":"Nevirapine + Artemether-lumefantrine ","6792":"Nevirapine + Artemether-lumefantrine ","6793":"Nevirapine + Artemether-lumefantrine ","6794":"Nevirapine + Artemether-lumefantrine ","6795":"Reduced smoking","6796":"Nifedipine","6797":"Nifedipine","6798":"Computerized cognitive behavioral therapy for insomnia","6799":"Computerized cognitive behavioral therapy for insomnia","6800":"Invitation letter ","6801":"Invitation letter ","6802":"Human adipose-derived stromal\/stem cells","6803":"Human adipose-derived stromal\/stem cells","6804":"High flow CO2 warming system","6805":"High flow CO2 warming system","6806":"Peficitinib 100 mg","6807":"Peficitinib 50 mg","6808":"Real-Time Continuous Glucose Monitoring","6809":"Real-Time Continuous Glucose Monitoring","6810":"Real-Time Continuous Glucose Monitoring","6811":"TV while eating","6812":"Drug-eluting balloon + bare metal stent","6813":"VM group","6814":"yoga","6815":"VM group","6816":"methylprednisolone group","6817":"lignocaine group","6818":"isolated lumbar extension","6819":"EGBP","6820":"EGNBP","6821":"neuromuscular exercise","6822":"Salmeterol\/fluticasone propionate ","6823":"Micronutrient Supplementation","6824":"Micronutrient Supplementation","6825":"Micronutrient Supplementation","6826":"Micronutrient Supplementation","6827":"Kinesio taping group","6828":"Kinesio taping group","6829":"Keishibukuryogan ","6830":"Keishibukuryogan ","6831":"VM202 plasmid (8mg)","6832":"VM202 plasmid (8mg)","6833":"Goal-directed fluid therapy","6834":"Goal-directed fluid therapy","6835":"PNA FISH-generated laboratory data notification ","6836":"PNA FISH-generated laboratory data notification ","6837":"PNA FISH-generated laboratory data notification ","6838":"Ranitidine ","6839":"Behavioral obesity treatment","6840":"Behavioral obesity treatment","6841":"Guided group exercise intervention","6842":"Guided group exercise intervention","6843":"Abdominal muscle strengthening training","6844":"Abdominal muscle strengthening training","6845":"Trueview\u00ae laryngoscope","6846":"Trueview\u00ae laryngoscope","6847":"Trueview\u00ae laryngoscope","6848":"Trueview\u00ae laryngoscope","6849":"Trueview\u00ae laryngoscope","6850":"McCoy blade","6851":"Pradhamana Nasya +l Trayodashanga Kwatha + Madhu","6852":"Pradhamana Nasya + Trikatu + Triphala Churna","6853":"Full-preparation + finishing with diamond bur","6854":"Large drain","6855":"Large drain","6856":"Outpatient Foley catheter","6857":"Outpatient Foley catheter","6858":"Outpatient Foley catheter","6859":"Outpatient Foley catheter","6860":"All therapy session","6861":"Olodaterol 5 \u03bcg via Respimat\u00ae","6862":"Olodaterol 5 \u03bcg via Respimat\u00ae","6863":"Web-Based Tool to Support Shared Decision Making","6864":"Balanced solutions","6865":"Balanced solutions","6866":"Balanced solutions","6867":"Balanced solutions","6868":"Balanced solutions","6869":"Radiofrequency ablation","6870":"Radiofrequency ablation","6871":"Radiofrequency ablation","6872":"Esmolol ","6873":"Dexmedetomidine","6874":"Dexmedetomidine","6875":"Paracetamol 125 mg","6876":"Fluticasone furoate 200 mcg once daily","6877":"Fluticasone furoate 400 mcg","6878":"Ketoprofen","6879":"Hypertension telemonitoring-based service","6880":"Hypertension telemonitoring-based service","6881":"Hypertension telemonitoring-based service","6882":"Hypertension telemonitoring-based service","6883":"Learning therapy","6884":"Learning therapy","6885":"Learning therapy","6886":"Job coaching sessions","6887":"Job coaching sessions","6888":"Job coaching sessions","6889":"Ciclesonide + Levocetirizine","6890":"Ciclesonide + Levocetirizine","6891":"Ciclesonide + Levocetirizine","6892":"Sulphadoxine-pyrimethamine + azithromycin","6893":"Sulphadoxine-pyrimethamine + azithromycin","6894":"Exclusion group","6895":"Exclusion group","6896":"Exclusion group","6897":"TSST Stress group","6898":"Dose-dense oxaliplatin + Irinotecan ","6899":"Dose-dense oxaliplatin + Irinotecan ","6900":"Dose-dense oxaliplatin + Irinotecan ","6901":"Arthroscopy + exercise","6902":"Perioperative chemotherapy + surgery","6903":"Diet intervention","6904":"Diet intervention","6905":"Exercise intervention","6906":"Exercise intervention","6907":"Filmasartan","6908":"Valsartan","6909":"Fimasartan","6910":"Core rewarming ","6911":"Core rewarming ","6912":"Total parenteral nutrition + Sepsis Survival Campaign guidelines ","6913":"Total parenteral nutrition + Sepsis Survival Campaign guidelines ","6914":"Total parenteral nutrition + Sepsis Survival Campaign guidelines ","6915":"Total parenteral nutrition + Sepsis Survival Campaign guidelines","6916":"Total parenteral nutrition + Sepsis Survival Campaign guidelines ","6917":"Medication therapy management","6918":"Medication therapy management","6919":"Simulated Obstructive Sleep Apnea","6920":"Obstructive hypopnea","6921":"liberal RBC transfusion strategy (transfusion when hemoglobin levels decreased below 9 g\/dl)","6922":"Central apnea","6923":"Sensory-based food education","6924":"Dexmedetomidine ","6925":"Dexmedetomidine ","6926":"Dexmedetomidine ","6927":"Family empowerment","6928":"Mannoheptulose","6929":"Mannoheptulose","6930":"Mannoheptulose","6931":"Mannoheptulose","6932":"MSDC-0160","6933":"MSDC-0160","6934":"MSDC-0160","6935":"MSDC-0160","6936":"Traffic-related particulate matter","6937":"Traffic-related particulate matter","6938":"Traffic-related particulate matter","6939":"Traffic-related particulate matter","6940":"Traffic-related particulate matter","6941":"Additional consent for anesthesia ","6942":"Additional consent for anesthesia ","6943":"Dexmedetomidine plus ketamine (Group I)","6944":"Dexmedetomidine plus ketamine (Group I)","6945":"Standard treatment plus Mizoribine","6946":"Standard treatment plus Mizoribine","6947":"Standard treatment plus Mizoribine","6948":"Virgin olive oil (VOO)","6949":"Virgin olive oil (VOO)","6950":"Virgin olive oil (VOO)","6951":"Virgin olive oil (VOO) and Optimized virgin olive oil (OVOO)","6952":"Optimized virgin olive oil (OVOO)","6953":"Education on pulmonary rehabilitation (experimental group)","6954":"Magnesium sulfate","6955":"Maintenance treatment plus neurofeedback sessions","6956":"Maintenance treatment plus neurofeedback sessions","6957":"Discharged to home on digoxin","6958":"Discharged to home on digoxin","6959":"TAK-438","6960":"TAK-438","6961":"TAK-438","6962":"Weight-loss intervention","6963":"Weight-loss intervention","6964":"antidepressant users (ADM)","6965":"antidepressant users (ADM) - intermittent (ADM)","6966":"initial trial","6967":"3-tier's shared care (SC)","6968":"3-tier's shared care (SC)","6969":"3-tier's shared care (SC)","6970":"3-tier's shared care (SC)","6971":"inhalative epinephrine","6972":"HP (high protein) -Legume meal","6973":"higher adherence to energy goals","6974":"XLHA, single injection form","6975":"XLHA, single injection form","6976":"XLHA, single injection form","6977":"XLHA, single injection form","6978":"memory game with fruit","6979":"memory game with fruit","6980":"memory game with fruit","6981":"AXOS","6982":"AXOS","6983":"RTEC","6984":"exercise","6985":"AGE + exercise","6986":"Sulphate-sulphide mineral water \"Mljec\u030canica\" plus kinesitherapy and electrotherapy","6987":"Computer assisted learning","6988":"Computer assisted learning","6989":"Computer assisted learning","6990":"Extracorporeal shockwave therapy","6991":"Urinary kallidinogenase","6992":"Belatacept ","6993":"Whey protein","6994":"Soy protein","6995":"Whey protein","6996":"Individualized occupational therapy","6997":"Individualized occupational therapy","6998":"Elbow band","6999":"Wrist splint","7000":"Elbow band","7001":"Elbow sleeve ","7002":"Vitamin K + supplementation","7003":"Individual cognition and self-regulation processes intervention ","7004":"Remifentanil 0.3 \u03bcg\/kg\/min","7005":"Remifentanil 0.3 \u03bcg\/kg\/min","7006":"Dexmedetomidine + remifentanil 0.3 \u03bcg\/kg\/min","7007":"Atrial natriuretic peptide at postprandial phase","7008":"Atrial natriuretic peptide at postprandial phase","7009":"Atrial natriuretic peptide at postprandial phase","7010":"Probiotics ","7011":"Probiotics ","7012":"Probiotics ","7013":"Soybean meal + prebiotics","7014":"Soybean meal + prebiotics","7015":"Soybean meal + prebiotics","7016":"Alcohol consumption ","7017":"Space Balance 3D exercise program","7018":"Space Balance 3D exercise program","7019":"Dihydroartemisin-piperaquine + primaquine ","7020":"Dihydroartemisin-piperaquine + primaquine ","7021":"Dihydroartemisin-piperaquine + primaquine ","7022":"95 dB sound","7023":"20 min exposure time","7024":"Alternate day fasting","7025":"Alternate day fasting","7026":"Alternate day fasting","7027":"Calorie restriction ","7028":"40% FiO2","7029":"40% FiO2","7030":"40% FiO2","7031":"40% FiO2","7032":"Pramipexole ","7033":"Pramipexole ","7034":"Direct methods of suggestion","7035":"Indirect methods of suggestion","7036":"Direct methods of suggestion","7037":"Tofacitinib 5mg","7038":"Tofacitinib 5mg","7039":"Tofacitinib 5mg","7040":"Leukocyte-reduced Platelet-Rich Plasma ","7041":"Leukocyte-reduced Platelet-Rich Plasma","7042":"Deep tissue massage ","7043":"Deep tissue massage ","7044":"Deep tissue massage ","7045":"Medicines reconciliation","7046":"Oral ondansetron","7047":"Oral ondansetron","7048":"Oral ondansetron","7049":"Physiotherapist-guided Ambulant Activity Feedback","7050":"Whole-body vibration","7051":"Whole-body vibration","7052":"Whole-body vibration","7053":"Fast\u2010acting insulin aspart","7054":"Fast\u2010acting insulin aspart","7055":"Fast\u2010acting insulin aspart","7056":"IV diazepam + periprostatic nerve block","7057":"IV diazepam + periprostatic nerve block","7058":"Internet version questionnaire","7059":"Internet version questionnaire","7060":"Starting Early support group","7061":"Mistletoe preparation with lectin content ","7062":"Rosa centifolia petals + epigallocatechin gallate shampoo","7063":"Rosa centifolia petals + epigallocatechin gallate shampoo","7064":"Rosa centifolia petals + epigallocatechin gallate shampoo","7065":"Recombinant\u2010human chorionic gonadotropin","7066":"Bupivacaine + ketamine 0.5 mg\/kg","7067":"Bupivacaine + ketamine 0.5 mg\/kg","7068":"Bupivacaine + ketamine 0.5 mg\/kg","7069":"Bupivacaine + ketamine 0.5 mg\/kg","7070":"GSK961081 1,200 \u03bcg + \u03b22 blockade","7071":"Subcutaneous specific immunotherapy","7072":"Amifostine ","7073":"Amifostine ","7074":"Propofol ","7075":"Propofol ","7076":"IV Lidocaine ","7077":"IV Lidocaine ","7078":"IV Lidocaine ","7079":"Remifentanil ","7080":"Remifentanil ","7081":"Adherence support","7082":"Adherence support","7083":"Adherence support","7084":"Daily exercise","7085":"Daily exercise","7086":"10-week yoga program ","7087":"10-week yoga program ","7088":"10-week yoga program ","7089":"Smoking group","7090":"Smoking group","7091":"Smoking group","7092":"Smoking group","7093":"Humidified nasal high flow oxygen","7094":"Humidified nasal high flow oxygen","7095":"Humidified nasal high flow oxygen","7096":"Litesse\u00ae Ultra polydextrose  \u0301+ Bifidobacterium animalisssp. lactis 420","7097":"Bifidobacterium animalisssp.lactis 420","7098":"Needle straight insertion ","7099":"23-guage needles","7100":"21-guage needles","7101":"Fixed in vitro fertilization","7102":"Fixed in vitro fertilization","7103":"Fixed in vitro fertilization","7104":"Partially hydrolyzed guar gum","7105":"Partially hydrolyzed guar gum","7106":"Partially hydrolyzed guar gum","7107":"Internet intervention","7108":"Dalteparin","7109":"Dalteparin","7110":"Dalteparin","7111":"Dalteparin","7112":"Transcranial direct-current stimulation condition","7113":"Self-care compact disks","7114":"Self-care compact disks","7115":"Self-care compact disks","7116":"Desflurane ","7117":"Lavander oil","7118":"Black pepper oil","7119":"Black pepper oil","7120":"Exacto glass fiber post","7121":"Exacto glass fiber post","7122":"Exacto glass fiber post","7123":"Hydrofluoroalkane pressurised inhaler of budesonide\/formoterol","7124":"Budesonide\/formoterol dry-powder inhaler","7125":"Budesonide\/formoterol dry-powder inhaler","7126":"Budesonide\/formoterol dry-powder inhaler","7127":"Budesonide\/formoterol dry-powder inhaler","7128":"Doxazosin","7129":"S. boulardii","7130":"S. boulardii","7131":"S. boulardii","7132":"S. boulardii","7133":"e-cigarette glamorous adverts","7134":"e-cigarette glamorous adverts","7135":"Atracurium","7136":"Atracurium","7137":"Atracurium","7138":"Soy shake ","7139":"Soy shake","7140":"Soy shake","7141":"Biperiden","7142":"Biperiden","7143":"Biperiden","7144":"Transperitoneal laparoscopic ureterolithotomy","7145":"Transperitoneal laparoscopic ureterolithotomy","7146":"Transperitoneal laparoscopic ureterolithotomy","7147":"Personalised feedback on alcohol intake","7148":"Personalised feedback on alcohol intake","7149":"Soft chew tablet","7150":"Kinesio taping ","7151":"Kinesio taping ","7152":"Kinesio taping ","7153":"Fast-track group","7154":"Intervention program","7155":"Intervention program","7156":"Intervention program","7157":"Intervention program","7158":"Radioiodine fixed dose","7159":"Text messaging intervention","7160":"Text messaging intervention","7161":"Text messaging intervention","7162":"Text messaging intervention","7163":"Gutta-percha + AH26 ","7164":"Gutta-percha + AH26 ","7165":"Gutta-percha + mineral trioxide aggregate","7166":"Biosimilar adalimumab","7167":"Biosimilar adalimumab","7168":"Regular aerobic exercise","7169":"Regular aerobic exercise","7170":"Face-to-Face Education","7171":"Face-to-Face Education","7172":"Face-to-Face Education","7173":"Creatine Supplementation","7174":"Creatine Supplementation","7175":"Allopurinol","7176":"Allopurinol","7177":"Allopurinol","7178":"an alcohol-based hand rub - 3 months","7179":"preoperative oral sedation (diazepam)","7180":"ASLA-modified transepithelial PRK in the other","7181":"ASLA-modified transepithelial PRK in the other","7182":"ASLA-modified transepithelial PRK in the other","7183":"ASLA-modified transepithelial PRK in the other, conventional alcohol-assisted PRK in one eye (control)","7184":"The Feeding Practices and Structure Questionnaire (FPSQ)","7185":"The Feeding Practices and Structure Questionnaire (FPSQ)","7186":"The Feeding Practices and Structure Questionnaire (FPSQ)","7187":"The Feeding Practices and Structure Questionnaire (FPSQ)","7188":"The Feeding Practices and Structure Questionnaire (FPSQ)","7189":"ketamine 0.3 mg\/kg","7190":"Lactobacillus rhamnosus GG (LGG)","7191":"ramosetron (0.3mg; group C)","7192":"Lactobacillus rhamnosus GG (LGG)","7193":"ramosetron (0.3mg; group C)","7194":"Lactobacillus rhamnosus GG (LGG)","7195":"ramosetron (0.3mg; group C)","7196":"ramosetron (0.3mg; group C)","7197":"high-grain (HG) diet","7198":"high-grain (HG) diet","7199":"high-grain (HG) diet","7200":"cassia fistula emulsion (CFE) ","7201":"high-grain (HG) diet","7202":"high-grain (HG) diet","7203":"high-grain (HG) diet","7204":"high-grain (HG) diet","7205":"high-grain (HG) diet","7206":"cassia fistula emulsion (CFE) ","7207":"mivacurium 250 \u03bcg\/kg","7208":"control group (CG)","7209":"mivacurium 250 \u03bcg\/kg","7210":"mivacurium 250 \u03bcg\/kg","7211":"(A group) graft of right internal mammary artery to the anterior interventricular branch","7212":"SRIs (clomipramine and paroxetine)","7213":"whole grain wheat sourdough bread","7214":"near-infrared (NIR) light photobiomodulation (PBM) to left forehead at F3","7215":"heat Patch","7216":"NIR to left forehead at F3 to right forehead at F4,","7217":"heat Patch","7218":"Detomidine at 80 \u03bcg kg\u22121 was administered to ten calves sublingually (GEL)","7219":"multiple micronutrient (MM) supplementation","7220":"multiple micronutrient (MM) supplementation","7221":"multiple micronutrient (MM) supplementation","7222":"positive ratings for positive Twitter messages","7223":"positive Twitter messages","7224":"wood-burning clay cookstove","7225":"positive Twitter messages","7226":"wood-burning clay cookstove","7227":"resistance training (3x\/wk)","7228":"wood-burning clay cookstove","7229":"appropriate weight (AW) control (AWC) and trained (AWT) groups, ","7230":"appropriate weight (AWT) groups, overweight (OWT) group obesity (OT) group","7231":"at risk' group","7232":"peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks","7233":"peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks","7234":"Saccharomyces boulardii","7235":"Saccharomyces boulardii","7236":"cohort B, the administration of hCG occurred just prior to embryo transfer on day 5 with top blastocysts and with non-top blastocysts ","7237":"relaxation group","7238":"post phase","7239":"The spiritual care program including supportive presence and support for religious rituals was implemented for 3 days.","7240":"intrathecal 15 mg 0.5% ropivacaine with 25 mcg fentanyl (Group RF)","7241":"(ACU) sodium citrate dihydrate (Na-CIT) supplementation (0.5kg-1; chronic sodium citrate dihydrate (Na-CIT) (CHR) supplementation (0.1kg-1 for three days and 0.3kg-1 on the forth day 120;min pre-trial","7242":"RT, radiation","7243":"intrathecal 15 mg 0.5% ropivacaine with 25 mcg fentanyl (Group RF)","7244":"metoclopramide (10mg\/2ml, slow injection)","7245":"walk for 5 minutes per hour for most waking hours for 24 weeks","7246":"amlodipine (5 mg\/day)","7247":"walk for 5 minutes per hour for most waking hours for 24 weeks","7248":"amlodipine (5 mg\/day)","7249":"amlodipine (5 mg\/day)","7250":"6-month hypocaloric diet","7251":"positive biopsy","7252":"childbirth companion intervention","7253":"childbirth companion intervention","7254":"liberal RBC transfusion strategy (transfusion when hemoglobin levels decreased below 9 g\/dl)","7255":"childbirth companion intervention","7256":"sit-stand desks (SSDs)","7257":"sit-stand desks (SSDs)","7258":"liberal RBC transfusion strategy (transfusion when hemoglobin levels decreased below 9 g\/dl)","7259":"liberal RBC transfusion strategy (transfusion when hemoglobin levels decreased below 9 g\/dl)","7260":"Digestive AdvantageTM Gas Defense Formula (GD) group","7261":"sit-stand desks (SSDs)","7262":"Bilastine updosing to 80 mg","7263":"bupropion plus nicotine replacement therapy (NRT)","7264":"bupropion plus nicotine replacement therapy (NRT)","7265":"memory enhancement training (MET)","7266":"memory enhancement training (MET)","7267":"memory enhancement training (MET)","7268":"memory enhancement training (MET)","7269":"experimental period - acupuncture","7270":"experimental period - acupuncture","7271":"experimental period - acupuncture","7272":"neurofeedback behavioural therapy (NFB)","7273":"neurofeedback behavioural therapy (NFB)","7274":"gluten-containing","7275":"gluten-containing","7276":"gluten-containing","7277":"cognitive-behavioral group therapy","7278":"cognitive-behavioral group therapy","7279":"GlideScope\u00ae video laryngoscope (G)","7280":"GlideScope\u00ae video laryngoscope (G)","7281":"etoricoxib","7282":"T-EO formulation","7283":"Preoperative oxygen delivery","7284":"Preoperative oxygen delivery","7285":"Preoperative oxygen delivery","7286":"Comprehensive Hand Repetitive Intensive Strength Training plus general rehabilitation therapy","7287":"Comprehensive Hand Repetitive Intensive Strength Training plus general rehabilitation therapy","7288":"Tailored intervention","7289":"Low-frequency right prefrontal followed by low-frequency left temporal rTMS","7290":"Injection of adrenaline solution and bipolar electrocoagulation (A + BE)","7291":"Porous \u03b2-calcium pyrophosphate (\u03b2-CPP) plus autograft","7292":"Porous \u03b2-calcium pyrophosphate (\u03b2-CPP) plus autograft","7293":"Gatorade and polyethylene glycol (PEG) with or without bisacodyl","7294":"Gatorade and polyethylene glycol (PEG) without bisacodyl","7295":"Gatorade and polyethylene glycol (PEG) without bisacodyl","7296":"Aero-Step group (DSUAS) group","7297":"Lopinavir\/ritonavir (LPV\/r) and raltegravir (RAL)","7298":"Lopinavir\/ritonavir (LPV\/r) and raltegravir (RAL)","7299":"Lopinavir\/ritonavir (LPV\/r) and raltegravir (RAL)","7300":"Continuous hyperfractionated accelerated radiation therapy ","7301":"Ashwagandha (Withania somnifera [L.] Dunal)","7302":"Ashwagandha (Withania somnifera [L.] Dunal)","7303":"Ashwagandha (Withania somnifera [L.] Dunal)","7304":"Dairy treatment","7305":"Dairy treatment","7306":"Dairy treatment","7307":"Alcohol-assisted epithelial removal","7308":"Alcohol-assisted epithelial removal","7309":"Positive psychology-based intervention","7310":"Positive psychology-based intervention","7311":"Lactobacillus GG","7312":"Lactobacillus GG","7313":"Frankincense extract","7314":"Semelil (ANGIPARSTM)","7315":"Semelil (ANGIPARSTM)","7316":"Usual care","7317":"Usual care","7318":"Use of positive end-expiratory pressure","7319":"Use of positive end-expiratory pressure","7320":"5, 7, and 10 cmH2O of positive end-expiratory pressure","7321":"Vilazodone","7322":"Vilazodone","7323":"Propofol","7324":"Propofol","7325":"Cone of pressure flap","7326":"Vaginal estriol plus viable Lactobacillus acidophilus KS400 ","7327":"Intracutaneous sterile water injection","7328":"Intracutaneous sterile water injection","7329":"Intracutaneous sterile water injection","7330":"Intracutaneous sterile water injection","7331":"Dexmedetomidine group","7332":"Dexmedetomidine group","7333":"Dexmedetomidine group","7334":"Non-social priming groups","7335":"Non-social priming groups","7336":"Intranasal salmon calcitonin","7337":"Methotrexate","7338":"Methotrexate","7339":"Methotrexate","7340":"Tacrolimus","7341":"Tacrolimus","7342":"Tacrolimus","7343":"BITT ","7344":"BITT ","7345":"Intensive lifestyle intervention (ILI) group","7346":"Intensive lifestyle intervention (ILI) group","7347":"Pap smear at enrollment","7348":"Pap smear at enrollment","7349":"Pap smear at enrollment","7350":"Atorvastatin","7351":"Atorvastatin","7352":"Mulberry leaf pellet at 600 g\/hd\/d","7353":"Mulberry leaf pellet at 600 g\/hd\/d","7354":"Mulberry leaf pellet at 600 g\/hd\/d","7355":"Resilon + Epiphany","7356":"Resilon + Epiphany","7357":"Creatine supplementation ","7358":"Creatine supplementation ","7359":"Creatine supplementation ","7360":"Creatine supplementation ","7361":"Video e-learning ","7362":"Religious programs","7363":"Religious programs","7364":"Religious programs","7365":"Calcitriol + Hind-limb suspension","7366":"Calcitriol + Hind-limb suspension","7367":"Calcitriol + Hind-limb suspension","7368":"Heated infusions ","7369":"Heated infusions ","7370":"Chitosan","7371":"Digital stereopsis","7372":"Bispectral monitoring ","7373":"Bispectral monitoring ","7374":"Bispectral monitoring ","7375":"Bispectral monitoring ","7376":"Phlebotomy training programme","7377":"Phlebotomy training programme","7378":"Motivational interviewing ","7379":"Dexamethasone + ramosetron","7380":"Aliskiren","7381":"Aliskiren","7382":"Aliskiren","7383":"Lixisenatide","7384":"Physical Activity Promotion Programme","7385":"Physical Activity Promotion Programme","7386":"Physical Activity Promotion Programme","7387":"Intravenous line placement","7388":"Intravenous line placement","7389":"<65 years","7390":"<65 years","7391":"Goal-directed therapy","7392":"Slow-stroke back massage","7393":"Slow-stroke back massage","7394":"Slow-stroke back massage","7395":"Radical surgery + surgical wound surface injection ","7396":"Radical surgery + surgical wound surface injection ","7397":"Radical surgery + surgical wound surface injection ","7398":"Pre-activity movement control exercise programme","7399":"Pre-activity movement control exercise programme","7400":"Pre-activity movement control exercise programme","7401":"Pre-invitation leaflet","7402":"Pre-invitation leaflet","7403":"Dry-cured ham","7404":"Dry-cured ham","7405":"Dry-cured ham","7406":"GC1107-T5.0 diphtheria vaccine","7407":"Beer","7408":"Dexmedetomidine ","7409":"Dexmedetomidine ","7410":"Dexmedetomidine ","7411":"PEG-based laxatives","7412":"PEG-based laxatives","7413":"Pentoxifylline ","7414":"Pentoxifylline ","7415":"Pentoxifylline ","7416":"Ginger","7417":"Ginger","7418":"Ginger","7419":"Ginger","7420":"Daily prednisone ","7421":"Exenatide ","7422":"Exenatide ","7423":"Exenatide ","7424":"Infliximab ","7425":"Infliximab ","7426":"Infliximab ","7427":"Naproxen sodium + diphenhydramine (440 mg\/50 mg)","7428":"Naproxen sodium + diphenhydramine (440mg\/50mg)","7429":"Naproxen sodium + diphenhydramine (440mg\/50mg)","7430":"Naproxen sodium + diphenhydramine (440mg\/50mg)","7431":"Original-xLosartan","7432":"Regular activity breaks","7433":"\u03b2-alanine ","7434":"\u03b2-alanine ","7435":"\u03b2-alanine ","7436":"\u03b2-alanine ","7437":"\u03b2-alanine ","7438":"ForsLeanTM","7439":"ForsLeanTM","7440":"ForsLeanTM","7441":"Ethylene di-amine tetra-acetic acid","7442":"Ethylene di-amine tetra-acetic acid","7443":"Ethylene di-amine tetra-acetic acid + Ethanol","7444":"Enhanced protein-energy provision","7445":"Enhanced protein-energy provision","7446":"Enhanced protein-energy provision","7447":"Enhanced protein-energy provision","7448":"Proanthocyanidin","7449":"Ampicillin\/sulbactam","7450":"Ischaemia + vehicle","7451":"Ischaemia + vehicle","7452":"Sublingual misoprostol and vaginal placebo ","7453":"Discharged 24 h after PM implant\/4\u20136 h after replacement","7454":"Discharged 24 h after PM implant\/4\u20136 h after replacement","7455":"Cognitive behavioral therapy","7456":"Budesonide ","7457":"Transbond XT self-etching primer + transillumination.","7458":"High-maintenance demand training","7459":"ABP 501","7460":"Ruxolitinib","7461":"Nevirapine + Artemether-lumefantrine ","7462":"Nifedipine","7463":"Nifedipine","7464":"Human adipose-derived stromal\/stem cells","7465":"Human adipose-derived stromal\/stem cells","7466":"High flow CO2 warming system","7467":"Peficitinib 50 mg","7468":"Peficitinib 150 mg","7469":"TV while eating","7470":"Drug-eluting balloon + bare metal stent","7471":"2.67\u20133.3 Gy fractions","7472":"PO esomeprazole ","7473":"Bio-active peptide supplement","7474":"Bio-active peptide supplement","7475":"Neolix ","7476":"Low molecular weight heparin ","7477":"Dexamethasone + epinephrine","7478":"Zoledronic acid","7479":"Telavancin ","7480":"Acupressure at distal points","7481":"glucosamine sulfate 1500 mg daily ","7482":"after Computer-based auditory training (CBAT) intervention","7483":"forest group - cognitive behavior therapy (CBT)-based psychotherapy plus pharmacotherapy","7484":"forest group - cognitive behavior therapy (CBT)-based psychotherapy plus pharmacotherapy","7485":"Wii Fit balance training (WBT)","7486":"Wii Fit balance training (WBT)","7487":"doctor of medicine (MD) degree","7488":"intubating laryngeal mask airway (ILMA) ","7489":"(PD) early-stage Parkinson's disease patients without cognitive or sensory impairment were investigated OFF medication","7490":"single operator hand-on-syringe (HS) needle technique","7491":"Superion\u00ae (63\/120, 52.5%)","7492":"Superion\u00ae (63\/120, 52.5%)","7493":"CIMT 3 hours of CIMT supervised by a therapist","7494":"intervention - e-learning programme on work-related stress","7495":"ankle-foot orthosis (AFO) group","7496":"pulsed radiofrequency (PRF) lumbar sympathectomy ","7497":"T3 concentrate feed containing 20% digestible crude protein","7498":"cerebral swelling on CT scan","7499":"daclizumab beta","7500":"daclizumab beta","7501":"daclizumab beta","7502":"vildagliptin\/metformin SPC (single-pill combination)","7503":"shared decision-making intervention (SDMI) for substance-dependent patients","7504":"caffeine (CAF)","7505":"weight management intervention targeting diet and physical activity plus usual care","7506":"femoral bone preparation with compaction on 1 side","7507":"femoral bone preparation with compaction on 1 side","7508":"Clinical full model","7509":"Diazepam + chlorpheniramine","7510":"Formoterol 4.5 \u03bcg","7511":"Formoterol 9 \u03bcg","7512":"Combining nateglinide + vildagliptin","7513":"pH 3.8 saliva ","7514":"pH 5.8 saliva","7515":"Protemp 3 Garan","7516":"i\u2013gelTM","7517":"Zinc","7518":"Mitoxantrone","7519":"Mitoxantrone","7520":"Rebamipide","7521":"Moderate intensity aerobic exercise","7522":"Moderate intensity aerobic exercise","7523":"Naloxegol ","7524":"Naloxegol ","7525":"Naloxegol ","7526":"Dexmedetomidine in hypertensive patients ","7527":"Lauroyl arginate\u2010containing mouthrinse ","7528":"Lauroyl arginate\u2010containing mouthrinse ","7529":"Oligosaccharides Prebiotic Formula","7530":"Mobile phone intervention","7531":"Simulation and team-training program","7532":"Simulation and team-training program","7533":"Andrographis paniculata","7534":"Mesalazine ","7535":"Heroin","7536":"Heroin","7537":"Active anodal tsDCS","7538":"Atorvastatin","7539":"Atorvastatin","7540":"Albendazole","7541":"Summative assessments","7542":"Comprehensive lifestyle intervention","7543":"Natural childbirth preparation","7544":"Natural childbirth preparation","7545":"Erlotinib ","7546":"Zingiber officinale 800 mg","7547":"Zingiber officinale 800 mg","7548":"N-acetylcysteine","7549":"N-acetylcysteine","7550":"Fentanyl + nitroglycerin","7551":"Risedronate 2.5 mg","7552":"Yoga","7553":"D-serine","7554":"D-serine","7555":"Candesartan","7556":"Ramipril ","7557":"Biofeedback ","7558":"Biofeedback ","7559":"Biofeedback ","7560":"Oral supplement 1","7561":"Oral supplement 2","7562":"Acupuncture ","7563":"Acupuncture ","7564":" group NC), receiving the analgesic treatment without receiving counseling","7565":"(group C), had to receive patient-centered counseling throughout the hospitalization","7566":"children whose mothers reported alcohol consumption during pregnancy","7567":"children whose mothers reported alcohol consumption during pregnancy","7568":"thiopental sodium-saline [TS]","7569":"receive daily GH treatment (GHT)","7570":"'baseball' suture technique","7571":"'baseball' suture technique","7572":"Elevation Training Masks\u00a9 (ETM) , ","7573":"craniosacral therapy (IG)","7574":"alginate impressions","7575":"alginate impressions","7576":"self-image at recruitment (early image) ","7577":"intensive lifestyle intervention group (ILG)","7578":"Drug-eluting balloon + bare metal stent","7579":"Daikenchuto (TJ-100)","7580":"Daikenchuto (TJ-100)","7581":"Daikenchuto (TJ-100)","7582":"Ferumoxytol ","7583":"Ferumoxytol ","7584":"Chronic Pain Self-Management Program in the Community","7585":"Clinic for Low-Income Patients","7586":"Chronic Pain Self-Management Program in the Community","7587":"Clinic for Low-Income Patients","7588":"2.67\u20133.3 Gy fractions","7589":"Lidocaine 1.0% 3 ml + epinephrine 5 \u03bcg","7590":"Lidocaine 1.0% 3 ml + epinephrine 5 \u03bcg","7591":"PO esomeprazole for 1 day","7592":"PO esomeprazole for 1 day","7593":"PO esomeprazole ","7594":"IV esomeprazole ","7595":"Bio-active peptide supplement","7596":"SWIFT Cast","7597":"SWIFT Cast","7598":"SWIFT Cast","7599":"SWIFT Cast","7600":"SafeSider","7601":"Neolix ","7602":"Autologous stem cell therapy","7603":"Autologous stem cell therapy","7604":"Autologous stem cell therapy","7605":"Autologous stem cell therapy","7606":"Low molecular weight heparin ","7607":"Placebo","7608":"Fluoxetine ","7609":"Shared decision-making strategy","7610":"Brodalumab ","7611":"Insurance","7612":"Insurance","7613":"Dexamethasone + salbutamol","7614":"Dexamethasone + epinephrine","7615":"Zoledronic acid","7616":"Zoledronic acid","7617":"Telavancin ","7618":"Telavancin ","7619":"Telavancin ","7620":"Allogeneic mesenchymal precursor cells","7621":"Allogeneic mesenchymal precursor cells","7622":"Acupressure at local points","7623":"Acupressure at local points","7624":"Acupressure at distal points","7625":"glucosamine sulfate 1500 mg daily ","7626":"glucosamine sulfate 1500 mg daily ","7627":"after Computer-based auditory training (CBAT) intervention","7628":"forest group - cognitive behavior therapy (CBT)-based psychotherapy plus pharmacotherapy","7629":"Wii Fit balance training (WBT)","7630":"male","7631":"intubating laryngeal mask airway (ILMA)","7632":"intubating laryngeal mask airway (ILMA) ","7633":"intubating laryngeal mask airway (ILMA) ","7634":"intubating laryngeal mask airway (ILMA) ","7635":"G-CSF plus stem-cell infusion","7636":"G-CSF","7637":"G-CSF plus stem-cell infusion","7638":"Haitian women","7639":"Latina women","7640":"(PD) early-stage Parkinson's disease patients without cognitive or sensory impairment were investigated OFF medication","7641":"(PD) early-stage Parkinson's disease patients without cognitive or sensory impairment were investigated OFF medication","7642":"(PD) early-stage Parkinson's disease patients without cognitive or sensory impairment were investigated OFF medication","7643":"single operator hand-on-syringe (HS) needle technique","7644":"CIMT 3 hours of CIMT supervised by a therapist","7645":"CIMT 3 hours of CIMT supervised by a therapist","7646":"CIMT 3 hours of CIMT supervised by a therapist","7647":"occluded exercise trained (Occl-Ex)","7648":"occluded exercise trained (Occl-Ex)","7649":"occluded-sedentary (Occl-Sed)","7650":"1,800 mg gepotidacin Healthy Volunteers","7651":"1,800 mg gepotidacin Healthy Volunteers","7652":"1,800 mg gepotidacin Healthy Volunteers","7653":"diaphragm with lubricant gel (MIRA)","7654":"diaphragm with lubricant gel (MIRA)","7655":"diaphragm with lubricant gel (MIRA)","7656":"Johannesburg","7657":"Harare ","7658":"intervention - e-learning programme on work-related stress","7659":"Completers","7660":"intervention - e-learning programme on work-related stress","7661":"ankle-foot orthosis (AFO) group","7662":"ankle-foot orthosis (AFO) group","7663":"Tai Chi Chuan group","7664":"Tai Chi Chuan group","7665":"Tai Chi Chuan group","7666":"high fidelity mannequins","7667":"high fidelity mannequins","7668":"delayed-release DMF 240 mg TID","7669":"delayed-release DMF 240 mg BID","7670":"delayed-release DMF 240 mg TID","7671":"delayed-release DMF 240 mg BID","7672":"delayed-release DMF 240 mg BID","7673":"MgSO4 - Group I, II, III: 30. 40\/ 50 mg\/kg","7674":"MgSO4 - Group III: 50 mg\/kg","7675":"MgSO4 - Group I, II, III: 30. 40\/ 50 mg\/kg","7676":"MgSO4 - Group I, II, III: 30. 40\/ 50 mg\/kg","7677":"pulsed radiofrequency (PRF) lumbar sympathectomy ","7678":"T3 concentrate feed containing 20% digestible crude protein","7679":"T2, T3, and T4 that received concentrate feed containing 16, 20, and 24% digestible crude protein","7680":"anti-leukotriene agent (pranlukast)","7681":"anti-leukotriene agent (pranlukast)","7682":"anti-leukotriene agent (pranlukast)","7683":"anti-leukotriene agent (pranlukast)","7684":"high CSF pressures (\u2265200 mmH2O)","7685":"High adherence; taking \u226580% of medication","7686":"relapse prevention (RP) intervention group (full completers)","7687":"relapse prevention (RP) intervention group (full completers)","7688":"Stimulant plus non-stimulant, guanfacine extended release (GXR) ","7689":"Stimulant plus non-stimulant, guanfacine extended release (GXR) ","7690":"Stimulant plus non-stimulant, guanfacine extended release (GXR)","7691":"T1 noise exposure (0\u20135 years of exposure)","7692":"CE-chirp ABR","7693":"T1 noise exposure (0\u20135 years of exposure)","7694":"daclizumab beta","7695":"daclizumab beta","7696":"real needles","7697":"real needles","7698":"vildagliptin\/metformin SPC (single-pill combination)","7699":"shared decision-making intervention (SDMI) for substance-dependent patients","7700":"shared decision-making intervention (SDMI) for substance-dependent patients","7701":"shared decision-making intervention (SDMI) for substance-dependent patients","7702":"shared decision-making intervention (SDMI) for substance-dependent patients","7703":"caffeine (CAF)","7704":"caffeine (CAF)","7705":"caffeine (CAF)","7706":"caffeine (CAF)","7707":"weight management intervention targeting diet and physical activity plus usual care","7708":"weight management intervention targeting diet and physical activity plus usual care","7709":"weight management intervention targeting diet and physical activity plus usual care","7710":"chronic kidney disease (CKD) group","7711":"renal tubular epithelial cells","7712":"adults or children completing the study","7713":"before intervention","7714":"participants in the current study","7715":"participants in the current study","7716":"femoral bone preparation with compaction on 1 side","7717":"arthroscopic partial repair","7718":"moderate-to-vigorous physical activity (MVPA) guideline","7719":"mixed laparoscopy group (LPS)","7720":"mixed laparoscopy group (LPS)","7721":"mixed laparoscopy group (LPS)","7722":"mixed laparoscopy group (LPS)","7723":"mixed laparoscopy group (LPS)","7724":"Terrestrial Trunked Radio Telecommunications System (TETRA)","7725":"insulin aspart 0.1 units\/kg or 0.2 units\/kg","7726":"rivastigmine","7727":"rivastigmine capsule and patch","7728":"rivastigmine capsule and patch with concurrent Vascular risk factors (VRF)","7729":"Transcranial direct current stimulation (tDCS)","7730":"Transcranial direct current stimulation (tDCS)","7731":"tempo-pace synchronized audio-devices with personalized music playlists + usual-care (rhythmic auditory stimulation (RAS)","7732":"7 in the chest expansion exercise with transcutaneous electrical nerve stimulation (TENS) group (experimental group)","7733":"laparoscopic (LP)","7734":"Sodium phosphates (L-NaP) preparation","7735":"Sodium phosphates (L-NaP) preparation","7736":"Sodium phosphates (L-NaP) preparation","7737":"peramivir (Rapiacta)","7738":"peramivir (Rapiacta)","7739":"patient drug adherence information (PDAI)","7740":"patient drug adherence information (PDAI)","7741":"dexamethasone 8 mg (Group D)","7742":"40 g of type 2 RS (HAM-RS2)","7743":"40 g of type 2 RS (HAM-RS2)","7744":"40 g of type 2 RS (HAM-RS2)","7745":"40 g of type 2 RS (HAM-RS2)","7746":"40 g of type 2 RS (HAM-RS2)","7747":"40 g of type 2 RS (HAM-RS2)","7748":"40 g of type 2 RS (HAM-RS2)","7749":"40 g of type 2 RS (HAM-RS2)","7750":"doxazosin","7751":"finasteride","7752":"dutasteride","7753":"tadalafil 5 mg","7754":"tadalafil ","7755":"doxazosin, placebo","7756":"tadalafil\/finasteride group","7757":"telephone-delivered weight loss intervention","7758":"telephone-delivered weight loss intervention","7759":"Fly-in, Fly-out (FIFO) settings","7760":"intravenous infusion of salbutamol aerosol combined with magnesium sulfate, budesonide atomization inhalation","7761":"intravenous infusion of salbutamol aerosol combined with magnesium sulfate, budesonide atomization inhalation","7762":"intravenous infusion of salbutamol aerosol combined with magnesium sulfate, ","7763":"intravenous infusion of salbutamol aerosol combined with magnesium sulfate, ","7764":"Abacavir\/lamivudine","7765":"Abacavir\/lamivudine","7766":"Aripiprazole low-dose","7767":"Aripiprazole low-dose","7768":"Aripiprazole high-dose","7769":"Physical activity promotion programme","7770":"Physical activity promotion programme","7771":"Physical activity promotion programme","7772":"Olive oil-based lipid emulsion","7773":"Olive oil-based lipid emulsion","7774":"DNA prime-rAd5 boost vaccine","7775":"Everolimus-eluting stent ","7776":"Everolimus-eluting stent ","7777":"Everolimus-eluting stent ","7778":"Work-related self-affirming implementation intention","7779":"Glucose-insulin-potassium","7780":"Glucose-insulin-potassium","7781":"Glucose-insulin-potassium","7782":"45\u00b0 head of bed elevation","7783":"45\u00b0 head of bed elevation","7784":"30\u00b0 head of bed elevation","7785":"45\u00b0 head of bed elevation","7786":"Angelica keiskei ","7787":"Clopidogrel ","7788":"Clopidogrel ","7789":"Home-based training with telemonitoring","7790":"Online Smoking Cessation Program","7791":"Online Smoking Cessation Program","7792":"Online Smoking Cessation Program","7793":"Online Smoking Cessation Program","7794":"Multi-component physical activity ","7795":"Betamethasone valerate medicated plaster (Betesil\u00ae)","7796":"Betamethasone valerate medicated plaster (Betesil\u00ae)","7797":"Betamethasone valerate medicated plaster (Betesil\u00ae)","7798":"Supplemental Se","7799":"Supplemental Se","7800":"Gum-chewing group","7801":"Gum-chewing group","7802":"Gum-chewing group","7803":"Vonoprazan 10 and 20 mg","7804":"Vonoprazan 10 and 20 mg","7805":"Vitamin D3 40.000 IU (DD group) or Vitamin D3 20.000 IU (DP group)","7806":"8 Gy in a single fraction","7807":"Myopic defocus group and Hyperopic defocus group ","7808":"Myopic defocus group and Hyperopic defocus group ","7809":"Bodyweight-based exercise with blood flow restriction","7810":"Bodyweight-based exercise with blood flow restriction","7811":"Bodyweight-based exercise with blood flow restriction","7812":"12 week physical activity tailored program","7813":"Oral carbohydrate group or oral rehydration solution group","7814":"Oral carbohydrate group or oral rehydration solution group","7815":"Oral carbohydrate group or oral rehydration solution group","7816":"Fentanyl","7817":"Fentanyl","7818":"Fentanyl","7819":"Multivitamin-mineral supplement","7820":"CT-PFNECII plus second-line chemotherapy (combination group)","7821":"Intravenous lidocaine","7822":"Physical exercise classes group ","7823":"Physical exercise classes group ","7824":"Physical exercise classes group ","7825":"Heavyweight mesh","7826":"therapy with adalimumab in addition to MTX","7827":"therapy with adalimumab in addition to MTX","7828":"on-time patient","7829":"on time patient","7830":"Mestizo group","7831":"nalbuphine hydrochloride in addition to levobupivacaine","7832":"nalbuphine hydrochloride in addition to levobupivacaine","7833":"nalbuphine + levobupivacaine","7834":"chlorhexidine + xylitol ","7835":"honey group","7836":"quetiapine 300 mg\/day","7837":"ropivacaine + diluted clonidine with saline","7838":"positive input","7839":"Nordic diet","7840":"methylprednisolone","7841":"methylprednisolone","7842":"routine pharmacological treatment","7843":"routine","7844":"80% LT","7845":"120% LT and 80% LT","7846":"80%LT","7847":"2-weekly and 4-weekly D2-treated groups","7848":"ultrabrief (at 8 times seizure threshold) RUL ECT","7849":"'one-time general consent' (asked written informed consent), 'opt-out plus' (had the opportunity to opt out by a form)","7850":"paravertebral block (PVB)","7851":"paravertebral block (PVB)","7852":"paravertebral block (PVB)","7853":"pre-workout dietary supplement (PWS) without p-synephrine, pre-workout dietary supplement (PWS) with p-synephrine (S);","7854":"pre-workout dietary supplement (PWS) with p-synephrine (S); ","7855":"electroacupuncture plus western conventional medication (WCM)","7856":"GnRH agonist","7857":"GnRH agonist","7858":"VS1 group: COCs were exposed to vitrification solution 1 (VS1) containing 7.5% ethylene glycol [EG] + 7.5% dimethyl sulfoxide [DMSO] + 20% calf serum [CS] in TCM-199 at 37 C for 5 min; VS1 + VS2 group: COCs were exposed to VS1 for 5 min followed by VS2 (15% EG + 15% DMSO + 17.1% sucrose + 20% CS) at 37 C for 45\u201360 sec; ","7859":"CE-chirp ABR","7860":"CE-chirp ABR","7861":"One therapy session","7862":"One therapy session","7863":"All therapy session","7864":"Olodaterol 10 \u03bcg via Respimat\u00ae","7865":"Olodaterol 10 \u03bcg via Respimat\u00ae","7866":"real needles","7867":"Olodaterol 10 \u03bcg via Respimat\u00ae","7868":"vildagliptin\/metformin SPC (single-pill combination) 50\/250 mg bid","7869":"Web-Based Tool to Support Shared Decision Making","7870":"vildagliptin\/metformin SPC (single-pill combination)","7871":"Balanced solutions","7872":"Radiofrequency ablation","7873":"Radiofrequency ablation","7874":"caffeine (CAF)","7875":"Dexmedetomidine","7876":"weight management intervention targeting diet and physical activity plus usual care","7877":"Repetitive transcranial magnetic stimulation","7878":"acute gastroenteritis (AG) group","7879":"Paracetamol 250 mg","7880":"metastatic and secondary carcinoma (MC) group","7881":"renal tubular epithelial cells","7882":"Paracetamol 250 mg","7883":"renal tubular epithelial cells","7884":"Fluticasone furoate 200 mcg twice a day ","7885":"Fluticasone furoate 200 mcg","7886":"Fluticasone furoate 400 mcg","7887":"participants in the current study","7888":"Ketoprofen","7889":"femoral bone preparation with compaction on 1 side","7890":"femoral bone preparation with compaction on 1 side","7891":"Hypertension telemonitoring-based service","7892":"National Lung Screening Trial (NLST)","7893":"Learning therapy","7894":"computerized tomography","7895":"Learning therapy","7896":"intervention - 8 sessions of consultation for delivery preparation","7897":"Job coaching sessions","7898":"Job coaching sessions","7899":"intervention group","7900":"Job coaching sessions","7901":"Ciclesonide + Levocetirizine","7902":"women in the three groups","7903":"Ciclesonide + Levocetirizine","7904":"1 mg morphine sulfate diluted by 4 cc normal saline 0.5% using nebulizer once daily for 5 days","7905":"Sulphadoxine-pyrimethamine + azithromycin","7906":"1 mg morphine sulfate diluted by 4 cc normal saline 0.5% using nebulizer once daily for 5 days","7907":"Sulphadoxine-pyrimethamine + azithromycin","7908":"Sulphadoxine-pyrimethamine + azithromycin","7909":"Exclusion group","7910":"Three groups: thinking protocol, the GPP, or both","7911":"Exclusion group","7912":"Dose-dense oxaliplatin + Irinotecan ","7913":"group II used chlorhexidine (CHX) followed by hydrogen peroxide (H2O2) 1.5%","7914":"Dose-dense oxaliplatin + Irinotecan ","7915":"group III used hydrogen peroxide (H2O2) 1.5% followed by chlorhexidine (CHX)","7916":"preeclamptics without vitamin supplements (group A) and with vitamin supplements (group B)","7917":"Arthroscopy + exercise","7918":"preeclamptics with vitamin supplements (group B)","7919":"Perioperative chemotherapy + surgery","7920":"Diet intervention","7921":"Diet intervention","7922":"Hot + Cooling conditions","7923":"Hot + Cooling conditions","7924":"Exercise - Hot + Cooling conditions","7925":"bisoprolol","7926":"Fimasartan","7927":"Valsartan","7928":"bisoprolol","7929":"bisoprolol","7930":"Core rewarming ","7931":"Clearfil SE Bond (0)","7932":"Core rewarming ","7933":"cecal ligation and puncture (CLP) - bone marrow-derived mononuclear cells (BMDMC)","7934":"Total parenteral nutrition + Sepsis Survival Campaign guidelines ","7935":"Medication therapy management","7936":"High adherence; taking \u226580% of medication","7937":"Medication therapy management","7938":"immediate recurrence of atrial premature beats (IRAPB) - after Catheter Ablation for Atrial Fibrillation","7939":"Simulated Obstructive Sleep Apnea","7940":"High Basal HB levels","7941":"Obstructive hypopnea","7942":"Central apnea","7943":"Roux-en-Y (R-Y) reconstruction after distal gastrectomy","7944":"Sensory-based food education","7945":"lisdexamfetamine dimesylate (LDX) - forced-dose study","7946":"Cadium + 20 mg\/L taurine","7947":"lisdexamfetamine dimesylate (LDX) - forced-dose study","7948":"Sensory-based food education","7949":"Dexmedetomidine ","7950":"mental clinical nursing pathway care","7951":"Computer-Aided Design\/Computer-Aided Manufacturing + numerical simulation","7952":"Computer-Aided Design\/Computer-Aided Manufacturing + numerical simulation","7953":"mental clinical nursing pathway care","7954":"Computer-Aided Design\/Computer-Aided Manufacturing + numerical simulation","7955":"Computer-Aided Design\/Computer-Aided Manufacturing + numerical simulation","7956":"Dexmedetomidine ","7957":"Family empowerment","7958":"umeclidinium\/vilanterol (UMEC\/VI)","7959":"Long infusion of peptide ","7960":"ON medication","7961":"Sublingual misoprostol and vaginal placebo ","7962":"Sublingual misoprostol and vaginal placebo ","7963":"ON medication","7964":"Mannoheptulose","7965":"observation group: combined MPR-CTU (multi-planar reconstruction (MPR) image post-processing technique-computed tomography (CT) urography (CTU))","7966":"Mannoheptulose","7967":"observation group: combined MPR-CTU (multi-planar reconstruction (MPR) image post-processing technique-computed tomography (CT) urography (CTU))","7968":"MSDC-0160","7969":"Discharged 24 h after PM implant\/4\u20136 h after replacement","7970":"Integrated community case management of malaria and pneumonia","7971":"Integrated community case management of malaria and pneumonia","7972":"Integrated community case management of malaria and pneumonia","7973":"intervention group","7974":"Additional consent for anesthesia ","7975":"Additional consent for anesthesia ","7976":"Bupivacaine (Group I)","7977":"sleepwalkers","7978":"sleepwalkers","7979":"continuous control of Pcuff","7980":"Cognitive behavioral therapy","7981":"Cognitive behavioral therapy","7982":"Cognitive behavioral therapy","7983":"Standard treatment plus Mizoribine","7984":"Bupivacaine (Group I)","7985":"Budesonide ","7986":"Continuous rPTH1-34 (group 2)","7987":"Budesonide ","7988":"Budesonide ","7989":"Continuous rPTH1-34 (group 2)","7990":"Transbond XT self-etching primer + direct illumination","7991":"Bloemfontein site","7992":"Magnesium sulfate","7993":"using oral contraceptive pills at enrollment","7994":"having had sex without using a condom in the 4-week interval before drug measurement","7995":"28 days of oral SRT2104 (2.0 g\/day)","7996":"Magnesium sulfate","7997":"Magnesium sulfate","7998":"Maintenance treatment plus neurofeedback sessions","7999":"28 days of oral SRT2104 (2.0 g\/day)","8000":"experimental FEC-D (fluorouracil-docetaxel)","8001":"Maintenance treatment plus neurofeedback sessions","8002":"Hyaluronic acid + chondroitin sulfate ","8003":"Hyaluronic acid + chondroitin sulfate ","8004":"Hyaluronic acid + chondroitin sulfate ","8005":"Hyaluronic acid + chondroitin sulfate ","8006":"Moderate-intensity exercise training","8007":"adolescents (trained and untrained)","8008":"Weight-loss intervention","8009":"adolescents (trained and untrained)","8010":"Pradhamana Nasya + Trikatu + Triphala Churna","8011":"antidepressant users (ADM)","8012":"early surgery <24 hours","8013":"early surgery <24 hours","8014":"Exogenous glucagon-like peptide-1 infusion","8015":"antidepressant users (ADM)","8016":"Dhatri Avaleha","8017":"Dhatri Avaleha","8018":"Dhatri Avaleha","8019":"simulator-learning","8020":"glargine 300 U\/ml (Gla-300)","8021":"glargine 300 U\/ml (Gla-300)","8022":"glargine 300 U\/ml (Gla-300)","8023":"initial trial","8024":"DCS D-cycloserine first","8025":"ABP 501","8026":"DCS D-cycloserine first","8027":"initial trial","8028":"ABP 501","8029":"morning (AM) PEG (polyethylene glycol) solution","8030":"morning (AM) PEG (polyethylene glycol) solution","8031":"Single incision laparoscopic surgery (SILS) cholecystectomy (group 1)","8032":"morning (AM) PEG (polyethylene glycol) solution","8033":"HP (high protein) -Legume meal","8034":"HP (high protein) -Legume meal","8035":"PEG-IFN \u03b1-2a - 24 weeks","8036":"HP (high protein) -Legume meal","8037":"Single incision laparoscopic surgery (SILS) cholecystectomy (group 1)","8038":"HP (high protein) -Legume meal","8039":"endovascular treatment","8040":"endovascular treatment","8041":"Nifedipine","8042":"endovascular treatment","8043":"endovascular treatment","8044":"Computerized cognitive behavioral therapy for insomnia","8045":"Standard treatment plus Mizoribine","8046":"Human adipose-derived stromal\/stem cells","8047":"Large drain","8048":"Moderate-intensity exercise training","8049":"Human adipose-derived stromal\/stem cells","8050":"High flow CO2 warming system","8051":"High flow CO2 warming system","8052":"Moderate-intensity exercise training","8053":"High flow CO2 warming system","8054":"Large drain","8055":"Peficitinib 150 mg","8056":"Moderate-intensity exercise training","8057":"Peficitinib 100 mg","8058":"Real-Time Continuous Glucose Monitoring","8059":"Real-Time Continuous Glucose Monitoring","8060":"TV while eating","8061":"TV while eating","8062":"Drug-eluting balloon + bare metal stent","8063":"Drug-eluting balloon + bare metal stent","8064":"Daikenchuto (TJ-100)","8065":"Exogenous glucagon-like peptide-1 infusion","8066":"Daikenchuto (TJ-100)","8067":"Ferumoxytol ","8068":"Ferumoxytol ","8069":"Chronic Pain Self-Management Program in the Community","8070":"Chronic Pain Self-Management Program in the Community","8071":"2.67\u20133.3 Gy fractions","8072":"2.67\u20133.3 Gy fractions","8073":"Lidocaine 1.0% 3 ml + epinephrine 5 \u03bcg","8074":"PO esomeprazole","8075":"PO esomeprazole for 1 day","8076":"Dhatri Avaleha","8077":"Bio-active peptide supplement","8078":"Bio-active peptide supplement","8079":"Bio-active peptide supplement","8080":"ProTaper Universal system","8081":"ProTaper Universal system","8082":"Autologous stem cell therapy","8083":"Low molecular weight heparin","8084":"Low molecular weight heparin + Insulin","8085":"Low molecular weight heparin","8086":"High-maintenance demand training","8087":"initial trial","8088":"Brodalumab ","8089":"Insurance","8090":"Dexamethasone + epinephrine","8091":"Dexamethasone + salbutamol","8092":"Zoledronic acid","8093":"Zoledronic acid","8094":"Telavancin ","8095":"Allogeneic mesenchymal precursor cells","8096":"Allogeneic mesenchymal precursor cells","8097":"Allogeneic mesenchymal precursor cells","8098":"Allogeneic mesenchymal precursor cells","8099":"3-tier's shared care (SC)","8100":"Allogeneic mesenchymal precursor cells","8101":"3-tier's shared care (SC)","8102":"Acupressure at local points","8103":"Acupressure at distal points","8104":"temephos","8105":"glucosamine sulfate 1500 mg daily ","8106":"glucosamine sulfate 1500 mg daily ","8107":"involvement of significant others","8108":"after Computer-based auditory training (CBAT) intervention","8109":"forest group - cognitive behavior therapy (CBT)-based psychotherapy plus pharmacotherapy","8110":"forest group - cognitive behavior therapy (CBT)-based psychotherapy plus pharmacotherapy","8111":"Wii Fit balance training (WBT)","8112":"Wii Fit balance training (WBT)","8113":"Wii Fit balance training (WBT)","8114":"letters","8115":"offered a book; by email","8116":"age group 45-65 years ","8117":"yoga","8118":"lignocaine group","8119":"isolated lumbar extension","8120":"low demanding\/high responsive feeding style","8121":"high demanding\/low responsive feeding style","8122":"huxin group","8123":"huxin group","8124":"huxin group","8125":"neuromuscular exercise","8126":"single operator hand-on-syringe (HS) needle technique","8127":"ACE-I + Calcium Antagonist fixed dose","8128":"single operator hand-on-syringe (HS) needle technique","8129":"Salmeterol\/fluticasone propionate ","8130":"Superion\u00ae (63\/120, 52.5%)","8131":"CIMT 3 hours of CIMT supervised by a therapist","8132":"Salmeterol\/fluticasone propionate ","8133":"ACE-I + Calcium Antagonist fixed dose","8134":"CIMT 3 hours of CIMT supervised by a therapist","8135":"occluded-sedentary (Occl-Sed)","8136":"occluded exercise trained (Occl-Ex)","8137":"Kinesio taping group","8138":"Kinesio taping group","8139":"occluded-sedentary (Occl-Sed)","8140":"subjects who did not experienced vomiting after the 1,800-mg gepotidacin dose","8141":"Kinesio taping group","8142":"Harare ","8143":"Keishibukuryogan ","8144":"VM202 plasmid (8mg)","8145":"VM202 plasmid (16mg)","8146":"VM202 plasmid (8mg)","8147":"VM202 plasmid (8mg)","8148":"intervention - e-learning programme on work-related stress","8149":"Goal-directed fluid therapy","8150":"Goal-directed fluid therapy","8151":"Goal-directed fluid therapy","8152":"Baduanjin groups","8153":"Tai Chi Chuan group","8154":"PNA FISH-generated laboratory data notification ","8155":"cerebral swelling on CT scan","8156":"PNA FISH-generated laboratory data notification ","8157":"high fidelity mannequins","8158":"high fidelity mannequins","8159":"high fidelity mannequins","8160":"Omeprazole twice\u2010daily ","8161":"Omeprazole once\u2010daily ","8162":"Omeprazole once\u2010daily ","8163":"Behavioral obesity treatment","8164":"MgSO4 - Group I, II, III: 30. 40\/ 50 mg\/kg","8165":"MgSO4 - Group I, II, III: 30. 40\/ 50 mg\/kg","8166":"Guided group exercise intervention","8167":"Health check","8168":"pulsed radiofrequency (PRF) lumbar sympathectomy ","8169":"Health check","8170":"pulsed radiofrequency (PRF) lumbar sympathectomy ","8171":"Abdominal muscle strengthening training","8172":"T2, T3, and T4 that received concentrate feed containing 16, 20, and 24% digestible crude protein","8173":"T2, T3, and T4 that received concentrate feed containing 16, 20, and 24% digestible crude protein","8174":"anti-leukotriene agent (pranlukast)","8175":"Pradhamana Nasya + Trikatu + Triphala Churna","8176":"cerebral swelling on CT scan","8177":"Pradhamana Nasya + Trikatu + Triphala Churna","8178":"cerebral swelling on CT scan","8179":"Transcranial Random Noise Stimulation","8180":"High adherence; taking \u226580% of medication","8181":"High adherence; taking \u226580% of medication","8182":"High adherence; taking \u226580% of medication","8183":"Grinding with diamond bur ","8184":"Grinding with diamond bur ","8185":"relapse prevention (RP) intervention group (full completers)","8186":"relapse prevention (RP) intervention group (full and partial completers)","8187":"Family empowerment","8188":"relapse prevention (RP) intervention group (full completers)","8189":"Stimulant plus non-stimulant, guanfacine extended release (GXR) ","8190":"Roux-en-Y (R-Y) reconstruction after distal gastrectomy","8191":"lisdexamfetamine dimesylate (LDX) - flexible-dose study","8192":"study group","8193":"mental clinical nursing pathway care","8194":"mental clinical nursing pathway care","8195":"umeclidinium\/vilanterol (UMEC\/VI)","8196":"umeclidinium\/vilanterol (UMEC\/VI)","8197":"ON medication","8198":"observation group: combined MPR-CTU (multi-planar reconstruction (MPR) image post-processing technique-computed tomography (CT) urography (CTU))","8199":"vitamin K in acupoint Spleen-6","8200":"Children in the intervention group had a choice of two online games to play at home over a period of four weeks","8201":"intervention group","8202":"patients with nightmares","8203":"computerized tomography","8204":"group A - 21 to 35 years","8205":"group B - 35 to 50 years","8206":"Continuous rPTH1-34 (group 2)","8207":"baseline","8208":"liking the color of the pill","8209":"couples: educational workshop","8210":"1 mg morphine sulfate diluted by 4 cc normal saline 0.5% using nebulizer once daily for 5 days","8211":"experimental FEC-D (fluorouracil-docetaxel)","8212":"1 mg morphine sulfate diluted by 4 cc normal saline 0.5% using nebulizer once daily for 5 days","8213":"1 mg morphine sulfate diluted by 4 cc normal saline 0.5% using nebulizer once daily for 5 days","8214":"Three groups: thinking protocol, the GPP, or both","8215":"experimental FEC-D (fluorouracil-docetaxel)","8216":"early surgery <24 hours","8217":"I\/V Human allogeneic mesenchymal stem cells (allo-hMSCs) 200M","8218":"I\/V Human allogeneic mesenchymal stem cells (allo-hMSCs) 100M","8219":"simulator-learning","8220":"simulator-learning","8221":"group II used chlorhexidine (CHX) followed by hydrogen peroxide (H2O2) 1.5%","8222":"glargine 300 U\/ml (Gla-300)","8223":"DCS D-cycloserine first","8224":"Exercise - Hot condition","8225":"Hot + Cooling conditions","8226":"morning (AM) PEG (polyethylene glycol) solution","8227":"bisoprolol","8228":"morning (AM) PEG (polyethylene glycol) solution","8229":"bisoprolol","8230":"Clearfil SE Bond","8231":"Clearfil SE Bond with no Epigallocatechin gallate (EGCG)","8232":"PEG-IFN \u03b1-2a - 24 weeks","8233":"PEG-IFN \u03b1-2a - 24 weeks","8234":"immediate recurrence of atrial premature beats (IRAPB) - after Catheter Ablation for Atrial Fibrillation","8235":"immediate recurrence of atrial premature beats (IRAPB) - after Catheter Ablation for Atrial Fibrillation","8236":"pathological complete response (pCR)","8237":"computerized tomography","8238":"computerized tomography","8239":"computerized tomography","8240":"computerized tomography","8241":"intervention - 8 sessions of consultation for delivery preparation","8242":"intervention group","8243":"baseline","8244":"baseline","8245":"mothers' age","8246":"after intervention","8247":"I\/V Human allogeneic mesenchymal stem cells (allo-hMSCs) 200M","8248":"Outpatient Foley catheter","8249":"Outpatient Foley catheter","8250":"Humidified nasal high flow oxygen","8251":"Humidified nasal high flow oxygen","8252":"Humidified nasal high flow oxygen","8253":"Formoterol","8254":"Aerobic exercise","8255":"Litesse\u00ae Ultra polydextrose  \u0301+ Bifidobacterium animalisssp. lactis 420","8256":"Bifidobacterium animalisssp. lactis 420","8257":"Litesse\u00ae Ultra polydextrose ","8258":"Bifidobacterium animalisssp.lactis 420","8259":"23-guage needles","8260":"23-guage needles","8261":"23-guage needles","8262":"Esmolol","8263":"Repetitive transcranial magnetic stimulation","8264":"Fixed in vitro fertilization","8265":"Paracetamol 250 mg","8266":"Partially hydrolyzed guar gum","8267":"abnormal finding","8268":"Partially hydrolyzed guar gum","8269":"Paracetamol 250 mg","8270":"MCA sphenoidal segment (M1) difficult exposure","8271":"Fluticasone furoate 200 mcg","8272":"Transcranial direct-current stimulation condition","8273":"Transcranial direct-current stimulation condition","8274":"Transcranial direct-current stimulation condition","8275":"Self-care compact disks","8276":"Learning therapy","8277":"Desflurane ","8278":"Lavander oil","8279":"Black pepper oil","8280":"Ciclesonide + Levocetirizine","8281":"Exacto glass fiber post + Reforpin accessories","8282":"Exacto glass fiber post + Reforpin accessories","8283":"Hydrofluoroalkane pressurised inhaler of budesonide\/formoterol","8284":"Budesonide\/formoterol dry-powder inhaler","8285":"Sulphadoxine-pyrimethamine + azithromycin","8286":"Doxazosin","8287":"S. boulardii","8288":"e-cigarette healthy adverts","8289":"Arthroscopy + exercise","8290":"e-cigarette glamorous adverts","8291":"e-cigarette glamorous adverts","8292":"e-cigarette healthy adverts","8293":"Atracurium","8294":"Soy shake","8295":"Biperiden","8296":"Core rewarming ","8297":"Biperiden","8298":"Biperiden","8299":"Transperitoneal laparoscopic ureterolithotomy","8300":"Transperitoneal laparoscopic ureterolithotomy","8301":"Transperitoneal laparoscopic ureterolithotomy","8302":"Medication therapy management","8303":"Personalised feedback on alcohol intake","8304":"Soft chew tablet","8305":"Soft chew tablet","8306":"Soft chew tablet","8307":"Sensory-based food education","8308":"Intervention program","8309":"Dexmedetomidine ","8310":"Text messaging intervention","8311":"Stress condition","8312":"Stress condition","8313":"Stress condition","8314":"Stress condition","8315":"Gutta-percha + new endodontic cement ","8316":"Biosimilar adalimumab","8317":"Biosimilar adalimumab","8318":"Biosimilar adalimumab","8319":"Regular aerobic exercise","8320":"Face-to-Face Education","8321":"Face-to-Face Education","8322":"Dexmedetomidine plus ketamine (Group I)","8323":"Creatine Supplementation","8324":"Dexmedetomidine plus ketamine (Group I)","8325":"Allopurinol","8326":"Allopurinol","8327":"Bupivacaine (Group I)","8328":"Allopurinol","8329":"an alcohol-based hand rub - 3 months","8330":"an alcohol-based hand rub - 3 months","8331":"preoperative oral sedation (diazepam)","8332":"ASLA-modified transepithelial PRK in the other","8333":"ASLA-modified transepithelial PRK in the other","8334":"Education on pulmonary rehabilitation (experimental group)","8335":"ASLA-modified transepithelial PRK in the other","8336":"The Feeding Practices and Structure Questionnaire (FPSQ)","8337":"Magnesium sulfate","8338":"Daily intake of synbiotic (SYN)","8339":"Daily intake of synbiotic (SYN)","8340":"The Feeding Practices and Structure Questionnaire (FPSQ)","8341":"The Feeding Practices and Structure Questionnaire (FPSQ)","8342":"propofol 0.25 mg\/kg, ","8343":"16-week lifestyle intervention","8344":"Lactobacillus rhamnosus GG (LGG)","8345":"Lactobacillus rhamnosus GG (LGG)","8346":"high-grain (HG) diet","8347":"initial trial","8348":"high-grain (HG) diet","8349":"high-grain (HG) diet","8350":"high-grain (HG) diet","8351":"Single incision laparoscopic surgery (SILS) cholecystectomy (group 1)","8352":"high-grain (HG) diet","8353":"three cycles of IP before (arm C), after CCRT with IP (arm D)","8354":"three cycles of IP before (arm C), after CCRT with IP (arm D)","8355":"greater attendance","8356":"more frequent self monitoring","8357":"conventional hospital-based care","8358":"higher adherence to exercise","8359":"heat Patch","8360":"heat Patch","8361":"multiple micronutrient (MM) supplementation","8362":"memory game with fruit","8363":"multiple micronutrient (MM) supplementation","8364":"memory game with fruit","8365":"multiple micronutrient (MM) supplementation","8366":"Large drain","8367":"wood-burning clay cookstove","8368":"bihevioral variables","8369":"wood-burning clay cookstove","8370":"wood-burning clay cookstove","8371":"grade I according to the asymmetry of cervical rotation - ultrasound and massage therapy for 30 minutes, in conjunction with passive stretching exercises, 3 times a week","8372":"grade III according to the asymmetry of cervical rotation - ultrasound and massage therapy for 30 minutes, in conjunction with passive stretching exercises, 3 times a week","8373":"Saccharomyces boulardii","8374":"AGE","8375":"Saccharomyces boulardii","8376":"Computer assisted learning","8377":"Saccharomyces boulardii","8378":"Computer assisted learning","8379":"Saccharomyces boulardii","8380":"TAU plus up to twelve sessions of CBT","8381":"TAU plus up to twelve sessions of CBT","8382":"The spiritual care program including supportive presence and support for religious rituals was implemented for 3 days.","8383":"Extracorporeal shockwave therapy","8384":"Extracorporeal shockwave therapy","8385":"Urinary kallidinogenase","8386":"intrathecal 15 mg 0.5% ropivacaine with 25 mcg fentanyl (Group RF)","8387":"intrathecal 15 mg 0.5% ropivacaine with 25 mcg fentanyl (Group RF)","8388":"Raloxifene ","8389":"Raloxifene ","8390":"Raloxifene ","8391":"Raloxifene ","8392":"Raloxifene ","8393":"amlodipine (5 mg\/day)","8394":"Soy protein","8395":"amlodipine (5 mg\/day)","8396":"Whey protein","8397":"Whey protein","8398":"sit-stand desks (SSDs)","8399":"Individualized occupational therapy","8400":"sit-stand desks (SSDs)","8401":"Individualized occupational therapy","8402":"sit-stand desks (SSDs)","8403":"TSH \u22652.2 \u03bcIU\/mL","8404":"migalastat","8405":"Elbow sleeve ","8406":"sit-stand desks (SSDs)","8407":"migalastat","8408":"transdiagnostic Internet-based maintenance treatment (TIMT) low high education level","8409":"transdiagnostic Internet-based maintenance treatment (TIMT) - anxiety disorder","8410":"Vitamin K + supplementation","8411":"recreationally endurance trained - men","8412":"Intervention + targeting environmental-level factors","8413":"recreationally endurance trained - women","8414":"Intervention + targeting environmental-level factors","8415":"Intervention + targeting environmental-level factors","8416":"Remifentanil 0.3 \u03bcg\/kg\/min","8417":"Dexmedetomidine + remifentanil 0.3 \u03bcg\/kg\/min","8418":"Atrial natriuretic peptide at postprandial phase","8419":"omeprazole (20 mg)","8420":"omeprazole (20 mg)","8421":"Atrial natriuretic peptide at postprandial phase","8422":"mesalamine at 2.4 g\/day (pH-2.4 g)","8423":"Probiotics ","8424":"Probiotics ","8425":"Probiotics ","8426":"Soybean meal ","8427":"Soybean meal + prebiotics","8428":"Alcohol consumption + H. pylori ","8429":"Alcohol consumption + H. pylori ","8430":"Alcohol consumption ","8431":"Space Balance 3D exercise program","8432":"95 dB sound","8433":"Alternate day fasting","8434":"Exercise ","8435":"40% FiO2","8436":"Pramipexole ","8437":"Tofacitinib 5mg","8438":"Tofacitinib 5mg","8439":"Tofacitinib 10 mg","8440":"Citrus sinensis oil inhalation","8441":"Leukocyte-reduced Platelet-Rich Plasma ","8442":"Leukocyte-reduced Platelet-Rich Plasma ","8443":"Leukocyte-reduced Platelet-Rich Plasma ","8444":"Oral ondansetron","8445":"Oral ondansetron","8446":"Oral ondansetron","8447":"Mindfulness-based cognitive therapy ","8448":"Physiotherapist-guided Ambulant Activity Feedback","8449":"Social media","8450":"Whole-body vibration","8451":"Fast\u2010acting insulin aspart","8452":"Fast\u2010acting insulin aspart","8453":"huxin group","8454":"huxin group","8455":"IV diazepam + periprostatic nerve block","8456":"neuromuscular exercise","8457":"neuromuscular exercise","8458":"IV diazepam + periprostatic nerve block","8459":"Internet version questionnaire","8460":"ACE-I + Calcium Antagonist fixed dose","8461":"Starting Early support group","8462":"Starting Early support group","8463":"Salmeterol\/fluticasone propionate ","8464":"Micronutrient Supplementation","8465":"Rosa centifolia petals + epigallocatechin gallate shampoo","8466":"Kinesio taping group","8467":"Rosa centifolia petals + epigallocatechin gallate shampoo","8468":"Rosa centifolia petals + epigallocatechin gallate shampoo","8469":"Atopalm MLE Cream ","8470":"Keishibukuryogan ","8471":"Recombinant\u2010human chorionic gonadotropin","8472":"Recombinant\u2010human chorionic gonadotropin","8473":"Recombinant\u2010human chorionic gonadotropin","8474":"Group exercise program","8475":"Bupivacaine + ketamine 0.5 mg\/kg","8476":"Goal-directed fluid therapy","8477":"Bupivacaine + ketamine 0.5 mg\/kg","8478":"GSK961081 1,200 \u03bcg + \u03b22 blockade","8479":"GSK961081 1,200 \u03bcg + \u03b22 blockade","8480":"GSK961081 1,200 \u03bcg + \u03b22 blockade","8481":"GSK961081 400 \u03bcg + \u03b22 blockade","8482":"Subcutaneous specific immunotherapy","8483":"GSK961081 400 \u03bcg + \u03b22 blockade","8484":"Subcutaneous specific immunotherapy","8485":"PNA FISH-generated laboratory data notification ","8486":"Subcutaneous specific immunotherapy","8487":"Omeprazole twice\u2010daily ","8488":"Amifostine ","8489":"Omeprazole twice\u2010daily ","8490":"Propofol ","8491":"Behavioral obesity treatment","8492":"Behavioral obesity treatment","8493":"Propofol ","8494":"Behavioral obesity treatment","8495":"IV Lidocaine ","8496":"IV Lidocaine ","8497":"IV Lidocaine ","8498":"Guided group exercise intervention","8499":"IV Lidocaine ","8500":"Pentacalcium hydroxy-triphosphate (repeated dose)","8501":"Pentacalcium hydroxy-triphosphate (repeated dose)","8502":"Remifentanil ","8503":"Remifentanil ","8504":"Pradhamana Nasya + Trikatu + Triphala Churna","8505":"Daily exercise","8506":"Daily exercise","8507":"Daily exercise","8508":"Daily exercise","8509":"Daily exercise","8510":"Group exercise program","8511":"10-week yoga program ","8512":"Large drain","8513":"Outpatient Foley catheter","8514":"Smoking group","8515":"baseline","8516":"morning (AM) PEG (polyethylene glycol) solution","8517":"experimental FEC-D (fluorouracil-docetaxel)","8518":"sleepwalkers","8519":"PEG-IFN \u03b1-2a - 24 weeks","8520":"GPP","8521":"thinking protocol","8522":"thinking protocol + GPP","8523":"Clearfil SE Bond","8524":"umeclidinium\/vilanterol (UMEC\/VI)","8525":"endovascular treatment","8526":"I\/V Human allogeneic mesenchymal stem cells (allo-hMSCs) 100M","8527":"immediate recurrence of atrial premature beats (IRAPB) - after Catheter Ablation for Atrial Fibrillation","8528":"preeclamptics with vitamin supplements (group B)","8529":"I\/V Human allogeneic mesenchymal stem cells (allo-hMSCs) 100M","8530":"group III used hydrogen peroxide (H2O2) 1.5% followed by chlorhexidine (CHX)","8531":"group II used chlorhexidine (CHX) followed by hydrogen peroxide (H2O2) 1.5%","8532":"preeclamptics with vitamin supplements (group B)","8533":"preeclamptics without vitamin supplements (group A)","8534":"bisoprolol","8535":"Clearfil SE Bond","8536":"cecal ligation and puncture (CLP) - bone marrow-derived mononuclear cells (BMDMC)","8537":"lipopolysaccharide (LPS) intraperitoneally - bone marrow-derived mononuclear cells (BMDMC)","8538":"cecal ligation and puncture (CLP) - bone marrow-derived mononuclear cells (BMDMC)","8539":"cecal ligation and puncture (CLP) - bone marrow-derived mononuclear cells (BMDMC)","8540":"immediate recurrence of atrial premature beats (IRAPB) - after Catheter Ablation for Atrial Fibrillation","8541":"immediate recurrence of atrial premature beats (IRAPB) - after Catheter Ablation for Atrial Fibrillation","8542":"complete treatment response","8543":"complete treatment response","8544":"Roux-en-Y (R-Y) reconstruction after distal gastrectomy","8545":"Roux-en-Y (R-Y) reconstruction after distal gastrectomy","8546":"Roux-en-Y (R-Y) reconstruction after distal gastrectomy","8547":"lisdexamfetamine dimesylate (LDX) - forced-dose study","8548":"mental clinical nursing pathway care","8549":"umeclidinium\/vilanterol (UMEC\/VI)","8550":"ON medication","8551":"ON medication","8552":"observation group: combined MPR-CTU (multi-planar reconstruction (MPR) image post-processing technique-computed tomography (CT) urography (CTU))","8553":"observation group: combined MPR-CTU (multi-planar reconstruction (MPR) image post-processing technique-computed tomography (CT) urography (CTU))","8554":"intervention group: choice of two online games to play at home over a period of four weeks","8555":"Children in the intervention group had a choice of two online games to play at home over a period of four weeks","8556":"Children in the intervention group had a choice of two online games to play at home over a period of four weeks","8557":"intervention group","8558":"intervention group","8559":"sleepwalkers","8560":"continuous control of Pcuff","8561":"continuous control of Pcuff","8562":"continuous control of Pcuff","8563":"group B - 35 to 50 years","8564":"Group 2 and 3 (rPTH1-34)","8565":"Group 2 and 3 (rPTH1-34)","8566":"liking the size of the pill","8567":"28 days of oral SRT2104 (2.0 g\/day)","8568":"28 days of oral SRT2104 (2.0 g\/day)","8569":"28 days of oral SRT2104 (2.0 g\/day)","8570":"experimental FEC-D (fluorouracil-docetaxel)","8571":"adolescents (trained and untrained)","8572":"adolescents (trained and untrained)","8573":"adolescents (trained and untrained)","8574":"early surgery <24 hours","8575":"low A scores","8576":"high E scores","8577":"glargine 300 U\/ml (Gla-300)","8578":"DCS D-cycloserine first","8579":"DCS D-cycloserine first","8580":"PEG-IFN \u03b1-2a - 24 weeks","8581":"aripiprazole (10-15mg\/day)","8582":"aripiprazole (10-15mg\/day)","8583":"ON SIROLIMUS AFTER 12 MONTHS group","8584":"ON SIROLIMUS AFTER 12 MONTHS group","8585":"60-minute session (30 minutes of land-based exercise dedicated to improving mobility, motor control, resistance and strengthening of the neck muscles, and 30 minutes of adapted swimming with aerobic exercise keeping a neutral neck position using a snorkel)","8586":"60-minute session (30 minutes of land-based exercise dedicated to improving mobility, motor control, resistance and strengthening of the neck muscles, and 30 minutes of adapted swimming with aerobic exercise keeping a neutral neck position using a snorkel)","8587":"60-minute session (30 minutes of land-based exercise dedicated to improving mobility, motor control, resistance and strengthening of the neck muscles, and 30 minutes of adapted swimming with aerobic exercise keeping a neutral neck position using a snorkel)","8588":"60-minute session (30 minutes of land-based exercise dedicated to improving mobility, motor control, resistance and strengthening of the neck muscles, and 30 minutes of adapted swimming with aerobic exercise keeping a neutral neck position using a snorkel)","8589":"60-minute session (30 minutes of land-based exercise dedicated to improving mobility, motor control, resistance and strengthening of the neck muscles, and 30 minutes of adapted swimming with aerobic exercise keeping a neutral neck position using a snorkel)","8590":"gefitinib alone","8591":"nimotuzumab (200 mg, i.v. weekly) plus gefitinib (250 mg p.o. daily)","8592":"1-year yoga","8593":"1-year yoga","8594":"1-year yoga","8595":"1-year yoga","8596":"1-year yoga","8597":"\"early ART\" - given within 14 days of starting acute OI treatment","8598":"\"early ART\" - given within 14 days of starting acute OI treatment","8599":"\"early ART\" - given within 14 days of starting acute OI treatment","8600":"Group B, who had undergone a combination of surgery and trocar techniques","8601":"Group B, who had undergone a combination of surgery and trocar techniques","8602":"non-caloric sweetened (NS)","8603":"nutrient-rich drink (yoghurt drink) ","8604":"nutrient-rich drink (yoghurt drink)","8605":"nutrient-rich drink (yoghurt drink)","8606":"non-caloric sweetened (NS)","8607":"nutrient-rich drink (yoghurt drink)","8608":"conventional training group watched the instructor performing TT on a cadaver","8609":"conventional training group watched the instructor performing TT on a cadaver","8610":"conventional training group watched the instructor performing TT on a cadaver","8611":"conventional training group watched the instructor performing TT on a cadaver","8612":"conventional training group watched the instructor performing TT on a cadaver","8613":"Baduanjin training","8614":"Baduanjin training","8615":"Baduanjin training","8616":"Baduanjin training","8617":"Baduanjin training","8618":"Baduanjin training","8619":"Baduanjin training","8620":"Baduanjin training","8621":"Baduanjin training","8622":"N-acetylcysteine (NAC)","8623":"N-acetylcysteine (NAC)","8624":"N-acetylcysteine (NAC)","8625":"(MET+NAC), metformin (MET),","8626":"(MET+NAC), metformin (MET),","8627":"N-acetylcysteine (NAC)","8628":"oral insulin","8629":"oral insulin","8630":"oral insulin","8631":"efavirenz 600mg (EFV group)","8632":"fosamprenavir\/ritonavir 1400\/100 mg (FPV\/r group)","8633":"fosamprenavir\/ritonavir 1400\/100 mg (FPV\/r group), efavirenz 600mg (EFV group)","8634":"efavirenz 600mg (EFV group)","8635":"fosamprenavir\/ritonavir 1400\/100 mg (FPV\/r group) ","8636":"fosamprenavir\/ritonavir 1400\/100 mg (FPV\/r group) , efavirenz 600mg (EFV group)","8637":"fosamprenavir\/ritonavir 1400\/100 mg (FPV\/r group)","8638":"efavirenz 600mg (EFV group)","8639":"efavirenz 600mg (EFV group), fosamprenavir\/ritonavir 1400\/100 mg (FPV\/r group)","8640":"fosamprenavir\/ritonavir 1400\/100 mg (FPV\/r group)","8641":"efavirenz 600mg (EFV group)","8642":"Responders (R) were defined as those achieving DAS28 remission (DAS28&nbsp;<&nbsp;2.6) or a good response (DAS28 improvement of&nbsp;>&nbsp;1.2 and DAS28&nbsp;\u2264&nbsp;3.2) at 6&nbsp;months","8643":"Vitamin\/mineral supplements","8644":"Vitamin\/mineral supplements","8645":"Vitamin\/mineral supplements","8646":"Vitamin\/mineral supplements","8647":"fish oil supplementation","8648":"fish oil supplementation","8649":"fish oil supplementation","8650":"fish oil supplementation","8651":"fish oil supplementation","8652":"fish oil supplementation","8653":"fish oil supplementation","8654":"Artiflex","8655":"Artiflex","8656":"STAAR\u00ae implantable contact lens (ICL)","8657":"STAAR\u00ae implantable contact lens (ICL)","8658":"STAAR\u00ae implantable contact lens (ICL)","8659":"STAAR\u00ae implantable contact lens (ICL)","8660":"STAAR\u00ae implantable contact lens (ICL)","8661":"STAAR\u00ae implantable contact lens (ICL)","8662":"bitter gourd juice at FBS range between 120 to 300mg per dl","8663":"Knol-khol, ash gourd juice respectively in the same range","8664":"three distant reiki sessions in addition to usual care","8665":"three distant reiki sessions in addition to usual care","8666":"three distant reiki sessions in addition to usual care","8667":"intensive sound masking therapy on tinnitus","8668":"intensive sound masking therapy on tinnitus in effective subgroup","8669":"intensive sound masking therapy on tinnitus in non-effective subgroup","8670":"intravenous ketamine (0.25 mg\/kg), immediately after the induction of anesthesia","8671":"intravenous ketamine (0.25 mg\/kg), immediately after the induction of anesthesia","8672":"intravenous ketamine (0.25 mg\/kg), immediately after the induction of anesthesia","8673":"intravenous ketamine (0.25 mg\/kg), immediately after the induction of anesthesia","8674":"intravenous ketamine (0.25 mg\/kg), immediately after the induction of anesthesia","8675":"bevacizumab plus lomustine","8676":"bevacizumab ","8677":"lomustine","8678":"Healthy Eating and Active Living for Diabetes (HEALD) intervention","8679":"Healthy Eating and Active Living for Diabetes (HEALD) intervention","8680":"health education program (HED) + yoga","8681":"health education program (HED) + yoga","8682":"health education program (HED) ","8683":"health education program (HED) + yoga","8684":"hyaluronic acid (HA)","8685":"control group","8686":"hyaluronic acid (HA)","8687":"hyaluronic acid (HA)","8688":"a combination of calcium carbonate and calcitriol group and calcitriol only group","8689":"a combination of calcium carbonate and calcitriol group ","8690":"a combination of calcium carbonate and calcitriol group ","8691":"a combination of calcium carbonate and calcitriol group and calcitriol only group","8692":"a combination of calcium carbonate and calcitriol group ","8693":"a combination of calcium carbonate and calcitriol group ","8694":"underwater treadmill group and control","8695":"underwater treadmill group ","8696":"underwater treadmill group , control","8697":"underwater treadmill group ","8698":"combined NPWT with open bone graft","8699":"combined NPWT with open bone graft","8700":"combined NPWT with open bone graft","8701":"combined NPWT with open bone graft","8702":"combined NPWT with open bone graft","8703":"group (D) received dexmedetomidine at a loading dose of 1 \u03bcg\/kg IV over 10 min followed by 0.5 \u03bcg\/kg\/h infusion until Ramsay Sedation Scale (RSS) reached 3\u20134","8704":"group (D) received dexmedetomidine at a loading dose of 1 \u03bcg\/kg IV over 10 min followed by 0.5 \u03bcg\/kg\/h infusion until Ramsay Sedation Scale (RSS) reached 3\u20134","8705":"group (D) received dexmedetomidine at a loading dose of 1 \u03bcg\/kg IV over 10 min followed by 0.5 \u03bcg\/kg\/h infusion until Ramsay Sedation Scale (RSS) reached 3\u20134","8706":"(B) the Mechanical insufflation-exsufflation (MI-E) extubation protocol (study group)","8707":"(B) the MI-E extubation protocol (study group)","8708":"(B) the MI-E extubation protocol (study group)","8709":"(B) the MI-E extubation protocol (study group)","8710":"P2 = Ethanol (99 %) 95 g (Sterillium\u00ae virugard, Bode Chemie Hamburg GmbH) and P3 = Ethanol (96 %) 57,6 g, 1-Propanol (Ph.Eur.) 10 g (Manorapid\u00ae Synergy, Antiseptica GmbH)","8711":"P1 = Ethanol (100 %) 45 g, 1-Propanol (Ph.Eur.) 18 g (Softa-Man\u00ae acute, B. Braun Melsungen AG),","8712":"P2 = Ethanol (99 %) 95 g (Sterillium\u00ae virugard, Bode Chemie Hamburg GmbH) ","8713":"P2 = Ethanol (99 %) 95 g (Sterillium\u00ae virugard, Bode Chemie Hamburg GmbH) and reference product R = Ethanol (100 %) 45 g, 1-Propanol (Ph.Eur.) 18 g (Softa-Man\u00ae pure, B. Braun Melsungen AG)","8714":"metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)","8715":"metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)","8716":"metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)","8717":"metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)","8718":"metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)","8719":"metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)","8720":"metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)","8721":"metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)","8722":"metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)","8723":"metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)","8724":"metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)","8725":"metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)","8726":"metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)","8727":"metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)","8728":"low copper diet and penicillamine","8729":"low copper diet and penicillamine","8730":"moderately painful Quantitative Sensory Testing (QST) procedures","8731":"nonpainful analogs to these testing procedures","8732":"moderately painful Quantitative Sensory Testing (QST) procedures","8733":"yoga","8734":"Oral tenofovir","8735":"Vaginal plus oral tenofovir","8736":"Smoking group","8737":"Chlorhexidine mouth rinse","8738":"Listerine mouth rinse","8739":"C. gigantea extract mouth rinse","8740":"Resistance exercise","8741":"Tapentadol","8742":"Aloe vera aqueous extract 10 mg\/kg ","8743":"Fixed in vitro fertilization","8744":"Partially hydrolyzed guar gum","8745":"MCA sphenoidal segment (M1) difficult exposure","8746":"Internet intervention","8747":"Chitosan + chlorhexidine + allantoin + despanthenol gel ","8748":"Islamic religious music","8749":"Islamic religious music","8750":"Islamic religious music","8751":"Desflurane ","8752":"Aerobic physical activity","8753":"Black pepper oil","8754":"Lavender oil ","8755":"Dw 5% with Quinine infusion","8756":"Saline + Quinine infusion","8757":"D. T. Light quartz fiber post","8758":"Atorvastatin 40 mg","8759":"Ganciclovir ","8760":"S. boulardii","8761":"Hyperbaric bupivacaine","8762":"Atracurium","8763":"Atracurium","8764":"Atracurium","8765":"Dexmedetomidine 0.25 \u03bcg\/kg\/hr","8766":"Radial shockwave therapy","8767":"Radial shockwave therapy","8768":"Carrying a backpack at 20 cm below C7","8769":"Personalised feedback on alcohol intake","8770":"Intervention program","8771":"Cognitive Behaviour Therapy","8772":"Text messaging intervention","8773":"Dexmedetomidine ","8774":"Stress condition","8775":"Dexmedetomidine ","8776":"Stress condition","8777":"Busulfan plus cyclophosphamide ","8778":"Busulfan plus cyclophosphamide ","8779":"Biosimilar adalimumab","8780":"Regular aerobic exercise","8781":"Polymorph alpha rifaximin 400 mg","8782":"Polymorph alpha rifaximin 400 mg","8783":"Polymorph alpha rifaximin 400 mg","8784":"Chemotherapy + goserelin","8785":"Median nerve neural mobilization (MNNM) or Cervical lateral glide (CLG)","8786":"Median nerve neural mobilization (MNNM) or Cervical lateral glide (CLG)","8787":"Adjunctive aripiprazole","8788":"Adjunctive aripiprazole","8789":"Empagliflozin","8790":"Abacavir\/lamivudine (ABC\/3TC) or tenofovir\/emtricitabine (TDF\/FTC)","8791":"Tenofovir\/emtricitabine (TDF\/FTC)","8792":"Selfmanagement group","8793":"The Feeding Practices and Structure Questionnaire (FPSQ)","8794":"Selfmanagement group","8795":"Practice nurse","8796":"Lactobacillus rhamnosus GG (LGG)","8797":"Tramadol 50 mg or 75 mg","8798":"neurofeedback training group (NFTG)","8799":"home-based care","8800":"conventional hospital-based care","8801":"higher adherence to fat gram goal","8802":"Palonosetron","8803":"wood-burning clay cookstove","8804":"AXOS","8805":"Cold-pressed turnip rapeseed oil (CPTRO)","8806":"wood-burning clay cookstove","8807":"Vitamin D","8808":"Cold-pressed turnip rapeseed oil (CPTRO)","8809":"wood-burning clay cookstove","8810":"AGE","8811":"AGE + exercise","8812":"experimental group I (4 mm\/60 Hz) - exercised on a vibration platform","8813":"experimental group I (4 mm\/60 Hz) and IV (2 mm\/60 Hz) - exercised on a vibration platform","8814":"Computer assisted learning","8815":"control","8816":"Urinary kallidinogenase","8817":"metoclopramide (10mg\/2ml, slow injection), ondansetron (4mg\/2ml, slow injection)","8818":"Raloxifene ","8819":"metoclopramide (10mg\/2ml, slow injection)","8820":"Group A received ketamine 0.3 mg\/kg","8821":"circumcised","8822":"Whey protein","8823":"childbirth companion intervention","8824":"tumours with diameter of 2cm or less (T1)","8825":"Individualized occupational therapy","8826":"Individualized occupational therapy","8827":"adjuvant chemotherapy (CMF) for 12 cycles","8828":"emotion-focused coping","8829":"flavonoid-rich blueberry drink","8830":"flavonoid-rich blueberry drink","8831":"Elbow band","8832":"carbon fiber post","8833":"Vitamin K + supplementation","8834":"Intervention + targeting environmental-level factors","8835":"Intervention + targeting environmental-level factors","8836":"intervention package for maternal care and essential newborn care practices","8837":"Dexmedetomidine + remifentanil 0.3 \u03bcg\/kg\/min","8838":"intervention package for maternal care and essential newborn care practices","8839":"Atrial natriuretic peptide at postprandial phase","8840":"treatment - low-level laser therapy (LLLT)","8841":"Atrial natriuretic peptide at postprandial phase","8842":"omeprazole (20 mg)","8843":"treatment - low-level laser therapy (LLLT)","8844":"intervention group","8845":"Environmental enrichment","8846":"Soybean meal ","8847":"Alcohol consumption + H. pylori ","8848":"Alcohol consumption + H. pylori ","8849":"Anifrolumab 1000 mg","8850":"soy drink enriched with 2.6 g plant sterol esters","8851":"Anifrolumab 1000 mg","8852":"Parecoxib\/valdecoxib ","8853":"Sodium nitrate supplementation in hypoxia ","8854":"group A patients received transtracheal block with 4 ml of 4% lidocaine","8855":"group A patients received transtracheal block with 4 ml of 4% lidocaine","8856":"Vildagliptin","8857":"group receiving topical antibiotic ","8858":"40% FiO2","8859":"Vortioxetine 10 mg","8860":"Vildagliptin","8861":"Vortioxetine 5 mg","8862":"Vortioxetine 15 mg","8863":"Exercise","8864":"Citrus sinensis oil inhalation ","8865":"SB4 (an etanercept biosimilar)","8866":"Leukocyte-reduced Platelet-Rich Plasma ","8867":"eribulin mesylate (1.4mg\/m2 on days 1 and 8 every 21days)","8868":"Medicines reconciliation","8869":"Medicines reconciliation","8870":"Medicines reconciliation","8871":"Cooling","8872":"Cooling","8873":"Metacognitive therapy (MCT)","8874":"mitoxantrone ","8875":"Laparoscopic appendectomy","8876":"Laparoscopic appendectomy","8877":"Laparoscopic appendectomy","8878":"IV diazepam + periprostatic nerve block","8879":"Internet version questionnaire","8880":"Internet version questionnaire","8881":"Parenting Matters intervention","8882":"EX exercise treatment for the regain (+50% of weight lost) phase","8883":"Starting Early support group","8884":"Active physical therapy","8885":"Starting Early support group","8886":"Rosa centifolia petals + epigallocatechin gallate shampoo","8887":"post-Yoga","8888":"Tranexamic acid","8889":"post-Yoga","8890":"power law models","8891":"Periodic Email Prompt","8892":"Artificial tear single dose ","8893":"Recombinant\u2010human chorionic gonadotropin","8894":"Artificial tear single dose ","8895":"Bupivacaine + ketamine 0.5 mg\/kg","8896":"Hypofractionation conformal treatment ","8897":"Amifostine ","8898":"Hypofractionation conformal treatment ","8899":"Continuous palonosetron infusion","8900":"Robotic-assisted gait training","8901":"Pentacalcium hydroxy-triphosphate (single dose)","8902":"Remifentanil ","8903":"Face-based attentional bias modification","8904":"Remifentanil ","8905":"Word-based attentional bias modification","8906":"Whey protein hydrolysate-carbohydrate beverage","8907":"Whey protein hydrolysate-carbohydrate beverage","8908":"Resveratrol ","8909":"10-week yoga program ","8910":"Oral tenofovir","8911":"Vaginal plus oral tenofovir","8912":"Automated Bilingual Text Message Intervention","8913":"Automated Bilingual Text Message Intervention","8914":"Listerine mouth rinse ","8915":"Tapentadol","8916":"Tapentadol","8917":"Tapentadol","8918":"Tapentadol","8919":"Aloe vera aqueous extract 40 mg\/kg ","8920":"Aloe vera aqueous extract 10 mg\/kg ","8921":"Aloe vera aqueous extract 10 mg\/kg ","8922":"Aloe vera aqueous extract 40 mg\/kg ","8923":"Ilio-inguinal\/ilio-hypogastric blocks","8924":"Ilio-inguinal\/ilio-hypogastric blocks","8925":"Aerobic exercise-training sessions","8926":"Aerobic exercise-training sessions","8927":"Aerobic exercise-training sessions","8928":"Aerobic exercise-training sessions","8929":"Chitosan + chlorhexidine + allantoin + despanthenol gel ","8930":"Chitosan + chlorhexidine + allantoin + despanthenol gel ","8931":"Chitosan + chlorhexidine + allantoin + despanthenol gel ","8932":"Islamic religious music","8933":"Islamic religious music","8934":"Chlorhexidene mouthrinse","8935":"Lifestyle Intervention","8936":"Lifestyle Intervention","8937":"Lifestyle Intervention","8938":"Saline + Quinine infusion","8939":"Saline + Quinine infusion","8940":"Dw 5%+ Quinine infusion","8941":"Saline + Quinine infusion","8942":"Oral melatonin","8943":"Oral melatonin","8944":"Oral melatonin","8945":"Oral melatonin","8946":"Oral melatonin","8947":"Sorafenib","8948":"Sorafenib","8949":"Atorvastatin 40 mg","8950":"Atorvastatin 40 mg","8951":"Atorvastatin 40 mg","8952":"Atorvastatin 40 mg","8953":"Ganciclovir ","8954":"Aciclovir ","8955":"Discharge-planning intervention","8956":"Discharge-planning intervention","8957":"Discharge-planning intervention","8958":"Discharge-planning intervention","8959":"Dexmedetomidine 0.25 \u03bcg\/kg\/hr","8960":"Dexmedetomidine 0.25 \u03bcg\/kg\/hr","8961":"Dexmedetomidine 0.25 \u03bcg\/kg\/hr","8962":"Radial shockwave therapy","8963":"Radial shockwave therapy","8964":"Radial shockwave therapy","8965":"Cognitive Behaviour Therapy + weekly telephone follow-up","8966":"Weekly telephone follow-up","8967":"Cognitive Behaviour Therapy + weekly telephone follow-up","8968":"Cognitive Behaviour Therapy + weekly telephone follow-up","8969":"Weekly telephone follow-up","8970":"Foot care education","8971":"Foot care education","8972":"Intensive Patient Education","8973":"Oral picosulfate with magnesium citrate","8974":"Oral picosulfate with magnesium citrate","8975":"Oral picosulfate with magnesium citrate","8976":"Oral picosulfate with magnesium citrate","8977":"80% maximal voluntary isometric contraction","8978":"50% maximal voluntary isometric contraction","8979":"Cognitive Behaviour Therapy","8980":"Cognitive Behaviour Therapy","8981":"Cognitive Behaviour Therapy","8982":"Cognitive Behaviour Therapy","8983":"Dexmedetomidine ","8984":"Dexmedetomidine ","8985":"Busulfan plus cyclophosphamide ","8986":"Busulfan plus cyclophosphamide ","8987":"Busulfan plus cyclophosphamide ","8988":"Uracil + Tegafur","8989":"Uracil + Tegafur","8990":"Agave derived fructans ","8991":"Agave derived fructans ","8992":"Agave derived fructans ","8993":"Agave derived fructans ","8994":"Polymorph alpha rifaximin 200 mg","8995":"Polymorph alpha rifaximin 200 mg","8996":"Ciprofloxacin ","8997":"Adjunctive aripiprazole","8998":"Adjunctive aripiprazole","8999":"Exenatide","9000":"Exenatide","9001":"Use of the ITP-specific tool","9002":"ProtecT trial patients","9003":"ProtecT trial patients","9004":"ProtecT trial patients","9005":"Empagliflozin","9006":"Tenofovir\/emtricitabine (TDF\/FTC)","9007":"Selfmanagement group","9008":"Selfmanagement group","9009":"Pilates training","9010":"Pilates training","9011":"Practice nurse","9012":"Practice nurse","9013":"Ropivacaine (group A)","9014":"Neuromuscular blocking agent (Group A)","9015":"Neuromuscular blocking agent (Group A)","9016":"Tramadol 50 mg or 75 mg","9017":"Tramadol 50 mg or 75 mg","9018":"Tramadol 50 mg or 75 mg","9019":"FAST treatment","9020":"FAST treatment","9021":"FAST treatment","9022":"Zinc","9023":"Zinc","9024":"Automated Bilingual Text Message Intervention","9025":"Chlorhexidine mouth rinse","9026":"Chlorhexidine mouth rinse","9027":"Tapentadol","9028":"Aloe vera aqueous extract 40 mg\/kg ","9029":"Paravertebral anesthetic","9030":"Paravertebral anesthetic","9031":"Paravertebral anesthetic","9032":"Paravertebral anesthetic","9033":"Paravertebral anesthetic","9034":"Paravertebral anesthetic","9035":"Ilio-inguinal\/ilio-hypogastric blocks","9036":"Ilio-inguinal\/ilio-hypogastric blocks","9037":"Ilio-inguinal\/ilio-hypogastric blocks","9038":"Ilio-inguinal\/ilio-hypogastric blocks","9039":"Aerobic exercise-training sessions","9040":"Aerobic exercise-training sessions","9041":"Human chorionic gonadotropin in typical PCOS patients","9042":"Human chorionic gonadotropin in typical PCOS patients","9043":"Chitosan + chlorhexidine + allantoin + despanthenol gel ","9044":"Chitosan + chlorhexidine + allantoin + despanthenol gel ","9045":"Islamic religious music","9046":"Aerobic physical activity","9047":"Aloe vera mouthrinse","9048":"Aloe vera mouthrinse","9049":"Lifestyle Intervention","9050":"Oral melatonin","9051":"Atorvastatin 40 mg","9052":"Ganciclovir ","9053":"Aciclovir ","9054":"Ganciclovir ","9055":"Dexmedetomidine 0.25 \u03bcg\/kg\/hr","9056":"Dexmedetomidine 0.25 \u03bcg\/kg\/hr","9057":"Cognitive Behaviour Therapy + weekly telephone follow-up","9058":"Carrying a backpack at 20 cm below C7","9059":"Carrying a backpack at 20 cm below C7","9060":"Carrying a backpack at 20 cm below C7","9061":"Carrying a backpack at 20 cm below C7","9062":"Carrying a backpack at 20 cm below C7","9063":"Oral picosulfate with magnesium citrate","9064":"Oral picosulfate with magnesium citrate","9065":"80% maximal voluntary isometric contraction","9066":"80% maximal voluntary isometric contraction","9067":"Cognitive Behaviour Therapy","9068":"Dexmedetomidine ","9069":"Dexmedetomidine ","9070":"Busulfan plus cyclophosphamide ","9071":"Uracil + Tegafur","9072":"Agave derived fructans ","9073":"Polymorph alpha rifaximin 200 mg","9074":"Chemotherapy + goserelin","9075":"Median nerve neural mobilization (MNNM) or Cervical lateral glide (CLG)","9076":"Median nerve neural mobilization (MNNM) or Cervical lateral glide (CLG)","9077":"Adjunctive aripiprazole","9078":"Use of the ITP-specific tool","9079":"Empagliflozin","9080":"Empagliflozin","9081":"Empagliflozin","9082":"Tenofovir\/emtricitabine (TDF\/FTC)","9083":"Selfmanagement group","9084":"Practice nurse","9085":"Practice nurse","9086":"Ropivacaine (group A)","9087":"Ropivacaine (group A)","9088":"Ropivacaine (group A)","9089":"Ropivacaine (group A)","9090":"Neuromuscular blocking agent (Group A)","9091":"Neuromuscular blocking agent (Group A)","9092":"Neuromuscular blocking agent (Group A)","9093":"Tramadol 50 mg or 75 mg","9094":"FAST treatment","9095":"FAST treatment","9096":"Zinc","9097":"Zinc","9098":"Standard treatment plus SDX","9099":"Four-drug combination therapy (study group)","9100":"Four-drug combination therapy (study group)","9101":"Palonosetron","9102":"Palonosetron","9103":"Debridement plus DFDBA (TG1), or debridement plus BBG (TG2)","9104":"Radial extracorporeal shock wave therapy (rESWT)","9105":"Radial extracorporeal shock wave therapy (rESWT)","9106":"Cold-pressed turnip rapeseed oil (CPTRO)","9107":"Cold-pressed turnip rapeseed oil (CPTRO)","9108":"Albendazole","9109":"experimental group I (4 mm\/60 Hz) and V (2 mm\/40 Hz) - exercised on a vibration platform","9110":"Kumarabharana rasa (KR) at a dose of 500 mg once daily for 30 days (Group A)","9111":"Kumarabharana rasa (KR) at a dose of 500 mg once daily for 30 days (Group A)","9112":"experimental - video-assisted teaching program regarding psoriasis","9113":"experimental - video-assisted teaching program regarding psoriasis","9114":"Group A received ketamine 0.3 mg\/kg","9115":"Group A received ketamine 0.3 mg\/kg","9116":"circumcised","9117":"emotion-focused coping","9118":"emotion-focused coping","9119":"emotion-focused coping","9120":"flavonoid-rich blueberry drink","9121":"carbon fiber posts","9122":"glass fiber posts","9123":"stainless steel posts","9124":"prefabricated stainless steel post","9125":"ultrasound guided needle aspiration","9126":"ultrasound guided needle aspiration","9127":"intervention package for maternal care and essential newborn care practices","9128":"treatment - low-level laser therapy (LLLT)","9129":"intervention group","9130":"intervention group","9131":"Mild TBI","9132":"Genoss drug-eluting stent (DES)","9133":"Genoss drug-eluting stent (DES)","9134":"Risk assessment ","9135":"soy drink enriched with 2.6 g plant sterol esters","9136":"Risk assessment ","9137":"Anifrolumab 300 mg","9138":"soy drink enriched with 2.6 g plant sterol esters","9139":"(KI) low intravenous dose of ketamine (0.04 mg\/kg)","9140":"Anifrolumab 1000 mg","9141":"Anifrolumab 1000 mg","9142":"Parecoxib\/valdecoxib ","9143":"Parecoxib\/valdecoxib ","9144":"Parecoxib\/valdecoxib ","9145":"(KI) low intravenous dose of ketamine (0.04 mg\/kg)","9146":"Parecoxib\/valdecoxib ","9147":"Sodium nitrate supplementation in hypoxia ","9148":"Sodium nitrate supplementation in normoxia ","9149":"group receiving topical colostrum","9150":"Newfactan","9151":"Newfactan","9152":"Vildagliptin","9153":"Newfactan","9154":"Newfactan","9155":"Newfactan","9156":"Newfactan","9157":"Vildagliptin","9158":"10-day course of zinc and two oral rehydration solution (ORS) sachets every two months at home","9159":"Exercise + cranial electrotherapy stimulation","9160":"Exercise + cranial electrotherapy stimulation","9161":"xeloda\/ epirubicin\/ cyclophosphamide (XEC)","9162":"xeloda\/ epirubicin\/ cyclophosphamide (XEC)","9163":"bioelectrical impedance analysis (BIA)","9164":"bioelectrical impedance analysis (BIA)","9165":"Oral health educational seminar ","9166":"SB4 (an etanercept biosimilar)","9167":"Otilonium bromide","9168":"Otilonium bromide","9169":"Otilonium bromide","9170":"Triamcinolone acetonide","9171":"Triamcinolone acetonide","9172":"women with Fibromyalgia syndrome (FMS)","9173":"CCC group - oral cholecalciferol (5000 IU\/ day)","9174":"CCC group - oral cholecalciferol (5000 IU\/ day)","9175":"High-level carbonated water with calcium ions","9176":"CCC group - oral cholecalciferol (5000 IU\/ day)","9177":"Low-level carbonated water with calcium ions","9178":"Metacognitive therapy (MCT)","9179":"Metacognitive therapy (MCT)","9180":"Metacognitive therapy (MCT)","9181":"Cooling","9182":"Butenafine ","9183":"Butenafine ","9184":"Butenafine ","9185":"mitoxantrone ","9186":"Butenafine ","9187":"mitoxantrone ","9188":"mitoxantrone ","9189":"mitoxantrone ","9190":"Laparoscopic appendectomy","9191":"Prostate cancer","9192":"Parenting Matters intervention","9193":"EX exercise treatment for the regain (+50% of weight lost) phase","9194":"Pasive physical therapy","9195":"\"capacity enhancement\" (CE)","9196":"fish oil group EPA","9197":"fish oil group EPA","9198":"fish oil group EPA","9199":"Retroperitoneal laparoscopic pyelolithotomy","9200":"post-Yoga","9201":"Tranexamic acid","9202":"Tranexamic acid","9203":"High flow","9204":"Artificial tear single dose ","9205":"Empagliflozin 25 mg","9206":"Modified lynch suture","9207":"Modified lynch suture","9208":"Modified lynch suture","9209":"Sodium nitroprusside 10 nmol\/ml","9210":"Sodium nitroprusside 50 nmol\/ml","9211":"Continuous palonosetron infusion","9212":"Intravitreal triamcinolone Acetonide","9213":"Intravitreal triamcinolone Acetonide","9214":"Intravitreal triamcinolone Acetonide","9215":"Integrated treatment for Substance abuse and Partner violence","9216":"Word-based attentional bias modification","9217":"Whey protein hydrolysate-carbohydrate beverage","9218":"Whey protein hydrolysate-carbohydrate beverage","9219":"Insulin aspart","9220":"Insulin aspart","9221":"Insulin aspart","9222":"Insulin aspart","9223":"Resveratrol ","9224":"Resveratrol ","9225":"Resveratrol ","9226":"Remifentanil 6 ng\/mL","9227":"intervention group, involving home visits","9228":"dulaglutide (1.5 or 0.75 mg)","9229":"dulaglutide (1.5 or 0.75 mg)","9230":"Remifentanil 6 ng\/mL","9231":"dulaglutide (1.5 or 0.75 mg)","9232":"Remifentanil 4 ng\/mL","9233":"intervention group, involving home visits","9234":"lubiprostone (24 mcg BID for CIC)","9235":"lubiprostone (24 mcg BID for OIC)","9236":"Glecaprevir 300mg + pibrentasvir 120 mg + ribavirin ","9237":"acute bronchiolitis group (BG); conventional physical therapy (CPT) for airway clearance and nasotracheal suction","9238":"triazolam 0.25 mg or 0.375 mg","9239":"Tissue plasminogen activator","9240":"triazolam 0.25 mg or 0.375 mg","9241":"administration via naso-duodenal tube","9242":"triazolam 0.25 mg or 0.375 mg","9243":"Mini-midvastus","9244":"right dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS)","9245":"left dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS)","9246":"p-prisms after training ","9247":"Dietitian-Based Nutrition Education Strategy","9248":"left dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS)","9249":"oxycodone (OXY) 30mg oral","9250":"zinc as an adjunct treatment","9251":"Dietitian-Based Nutrition Education Strategy","9252":"zinc as an adjunct treatment","9253":"Dietitian-Based Nutrition Education Strategy","9254":"zinc as an adjunct treatment","9255":"subgingival instrumentation with an ultrasonic device using PVP-I (10%) as the cooling liquid (test group)","9256":"zinc as an adjunct treatment","9257":"fish oil group EPA","9258":"elosulfase alfa 2.0 mg\/kg\/week (weekly)","9259":"Prednisone","9260":"CKD-828 2.5\/80 mg (who failed to respond after 4-week S-amlodipine 2.5 mg monotherapy)","9261":"elosulfase alfa 2.0mg\/kg\/every other week (qow)","9262":"banner","9263":"elosulfase alfa 2.0mg\/kg\/week (weekly)","9264":"1 week of standard therapy","9265":"CKD-828 2.5\/40 mg (who failed to respond after 4-week S-amlodipine 2.5 mg monotherapy)","9266":"real stimulation sessions","9267":"xeloda\/ epirubicin\/ cyclophosphamide (XEC)","9268":"first of the repeated stimulation sessions","9269":"pravastatin 40 mg daily","9270":"fatal CVD events","9271":"CKD-828 2.5\/80 mg (who failed to respond after 4-week S-amlodipine 2.5 mg monotherapy)","9272":"non-CVD mortality","9273":"exercise group before intervention","9274":"exercise group","9275":"Mini-midvastus","9276":"exercise group","9277":"Nurse-midwife","9278":"eribulin mesylate (1.4 mg\/m2 on days 1 and 8 every 21 days)","9279":"eribulin mesylate (1.4mg\/m2 on days 1 and 8 every 21 days)","9280":"10 grams cocoa powder and 10 grams milk powder","9281":"eribulin mesylate (1.4mg\/m2 on days 1 and 8 every 21 days)","9282":"acarbose","9283":"acarbose","9284":"Standard treatment plus SDX","9285":"Standard treatment plus SDX","9286":"Four-drug combination therapy (study group)","9287":"Four-drug combination therapy (study group)","9288":"women with Fibromyalgia syndrome (FMS)","9289":"Four-drug combination therapy (study group)","9290":"patients with minimal-risk","9291":"Palonosetron","9292":"Palonosetron","9293":"Debridement plus DFDBA (TG1), or debridement plus BBG (TG2)","9294":"women with Fibromyalgia syndrome (FMS)","9295":"Debridement plus DFDBA (TG1), or debridement plus BBG (TG2)","9296":"PROMISE minimal-risk tool","9297":"Radial extracorporeal shock wave therapy (rESWT)","9298":"Information sessions plus digital resources","9299":"Cold-pressed turnip rapeseed oil (CPTRO)","9300":"Optimised land-based exercises plus aquatic therapy","9301":"Optimised land-based exercises plus aquatic therapy","9302":"Albendazole","9303":"Albendazole","9304":"Albendazole","9305":"experimental group I (4 mm\/60 Hz) and V (2 mm\/40 Hz) - exercised on a vibration platform","9306":"experimental group I (4 mm\/60 Hz) and V (2 mm\/40 Hz) - exercised on a vibration platform","9307":"abatacept","9308":"experimental group I (4 mm\/60 Hz) and IV (2 mm\/60 Hz) - exercised on a vibration platform","9309":"Kumarabharana rasa (KR) at a dose of 500 mg once daily for 30 days (Group A)","9310":"Kumarabharana rasa (KR) at a dose of 500 mg once daily for 30 days (Group A)","9311":"experimental - video-assisted teaching program regarding psoriasis","9312":"experimental - video-assisted teaching program regarding psoriasis","9313":"experimental - video-assisted teaching program regarding psoriasis","9314":"experimental - video-assisted teaching program regarding psoriasis","9315":"abatacept","9316":"tourniquet group","9317":"patients with HLA-A*2402 with positive CTL response","9318":"Group A received ketamine 0.3 mg\/kg","9319":"circumcised","9320":"circumcised","9321":"circumcised","9322":"adjuvant chemotherapy (CMF) for 12 cycles","9323":"Digestive AdvantageTM Gas Defense Formula (GD) group","9324":"hogs lairaged for 3 h","9325":"tourniquet group","9326":"hogs being transported for 6 h - lairaged for 3 h","9327":"hogs being transported for 6 h - lairaged for 6 h","9328":"flavonoid-rich blueberry drink","9329":"migalastat","9330":"hogs lairaged for 3 h","9331":"transdiagnostic Internet-based maintenance treatment (TIMT)","9332":"10 grams cocoa powder and 10 grams milk powder","9333":"10 grams cocoa powder and 10 grams milk powder","9334":"Health Belief Model (HBM)-based education","9335":"Health Belief Model (HBM)-based education","9336":"all the prefabricated posts","9337":"recreationally endurance trained - men","9338":"recreationally endurance trained - men","9339":"ultrasound guided needle aspiration","9340":"recreationally endurance trained - men","9341":"ultrasound guided needle aspiration","9342":"recreationally endurance trained - men","9343":"proton pump inhibitor (PPI)","9344":"video game training (TG)","9345":"three targeted pictorial messages regarding vaccines","9346":"group 1, treated with an injection of hyaluronic acid alone (66 mg) into each knee; group 2, treated with an injection of hyaluronic acid (49.5 mg) plus diclofenac sodium (5 mg) into each knee;","9347":"group 1, treated with an injection of hyaluronic acid alone (66 mg) into each knee; group 2, treated with an injection of hyaluronic acid (49.5 mg) plus diclofenac sodium (5 mg) into each knee;","9348":"peginterferon alfa-2a (180 \u03bcg\/week) \u00b1 lamivudine (100 mg\/day)","9349":"omeprazole (20 mg)","9350":"intervention package for maternal care and essential newborn care practices","9351":"intervention package for maternal care and essential newborn care practices","9352":"intervention package for maternal care and essential newborn care practices","9353":"implementation of a participatory organizational-level intervention","9354":"Hickman catheters","9355":"mesalamine at 2.4 g\/day (pH-2.4 g)","9356":"Probiotics ","9357":"mesalamine at 2.4 g\/day (pH-2.4 g)","9358":"Environmental enrichment","9359":"Mild TBI","9360":"treatment - low-level laser therapy (LLLT)","9361":"intervention group","9362":"Mild TBI","9363":"Environmental enrichment","9364":"Risk assessment ","9365":"ultrasound guided needle aspiration","9366":"Risk assessment ","9367":"Risk assessment ","9368":"Genoss drug-eluting stent (DES)","9369":"Genoss drug-eluting stent (DES)","9370":"Genoss drug-eluting stent (DES)","9371":"soy drink enriched with 2.6 g plant sterol esters","9372":"Anifrolumab 300 mg","9373":"soy drink enriched with 2.6 g plant sterol esters","9374":"(KI) low intravenous dose of ketamine (0.04 mg\/kg)","9375":"(KI) low intravenous dose of ketamine (0.04 mg\/kg)","9376":"HCHO diet (High CHO diet)","9377":"HCHO diet (High CHO diet)","9378":"HCHO diet (High CHO diet)","9379":"Parecoxib\/valdecoxib ","9380":"Parecoxib\/valdecoxib ","9381":"HCHO diet (High CHO diet)","9382":"group A patients received transtracheal block with 4 ml of 4% lidocaine","9383":"HCHO diet (High CHO diet)","9384":"Sodium nitrate supplementation in normoxia ","9385":"group A patients received transtracheal block with 4 ml of 4% lidocaine","9386":"Hypoxia ","9387":"group receiving topical colostrum ","9388":"mitoxantrone ","9389":"Vildagliptin","9390":"LISTEN group (Loneliness Intervention)","9391":"oxycodone (OXY) intranasal","9392":"arformoterol","9393":"arformoterol","9394":"Vortioxetine 20 mg","9395":"zinc villages","9396":"10-day course of zinc and two oral rehydration solution (ORS) sachets every two months at home","9397":"Vortioxetine 10 mg","9398":"Vortioxetine 5 mg","9399":"zinc villages","9400":"zinc villages","9401":"Exercise + cranial electrotherapy stimulation","9402":"Exercise + cranial electrotherapy stimulation","9403":"treatment - low-level laser therapy (LLLT)","9404":"Exercise + cranial electrotherapy stimulation","9405":"Pramlintide ","9406":"Pramlintide ","9407":"Pramlintide ","9408":"Oral health educational seminar ","9409":"xeloda\/ epirubicin\/ cyclophosphamide (XEC)","9410":"Oral health educational seminar ","9411":"xeloda\/ epirubicin\/ cyclophosphamide (XEC)","9412":"bioelectrical impedance analysis (BIA)","9413":"Otilonium bromide","9414":"SB4 (an etanercept biosimilar)","9415":"Otilonium bromide","9416":"Propolis gel","9417":"SB4 (an etanercept biosimilar)","9418":"Propolis gel","9419":"Propolis gel","9420":"SB4 (an etanercept biosimilar)","9421":"Propolis gel","9422":"Low-level carbonated water","9423":"High-level carbonated water","9424":"Low-level carbonated water with calcium ions","9425":"eribulin mesylate (1.4mg\/m2 on days 1 and 8 every 21 days)","9426":"High-level carbonated water","9427":"women with Fibromyalgia syndrome (FMS)","9428":"women with Fibromyalgia syndrome (FMS)","9429":"Cooling","9430":"CCC group - oral cholecalciferol (5000 IU\/ day)","9431":"Cooling","9432":"Cooling","9433":"Metacognitive therapy (MCT)","9434":"patient-centered intervention group","9435":"patient-centered intervention group","9436":"patient-centered intervention group","9437":"Butenafine ","9438":"patient-centered intervention group","9439":"Butenafine ","9440":"Laparoscopic appendectomy","9441":"Laparoscopic appendectomy","9442":"LISTEN group (Loneliness Intervention)","9443":"intervention group","9444":"LISTEN group (Loneliness Intervention)","9445":"LISTEN group (Loneliness Intervention)","9446":"LISTEN group (Loneliness Intervention)","9447":"Prostate cancer","9448":"Parenting Matters intervention","9449":"EX exercise treatment for the regain (+50% of weight lost) phase","9450":"EX exercise treatment for the regain (+50% of weight lost) phase","9451":"Active physical therapy","9452":"fish oil group EPA","9453":"Active physical therapy","9454":"Active physical therapy","9455":"HPFS (Health Professionals Follow-Up Study) cohort","9456":"Active physical therapy","9457":"Retroperitoneal laparoscopic pyelolithotomy","9458":"Retroperitoneal laparoscopic pyelolithotomy","9459":"HPFS (Health Professionals Follow-Up Study) cohort","9460":"Retroperitoneal laparoscopic pyelolithotomy","9461":"Retroperitoneal laparoscopic pyelolithotomy","9462":"Retroperitoneal laparoscopic pyelolithotomy","9463":"Tranexamic acid","9464":"post-Yoga","9465":"Tranexamic acid","9466":"post-Yoga","9467":"post-Yoga","9468":"Tranexamic acid","9469":"High flow","9470":"subgingival instrumentation with an ultrasonic device using PVP-I (10%) as the cooling liquid (test group)","9471":"Artificial tear single dose ","9472":"Artificial tear single dose ","9473":"oldest age cohort","9474":"men with BPH medication","9475":"Empagliflozin 10 mg","9476":"Empagliflozin 25 mg","9477":"Empagliflozin 10 mg","9478":"administration via distal-release pellets","9479":"Empagliflozin 25 mg","9480":"Empagliflozin 25 mg","9481":"Modified lynch suture","9482":"fentanyl-midazolam-medetomidine (FMM)","9483":"EX exercise treatment for the regain (+50% of weight lost) phase","9484":"subgingival instrumentation with an ultrasonic device using PVP-I (10%) as the cooling liquid (test group)","9485":"Modified lynch suture","9486":"Modified lynch suture","9487":"Ropivacaine","9488":"Red meat\/refined grain diet ","9489":"Sodium nitroprusside 100 nmol\/ml","9490":"oxycodone (OXY) 30mg oral","9491":"Sodium nitroprusside 100 nmol\/ml","9492":"tourniquet group","9493":"Hypofractionation conformal treatment ","9494":"group 1, the patients were given warfarin (INR) between 2-3) together with 80 mg aspirin daily for 3 months","9495":"Hypofractionation conformal treatment ","9496":"Red meat\/refined grain diet ","9497":"Red meat\/refined grain diet ","9498":"Continuous palonosetron infusion","9499":"Continuous palonosetron infusion","9500":"Continuous palonosetron infusion","9501":"Continuous palonosetron infusion","9502":"Intravitreal triamcinolone Acetonide","9503":"administration via proximal-release pellets","9504":"group 1, the patients were given warfarin (INR) between 2-3) together with 80 mg aspirin daily for 3 months","9505":"Glecaprevir 300mg + pibrentasvir 120 mg + ribavirin ","9506":"Intravitreal triamcinolone Acetonide","9507":"fentanyl-midazolam-medetomidine (FMM)","9508":"Robotic-assisted gait training","9509":"Integrated treatment for Substance abuse and Partner violence","9510":"Tissue plasminogen activator + deoxyribonuclease ","9511":"Integrated treatment for Substance abuse and Partner violence","9512":"Integrated treatment for Substance abuse and Partner violence","9513":"Integrated treatment for Substance abuse and Partner violence","9514":"Integrated treatment for Substance abuse and Partner violence","9515":"Face-based attentional bias modification","9516":"Word-based attentional bias modification","9517":"patients with HLA-A*2402 ","9518":"Red meat\/refined grain diet ","9519":"Dietitian-Based Nutrition Education Strategy","9520":"Whey protein hydrolysate-carbohydrate beverage","9521":"Whey protein hydrolysate-carbohydrate beverage","9522":"Red meat\/refined grain diet ","9523":"Nostril yoga breathing","9524":"Nostril yoga breathing","9525":"p-prisms after 2 weeks but before training ","9526":"Insulin aspart","9527":"Negative Cues","9528":"Negative Cues","9529":"arformoterol","9530":"Negative Cues","9531":"Insulin aspart","9532":"Negative Cues","9533":"\"capacity enhancement\" (CE)","9534":"Resveratrol ","9535":"Negative Cues","9536":"Nurse-midwife","9537":"Nurse-midwife","9538":"Oral tenofovir","9539":"Oral tenofovir","9540":"Intuitive Eating and Acceptance and Commitment Therapy","9541":"Intuitive Eating and Acceptance and Commitment Therapy","9542":"Intuitive Eating and Acceptance and Commitment Therapy","9543":"Intuitive Eating and Acceptance and Commitment Therapy","9544":"Intuitive Eating and Acceptance and Commitment Therapy","9545":"Intuitive Eating and Acceptance and Commitment Therapy","9546":"Plavix","9547":"Plavix","9548":"Plavix","9549":"Plavix","9550":"Plavix","9551":"Plavix","9552":"Household heads training","9553":"Household heads training","9554":"Pharmaceutical care","9555":"Pharmaceutical care","9556":"Glycopyrronium bromide 12.5 \u03bcg OD","9557":"Glycopyrronium bromide 25 \u03bcg OD","9558":"Glycopyrronium bromide 12.5 \u03bcg BID","9559":"Glycopyrronium bromide 50 \u03bcg BID","9560":"Glycopyrronium bromide 25 \u03bcg BID","9561":"Glycopyrronium bromide 100 \u03bcg OD","9562":"Critical weight loss","9563":"Critical weight loss","9564":"Paracetamol ","9565":"Paracetamol ","9566":"Paracetamol ","9567":"Paracetamol ","9568":"Paracetamol ","9569":"Paracetamol ","9570":"Perindopril","9571":"Perindopril","9572":"Perindopril","9573":"Preoperative conventional chemoradiotherapy","9574":"Preoperative conventional chemoradiotherapy","9575":"Preoperative conventional chemoradiotherapy","9576":"Preoperative conventional chemoradiotherapy","9577":"Preoperative conventional chemoradiotherapy","9578":"Preoperative conventional chemoradiotherapy","9579":"Preemptive anidulafungin","9580":"Synbiotic group","9581":"Synbiotic group","9582":"Synbiotic group","9583":"Synbiotic group","9584":"Implementation intention condition","9585":"Implementation intention condition","9586":"Implementation intention condition","9587":"Implementation intention condition","9588":"Glycopyrronium bromide 50 \u03bcg","9589":"Glycopyrronium bromide 100 \u03bcg","9590":"Glycopyrronium bromide 200 \u03bcg","9591":"Glycopyrronium bromide 50 \u03bcg","9592":"Glycopyrronium bromide 50 \u03bcg","9593":"Glycopyrronium bromide 100 \u03bcg","9594":"Last menstrual period method","9595":"Last menstrual period method","9596":"Oligomeric Proanthocyanidin Supplement","9597":"Oligomeric Proanthocyanidin Supplement","9598":"Oligomeric Proanthocyanidin Supplement","9599":"Oligomeric Proanthocyanidin Supplement","9600":"Calcipotriol + betamethasone dipropionate ","9601":"Calcipotriol + betamethasone dipropionate ","9602":"Sick leave-related intervention with early assessment","9603":"Sick leave-related intervention with early assessment","9604":"Sick leave-related intervention with early assessment","9605":"Sick leave-related intervention with early assessment","9606":"Sick leave-related intervention with early assessment","9607":"Sick leave-related intervention with early assessment","9608":"Educational intervention","9609":"Educational intervention","9610":"Educational intervention","9611":"I-gel supraglottic device","9612":"I-gel supraglottic device","9613":"I-gel supraglottic device","9614":"I-gel supraglottic device","9615":"I-gel supraglottic device","9616":"I-gel supraglottic device","9617":"Nitrate supplementation","9618":"Nitrate supplementation","9619":"Nitrate supplementation","9620":"Nitrate supplementation","9621":"Nitrate supplementation","9622":"Glucosamine sulfate","9623":"Aquamin","9624":"Glucosamine sulfate","9625":"Aquamin ","9626":"Glucosamine sulfate","9627":"Aquamin ","9628":"Magnesium sulfate","9629":"Remifentanil ","9630":"Magnesium sulfate","9631":"Remifentanil ","9632":"Magnesium sulfate","9633":"Magnesium sulfate","9634":"Caudal block","9635":"Saddle","9636":"Caudal block","9637":"Saddle","9638":"Saddle","9639":"Caudal block","9640":"LR14 point stimulation","9641":"LR8 point stimulation","9642":"Control point stimulation","9643":"Add-on lithium","9644":"Add-on lithium","9645":"Add-on lithium","9646":"Add-on lithium","9647":"Add-on lithium","9648":"Add-on lithium","9649":"Pioglitazone ","9650":"Pioglitazone ","9651":"Pioglitazone ","9652":"Pioglitazone ","9653":"Hyaluronic acid\/carboxymethylcellulose","9654":"Hyaluronic acid\/carboxymethylcellulose","9655":"Hyaluronic acid\/carboxymethylcellulose","9656":"Hyaluronic acid\/carboxymethylcellulose","9657":"Hyaluronic acid\/carboxymethylcellulose","9658":"Hyaluronic acid\/carboxymethylcellulose","9659":"Attached stent to Foley catheter","9660":"Attached stent to Foley catheter","9661":"Attached stent to Foley catheter","9662":"Attached stent to Foley catheter","9663":"Attached stent to Foley catheter","9664":"NSI-189 ","9665":"NSI-189","9666":"NSI-189 ","9667":"NSI-189 ","9668":"NSI-189","9669":"NSI-189 ","9670":"Eligibility for randomization ","9671":"Eligibility for randomization ","9672":"Eligibility for randomization ","9673":"Eligibility for randomization ","9674":"Eligibility for randomization ","9675":"Eligibility for randomization ","9676":"Kegel exercises program","9677":"Kegel exercises program","9678":"Kegel exercises program","9679":"Kegel exercises program","9680":"Kegel exercises program","9681":"Internet-based self-management support","9682":"Internet-based self-management support","9683":"Internet-based self-management support","9684":"Internet-based self-management support","9685":"High-fat emulsion 20 ml","9686":"High-fat emulsion 20 ml","9687":"High-fat emulsion 20 ml","9688":"High-fat emulsion 20 ml","9689":"High-fat emulsion 20 ml","9690":"Betahistine ","9691":"Trabedersen 10 \u03bcM ","9692":"Trabedersen 10 \u03bcM ","9693":"Trabedersen 80 \u03bcM ","9694":"Trabedersen 10 \u03bcM ","9695":"Trabedersen 10 \u03bcM ","9696":"Trabedersen 80 \u03bcM ","9697":"Crushed intranasal Morphine ARER","9698":"Crushed intranasal Morphine ARER","9699":"Crushed intranasal Morphine ARER","9700":"Crushed intranasal Morphine ARER","9701":"Crushed intranasal Morphine ARER","9702":"Posterior-stabilized symmetric tibial baseplate","9703":"Posterior-stabilized symmetric tibial baseplate","9704":"Posterior-stabilized symmetric tibial baseplate","9705":"Posterior-stabilized symmetric tibial baseplate","9706":"Posterior-stabilized symmetric tibial baseplate","9707":"Posterior-stabilized symmetric tibial baseplate","9708":"Piezon Master 700","9709":"Canagliflozin ","9710":"Canagliflozin ","9711":"Canagliflozin ","9712":"Canagliflozin ","9713":"Canagliflozin ","9714":"Caregiver Training in Mindfulness ","9715":"Caregiver Training in Mindfulness ","9716":"Caregiver Training in Mindfulness ","9717":"Caregiver Training in Mindfulness ","9718":"Caregiver Training in Mindfulness ","9719":"Correctional insulin","9720":"Correctional insulin","9721":"Correctional insulin","9722":"Correctional insulin","9723":"Correctional insulin","9724":"Salbutamol ","9725":"Salbutamol ","9726":"Salbutamol ","9727":"Salbutamol ","9728":"Insulin glargine","9729":"Insulin glargine","9730":"Whole-body vibration","9731":"Whole-body vibration","9732":"Whole-body vibration","9733":"Whole-body vibration","9734":"Whole-body vibration","9735":"Sugarsquare web portal intervention","9736":"Sugarsquare web portal intervention","9737":"Aprepitant 5 days","9738":"Aprepitant 5 days","9739":"Aprepitant 5 days","9740":"Aprepitant 5 days","9741":"Aprepitant 5 days","9742":"Low pressure carbon dioxide ","9743":"Low pressure carbon dioxide ","9744":"Low pressure carbon dioxide ","9745":"Levosimendan + sodium nitroprusside","9746":"Levosimendan + sodium nitroprusside","9747":"Levosimendan + sodium nitroprusside","9748":"Levosimendan + sodium nitroprusside","9749":"Levosimendan + sodium nitroprusside","9750":"Propofol ","9751":"Propofol ","9752":"Propofol ","9753":"Propofol ","9754":"Propofol ","9755":"Propofol ","9756":"Propofol ","9757":"Daikenchuto ","9758":"Daikenchuto ","9759":"Daikenchuto ","9760":"Daikenchuto ","9761":"Daikenchuto ","9762":"Daikenchuto ","9763":"Phase I Surgery","9764":"Phase I Surgery","9765":"Phase I Surgery","9766":"Phase I Surgery","9767":"Ropivacaine ","9768":"Ropivacaine ","9769":"Ropivacaine ","9770":"Ropivacaine ","9771":"Ropivacaine ","9772":"Ropivacaine ","9773":"Partial matrix excision","9774":"Partial matrix excision","9775":"Low-Sodium, High-Potassium Salt Substitute","9776":"Low-Sodium, High-Potassium Salt Substitute","9777":"Low-Sodium, High-Potassium Salt Substitute","9778":"Chronic Disease Self-management Program","9779":"Chronic Disease Self-management Program","9780":"Chronic Disease Self-management Program","9781":"Chronic Disease Self-management Program","9782":"Chronic Disease Self-management Program","9783":"Duloxetine ","9784":"Duloxetine ","9785":"Duloxetine ","9786":"Duloxetine ","9787":"FACETS programme","9788":"FACETS programme","9789":"FACETS programme","9790":"Levonorgestrel-releasing intrauterine system","9791":"Levonorgestrel-releasing intrauterine system","9792":"Ropivacaine-fentanyl-clonidine ","9793":"Ropivacaine-clonidine ","9794":"Gelatin sponge + moist wound-healing","9795":"Gelatin sponge + moist wound-healing","9796":"Gelatin sponge + moist wound-healing","9797":"Gelatin sponge + moist wound-healing","9798":"Oral phloroglucin","9799":"Oral phloroglucin","9800":"Oral phloroglucin","9801":"Oral phloroglucin","9802":"Oral phloroglucin","9803":"Alirocumab + ezetimibe","9804":"Alirocumab + ezetimibe","9805":"Veterans Affairs Diabetes Prevention Program","9806":"Veterans Affairs Diabetes Prevention Program","9807":"Veterans Affairs Diabetes Prevention Program","9808":"Multivitamins and minerals - 2 sachets per week ","9809":"Multivitamins and minerals - 1 sachet daily","9810":"Multivitamins and minerals - 1 sachet a day","9811":"Humidified heated breathing circuits","9812":"Stent-less group","9813":"Stent-less group","9814":"Homeopathic combination preparation","9815":"Implicitly priming mindfulness","9816":"Laparoscopic appendectomy","9817":"Tadalafil 20 mg on demand","9818":"Oral perhexiline","9819":"Oral perhexiline","9820":"Oral perhexiline","9821":"Educational program ","9822":"Aloe vera gel wound-dressing ","9823":"Aloe vera gel wound-dressing ","9824":"Aloe vera gel wound-dressing ","9825":"Lidocaine","9826":"Lidocaine","9827":"Turmeric gel","9828":"Turmeric gel","9829":"Chlorhexidine gel","9830":"Knifelight","9831":"Knifelight","9832":"Dosing titration IGF0T","9833":"Dosing titration IGF0T","9834":"Roy's Adaptation Model-Guided Education","9835":"Roy's Adaptation Model-Guided Education","9836":"Roy's Adaptation Model-Guided Education","9837":"Antidepressants + injectable vitamin B12 ","9838":"Antidepressants + injectable vitamin B12 ","9839":"Oxybutinin ","9840":"Tolterodine ","9841":"Tolterodine ","9842":"Tranexamic Acid","9843":"Enalapril","9844":"Enalapril","9845":"Escitalopram ","9846":"Escitalopram ","9847":"Escitalopram ","9848":"Lixisenatide with normal renal function ","9849":"Lixisenatide with normal renal function ","9850":"Lixisenatide with moderate impairment ","9851":"Posterior lamellar tarsal rotation surgery","9852":"Posterior lamellar tarsal rotation surgery","9853":"Posterior lamellar tarsal rotation surgery","9854":"Posterior lamellar tarsal rotation surgery","9855":"Traditional Acupuncture Group ","9856":"Control Acupuncture Group","9857":"Medial approach arthroplasty","9858":"Medial approach arthroplasty","9859":"Medial approach arthroplasty","9860":"Tongue strength training","9861":"Tongue strength training","9862":"Selenium ","9863":"Selenium ","9864":"Selenium ","9865":"Selenium ","9866":"Selenium ","9867":"Systematic depression screening","9868":"Systematic depression screening","9869":"Drug-coated balloon","9870":"Drug-coated balloon","9871":"Drug-coated balloon","9872":"Walking","9873":"Walking","9874":"Aquatic physical therapy","9875":"Aquatic physical therapy","9876":"Aquatic physical therapy","9877":"Comfrey root extract + methyl nicotinate","9878":"Isomaltulose ","9879":"Isomaltulose ","9880":"Isomaltulose ","9881":"Isomaltulose ","9882":"Isomaltulose ","9883":"Isomaltulose ","9884":"Early Post Operative Enteral Feeding ","9885":"Clonidine","9886":"Clonidine","9887":"Septoplasty","9888":"Comprehensive care","9889":"Interdisciplinary care","9890":"Comprehensive care","9891":"Interdisciplinary care","9892":"Plantar-flexor Static Stretch Training in non-trained patients ","9893":"Plantar-flexor Static Stretch Training in non-trained patients ","9894":"X-ray low dose irradiation ","9895":"X-ray low dose irradiation ","9896":"Partial matrix excision","9897":"Partial matrix excision","9898":"Partial matrix excision","9899":"Low-Sodium, High-Potassium Salt Substitute","9900":"Chronic Disease Self-management Program","9901":"Psycho-educational program ","9902":"Psycho-educational program ","9903":"Psycho-educational program ","9904":"Psycho-educational program ","9905":"Duloxetine ","9906":"FACETS programme","9907":"FACETS programme","9908":"Levonorgestrel-releasing intrauterine system","9909":"Levonorgestrel-releasing intrauterine system","9910":"Levonorgestrel-releasing intrauterine system","9911":"Ropivacaine-fentanyl-clonidine ","9912":"Ropivacaine-fentanyl-clonidine ","9913":"Ropivacaine-fentanyl-clonidine ","9914":"Ropivacaine-fentanyl-clonidine ","9915":"Gelatin sponge + moist wound-healing","9916":"Gelatin sponge + moist wound-healing","9917":"Oral phloroglucin","9918":"Alirocumab + fenofibrate ","9919":"Alirocumab + ezetimibe","9920":"Alirocumab + ezetimibe","9921":"Veterans Affairs Diabetes Prevention Program","9922":"Veterans Affairs Diabetes Prevention Program","9923":"Multivitamins and minerals - 2 sachets per week ","9924":"Multivitamins and minerals - 1 sachet daily","9925":"Multivitamins and minerals - 2 sachets a week","9926":"Humidified heated breathing circuits","9927":"Humidified heated breathing circuits","9928":"Stent-less group","9929":"Stent-less group","9930":"Stent-less group","9931":"Homeopathic combination preparation","9932":"Homeopathic combination preparation","9933":"Implicitly priming mindfulness","9934":"Implicitly priming mindfulness","9935":"Implicitly priming mindfulness","9936":"Laparoscopic appendectomy","9937":"Laparoscopic appendectomy","9938":"Laparoscopic appendectomy","9939":"Laparoscopic appendectomy","9940":"Laparoscopic appendectomy","9941":"Tadalafil 5 mg once daily","9942":" Aequasyal\u00ae","9943":" Aequasyal\u00ae","9944":" Aequasyal\u00ae","9945":"DC161\u2010DP0291","9946":"DC161\u2010DP0291","9947":"Oral perhexiline","9948":"Oral perhexiline","9949":"Oral perhexiline","9950":"Educational program ","9951":"Educational program ","9952":"Educational program ","9953":"Educational program ","9954":"Educational program ","9955":"Aloe vera gel wound-dressing ","9956":"Lidocaine","9957":"Lidocaine","9958":"Lidocaine","9959":"Turmeric gel","9960":"Chlorhexidine gel","9961":"Turmeric gel","9962":"Knifelight","9963":"Knifelight","9964":"Dosing titration IGF0T","9965":"Dosing titration IGF0T","9966":"Roy's Adaptation Model-Guided Education","9967":"Roy's Adaptation Model-Guided Education","9968":"Corticosteroid periarticular injections","9969":"Corticosteroid periarticular injections","9970":"Corticosteroid periarticular injections","9971":"Corticosteroid periarticular injections","9972":"Corticosteroid periarticular injections","9973":"Antidepressants + injectable vitamin B12 ","9974":"Oxybutinin ","9975":"Oxybutinin ","9976":"Tranexamic Acid","9977":"Tranexamic Acid","9978":"Tranexamic Acid","9979":"Enalapril","9980":"Enalapril","9981":"Lixisenatide with moderate impairment ","9982":"Lixisenatide with moderate impairment ","9983":"Posterior lamellar tarsal rotation surgery","9984":"Posterior lamellar tarsal rotation surgery","9985":"Next-day review","9986":"Next-day review","9987":"Medial approach arthroplasty","9988":"Tongue strength training","9989":"Systematic depression screening","9990":"Systematic depression screening","9991":"Systematic depression screening","9992":"Systematic depression screening","9993":"Drug-coated balloon","9994":"Drug-coated balloon","9995":"Drumming on drum pads","9996":"Virtual drumming ","9997":"Aquatic physical therapy","9998":"Aquatic physical therapy","9999":"Aquatic physical therapy","10000":"Comfrey root extract + methyl nicotinate","10001":"Comfrey root extract + methyl nicotinate","10002":"Comfrey root extract + methyl nicotinate","10003":"Early Post Operative Enteral Feeding ","10004":"Early Post Operative Enteral Feeding ","10005":"Early Post Operative Enteral Feeding ","10006":"Early Post Operative Enteral Feeding ","10007":"Early Post Operative Enteral Feeding ","10008":"Clonidine","10009":"Septoplasty","10010":"Septoplasty","10011":"Plantar-flexor Static Stretch Training in trained patients ","10012":"Plantar-flexor Static Stretch Training in trained patients ","10013":"X-ray low dose irradiation ","10014":"X-ray low dose irradiation ","10015":"X-ray low dose irradiation ","10016":"X-ray low dose irradiation ","10017":"Transcranial direct current stimulation","10018":"Transcranial direct current stimulation","10019":"Rosiglitazone plus glimepiride","10020":"Budesonide\/formoterol pMDI 160\/9 \u03bcg","10021":"soundfield amplification devices in the classroom","10022":"oral metformin 500 mg TDS (Group-A)","10023":"Charite\u0301 artificial disc","10024":"smelled and rated an odorant and were told that the odorant increases creativity and reduces inhibitions ","10025":"Cerebral NIRS monitoring in combination with an evidence based intervention guideline","10026":"Interaction with an obese patient in a digital environment","10027":"tablet colchicine orally, 0.5 mg twice daily and 0.5 ml intralesional injection Hyaluronidase 1,500 IU into each buccal mucosa once a week","10028":"deep breathing with essential oils","10029":"donepezil in addition to lithium","10030":"ASV group","10031":"Sitagliptin","10032":"Stress managin training","10033":"\"Question writing\" method","10034":"certolizumab pegol (CZP) 400 mg every 4 weeks + methotrexate","10035":"Offering free continuing medical education","10036":"Standard group","10037":"placebo","10038":"Prednisone","10039":"PEG-based laxatives","10040":"Dexamethasone + epinephrine","10041":"mothers: educational workshop","10042":"nonbiopsied patients"},"Comparator":{"0":"identical amounts of gelatin infusion","1":"Rosiglitazone plus glimepiride","2":"Placebo","3":"Rosiglitazone plus glimepiride","4":"Body-weight supported treadmill training combined with Lokomat (Pre-test)","5":"Rosiglitazone plus glimepiride","6":"Placebo plus glimepiride","7":"Chloroquine","8":"Body-weight supported treadmill training combined with Lokomat (Pre-test)","9":"Placebo plus glimepiride ","10":"Chloroquine","11":"Rosiglitazone plus glimepiride","12":"Normal unit & Special unit","13":"Rosiglitazone plus glimepiride","14":"Placebo plus glimepiride","15":"Placebo plus glimepiride","16":"Rosiglitazone plus glimepiride","17":"Rosiglitazone plus glimepiride","18":"placebo group","19":"Placebo plus glimepiride","20":"Slow treadmill speed","21":"Rosiglitazone plus glimepiride","22":"Chloroquine","23":"Chloroquine","24":"Manually-assisted body-weight supported treadmill training","25":"Chloroquine","26":"Chloroquine","27":"Placebo plus glimepiride","28":"Placebo","29":"Rosiglitazone plus glimepiride ","30":"Placebo plus glimepiride","31":"Body-weight supported treadmill training combined with Lokomat (Pre-test)","32":"Chloroquine","33":"Chloroquine","34":"Placebo plus glimepiride","35":"Placebo plus glimepiride","36":"Placebo plus glimepiride ","37":"Normal unit & Special unit","38":"Placebo","39":"Rosiglitazone plus glimepiride","40":"identical amounts of gelatin infusion","41":"Normal unit & Special unit","42":"Chloroquine","43":"Comparison arm ","44":"placebo","45":"table-based PEEP (control) group","46":"Placebo plus glimepiride ","47":"Placebo","48":"Rosiglitazone plus glimepiride","49":"Rosiglitazone plus glimepiride","50":"Rosiglitazone plus glimepiride","51":"Rosiglitazone plus glimepiride","52":"Rosiglitazone plus glimepiride","53":"Normal unit & Special unit","54":"Rosiglitazone plus glimepiride","55":"non-abstainers in the placebo group","56":"Placebo plus glimepiride","57":"Chloroquine","58":"Rosiglitazone plus glimepiride ","59":"identical amounts of gelatin infusion","60":"Placebo","61":"Comparison arm ","62":"Normal unit & Special unit","63":"Body-weight supported treadmill training combined with Lokomat (Pre-test)","64":"Placebo","65":"table-based PEEP (control) group","66":"Placebo plus glimepiride","67":"Chloroquine","68":"placebo","69":"Rosiglitazone plus glimepiride ","70":"Placebo plus glimepiride","71":"Placebo","72":"Placebo plus glimepiride","73":"identical amounts of gelatin infusion","74":"Rosiglitazone plus glimepiride ","75":"Placebo","76":"Body-weight supported treadmill training combined with Lokomat (Pre-test)","77":"Placebo plus glimepiride","78":"Placebo plus glimepiride","79":"Manually-assisted body-weight supported treadmill training","80":"identical amounts of gelatin infusion","81":"Rosiglitazone plus glimepiride","82":"Rosiglitazone plus glimepiride ","83":"Comparison arm ","84":"Placebo plus glimepiride","85":"Placebo plus glimepiride ","86":"Liraglutide (1.2 mg) plus glimepiride","87":"identical amounts of gelatin infusion","88":"Rosiglitazone plus glimepiride","89":"Placebo plus glimepiride","90":"Normal unit & Special unit","91":"Body-weight supported treadmill training combined with Lokomat (Pre-test)","92":"Placebo","93":"Placebo plus glimepiride ","94":"Chloroquine","95":"Placebo","96":"Chloroquine","97":"Placebo plus glimepiride","98":"Placebo plus glimepiride","99":"Rosiglitazone plus glimepiride ","100":"Placebo plus glimepiride","101":"Rosiglitazone plus glimepiride","102":"placebo","103":"Intravenous piperacillin\u2013tazobactam, 3.375 g every 6 hours","104":"Placebo plus glimepiride","105":"Rosiglitazone plus glimepiride","106":"placebo","107":"Placebo plus glimepiride ","108":"Normal unit & Special unit","109":"Placebo plus glimepiride","110":"Midline incision","111":"Placebo","112":"Placebo","113":"Placebo","114":"Placebo","115":"Patients who didn't receive a question prompt sheet","116":"placebo","117":"Placebo","118":"Midline incision","119":"anterior cervical decompression and fusion (ACDF) with Trabecular MetalTM (TM)","120":"Standard information about self-care","121":"Formoterol DPI 9 \u03bcg","122":"Placebo","123":"dihydroartemisinin-piperaquine (AP)","124":"Conventional open approach","125":"Usual care","126":"Hepatic resection","127":"Thin-flap laser in situ keratomileusis (LASIK)","128":"Standard information about self-care","129":"Hepatic resection","130":"Hepatic resection","131":"Placebo","132":"no enema","133":"Formoterol DPI 9 \u03bcg","134":"Midline incision","135":"Placebo","136":"Thin-flap laser in situ keratomileusis (LASIK)","137":"Midline incision","138":"anterior cervical decompression and fusion (ACDF) with Trabecular MetalTM (TM)","139":"Placebo","140":"Midline incision","141":"Etoposide with 5-fluorouracil plus leucovorin (ELF)","142":"Midline incision","143":"Thin-flap laser in situ keratomileusis (LASIK)","144":"Baseline communities that received standard Government services","145":"Etoposide with 5-fluorouracil plus leucovorin (ELF)","146":"standard care","147":"Bladder training only (BT)","148":"intravenous immunoglobulin (IVIG)","149":"Hepatic resection","150":"Conventional open approach","151":"control group","152":"Conventional open approach","153":"artemether-lumefantrine","154":"Pre-surgery baseline","155":"Conventional open approach","156":"Midline incision","157":"Conventional open approach","158":"Patients who didn't receive a question prompt sheet","159":"Formoterol DPI 9 \u03bcg","160":"placebo","161":"Baseline communities that received standard Government services","162":"Tolterodine only (To)","163":"Patients who didn't receive a question prompt sheet","164":"Pre-surgery baseline","165":"Usual care","166":"Usual care","167":"No exercise","168":"Placebo","169":"Usual care","170":"Placebo","171":"Standard information about self-care","172":"Baseline communities that received standard Government services","173":"dihydroartemisinin-piperaquine (AP)","174":"Placebo","175":"Standard information about self-care","176":"Baseline communities that received standard Government services","177":"Midline incision","178":"Usual care","179":"Placebo","180":"Standard information about self-care","181":"Patients who didn't receive a question prompt sheet","182":"Midline incision","183":"Placebo","184":"Placebo","185":"Usual care","186":"No exercise","187":"Usual care","188":"Midline incision","189":"Bladder training only (BT)","190":"Baseline communities that received standard Government services","191":"Midline incision","192":"Standard information about self-care","193":"Formoterol DPI 9 \u03bcg","194":"Baseline communities that received standard Government services","195":"Standard information about self-care","196":"Formoterol DPI 9 \u03bcg","197":"Usual airway clearance techniques","198":"placebo","199":"Thin-flap laser in situ keratomileusis (LASIK)","200":"Standard information about self-care","201":"placebo","202":"Usual care","203":"Usual care","204":"Etoposide with 5-fluorouracil plus leucovorin (ELF)","205":"Conventional open approach","206":"Usual care","207":"Formoterol DPI 9 \u03bcg","208":"Baseline communities that received standard Government services","209":"Etoposide with 5-fluorouracil plus leucovorin (ELF)","210":"Placebo","211":"Usual care","212":"Placebo","213":"artemether-lumefantrine","214":"Placebo","215":"Usual care","216":"Tolterodine only (To)","217":"Placebo","218":"placebo","219":"control group","220":"Placebo","221":"Placebo","222":"Placebo","223":"Prostaglandin gel","224":"control group","225":"Pentobarbital","226":"Thin-flap laser in situ keratomileusis (LASIK)","227":"prosthetic repair with e-PTFE patch (PR)","228":"Etoposide with 5-fluorouracil plus leucovorin (ELF)","229":"Pre-surgery baseline","230":"Placebo","231":"placebo","232":"intravenous immunoglobulin (IVIG)","233":"Formoterol DPI 9 \u03bcg","234":"Placebo","235":"placebo","236":"Standard information about self-care","237":"Formoterol DPI 9 \u03bcg","238":"Usual airway clearance techniques","239":"Conventional open approach","240":"Pentobarbital","241":"Placebo","242":"Placebo","243":"Thin-flap laser in situ keratomileusis (LASIK)","244":"vehicle control solution (carrier with no diclofenac)","245":"Midline incision","246":"Standard information about self-care","247":"Hepatic resection","248":"Communities that received standard Government services","249":"Placebo","250":"Standard information about self-care","251":"Placebo","252":"Midline incision","253":"Usual care","254":"no enema","255":"artemether-lumefantrine","256":"Midline incision","257":"Placebo","258":"Formoterol DPI 9 \u03bcg","259":"Standard information about self-care","260":"Thin-flap laser in situ keratomileusis (LASIK)","261":"Placebo","262":"Hepatic resection","263":"Prostaglandin gel","264":"placebo","265":"Formoterol DPI 9 \u03bcg","266":"Baseline communities that received standard Government services","267":"Formoterol DPI 9 \u03bcg","268":"Formoterol DPI 9 \u03bcg","269":"Placebo","270":"Formoterol DPI 9 \u03bcg","271":"Usual care","272":"Conventional open approach","273":"Usual airway clearance techniques","274":"Conventional open approach","275":"Midline incision","276":"Formoterol DPI 9 \u03bcg","277":"artemether-lumefantrine (AL) and and Artesunate+chlorproguanil-dapsone (AS+CD)","278":"Formoterol DPI 9 \u03bcg","279":"dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)","280":"inadequate motivation\/capability","281":"free stride frequency","282":"Practitioner-delivered brief advice","283":"similar placebo, twice daily after a meal for 14 consecutive days","284":"dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)","285":"surgery","286":"surgery","287":"received only standard therapy for sepsis","288":"local anesthetic infiltration of the port site.","289":"standard maternity care","290":"Mefloquine-artesunate","291":"similar placebo, twice daily after a meal for 14 consecutive days","292":"surgery","293":"Ultrasound\u2010guided foam sclerotherapy","294":"Godugdha sodhit Langali moola with honey for external application","295":"fibromyalgia (FM) education control (FME) group - received information and support","296":"Facility-based HIV-care strategy","297":"Placebo gel","298":"fibromyalgia (FM) education control (FME) group - received information and support","299":"high-fiber moderate-GI diet (HF) (target glycemic index GI ~60)","300":"Placebo gel","301":"surgery","302":"glucose 5% solution","303":"BioModular\u00ae shoulder prosthesis","304":"local anesthetic infiltration of the port site.","305":"normal saline 0.9% solution","306":"Atorvastatin","307":"dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)","308":"inadequate motivation\/capability","309":"Mefloquine-artesunate","310":"opening subcutaneous tissues with scalpel","311":"Cisplatin and Cyclophosphamide","312":"high-fiber moderate-GI diet (HF) (target glycemic index GI ~60)","313":"Placebo gel","314":"Placebo","315":"Facility-based HIV-care strategy","316":"dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)","317":"surgery","318":"received antibiotics only when infection was suspected or established","319":"control group","320":"inadequate motivation\/capability","321":"set a quit date and received a general health video message sent to their phone every 2 weeks.","322":"Placebo","323":"Formoterol DPI 9 \u03bcg","324":"Formoterol DPI 9 \u03bcg","325":"Midline incision","326":"Placebo","327":"No exercise","328":"Placebo","329":"Formoterol DPI 9 \u03bcg","330":"Formoterol DPI 9 \u03bcg","331":"Thin-flap laser in situ keratomileusis (LASIK)","332":"Placebo","333":"Bladder training only (BT)","334":"Pentobarbital","335":"Usual airway clearance techniques","336":"intravenous immunoglobulin (IVIG)","337":"Standard information about self-care","338":"Placebo","339":"Standard information about self-care","340":"Placebo","341":"Formoterol DPI 9 \u03bcg","342":"no enema","343":"Usual airway clearance techniques","344":"Conventional open approach","345":"Hepatic resection","346":"Placebo","347":"placebo","348":"Pentobarbital","349":"placebo","350":"vehicle control solution (carrier with no diclofenac)","351":"anterior cervical decompression and fusion (ACDF) with Trabecular MetalTM (TM)","352":"No medication was given to the control group","353":"No exercise","354":"Midline incision","355":"Pre-surgery baseline","356":"Formoterol DPI 9 \u03bcg","357":"Usual airway clearance techniques","358":"Communities that received standard Government services","359":"prosthetic repair with e-PTFE patch (PR)","360":"Formoterol DPI 9 \u03bcg","361":"Prostaglandin gel","362":"Placebo","363":"placebo","364":"Pentobarbital","365":"Placebo","366":"Prostaglandin gel","367":"vehicle control solution (carrier with no diclofenac)","368":"Formoterol DPI 9 \u03bcg","369":"Conventional open approach","370":"Placebo","371":"Midline incision","372":"Placebo","373":"placebo","374":"Usual airway clearance techniques","375":"Hepatic resection","376":"No exercise","377":"Standard information about self-care","378":"intravenous immunoglobulin (IVIG)","379":"Placebo","380":"No exercise","381":"Midline incision","382":"Pre-surgery baseline","383":"Usual care","384":"Conventional open approach","385":"Hepatic resection","386":"Thin-flap laser in situ keratomileusis (LASIK)","387":"Usual airway clearance techniques","388":"Placebo","389":"Baseline communities that received standard Government services","390":"Formoterol DPI 9 \u03bcg","391":"vehicle control solution (carrier with no diclofenac)","392":"Placebo","393":"Formoterol DPI 9 \u03bcg","394":"Pentobarbital","395":"Pentobarbital","396":"Formoterol DPI 9 \u03bcg","397":"artemether-lumefantrine (AL)","398":"Pentobarbital","399":"Formoterol DPI 9 \u03bcg","400":"Formoterol DPI 9 \u03bcg","401":"intravenous immunoglobulin (IVIG)","402":"Midline incision","403":"Pentobarbital","404":"Atorvastatin","405":"Atorvastatin","406":"Mefloquine-artesunate","407":"Interferon (IFN)-\u03b1","408":"palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16 Gy\/2 fr\/day 1 and 8 (arm B)","409":"high-fiber moderate-GI diet (HF) (target glycemic index GI ~60)","410":"received antibiotics only when infection was suspected or established","411":"control group","412":"No exercise","413":"received no treatment","414":"received no treatment","415":"standard maternity care","416":"standard maternity care","417":"Usual care comprised of 7 weeks of group support sessions","418":"Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA)","419":"Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA)","420":"control","421":"free stride frequency","422":"free stride frequency","423":"surgery","424":"surgery","425":"surgery","426":"surgery","427":"surgery","428":"surgery","429":"equal volume of normal saline, 30 min before spinal anesthesia","430":"dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)","431":"passive physical therapy","432":"Facility-based HIV-care strategy","433":"Facility-based HIV-care strategy","434":"Facility-based HIV-care strategy","435":"similar placebo, twice daily after a meal for 14 consecutive days","436":"Cisplatin and Cyclophosphamide","437":"Practitioner-delivered brief advice","438":"Placebo lozenge","439":"Placebo lozenge","440":"BioModular\u00ae shoulder prosthesis","441":"Atorvastatin","442":"Atorvastatin","443":"Mefloquine-artesunate","444":"Mefloquine-artesunate","445":"Mefloquine-artesunate","446":"Interferon (IFN)-\u03b1","447":"Interferon (IFN)-\u03b1","448":"Interferon (IFN)-\u03b1","449":"Interferon (IFN)-\u03b1","450":"palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16 Gy\/2 fr\/day 1 and 8 (arm B)","451":"palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16 Gy\/2 fr\/day 1 and 8 (arm B)","452":"set a quit date and received a general health video message sent to their phone every 2 weeks.","453":"received antibiotics only when infection was suspected or established","454":"received antibiotics only when infection was suspected or established","455":"control group","456":"received only standard therapy for sepsis","457":"received only standard therapy for sepsis","458":"received no treatment","459":"received no treatment","460":"fibromyalgia (FM) education control (FME) group - received information and support","461":"fibromyalgia (FM) education control (FME) group - received information and support","462":"fibromyalgia (FM) education control (FME) group - received information and support","463":"fibromyalgia (FM) education control (FME) group - received information and support","464":"Usual care comprised of 7 weeks of group support sessions","465":"Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA)","466":"free stride frequency","467":"2\u20134 stereo radiograph pair examinations","468":"surgery","469":"surgery","470":"surgery","471":"Ultrasound\u2010guided foam sclerotherapy","472":"equal volume of normal saline, 30 min before spinal anesthesia","473":"passive physical therapy","474":"standard care","475":"routine replacement","476":"placebo","477":"Usual airway clearance techniques","478":"palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16?Gy\/2 fr\/day 1 and 8 (arm B)","479":"Etoposide with 5-fluorouracil plus leucovorin (ELF)","480":"surgery","481":"surgery","482":"surgery","483":"Ultrasound?guided foam sclerotherapy","484":"Ultrasound?guided foam sclerotherapy","485":"placebo","486":"the placebo group receiving an equivalent number of identical placebo capsules, which were continued daily for a period of 16 weeks","487":"before repetitive facilitative exercises and orthotic treatment.","488":"Before trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results.","489":"no treatment","490":"\"no phone calls\" group","491":"standard group","492":"placebo (n = 30) every 2 weeks for 12 weeks","493":"placebo (n = 30) every 2 weeks for 12 weeks","494":"tacrolimus groups","495":"Placebo","496":"placebo","497":"placebo","498":"placebo","499":"0.9% saline","500":"24-hour recall","501":"undergo a tubal resection after bipolar coagulation with Kleppinger forceps","502":"undergo a tubal resection after bipolar coagulation with Kleppinger forceps","503":"coronally positioned flap (CPF) without acellular dermal matrix allograft (ADMA).","504":"10-15 mg\/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was administered at 09.00-10.00 pm ","505":"no text message","506":"baseline","507":"Custodiol","508":"Custodiol","509":"cemented component.","510":"Employee Assistance Program","511":"manual chest compression for cardiopulmonary resuscitation (CPR) of out-of-hospital cardiac arrest (OHCA)","512":"Cisplatin and Cyclophosphamide","513":"Cisplatin and Cyclophosphamide","514":"Practitioner-delivered brief advice","515":"Placebo","516":"Placebo gel","517":"Placebo lozenge","518":"Placebo lozenge","519":"BioModular\u00ae shoulder prosthesis","520":"Atorvastatin","521":"goat milk","522":"palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16?Gy\/2 fr\/day 1 and 8 (arm B)","523":"dihydroartemisinin-piperaquine (AP)","524":"placebo","525":"0.9% saline","526":"24-hour recall","527":"black women","528":"placebo from 9-16 weeks gestation until delivery.","529":"Haptoglobin's (Hp) 2-2 phenotypes","530":"undergo a tubal resection after bipolar coagulation with Kleppinger forceps","531":"10-15 mg\/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was replaced by equivalent dose of prednisolone suspension which was administered at 10.00 pm.","532":"minimally exposed volunteers for both antigens","533":"nothing","534":"nothing","535":"clear IOL was used as a control.","536":"no antibiotics","537":"no antibiotics","538":"Custodiol","539":"placebo","540":"surgery","541":"surgery","542":"Employee Assistance Program","543":"surgery","544":"usual care","545":"surgery","546":"nothing","547":"surgery","548":"equal volume of normal saline, 30 min before spinal anesthesia","549":"placebo","550":"before repetitive facilitative exercises and orthotic treatment.","551":"before repetitive facilitative exercises and orthotic treatment.","552":"Before trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results.","553":"no treatment","554":"\"no phone calls\" group","555":"standard mental health care","556":"major salivary gland cancer in high risk group without adjuvant radiation therapy","557":"major salivary gland cancer in low\/intermediate risk group without adjuvant radiation therapy","558":"placebo (n = 30) every 2 weeks for 12 weeks","559":"amoxicillin (750 mg), clarithromycin (200 mg), and rabeprazole (10 mg) (RAC group), twice a day for one week.","560":"Technology Enhanced Quitline-20","561":"Placebo","562":"baseline","563":"baseline","564":"Inpatient treatment","565":"Inpatient treatment","566":"baseline","567":"placebo","568":"Conventional tobacco cigarette","569":"placebo","570":"Basic weight loss maintenance program","571":"Standard care","572":"Standard care","573":"pressure support ventilation (PSV)","574":"Standard care","575":"Standard care","576":"pressure support ventilation (PSV)","577":"Placebo?plus MTX or Golimumab","578":"sodium bicarbonate solution using the long regimen (initial intravenous bolus of 3 mL\/kg\/h of 166 mEq\/L sodium bicarbonate for 6 hr).","579":"Long-term psychotherapy","580":"placebo","581":"no therapy","582":"Oral etoposide","583":"no therapy","584":"traditional on-site learning activity","585":"Exercise alone","586":"Exercise alone","587":"no breathing exercises ","588":"no breathing exercises ","589":"received normal saline","590":"placebo","591":"analysis of covariance (ANOVA or ANCOVA) with missing data imputed by the last observation carried forward approach (LOCF_ANCOVA)","592":"placebo","593":"placebo","594":"core decompression only","595":"core decompression only","596":"placebo","597":"hip abduction at 0\u00b0 and 30\u00b0","598":"received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA) ","599":"maltodextrin (placebo)","600":"primary trabeculectomy group 2","601":"cervical stability training (CST)","602":"spice-free control meal","603":"morphine","604":"basal diet","605":"basal diet","606":"Walking intervention (W)","607":"Walking intervention (W)","608":"Commercial sponsored trials","609":"no helium","610":"Medication only","611":"Ropivacaine 0.2% alone (Group A) ","612":"Ropivacaine 0.2% alone (Group A) ","613":"Ropivacaine 0.2% alone (Group A)","614":"Usual care","615":"Usual care","616":"receive the usual health messages from the Matlab regular health staff","617":"website without social presence elements.","618":"website without social presence elements.","619":"Non-mentored group","620":"EDSS\/T25FW or EDSS\/9HPT","621":"administered Sarkaradi Granules (SG).","622":"Relaxation","623":"CAPOX","624":"ASH group","625":"No exercises","626":"continuous training (CT) 12-weeks inpatients NYHA II-III","627":"Low-dose bupivacaine spinal anesthesia in healthy parturients","628":"octylonium 20 mg","629":"Placebo","630":"C-group - the Newborn Intensive Care Unit (NICU) experience (exposure to bright lights, heightened sound, frequent interventions), which alters brain development.","631":"Baseline characteristics","632":"Betadine ointment","633":"Betadine ointment","634":"Standard quitline treatment","635":"Standard quitline treatment","636":"Conventional tobacco cigarette","637":"Basic weight loss maintenance program","638":"Basic weight loss maintenance program","639":"Standard care","640":"Oral etoposide","641":"Exercise alone","642":"Exercise alone","643":"Conventional Ventilation","644":"Conventional Ventilation","645":"hip abduction at 0\u00b0 and 30\u00b0","646":"hip abduction at 0\u00b0 and 30\u00b0","647":"Placebo","648":"primary trabeculectomy group 2","649":"cervical stability training (CST)","650":"spice-free control meal","651":"basal diet","652":"basal diet","653":"basal diet","654":"basal diet","655":"no helium","656":"no helium","657":"Group N, the same volume (5 mL) of normal saline was injected","658":"no exercise","659":"no exercise","660":"no exercise","661":"9-hole peg test [9HPT]","662":"administered Sarkaradi Granules (SG).","663":"the SCBT with medication group or regular medication group","664":"the SCBT with medication group ","665":"a single dose of Ad35-GRIN or SeV-Gag","666":"SLA, SHA, SHSH, and placebo groups,","667":"continuous training (CT) 12-weeks inpatients NYHA II-III","668":"octylonium 20 mg","669":"octylonium 20 mg","670":"no comorbidities","671":"Placebo\u2014PL","672":"baseline","673":"baseline","674":"placebo","675":"before treatment","676":"sodium bicarbonate solution using the long regimen (initial intravenous bolus of 3 mL\/kg\/h of 166 mEq\/L sodium bicarbonate for 6 hr).","677":"sodium bicarbonate solution using the long regimen (initial intravenous bolus of 3 mL\/kg\/h of 166 mEq\/L sodium bicarbonate for 6 hr).","678":"placebo","679":"a balance training group for an 8-week balance training period.","680":"received normal saline","681":"placebo","682":"placebo","683":"placebo","684":"placebo","685":"placebo","686":"placebo","687":"placebo","688":"received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA) ","689":"placebo","690":"healthy","691":"not displayed in the control.","692":"the placebo group receiving an equivalent number of identical placebo capsules, which were continued daily for a period of 16 weeks","693":"standard mental health care","694":"standard mental health care","695":"amoxicillin (750 mg), clarithromycin (200 mg), and rabeprazole (10 mg) (RAC group), twice a day for one week.","696":"before Non-Invasive Brain Stimulation (NIBS)","697":"tacrolimus groups","698":"goat milk","699":"before intervention","700":"nothing","701":"nothing","702":"no weight lost","703":"nothing","704":"nothing","705":"Self-directed control (C)","706":"Self-directed control (C)","707":"Commercial sponsored trials","708":"Medication only","709":"Medication only","710":"Ropivacaine 0.2% with injection dexamethasone 8 mg (Group C)","711":"Usual care","712":"Non-mentored group","713":"Relaxation","714":"No exercises","715":"Low-dose bupivacaine spinal anesthesia in healthy parturients","716":"Placebo","717":"Placebo","718":"Baseline characteristics","719":"Betadine ointment","720":"Standard quitline treatment","721":"Placebo","722":"Placebo","723":"Inpatient treatment","724":"Conventional tobacco cigarette","725":"Conventional Ventilation","726":"core decompression only","727":"maltodextrin (placebo)","728":"primary trabeculectomy group 2","729":"morphine","730":"morphine","731":"morphine","732":"basal diet","733":"basal diet","734":"Group N, the same volume (5 mL) of normal saline was injected","735":"Group N, the same volume (5 mL) of normal saline was injected","736":"Group N, the same volume (5 mL) of normal saline was injected","737":"placebo (cellulose powder) for 6?wks","738":"administered Sarkaradi Granules (SG).","739":"administered Sarkaradi Granules (SG).","740":"continuous training (CT) 12-weeks inpatients NYHA II-III","741":"octylonium 20 mg","742":"standard care (control)","743":"standard care (control)","744":"standard care (control)","745":"standard care (control)","746":"pressure support ventilation (PSV)","747":"prosthetic repair with e-PTFE patch (PR)","748":"placebo","749":"a balance training group for an 8-week balance training period.","750":"no breathing exercises ","751":"artemether-lumefantrine (AL) and Artesunate+chlorproguanil-dapsone (AS+CD)","752":"received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA) ","753":"received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA) ","754":"not displayed in the control.","755":"palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16?Gy\/2 fr\/day 1 and 8 (arm B)","756":"Usual care comprised of 7?weeks of group support sessions","757":"Usual care comprised of 7?weeks of group support sessions","758":"control","759":"ranibizumab combined with laser therapy","760":"surgery","761":"surgery","762":"surgery","763":"surgery","764":"surgery","765":"placebo","766":"the placebo group receiving an equivalent number of identical placebo capsules, which were continued daily for a period of 16 weeks","767":"\"no phone calls\" group","768":"standard group","769":"tacrolimus groups","770":"goat milk","771":"placebo","772":"salbutamol","773":"black women","774":"no treatment before operation.","775":"no treatment before operation.","776":"no treatment before operation.","777":"watchful waiting (WW)","778":"placebo from 9-16 weeks gestation until delivery.","779":"no text message","780":"no text message","781":"baseline","782":"nothing","783":"no awareness of wearing an accelerometer (blinded group)","784":"no awareness of wearing an accelerometer (blinded group)","785":"cemented component.","786":"cemented component.","787":"The routine interventions included praziquantel chemotherapy and controlling snails,","788":"The routine interventions included praziquantel chemotherapy and controlling snails,","789":"Employee Assistance Program","790":"control groups","791":"manual chest compression for cardiopulmonary resuscitation (CPR) of out-of-hospital cardiac arrest (OHCA)","792":"manual chest compression for cardiopulmonary resuscitation (CPR) of out-of-hospital cardiac arrest (OHCA)","793":"manual chest compression for cardiopulmonary resuscitation (CPR) of out-of-hospital cardiac arrest (OHCA)","794":"Self-directed control (C)","795":"Commercial sponsored trials","796":"Medication only","797":"Standard end-tidal anesthetic gas (ETAG) guided anesthesia","798":"Usual care","799":"Usual care","800":"Non-mentored group","801":"Relaxation","802":"Low-dose bupivacaine spinal anesthesia in healthy parturients","803":"Low-dose bupivacaine spinal anesthesia in healthy parturients","804":"Baseline characteristics","805":"Betadine ointment","806":"clopidogrel","807":"clopidogrel","808":"clopidogrel","809":"clopidogrel","810":"completing 6 days of assessment (four sets of questions per day) with the SMS text-only implementation","811":"receive weekly intravenous infusions of oxaliplatin 40?mg\/m2, 5-FU 500 mg\/m2, and leucovorin 250?mg\/m2 (3 weeks on, 1 week off)","812":"receive the injection with conventional syringe","813":"receive the injection with conventional syringe","814":"placebo tablets","815":"continuation of unsupervised habitual physical activity","816":"placebo","817":"placebo","818":"assigned to the dietary fat components without this genotype","819":"intravenous cyclophosphamide (CYC) 0.5\u20131?g\/m2 monthly","820":"received scaling and root planing with hand instruments","821":"insulin 0.8-0.9 mg\/kg\/day in two divided doses subcutaneously (Group-B)","822":"Low-molecular-weight heparin only before the surgery","823":"surgery","824":"No standardized guidelines or educational programs","825":"No standardized guidelines or educational programs","826":"No standardized guidelines or educational programs","827":"Placebo","828":"placebo for 2 months","829":"the spelling training and the reading groups","830":"general anesthesia","831":"general anesthesia","832":"general anesthesia","833":"baseline","834":"stay on their baseline regimen","835":"placebo","836":"hydroxyethylcellulose (HEC) placebo gel twice daily for 14 consecutive days","837":"sertraline hydrochloride","838":"placebo pill","839":"0.5 mg\/kg of normal saline was injected","840":"local anesthetic infiltration of the port site.","841":"placebo (starch)","842":"no-exposure control group","843":"no-exposure control group","844":"no-exposure control group","845":"female","846":"safflower oil placebo for 4 weeks","847":"Placebo lozenge","848":"paracetamol (20 mg\/kg) and propofol","849":"GLPG0259 ","850":"untreated (control)","851":"untreated (control)","852":"fresh frozen plasma","853":"fresh frozen plasma","854":"completers of in-laboratory (Part A) only","855":"completers of in-laboratory (Part A) only","856":"placebo group","857":"placebo group","858":"wait-list control condition","859":"cup of milk only twice a day while continuing with their normal\/routine diet.","860":"cup of milk only twice a day while continuing with their normal\/routine diet.","861":"vehicle","862":"vehicle","863":"atenolol","864":"atenolol","865":"atenolol","866":"atenolol","867":"baseline","868":"clinical training only","869":"Palacos R acrylic bone cements (without antibiotics)","870":"Palacos R acrylic bone cements (without antibiotics)","871":"Palacos R acrylic bone cements (without antibiotics)","872":"Trendelenburg (TBG) tilt <30\u00b0","873":"consumed a standardized breakfast [Control (C)avocado-free]","874":"50-Hz whole-body vibration training","875":"consumed a standardized breakfast [Control (C)avocado-free]","876":"consumed a standardized breakfast with Avocado Added (AA) or consumed a standardized breakfast [Control (C)avocado-free]","877":"50-Hz whole-body vibration training","878":"Outpatient program","879":"consumed a standardized breakfast [Control (C)avocado-free]","880":"Outpatient program","881":"Sham chest wall oscillation treatment","882":"traditional","883":"traditional","884":"Sham chest wall oscillation treatment","885":"baseline","886":"Placebo","887":"Istradefylline 40 mg","888":"use the Abhaibhubejhr ","889":"ALIF with BAK cages","890":"Pre-existing syndromic surveillance infrastructure and processes","891":"Pre-existing syndromic surveillance infrastructure and processes","892":"bupivacaine ","893":"Laparoscopic surgery","894":"ingest placebo","895":"unilateral TENS+TOT","896":"baseline","897":"unilateral TENS+TOT","898":"Placebo","899":"receive delayed treatment","900":"Placebo","901":"smelled and rated an odorant","902":"received saline solution (placebo)","903":"smelled and rated an odorant","904":"centers admitting less than 200 patients\/year","905":"radiotherapy alone","906":"PF alone (PF group)","907":"PF alone (PF group)","908":"PF alone (PF group)","909":"PF alone (PF group)","910":"PF alone (PF group)","911":"surgery","912":"Low-molecular-weight heparin only before the surgery","913":"Placebo","914":"Placebo","915":"Placebo","916":"HandiHaler\u00ae","917":"baseline","918":"stay on their baseline regimen","919":"stay on their baseline regimen","920":"stay on their baseline regimen","921":"hydroxyethylcellulose (HEC) placebo gel twice daily for 14 consecutive days","922":"hydroxyethylcellulose (HEC) placebo gel twice daily for 14 consecutive days","923":"placebo pill","924":"0.5 mg\/kg of normal saline was injected","925":"0.5 mg\/kg of normal saline was injected","926":"placebo (starch)","927":"Uganda","928":"baseline","929":"baseline","930":"other educations","931":"safflower oil placebo for 4 weeks","932":"placebo for eight consecutive weeks","933":"GLPG0259 ","934":"ProRoot MTA or Biodentine calcium silicate cements","935":"clopidogrel","936":"clopidogrel","937":"control group","938":"control group","939":"completing 6 days of assessment (four sets of questions per day) with the SMS text-only implementation","940":"control","941":"empagliflozin after administration to Egyptian volunteers","942":"empagliflozin after administration to Egyptian volunteers","943":"receive the injection with conventional syringe","944":"78-week treatment with placebo","945":"78-week treatment with placebo","946":"50?g OGTT (A)","947":"50?g OGTT (A)","948":"50?g OGTT (A)","949":"50?g OGTT (A)","950":"placebo","951":"intravenous cyclophosphamide (CYC) 0.5\u20131?g\/m2 monthly","952":"received scaling and root planing with hand instruments","953":"insulin 0.8-0.9 mg\/kg\/day in two divided doses subcutaneously (Group-B)","954":"baseline","955":"muffins enriched with 0 g HAM-RS2 (control)","956":"Sham chest wall oscillation treatment","957":"Placebo","958":"ALIF with BAK cages","959":"Pre-existing syndromic surveillance infrastructure and processes","960":"Laparoscopic surgery","961":"Laparoscopic surgery","962":"Supine position","963":"Supine position","964":"Supine position","965":"Supine position","966":"Phototherapy only","967":"Phototherapy only","968":"received saline solution (placebo)","969":"transfusions","970":"PF alone (PF group)","971":"completers of in-laboratory (Part A) only","972":"completers of in-laboratory (Part A) only","973":"cytological screening","974":"wait-list control condition","975":"cup of milk only twice a day while continuing with their normal\/routine diet.","976":"cup of milk only twice a day while continuing with their normal\/routine diet.","977":"vehicle","978":"vehicle","979":"vehicle","980":"quietly read","981":"baseline","982":"baseline","983":"baseline","984":"clinical training only","985":"clinical training only","986":"clinical training only","987":"Palacos R acrylic bone cements (without antibiotics)","988":"Trendelenburg (TBG) tilt <30\u00b0","989":"Trendelenburg (TBG) tilt <30\u00b0","990":"Trendelenburg (TBG) tilt <30\u00b0","991":"consumed a standardized breakfast [Control (C)avocado-free]","992":"traditional","993":"baseline","994":"baseline","995":"control (warfarin)","996":"control (warfarin)","997":"placebo","998":"placebo","999":"placebo","1000":"placebo","1001":"bupivacaine ","1002":"bupivacaine ","1003":"ingest placebo","1004":"placebo training","1005":"pertuzumab 840 mg q3w for six cycles (Arm B)","1006":"pertuzumab 840 mg q3w for six cycles (Arm B)","1007":"receive delayed treatment","1008":"receive delayed treatment","1009":"centers without stroke unit","1010":"centers without stroke unit","1011":"soybean meal","1012":"soybean meal","1013":"Placebo","1014":"clopidogrel","1015":"Conventional tobacco cigarette","1016":"placebo","1017":"type 2 DM","1018":"Placebo?plus MTX or Golimumab","1019":"Long-term psychotherapy","1020":"placebo","1021":"Long-term psychotherapy","1022":"78-week treatment with placebo","1023":"continuation of unsupervised habitual physical activity","1024":"Exercise alone","1025":"continuation of unsupervised habitual physical activity","1026":"Conventional Ventilation","1027":"analysis of covariance (ANOVA or ANCOVA) with missing data imputed by the last observation carried forward approach (LOCF_ANCOVA)","1028":"placebo","1029":"intravenous cyclophosphamide (CYC) 0.5\u20131?g\/m2 monthly","1030":"fibromyalgia (FM) education control (FME) group - received information and support","1031":"received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA) ","1032":"insulin 0.8-0.9 mg\/kg\/day in two divided doses subcutaneously (Group-B)","1033":"No standardized guidelines or educational programs","1034":"muffins enriched with 0 g HAM-RS2 (control)","1035":"spice-free control meal","1036":"Placebo","1037":"morphine","1038":"basal diet","1039":"stay on their baseline regimen","1040":"stay on their baseline regimen","1041":"Placebo","1042":"Standard end-tidal anesthetic gas (ETAG) guided anesthesia","1043":"placebo","1044":"receive the usual health messages from the Matlab regular health staff","1045":"hydroxyethylcellulose (HEC) placebo gel twice daily for 14 consecutive days","1046":"website without social presence elements.","1047":"Expanded Disability Status Scale [EDSS]","1048":"placebo pill","1049":"Relaxation","1050":"a single dose of Ad35-GRIN or SeV-Gag","1051":"factual information alon","1052":"CAPOX","1053":"continuous training (CT) 12-weeks inpatients NYHA II-III","1054":"no training for 12-weeks inpatients NYHA II-III","1055":"placebo for eight consecutive weeks","1056":"Placebo","1057":"paracetamol (20 mg\/kg) and propofol","1058":"paracetamol (20 mg\/kg) and propofol","1059":"standard care (control)","1060":"Placebo","1061":"Placebo","1062":"standard consultation (UNN)","1063":"standard consultation (UNN)","1064":"standard consultation","1065":"Vinorelbine 6mg\/m2","1066":"control shoe","1067":"control condition","1068":"control condition","1069":"Traditional moderate-intensity continuous training","1070":"Traditional moderate-intensity continuous training","1071":"control condition","1072":"No treatment","1073":"No treatment","1074":"Orange juice intake with each meal (WM) ","1075":"Placebo","1076":"Placebo","1077":"Usual diet","1078":"Without catheter (group I)","1079":"Without catheter (group I)","1080":"Without catheter (group I)","1081":"Liraglutide and metformin plus placebo","1082":"Liraglutide and metformin plus placebo","1083":"Lunch meals with meat (meat group) or lunch meals with n-3 LCPUFAs supplements (supplements group)","1084":"Lunch meals with meat (meat group) or lunch meals with n-3 LCPUFAs supplements (supplements group)","1085":"T-HS\/SE, T-HS\/EAA","1086":"Control groups","1087":"Isoflurane-fentanyl anesthesia","1088":"Patients not receiving text message assistance during follow-up","1089":"Patients not receiving text message assistance during follow-up","1090":"Patients not receiving text message assistance during follow-up","1091":"Remifentanil","1092":"Remifentanil","1093":"Standard sequential culture medium ISM1","1094":"Standard sequential culture medium ISM1","1095":"Standard sequential culture medium ISM1","1096":"subpleural intermittent analgesia (SIA) (0.1cc\/kg\/6h of 0.5% bupivacaine)","1097":"received just routine education","1098":"spinal anesthesia with 2.5 ml of 0.5% bupivacaine ","1099":"spinal anesthesia with 2.5 ml of 0.5% bupivacaine ","1100":"placebo","1101":"100 I\u03021\u20444g dose of LSD","1102":"baseline","1103":"stabilization in supine (SIS) or prone and supine (SIPS) position group","1104":"placebo","1105":"placebo","1106":"20 mg\/day for enalapril","1107":"Synthetic bone substitute material (NanoBone\u00ae, NB) ","1108":"100 grams of wheat flour-based noodles","1109":"clopidogrel","1110":"clopidogrel","1111":"completing 6 days of assessment (four sets of questions per day) with the SMS text-only implementation","1112":"conventional fractionation (39?\u00d7?2.0 Gy?=?78.0 Gy given once a day, five days per week) ","1113":"control","1114":"control","1115":"received only general health guidance.","1116":"continuation of unsupervised habitual physical activity","1117":"assigned to the high-protein diet without this genotype","1118":"intravenous cyclophosphamide (CYC) 0.5\u20131?g\/m2 monthly","1119":"insulin 0.8-0.9 mg\/kg\/day in two divided doses subcutaneously (Group-B)","1120":"insulin 0.8-0.9 mg\/kg\/day in two divided doses subcutaneously (Group-B)","1121":"muffins enriched with 0 g HAM-RS2 (control)","1122":"Placebo","1123":"Placebo and routine unit care","1124":"surgery","1125":"general anesthesia","1126":"baseline","1127":"paracetamol (20 mg\/kg) and propofol","1128":"Standard marrow needle","1129":"Standard marrow needle","1130":"General anesthesia plus intravenous analgesia (PCIA)","1131":"General anesthesia plus intravenous analgesia (PCIA)","1132":"General anesthesia plus intravenous analgesia (PCIA)","1133":"Traditional moderate-intensity continuous training","1134":"control condition","1135":"control condition","1136":"barefoot walking","1137":"No treatment","1138":"mobility shoe","1139":"No treatment","1140":"control shoe","1141":"Orange juice intake with each meal (WM) ","1142":"Placebo","1143":"Placebo","1144":"Hospital-based approach","1145":"100 grams of wheat flour-based noodles","1146":"Usual diet","1147":"100 grams of wheat flour-based noodles","1148":"Lunch meals with meat (meat group) ","1149":"T-HS\/SE","1150":"PF group","1151":"Isoflurane-fentanyl anesthesia","1152":"Isoflurane-fentanyl anesthesia","1153":"Patients not receiving text message assistance during follow-up","1154":"Remifentanil","1155":"Remifentanil","1156":"Standard sequential culture medium ISM1","1157":"Standard sequential culture medium ISM1","1158":"no histologic response (>6 eos\/hpf) after treatment","1159":"patients without these symptoms","1160":"subpleural intermittent analgesia (SIA) (0.1cc\/kg\/6h of 0.5% bupivacaine)","1161":"subpleural intermittent analgesia (SIA) (0.1cc\/kg\/6h of 0.5% bupivacaine)","1162":"subpleural intermittent analgesia (SIA) (0.1cc\/kg\/6h of 0.5% bupivacaine)","1163":"received just routine education","1164":"received just routine education","1165":"spinal anesthesia with 2.5 ml of 0.5% bupivacaine ","1166":"placebo","1167":"Follistim(R","1168":"Follistim(R","1169":"adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)","1170":"adults with LBP with radicular pain (group C)","1171":"baseline","1172":"Pressure support ventilation (PSV)","1173":"Pressure support ventilation (PSV)","1174":"Pressure support ventilation (PSV)","1175":"placebo ","1176":"20 mg\/day for enalapril","1177":"Synthetic bone substitute material (NanoBone\u00ae, NB) ","1178":"100 grams of wheat flour-based noodles","1179":"Placebo","1180":"Warfarin","1181":"Presternal catheter with continuous saline infusion (Group C)","1182":"No preoperative hemodilution (non-ANH)","1183":"No preoperative hemodilution (non-ANH)","1184":"Placebo ","1185":"Usual care","1186":"Usual care","1187":"Blinded collection of NIRS values combined with treatment as usual","1188":"Pressure support ventilation","1189":"Standard medical care alone","1190":"Nonlocking plate fixation","1191":"Nonlocking plate fixation","1192":"Control group","1193":"Low dose (5 mg\/day) haloperidol","1194":"No PAN administered before the surgery","1195":"No PAN administered before the surgery","1196":"Fentanyl-based IV-PCA only (IV-PCA group)","1197":"No PAN administered before the surgery","1198":"Conventional thoracic epidural patient-controlled analgesia (E-PCA group)","1199":"Placebo","1200":"Placebo","1201":"Pentoxifylline alone (Group 1)","1202":"Nonusers","1203":"Nonusers","1204":"Nonusers","1205":"Sachets of \"Sprinkles\ufffd without vitamin A","1206":"Sachets of \"Sprinkles\ufffd without vitamin A","1207":"Dexmedetomidine (Group D)","1208":"Dexmedetomidine (Group D)","1209":"Dexmedetomidine (Group D)","1210":"Milk protein ","1211":"No exercise","1212":"untreated (control)","1213":"soybean meal","1214":"fresh frozen plasma","1215":"cytological screening","1216":"no intervention (control group, which continued clinical practice as normal)","1217":"placebo group","1218":"wait-list control condition","1219":"cup of milk only twice a day while continuing with their normal\/routine diet.","1220":"vehicle","1221":"vehicle","1222":"quietly read","1223":"atenolol","1224":"baseline","1225":"baseline","1226":"clinical training only","1227":"Trendelenburg (TBG) tilt <30\u00b0","1228":"50-Hz whole-body vibration training","1229":"Outpatient program","1230":"Sham chest wall oscillation treatment","1231":"baseline","1232":"Non-Clinical Group","1233":"nickel-titanium (NiTi) round archwires with increasing diameters applied sequentially to the mandibular arch","1234":"nickel-titanium (NiTi) round archwires with increasing diameters applied sequentially to the mandibular arch","1235":"use the Cavity Protection toothpaste","1236":"Istradefylline 40 mg","1237":"Pre-existing syndromic surveillance infrastructure and processes","1238":"Laparoscopic surgery","1239":"hydroxyethylcellulose (HEC) placebo gel twice daily for 14 consecutive days","1240":"Supine position","1241":"Phototherapy only","1242":"Phototherapy only","1243":"Phototherapy only","1244":"receive delayed treatment","1245":"Placebo","1246":"Placebo","1247":"smelled and rated an odorant","1248":"received saline solution (placebo)","1249":"centers admitting less than 200 patients\/year","1250":"irinotecan (FOLFIRI) plus bevacizumab ","1251":"PF alone (PF group)","1252":"endotracheal tube (ETT)","1253":"Standard marrow needle","1254":"standard consultation","1255":"Standard marrow needle","1256":"Vinorelbine 6mg\/m2","1257":"General anesthesia plus intravenous analgesia (PCIA)","1258":"Vinorelbine 6mg\/m2","1259":"General anesthesia plus intravenous analgesia (PCIA)","1260":"Traditional moderate-intensity continuous training","1261":"mobility shoe","1262":"Orange juice intake with each meal (WM) ","1263":"control shoe","1264":"Orange juice intake with each meal (WM) ","1265":"vehicle","1266":"quietly read","1267":"Usual diet","1268":"atenolol","1269":"Liraglutide and metformin plus placebo","1270":"Liraglutide and metformin plus placebo","1271":"Liraglutide and metformin plus placebo","1272":"T-HS\/Ctr","1273":"T-HS\/Ctr and T-HS\/SE ","1274":"Control groups","1275":"Isoflurane-fentanyl anesthesia","1276":"consumed a standardized breakfast [Control (C)avocado-free]","1277":"50-Hz whole-body vibration training","1278":"traditional","1279":"Non-Clinical Group","1280":"subpleural intermittent analgesia (SIA) (0.1cc\/kg\/6h of 0.5% bupivacaine)","1281":"saline","1282":"spinal anesthesia with 2.5 ml of 0.5% bupivacaine ","1283":"spinal anesthesia with 2.5 ml of 0.5% bupivacaine ","1284":"pertuzumab 840 mg q3w for six cycles (Arm B)","1285":"Placebo","1286":"Follistim(R","1287":"received saline solution (placebo)","1288":"received saline solution (placebo)","1289":"baseline","1290":"chelation (Standard Arm)","1291":"Equivalent normal saline was administered in the placebo group.","1292":"Synthetic bone substitute material (NanoBone\u00ae, NB) ","1293":"100 grams of wheat flour-based noodles","1294":"Placebo","1295":"endotracheal tube (ETT)","1296":"Placebo","1297":"Presternal catheter with continuous saline infusion (Group C)","1298":"No preoperative hemodilution (non-ANH)","1299":"Placebo","1300":"Pressure support ventilation","1301":"Standard medical care alone","1302":"Standard medical care alone","1303":"Nonlocking plate fixation","1304":"Nonlocking plate fixation","1305":"Control group","1306":"Sham control group","1307":"Sham control group","1308":"Fentanyl-based IV-PCA only (IV-PCA group)","1309":"Conventional thoracic epidural patient-controlled analgesia (E-PCA group)","1310":"Placebo","1311":"Placebo","1312":"Placebo","1313":"Pentoxifylline alone (Group 1)","1314":"Pentoxifylline alone (Group 1)","1315":"Nonusers","1316":"Sachets of \"Sprinkles\ufffd without vitamin A","1317":"Transparent dressings","1318":"Transparent dressings","1319":"Dexmedetomidine (Group D)","1320":"WPC-80 protein and milk protein","1321":"No exercise","1322":"No exercise","1323":"Enoxaparin or placebo","1324":"Warfarin","1325":"Group 2-Patients were administered 0.5 ml intralesional injection Hyaluronidase 1,500 IU and 0.5 ml intralesional injection Hydrocortisone acetate 25 mg\/ml in each buccal mucosa once a week","1326":"The control group received no paracetamol.","1327":"baseline","1328":"PLACEBO","1329":"placebo","1330":"rtfMRI-nf from the horizontal segment of the intraparietal sulcus (HIPS","1331":"rtfMRI-nf from the horizontal segment of the intraparietal sulcus (HIPS","1332":"rtfMRI-nf from the horizontal segment of the intraparietal sulcus (HIPS","1333":"placebo orally for 8 weeks","1334":"placebo orally for 8 weeks","1335":"placebo orally for 8 weeks","1336":"conscious-thought condition","1337":"placebo","1338":"topotecan","1339":"topotecan","1340":"placebo","1341":"placebo","1342":"30 ml 0.5% ropivacaine + 75 I\u03021\u20444g clonidine (RC)","1343":"30 ml 0.5% ropivacaine + 75 I\u03021\u20444g clonidine (RC)","1344":"No standardized guidelines or educational programs","1345":"78-week treatment with placebo","1346":"PPIs, lifestyle changes, and placebo","1347":"PPIs, lifestyle changes, and placebo","1348":"no intervention","1349":"propofol induction guided by clinical signs","1350":"sucrose solution","1351":"sucrose-containing meal","1352":"sucrose solution","1353":"lidocaine spray and viscous solution","1354":"lidocaine spray and viscous solution","1355":"normal saline, lidocaine, or ketamine","1356":"usual care","1357":"placebo and sucralose","1358":"placebo and sucralose","1359":"Intranasal saline 0.9% (Group C)","1360":"Intranasal saline 0.9% (Group C)","1361":"Intranasal saline 0.9% (Group C)","1362":"Placebo","1363":"Placebo","1364":"Interaction with a non-obese patient in a digital environment","1365":"pioglitazone","1366":"control","1367":"control","1368":"placebo ","1369":"placebo","1370":"baseline","1371":"baeeline","1372":"control","1373":"weekly paclitaxel\u2013epirubicin (PE) regimen","1374":"weekly paclitaxel\u2013epirubicin (PE) regimen","1375":"baseline","1376":"baseline","1377":"implants were placed in healed sites","1378":"control group","1379":"Head-up (HU): the swimmer looked directly forward, and his ears were above the forearms and fully extended over the head.","1380":"routine activity","1381":"medical seminar","1382":"medical seminar","1383":"medical seminar","1384":"control","1385":"standard 'gut-directed' hypnotherapy","1386":"placebo","1387":"underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with no feedback (NF) ","1388":"underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with no feedback (NF) ","1389":"no off-scanner training","1390":"MRI + NE","1391":"baseline","1392":"intravitreal triamcinolone acetonide (IVT) or intravitreal bevacizumab (IVB)","1393":"baseline","1394":"baseline","1395":"ch14.18-NCI","1396":"ch14.18-NCI","1397":"control","1398":"control","1399":"control","1400":"placebo","1401":"Late extubation ","1402":"Late extubation ","1403":"group H - 1.0 \u03bcg\/kg","1404":"group H - 1.0 \u03bcg\/kg","1405":"Standard marrow needle","1406":"baseline","1407":"Orange juice intake with each meal (WM) ","1408":"Hospital-based approach","1409":"Usual diet","1410":"Usual diet","1411":"Without catheter (group I)","1412":"Without catheter (group I)","1413":"Patients not receiving text message assistance during follow-up","1414":"Remifentanil","1415":"saline","1416":"received just routine education","1417":"spinal anesthesia with 2.5 ml of 0.5% bupivacaine ","1418":"Follistim(R","1419":"adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)","1420":"Pressure support ventilation (PSV)","1421":"100 grams of wheat flour-based noodles","1422":"standard consultation","1423":"barefoot","1424":"barefoot","1425":"control shoe and all other conditions","1426":"Blinded collection of NIRS values combined with treatment as usual","1427":"Pressure support ventilation","1428":"Pressure support ventilation","1429":"Pressure support ventilation","1430":"Nonlocking plate fixation","1431":"Sham control group","1432":"No PAN administered before the surgery","1433":"Pentoxifylline alone (Group 1)","1434":"Nonusers","1435":"Sachets of \"Sprinkles\ufffd without vitamin A","1436":"Sachets of \"Sprinkles\ufffd without vitamin A","1437":"Transparent dressings","1438":"Transparent dressings","1439":"Dexmedetomidine (Group D)","1440":"Milk protein and WPC-80 protein","1441":"Milk protein ","1442":"WPC-80 protein","1443":"No exercise","1444":"Placebo or dabigatran 50 mg","1445":"Presternal catheter with continuous saline infusion (Group C)","1446":"Presternal catheter with continuous saline infusion (Group C)","1447":"Presternal catheter with continuous saline infusion (Group C)","1448":"No preoperative hemodilution (non-ANH)","1449":"No preoperative hemodilution (non-ANH)","1450":"Placebo","1451":"Usual care","1452":"Usual care","1453":"Usual care","1454":"Standard medical care alone","1455":"Control group","1456":"Control group","1457":"Control group","1458":"Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and Conventional thoracic epidural patient-controlled analgesia (E-PCA group)","1459":"alternative education program consisting of information about management of paediatric ear, nose and throat (ENT) problems, without receiving any adapted asthma resource materials until the end of the trial","1460":"PPIs, lifestyle changes, and placebo","1461":"normal saline, lidocaine, or ketamine","1462":"control","1463":"implants were placed in healed sites","1464":"baseline","1465":"baseline","1466":"baseline","1467":"baseline","1468":"Synthetic bone substitute material (NanoBone\u00ae, NB) ","1469":"Synthetic bone substitute material (NanoBone\u00ae, NB) ","1470":"sham-controlled group","1471":"insulin glargine 100 U\/ml (Gla\ufffd100)","1472":"insulin glargine 100 U\/ml (Gla\ufffd100)","1473":"insulin glargine 100 U\/ml (Gla\ufffd100)","1474":"\ufffdontrol group","1475":"PLACEBO","1476":"baseline","1477":"PLACEBO","1478":"placebo","1479":"placebo orally for 8 weeks","1480":"placebo orally for 8 weeks","1481":"placebo orally for 8 weeks","1482":"placebo orally for 8 weeks","1483":"placebo","1484":"placebo","1485":"baseline","1486":"30 ml 0.5% ropivacaine + 75 I\u03021\u20444g clonidine (RC)","1487":"conventional recover","1488":"control group that did not receive any bladder wash","1489":"alternative education program consisting of information about management of paediatric ear, nose and throat (ENT) problems, without receiving any adapted asthma resource materials until the end of the trial","1490":"alternative education program consisting of information about management of paediatric ENT problems, without receiving any adapted asthma resource materials until the end of the trial","1491":"PIs, lifestyle changes, and placebo","1492":"PPIs, lifestyle changes, and placebo","1493":"no intervention","1494":"no intervention","1495":"U.S. diet","1496":"U.S. diet","1497":"U.S. diet","1498":"propofol induction guided by clinical signs","1499":"usual care","1500":"sucrose solution","1501":"sucrose-containing meal","1502":"lidocaine spray and viscous solution","1503":"normal saline","1504":"usual care","1505":"sucralose","1506":"Intranasal saline 0.9% (Group C)","1507":"Placebo","1508":"Interaction with a non-obese patient in a digital environment","1509":"Interaction with a non-obese patient in a digital environment","1510":"Fluticasone propionate (FLP)","1511":"Fluticasone propionate (FLP)","1512":"control","1513":"control","1514":"without orthodontic treatment","1515":"placebo ","1516":"Control","1517":"Control","1518":"placebo","1519":"placebo","1520":"control","1521":"weekly paclitaxel\u2013epirubicin (PE) regimen","1522":"baseline","1523":"placebo","1524":"implants were placed in healed sites","1525":"control group","1526":"Head-down (HD): the swimmer looked backwards, and his ears were below the forearms, which were fully extended over the head.","1527":"routine activity","1528":"medical seminar","1529":"control","1530":"control","1531":"baseline","1532":"underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with no feedback (NF) ","1533":"underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with no feedback (NF) ","1534":"control group","1535":"received only a standard written information on the health risk from maternal smoking to the foetus","1536":"received only a standard written information on the health risk from maternal smoking to the foetus","1537":"received only a standard written information on the health risk from maternal smoking to the foetus","1538":"preparation of the mesiobuccal canal with M-One rotary systems","1539":"exposed filtered air for one hour during intermittent exercise","1540":"exposed filtered air for one hour during intermittent exercise","1541":"exposed filtered air for one hour during intermittent exercise","1542":"intra-brachial infusion of verapamil","1543":"intravitreal triamcinolone acetonide (IVT) or intravitreal bevacizumab (IVB)","1544":"intravitreal triamcinolone acetonide (IVT) or intravitreal bevacizumab (IVB)","1545":"placebo","1546":"ch14.18-NCI","1547":"group H - 1.0 \u03bcg\/kg","1548":"group H - 1.0 \u03bcg\/kg","1549":"Red yeast rice","1550":"Red yeast rice","1551":"Hypertonic saline plus dextran (group III)","1552":"Low-dose isotretinoin ","1553":"Low-dose isotretinoin ","1554":"Low-dose isotretinoin ","1555":"Routine anticipatory guidance program","1556":"Pressure-controlled ventilation (PCV)","1557":"Ibuprofen group","1558":"Normal saline (control group)","1559":"Normal saline (control group)","1560":"Long-term oxygen therapy 24 h\/day","1561":"Placebo (ACCORD)","1562":"Delayed loading implants (group II)","1563":"Roux-en-Y gastric bypass (RYGB) procedure","1564":"Roux-en-Y gastric bypass (RYGB) procedure","1565":"standard care clinical guidelines","1566":"midline approach technique group (R group)","1567":"midline approach technique group (R group)","1568":"midline approach technique group (R group)","1569":"midline approach technique group (R group)","1570":"midline approach technique group (R group)","1571":"baseline","1572":"10 units of Oxytip (Caspian Tamin Company Iran) in 500 cc serum","1573":"10 units of Oxytip (Caspian Tamin Company Iran) in 500 cc serum","1574":"20-30 grams of lactulose orally or by a nasogastric tube, or 200 grams of lactulose enema by a rectal tube","1575":"20-30 grams of lactulose orally or by a nasogastric tube, or 200 grams of lactulose enema by a rectal tube","1576":"group B brimonidine 0.2% eye drops twice daily for a period of 4 weeks","1577":"placebo for 2 doses","1578":"customary care","1579":"customary care","1580":"customary care","1581":"placebo","1582":"placebo","1583":"Group B received 20 mg of Esomeprazole, 1000 mg of Amoxicillin for the first 5 days, followed by 20 mg of Esomeprazole, 500 mg of Clarithromycin, and 1000 mg of Amoxicillin for the remaining 5 days.","1584":"Group C received 20 mg of Esomeprazole, 500 mg of Clarithromycin, and 1000 mg of Amoxicillin for standard 10-day therapy.","1585":"Group C received 20 mg of Esomeprazole, 500 mg of Clarithromycin, and 1000 mg of Amoxicillin for standard 10-day therapy.","1586":"propofol and remifentanil","1587":"received an Attention bias modification procedure designed to induce a bias in attention toward negative material","1588":"nitrate-depleted beetroot juice (PLA) for six subsequent days","1589":"nitrate-depleted beetroot juice (PLA) for six subsequent days","1590":"nitrate-depleted beetroot juice (PLA) for six subsequent days","1591":"baseline","1592":"baseline","1593":"baseline","1594":"baseline","1595":"usual care","1596":"Group 2: Self-adjusting file (SAF; ReDent-Nova, Ra'anana, Israel) (1.5 mm) Group 3: ProTaper NEXT X1 and X2 (PTN; Dentsply Tulsa Dental, Tulsa, OK) (25\/06)","1597":"pancreaticoduodenectomy","1598":"pancreaticoduodenectomy","1599":"pancreaticoduodenectomy","1600":"pancreaticoduodenectomy","1601":"pancreaticoduodenectomy","1602":"pancreaticoduodenectomy","1603":"pancreaticoduodenectomy","1604":"pancreaticoduodenectomy","1605":"pancreaticoduodenectomy","1606":"pancreaticoduodenectomy","1607":"pancreaticoduodenectomy","1608":"groups A (hMG) and D (hFSH\/rFSH)","1609":"groups B ( hFSH) and C(rFSH)","1610":"baseline","1611":"control treatment","1612":"control group (chemotherapy alone) received three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg\/m2 epirubicin and 60 mg\/m2 cisplatin on day 1 and 1250 mg\/m2 oral capecitabine on days 1\u201321.","1613":"control group (chemotherapy alone) received three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg\/m2 epirubicin and 60 mg\/m2 cisplatin on day 1 and 1250 mg\/m2 oral capecitabine on days 1\u201321.","1614":"baseline","1615":"neurodevelopmental treatment","1616":"low-carbohydrate diet (LCD)","1617":"control","1618":"control","1619":"control","1620":"conventional craniotomy (CC)","1621":"insulin glargine 100 U\/ml (Gla\ufffd100)","1622":"insulin glargine 100 U\/ml (Gla\ufffd100)","1623":"The control group received no paracetamol.","1624":"baseline","1625":"10 I\u03021\u20444g (arm A) of CEA peptide emulsified in Montanide and GM-CSF, given every 2 weeks until disease progression.","1626":"baseline","1627":"placebo","1628":"placebo orally for 8 weeks","1629":"placebo orally for 8 weeks","1630":"placebo orally for 8 weeks","1631":"the immediate-decision condition","1632":"topotecan","1633":"placebo","1634":"placebo","1635":"control","1636":"30 ml 0.5% ropivacaine + 75 I\u03021\u20444g clonidine (RC)","1637":"30 ml 0.5% ropivacaine + 75 I\u03021\u20444g clonidine (RC)","1638":"conventional recover","1639":"conventional recover","1640":"conventional recover","1641":"conventional recover","1642":"conventional recover","1643":"water-soaked gauze","1644":"Base line","1645":"alternative education program consisting of information about management of paediatric ear, nose and throat (ENT) problems, without receiving any adapted asthma resource materials until the end of the trial","1646":"Narrowband ultraviolet B (NB-UVB)","1647":"Individual-based computer-prompt program and Usual-break control group","1648":"no intervention","1649":"no intervention","1650":"U.S. diet","1651":"U.S. diet","1652":"propofol induction guided by clinical signs","1653":"Any other food","1654":"usual care","1655":"usual care","1656":"lidocaine spray and viscous solution","1657":"lidocaine spray and viscous solution","1658":"McGRATH MAC and C-MAC","1659":"placebo and sucralose","1660":"Intranasal saline 0.9% (Group C)","1661":"control group","1662":"Interaction with a non-obese patient in a digital environment","1663":"Fluticasone propionate (FLP)","1664":"Fluticasone propionate (FLP)","1665":"pioglitazone","1666":"pioglitazone","1667":"control","1668":"control","1669":"without orthodontic treatment","1670":"placebo or baseline","1671":"baseline","1672":"control","1673":"weekly paclitaxel\u2013epirubicin (PE) regimen","1674":"high AGE diet","1675":"placebo","1676":"placebo","1677":"placebo","1678":"placebo","1679":"implants were placed in healed sites","1680":"implants were placed in healed sites","1681":"implants were placed in healed sites","1682":"control","1683":"routine activity","1684":"Arm A triple therapy (omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily) plus polaprezinc 75 mg twice daily; Arm C triple therapy alone","1685":"medical seminar","1686":"control","1687":"baseline","1688":"performed 3 short bouts of exercise (Short-bouts group: 10 min \u00d7 3) 3 d per week","1689":"Measuring BPs in the upper arm (UA)","1690":"relaxation therapy","1691":"baseline","1692":"individual support","1693":"baseline","1694":"primary care physicians assisted by nurse educators (PCP-NE)","1695":"control groups","1696":"long-term nonimprovers (NIMPs)","1697":"received only a standard written information on the health risk from maternal smoking to the foetus","1698":"exposed filtered air for one hour during intermittent exercise","1699":"exposed filtered air for one hour during intermittent exercise","1700":"baseline","1701":"baseline","1702":"group H - 1.0 \u03bcg\/kg","1703":"Red yeast rice","1704":"Red yeast rice","1705":"No treatment (group I)","1706":"Hypertonic saline plus dextran (group III)","1707":"Hypertonic saline plus dextran (group III) and no treatment (group I)","1708":"Low-dose isotretinoin ","1709":"Routine anticipatory guidance program","1710":"Routine anticipatory guidance program","1711":"Pressure-controlled ventilation (PCV)","1712":"Pressure-controlled ventilation (PCV)","1713":"Pressure-controlled ventilation (PCV)","1714":"Pressure-controlled ventilation (PCV)","1715":"Paracetamol group and ibuprofen group","1716":"Ibuprofen group","1717":"Normal saline (control group)","1718":"Normal saline (control group)","1719":"Normal saline (control group)","1720":"Long-term oxygen therapy 24 h\/day","1721":"Placebo (ATTAIN)","1722":"Placebo (active-comparator study)","1723":"Placebo (active-comparator study)","1724":"Placebo (ACCORD)","1725":"Delayed loading implants (group II)","1726":"Delayed loading implants (group II)","1727":"baseline","1728":"control group","1729":"standard care clinical guidelines","1730":"standard care clinical guidelines","1731":"control group","1732":"baseline","1733":"baseline","1734":"10 units of Oxytip (Caspian Tamin Company Iran) in 500 cc serum","1735":"10 units of Oxytip (Caspian Tamin Company Iran) in 500 cc serum","1736":"higher maintenance doses of ICS\/LABA plus SABA or formoterol","1737":"fixed-dose salmeterol\/fluticasone","1738":"20-30 grams of lactulose orally or by a nasogastric tube, or 200 grams of lactulose enema by a rectal tube","1739":"placebo for 2 doses","1740":"placebo for 2 doses","1741":"placebo for 2 doses","1742":"customary care","1743":"placebo","1744":"baseline","1745":"baseline","1746":"baseline","1747":"endotracheal intubation (ETT)","1748":"endotracheal intubation (ETT)","1749":"baseline","1750":"received an Attention bias modification procedure designed to induce a bias in attention toward negative material","1751":"gemcitabine plus placebo (GP)","1752":"gemcitabine plus placebo (GP)","1753":"gemcitabine plus placebo (GP)","1754":"gemcitabine plus placebo (GP)","1755":"nitrate-depleted beetroot juice (PLA) for six subsequent days","1756":"Waitlist","1757":"control group","1758":"usual care","1759":"Noise condition","1760":"Noise condition","1761":"Group 1: WaveOne (primary) single reciprocating file (WO; Dentsply Maillefer, Ballaigues, Switzerland) (25\/08)\u0431 Group 3: ProTaper NEXT X1 and X2 (PTN; Dentsply Tulsa Dental, Tulsa, OK) (25\/06)","1762":"Group 2: Self-adjusting file (SAF; ReDent-Nova, Ra'anana, Israel) (1.5 mm) ","1763":"Group 2: Self-adjusting file (SAF; ReDent-Nova, Ra'anana, Israel) (1.5 mm) ","1764":"pancreaticoduodenectomy","1765":"pancreaticoduodenectomy","1766":"pancreaticoduodenectomy","1767":"pancreaticoduodenectomy","1768":"pancreaticoduodenectomy","1769":"pancreaticoduodenectomy","1770":"groups A human menopausal gonadotropin (hMG), B Human Follicle Stimulating Hormone (hFSH), and C Recombinant Follicle Stimulating Hormone (rFSH)","1771":"placebo","1772":"baseline","1773":"control group (chemotherapy alone) received three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg\/m2 epirubicin and 60 mg\/m2 cisplatin on day 1 and 1250 mg\/m2 oral capecitabine on days 1\u201321.","1774":"baseline","1775":"baseline","1776":"low-carbohydrate diet (LCD)","1777":"traditional low-fat diet (LFD)","1778":"control","1779":"alternative education program consisting of information about management of paediatric ear, nose and throat (ENT) conditions, without receiving any adapted asthma resource materials until the end of the trial","1780":"usual group","1781":"usual group","1782":"placebo","1783":"baseline","1784":"placebo","1785":"conventional surgery","1786":"conventional surgery","1787":"varenicline (VR)","1788":"valsartan 160 mg combined with hydrochlorothiazide (HCTZ) 25 mg","1789":"valsartan 160 mg combined with hydrochlorothiazide (HCTZ) 25 mg","1790":"valsartan 160 mg combined with hydrochlorothiazide (HCTZ) 25 mg","1791":"povidone-iodine","1792":"povidone-iodine","1793":"povidone-iodine","1794":"povidone-iodine","1795":"placebo","1796":"placebo","1797":"oral alendronate 35 mg weekly","1798":"routine lab culture medium (G-1TM v5; Vitrolife,","1799":"routine lab culture medium (G-1TM v5; Vitrolife,","1800":"sorbitol 10%","1801":"baseline","1802":"control ","1803":"17 G\/ 35 mm (standard) needle","1804":"17 G\/ 35 mm (standard) needle","1805":"baseline","1806":"baseline","1807":"control","1808":"baseline","1809":"baseline","1810":"baseline","1811":"placebo","1812":"placebo","1813":"placebo","1814":"placebo","1815":"placebo","1816":"placebo","1817":"control group","1818":"control group","1819":"control group","1820":"control group (blind reduction) Plane II fracture","1821":"Group B: SRP with placebo gel","1822":"Group B: SRP with placebo gel","1823":"placebo","1824":"medical-management group","1825":"low vaccine coverage rings","1826":"the bupivacaine-fentanyl group (Group BF) received 0.25% bupivacaine (1 mL\/kg) plus 2 \u03bcg\/kg fentanyl and the bupivacaine group (Group B) received 0.25% bupivacaine (1 ml\/kg)","1827":"the bupivacaine-fentanyl group (Group BF) received 0.25% bupivacaine (1 mL\/kg) plus 2 \u03bcg\/kg fentanyl and the bupivacaine group (Group B) received 0.25% bupivacaine (1 ml\/kg) ","1828":"placebo","1829":"placebo","1830":"placebo","1831":"prenatal knowledge, attitudes,behaviors beliefs in usual care","1832":"decrease in the levels of impulsivity and aggressiveness in control grup","1833":"sham trigger point dry needling","1834":"A 1-year follow-up of the RxING study","1835":"base line","1836":"intravenous lidocaine","1837":"Placebo","1838":"Placebo","1839":"Placebo","1840":"Placebo","1841":"Ginger alone","1842":"Ginger alone","1843":"Ginger alone","1844":"Prescribed medication without yogic intervention","1845":"All covered nevi","1846":"Narrowband ultraviolet B (NB-UVB)","1847":"Narrowband ultraviolet B (NB-UVB)","1848":"Any other food","1849":"control group","1850":"control group","1851":"Macintosh blade","1852":"placebo","1853":"saline 9 mg\/ml for injection in polyethylene package","1854":"control group","1855":"(2) medium group (2 weeks after stroke); and (3) late group (1-month after stroke) with swallowing therapy ","1856":"(2) medium group (2 weeks after stroke); and (3) late group (1-month after stroke) with swallowing therapy ","1857":"(3) late group (1-month after stroke) with swallowing therapy ","1858":"WR 279,396 (15% paromomycin + 0.5% gentamicin)","1859":"Placebo","1860":"Placebo","1861":"Placebo","1862":"the Supreme Laryngeal Mask Airway (SLMA)","1863":"The Laryngeal Tube Suction Disposable (LTS-D) ","1864":"tamoxifen","1865":"tamoxifen","1866":"groups with exercise energy expenditure of 4 , 8 , or 12 kcal\/kg\/week (KKW)","1867":"control group, which received standard care","1868":"control group, which received standard care","1869":"control group, which received standard care","1870":"high AGE diet","1871":"high AGE diet","1872":"high AGE diet","1873":"high AGE diet","1874":"placebo (Plac)","1875":"10 mg rosuvastatin over 4 months","1876":"sleep without receiving the lavender aroma oil","1877":"sleep without receiving the lavender aroma oil","1878":"passive interval (PIG)","1879":"baseline","1880":"control","1881":"an experimental diet (control)","1882":"an experimental diet (control)","1883":"an experimental diet (control)","1884":"an experimental diet (control)","1885":"individual support","1886":"an experimental diet (control)","1887":"Group I, II and Group III (positive control)","1888":"baseline","1889":"intraarticular indwelling closed suction drainage method","1890":"intraarticular indwelling closed suction drainage method","1891":"Placebo","1892":"Wait-list control group","1893":"Wait-list control group","1894":"Group A was treated using a hook plate","1895":"Group A was treated using a hook plate","1896":"placebo on all days","1897":"placebo on all days","1898":"conventional care group","1899":"conventional care group","1900":"attitudes and behaviors related to Usual care alone","1901":"composite Z100\u00ae","1902":"post-exercise vibration stimulation ","1903":"control group, which received standard care - females","1904":"control group, which received standard care - males","1905":"control groups","1906":"high AGE diet","1907":"high AGE diet","1908":"intravenous lidocaine","1909":"high AGE diet","1910":"high AGE diet","1911":"Normoxic trials","1912":"Exercise trial in normoxia (NOR-Ex)","1913":"Ginger alone","1914":"baseline","1915":"Prescribed medication without yogic intervention","1916":"Prescribed medication without yogic intervention","1917":"Prescribed medication without yogic intervention","1918":"treatment with tamsulosin (group A) + 5-mg prednisolone once daily (maximum 1 week)","1919":"treatment with tamsulosin (group A) + 5-mg prednisolone once daily (maximum 1 week)","1920":"IV pantoprazole (40 mg every day) for up to 14 days","1921":"Narrowband ultraviolet B (NB-UVB)","1922":"IV pantoprazole (40 mg every day) for up to 14 days","1923":"Individual-based computer-prompt program and Usual-break control group","1924":"ultrasound-guided paravertebral block using the needle guide (Group II)","1925":"ultrasound-guided paravertebral block using the needle guide (Group II)","1926":"ultrasound-guided paravertebral block using the needle guide (Group II)","1927":"trail running shoes or control","1928":"trail running shoes or control","1929":"Any other food","1930":"an experimental diet (control)","1931":"control group","1932":"control group","1933":"control group","1934":"primary care physicians (PCP) alone","1935":"baseline","1936":"baseline","1937":"baseline","1938":"intraarticular indwelling closed suction drainage method","1939":"placebo","1940":"placebo","1941":"control group","1942":"control group","1943":"control group","1944":"control group","1945":"the dusting medial exercise","1946":"the Supreme Laryngeal Mask Airway (SLMA)","1947":"usual group","1948":"usual group","1949":"usual group","1950":"conventional surgery","1951":"varenicline (VR)","1952":"varenicline (VR)","1953":"povidone-iodine","1954":"placebo","1955":"placebo","1956":"placebo","1957":"control ","1958":"control ","1959":"17 G\/ 35 mm (standard) needle","1960":"17 G\/ 35 mm (standard) needle","1961":"control","1962":"control","1963":"baseline","1964":"control","1965":"placebo","1966":"placebo","1967":"placebo","1968":"placebo","1969":"placebo","1970":"placebo","1971":"control group (blind reduction) Plane II fracture","1972":"control group (blind reduction) Plane II fracture","1973":"Group B: SRP with placebo gel","1974":"placebo","1975":"medical-management group","1976":"medical-management group","1977":"the bupivacaine-fentanyl group (Group BF) received 0.25% bupivacaine (1 mL\/kg) plus 2 \u03bcg\/kg fentanyl and the bupivacaine-dexmedetomidine group (Group BD) received 0.25% bupivacaine (1 mL\/kg) plus 2 \u03bcg\/kg dexmedetomidine","1978":"1 week with levocetirizine","1979":"placebo","1980":"placebo","1981":"methadone","1982":"methadone","1983":"methadone","1984":"methadone","1985":"citalopram","1986":"citalopram","1987":"citalopram","1988":"A 1-year follow-up of the RxING study","1989":"iron supplementation + mebendazole","1990":"iron supplementation + mebendazole","1991":"Vitamin D Non-deficient","1992":"Vitamin D Non-deficient","1993":"Placebo","1994":"Normoxic trials","1995":"Exercise trial in normoxia (NOR-Ex)","1996":"Normoxic trials","1997":"Ginger alone","1998":"Individual-based computer-prompt program and Usual-break control group","1999":"ultrasound-guided paravertebral block using the needle guide (Group II)","2000":"ultrasound-guided paravertebral block using the needle guide (Group II)","2001":"Any other food","2002":"Any other food","2003":"Macintosh blade","2004":"placebo","2005":"placebo","2006":"control group","2007":"control group","2008":"control group","2009":"control group","2010":"Paromomycin Alone (15% paromomycin) for 20 days","2011":"the gravity-minimized exercises","2012":"Placebo","2013":"Placebo","2014":"the Supreme Laryngeal Mask Airway (SLMA)","2015":"The Laryngeal Tube Suction Disposable (LTS-D) ","2016":"the Supreme Laryngeal Mask Airway (SLMA)","2017":"the Supreme Laryngeal Mask Airway (SLMA)","2018":"conventional care group","2019":"tamoxifen","2020":"control group","2021":"control group (Group C) were premedicated with 2 mL normal saline","2022":"control group, which received standard care","2023":"high AGE diet","2024":"high AGE diet","2025":"high AGE diet","2026":"high AGE diet","2027":"placebo (Plac)","2028":"10 mg rosuvastatin over 4 months","2029":"10 mg rosuvastatin over 4 months","2030":"10 mg rosuvastatin over 4 months with selenium (150 I\u03021\u20444g\/d) supplementation.","2031":"CO2 pneumoperitoneum - 15 mm Hg).","2032":"sleep without receiving the lavender aroma oil","2033":"sleep without receiving the lavender aroma oil","2034":"sleep without receiving the lavender aroma oil","2035":"Arm C triple therapy alone","2036":"tamsulosin with tadalafil (group B) + 5-mg prednisolone once daily (maximum 1 week)","2037":"tamsulosin with tadalafil (group B) + 5-mg prednisolone once daily (maximum 1 week)","2038":"treatment with tamsulosin (group A) + 5-mg prednisolone once daily (maximum 1 week)","2039":"treatment with tamsulosin (group A) + 5-mg prednisolone once daily (maximum 1 week)","2040":"passive interval (PIG)","2041":"an experimental diet (control)","2042":"an experimental diet (control)","2043":"placebo beverage","2044":"placebo beverage","2045":"placebo beverage","2046":"baseline","2047":"intraarticular indwelling closed suction drainage method","2048":"Group E received esmolol in a loading and maintenance dose of 1 mg\/kg over 1 min and 0.5-1.0 mg\/kg\/h and group N received nitroglycerine infusion at a dose of 0.5-2 I\u03021\u20444g\/kg\/min","2049":"Group E received esmolol in a loading and maintenance dose of 1 mg\/kg over 1 min and 0.5-1.0 mg\/kg\/h and group N received nitroglycerine infusion at a dose of 0.5-2 I\u03021\u20444g\/kg\/min","2050":"Group E received esmolol in a loading and maintenance dose of 1 mg\/kg over 1 min and 0.5-1.0 mg\/kg\/h and group N received nitroglycerine infusion at a dose of 0.5-2 I\u03021\u20444g\/kg\/min","2051":"ZnOE-based sealer (Roth-811)","2052":"Only normal saline (Group C)","2053":"Only normal saline (Group C)","2054":"Only normal saline (Group C)","2055":"Placebo","2056":"Placebo","2057":"Placebo","2058":"Wait-list control group","2059":"Wait-list control group","2060":"Wait-list control group","2061":"Formula-fed infants","2062":"Unfortified formula group","2063":"Formula-fed infants","2064":"Group A was treated using a hook plate","2065":"Group A was treated using a hook plate","2066":"Group A was treated using a hook plate","2067":"placebo on all days","2068":"Medical treatment","2069":"Midazolam plus remifentanil","2070":"Midazolam plus remifentanil","2071":"Midazolam plus remifentanil","2072":"Sequential azacitidine and lenalidomide group and azacitidine only group","2073":"Placebo","2074":"Placebo","2075":"Topical betamethasone valerate cream (Group A)","2076":"No breakfast before exercise","2077":"No breakfast before exercise","2078":"Placebo group","2079":"Placebo","2080":"Saliva in situ (G1)","2081":"Exercises with whole-body vibration (Groups II and III) and exercises without the application of concurrent vibration (Group IV)","2082":"Exercises with whole-body vibration (Groups II and III) ","2083":"Exercises with whole-body vibration (Groups II and III) ","2084":"Uninformed group","2085":"placebo (PLA)","2086":"control","2087":"placebo","2088":"control group (CG) received only scaling and root planing (SRP)","2089":"control group (CG) received only scaling and root planing (SRP)","2090":"control","2091":"no injection (B)","2092":"no intervention","2093":"no intervention","2094":"conventional dietary education (group C)","2095":"standard dose MMC (SDMMC","2096":"standard dose MMC (SDMMC","2097":"standard dose MMC (SDMMC","2098":"the 0.9% saline continuous infusion (the control group)","2099":"the 0.9% saline continuous infusion (the control group)","2100":"placebo in addition to lithium","2101":"placebo in addition to lithium","2102":"three times of telephone call was established to record blood sugar levels","2103":"three times of telephone call was established to record blood sugar levels","2104":"Group C receiving identical-looking placebo","2105":"Control","2106":"Control","2107":"placebo (PLC)","2108":"placebo (PLC)","2109":"placebo","2110":"Local Infiltration Group received 0.2 ml\/kg 0.25% bupivacaine","2111":"patients with hyperglycemia relapse without significant changes in insulin sensitivity (Si)","2112":"the age-matched controls hypertensive group","2113":"placebo","2114":"control group","2115":"control group","2116":"pneumatic cuff was applied to the calf and inflated to 0 mmHg","2117":"stock","2118":"After the intake (T 0) and implant placement","2119":"stock","2120":"Resilon\/RealSeal SE samples","2121":"epinephrine 1:200000 and 0.4 mL normal saline (A-saline group)","2122":"control","2123":"control","2124":"control","2125":"conventional anterior extraperitoneal approach focal cleaning combined with posterior internal fixation in period I - group B","2126":"propofol (1.5 mg\/kg) combination in Group II ","2127":"G3 was prepared with an occlusal extension that extended one-third of buccolingual width and 2 mm in depth","2128":"pacemaker Talos DR (Biotronik, Berlin, Germany)","2129":"rizatriptan","2130":"baseline","2131":"placebo","2132":"placebo","2133":"placebo","2134":"baseline","2135":"control","2136":"ACVC","2137":"self-expectoration (ES)","2138":"oral conjugated equine estrogens (o-CEE; 0.45 mg\/d) ","2139":"placebo","2140":"oral conjugated equine estrogens (o-CEE; 0.45 mg\/d) ","2141":"Local Infiltration Group received 0.2 ml\/kg 0.25% bupivacaine","2142":"Saliva in situ (G1)","2143":"placebo","2144":"sitagliptin 100 mg daily","2145":"sitagliptin 100 mg daily","2146":"baseline","2147":"no injection (B)","2148":"No interventions","2149":"5 mg axitinib alone","2150":"Group C receiving identical-looking placebo","2151":"no intervention","2152":"Control","2153":"control group","2154":"control group","2155":"Placebo group","2156":"placebo","2157":"Placebo","2158":"Placebo","2159":"Uninformed group","2160":"placebo (PLA)","2161":"naproxen sodium 550 mg (NAP)","2162":"control group","2163":"control group","2164":"placebo","2165":"control","2166":"17 G\/ 35 mm (standard) needle","2167":"control","2168":"control","2169":"control","2170":"qIHC of Ki-67 or vIHC of Ki-67","2171":"no injection (B)","2172":"no injection (B)","2173":"no injection (B)","2174":"no intervention","2175":"control group","2176":"standard dose MMC (SDMMC","2177":"laparotomies for various reasons","2178":"the 0.9% saline continuous infusion (the control group)","2179":"the 0.9% saline continuous infusion (the control group)","2180":"three times of telephone call was established to record blood sugar levels","2181":"three times of telephone call was established to record blood sugar levels","2182":"Control","2183":"Control","2184":"Control","2185":"placebo (PLC)","2186":"Medical treatment","2187":"placebo","2188":"Midazolam plus remifentanil","2189":"Sequential azacitidine and lenalidomide group and azacitidine only group","2190":"placebo","2191":"No interventions","2192":"placebo","2193":"Topical betamethasone valerate cream (Group A)","2194":"Topical betamethasone valerate cream (Group A)","2195":"placebo","2196":"No breakfast before exercise","2197":"placebo","2198":"placebo","2199":"control group","2200":"Placebo group","2201":"control group","2202":"Placebo group","2203":"control","2204":"control","2205":"a program of emotional intelligence (EI) 20 one-hour sessions - girls","2206":"pneumatic cuff was applied to the calf and inflated to 0 mmHg","2207":"baseline","2208":"pacemaker Talos DR (Biotronik, Berlin, Germany)","2209":"pacemaker Talos DR (Biotronik, Berlin, Germany)","2210":"baseline","2211":"baseline","2212":"control before scanning","2213":"primaquine phosphate","2214":"primaquine phosphate","2215":"positive training (vice versa)","2216":"received a routine program","2217":"received a routine program","2218":"received a routine program","2219":"received a routine program","2220":"self-expectoration (ES)","2221":"oral conjugated equine estrogens (o-CEE; 0.45 mg\/d) ","2222":"Placebo","2223":"Uninformed group","2224":"naproxen sodium 550 mg (NAP)","2225":"control","2226":"control","2227":"placebo","2228":"conventional dietary education (group C)","2229":"control","2230":"laparotomies for various reasons","2231":"the 0.9% saline continuous infusion (the control group)","2232":"three times of telephone call was established to record blood sugar levels","2233":"Group C receiving identical-looking placebo","2234":"Control","2235":"Control","2236":"placebo (PLC)","2237":"placebo","2238":"placebo","2239":"Routine care group","2240":"placebo","2241":"Routine care group ","2242":"No interventions","2243":"placebo","2244":"placebo","2245":"No breakfast before exercise","2246":"placebo","2247":"Placebo group","2248":"control","2249":"control","2250":"control","2251":"pneumatic cuff was applied to the calf and inflated to 0 mmHg","2252":"15 mg, 30 mg or 60 mg once daily - non-erosive reflux disease (ERD)","2253":"lansoprazole at a dose of 60 mg once daily ","2254":"double-dose statin (DST) ","2255":"intravenous chemotherapy consisting of either dacarbazine (1000 mg\/m2) or paclitaxel (175 mg\/m2), every 3 weeks","2256":"intravenous chemotherapy consisting of either dacarbazine (1000mg\/m2) or paclitaxel (175mg\/m2), every 3weeks","2257":"docetaxel plus placebo","2258":"Uninformed group","2259":"baseline - three weeks and six weeks","2260":"Resilon\/RealSeal SE negative control - six weeks","2261":"control","2262":"baseline","2263":"conventional anterior extraperitoneal approach focal cleaning combined with posterior internal fixation in period I - group B","2264":"baseline","2265":"conventional anterior extraperitoneal approach focal cleaning combined with posterior internal fixation in period I - group B","2266":"fentanyl (1 \u03bcg\/kg) + propofol (1.5 mg\/kg) combination in Group III","2267":"fentanyl (1 \u03bcg\/kg) + propofol (1.5 mg\/kg) combination in Group III","2268":"G6: The occlusal extension was 2 mm in depth and 1 mm in width.","2269":"pacemaker Talos DR (Biotronik, Berlin, Germany)","2270":"rizatriptan","2271":"rizatriptan","2272":"baseline","2273":"baseline","2274":"control ","2275":"control before scanning","2276":"placebo","2277":"placebo","2278":"placebo","2279":"placebo","2280":"dihydroartemisinin-piperaquine","2281":"primaquine phosphate","2282":"primaquine phosphate","2283":"primaquine phosphate","2284":"primaquine phosphate","2285":"placebo","2286":"positive training (PT) (vice versa)","2287":"non-dysphoric","2288":"sham-training (dysphoric, non-dysphoric)","2289":"sham-training (dysphoric, non-dysphoric)","2290":"sham-training (dysphoric, non-dysphoric)","2291":"baseline","2292":"received a routine program","2293":"received a routine program","2294":"anterior cervical corpectomy and fusion (ACCF)","2295":"anterior cervical corpectomy and fusion (ACCF)","2296":"self-expectoration (ES)","2297":"control","2298":"control","2299":"untreated","2300":"Panretinal photocoagulation (PRP) with red laser","2301":"Panretinal photocoagulation (PRP) with red laser","2302":"a combination of the FA with high-pull headgear worn at night","2303":"Placebo (CG group)","2304":"Placebo (CG group)","2305":"a combination of the FA with high-pull headgear worn at night","2306":"BDP 100 I\u03021\u20444g (four puffs twice a day)","2307":"BDP 100 I\u03021\u20444g (four puffs twice a day)","2308":"Control (C group)","2309":"consumed 200 ml\/day of soy milk for 8 weeks","2310":"Placebo","2311":"Normal saline followed by general anesthesia (Group N)","2312":"Normal saline followed by general anesthesia (Group N)","2313":"Placebo (PLAC)","2314":"Mild-cooling","2315":"No cooling","2316":"Intensive individual intervention (III)","2317":"G6: The occlusal extension was 2 mm in depth and 1 mm in width.","2318":"baseline","2319":"saline control","2320":"injected with placebo saline solution in the articular cavity","2321":"control","2322":"glargine, NPH insuline","2323":"baseline","2324":"baseline","2325":"waitlist condition","2326":"control or not at risk","2327":"telmisartan 80 mg ","2328":"injected with placebo saline solution in the articular cavity","2329":"400 mg of metronidazole tablets (as a placebo)","2330":"placebo, or oral olanzapine 5-20 mg once daily for 3 weeks","2331":"baseline","2332":"Kaltenborn mobilization","2333":"placebo","2334":"baseline","2335":"baseline","2336":"untreated","2337":"non-dominant hand","2338":"Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 I\u03021\u20444g (0.5ml) , Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 I\u03021\u20444g (0.5 ml)","2339":"baseline","2340":"baseline","2341":"used a conventional dentifrice","2342":"PHiD-CV Commercial lot (Com group)","2343":"PHiD-CV Commercial lot (Com group)","2344":"PHiD-CV Commercial lot (Com group)","2345":"used a conventional dentifrice","2346":"no aspirin","2347":"Human menopausal gonadotropin (HMG) plus r-FSH","2348":"injected with placebo saline solution in the articular cavity","2349":"Sulphadoxine-pyrimethamine (SP) ","2350":"Sulphadoxine-pyrimethamine (SP) ","2351":"untreated","2352":"Panretinal photocoagulation (PRP) with red laser","2353":"control","2354":"Placebo (CG group)","2355":"No- users of IDCT","2356":"Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 I\u03021\u20444g (0.5ml) , Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 I\u03021\u20444g (0.5 ml)","2357":"No cooling","2358":"completed the word jumble","2359":"Routine care group and walking group","2360":"diabetes support and education (DSE)","2361":"Control (C group)","2362":"Control (C group)","2363":"no intervention","2364":"Baseline","2365":"Normal saline followed by general anesthesia (Group N)","2366":"placebo (PLC)","2367":"Cycling time trial to exhaustion at 100%VO2max at 1657 m of altitude (ALT)","2368":"Panretinal photocoagulation (PRP) with red laser","2369":"a combination of the FA with high-pull headgear worn at night","2370":"control","2371":"Placebo","2372":"Placebo","2373":"Placebo","2374":"BDP 100 I\u03021\u20444g (four puffs twice a day)","2375":"Control (C group)","2376":"BDP 100 I\u03021\u20444g (four puffs twice a day)","2377":"Crystalloid (RS group) and control (C group)","2378":"alfacalcidol (AC)","2379":"alfacalcidol (AC)","2380":"Placebo","2381":"Placebo","2382":"consumed 200 ml\/day of soy milk for 8 weeks","2383":"Placebo","2384":"Normal saline followed by general anesthesia (Group N)","2385":"Exercise at 1657 m of altitude plus Placebo (ALTPLAC)","2386":"Placebo (PLAC)","2387":"Usual Quality Improvement Program (UQIP)","2388":"Usual Quality Improvement Program (UQIP)","2389":"No- users of IDCT","2390":"Minimal intervention (MI)","2391":"group 3 involved bispectral index (BIS) of 40","2392":"baseline","2393":"baseline","2394":"saline control","2395":"glargine, NPH insuline","2396":"waitlist condition","2397":"waitlist condition","2398":"placebo","2399":"placebo","2400":"injected with placebo saline solution in the articular cavity","2401":"no NIV","2402":"400 mg of metronidazole tablets (as a placebo)","2403":"placebo, or oral olanzapine 5-20 mg once daily for 3 weeks","2404":"placebo, or oral olanzapine 5-20 mg once daily for 3 weeks","2405":"placebo, or oral olanzapine 5-20 mg once daily for 3 weeks","2406":"placebo, or oral olanzapine 5-20 mg once daily for 3 weeks","2407":"placebo","2408":"baseline","2409":"placebo","2410":"Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 I\u03021\u20444g (0.5ml) , Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 I\u03021\u20444g (0.5 ml)","2411":"PHiD-CV Commercial lot (Com group)","2412":"Ibuprofen and placebo","2413":"Ibuprofen and placebo","2414":"placebo","2415":"took part in the horse riding exercises without a blindfold","2416":"baseline","2417":"Human menopausal gonadotropin (HMG) plus r-FSH","2418":"no aspirin","2419":"injected with placebo saline solution in the articular cavity","2420":"Sulphadoxine-pyrimethamine (SP) or chlorproguanil-dapsone (CPD)","2421":"Sulphadoxine-pyrimethamine (SP) ","2422":"baseline","2423":"liposomal amphotericin B (3 mg\/kg\/day)","2424":"control group","2425":"traditional cold instruments (scalpel and scissors)","2426":"placebo","2427":"adefovir (ADV) (10 mg\/day)","2428":"cup","2429":"placebo","2430":"placebo","2431":"placebo","2432":"baseline","2433":"flat intermittent constant rate infusion (Arm B) of DDP and 5-FU followed by radical radiotherapy","2434":"baseline","2435":"Couples Health CoOp [CHC]","2436":"conventional thoracotomy (CT)","2437":"pioglitazone","2438":"acarbose","2439":"memantine 5\u201320 mg\/d","2440":"question: Doctors tells you that although you particularly like to eat bacon, if you continue to eat, your body cholesterol content will significantly rise, and thus the possibility of suffering from cardiovascular disease would be greatly increased. Would you continue to eat bacon?","2441":"Eye surgery may lead to two potential sequelas: one is a minor decline of visual acuity and the other is keratitis. Imagine you will take this kind of surgery and two doctors' medical records revealed that: Doctor A: Of 200 patients, 197 didn't suffer from keratitis but 9 were found visual acuity declined. Doctor B: Of 200 patients, 190 didn't suffer from keratitis but 2 were found visual acuity declined. Which doctor you will choose?","2442":"normally diet (ND)","2443":"normally diet (ND)","2444":"normally diet (ND)","2445":"normally diet (ND)","2446":"trigger point injections (TPI)+transcutaneous electrical nerve stimulation (TENS)","2447":"trigger point injections (TPI)+transcutaneous electrical nerve stimulation (TENS)","2448":"visual disuse group (VDG)","2449":"visual disuse group (VDG)","2450":"Kuntai, Tibolone","2451":"Kuntai, Control","2452":"Kuntai, Control","2453":"a combination of the FA with high-pull headgear worn at night","2454":"a combination of the FA with high-pull headgear worn at night","2455":"Placebo (CG group)","2456":"Placebo (CG group)","2457":"Placebo","2458":"BDP 100 \u03bcg (four puffs twice a day)","2459":"Placebo","2460":"alfacalcidol (AC)","2461":"Placebo","2462":"Normal saline followed by general anesthesia (Group N)","2463":"Exercise at sea-level plus Placebo (SEAPLAC)","2464":"No cooling","2465":"Minimal intervention (MI)","2466":"control","2467":"placebo","2468":"400 mg of metronidazole tablets (as a placebo)","2469":"baseline","2470":"baseline","2471":"baseline","2472":"without an ICU-AW diagnosis","2473":"Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 \u03bcg (0.5 ml), Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 \u03bcg (0.5 ml)","2474":"baseline","2475":"used a conventional dentifrice","2476":"placebo","2477":"Ibuprofen and placebo","2478":"placebo","2479":"Ibuprofen ","2480":"Human menopausal gonadotropin (HMG) plus r-FSH","2481":"Human menopausal gonadotropin (HMG) plus r-FSH","2482":"Human menopausal gonadotropin (HMG) plus r-FSH","2483":"untreated","2484":"baseline","2485":"MDZ: FEN and 'DEX half'","2486":"200 IU vitamin D3","2487":"liposomal amphotericin B (3 mg\/kg\/day)","2488":"baseline","2489":"baseline","2490":"Control Group","2491":"Patients in the 20h group","2492":"stentless cases,","2493":"control group","2494":"control group","2495":"control group","2496":"validation group","2497":"traditional cold instruments (scalpel and scissors)","2498":"traditional cold instruments (scalpel and scissors)","2499":"placebo","2500":"cup","2501":"placebo","2502":"placebo","2503":"placebo","2504":"flat intermittent constant rate infusion (Arm B) of DDP and 5-FU followed by radical radiotherapy","2505":"conventional treatment group (NVM)","2506":"Men's Health CoOp\/Women's Health CoOp [MHC\/WHC]","2507":"conventional thoracotomy (CT)","2508":"pioglitazone","2509":"memantine 5\u201320 mg\/d","2510":"question: 100 patients taking one kind of medicine, 30 patients didn't become better. How would you evaluate the drug effect?","2511":"There are 600 critically ill patients in one hospital. Two rescue programs are under consideration. If program A is adopted, 400 patients will die; If program B is adopted, there is a 1\/3 chance that none of the patients will die and there is 2\/3 chance that all will die Which program will you choose?","2512":"normally diet (ND)","2513":"visual disuse group (VDG)","2514":"visual disuse group (VDG)","2515":"visual disuse group (VDG)","2516":"baseline","2517":"baseline","2518":"Kuntai","2519":"Standard care (Control group, CG)","2520":"Standard care (Control group, CG)","2521":"Standard clinical care","2522":"Standard clinical care","2523":"Standard clinical care","2524":"Standard clinical care","2525":"Sham rTMS","2526":"Calendula ointment","2527":"Perspecta plans","2528":"Clopidogrel 75 mg","2529":"Placebo laser therapy (Group II)","2530":"Provider-collected cervical swabs","2531":"2% lidocaine with 1:200,000 epinephrine ","2532":"2% lidocaine with 1:200,000 epinephrine ","2533":"2% lidocaine with 1:200,000 epinephrine ","2534":"2% lidocaine with 1:200,000 epinephrine ","2535":"Partial closure of the wound","2536":"Placebo","2537":"Placebo","2538":"Placebo","2539":"Vycross 20 mg\/ml HA (VYC-20)","2540":"Vycross 20 mg\/ml HA (VYC-20)","2541":"Placebo","2542":"Placebo","2543":"Remifentanil 0.3 + ketamine 0.5 (group KRH)","2544":"Remifentanil 0.3 + ketamine 0.5 (group KRH) or remifentanil 0.05 (Group RL) ","2545":"Remifentanil 0.3 + ketamine 0.5 (group KRH) or remifentanil 0.05 (Group RL) ","2546":"Eetanercept alone","2547":"Eetanercept alone","2548":"Eetanercept alone","2549":"Only vitamin B12 supplement","2550":"Placebo group","2551":"Placebo group","2552":"Placebo group","2553":"Center-near lens (AOMF)","2554":"MDZ:FEN and DEX half","2555":"a combination of the FA with high-pull headgear worn at night","2556":"liposomal amphotericin B (3 mg\/kg\/day)","2557":"Patients in the 20h group","2558":"Glady's algorithm","2559":"DERIVATION GROUP sensitivity, specificity, PPV, NPV were 95%, 42%, 25%, and 98% ","2560":"diabetes support and education (DSE)","2561":"traditional cold instruments (scalpel and scissors)","2562":"traditional cold instruments (scalpel and scissors)","2563":"placebo","2564":"baseline","2565":"400 mg of metronidazole tablets (as a placebo)","2566":"conventional treatment group (NVM)","2567":"Couples Health CoOp [CHC], Women's Health CoOp","2568":"conventional thoracotomy (CT)","2569":"baseline","2570":"placebo","2571":"normally diet (ND)","2572":"hyperbaric bupivacaine 12.5 mg along with 0.4 mL of normal saline in the subarachnoid block","2573":"normally diet (ND)","2574":"control","2575":"trigger point injections (TPI)+transcutaneous electrical nerve stimulation (TENS)","2576":"baseline","2577":"Tibolone","2578":"baseline","2579":"Sulphadoxine-pyrimethamine (SP) ","2580":"Minimal version of the app","2581":"Minimal version of the app","2582":"Minimal version of the app","2583":"Sham rTMS","2584":"Perspecta plans","2585":"Perspecta plans","2586":"Perspecta plans","2587":"Perspecta plans","2588":"Clopidogrel 75 mg","2589":"Prasugrel 10 mg","2590":"Placebo laser therapy (Group II)","2591":"Placebo laser therapy (Group II)","2592":"Placebo laser therapy (Group II)","2593":"2% lidocaine with 1:200,000 epinephrine ","2594":"Placebo","2595":"Placebo","2596":"Placebo","2597":"Placebo","2598":"No label group and TL+SNL group","2599":"No label group and choices group","2600":"flat intermittent constant rate infusion (Arm B) of DDP and 5-FU followed by radical radiotherapy","2601":"Vycross 20 mg\/ml HA (VYC-20)","2602":"Placebo","2603":"Control group","2604":"FOLFOX4","2605":"FOLFOX4","2606":"FOLFOX4","2607":"Only Judo training (CG)","2608":"Interval training combined with Judo training (IJ)","2609":"Only Judo training (CG)","2610":"Only vitamin B12 supplement","2611":"Only vitamin B12 supplement","2612":"Placebo group","2613":"Placebo group","2614":"Hydrodistension only","2615":"control","2616":"placebo","2617":"placebo","2618":"fluid resuscitation and norepinephrine infusion (SD0)","2619":"placebo","2620":"regular in-office FU (HM OFF)","2621":"regular in-office FU (HM OFF)","2622":"regular in-office FU (HM OFF)","2623":"regular in-office FU (HM OFF)","2624":"regular in-office FU (HM OFF)","2625":"regular in-office FU (HM OFF)","2626":"regular in-office FU (HM OFF)","2627":"placebo","2628":"placebo","2629":"placebo","2630":"placebo","2631":"usual care","2632":"placebo (plain flour)","2633":"gemcitabine (300 mg m\u22122), and cisplatin (30 mg m\u22122) on days 1, 8, 22, and 29 (RT-GC arm), or the same concurrent treatment followed by sequential full-dose gemcitabine (1000 mg m\u22122) and cisplatin (50 mg m\u22122) every 2 weeks (RT-GC+GC arm)","2634":"twice-daily SFC 50 \u03bcg\/500 \u03bcg","2635":"ketamine group","2636":"hyoscine group","2637":"computed tomography (CT)","2638":"computed tomography (CT)","2639":"computed tomography (CT)","2640":"nothing (waiting list group) ","2641":"control","2642":"pre\u2013alvimopan","2643":"pre\u2013alvimopan","2644":"baseline","2645":"baseline","2646":"Prehospital administration of ticagrelor","2647":"480 g\/day of raw banana for 6 days","2648":"500 g\/day of cooked banana for 4 days","2649":"500 g\/day of cooked banana for 4 days","2650":"baseline","2651":"societal costs","2652":"baseline","2653":"non-consumers","2654":"placebo","2655":"control","2656":"warfarin","2657":"rivaroxaban","2658":"FOLFOX4","2659":"adjuvant dose-dense doxorubicin-cyclophosphamide (ddAC) ","2660":"control","2661":"Cisatracurium group","2662":"Cisatracurium group","2663":"Cisatracurium group","2664":"late tracheotomy","2665":"control group","2666":"Group 2: low GI foods","2667":"gestational diabetes mellitus (GDM)","2668":"baseline","2669":"treatment as usual (TAU)","2670":"baseline","2671":"40 mg\/day of lovastatin","2672":"40 mg\/day of lovastatin","2673":"Group I - herbal combination of Acacia nilotica and Licorice (A and L)","2674":"control","2675":"control","2676":"200 IU vitamin D3","2677":"Standard care (Control group, CG)","2678":"Calendula ointment","2679":"Calendula ointment","2680":"Calendula ointment","2681":"Prasugrel 10 mg","2682":"traditional cold instruments (scalpel and scissors)","2683":"placebo","2684":"flat intermittent constant rate infusion (Arm B) of DDP and 5-FU followed by radical radiotherapy","2685":"conventional thoracotomy (CT)","2686":"pioglitazone","2687":"acarbose","2688":"Remifentanil 0.3 + ketamine 0.5 (group KRH) or remifentanil 0.05 (Group RL) ","2689":"Imagine one of your relatives was diagnosed with a cancer that must be treated. His choices are as follows: Surgery: Of 100 people having surgery, 50 die because of the operation and 10 of the 50 survivals die by the end of five years. Radiation therapy: Of 100 people having radiation therapy, none die during the treatment, and 80 die by the end of five years. Which treatment would you advise him to choose?","2690":"FOLFOX4","2691":"Eetanercept alone","2692":"extracorporeal shock wave therapy (ESWT)","2693":"Group II (CHX mouthwash-Behsa)","2694":"Group II (CHX mouthwash-Behsa)","2695":"Hydrodistension only","2696":"Hydrodistension only","2697":"Hydrodistension only","2698":"control","2699":"baseline","2700":"control","2701":"D2 (Sensodyne Rapid Relief\u00ae), D4 (Colgate Maximum Cavity Protection\u00ae)","2702":"control","2703":"two doses of vaccine","2704":"control","2705":"propofol SD1","2706":"fluid resuscitation and norepinephrine infusion (SD0)","2707":"Dexmedetomidine ","2708":"placebo","2709":"regular in-office FU (HM OFF)","2710":"hand instrumentation","2711":"placebo","2712":"placebo","2713":"usual care","2714":"gemcitabine (300 mg m\u22122), and cisplatin (30 mg m\u22122) on days 1, 8, 22, and 29 (RT-GC arm), or the same concurrent treatment followed by sequential full-dose gemcitabine (1000 mg m\u22122) and cisplatin (50 mg m\u22122) every 2 weeks (RT-GC+GC arm)","2715":"capecitabine 1250 mg m\u22122 two times daily on days 1\u201314 every 3 weeks","2716":"twice-daily SFC 50 \u03bcg\/500 \u03bcg","2717":"twice-daily SFC 50 \u03bcg\/500 \u03bcg","2718":"twice-daily SFC 50 \u03bcg\/500 \u03bcg","2719":"baseline","2720":"baseline","2721":"computed tomography (CT)","2722":"computed tomography (CT)","2723":"nothing (waiting list group)","2724":"nothing (waiting list group)","2725":"nothing (waiting list group) or two sessions of 1.5 hours each of psychoeducation","2726":"nothing (waiting list group) or two sessions of 1.5 hours each of psychoeducation","2727":"control","2728":"pre\u2013alvimopan","2729":"pre\u2013alvimopan","2730":"ferrous sulfate twice daily, (both 5 mg iron\/kg\/day)","2731":"baseline","2732":"500 g\/day of cooked banana for 4 days","2733":"high-field horizontal open MR scanner","2734":"high-field horizontal open MR scanner","2735":"short-bore MR scanner","2736":"high-field horizontal open MR scanner","2737":"atorvastatin 40 mg daily ","2738":"atorvastatin 40 mg daily ","2739":"atorvastatin 40 mg daily ","2740":"atorvastatin 40 mg daily ","2741":"any other NOAC","2742":"warfarin","2743":"warfarin","2744":"docetaxel-doxorubicin-cyclophosphamide (TAC)","2745":"adjuvant dose-dense doxorubicin-cyclophosphamide (ddAC) ","2746":"docetaxel-doxorubicin-cyclophosphamide (TAC)","2747":"adjuvant dose-dense doxorubicin-cyclophosphamide (ddAC) ","2748":"adjuvant dose-dense doxorubicin-cyclophosphamide (ddAC) ","2749":"docetaxel-doxorubicin-cyclophosphamide (TAC)","2750":"Only Judo training (CG)","2751":"Cisatracurium group","2752":"early tracheotomy ","2753":"late tracheotomy","2754":"late tracheotomy","2755":"late tracheotomy","2756":"control group","2757":"continuous smokers","2758":"baseline","2759":"Group 2: low GI foods","2760":"Group 2: low GI foods","2761":"treatment as usual (TAU)","2762":"control","2763":"control","2764":"control","2765":"control","2766":"control","2767":"control","2768":"Placebo","2769":"Placebo","2770":"fixed-combination bimatoprost 0.03%\/timolol 0.5% (FCBT PF) in previously treated patients","2771":"linseed oil (LO)","2772":"Placebo","2773":"Placebo","2774":"different TNFi","2775":"No intervention (control group)","2776":"No intervention (control group)","2777":"Standard education session","2778":"Standard education session","2779":"Group C (control)","2780":"Group C (control)","2781":"Irradiation with Er:YAG laser at 1 W (group 2) and irradiation with Er:YAG laser at 1.5 W (group 3)","2782":"Irradiation with Er:YAG laser at 1 W (group 2) and irradiation with Er:YAG laser at 1.5 W (group 3)","2783":"Low glycemic index intervention","2784":"Low glycemic index intervention","2785":"Intravenous crystalloid","2786":"Rectangular-walking or Free-generation or Random-experienced ","2787":"rinse their mouths with triphala mouthwash for 1 minute twice daily for two weeks ","2788":"placebo","2789":"placebo","2790":"baseline","2791":"prednisolon 0.3 mg\/kg for 6 weeks","2792":"control","2793":"levofloxacin (500 mg\/d) (group L, 40 patients) for 6 weeks","2794":"angioplasty alone","2795":"angioplasty alone","2796":"Educational Control (EC)","2797":"remaining participants","2798":"bright white light (10,000 lux), dim red light (< 500 lux) pre-treatment ","2799":"bright white light (10,000 lux), dim red light (< 500 lux) pre-treatment ","2800":"bright white light (10,000 lux), dim red light (< 500 lux) pre-treatment ","2801":"Standard care (Control group, CG)","2802":"Standard care (Control group, CG)","2803":"Sham rTMS","2804":"Prasugrel 10 mg","2805":"Placebo laser therapy (Group II)","2806":"Provider-collected cervical swabs","2807":"Placebo","2808":"No label group and choices group","2809":"Partial closure of the wound","2810":"Partial closure of the wound","2811":"Placebo","2812":"Control group (CTRg)","2813":"Placebo","2814":"Control group","2815":"Remifentanil 0.3 + ketamine 0.5 (group KRH) or remifentanil 0.05 (Group RL) ","2816":"Only Judo training (CG)","2817":"Only vitamin B12 supplement","2818":"Only vitamin B12 supplement","2819":"Center-near lens (AOMF)","2820":"Center-near lens (AOMF)","2821":"Center-near lens (AOMF)","2822":"distal extensive HAS","2823":"self-administered therapy (SAT)","2824":"linseed oil (LO)","2825":"rituximab","2826":"abatacept","2827":"K-file","2828":"Mtwo","2829":"K-file ","2830":"K-file, Mtwo","2831":"lower dose 2.25 mg\/kg (lowATG)","2832":"lower dose 2.25 mg\/kg (lowATG)","2833":"lower dose 2.25 mg\/kg (lowATG)","2834":"lower dose 2.25 mg\/kg (lowATG)","2835":"lower dose 2.25 mg\/kg (lowATG)","2836":"normal weight group following consumption of the high protein, low fat meal","2837":"overweight","2838":"normal weight group - high protein, low fat meal","2839":"Neoadjuvant chemotherapy (NC) alone","2840":"Neoadjuvant chemotherapy (NC) alone","2841":"Neoadjuvant chemotherapy (NC) alone","2842":"PS-sunflower oil (SO) and PS-olive oil (OO)","2843":"PS-sunflower oil (SO) ","2844":"PS-sunflower oil (SO) ","2845":"PS-olive oil (OO)","2846":"placebo","2847":"neoadjuvant DE combined with rh-endostatin (7.5 mg\/m2, d1-d14, every 3 weeks)","2848":"neoadjuvant DE combined with rh-endostatin (7.5 mg\/m2, d1-d14, every 3 weeks)","2849":"conventional treatment (CT)","2850":"salutogenic dialogue (IT)","2851":"attention-comparison group (where only daily activities were monitored)","2852":"attention-comparison group (where only daily activities were monitored)","2853":"baseline","2854":"weight loss program in the consistent , and some user group","2855":"weight loss program in the some, and minimal user group","2856":"control","2857":"control","2858":"control","2859":"control","2860":"baseline","2861":"baseline","2862":"placebo","2863":"baseline","2864":"placebo","2865":"baseline","2866":"baseline","2867":"baseline","2868":"baseline","2869":"Group C received saline plus bupivacaine intra-articularly","2870":"placebo","2871":"placebo","2872":"placebo","2873":"100 ml 0.9% saline (group C)","2874":"baseline","2875":"placebo","2876":"placebo","2877":"placebo","2878":"Cal\/BD ointment at week 1 and week 4","2879":"midazolam 0.75 mg\/kg in group M, ondansetron 4 mg in group O, midazolam 0.75 mg\/kg and ondansetron 4 mg in group MO","2880":"midazolam 0.75 mg\/kg in group M, ondansetron 4 mg in group O, and saline 0.90% in group S","2881":"midazolam 0.75 mg\/kg in group M","2882":"saline 0.90% in group S","2883":"midazolam 0.75 mg\/kg in group M, ondansetron 4 mg in group O, and saline 0.90% in group S","2884":"midazolam 0.75 mg\/kg in group M, ondansetron 4 mg in group O, and saline 0.90% in group S","2885":"placebo","2886":"placebo","2887":"placebo","2888":"placebo","2889":"200 mg\/day palmvitee nonsmokers","2890":"200 mg\/day palmvitee nonsmokers","2891":"baseline","2892":"baseline","2893":"200 mg\/day palmvitee nonsmokers","2894":"baseline","2895":"baseline","2896":"baseline","2897":"baseline","2898":"baseline","2899":"baseline","2900":"baseline","2901":"control","2902":"control","2903":"control","2904":"control","2905":"Group B received same dose of dexmedetomidine by intravenous administration before 5 min of intrathecal bupivacaine injection","2906":"Group B received same dose of dexmedetomidine by intravenous administration before 5min of intrathecal bupivacaine injection","2907":"Group B received same dose of dexmedetomidine by intravenous administration before 5min of intrathecal bupivacaine injection","2908":"catheter, given in 5 mL increments spaced 2 minutes apart","2909":"catheter, given in 5 mL increments spaced 2 minutes apart","2910":"catheter, given in 5 mL increments spaced 2 minutes apart","2911":"catheter, given in 5 mL increments spaced 2 minutes apart","2912":"colloid","2913":"Placebo","2914":"Placebo","2915":"Placebo group","2916":"Placebo group","2917":"Placebo group","2918":"Control group","2919":"Standard education session","2920":"Group C (control)","2921":"Placebo","2922":"Placebo","2923":"Placebo","2924":"Placebo","2925":"Low glycemic index intervention","2926":"No prophylaxis","2927":"Intravenous crystalloid","2928":"Intravenous crystalloid","2929":"Intravenous crystalloid","2930":"Intravenous crystalloid","2931":"group B","2932":"received only inguino-femoral lymph node dissection","2933":"received only inguino-femoral lymph node dissection","2934":"non-smoking","2935":"baseline","2936":"prednisolon 0.3 mg\/kg for 6 weeks","2937":"prednisolon 0.3 mg\/kg for 6 weeks","2938":"control","2939":"screening with the help of clinical staff","2940":"baseline","2941":"placebo","2942":"placebo","2943":"placebo","2944":"Educational Control (EC)","2945":"bright white light (10,000 lux), dim red light (< 500 lux) pre-treatment ","2946":"Hydralazine","2947":"Hydralazine","2948":"Placebo","2949":"Placebo","2950":"No treatment","2951":"Control group","2952":"Treatment-as-usual","2953":"Control group","2954":"Caudal Sufentanil + Adrenaline","2955":"Control group","2956":"Caudal Sufentanil ","2957":"Caudal Sufentanil ","2958":"Soya Beans","2959":"Soya Beans","2960":"Generic desogestrel ","2961":"Generic desogestrel ","2962":"placebo","2963":"placebo","2964":"mefenamic acid","2965":"placebo","2966":"Conventional Postoperative Epidural Analgesia (Group C)","2967":"Conventional Postoperative Epidural Analgesia (Group C)","2968":"extended-release oxycodone\/naloxone","2969":"extended-release oxycodone\/naloxone","2970":"extended-release oxycodone\/naloxone","2971":"triamcinolone acetonide oral paste 0.1%","2972":"triamcinolone acetonide oral paste 0.1%","2973":"2% lidocaine along with 1:100,000 epinephrine","2974":"control","2975":"4% lidocaine along with 1:100,000 epinephrine","2976":"control group","2977":"Conjugated estrogen (Premarin)","2978":"Conjugated estrogen (Premarin)","2979":"General instructions","2980":"No medication","2981":"Sham catgut implantation group","2982":"Isoflavone diet (GI)","2983":"Control diet (GC)","2984":"Sham catgut implantation group","2985":"Placebo","2986":"Placebo","2987":"Placebo","2988":"Placebo","2989":"Placebo","2990":"Placebo","2991":"Control","2992":"Control","2993":"Control","2994":"Baseline (No exercise)","2995":"Repulsive cuing","2996":"No treatment","2997":"0.9 % sodium chloride 3 mL flush","2998":"Flush frequency every 6 hours","2999":"Flush volume","3000":"Endotracheal tube","3001":"Control group","3002":"Ropivacaine (0.5%) 20ml","3003":"Ropivacaine (0.5%) 20ml","3004":"Surgery alone","3005":"Abacavir","3006":"Abacavir","3007":"Hydralazine","3008":"Calcium ","3009":"Lipid based nutrients","3010":"less extensive hyperdense artery sign (HAS)","3011":"fixed-combination bimatoprost 0.03%\/timolol 0.5% (FCBT PF) in previously treated patients","3012":"Placebo","3013":"Placebo","3014":"linseed oil (LO), echium oil (EO), olive oil (OO)","3015":"linseed oil (LO)","3016":"Placebo","3017":"Placebo group","3018":"Placebo group","3019":"Standard education session","3020":"Standard education session","3021":"Group C (control)","3022":"Group C (control)","3023":"Placebo","3024":"Low glycemic index intervention","3025":"Low glycemic index intervention","3026":"No prophylaxis","3027":"Control group","3028":"Control group","3029":"Rectangular-walking or Random-experienced ","3030":"Rectangular-walking or Free-generation or Random-experienced ","3031":"Rectangular-walking","3032":"rinse their mouths with 10 mL of distilled water for 1 minute twice daily for two weeks ","3033":"supervision by non-TBHVs","3034":"supervision by non-TBHVs","3035":"Placebo device","3036":"non-smoking","3037":"baseline","3038":"placebo","3039":"placebo","3040":"prednisolon 0.3 mg\/kg for 6 weeks","3041":"levofloxacin (500 mg\/d) (group L, 40 patients) for 6 weeks","3042":"less than 70% restenosis in the first year","3043":"placebo","3044":"placebo","3045":"Educational Control (EC)","3046":"dim red light (< 500 lux)","3047":"bright white light (10,000 lux), dim red light (< 500 lux) pre-treatment ","3048":"less extensive hyperdense artery sign (HAS)","3049":"distal extensive HAS","3050":"peribulbuar block with 5ml lignocaine 2% +3 ml bupivacaine 0.5% +1 ml hyaluronidase (250 IU) + 25 \u03bcg fentanyl to Group F, peribulbuar block with 5ml lignocaine 2% +3 ml bupivacaine 0.5% +1 ml hyaluronidase (250 IU) + 25 \u03bcg clonidine to Group C","3051":"Mtwo","3052":"K-file","3053":"lower dose 2.25 mg\/kg (lowATG)","3054":"normal weight group, underweight group.","3055":"Neoadjuvant chemotherapy (NC) alone","3056":"PS-sunflower oil (SO) and PS-olive oil (OO)","3057":"PS-olive oil (OO)","3058":"PS-sunflower oil (SO)","3059":"PS-olive oil (OO)","3060":"placebo","3061":"placebo","3062":"exercise only","3063":"exercise only","3064":"neoadjuvant DE combined with rh-endostatin (7.5 mg\/m2, d1-d14, every 3 weeks)","3065":"neoadjuvant DE combined with rh-endostatin (7.5 mg\/m2, d1-d14, every 3 weeks)","3066":"salutogenic dialogue (IT), therapeutic acupuncture ","3067":"attention-comparison group (where only daily activities were monitored)","3068":"baseline","3069":"the high-protein diet with isocaloric placebo supplements (PLA), no change in diet (CON)","3070":"the high-protein diet with isocaloric placebo supplements (PLA)","3071":"baseline","3072":"PLA","3073":"control","3074":"control","3075":"control","3076":"weight loss program in the some, and minimal user group","3077":"weight loss program in the some, and minimal user group","3078":"8 mg betahistine tablets (group B)","3079":"promethazine intramuscularly at a dose of 25 mg (group A)","3080":"8 mg betahistine tablets (group B)","3081":"control","3082":"placebo","3083":"placebo","3084":"baseline","3085":"baseline","3086":"baseline","3087":"baseline","3088":"baseline","3089":"baseline","3090":"Group C received saline plus bupivacaine intra-articularly","3091":"Group T - triamcinolone plus bupivacaine intra-articularly ","3092":"Group C - saline plus bupivacaine intra-articularly","3093":"Group T - triamcinolone plus bupivacaine intra-articularly ","3094":"Group C - saline plus bupivacaine intra-articularly","3095":"placebo","3096":"placebo","3097":"placebo","3098":"duloxetine 60 mg","3099":"100 ml 0.9% saline (group C)","3100":"100 ml 0.9% saline (group C)","3101":"placebo","3102":"baseline","3103":"placebo","3104":"placebo","3105":"placebo","3106":"Cal\/BD ointment","3107":"midazolam 0.75 mg\/kg in group M, ondansetron 4 mg in group O, and saline 0.90% in group S","3108":"midazolam 0.75 mg\/kg in group M, ondansetron 4 mg in group O, and saline 0.90% in group S","3109":"sunlight exposure","3110":"sunlight exposure","3111":"sunlight exposure","3112":"placebo","3113":"failure group","3114":"failure group","3115":"placebo","3116":"baseline","3117":"200 mg\/day palmvitee nonsmokers","3118":"baseline","3119":"baseline","3120":"baseline","3121":"FOBT alone","3122":"control","3123":"control","3124":"Group B received same dose of dexmedetomidine by intravenous administration before 5min of intrathecal bupivacaine injection","3125":"catheter, given in 5 mL increments spaced 2 minutes apart","3126":"BV juice placebo at the same time (480 mL\/day,","3127":"placebo","3128":"placebo","3129":"Group I - IV amikacin 20 mg\/kg\/24 h and meropenem 2 g over 30 min\/8 h.","3130":"Group I - IV amikacin 20 mg\/kg\/24 h and meropenem 2 g over 30 min\/8 h.","3131":"Group II -IV amikacin 20 mg\/kg\/24 h and meropenem 2 g over 30 min\/8 h in addition to nebulized amikacin 25 mg\/kg\/day every 8 h.","3132":"Group II -IV amikacin 20 mg\/kg\/24 h and meropenem 2 g over 30 min\/8 h in addition to nebulized amikacin 25 mg\/kg\/day every 8 h.","3133":"Control diet (GC)","3134":"Control diet (GC)","3135":"Walking","3136":"Baseline (No exercise)","3137":"No treatment","3138":"Endotracheal tube","3139":"Endotracheal tube","3140":"Endotracheal tube","3141":"Ropivacaine (0.5%) 20ml","3142":"Ropivacaine (0.5%) 20ml","3143":"Abacavir","3144":"Abacavir","3145":"Abacavir","3146":"Placebo (Olive oil)","3147":"Placebo (Olive oil)","3148":"Lipid based nutrients","3149":"Lipid based nutrients","3150":"Lipid based nutrients","3151":"Placebo","3152":"Placebo","3153":"Placebo","3154":"No Bevacizumab","3155":"Caudal Sufentanil + neostigmine","3156":"Generic desogestrel ","3157":"placebo","3158":"2% lidocaine along with 1:100,000 epinephrine","3159":"CEA, CA19-9 and CA72-4 alone","3160":"control group","3161":"control group","3162":"controls","3163":"Acetic acid","3164":"Acetic acid","3165":"Acetic acid","3166":"Conjugated estrogen (Premarin)","3167":"No medication","3168":"No medication","3169":"No medication","3170":"Sham catgut implantation group","3171":"Sham catgut implantation group","3172":"Placebo","3173":"Control","3174":"Repulsive cuing","3175":"Repulsive cuing","3176":"Control group","3177":"Control group","3178":"Surgery alone","3179":"Surgery alone","3180":"Clinical judgement","3181":"Clinical judgement","3182":"Clinical judgement","3183":"Cochlear Implant","3184":"Cochlear Implant","3185":"Cochlear Implant","3186":"Calcium ","3187":"Calcium ","3188":"Almond oil inhalation","3189":"Almond oil inhalation","3190":"Hydralazine","3191":"Placebo","3192":"network B","3193":"Control group","3194":"Treatment-as-usual","3195":"Treatment-as-usual","3196":"Soya Beans","3197":"Soya Beans","3198":"Soya Beans","3199":"Conventional Postoperative Epidural Analgesia (Group C)","3200":"Conventional Postoperative Epidural Analgesia (Group C)","3201":"No Bevacizumab","3202":"Generic desogestrel ","3203":"Generic desogestrel ","3204":"Their regular health promotion programme","3205":"extended-release oxycodone\/naloxone","3206":"placebo","3207":"Conjugated estrogen (Premarin)","3208":"Sham catgut implantation group","3209":"Isoflavone diet (GI)","3210":"Placebo","3211":"Placebo","3212":"Placebo","3213":"Walking","3214":"Endotracheal tube","3215":"Control group","3216":"Surgery alone","3217":"Clinical judgement","3218":"Clinical judgement","3219":"Placebo (Olive oil)","3220":"thiabendazole","3221":"Thiabendazole","3222":"Hydralazine","3223":"placebo","3224":"baseline","3225":"saline","3226":"decaffeinated coffee","3227":"2 mg of melatonin given 4 days for tetraplegic patients and placebo for tetraplegic patients","3228":"able-bodied men without any intervention","3229":"able-bodied men without any intervention","3230":"able-bodied men without any intervention","3231":"baseline","3232":"not receive any prebiotic","3233":"not receive any prebiotic","3234":"not receive any prebiotic","3235":"not receive any prebiotic","3236":"TachoSil\u00ae (control)","3237":"G, outdoor with no supplement","3238":"G, outdoor with no supplement","3239":"no continued contact","3240":"no continued contact","3241":"no continued contact","3242":"no continued contact","3243":"no continued contact","3244":"baseline","3245":"baseline","3246":"placebo","3247":"placebo","3248":"non- low frequency transcutaneous electrical nerve stimulation (TENS)","3249":"baseline","3250":"baseline","3251":"baseline","3252":"baseline","3253":"40 SC enoxaparin for a period of 24 hours","3254":"Smear Clear, 2.5% sodium hypochlorite (NaOCl), 2% chlorhexidine (CHX) and saline","3255":"Smear Clear","3256":"donepezil hydrochloride once daily (5mg\/day for the first 4weeks and 10mg\/day thereafter)","3257":"donepezil hydrochloride once daily (5mg\/day for the first 4weeks and 10mg\/day thereafter)","3258":"baseline","3259":"baseline","3260":"was not able to record their steps daily","3261":"baseline","3262":"was not able to record their steps daily","3263":"baseline","3264":"baseline","3265":"virtual-reality (VR) balance training","3266":"virtual-reality (VR) balance training","3267":"placebo","3268":"placebo","3269":"group B ('selective'\u2014clopidogrel 600 mg in the cath-lab after CAG, only in case of PCI;","3270":"group B ('selective'\u2014clopidogrel 600 mg in the cath-lab after CAG, only in case of PCI; in subgroup of patients who underwent PCI","3271":"group B ('selective'\u2014clopidogrel 600 mg in the cath-lab after CAG, only in case of PCI; in subgroup of patients who underwent PCI","3272":"bupivacaine HCl and placebo","3273":"bupivacaine HCl","3274":"placebo","3275":"placebo","3276":"placebo","3277":"placebo","3278":"placebo","3279":"placebo","3280":"quetiapine (QT)","3281":"standard group CBT for depression standard group","3282":"standard group CBT for depression standard group","3283":"baseline","3284":"CBT for depression with the addition of a text messaging adjunct","3285":"saline","3286":"saline","3287":"decaffeinated coffee","3288":"placebo for tetraplegic patients","3289":"standard care","3290":"not receive any prebiotic","3291":"TachoSil\u00ae (control)","3292":"TachoSil\u00ae (control)","3293":"G, outdoor with no supplement","3294":"baseline","3295":"G, outdoor with no supplement","3296":"G, outdoor with no supplement, group C, indoor with no supplement; ","3297":"Prenatal care only","3298":"Prenatal care only","3299":"Prenatal care only","3300":"Prenatal care only","3301":"Prenatal care only","3302":"No treatment","3303":"No treatment","3304":"No treatment","3305":"No treatment","3306":"No treatment","3307":"Vaginal progesterone","3308":"Vaginal progesterone","3309":"Vaginal progesterone","3310":"Vaginal progesterone","3311":"Placebo","3312":"Placebo","3313":"Placebo","3314":"Insulin alone","3315":"Insulin alone","3316":"Placebo","3317":"Placebo","3318":"No program","3319":"No program","3320":"No program","3321":"C-mode Endoscopic sphincterotomy","3322":"C-mode Endoscopic sphincterotomy","3323":"C-mode Endoscopic sphincterotomy","3324":"C-mode Endoscopic sphincterotomy","3325":"Questionnaire sent by post","3326":"Control (distilled water)","3327":"Control ","3328":"Control (distilled water)","3329":"Conventional open thyroidectomy ","3330":"Conventional open thyroidectomy ","3331":"Conventional open thyroidectomy ","3332":"Conventional open thyroidectomy ","3333":"No Vitamin D supplementation","3334":"Placebo","3335":"Macintosh direct laryngoscope","3336":"Macintosh direct laryngoscope","3337":"Macintosh direct laryngoscope","3338":"No HRA","3339":"No HRA","3340":"No HRA","3341":"Placebo","3342":"Placebo","3343":"Propofol alone","3344":"Sevoflurane alone","3345":"Sevoflurane alone","3346":"Sevoflurane alone","3347":"Irinotecan + Raltitrexed","3348":"Irinotecan + Raltitrexed","3349":"Irinotecan + Raltitrexed","3350":"Irinotecan + Raltitrexed","3351":"No training","3352":"Resistance training (Three times a week)","3353":"Approved inhaler","3354":"Approved inhaler","3355":"Visual warning (text)","3356":"No system","3357":"Control","3358":"Control","3359":"Control","3360":"Intuitive approach (ad hoc)","3361":"Control","3362":"Oxaliplatin","3363":"Oxaliplatin","3364":"Oxaliplatin","3365":"High Ang-2 ","3366":"Control","3367":"Improved cookstove + No smoking","3368":"Control","3369":"Control","3370":"Control","3371":"Control","3372":"Control","3373":"Control","3374":"No exercise","3375":"TTM based posts (later)","3376":"placebo","3377":"placebo","3378":"in-person","3379":"$152.45 for the in-person","3380":"in-person","3381":"Lipid based nutrient","3382":"no continued contact","3383":"routine care from health-care center","3384":"routine care from health-care center","3385":"routine care from health-care center","3386":"placebo ","3387":"baseline","3388":"baseline","3389":"onabotulinumtoxinA (100 U)","3390":"placebo","3391":"placebo","3392":"non- low frequency transcutaneous electrical nerve stimulation (TENS)","3393":"baseline","3394":"40, 50, 60 mg SC enoxaparin for a period of 24 hours","3395":"no touching","3396":"sodium hypochlorite","3397":"chlorhexidine (CHX)","3398":"donepezil hydrochloride once daily (5 mg\/day for the first 4 weeks and 10 mg\/day thereafter)","3399":"baseline","3400":"did not receive the intervention","3401":"Reciproc Group","3402":"baseline","3403":"baseline","3404":"was not able to record their steps daily","3405":"baseline","3406":"baseline","3407":"baseline","3408":"alogliptin (25 mg once daily)","3409":"virtual-reality (VR) balance training","3410":"virtual-reality (VR) balance training","3411":"placebo","3412":"group B ('selective'\u2014clopidogrel 600 mg in the cath-lab after CAG, only in case of PCI;","3413":"group B ('selective'\u2014clopidogrel 600 mg in the cath-lab after CAG, only in case of PCI; in subgroup of patients who underwent PCI","3414":"placebo","3415":"placebo","3416":"placebo","3417":"bupivacaine HCl 150 mg group at day 8","3418":"bupivacaine HCl 75 mg","3419":"placebo","3420":"placebo","3421":"placebo","3422":"placebo","3423":"placebo","3424":"placebo","3425":"placebo","3426":"placebo","3427":"quetiapine (QT)","3428":"Control group","3429":"No treatment","3430":"Treatment-as-usual","3431":"Caudal Sufentanil + Adrenaline","3432":"Generic desogestrel ","3433":"Placebo","3434":"placebo","3435":"Conventional Postoperative Epidural Analgesia (Group C)","3436":"triamcinolone acetonide oral paste 0.1%","3437":"2% lidocaine along with 1:100,000 epinephrine","3438":"Acetic acid","3439":"Placebo","3440":"Placebo","3441":"Distilled water ","3442":"Placebo","3443":"Distilled water ","3444":"Walking","3445":"Repulsive cuing","3446":"No treatment","3447":"Laryngeal mask ","3448":"Control group","3449":"Cochlear Implant","3450":"Placebo (Olive oil)","3451":"Placebo (Olive oil)","3452":"Placebo (Olive oil)","3453":"Thiabendazole","3454":"Almond oil inhalation","3455":"Thiabendazole","3456":"Almond oil inhalation","3457":"Care at clinic","3458":"Care at clinic","3459":"Care at clinic","3460":"Care at clinic","3461":"Placebo","3462":"Placebo","3463":"Amoxicillin + Omeprazole","3464":"Placebo","3465":"Placebo","3466":"Semi-rigid ankle support ","3467":"CYP2C9 Extensive metabolizers ","3468":"CYP2C9 Poor metabolizers ","3469":"Control","3470":"Control","3471":"Control","3472":"Control","3473":"Control","3474":"Sildenafil 50 mg","3475":"vehicle adjunctive treatment and prostaglandin analog (PGA)","3476":"olopatadine 0.2%","3477":"vehicle","3478":"oral dihydrocodeine","3479":"oral dihydrocodeine","3480":"measured resection (MR)","3481":"measured resection (MR)","3482":"baseline","3483":"placebo","3484":"baseline","3485":"standard care","3486":"chocolate, or potato crisps, control","3487":"chocolate","3488":"Conventional laboratory-based culture screens (CS)","3489":"routine","3490":"routine","3491":"baseline","3492":"baseline","3493":"baseline","3494":"control","3495":"bottled water (BW), carbohydrate-electrolyte sport drink (SD)","3496":"bottled water (BW)","3497":"baseline","3498":"tofacitinib 5 or 10 mg twice daily bDMARD-IR patients ","3499":"Yoga (NG IV) for 30 to 45 minutes\/day, five days\/week","3500":"placebo","3501":"baseline","3502":"high fat (HF) diet","3503":"Placebo therapy","3504":"Placebo therapy","3505":"Placebo therapy","3506":"No monitoring","3507":"Placebo","3508":"Placebo","3509":"NonHispanic whites","3510":"Roux-en-Y gastric bypass","3511":"Roux-en-Y gastric bypass","3512":"Roux-en-Y gastric bypass","3513":"Fentanyl and normal saline (group II)","3514":"Fentanyl and normal saline (group II)","3515":"Normal saline (group I)","3516":"Normal saline (group I)","3517":"Placebo","3518":"Placebo","3519":"Placebo","3520":"Nature-based images","3521":"Control group","3522":"Control group","3523":"Control group","3524":"Control group","3525":"Control group","3526":"Routine treatment","3527":"Routine treatment","3528":"Placebo","3529":"Gait training alone","3530":"Placebo","3531":"Placebo","3532":"Placebo","3533":"Placebo","3534":"Treatment as usual","3535":"Direct grasping, fixation, or combination","3536":"Control","3537":"Combination","3538":"Traditional controllers","3539":"Traditional controllers","3540":"Traditional controllers","3541":"Isoenergetic placebo drink","3542":"Isoenergetic placebo drink","3543":"Isoenergetic placebo drink","3544":"Isoenergetic placebo drink","3545":"Fentanyl (Group F)","3546":"Fentanyl (Group F)","3547":"Fentanyl (Group F)","3548":"Fentanyl (Group F)","3549":"Sham group","3550":"Sham group","3551":"Massage (group 2)","3552":"Control (group 3)","3553":"Control (group 3)","3554":"Placebo","3555":"Placebo","3556":"Placebo","3557":"Single cartridges of 4% articaine","3558":"Single cartridges of 4% articaine","3559":"Single cartridges of 4% articaine","3560":"Placebo","3561":"Placebo","3562":"Docetaxel alone (group D)","3563":"Docetaxel alone (group D)","3564":"Placebo","3565":"Pramipexole immediate-release","3566":"Pramipexole immediate-release","3567":"Placebo","3568":"Normal saline","3569":"Normal saline","3570":"kinetin (1.5 mg\/L) + NAA (0.3 mg\/L), and\/or MS media containing 0.15 mg\/L NAA along with kinetin 1.5 or 2.0 mg\/L","3571":"Placebo","3572":"Placebo","3573":"Placebo","3574":"Being in the Stop gruop","3575":"Placebo","3576":"Oral Palonosetron 0.25 mg","3577":"Oral Palonosetron 0.25 mg","3578":"Control","3579":"Control","3580":"Being on Class 2","3581":"Being on Class 3","3582":"Unilateral training","3583":"Unilateral training","3584":"Unilateral training","3585":"Tipranavir\/Ritonavir (500\/200)","3586":"Tipranavir\/Ritonavir (500\/100)","3587":"Conventional training","3588":"Conventional inpatient procedures","3589":"Standard treatment of glycemia and BP","3590":"Standard treatment of glycemia and lipids","3591":"Macintosh laryngoscope","3592":"Control","3593":"Control","3594":"2 auricular acupressure beads","3595":"Placebo","3596":"Olopatadine 5 mg","3597":"Control","3598":"Control","3599":"Low PSP Score","3600":"Control","3601":"Control","3602":"30.000 IU monthly","3603":"MOR approach","3604":"MOR approach","3605":"MOR approach","3606":"Normal flour","3607":"Normal flour","3608":"Normal flour","3609":"Control","3610":"Control","3611":"Control","3612":"Control","3613":"Control","3614":"Control","3615":"Voglibose","3616":"Voglibose","3617":"Printed instruction material","3618":"Printed instruction material","3619":"Control","3620":"Usual care","3621":"Care at clinic","3622":"Placebo","3623":"Control","3624":"Placebo","3625":"No Bevacizumab","3626":"Placebo","3627":"Standard treatment of glycemia ","3628":"triamcinolone acetate","3629":"0.5 M EDC treatment ","3630":"Placebo","3631":"Conjugated estrogen (Premarin)","3632":"< 75 group PANSS","3633":"< 75 group PANSS","3634":"Placebo","3635":"Distilled water ","3636":"Placebo","3637":"Control","3638":"Highly active antiretroviral treatment","3639":"Control ","3640":"Control","3641":"Placebo (Olive oil)","3642":"Placebo","3643":"Calcium ","3644":"Calcium ","3645":"Usual care","3646":"Placebo","3647":"Amoxicillin + Omeprazol","3648":"Placebo","3649":"Placebo","3650":"Placebo","3651":"Placebo","3652":"Semi-rigid ankle support ","3653":"Lace-up ankle support ","3654":"Semi-rigid ankle support ","3655":"Semi-rigid ankle support ","3656":"CYP3A4 Extensive metabolizers ","3657":"CYP2C9 Extensive metabolizers ","3658":"Control","3659":"Prenatal care only","3660":"No treatment","3661":"0.3 M EDC treatment ","3662":"Mitoxantrone only","3663":"Control","3664":"Mitoxantrone only","3665":"Mitoxantrone only","3666":"Vaginal progesterone","3667":"Placebo","3668":"Sildenafil 50 mg","3669":"Vaginal progesterone","3670":"vehicle adjunctive treatment and prostaglandin analog (PGA)","3671":"Placebo","3672":"vehicle ","3673":"Placebo","3674":"Placebo","3675":"olopatadine 0.2%","3676":"Insulin + Pramlintide (12 mcg\/U)","3677":"Insulin alone","3678":"olopatadine 0.2% and vehicle","3679":"Insulin alone","3680":"Placebo","3681":"neostigmine 70 \u03bcg\/kg with glycopyrrolate 14 \u03bcg\/kg at 1-2 post-tetanic counts","3682":"Placebo","3683":"Placebo","3684":"measured resection (MR)","3685":"measured resection (MR)","3686":"placebo","3687":"C-mode Endoscopic sphincterotomy","3688":"Questionnaire sent by post","3689":"non-seafood diet period","3690":"Fluoride mouth rinse (250 ppm) ","3691":"the lean-seafood diet period ","3692":"the lean-seafood diet period","3693":"Fluoride mouth rinse (250 ppm) ","3694":"Conventional open thyroidectomy ","3695":"Conventional open thyroidectomy ","3696":"control","3697":"Conventional laboratory-based culture screens (CS)","3698":"No Vitamin D supplementation","3699":"No Vitamin D supplementation","3700":"No Vitamin D supplementation","3701":"baseline","3702":"No Vitamin D supplementation","3703":"No Vitamin D supplementation","3704":"Placebo","3705":"Placebo","3706":"extensively hydrolyzed whey-based formula without (control) short-chain galacto-oligosaccharides\/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).","3707":"Placebo","3708":"Placebo","3709":"extensively hydrolyzed whey-based formula without (control) short-chain galacto-oligosaccharides\/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).","3710":"without breast shielding","3711":"Macintosh direct laryngoscope","3712":"effects soy milk","3713":"Macintosh direct laryngoscope","3714":"effects soy milk","3715":"No HRA","3716":"daunorubicin\/ara-C (DA)","3717":"daunorubicin\/ara-C (DA)","3718":"Placebo","3719":"Placebo","3720":"baseline","3721":"Placebo","3722":"Placebo","3723":"Sevoflurane alone","3724":"MI training (MI-AU)","3725":"control","3726":"control","3727":"Propofol alone","3728":"control","3729":"Irinotecan + Raltitrexed","3730":"bottled water (BW), carbohydrate-electrolyte sport drink (SD)","3731":"low-fat diet group among rs1522813 A-allele carriers","3732":"low-fat diet group among CC genotype or among participants with CT\/TT genotype","3733":"low-fat diet group among participants with GG genotype","3734":"direct control","3735":"baseline","3736":"baseline","3737":"Approved inhaler","3738":"placebo, as monotherapy or with background methotrexate or other csDMARDs","3739":"Approved inhaler","3740":"Approved inhaler","3741":"No warning","3742":"No warning","3743":"No warning","3744":"No warning","3745":"Visual warning (text)","3746":"No system","3747":"Control (New Group I)","3748":"No system","3749":"No system","3750":"No system","3751":"placebo","3752":"placebo","3753":"high fat (HF) diet","3754":"Control","3755":"Control","3756":"high fat (HF) diet","3757":"Intuitive approach (ad hoc)","3758":"Academic sponsor","3759":"Control","3760":"Control","3761":"ezetimibe (EZ), high fat (HF) diet","3762":"Control","3763":"Control","3764":"Oxaliplatin","3765":"Oxaliplatin","3766":"High Ang-2 + bevacizumab","3767":"Control","3768":"Improved cookstove + No smoking","3769":"Control","3770":"Control (nothing)","3771":"Control (nothing)","3772":"Control (nothing)","3773":"No exercise","3774":"No exercise","3775":"Other intervention content based on the TTM","3776":"Other intervention content based on the TTM","3777":"Other intervention content based on the TTM","3778":"4 cm pillow during tracheal intubation","3779":"4 cm pillow during tracheal intubation","3780":"4 cm pillow during tracheal intubation","3781":"4 cm pillow during tracheal intubation","3782":"baseline","3783":"placebo","3784":"placebo","3785":"placebo","3786":"pre-consultation","3787":"MI training (MI-AU)","3788":"Placebo therapy","3789":"baseline","3790":"No monitoring","3791":"No monitoring","3792":"No monitoring","3793":"No monitoring","3794":"Placebo","3795":"Placebo","3796":"Placebo","3797":"NonHispanic whites","3798":"NonHispanic whites","3799":"Roux-en-Y gastric bypass","3800":"Roux-en-Y gastric bypass","3801":"Normal saline (group I)","3802":"Placebo","3803":"Placebo","3804":"Nature-based images","3805":"Nature-based images","3806":"Nature-based images","3807":"Nature-based images","3808":"Placebo","3809":"Placebo","3810":"Gait training alone","3811":"Gait training alone","3812":"Placebo","3813":"Placebo","3814":"Placebo","3815":"Placebo","3816":"Placebo","3817":"Treatment as usual","3818":"Treatment as usual","3819":"Direct grasping","3820":"Autohemotherapy with blood exposure to oxygen","3821":"Autohemotherapy with blood exposure to oxygen","3822":"Isoenergetic placebo drink","3823":"Fentanyl (Group F)","3824":"Exercise group","3825":"Sham group or exercise group","3826":"Control (group 3)","3827":"Glucose control in 24\/7 closed-loop control (CLC) mode","3828":"Glucose control in 24\/7 closed-loop control (CLC) mode","3829":"Placebo","3830":"Placebo","3831":"Single cartridges of 4% articaine","3832":"Single cartridges of 4% articaine","3833":"Placebo","3834":"Placebo","3835":"Placebo","3836":"Docetaxel alone (group D)","3837":"Docetaxel alone (group D)","3838":"Distilled and deionized water (group A)","3839":"Nd:YAG laser (group B)","3840":"CPP-ACP cre\u0300me (group C)","3841":"Distilled and deionized water (group A), Nd:YAG laser (group B), or CPP-ACP cre\u0300me (group C)","3842":"Control group and Orientation group","3843":"Control group and Orientation group","3844":"Control group and Orientation group","3845":"Control group and Orientation group","3846":"Placebo","3847":"Placebo","3848":"Placebo","3849":"Placebo","3850":"Pramipexole immediate-release","3851":"Pramipexole immediate-release","3852":"Placebo","3853":"Normal saline","3854":"BAP+ NAA","3855":"Placebo","3856":"Placebo","3857":"Placebo","3858":"Placebo","3859":"Placebo","3860":"Placebo","3861":"Control","3862":"Control","3863":"Being in the Caution gruop","3864":"Being in the Stop gruop","3865":"Placebo","3866":"Placebo","3867":"Placebo","3868":"Yoga (NG IV) for 30 to 45 minutes\/day, five days\/week","3869":"Oral Palonosetron 0.75 mg","3870":"Oral Palonosetron 0.25 mg","3871":"General training ","3872":"General training ","3873":"General training ","3874":"Control","3875":"Control","3876":"Control","3877":"Control","3878":"Unilateral training","3879":"Unilateral training","3880":"Tipranavir\/Ritonavir (500\/200)","3881":"Conventional training","3882":"Standard treatment of glycemia and BP","3883":"Standard treatment of BP","3884":"Macintosh laryngoscope","3885":"Macintosh laryngoscope","3886":"Macintosh laryngoscope","3887":"Control","3888":"Control","3889":"Control","3890":"Control","3891":"2 auricular acupressure beads","3892":"Placebo","3893":"Control","3894":"Control","3895":"Middle PSP Score","3896":"< 75 group PANSS","3897":"MOR approach","3898":"MOR approach","3899":"Paravertebral block","3900":"Placebo","3901":"Control ","3902":"Control ","3903":"Voglibose","3904":"Control","3905":"Control","3906":"bottled water (BW)","3907":"bottled water (BW), carbohydrate-electrolyte sport drink (SD)","3908":"direct control","3909":"baseline","3910":"Salt Intake Reduction (NG III) to at least half of their previous intake;","3911":"placebo","3912":"placebo","3913":"vehicle adjunctive treatment and prostaglandin analog (PGA)","3914":"vehicle (at onset and 24 hours)","3915":"olopatadine 0.2%","3916":"neostigmine 70 \u03bcg\/kg with glycopyrrolate 14 \u03bcg\/kg at 1-2 post-tetanic counts","3917":"measured resection (MR)","3918":"the acupressure","3919":"non-seafood diet period","3920":"the lean-seafood diet period","3921":"standard care","3922":"standard care","3923":"chocolate, or potato crisps, control","3924":"daunorubicin\/ara-C (DA) ","3925":"carbohydrate-electrolyte sport drink (SD)","3926":"bottled water (BW), carbohydrate-electrolyte sport drink (SD)","3927":"Control","3928":"Tipranavir\/Ritonavir (500\/200)","3929":"Unilateral training","3930":"immunomonitoring without immunomodulation","3931":"LHCP","3932":"propofol","3933":"Group III, only surgical management was performed","3934":"competitive meal replacement (CMR)","3935":"competitive meal replacement (CMR)","3936":"competitive meal replacement (CMR)","3937":"baseline","3938":"placebo","3939":"moderate-intensity aerobic and resistance training (ART)","3940":"moderate-intensity aerobic and resistance training (ART)","3941":"moderate-intensity aerobic and resistance training (ART)","3942":"moderate-intensity aerobic and resistance training (ART)","3943":"no treatment","3944":"group B (irinotecan, leucovorin, fluorouracil, bevacizumab, every 2 weeks; FOLFIRI-bevacizumab)","3945":"conventional therapy plus hydrocortisone IV (100 mg in 2 ml 8 hourly for 48 h)","3946":"placebo","3947":"Group A, which were treated with the envelope type of CAF","3948":"400 mg Nurofen\u00ae forte and 400 mg Migra\u0308nin\u00ae","3949":"H0 (saline), H1(haloperidol 1 mg),","3950":"control group","3951":"normal saline-pharmacopuncture-treated group","3952":"relaxation group","3953":"control group","3954":"control group","3955":"usual care and a relaxation CD","3956":"standard radiotherapy (RT) (50.4 Gy\/28 fractions)","3957":"placebo and midazolam (10 mg)","3958":"small-incision cholecystectomy","3959":"small-incision cholecystectomy","3960":"45 Gy radiotherapy in 30 twice-daily fractions of 1\u00b75 Gy over 19 days","3961":"Full \u03bc-opioid agonist*","3962":"Full \u03bc-opioid agonist*","3963":"control","3964":"medication","3965":"group 2 treated with the Quad Pendulum (QP) and fixed appliances","3966":"group 2 treated with the Quad Pendulum (QP) and fixed appliances","3967":"self-management education (DSME)","3968":"standard navigation","3969":"standard navigation","3970":"Varenicline","3971":"Varenicline","3972":"baseline","3973":"Z250 conventional composite","3974":"UDCA monotherapy","3975":"General training ","3976":"Control","3977":"baseline","3978":"baseline","3979":"Being on Class 3","3980":"Placebo","3981":"control","3982":"Placebo","3983":"Tipranavir\/Ritonavir (500\/100)","3984":"crystalloid preload - Lactated Ringer's solution (1500 ml)","3985":"Tipranavir\/Ritonavir (500\/200)","3986":"crystalloid preload - Lactated Ringer's solution (1500 ml)","3987":"Conventional inpatient procedures","3988":"Conventional inpatient procedures","3989":"Conventional inpatient procedures","3990":"Conventional inpatient procedures","3991":"Lace-up ankle support ","3992":"CYP3A5 Extensive metabolizers ","3993":"Standard treatment of glycemia and BP","3994":"Control","3995":"baseline","3996":"Control","3997":"Control","3998":"Control","3999":"Control","4000":"Control","4001":"0.3 M EDC treatment ","4002":"Placebo","4003":"placebo","4004":"Sildenafil 50 mg","4005":"Control","4006":"Sildenafil 50 mg","4007":"Placebo","4008":"Placebo","4009":"Control","4010":"control group","4011":"control","4012":"< 75 group PANSS","4013":"usual care and a relaxation CD","4014":"MOR approach","4015":"Normal flour","4016":"Normal flour","4017":"Paravertebral block","4018":"Paravertebral block","4019":"Placebo","4020":"Placebo","4021":"Control ","4022":"Placebo","4023":"Control","4024":"self-management education (DSME)","4025":"Voglibose","4026":"Being in the Caution gruop","4027":"Being in the Stop gruop","4028":"Voglibose","4029":"Printed instruction material","4030":"baseline","4031":"Printed instruction material","4032":"MI training (MI-AU)","4033":"Control","4034":"Control","4035":"General training ","4036":"Usual care","4037":"General training ","4038":"Care at clinic","4039":"group B (irinotecan, leucovorin, fluorouracil, bevacizumab, every 2 weeks; FOLFIRI-bevacizumab)","4040":"group B (irinotecan, leucovorin, fluorouracil, bevacizumab, every 2 weeks; FOLFIRI-bevacizumab)","4041":"donepezil hydrochloride (DH) group group at 24 week","4042":"control","4043":"control","4044":"fasting + non exercise (FNE)","4045":"baseline","4046":"placebo","4047":"400 mg Nurofen\u00ae forte and 400 mg Migra\u0308nin\u00ae","4048":"400 mg\/day imatinib","4049":"Remifentanil 0.5 \u03bcg\/kg, infusion of Remifentanil 0.1 \u03bcg\/kg\/min","4050":"IDHmt\/codel (5.6 months) and IDHwt (3.4 months)","4051":"males","4052":"baseline","4053":"baseline","4054":"small-incision cholecystectomy","4055":"Full \u03bc-opioid agonist*","4056":"group 2 treated with the Quad Pendulum (QP) and fixed appliances","4057":"group 2 treated with the Quad Pendulum (QP) and fixed appliances","4058":"group 2 treated with the Quad Pendulum (QP) and fixed appliances","4059":"control","4060":"reading group","4061":"doses suggested in the practice guidelines (GD) or to receive GD therapy alone","4062":"doses suggested in the practice guidelines (GD) or to receive GD therapy alone","4063":"doses suggested in the practice guidelines (GD) or to receive GD therapy alone","4064":"doses suggested in the practice guidelines (GD) or to receive GD therapy alone","4065":"doses suggested in the practice guidelines (GD) or to receive GD therapy alone","4066":"wristband","4067":"baseline","4068":"baseline","4069":"control","4070":"Control","4071":"Control","4072":"competitive meal replacement (CMR)","4073":"competitive meal replacement (CMR)","4074":"baseline","4075":"placebo","4076":"baseline","4077":"baseline","4078":"ramosetron plus dexamethasone group (group RD)","4079":"ramosetron plus dexamethasone group (group RD)","4080":"conventional therapy plus hydrocortisone IV (100 mg in 2 ml 8 hourly for 48 h)","4081":"conventional therapy plus hydrocortisone IV (100 mg in 2 ml 8 hourly for 48 h)","4082":"placebo","4083":"placebo US plus exercise","4084":"Group A, which were treated with the envelope type of CAF","4085":"normal saline-pharmacopuncture-treated group","4086":"placebo","4087":"placebo","4088":"usual care and a relaxation CD","4089":"poor outcome group","4090":"control group with Carborade Drink\u00ae alone","4091":"control group with Carborade Drink\u00ae alone","4092":"45 Gy radiotherapy in 30 twice-daily fractions of 1\u00b75 Gy over 19 days","4093":"control group","4094":"19.0 \u00b1 4.1 days in the control group","4095":"31.0 \u00b1 5.8 days in the control group.","4096":"medication","4097":"self-management education (DSME)","4098":"self-management education (DSME)","4099":"Varenicline","4100":"Varenicline","4101":"SonicFill","4102":"occlusal margin of all groups","4103":"placebo","4104":"placebo","4105":"placebo","4106":"placebo","4107":"UDCA monotherapy","4108":"UDCA monotherapy","4109":"UDCA monotherapy","4110":"Control","4111":"low-carbohydrate\/high-protein (LCHP)","4112":"LHCP","4113":"Less Than 70 measured subjects (35 per group) ","4114":"Less than 120 subjects ","4115":"Less than 60 subjects in a single group","4116":"propofol","4117":"propofol","4118":"placebo","4119":"placebo","4120":"no treatment","4121":"placebo","4122":"group 4: XP-endo Finisher file for 30 seconds in association with 2.5% NaOCl and 17% EDTA for 30 seconds","4123":"Rigid cystoscopy (CS)","4124":"placebo","4125":"placebo","4126":"control group","4127":"control group","4128":"40 mg\/day of lovastatin","4129":"Placebo","4130":"the rivaroxaban or apixaban ","4131":"Placebo","4132":"Acetic acid","4133":"2 DM","4134":"baseline","4135":"Only normal saline (Group C)","4136":"Group T - triamcinolone plus bupivacaine intra-articularly ","4137":"Sitagliptin","4138":"Contractive posture","4139":"Contractive posture","4140":"Placebo","4141":"Placebo","4142":"Placebo then placebo again","4143":"Bilayer membrane","4144":"Bilayer membrane","4145":"Control","4146":"Control","4147":"Bilayer membrane","4148":"Control","4149":"Control","4150":"Placebo","4151":"Shoulder type covered stent","4152":"Shoulder type covered stent","4153":"Flare type covered stent","4154":"Shoulder type covered stent","4155":"Shoulder type covered stent","4156":"Control","4157":"Control","4158":"4.8 mm drain","4159":"4.8 mm drain","4160":"4.8 mm drain","4161":"4.8 mm drain","4162":"Carbohydrates alone ","4163":"Carbohydrates alone ","4164":"Carbohydrates alone ","4165":"Control","4166":"Control","4167":"Control","4168":"Exenatide","4169":"Exenatide","4170":"Exenatide","4171":"Remifentanil 3 ng\/ml and sufentanil 0,3 ng\/ml (induction and maintenance) ","4172":"Remifentanil 2 ng\/ml and sufentanil 0,5 ng\/ml (induction) and Remifentanil 3 ng\/ml and sufentanil 0,2 ng\/ml (maintenance) ","4173":"Remifentanil 3 ng\/ml and sufentanil 0,3 ng\/ml (induction and maintenance)","4174":"Placebo","4175":"Placebo","4176":"Placebo","4177":"Placebo","4178":"Wheat","4179":"Wheat","4180":"Control","4181":"Control","4182":"Control","4183":"Control","4184":"Placebo","4185":"Placebo","4186":"Placebo","4187":"Placebo","4188":"Control","4189":"Control","4190":"Control","4191":"Control","4192":"Control","4193":"ProTaper system","4194":"Control","4195":"Control","4196":"Granulocyte-colony stimulating factor + peripheral blood monocyte cell","4197":"Control","4198":"Fruits and vegetables 1 portion","4199":"Fruits and vegetables 1 portion","4200":"Control","4201":"Control","4202":"Control ","4203":"ILM peeling","4204":"Control","4205":"ILM peeling","4206":"Control","4207":"Mani NRT-GPR","4208":"Mani NRT-GPR","4209":"granulocyte-macrophage colony-stimulating factor (GM-CSF)","4210":"Thymoglobulin four infusions of 1.5 mg\/kg ","4211":"Thymoglobulin four infusions of 1.5 mg\/kg ","4212":"control","4213":"baseline","4214":"Control","4215":"baseline","4216":"placebo","4217":"Before restraint reduction program","4218":"400 mg\/day imatinib","4219":"relaxation group","4220":"relaxation group","4221":"Control","4222":"Control","4223":"Traditional measurement ","4224":"cycling ","4225":"cycling","4226":"Basal bolus","4227":"Remifentanil 0.5 \u03bcg\/kg, infusion of Remifentanil 0.1 \u03bcg\/kg\/min","4228":"Control","4229":"and control 2 (C2; pure control)","4230":"Control","4231":"Control","4232":"Half bath","4233":"Control","4234":"Ischemic pressure ","4235":"Ischemic pressure ","4236":"standard navigation","4237":"Control","4238":"control","4239":"3-weekly docetaxel","4240":"3-weekly docetaxel","4241":"control","4242":"Standard management ","4243":"Standard management ","4244":"baseline","4245":"baseline","4246":"baseline","4247":"Standard management ","4248":"Ultraviolet sanitization","4249":"baseline","4250":"Control","4251":"Control","4252":"Control","4253":"Control","4254":"Breast milk alone","4255":"baseline","4256":"IV ovine lipopolysaccharide","4257":"baseline","4258":"Placebo","4259":"Placebo","4260":"placebo","4261":"Placebo","4262":"baseline","4263":"Placebo","4264":"Placebo","4265":"Group A, which were treated with the envelope type of CAF","4266":"H0 (saline)","4267":"Control","4268":"H1(haloperidol 1 mg),","4269":"Control","4270":"Control","4271":"Control group","4272":"Control group","4273":"Control group","4274":"No atricurium","4275":"No atricurium","4276":"Control","4277":"control group","4278":"Control","4279":"poor outcome group","4280":"poor outcome group","4281":"Control","4282":"control group with Carborade Drink\u00ae alone","4283":"Control","4284":"Control","4285":"45 Gy radiotherapy in 30 twice-daily fractions of 1\u00b75 Gy over 19 days","4286":"45 Gy radiotherapy in 30 twice-daily fractions of 1\u00b75 Gy over 19 days","4287":"Control","4288":"Control","4289":"Control","4290":"Control","4291":"Control","4292":"Control","4293":"Z250 conventional composite","4294":"Control","4295":"Control","4296":"Control","4297":"crystalloid preload - Lactated Ringer's solution (1500 ml)","4298":"no treatment","4299":"placebo","4300":"negative control group","4301":"Positive and Negative control groups","4302":"4th edition (1987)","4303":"4th edition (1987)","4304":"placebo","4305":"placebo","4306":"Iron and folic acid","4307":"Iron and folic acid","4308":"Multiple micronutrient ","4309":"Control","4310":"Control","4311":"Control","4312":"Room temperature CO2","4313":"Room temperature CO2","4314":"Placbeo","4315":"Placbeo","4316":"Placbeo","4317":"Control","4318":"Tunnel + endoclips","4319":"Knife + ballon + OTSC","4320":"Knife + ballon + OTSC","4321":"No treatment","4322":"Oxygen + inotropic agents","4323":"Oxygen + inotropic agents","4324":"Control","4325":"Control","4326":"Control","4327":"Control","4328":"Control","4329":"Colorectal anastomosis with leakage","4330":"Colorectal anastomosis with leakage","4331":"Control","4332":"Control","4333":"Control","4334":"Control","4335":"immunomonitoring without immunomodulation","4336":"inflated estimates","4337":"propofol","4338":"baseline","4339":"baseline","4340":"crystalloid preload - Lactated Ringer's solution (1500 ml)","4341":"baseline","4342":"baseline","4343":"group B, TLH was done by ligating both uterine arteries at the beginning of the procedure","4344":"granulocyte-macrophage colony-stimulating factor (GM-CSF)","4345":"no treatment","4346":"granulocyte-macrophage colony-stimulating factor (GM-CSF)","4347":"group B (irinotecan, leucovorin, fluorouracil, bevacizumab, every 2 weeks; FOLFIRI-bevacizumab)","4348":"donepezil hydrochloride (DH) group","4349":"control","4350":"placebo","4351":"baseline","4352":"placebo US plus exercise","4353":"Rigid cystoscopy (CS)","4354":"4th edition (1987)","4355":"baseline","4356":"Semagacestat 140 mg","4357":"normal saline-pharmacopuncture-treated group","4358":"relaxation group","4359":"usual care and a relaxation CD","4360":"control 1 (C1; enhanced financing) group","4361":"poor outcome group","4362":"control 1 (C1; enhanced financing) group","4363":"and control 2 (C2; pure control)","4364":"poor outcome group","4365":"and control 2 (C2; pure control)","4366":"control group with Carborade Drink\u00ae alone","4367":"baseline","4368":"group 2 treated with the Quad Pendulum (QP) and fixed appliances","4369":"control","4370":"group 2 treated with the Quad Pendulum (QP) and fixed appliances","4371":"baseline","4372":"UDCA monotherapy","4373":"Contractive posture","4374":"Contractive posture","4375":"Contractive posture","4376":"Contractive posture","4377":"Placebo","4378":"Placebo","4379":"Placebo then placebo again","4380":"Placebo then placebo again","4381":"Placebo then protein","4382":"Placebo then placebo again","4383":"Placebo then placebo again","4384":"Placebo then placebo again","4385":"Control","4386":"Control","4387":"Control","4388":"Control","4389":"Control","4390":"Placebo","4391":"Placebo","4392":"Flare type covered stent","4393":"Control","4394":"Control","4395":"Control","4396":"4.8 mm drain","4397":"4.8 mm drain","4398":"Carbohydrates alone ","4399":"Carbohydrates alone ","4400":"placebo","4401":"Control","4402":"Control","4403":"Control","4404":"Control","4405":"Control","4406":"Control","4407":"Control","4408":"Exenatide","4409":"Exenatide","4410":"Exenatide","4411":"Remifentanil 2 ng\/ml and sufentanil 0,5 ng\/ml (induction) and Remifentanil 3 ng\/ml and sufentanil 0,2 ng\/ml (maintenance) ","4412":"Remifentanil 2 ng\/ml and sufentanil 0,5 ng\/ml (induction) and Remifentanil 3 ng\/ml and sufentanil 0,2 ng\/ml (maintenance) ","4413":"Remifentanil 3 ng\/ml and sufentanil 0,3 ng\/ml (induction and maintenance)","4414":"Placebo","4415":"Placebo","4416":"Wheat","4417":"Wheat","4418":"Wheat","4419":"Wheat","4420":"Control","4421":"Control","4422":"Control","4423":"Control","4424":"Placebo","4425":"Placebo","4426":"Control","4427":"Control","4428":"ProTaper system","4429":"Mtwo system","4430":"Control","4431":"Control","4432":"Control","4433":"Control","4434":"Control","4435":"Control","4436":"Control","4437":"Granulocyte-colony stimulating factor + peripheral blood monocyte cell","4438":"Control","4439":"low-fat diet group among participants with GA\/AA genotype","4440":"Control","4441":"Fruits and vegetables 1 portion","4442":"Fruits and vegetables 1 portion","4443":"Fruits and vegetables 1 portion","4444":"Fruits and vegetables 1 portion","4445":"Fruits and vegetables 1 portion","4446":"Control","4447":"Control","4448":"Control","4449":"Control","4450":"Control","4451":"Control ","4452":"Control ","4453":"Control ","4454":"Control ","4455":"Control ","4456":"Control","4457":"Control","4458":"Control","4459":"Mani NRT-GPR","4460":"Mani NRT-GPR","4461":"Mani NRT-GPR","4462":"Thymoglobulin four infusions of 1.5 mg\/kg ","4463":"Thymoglobulin four infusions of 1.5 mg\/kg ","4464":"Thymoglobulin four infusions of 1.5 mg\/kg ","4465":"Placebo","4466":"Placebo","4467":"Placebo","4468":"Placebo","4469":"Control","4470":"Control","4471":"Before restraint reduction program","4472":"Before restraint reduction program","4473":"Control","4474":"Control","4475":"Traditional measurement ","4476":"Control group (CTRg)","4477":"Up-titration of IGlargine ","4478":"Control","4479":"Galacto-oligosaccharides","4480":"Control","4481":"Control","4482":"Control","4483":"Control","4484":"Control","4485":"Traditional exercise ","4486":"Control","4487":"Ischemic pressure ","4488":"Control","4489":"Control","4490":"Control","4491":"Control","4492":"Control","4493":"Antibiotics alone ","4494":"Antibiotics alone ","4495":"Antibiotics alone ","4496":"Antibiotics alone ","4497":"Antibiotics alone ","4498":"3-weekly docetaxel","4499":"3-weekly docetaxel","4500":"Buprenophine 64 mg","4501":"Buprenophine 96 mg","4502":"Standard management ","4503":"Control","4504":"Control","4505":"Control","4506":"Control","4507":"Control","4508":"Siltuximab 6mg\/kg (\u2264 4 infusions)","4509":"Siltuximab 6mg\/kg (\u2264 6 infusions)","4510":"Siltuximab 6mg\/kg (\u2264 6 infusions)","4511":"Breast milk + Vit. D","4512":"Breast milk alone","4513":"IV ovine lipopolysaccharide","4514":"IV ovine lipopolysaccharide","4515":"IV ovine lipopolysaccharide","4516":"IV ovine lipopolysaccharide","4517":"Placebo","4518":"Placebo","4519":"Placebo","4520":"Placebo","4521":"Placebo","4522":"Control","4523":"Control","4524":"Control","4525":"Control","4526":"Placebo","4527":"Placebo","4528":"Placebo","4529":"Placebo","4530":"Placebo","4531":"Control","4532":"Control","4533":"Control","4534":"Control","4535":"Control","4536":"Control","4537":"Control","4538":"No atricurium","4539":"No atricurium ","4540":"Atracurium 25% dose ","4541":"Training only","4542":"Control","4543":"Control","4544":"Control","4545":"Control","4546":"Control","4547":"Control","4548":"Control","4549":"Control","4550":"Control","4551":"Lavander","4552":"Lavander","4553":"Control","4554":"Control","4555":"Control","4556":"Control","4557":"Control","4558":"Control","4559":"Multiple micronutrient ","4560":"Multiple micronutrient ","4561":"Iron and folic acid","4562":"Control","4563":"Room temperature CO2","4564":"Room temperature CO2","4565":"Room temperature CO2","4566":"Room temperature CO2","4567":"Placbeo","4568":"Placbeo","4569":"Placbeo","4570":"Control","4571":"Control","4572":"Knife + ballon + OTSC","4573":"Tunnel + OTSC ","4574":"Knife + ballon + OTSC","4575":"sham-tDCS + iTBS","4576":"anodal-tDCS + iTBS condition","4577":"No treatment","4578":"No treatment","4579":"Oxygen + inotropic agents","4580":"Control","4581":"Control","4582":"Control","4583":"Tocilizumab 8 mg\/kg","4584":"Control","4585":"Control","4586":"Duloxetine (D)","4587":"placebo","4588":"P group","4589":"no interest group","4590":"no interest group","4591":"no interest group","4592":"placebo","4593":"placebo","4594":"placebo","4595":"placebo","4596":"placebo","4597":"conventionally immobilized in palmar flexion and ulnar deviation (PF)","4598":"conventionally immobilized in palmar flexion and ulnar deviation (PF)","4599":"conventionally immobilized in palmar flexion and ulnar deviation (PF)","4600":"conventionally immobilized in palmar flexion and ulnar deviation (PF)","4601":"HCT in the range 45%\u201350%","4602":"placebo","4603":"placebo","4604":"computer-based testing","4605":"computer-based testing","4606":"computer-based testing","4607":"reference formulation","4608":"placebo + methotrexate","4609":"unchanged cART regimen","4610":"unchanged cART regimen","4611":"unchanged cART regimen","4612":"unchanged cART regimen","4613":"unchanged cART regimen","4614":"ETN","4615":"treatment arms with repeated switches (pooled switched)","4616":"treatment arms with repeated switches (pooled switched)","4617":"two treatment arms with repeated switches (pooled switched)","4618":"<12 years of education","4619":"control","4620":"single coil rTMS","4621":"placebo","4622":"placebo","4623":"control group (CG) received lessons as usual","4624":"before rehabilitation program","4625":"before rehabilitation program","4626":"before rehabilitation program","4627":"scaling and root planning (SRP) alone (control)","4628":"placebo","4629":"placebo","4630":"reference intervention","4631":"reference intervention","4632":"reference intervention","4633":"reference intervention","4634":"control group C (no panty liner wear)","4635":"control group C (no panty liner wear)","4636":"control group C (no panty liner wear)","4637":"vagina","4638":"placebo","4639":"mannequin-based scenarios ","4640":"mannequin-based scenarios","4641":"Before vitamin D supplementation in COPD patients","4642":"Before vitamin D supplementation in COPD patients","4643":"Before vitamin D supplementation in COPD patients","4644":"Before vitamin D supplementation in COPD patients","4645":"placebo","4646":"Control","4647":"class II anginal symptoms","4648":"noncompleters","4649":"Control","4650":"Control","4651":"Control","4652":"Lutein","4653":"Control","4654":"Control ","4655":"Control ","4656":"Control ","4657":"Control ","4658":"Control","4659":"Mani NRT-GPR","4660":"Control","4661":"Control","4662":"Control","4663":"Control","4664":"Control","4665":"Thymoglobulin four infusions of 1.5 mg\/kg ","4666":"Placebo","4667":"Placebo","4668":"Control","4669":"Control","4670":"Control","4671":"GnRH agonist luteal low-dose","4672":"GnRH antagonist + oral contraceptive pill","4673":"Control","4674":"Before restraint reduction program","4675":"Control","4676":"Traditional measurement ","4677":"Control","4678":"Traditional measurement ","4679":"Basal bolus","4680":"Control","4681":"Calcium ","4682":"Basal bolus","4683":"Glucagon-like peptide-1 receptor agonist + basal insulin","4684":"Control","4685":"Low user control","4686":"Low user control","4687":"Control","4688":"Low user control","4689":"Control","4690":"Control","4691":"Traditional exercise ","4692":"Control","4693":"Half bath","4694":"Standard running program","4695":"Standard running program","4696":"Standard running program","4697":"Control","4698":"Ischemic pressure ","4699":"Ischemic pressure ","4700":"Low hepatocyte growth factor levels","4701":"Passive range of motion","4702":"Passive range of motion","4703":"Climbing profile 2","4704":"Climbing profile 2","4705":"Climbing profile 2","4706":"Control","4707":"Control","4708":"Control","4709":"Control","4710":"Candesartan","4711":"Candesartan","4712":"Candesartan","4713":"Antibiotics alone ","4714":"Candesartan","4715":"Control","4716":"Control","4717":"Control","4718":"3-weekly docetaxel","4719":"Control","4720":"3-weekly docetaxel","4721":"No treatment","4722":"No treatment","4723":"No treatment","4724":"Control","4725":"Control","4726":"Buprenophine 96 mg","4727":"Control","4728":"Control","4729":"Standard management ","4730":"Control","4731":"Control","4732":"Control","4733":"Control","4734":"Pressurized metered-dose inhalers","4735":"Pressurized metered-dose inhalers","4736":"Control","4737":"Placebo","4738":"Control","4739":"Placebo","4740":"Placebo","4741":"Placebo","4742":"Control","4743":"Control","4744":"Breast milk + Vit. D","4745":"Breast milk alone","4746":"50 grams of lipids ","4747":"0.6 grams of lipids ","4748":"5 grams of lipids ","4749":"IV ovine lipopolysaccharide","4750":"Foot orthoses ","4751":"zinc with multi-nutrients","4752":"zinc with multi-nutrients","4753":"multi-nutrients","4754":"galunisertib plus lomustine","4755":"placebo+lomustine","4756":"galunisertib plus lomustine","4757":"appendicitis group","4758":"appendicitis group","4759":"appendicitis group","4760":"appendicitis group","4761":"appendicitis group","4762":"appendicitis group","4763":"Placebo","4764":"Placebo","4765":"placebo group","4766":"control group","4767":"control group","4768":"control group","4769":"control group","4770":"interdisciplinary multifaceted treatment","4771":"usual health care and support services","4772":"Control","4773":"box stalls","4774":"box stalls","4775":"water","4776":"Control","4777":"No atricurium","4778":"water","4779":"neutral priming conditions","4780":"neutral priming conditions","4781":"neutral priming conditions","4782":"neutral priming conditions","4783":"low-risk group","4784":"advanced CRN (ACN) index","4785":"Asia-Pacific Colorectal Screening score (APCS)","4786":"control","4787":"phase 1","4788":"phase 1","4789":"Control","4790":"HC2 or COBAS at baseline","4791":"Control","4792":"Control","4793":"Control","4794":"Control","4795":"Control","4796":"Control","4797":"Control","4798":"Control","4799":"Control","4800":"Control","4801":"Control","4802":"Standard formula","4803":"Standard formula","4804":"Standard formula","4805":"Standard formula","4806":"Control","4807":"Ciclosporin","4808":"Ciclosporin","4809":"Ciclosporin","4810":"Ciclosporin","4811":"Ciclosporin","4812":"clarithromycin + rifampin","4813":"clarithromycin + rifampin","4814":"Control","4815":"Control","4816":"Control","4817":"Control","4818":"Control","4819":"Control","4820":"Control","4821":"Control","4822":"Control","4823":"Control","4824":"Control","4825":"Control","4826":"Control","4827":"Control","4828":"Control","4829":"Moxifloxacin","4830":"Control","4831":"Control","4832":"Control","4833":"Control","4834":"Control","4835":"Control","4836":"Control","4837":"Control","4838":"Conventional technique","4839":"Conventional technique","4840":"Control","4841":"Control","4842":"Control","4843":"Oral iron ","4844":"Short-term buprenorphine-naloxone","4845":"Full bifocals ","4846":"Full bifocals ","4847":"Distance single vision lenses","4848":"Control","4849":"Control","4850":"Control","4851":"Control ","4852":"Control ","4853":"Control ","4854":"Ketamine ","4855":"Placebo","4856":"Placebo","4857":"Warm vertical compaction ","4858":"Guttaflow system ","4859":"5% EG in DPBS + 0.5 M sucrose + 20% FBS","4860":"10% EG in DPBS + 0.5 M sucrose + 20% FBS group","4861":"5% EG + 5% DMSO in DPBS with 0.5 M sucrose + 20% FBS group","4862":"acute supplementation of Q10","4863":"placebo","4864":"placebo","4865":"placebo","4866":"placebo","4867":"control","4868":"high-carbohydrate\/low-protein (HCLP)","4869":"baseline","4870":"HCLP","4871":"usual classic cigarettes","4872":"normal\/mild group","4873":"competitive meal replacement (CMR)","4874":"crystalloid preload - Lactated Ringer's solution (1500 ml)","4875":"placebo","4876":"placebo","4877":"moderate-intensity aerobic and resistance training (ART)","4878":"control group (group C)","4879":"ILM peeling","4880":"group B, TLH was done by ligating both uterine arteries at the beginning of the procedure","4881":"baseline","4882":"placebo","4883":"conventional therapy plus hydrocortisone IV (100 mg in 2 ml 8 hourly for 48 h)","4884":"placebo","4885":"placebo","4886":"placebo","4887":"negative control group","4888":"Rigid cystoscopy (CS)","4889":"control","4890":"usual care (UC)","4891":"placebo","4892":"H2 (haloperidol 2 mg)","4893":"placebo","4894":"relaxation group","4895":"rowing","4896":"older subjects","4897":"Remifentanil 0.5 \u03bcg\/kg, infusion of Remifentanil 0.1 \u03bcg\/kg\/min","4898":"control","4899":"standard radiotherapy (RT) (50.4 Gy\/28 fractions)","4900":"FOLFIRI arm (irinotecan 180 mg\/m2, 5-FU 400 mg\/m2, LV 200 mg\/m2, 5-FU 2400 mg\/m2 (46-h infusion) \u2013 all given on day one, every 14 days)","4901":"baseline","4902":"group 2 treated with the Quad Pendulum (QP) and fixed appliances","4903":"control","4904":"naproxen","4905":"naproxen","4906":"usual classic cigarettes","4907":"placebo","4908":"control group","4909":"control group","4910":"sufentanil 50 mcg (S)","4911":"morphine 4 mg (M)","4912":"morphine 4 mg (M)","4913":"morphine 4 mg (M)","4914":"chemoimmunotherapy without bevacizumab (PCR)","4915":"chemoimmunotherapy without bevacizumab (PCR)","4916":"chemoimmunotherapy without bevacizumab (PCR)","4917":"control group","4918":"control group","4919":"control group (group C)","4920":"control group (group C)","4921":"control","4922":"control","4923":"control","4924":"group with no postpartum depression symptoms","4925":"placebo","4926":"placebo","4927":"placebo","4928":"usual care (UC)","4929":"usual care (UC)","4930":"not-prepared","4931":"not-prepared","4932":"group 2 with Path-File (Dentsply Maillefer) #1, #2, and #3","4933":"normal saline","4934":"normal saline","4935":"control group (did not receive any add-on drugs)","4936":"group B, fractures treated with cephalomedullary nails","4937":"group B, fractures treated with cephalomedullary nails","4938":"group counselling","4939":"control - text messages unrelated to quitting","4940":"control - text messages unrelated to quitting","4941":"control - text messages unrelated to quitting","4942":"normal protein (NP) diet in infants following cardiac surgery","4943":"normal protein (NP) diet in infants following cardiac surgery","4944":"normal protein (NP) diet in infants following cardiac surgery","4945":"FOLFIRI arm (irinotecan 180 mg\/m2, 5-FU 400 mg\/m2, LV 200 mg\/m2, 5-FU 2400 mg\/m2 (46-h infusion) \u2013 all given on day one, every 14 days)","4946":"FOLFIRI arm (irinotecan 180 mg\/m2, 5-FU 400 mg\/m2, LV 200 mg\/m2, 5-FU 2400 mg\/m2 (46-h infusion) \u2013 all given on day one, every 14 days)","4947":"FOLFIRI arm (irinotecan 180 mg\/m2, 5-FU 400 mg\/m2, LV 200 mg\/m2, 5-FU 2400 mg\/m2 (46-h infusion) \u2013 all given on day one, every 14 days)","4948":"placebo","4949":"placebo","4950":"placebo","4951":"bupropion OR nicotine replacement therapy (NRT)","4952":"nicotine replacement therapy (NRT)","4953":"bupropion OR nicotine replacement therapy (NRT)","4954":"bupropion OR nicotine replacement therapy (NRT)","4955":"treatment as usual period","4956":"treatment as usual period","4957":"control group","4958":"control group","4959":"control group","4960":"control group","4961":"flexible fibre-optic bronchoscope (F)","4962":"flexible fibre-optic bronchoscope (F)","4963":"control groups","4964":"control groups","4965":"placebo","4966":"normal\/mild group","4967":"Control","4968":"Standard formula","4969":"Standard formula","4970":"Control","4971":"Ciclosporin","4972":"Ciclosporin","4973":"clarithromycin + rifampin","4974":"clarithromycin + rifampin","4975":"Control","4976":"Control","4977":"Control","4978":"Control","4979":"Control","4980":"Control","4981":"Control","4982":"Control","4983":"Control","4984":"Control","4985":"Control","4986":"Control","4987":"Control","4988":"Control","4989":"Control","4990":"Control","4991":"Control","4992":"Control","4993":"Control","4994":"Control","4995":"Control","4996":"Control","4997":"Control","4998":"Conventional technique","4999":"Conventional technique","5000":"Conventional technique","5001":"Control","5002":"Control","5003":"Control","5004":"Oral iron ","5005":"Oral iron ","5006":"Oral iron ","5007":"Short-term buprenorphine-naloxone","5008":"Distance single vision lenses","5009":"Control","5010":"Control","5011":"Control","5012":"Control ","5013":"Control ","5014":"Placebo","5015":"Placebo","5016":"Guttaflow system ","5017":"5% DMSO in DPBS with 0.5 M sucrose + 20% FBS","5018":"10% DMSO in DPBS with 0.5 M sucrose + 20% FBS","5019":"placebo","5020":"placebo","5021":"study team","5022":"placebo","5023":"placebo","5024":"placebo","5025":"Placebo group (P)","5026":"etoricoxib (E)","5027":"no interest group","5028":"near sea level","5029":"near sea level","5030":"near sea level","5031":"near sea level","5032":"platinum-based chemotherapy","5033":"platinum-based chemotherapy","5034":"placebo","5035":"conventionally immobilized in palmar flexion and ulnar deviation (PF)","5036":"conventionally immobilized in palmar flexion and ulnar deviation (PF)","5037":"HCT in the range 45%\u201350%","5038":"HCT in the range 45%\u201350%","5039":"placebo","5040":"non-responders","5041":"no feeding intolerance","5042":"placebo","5043":"placebo","5044":"placebo","5045":"placebo","5046":"computer-based testing","5047":"reference formulation","5048":"reference formulation","5049":"reference formulation","5050":"reference formulation","5051":"placebo + methotrexate","5052":"unchanged cART regimen","5053":"unchanged cART regimen","5054":"self-monitoring of urine glucose (SMUG)","5055":"self-monitoring of urine glucose (SMUG)","5056":"treatment arms with repeated switches (pooled switched)","5057":"treatment arms with repeated switches (pooled switched)","5058":"control","5059":"control","5060":"control","5061":"single coil rTMS","5062":"control group (CG) received lessons as usual","5063":"control group (CG) received lessons as usual","5064":"control group (CG) received lessons as usual","5065":"control group (CG) received lessons as usual","5066":"before rehabilitation program","5067":"before rehabilitation program","5068":"before rehabilitation program","5069":"scaling and root planning (SRP) alone (control)","5070":"scaling and root planning (SRP) alone (control)","5071":"scaling and root planning (SRP) alone (control)","5072":"scaling and root planning (SRP) alone (control)","5073":"placebo","5074":"placebo","5075":"placebo","5076":"reference intervention","5077":"control group C (no panty liner wear)","5078":"placebo","5079":"placebo","5080":"placebo","5081":"placebo","5082":"mannequin-based scenarios","5083":"mannequin-based scenarios","5084":"mannequin-based scenarios","5085":"mannequin-based scenarios","5086":"Before vitamin D supplementation in COPD patients","5087":"Before vitamin D supplementation in COPD patients","5088":"Before vitamin D supplementation in COPD patients","5089":"\"non-responders\ufffd were defined as individuals with less or lack of improvement.","5090":"placebo","5091":"Hispanics","5092":"referral by a printed card","5093":"Control","5094":"Control","5095":"Control","5096":"Control","5097":"Control","5098":"Control","5099":"Control","5100":"Lutein","5101":"Control ","5102":"Control ","5103":"Control","5104":"Control","5105":"Control","5106":"Control","5107":"Control","5108":"Control","5109":"Control","5110":"Control","5111":"Control","5112":"Control","5113":"Control","5114":"GnRH antagonist + oral contraceptive pill","5115":"GnRH agonist luteal low-dose","5116":"GnRH agonist luteal low-dose","5117":"GnRH agonist luteal low-dose","5118":"Control","5119":"Control","5120":"Control","5121":"Control","5122":"Tetrahydrocannabinol + Cannabidiol","5123":"Control","5124":"Control","5125":"Placebo","5126":"Placebo","5127":"Placebo","5128":"Control","5129":"Control","5130":"Control","5131":"Control","5132":"Low user control","5133":"Low user control","5134":"Low user control","5135":"Standard running program","5136":"Control","5137":"Low insulin levels","5138":"Passive range of motion","5139":"Control","5140":"Control","5141":"Control","5142":"Control","5143":"Candesartan","5144":"Candesartan","5145":"Control","5146":"Control","5147":"Control","5148":"Control","5149":"Control","5150":"Control","5151":"Control","5152":"Control","5153":"Control","5154":"Control","5155":"Control","5156":"Pressurized metered-dose inhalers","5157":"Placebo","5158":"Placebo","5159":"Control","5160":"Control","5161":"Control","5162":"5 grams of lipids ","5163":"0.6 grams of lipids ","5164":"50 grams of lipids ","5165":"placebo","5166":"zinc with multi-nutrients","5167":"appendicitis group","5168":"appendicitis group","5169":"placebo group","5170":"placebo group","5171":"placebo group","5172":"control group","5173":"usual health care and support services","5174":"usual health care and support services","5175":"usual health care and support services","5176":"box stalls","5177":"box stalls","5178":"box stalls","5179":"water","5180":"water","5181":"phase 1","5182":"phase 1","5183":"non-HPV 16\/18","5184":"HPV 18","5185":"COBAS","5186":"COBAS","5187":"lanreotide microparticles","5188":"lanreotide microparticles","5189":"lanreotide microparticles","5190":"lanreotide microparticles","5191":"placebo","5192":"salmeterol, 50 \u03bcg","5193":"salmeterol, 50 \u03bcg","5194":"placebo","5195":"placebo","5196":"tiotropium 18 \u03bcg once daily","5197":"placebo","5198":"placebo","5199":"remifentanil","5200":"fentanyl, sufentanil","5201":"remifentanil","5202":"fentanyl, sufentanil","5203":"fentanyl, sufentanil","5204":"fentanyl, sufentanil","5205":"routine care","5206":"routine care","5207":"routine care","5208":"baseline","5209":"baseline","5210":"exemestane 25 mg","5211":"baseline","5212":"baseline","5213":"baseline","5214":"baseline","5215":"baseline","5216":"45 mg pioglitazone HCl (a PPAR-\u03b3 agonist)","5217":"45 mg pioglitazone HCl (a PPAR-\u03b3 agonist)","5218":"45 mg pioglitazone HCl (a PPAR-\u03b3 agonist)","5219":"Positive related, Negative related","5220":"Positive related, Negative related","5221":"Positive related, Negative related","5222":"Negative related","5223":"bupivacaine 10 mg combined with 0.5 mL fentanyl (group F), and bupivacaine 10 mg combined with 0.5 mL distilled water (group P)","5224":"bupivacaine 10 mg combined with 0.5 mL fentanyl (group F), and bupivacaine 10 mg combined with 0.5 mL distilled water (group P)","5225":"baseline","5226":"baseline","5227":"12 hours of game play (game group) for teaching optometry students elements of the core optometric curriculum","5228":"time pH < 4","5229":"time pH < 4","5230":"time pH < 4","5231":"time pH < 4","5232":"nelfinavir (NVP)-based regimens","5233":"nelfinavir (NVP)-based regimens","5234":"placebo","5235":"placebo","5236":"placebo","5237":"placebo","5238":"placebo","5239":"pre-surgical visit","5240":"placebo (P group)","5241":"baseline","5242":"baseline","5243":"baseline","5244":"baseline","5245":"baseline","5246":"baseline","5247":"baseline","5248":"baseline","5249":"baseline","5250":"baseline","5251":"baseline","5252":"baseline","5253":"baseline","5254":"baseline","5255":"baseline","5256":"baseline","5257":"baseline","5258":"baseline","5259":"baseline","5260":"baseline","5261":"baseline","5262":"baseline","5263":"baseline","5264":"baseline","5265":"baseline","5266":"baseline","5267":"control","5268":"baseline","5269":"ethnic control groups","5270":"nothing before radiation","5271":"nothing before radiation","5272":"baseline","5273":"nothing before radiation","5274":"nothing before radiation","5275":"placebo","5276":"formoterol fumarate (FF) 12 \u03bcg ","5277":"aclidinium bromide (AB) 400 \u03bcg ","5278":"placebo","5279":"placebo","5280":"formoterol fumarate (FF) 12 \u03bcg","5281":"control","5282":"control","5283":"control","5284":"baseline","5285":"baseline","5286":"restrictive fluid management protocol","5287":"UK Lung Cancer Screening (UKLS) among man","5288":"UK Lung Cancer Screening (UKLS) among ex-smokers","5289":"UK Lung Cancer Screening (UKLS) among younger individuals","5290":"UK Lung Cancer Screening (UKLS) among recently retired","5291":"UK Lung Cancer Screening (UKLS) among highest socioeconomic group","5292":"UK Lung Cancer Screening (UKLS) among lower levels of affective risk perception","5293":"usual care in MS patients","5294":"baseline","5295":"baseline","5296":"baseline","5297":"baseline","5298":"baseline","5299":"baseline","5300":"baseline","5301":"baseline","5302":"treatment as usual (TAU)","5303":"baseline","5304":"baseline","5305":"control period","5306":"control period","5307":"control period","5308":"control period","5309":"G-aenial Universal Flo\u00ae (GC Europe) (used with one-step self-etch system) - (GUF); Tetric\u00ae N-Flow (Ivoclar\/Vivadent) (used with two-step total etch system) - (TNF)","5310":"Tetric\u00ae N-Flow (Ivoclar\/Vivadent) (used with two-step total etch system) - (TNF)","5311":"baseline","5312":"baseline","5313":"baseline","5314":"practised mild to moderate physical exercises (PE)","5315":"practised mild to moderate physical exercises (PE)","5316":"metal cup","5317":"metal cup","5318":"plastic\/placebo","5319":"baseline","5320":"baseline","5321":"baseline","5322":"baseline","5323":"placebo","5324":"placebo","5325":"Placebo","5326":"placebo","5327":"(i-gel kept at room temperature; C group;","5328":"(i-gel kept at room temperature; C group;","5329":"(i-gel kept at room temperature; C group;","5330":"placebo","5331":"placebo","5332":"placebo","5333":"placebo","5334":"placebo","5335":"Ibuprofen","5336":"two type e-cigarettes","5337":"Af-EO formulation","5338":"Sterile water","5339":"Af-EO formulation","5340":"Protocolized standard of care","5341":"Control group","5342":"Control group","5343":"Intraabdominal pressure 12 mm Hg","5344":"Intraabdominal pressure 12 mm Hg","5345":"Intraabdominal pressure 12 mm Hg","5346":"Tac target whole-blood predose concentrations","5347":"Only low-frequency left temporal rTMS ","5348":"Injection of adrenaline with mechanical therapy (haemostatic clips) (A + HC)","5349":"Injection of adrenaline with mechanical therapy (haemostatic clips) (A + HC)","5350":"Injection of adrenaline with mechanical therapy (haemostatic clips) (A + HC)","5351":"Injection of adrenaline with mechanical therapy (haemostatic clips) (A + HC)","5352":"Autograft alone","5353":"Autograft alone","5354":"Autograft alone","5355":"Gatorade and polyethylene glycol (PEG) without bisacodyl","5356":"Gatorade and polyethylene glycol (PEG) without bisacodyl","5357":"LPV\/r with nucleoside\/nucleotide reverse transcriptase inhibitors (Control)","5358":"Conventional radiotherapy","5359":"Conventional radiotherapy","5360":"Placebo","5361":"Nondairy treatment","5362":"Nondairy treatment","5363":"Mechanical epithelial removal","5364":"Mechanical epithelial removal","5365":"Mechanical epithelial removal","5366":"Wait-list control ","5367":"Wait-list control ","5368":"Wait-list control ","5369":"No probiotic medication","5370":"No probiotic medication","5371":"No probiotic medication","5372":"Group 1(only extract), group 2 (only powder), group 3 (no medicament and no SRP), and group 6 (only SRP)","5373":"Scaling and root planning","5374":"Placebo","5375":"Manual therapy","5376":"No use of positive end-expiratory pressure","5377":"3, 5, and 7 cmH2O of positive end-expiratory pressure","5378":"Placebo","5379":"Placebo","5380":"Sevoflurane","5381":"Conventional flap","5382":"Conventional flap","5383":"Placebo","5384":"Intracutaneous isotonic saline injections (placebo)","5385":"Saline group","5386":"Saline group","5387":"No medication","5388":"No medication","5389":"Non-social or anti-social priming groups","5390":"Non-social or anti-social priming groups","5391":"Placebo","5392":"Azathioprine","5393":"Azathioprine","5394":"Cyclosporine","5395":"Cyclosporine","5396":"No-BITT","5397":"No-BITT","5398":"no-BoNT-A and BITT-only","5399":"Validation cohort","5400":"Waiting list control","5401":"Waiting list control","5402":"Waiting list control","5403":"No intervention at enrollment","5404":"No intervention at enrollment","5405":"Control","5406":"Control","5407":"Control","5408":"Control","5409":"Mulberry leaf pellet at 200 g\/hd\/d","5410":"Mulberry leaf pellet at 200 g\/hd\/d","5411":"Mulberry leaf pellet at 200 g\/hd\/d","5412":"Control","5413":"Control","5414":"Control","5415":"Text\/image e-learning","5416":"Text\/image e-learning","5417":"Text\/image e-learning","5418":"Text\/image e-learning","5419":"Control ","5420":"Control ","5421":"Control ","5422":"Hind-limb suspension","5423":"Control ","5424":"Control","5425":"Control","5426":"Control","5427":"Control","5428":"Control","5429":"Ethylenediaminetetraacetic acid ","5430":"Ethylenediaminetetraacetic acid ","5431":"Control","5432":"Control","5433":"Control","5434":"Control","5435":"Control","5436":"Standard practice","5437":"Standard practice","5438":"Standard practice","5439":"Control","5440":"Control","5441":"Ramosetron","5442":"Ramosetron","5443":"Ramosetron","5444":"Control","5445":"Control","5446":"Control","5447":"Control","5448":"Control","5449":"Control","5450":"Control","5451":"Control","5452":"Control","5453":"Macintosh laryngoscope","5454":"Macintosh laryngoscope","5455":"Macintosh laryngoscope","5456":"Control","5457":"Control","5458":"Control","5459":"Control","5460":"Control","5461":"Control","5462":"Control","5463":"Control","5464":"Control","5465":"Control","5466":"Control","5467":"Control","5468":"Control","5469":"Control","5470":"Control","5471":"Control","5472":"MTX","5473":"MTX","5474":"Control","5475":"Control","5476":"Control","5477":"Control","5478":"Hydroxyethylcellulose gel","5479":"Drug-eluting bead transarterial chemoembolization","5480":"Drug-eluting bead transarterial chemoembolization","5481":"Drug-eluting bead transarterial chemoembolization","5482":"Calcifediol","5483":"Calcifediol","5484":"Control","5485":"Control","5486":"Placebo","5487":"Placebo","5488":"Placebo","5489":"Control","5490":"Placebo analgesic + Naloxone","5491":"Placebo analgesic alone","5492":"Metronidazole ","5493":"Control","5494":"Control","5495":"Control","5496":"Control","5497":"Control","5498":"Control","5499":"Control","5500":"Control","5501":"Control","5502":"Self-directed diet","5503":"Self-directed diet","5504":"Self-directed diet","5505":"Self-directed diet","5506":"Small-sided game","5507":"Small-sided game","5508":"Small-sided game","5509":"Control","5510":"Control","5511":"Control","5512":"Control","5513":"Standard arm therapy","5514":"Standard arm therapy","5515":"Standard arm therapy","5516":"Standard arm therapy","5517":"Control","5518":"Not engaging in prohibited street-based income generation","5519":"Not engaging in illegal income generating activities ","5520":"No incarceration in the last 6 months ","5521":"2 % lidocaine","5522":"Pirfenidone capsules","5523":"Pirfenidone capsules","5524":"Pirfenidone capsules","5525":"Viewing stereotype-inconsistent performances","5526":"White student ","5527":"White student ","5528":"White student ","5529":"White student ","5530":"Cannula I","5531":"Cannula I","5532":"Control","5533":"Protein alone","5534":"Protein alone","5535":"Protein alone","5536":"Control","5537":"Control","5538":"Control","5539":"Control","5540":"Control","5541":"Gelatin sponge","5542":"Gelatin sponge","5543":"Gelatin sponge","5544":"Paracetamol + oxycodone for 24 hours","5545":"Paracetamol + oxycodone for 24 hours","5546":"Paracetamol + oxycodone for 48 hours","5547":"Paracetamol + oxycodone for 48 hours","5548":"Sulfonylureas alone","5549":"Biguanides alone","5550":"DPP-4 inhibitors alone","5551":"Thiazolidinediones alone","5552":"Glinides alone","5553":"Questionnaires made by independent researchers ","5554":"Questionnaires made by independent researchers ","5555":"Control","5556":"Control","5557":"Fentanyl + morphine","5558":"Remifentanyl","5559":"Remifentanyl","5560":"Remifentanyl","5561":"Trichloroacetic acid","5562":"Trichloroacetic acid","5563":"Decapeptyl","5564":"Decapeptyl","5565":"Decapeptyl","5566":"Evaluation without feedback","5567":"mometasone furoate nasal spray","5568":"Morphine","5569":"Morphine","5570":"Morphine","5571":"Morphine","5572":"Control","5573":"Control","5574":"Control","5575":"Artesunate + mefloquine","5576":"Artesunate + mefloquine","5577":"Artesunate + mefloquine","5578":"Artesunate + mefloquine","5579":"Starch","5580":"Glucose low dose","5581":"Vehicle + celecoxib","5582":"Vehicle + celecoxib","5583":"Vehicle + celecoxib","5584":"Vehicle alone","5585":"Control","5586":"Control","5587":"Azasetron","5588":"Azasetron","5589":"Lidocaine ","5590":"Oxymetazoline","5591":"Saline","5592":"Crossed mattress suture","5593":"Crossed mattress suture","5594":"Crossed mattress suture","5595":"Crossed mattress suture","5596":"Crossed mattress suture","5597":"Conventional insertion ","5598":"Conventional insertion ","5599":"Conventional insertion ","5600":"Control","5601":"Control","5602":"Control","5603":"Metformin 1500 mg","5604":"Control ","5605":"Control ","5606":"Control","5607":"Control","5608":"Control","5609":"Standardized acupuncture","5610":"Standardized acupuncture","5611":"Caffeine","5612":"Caffeine","5613":"Caffeine","5614":"Caffeine","5615":"Caffeine","5616":"Control","5617":"Control","5618":"Olanzapine conventional tablet","5619":"Olanzapine conventional tablet","5620":"Olanzapine conventional tablet","5621":"Placebo","5622":"Placebo","5623":"Placebo","5624":"Insulin 0.07 IU\/kg load + 0.07 IU\/kg infusion","5625":"Insulin 0.07 IU\/kg load + 0.07 IU\/kg infusion","5626":"stem cell infusion - one session treatment (G-I)","5627":"control group (G-III) who received regular liver treatment","5628":"stem cell infusion - one session treatment (G-I)","5629":"group DLS, Direct Laryngoscopy","5630":"group DLS, Direct Laryngoscopy","5631":"group DLS, Direct Laryngoscopy","5632":"group DLS, Direct Laryngoscopy","5633":"general practitioners (GPs)","5634":"general practitioners (GPs)","5635":"general practitioners (GPs)","5636":"general practitioners (GPs)","5637":"phenylhydrazine (PHZ)","5638":"control group - normal saline","5639":"control group - normal saline","5640":"control group - normal saline","5641":"before intervention","5642":"before intervention","5643":"whole-body except the head (partial-body cryostimulation, PBC)","5644":"whole-body except the head (partial-body cryostimulation, PBC)","5645":"whole-body except the head (partial-body cryostimulation, PBC)","5646":"triple placebos","5647":"triple placebos","5648":"triple placebos","5649":"triple placebos","5650":"Manual hyperinflation (MH) and suctioning","5651":"Manual hyperinflation (MH) and suctioning","5652":"internal standard (IS) - Tizanidine hydrochloride","5653":"control - vitamin E soft capsules","5654":"control - vitamin E soft capsules","5655":"control - vitamin E soft capsules","5656":"diabetes mellitus patients without neuropathy (GI)","5657":"control - healthy (GIII)","5658":"T14 (lansoprazole, amoxicillin and clarithromycin for 14 days)","5659":"T14 (lansoprazole, amoxicillin and clarithromycin for 14 days)","5660":"T14 (lansoprazole, amoxicillin and clarithromycin for 14 days)","5661":"T14 (lansoprazole, amoxicillin and clarithromycin for 14 days)","5662":"normal saline (Group 3) (control)","5663":"Balloon-induced control (BIC)","5664":"Sham-operated control (SO)","5665":"resected glands below 36.5 cm","5666":"no-drain group","5667":"no-drain group","5668":"completion thyroidectomy","5669":"standard implant protocol treatment","5670":"standard implant protocol treatment","5671":"standard implant protocol treatment","5672":"dorsal onlay BMG urethroplasty (Group A) (Barbagli)","5673":"dorsal onlay BMG urethroplasty (Group A) (Barbagli)","5674":"dorsal onlay BMG urethroplasty (Group A) (Barbagli)","5675":"dorsal onlay BMG urethroplasty (Group A) (Barbagli)","5676":"healthy controls","5677":"healthy controls","5678":"healthy controls","5679":"emedastine difumarate 0.05% twice a day","5680":"loteprednol etabonate (LE) 0.5% 4 times a day","5681":"placebo","5682":"Patients operated with no fluoroscopy assistance (C)","5683":"control group did not receive any intervention","5684":"Foley catheter","5685":"Foley catheter","5686":"control group (who did not receive it)","5687":"doubling the statin dose","5688":"statin dose\u2010doubling","5689":"rosuvastatin 10mg (R10)","5690":"doubling the statin dose","5691":"control","5692":"control","5693":"control","5694":"control","5695":"eyes open","5696":"eyes open","5697":"Monovisc","5698":"saline","5699":"other mouthwashes","5700":"in home deliveries","5701":"other sites","5702":"unflavoured, non-medicated lozenge","5703":"unflavoured, non-medicated lozenge","5704":"unflavoured, non-medicated lozenge","5705":"placebo group (simulated treatment with disconnected ultrasound)","5706":"placebo group (simulated treatment with disconnected ultrasound)","5707":"placebo","5708":"placebo","5709":"exercise group","5710":"exercise group","5711":"exercise group","5712":"placebo","5713":"placebo","5714":"placebo","5715":"placebo","5716":"placebo group","5717":"placebo group","5718":"group B, who were NOT allowed to observe DJ stent insertion","5719":"group B, who were NOT allowed to observe DJ stent insertion","5720":"group B, who were NOT allowed to observe DJ stent insertion","5721":"non-routine counseling group","5722":"rizatriptan","5723":"rizatriptan","5724":"rizatriptan","5725":"dexmedetomidine ","5726":"dexmedetomidine ","5727":"placebo","5728":"placebo","5729":"placebo","5730":"non-relevant tutorial = \"out of sequence\"","5731":"non-relevant tutorial = \"out of sequence\"","5732":"Control","5733":"Control","5734":"Switching from nateglinide to vildagliptin","5735":"Switching from nateglinide to vildagliptin","5736":"pH 6.8 saliva","5737":"pH 5.8 saliva","5738":"Control ","5739":"Control ","5740":"Luxatemp","5741":"Control","5742":"Control","5743":"Control","5744":"Control","5745":"Control","5746":"Laryngeal mask airway","5747":"Laryngeal mask airway","5748":"Abdominal hysterectom","5749":"Carboplatin","5750":"Carboplatin","5751":"Control","5752":"Control","5753":"Control","5754":"Placebo","5755":"Control","5756":"Control","5757":"Control","5758":"Control","5759":"Midazolam in hypertensive patients ","5760":"Short-ramp extinction","5761":"Control","5762":"Control","5763":"Control","5764":"Metoclopramide","5765":"Metoclopramide","5766":"Metoclopramide","5767":"Regular formula","5768":"Regular formula","5769":"Standard care","5770":"Standard care","5771":"Control","5772":"Placebo","5773":"Placebo","5774":"Control","5775":"Prolonged uptitration","5776":"Control","5777":"Control","5778":"Control","5779":"Sham tsDCS","5780":"Sham tsDCS","5781":"Sham tsDCS","5782":"Rosuvastatin","5783":"Control","5784":"Control","5785":"Control","5786":"Control","5787":"Control","5788":"Standard antenatal education","5789":"Standard antenatal education","5790":"Standard antenatal education","5791":"Placebo ","5792":"Control","5793":"Control","5794":"Fentanyl ","5795":"Control","5796":"Control","5797":"Control","5798":"Regular exercise ","5799":"Control","5800":"Control","5801":"Control","5802":"Placebo","5803":"Placebo","5804":"Sham control","5805":"Sham control","5806":"cryotherapy, no treatment preference","5807":"baseline","5808":"baseline","5809":"placebo","5810":"placebo","5811":"baseline","5812":"baseline","5813":"conventional therapy (Conv)","5814":"no smoking cigarettes","5815":"without the mask","5816":"control","5817":"silicone impressions","5818":"self-image at recruitment after 8 weeks (delayed image)","5819":"usual care group (UCG)","5820":"film club","5821":"baseline","5822":"(1) a control group asked not to change their normal everyday activities and not to start any regular physical exercise program","5823":"mailed paper-and-pencil versions","5824":"procedure with conventional balloons","5825":"procedure with conventional balloons","5826":"baseline","5827":"group II lignocaine1% (9ml) with neostigmine 100\u03bcg in saline (1ml) and group III received lignocaine 1% (9ml) with neostigmine 200\u03bcg in NS (1ml)","5828":"placebo","5829":"baseline","5830":"recombinant human growth hormone (rhGH) 0.05 U\/kg ","5831":"baseline","5832":"baseline","5833":"1 mg of ranibizumab (group 2)","5834":"baseline","5835":"arthroscopic debridement","5836":"baseline","5837":"open surgery group (LPT)","5838":"Group 2 received 4 mg fesoterodine per day","5839":"placebo","5840":"controls","5841":"insulin aspart 0.2 units\/kg","5842":"placebo","5843":"placebo","5844":"placebo","5845":"placebo","5846":"no music usual-care control","5847":"no music usual-care control","5848":"baseline","5849":"pyeloplasty (OP)","5850":"polyethylene glycol (PEG) preparation","5851":"polyethylene glycol (PEG) preparation","5852":"oseltamivir (Tamiflu)","5853":"control","5854":"control","5855":"baseline","5856":"placebo","5857":"baseline","5858":"placebo","5859":"placebo","5860":"baseline","5861":"placebo","5862":"flexible fibre-optic bronchoscope (F)","5863":"control groups","5864":"intervention groups - post test","5865":"ramipril (10 mg\/day)","5866":"Control group","5867":"ramipril (10 mg\/day)","5868":"placebo","5869":"less than four weeks clinical rotation in psychiatry","5870":"hypnotic based sedative techniques","5871":"sufentanil 50 mcg (S)","5872":"chemoimmunotherapy without bevacizumab (PCR)","5873":"chemoimmunotherapy without bevacizumab (PCR)","5874":"chemoimmunotherapy without bevacizumab (PCR)","5875":"control group","5876":"control group","5877":"control group (group C)","5878":"control","5879":"control","5880":"group with no postpartum depression symptoms","5881":"group with no postpartum depression symptoms","5882":"group with no postpartum depression symptoms","5883":"placebo","5884":"usual care (UC)","5885":"group 3 with #16 ProGlider (Dentsply Maillefer) rotary instruments","5886":"not-prepared","5887":"group 3 with #16 ProGlider (Dentsply Maillefer) rotary instruments","5888":"normal saline","5889":"normal saline","5890":"control group (did not receive any add-on drugs)","5891":"control group (did not receive any add-on drugs)","5892":"group B, fractures treated with cephalomedullary nails","5893":"group B, fractures treated with cephalomedullary nails","5894":"group B, fractures treated with cephalomedullary nails","5895":"normal protein (NP) diet in infants following cardiac surgery","5896":"FOLFIRI arm (irinotecan 180 mg\/m2, 5-FU 400 mg\/m2, LV 200 mg\/m2, 5-FU 2400 mg\/m2 (46-h infusion) \u2013 all given on day one, every 14 days)","5897":"placebo","5898":"placebo","5899":"Control","5900":"Control","5901":"Control","5902":"Control","5903":"Control","5904":"Control","5905":"Control","5906":"Macintosh laryngoscope","5907":"Macintosh laryngoscope","5908":"Control","5909":"Control","5910":"Control","5911":"Control","5912":"Control","5913":"Control","5914":"Control","5915":"Control","5916":"Control","5917":"Control","5918":"Control","5919":"Control","5920":"Control","5921":"Control","5922":"Control","5923":"Control","5924":"Control","5925":"MTX","5926":"MTX","5927":"MTX","5928":"MTX","5929":"Control","5930":"Control","5931":"Control","5932":"Sulphonylurea","5933":"Sulphonylurea","5934":"Drug-eluting bead transarterial chemoembolization","5935":"Control","5936":"Calcifediol","5937":"Calcifediol","5938":"Calcifediol","5939":"Calcifediol","5940":"Calcifediol","5941":"Control","5942":"Control","5943":"Control","5944":"Control","5945":"Placebo","5946":"Placebo","5947":"Placebo","5948":"Control","5949":"Control","5950":"Control","5951":"Metronidazole ","5952":"Metronidazole ","5953":"Ornidazole ","5954":"Control","5955":"Control","5956":"Control","5957":"Control","5958":"Self-directed diet","5959":"Self-directed diet","5960":"Small-sided game","5961":"Small-sided game","5962":"Small-sided game","5963":"Control","5964":"Control","5965":"Haptic Knob","5966":"Control","5967":"Control","5968":"Not dealin drugs","5969":"Not engaging in sexual work ","5970":"2 % lidocaine","5971":"Pirfenidone capsules","5972":"White student ","5973":"Cannula I","5974":"Cannula I","5975":"Cannula I","5976":"Control","5977":"Control","5978":"Control","5979":"Placebo","5980":"Protein alone","5981":"Protein alone","5982":"Control","5983":"Control","5984":"Control","5985":"Gelatin sponge","5986":"Gelatin sponge","5987":"Gelatin sponge","5988":"Paracetamol + oxycodone for 48 hours","5989":"Paracetamol + oxycodone for 48 hours","5990":"\u03b1-glucosidase inhibitor alone","5991":"Questionnaires made by independent researchers ","5992":"Questionnaires made by independent researchers ","5993":"Questionnaires made by independent researchers ","5994":"Questionnaires made by independent researchers ","5995":"Control","5996":"Remifentanyl","5997":"Remifentanyl","5998":"Fentanyl + morphine","5999":"Potassium hydroxide","6000":"Potassium hydroxide","6001":"Potassium hydroxide","6002":"Potassium hydroxide","6003":"Decapeptyl","6004":"Decapeptyl","6005":"Decapeptyl","6006":"Evaluation without feedback","6007":"mometasone furoate nasal spray","6008":"mometasone furoate nasal spray","6009":"mometasone furoate nasal spray","6010":"mometasone furoate nasal spray","6011":"Morphine","6012":"Morphine","6013":"Control","6014":"Control","6015":"Control","6016":"Artesunate + mefloquine","6017":"Artesunate + mefloquine","6018":"Starch","6019":"Glucose low dose","6020":"Glucose low dose","6021":"Glucose low dose","6022":"Vehicle alone","6023":"Vehicle + celecoxib","6024":"Control","6025":"Control","6026":"Control","6027":"Control","6028":"Azasetron","6029":"Azasetron","6030":"Azasetron","6031":"Oxymetazoline","6032":"Saline","6033":"Lidocaine","6034":"Oxymetazoline","6035":"Oxymetazoline","6036":"Crossed mattress suture","6037":"Conventional insertion ","6038":"Conventional insertion ","6039":"Conventional insertion ","6040":"Control","6041":"Control","6042":"Control","6043":"Control","6044":"Metformin 1500 mg","6045":"Control ","6046":"Control ","6047":"Control ","6048":"Control ","6049":"Control","6050":"Control","6051":"Control","6052":"Control","6053":"Bispectral index monitoring","6054":"Control","6055":"Bispectral index monitoring","6056":"Bispectral index monitoring","6057":"Bispectral index monitoring","6058":"Standardized acupuncture","6059":"Standardized acupuncture","6060":"Standardized acupuncture","6061":"Standardized acupuncture","6062":"Caffeine","6063":"Control","6064":"Control","6065":"Olanzapine conventional tablet","6066":"Olanzapine conventional tablet","6067":"Placebo","6068":"Placebo","6069":"Placebo","6070":"Placebo","6071":"Placebo","6072":"Placebo","6073":"Placebo","6074":"Placebo","6075":" Insulin 0.14 IU\/kg infusion","6076":"Insulin 0.07 IU\/kg load + 0.07 IU\/kg infusion","6077":"Insulin 0.07 IU\/kg load + 0.07 IU\/kg infusion","6078":"Insulin 0.07 IU\/kg load + 0.07 IU\/kg infusion","6079":"Usual care","6080":"Usual care","6081":"Usual care","6082":"Usual care","6083":"Usual care","6084":"Usual care","6085":"group DLS, Direct Laryngoscopy","6086":"general practitioners (GPs)","6087":"control group","6088":"before intervention","6089":"before intervention","6090":"before intervention","6091":"whole-body except the head (partial-body cryostimulation, PBC)","6092":"whole-body except the head (partial-body cryostimulation, PBC)","6093":"triple placebos","6094":"Manual hyperinflation (MH) and suctioning","6095":"Manual hyperinflation (MH) and suctioning","6096":"Manual hyperinflation (MH) and suctioning","6097":"internal standard (IS) - Tizanidine hydrochloride","6098":"control - vitamin E soft capsules","6099":"control - healthy (GIII)","6100":"diabetes mellitus patients without neuropathy (GI)","6101":"diabetes mellitus patients without neuropathy (GI)","6102":"T14 (lansoprazole, amoxicillin and clarithromycin for 14 days)","6103":"normal saline (Group 3) (control)","6104":"clonidine (Group 2)","6105":"normal saline (Group 3) (control)","6106":"normal saline (Group 3) (control)","6107":"Balloon-induced control (BIC)","6108":"Balloon-induced control (BIC)","6109":"Balloon-induced control (BIC)","6110":"no-drain group","6111":"control group (routine treatment and nursing)","6112":"control group (routine treatment and nursing)","6113":"control group (routine treatment and nursing)","6114":"control group (routine treatment and nursing)","6115":"standard implant protocol treatment","6116":"healthy controls","6117":"healthy controls","6118":"loteprednol etabonate (LE) 0.5% 4 times a day","6119":"control group received artificial tears (AT) 0.5% 3 times a day","6120":"control group received artificial tears (AT) 0.5% 3 times a day","6121":"placebo","6122":"placebo","6123":"placebo","6124":"Patients operated with no fluoroscopy assistance (C)","6125":"Patients operated with no fluoroscopy assistance (C)","6126":"Patients operated with no fluoroscopy assistance (C)","6127":"Patients operated with no fluoroscopy assistance (C)","6128":"Patients operated with no fluoroscopy assistance (C)","6129":"control group did not receive any intervention","6130":"control group did not receive any intervention","6131":"control group did not receive any intervention","6132":"control group did not receive any intervention","6133":"Foley catheter","6134":"control group (who did not receive it)","6135":"control group (who did not receive it)","6136":"control group (who did not receive it)","6137":"control group (who did not receive it)","6138":"rosuvastatin 10mg (R10)","6139":"rosuvastatin 10mg (R10)","6140":"doubling the statin dose","6141":"control","6142":"control","6143":"control","6144":"control","6145":"control","6146":"eyes open","6147":"eyes open","6148":"saline","6149":"saline","6150":"other mouthwashes","6151":"other mouthwashes","6152":"other mouthwashes","6153":"other sites","6154":"other sites","6155":"unflavoured, non-medicated lozenge","6156":"unflavoured, non-medicated lozenge","6157":"placebo group (simulated treatment with disconnected ultrasound)","6158":"placebo","6159":"exercise group","6160":"placebo","6161":"placebo","6162":"placebo group","6163":"placebo group","6164":"placebo group","6165":"group B, who were NOT allowed to observe DJ stent insertion","6166":"group B, who were NOT allowed to observe DJ stent insertion","6167":"placebo","6168":"placebo","6169":"placebo","6170":"placebo","6171":"placebo","6172":"no JDA membership","6173":"non-routine counseling group","6174":"non-routine counseling group","6175":"rizatriptan","6176":"dexmedetomidine ","6177":"placebo","6178":"placebo","6179":"non-relevant tutorial = \"out of sequence\"","6180":"non-relevant tutorial = \"out of sequence\"","6181":"non-relevant tutorial = \"out of sequence\"","6182":"Clinical base model","6183":"Control","6184":"Control","6185":"Control","6186":"Control","6187":"Placebo","6188":"Placebo","6189":"Placebo","6190":"Placebo","6191":"Placebo","6192":"Switching from nateglinide to vildagliptin","6193":"Switching from nateglinide to vildagliptin","6194":"Switching from nateglinide to vildagliptin","6195":"pH 5.8 saliva","6196":"pH 4.8 saliva","6197":"Control ","6198":"Control ","6199":"Luxatemp","6200":"Fast set Temphase","6201":"Control","6202":"Laryngeal mask airway","6203":"Laryngeal mask airway","6204":"Laryngeal mask airway","6205":"Abdominal hysterectom","6206":"Abdominal hysterectom","6207":"Abdominal hysterectom","6208":"Zinc","6209":"Zinc","6210":"Placebo","6211":"Zinc + multivitamin ","6212":"Carboplatin","6213":"Carboplatin","6214":"Control","6215":"Control","6216":"Placebo","6217":"Control","6218":"Control","6219":"Control","6220":"Control","6221":"Control","6222":"Control","6223":"Control","6224":"Control","6225":"Short-ramp extinction","6226":"Metoclopramide","6227":"Metoclopramide","6228":"Metoclopramide","6229":"Self-explanation condition","6230":"Regular formula","6231":"Regular formula","6232":"Regular formula","6233":"Standard care","6234":"Standard care","6235":"Control","6236":"Placebo","6237":"Placebo","6238":"Placebo","6239":"Placebo","6240":"Placebo","6241":"Pennsylvania Smell Identification Test","6242":"Control","6243":"Control","6244":"Control","6245":"Control","6246":"Control","6247":"Placebo","6248":"Placebo","6249":"Placebo","6250":"Prolonged uptitration","6251":"Prolonged uptitration","6252":"Prolonged uptitration","6253":"Prolonged uptitration","6254":"Prolonged uptitration","6255":"Natural citrus sinensis juice","6256":"Natural citrus sinensis juice","6257":"Control","6258":"Control","6259":"Placebo","6260":"Placebo","6261":"Sham tsDCS","6262":"Sham tsDCS","6263":"Rosuvastatin","6264":"Rosuvastatin","6265":"Rosuvastatin","6266":"Control","6267":"Control","6268":"Control","6269":"Formative assessments","6270":"Formative assessments","6271":"Control","6272":"Control","6273":"Standard antenatal education","6274":"Placebo ","6275":"Placebo ","6276":"Control","6277":"Control","6278":"Control","6279":"Control","6280":"Control","6281":"Control","6282":"Control","6283":"Control","6284":"Fentanyl ","6285":"Fentanyl ","6286":"Fentanyl ","6287":"Fentanyl ","6288":"Placebo","6289":"Control","6290":"Regular exercise ","6291":"Control","6292":"Candesartan","6293":"Candesartan","6294":"Placebo","6295":"Placebo","6296":"Control","6297":"Placebo","6298":"Placebo","6299":"Oral supplement 2","6300":"Oral supplement 2","6301":"Sham control","6302":"Acupuncture wait-list control","6303":"cryotherapy, no treatment preference","6304":"baseline","6305":"baseline","6306":"(group NC), receiving the analgesic treatment without receiving counseling","6307":"baseline","6308":"control","6309":"control","6310":"propofol-saline [PS], thiopental sodium-lidocaine [TL]","6311":"propofol-saline [PS], thiopental sodium-lidocaine [TL] propofol-lidocaine [PL]","6312":"propofol-saline [PS], thiopental sodium-lidocaine [TL] propofol-lidocaine [PL]","6313":"daily GH treatment (GHT)","6314":"baseline","6315":"conventional therapy (Conv)","6316":"conventional therapy (Conv)","6317":"conventional therapy (Conv)","6318":"placebo","6319":"placebo","6320":"placebo","6321":"placebo","6322":"placebo","6323":"standard suture method","6324":"no smoking cigarettes","6325":"Macintosh, McCoyTM","6326":"Macintosh, McCoyTM","6327":"AirtraqTM, McCoyTM","6328":"baseline","6329":"standard care (CG)","6330":"control","6331":"control","6332":"no intervention","6333":"the control group had the usual care","6334":"silicone impressions","6335":"silicone impressions","6336":"baseline","6337":"baseline","6338":"usual care group (UCG)","6339":"usual care group (UCG)","6340":"baseline","6341":"film club","6342":"baseline","6343":"baseline","6344":"baseline","6345":"mailed paper-and-pencil versions","6346":"mailed paper-and-pencil versions","6347":"mailed paper-and-pencil versions","6348":"clonidine 200 \u03bcg","6349":"placebo","6350":"baseline","6351":"Group I received lignocaine 1% (9ml) with normal saline (1ml), ","6352":"group III received lignocaine 1% (9ml) with neostigmine 200\u03bcg in NS (1ml)","6353":"no active treatment (noNC)","6354":"group B (only noninvasive tests)","6355":"baseline","6356":"placebo","6357":"placebo","6358":"placebo","6359":"placebo","6360":"Group III - sufentanil","6361":"mastectomy","6362":"recombinant human growth hormone (rhGH) 0.05 U\/kg ","6363":"recombinant human growth hormone (rhGH) 0.05 U\/kg ","6364":"1 mg of ranibizumab (group 2)","6365":"withholding PN for one week in PICU (late PN)","6366":"Low-dose aspirin","6367":"Low-dose aspirin","6368":"Low-dose aspirin","6369":"Centre-based training","6370":"Centre-based training","6371":"Control","6372":"Usual PE and sport programmes","6373":"Usual PE and sport programmes","6374":"Usual PE and sport programmes","6375":"Placebo therapy","6376":"Placebo therapy","6377":"No intervention","6378":"8 Gy TLI + anti-thymocyte globulin (TLI-ATG arm)","6379":"8 Gy TLI + anti-thymocyte globulin (TLI-ATG arm)","6380":"Control patients","6381":"Control patients","6382":"No gum group","6383":"Lansoprazole 15 mg","6384":"Placebo (PP group)","6385":"Placebo (PP group)","6386":"Myopic defocus group ","6387":"Routine postpartum care","6388":"Routine postpartum care","6389":"Placebo","6390":"Placebo","6391":"Control group","6392":"Control group","6393":"Follow-up invitation by mail","6394":"Follow-up invitation by mail","6395":"Multivitamin supplement","6396":"Multivitamin supplement","6397":"Multivitamin supplement","6398":"Second-line chemotherapy alone (chemotherapy group)","6399":"Second-line chemotherapy alone (chemotherapy group)","6400":"Second-line chemotherapy alone (chemotherapy group)","6401":"Second-line chemotherapy alone (chemotherapy group)","6402":"Intravenous morphine","6403":"Lightweight mesh","6404":"Placebo","6405":"therapy with placebo in addition to MTX","6406":"therapy with placebo in addition to MTX","6407":"patients who came late","6408":"late patients","6409":"return patient","6410":"normal saline in addition to levobupivacaine","6411":"levobupivacaine + normal saline","6412":"Saline axposure","6413":"placebo exposure","6414":"placebo","6415":"ropivacaine + saline","6416":"ropivacaine + saline","6417":"ropivacaine + saline","6418":"ropivacaine + saline","6419":"negative input","6420":"no steroid","6421":"epinephrine","6422":"epinephrine","6423":"routine treatment and NIV","6424":"routine + NIV","6425":"usual pump therapy","6426":"midpoint of ECL","6427":"baseline","6428":"placebo","6429":"brief (at 5 times seizure threshold) pulse RUL ECT","6430":"brief (at 5 times seizure threshold) pulse RUL ECT","6431":"the standard hospital procedure (control group)","6432":"control","6433":"control","6434":"maltodextrin placebo (PLA)","6435":"maltodextrin placebo (PLA)","6436":"maltodextrin placebo (PLA)","6437":"maltodextrin placebo (PLA)","6438":"single western conventional medication (WCM)","6439":"single western conventional medication (WCM)","6440":"control","6441":"control","6442":"Control group: no treatment; VS1 group: COCs were exposed to vitrification solution 1 (VS1) containing 7.5% ethylene glycol [EG] + 7.5% dimethyl sulfoxide [DMSO] + 20% calf serum [CS] in TCM-199 at 37 C for 5 min; VS1 + VS2 group: COCs were exposed to VS1 for 5 min followed by VS2 (15% EG + 15% DMSO + 17.1% sucrose + 20% CS) at 37 C for 45\u201360 sec;","6443":"ondansetron (4mg; group A), ondansetron (8 mg; group B) ","6444":"control","6445":"control","6446":"mineral oil (MO)","6447":"mineral oil (MO)","6448":"mineral oil (MO)","6449":"mivacurium 200 \u03bcg\/kg","6450":"(B group) graft of left internal mammary artery to the same branch","6451":"(B group) graft of left internal mammary artery to the same branch","6452":"white bread","6453":"baseline","6454":"30kg\u22121 to ten control calves IV (V. jugularis)","6455":"negative Twitter messages","6456":"standard of care (controls)","6457":"standard of care (controls)","6458":"baseline","6459":"baseline","6460":"obesity (O) control (OC) group","6461":"Control","6462":"appropriate weight (AWT) groups, overweight (OWT) group ","6463":"'not at risk' group","6464":"'not at risk' group","6465":"peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks","6466":"cohort B, the administration of hCG occurred just prior to embryo transfer on day 5","6467":"older adults","6468":"acute placebo (PLC-A),), and chronic placebo (PLC-C)","6469":"baseline","6470":"baseline","6471":"baseline","6472":"baseline","6473":"(1) a control group asked not to change their normal everyday activities and not to start any regular physical exercise program","6474":"baseline","6475":"control","6476":"control","6477":"mailed paper-and-pencil versions","6478":"Placebo group","6479":"Placebo group","6480":"emain in the sitting position for 2 minutes before they also assumed the supine position (S group)","6481":"Placebo group","6482":"clonidine 200 \u03bcg, gabapentin 900mg","6483":"hogs transported for only 3 h","6484":"mofetil (MMF) ","6485":"10 grams milk powder","6486":"group II lignocaine1% (9ml) with neostigmine 100\u03bcg in saline (1ml) and group III received lignocaine 1% (9ml) with neostigmine 200\u03bcg in NS (1ml)","6487":"group II lignocaine1% (9ml) with neostigmine 100\u03bcg in saline (1ml) and group III received lignocaine 1% (9ml) with neostigmine 200\u03bcg in NS (1ml)","6488":"10 grams milk powder","6489":"10 grams milk powder","6490":"placebo","6491":"i.m. epinephrine","6492":"i.m. epinephrine","6493":"after 10 days therapy- Sulphate-sulphide mineral water \"Mljec\u030canica\" plus kinesitherapy and electrotherapy","6494":"kinesitherapy and electrotherapy","6495":"no active treatment (noNC)","6496":"baseline","6497":"placebo","6498":"adalimumab","6499":"TNF-alpha treatment","6500":"ketamine (KET)","6501":"baseline","6502":"ketamine (KET)","6503":"ketamine (KET)","6504":"control group (CG); conventional physical therapy (CPT) for airway clearance","6505":"control group (CG); conventional physical therapy (CPT) for airway clearance","6506":"S-amlodipine 2.5 mg (who failed to respond after 4-week S-amlodipine 2.5 mg monotherapy)","6507":"S-amlodipine 2.5 mg (who failed to respond after 4-week S-amlodipine 2.5 mg monotherapy)","6508":"S-amlodipine 2.5 mg (who failed to respond after 4-week S-amlodipine 2.5 mg monotherapy)","6509":"placebo (PBO)","6510":"eluxadoline 100, 300, and 1000 mg","6511":"withholding PN for one week in PICU (late PN)","6512":"administration via distal-release pellets","6513":"p-prisms after 2 weeks but before training","6514":"arthroscopic debridement","6515":"baseline","6516":"baseline","6517":"p-prisms after 2 weeks but before training","6518":"baseline","6519":"p-prisms after 2 weeks but before training","6520":"identical treatment using distilled water as the cooling liquid (control group).","6521":"identical treatment using distilled water as the cooling liquid (control group).","6522":"In group 2, the patients were given 75 mg plavix (clopidogrel) daily together with 80 mg aspirin daily for 3 months","6523":"In group 2, the patients were given 75 mg plavix (clopidogrel) daily together with 80 mg aspirin daily for 3 months","6524":"baseline","6525":"In group 2, the patients were given 75 mg plavix (clopidogrel) daily together with 80 mg aspirin daily for 3 months","6526":"open surgery group (LPT)","6527":"placebo","6528":"placebo","6529":"Group 2 received 4 mg fesoterodine per day","6530":"placebo","6531":"sitagliptin 100 mg","6532":"placebo for each indication","6533":"placebo for each indication","6534":"no premedication","6535":"no premedication","6536":"baseline","6537":"sham stimulation","6538":"sham stimulation","6539":"baseline","6540":"placebo","6541":"7 in the chest expansion exercise with placebo TENS (control group)","6542":"baseline","6543":"pyeloplasty (OP)","6544":"placebo","6545":"single sham session combined with neglect therapy","6546":"polyethylene glycol (PEG) preparation","6547":"nonfatal CVD","6548":"control group after intervention","6549":"oseltamivir (Tamiflu)","6550":"control group","6551":"metformin","6552":"metformin","6553":"remainder of the cohort","6554":"CADC model","6555":"F2 (fentanyl 2 mcg\/kg)","6556":"F2 (fentanyl 2 mcg\/kg)","6557":"F2 (fentanyl 2 mcg\/kg)","6558":"F2 (fentanyl 2 mcg\/kg)","6559":"F2 (fentanyl 2 mcg\/kg)","6560":"control group","6561":"control group","6562":"control","6563":"control group","6564":"news feed","6565":"news feed","6566":"patients without HLA-A*2402 ","6567":"patients without HLA-A*2402","6568":"patients without HLA-A*2402","6569":"G3: infrared","6570":"Control","6571":"Control","6572":"Control","6573":"G2: neural mobilization","6574":"usual care","6575":"men without BPH medication","6576":"first round","6577":"men without BPH medication","6578":"Standard approach","6579":"Standard approach","6580":"budesonide atomization inhalation","6581":"Standard approach","6582":"Standard approach","6583":"Placebo","6584":"Tenofovir\/emtricitabine","6585":"Placebo","6586":"Placebo","6587":"Placebo","6588":"Placebo","6589":"Placebo","6590":"Dairy\/chicken\/nuts\/whole grain diet","6591":"Remifentanil 2 ng\/mL","6592":"Control","6593":"Remifentanil 2 ng\/mL","6594":"Medium\/long chain triglyceride emulsion","6595":"Remifentanil 2 ng\/mL","6596":"Glecaprevir 300mg + pibrentasvir 120 mg","6597":"Medium\/long chain triglyceride emulsion","6598":"Glecaprevir 300mg + pibrentasvir 120 mg","6599":"Placebo","6600":"Medium\/long chain triglyceride emulsion","6601":"Placebo","6602":"Control","6603":"Placebo","6604":"Control","6605":"Control","6606":"Control","6607":"Filtered Technetium Sulfur Colloid","6608":"Filtered Technetium Sulfur Colloid","6609":"Control","6610":"Filtered Technetium Sulfur Colloid","6611":"Cognitive behavioral therapy","6612":"Control","6613":"Metformin ","6614":"Control","6615":"Control","6616":"Control","6617":"Positive Cues","6618":"Positive Cues","6619":"Control","6620":"Placebo","6621":"Placebo","6622":"Placebo","6623":"Placebo","6624":"Placebo","6625":"Control","6626":"Supine position ","6627":"Low-dose aspirin","6628":"Centre-based training","6629":"Centre-based training","6630":"Centre-based training","6631":"Control","6632":"Placebo therapy","6633":"Periodontitis group","6634":"8 Gy TLI + anti-thymocyte globulin (TLI-ATG arm)","6635":"8 Gy TLI + anti-thymocyte globulin (TLI-ATG arm)","6636":"8 Gy TLI + anti-thymocyte globulin (TLI-ATG arm)","6637":"Men diagnosed with HF","6638":"Men diagnosed with HF","6639":"Control patients","6640":"No gum group","6641":"Vonoprazan 20 mg","6642":"Lansoprazole 15 mg","6643":"Placebo (PP group)","6644":"30 Gy in 10 fractions","6645":"Placebo","6646":"Placebo","6647":"Control group and physical exercise classes group ","6648":"Bodyweight-based exercise groups","6649":"Routine postpartum care","6650":"Lightweight mesh","6651":"Control","6652":"Routine postpartum care","6653":"Placebo","6654":"Medium\/long chain triglyceride emulsion","6655":"Placebo","6656":"Medium\/long chain triglyceride emulsion","6657":"Control","6658":"Control","6659":"Follow-up invitation by mail","6660":"Control","6661":"Normal saline","6662":"Control","6663":"Normal saline","6664":"Filtered Technetium Sulfur Colloid","6665":"Multivitamin supplement","6666":"Metformin ","6667":"Placebo","6668":"Placebo","6669":"Paclitaxel-eluting stent","6670":"Placebo","6671":"Paclitaxel-eluting stent","6672":"Control","6673":"Control","6674":"Intravenous morphine","6675":"Control","6676":"Control","6677":"Control","6678":"Intravenous morphine","6679":"Control","6680":"Lightweight mesh","6681":"Control","6682":"Control","6683":"Supine position ","6684":"\u226565 years","6685":"\u226565 years","6686":"\u226565 years","6687":"Control","6688":"Control","6689":"Control","6690":"Control","6691":"Control","6692":"Control","6693":"Control ","6694":"Control ","6695":"Radical surgery alone ","6696":"Control","6697":"Cooked ham","6698":"Control ","6699":"Control ","6700":"Control ","6701":"Control ","6702":"Control ","6703":"Control","6704":"Control","6705":"Control","6706":"Placebo","6707":"Placebo","6708":"Placebo","6709":"Placebo","6710":"Control","6711":"PEG-based laxatives + electrolytes","6712":"PEG-based laxatives + electrolytes","6713":"PEG-based laxatives + electrolytes","6714":"Placebo","6715":"Placebo","6716":"Placebo","6717":"Placebo","6718":"No intervention","6719":"Placebo","6720":"Placebo","6721":"Placebo","6722":"Glimepiride","6723":"Glimepiride","6724":"Glimepiride","6725":"Conventional treatment","6726":"Conventional treatment","6727":"Naproxen sodium","6728":"Diphenhydramine ","6729":"Generic Losartan","6730":"Generic Losartan","6731":"Prolonged sitting","6732":"Prolonged sitting","6733":"Prolonged sitting","6734":"Placebo","6735":"Placebo","6736":"Placebo","6737":"Placebo","6738":"Placebo","6739":"Ethylene di-amine tetra-acetic acid + Ethanol","6740":"Control","6741":"Control","6742":"Placebo","6743":"Placebo","6744":"Casein phosphopeptide amorphous calcium phosphate","6745":"Fluoride varnish + Casein phosphopeptide amorphous calcium phosphate","6746":"Fluoride varnish + Casein phosphopeptide amorphous calcium phosphate","6747":"Proanthocyanidin + casein phosphopeptide amorphous calcium phosphate","6748":"Cadium + 20 mg\/L taurine","6749":"Cefuroxime","6750":"Cefuroxime","6751":"Control","6752":"Sham ischaemia","6753":"Sham ischaemia","6754":"Ischaemia + vehicle","6755":"Vaginal misoprostol and sublingual placebo","6756":"Vaginal misoprostol and sublingual placebo","6757":"Vaginal misoprostol and sublingual placebo","6758":"Usual medical practices","6759":"Control","6760":"Control","6761":"Control","6762":"Control group","6763":"Control group","6764":"Control group","6765":"Control group","6766":"Control group","6767":"Control","6768":"Control","6769":"Control","6770":"Control","6771":"Control","6772":"Vandetanib 300mg on day 1","6773":"Vandetanib 300mg on day 1","6774":"Vandetanib 300mg on day 1.","6775":"Vandetanib 300mg on day 1.","6776":"Vandetanib 300mg on day 1","6777":"Vandetanib 300mg on day 1","6778":"Control","6779":"Control","6780":"Control","6781":"Control","6782":"Control","6783":"Control","6784":"Control","6785":"Adalimumab","6786":"Adalimumab","6787":"Adalimumab","6788":"BAT (Control)","6789":"Ruxolitinib ","6790":"Artemether-lumefantrine","6791":"Artemether-lumefantrine","6792":"Artemether-lumefantrine","6793":"Artemether-lumefantrine","6794":"Artemether-lumefantrine","6795":"Control","6796":"Placebo","6797":"Placebo","6798":"Control","6799":"Control","6800":"Control","6801":"Control","6802":"Placebo","6803":"Placebo","6804":"Control","6805":"Control","6806":"Placebo","6807":"Placebo","6808":"Control","6809":"Control","6810":"Control","6811":"Control","6812":"Zotarolimus-eluting stent","6813":"control group","6814":"control group","6815":"control group","6816":"saline group","6817":"methylprednisolone group","6818":"other treatment","6819":"control","6820":"control","6821":"traditional quadriceps strengthening exercises","6822":"Formoterol\/budesonide","6823":"Control","6824":"Control","6825":"Control","6826":"Control","6827":"Control","6828":"Control","6829":"Control","6830":"Control","6831":"Placebo","6832":"Placebo","6833":"Control","6834":"Control","6835":"Control","6836":"Control","6837":"Control","6838":"Placebo","6839":"Control","6840":"Control","6841":"Health check","6842":"Control","6843":"Control","6844":"Control","6845":"Macintosh blade","6846":"Miller blade","6847":"McCoy blade","6848":"McCoy blade","6849":"Macintosh blade","6850":"Macintosh blade","6851":"Trayodashanga Kwatha + Madhu","6852":"Pradhamana Nasya +l Trayodashanga Kwatha + Madhu","6853":"Full-preparation","6854":"Small drain","6855":"Small drain","6856":"Inpatient vaginal PGE2","6857":"Inpatient vaginal PGE2","6858":"Inpatient vaginal PGE2","6859":"Inpatient vaginal PGE2","6860":"Zero sessions","6861":"Placebo","6862":"Placebo","6863":"Control","6864":"Unbalanced solutions","6865":"Unbalanced solutions","6866":"Unbalanced solutions","6867":"Unbalanced solutions","6868":"Unbalanced solutions","6869":"Hepatic resection","6870":"Hepatic resection","6871":"Hepatic resection","6872":"Control","6873":"Control","6874":"Control","6875":"Control","6876":"Placebo","6877":"Placebo","6878":"Control","6879":"Control","6880":"Control","6881":"Control","6882":"Control","6883":"Control","6884":"Control","6885":"Control","6886":"Control","6887":"Control","6888":"Control","6889":"Levocetirizine","6890":"Levocetirizine","6891":"Levocetirizine","6892":"Control","6893":"Control","6894":"Inclusion group","6895":"Inclusion group","6896":"Inclusion group","6897":"No stress control group","6898":"Oxaliplatin ","6899":"Oxaliplatin ","6900":"Oxaliplatin ","6901":"Control","6902":"Surgery alone","6903":"Control","6904":"Control","6905":"Control","6906":"Control","6907":"Atenolol","6908":"Atenolol","6909":"Atenolol","6910":"Passive external rewarming","6911":"Passive external rewarming","6912":"Sepsis Survival Campaign guidelines","6913":"Sepsis Survival Campaign guidelines","6914":"Sepsis Survival Campaign guidelines","6915":"Sepsis Survival Campaign guidelines","6916":"Sepsis Survival Campaign guidelines","6917":"Control","6918":"Control","6919":"Normal breathing","6920":"Normal breathing ","6921":"restrictive RBC transfusion strategy (transfusion when hemoglobin levels decreased below 7 g\/dl)","6922":"Normal breathing","6923":"Control","6924":"Control","6925":"Control","6926":"Control","6927":"Control","6928":"Control","6929":"Control","6930":"Control","6931":"Control","6932":"Control","6933":"Control","6934":"Control","6935":"Control","6936":"Control","6937":"Control","6938":"Control","6939":"Control","6940":"Control","6941":"Control","6942":"Control","6943":"Dexmedetomidine alone (Group II)","6944":"Dexmedetomidine alone (Group II)","6945":"Standard treatment","6946":"Standard treatment","6947":"Standard treatment","6948":"Optimized virgin olive oil (OVOO) and functional olive oil (FOO)","6949":"Optimized virgin olive oil (OVOO) and functional olive oil (FOO)","6950":"Optimized virgin olive oil (OVOO) and functional olive oil (FOO)","6951":"Functional olive oil (FOO)","6952":"Functional olive oil (FOO)","6953":"General management advice (control group)","6954":"Standard treatment","6955":"Maintenance treatment","6956":"Maintenance treatment","6957":"Discharged to home not on digoxin","6958":"Discharged to home not on digoxin","6959":"Placebo","6960":"Placebo","6961":"Placebo","6962":"Control group","6963":"Control group","6964":"non users","6965":"non users","6966":"final trial","6967":"usual care (UC)","6968":"usual care (UC)","6969":"usual care (UC)","6970":"usual care (UC)","6971":"placebo","6972":"HP (high protein) - Meat meal and the LP (low protein) - Legume meal","6973":"lesser adherence to energy goals","6974":"HMWHA, thrice injection form","6975":"HMWHA, thrice injection form","6976":"HMWHA, thrice injection form","6977":"HMWHA, thrice injection form","6978":"no fruit game","6979":"no fruit game","6980":"no fruit game","6981":"FLAX","6982":"FLAX","6983":"FLAX","6984":"HFD","6985":"HFD","6986":"kinesitherapy and electrotherapy","6987":"Control","6988":"Control","6989":"Control","6990":"Placebo","6991":"Control","6992":"Cyclosporine","6993":"Placebo","6994":"Placebo","6995":"Soy protein","6996":"Control ","6997":"Control ","6998":"Control","6999":"Control","7000":"Elbow sleeve ","7001":"Wrist splint","7002":"Supplementation alone","7003":"Control","7004":"Dexmedetomidine + remifentanil 0.3 \u03bcg\/kg\/min","7005":"Remifentanil 0.05 \u03bcg\/kg\/min","7006":"Remifentanil 0.3 \u03bcg\/kg\/min","7007":"Placbeo","7008":"Placbeo","7009":"Placbeo","7010":"Placebo","7011":"Placebo","7012":"Placebo","7013":"Control","7014":"Control","7015":"Control","7016":"Control","7017":"Control","7018":"Control","7019":"Dihydroartemisin-piperaquine","7020":"Dihydroartemisin-piperaquine","7021":"Dihydroartemisin-piperaquine","7022":"65 dB sound","7023":"40 min exposure time","7024":"Calorie restriction","7025":"Endurance exercise","7026":"Control","7027":"Control","7028":"21% FiO2","7029":"21% FiO2","7030":"21% FiO2","7031":"21% FiO2","7032":"Placebo","7033":"Placebo","7034":"Control","7035":"Control","7036":"Indirect methods of suggestion","7037":"Placebo","7038":"Placebo","7039":"Placebo","7040":"Control","7041":"Control","7042":"Deep tissue massage + NSAID","7043":"Deep tissue massage + NSAID","7044":"Deep tissue massage + NSAID","7045":"Control","7046":"Placebo","7047":"Placebo","7048":"Placebo","7049":"Control","7050":"Control","7051":"Control","7052":"Control","7053":"Normal insulin aspart","7054":"Normal insulin aspart","7055":"Normal insulin aspart","7056":"Periprostatic nerve block","7057":"IV diazepam","7058":"Paper-and-pencil questionnaire","7059":"Paper-and-pencil questionnaire","7060":"Control","7061":"Intrapleural bleomycin","7062":"Ketoconazole shampoo","7063":"Zinc- pyrithione shampoo","7064":"Ketoconazole shampoo","7065":"Urine\u2010derived human chorionic gonadotropin","7066":"Bupivacaine alone","7067":"Ketamine alone","7068":"Ketamine alone","7069":"Bupivacaine alone","7070":"Control","7071":"Control","7072":"Control","7073":"Control","7074":"Thiopental","7075":"Thiopental","7076":"Control","7077":"Control","7078":"Control","7079":"Fentanyl\/midazolam","7080":"Fentanyl\/midazolam","7081":"Control","7082":"Control","7083":"Control","7084":"Non-daily exercise","7085":"Non-daily exercise","7086":"Control","7087":"Control","7088":"Control","7089":"Control","7090":"Control","7091":"Control","7092":"Control","7093":"Long-term oxygen therapy","7094":"Long-term oxygen therapy","7095":"Long-term oxygen therapy","7096":"Placebo","7097":"Placebo","7098":"Subcutaneous tissue insertion + flushing normal saline ","7099":"19-guage needles","7100":"19-guage needles","7101":"Flexible in vitro fertilization","7102":"Flexible in vitro fertilization","7103":"Flexible in vitro fertilization","7104":"Control","7105":"Control","7106":"Control","7107":"Minimal intervention","7108":"Vitamin K antagonist","7109":"Vitamin K antagonist","7110":"Vitamin K antagonist","7111":"Vitamin K antagonist","7112":"Control","7113":"Control","7114":"Control","7115":"Control","7116":"Intravenous anesthesia + propofol + remifentanil","7117":"Distilled water","7118":"Distilled water","7119":"Lavender oil ","7120":"Exacto glass fiber post + Reforpin accessories","7121":"D. T. Light quartz fiber post","7122":"D. T. Light quartz fiber post + Fibercone accessories","7123":"Budesonide pressurised inhaler ","7124":"Budesonide pressurised inhaler ","7125":"Budesonide pressurised inhaler ","7126":"Budesonide pressurised inhaler ","7127":"Budesonide pressurised inhaler ","7128":"Placebo","7129":"Placebo","7130":"Placebo","7131":"Placebo","7132":"Placebo","7133":"Control","7134":"e-cigarette healthy adverts","7135":"Placebo","7136":"Placebo","7137":"Placebo","7138":"Casein shake (Placebo)","7139":"Control","7140":"Casein shake (Placebo)","7141":"Placebo","7142":"Placebo","7143":"Placebo","7144":"Flexible ureteroscopy","7145":"Flexible ureteroscopy","7146":"Flexible ureteroscopy","7147":"General feedback ","7148":"General feedback ","7149":"Enriched kibbles","7150":"Control","7151":"Control","7152":"Control","7153":"Standard best practice","7154":"Control","7155":"Control","7156":"Control","7157":"Control","7158":"Radioiodine calculated dose","7159":"Control","7160":"Control","7161":"Control","7162":"Control","7163":"Gutta-percha + mineral trioxide aggregate","7164":"Gutta-percha + new endodontic cement ","7165":"Gutta-percha + new endodontic cement","7166":"Reference adalimumab","7167":"Reference adalimumab","7168":"Control","7169":"Control","7170":"Control","7171":"Control","7172":"Control","7173":"Placebo","7174":"Placebo","7175":"Control","7176":"Control","7177":"Control","7178":"control","7179":"without it","7180":"conventional alcohol-assisted PRK in one eye (control)","7181":"conventional alcohol-assisted PRK in one eye (control)","7182":"conventional alcohol-assisted PRK in one eye (control)","7183":"baseline","7184":"control","7185":"control","7186":"control","7187":"control","7188":"control","7189":"propofol 0.25 mg\/kg, remifentanil 0.25 mic\/kg","7190":"placebo","7191":"ondansetron (4mg; group A), ondansetron (8 mg; group B) ","7192":"placebo","7193":"ondansetron (4mg; group A), ondansetron (8 mg; group B) ","7194":"placebo","7195":"ondansetron (4mg; group A), ondansetron (8 mg; group B) ","7196":"ondansetron (4mg; group A), ondansetron (8 mg; group B) ","7197":"low grain diet (LG)","7198":"low grain diet (LG)","7199":"low grain diet (LG)","7200":"mineral oil (MO)","7201":"low grain diet (LG)","7202":"low grain diet (LG)","7203":"low grain diet (LG)","7204":"low grain diet (LG)","7205":"low grain diet (LG)","7206":"mineral oil (MO)","7207":"mivacurium 200 \u03bcg\/kg","7208":"baseline","7209":"mivacurium 200 \u03bcg\/kg","7210":"mivacurium 200 \u03bcg\/kg","7211":"(B group) graft of left internal mammary artery to the same branch","7212":"placebo","7213":"white bread","7214":"baseline","7215":"ibuprofen","7216":"baseline","7217":"baseline","7218":"30 \u03bcg kg\u22121 to ten control calves IV (V. jugularis)","7219":"placebo","7220":"placebo","7221":"placebo","7222":"negative ratings for negative Twitter messages","7223":"negative Twitter messages","7224":"open fire","7225":"negative Twitter messages","7226":"open fire","7227":"standard of care (controls)","7228":"open fire","7229":"overweight (OW) control (OWC) and trained (OWT) groups, and obesity (O) control (OC) group","7230":"AWC; OWC; OC","7231":"'not at risk' group","7232":"peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks","7233":"peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks","7234":"placebo","7235":"placebo","7236":"control","7237":"control","7238":"pre phase","7239":"control","7240":"15 mg 0.5% bupivacaine with 25 mcg fentanyl (Group BF)","7241":"baseline","7242":"CRT, chemoradiation","7243":"15 mg 0.5% bupivacaine with 25 mcg fentanyl (Group BF)","7244":"ondansetron (4mg\/2ml, slow injection)","7245":"baseline","7246":"losartan (100 mg\/day)","7247":"control","7248":"losartan (100 mg\/day)","7249":"losartan (100 mg\/day)","7250":"baseline","7251":"negative and suspicious biopsies","7252":"baseline","7253":"baseline","7254":"restrictive RBC transfusion strategy (transfusion when hemoglobin levels decreased below 7 g\/dl)","7255":"baseline","7256":"baseline","7257":"baseline","7258":"restrictive RBC transfusion strategy (transfusion when hemoglobin levels decreased below 7 g\/dl)","7259":"restrictive RBC transfusion strategy (transfusion when hemoglobin levels decreased below 7 g\/dl)","7260":"Placebo group","7261":"baseline","7262":"placebo","7263":"nicotine replacement therapy (NRT)","7264":"bupropion ","7265":"mind-body practice (yogic meditation)","7266":"mind-body practice (yogic meditation)","7267":"mind-body practice (yogic meditation)","7268":"mind-body practice (yogic meditation)","7269":"treatment as usual period","7270":"treatment as usual period","7271":"treatment as usual period","7272":"transcutaneous electrical nerve stimulation (TENS)","7273":"control group","7274":"placebo","7275":"placebo","7276":"placebo","7277":"control group","7278":"control group","7279":"flexible fibre-optic bronchoscope (F)","7280":"flexible fibre-optic bronchoscope (F)","7281":"celecoxi","7282":"Af-EO formulation","7283":"Protocolized standard of care","7284":"Protocolized standard of care","7285":"Protocolized standard of care","7286":"Home program plus general rehabilitation therapy","7287":"Home program plus general rehabilitation therapy","7288":"Control group","7289":"Only low-frequency left temporal rTMS ","7290":"Injection of adrenaline with mechanical therapy (haemostatic clips) (A + HC)","7291":"Autograft alone","7292":"Autograft alone","7293":"NuLYTELY arm","7294":"NuLYTELY arm","7295":"NuLYTELY arm","7296":"Static stretching (SS) group","7297":"LPV\/r with nucleoside\/nucleotide reverse transcriptase inhibitors (Control)","7298":"LPV\/r with nucleoside\/nucleotide reverse transcriptase inhibitors (Control)","7299":"LPV\/r with nucleoside\/nucleotide reverse transcriptase inhibitors (Control)","7300":"Conventional radiotherapy","7301":"Placebo","7302":"Placebo","7303":"Placebo","7304":"Nondairy treatment","7305":"Nondairy treatment","7306":"Nondairy treatment","7307":"Mechanical epithelial removal","7308":"Mechanical epithelial removal","7309":"Wait-list control ","7310":"Wait-list control ","7311":"No probiotic medication","7312":"No probiotic medication","7313":"Frankincense powder","7314":"Placebo","7315":"Placebo","7316":"Manual therapy","7317":"Manual therapy","7318":"No use of positive end-expiratory pressure","7319":"No use of positive end-expiratory pressure","7320":"0 and 3 cmH2O of positive end-expiratory pressure","7321":"Placebo","7322":"Placebo","7323":"Sevoflurane","7324":"Sevoflurane","7325":"Conventional flap","7326":"Placebo","7327":"Intracutaneous isotonic saline injections (placebo)","7328":"Intracutaneous isotonic saline injections (placebo)","7329":"Intracutaneous isotonic saline injections (placebo)","7330":"Intracutaneous isotonic saline injections (placebo)","7331":"Saline group","7332":"Saline group","7333":"Saline group","7334":"Anti-social priming groups","7335":"Anti-social priming groups","7336":"Placebo","7337":"Azathioprine","7338":"Azathioprine","7339":"Azathioprine","7340":"Cyclosporine","7341":"Cyclosporine","7342":"Cyclosporine","7343":"BoNT-A and control","7344":"BoNT-A and control","7345":"Waiting list control","7346":"Waiting list control","7347":"No intervention at enrollment","7348":"No intervention at enrollment","7349":"No intervention at enrollment","7350":"Control","7351":"Control","7352":"Mulberry leaf pellet at 200 g\/hd\/d","7353":"Mulberry leaf pellet at 200 g\/hd\/d","7354":"Mulberry leaf pellet at 200 g\/hd\/d","7355":"Control","7356":"Gutta-percha","7357":"Control","7358":"Control","7359":"Control","7360":"Control","7361":"Text\/image e-learning","7362":"Control ","7363":"Control ","7364":"Control ","7365":"Hind-limb suspension","7366":"Hind-limb suspension","7367":"Control ","7368":"Control","7369":"Control","7370":"Ethylenediaminetetraacetic acid ","7371":"Control","7372":"Control","7373":"Control","7374":"Control","7375":"Control","7376":"Control","7377":"Control","7378":"Standard practice","7379":"Control","7380":"Control","7381":"Control","7382":"Control","7383":"Control","7384":"Health education","7385":"Health education","7386":"Health education","7387":"Control","7388":"Control","7389":"\u226565 years","7390":"\u226565 years","7391":"Control","7392":"Control ","7393":"Control ","7394":"Control ","7395":"Radical surgery alone ","7396":"Radical surgery alone ","7397":"Radical surgery alone ","7398":"Control","7399":"Control","7400":"Control","7401":"Control","7402":"Control","7403":"Cooked ham","7404":"Cooked ham","7405":"Cooked ham","7406":"Control ","7407":"Control","7408":"Placebo","7409":"Placebo","7410":"Placebo","7411":"PEG-based laxatives + electrolytes","7412":"PEG-based laxatives + electrolytes","7413":"Placebo","7414":"Placebo","7415":"Placebo","7416":"Placebo","7417":"No intervention","7418":"Placebo","7419":"No intervention ","7420":"Placebo","7421":"Glimepiride","7422":"Glimepiride","7423":"Glimepiride","7424":"Conventional treatment","7425":"Conventional treatment","7426":"Conventional treatment","7427":"Naproxen sodium","7428":"Diphenhydramine","7429":"Naproxen sodium + diphenhydramine (220mg\/50mg)","7430":"Naproxen sodium + diphenhydramine (220mg\/50mg)","7431":"Generic Losartan","7432":"Prolonged sitting","7433":"Placebo","7434":"Placebo","7435":"Placebo","7436":"Placebo","7437":"Placebo","7438":"Placebo","7439":"Placebo","7440":"Placebo","7441":"Ethanol","7442":"Control","7443":"Ethanol","7444":"Placebo","7445":"Placebo","7446":"Placebo","7447":"Placebo","7448":"Control","7449":"Cefuroxime","7450":"Sham ischaemia","7451":"Sham ischaemia","7452":"Vaginal misoprostol and sublingual placebo","7453":"Usual medical practices","7454":"Usual medical practices","7455":"Control","7456":"Control","7457":"Control","7458":"Low-maintenance demand","7459":"Adalimumab","7460":"BAT (Control)","7461":"Artemether-lumefantrine","7462":"Placebo","7463":"Placebo","7464":"Placebo","7465":"Placebo","7466":"Control","7467":"Placebo","7468":"Placebo","7469":"Control","7470":"Zotarolimus-eluting stent","7471":"2.0 Gy fractions","7472":"IV esomeprazole ","7473":"Placebo","7474":"Placebo","7475":"SafeSider","7476":"Insulin","7477":"Placebo + epinephrine","7478":"Placebo","7479":"Vancomycin","7480":"Control","7481":"ibuprofen 400 mg twice a day","7482":"before Computer-based auditory training (CBAT) intervention","7483":"control group - pharmacotherapy in outpatient","7484":"control group - pharmacotherapy in outpatient","7485":"progressive balance training (PBT)","7486":"progressive balance training (PBT)","7487":"doctor of osteopathy (DO) degree","7488":"conventional laryngoscopy (CL)","7489":"(HC) age-matched healthy control subjects","7490":"two-operator hand-on-needle (HN) technique","7491":"X-STOP\u00ae (49\/129, 38.0%)","7492":"X-STOP\u00ae (49\/129, 38.0%)","7493":"CIMT 1.5 hours of supervised CIMT+1.5 hours home exercises supervised by a caregiver","7494":"control","7495":"patients wore only their shoes","7496":"transcutaneous electrical nerve stimulation (TENS)","7497":"T2 feed containing 16% digestible crude protein","7498":"without cerebral swelling on CT scan","7499":"intramuscular (IM) interferon (IFN) beta-1a","7500":"intramuscular (IM) interferon (IFN) beta-1a","7501":"intramuscular (IM) interferon (IFN) beta-1a","7502":"vildagliptin monotherapy","7503":"usual treatment for substance-dependent patients","7504":"placebo (CON)","7505":"usual care","7506":"femoral bone preparation with broaching on the other side","7507":"femoral bone preparation with broaching on the other side","7508":"Clinical base model + free PSA","7509":"Control","7510":"Placebo","7511":"Formoterol 4.5 \u03bcg","7512":"Switching from nateglinide to vildagliptin","7513":"pH 4.8 saliva","7514":"pH 4.8 saliva","7515":"Luxatemp","7516":"Laryngeal mask airway","7517":"Placebo","7518":"Carboplatin","7519":"Carboplatin","7520":"Placebo","7521":"Control","7522":"Control","7523":"Control","7524":"Control","7525":"Control","7526":"Midazolam in hypertensive patients ","7527":"Control","7528":"Control","7529":"Breastfeeding","7530":"Standard care","7531":"Control","7532":"Control","7533":"Placebo","7534":"Control","7535":"Placebo","7536":"Placebo","7537":"Sham tsDCS","7538":"Rosuvastatin","7539":"Rosuvastatin","7540":"Control","7541":"Formative assessments","7542":"Control","7543":"Standard antenatal education","7544":"Standard antenatal education","7545":"Placebo ","7546":"Control","7547":"Control","7548":"Control","7549":"Control","7550":"Fentanyl ","7551":"Placebo","7552":"Regular exercise ","7553":"Control","7554":"Control","7555":"Placebo","7556":"Placebo","7557":"Control","7558":"Control","7559":"Control","7560":"Placebo","7561":"Placebo","7562":"Sham control","7563":"Acupuncture wait-list control","7564":"baseline","7565":"baseline","7566":"children whose mothers did not consume alcohol during pregnancy","7567":"children whose mothers did not consume alcohol during pregnancy","7568":"propofol-saline [PS], thiopental sodium-lidocaine [TL] propofol-lidocaine [PL]","7569":"baseline ","7570":"standard suture method","7571":"standard suture method","7572":"without the mask","7573":"standard care (CG)","7574":"silicone impressions","7575":"silicone impressions","7576":"self-image at recruitment after 8 weeks (delayed image)","7577":"usual care group (UCG)","7578":"Zotarolimus-eluting stent","7579":"Control","7580":"Control","7581":"Control","7582":"Iron sucrose","7583":"Iron sucrose","7584":"Clinic for Low-Income Patients","7585":"Control","7586":"Control","7587":"Control","7588":"2.0 Gy fractions","7589":"Lidocaine 1.0% 3 ml + epinephrine 10 \u03bcg","7590":"Lidocaine 1.0% 3 ml + epinephrine 10 \u03bcg","7591":"PO esomeprazole for 5 day","7592":"PO esomeprazole for 5 day","7593":"Subcutaneous esomeprazole ","7594":"Subcutaneous esomeprazole ","7595":"Placebo","7596":"Conventional physical therapy","7597":"Conventional physical therapy","7598":"Conventional physical therapy","7599":"Conventional physical therapy","7600":"Neolix ","7601":"Control","7602":"Control","7603":"Control","7604":"Control","7605":"Control","7606":"Insulin","7607":"Control","7608":"Control","7609":"Control","7610":"Control","7611":"Control","7612":"Control","7613":"Placebo + salbutamol","7614":"Placebo + salbutamol ","7615":"Placebo","7616":"Placebo","7617":"Vancomycin","7618":"Vancomycin + cloxacillin","7619":"Vancomycin + cloxacillin","7620":"Control","7621":"Control","7622":"Control","7623":"Control","7624":"Acupressure at local points","7625":"ibuprofen 400 mg twice a day","7626":"ibuprofen 400 mg twice a day","7627":"before Computer-based auditory training (CBAT) intervention","7628":"hospital group - cognitive behavior therapy (CBT)-based psychotherapy plus pharmacotherapy","7629":"progressive balance training (PBT)","7630":"female","7631":"conventional laryngoscopy (CL) ","7632":"conventional laryngoscopy (CL)","7633":"conventional laryngoscopy (CL)","7634":"conventional laryngoscopy (CL)","7635":"standard care","7636":"standard care","7637":"standard care","7638":"Brazilians and Latinas","7639":"Brazilian and Haitian","7640":"(HC) age-matched healthy control subjects","7641":"(HC) age-matched healthy control subjects","7642":"(HC) age-matched healthy control subjects","7643":"two-operator hand-on-needle (HN) technique","7644":"CIMT 1.5 hours of supervised CIMT+1.5 hours home exercises supervised by a caregiver","7645":"CIMT 1.5 hours of supervised CIMT+1.5 hours home exercises supervised by a caregiver","7646":"CIMT 1.5 hours of supervised CIMT+1.5 hours home exercises supervised by a caregiver","7647":"non-occluded, non-exercised control (Non-Occl-Con)","7648":"non-occluded, non-exercised control (Non-Occl-Con)","7649":"non-occluded, non-exercised control (Non-Occl-Con)","7650":"1,000 mg gepotidacin Healthy Volunteers","7651":"1,000 mg gepotidacin Healthy Volunteers","7652":"1,000 mg gepotidacin Healthy Volunteers","7653":"control","7654":"control","7655":"control","7656":"Durban and Harare","7657":"Durban and Johannesburg","7658":"control","7659":"Non-Completers","7660":"control","7661":"patients wore only their shoes","7662":"patients wore only their shoes","7663":"Control group","7664":"Baduanjin group","7665":"Baduanjin group","7666":"low fidelity mannequins","7667":"low fidelity mannequins","7668":"placebo","7669":"placebo","7670":"placebo","7671":"placebo","7672":"placebo","7673":"normal saline as a control group (S)","7674":"normal saline as a control group (S)","7675":"normal saline as a control group (S)","7676":"normal saline as a control group (S)","7677":"transcutaneous electrical nerve stimulation (TENS)","7678":"T1, served as a negative control ","7679":"T1, served as a negative control","7680":"antihistamine","7681":"antihistamine","7682":"antihistamine","7683":"antihistamine","7684":"patients with pressures <200 mmH2O","7685":"Low adherence; taking <80% of medication","7686":"relapse prevention (RP) intervention group (partial completers)","7687":"control group","7688":"Stimulant","7689":"Stimulant","7690":"Stimulant ","7691":"T3 noise exposure (>10 years of exposure)","7692":"click ABR","7693":"T3 noise exposure (>10 years of exposure)","7694":"intramuscular (IM) interferon (IFN) beta-1a","7695":"intramuscular (IM) interferon (IFN) beta-1a","7696":"placebo needles","7697":"placebo needles","7698":"vildagliptin monotherapy","7699":"usual treatment for substance-dependent patients","7700":"usual treatment for substance-dependent patients","7701":"usual treatment for substance-dependent patients","7702":"usual treatment for substance-dependent patients","7703":"200 mg of dextrose (PLA)","7704":"placebo (CON)","7705":"placebo (CON)","7706":"200 mg of dextrose (PLA)","7707":"usual care","7708":"usual care","7709":"usual care","7710":"other clinical diseases groups","7711":"renal glomeruli","7712":"adults or children not completing the study","7713":"after intervention","7714":"national average","7715":"national average","7716":"femoral bone preparation with broaching on the other side","7717":"arthroscopic debridement","7718":"healthy eating attention control","7719":"baseline","7720":"baseline","7721":"baseline","7722":"baseline","7723":"baseline","7724":"controls","7725":"placebo","7726":"placebo","7727":"placebo","7728":"rivastigmine capsule and patch without concurrent Vascular risk factors (VRF)","7729":"baseline","7730":"baseline","7731":"no music usual-care control","7732":"7 in the chest expansion exercise with placebo TENS (control group)","7733":"pyeloplasty (OP)","7734":"polyethylene glycol (PEG) preparation","7735":"polyethylene glycol (PEG) preparation","7736":"polyethylene glycol (PEG) preparation","7737":"oseltamivir (Tamiflu)","7738":"oseltamivir (Tamiflu)","7739":"control","7740":"control","7741":"palonosetron 0.075 mg (Group P)","7742":"baseline","7743":"baseline","7744":"baseline","7745":"placebo","7746":"placebo","7747":"placebo","7748":"placebo","7749":"placebo","7750":"placebo","7751":"placebo","7752":"placebo","7753":"placebo","7754":"tadalafil with tamsulosin","7755":"tadalafil with tamsulosin","7756":"placebo","7757":"baseline","7758":"baseline","7759":"residential based settings","7760":"baseline","7761":"baseline","7762":"budesonide atomization inhalation","7763":"budesonide atomization inhalation","7764":"Tenofovir\/emtricitabine","7765":"Tenofovir\/emtricitabine","7766":"Placebo","7767":"Placebo","7768":"Placebo","7769":"Control","7770":"Control","7771":"Control","7772":"Medium\/long chain triglyceride emulsion","7773":"Medium\/long chain triglyceride emulsion","7774":"Control","7775":"Paclitaxel-eluting stent","7776":"Paclitaxel-eluting stent","7777":"Paclitaxel-eluting stent","7778":"Control","7779":"Control","7780":"Control","7781":"Control","7782":"30\u00b0 head of bed elevation","7783":"Supine position ","7784":"Supine position ","7785":"30\u00b0 head of bed elevation","7786":"Control","7787":"Low-dose aspirin","7788":"Low-dose aspirin","7789":"Centre-based training","7790":"Control","7791":"Control","7792":"Control","7793":"Control","7794":"Usual PE and sport programmes","7795":"Aescin 10% cream","7796":"Aescin 10% cream","7797":"Aescin 10% cream","7798":"Control patients","7799":"Control patients","7800":"No gum group","7801":"No gum group","7802":"No gum group","7803":"Lansoprazole 15 mg","7804":"Lansoprazole 15 mg","7805":"Placebo (PP group)","7806":"30 Gy in 10 fractions","7807":"Control group","7808":"Control group","7809":"Bodyweight-based exercise groups","7810":"Bodyweight-based exercise groups","7811":"Bodyweight-based exercise groups","7812":"Routine postpartum care","7813":"Control group","7814":"Control group","7815":"Control group","7816":"Normal saline","7817":"Normal saline","7818":"Normal saline","7819":"Multivitamin supplement","7820":"Second-line chemotherapy alone (chemotherapy group)","7821":"Intravenous morphine","7822":"Control group and health education group","7823":"Control group","7824":"Control group and health education group","7825":"Lightweight mesh","7826":"therapy with placebo in addition to MTX","7827":"therapy with placebo in addition to MTX","7828":"late patient","7829":"late patient","7830":"Indigenous group","7831":"normal saline in addition to levobupivacaine","7832":"normal saline in addition to levobupivacaine","7833":"levobupivacaine + saline","7834":"chlorhexidine alone","7835":"chlorhexidine + xylitol","7836":"placebo","7837":"ropivacaine + saline","7838":"negative input","7839":"Control group","7840":"serratiopeptidase","7841":"serratiopeptidase","7842":"routine + NIV","7843":"routine + NIV","7844":"control","7845":"control","7846":"control","7847":"baseline","7848":"brief (at 5 times seizure threshold) pulse RUL ECT","7849":"the standard hospital procedure (control group)","7850":"control","7851":"control","7852":"control","7853":"maltodextrin placebo (PLA)","7854":"maltodextrin placebo (PLA)","7855":"single western conventional medication (WCM)","7856":"control","7857":"control","7858":"Control group: no treatment","7859":"click ABR","7860":"click ABR","7861":"Zero sessions","7862":"Zero sessions","7863":"Zero sessions","7864":"Placebo","7865":"Placebo","7866":"placebo needles","7867":"Placebo","7868":"vildagliptin\/metformin SPC (single-pill combination) 50\/500 mg bid","7869":"Control","7870":"vildagliptin monotherapy","7871":"Unbalanced solutions","7872":"Hepatic resection","7873":"Hepatic resection","7874":"placebo (CON)","7875":"Control","7876":"usual care","7877":"Sham stimulation","7878":"other clinical diseases groups","7879":"Control","7880":"other clinical diseases groups","7881":"renal interstitium","7882":"Control","7883":"peritubular capillaries","7884":"Placebo","7885":"Placebo","7886":"Placebo","7887":"national average","7888":"Control","7889":"femoral bone preparation with broaching on the other side","7890":"femoral bone preparation with broaching on the other side","7891":"Control","7892":"ACRIN study","7893":"Control","7894":"chest radiograph","7895":"Control","7896":"control - received only the routine care","7897":"Control","7898":"Control","7899":"control group","7900":"Control","7901":"Levocetirizine","7902":"men in the three groups","7903":"Levocetirizine","7904":"normal saline as placebo","7905":"Control","7906":"normal saline as placebo","7907":"Control","7908":"Control","7909":"Inclusion group","7910":"fourth group: control","7911":"Inclusion group","7912":"Oxaliplatin ","7913":"group I rinsed with chlorhexidine (CHX) 0.2% alone","7914":"Oxaliplatin ","7915":"group I rinsed with chlorhexidine (CHX) 0.2% alone","7916":"placebo (group P)","7917":"Control","7918":"placebo (group P)","7919":"Surgery alone","7920":"Control","7921":"Control","7922":"Hot conditions","7923":"Hot conditions","7924":"At rest - Hot + Cooling conditions","7925":"losartan\/ amlodipine\/ hydrochlorothiazide","7926":"Atenolol","7927":"Atenolol","7928":"losartan\/ amlodipine\/ hydrochlorothiazide","7929":"losartan\/ amlodipine\/ hydrochlorothiazide","7930":"Passive external rewarming","7931":"Filtek Silorane System","7932":"Passive external rewarming","7933":"Control mice","7934":"Sepsis Survival Campaign guidelines","7935":"Control","7936":"Low adherence; taking <80% of medication","7937":"Control","7938":"those who did not","7939":"Normal breathing","7940":"Low Basal HB levels","7941":"Normal breathing ","7942":"Normal breathing","7943":"Billroth-I (B-I) reconstruction after distal gastrectomy","7944":"Control","7945":"osmotic-release oral system methylphenidate (OROS-MPH) - forced-dose study","7946":"Control","7947":"osmotic-release oral system methylphenidate (OROS-MPH) - forced-dose study","7948":"Control","7949":"Control","7950":"usual nursing care","7951":"Control","7952":"Control","7953":"usual nursing care","7954":"Control","7955":"Control","7956":"Control","7957":"Control","7958":"tiotropium\/olodaterol (TIO\/OLO)","7959":"Ischaemia + vehicle","7960":"control","7961":"Vaginal misoprostol and sublingual placebo","7962":"Vaginal misoprostol and sublingual placebo","7963":"OFF medication","7964":"Control","7965":"control group: under ultrasound guidance","7966":"Control","7967":"control group: under ultrasound guidance","7968":"Control","7969":"Usual medical practices","7970":"Control","7971":"Control","7972":"Control","7973":"control group","7974":"Control","7975":"Control","7976":"Bupivacaine plus buprenorphine (Group II)","7977":"patients with nightmares","7978":"patients with nightmares","7979":"routine care","7980":"Control","7981":"Control","7982":"Control","7983":"Standard treatment","7984":"Bupivacaine plus buprenorphine (Group II)","7985":"Control","7986":"Placebo (group 1)","7987":"Control","7988":"Control","7989":"Placebo (group 1)","7990":"Control","7991":"Pretoria and Bondo sites","7992":"Standard treatment","7993":"not using oral contraceptive pills at enrollment","7994":"having had no sex without using a condom in the 4-week interval before drug measurement","7995":"placebo","7996":"Standard treatment","7997":"Standard treatment","7998":"Maintenance treatment","7999":"placebo","8000":"control FEC (fluorouracil) or E-CMF (epirubicin plus cyclophosphamide)","8001":"Maintenance treatment","8002":"Control","8003":"Control","8004":"Control","8005":"Control","8006":"Control","8007":"adults (trained and untrained)","8008":"Control group","8009":"adults (trained and untrained)","8010":"Pradhamana Nasya +l Trayodashanga Kwatha + Madhu","8011":"non users","8012":"late surgery 24-72 hours","8013":"late surgery 24-72 hours","8014":"Control","8015":"non users","8016":"Control","8017":"Control","8018":"Control","8019":"video-learning groups","8020":"glargine 100 U\/ml (Gla-100)","8021":"glargine 100 U\/ml (Gla-100)","8022":"glargine 100 U\/ml (Gla-100)","8023":"final trial","8024":"PCB placebo first","8025":"Adalimumab","8026":"PCB placebo first","8027":"final trial","8028":"Adalimumab","8029":"previous-evening (PM) PEG solutio","8030":"previous-evening (PM) PEG solutio","8031":"Single incision laparoscopic surgery (SILS) cholecystectomy (group 2)","8032":"previous-evening (PM) PEG solutio","8033":"LP (low protein) - Legume meal","8034":"HP (high protein) - Meat meal and the LP (low protein) - Legume meal","8035":"PEG-IFN \u03b1-2a - 48 weeks","8036":"HP (high protein) - Meat meal and the LP (low protein) - Legume meal","8037":"Single incision laparoscopic surgery (SILS) cholecystectomy (group 2)","8038":"HP (high protein) - Meat meal ","8039":"endarterectomy","8040":"endarterectomy","8041":"Placebo","8042":"endarterectomy","8043":"endarterectomy","8044":"Control","8045":"Standard treatment","8046":"Placebo","8047":"Small drain","8048":"Control","8049":"Placebo","8050":"Control","8051":"Control","8052":"Control","8053":"Control","8054":"Small drain","8055":"Placebo","8056":"Control","8057":"Placebo","8058":"Control","8059":"Control","8060":"Control","8061":"Control","8062":"Zotarolimus-eluting stent","8063":"Zotarolimus-eluting stent","8064":"Control","8065":"Control","8066":"Control","8067":"Iron sucrose","8068":"Iron sucrose","8069":"Clinic for Low-Income Patients","8070":"Control","8071":"2.0 Gy fractions","8072":"2.0 Gy fractions","8073":"Lidocaine 1.0% 3 ml + epinephrine 10 \u03bcg","8074":"IV esomeprazole","8075":"PO esomeprazole for 5 day","8076":"Control","8077":"Placebo","8078":"Placebo","8079":"Placebo","8080":"SafeSider","8081":"Neolix ","8082":"Control","8083":"Control","8084":"Control","8085":"Control","8086":"Low-maintenance demand","8087":"final trial","8088":"Control","8089":"Control","8090":"Placebo + salbutamol","8091":"Placebo + epinephrine","8092":"Placebo","8093":"Placebo","8094":"Vancomycin + cloxacillin","8095":"Control","8096":"Control","8097":"Control","8098":"Control","8099":"usual care (UC)","8100":"Control","8101":"usual care (UC)","8102":"Control","8103":"Control","8104":"no temephos","8105":"ibuprofen 400 mg twice a day","8106":"ibuprofen 400 mg twice a day","8107":"no involvement of significant others","8108":"before Computer-based auditory training (CBAT) intervention","8109":"control group - pharmacotherapy in outpatient","8110":"hospital group - cognitive behavior therapy (CBT)-based psychotherapy plus pharmacotherapy","8111":"progressive balance training (PBT)","8112":"progressive balance training (PBT)","8113":"progressive balance training (PBT)","8114":"postcards","8115":"not offered a book; by email","8116":"younger and older","8117":"control group","8118":"saline group","8119":"other treatment","8120":"high demanding\/high responsive feeding style","8121":"low demanding\/high responsive feeding style","8122":"control","8123":"control","8124":"control","8125":"traditional quadriceps strengthening exercises","8126":"two-operator hand-on-needle (HN) technique","8127":"ACE-I + Calcium Antagonist free dose","8128":"two-operator hand-on-needle (HN) technique","8129":"Formoterol\/budesonide","8130":"X-STOP\u00ae (49\/129, 38.0%)","8131":"CIMT 1.5 hours of supervised CIMT+1.5 hours home exercises supervised by a caregiver","8132":"Formoterol\/budesonide","8133":"ACE-I + Calcium Antagonist free dose","8134":"CIMT 1.5 hours of supervised CIMT+1.5 hours home exercises supervised by a caregiver","8135":"non-occluded, non-exercised control (Non-Occl-Con)","8136":"non-occluded, non-exercised control (Non-Occl-Con)","8137":"McConnell taping group","8138":"McConnell taping group","8139":"non-occluded, non-exercised control (Non-Occl-Con)","8140":"full population","8141":"Control","8142":"Durban and Johannesburg ","8143":"Control","8144":"Placebo","8145":"Placebo","8146":"Placebo","8147":"Placebo","8148":"control","8149":"Control","8150":"Control","8151":"Control","8152":"Control group","8153":"Control group","8154":"Control","8155":"without cerebral swelling on CT scan","8156":"Control","8157":"low fidelity mannequins","8158":"low fidelity mannequins","8159":"low fidelity mannequins","8160":"Placebo","8161":"Ranitidine ","8162":"Placebo","8163":"Control","8164":"normal saline as a control group (S)","8165":"normal saline as a control group (S)","8166":"Control","8167":"Control","8168":"transcutaneous electrical nerve stimulation (TENS)","8169":"Control","8170":"transcutaneous electrical nerve stimulation (TENS)","8171":"Control","8172":"T1, served as a negative control","8173":"T1, served as a negative control","8174":"antihistamine","8175":"Trayodashanga Kwatha + Madhu","8176":"without cerebral swelling on CT scan","8177":"Trayodashanga Kwatha + Madhu","8178":"without cerebral swelling on CT scan","8179":"Control","8180":"Low adherence; taking <80% of medication","8181":"Low adherence; taking <80% of medication","8182":"Low adherence; taking <80% of medication","8183":"Full-preparation + finishing with diamond bur","8184":"Full-preparation","8185":"relapse prevention (RP) intervention group (partial completers)","8186":"control group","8187":"Control","8188":"control group","8189":"Stimulant","8190":"Billroth-I (B-I) reconstruction after distal gastrectomy","8191":"osmotic-release oral system methylphenidate (OROS-MPH) - flexible-dose study","8192":"control group","8193":"usual nursing care","8194":"usual nursing care","8195":"tiotropium\/olodaterol (TIO\/OLO)","8196":"tiotropium\/olodaterol (TIO\/OLO)","8197":"control","8198":"control group: under ultrasound guidance","8199":"saline in a non-acupoint","8200":"children in the control group were not given these games to play","8201":"control group","8202":"healthy subjects","8203":"chest radiograph","8204":"group C - above 51 years","8205":"group C - above 51 years","8206":"Placebo (group 1)","8207":"3 weeks after the intervention","8208":"not liking the color of the pill","8209":"control: no educational workshop","8210":"normal saline as placebo","8211":"control FEC (fluorouracil) or E-CMF (epirubicin plus cyclophosphamide)","8212":"normal saline as placebo","8213":"normal saline as placebo","8214":"fourth group: control","8215":"control FEC (fluorouracil) or E-CMF (epirubicin plus cyclophosphamide)","8216":"late surgery 24-72 hours","8217":"placebo","8218":"placebo","8219":"video-learning groups","8220":"video-learning groups","8221":"group I rinsed with chlorhexidine (CHX) 0.2% alone","8222":"glargine 100 U\/ml (Gla-100)","8223":"PCB placebo first","8224":"At rest - Hot condition","8225":"Hot conditions","8226":"previous-evening (PM) PEG solutio","8227":"losartan\/ amlodipine\/ hydrochlorothiazide","8228":"previous-evening (PM) PEG solutio","8229":"losartan\/ amlodipine\/ hydrochlorothiazide","8230":"Filtek Silorane System","8231":"Filtek Silorane System","8232":"PEG-IFN \u03b1-2a - 48 weeks","8233":"PEG-IFN \u03b1-2a - 48 weeks","8234":"those who did not","8235":"those who did not","8236":"NON-pathological complete response","8237":"chest radiograph","8238":"chest radiograph","8239":"chest radiograph","8240":"chest radiograph","8241":"control - received only the routine care","8242":"control group","8243":"3 weeks after the intervention","8244":"3 weeks after the intervention","8245":"spouses' age","8246":"before intervention","8247":"placebo","8248":"Inpatient vaginal PGE2","8249":"Inpatient vaginal PGE2","8250":"Long-term oxygen therapy","8251":"Long-term oxygen therapy","8252":"Long-term oxygen therapy","8253":"Placebo","8254":"Control","8255":"Placebo","8256":"Placebo","8257":"Placebo","8258":"Placebo","8259":"21-guage needles","8260":"21-guage needles","8261":"21-guage needles","8262":"Control","8263":"Sham stimulation","8264":"Flexible in vitro fertilization","8265":"Control","8266":"Control","8267":"normal finding","8268":"Control","8269":"Control","8270":"MCA sphenoidal segment (M1) easy exposure ","8271":"Placebo","8272":"Control","8273":"Control","8274":"Control","8275":"Control","8276":"Control","8277":"Intravenous anesthesia + propofol + remifentanil","8278":"Black pepper oil","8279":"Lavender oil ","8280":"Levocetirizine","8281":"D. T. Light quartz fiber post","8282":"D. T. Light quartz fiber post + Fibercone accessories","8283":"Budesonide\/formoterol dry-powder inhaler","8284":"Budesonide pressurised inhaler ","8285":"Control","8286":"Placebo","8287":"Placebo","8288":"Control","8289":"Control","8290":"Control","8291":"e-cigarette healthy adverts","8292":"Control","8293":"Placebo","8294":"Control","8295":"Placebo","8296":"Passive external rewarming","8297":"Placebo","8298":"Placebo","8299":"Flexible ureteroscopy","8300":"Flexible ureteroscopy","8301":"Flexible ureteroscopy","8302":"Control","8303":"General feedback ","8304":"Liquid fish oil","8305":"Liquid fish oil","8306":"Enriched kibbles","8307":"Control","8308":"Control","8309":"Control","8310":"Control","8311":"Control","8312":"Control","8313":"Control","8314":"Control","8315":"Gutta-percha + AH26 ","8316":"Reference adalimumab","8317":"Reference adalimumab","8318":"Reference adalimumab","8319":"Control","8320":"Control","8321":"Control","8322":"Dexmedetomidine alone (Group II)","8323":"Placebo","8324":"Dexmedetomidine alone (Group II)","8325":"Control","8326":"Control","8327":"Bupivacaine plus buprenorphine (Group II)","8328":"Control","8329":"control","8330":"control","8331":"without it","8332":"conventional alcohol-assisted PRK in one eye (control)","8333":"conventional alcohol-assisted PRK in one eye (control)","8334":"General management advice (control group)","8335":"conventional alcohol-assisted PRK in one eye (control)","8336":"control","8337":"Standard treatment","8338":"Placebo","8339":"Placebo","8340":"control","8341":"control","8342":"remifentanil 0.25 mic\/kg","8343":"usual care","8344":"placebo","8345":"placebo","8346":"low grain diet (LG)","8347":"final trial","8348":"low grain diet (LG)","8349":"low grain diet (LG)","8350":"low grain diet (LG)","8351":"Single incision laparoscopic surgery (SILS) cholecystectomy (group 2)","8352":"low grain diet (LG)","8353":"erlotinib first and then either CCRT with erlotinib followed by erlotinib (arm A), CCRT with IP only (arm B)","8354":"baseline","8355":"lesser attendance","8356":"less frequent monitoring","8357":"home-based care ","8358":"lesser adherence to exercise","8359":"baseline","8360":"baseline","8361":"placebo","8362":"no fruit game","8363":"placebo","8364":"no fruit game","8365":"placebo","8366":"Small drain","8367":"open fire","8368":"cognitive variables","8369":"open fire","8370":"open fire","8371":"grade II, and grade III according to the asymmetry of cervical rotation - ultrasound and massage therapy for 30 minutes, in conjunction with passive stretching exercises, 3 times a week","8372":"grade I, and grade II according to the asymmetry of cervical rotation - ultrasound and massage therapy for 30 minutes, in conjunction with passive stretching exercises, 3 times a week","8373":"placebo","8374":"HFD","8375":"placebo","8376":"Control","8377":"placebo","8378":"Control","8379":"placebo","8380":"treatment as usual (TAU)","8381":"treatment as usual (TAU), talking control (TC)","8382":"baseline","8383":"Placebo","8384":"Placebo","8385":"Control","8386":"15 mg 0.5% bupivacaine with 25 mcg fentanyl (Group BF)","8387":"15 mg 0.5% bupivacaine with 25 mcg fentanyl (Group BF)","8388":"Control ","8389":"Control ","8390":"Control ","8391":"Control ","8392":"Control ","8393":"losartan (100 mg\/day)","8394":"Placebo","8395":"losartan (100 mg\/day)","8396":"Soy protein","8397":"Soy protein","8398":"baseline","8399":"Control ","8400":"baseline","8401":"Control ","8402":"baseline","8403":"TSH<2.2 \u03bcIU\/mL","8404":"enzyme replacement therapy (ERT)","8405":"Control","8406":"baseline","8407":"enzyme replacement therapy (ERT)","8408":"transdiagnostic Internet-based maintenance treatment (TIMT) high education level","8409":"transdiagnostic Internet-based maintenance treatment (TIMT) - mood disorder","8410":"Supplementation alone","8411":"recreationally endurance trained - women","8412":"Control","8413":"baseline","8414":"Control","8415":"Individual cognition and self-regulation processes intervention ","8416":"Remifentanil 0.05 \u03bcg\/kg\/min","8417":"Remifentanil 0.05 \u03bcg\/kg\/min","8418":"Placbeo","8419":"placebo","8420":"placebo","8421":"Placbeo","8422":"mesalamine at 2.25 g\/day (Time-2.25 g)","8423":"Placebo","8424":"Placebo","8425":"Placebo","8426":"Control","8427":"Control","8428":"Alcohol consumption","8429":"Control","8430":"Control","8431":"Control","8432":"65 dB sound","8433":"Endurance exercise","8434":"Control","8435":"21% FiO2","8436":"Placebo","8437":"Placebo","8438":"Placebo","8439":"Placebo","8440":"Control ","8441":"Control","8442":"Control","8443":"Control","8444":"Placebo","8445":"Placebo","8446":"Placebo","8447":"Control","8448":"Mindfulness-based cognitive therapy ","8449":"Control","8450":"Control","8451":"Normal insulin aspart","8452":"Normal insulin aspart","8453":"control","8454":"control","8455":"Periprostatic nerve block","8456":"traditional quadriceps strengthening exercises","8457":"traditional quadriceps strengthening exercises","8458":"Periprostatic nerve block","8459":"Paper-and-pencil questionnaire","8460":"ACE-I + Calcium Antagonist free dose","8461":"Control","8462":"Control","8463":"Formoterol\/budesonide","8464":"Control","8465":"Ketoconazole shampoo","8466":"Control","8467":"Zinc- pyrithione shampoo","8468":"Zinc- pyrithione shampoo","8469":"Physiogel Intensive Cream","8470":"Control","8471":"Urine\u2010derived human chorionic gonadotropin","8472":"Urine\u2010derived human chorionic gonadotropin","8473":"Urine\u2010derived human chorionic gonadotropin","8474":"Control","8475":"Bupivacaine alone","8476":"Control","8477":"Ketamine alone","8478":"Control","8479":"Control","8480":"Control","8481":"Control","8482":"Control","8483":"Control","8484":"Control","8485":"Control","8486":"Control","8487":"Omeprazole once\u2010daily ","8488":"Control","8489":"Ranitidine","8490":"Thiopental","8491":"Control","8492":"Control","8493":"Thiopental","8494":"Control","8495":"Control","8496":"Control","8497":"Control","8498":"Control","8499":"Control","8500":"Placebo","8501":"Placebo","8502":"Fentanyl\/midazolam","8503":"Fentanyl\/midazolam","8504":"Trayodashanga Kwatha + Madhu","8505":"Control","8506":"Control","8507":"Non-daily exercise","8508":"Non-daily exercise","8509":"Non-daily exercise","8510":"Control","8511":"Control","8512":"Small drain","8513":"Inpatient vaginal PGE2","8514":"Control","8515":"3 weeks after the intervention","8516":"previous-evening (PM) PEG solutio","8517":"control FEC (fluorouracil) or E-CMF (epirubicin plus cyclophosphamide)","8518":"healthy subjects","8519":"PEG-IFN \u03b1-2a - 48 weeks","8520":"control","8521":"control","8522":"control","8523":"Filtek Silorane System","8524":"tiotropium\/olodaterol (TIO\/OLO)","8525":"endarterectomy","8526":"placebo","8527":"those who did not","8528":"preeclamptics without vitamin supplements (group A)","8529":"placebo","8530":"group I rinsed with chlorhexidine (CHX) 0.2% alone","8531":"group I rinsed with chlorhexidine (CHX) 0.2% alone","8532":"preeclamptics without vitamin supplements (group A)","8533":"placebo (group P)","8534":"losartan\/ amlodipine\/ hydrochlorothiazide","8535":"Filtek Silorane System","8536":"Control mice","8537":"LPS-SAL","8538":"Control mice","8539":"Control mice","8540":"those who did not","8541":"those who did not","8542":"partial treatment response","8543":"partial treatment response","8544":"Billroth-I (B-I) reconstruction after distal gastrectomy","8545":"Billroth-I (B-I) reconstruction after distal gastrectomy","8546":"Billroth-I (B-I) reconstruction after distal gastrectomy","8547":"osmotic-release oral system methylphenidate (OROS-MPH) - forced-dose study","8548":"usual nursing care","8549":"tiotropium\/olodaterol (TIO\/OLO)","8550":"control","8551":"OFF medication","8552":"control group: under ultrasound guidance","8553":"control group: under ultrasound guidance","8554":"control group: not given these games to play","8555":"children in the control group were not given these games to play","8556":"children in the control group were not given these games to play","8557":"control group","8558":"control group","8559":"patients with nightmares","8560":"routine care","8561":"routine care","8562":"routine care","8563":"group A - 21 to 35 years","8564":"Placebo (group 1)","8565":"Group 1","8566":"not liking the size of the pill","8567":"placebo","8568":"placebo","8569":"placebo","8570":"control FEC (fluorouracil) or E-CMF (epirubicin plus cyclophosphamide)","8571":"adults (trained and untrained)","8572":"adults (trained and untrained)","8573":"adults (trained and untrained)","8574":"late surgery 24-72 hours","8575":"average A scores","8576":"average E scores","8577":"glargine 100 U\/ml (Gla-100)","8578":"PCB placebo first","8579":"PCB placebo first","8580":"PEG-IFN \u03b1-2a - 48 weeks","8581":"baseline","8582":"baseline","8583":"baseline","8584":"baseline","8585":"baseline","8586":"baseline","8587":"baseline","8588":"baseline","8589":"baseline","8590":"baseline","8591":"gefitinib alone","8592":"control","8593":"baseline","8594":"baseline","8595":"baseline","8596":"baseline","8597":"\"deferred ART\" - given after acute OI treatment is completed","8598":"\"deferred ART\" - given after acute OI treatment is completed","8599":"\"deferred ART\" - given after acute OI treatment is completed","8600":"Group A, who had undergone classical surgical technique","8601":"Group A, who had undergone classical surgical technique","8602":"sugar sweetened (SS)","8603":"nutrient-empty drink (soft drink)","8604":"nutrient-empty drink (soft drink)","8605":"nutrient-empty drink (soft drink)","8606":"sugar sweetened (SS)","8607":"nutrient-empty drink (soft drink)","8608":"simulator training group used the simulator to train TT","8609":"simulator training group used the simulator to train TT","8610":"simulator training group used the simulator to train TT","8611":"simulator training group used the simulator to train TT","8612":"simulator training group used the simulator to train TT","8613":"control","8614":"control","8615":"control","8616":"control","8617":"control","8618":"control","8619":"control","8620":"control","8621":"control","8622":"(MET+NAC), metformin (MET),","8623":"(MET+NAC), metformin (MET),","8624":"(MET+NAC), metformin (MET),","8625":"control","8626":"control","8627":"(MET+NAC), metformin (MET),","8628":"baseline","8629":"placebo","8630":"placebo","8631":"baseline","8632":"baseline","8633":"baseline","8634":"baseline","8635":"baseline","8636":"baseline","8637":"baseline","8638":"baseline","8639":"baseline","8640":"baseline","8641":"baseline","8642":"Non-responders (NR) were defined as patients who had no improvement in DAS28 (\u2264 0.6) by 6 months","8643":"baseline","8644":"baseline","8645":"baseline","8646":"placebo","8647":"olive oil placebo","8648":"olive oil placebo","8649":"olive oil placebo","8650":"olive oil placebo","8651":"olive oil placebo","8652":"olive oil placebo","8653":"olive oil placebo","8654":"baseline","8655":"baseline","8656":"baseline","8657":"baseline","8658":"Artiflex","8659":"Artiflex","8660":"Artiflex","8661":"Artiflex","8662":"baseline","8663":"baseline","8664":"usual care","8665":"usual care","8666":"usual care","8667":"control","8668":"baseline","8669":"baseline","8670":"paracetamol (15 mg\/kg), magnesium sulfate (7.5 mg\/kg), placebo (normal saline) immediately after the induction of anesthesia","8671":"paracetamol (15 mg\/kg), magnesium sulfate (7.5 mg\/kg), placebo (normal saline) immediately after the induction of anesthesia","8672":"paracetamol (15 mg\/kg), magnesium sulfate (7.5 mg\/kg), placebo (normal saline) immediately after the induction of anesthesia","8673":"paracetamol (15 mg\/kg), magnesium sulfate (7.5 mg\/kg), placebo (normal saline) immediately after the induction of anesthesia","8674":"paracetamol (15 mg\/kg), magnesium sulfate (7.5 mg\/kg), placebo (normal saline) immediately after the induction of anesthesia","8675":"baseline","8676":"baseline","8677":"baseline","8678":"control","8679":"usual care","8680":"health education program (HED)","8681":"baseline","8682":"baseline","8683":"health education program (HED)","8684":"baseline","8685":"baseline","8686":"control","8687":"control","8688":"baseline","8689":"calcitriol only group","8690":"calcitriol only group","8691":"baseline","8692":"calcitriol only group","8693":"calcitriol only group","8694":"baseline","8695":"control","8696":"baseline","8697":"control","8698":"baseline","8699":"baseline","8700":"only open bone graft","8701":"only open bone graft","8702":"only open bone graft","8703":"group (M) received a loading dose of midazolam 0.06 mg\/kg IV over 10 min followed by 0.5 mg incremental doses until RSS reached 3\u20134","8704":"group (M) received a loading dose of midazolam 0.06 mg\/kg IV over 10 min followed by 0.5 mg incremental doses until RSS reached 3\u20134","8705":"group (M) received a loading dose of midazolam 0.06 mg\/kg IV over 10 min followed by 0.5 mg incremental doses until RSS reached 3\u20134","8706":"(A) a conventional extubation protocol (control group)","8707":"(A) a conventional extubation protocol (control group)","8708":"(A) a conventional extubation protocol (control group)","8709":"(A) a conventional extubation protocol (control group)","8710":"reference product R = Ethanol (100 %) 45 g, 1-Propanol (Ph.Eur.) 18 g (Softa-Man\u00ae pure, B. Braun Melsungen AG)","8711":"reference product R = Ethanol (100 %) 45 g, 1-Propanol (Ph.Eur.) 18 g (Softa-Man\u00ae pure, B. Braun Melsungen AG)","8712":"P3 = Ethanol (96 %) 57,6 g, 1-Propanol (Ph.Eur.) 10 g (Manorapid\u00ae Synergy, Antiseptica GmbH)","8713":"P1 = Ethanol (100 %) 45 g, 1-Propanol (Ph.Eur.) 18 g (Softa-Man\u00ae acute, B. Braun Melsungen AG), and P3 = Ethanol (96 %) 57,6 g, 1-Propanol (Ph.Eur.) 10 g (Manorapid\u00ae Synergy, Antiseptica GmbH)","8714":"metformin (1000 mg, bid po)","8715":"metformin (1000 mg, bid po)","8716":"metformin (1000 mg, bid po)","8717":"metformin (1000 mg, bid po)","8718":"metformin (1000 mg, bid po)","8719":"metformin (1000 mg, bid po)","8720":"metformin (1000 mg, bid po)","8721":"metformin (1000 mg, bid po)","8722":"metformin (1000 mg, bid po)","8723":"metformin (1000 mg, bid po)","8724":"metformin (1000 mg, bid po)","8725":"metformin (1000 mg, bid po)","8726":"metformin (1000 mg, bid po)","8727":"metformin (1000 mg, bid po)","8728":"usual diet","8729":"usual diet","8730":"baseline","8731":"baseline","8732":"nonpainful analogs to these testing procedures","8733":"control group","8734":"Vaginal tenofovir","8735":"Vaginal tenofovir","8736":"Control","8737":"Control","8738":"Control","8739":"Control","8740":"Control","8741":"Tramadol","8742":"Control","8743":"Flexible in vitro fertilization","8744":"Control","8745":"MCA sphenoidal segment (M1) easy exposure ","8746":"Minimal intervention","8747":"Control","8748":"Classical music","8749":"Control","8750":"Classical music","8751":"Intravenous anesthesia + propofol + remifentanil","8752":"Control","8753":"Distilled water","8754":"Distilled water","8755":"Dw 5% without Quinine infusion","8756":"Dw 5% + Quinine infusion","8757":"D. T. Light quartz fiber post + Fibercone accessories","8758":"Control","8759":"Aciclovir ","8760":"Placebo","8761":"Plain bupivacaine","8762":"Placebo","8763":"Placebo","8764":"Placebo","8765":"Dexmedetomidine 0.75 \u03bcg\/kg\/hr","8766":"Physiotherapy sessions + kinesiotherapy","8767":"Physiotherapy sessions + kinesiotherapy","8768":"Carrying a backpack at C7","8769":"General feedback ","8770":"Control","8771":"Attention control health information package","8772":"Control","8773":"Control","8774":"Control","8775":"Control","8776":"Control","8777":"Busulfan plus fludarabine","8778":"Busulfan plus fludarabine","8779":"Reference adalimumab","8780":"Control","8781":"Amorphous rifaximin 400 mg","8782":"Amorphous rifaximin 400 mg","8783":"Amorphous rifaximin 400 mg","8784":"Chemotherapy ","8785":"Oral ibuprofen (OI)","8786":"Oral ibuprofen (OI)","8787":"No additional treatment","8788":"No additional treatment","8789":"Placebo","8790":"Zidovudine\/lamivudine (AZT\/3TC)","8791":"Abacavir\/lamivudine (ABC\/3TC) ","8792":"Treatment as usual","8793":"control","8794":"Treatment as usual","8795":"Lay educator","8796":"placebo","8797":"Tramadol 100 mg ","8798":"baseline","8799":"baseline","8800":"baseline","8801":"lesser adherence to fat gram goal","8802":"Ondansetron","8803":"open fire","8804":"FLAX","8805":"Butter","8806":"open fire","8807":"control","8808":"Butter","8809":"open fire","8810":"HFD","8811":"HFD","8812":"experimental group II to VI - exercised on a vibration platform","8813":"experimental group II, III, V and VI - exercised on a vibration platform","8814":"Control","8815":"baseline","8816":"Control","8817":"baseline","8818":"Control ","8819":"ondansetron (4mg\/2ml, slow injection)","8820":"Group B saline bolus in a blinded manner","8821":"uncircumcised","8822":"Soy protein","8823":"baseline","8824":"larger tumours (T2\/T3)","8825":"Control ","8826":"Control ","8827":"no further treatment","8828":"problem-focused coping","8829":"matched placebo","8830":"matched placebo","8831":"Wrist splint","8832":"Cast metal post - control group","8833":"Supplementation alone","8834":"Control","8835":"Individual cognition and self-regulation processes intervention ","8836":"usual maternal and newborn educational messages","8837":"Remifentanil 0.05 \u03bcg\/kg\/min","8838":"usual maternal and newborn educational messages","8839":"Placbeo","8840":"placebo","8841":"Placbeo","8842":"placebo","8843":"placebo","8844":"control group","8845":"Control","8846":"Control","8847":"Alcohol consumption","8848":"Control","8849":"Placebo","8850":"soy drink not enriched with 2.6 g plant sterol esters","8851":"Placebo","8852":"Placebo ","8853":"Control","8854":"no block was given to patients in group B","8855":"no block was given to patients in group B","8856":"Placebo","8857":"control group","8858":"21% FiO2","8859":"Control","8860":"Placebo","8861":"Control","8862":"Control","8863":"Control","8864":"Control ","8865":"etanercept (ETN)","8866":"Control","8867":"capecitabine (1.25g\/m2 twice daily on days 1\u201314 every 21 days)","8868":"Control","8869":"Control","8870":"Control","8871":"Control","8872":"Control","8873":"control group received training in applied relaxation (AR)","8874":"idarubicin","8875":"Open appendectomy","8876":"Open appendectomy","8877":"Open appendectomy","8878":"Periprostatic nerve block","8879":"Paper-and-pencil questionnaire","8880":"Paper-and-pencil questionnaire","8881":"Control","8882":"NOEX no-exercise treatment for the regain (+50% of weight lost) phase","8883":"Control","8884":"Acting as usual","8885":"Control","8886":"Zinc- pyrithione shampoo","8887":"pre-Yoga","8888":"Control","8889":"pre-Yoga","8890":"linear models","8891":"Control","8892":"Artificial tear multiple dose ","8893":"Urine\u2010derived human chorionic gonadotropin","8894":"Artificial tear multiple dose ","8895":"Saline","8896":"Conventional schedule","8897":"Control","8898":"Conventional schedule","8899":"Single-injection palonosetron","8900":"Conventional overground training","8901":"Placebo","8902":"Fentanyl\/midazolam","8903":"Placebo","8904":"Fentanyl\/midazolam","8905":"Face-based attentional bias modification","8906":"Isocaloric carbohydrate beverage","8907":"Isocaloric carbohydrate beverage","8908":"Placebo","8909":"Control","8910":"Vaginal tenofovir","8911":"Vaginal tenofovir","8912":"Control","8913":"Control","8914":"C. gigantea extract mouth rinse","8915":"Tramadol","8916":"Tramadol","8917":"Tramadol","8918":"Tramadol","8919":"Control","8920":"Control","8921":"Aloe vera aqueous extract 20 mg\/kg ","8922":"Control","8923":"Caudal block","8924":"Transversus abdominis plane block","8925":"Control","8926":"Control","8927":"Control","8928":"Control","8929":"Control","8930":"Control","8931":"Control","8932":"Control","8933":"Control","8934":"Placebo","8935":"Control","8936":"Control","8937":"Control","8938":"Saline without Quinine infusion","8939":"Saline without Quinine infusion","8940":"Dw 5% without Quinine infusion","8941":"Saline without Quinine infusion","8942":"Placebo","8943":"Placebo","8944":"Placebo","8945":"Placebo","8946":"Placebo","8947":"Control","8948":"Control","8949":"Control","8950":"Control","8951":"Control","8952":"Control","8953":"Placebo","8954":"Placebo","8955":"Control","8956":"Control","8957":"Control","8958":"Control","8959":"Dexmedetomidine 0.50 \u03bcg\/kg\/hr","8960":"Dexmedetomidine 0.50 \u03bcg\/kg\/hr","8961":"Dexmedetomidine 0.75 \u03bcg\/kg\/hr","8962":"Physiotherapy sessions + kinesiotherapy","8963":"Physiotherapy sessions + kinesiotherapy","8964":"Physiotherapy sessions + kinesiotherapy","8965":"Control (usual care)","8966":"Control (usual care)","8967":"Control (usual care)","8968":"Weekly telephone follow-up","8969":"Control (usual care)","8970":"Control","8971":"Control","8972":"Conventional Education","8973":"Oral picosulfate with magnesium citrate + enema","8974":"Enema alone","8975":"Enema alone","8976":"Enema alone","8977":"50% maximal voluntary isometric contraction","8978":"10% maximal voluntary isometric contraction","8979":"Attention control health information package","8980":"Attention control health information package","8981":"Attention control health information package","8982":"Attention control health information package","8983":"Control","8984":"Control","8985":"Busulfan plus fludarabine","8986":"Busulfan plus fludarabine","8987":"Busulfan plus fludarabine","8988":"Observation","8989":"Observation","8990":"Breast milk","8991":"Formula","8992":"Formula","8993":"Formula","8994":"Amorphous rifaximin 200 mg","8995":"Amorphous rifaximin 200 mg","8996":"Amoxicillin","8997":"No additional treatment","8998":"No additional treatment","8999":"Insulin glargine","9000":"Insulin glargine","9001":"Not use of the tool","9002":"Patients excluded from the ProtecT","9003":"Patients excluded from the ProtecT","9004":"Patients excluded from the ProtecT","9005":"Placebo","9006":"Abacavir\/lamivudine (ABC\/3TC) ","9007":"Treatment as usual","9008":"Treatment as usual","9009":"McKenzie training","9010":"McKenzie training","9011":"Lay educator","9012":"Lay educator","9013":"Ropivacaine plus clonidine (group B)","9014":"Atracurium infusion (Group B)","9015":"Atracurium infusion (Group B)","9016":"Tramadol 100 mg ","9017":"Tramadol 100 mg ","9018":"Tramadol 100 mg ","9019":"SLOW treatment","9020":"SLOW treatment","9021":"SLOW treatment","9022":"Placebo","9023":"Placebo","9024":"Control","9025":"Listerine mouth rinse","9026":"C. gigantea extract mouth rinse","9027":"Tramadol","9028":"Control","9029":"Epidural anesthetic","9030":"Epidural anesthetic","9031":"Epidural anesthetic","9032":"Epidural anesthetic","9033":"Epidural anesthetic","9034":"Epidural anesthetic","9035":"Transversus abdominis plane block","9036":"Transversus abdominis plane block","9037":"Caudal block","9038":"Transversus abdominis plane block","9039":"Control","9040":"Control","9041":"Human chorionic gonadotropin in controls","9042":"Human chorionic gonadotropin in controls","9043":"Control","9044":"Control","9045":"Classical music","9046":"Control","9047":"Placebo","9048":"Chlorhexidene mouthrinse","9049":"Control","9050":"Placebo","9051":"Control","9052":"Placebo","9053":"Placebo","9054":"Aciclovir ","9055":"Dexmedetomidine 0.75 \u03bcg\/kg\/hr","9056":"Dexmedetomidine 0.75 \u03bcg\/kg\/hr","9057":"Weekly telephone follow-up","9058":"Carrying a backpack at 10 cm below C7","9059":"Carrying a backpack at 10 cm below C7","9060":"Carrying a backpack at C7","9061":"Carrying a backpack at 10 cm below C7","9062":"Carrying a backpack at C7","9063":"Oral picosulfate with magnesium citrate + enema","9064":"Enema alone","9065":"10% maximal voluntary isometric contraction","9066":"10% maximal voluntary isometric contraction","9067":"Attention control health information package","9068":"Control","9069":"Control","9070":"Busulfan plus fludarabine","9071":"Observation","9072":"Breast milk","9073":"Amorphous rifaximin 200 mg","9074":"Chemotherapy ","9075":"Oral ibuprofen (OI)","9076":"Oral ibuprofen (OI)","9077":"No additional treatment","9078":"Not use of the tool","9079":"Placebo","9080":"Placebo","9081":"Placebo","9082":"Abacavir\/lamivudine (ABC\/3TC) ","9083":"Treatment as usual","9084":"Lay educator","9085":"Lay educator","9086":"Ropivacaine plus clonidine (group B)","9087":"Ropivacaine plus clonidine (group B)","9088":"Ropivacaine plus clonidine (group B)","9089":"Ropivacaine plus clonidine (group B)","9090":"Atracurium infusion (Group B)","9091":"Atracurium infusion (Group B)","9092":"Atracurium infusion (Group B)","9093":"Tramadol 100 mg ","9094":"SLOW treatment","9095":"SLOW treatment","9096":"Placebo","9097":"Placebo","9098":"Standard treatment only","9099":"Three-drug combination therapy (control group)","9100":"Three-drug combination therapy (control group)","9101":"Ondansetron","9102":"Ondansetron","9103":"Only debridement","9104":"Control","9105":"Control","9106":"Butter","9107":"Butter","9108":"Placebo","9109":"experimental group II, III, IV and VI - exercised on a vibration platform","9110":"Godhuma Vati (placebo) at a dose of 500 mg once daily for 30 days (Group B)","9111":"Godhuma Vati (placebo) at a dose of 500 mg once daily for 30 days (Group B)","9112":"control group","9113":"control group","9114":"Group B saline bolus in a blinded manner","9115":"Group B saline bolus in a blinded manner","9116":"uncircumcised","9117":"problem-focused coping","9118":"problem-focused coping","9119":"problem-focused coping","9120":"matched placebo","9121":"glass fiber posts, stainless steel posts","9122":"Cast metal post - control group","9123":"Cast metal post - control group","9124":"carbon fiber posts, glass fiber posts","9125":"Incision and drainage","9126":"Incision and drainage","9127":"usual maternal and newborn educational messages","9128":"placebo","9129":"control group","9130":"control group","9131":"Control","9132":"Promus Element","9133":"Promus Element","9134":"Risk assessment + a nasal flow monitor","9135":"soy drink not enriched with 2.6 g plant sterol esters","9136":"Risk assessment + a nasal flow monitor","9137":"Placebo","9138":"soy drink not enriched with 2.6 g plant sterol esters","9139":"(NG) 4 mg dose of nicotine gum","9140":"Placebo","9141":"Placebo","9142":"Placebo ","9143":"Placebo ","9144":"Placebo ","9145":"(NG) 4 mg dose of nicotine gum","9146":"Placebo ","9147":"Control","9148":"Control","9149":"control group","9150":"Surfacten","9151":"Surfacten","9152":"Placebo","9153":"Surfacten","9154":"Surfacten","9155":"Surfacten","9156":"Surfacten","9157":"Placebo","9158":"receive ORS at home, but zinc at the health\u2013facility only","9159":"Exercise ","9160":"Control","9161":"5-fluorouracil\/ epirubicin\/ cyclophosphamide (FEC)","9162":"5-fluorouracil\/ epirubicin\/ cyclophosphamide (FEC)","9163":"dual energy X-ray absorptiometry (DXA)","9164":"dual energy X-ray absorptiometry (DXA)","9165":"Control","9166":"etanercept (ETN)","9167":"Control","9168":"Mebeverine ","9169":"Mebeverine ","9170":"No treatment ","9171":"No treatment ","9172":"healthy women (CON)","9173":"CCP group - received a placebo","9174":"CCP group - received a placebo","9175":"Control","9176":"CCP group - received a placebo","9177":"Low-level carbonated water ","9178":"control group received training in applied relaxation (AR)","9179":"control group received training in applied relaxation (AR)","9180":"control group received training in applied relaxation (AR)","9181":"Control","9182":"Bifonazole","9183":"Bifonazole","9184":"Bifonazole","9185":"idarubicin","9186":"Bifonazole","9187":"idarubicin","9188":"idarubicin","9189":"idarubicin","9190":"Open appendectomy","9191":"Benign result","9192":"Control","9193":"NOEX no-exercise treatment for the regain (+50% of weight lost) phase","9194":"Acting as usual","9195":"\"standard dissemination\" (SD)","9196":"control group CON","9197":"control group CON","9198":"control group CON","9199":"Open pyelolithotomy","9200":"pre-Yoga","9201":"Control","9202":"Control","9203":"Low flow","9204":"Artificial tear multiple dose ","9205":"Control","9206":"Classic technique","9207":"Classic technique","9208":"Classic technique","9209":"Control","9210":"Control","9211":"Single-injection palonosetron","9212":"Posterior subtenon triamcinolone Acetonide","9213":"Posterior subtenon triamcinolone Acetonide","9214":"Posterior subtenon triamcinolone Acetonide","9215":"Cognitive-Behavioral Therapy for Substance Use Disorders","9216":"Placebo","9217":"Isocaloric carbohydrate beverage","9218":"Isocaloric carbohydrate beverage","9219":"Insulin lispro","9220":"Insulin lispro","9221":"Insulin lispro","9222":"Insulin lispro","9223":"Placebo","9224":"Placebo","9225":"Placebo","9226":"Remifentanil 4 ng\/mL","9227":"control group","9228":"sitagliptin 100 mg","9229":"sitagliptin 100 mg","9230":"Remifentanil 2 ng\/mL","9231":"sitagliptin 100 mg","9232":"Remifentanil 2 ng\/mL","9233":"control group","9234":"placebo for each indication","9235":"placebo for each indication","9236":"Glecaprevir 300mg + pibrentasvir 120 mg","9237":"control group (CG); conventional physical therapy (CPT) for airway clearance","9238":"no premedication","9239":"Placebo","9240":"no premedication","9241":"placebo","9242":"no premedication","9243":"Standard approach","9244":"left dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS)","9245":"sham stimulation","9246":"p-prisms after 2 weeks but before training","9247":"Control","9248":"sham stimulation","9249":"eluxadoline 100, 300, and 1000 mg","9250":"placebo","9251":"Control","9252":"placebo","9253":"Control","9254":"placebo","9255":"identical treatment using distilled water as the cooling liquid (control group).","9256":"placebo","9257":"control group CON","9258":"placebo","9259":"Placebo","9260":"S-amlodipine 2.5 mg (who failed to respond after 4-week S-amlodipine 2.5 mg monotherapy)","9261":"placebo","9262":"news feed","9263":"placebo","9264":"sham therapy","9265":"S-amlodipine 2.5 mg (who failed to respond after 4-week S-amlodipine 2.5 mg monotherapy)","9266":"sham","9267":"5-fluorouracil\/ epirubicin\/ cyclophosphamide (FEC)","9268":"repeated stimulation sessions","9269":"matching placebo","9270":"nonfatal CVD","9271":"S-amlodipine 2.5 mg (who failed to respond after 4-week S-amlodipine 2.5 mg monotherapy)","9272":"nonfatal CVD","9273":"exercise group after intervention","9274":"control group","9275":"Standard approach","9276":"control group","9277":"Standard treatment ","9278":"capecitabine (1.25 g\/m2 twice daily on days 1\u201314 every 21 days)","9279":"capecitabine (1.25g\/m2 twice daily on days 1\u201314 every 21 days)","9280":"10 grams milk powder","9281":"capecitabine (1.25g\/m2 twice daily on days 1\u201314 every 21 days)","9282":"metformin","9283":"metformin","9284":"Standard treatment only","9285":"Standard treatment only","9286":"Three-drug combination therapy (control group)","9287":"Three-drug combination therapy (control group)","9288":"healthy women (CON)","9289":"Three-drug combination therapy (control group)","9290":"remainder of the cohort","9291":"Ondansetron","9292":"Ondansetron","9293":"Only debridement","9294":"healthy women (CON)","9295":"Only debridement","9296":"CADC model","9297":"Control","9298":"Control","9299":"Butter","9300":"Optimised land-based exercises only","9301":"Optimised land-based exercises only","9302":"Placebo","9303":"Placebo","9304":"Placebo","9305":"experimental group II, III, IV and VI - exercised on a vibration platform","9306":"experimental group II, III, IV and VI - exercised on a vibration platform","9307":"TNF-alpha treatment","9308":"experimental group II, III, V and VI - exercised on a vibration platform","9309":"Godhuma Vati (placebo) at a dose of 500 mg once daily for 30 days (Group B)","9310":"Godhuma Vati (placebo) at a dose of 500 mg once daily for 30 days (Group B)","9311":"control group","9312":"control group","9313":"control group","9314":"control group","9315":"tocilizumab","9316":"non-tourniquet group","9317":"patients with HLA-A*2402 without positive CTL response","9318":"Group B saline bolus in a blinded manner","9319":"uncircumcised","9320":"uncircumcised","9321":"uncircumcised","9322":"no further treatment","9323":"Placebo group","9324":"hogs lairaged for 6 h","9325":"non-tourniquet group","9326":"hogs transported for only 3 h - lairaged for 3 h","9327":"hogs transported for only 3 h - lairaged for 6 h","9328":"matched placebo","9329":"enzyme replacement therapy (ERT)","9330":"hogs lairaged for 6 h","9331":"treatment-as-usual control condition","9332":"10 grams milk powder","9333":"10 grams milk powder","9334":"control ","9335":"baseline","9336":"Cast metal post - control group","9337":"baseline","9338":"baseline","9339":"Incision and drainage","9340":"baseline","9341":"Incision and drainage","9342":"baseline","9343":"placebo","9344":"control","9345":"baseline","9346":"group 3, treated with an injection of hyaluronic acid (49.5 mg) plus sodium clodronate (5 mg) into each knee","9347":"group 3, treated with an injection of hyaluronic acid (49.5 mg) plus sodium clodronate (5 mg) into each knee","9348":"baseline","9349":"placebo","9350":"usual maternal and newborn educational messages","9351":"usual maternal and newborn educational messages","9352":"usual maternal and newborn educational messages","9353":"control","9354":"totally implantable venous access systems (TIVAS)","9355":"mesalamine at 2.25 g\/day","9356":"Placebo","9357":"mesalamine at 2.25 g\/day (Time-2.25 g)","9358":"Control","9359":"Control","9360":"placebo","9361":"control group","9362":"Control","9363":"Control","9364":"Risk assessment + a nasal flow monitor","9365":"Incision and drainage","9366":"Risk assessment + a nasal flow monitor","9367":"Risk assessment + a nasal flow monitor","9368":"Promus Element","9369":"Promus Element","9370":"Promus Element","9371":"soy drink not enriched with 2.6 g plant sterol esters","9372":"Placebo","9373":"soy drink not enriched with 2.6 g plant sterol esters","9374":"(NG) 4 mg dose of nicotine gum","9375":"(NG) 4 mg dose of nicotine gum","9376":"low carbohydrate, high fat (LCHF)","9377":"PCHO diet (Periodised CHO diet)","9378":"PCHO diet (Periodised CHO diet)","9379":"Placebo ","9380":"Placebo ","9381":"PCHO diet (Periodised CHO diet)","9382":"no block was given to patients in group B","9383":"low carbohydrate, high fat (LCHF)","9384":"Control","9385":"no block was given to patients in group B","9386":"Normoxia ","9387":"control group","9388":"idarubicin","9389":"Placebo","9390":"AC (attention control) group (healthy aging education)","9391":"eluxadoline","9392":"placebo","9393":"placebo","9394":"Control","9395":"comparison villages","9396":"receive ORS at home, but zinc at the health\u2013facility only","9397":"Control","9398":"Vortioxetine 15 mg","9399":"comparison villages","9400":"comparison villages","9401":"Exercise ","9402":"Control","9403":"placebo","9404":"Exercise ","9405":"Placebo","9406":"Placebo","9407":"Placebo","9408":"Control","9409":"5-fluorouracil\/ epirubicin\/ cyclophosphamide (FEC)","9410":"Control","9411":"5-fluorouracil\/ epirubicin\/ cyclophosphamide (FEC)","9412":"dual energy X-ray absorptiometry (DXA)","9413":"Mebeverine ","9414":"etanercept (ETN)","9415":"Mebeverine ","9416":"No treatment ","9417":"etanercept (ETN)","9418":"Triamcinolone acetonide","9419":"No treatment ","9420":"etanercept (ETN)","9421":"Triamcinolone acetonide","9422":"Control","9423":"Control","9424":"Control","9425":"capecitabine (1.25 g\/m2 twice daily on days 1\u201314 every 21 days)","9426":"Low-level carbonated water","9427":"healthy women (CON)","9428":"healthy women (CON)","9429":"Control","9430":"CCP group - received a placebo","9431":"Control","9432":"Control","9433":"control group received training in applied relaxation (AR)","9434":"control group","9435":"control group","9436":"control group","9437":"Bifonazole","9438":"control group","9439":"Bifonazole","9440":"Open appendectomy","9441":"Open appendectomy","9442":"AC (attention control) group (healthy aging education)","9443":"control group","9444":"AC (attention control) group (healthy aging education)","9445":"AC (attention control) group (healthy aging education)","9446":"AC (attention control) group (healthy aging education)","9447":"Benign result","9448":"Control","9449":"NOEX no-exercise treatment for the regain (+50% of weight lost) phase","9450":"NOEX no-exercise treatment for the regain (+50% of weight lost) phase","9451":"Acting as usual","9452":"control group CON","9453":"Acting as usual","9454":"Pasive physical therapy","9455":"NHS (Nurses' Health Study) cohort","9456":"Pasive physical therapy","9457":"Open pyelolithotomy","9458":"Open pyelolithotomy","9459":"NHS (Nurses' Health Study) cohort","9460":"Open pyelolithotomy","9461":"Open pyelolithotomy","9462":"Open pyelolithotomy","9463":"Control","9464":"pre-Yoga","9465":"Control","9466":"pre-Yoga","9467":"pre-Yoga","9468":"Control","9469":"Medium","9470":"identical treatment using distilled water as the cooling liquid (control group).","9471":"Artificial tear multiple dose ","9472":"Artificial tear multiple dose ","9473":"youngest age cohort","9474":"men without BPH medication","9475":"Control","9476":"Control","9477":"Control","9478":"placebo","9479":"Control","9480":"Control","9481":"Classic technique","9482":"ketamine (KET)","9483":"NOEX no-exercise treatment for the regain (+50% of weight lost) phase","9484":"identical treatment using distilled water as the cooling liquid (control group).","9485":"Classic technique","9486":"Classic technique","9487":"Placebo","9488":"Dairy\/chicken\/nuts\/whole grain diet","9489":"Control","9490":"placebo (PBO)","9491":"Control","9492":"non-tourniquet group","9493":"Conventional schedule","9494":"In group 2, the patients were given 75 mg plavix (clopidogrel) daily together with 80 mg aspirin daily for 3 months","9495":"Conventional schedule","9496":"Dairy\/chicken\/nuts\/whole grain diet","9497":"Dairy\/chicken\/nuts\/whole grain diet","9498":"Single-injection palonosetron","9499":"Single-injection palonosetron","9500":"Single-injection palonosetron","9501":"Single-injection palonosetron","9502":"Posterior subtenon triamcinolone Acetonide","9503":"placebo","9504":"In group 2, the patients were given 75 mg plavix (clopidogrel) daily together with 80 mg aspirin daily for 3 months","9505":"Glecaprevir 300mg + pibrentasvir 120 mg","9506":"Posterior subtenon triamcinolone Acetonide","9507":"ketamine (KET)","9508":"Conventional overground training","9509":"Cognitive-Behavioral Therapy for Substance Use Disorders","9510":"Placebo","9511":"Cognitive-Behavioral Therapy for Substance Use Disorders","9512":"Cognitive-Behavioral Therapy for Substance Use Disorders","9513":"Cognitive-Behavioral Therapy for Substance Use Disorders","9514":"Cognitive-Behavioral Therapy for Substance Use Disorders","9515":"Placebo","9516":"Placebo","9517":"patients without HLA-A*2402 ","9518":"Dairy\/chicken\/nuts\/whole grain diet","9519":"Control","9520":"Isocaloric carbohydrate beverage","9521":"Isocaloric carbohydrate beverage","9522":"Dairy\/chicken\/nuts\/whole grain diet","9523":"Control","9524":"Breath awareness control session","9525":"without p-prisms at baseline ","9526":"Insulin lispro","9527":"Positive Cues","9528":"Positive Cues","9529":"placebo","9530":"Positive Cues","9531":"Insulin lispro","9532":"Positive Cues","9533":"\"standard dissemination\" (SD)","9534":"Placebo","9535":"Positive Cues","9536":"Standard treatment ","9537":"Standard treatment ","9538":"Vaginal tenofovir","9539":"Vaginal tenofovir","9540":"Control","9541":"Control","9542":"Control","9543":"Control","9544":"Control","9545":"Control","9546":"Clopidex","9547":"Clopidex","9548":"Clopidex","9549":"Clopidex","9550":"Clopidex","9551":"Clopidex","9552":"Control","9553":"Control","9554":"Usual care","9555":"Usual care","9556":"Placebo","9557":"Placebo","9558":"Placebo","9559":"Placebo","9560":"Placebo","9561":"Placebo","9562":"No critical weight loss","9563":"No critical weight loss","9564":"Ibuprofen","9565":"Ibuprofen","9566":"Ibuprofen","9567":"Ibuprofen","9568":"Ibuprofen","9569":"Ibuprofen","9570":"Placebo","9571":"Placebo","9572":"Placebo","9573":"Short-course radiotherapy","9574":"Short-course radiotherapy","9575":"Short-course radiotherapy","9576":"Short-course radiotherapy","9577":"Short-course radiotherapy","9578":"Short-course radiotherapy","9579":"Empiric antifungal treatment","9580":"Placebo group","9581":"Placebo group","9582":"Placebo group","9583":"Placebo group","9584":"Control","9585":"Control","9586":"Control","9587":"Control","9588":"Placebo","9589":"Placebo","9590":"Placebo","9591":"Glycopyrronium bromide 100 \u03bcg","9592":"Glycopyrronium bromide 200 \u03bcg","9593":"Glycopyrronium bromide 200 \u03bcg","9594":"Crown-rump length method","9595":"Crown-rump length method","9596":"Control","9597":"Control","9598":"Control","9599":"Control","9600":"Vehicle ","9601":"Vehicle ","9602":"Usual care","9603":"Usual care","9604":"Usual care","9605":"Usual care","9606":"Usual care","9607":"Usual care","9608":"Control","9609":"Control","9610":"Control","9611":"Proseal laryngeal mask airway","9612":"Proseal laryngeal mask airway","9613":"Proseal laryngeal mask airway","9614":"Proseal laryngeal mask airway","9615":"Proseal laryngeal mask airway","9616":"Proseal laryngeal mask airway","9617":"Placebo ","9618":"Placebo ","9619":"Placebo ","9620":"Placebo ","9621":"Placebo ","9622":"Placebo","9623":"Placebo","9624":"Placebo","9625":"Placebo","9626":"Placebo","9627":"Placebo","9628":"Placebo ","9629":"Placebo ","9630":"Placebo ","9631":"Placebo ","9632":"Placebo ","9633":"Remifentanil","9634":"Lumbar epidural","9635":"Lumbar epidural","9636":"Saddle","9637":"Lumbar epidural","9638":"Caudal block","9639":"Lumbar epidural","9640":"CV14 point stimulation","9641":"CV14 point stimulation","9642":"CV14 point stimulation","9643":"Placebo","9644":"Placebo","9645":"Placebo","9646":"Placebo","9647":"Placebo","9648":"Placebo","9649":"Placebo","9650":"Placebo","9651":"Placebo","9652":"Placebo","9653":"No adhesion barrier","9654":"No adhesion barrier","9655":"No adhesion barrier","9656":"No adhesion barrier","9657":"No adhesion barrier","9658":"No adhesion barrier","9659":"Control","9660":"Control","9661":"Control","9662":"Control","9663":"Control","9664":"Placebo","9665":"Placebo","9666":"Placebo","9667":"Placebo","9668":"Placebo","9669":"Placebo","9670":"No randomization ","9671":"No randomization ","9672":"No randomization ","9673":"No randomization ","9674":"No randomization ","9675":"No randomization ","9676":"Control","9677":"Control","9678":"Control","9679":"Control","9680":"Control","9681":"Control","9682":"Control","9683":"Control","9684":"Control","9685":"Tea","9686":"Yogurt","9687":"Semi skimmed milk","9688":"High-fat emulsion 4 ml","9689":"Coffee","9690":"Placebo","9691":"Trabedersen 80 \u03bcM ","9692":"Control","9693":"Control","9694":"Trabedersen 80 \u03bcM ","9695":"Control","9696":"Control","9697":"Crushed intranasal extended release morphine","9698":"Crushed intranasal extended release morphine","9699":"Crushed intranasal extended release morphine","9700":"Crushed intranasal extended release morphine","9701":"Crushed intranasal extended release morphine","9702":"Posterior-stabilized anatomical tibial component","9703":"Posterior-stabilized anatomical tibial component","9704":"Posterior-stabilized anatomical tibial component","9705":"Posterior-stabilized anatomical tibial component","9706":"Posterior-stabilized anatomical tibial component","9707":"Posterior-stabilized anatomical tibial component","9708":"Mini Piezon","9709":"Placebo","9710":"Placebo","9711":"Placebo","9712":"Placebo","9713":"Placebo","9714":"Usual Training ","9715":"Usual Training ","9716":"Usual Training ","9717":"Usual Training ","9718":"Usual Training ","9719":"Standard basal-bolus insulin","9720":"Standard basal-bolus insulin","9721":"Standard basal-bolus insulin","9722":"Standard basal-bolus insulin","9723":"Standard basal-bolus insulin","9724":"Placebo","9725":"Placebo","9726":"Placebo","9727":"Placebo","9728":"Standard glycemic care","9729":"Standard glycemic care","9730":"Walking","9731":"Walking","9732":"Walking","9733":"Walking","9734":"Walking","9735":"Control","9736":"Control","9737":"Fosaprepitant single dose","9738":"Fosaprepitant single dose","9739":"Fosaprepitant single dose","9740":"Fosaprepitant single dose","9741":"Fosaprepitant single dose","9742":"Standard pressure carbon dioxide ","9743":"Standard pressure carbon dioxide ","9744":"Standard pressure carbon dioxide ","9745":"Placebo","9746":"Placebo","9747":"Placebo","9748":"Placebo","9749":"Placebo","9750":"Sevoflurane","9751":"Sevoflurane","9752":"Sevoflurane","9753":"Sevoflurane","9754":"Sevoflurane","9755":"Sevoflurane","9756":"Sevoflurane","9757":"Control","9758":"Control","9759":"Control","9760":"Control","9761":"Control","9762":"Control","9763":"Phase II Surgery","9764":"Phase II Surgery","9765":"Phase II Surgery","9766":"Phase II Surgery","9767":"Control","9768":"Control","9769":"Control","9770":"Control","9771":"Control","9772":"Control","9773":"Segmental phenolization","9774":"Segmental phenolization","9775":"Control","9776":"Control","9777":"Control","9778":"Control","9779":"Control","9780":"Control","9781":"Control","9782":"Control","9783":"Placebo","9784":"Placebo","9785":"Placebo","9786":"Placebo","9787":"Control","9788":"Control","9789":"Control","9790":"Oral norethisterone acetate","9791":"Oral norethisterone acetate","9792":"Ropivacaine-clonidine ","9793":"Ropivacaine-fentanyl","9794":"Control","9795":"Control","9796":"Control","9797":"Control","9798":"Cimetropium bromide","9799":"Cimetropium bromide","9800":"Cimetropium bromide","9801":"Cimetropium bromide","9802":"Cimetropium bromide","9803":"Alirocumab + placebo","9804":"Alirocumab + placebo","9805":"MOVE!\u00ae weight management program","9806":"MOVE!\u00ae weight management program","9807":"MOVE!\u00ae weight management program","9808":"Control","9809":"Control","9810":"Control","9811":"Control","9812":"Stented group","9813":"Stented group","9814":"Placebo","9815":"Control","9816":"Open appendectomy","9817":"Placebo","9818":"Placebo","9819":"Placebo","9820":"Placebo","9821":"Control","9822":"Control","9823":"Control","9824":"Control","9825":"Lidocaine + ketorolac","9826":"Lidocaine + ketorolac","9827":"Control","9828":"Chlorhexidine gel","9829":"Control","9830":"Open surgery","9831":"Open surgery","9832":"Conventional dosing","9833":"Conventional dosing","9834":"Control","9835":"Control","9836":"Control","9837":"Antidepressants only","9838":"Antidepressants only","9839":"Control","9840":"Control","9841":"Control","9842":"Control","9843":"Olmesartan","9844":"Olmesartan","9845":"Placebo","9846":"Placebo","9847":"Placebo","9848":"Lixisenatide with mild impairment ","9849":"Lixisenatide with mild impairment ","9850":"Lixisenatide with mild impairment ","9851":"Bilamellar tarsal rotation surgery","9852":"Bilamellar tarsal rotation surgery","9853":"Bilamellar tarsal rotation surgery","9854":"Bilamellar tarsal rotation surgery","9855":"Control","9856":"Control","9857":"Lateral approach arthroplasty","9858":"Lateral approach arthroplasty","9859":"Lateral approach arthroplasty","9860":"Control","9861":"Control","9862":"Placebo","9863":"Placebo","9864":"Placebo","9865":"Placebo","9866":"Placebo","9867":"Control","9868":"Control","9869":"Percutaneous transluminal angioplasty","9870":"Percutaneous transluminal angioplasty","9871":"Percutaneous transluminal angioplasty","9872":"Drumming on drum pads","9873":"Virtual drumming","9874":"Land physical therapy","9875":"Land physical therapy","9876":"Land physical therapy","9877":"Placebo","9878":"Sucrose","9879":"Sucrose","9880":"Sucrose","9881":"Sucrose","9882":"Sucrose","9883":"Sucrose","9884":"Parenteral Feeding ","9885":"Placebo","9886":"Placebo","9887":"Control","9888":"Control","9889":"Control","9890":"Control","9891":"Control","9892":"Control","9893":"Control","9894":"X-ray high dose irradiation ","9895":"X-ray medium dose irradiation ","9896":"Segmental phenolization","9897":"Segmental phenolization","9898":"Segmental phenolization","9899":"Control","9900":"Control","9901":"Control","9902":"Control","9903":"Control","9904":"Control","9905":"Placebo","9906":"Control","9907":"Control","9908":"Oral norethisterone acetate","9909":"Oral norethisterone acetate","9910":"Oral norethisterone acetate","9911":"Ropivacaine-fentanyl","9912":"Ropivacaine-clonidine ","9913":"Ropivacaine-fentanyl","9914":"Ropivacaine-fentanyl","9915":"Control","9916":"Control","9917":"Cimetropium bromide","9918":"Alirocumab + placebo","9919":"Alirocumab + placebo","9920":"Alirocumab + placebo","9921":"MOVE!\u00ae weight management program","9922":"MOVE!\u00ae weight management program","9923":"Control","9924":"Control","9925":"Control","9926":"Control","9927":"Control","9928":"Stented group","9929":"Stented group","9930":"Stented group","9931":"Placebo","9932":"Placebo","9933":"Control","9934":"Control","9935":"Control","9936":"Open appendectomy","9937":"Open appendectomy","9938":"Open appendectomy","9939":"Open appendectomy","9940":"Open appendectomy","9941":"Placebo","9942":"DC161\u2010DP0291","9943":"DC161\u2010DP0292","9944":"DC161\u2010DP0293","9945":"DC161\u2010DP0292","9946":"DC161\u2010DP0293","9947":"Placebo","9948":"Placebo","9949":"Placebo","9950":"Control","9951":"Control","9952":"Control","9953":"Control","9954":"Control","9955":"Control","9956":"Lidocaine + ketorolac","9957":"Lidocaine + ketorolac","9958":"Lidocaine + ketorolac","9959":"Chlorhexidine gel","9960":"Control","9961":"Control","9962":"Open surgery","9963":"Open surgery","9964":"IGF-I target of +2 SDs","9965":"IGF-I target of +2 SDs","9966":"Control","9967":"Control","9968":"Control","9969":"Control","9970":"Control","9971":"Control","9972":"Control","9973":"Antidepressants only","9974":"Control","9975":"Tolterodine","9976":"Control","9977":"Control","9978":"Control","9979":"Olmesartan","9980":"Olmesartan","9981":"Lixisenatide with mild impairment ","9982":"Lixisenatide with normal renal function ","9983":"Bilamellar tarsal rotation surgery","9984":"Bilamellar tarsal rotation surgery","9985":"No next-day review","9986":"No next-day review","9987":"Lateral approach arthroplasty","9988":"Control","9989":"Control","9990":"Control","9991":"Control","9992":"Control","9993":"Percutaneous transluminal angioplasty","9994":"Percutaneous transluminal angioplasty","9995":"Virtual drumming ","9996":"Control","9997":"Land physical therapy","9998":"Land physical therapy","9999":"Land physical therapy","10000":"Methyl nicotinate","10001":"Methyl nicotinate","10002":"Placebo","10003":"Parenteral Feeding ","10004":"Parenteral Feeding ","10005":"Parenteral Feeding ","10006":"Parenteral Feeding ","10007":"Parenteral Feeding ","10008":"Placebo","10009":"Control","10010":"Control","10011":"Control","10012":"Control","10013":"X-ray medium dose irradiation ","10014":"X-ray high dose irradiation ","10015":"X-ray medium dose irradiation ","10016":"X-ray high dose irradiation ","10017":"Control","10018":"Control","10019":"Liraglutide plus glimepiride","10020":"Formoterol DPI 9 \u03bcg","10021":"nothing","10022":"insulin 0.8-0.9 mg\/kg\/day in two divided doses subcutaneously (Group-B)","10023":"ALIF with BAK cages","10024":"smelled and rated an odorant","10025":"Blinded collection of NIRS values combined with treatment as usual","10026":"Interaction with a non-obese patient in a digital environment","10027":"Group 2-Patients were administered 0.5 ml intralesional injection Hyaluronidase 1,500 IU and 0.5 ml intralesional injection Hydrocortisone acetate 25 mg\/ml in each buccal mucosa once a week","10028":"sleep without receiving the lavender aroma oil","10029":"placebo in addition to lithium","10030":"Control group","10031":"Voglibose","10032":"Control","10033":"Control","10034":"placebo + methotrexate","10035":"Control","10036":"baseline","10037":"baseline","10038":"Placebo","10039":"PEG-based laxatives + electrolytes","10040":"Placebo + epinephrine","10041":"control: no educational workshop","10042":"biopsied patients"}}